<SEC-DOCUMENT>0001193125-13-324273.txt : 20130807
<SEC-HEADER>0001193125-13-324273.hdr.sgml : 20130807
<ACCEPTANCE-DATETIME>20130807162536
ACCESSION NUMBER:		0001193125-13-324273
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20130807
DATE AS OF CHANGE:		20130807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AxoGen, Inc.
		CENTRAL INDEX KEY:			0000805928
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				411301878
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-188597
		FILM NUMBER:		131017907

	BUSINESS ADDRESS:	
		STREET 1:		13859 PROGRESS BLVD.
		STREET 2:		SUITE 100
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615
		BUSINESS PHONE:		(386) 462-6817

	MAIL ADDRESS:	
		STREET 1:		13859 PROGRESS BLVD.
		STREET 2:		SUITE 100
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LECTEC CORP /MN/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d532389ds1a.htm
<DESCRIPTION>AMENDMENT NO. 6 TO FORM S-1
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 6 to Form S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>As filed with the Securities and Exchange Commission on August&nbsp;7, 2013
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registration No.&nbsp;333-188597 </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>AMENDMENT NO.&nbsp;6 </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>TO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM S-1 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>REGISTRATION STATEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B><I>UNDER </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B><I>THE SECURITIES ACT OF 1933 </I></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>AXOGEN, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Minnesota</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5047</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>41-1301878</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Primary Standard Industrial</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Classification Code Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13859 Progress Blvd., Suite 100 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Alachua, Florida 32615 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(386) 462-6800 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address, including zip code and telephone number,
including area code, of registrant&#146;s principal executive offices) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Karen Zaderej
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Chief Executive Officer </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>AxoGen, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13859 Progress Blvd., Suite 100 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Alachua, Florida 32615 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(386) 462-6800 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name, address, including zip code and telephone number,
including area code, of agent for service) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Copies to:
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory G. Freitag </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Chief Financial Officer and General Counsel </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AxoGen, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13859 Progress Blvd., Suite 100 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Alachua, Florida 32615 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(386) 462-6800 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px;page-break-before:always"></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fahd M.T. Riaz</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Andrew D. Thorpe</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Emilio Ragosa</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Orrick, Herrington &amp; Sutcliffe LLP</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Morgan, Lewis&nbsp;&amp; Bockius LLP</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>405 Howard Street</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1701 Market Street</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>San Francisco, CA 94105</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Philadelphia, PA 19103</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Telephone: (415) 773-5700</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(215) 963-5000</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this
Registration Statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of the securities being registered on this form are to be offered on a delayed or continuous
basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this
Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2
of the Exchange Act. (Check one): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until
the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the registration statement shall
become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2" COLOR="#de1a1e"><B>The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is declared effective. This prospectus is not an offer to sell
these securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2" COLOR="#de1a1e"><B>Subject to Completion, dated August&nbsp;7, 2013 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Prospectus </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>4,186,046 Shares </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>


<IMG SRC="g532389g00k21.jpg" ALT="LOGO">
 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>AXOGEN, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>Common Shares </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are offering 4,186,046
common shares, par value $0.01 per share. Our common shares currently trade on the OTCQB Marketplace, operated by OTC Markets Group, under the symbol &#147;AXGN.&#148; The last reported sale price of our common shares on the OTCQB Marketplace on
August 5, 2013 was $4.30&nbsp;per share. We have been approved to list our common shares on the NASDAQ Capital Market under the symbol &#147;AXGN.&#148; </FONT></P>  <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Investing in
our securities involves a high degree of risk. See &#147;<A HREF="#toc532389_2">Risk Factors</A>&#148; beginning on page&nbsp;8. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per&nbsp;Share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discounts and commissions(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds, before expenses, to us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(1)</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>See &#147;Underwriting&#148; in this prospectus for a description of compensation payable to the underwriters. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted to the underwriters an option to purchase up to 627,906 additional common shares to cover over-allotments, if any, exercisable at any
time until 30 days after the date of this prospectus. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
and the total proceeds to us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters expect to deliver the common shares on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>JMP&nbsp;Securities </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>Ladenburg&nbsp;Thalmann&nbsp;&amp;&nbsp;Co. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The date of this prospectus is
<B></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g532389g33w70.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A NAME="toc"></A>TABLE OF CONTENTS </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Page</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_1">PROSPECTUS SUMMARY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_2">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_3">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_4">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_5">DIVIDEND POLICY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_6">COMMON SHARE PRICE RANGE</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_7">CAPITALIZATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_8">DILUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_9">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_100">BUSINESS </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_10">MANAGEMENT</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_11">EXECUTIVE COMPENSATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_12">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_13">PRINCIPAL SHAREHOLDERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_14">DESCRIPTION OF COMMON SHARES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_15">UNDERWRITING</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_16">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_17">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_18">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc532389_19">INDEX TO FINANCIAL STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neither we nor any of the underwriters has authorized anyone to provide you with information different from, or in addition to, that
contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor any of the underwriters is making an offer to sell or seeking offers to buy these securities in any
jurisdiction where, or to any person to whom, the offer or sale is not permitted. The information in this prospectus is accurate only as of its date regardless of the time of delivery of this prospectus or of any sale of our common shares. Our
business, financial condition, results of operations and future growth prospects may have changed since those dates. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For investors outside the United States: neither we nor any of the underwriters has done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and
the distribution of this prospectus outside of the United States. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>This prospectus includes estimates, statistics and
other industry and market data that we obtained from industry publications, research, surveys and studies conducted by third parties and publicly available information. Such data involves a number of assumptions and limitations and contains
projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty. This prospectus also includes data based on our own internal estimates. We caution you not to give undue
weight to such projections, assumptions and estimates. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_1"></A>PROSPECTUS SUMMARY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights information contained in other parts of this prospectus. Because it is only a summary, it does not contain all
of the information that you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. You should read the
entire prospectus carefully, especially the section entitled &#147;Risk Factors&#148; and our consolidated financial statements and related notes, before deciding to buy our securities. Unless otherwise stated, all references to &#147;us,&#148;
&#147;our,&#148; &#147;we,&#148; &#147;AxoGen,&#148; the &#147;Company&#148; and similar designations refer to AxoGen, Inc. and its subsidiary AxoGen Corporation. </I></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Company Overview </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a leading regenerative medicine company dedicated
to advancing the science and commercialization of peripheral nerve repair solutions. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of muscle function and/or
feeling. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nerves can be damaged in a number of ways. When a nerve is cut due to a traumatic injury or surgery, functionality
of the nerve may be compromised, causing the nerve to no longer carry the signals to and from the brain to the muscles and skin. This type of injury generally requires a surgical repair. The traditional gold standard has been to either suture the
nerve ends together directly without tension or to bridge the gap between the nerve ends with a less important nerve surgically removed from elsewhere in the patient&#146;s own body referred to as nerve autograft. In addition, pressure on a nerve or
blunt force trauma can cause nerve injuries that may require surgical intervention. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to improve
the options available for the surgical repair and regeneration of peripheral nerves, we have developed and licensed patented and patent pending technologies. Our innovative approach to regenerative medicine has resulted in first-in-class products
that we believe will define their product categories. Our products offer a full suite of surgical nerve repair solutions including Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, the only off-the-shelf commercially available processed nerve allograft, human nerve tissue obtained from a donor, for bridging severed nerves without
the comorbidities of an autograft second surgical site, such as loss of feeling where the nerve was removed and potential pain at the donor site. Our AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> line of products are a natural scaffold ExtraCellular Matrix, or ECM, derived from pig tissue. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is used to facilitate the tensionless repair of severed nerves, and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector is used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s products are used by surgeons during surgical interventions to repair a wide variety of traumatic
nerve injuries ranging from a simple laceration of a finger to complex brachial plexus (an injury to the network of nerves that originate in the neck). The Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft provides surgeons with a three-dimensional structure of a natural nerve. This structure is essential and allows for bridging nerve gaps or discontinuities
in the range of 5mm to 70mm. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The January 2012 edition of Microsurgery and November 2012 edition of The
Journal of Hand Surgery each contain an article summarizing study results from patients included in our ongoing
RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study, an observational study of outcomes from the use of Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. The most recent presentation of data from the RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study found that in 113 nerve repairs, the use of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft has been associated with meaningful motor and sensory recovery in 87% of nerve discontinuities between 5 and 50 mm. According to Brooks, et al.,
&#147;outcomes of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft compare favorably with those reported in the literature for nerve
autograft and the processed nerve allograft returned a higher rate of meaningful functional recovery than those reported in the literature for nerve conduits.&#148;</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Additionally, no implant related adverse events have been reported. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft has beneficial product and sales synergies with the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Connector. Complementary to our Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, our AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is used to align and connect nerves with less than a 5mm gap between the severed nerve ends. Our
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector is designed to protect and isolate the nerve during the healing process after surgery.
Furthermore, our AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products provide the unique features of pliability, suturability, and translucence
for visualization of the underlying nerve, while also allowing the patient&#146;s own cells to incorporate into the product to remodel and form a tissue similar to the nerve epineurium. </FONT></P>
<P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP>&nbsp;</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">See &#147;Business&#151; Sales and Marketing &#151; Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Performance&#148; for full citation information. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft has been processed and distributed since 2007 as a human cell, tissue, and cellular and tissue-based product, hereafter referred herein as HCT/P, pursuant
to section 361 of the Public Health Service Act and 21 CFR &#167; 1271 controls, based on AxoGen&#146;s good faith belief that the Avance Nerve Graft was a HCT/P tissue product. In 2010, the Food and Drug Administration, or FDA, determined that the
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft was a biological product that would be reviewed and regulated by the Center for Biologics
Evaluation and Research, or CBER, under the biologics licensing provision of the Public Health Service, or PHS, Act. We subsequently agreed with the FDA on a transition plan for Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft from a HCT/P product to a licensed biological product. We are able to continue to sell Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft pursuant to a November 2010 letter from the FDA stating the agency&#146;s intent to exercise enforcement discretion with respect to the introduction or
delivery for introduction into interstate commerce of the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft provided we meet the conditions
for the transition specified in the letter. One such condition is that we conduct a phase 3 clinical trial to demonstrate the safety, purity and potency of the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft under a Special Protocol Assessment, or SPA, and the FDA has subsequently agreed to our SPA. In accordance with FDA regulations in 21 CFR &#167;312, we
submitted an Investigational New Drug Application, or IND, to the FDA in April 2013 and we are currently responding to FDA comments regarding it. We expect that enrollment of patients into the phase 3 clinical trial will occur later this year
following approval of the IND. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products are manufactured by Cook Biotech Incorporated, referred to herein as Cook Biotech. Under the license agreement with Cook Biotech, we are the exclusive
worldwide distributor of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products for use in the peripheral and central nervous system, but
excluding use of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product in the oral cavity for endodontic and periodontal applications and oral
and maxillofacial surgery solely as they relate to dental, soft or hard, tissue repair or reconstruction. The exclusion results in certain areas of AxoGen&#146;s market expansion into the oral surgery market being limited to the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. The AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products are Class II medical devices that FDA found substantially equivalent to class II predicate devices, and thus, cleared for marketing under FDA&#146;s 510(k)
program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, we entered into a Revenue Interests Purchase Agreement, which we refer
to as the Royalty Contract, with PDL BioPharma, Inc., or PDL, pursuant to which we sold to PDL the right to receive specified royalties on our Net Revenues, as defined in the Royalty Contract, generated by the sale, distribution or other use of our
products Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Protector, referred to as the Assigned Interests. The Royalty Contract has a term of eight years. Under the Royalty Contract, PDL is to receive royalty payments based on a 9.95% royalty rate of our Net Revenues, as defined in the Royalty
Contract, subject to certain agreed upon minimum payment requirements of approximately $1.3 to $2.5 million per quarter which begin in the fourth quarter of 2014 as provided in the Royalty Contract. The total consideration PDL paid to AxoGen was
$20,800,000, or the Funded Amount. The Royalty Contract also contains certain call provisions, including a call right by PDL in connection with a change of control, is secured by our Net Revenues, restricts our ability to pay dividends and grants
PDL a right to a designee on our Board of Directors. Further, on October 5, 2016, or in the event of the occurrence of a material adverse event, our transfer of revenue interest or substantially all of our interest in the products or our bankruptcy
or material breach of the Royalty Contract, PDL may require us to repurchase the Assigned Interests, referred to herein as the Put, at the Put Price which is equal to the sum of (i) an amount that, when paid to PDL, would generate a 20% internal
rate of return to PDL, called the Put Rate, on the Funded Amount, taking into consideration payments made to PDL by us, and (ii) any Delinquent Assigned Interests Payment, as defined in the Royalty Contract, we owed to PDL. The arrangement was
entered into because we could not obtain debt financing under a traditional credit facility with a lender to the extent of the Funded Amount and we believed the cost of capital for an equity transaction at the time was prohibitive. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently promote, market and sell our family of products through our own direct sales force and independent
sales representatives. Following the publication of results from our RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study in 2012, we invested in
expanding our commercial capabilities and implemented a number of sales initiatives which we believe position us to further build awareness and drive sales growth of our Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
products. For the three months ended March&nbsp;31, 2013, our total revenue was approximately $2.1 million and our net loss was approximately $3.4 million, with a gross margin of approximately 74%. For the twelve months ended December&nbsp;31, 2012,
our total revenue was approximately $7.7 million and our net loss was approximately $9.4 million, with a gross margin of approximately 75%. For the year ended December&nbsp;31, 2011, our total revenue was approximately $4.8 million, and our net loss
was approximately $10.2 million, with a gross margin of approximately 50%. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Associated with Our Business </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are described
in more detail in the &#147;Risk Factors&#148; section of this prospectus immediately following this prospectus summary. These risks include the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has not experienced positive cash flow from its operations, and the ability to achieve positive cash flow from operations will depend on
increasing sales of its products, which may not be achievable. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s revenue growth depends on its ability to expand its sales force and develop new customers, and there can be no assurance that these
efforts will result in significant increase in sales. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s revenue depends solely on three products. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is a party to the Royalty Contract with PDL which requires it to pay royalty fees that could materially adversely affect its financial position.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s business is subject to continuing regulatory compliance by the FDA and other authorities which is costly and could result in negative
effects on its business. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Failure to protect AxoGen&#146;s Intellectual Property rights could result in costly and time consuming litigation and its loss of any potential
competitive advantage. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The price of AxoGen&#146;s common shares could be highly volatile due to a number of factors, which could lead to losses by investors and costly
securities litigation. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Developments </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;11, 2013, we announced the following operating results for the quarter ended June&nbsp;30, 2013. The following results have
been prepared by, and are the responsibility of, management and have not been reviewed or audited by our independent registered public accounting firm. We believe the following results constitute a fair representation of the financial status of
AxoGen. Our financial statements for the 2013 second quarter have not yet been finalized and therefore are not available at this time. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Revenue </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues for the second quarter 2013 were $2.86 million, up 42.2%
compared to $2.01 million in the second quarter 2012, driven by an increase in the number of facilities utilizing our products and increased penetration of existing accounts. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Gross Profit </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross profit for the second quarter 2013 was $2.23 million,
up 47.6% compared to $1.51 million in the second quarter 2012. Gross profit margin for the second quarter 2013 was 77.9%, up 2.8% compared to 75.1% in the second quarter 2012. The year-over-year improvement in gross profit and gross margin was
primarily attributable to revenue growth and a product price increase implemented during the first quarter 2013, respectively. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Operating Expenses </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses in the second quarter 2013 were $4.42 million, up 42.8% compared to $3.10 million in the second quarter 2012. As a percentage of revenues, operating expenses were up 0.73% in the
second quarter 2013 as compared to the same period in 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second quarter 2013 sales and marketing expense was $2.53
million, up 60.0% compared to $1.58 million in the second quarter 2012. The increase was primarily attributable to increased commissions due to higher sales and the expansion of the Company&#146;s marketing efforts and direct sales force. Direct
sales force personnel require time to become effective in the territory and new sales personnel hired during the first and second quarters of 2013 are not expected to contribute significantly to revenue in the third quarter of this year. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second quarter 2013 general and administrative expense was $1.40 million, up 21.8% compared to $1.15 million in the second quarter 2012.
The increase was primarily attributable to increased salary expense and benefits, travel and public company expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second
quarter 2013 research and development expense was $0.50 million, up 35.7% compared to $0.37 million in the second quarter 2012. The increase was primarily attributable to costs associated with the Company&#146;s investment in clinical studies that
support the use and regulatory position of the Company&#146;s products. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Loss from Operations and Net Loss </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating loss in the second quarter 2013 was $2.20 million, compared to $1.59 million in the second quarter 2012. Net loss in the second
quarter 2013 was $3.45 million, or ($0.31) per share, compared to net loss of $1.03 million, or ($0.09) per share, in the second quarter 2012. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Balance Sheet </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2013, the Company had $8.69 million in cash and cash equivalents and approximately $23.38 million in long-term note
payable &#150; revenue interest purchase agreement. AxoGen had working capital of approximately $12.22 million and a current ratio of 8.7 at June&nbsp;30, 2013, compared to working capital of $16.82 million and a current ratio of 12.4 at
December&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Information </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We were incorporated under the laws of Minnesota in 1977. Our principal executive offices are located at 13859 Progress Blvd., Suite 100, Alachua, Florida 32615 and our telephone number is
(386)&nbsp;462-6800. Our website address is <U>www.axogeninc.com</U>. We have included our website address in this prospectus solely as an inactive textual reference. The information contained on, or that can be accessed through, our website is not
part of this prospectus. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Offering </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="57%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Common shares offered by us</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,186,046 shares (or 4,813,952 shares if the underwriters&#146; over-allotment option is exercised in full)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Common shares outstanding after this offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,325,985 shares (or 15,953,891 shares if the underwriters&#146; over-allotment option is exercised in full)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Use of proceeds</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds to us from the sale of common shares in this offering will be approximately $16,180,000 or approximately $18,691,000 if the underwriters
exercise their over-allotment option in full, in each case assuming a public offering price of $4.30 per common share and after deducting estimated underwriting discounts and commissions and offering expenses payable by us. We intend to use the net
proceeds from this offering to continue our product commercialization and marketing efforts, development of our product pipeline, including product line extensions, and for general working capital purposes. See &#147;Use of
Proceeds.&#148;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current trading on OTCQB Marketplace</B><B> </B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common shares currently trade on the OTCQB Marketplace under the symbol &#147;AXGN.&#148;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Listing</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering we have been approved to list our common shares on the NASDAQ Capital Market under the symbol &#147;AXGN.&#148;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risk factors</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in our common
shares.</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of our common shares outstanding after this offering is based on 11,139,939 common shares outstanding as of August 5, 2013 and assumes no exercise of the
underwriter&#146;s option to purchase an additional 627,906 shares to cover over-allotments, and excludes: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,986,276 common shares issuable upon the exercise of options outstanding as of August 5, 2013 at a weighted average exercise price of $2.67 per share;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">89,686 common shares issuable upon the exercise of warrants outstanding as of August 5, 2013 at an exercise price of $2.23 per share; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">602,914 additional common shares available for future issuance as of August 5, 2013 under our AxoGen 2010 Stock Incentive Plan.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated, all information in this prospectus assumes no exercise of the outstanding
options or the warrants described above. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary Consolidated Financial Data </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The summary financial data below as of and for the years ended December&nbsp;31, 2012, 2011 and 2010 have been derived from our audited
consolidated financial statements. Our audited consolidated financial statements as of December&nbsp;31, 2012 and 2011 and for the years ended December&nbsp;31, 2012 and 2011 are included elsewhere in this prospectus. Our audited consolidated
financial statements as of December&nbsp;31, 2010 and for the year ended December&nbsp;31, 2010 are not included in this prospectus. The summary financial data as of March&nbsp;31, 2013 and 2012 and for the three months ended March&nbsp;31, 2013 and
2012 have been derived from our consolidated financial statements included elsewhere in this prospectus. You should read the summary financial data together with &#147;Capitalization,&#148; &#147;Management&#146;s Discussion and Analysis of
Financial Condition&#148; and &#147;Results of Operations&#148; and our financial statements and the related notes included elsewhere in this prospectus. Our historical results for any prior period are not necessarily indicative of results to be
expected in any future period. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three months ended March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Statement of operations data:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,692</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of goods sold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">439</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross Profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,214</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,422</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs and expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales and marketing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,629</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,884</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">697</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,606</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,316</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,664</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Costs and Expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,907</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,802</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,970</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(942</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,424</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss available to common shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,418</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average basic and diluted common shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,124,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,062,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,089,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,697,390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">836,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss Per Common Share &#150; basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8.35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance sheets data:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and Cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,642</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,907</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,799</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,477</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,495</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,357</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,424</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Temporary equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total shareholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,829</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,071</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(27,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Statements of cash flows data:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used for operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,651</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,478</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,662</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash (used for) provided by investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,531</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_2"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Investing in our common shares involves a high degree of risk. Before you decide to invest in our securities, you should consider
carefully the risks described below, as well as the other information contained in this prospectus. The risks described below are not the only ones facing us. Additional risks not presently known to us or that we currently deemed immaterial may also
impair our business operations. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>If any of the following risks actually occurs, our business, financial condition,
results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common shares could decline, and you may lose all or part of your investment. </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related To Company </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen has not experienced positive cash flow from its operations, and the ability to achieve positive cash flow from operations
will depend on increasing sales of its products, which may not be achievable. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has historically operated with
negative cash flow from its operations. As of March&nbsp;31, 2013, AxoGen had an accumulated deficit of approximately $61.0 million. If AxoGen product sales do not increase as anticipated, then it will continue to experience negative cash flows and
adverse operating conditions. AxoGen&#146;s continuing capital needs and other factors, could cause the Company to raise additional funds through public or private equity offerings, debt financings or from other sources. The sale of additional
equity may result in dilution to AxoGen&#146;s shareholders. There is no assurance that AxoGen will be able to secure funding on terms acceptable to it, or at all. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s revenue growth depends on its ability to expand its sales force and develop new customers, and there can be no assurance that these efforts will result in significant increase in
sales. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is in the process of investing in its sales channel composed of a combination of its direct sales force
and independent distributors to allow it to reach new customers. There can be no assurance that these efforts will be successful in expanding AxoGen&#146;s product sales. AxoGen currently sells products directly through its employees and indirectly
through distributor relationships. AxoGen is engaged in a major initiative to build and further expand sales and marketing capabilities. The incurrence of these expenses impacts AxoGen&#146;s operating results, and there can be no assurance of their
effectiveness. If AxoGen is unable to develop its sales force and new customers, or increase sales to existing customers, it may not be able to grow revenue or maintain its current level of revenue generation. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s revenue depends solely on three products. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">All of AxoGen&#146;s revenue is currently derived from only three products, the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Connector, for the treatment of peripheral nerve damage. Its ability to generate revenue is dependent on the success of these products. Accordingly, any disruption in AxoGen&#146;s ability to generate revenue from the sale of these products
will have a material adverse impact on its business, results of operations, financial condition and growth prospects. In addition, AxoGen&#146;s expenditures for research and development are minimal and funding to develop, or increase efforts to
find collaboration or licensing opportunities to obtain, additional products will be necessary. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products are only available through an exclusive distribution agreement with Cook Biotech. Such
contract is for an initial seven year term and following such initial term, the agreement automatically renews for an additional seven (7)&nbsp;year period provided that the parties agree to meet at least ninety (90)&nbsp;days before the end of such
initial term to review whether the purchase price of the products obtained from Cook Biotech need to be adjusted and reasonably agree to such adjustment in writing, where such agreement shall not be unreasonably withheld. However, there are
conditions for continuation of the agreement, including payment terms and minimum purchase requirements, that if breached could result in an earlier termination of the agreement; except that through mutual agreement the parties have not established
such minimums and to date have not enforce such minimum purchase provision. Additionally, in the event that AxoGen and Cook Biotech were to fail to reach an agreement as to minimum purchase </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
quantities, Cook Biotech could terminate the agreement if it was deemed that AxoGen had failed to generate commercially reasonable sales of AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> as measured by sales similar to a competitive product at the same stage in its commercial launch as verified by a
mutually acceptable third-party. Although there are products that AxoGen believes it could develop or obtain that would replace the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products, the loss of the ability to sell the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products could have a material adverse effect on AxoGen&#146;s business until other replacement products are available. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s success will be dependent on continued acceptance of its products by the medical community. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Continued market acceptance of AxoGen&#146;s products will depend on its ability to demonstrate that its products are
an attractive alternative to existing nerve reconstruction treatment options. Its ability to do so will depend on surgeons&#146; evaluations of clinical safety, efficacy, ease of use, reliability, and cost-effectiveness of AxoGen&#146;s nerve repair
products. For example, although AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft follows stringent safety standards, including
sterilization by gamma irradiation, AxoGen believes that a small portion of the medical community has lingering concerns over the risk of disease transmission through the use of allografts in general. Furthermore, AxoGen believes that even if its
products receive general acceptance within the medical community, acceptance and clinical recommendations by influential surgeons will be important to the commercial success of AxoGen&#146;s products. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Negative publicity concerning methods of donating human tissue and screening of donated tissue, in the industry in which AxoGen
operates, may reduce demand for its Avance Nerve Graft product and negatively impact the supply of available donor tissue. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen is highly dependent on its ability to recover cadaveric nerves from tissue donors for its Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product. The availability of acceptable donors is relatively limited, and this availability is impacted by regulatory changes, general public opinion of
the donation process and AxoGen&#146;s reputation for its handling of the donation process. Media reports or other negative publicity concerning both improper methods of tissue recovery from donors and disease transmission from donated cadaver
tissue (allografts) including bones, tendon, etc. may limit widespread acceptance of AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Graft. Unfavorable reports of improper or illegal tissue recovery practices, both in the U.S. and internationally, as well as incidents of improperly processed tissue leading to transmission of disease, may broadly affect the rate of future tissue
donation and market acceptance of allograft technologies. Potential patients may not be able to distinguish AxoGen products, technologies, and tissue recovery and processing procedures from others engaged in tissue recovery. In addition, unfavorable
reports could make families of potential donors from whom AxoGen is required to obtain consent before processing tissue reluctant to agree to donate tissue to for-profit tissue processors. Any disruption in the supply could have negative
consequences for AxoGen&#146;s revenue, operating results and continued operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen is highly dependent on the
continued availability of its facilities and could be harmed if the facilities are unavailable for any prolonged period of time. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any failure in the physical infrastructure of AxoGen&#146;s facilities, including the facility it leases from LifeNet Health, could lead to significant costs and disruptions that could reduce its revenues
and harm its business reputation and financial results. Any natural or man-made event that impacts AxoGen&#146;s ability to utilize its facilities could have a significant impact on its operating results, reputation and ability to continue
operations. This includes termination of the LifeNet Health facility lease which can occur upon six months&#146; notice from either party. Although AxoGen believes it can find and make operational a new facility in less than six months, the
regulatory process for approval of facilities is time-consuming and unpredictable. AxoGen&#146;s ability to rebuild or find acceptable lease facilities would take a considerable amount of time and expense and could cause a significant disruption in
service to its customers. Although AxoGen has business interruption insurance which would, in instances other than lease termination, cover certain costs, it may not cover all costs nor help to regain AxoGen&#146;s standing in the market.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen must maintain high quality manufacturing and processing. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is processed through its
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Process which requires careful calibration and precise, high-quality processing and manufacturing.
Achieving precision and quality control requires skill and diligence by its personnel. If it fails to achieve and maintain these high quality controls, processing and manufacturing standards, including avoidance of manufacturing errors, defects or
product failures, AxoGen could experience recalls or withdrawals of its product, delays in delivery, cost overruns or other problems that would adversely affect its business. AxoGen cannot completely eliminate the risk of errors, defects or
failures. In addition, AxoGen may experience difficulties in scaling-up manufacturing of its Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product,
including problems related to yields, quality control and assurance, tissue availability, adequacy of control policies and procedures, and lack of skilled personnel. If AxoGen is unable to process and produce its allografts on a timely basis, at
acceptable quality and costs, and in sufficient quantities, or if it experiences unanticipated technological problems or delays in production, its business would be adversely affected. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen relies on third-party suppliers, some of which are currently the only source for the respective components or materials they
supply to it. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Most of the raw materials used in the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Process for the production of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft are available from more than one supplier. However, one of the chemicals AxoGen uses in the manufacture of Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is no longer provided by the original single source provider. AxoGen has inventory of such chemical
which it believes provides more than one year of production. AxoGen is currently evaluating a new supplier of the chemical. In addition, some of the test results, packaging and reagents/chemicals AxoGen uses in its manufacturing process are also
obtained from single suppliers. We do not have written contracts with any of our single source suppliers, and at any time they could stop supplying our orders. FDA approval of a new supplier may be required if these materials become unavailable from
AxoGen&#146;s current suppliers. Although there may be other suppliers that have equivalent materials that would be available to AxoGen, FDA approval of any alternate suppliers if required could take several months or years to obtain, if able to be
obtained at all. Any delay, interruption or cessation of production by AxoGen&#146;s third-party suppliers of important materials, or any delay in qualifying new materials, if necessary, would prevent or delay AxoGen&#146;s ability to manufacture
products. In addition, an uncorrected impurity, a supplier&#146;s variation in a raw material or testing, either unknown to AxoGen or incompatible with its manufacturing process, or any other problem with AxoGen&#146;s materials, testing or
components, would prevent or delay its ability to manufacture products. These delays may limit AxoGen&#146;s ability to meet demand for its products and delay its clinical trial, which would have a material adverse impact on its business, results of
operations and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen relies on third parties to perform many necessary
services for the commercialization of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, including services related to the recovery,
distribution, storage and transportation. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen relies upon third parties for certain recovery,
distribution, and transportation services. In accordance with product specifications, these third parties ship
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft in specially validated shipping containers at frozen temperatures. If any of the third
parties that AxoGen relies upon in its recovery, distribution, storage or transportation process fail to comply with applicable laws and regulations, fail to meet expected deadlines, or otherwise do not carry out their contractual duties to AxoGen,
or encounter physical damage or natural disaster at their facilities, AxoGen&#146;s ability to deliver product to meet commercial demand may be significantly impaired. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen is dependent on its relationships with distributors to generate revenue. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen derives material revenues through its relationships with distributors. If such distributor relationships were terminated for any reason, it could materially and adversely affect AxoGen&#146;s
ability to generate revenues and profits. AxoGen intends to obtain the assistance of additional distributors to continue its sales growth. It may not be able to find additional distributors who will agree to market and distribute its products on
commercially reasonable terms, if at all. If it is unable to establish new distribution relationships or renew current distribution agreements on commercially acceptable terms, operating results could suffer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Loss of key members of management, who it needs to succeed, could adversely affect its
business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s future success depends on the continued efforts of the members of its senior management team.
Competition for experienced management personnel in the healthcare industry is intense. If one or more of AxoGen&#146;s senior executives or other key personnel are unable or unwilling to continue in their present positions, or if AxoGen is unable
to attract and retain high quality senior executives or key personnel in the future, its business may be adversely affected. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s operating results will be harmed if it is unable to effectively manage and sustain its future growth.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There can be no assurance that AxoGen will be able to manage its future growth efficiently or profitably. Its business
is unproven on a large scale and actual revenue and operating margins, or revenue and margin growth, may be less than expected. If AxoGen is unable to scale its production capabilities efficiently, it may fail to achieve expected operating margins,
which would have a material and adverse effect on its operating results. Growth may also stress AxoGen&#146;s ability to adequately manage its operations, quality of products, safety and regulatory compliance. If growth significantly decreases
AxoGen&#146;s cash reserves, it may be required to obtain additional financing, which may increase indebtedness or result in dilution to shareholders. Further, there can be no assurance that AxoGen would be able to obtain additional financing on
acceptable terms if all at. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>There may be significant fluctuations in AxoGen&#146;s operating results.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significant quarterly fluctuations in AxoGen&#146;s results of operations may be caused by, among other factors, its
volume of revenues, seasonal changes in nerve repair activity, timing of sales force expansion and general economic conditions. There can be no assurance that the level of revenues and profits, if any, achieved by AxoGen in any particular fiscal
period, will not be significantly lower than in other comparable fiscal periods. AxoGen&#146;s expense levels are based, in part, on its expectations as to future revenues. As a result, if future revenues are below expectations, net income or loss
may be disproportionately affected by a reduction in revenues, as any corresponding reduction in expenses may not be proportionate to the reduction in revenues. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s revenues depend upon prompt and adequate reimbursement from public and private insurers and national health systems. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Political, economic and regulatory influences are subjecting the healthcare industry in the U.S. to fundamental change. The ability of
hospitals to pay fees for AxoGen&#146;s products depends in part on the extent to which reimbursement for the costs of such materials and related treatments will continue to be available from governmental health administration authorities, private
health coverage insurers and other organizations. Major third-party payers of hospital services and hospital outpatient services, including Medicare, Medicaid and private healthcare insurers, annually revise their payment methodologies, which can
result in stricter standards for reimbursement of hospital charges for certain medical procedures or the elimination of reimbursement. Further, Medicare, Medicaid and private healthcare insurer cutbacks could create downward price pressure on
AxoGen&#146;s products. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen may be subject to future product liability litigation that could be expensive and its
insurance coverage may not be adequate. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although AxoGen is not currently subject to any product liability proceedings,
and it has no reserves for product liability disbursements, it may incur material liabilities relating to product liability claims in the future, including product liability claims arising out of the usage of AxoGen products. AxoGen currently
carries product liability insurance in an amount consistent with industry averages, however, its insurance coverage and any reserves it may maintain in the future for product related liabilities may not be adequate and AxoGen&#146;s business could
suffer material adverse consequences. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Technological change could reduce demand for AxoGen&#146;s products.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The medical technology industry is intensely competitive. AxoGen competes with both U.S. and international companies
that engage in the development and production of medical technologies and processes including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">biotechnology, orthopedic, pharmaceutical, biomaterial, chemical and other companies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">academic and scientific institutions; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">public and private research organizations. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen products compete with autograft and hollow-tube conduits, as well as with alternative medical procedures. For the foreseeable future, AxoGen believes a significant number of surgeons will continue
to choose to perform autograft procedures when feasible, despite the necessity of performing a second operation and its drawbacks. In addition, many members of the medical community will continue to prefer the use of hollow-tube conduits due in part
to their familiarity with these products and the procedures required for their use. Also, steady improvements have been made in synthetic human tissue substitutes, which could compete with AxoGen&#146;s products. Unlike allografts, synthetic tissue
technologies are not dependent on the availability of human or animal tissue. Although AxoGen&#146;s growth strategy contemplates the introduction of new technologies, the development of these technologies is a complex and uncertain process,
requiring a high level of innovation, as well as the ability to accurately predict future technology and market trends. AxoGen may not be able to respond effectively to technological changes and emerging industry standards, or to successfully
identify, develop or support new technologies or enhancements to existing products in a timely and cost effective manner, if at all. Finally, there can be no assurance that in the future AxoGen&#146;s competitors will not develop products that have
superior performance or are less expensive relative to its products rendering them obsolete or noncompetitive. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen
may be unsuccessful in commercializing its products outside the U.S. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, AxoGen has focused
its commercialization efforts in the U.S., except for minor revenues from the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft in the United
Kingdom, the Netherlands, Switzerland, Italy, Austria and Canada. It intends to expand sales beyond these countries outside the U.S. and will need to comply with applicable foreign regulatory requirements, including obtaining the requisite approvals
to do so. Additionally, AxoGen will need to either enter into distribution agreements with third parties or develop a direct sales force in these foreign markets. If it does not obtain adequate levels of reimbursement from third-party payers outside
of the U.S., it may be unable to develop and grow its product sales internationally. Outside of the U.S., reimbursement systems vary significantly by country. Many foreign markets have government-managed healthcare systems that govern reimbursement
for medical devices and procedures. Additionally, some foreign reimbursement systems provide for limited payments in a given period and therefore result in extended payment periods. If AxoGen is unable to successfully commercialize its products
internationally, its long term growth prospects may be limited. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If AxoGen does not manage tissue and tissue donation in
an effective and efficient manner, it could adversely affect its business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many factors affect the supply, quantity
and timing of donor medical releases, such as effectiveness of donor screening (currently performed by donor recovery groups), the effective recovery of tissue, the timely receipt, recording and review of required medical documentation, and employee
loss and turnover in AxoGen&#146;s and its contractor&#146;s recovery department. AxoGen can provide no assurance that tissue recovery or donor medical releases will occur at levels that will maximize processing efficiency and minimize AxoGen&#146;s
cost per allograft processed. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If AxoGen does not manage product inventory in an effective and efficient manner, it
could adversely affect profitability. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many factors affect the efficient use and planning of product inventory, such as
effectiveness of predicting demand, effectiveness of preparing manufacturing to meet demand, efficiently meeting product mix and product demand requirements and product expiration. AxoGen may be unable to manage its inventory efficiently, keep
inventory within expected budget goals, keep its work-in-process inventory on hand or manage it efficiently, or keep sufficient product on hand to meet demand, and AxoGen can provide no assurance that it can keep inventory costs within its target
levels. Failing to do so may require AxoGen to raise additional cash resources or may harm long term growth prospects. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen is a party to a Royalty Contract which requires it to pay royalty fees that could materially adversely affect its financial
position. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, AxoGen entered into a Royalty Contract with PDL, pursuant to
which AxoGen sold to PDL the right to receive specified royalties on AxoGen&#146;s Net Revenues generated by the sale, distribution or other use of AxoGen&#146;s products Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Protector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector (the Assigned Interests as defined in the Royalty Contract). The Royalty
Contract has a term of eight years. Under the Royalty Contract, PDL is to receive royalty payments, currently paid weekly, based on a 9.95% royalty rate of AxoGen&#146;s Net Revenues, subject to certain agreed upon minimum guaranteed quarterly
payment amounts of approximately $1.3 to $2.5 million per quarter that commence in the quarter ending December&nbsp;31, 2014. The minimum annual payment amounts are as follows: 2014&#151;$1,250,805, 2015&#151;$6,781,440, 2016&#151;$9,232,642, 2017
and 2018&#151;$9,000,000, 2019&#151;$9,063,000 and 2020&#151;$6,939,000. Further, on October&nbsp;5, 2016, or in the event of the occurrence of a material adverse event, our transfer of revenue interest or substantially all of our interest in the
products or AxoGen&#146;s bankruptcy or material breach of the Royalty Contract, PDL may require AxoGen to repurchase the Assigned Interests (the &#147;Put&#148;) at the Put Price (as defined in the Royalty Contract). The Put Price is equal to the
sum of (i)&nbsp;an amount that, when paid to PDL, would generate a 20% internal rate of return to PDL (the &#147;Put Rate&#148;) on the Funded Amount, taking into consideration payments made to PDL by AxoGen, and (ii)&nbsp;any &#147;Delinquent
Assigned Interests Payment&#148; (as defined in the Royalty Contract) AxoGen owed to PDL. For purposes of estimating the effective interest rate of the Royalty Contract, we considered that the effective rate of 20% (currently the Put Rate) is
currently slightly higher than the implicit rate of return and, as a result, we assume for accounting purposes that PDL will exercise its put option in order to receive the higher rate of return. However we have no actual knowledge or other
indications of PDL&#146;s intent to do so. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2012, AxoGen&#146;s monthly expenses exceeded its revenues and thus it
operated at a cash loss. Royalty payments to PDL are owed without consideration to any negative affect it has on AxoGen&#146;s cash or loss position. In addition, minimum payments under the Royalty Contract start in October 2014 and if AxoGen is
required to pay an amount greater than the royalty fee, AxoGen would have an even greater cash burden. Finally, there is no assurance that AxoGen will have sufficient capital to pay the Put Price if it was exercised. If AxoGen does not have
sufficient cash to pay PDL, AxoGen would need to raise additional capital. The sale of additional equity to further finance the company may result in dilution to AxoGen&#146;s shareholders. There is no assurance that if AxoGen is required to secure
funding it can do so on terms acceptable to it, or at all. The increasing need for capital as the PDL transaction matures could also make it more difficult to obtain funding through either equity or debt. See &#147;Notes to Consolidated Financial
Statements &#150; Footnote 7 Long-Term Debt/Note Payable.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>PDL Royalty Contract has Change of Control provision
that could have material impact on price received by AxoGen shareholders in the event of a Change of Control. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the
event of a &#147;Change of Control&#148; (as defined in the Royalty Contract), AxoGen must repurchase the Assigned Interests from PDL for a repurchase price equal to the &#147;Change of Control Price&#148; on or prior to the third business day after
the occurrence of the Change of Control. The Change of Control Price is the sum of (i)&nbsp;an amount that, when paid to PDL, would generate an internal rate of return to PDL of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
thirty-two and one half percent (32.5%)&nbsp;on all payments made by PDL pursuant to the Royalty Contract as of the date of the Change of Control Payment (as defined in the Royalty Contract),
taking into account the amount and timing of all payments made by AxoGen to PDL (and retained by PDL) prior to and as of the date of payment of the Change of Control Payment, plus (ii)&nbsp;any Delinquent Assigned Interests Payment owed. For
purposes of example only, the Change of Control payment at March&nbsp;31, 2013 would have been $23,439,186. Payment of the Change of Control Price could materially reduce the consideration to be received by AxoGen shareholders if the Change of
Control event was in conjunction with the acquisition of the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen incurs costs as a result of operating as a
public company, and its management is required to devote substantial time to compliance initiatives. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a public
company, AxoGen incurs legal, accounting and other expenses to comply with relevant securities laws and regulations, including, without limitation, the requirement of establishment and maintenance of effective disclosure and financial controls and
corporate governance practices. AxoGen&#146;s management devotes substantial time and financial resources to these compliance initiatives. Failure to comply with public company requirements could have a material adverse effect on AxoGen&#146;s
business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our Business and Stock Price May Be Adversely Affected if Our Internal Controls Are Not Effective.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 requires companies to conduct a comprehensive evaluation of their
internal control over financial reporting. To comply with this statute, each year we are required to document and test our internal control over financial reporting and our management is required to assess and issue a report concerning our internal
control over financial reporting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our annual report for the period ended December&nbsp;31, 2011, we reported a material
weakness in our internal control over financial reporting, which related to an instance in which the accounting for a contract was inappropriately treated as an expense as opposed to a prepaid asset. Specifically, an effective control was not
operating to ensure that accounting for the contract was completely and accurately recorded during the 4th quarter of 2011. This control deficiency could have resulted in misstatement of net loss that would not have been prevented or detected.
Accordingly, we determined that this control deficiency constituted a material weakness. During the first quarter of 2012, in response to the conclusion reached by our Chief Executive and Chief Financial Officers that, as of December&nbsp;31, 2011,
our disclosure controls and procedures were not effective, we implemented a control procedure whereby all significant contracts will be reviewed by the Chief Financial Officer, and at the end of each quarter, the Chief Financial Officer will then
review the accounting with the Company&#146;s corporate controller prior to the recording of all such contracts. Based on its most recent evaluation, management concluded that internal control over financial reporting was effective as of
December&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we believe we took appropriate actions to remediate the control deficiencies we identified
and to strengthen our internal control over financial reporting, we cannot assure you that we will not discover other material weaknesses in the future or that no material weakness will result from any difficulties, errors, delays or disruptions
while we implement and transition to new internal systems. The existence of one or more material weaknesses could result in errors in our financial statements, and substantial costs and resources may be required to rectify these or other internal
control deficiencies. If we cannot produce reliable financial reports, investors could lose confidence in our reported financial information, the market price of our common stock could decline significantly, we may be unable to obtain additional
financing to operate and expand our business, and our business and financial condition could be harmed. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to the Regulatory Environment in which AxoGen Operates </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s business is subject to continuing regulatory compliance by the FDA and other authorities which is costly and could
result in negative effects on its business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is subject to extensive regulation. Its
products are subject to regulation by the FDA in the U.S., the Center for Medicare Services of the U.S. Department of Health and Human Services and other federal governmental agencies and, in some jurisdictions, by state and foreign governmental
authorities. The FDA regulates the development, clinical testing, marketing, distribution, manufacturing, labeling, and promotion of biological products, such as that of AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product. The FDA also regulates medical devices, such as the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products. The FDA requires the approval of a biological product, such as the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product, through a biological license application, or BLA, prior to marketing. Although the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product has not yet been approved by FDA through a BLA, FDA is permitting the product to be sold pursuant to a transition plan while AxoGen performs
clinical testing and prepares a BLA submission for the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. See &#147;Business &#151; Government
Regulations &#151; U.S. Government Regulation Review.&#148; The FDA also regulates medical devices and requires that certain medical devices, such as the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products, be cleared through the 510(k) premarket notification process prior to marketing. The FDA&#146;s premarket review process for new and modified existing
devices that precedes product marketing can be time consuming and expensive. Some of the future products and enhancements to such products that AxoGen expects to develop and market may require marketing clearance or approval from the FDA. There can
be no assurance, however, that clearance or approval will be granted with respect to any of AxoGen&#146;s products or enhancements or that FDA review will not involve delays that would adversely affect AxoGen&#146;s ability to market such products
or enhancements. In addition, there can be no assurance that AxoGen products, including the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft,
or enhancements will not be subject to a lengthy and expensive approval process with the FDA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is possible that if
regulatory clearances or approvals to market a product are obtained from the FDA, the clearances or approvals may contain limitations on the indicated uses of such product and other uses may be prohibited. Product approvals by the FDA can also be
withdrawn due to failure to comply with regulatory standards or the occurrence of unforeseen problems following initial approval. Also, the FDA could limit or prevent the distribution of AxoGen products and has the power to require the recall of
such products. FDA regulations depend heavily on administrative interpretation, and there can be no assurance that future interpretations made by the FDA or other regulatory bodies will not adversely affect AxoGen&#146;s operations. AxoGen, and its
facilities, may be inspected by the FDA from time to time to determine whether it is in compliance with various regulations relating to specification, development, documentation, validation, testing, quality control, and product labeling. A
determination that AxoGen is in violation of such regulations could lead to imposition of civil penalties, including fines, product recalls or product seizures and, in certain cases, criminal sanctions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The use, misuse or off-label use of AxoGen&#146;s products may harm its reputation or the image of its products in
the marketplace, or result in injuries that lead to product liability suits, which could be costly to AxoGen&#146;s business or result in FDA sanctions if the company is deemed to have engaged in off-label promotion. AxoGen is seeking a biologics
license through the BLA process for specific uses of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft under specific circumstances. Its
promotional materials and training methods must comply with FDA requirements and other applicable laws and regulations, including the prohibition against off-label promotion. AxoGen&#146;s promotion of the AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products, which are regulated as medical devices, also must comply with FDA&#146;s requirements and must only use
labeling that is consistent with the specific indication(s) for use included in FDA&#146;s substantial equivalence order that results in marketing the devices. The FDA does not restrict or regulate a physician&#146;s use of a medical product within
the practice of medicine, and AxoGen cannot prevent a physician from using its products for an off-label use. However, the Federal Food, Drug, and Cosmetic Act, referred to herein as the FD&amp;C Act, and the FDA&#146;s regulations restrict the kind
of promotional communications that may be made about AxoGen&#146;s products and if the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
FDA determines that AxoGen&#146;s promotional or training materials constitute the unlawful promotion of an off-label use, it could request that AxoGen modify its training or promotional
materials and/or subject the Company to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, civil money penalties, or criminal fines and penalties. Other federal, state or foreign governmental
authorities might also take action if they consider AxoGen promotion or training materials to constitute promotion of an uncleared or unapproved use, which could result in significant fines or penalties under other statutory authorities, such as
laws prohibiting false claims for reimbursement, or exclusion from participation in federal health programs. In that event, AxoGen&#146;s reputation could be damaged and the use of its products in the marketplace could be impaired. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, there may be increased risk of injury if physicians or others attempt to use AxoGen products off-label. Furthermore, the use
of AxoGen&#146;s product for indications other than those for which its products have been approved, cleared or licensed by the FDA may not effectively treat the conditions not referenced in product indications, which could harm AxoGen&#146;s
reputation in the marketplace among physicians and patients. Physicians may also misuse AxoGen&#146;s product or use improper techniques if they are not adequately trained in the particular use, potentially leading to injury and an increased risk of
product liability. Product liability claims are expensive to defend and could divert management&#146;s attention from its primary business and result in substantial damage awards against AxoGen. Any of these events could harm AxoGen&#146;s business,
results of operations and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product is currently allowed to be sold pursuant to a transition plan with the FDA and a change in
position by the FDA regarding its use of enforcement discretion to permit the sale of Avance would have a material adverse effect on AxoGen. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">The FDA considers the AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product to
be a biological product, subject to BLA approval requirements. Although the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product has not
yet been approved by FDA through a BLA, AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product is currently sold under the
controls applicable to a HCT/P pursuant to section 361 of the Public Health Service Act and 21 CFR Part 1271 of FDA&#146;s regulations, in accordance with a transition plan with the FDA in which the agency will monitor AxoGen&#146;s compliance with
21 CFR Part 1271. See &#147;Business &#151; Government Regulations &#151; U.S. Government Regulation Review.&#148; AxoGen has continued to communicate with FDA&#146;s CBER since the acceptance of the transition plan on clinical trial design and
Chemistry, Manufacturing, and Controls (&#147;CMC&#148;) for the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. AxoGen can commercially
distribute the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft subject to the controls HCT/Ps until FDA makes a final determination on an
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft BLA submission, assuming AxoGen remains in compliance with the transition plan. In the event
that the FDA becomes dissatisfied with AxoGen&#146;s progress or actions with respect to the transition plan or FDA otherwise changes its position regarding its use of enforcement discretion to permit AxoGen to provide the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product in accordance with the transition plan, AxoGen would no longer be able to sell the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product, which would have a material adverse effect on AxoGen&#146;s operations and financial viability.
In addition, if AxoGen does not meet the conditions for the transition plan, fails to comply with applicable regulatory requirements or fails to comply with the ongoing requirements of the premarket submission to transition to a biological product,
the FDA could deny approval of the premarket application, or impose civil penalties, including fines, product seizures, injunctions or product recalls and, in certain cases, criminal sanctions. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s AxoGuard products are subject to FDA and other regulatory requirements. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line is regulated as a medical device under the FD&amp;C Act and subject to premarket notification and clearance requirements under section 510(k) of the
FD&amp;C Act, 21 CFR Part 820 (Quality System Regulation) and other FDA regulations. AxoGen distributes for Cook Biotech Incorporated the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line and Cook Biotech is responsible for the regulatory compliance of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line. Cook Biotech has obtained a 510(k) premarket clearance from the FDA for porcine small intestine submucosa for the repair of peripheral nerve
discontinuities where gap closure can </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
be achieved by flexion of the extremity. If AxoGen or Cook Biotech Incorporated fails to comply with applicable regulatory requirements the FDA could deny or withdraw 510(k) clearance for the
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products, or impose civil penalties, including fines, product seizures or product recalls and, in
certain cases, criminal sanctions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Defective AxoGen product could lead to recall or other negative business conditions.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">If AxoGen&#146;s products are defective or otherwise pose safety risks, the FDA could require
their recall, or AxoGen may initiate a voluntary recall of its products. The FDA may require recall of a marketed medical device product, such as the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products, in the event that it determines that due to material deficiencies or defects that use of the medical device product would pose a reasonable probability of
serious adverse health consequences or death. However, FDA does not have authority to require most device recalls because they do not rise to this level of health significance. FDA may request, but not require, the recall of a biological product,
such as the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. However, if a company does not comply with an FDA request for a recall, FDA can
pursue other enforcement actions, such as product seizure. In addition, manufacturers may, on their own initiative, recall a product to remove or correct a deficiency or to remedy a violation of the Federal Food, Drug, and Cosmetic Act that may pose
a risk to health. A government-mandated, government-requested or voluntary recall could occur as a result of an unacceptable risk to health, reports of safety issues, failures, manufacturing errors, design or labeling defects or other deficiencies
and issues. Recalls and other field corrections for any of AxoGen&#146;s products would divert managerial and financial resources and have an adverse effect on its business, results of operations and financial condition. A recall could harm
AxoGen&#146;s reputation with customers and negatively affect its sales. AxoGen may initiate recalls involving some of its products in the future that it determines do not require notification of the FDA. If the FDA were to disagree with
AxoGen&#146;s determinations, it could request that it report those actions as recalls, and take regulatory or enforcement action against AxoGen or the product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If AxoGen&#146;s products cause or contribute to a death, a serious injury or any adverse reaction involving a communicable disease related to its products, or malfunction in certain ways, it will be
subject to reporting regulations, which can result in voluntary corrective actions or agency enforcement actions. See &#147;Business &#151; Regulation &#151; Education Grants, U.S. Anti-kickback, False Claims and Other Healthcare Fraud and Abuse
Laws &#151; Pervasive and Continuing Regulation.&#148; If AxoGen fails to report these events to the FDA within the required timeframes, or at all, the FDA could take regulatory or enforcement action against AxoGen. Any adverse event involving
AxoGen&#146;s products could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection, mandatory recall or other enforcement action. Any corrective action, whether voluntary or
involuntary, as well as AxoGen defending itself in a lawsuit, would require the dedication of time and capital, distract management from operating its business, and may harm AxoGen&#146;s reputation, business, results of operations and financial
condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen&#146;s manufacturing operations must comply with FDA and other governmental requirements.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s manufacturing operations require it to comply with the FDA&#146;s and other governmental
authorities&#146; laws and regulations regarding the manufacture and production of medical products, which is costly and could subject AxoGen to enforcement action. See Business &#151; Government Regulations &#151; Education Grants, U.S.
Anti-kickback, False Claims and Other Healthcare Fraud and Abuse Laws &#151; Pervasive and Continuing Regulation. Any of these actions could impair AxoGen&#146;s ability to produce its products in a cost-effective and timely manner in order to meet
customer demands. AxoGen may also be required to bear other costs or take other actions that may have an adverse impact on its future sales and its ability to generate profits. Furthermore, AxoGen key material suppliers, licensors and or other
contractors may not continue to be in compliance with all applicable regulatory requirements, which could result in AxoGen&#146;s failure to produce its products on a timely basis and in the required quantities, if at all. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of AxoGen products outside the U.S. are subject to foreign regulatory requirements
that vary from country to country. In the European Union (the &#147;E.U.&#148;), regulations, if applicable, differ from one E.U. member state to the next. Because of the absence of a harmonized regulatory framework and the proposed regulation for
advanced therapy medicinal products in the E.U., as well as for other countries, the approval process for human derived cell or tissue based medical products may be extensive, lengthy, expensive and unpredictable. AxoGen products will be subject to
E.U. member states&#146; regulations that govern the donation, procurement, testing, coding, traceability, processing, preservation, storage, and distribution of human tissues and cells and cellular or tissue-based products. In addition, some E.U.
member states have their own tissue banking regulations. The inability to meet foreign regulatory requirements could materially affect AxoGen&#146;s future growth and compliance with such requirements could place a significant financial burden on
AxoGen. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical trials can be long, expensive and ultimately uncertain which could jeopardize
AxoGen&#146;s ability to obtain regulatory approval and continue to market its Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is required to perform a clinical trial for its Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft pursuant to requirements of the FDA to obtain approval of a BLA for the product. This trial is
expensive, is expected to take several years to execute, and is subject to factors within and outside of AxoGen&#146;s control. The outcome of this trial is uncertain. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has continued to communicate with the FDA regarding clinical trial design, preclinical studies and CMC for
the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, and will have significant work to continue to meet the requirements asked of AxoGen by
the FDA for each of these components to begin its clinical study and receive approval of its BLA approval. If AxoGen is unable to agree with FDA, or unable to meet the standards required of it by the FDA, regarding preclinical studies, clinical
studies and CMC, the approval of AxoGen&#146;s BLA may be impossible, delayed and/or may add significant costs to the ongoing production of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The
results of non-clinical studies do not necessarily predict future clinical trial results, and predecessor clinical trial results may not be repeated in subsequent clinical trials. Additionally, the FDA may disagree with AxoGen&#146;s interpretation
of the data from its non-clinical studies and clinical trials and may require it to pursue additional non-clinical studies or clinical trials, or not approve AxoGen&#146;s BLA or future supplements, which could further delay the BLA for the
Avance<B><I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></I></B> Nerve Graft of AxoGen&#146;s products. If AxoGen is unable to demonstrate the safety and
efficacy of its product through its clinical trials, it will be unable to obtain regulatory approval to market the
Avance<B><I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></I></B> Nerve Graft and will not be able to continue to sell it. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen will rely on third parties to conduct its clinical trial and they may not perform as contractually required or expected.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen will rely on third parties, such as contract research organizations (&#147;CROs&#148;), medical institutions,
clinical investigators and contract laboratories to conduct its clinical trial and certain nonclinical studies. AxoGen and its CROs are required to comply with all applicable regulations governing clinical research, including good clinical practice,
or GCP. The FDA enforces these regulations through periodic inspections of trial sponsors, principal investigators, CROs and trial sites. If AxoGen or its CROs fail to comply with applicable FDA regulations, the data generated in its clinical trials
may be deemed unreliable and the FDA may require AxoGen to perform additional clinical trials before approving its applications. AxoGen cannot be certain that, upon inspection, the FDA and similar foreign regulatory authorities will determine that
AxoGen&#146;s clinical trial complies or complied with clinical trial regulations, including GCP. In addition, AxoGen&#146;s clinical trial must be conducted with product produced under applicable current Good Manufacturing Practice, or GMP,
regulations. Failure to comply with the clinical trial regulations may require AxoGen to repeat clinical trials, which would delay the regulatory approval process. If these third parties do not successfully carry out their contractual duties or
regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
they obtain is compromised due to the failure to adhere to AxoGen&#146;s clinical protocols or regulatory requirements or for other reasons, AxoGen&#146;s non-clinical development activities or
clinical trials may be extended, delayed, suspended or terminated, and it would not be able to obtain regulatory approval for, its products on a timely basis, if at all, and its business, results of operations, financial condition and growth
prospects would be adversely affected. Furthermore, AxoGen&#146;s third-party clinical trial investigators may be delayed in conducting its clinical trials for reasons outside of their control. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.S. governmental regulation could restrict the use of AxoGen&#146;s Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product, restrict AxoGen&#146;s procurement of tissue or increase costs. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the FDA requirements for biological products, the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft will continue to be subject to various requirements for human tissue under 21 CFR Part 1271 controls.
Human tissues intended for transplantation have been regulated by the FDA since 1993. In May 2005, three new comprehensive regulations went into effect that address manufacturing activities associated with HCT/P. The first requires that companies
that produce and distribute HCT/Ps register with the FDA. The second provides criteria that must be met for donors to be eligible to donate tissues and is referred to as the &#147;Donor Eligibility&#148; rule. The third rule governs the processing
and distribution of the tissues and is often referred to as the Current Good Tissue Practices rule. The Current Good Tissue Practices rule covers all stages of allograft processing, from procurement of tissue to distribution of final allografts.
Together, they are designed to ensure that sound, high quality practices are followed to reduce the risk of tissue contamination and of communicable disease transmission to recipients. These regulations increased regulatory scrutiny within the
industry in which AxoGen operates and have led to increased enforcement action, which affects the conduct of its business. See &#147;Business &#151; Government Regulations.&#148; These regulations can also increase the cost of tissue recovery
activities. Additionally, the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is subjected to certain state and local regulations, as well
as compliance to the standards of the tissue bank industry&#146;s accrediting organization, the American Association of Tissue Banks (&#147;AATB&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The procurement and transplantation of allograft nerve tissue is also subject to federal law pursuant to the National Organ Transplant Act (&#147;NOTA&#148;), a criminal statute which prohibits the
purchase and sale of human organs used in human transplantation, including nerve and related tissue, for &#147;valuable consideration.&#148; NOTA only permits reasonable payments associated with the removal, transportation, processing, preservation,
quality control, implantation and storage of human nerve tissue. AxoGen makes payments to certain of its clients and tissue banks for their services related to recovering allograft nerve tissue on its behalf. If NOTA is interpreted or enforced in a
manner which prevents AxoGen from receiving payment for services it renders, or which prevents it from paying tissue banks or certain of its clients for the services they render for AxoGen, its business could be materially and adversely affected.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has engaged, through its marketing employees, independent sales agents and sales representatives, in ongoing efforts
designed to educate the medical community as to the benefits of AxoGen products, and AxoGen intends to continue its educational activities. Although AxoGen believes that NOTA permits payments in connection with these educational efforts as
reasonable payments associated with the processing, transportation and implantation of AxoGen products, payments in connection with such education efforts are not exempt from NOTA&#146;s restrictions and AxoGen&#146;s inability to make such payments
in connection with its education efforts may prevent it from paying AxoGen sales representatives for their education efforts and could adversely affect AxoGen&#146;s business and prospects. No federal agency or court has determined whether NOTA is,
or will be, applicable to every allograft nerve tissue-based material which AxoGen&#146;s processing technologies may generate. Assuming that NOTA applies to AxoGen&#146;s processing of allograft nerve tissue, AxoGen believes that it complies with
NOTA, but there can be no assurance that more restrictive interpretations of, or amendments to, NOTA will not be adopted in the future, which would call into question one or more aspects of AxoGen&#146;s method of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other regulatory entities include state agencies with statutes covering tissue banking.
Regulations issued by Florida, New York, California and Maryland, among others, will be particularly relevant to AxoGen&#146;s business. Most states do not currently have tissue banking regulations. However, incidents of allograft related infections
in the industry may stimulate the development of regulation in other states. It is possible that others may make allegations against AxoGen or against donor recovery groups or tissue banks about non-compliance with applicable FDA regulations or
other relevant statutes or regulations. Allegations like these could cause regulators or other authorities to take investigative or other action, or could cause negative publicity for AxoGen&#146;s business and the industry in which it operates.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Healthcare policy changes may have a material adverse effect on AxoGen. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Affordability Reconciliation Act, which substantially changes the way healthcare is financed by both governmental and private insurers, and encourages improvements in the quality of healthcare items and services. This Act significantly impacts the
biotechnology and medical device industries and could have a material adverse impact on numerous aspects of AxoGen&#146;s business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This Act includes, among other things, the following measures: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a 2.3% excise tax on any entity that manufactures or imports medical devices offered for sale in the U.S., with limited exceptions, beginning in 2013,
referred to as the Device Tax; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities and conduct comparative clinical effectiveness research;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">new reporting and disclosure requirements on healthcare manufacturers for any &#147;transfer of value&#148; made or distributed to physicians and
teaching hospitals, as well as reporting of certain physician ownership interests, with the first of such reports due March&nbsp;31, 2014 for calendar year 2013 (&#147;Sunshine Act&#148;); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the
coordination, quality and efficiency of certain healthcare services through bundled payment models which began January 2013; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an independent payment advisory board that will submit recommendations to reduce Medicare spending if projected Medicare spending exceeds a specified
growth rate; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new abbreviated pathway for the licensure of biologic products that are demonstrated to be biosimilar or interchangeable with a licensed biologic
product. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Because the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is a biological product and is not a medical device it is not subject to the Device Tax. Cook Biotech is the manufacturer of the AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products and AxoGen is the distributor. As such, Cook Biotech is responsible for payment of the Device Tax on the
transfer price of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products from Cook Biotech to AxoGen and AxoGen has no further Device Tax
obligations with respect to its resale. Although AxoGen currently has no Device Tax obligations, there can be no assurance that changes in regulations will not subject it to such obligations in the future. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are also a number of states (such as Vermont, Massachusetts, Minnesota) with their own Sunshine Acts that implement the reporting
and disclosure requirements on healthcare manufacturers for any &#147;transfer of value&#148; made or distributed to physicians and teaching hospitals, as well as reporting of certain physician ownership interests. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the future, there may continue to be additional proposals relating to the reform of the U.S. healthcare system. Certain of these
proposals could limit the prices AxoGen is able to charge for its products or the amounts of reimbursement available for its products and could also limit the acceptance and availability of its products. The adoption of some or all of these
proposals could have a material adverse effect on AxoGen&#146;s business, results of operations and financial condition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, initiatives sponsored by government agencies, legislative bodies and the
private sector to limit the growth of healthcare costs, including price regulation and competitive pricing, are ongoing in markets where AxoGen does business. AxoGen could experience an adverse impact on operating results due to increased pricing
pressure in the U.S. and in other markets. Governments, hospitals and other third-party payors could reduce the amount of approved reimbursement for AxoGen&#146;s products or deny coverage altogether. Reductions in reimbursement levels or coverage
or other cost-containment measures could unfavorably affect AxoGen&#146;s future operating results. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to AxoGen&#146;s
Intellectual Property </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Failure to protect AxoGen&#146;s Intellectual Property rights could result in costly and time
consuming litigation and its loss of any potential competitive advantage. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s success will depend, to a
large extent, on its ability to successfully obtain and maintain patents, prevent misappropriation or infringement of intellectual property, or IP, maintain trade secret protection, and conduct operations without violating or infringing on the IP
rights of third parties. See &#147;Business &#151; Intellectual Property.&#148; There can be no assurance that AxoGen&#146;s patented and patent pending technologies will provide it with a competitive advantage, that AxoGen will be able to develop
or acquire additional technology that is patentable, or that third parties will not develop and offer technologies which are similar to AxoGen&#146;s. Moreover, AxoGen can provide no assurance that confidentiality agreements with its employees,
consultants and other parties, trade secrecy agreements or similar agreements intended to protect unpatented technology will provide the intended protection. IP litigation is extremely expensive and time-consuming, and it is often difficult, if not
impossible, to predict the outcome of such litigation. A failure by AxoGen to protect its IP could have a materially adverse effect on its business and operating results and its ability to successfully compete in its industry. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future protection for AxoGen&#146;s proprietary rights is uncertain which may impact its ability to successfully compete in its
industry. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The degree of future protection for AxoGen&#146;s proprietary rights is uncertain. AxoGen cannot ensure
that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">it, or its licensors, were the first to make the inventions covered by each of AxoGen&#146;s patents; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">it, or its licensors, were the first to file patent applications for these inventions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">others will not independently develop similar or alternative technologies or duplicate any of AxoGen&#146;s technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any of AxoGen&#146;s pending patent applications will result in issued patents; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any of AxoGen&#146;s issued patents or those of its licensors will be valid and enforceable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any patents issued to AxoGen or its collaborators will provide any competitive advantages or will not be challenged by third parties;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">it will develop additional proprietary technologies that are patentable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the patents of others will not have a material adverse effect on its business rights; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the measures AxoGen relies on to protect its IP underlying their products may not be adequate to prevent third parties from using its technology, all
of which could harm its ability to compete in the market. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s success depends on its ability to
avoid infringing on the intellectual property rights of third parties which could expose it to litigation or commercially unfavorable licensing arrangements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s commercial success depends in part on its ability and the ability of its
collaborators and licensors to avoid infringing patents and proprietary rights of third parties. Third parties may accuse AxoGen or collaborators and licensors of employing their proprietary technology in AxoGen products, or in the materials or
processes used to research or develop AxoGen products, without authorization. Any legal action against AxoGen collaborators, licensors or it claiming damages and/or seeking to stop AxoGen&#146;s commercial activities relating to the affected
products, materials and processes could, in addition to subjecting AxoGen to potential liability for damages, require it or its collaborators and licensors to obtain a license to continue to utilize the affected materials or processes or to
manufacture or market the affected products. AxoGen cannot predict whether AxoGen or its collaborators and licensors would prevail in any of these actions or whether any license required under any of these patents would be made available on
commercially reasonable terms, if at all. If AxoGen were unable to obtain such a license, it and its collaborators and licensors may be unable to continue to utilize the affected materials or processes, or manufacture or market the affected
products, or AxoGen may be obligated by a court to pay substantial royalties and/or other damages to the patent holder. Even if AxoGen were able to obtain such a license, the terms of such a license could substantially reduce the commercial value of
the affected product or products and impair AxoGen&#146;s prospects for profitability. Accordingly, AxoGen cannot predict whether, or to what extent, the commercial value of the affected product or products, or AxoGen&#146;s prospects for
profitability may be harmed as a result of any of the liabilities discussed above. Furthermore, infringement and other IP claims, with or without merit, can be expensive and time-consuming to litigate and can divert management&#146;s attention from
its core business. AxoGen and its licensors may be unable to obtain and enforce IP rights to adequately protect its products and related IP. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>The patent protection for our products may expire before we are able to maximize their commercial value which may subject us to increased competition and reduce or eliminate our opportunity to
generate product revenue. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The patents for our commercialized products and products in development
have varying expiration dates and, when these patents expire, we may be subject to increased competition and we may not be able to recover our development costs. For example, the two U.S. patents covering the formulations used in our AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line, which are held by Cook Biotech, are scheduled to expire in August and September 2016. Although we
expect that Cook Biotech is using best efforts to take any action possible to extend the life of these patents, there can be no assurance that any action is possible or action taken will be successful. If these patents expire while we have the right
to distribute and market the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products, it could adversely affect our ability to successfully execute
our business strategy to maximize the value of AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products and could likely negatively impact our future
financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Others may claim an ownership interest in AxoGen IP which could expose
it to litigation and have a significant adverse effect on its prospects. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A third party may claim an ownership interest
in one or more of AxoGen&#146;s patents or other IP. A third party could bring legal actions against AxoGen claiming it infringes their patents or proprietary rights, and seek monetary damages and/or enjoin clinical testing, manufacturing and
marketing of the affected product or products. While AxoGen believes it owns the right, title and interest in the patents for which it or its licensors have applied and AxoGen&#146;s other IP (including that which is licensed from third parties),
and is presently unaware of any claims or assertions by third-parties with respect to AxoGen&#146;s patents or IP, it cannot guarantee that a third-party will not assert a claim or an interest in any of such patents or IP. If AxoGen becomes involved
in any litigation, it could consume a substantial portion of AxoGen&#146;s resources, and cause a significant diversion of effort by AxoGen&#146;s technical and management personnel regardless of the outcome of the litigation. If any of these
actions were successful, in addition to any potential liability for damages, AxoGen could be required to obtain a license to continue to manufacture or market the affected product, in which case AxoGen may be required to pay substantial royalties or
grant cross-licenses to AxoGen&#146;s patents. AxoGen cannot, however, assure you that any such license will be available on acceptable terms, if at all. Ultimately, AxoGen could be prevented from commercializing a product, or be forced to cease
some aspect of its business operations as a result of claims of patent infringement or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
violation of other IP rights, which could have a material and adverse effect on AxoGen&#146;s business, financial condition, and results of operations. Further, the outcome of IP litigation is
subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of the adverse party. This is especially true in IP cases that may turn on the testimony of experts as to
technical facts upon which experts may reasonably disagree. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen depends on maintenance of exclusive licenses.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen depends fundamentally on keeping and satisfying the terms of exclusive licenses of its nerve repair
technologies from the University of Florida Research Foundation (the &#147;UFRF&#148;) and the University of Texas at Austin (&#147;UT&#148;)where the original technologies are purported to be invented. Though AxoGen makes an effort to follow these
agreements strictly, a disagreement between AxoGen and either party could have negative impacts on its ability to operate its business effectively. In addition, AxoGen could learn that the technologies it has licensed from UFRF and UT do not perform
as purported, are not efficacious, or are not the property of UFRF or UT, or some similar problem with the license, any of which would have an immediate and negative impact on AxoGen&#146;s business. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risk Related to this Offering </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Until our common stock is listed on a qualified national securities exchange or our common stock price exceeds $5 per share, our common stock will be considered a &#147;penny stock&#148; and will
not qualify for exemption from the &#147;penny stock&#148; restrictions, which may make it more difficult for you to sell your shares. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, our common shares have traded on the OTCQB Marketplace at a price of less than $5.00 per share and, as a result, is considered as a &#147;penny stock&#148; by the SEC and subject
to rules adopted by the SEC regulating broker-dealer practices in connection with transactions in &#147;penny stocks.&#148; The SEC has adopted regulations which generally define a &#147;penny stock&#148; to be any equity security that is not listed
on a qualified national securities exchange and that has a market price of less than $5.00 per share, or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt,
these rules require delivery, prior to any transaction in a penny stock, of a disclosure schedule relating to the penny stock market. Disclosure is also required to be made about current quotations for the securities and commissions payable to both
the broker-dealer and the registered representative. Finally, broker-dealers must send monthly statements to purchasers of penny stocks disclosing recent price information for the penny stock held in the account and information on the limited market
in penny stocks. As a result of our common shares being subject to the rules on penny stocks, the liquidity of our common shares may be adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering, we have been approved to list our common shares on the NASDAQ Capital Market. To the extent that our common shares continue to be listed on the NASDAQ Capital Market, and
we meet certain minimum financial metrics, our common shares will no longer be considered as a &#147;penny stock.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The price of AxoGen&#146;s common shares could be highly volatile due to a number of factors, which could lead to losses by
investors and costly securities litigation. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, our common shares have traded on the OTCQB
Marketplace in limited volumes. In connection with this offering, we have been approved to list our common shares on the NASDAQ Capital Market. We cannot predict the extent to which investor interest in our company will lead to the development of an
active trading market on that stock exchange or any other exchange in the future. The trading price of our common shares has experienced substantial volatility while trading on the OTCQB Marketplace and is likely to continue to be highly volatile in
response to a number of factors including, without limitation, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">trading of AxoGen common shares on the OTCQB; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limited daily trading volume resulting in the lack of a liquid market; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fluctuations in price and volume due to investor speculation and other factors that may not be tied to the financial performance of AxoGen;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">performance by AxoGen in the execution of its business plan; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">financial viability; actual or anticipated variations in our operating results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements of developments by us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">market conditions in our industry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adoption of new accounting standards affecting our industry; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">additions or departures of key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">introduction of new products by us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales of our common shares or other securities in the open market; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory developments in both the United States and foreign countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">performance of products sold and advertised by licensees in the marketplace; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic and other external factors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">period-to-period fluctuations in financial results; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">other events or factors, many of which are beyond our control. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The stock market is subject to significant price and volume fluctuations. In the past, and several recent situations, following periods
of volatility in the market price of a company&#146;s securities, securities class action litigation has been initiated against such company. Litigation initiated against us, whether or not successful, could result in substantial costs and diversion
of our management&#146;s attention and resources, which could harm our business and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Prior to this
offering, AxoGen did not meet the criteria to list its common shares on an exchange such as the NYSE &#151; MKT or NASDAQ Stock Market and its common shares lack liquidity and may be difficult to sell. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, trading of AxoGen&#146;s common stock has been conducted on the OTCQB. Generally, securities that are quoted on
the OTCQB lack liquidity and analyst coverage. This may result in lower prices for its common shares and a larger spread between the bid and asked prices for its common shares than might otherwise be obtained if it met the criteria to list its
securities on a larger or more established exchange. We have been approved to list our common shares on the NASDAQ Capital Market and anticipate that simultaneously with the closing of the sale of the shares pursuant to this Prospectus our common
stock will trade on such exchange. The NASDAQ Capital Market has provided us requirements necessary to obtain such listing, which include completion of this offering and payment of the applicable listing entry fee. We cannot predict the extent to
which investor interest in our company will lead to the development of an active trading market on that stock exchange or any other exchange in the future. Additionally, listing on an exchange will result in increased costs and regulatory
requirements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our use of the offering proceeds may not yield a favorable return on your investment. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently anticipate that the net proceeds from this offering will be used primarily for continued product commercialization and
marketing efforts, development of product pipeline, including product line extension, and for general working capital purposes. Pending the application of the net proceeds, we intend to invest the net proceeds in investment-grade, interest-bearing
securities. Our management has broad discretion over how these proceeds are used and could spend the proceeds in ways with which you may not agree, and the proceeds may not be invested in a manner that yields a favorable or any return. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>As a new investor, you will incur substantial dilution as a result of this offering
and future equity issuances, and as a result, our share price could decline. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The offering price will be substantially
higher than the net tangible book value per share of our outstanding common shares. As a result, based on our capitalization as of March&nbsp;31, 2013, investors purchasing common shares in this offering will incur immediate and substantial dilution
of $3.08 per share, based on the assumed offering price of $4.30 per share. In addition to this offering, subject to market conditions and other factors, we likely will pursue raising additional funds in the future, as we continue to build our
business. In future years, we will likely need to raise significant additional funding to finance our operations and to fund clinical trials, regulatory submissions and the development, manufacture and marketing of other products under development
and new product opportunities. Accordingly, we may conduct substantial future offerings of equity or debt securities. The exercise of outstanding options and warrants and future equity issuances, including future public offerings or future private
placements of equity securities and any additional shares issued in connection with acquisitions, will also result in dilution to investors. In addition, the market price of our common shares could fall as a result of resales of any of these shares
of common stock due to an increased number of shares available for sale in the market. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We do not anticipate paying any
cash dividends in the foreseeable future. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The continued operation and expansion of our business will require
substantial funding. In additional, the PDL Royalty Contract places certain restrictions on our ability to pay dividends. Accordingly, we do not anticipate that we will pay any cash dividends on our common shares for the foreseeable future. Any
determination to pay dividends in the future will be at the discretion of our board of directors and will depend upon results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our
board of directors deems relevant. Accordingly, if you purchase shares in this offering, realization of a gain on your investment will depend on the appreciation of the price of our common shares, which may never occur. Investors seeking cash
dividends in the foreseeable future should not purchase our common shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Anti-takeover provisions in Minnesota law
may deter acquisition bids for us that you might consider favorable. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are governed by the provisions of Sections
302A.671, 302A.673 and 302A.675 of the Minnesota Business Corporation Act (the &#147;MBCA&#148;). These provisions may discourage a negotiated acquisition or unsolicited takeover of us and deprive our shareholders of an opportunity to sell their
shares at a premium over the market price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, Section&nbsp;302A.671 of the MBCA provides that a corporation&#146;s
shares acquired in a control share acquisition have no voting rights unless voting rights are approved in a prescribed manner. A &#147;control share acquisition&#148; is a direct or indirect acquisition of beneficial ownership of shares that would,
when added to all other shares beneficially owned by the acquiring person, entitle the acquiring person to have voting power of 20% or more in the election of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In general, Section&nbsp;302A.673 of the MBCA prohibits a public Minnesota corporation from engaging in a business combination with an interested shareholder for a period of four years after the date of
the transaction in which the person became an interested shareholder, unless the business combination is approved in a prescribed manner. The term &#147;business combination&#148; includes mergers, asset sales and other transactions resulting in a
financial benefit to the interested shareholder. An &#147;interested shareholder&#148; is a person who is the beneficial owner, directly or indirectly, of 10% or more of a corporation&#146;s voting stock, or who is an affiliate or associate of the
corporation, and who, at any time within four years before the date in question, was the beneficial owner, directly or indirectly, of 10% or more of the corporation&#146;s voting stock. Section&nbsp;302A.673 does not apply if a committee of our
Board of Directors consisting of all of its disinterested directors (excluding current and former officers) approves the proposed transaction or the interested shareholder&#146;s acquisition of shares before the interested shareholder becomes an
interested shareholder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a tender offer is made for our common shares, Section&nbsp;302A.675 of the MBCA precludes
the offer or from acquiring additional shares of stock (including in acquisitions pursuant to mergers, consolidations or statutory share exchanges) within two years following the completion of the tender offer, unless shareholders selling their
shares in the later acquisition are given the opportunity to sell their shares on terms that are substantially the same as those contained in the earlier tender offer. Section&nbsp;302A.675 does not apply if a committee of our Board of Directors
consisting of all of its disinterested directors (excluding its current and former officers) approves the proposed acquisition before any shares are acquired pursuant to the earlier tender offer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_3"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, in reports filed with the Securities and Exchange Commission (including this registration statement),
in press releases, and in other communications to shareholders or the investment community, the Company may provide forward-looking statements concerning possible or anticipated future results of operations or business developments. These statements
are based on management&#146;s current expectations or predictions of future conditions, events or results based on various assumptions and management&#146;s estimates of trends and economic factors in the markets in which we are active, as well as
our business plans. Words such as &#147;expects&#148;, &#147;anticipates&#148;, &#147;intends&#148;, &#147;plans&#148;, &#147;believes&#148;, &#147;seeks&#148;, &#147;estimates&#148;, &#147;projects&#148;, &#147;forecasts&#148;, &#147;may&#148;,
&#147;should&#148;, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product
potential, regulatory environment, sales and marketing strategies, capital resources or operating performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth
in the statements. Forward-looking statements in this registration statement should be evaluated together with the many uncertainties that affect the Company&#146;s business and its market, particularly those discussed in the risk factors and
cautionary statements in the Company&#146;s filings with the Securities and Exchange Commission, including as described in &#147;Risk Factors&#148; included in this registration statement. Forward-looking statements are not guarantees of future
performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and the Company assumes no responsibility to update any forward-looking statements,
whether as a result of new information, future events or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read this prospectus and the documents that we
reference in this prospectus and have been filed as exhibits to the registration statement of which this prospectus is a part completely and with the understanding that our actual future results may be materially different from what we expect. The
information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any issuance or sale of our common shares. Except as required by law, we do not assume any
obligation to update any forward-looking statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_4"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds to us from the sale of common shares in this offering will be approximately $16,180,000 or
approximately $18,691,000 if the underwriters exercise their over-allotment option in full, assuming a public offering price of $4.30 per share and after deducting estimated underwriting discounts and commissions and offering expenses payable by us.
Each $0.10 increase or decrease in the assumed public offering price would increase or decrease, respectively, the net proceeds to us by approximately $0.09, assuming the number of shares offered by us, as set forth above, remains the same and after
deducting underwriting discounts and commissions and estimated offering expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use the net proceeds from this
offering for continued product commercialization and marketing efforts, development of product pipeline, including product line extension, and for general working capital purposes. We have not determined the amounts we plan to spend on any of the
areas listed above or the timing of these expenditures. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Therefore, investors will be relying on the judgment of our
management, who will have broad discretion regarding the application of the proceeds of this offering. The amounts and timing of our actual expenditures will depend upon numerous factors, including the amount of cash generated by our operations, our
cash needs, the rate of adoption of our products by the medical community and efficiency of our product development. We may find it necessary or advisable to use portions of the proceeds from this offering for other purposes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pending the application of the net proceeds, we intend to invest the net proceeds in investment-grade, interest-bearing securities. Our
management has broad discretion over how these proceeds are used and could spend the proceeds in ways with which you may not agree, and the proceeds may not be invested in a manner that yields a favorable or any return. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_5"></A>DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen currently intends to retain earnings, if any, to finance the growth and development of its business, and does not expect to pay
any cash dividends to its shareholders in the foreseeable future. In additional, the PDL Royalty Contract places certain restrictions on AxoGen&#146;s ability to pay dividends. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_6"></A>COMMON SHARE PRICE RANGE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this
offering, our common shares have been traded on the OTCQB Marketplace under the symbol &#147;AXGN.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table
sets forth, for each of the calendar periods indicated, the quarterly high and low closing bid prices for our common shares quoted on the OTCQB Marketplace. The prices in the table represent prices between dealers and do not include adjustments for
retail mark-up, markdown or commission and may not represent actual transactions. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>January&nbsp;1,
2013</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>through&nbsp;August&nbsp;5,&nbsp;2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Quarter </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.95</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Quarter (through August&nbsp;5, 2013)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The last reported sale price for our common shares on August&nbsp;5, 2013 was $4.30 per share. As of
June&nbsp;14, 2013, there were approximately 303 registered holders of record of our common shares, based upon information received from our stock transfer agent. However, this number does not include beneficial owners whose shares were held of
record by nominees or broker dealers. We believe that there are a significantly larger number of beneficial owners of our common shares than the number of record holders. In connection with this offering, we have been approved to list our shares on
the NASDAQ Capital Market under the symbol &#147;AXGN.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_7"></A>CAPITALIZATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table describes our capitalization as of March&nbsp;31, 2013: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on an actual basis; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>on an as adjusted basis to give effect to the sale of 4,186,046 of our shares in this offering at an assumed public offering price of
$4.30&nbsp;per share, after deducting estimated underwriting discounts and commissions and offering expenses. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read this capitalization table together with our consolidated financial statements and the related notes appearing at the end
of this prospectus and the &#147;Use of Proceeds,&#148; &#147;Summary Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections and other financial
information included in this prospectus. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of March&nbsp;31, 2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As Adjusted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shareholders&#146; equity (deficit):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Share, $.01 par value; 50,000,000 shares authorized, 11,127,869 shares issued and outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">153</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(61,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(61,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total shareholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,613</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of our common shares outstanding after this offering is based on 11,139,939 common shares outstanding as of
August&nbsp;5, 2013 and assumes no exercise of the underwriter&#146;s option to purchase an additional 627,906&nbsp;shares to cover over-allotments, and excludes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,986,276 common shares issuable upon the exercise of options outstanding as of August&nbsp;5, 2013 at a weighted average exercise price of $2.67 per
share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">89,686 common shares issuable upon the exercise of warrants outstanding as of August&nbsp;5, 2013 at an exercise price of $2.23&nbsp;per share; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">602,914 additional common shares available for future issuance as of August&nbsp;5, 2013 under our AxoGen 2010 Stock Incentive Plan.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated, all information in this prospectus assumes no exercise of the outstanding
options or the warrants described above. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_8"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our net tangible book value as of March&nbsp;31, 2013 was approximately $(6.6) million, or $(0.59) per common share. Net tangible book
value per share is determined by dividing our total tangible assets less total liabilities by the actual number of outstanding shares of our common shares. After giving effect to our issuance of 4,186,046 shares at the assumed public offering price
of $4.30&nbsp;per share, and after deducting estimated underwriting discounts and commissions and offering expenses payable by us, our net tangible book value as of March&nbsp;31, 2013 would have been $9.6&nbsp;million or $0.63&nbsp;per common
share. This represents an immediate increase in pro forma net tangible book value of $1.22&nbsp;per share to our existing shareholders and an immediate dilution of $3.08&nbsp;per share to new investors in this offering. The following table
illustrates this per share dilution: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assumed public offering price per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net tangible book value per share as of March&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase per share attributable to new investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma net tangible book value per share after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilution per share to new investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Information in the above table is based on 11,127,869 shares of common stock outstanding as of March&nbsp;31, 2013, and
excludes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,943,689 common shares issuable upon the exercise of options outstanding as of March&nbsp;31, 2013 at a weighted average exercise price of $2.60 per
share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">89,686 common shares issuable upon the exercise of warrants outstanding as of March&nbsp;31, 2013 at an exercise price of $2.23 per share; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">657,571 additional common shares available for future issuance as of March&nbsp;31, 2013 under our AxoGen 2010 Stock Incentive Plan.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilution per share to new investors is determined by subtracting pro forma net tangible book value per
share after this offering from the assumed public offering price per share paid by a new investor. If any shares are issued in connection with outstanding options or the underwriter&#146;s over-allotment option, you will experience further dilution.
A $0.10 increase or decrease in the assumed public offering price would increase or decrease, respectively, the pro forma as adjusted net tangible book value as of March&nbsp;31, 2013 by approximately $0.4 million, or $0.03&nbsp;per common share,
and the dilution per share to new investors by $0.07&nbsp;per share, assuming the number of shares offered by us, as set forth above, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The following discussion of our financial condition and results of operations should be read
in conjunction with our consolidated financial statements and the related notes, and the financial and other information included elsewhere in this prospectus. Among other things, those financial statements include more detailed information
regarding the basis of presentation for the following information. The financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, and are presented in U.S. dollars. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This discussion contains forward-looking statements that involve risks and uncertainties based on assumptions about our future
business. Our actual results may differ from those contained in the forward-looking statements and such differences may be material as a result of a number of factors. Please read &#147;Risk Factors&#148; and &#147;Cautionary Note Regarding
Forward-Looking Statements.&#148; </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, LecTec Corporation (&#147;LecTec&#148;) completed its business combination with AxoGen Corporation (&#147;AC&#148;) in accordance with the terms of an Agreement and Plan of
Merger, dated as of May&nbsp;31, 2011, by and among LecTec, Nerve Merger Sub Corp., a subsidiary of LecTec (&#147;Merger Sub&#148;), and AC, which the parties amended on September&nbsp;30, 2011 and August&nbsp;9, 2011 (as amended, the &#147;Merger
Agreement&#148;). Pursuant to the Merger Agreement, Merger Sub merged with and into AC, with AC continuing after the Merger as the surviving corporation and a wholly owned subsidiary of LecTec. Immediately following the Merger, LecTec changed its
name to AxoGen, Inc. In October 2011, AxoGen, Inc. moved its corporate headquarter facilities (principal executive office) from Texarkana, Texas to 13859 Progress Blvd., Suite 100, Alachua, Florida 32615. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For accounting purposes, AC was identified as the acquiring entity and LecTec as the acquired entity. The Merger was accounted for using
the purchase method of accounting for financial reporting purposes. The purchase method requires the identification of the acquiring entity, based on the criteria of Accounting Standards Codification 805-10-55-12, Accounting for Business
Combinations. Under purchase accounting, the assets and liabilities of an acquired company (LecTec) as of the effective date of the acquisition were recorded at their respective estimated fair values and added to those of the acquiring company.
Accordingly, the consolidated financial statements and related footnote disclosures presented for periods prior to the Merger are those of AC alone. The consolidated Statement of Operations for the years ended December&nbsp;31, 2011 and 2010 include
the operations and cash flows of AC through September&nbsp;30, 2011 and the combined operations and cash flows of the Company subsequent to the Merger. The common stock of AC has been retrospectively adjusted to reflect the exchange ratio of one
share of AC common stock for 0.03727336 share of the Company&#146;s common shares as established in the Merger Agreement. Historical results for LecTec prior to the Merger are not included in the Company&#146;s consolidated financial statements.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is a leading regenerative medicine company dedicated to advancing the science and
commercialization of peripheral nerve repair solutions. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of muscle function and feeling. In order to improve the
options available for the surgical repair and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent pending technologies. AxoGen&#146;s innovative approach to regenerative medicine has resulted in first-in-class
products that it believes will define their product categories. AxoGen&#146;s products offer a full suite of surgical nerve repair solutions including Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, the only off-the-shelf commercially available processed nerve allograft, human nerve tissue obtained from a donor, for bridging severed nerves without
the comorbidities of an autograft second surgical site, such as loss of feeling where the nerve was removed and potential pain at the donor site. The Company&#146;s AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> line of products are a natural scaffold ExtraCellular Matrix, or ECM, derived from pig tissue. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is used to facilitate the tensionless repair of severed nerves and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector is used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from the distribution of these products is the main contributor to AxoGen&#146;s total reported sales and has been the key
component of its growth to date. AxoGen revenues increased in the first quarter of 2013 and the twelve months of 2012 compared to the first quarter 2012 and the twelve months of 2011, respectively, as a result of increased usage in the number of
accounts utilizing our products. AxoGen has continued to broaden its sales and marketing focus which is expected to have a positive contribution to its revenue growth in the long term, even though in the near term revenue growth may lag behind
expense increase. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">From May 2009 to December 2010, AxoGen temporarily stopped the
manufacturing of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft due to adequate inventory. In December 2010, AxoGen resumed the
manufacturing of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, and as a result incurred higher processing and testing fees, travel costs
and temporary labor costs in 2011 compared to 2012. In 2011 AxoGen reviewed inventory expiration and wrote off inventory for products manufactured in early 2009. Additionally AxoGen reviewed and adjusted inventories and established reserves to
adequately reflect inventory value in 2011. AxoGen believes that such actions will not be required in the future and that it has the necessary inventories, inventory reserves and manufacturing capabilities for its anticipated sales growth.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Critical Accounting Policies and Estimates </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The discussion and analysis of the Company&#146;s financial condition and results of operations is based upon the Company&#146;s consolidated financial statements, which have been prepared in accordance
with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements, and reported amount of expenses during the period reported. Management bases its estimates and judgments on historical experience, observance of trends in the
industry, information provided by outside sources and on various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our significant accounting policies are described in Note 3 to the consolidated financial statements contained in F-7 of this
registration statement. We have identified the following policies as critical to our business operations and the understanding of our consolidated results of operations: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Accounts Receivable and Concentration of Credit Risk &#150; Doubtful Accounts </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. If deemed necessary we maintain an allowance for doubtful accounts for estimated losses inherent in our accounts
receivable portfolio. In establishing the required allowance, management considers customers&#146; financial condition, credit history and current economic conditions. To date, we have not reserved for doubtful accounts as they have been immaterial
both in number and dollar amount. Account balances are charged off after all means of collection have been exhausted and the potential for recovery is considered remote. Our internal financial operations have primary responsibility for billing and
collecting our accounts receivable. We utilize various processes and procedures in our collection efforts; these efforts include monthly statements, written collection notices and telephonic follow-ups. In the event the current conditions as to
doubtful accounts negatively changes, management will consider reserving for doubtful accounts. Management judgment as to identifying negative trends is important in its assumption of exposure to uncollectable receivables requiring a reserve and if
revenues expand as expected accounts receivable will rise potentially causing management to reevaluate its underlying assumptions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Goodwill </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill represents the excess of the purchase price over the net
tangible and intangible assets acquired in business combinations. The Company is required to perform a review for impairment of goodwill in accordance with FASB ASC 350, Intangibles &#151; Goodwill and Other. Goodwill is considered to be impaired if
it is determined that the carrying value of goodwill exceeds its fair value. The Company conducts an impairment test of goodwill each year end. In addition to the annual review, an interim review is required if an event occurs or circumstances
change that would more likely than not reduce the fair value of the goodwill below its carrying amount. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Effective Interest
Rate on Note Payable </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The PDL Royalty Contract is accounted for as long-term debt. The Company records interest using its
best estimate of the effective interest rate. This estimate takes into account both the internal rate of return (IRR) of the PDL agreement and the rate of return as the result of exercise of the Put option. The IRR of the PDL Royalty Contract is
based on the actual&nbsp;payments to date, projected future revenues and required minimum payments, and is calculated at 19.85%. The PDL Royalty Contract Put option provides PDL a 20% return, if exercised. As a result of the return of the Put option
being higher than the IRR of the PDL agreement, management believes the best estimate of the effective interest rate on this instrument would be the Put rate. As a result, the Company is accruing interest using the specified internal rate of return
for the Put which is 20%. We currently have no knowledge of PDL&#146;s intent to exercise the Put, but will monitor this on an ongoing basis. From time to time, the Company will reevaluate the expected cash flows and may adjust the effective
interest rate. Since inception of the Royalty Contract, if the interest rate utilized were to change by 1% the effect on interest expense through March&nbsp;31, 2013 would increase or decrease by approximately $110,000. Determining the effective
interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams and PDL&#146;s ultimate decision to exercise the Put. Determination of these assumptions is highly
subjective and different assumptions could lead to materially different outcomes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Income Taxes </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Deferred income taxes reflect the impact of temporary differences between the reported amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and
regulations. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. A valuation allowance is
provided for deferred tax assets when management concludes it is more-likely-than-not that some portion of the deferred tax assets will not be recognized. We have a full valuation allowance established on the deferred tax asset upon
management&#146;s best estimate of final outcomes based upon estimated future revenue and changes in business capitalization. Factors used to establish the valuation allowance are complicated and could cause variability in application over time.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Comparison of Three Months Ended March&nbsp;31, 2013 and 2012 and the Years Ended December&nbsp;31, 2012 and 2011 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Revenues </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues for the three months ended March&nbsp;31, 2013 increased
29.6% to approximately $2,143,000 as compared to approximately $1,653,000 for the three months ended March&nbsp;31, 2012. Additionally, revenues for the year ended December&nbsp;31, 2012 increased 59% to approximately $7,692,000 as compared to
approximately $4,849,000 for the year ended December&nbsp;31, 2011. Such increases were principally due to a greater number of customers utilizing AxoGen products and increased product usage by existing accounts. For the three months ended
March&nbsp;31, 2013, new AxoGen customers in that quarter represented approximately $149,000 of total revenue for such quarter or approximately 7%. For the year ended December&nbsp;31, 2012 new customers in 2012 represented approximately $859,000 of
total revenue in 2012 or approximately 11%. Each new customer in a defined period has the potential to become an established customer that increases its purchasing. As such, revenue growth occurs from both new customers who purchase for the first
time in a period and increased purchasing from established customers. Each new period of measurement is thus benefited from the additional new customers added in the prior period. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Gross Profit </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Gross profit for the three months ended March&nbsp;31, 2013 increased 30.4% to approximately $1,583,000 as compared to approximately $1,214,000 for the three months ended March&nbsp;31, 2012, primarily
attributable to the increased revenues in the first quarter of 2013, manufacturing efficiencies and a product price increase instituted in March 2013 which contributed approximately $30,000 or approximately 1.5%, partially offset by an increase in
the inventory reserve. Gross profit for the year ended December&nbsp;31, 2012 increased 136% to approximately $5,730,000 as compared to approximately $2,423,000 for the year ended December&nbsp;31, 2011. This increase was primarily attributable to
the increased revenues and gross margin in 2012 and not incurring inventory write-offs in the aggregate amount of $828,000 or higher processing and testing fees, travel costs and temporary labor costs due to the resumption of the manufacturing of
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft as experienced in 2011. The 2011 inventory write-offs consisted of two items. The first item
was approximately $614,000 for Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft finished goods inventory and the second was related to
$214,000 of raw materials related to the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, both of these items were deemed to be excess
inventory. During the third quarter of 2011 management made certain strategic decisions in response to market demand, and anticipated trends, that resulted in a portion of the finished goods and raw materials inventory to become excess. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Costs and Expenses </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Total cost and expenses increased 23.8% to approximately $3,906,000 for the three months ended March&nbsp;31, 2013 as compared to approximately $3,155,000 for the three months ended March&nbsp;31, 2012.
Total cost and expenses increased 44% to approximately $13,532,000 for the year ended December&nbsp;31, 2012 as compared to approximately $9,392,000 for the year ended December&nbsp;31, 2011. These increases in the first quarter 2013 and the 2012
fiscal year were primarily due to increasing sales and marketing activities and increases in salaries as AxoGen hired additional personnel to meet its current and expected growth. To a lesser extent, these increases were also attributable to
expenses associated with being a public company and research and development costs associated with the Company&#146;s preparation for its clinical trial. For the fiscal year 2012 these increases were partially offset by decreases in certain
professional services and financing costs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a percentage of revenues, total operating expenses were 182.3% for the three months ended
March&nbsp;31, 2013 compared to 190.9% for the three months ended March&nbsp;31, 2012. As a percentage of revenues, total operating expenses were 175.9% for the year ended December&nbsp;31, 2012 compared to 193.7% for the year ended
December&nbsp;31, 2011. Such lower total costs and expenses as a percentage of revenue in the first quarter 2013 and the 2012 fiscal year were primarily a result of the Company&#146;s revenue increase outpacing costs and expenses increase.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales and marketing expenses increased 16.3% to approximately $1,894,000 for the three months ended March&nbsp;31, 2013 as
compared to approximately $1,629,000 for the three months ended March&nbsp;31, 2012. Sales and marketing expenses increased 57.2% to approximately $6,884,000 for the year ended December&nbsp;31, 2012 as compared to approximately $4,379,000 for the
year ended December&nbsp;31, 2011. The increases in the first quarter 2013 and the 2012 fiscal year were primarily due to an increase in sales and marketing activity as the Company expands support for both its direct sales force and independent
distributors and in fiscal year 2012 increasing the number of its direct sales representatives. As a percentage of revenues, sales and marketing expenses were 88.4% for the three months ended March&nbsp;31, 2013 compared to 98.5% for the three
months ended March&nbsp;31, 2012. As a percentage of revenues, sales and marketing expenses were 89.4% for the year ended December&nbsp;31, 2012 compared to 90.3% for the year ended December&nbsp;31, 2011. Such lower sales and marketing expenses as
a percentage of revenue were a result of the revenue increases outpacing costs and expenses increases. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and
administrative expenses increased 30.5% to approximately $1,606,000 for the three months ended March&nbsp;31, 2013 as compared to approximately $1,231,000 for the three months ended March&nbsp;31, 2012. General and administrative expenses increased
21.0% to approximately $5,221,000 for the year ended December&nbsp;31, 2012 as compared to approximately $4,316,000 for the year ended December&nbsp;31, 2011. As a percentage of revenues, general and administrative expenses were 74.9% for the three
months ended March&nbsp;31, 2013 compared to 74.5% for the three months ended March&nbsp;31, 2012. As a percentage of revenues, general and administrative expenses were 67.9% for the year ended December&nbsp;31, 2012 compared to 89.0% for the year
ended December&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The increase in aggregate dollars spent in the first quarter 2013 and the 2012 fiscal year were
a result of increased payroll and benefits, public company related expenditures, travel and other general expenses. As a percentage of revenue, general and administrative expenses decreased in the 2012 fiscal year as the increase in aggregate
dollars spent were absorbed by the increase in revenues. In the first quarter 2013 as a percentage of revenue, general and administrative expenses were slighter higher as the percentage increase rise in revenue was similar to the percentage increase
rise in general and administrative expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses increased 37.5% to approximately $407,000 in
the three months ended March&nbsp;31, 2013 as compared to approximately $296,000 for the three months ended March&nbsp;31, 2012. Research and development expenses increased 104.7% to approximately $1,427,000 in the year ended December&nbsp;31, 2012
as compared to approximately $697,000 for the year ended December&nbsp;31, 2011. Development includes AxoGen&#146;s clinical efforts and a large portion of the increase in the first quarter 2013 and the 2012 fiscal year in research and development
expenses over the comparable periods related to expenditures for such clinical activity. Because AxoGen&#146;s products are developed for sale in their current use, it conducts limited direct research and product development, but intends to pursue
new products and new applications for existing products in the future that may result in increased spending. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Other Income
and Expenses </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense increased 754% to approximately $1,068,000 in the three months ended March&nbsp;31, 2013 as
compared to approximately $125,000 for the three months ended March&nbsp;31, 2012. This increase was a result of the interest expense related to the PDL transaction. As a result of the accounting treatment for the PDL transaction, interest expense
included approximately $895,000 of non-cash expense that is expected to be paid in the future based upon the terms of the PDL transaction and increases in AxoGen revenues. The $895,000 of non cash expense was derived from taking the total amount of
imputed interest for the quarter on the PDL agreement less the actual cash payment made to PDL in the quarter. Other than the $895,000 non-cash expense, the remaining $173,000 in interest expense for the three months ended March&nbsp;31, 2013 is
related to cash paid for interest on the note payable. The $125,000 interest expense for the three months ended March&nbsp;31, 2012 was cash paid for interest on the previous debt. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense increased 27% to approximately $1,391,000 for the year ended
December&nbsp;31, 2012 as compared to approximately $1,095,000 for the year ended December&nbsp;31, 2011. This increase was a result of the interest expense related to the PDL transaction. As a result of the accounting treatment for the PDL
transaction, interest expense included approximately $780,000 of non-cash expense that is expected to be paid in the future based upon the terms of the PDL transaction and increases in AxoGen revenues. The $780,000 of non cash expense was derived
from taking the total amount of imputed interest for the year ended December&nbsp;31, 2012 on the PDL agreement less the actual cash payment made to PDL for that period. Excluding this non-cash component, cash paid for interest decreased in 2012 by
approximately $381,000 compared to 2011 as a result of accrued interest on convertible debt and an increased interest rate on borrowed money in 2011 not recurring in 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Interest expense&#151;deferred financing costs increased 25.7% to approximately $44,000 for the three months ended March&nbsp;31, 2013 as compared to approximately $35,000 for the three months ended
March&nbsp;31, 2012. This increase is primarily due to higher deferred financing cost amortization associated with the PDL agreement when compared to the previous bank debt. Interest expense&#151;deferred financing costs decreased 19.3% to
approximately $987,000 for the year ended December&nbsp;31, 2012 as compared to approximately $1,223,000 for the year ended December&nbsp;31, 2011. This decrease is primarily due to certain deferred financing costs associated with warrants issued as
consideration for several amendments executed during 2010 related to the Loan and Security agreement originally entered into in April 2008 becoming fully amortized by March&nbsp;31, 2011. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Income Taxes </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company had no income tax expenses or income tax benefit for each of the three months ended March&nbsp;31, 2013 and 2012 due to incurrence of net operating loss in each of these periods. Income tax
benefit of approximately $738,000 for the year ended December&nbsp;31, 2012 was the result of the Company&#146;s ability to utilize net operating losses and franchise tax adjustments which resulted in tax refunds. The company had no income tax
expense or income tax benefit for 2011 due to incurrence of net operating losses. The Company does not believe there are any additional tax refund opportunities currently available. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>Effect of Inflation </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inflation has not had a significant impact on
the Company&#146;s operations or cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Long-Term Debt / Note Payable </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, AxoGen entered into the Royalty Contract with PDL. Proceeds from the PDL transaction were used to fully repay the MidCap Loan, as defined below, and extinguish AxoGen&#146;s
long-term debt obligations thereunder. The Royalty Contract has a term of eight years. Under the Royalty Contract, PDL is to receive royalty payments currently paid weekly based on a 9.95% royalty rate of certain of the Company&#146;s Net Revenues
(the &#147;Assigned Interests&#148;), subject to certain guaranteed quarterly payment amounts of approximately $1.3 to $2.5 million per quarter that commence in the quarter ending December&nbsp;31, 2014. The minimum annual payment amounts are as
follows: 2014 - $1,250,805, 2015 - $6,781,440, 2016 - $9,232,642, 2017 and 2018 - $9,000,000, 2019 - $9,063,000 and 2020 - $6,939,000. The royalty payment is based on only that portion of Company Net Revenue that is generated by the sale,
distribution or other use of the Company&#146;s products Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector (the &#147;Acquired Revenues&#148;), which at this time represents all of the Company&#146;s Net Revenue with the exception of shipping and handling
fees which represent less than 2.3% of total revenues. Future revenue, if any, from other products or services will not be subject to the PDL royalty payment. Further, on October&nbsp;5, 2016, or in the event of the occurrence of a material adverse
event, our transfer of revenue interest or substantially all of our interest in the products or AxoGen&#146;s bankruptcy or material breach of the Royalty Contract, PDL may require AxoGen to repurchase the Assigned Interests at the Put Price. The
Put Price is equal to the sum of (i)&nbsp;an amount that, when paid to PDL, would generate a 20% internal rate of return to PDL on the Funded Amount, taking into consideration payments made to PDL by AxoGen, and (ii)&nbsp;any Delinquent Assigned
Interests Payment AxoGen owed to PDL. Although we have no knowledge of PDL&#146;s intent to exercise the Put, based on actual payments to date, projected future revenues and the required minimum payments, we currently believe the Put Rate is the
best estimate of the effective interest rate of the Royalty Contract. Finally, in the event of a Change of Control, AxoGen must repurchase the Assigned Interests from PDL for a repurchase price equal to the Change of Control Price on or prior to the
third business day after the occurrence of the Change of Control. The Change of Control Price is the sum of (i)&nbsp;an amount that, when paid to PDL, would generate an internal rate of return to PDL of thirty-two and one half percent
(32.5%)&nbsp;on all payments made by PDL pursuant to the Royalty Contract as of the date </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the Change of Control Payment, taking into account the amount and timing of all payments made by AxoGen to PDL (and retained by PDL) prior to and as of the date of payment of the Change of
Control Payment, plus (ii)&nbsp;any Delinquent Assigned Interests Payment owed. The total consideration PDL paid to the Company was $20,800,000 (the &#147;Funded Amount&#148;), including $19,050,000 PDL paid to the Company on October&nbsp;5, 2012,
and $1,750,000 PDL paid to the Company on August&nbsp;14, 2012 pursuant to the Interim Royalty Contract. Upon the closing of PDL&#146;s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty
Contract, the Interim Royalty Contract was terminated. There are no financial covenants or other restrictions on the use of capital by AxoGen as a result of the Royalty Contract, however, PDL has a first perfected security interest in the Assigned
Interests. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, the Company, entered into the Loan and Security Agreement with MidCap Financial SBIC,
LP (&#147;MidCap&#148;), as administrative agent, and the Lenders listed on Schedule 1 thereto (the &#147;MidCap Loan&#148;). The MidCap Loan had a principal amount of $5.0 million and a term of 42 months, and was subject to prepayment penalties.
Under this agreement, AxoGen was required to make interest only payments for the first 12 months, and payments of both interest and straight line amortization of principal for the remaining 30 months. The interest rate was 9.9%&nbsp;per annum, and
interest was computed on the basis of a 360-day year and the actual number of days elapsed during which such interest accrues. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The MidCap Loan contained customary affirmative and negative covenants, including, without limitation, (i)&nbsp;covenants requiring
AxoGen to comply with applicable laws, provide to MidCap copies of AxoGen&#146;s financial statements, maintain appropriate levels of insurance and protect, defend and maintain the validity and enforceability of AxoGen&#146;s material intellectual
property, (ii)&nbsp;covenants restricting AxoGen&#146;s ability to dispose of all or any part of its assets (subject to certain exceptions), engage in other lines of business, changes in its senior management, enter into merger or consolidation
transactions, incur or assume additional indebtedness, or incur liens on its assets, and (iii)&nbsp;covenants requiring the Company to meet certain minimum Net Invoiced Revenue, as defined in the agreement, or maintain a cash balance of 80% of the
loan principal amount. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The MidCap Loan was secured by all of AxoGen&#146;s assets. The Lenders also received a ten-year
warrant to purchase 89,686 shares of AxoGen&#146;s common shares at $2.23 per share. Proceeds from the PDL transaction were used to fully repay the MidCap Loan, along with a $172,581 prepayment penalty, and extinguish AxoGen&#146;s obligations
thereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;21, 2008, AxoGen entered into a Loan and Security Agreement with Oxford Finance Corporation and
ATEL Ventures, Inc., as subsequently amended (the &#147;2008 Loan and Security Agreement&#148;), which provided for a loan with an aggregate principal amount of $7.5 million. The loan&#146;s maturity date was October&nbsp;1, 2011. The loan bore
interest at a rate of 18%&nbsp;per month and was secured by all of AxoGen&#146;s assets. On September&nbsp;30, 2011, AxoGen paid in full the entire outstanding balance of the 2008 Loan and Security Agreement, using the proceeds from the MidCap Loan.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;11, 2010, AxoGen entered into Convertible Debt Agreements for an aggregate principal amount of $3.7 million with
8% interest and principal and interest payable in full on June&nbsp;30, 2013, as amended. The Convertible Debt Agreements were collateralized by a third lien on certain property and were subordinated to the 2008 Loan and Security Agreement.
Immediately prior to the closing of the Merger, the Convertible Debt Agreements pursuant to their terms automatically converted into AC common stock which was then exchanged for Company common shares pursuant to the terms of the Merger Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;3, 2011, AxoGen issued an 8% Convertible Note Payable to LecTec Corporation for $500,000. On May&nbsp;31, 2011,
AxoGen issued additional convertible notes payable under the same terms of which $2,000,000 was issued to LecTec and $500,000 was issued to certain AC shareholders. On August&nbsp;29, 2011, AxoGen issued an additional subordinated secured
convertible promissory note in the principal amount of $2,000,000 to LecTec and $500,000 to certain AC shareholders. These notes were collateralized by all of AxoGen&#146;s assets and subordinated to the 2008 Loan and Security Agreement. Immediately
prior to the closing of the Merger, the notes held by investors other than LecTec automatically converted into AC&#146;s common stock which was then exchanged for LecTec common stock pursuant to the terms of the Merger Agreement. Immediately after
to the closing of the Merger, the notes held by LecTec were retired. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company had no material commitments for capital
expenditures at March&nbsp;31, 2013 or December&nbsp;31, 2012 or 2011. Under the Royalty Contract, the Company sold to PDL the Acquired Revenues and PDL is to receive for eight years the Assigned Interests, i.e., a royalty payment based on a 9.95%
royalty rate of the Company&#146;s Net Revenues, subject to certain agreed upon minimum payments of approximately $1.3 to $2.5 million per quarter, and was provided the Put and receives certain payments in the event of a
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Change of Control. The total consideration PDL paid to the Company was $20,800,000, including $19,050,000 PDL paid to the Company on October&nbsp;5, 2012, and $1,750,000 PDL paid to the Company
on August&nbsp;14, 2012, pursuant to the Interim Royalty Contract. Upon the closing of PDL&#146;s purchase of the specified royalties under the Royalty contract, which was concurrent with its execution, the Interim Royalty Contract was terminated.
Proceeds from the PDL Royalty Contract transaction where used to fully repay the MidCap Loan and extinguish AxoGen&#146;s obligations thereunder. There are no financial covenants or other restrictions on the use of capital by AxoGen as a result of
the Royalty Contract, however, PDL has a first perfected security interest in the Assigned Interests. In the event that the Company is unable to generate revenue in excess of its PDL Assigned Interests payments and other expenses, or PDL were to
exercise the Put at a time when the Company did not have sufficient capital to pay the Put Price, AxoGen would need to raise additional capital. There is no assurance that if AxoGen is required to secure funding it can do so on terms acceptable to
it, or at all, and its liquidity would be severely compromised. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Cash Flow Information </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen had working capital of approximately $14.5 million and a current ratio of 11.23 at March&nbsp;31, 2013, compared to working capital
of $16.8 million and a current ratio of 12.4 at December&nbsp;31, 2012. The decrease in working capital and the current ratio at March&nbsp;31, 2013 as compared to December&nbsp;31, 2012 was primarily due to the use of working capital for operations
in excess of revenues. The Company believes it has sufficient cash resources to meet its liquidity requirements for the next 12 months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s future capital requirements depend on a number of factors, including, without limitation, revenue increases consistent with its business plan, and the corresponding royalty payments of
approximately $1.3 to $2.5 million per quarter due to PDL and pursuant to AxoGen&#146;s licensing agreements in connection with Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, cost of products and acquisition and/or development of new products. In particular, if revenue does not increase by fourth quarter 2014 to a level
whereby the 9.95% royalty owed to PDL on AxoGen&#146;s gross revenues exceeds the PDL minimum royalty payments at such time of approximately $1.3 million, and such differential continues, or grows larger as the PDL minimum royalty payments increase,
AxoGen would face increasing capital needs. Such capital needs could be substantial depending on the extent to which AxoGen is unable to increase revenue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a result of AxoGen&#146;s continuing capital needs and other factors, it has decided to raise additional funds through this registration statement. The sale of additional equity may result in dilution
to AxoGen&#146;s shareholders. There is no assurance that AxoGen will be able to secure funding on terms acceptable to it, or at all. The increasing need for capital as the PDL transaction matures could also make it more difficult to obtain funding
through either equity or debt. Should additional capital not become available to AxoGen as needed, AxoGen may be required to take certain action, such as, slowing sales and marketing expansion, delaying regulatory approvals or reducing headcount.
During the three months ended March&nbsp;31, 2013, the Company had a net decrease in cash and cash equivalents of approximately $2,707,000 as compared to a net decrease of cash and cash equivalents of approximately $2,549,000 in the three months
ended March&nbsp;31, 2012. The Company&#146;s principal sources and uses of funds are explained below: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash used in operating
activities </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company used approximately $2,651,000 of cash for operating activities in the three months ended March&nbsp;31,
2013, as compared to using approximately $2,478,000 of cash for operating activities in the three months ended March&nbsp;31, 2012. This increase in cash used in operating activities is primarily attributed to the net loss generated in the three
months ended March&nbsp;31, 2013, along with an increase in our accounts receivable and inventory. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash used for investing
activities </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing activities for the three months ended March&nbsp;31, 2013 used approximately $57,000 of cash as compared
to using approximately $71,000 of cash in the three months ended March&nbsp;31, 2012. This increase in use is principally attributable to the purchase of certain fixed and intangible assets. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash provided by financing activities </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Financing activities in the three months ended March&nbsp;31, 2013 provided $1,654 of cash as compared to providing $0 of cash in the three months ended March&nbsp;31, 2012. The Company did not incur any
debt issuance costs in 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Off-Balance Sheet Arrangements </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen does not have any off-balance sheet arrangements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_100"></A>BUSINESS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a
leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can
result in the loss of muscle function and/or feeling. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nerves can be damaged in a number of ways. When a nerve is cut due to a
traumatic injury or surgery, functionality of the nerve may be compromised, causing the nerve to no longer carry the signals to and from the brain to the muscles and skin. This type of injury generally requires a surgical repair. The traditional
gold standard has been to either suture the nerve ends together directly without tension or to bridge the gap between the nerve ends with a less important nerve surgically removed from elsewhere in the patient&#146;s own body referred to as nerve
autograft. In addition, pressure on a nerve or blunt force trauma can cause nerve injuries that may require surgical intervention. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In order to improve the options available for the surgical repair and regeneration of peripheral nerves, we have developed and licensed patented and patent pending technologies. Our innovative approach to
regenerative medicine has resulted in first-in-class products that we believe will define their product categories. Our products offer a full suite of surgical nerve repair solutions including
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, the only off-the-shelf commercially available processed nerve allograft, human nerve tissue
obtained from a donor, for bridging severed nerves without the comorbidities of an autograft second surgical site, such as loss of feeling where the nerve was removed and potential pain at the donor site. Our AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> line of products are a natural scaffold ExtraCellular Matrix or ECM derived from pig tissue. AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is used to facilitate the tensionless repair of severed nerves, and AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector is used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while
preventing soft tissue attachments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s products are used by surgeons during surgical
interventions to repair a wide variety of traumatic nerve injuries ranging from a simple laceration of a finger to complex brachial plexus (an injury to the network of nerves that originate in the neck). The Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft provides surgeons with a three-dimensional structure of a natural nerve. This structure is essential and
allows for bridging nerve gaps or discontinuities the range of 5mm to 70mm. Additionally, the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Graft has product and sales synergies with the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector and AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products provide the unique features of pliability, suturability, and translucence for visualization of the underlying nerve, while also allowing the patient&#146;s
own cells to incorporate into the extracellular matrix to remodel and form a tissue similar to the outermost layer of the nerve (nerve epineurium). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Regenerative Medical Products Industry </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regenerative medical products
enable the repair, restoration, replacement or regeneration of tissue or organ systems of the body. Regenerative medical products are becoming common in various medical arenas because they have been shown to be effective repairing injured or
defective tissues, such as bone, tendons, dermis and other tissues of the body. Surgeons utilize regenerative medical products because they can provide the complex structure required for implant integration and regeneration in the body. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe the primary driver of sustained growth in the regenerative medical product market is continued favorable
efficacy as compared to autograft and synthetic medical products, and a wider understanding of this advantage by practitioners. Repair with nerve autograft requires a secondary recovery procedure to remove tissue from another location of the body to
repair the injured area and can result in loss of function at the site of donation. Nerve autograft may also be costly and time consuming and may result in complications such as infection. In addition to nerve allograft (Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft), alternatives to nerve autograft include hollow-tube synthetic or collagen-based medical products that
are designed to provide some restoration of function but may </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
be limited by biocompatibility with the body or manufacturing technologies and capabilities. Regenerative medical products often provide more desirable conditions for reconstruction and
regeneration of tissue, creating a superior solution for patients and physicians. AxoGen follows this trend, providing regenerative medical products for peripheral nerve reconstruction. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regenerative medicine products typically consist of and rely on: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">i.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">A scaffold or ECM to support the cells and/or provide the architecture of the tissue: and/or </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cells to regenerate or recellularize the scaffold. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s products are scaffolds, and the patients&#146; own body provides the cells to regenerate or recellularize these scaffolds. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Peripheral Nerves and Their Regeneration </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The peripheral nervous system, or PNS, consists of nerves that either extend outside of, or reside outside of, the central nervous system (the brain and spinal cord). Peripheral nerves provide the pathway
for signals between the central nervous system and target organs, regulating movement (motor nerves) and touch (sensory nerves). Therefore, if a peripheral nerve is crushed, severed, or otherwise damaged, its ability to deliver signals to the target
organs is eliminated, or significantly reduced, and could result in a loss of sensation and/or functionality. The axon portion of the nerve cell, consisting of cell cytoplasm and resembling a hair-like fiber, carries signals from the cell body to
the target organ. Axons can be quite long, even exceeding one meter, but are only a few micrometers in diameter. A typical nerve consists of hundreds of axons that lie within long, thin tubes (basal lamina tubes). Analogous to a fiber-optic cable,
these basal lamina tubes are bundled together in groups called fascicles, and each nerve may contain numerous fascicles. This sheath structure provides protection for the axons and support for regeneration in the event of injury. Nerve injury occurs
when a sufficient number of axons have been crushed or transected (severed), thereby disrupting signals to the target motor or sensory organ. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Given the right conditions, peripheral nerves have the ability to regenerate. Regenerating axons require the proper environmental conditions including; structure and guidance of axons in a tension and
compression free environment. In an untreated severe crush injury or transected nerve, errant axons that are not guided by the nerve sheath structure, or other mechanism, can form painful and ineffective nerve proliferation (neuromas). This can then
require revision surgery to relieve pain or bring back sensory and/or motor functionality. Therefore, the surgical treatment of nerve injuries is typically focused on restoring nerve functionality by providing structural guidance to regenerating
axons while alleviating compression and tension on the nerve. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Peripheral Nerve Regeneration Market Overview
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Everyday patients suffer traumatic wounds to peripheral nerves severe enough to require surgical treatment, including
injuries from motor vehicle accidents, collisions, gun wounds, dislocations, fractures, lacerations, or other forms of penetrating trauma. Specifically, military service men and women may suffer severe wounds from explosions and other
military-related injuries. The peripheral nerves commonly injured from these traumas include the digital, median, ulnar, radial, facial, spinal accessory and brachial plexus nerves. Based upon epidemiological studies regarding the number of trauma
patients and incidence of peripheral nerve injury in the population, each year in the U.S. more than 1.4&nbsp;million people suffer traumatic injuries to peripheral nerves resulting in at least 700,000 nerve repair procedures in the U.S. annually.
(&#147;Health&#148;, United States, 2011, Publication of U.S. Department of Health&nbsp;&amp; Human Services; Noble, et al. J of Trauma Injury Infection and Critical Care 1998). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beyond traumatic injury to nerves, nerve damage also occurs due to surgical intervention.
Some of these nerve cases occur after dental or oral surgery when patients lose sensory and taste function in the mouth, including complications from third molar extractions and dental implants. Also, nerves that support erectile function may be
injured or removed following a surgical prostatectomy to remove prostate cancer. Further, breast cancer patients may have reduced sensation in the tissue used to reconstruct the breast after mastectomy. Finally, nerves are also damaged or
compromised due to repetitive stress or compression injuries. For instance, severe and recurrent carpal tunnel cases may result in complications and damage to the nerve that requires further surgical intervention and protection of the nerve.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peripheral nerve injury is a major source of disability impairing the ability to move muscles or to feel normal sensations.
Failure to treat nerve damage can in severe cases lead to full loss of function and sometimes amputation. Many peripheral nerve injury patients who receive treatment do not optimally recover. They may suffer from both reduced, or no, muscle strength
and reduced, or no, sensitivity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the cases where a nerve is severed, if the gap between the two ends of the nerve is
extremely small, the surgeon can reconnect the nerve without tension through direct suturing. Because a tension-free repair is important, when the gap is more than a few millimeters in length, the surgeon typically needs to bridge the gap between
the nerve ends. Historically, to repair a severed nerve gap, surgeons have relied on an autotransplantation (autologous grafting or autograft). In autograft procedures, surgeons remove nerve from another part of the patient&#146;s body, frequently
from the back of the lower leg, to repair the damaged nerve. Autografting is often effective in repairing a damaged peripheral nerve, but it presents a tradeoff &#150; the surgeon can attempt to fix the damaged nerve but must create an additional
nerve deficit. For example, a patient may opt to get movement and feeling back in their finger while losing some sensation in their foot. Additionally, the secondary surgery to obtain the needed autograft also increases operating time, and thus
medical expenses, and increases the risk of surgical infection and other complications. In the case of extreme trauma where multiple nerves need to be repaired, it may not be possible to recover enough nerve from the patient to complete the repair.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Drawbacks of repair with autograft eventually led to the development of hollow-tube conduits, or hollow-tube nerve cuffs, for
peripheral nerve repair made of, for instance, bovine collagen or polyglycolic acid. The nerve cuff is typically an absorbable hollow tube that, unlike natural nerve, does not have basal lamina tubes to support regenerating axons; as a result, it is
deficient in the qualities that natural nerve possesses to support nerve regeneration. Hollow-tube conduits may also lack pliability and structural integrity needed when used around joints and may be difficult to use in a confined space.
Additionally, hollow-tube conduits do not provide familiar handling characteristics to the surgeon and in some instances are contraindicated for use in infected wound beds. Clinical data has demonstrated that conduits are most effective only when
used in very short gaps and the reliability of successful nerve recovery diminishes as gap length increases. However, we believe with surgeons seeking alternatives to autografts, the annual number of procedures using hollow-tube conduits has grown.
AxoGen believes this demand has resulted in hollow-tube conduits being used for gap lengths where their likelihood of effectiveness is greatly diminished. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The growth of hollow-tube conduit use demonstrates there is market demand for products that do not have the drawbacks of autografting. However, as stated above, the shortcomings of conduits limit where
they may be used effectively. Thus, the nerve repair market needs an alternative off-the-shelf product that provides the natural ECM scaffold and three-dimensional structure of a typical nerve for bridging nerve discontinuities without the
comorbidities of a second surgical site of an autograft. AxoGen believes its product portfolio meets this market need. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AxoGen&#146;s Product Portfolio </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview of AxoGen&#146;s Products </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s proprietary products and technologies are designed to overcome fundamental challenges in nerve repair. AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is an alternative to autografts for nerve gaps up to 70mm in length. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is the surgical solution for nerve gaps of less than 5mm in length. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector completes the product portfolio by allowing a protective wrap in cases of nerves damaged by compression, or where the surgeon wants to protect and
isolate the nerve during the healing process after surgery. This product portfolio, depicted below, provides surgeons off-the-shelf solutions for a wide variety of peripheral nerve injuries. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table provides a summary of certain peripheral nerve injuries for which AxoGen products are used: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g532389g54c00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across
the defect (a gap created when the nerve is severed). It is intended to act as a bridge in order to guide and structurally support axonal regeneration across a nerve gap caused by traumatic injury or surgical intervention. Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is decellularized and sterile extracellular matrix (ECM) processed from human peripheral nerve tissue.
AxoGen developed the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft by following the guiding principle that the human body created the
optimal nerve structure. AxoGen, through its licensing efforts and research, developed the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Process, a
proprietary method for processing recovered human peripheral nerve tissue in a manner that preserves the essential structure of the ECM while cleansing away cellular and noncellular debris. Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft provides the natural nerve structure of an autograft and the ease and availability of an off-the-shelf product. AxoGen believes that Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is the first and only off-the-shelf commercially available allograft nerve for bridging nerve
discontinuities. The Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is comprised of bundles of small diameter endoneurial tubes that are
held together by an outer sheath called the epineurium. Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft has
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
been processed to remove cellular and noncellular factors such as cells, fat, blood, axonal debris and chondroitin sulfate proteoglycans, (&#147;CSPG&#148;), while preserving the
three-dimensional scaffold, basal lamina tubular structure, epineurium and microvasculature of the peripheral nerve. After processing, Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is flexible and pliable, and its epineurium can be sutured in place allowing for tension-free approximation of the proximal and distal peripheral nerve
stumps. The design results in a product that has clean and clear pathways for the regenerating axons to grow through. During the healing process, the body revascularizes and gradually remodels the graft into the patient&#146;s own tissue while
allowing the processed nerve allograft to physically support axonal regeneration across the nerve discontinuity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">With lengths up to 70 mm and diameters up to 5 mm, the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Graft allows surgeons to choose the correct length for the relevant nerve gap for repairs up to 70 mm, as well as to match the diameter to the proximal and distal end of the severed nerve. The Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is stored frozen and utilizes packaging that maintains the graft in a sterile condition. The packaging
is typical for medical products so the surgical staff is familiar with opening the package for transfer of the
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft into the sterile surgical field. Such packaging also provides protection during shipment and
storage and a reservoir for the addition of sterile fluid to aid in thawing the product. The Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft
thaws in less than 10 minutes, and once thawed, it is ready for implantation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft provides the following key advantages: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provides a three-dimensional bioscaffold for bridging a nerve gap; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">No patient donor-nerve surgery, therefore no comorbidities associated with a secondary surgical site; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Available in a variety of diameters, 1-2 mm to 4-5mm, to meet a range of anatomical needs </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Available in a variety of lengths, 15mm to 70mm, to meet a range of gap lengths, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decellularized and cleansed extracellular matrix that remodels into patient&#146;s own tissue; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Structurally supports the body&#146;s own regeneration process; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Handles similar to an autograft, and is flexible and pliable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alleviates tension at the repair site; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Three year shelf life; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supplied sterile. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is an ECM for tensionless repair of severed nerves. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is a tubular, multilaminar extracellular matrix with an open lumen where the severed nerve ends are placed. Typically, the AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is used to align and connect nerves with less than a 5mm gap between the severed nerve ends. The
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector material allows the body&#146;s natural healing process to repair the nerve by
isolating and protecting it during the healing process. The patient&#146;s own cells incorporate into the extracellular matrix product to remodel and form a tissue similar to the outermost layer of the nerve (nerve epineurium). AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector is provided sterile, for single use only, and in a variety of sizes to meet the surgeon&#146;s
needs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector can be used to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bridge gaps up to 5 mm; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aid coaptation in direct repair, grafting, or cable grafting repairs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reinforce the coaptation site. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector has the following advantages: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Only porcine submucosa extra-cellular matrix product to bridge gaps up to 5 mm; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alleviates tension at the repair site; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reduces the number of required sutures (versus direct repair); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Moves location of sutures away from the coaptation face; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reduces potential for fascicular mismatch; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Allows visualization of underlying nerve; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Strong and flexible, easy to suture; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stored at room temperature with an 18 month shelf life. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector is a product used to wrap and protect injured peripheral nerves and reinforce reconstructed nerve gaps while preventing soft tissue attachments. It is
designed to protect and isolate the nerve during the healing process after surgery. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is a multilaminar
extracellular matrix that separates and protects the nerve from the surrounding tissues. The patient&#146;s own cells incorporate into the extracellular matrix to remodel and form a tissue similar to the nerve epineurium. AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector is provided sterile, for single use only, and in a variety of sizes to meet the surgeon&#146;s
needs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector can be used to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wrap injured nerves; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Minimize risk of entrapment in compressed nerves; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect partially severed nerves; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect nerves in a traumatized wound bed; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reinforce a coaptation site. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector has the following advantages: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Only porcine submucosa bio scaffold used to reinforce a coaptation site, wrap a partially severed nerve or protect nerve tissue;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Isolates and protects the nerve in a traumatized wound bed; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Easily conforms and wraps the injured nerve; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Minimizes the potential for soft tissue attachments and nerve entrapment by physically isolating the nerve during the healing process;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Allows nerve gliding; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Strong and flexible, plus easy to suture; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stored at room temperature with an 18 month shelf life. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tissue Recovery and Processing for Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Processing Overview </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Over several years, AxoGen has developed the Avance<B><I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></I></B> Process, an advanced and proprietary technique to process the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft from donated peripheral nerve tissue. The Avance<B><I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></I></B> Process requires special training over several months for each manufacturing associate who processes Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Grafts. The processing and manufacturing system for Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft has required significant capital investment, and AxoGen plans to make additional investments to continually improve its manufacturing and quality
assurance processes and systems. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Process requires several steps, including peripheral nerve tissue recovery and testing, donor medical review and release, processing, packaging, and sterilization to
meet or exceed all applicable FDA, state, and international regulations and AATB standards. As an FDA registered tissue establishment, AxoGen utilizes both its own personnel and a variety of subcontractors for recovery, storage, testing, processing
and sterilization of the donated peripheral nerve tissue. Additionally, independent certified laboratories have been contracted by AxoGen and its subcontractors to perform testing. The safety of
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is supported by donor screening, process validation, process controls, and validated
terminal sterilization methods. The AxoGen Quality System has built in redundancies so that each Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Graft released for implantation meets AxoGen&#146;s stringent quality control and product requirements. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Tissue Recovery and Processing </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen partners with FDA registered tissue establishments and AATB accredited recovery agencies or recovery agencies in compliance with AATB standards to recover human peripheral nerve tissue for Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft processing. After consent for donation is obtained, donations are screened and tested in detail for
safety in compliance with the federal regulations and AATB standards on communicable disease transmission. AxoGen processes and packages Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft using its employees and equipment located at LifeNet Health, Virginia Beach, Virginia, an FDA registered tissue establishment, from the donated nerve
tissue. Under the agreement with LifeNet Health, AxoGen pays LifeNet Health a facility fee. Either party may terminate the agreement with six months&#146; written notice. The LifeNet Health facility provides a cost effective, quality controlled and
licensed facility, however, AxoGen could reproduce a manufacturing space that would meet its needs if it no longer continued its relationship with LifeNet. AxoGen&#146;s processing methods and process controls have been developed and validated to
ensure product uniformity and quality. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Packaging </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">After processing, each Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is visually inspected
and organized by size (length and diameter) into finished product codes. It is then packaged in individual medical grade clamshells and primary packaging. The outer pouch is the primary sterility and moisture barrier. The packaging operation is
performed in a controlled environment at LifeNet Health. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Sterilization and Labeling </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">After being processed and packaged, Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is then irradiated and returned to AxoGen&#146;s headquarters in Alachua, Florida. There, the product receives its final labels and is released following
a final stringent technical and quality review. Orders for Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft are placed with AxoGen&#146;s
customer care team and product is shipped from the distribution facilities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Product Release </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
AxoGen Quality System meets the requirements set forth under 21 CFR &#167; 1271 for Human Cells, Tissues and Cellular and Tissue-Based Products, including Good Tissue Practices (&#147;GTP&#148;) and is compliant with the 21 CFR &#167; 820 Quality
System Regulations (&#147;QSR&#148;). AxoGen has established quality procedures for review of tissue recovery, relevant donor medical record review and release to processing that meet or exceed FDA requirements as defined in 21 CFR &#167;1271, state
regulations, international regulations and AATB standards. Furthermore, AxoGen utilizes validated processes for the handling of raw material components, environmental control, processing, packaging and terminal sterilization. In addition to ongoing
monitoring activities for product conformity to specifications and sterility, product biocompatibility, shipping methods and shelf life have been validated in accordance with applicable industry standards. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Manufacturing for the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Product Line </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is manufactured by Cook Biotech, West Lafayette, Indiana, which was established in 1995 to develop and manufacture tissue grafts utilizing porcine extracellular
matrix technology. AxoGen decided to expand its portfolio of products and felt that the unique ECM material offered by Cook Biotech provided the combination of properties needed in nerve reconstruction. Cook Biotech&#146;s ECM material is pliable,
capable of being sutured, translucent and allows the patient&#146;s own cells to incorporate into the extracellular matrix to remodel and form a tissue similar to the nerve&#146;s epineurium. In August 2008, Cook Biotech entered into an agreement
with AxoGen to distribute its product worldwide in the field of the peripheral and central nervous system, but excluding use of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product in the oral cavity for endodontic and periodontal applications and oral and maxillofacial surgery solely as they relate to dental, soft or hard, tissue repair
or reconstruction, and the parties subsequently amended the agreement in March, 2012. The exclusion results in certain areas of AxoGen&#146;s market expansion into the oral surgery market being limited to the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">The agreement has an initial seven-year term from the date of the original agreement and following such initial term, the agreement automatically renews for an additional seven (7)&nbsp;year period
provided that the parties agree to meet at least ninety (90)&nbsp;days before the end of such initial term to review whether the purchase price of the products obtained from Cook Biotech need to be adjusted and reasonably agree to such adjustment in
writing, where such agreement shall not be unreasonably withheld. The Cook Biotech agreement also requires certain minimum purchases, although through mutual agreement the parties have not established such minimums and to date have not enforce such
provision, and establishes a formula for the transfer cost of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products. Under the agreement,
AxoGen provides purchase orders to Cook Biotech, and Cook Biotech fulfills the purchase orders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Sales and Marketing </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The AxoGen portfolio of nerve repair solutions offers a full range of products for all surgical peripheral nerve repair needs. AxoGen is
focused on the developing market of peripheral nerve repair and regeneration and is committed to improving awareness of new surgical peripheral nerve repair options, as well as building additional scientific and clinical data to assist surgeons and
patients in making informed choices. AxoGen believes this approach will solidify its position as a leader in the field of products for peripheral nerve injuries. The following provides the key elements of AxoGen&#146;s sales and marketing strategy.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Increase Awareness of AxoGen&#146;s Products </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to the introduction of AxoGen&#146;s portfolio of products, surgeons had a limited number of options available for the surgical
repair of nerve injuries. AxoGen entered the market to improve the standard of care for patients. It has brought the science of nerve repair to life by developing reconstruction options based on extracellular matrix tissue. Unlike other
off-the-shelf nerve reconstruction options, an extracellular matrix remodels into the patient&#146;s own tissue and provides physical support for the body&#146;s natural healing process. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen intends to increase market share by improving awareness of its products through the use of educational
conferences and presentations, surgical resident and fellow training, scientific publications, and a knowledgeable and professional sales team. AxoGen expects to increase usage with existing customers as well as expand the overall customer base.
Initially, AxoGen will focus on plastic reconstructive surgeons and orthopedic and plastic surgeons who perform surgeries on patients suffering traumatic nerve injuries and who perform hand reconstructive surgeries. In select hospital accounts and
in conformity with AxoGen&#146;s agreement with Cook Biotech restricting certain use of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Products,
AxoGen is also expanding into the market for the reconstruction of nerve injuries in oral surgery. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expand Clinical and
Scientific Data Regarding the Performance of AxoGen Products </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Data will be a mainstay of AxoGen&#146;s
marketing strategy. AxoGen will continue to accept patients in its RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> clinical study (defined below in
&#147;Government Regulations&#148;), a utilization registry of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. A multicenter prospective
randomized comparative pilot study of hollow tube conduits and Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft is in process. A case series
in digital nerve repair has already been published and other studies have been completed. Case series in brachial plexus, military trauma, prostate cancer, neurotization of breast reconstruction and compressive neuropathy are also being developed.
AxoGen also supports outside research and will continue to work with investigators working on grants with a translational focus. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Expand the AxoGen Sales Team for National Coverage </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen provides full
sales and distribution services through both a direct sales force and a team of independent distributors. AxoGen provides support and resources for independent distributors and is increasing its direct sales force in selected territories. AxoGen
provides products to hospitals, surgery centers and military hospitals, calling on plastic reconstructive surgeons and orthopedic and plastic hand surgeons to review the benefits of the AxoGen products. While surgeons make the decision to implant
the products in appropriate patients, hospitals make the decision to buy the products from AxoGen. In today&#146;s budget constrained environment, hospital committees review new technologies for cost effectiveness as well as quality. AxoGen believes
that it has been successful in meeting the needs of these hospital committees by demonstrating the cost/benefit of its products and providing a fair value to the hospital. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>AxoGen Strengths </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen believes that it has the following strengths in
the field of nerve reconstruction and regeneration: </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Established Surgical Nerve Repair and Regeneration Expertise</U>
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has made a significant investment in understanding surgical nerve repair and regeneration through interaction with
leading academic centers throughout the United States and by striving to build an outstanding internal team of technical and clinical experts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Surgical Implant Commercialization Experience</U> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The AxoGen commercialization team consists of sales, marketing, and customer service professionals with backgrounds
in the medical device and biotechnology industries. The commercial team has been instrumental in beginning to establish the
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft and the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line as a new standard of care for the surgical treatment of nerve injuries. AxoGen believes it can leverage these capabilities in expanding the commercial
success of the current AxoGen products and future product opportunities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Performance </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has worked with leading institutions, researchers and surgeons to support innovation in the field of surgical
peripheral nerve repair. To date, AxoGen&#146;s RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study (defined below in &#147;Government
Regulations&#148;) is the largest multi-center clinical study conducted in peripheral nerve gap repair. AxoGen&#146;s RECON study will also continue AxoGen&#146;s clinical work, providing a new multi-center, prospective, randomized, clinical study
on the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. The January, 2012 edition of Microsurgery and November 2012 edition of The Journal
of Hand Surgery each contain an article summarizing the RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study results. The publication reported on 55
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft nerve repairs and resulted in meaningful motor and sensory recovery in 87% of nerve
discontinuities between 5 and 50 mm. Additionally no implant related adverse events have been reported. (Brooks, D. N., Weber, R. V., Chao, J. D., Rinker, B. D., Zoldos, J., Robichaux, M. R., Ruggeri, S. B., Anderson, K. A., Bonatz, E. E., Wisotsky,
S. M., Cho, M. S., Wilson, C., Cooper, E. O., Ingari, J. V., Safa, B., Parrett, B. M. and Buncke, G. M. (2012), Processed nerve allografts for peripheral nerve reconstruction: A multicenter study of utilization and outcomes in sensory, mixed, and
motor nerve reconstructions. Microsurgery, 32: 1&#150;14. doi: 10.1002/micr.20975 and Cho, et al. 2012, J Hand Surg Am 37(11):2340-9). A meta-analysis of available clinical outcomes data from published papers on the leading synthetic collagen
conduit showed meaningful improvement in only 53% of cases bridging a gap in the nerve. A similar meta-analysis for nerve autograft reported meaningful improvement in 60-88% of nerve repairs. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>International Opportunity for Product Sales </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen currently focuses on the U.S. market, with additional limited foreign sales in the United Kingdom, the
Netherlands, Canada, Italy, Austria and Switzerland. The need for the surgical repair of injured nerves is a global issue. Through its foreign sales, AxoGen has shown the capability to take its current product offering into new geographical markets.
AxoGen does not currently have E.U.-wide approval for the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, but received its CE Mark for
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products in April 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Research and Development </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen believes it provides
the most extensive product portfolio for peripheral nerve repair available. Our current development focus is to expand clinical data in both traumatic nerve repair and other surgical applications. Additional product line extensions of the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products may be developed. AxoGen&#146;s current intention is to spend limited direct resources on extensive research into new unmet peripheral nerve needs. AxoGen
does, however, work with academic intuitions in the expansion of treatments for peripheral nerve. For the three months ended March&nbsp;31, 2013 and 2012 AxoGen spent approximately $406,000, and $296,000, respectively, and for the years ended
December&nbsp;31, 2012 and 2011, AxoGen spent $1,427,211, and $697,355, respectively, on research and development expenses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Competition
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The medical device and biotechnology industries are characterized by rapidly advancing technologies, intense competition
and a strong emphasis on proprietary products. As such, AxoGen cannot predict what products may be offered in the future that may compete with AxoGen&#146;s </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
products. Currently, AxoGen competes primarily against autograft and hollow-tube conduits based on product features and performance, price, surgical application, ease of use and healthcare
provider education. AxoGen&#146;s major competitors for off-the-shelf repair option in hollow-tube conduits are the following companies: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Integra LifeSciences Holding Corporation (NASDAQ: IART) (&#147;Integra&#148;). Integra offers
NeuraGen<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, a hollow bovine collagen conduit and NeuraWrapTM, a nerve repair conduit also made from bovine
collagen; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Baxter International, Inc. (NYSE: BAX) (&#147;Baxter&#148;). Baxter acquired Synovis that offered the Neurotube, which is a hollow conduit comprised of
polyglycolic acid; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stryker Corporation (NYSE: SYK), (&#147;Stryker&#148;). Stryker offers the NeuroMatrix and Neuroflex products, both of which are hollow conduits
derived from bovine collagen. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen believes that surgeons use Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft because, unlike hollow-tube conduits, it provides them with the natural three-dimensional structure of a
typical nerve for bridging nerve discontinuities (severed nerves) without the comorbidities of an autograft second surgical site. AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Connector provide the unique features of pliability, suturability, and translucence for visualization of the underlying nerve while also allowing the patient&#146;s own cells to incorporate into the extracellular matrix to remodel and form a
tissue similar to the outermost layer of the nerve (nerve epineurium). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen believes any current or
future competitors face the following important barriers to entry as it relates to the market for its products. AxoGen&#146;s intellectual property, and that of its partners, including patents and patents-pending, is believed to be an important
barrier. Additionally, AxoGen has developed knowledge and experience in understanding and meeting FDA regulatory requirements for Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, including having made a substantial investment in validating, testing for, and meeting and preparing a submission for FDA BLA requirements. However, due
to its limited resources, its smaller size and its relatively early stage, AxoGen believes it may face competitive challenges and barriers that are difficult to overcome and could negatively impact its growth. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intellectual Property </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen relies on a combination of patent, trademark, trade secret, and copyright, as well as other intellectual property laws, to protect IP rights. In addition, AxoGen utilizes license, non-disclosure,
and assignment agreements to protect these IP rights. Specifically, AxoGen requires vendors, contract organizations, consultants, advisors and employees to execute nondisclosure agreements. AxoGen also requires consultants, advisors and employees
who develop IP to assign to AxoGen any of their rights to all IP conceived in connection with their relationship with AxoGen. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>License Agreements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has entered into license agreements with the UFRF and UT. Under the terms of these license agreements, AxoGen has exclusive
worldwide licenses for the underlying technologies used by AxoGen in repairing and regenerating nerves. The license agreements include both the right to issued patents and patents pending in the U.S. and international markets. The effective term of
the license agreements extends through the term of the related patents. In the event of default, licensors may also terminate an agreement (after written notice) if AxoGen fails to cure a breach. The license agreements contain the following key
terms: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of annual license maintenance fees, some of which may be credited against future royalty payments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of royalty fees of 1%-3% based on net sales of the licensed products, the level depending on the agreement, which may include a minimum
quarterly royalty payment with discounts off royalty rates when royalty stacking applies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of a percentage of sublicense fees received; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reimbursement of certain legal expenses incurred for patent prosecution and defense; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other payments of various amounts based on achieving certain milestones. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently, AxoGen pays royalties to UFRF and UT specific to the licensed technologies related to the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Patents </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of the date of this registration statement, AxoGen owned
or was the exclusive licensee of five issued U.S. patents, three pending U.S. patent applications, one U.S. patent application for which a Notice of Allowance has been issued, six issued international patents and nine pending international patent
applications with regard to its peripheral nerve products. Additionally, the granted European Patent No. EP1425390 has been validated in France, Germany, Italy, Spain, Sweden, Switzerland, and the United Kingdom. The following table illustrates the
issued U.S. patents owned or licensed by AxoGen with regard to it peripheral nerve products, including the patent number, a description of each patent, and the estimated expiration date of each patent. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Patent No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated&nbsp;expiration&nbsp;date</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">US 6,972,168</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Materials and Methods for Nerve Grafting, Selection of Nerve Grafts, and in vitro Nerve Tissue Culture</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 13, 2021</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">US 7,402,319</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cell Free Tissue Replacement for Tissue Engineering</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;26,&nbsp;2023</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">US 7,732,200</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Materials and Methods for Nerve Grafting, Selection of Nerve Grafts, and in vitro Nerve Tissue Culture</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">December 21, 2022</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">US 6,696,575</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biodegradable, electrically conducting polymer for tissue engineering applications</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 27, 2021</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">US 7,851,447</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Materials and Methods for Nerve Repair</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;18,&nbsp;2023</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, AxoGen entered into an exclusive distribution agreement with Cook
Biotech in August 2008, as subsequently amended in March 2012, to distribute its ECM technology in the form of the
Surgisis<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Cuff, the form of a nerve wrap or patch, or the form of any other mutually-agreed-to
configuration in the field of peripheral nervous system and central nervous system use, but excluding use of the
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product in the oral cavity for endodontic and periodontal applications and oral and maxillofacial
surgery solely as they relate to dental, soft or hard, tissue repair or reconstruction. AxoGen has subsequently rebranded the Surgisis products under the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> name. Cook Biotech holds multiple issued and pending U.S. and international patents covering its ECM technology. The following table illustrates the two
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
non-licensed U.S. patents held by Cook Biotech that are specifically identified on AxoGen&#146;s AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Protector product labeling. The table includes the U.S. Patent number, a description of each patent, and the estimated expiration date of each patent. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>U.S. Patent No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated expiration date</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,206,931</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Graft Prosthesis Material</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 23, 2016</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,241,981</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Composition and Method for Repairing Neurological Tissue</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;16,&nbsp;2016</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of the length of time and expense associated with bringing new products through development and
the governmental approval process, medical technology companies have traditionally placed considerable importance on obtaining and maintaining patent protection for significant new technologies, products and processes. AxoGen intends to seek patent
protection for appropriate proprietary technologies by filing patent applications when possible in the U.S. and selected other jurisdictions. AxoGen&#146;s policy is to seek patent protection for the inventions that it considers important to the
development of its business. AxoGen also intends to use its scientific expertise to pursue and file patent applications on new developments with respect to uses, methods, and compositions to enhance its IP position in the areas that are important to
the development of its business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finally, AxoGen continues to hold IP, including patents, related to LecTec&#146;s original
hydrogel patch technology and hand sanitizer patch. AxoGen has not been able to monetize the IP regarding the hand sanitizer patch and issues regarding the enforceability of such IP has resulted in AxoGen determining that it has no future value.
AxoGen continues to take all action necessary to maintain relevant patents licensed to Novartis Consumer Health, Inc., however, Novartis has discontinued sale of products related to the license in certain countries and as such AxoGen has determined
that the value of the Novartis license has been impaired. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Trademarks, Trade Secrets, Copyrights and Domain Names
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has registered and filed numerous trademark applications with the U.S. Patent and Trademark Office and
appropriate offices in foreign countries in order to distinguish its products from competitors&#146; products. It possesses trade secrets and material know-how in the following general subject matters: nerve processing, nerve repair, product testing
methods, and pre-clinical and clinical expertise. AxoGen has registered copyrights for training tools and artistic renderings. It has entered into an agreement with an independent artistic creator, under which the artistic director retains copyright
rights to any copyrighted material under agreement with AxoGen and provides AxoGen a license to such copyrights. AxoGen has also registered approximately 50 domain names. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Government Regulations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.S. Government Regulation Overview
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s products are subject to regulation by the FDA, as well as other federal and state
regulatory bodies in the U.S. and comparable authorities in other countries. In addition, its Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Graft must comply with the standards of the tissue bank industry&#146;s accrediting organization, the American Association of Tissue Banks. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen distributes for Cook Biotech the AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line and Cook Biotech is responsible for the regulatory compliance of the AxoGuard product line. AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products are regulated as medical devices and subject to premarket notification classification requirements under
section 510(k) of the FD&amp;C Act that usually result in the marketing of devices, 21 CFR &#167; 820 (&#147;Quality System Regulation&#148;) and related laws and regulations. Cook Biotech has obtained a 510(k) premarket clearance from the FDA for
the use of porcine (pig) small intestine submucosa for the repair of peripheral nerve discontinuities where gap closure can be achieved by flexion of the extremity. We sell the 510(k)-cleared device under the trade name AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In 2007, AxoGen began to process and distribute its Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Graft pursuant to Section&nbsp;361 of the PHS Act and 21 CFR Part 1271 Human Cells, Tissues, and Cellular and Tissue Based Products controls. Such action was based on AxoGen&#146;s good faith belief that the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft product was a HCT/P tissue product regulated solely under Section&nbsp;361. From October 2008 through
early 2010, AxoGen was in communication with the FDA concerning the regulatory status of the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft
product. In April 2010, in response to a Request For Designation filed by AxoGen, the FDA determined that the
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft was a biologic product that would be reviewed and regulated by CBER under the biologics
licensing provision under section 351 of the PHS Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen met with CBER in July 2010 and, between
July 2010 and November 2010, provided information to CBER that resulted in the FDA issuing a letter stating the agency&#146;s intent to exercise enforcement discretion with respect to the introduction or delivery for introduction into interstate
commerce of the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft assuming that certain conditions are met relating to the transition of the
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft to regulation as a biological product under section 351 of the PHS Act. The conditions and
AxoGen&#146;s current status with respect to these conditions are: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen transitions to compliance with the Section&nbsp;501(a)(2)(B) of the FD&amp;C Act, the current GMP regulations in 21 CFR &#167; 210 and 211 and
the applicable regulations and standards in 21 CFR &#167; 600-610 prior to initiation of a phase 3 clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has performed several gap analyses of its quality system for compliance with 21 CFR &#167;210/211 and 600-610 regulations. The gap analyses
indicate that procedural changes are necessary to establish compliance with these regulations.&nbsp;The quality system procedures must be updated to establish compliance with 21 CFR &#167;&#167; 210/211 and 600-610 regulations. We must review the
regulations and update our quality procedures to create appropriate documentation systems, and train personnel on the procedural updates. Once procedures, training, and implementation are accomplished, we will, through internal auditing, verify
compliance with these regulations.&nbsp;After such verification, we will retain an external audit firm with experience in auditing to 21 CFR &#167;&#167; 210/211 and 600-610 regulations to verify quality system compliance to the
regulations.&nbsp;The associated costs for these activities are not material and the Company believes it can appropriately implement all necessary changes; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen conducts a phase 3 clinical trial to demonstrate safety, purity and potency of the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft under a SPA; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen and the FDA agreed to the SPA in August 2011 and in accordance with FDA regulations 21CFR &#167;312, AxoGen submitted an IND to the FDA and we
are currently responding to FDA comments regarding the IND. We expect enrollment of patients into the phase 3 clinical trial later this year; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen continues to comply with the regulations and standards for 21 CFR &#167; 1271 and exercises due diligence in executing the transition;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen was audited by the FDA in March 2013 and the quality system was found to be in compliance with 21 CFR &#167;1271. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen submitted an IND for the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft in April, 2013. AxoGen is working with the FDA to ensure compliance with the applicable regulations by
having continual discussions on the transition of the quality system to 21 CFR &#167;210/211 and 600-610 regulations with the FDA and being audited by the FDA for compliance to 21 CFR &#167;1271 regulations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA will end the period of enforcement discretion upon a final determination of AxoGen&#146;s BLA future
submission or if the FDA finds that AxoGen does not meet the conditions for the transition plan. Until final FDA action on the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft submission, and assuming AxoGen&#146;s compliance with the provisions in the transition plan, AxoGen will be able to continue to distribute the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. If final action on the BLA is negative or AxoGen is found to not meet the conditions for the transition
plan, AxoGen will not be able to continue to distribute the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The BLA application of the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, if approved, will require a potentially substantial user fee payment to the FDA, although certain exemptions, waivers and discounts of the user fees may
apply, including certain waivers or discounts for small businesses. AxoGen has continued to communicate with CBER since the acceptance of the transition plan on clinical trial design and CMC and continues to move with diligence toward the completion
of the BLA. A SPA has been submitted, reviewed and approved by CBER. In compliance with the transition plan established by the FDA, AxoGen is able to continue to distribute the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Food and Drug
Administration Safety and Innovation Act, referred to herein as FDASIA (Public Law 112-144), which was signed into law on July&nbsp;9, 2012, amended the Federal Food, Drug, and Cosmetic Act. FDASIA includes the Prescription Drug User Fee Amendments
of 2012 which authorizes the FDA to continue to collect the following user fees from applicants who submit certain new drug and biological product applications and supplements: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Application Fee: Each new BLA has a fee required upon submission. In FY 2013, this fee for a BLA requiring clinical data is $1,958,800. The fee is
adjusted each year so we cannot provide an accurate estimate of what our fee will be upon submission of our BLA. For small companies (fewer than 500 employees and no other approved biologic product on the market) submitting its first application, a
waiver of the application fee is available. AxoGen expects to apply for this waiver for the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft
BLA. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Establishment Fee: Establishment fees (for where the biologic product is manufactured) are based on the FDA budget divided by the total number of
establishments. In FY 2013, the Establishment Fee is $526,500. This fee is adjusted each year so we cannot provide an accurate estimate of what our fee will be upon approval of our BLA. AxoGen will have to pay an establishment fee after BLA approval
and then pay such fee annually thereafter. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA &#151; General </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">FDA regulations govern nearly all the activities that AxoGen performs, or that are performed on its behalf, to ensure that medical
products distributed domestically or exported internationally are safe and effective for their intended uses. The activities the FDA regulates include the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product design, development and manufacture; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product safety, testing, labeling and storage; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pre-clinical testing in animals and in the laboratory; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical investigations in humans; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">premarketing clearance or approval and licensing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">record-keeping and document-retention procedures; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">advertising and promotion; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the import and export of products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product marketing, sales and distribution; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">post-marketing surveillance and medical device reporting, including reporting of deaths, serious injuries, communicable diseases, device malfunctions
or other adverse events; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">corrective actions, removals and recalls. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Failure to comply with applicable FDA regulatory requirements may subject AxoGen to a variety of administrative or judicially-imposed penalties or sanctions and/or prevent it from obtaining or maintaining
required approvals, clearances or licenses to manufacture and market its products. Such failure to comply with the applicable FDA requirements may subject AxoGen to stringent administrative or judicial actions or sanctions, such as agency refusal to
approve pending applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution of products, injunctions, or civil or criminal prosecution. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA&#146;s Premarket Clearance and Approval Requirements&#151;Medical Devices </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless an exemption applies, each medical device distributed commercially in the U.S. requires either 510(k) premarket notification
submission or a Pre-Market Approval Application, or PMA, from the FDA. Medical devices are classified into one of three classes&#151;Class I, Class II, or Class III&#151;depending on the degree of risk and the level of control necessary to assure
the safety and effectiveness of each medical device. Medical devices deemed to pose lower risks are generally placed in either Class I or II. Pre-market review and clearance by the FDA for Class I and II medical devices is accomplished through the
510(k) pre-market notification procedure, unless the device is exempt. Most Class I medical devices are exempt from the 510(k) premarket notification requirement. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining,
life-supporting or implantable devices, and novel devices, including devices deemed not substantially equivalent to a previously cleared 510(k) device are generally placed in Class III. Class III devices generally require an approved PMA to be
marketed. A PMA must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#146;s satisfaction, the safety and effectiveness of the device.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA&#146;s Premarket Approval Requirements&#151;Biologic Products </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Biologics License Application Pathway </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Biological products require FDA approval of a BLA to be marketed. In order to be approved, a BLA must demonstrate the safety, purity, and potency of the product candidate based on results of preclinical
studies and clinical trials. A BLA must also contain extensive CMC and other manufacturing information, and the applicant must pass an FDA pre-approval inspection of the manufacturing facility or facilities at which the biologic product is produced
to assess compliance with the FDA&#146;s current good manufacturing practice. Satisfaction of FDA approval requirements for biologics typically takes several years and the actual time required may vary substantially based on the type, complexity and
novelty of the product. AxoGen cannot be certain that any BLA approvals for its products will be granted on a timely basis, or at all. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The steps for obtaining FDA approval of a BLA to market a biologic product in the U.S.
include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">completion of preclinical laboratory tests, animal studies and formulation studies under the FDA&#146;s good laboratory practices regulations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission to the FDA of an IND, for human clinical testing, which must become effective before human clinical trials may begin and which must include
independent Institutional Review Board, or IRB, approval at each clinical site before the trials may be initiated; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">performance of adequate and well-controlled clinical trials in accordance with Good Clinical Practices to establish the safety and efficacy of the
product for each indication; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission to the FDA of a BLA, which contains detailed information about the CMC for the product, reports of the outcomes and full data sets of the
preclinical testing and clinical trials, and proposed labeling and packaging for the product; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">satisfactory review of the contents of the BLA by the FDA, including the satisfactory resolution of any questions raised during the review;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">satisfactory completion of an FDA Advisory Committee review, if applicable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with
current good manufacturing practice, or cGMP, regulations, to assure that the facilities, methods and controls are adequate to ensure the product&#146;s identity, strength, quality and purity; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">FDA approval of the BLA including agreement on post-marketing commitments, if applicable. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND
sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some preclinical testing may continue after the IND is submitted. The IND must become effective
before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about issues such as the conduct of the trials and or supporting
preclinical data as outlined in the IND. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns or questions before clinical trials can proceed. In other words, submission of an IND may not result in the FDA allowing
clinical trials to commence. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Biosimilar Biological Products </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A new regulatory approval pathway for biosimilars was established by The Biologics Price Competition and Innovation Act
(&#147;BPCIA&#148;), as part of the Patient Protection and Affordable Care Act of 2010. An important component of the legislation specified that a manufacturer of a reference biological product would be granted 12 years of exclusive use before a
biosimilar could be approved for marketing in the US. An application for a biosimilar product may not be submitted to FDA until 4 years after the approval date of the BLA for the reference biological product. BPCIA provides for an abbreviated
licensure process for a biosimilar, which is defined to mean a biological product that is highly similar to the reference product, notwithstanding minor differences in clinically inactive components, and there are no clinically meaningful
differences between the biological product and the reference product in terms of safety, purity and potency. At its discretion, FDA can waive a requirement for any required element in an application for a biosimilar product. In addition, the
legislation distinguished approval of a biosimilar from approval of such a product as a substitute for the reference biologic. Where a product is a substitution for the reference biologic it is considered an interchangeable product. Approval as
interchangeable requires that the product is biosimilar </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and can be expected to produce the same clinical results as the reference product in any given patient, and a demonstration that the risk in terms of safety or diminished efficacy of alternating
or switching between the use of the interchangeable and reference product is not greater than the risk of using the reference product without such alternation or switch. Several states have enacted or are considering laws that also regulate the use
and substitution of biosimilar drugs. For example, Virginia requires licensure as interchangeable by FDA for a pharmacist to dispense a biosimilar in place of a prescribed biological product<BR>
<FONT STYLE="white-space:nowrap">(Virginia&nbsp;&#167;&nbsp;54.1-3408.04).</FONT> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U></U></I><B><U>FDA&#146;s Pre-Approval
and Pre-Licensing Requirements.</U></B><I><U> </U></I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before approving a BLA, the FDA generally inspects the facility or the
facilities at which the product is manufactured. The FDA will not approve the product if it finds that the facility does not appear to be in cGMP compliance. If the FDA determines the application, manufacturing process or manufacturing facilities
are not acceptable, it will either not approve the application or issue an approvable letter in which it will outline the deficiencies in the BLA and provide the applicant an opportunity to meet with FDA representatives and subsequently to submit
additional information or data to address the deficiencies. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The testing and approval process requires substantial time, effort and financial resources, and each may take several years to complete.
Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. AxoGen may
encounter difficulties or unanticipated costs in its efforts to secure necessary governmental approvals, which could delay or preclude it from marketing its products. The FDA may limit the indications for use or place other conditions on any
approvals that could restrict the commercial application of the products. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further
testing requirements and FDA review and approval. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Post-Approval Requirements </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After regulatory approval of a product is obtained, AxoGen will be required to comply with a number of post-approval requirements. For
example, as a condition of approval of a BLA, the FDA may require post marketing testing and surveillance to monitor the product&#146;s safety or efficacy. In addition, holders of an approved BLA are required to keep extensive records, to report
certain adverse reactions and production problems to the FDA, to provide updated safety and efficacy information and to comply with requirements concerning advertising and promotional labeling for their products. Also, quality control and
manufacturing procedures must continue to conform to cGMP regulations as well as the manufacturing conditions of approval set forth in the BLA. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP regulations, which
imposes certain procedural, substantive and recordkeeping requirements. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of
regulatory compliance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future FDA inspections may identify compliance issues at AxoGen&#146;s facilities or at the facilities
of its contract manufacturers that may disrupt production or distribution, or require substantial resources to correct and prevent recurrence of any deficiencies. In addition, discovery of problems with a product or the failure to comply with
applicable requirements may result in restrictions on a product, manufacturer or holder of an approved BLA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
delay or prohibit further marketing. Newly discovered or developed safety or effectiveness data may require changes to a product&#146;s approved labeling, including the addition of new warnings
and contraindications. Finally, new government requirements, including those resulting from new legislation, may be established that could delay or prevent regulatory approval of AxoGen products that are currently under development or regulatory
activity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that AxoGen failed to comply
with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, such as issuing a FDA Form 483 notice of inspectional observations, warning letter, or untitled letter, imposing civil money penalties, suspending
or delaying issuance of approvals, requiring product recall, imposing a total or partial shutdown of production, withdrawal of approvals or clearances already granted, and pursuing product seizures, consent decrees or other injunctive relief, and
criminal prosecution through the Department of Justice. The FDA can also require AxoGen to repair, replace or refund the cost of devices that it manufactured or distributed. If any of these events were to occur, it could materially adversely affect
AxoGen&#146;s business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Clinical Trials </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Clinical trials are required to support a BLA and are sometimes required for 510(k) clearance. Clinical trials involve the administration of the investigational product to human subjects under the
supervision of qualified investigators. Clinical trials are conducted under strict requirements to ensure the protection of human subjects participating in the trial and under protocols detailing, among other things, the objectives of the study, the
parameters to be used in monitoring and safety, and the effectiveness criteria to be evaluated. Clinical trials for biological products require the submission and FDA approval of an IND and clinical trials for medical devices require the submission
and FDA approval of an Investigational Device Exemption application, or IDE, unless the device regulations would not require an IDE for a study. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA
as part of the IND or IDE, for significant risk devices. In addition, for these studies, an IRB at each site at which the study is conducted must approve the protocol, subject consent form and any amendments for each site at which the study is
conducted. All research subjects must be informed, among other things, about the risks and benefits of the investigational product and provide their informed consent in writing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials under an IND typically are conducted in three sequential phases, but the phases may overlap or be
combined. In AxoGen&#146;s case, AxoGen believes that the Phase 3 clinical trial study for the Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Graft represents the only new clinical data that will be required to evaluate safety and effectiveness. Phase 1 clinical trials usually involve the initial introduction of the investigational product into a small group of healthy volunteers (e.g.,
10 to 20) to evaluate the product&#146;s safety, (dosage tolerance and pharmacokinetics if a biologic product) and, if possible, to gain an early indication of its effectiveness. Phase 2 clinical trials usually involve controlled trials in a larger
but limited patient population (e.g., a few hundred) to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">evaluate dosage tolerance and appropriate dosage; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">identify possible adverse effects and safety risks; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">provide a preliminary evaluation of the efficacy of the product for specific indications. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3 clinical trials usually further evaluate clinical efficacy and test further for safety in an expanded patient population (e.g., a
hundred to several thousand). Phase 3 clinical trials usually involve comparison with placebo, standard treatments or other comparators. Usually at least one well-controlled large Phase 3 or pivotal clinical trial demonstrating safety and efficacy
is required to support a BLA. These trials are intended to establish the overall risk-benefit profile of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
product and provide an adequate basis for physician labeling. Phase 3 trials are almost always larger, more time consuming, complex and costly than Phase 1 and Phase 2 clinical trials. Phase 1,
Phase 2 and Phase 3 clinical testing may not be completed successfully within any specified period, if at all. Furthermore, the FDA or AxoGen may suspend or terminate clinical trials at any time on various grounds, including a finding that the
subjects or patients are being exposed to an unacceptable health risk, have experienced a serious and unexpected adverse event, or that continued use in an investigational setting may be unethical. Similarly, an IRB can suspend or terminate approval
of research if the research is not being conducted in accordance with the IRB&#146;s requirements or if the research has been associated with unexpected serious harm to patients. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Investigational New Drug Application </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For a biologic product, an IND must be submitted prior to the initiation of the clinical study. The IND application must contain information in three broad areas: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Animal Pharmacology and Toxicology Studies&#151;Preclinical data to permit an assessment as to whether the product is reasonably safe for initial
testing in humans. Also included are any previous experiences with the product in humans (often foreign use). </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Manufacturing Information&#151;Information pertaining to the composition, manufacturer, stability, and controls used for manufacturing of the drug
substance and the drug product. This information is assessed to ensure that the company can adequately produce and supply consistent batches of the drug. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical Protocols and Investigator Information&#151;Detailed protocols for proposed clinical studies to assess whether the initial-phase trials will
expose subjects to unnecessary risks. Also, information on the qualifications of clinical investigators&#151;professionals (generally physicians) who oversee the administration of the experimental compound&#151;to assess whether they are qualified
to fulfill their clinical trial duties. Finally, commitments to obtain informed consent from the research subjects, to obtain review of the study by an IRB, and to adhere to the investigational new drug regulations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, FDA has an
opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AxoGen Clinical Trials </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen is currently performing three clinical studies to gather data on the
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. The studies are &#147;A Multicenter Retrospective Study of Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair (&#147;RANGER<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>&#148;)&#148;, &#147;A Multicenter, Prospective, Randomized, Comparative Study of Hollow Nerve Conduit and Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft Evaluation Recovery Outcomes of the Nerve Repair in the Hand (&#147;CHANGE&#148;)&#148; and a pilot
study to evaluate the use of Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft in the reconstruction of nerves following prostatectomy.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study is an observational study in current enrollment. It is designed to allow enrollment of up to a total of 1000 subjects over the next several years. The follow-up
for the RANGER<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> study is standard of care up to 36 months post nerve repair. At the time of the BLA submission,
if 1000 subjects have not been enrolled and follow-up completed, AxoGen will submit an interim report in the BLA for the enrolled subjects. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The CHANGE study is being run as a pilot comparative study and enrollment was completed
November 2011. The study has a 12 month follow-up post nerve repair. After the completion of the follow-up period, data management and report development are anticipated to take an additional 9 months. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The study regarding prostatectomy has also completed enrollment as of the first quarter 2013. The study has a 24 month follow-up post
nerve repair. After the completion of the follow-up period, data management and report development are anticipated to take an additional 9 months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Clinical trials are subject to extensive recordkeeping and reporting requirements. AxoGen&#146;s clinical trials must be conducted under the oversight of an IRB for the relevant clinical trial sites
and must comply with FDA regulations, including but not limited to those relating to good clinical practices. AxoGen is also required to obtain the patients&#146; written informed consent in form and substance that complies with both FDA
requirements and state and federal privacy and human subject protection regulations. AxoGen, the FDA or the IRB may suspend a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the
anticipated benefits. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the biological product or device, or may otherwise not be sufficient to obtain FDA approval to market the
product in the U.S. Similarly, in Europe, the clinical study for a medicine product must be authorized by the Competent Authority in each Member State in which the clinical trial is to be conducted, and must receive a favorable opinion from an
ethics committee. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Pervasive and Continuing Regulation </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are numerous regulatory requirements that apply after a product is cleared or approved. For medical devices, these include, but are
not limited to: the FDA&#146;s regulations for device labeling (21 CFR &#167; 801), medical device reporting (21 CFR &#167; 803), reporting of corrections and removals (21 CFR &#167; 806), establishment registration and device listing requirements
(21 C.F.R. &#167; 807); and compliance with the Quality System Regulation (QSR) per 21 CFR &#167; 820. For tissue and biologic products, these include: the FDA&#146;s registration and listing requirements, donor eligibility, and Good Tissue
Practices (GTP) per 21 CFR &#167;1271 for human tissue products, the FDA&#146;s Good Manufacturing Practices (GMP) per 21 CFR &#167; 210, 211, and 600 for biologic products, and postmarket BLA requirements (21 CFR &#167; 601). Among other things,
these regulations require manufacturers, including third-party manufacturers: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to comply with labeling regulations and FDA prohibitions against the false or misleading promotion or the promotion of products for uncleared,
unapproved or off-label uses or indications; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to comply with requirements to obtain clearance or approval for certain changes affecting the product, including changes to the product&#146;s
manufacturing, labeling, or intended use; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to report to the FDA certain adverse events, adverse reactions and deviations: (a)&nbsp;for medical devices, a report to FDA is required if the device
may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur; (b)&nbsp;for biologics, a deviation from current GMP or an
unexpected or unforeseeable event that may affect the safety, purity, or potency of the product must be reported; and (c)&nbsp;for human tissue products, FDA requires reporting of certain adverse reactions involving a communicable disease related to
an HCT/P that the company made available for distribution; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to comply with post-approval restrictions or conditions, including post-approval study commitments and post-market safety and annual reporting
requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to follow post-market surveillance regulations that may apply when necessary to protect the public health or to provide additional safety and
effectiveness data for the device; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to follow requirements to issue notices of correction or removal, or conduct market withdrawals or recalls where quality or other issues arise.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has not had any adverse events concerning the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft or the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products and has not had to submit any Medical Device Reports (&#147;MDRs&#148;), biological deviation reports, or tissue adverse reaction reports to the FDA.
Although AxoGen has had no adverse events to date, there may have been other incidents, including patient deaths, which may have occurred during procedures utilizing AxoGen&#146;s products without AxoGen being aware of any such incidents. In
addition, there can be no assurance that in the future AxoGen will not have an adverse event or will not submit any MDRs, biological deviation reports, or tissue adverse reaction reports to the FDA. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The advertising and promotion of medical products are also regulated by the Federal Trade Commission and by state regulatory and
enforcement authorities. Recently, some promotional activities for FDA-regulated products have been the subject of enforcement action brought under healthcare reimbursement laws and consumer protection statutes. In addition, under the Federal Lanham
Act and similar state laws, competitors and others can initiate litigation relating to advertising claims. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is registered with the FDA as a tissue establishment for the Avance<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft. The FDA has broad post-market and regulatory enforcement powers. AxoGen is subject to unannounced
inspections by the FDA to determine compliance with the GTP, GMP and other regulations, and these inspections may also include the manufacturing facilities of suppliers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Failure by AxoGen or by AxoGen&#146;s suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA or other federal or state authorities, which may include any
of the following sanctions, among others: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">warning letters, fines, injunctions, consent decrees and civil penalties; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">customer notifications, repair, replacement, refunds, recall or seizure of our products; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">operating restrictions, partial suspension or total shutdown of production; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspension or termination of our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">refusing our PMA or BLA for new products, new intended uses or modifications to existing products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">withdrawing premarket approvals that have already been granted; and criminal prosecution. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Education Grants, U.S. Anti-kickback, False Claims and Other Healthcare Fraud and Abuse Laws </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Educational Grants </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A medical product manufacturer may provide financial support, including support by way of grants, to third-parties for the purpose of conducting medical educational activities. If these funded activities
are considered by the FDA to be independent of the manufacturer, then the activities fall outside the FDA restrictions on promotion to which the manufacturer is subject. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The FDA considers several factors in determining whether an educational event or activity is independent from the substantive influence of the product manufacturer and therefore non-promotional,
including, but not limited to, the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the intent of the funded activity is to present clearly defined educational content, free from commercial influence or bias;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the third-party grant recipient and not the manufacturer has maintained control over selecting the faculty, speakers, audience, program content
and materials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the program focuses on a single product of the manufacturer without a discussion of other relevant existing competitive products or treatment
options; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether there was meaningful disclosure to the audience, at the time of the program, regarding the manufacturer&#146;s funding of the program, any
significant relationships between the provider, presenters, or speakers and the supporting manufacturer; whether any unapproved uses will be discussed; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether there are legal, business, or other relationships between the supporting manufacturer and provider or its employees that could permit the
supporting manufacturer to exert influence over the content of the program; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the individuals employed by the provider and involved in designing or conducting the educational activities are also involved in advising or
assisting the company with respect to sales or marketing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the information about the company&#146;s products is further disseminated after the initial program, by or at the direction of the company,
other than in response to an unsolicited request or through an independent provider; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the provider is compliant with standards for independence, balance, objectivity, and scientific rigor when putting on ostensibly independent
educational programs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen seeks to ensure that the activities it supports pursuant to educational grants
program are in accordance with these criteria for independent educational activities. However, AxoGen cannot provide an assurance that the FDA or other government authorities would view the programs supported as being independent. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Fraud, Abuse and False Claims </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen is directly and indirectly subject to various federal and state laws governing relationships with healthcare providers and
pertaining to healthcare fraud and abuse, including anti-kickback laws. In particular, the federal healthcare program Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration,
directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for or recommending a good or service for which payment may be made in whole or part under federal healthcare programs, such as
the Medicare and Medicaid programs. Penalties for violations include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs. The Anti-Kickback Statute
is broad and prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. In implementing the statute, the Office of Inspector General of the U.S. Department of Health and Human Services
(&#147;OIG&#148;) has issued a series of regulations, known as the &#147;safe harbors.&#148; These safe harbors set forth provisions that, if all their applicable requirements are met, will assure healthcare providers and other parties that they
will not be prosecuted under the Anti-Kickback Statute. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct
and business arrangements that do not fully satisfy each applicable element of a safe harbor may result in increased scrutiny by government enforcement authorities, such as the OIG. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Federal False Claims Act (&#147;FCA&#148;) imposes civil liability on any person or entity that submits, or causes the submission of,
a false or fraudulent claim to the U.S. Government. Damages under the FCA can be significant and consist of the imposition of fines and penalties. The FCA also allows a private individual or entity with knowledge of past or present fraud against the
federal government to sue on behalf of the government to recover the civil penalties and treble damages. The U.S. Department of Justice (&#147;DOJ&#148;) on behalf of the government has previously alleged that the marketing and promotional practices
of pharmaceutical and medical device manufacturers included the off-label promotion of products or the payment of prohibited kickbacks to doctors violated the FCA resulting in the submission of improper claims to federal and state healthcare
entitlement programs such as Medicaid. In certain cases, manufacturers have entered into criminal and civil settlements with the federal government under which they entered into plea agreements, paid substantial monetary amounts and entered into
corporate integrity agreements that require, among other things, substantial reporting and remedial actions going forward. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AdvaMed is one of the primary voluntary U.S. trade associations for medical device manufacturers. This association has established
guidelines and protocols for medical device manufacturers in their relationships with healthcare professionals on matters including research and development, product training and education, grants and charitable contributions, support of third-party
educational conferences, and consulting arrangements. Adoption of the AdvaMed Code by a medical device manufacturer is voluntary, and while the OIG and other federal and state healthcare regulatory agencies encourage its adoption and may look to the
AdvaMed Code, they do not view adoption of the AdvaMed Code as proof of compliance with applicable laws. AxoGen has incorporated the principles of the AdvaMed Code in its standard operating procedures, sales force training programs, and
relationships with doctors. Key to the underlying principles of the AdvaMed Code is the need to focus the relationships between manufacturers and healthcare professionals on matters of training, education and scientific research, and limit payments
between manufacturers and healthcare professionals to fair market value for legitimate services provided and payment of modest meal, travel and other expenses for a healthcare professional under limited circumstances. AxoGen has incorporated these
principles into its relationships with healthcare professionals under its consulting agreements, payment of travel and lodging expenses, research and educational grant </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
procedures and sponsorship of third-party conferences. In addition, AxoGen has conducted training sessions on these principles. However, AxoGen cannot provide any assurance that regulatory or
enforcement authorities will view these arrangements as being in compliance with applicable laws. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Regulation Outside of
the United States </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of medical products outside of the U.S. are subject to foreign governmental regulations that
vary substantially from country to country. The time required to obtain certification or approval by a foreign country may be longer or shorter than that required for FDA clearance or approval and the requirements may be different. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are restrictions under U.S. law on the export from the U.S. of medical devices and biologic product that cannot be legally
distributed in the U.S. If a Class I or Class II medical device does not have 510(k) clearance, and the manufacturer reasonably believes that the device could obtain 510(k) clearance in the U.S., then the device can be exported to a foreign country
for commercial marketing without the submission of any type of export request or prior FDA approval, if the device is not sold or offered for sale in the U.S., is labeled for export only and satisfies certain criteria relating primarily to
specifications of the foreign purchaser and compliance with the laws of the country to which it is being exported, known as Importing Country Criteria. An unapproved Class III medical device can be exported if it complies with the criteria discussed
above for devices that could obtain 510(k) clearance, meets certain other quality and labeling requirements, and has a valid marketing authorization from one of a list of countries listed in the Federal Food, Drug, and Cosmetic Act. If an unapproved
Class III medical device does not have a valid marketing authorization from one of the listed countries, an export permit from the FDA is required in order to export it. An unapproved biologic product can be exported without submitting an export
request to FDA if the product has received a marketing authorization in one of a list of countries listed in the FD&amp;C Act and it meets applicable requirements of the FD&amp;C Act and the laws of the country to which it is exported. An
investigational biologic product may also be exported under an IND if a listed investigator is in a foreign country and certain requirements specified in FDA&#146;s regulations are met. AxoGen currently complies with applicable regulations when
exporting its products and intends to continue such compliance in the event there are any regulatory changes regarding its products in the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The primary regulatory body in Europe is that of the E.U., which has adopted numerous directives and promulgated voluntary standards regulating the design, manufacture and labeling of, and clinical trials
and adverse event reporting for, medical devices. Devices that comply with the requirements of a relevant directive will be entitled to bear CE marking, indicating that the device conforms to the essential requirements of the applicable directives
and, accordingly, can be commercially distributed throughout the member states of the E.U. and other countries that comply with or mirror these directives. The method for assessing conformity varies depending on the type and class of the product,
but normally involves an assessment by the manufacturer and a third-party assessment by a notified body, an independent and neutral institution appointed by a country to conduct the conformity assessment. This third-party assessment may consist of
an audit of the manufacturer&#146;s quality system and specific testing of the manufacturer&#146;s device. Such an assessment is required for a manufacturer to commercially distribute the product throughout these countries. AxoGen has prepared the
Quality System and is ready for an assessment by the International Organization for Standardization, (ISO) 13485:2003 Quality Management System. If a country or international customer requires AxoGen to have its quality system registered for
compliance to ISO 13485, AxoGen will begin the registration process (selecting a registering body, scheduling audits and report completion). This process is expected to take less than 9 months. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Cook Biotech is responsible for all regulatory filings for the AxoGuard
products including international registrations. AxoGen works with Cook Biotech by providing the countries for Cook to register or get approval for the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products. Cook Biotech prepares the product filing documentation and submits this documentation to the Ministry of Health (&#147;MOH&#148;) for the country. Each
country or region has its own regulations and the documentation required for submission varies. It typically takes less than 9 months from the initiation of the project to obtain AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> clearance in a given country or region. To date, the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product line has been registered in Canada for distribution (May 2013) and has been awarded the CE Mark (April 2013) allowing distribution into the European Union and
other countries that accept the CE Mark. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Tissue products are not currently regulated under the CE Mark
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although some standards of harmonization exist, each country in which AxoGen conducts business has its own specific
regulatory requirements. AxoGen procures and processes its tissue products in the U.S., and markets in the U.S., the United Kingdom, the Netherlands , Canada, Switzerland, Austria and Italy under compliance with the individual country regulations.
These requirements are dynamic in nature and, as such, are continually changing. New regulations may be promulgated at any time and with limited notice. AxoGen will review the regulations at the time of submission of the product dossier for
regulatory review. This review involves reviewing the appropriate MOH regulations, discussion with in-country distributors and use of consultants. It typically takes less than 9 months from the initiation of the product to develop a product dossier
(specific for that country), submission of the documentation and MOH review of the product filing. While AxoGen believes that it is in compliance with all existing pertinent international and domestic laws and regulations, there can be no assurance
that changes in governmental administrations and regulations will not negatively impact AxoGen&#146;s operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA and
international regulatory bodies conduct periodic compliance inspections of AxoGen&#146;s U.S. processing facilities. AxoGen&#146;s operations are registered with the CBER, as a tissue establishment. AxoGen is also accredited by the AATB and is
licensed in the states of Florida, New York, California, Maryland, Delaware, Oregon and Illinois. AxoGen believes that worldwide regulation of tissue products is likely to intensify as the international regulatory community focuses on the growing
demand for these implant products and the attendant safety and efficacy issues of citizen recipients. Changes in governing laws and regulations could have a material adverse effect on AxoGen&#146;s financial condition and results of operations.
AxoGen management further believes that it can help to mitigate this exposure by continuing to work closely with government and industry regulators. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Environmental </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s products, as well as the chemicals used in
processing, are handled and disposed of in accordance with country-specific, federal, state and local regulations. Since 2007, AxoGen has used outside third parties to perform all biohazard waste disposal. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen contracts with independent, third parties to perform sterilization of its allografts. In view of the engagement of a third party
to perform irradiation services, the requirements for compliance with radiation hazardous waste do not apply, and therefore AxoGen does not anticipate that having any material adverse effect upon its capital expenditures, results of operations or
financial condition. However, AxoGen is responsible for assuring that the service is being performed in accordance with applicable regulations. Although AxoGen believes it is in compliance with all applicable environmental regulations, the failure
to fully comply with any such regulations could result in the imposition of penalties, fines and/or sanctions which could have a material adverse effect on AxoGen&#146;s business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LecTec Corporation Merger </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, LecTec Corporation (&#147;LecTec&#148;) completed its business combination with AxoGen Corporation (&#147;AC&#148;) in accordance with the terms of an Agreement and Plan of
Merger, dated as of May&nbsp;31, 2011, by and among LecTec, Nerve Merger Sub Corp., a subsidiary of LecTec (&#147;Merger Sub&#148;), and AC, which the parties amended on September&nbsp;30, 2011 and August&nbsp;9, 2011 (as amended, the &#147;Merger
Agreement&#148;). Pursuant to the Merger Agreement, Merger Sub merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the &#147;Merger&#148;). Immediately following the
Merger, LecTec changed its name to AxoGen, Inc. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PDL BioPharma, Inc. Revenue Interests Purchase Agreement </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>General </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, AxoGen entered into a Royalty Contract with PDL, pursuant to which AxoGen sold to PDL the right to receive specified royalties on AxoGen&#146;s Net Revenues generated by the sale,
distribution or other use of AxoGen&#146;s products Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector. The Royalty Contract has a term of eight years. Under the Royalty Contract, PDL is to receive royalty payments based on a 9.95% royalty rate of
AxoGen&#146;s Net Revenues, subject to certain agreed upon minimum payment requirements of approximately $1.3 to $2.5 million per quarter, which begin in the fourth quarter of 2014 as provided in the Royalty Contract. The total consideration PDL
paid to AxoGen was the Funded Amount of $20,800,000, including $19,050,000 PDL paid to AxoGen on October&nbsp;5, 2012, and $1,750,000 PDL paid to AxoGen on August&nbsp;14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between
AxoGen and PDL, dated August&nbsp;14, 2012 (the &#147;Interim Royalty Contract&#148;). Upon the closing of PDL&#146;s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim
Royalty Contract was terminated. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Put Option </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, on October&nbsp;5, 2016, or in the event of the occurrence of a material adverse event, our transfer of revenue interest or substantially all of our interest in the products or
AxoGen&#146;s bankruptcy or material breach of the Royalty Contract, PDL may require AxoGen to repurchase the Assigned Interests at the &#147;Put Price.&#148; The Put Price is equal to the sum of (i)&nbsp;an amount that, when paid to PDL, would
generate a 20% rate of return to PDL on the Funded Amount, taking into consideration payments made to PDL by AxoGen, and (ii)&nbsp;any &#147;Delinquent Assigned Interest Payment&#148; (as defined in the Royalty Contract) AxoGen owed to PDL.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Change of Control; Call Option </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, in the event of a &#147;Change of Control&#148;, AxoGen must repurchase the assigned Interests from PDL for a repurchase price equal to the &#147;Change of Control Price&#148; on or prior to
the third business day after the occurrence of the Change of Control. The Change of Control Price is equal to the sum of (i)&nbsp;an amount that, when paid to PDL, would generate a 32.5% internal rate of return to PDL on the Funded Amount, taking
into consideration payments made to PDL by AxoGen, and (ii)&nbsp;any &#147;Delinquent Assigned Interest Payment&#148; AxoGen owed to PDL. In addition, at any time after October&nbsp;5, 2016, AxoGen, at its option, can call the Royalty Contract for a
price equal to the Change of Control Price. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Board Designee </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, during the term of the Royalty Contract, PDL is entitled to designate, and AxoGen shall appoint an individual
designated by PDL, who shall serve on the Board of Directors of AxoGen (the &#147;Board&#148;) until AxoGen&#146;s 2013 Annual Meeting of Shareholders (the &#147;2013 Annual Meeting&#148;). For the 2013 Annual Meeting and each annual meeting
thereafter during the term of the Royalty Contract, the Board shall nominate and recommend the PDL designee as a director nominee to serve on the Board until the next annual meeting and shall include such nomination in AxoGen&#146;s proxy statement
for the 2013 Annual Meeting and each annual meeting thereafter, provided that the election of the PDL designee is subject to shareholders&#146; approval. Should at any time there become a vacancy on the Board as a result of (i)&nbsp;the resignation,
death or removal of the PDL designee or (ii)&nbsp;such PDL designee failing to obtain the requisite approval of AxoGen&#146;s shareholders at any annual or special meeting of AxoGen&#146;s shareholders and where no other individual is elected to
such vacancy, PDL shall have the right to designate an individual to fill such vacancy, and AxoGen shall take such actions necessary to appoint, such individual to the Board. AxoGen was required to have taken all actions necessary at or prior to the
Closing to ensure there is a vacancy on the Board as of the Closing to permit the appointment of the PDL designee to the Board as of the Closing. PDL has exercised this right and nominated John P. McLaughlin, PDL&#146;s President and Chief Executive
Officer. On October&nbsp;5, 2012, upon the Closing, the Board approved to increase its size from seven directors to eight directors, and Mr.&nbsp;McLaughlin was elected to the Board to serve until the 2013 Annual Meeting. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Preemptive Rights </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, PDL has preemptive rights with respect to new issuances of AxoGen&#146;s equity securities and securities convertible, exchangeable or exercisable into such equity securities,
subject to certain restrictions, including restrictions regarding issuance of securities in a registered public offering by the Company. Therefore, due to such restrictions, the preemptive right does not apply to this offering. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restriction on Dividends </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, during the period from the October&nbsp;5, 2012 to December&nbsp;4, 2016 (or the payment of the Put Price in the event PDL exercises its put option on or prior to
December&nbsp;4, 2016), AxoGen shall not, nor shall it permit any subsidiary to, declare, pay or make any dividend or distribution on any shares of the common stock or preferred stock of such entity (other than dividends or distributions payable in
its stock, or split-ups or reclassifications of its stock) or apply any of its funds, property or assets to the purchase, redemption or other retirement of any common or preferred stock, or of any options to purchase or acquire any such shares of
common or preferred stock of any such entity (collectively, &#147;Restricted Payments&#148;), except that: (i)&nbsp;each subsidiary may make direct or indirect Restricted Payments to AxoGen; and (ii)&nbsp;AxoGen and each subsidiary may purchase,
redeem or otherwise acquire Equity Interests issued by it solely with the proceeds received from the substantially concurrent issue of new shares of its common stock or other common Equity Interests. For purposes of the Royalty Contract,
&#147;Equity Interests&#148; of any person means any and all shares, rights to purchase, options, warrants, general, limited or limited liability partnership interests, member interests, participation or other equivalents of or interest in
(regardless of how designated) equity of such entity, whether voting or nonvoting, including common stock, preferred stock, convertible securities or any other &#147;equity security&#148; (as such term is defined in Rule 3a11-1 under the Securities
Exchange Act of 1934, as amended). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Guarantee and Collateral Agreement </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Royalty Contract, on October&nbsp;5, 2012, AxoGen and AC, entered into a Guarantee and Collateral Agreement (the
&#147;Guarantee and Collateral Agreement&#148;) with PDL, pursuant to which (i)&nbsp;AC unconditionally and irrevocably guarantees to PDL the prompt and complete payment and performance by AxoGen when due of the &#147;Secured Obligations,&#148;
which include AxoGen&#146;s obligations under the Royalty Contract, and any other obligations that AxoGen may owe to PDL under the Royalty Contract and other transaction documents; and (ii)&nbsp;each of AxoGen and AC grants to PDL a security
interest in certain collateral as specified in the Guarantee and Collateral Agreement for the prompt and complete payment and performance when due of the Secured Obligations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employees </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At August&nbsp;5, 2013, AxoGen had 67 full time employees which included 13 in administration, information technology and finance, 9 in manufacturing and quality control, 9 in research and development and
regulatory and 36 in sales and marketing. As of the date of this registration statement AxoGen has not had a work stoppage and no employees are represented by a labor union. AxoGen believes its relationship with its employees is satisfactory.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Properties </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s corporate headquarters are currently located in Alachua, Florida, in a facility with a lease for 4,742 square feet of office
space until April 2014. AxoGen also leases 2,224 square feet of laboratory and distribution space in University of Florida&#146;s Sid Martin Biotechnology Incubator in Alachua, Florida under a one-year lease until September 2013 and leases space and
maintains records at certain facilities, which includes AxoGen&#146;s prior corporate headquarters at 1407 South Kings Highway, Texarkana, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Texas 75501. AxoGen&#146;s aggregate cost of such properties is approximately $176,000 per year. AxoGen believes that these facilities are sufficient to operate its business for the next 12 months and
that lease obligations will not change materially, although AxoGen will likely require additional space in the future to accommodate its expansion. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Legal Proceedings </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;25, 2008, LecTec filed a complaint for
patent infringement (the &#147;Complaint&#148;) against five companies, including Chattem, Inc. (Ticker: CHTT), Endo Pharmaceuticals, Inc. (Ticker: ENDP), Johnson&nbsp;&amp; Johnson Consumer Company, Inc. (Ticker: JNJ), The Mentholatum Company, Inc.
(Division of Rohto Pharmaceuticals, Ticker RPHCF.PK), and Prince of Peace Enterprises, Inc. (Private Company) (collectively, the &#147;Defendants&#148;) in the U.S. District Court for the Eastern District of Texas. The Complaint alleged, among other
things, that the Defendants infringed two of LecTec&#146;s patents (the &#147;Patents-In-Suit&#148;), which related to LecTec&#146;s medicated patch technology. LecTec sought to enjoin the Defendants from infringing the Patents-In-Suit and to
recover monetary damages related to such infringement, as well as interest and litigation costs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31,
2010, LecTec had settlement with Endo Pharmaceuticals, Inc., Johnson&nbsp;&amp; Johnson Consumer Company, Inc. and The Mentholatum Company. On March&nbsp;23, 2011, LecTec entered into a Confidential Settlement Agreement and Mutual Release (the
&#147;Chattem Settlement Agreement&#148;) with Chattem to settle LecTec&#146;s claims against Chattem that Chattem infringed the Patents-In-Suit. Pursuant to the Chattem Settlement Agreement, Chattem paid a one-time sum of $3,600,000 to LecTec. and
LecTec granted to Chattem a fully paid-up, world-wide, non-exclusive and irrevocable license to (a)&nbsp;the Patents-In-Suit, (b)&nbsp;any patent that claims priority, directly or indirectly, from the Patents-In-Suit (the &#147;Family Patents&#148;)
and (c)&nbsp;any foreign counterparts of the Family Patents, for use in connection with any product or process sold or used by Chattem, other than products covered by exclusive licenses previously granted to other companies. Such settlement proceeds
were before payment of contingent legal fees and any applicable taxes. In addition, under the Chattem Settlement Agreement, LecTec and Chattem entered into mutual releases of all claims. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;25, 2011, LecTec entered into a Confidential Settlement Agreement and Mutual Release (the &#147;POP Settlement
Agreement&#148;) with Prince of Peace Enterprises, Inc. (&#147;POP&#148;) to settle LecTec&#146;s claims against POP that POP infringed the Patents-In-Suit. Pursuant to the Settlement Agreement, POP paid LecTec a one-time sum of $225,000 and LecTec
granted to POP a fully paidup, world-wide, non-exclusive and irrevocable license to (a)&nbsp;the Patents-In-Suit, (b)&nbsp;the &#147;Family Patents&#148; and (c)&nbsp;any foreign counterparts of the Family Patents, for use in connection with
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any product or process sold or used by POP, other than products covered by exclusive licenses previously granted to other companies. Such settlement proceeds were before payment of contingent
legal fees and any applicable taxes. In addition, under the POP Settlement Agreement, LecTec and POP entered into mutual releases of all claims. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have completed, through settlement, our previous material legal action against the five defendants. We currently have no active or pending material legal proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_10"></A>MANAGEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Officers and Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Executive Officers </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to the Merger, Mr.&nbsp;Gregory Freitag was
LecTec&#146;s only executive officer serving as CEO and CFO. The following table, except as noted, lists the names and positions of the individuals who have served since the completion of the Merger, and who are, as of March&nbsp;31, 2013, executive
officers of the Company: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:15pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Chief Executive Officer and Director</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory G. Freitag, J.D. CPA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer, General Counsel and Director</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John P. Engels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jill F. Schiaparelli</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Business Strategy and Marketing</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Friedman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President of Regulatory and Quality</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Hansen</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate Controller</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shawn McCarrey</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President of Sales</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biographical information for each of our executive officers is included below. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Karen Zaderej, President, Chief Executive Officer and Director (Age 51) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Zaderej has served as AxoGen&#146;s President, Chief Executive Officer and a member of its board of directors since September,
2011. She has served as AC&#146;s Chief Executive Officer and a member of its board of directors since May 2010. Ms.&nbsp;Zaderej joined AC in May 2006 and served as Vice President of Marketing and Sales from May 2006 to October 2007 and as Chief
Operating Officer from October 2007 to May 2010. From October 2004 to May 2006, Ms.&nbsp;Zaderej worked for Zaderej Medical Consulting, a consulting firm she founded, which assisted medical device companies build and execute successful
commercialization plans. From 1987 to 2004, Ms.&nbsp;Zaderej worked at Ethicon, Inc., a Johnson&nbsp;&amp; Johnson company, where she held senior positions in marketing, business development, and research&nbsp;&amp; development, as well as ran a
manufacturing business. Ms.&nbsp;Zaderej has a MBA from the Kellogg Graduate School of Business and a BS in Chemical Engineering from Purdue University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Gregory G. Freitag, J.D., CPA, Chief Financial Officer, General Counsel and Director (Age 51) </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Freitag, J.D., CPA, has been AxoGen&#146;s Chief Financial Officer, General Counsel and a member of its Board of Directors since September 2011 and was LecTec&#146;s Chief Executive Officer,
Chief Financial Officer and board member from June 2010 through September 2011. From May 2009 to the present, Mr.&nbsp;Freitag has been a principal of FreiMc, LLC, a consulting and advisory firm he founded that provides strategic guidance and
business development advisory services. Prior to founding FreiMc, LLC, Mr.&nbsp;Freitag was a Director of Business Development at Pfizer Health Solutions, a former subsidiary of Pfizer, Inc., from January 2006 to May 2009. From July 2005 to January
2006, Mr.&nbsp;Freitag worked for Guidant Corporation in their business development group. Prior to Guidant Corporation, Mr.&nbsp;Freitag was the Chief Executive Officer of HTS Biosystems, a biotechnology tools start-up company, from March 2000
until its sale in early 2005. Mr.&nbsp;Freitag was the Chief Operating Officer, Chief Financial Officer and General Counsel of Quantech, Ltd., a public point of care diagnostic company, from December 1995 to March 2000. Prior to that time,
Mr.&nbsp;Freitag practiced corporate law in Minneapolis, Minnesota. Mr.&nbsp;Freitag is also a director of the Foundation Board of HealthEast Care System, a health care system in Minnesota. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>John P. Engels, Vice President (Age 41) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Engels has served as AxoGen&#146;s Vice President since September, 2011. He is a co-founder of AC and has served as AC&#146;s
Vice President since June 2006, providing operational and financial leadership and managing AxoGen&#146;s strategic and product development partnerships. From 1999 to 2002, Mr.&nbsp;Engels worked as a consultant for the University of Florida,
Saffron Hill Ventures and PA Early Stage Partners, among other companies. From 1993 to 1997, Mr.&nbsp;Engels was an analyst and associate at CACM, a boutique investment banking firm. Mr.&nbsp;Engels is currently a member of the board of directors of
Oxicool, Inc., a privately-held company developing new cooling technologies. Mr.&nbsp;Engels holds a MBA in Management and Operations from the Wharton School of Business at the University of Pennsylvania, and a BA from the University of Chicago.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Jill F. Schiaparelli, Senior Vice President, Business Strategy&nbsp;&amp; Marketing (Age 47) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Schiaparelli has served as AxoGen&#146;s Senior Vice President, Business Strategy&nbsp;&amp; Marketing since February 2012. From
January 2011 to February 2012 and from June, 2007 to December 2008, Ms.&nbsp;Schiaparelli was employed by JS Strategic Partners, LLC, a consulting firm she founded to provide business strategy, commercialization and marketing services to
biotechnology companies and health care providers. From December 2008 to December 2010, Ms.&nbsp;Schiaparelli was the Vice President, Commercial Strategy&nbsp;&amp; Business Development for ApaTech, a venture-back global orthopedic graft company
based in the UK that was later acquired by Baxter Healthcare. From 1996 to 2007, Ms.&nbsp;Schiaparelli was employed by Johnson&nbsp;&amp; Johnson family of companies where she held several senior positions in strategic marketing, marketing, sales
operations and healthcare analytics within the Ethicon Endo-Surgery, Ethicon and Healthcare Systems operating companies. Prior to working in the healthcare industry, Ms.&nbsp;Schiaparelli worked for 8 years in the investment banking and financial
services industry. Ms.&nbsp;Schiaparelli has an MBA from the Stern School of Business at New York University and a BS in Business Administration from Boston University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Mark Friedman, Ph.D., Vice President of Regulatory and Quality (Age 55) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Friedman has served as AxoGen&#146;s Vice President of Regulatory and Quality since September, 2011. He has served as AC&#146;s
Vice President of Regulatory and Quality since June 2011 and served as AC&#146;s Director of Quality Assurance and Regulatory Affairs from September 2006 to June 2011. Prior to joining AxoGen, Dr.&nbsp;Friedman held several regulatory and quality
leadership positions at Enable Medical Corporation, a medical device company, including Director of Quality Assurance from 1997 to 1998 and Vice President of Quality and Regulatory from 1998 to 2001 and from 2004 to 2005. Dr.&nbsp;Friedman also
worked for AtriCure, Inc., a company that develops, manufactures and sells surgical ablation systems to treat atrial fibrillation, as Vice President of Quality and Regulatory from 2001 to 2004 and as Vice President of Operations in 2004. AtriCure
acquired Enable Medical in 2005. Mr.&nbsp;Friedman has over 24 years of experience in developing and directing regulatory strategy and quality systems for medical products, including 15 years with start-up medical product firms. Dr.&nbsp;Friedman
has a Ph.D. in Chemistry specializing in protein biochemistry from the University of Cincinnati. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>David Hansen, Corporate Controller (Age 52) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Hansen has served as AxoGen&#146;s Corporate Controller since September, 2011. He has served as AC&#146;s Corporate Controller
since June 2006. Mr.&nbsp;Hansen was Vice President of Finance&#151;Corporate Controller and Treasurer of Perma-Fix Environmental Services, Inc., a publicly-traded environmental services company, and held other corporate and regional accounting
positions at Perma-Fix Environmental Services from 1995 to 2005. Mr.&nbsp;Hansen was also Controller at Kraft Foodservice, Inc. from 1994 to 1995 and held other accounting and procurement positions at Kraft Foodservice, Inc. from 1985 to 1994.
Mr.&nbsp;Hansen has over 20 years of experience in senior financial positions at both publicly traded and private companies. Mr.&nbsp;Hansen holds a Bachelor of Business Administration degree in Accounting from the University of Oklahoma.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Shawn McCarrey, Vice President of Sales (Age 55) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;McCarrey has served as AxoGen&#146;s Senior Vice President of Sales since February, 2013. Mr.&nbsp;McCarrey was Executive Vice
President of North American Cardiovascular Sales at Bayer Interventional/MEDRAD Interventional from January, 2009 to May 2012. Bayer HealthCare, a subgroup of Bayer AG, is one of the world&#146;s leading, innovative companies in the healthcare and
medical products industry. Bayer Interventional, now doing business as part of Bayer Medical Care&#146;s Radiology and Interventional business, is the Interventional franchise formerly operated under Bayer&#146;s MEDRAD brand. From 1998 to 2009,
Mr.&nbsp;McCarrey held multiple escalating positions with Possis Medical, Inc., a company that developed, manufactured, and marketed medical devices for the cardiovascular and vascular treatment markets, and served as Director or Sales, VP of US
Sales, VP of Worldwide Sales and EVP of Worldside Sales&nbsp;&amp; Marketing. For more than 15 years prior to joining Possis, Mr.&nbsp;McCarrey served in a series of progressively responsible roles with two divisions of C.R. Bard, United States
Catheter and Instrument Corporation (USCI) which specialized in the treatment of coronary disease in the cardiac catheterization laboratory and Davol, an operating room division that promoted Thoraclex and Simpulse to cardiovascular and orthopedic
surgeons. Mr.&nbsp;McCarrey holds a Bachelor of Science degree in Marketing from Central Michigan University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen has a
key-person life insurance policy for $3,000,000 insuring the life of Ms.&nbsp;Zaderej. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the Company&#146;s 2012 annual
meeting of shareholders (the &#147;Annual Meeting&#148;), Greg Freitag, Mark Gold, M.D., Jamie M. Grooms, John Harper, Joe Mandato, Karen Zaderej and Robert Rudelius were nominated for re-election to AxoGen&#146;s Board of Directors (the
&#147;Board&#148;) and the AxoGen shareholders approved their election. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, the AxoGen Board approved
the increase in its size from seven directors to eight directors, and Mr.&nbsp;McLaughlin, a PDL designee, was elected to the Board to serve until the 2013 Annual Meeting. See &#147;Business &#151; PDL BioPharma, Inc. Revenue Interest Purchase
Agreement &#151;Board Designee.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Directors </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each elected director was to hold office for a term of one year and until their successors are duly elected and qualified (except in the
case of earlier death, resignation or removal). The following table lists the names, age and positions of the individuals who serve on the Board of Directors of the Company as of May&nbsp;10, 2013, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory Freitag</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer, General Counsel and Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jamie M. Grooms</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director, Chairman of the Board of Directors</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Gold, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Harper</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joe Mandato</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Rudelius</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John P. McLaughlin</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Karen Zaderej, President, Chief Executive Officer and Director (Age 51) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Zaderej&#146;s biographical information is provided above under &#147;&#151;Executive Officers.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Gregory G. Freitag, Chief Financial Officer and Director (Age 51) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Freitag&#146;s biographical information is provided above under &#147;&#151;Executive Officers.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Jamie M. Grooms, Chairman and Director (Age 53) </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Grooms has served as Chairman of the Company&#146;s board of directors since September&nbsp;30, 2011 and AC&#146;s board of directors since 2002. Mr.&nbsp;Grooms is a co-founder of AC and from
2002 to May 2010 served as AC&#146;s Chief Executive Officer. Since leaving AC in May 2010, Mr.&nbsp;Grooms has provided consulting services to start-up companies and serves on the board of directors of several companies. From 1998 to 2002,
Mr.&nbsp;Grooms served as the founding Chief Executive Officer and Chairman of the Board of Regeneration Technologies, Inc. a publicly-traded company involved in processing human tissue for allogenic grafts used in orthopedic, oral maxillofacial,
urinary and cardiovascular surgeries. Mr.&nbsp;Grooms has extensive experience in all areas of operations of the allograft business and has worked at the Virginia Tissue Bank (now LifeNet Health), Osteotech, Inc., and CryoLife, Inc. in various
positions of leadership. In addition, Mr.&nbsp;Grooms has served as Director of the University of Florida Tissue Bank from 1992 to 1995. Mr.&nbsp;Grooms holds a Bachelor&#146;s degree in biology from Old Dominion University. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Mark Gold, MD, Director (Age 63) </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Gold has served as a member of the Company&#146;s board of directors since September&nbsp;30, 2011 and AC&#146;s board of directors since July 2007. Since 1991, Dr.&nbsp;Gold has been a Professor
at the University of Florida College of Medicine&#146;s McKnight Brain Institute. Dr.&nbsp;Gold has taught medical neuroscience for four decades and has been a pioneer in translational neuroscience research for over three decades. Dr.&nbsp;Gold was
also a Founder of Somerset Valley Bank and served on its board of directors from its formation through its initial public offering to its acquisition by Fulton Financial Corporation, a publicly-traded financial holding company Dr.&nbsp;Gold has
consulted for many major global pharmaceutical companies as well as firms such as the Carlyle Group and Cressey&nbsp;&amp; Company. Dr.&nbsp;Gold has authored hundreds of scientific research articles, chapters, and abstracts on a wide variety of
research subjects and is frequently interviewed for comment by the Wall Street Journal, CNN and other major business and national publications concerned with the strengths and limitations of new technology and treatments. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>John Harper, Director (Age 62) </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Harper has served as a member of the Company&#146;s board of directors since September&nbsp;30, 2011 and AC&#146;s board of directors since June 2006. From January 2012 until present,
Mr.&nbsp;Harper has been Executive Chairman of Xhale, Inc., a company that provides patient-centric monitoring solutions, from patient monitoring to medication adherence to anesthesia monitoring. From June
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
2005 to January 2006, Mr.&nbsp;Harper was the Entrepreneur-in-Residence at The Innovation Factory, a medical device incubator. From August 2000 to October 2001, Mr.&nbsp;Harper served as
President and Chief Executive Officer of ATI Medical, Inc. and from February 1998 to May 1999, he served as Executive Chairman of Meretek Diagnostics, Inc., which was acquired by American Standard Companies. From November 1995 to March 1997,
Mr.&nbsp;Harper served as President and Chief Executive Officer of Indigo Medical, Inc., which merged with Johnson&nbsp;&amp; Johnson. Mr.&nbsp;Harper also served as Vice President of Sales and Marketing, and then President and Chief Executive
Officer, of Menlo Care, Inc. from June 1989 to June 1995. Menlo Care, Inc. merged with Johnson&nbsp;&amp; Johnson in 1995. Mr.&nbsp;Harper has served on the board of directors for a number of medical device and biotechnology companies since 1999. He
received his BA in Economics from Davidson College in 1971. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Joe Mandato, Director (Age 68) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Mandato has served as a member of the Company&#146;s board of directors since September&nbsp;30, 2011 and AC&#146;s board of
directors since February 2006. From March 2003 to the present, Mr.&nbsp;Mandato has served as a Managing Director of DeNovo Ventures, a venture capital firm and a shareholder of AxoGen. From February 1999 to September 2000, Mr.&nbsp;Mandato served
as Chairman of Confer Software, Inc., a developer of enterprise software used to automate healthcare business processes. From September 1995 to February 1999, Mr.&nbsp;Mandato served as Confer Software&#146;s Chief Executive Officer. From September
1994 to May 1995, Mr.&nbsp;Mandato served as a Vice President, member of founding management committee and Chief Executive Officer of two of Guidant Corporation&#146;s five operating units, Origin Medsystems and Heart Rhythm Technology. He also
served as President and Chief Executive Officer of Origin Medsystems from May 1991 to May 1995. In March 1994, Mr.&nbsp;Mandato co-founded Gynecare, Inc., a developer of devices used in gynecology, which was spun out of Guidant Corporation., and
served as its Chief Executive Officer until April 1995. From July 1986 to November 1990, Mr.&nbsp;Mandato was Chief Executive Officer of Ioptex Research Inc., an ophthalmic device company. Mr.&nbsp;Mandato serves on the board of directors of several
companies and non-profit organizations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Robert J. Rudelius, Director (Age 57) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Rudelius has served as a member of the Board of Directors since September 2010. Since 2003, Mr.&nbsp;Rudelius has been the
Managing Director and Chief Executive Officer of Noble Ventures, LLC, a company he founded that provides advisory and consulting services to early-stage companies in the information technology, renewable energy and loyalty marketing fields.
Mr.&nbsp;Rudelius is also the Managing Director and Chief Executive Officer of Noble Logistics, LLC, a holding company he founded in 2002 to create, acquire and grow a variety of businesses in the freight management, logistics and information
technology industries. From April 1999 through May 2001, when it was acquired by StarNet L.P., Mr.&nbsp;Rudelius was the founder and Chief Executive Officer of Media DVX, Inc., a start-up business that provided a satellite-based, IP-multicasting
alternative to transmitting television commercials via analog videotapes to television stations, networks and cable television operators throughout North America. Mr.&nbsp;Rudelius assisted StarNet L.P. with the transition and integration of the
Media DVX, Inc. business through January 2002. From April 1998 to April 1999, Mr.&nbsp;Rudelius was the President and Chief Operating Officer of Control Data Systems, Inc., during which time Mr.&nbsp;Rudelius reorganized and repositioned the
software company as a professional services company, which resulted in the successful sale of Control Data Systems, Inc. to Syntegra, British Telecom&#146;s systems integration subsidiary. From October 1995 through April 1998, Mr.&nbsp;Rudelius was
the founding Managing Partner of AT&amp;T Solution&#146;s Media, Entertainment&nbsp;&amp; Communications industry group. From January 1990 through September 1995, Mr.&nbsp;Rudelius was a partner in McKinsey&nbsp;&amp; Company&#146;s Information,
Technology and Systems practice group, during which time he headed the practice group in Tokyo and co&#150;led the practice group in London. Mr.&nbsp;Rudelius is currently a member of the Board of Directors of ProUroCare Medical, Inc., a
publicly&#150;held medical device company that develops and markets prostate imaging systems. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>John P. McLaughlin, Director (age 61) </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;McLaughlin has served as a member of the Board of Directors since October 2012. Mr.&nbsp;McLaughlin has been PDL&#146;s President
and Chief Executive Officer since December&nbsp;18, 2008, when PDL spun-off Facet Biotech Corporation and was elected a director of PDL in October 2008. From November&nbsp;6, 2008, until the spinoff, he served as a Senior Advisor to PDL. From
January 2000 to June 2008, Mr.&nbsp;McLaughlin was the Chief Executive Officer and a director of Anesiva, Inc., formerly known as Corgentech, Inc., a publicly-traded biopharmaceutical company. From December 1997 to September 1999,
Mr.&nbsp;McLaughlin was President of Tularik Inc., a biopharmaceutical company. From September 1987 to December 1997, Mr.&nbsp;McLaughlin held a number of senior management positions at Genentech, Inc., a biopharmaceutical company, including
Executive Vice President and General Counsel. From January 1985 to September 1987, Mr.&nbsp;McLaughlin was a partner at a Washington, D.C. law firm specializing in food and drug law. Prior to that, Mr.&nbsp;McLaughlin served as counsel to various
subcommittees in the United States House of Representatives, where he drafted numerous measures that became FDA laws. Mr.&nbsp;McLaughlin co-founded and served as Chairman of the Board of Directors of Eyetech Pharmaceuticals, Inc., a publicly-traded
biopharmaceutical company subsequently bought by OSI Pharmaceuticals, Inc., and co-founded and served as a director of Peak Surgical, Inc., a private medical device company, until it was acquired by Medtronic in 2011. Mr.&nbsp;McLaughlin currently
serves as a director of Seattle Genetics, Inc., a publicly-traded biopharmaceutical company. He received a B.A. from the University of Notre Dame and a J.D. from Catholic University of America. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director Independence </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is not a listed issuer and so is not subject to the director independence requirements of any exchange or interdealer
quotation system. Nevertheless, in determining whether its directors and director nominees are independent, the Company uses the definition of independence provided in the NASDAQ Stock Market&#146;s Marketplace Rules. Under this definition of
independence, Messrs. Grooms, Gold, Harper, Mandato and Rudelius would be considered independent directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection
with this offering, we have been approved to list our common shares on the NASDAQ Capital Market and will be subject to certain rules of such exchange. Although we are not currently subject to director independence requirements, we have,
nevertheless, in determining whether our directors and director nominees are independent, used the definition of independence provided in Rule 5605 (a)(2) of The NASDAQ Stock Market&#146;s Marketplace Rules. Under this definition of independence,
directors Jamie Grooms, Robert Rudelius, John Harper, Joe Mandato and Dr.&nbsp;Mark Gold would be considered independent directors. Members of our Board Gregory Freitag and Karen Zaderej would not be considered independent because they serve as
Executive Officers, John McLaughlin would not be considered independent because he is an executive officer of PDL and PDL&#146;s payments to the Company under the Interim Revenue Interest Purchase Agreement exceeded the limit set forth in
independence standards under the NASDAQ rules as to Audit Committee consideration and the Board has not otherwise deemed him independent. The Company believes it complies with applicable independence standards of the NASDAQ Capital Market.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Committees </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The standing committees of AxoGen&#146;s Board of Directors include an Audit Committee, a Compensation Committee and a Governance and Nominating Committees. Messrs. Rudelius (Chairman), Grooms and Harper
are the members of the Audit Committee. Messrs. Harper (Chairman), Rudelius and Dr.&nbsp;Gold are members of the Compensation Committee. Dr.&nbsp;Gold (Chairman) and Messrs. Grooms and Harper are members of the Nominating and Governance Committees.
The Charters of each of the Audit Committee, the Compensation, and Governance and Nominating Committee can be found on our website under &#147;About AxoGen&#151;Investors&#151;Corporate Governance.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Audit Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Audit Committee is responsible for review of audits, financial reporting and compliance, and accounting and internal controls policy. For audit services, the Audit Committee is responsible for the engagement and compensation of independent auditors,
oversight of their activities and evaluation of their independence. The Audit Committee has instituted procedures for receiving reports of improper record keeping, accounting or disclosure. In the opinion of the AxoGen Board of Directors, each of
the members of the Audit Committee has both business experience and an understanding of generally accepted accounting principles and financial statements enabling them to effectively discharge their responsibilities as members of that Committee.
Moreover, the AxoGen Board of Directors has determined that each of Messrs. Rudelius, Grooms and Harper is an &#147;audit committee financial expert&#148; as such term is defined in Item&nbsp;407(d)(5) of Regulation S-K promulgated by the SEC.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee is responsible for establishing executive compensation and administering AxoGen&#146;s Incentive Compensation Plan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Governance and Nominating Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Governance and Nominating
Committee is responsible to provide oversight in relation to the corporate governance of AxoGen and also identifies director nominees for election to fill vacancies on the AxoGen Board of Directors. Nominees are approved by the AxoGen Board of
Directors on recommendation of the Governance and Nominating Committee. In evaluating nominees, the Governance and Nominating Committee particularly seeks candidates of high ethical character with significant business experience at the senior
management level who have the time and energy to attend to board responsibilities. Candidates should also satisfy such other particular requirements that the Governance and Nominating Committee may consider important to AxoGen&#146;s business at the
time. When a vacancy occurs on the AxoGen Board of Directors, the Governance and Nominating Committee will consider nominees from all sources, including shareholders, nominees recommended by other parties, and candidates known to the directors or
AxoGen&#146;s management. The best candidate from all evaluated will be recommended to the AxoGen Board of Directors to consider for nomination. Shareholders who wish to recommend candidates for consideration as nominees should on or before
January&nbsp;1 of each year furnish in writing detailed biographical information concerning the candidate to the Governance and Nominating Committee addressed to the Corporate Secretary of AxoGen at 13859 Progress Blvd., Suite 100, Alachua, FL
32615. No material changes have been made to the procedures by which security holders may recommend nominees to AxoGen&#146;s Board of Directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_11"></A>EXECUTIVE COMPENSATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Compensation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Summary Compensation Table </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the cash and non&#150;cash compensation for the fiscal years 2012 and 2011 for: (i)&nbsp;each individual serving as the Company&#146;s Chief Executive Officer
(&#147;CEO&#148;) or acting in a similar capacity during any part of such fiscal years; and (ii)&nbsp;the other two most highly paid executive officers who were serving as executive officers during such periods (our &#147;named executive
officers&#148;). </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:97pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Principal Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Bonus($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock<BR>Awards($)(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards(#)(1)(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other<BR>Compensation($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej<BR>CEO (3)(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">291,200</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">252,403</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,646</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,254</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">516,697</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,893</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,537</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">310,739</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">799,891</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory G. Freitag(5)<BR>Former CEO and CFO and General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">204,069</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154,808</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,161</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,000</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">172,859</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,594</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">217,824</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">427,667</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John P. Engels<BR>Vice President(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">174,888</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">171,138</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,689</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,833</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><BR>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121,998</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,600</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,453</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">189,177</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">315,422</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jill Schiaparelli</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">173,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">208,672</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">393,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President Business Strategy and Marketing(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts in this column are calculated based on the aggregate grant date fair value computed in accordance with Accounting Standards Codification (&#147;ASC&#148;)
Topic 718 as of December&nbsp;31 of the year indicated. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts shown for option awards relate to option awards granted under the AxoGen Corporation 2002 Stock Incentive Plan, as amended. These amounts are equal to the
aggregate grant date fair value of the options computed in accordance with FASB ASC Topic 718 using the assumptions set forth in Note 10 to AxoGen&#146;s audited consolidated financial statements included elsewhere in this Form 10-K.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms. Zaderej voluntarily accepted reduced salaries for a portion of 2011. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms. Zaderej has been CEO of the Company since September&nbsp;30, 2011 as a result of the Merger, CEO of AC since May 2010 and was Chief Operating Officer of AC from
2007 through May 2010. The amounts include life insurance premiums paid by AxoGen on behalf of Zaderej in 2011 of $365 and $393 in 2012 and also includes amounts contributed by the Company to the SIMPLE IRA plan on her behalf for 2011 of $7,172 and
2012 of $7,500. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Gregory G. Freitag is our current CFO and General Counsel and has been serving in such capacity since June&nbsp;1, 2010. Mr. Freitag stepped down as CEO on
September&nbsp;30, 2011 in conjunction with the Merger. On September&nbsp;30, 2011, Mr. Freitag received a one-time bonus as a result of completing the Merger. The amounts include life insurance premiums paid by AxoGen on behalf of Mr. Freitag in
2012 of $411 and also includes amounts contributed by the Company to the SIMPLE IRA plan on his behalf for 2012 of $5,183. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts include life insurance premiums paid by AxoGen on behalf of Mr. Engels in 2011 of $319 and $353 in 2012 and also includes amounts contributed by the Company
to the SIMPLE IRA plan on his behalf for 2011 of $5,134 and 2012 of $5,247. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts include life insurance premiums paid by AxoGen on behalf of Ms. Schiaparelli in 2012 of $167 and also includes amounts contributed by the Company to the
SIMPLE IRA plan on her behalf for 2012 of $5,210. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Outstanding Equity Awards at Fiscal Year End </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the equity awards granted to our named executive officers that remain outstanding as of December&nbsp;31,
2012. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="20" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option Awards</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Grant Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Securities</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option&nbsp;Expiration<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/18/2008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;(1)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/18/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/9/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,167(1)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/26/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206,250(2)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/26/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/26/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;(3)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/26/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory G. Freitag</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,000(4)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/1/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/26/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69,000(5)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/26/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John P. Engels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/7/2006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,727(6)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/7/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/6/2007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">719(6)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/6/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/18/2008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406(6)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/18/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/9/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,554(6)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,131(6)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/9/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/16/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,750(7)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/16/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jill Schiaparelli</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/27/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,913(8)</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/27/2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Zaderej received these options to purchase shares of AC common stock, which options pursuant to the Merger have been adjusted and provide for the right to
purchase Company common Shares. The options vest semi-annually and become fully vested and exercisable four years from the grant date. The options were granted under plans previously approved by AxoGen&#146;s shareholders and the exercise price for
the options were issued at a price equal to the fair market value of the AxoGen&#146;s common shares on the date of grant. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Zaderej received this option to purchase 275,000 shares of the Company&#146;s common shares. All shares pursuant to the option will be fully vested on
December&nbsp;26, 2015 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December&nbsp;26, 2012 (12 months from the option grant date) and an additional 12.5% of aggregate shares each 6
months thereafter and will expire December&nbsp;26, 2018. The option was granted under plans previously approved by the Company&#146;s shareholders and the exercise price for the options were issued at a price equal to the fair market value of the
Company&#146;s common shares on the date of grant. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Zaderej received this option to purchase 100,000 shares of the Company&#146;s common shares. The shares under the Option are subject to a performance vesting
provision (the &#147;Performance Shares&#148;) whereby all, none or a portion of the Performance Shares, to the extent to which the performance standards established by the Board of Directors are met, will vest as to 25% of the Performance Shares on
March&nbsp;31, 2013, and an additional 12.5% of the Performance Shares each six months thereafter, with all Performance Shares being fully vested on December&nbsp;26, 2015 (4 years from the Option grant date) and will expire December&nbsp;26, 2018.
The option was granted under plans previously approved by the Company&#146;s shareholders and the exercise price for the options were issued at a price equal to the fair market value of the Company&#146;s common shares on the date of grant. These
options were forfeited on December&nbsp;31, 2012 due to not achieving the performance standard. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Freitag received this option which became fully vested and exercisable on August&nbsp;29, 2011 pursuant to the vesting terms of the option. The option was
granted outside of plans previously approved by the Company&#146;s shareholders and the exercise price for the option was issued at a price equal to the fair market value of the Company&#146;s common shares on the date of grant.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Freitag received this option to purchase 92,000 shares of the Company&#146;s common shares. All shares pursuant to the option will be fully vested on
December&nbsp;26, 2015 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December&nbsp;26, 2012 (12 months from the option grant date) and an additional 12.5% of aggregate shares each 6
months thereafter and will expire December&nbsp;26, 2018. The option was granted under plans previously approved by the Company&#146;s shareholders and the exercise price for the options were issued at a price equal to the fair market value of the
Company&#146;s common shares on the date of grant. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Engels received these options to purchase shares of AC common stock, which options pursuant to the Merger have been adjusted and provide for the right to
purchase Company common shares. The options vest semi-annually and become fully vested and exercisable four years from the grant date. The options were granted under plans previously approved by AxoGen&#146;s shareholders and the exercise price for
the options were issued at a price equal to the fair market value of the AxoGen&#146;s common shares on the date of grant. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Engels received this option to purchase 65,000 shares of the Company&#146;s common shares. All shares pursuant to the option will be fully vested on
December&nbsp;16, 2015 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December&nbsp;26, 2012 (12 months from the option grant date) and an additional 12.5% of aggregate shares each 6
months thereafter and will expire December&nbsp;16, 2018. The option was granted under plans previously approved by the Company&#146;s shareholders and the exercise price for the options were issued at a price equal to the fair market value of the
Company&#146;s common shares on the date of grant. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Schiaparelli received this option to purchase 90,913 shares of the Company&#146;s common shares. All shares pursuant to the option will be fully vested on
February&nbsp;2, 2016 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on February&nbsp;2, 2013 (12 months from the option grant date) and an additional 12.5% of aggregate shares each 6
months thereafter and will expire February&nbsp;27, 2019. The option was granted under plans previously approved by the Company&#146;s shareholders and the exercise price for the options were issued at a price equal to the fair market value of the
Company&#146;s common shares on the date of grant. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Employment Agreements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC is a party to employment agreements with each of Karen Zaderej, effective October&nbsp;15, 2007 and as amended September&nbsp;29, 2011,
John P. Engels, effective May&nbsp;6, 2003 and as amended September&nbsp;29, 2011, Gregory Freitag, effective October&nbsp;1, 2011, Jill Schiaparelli, effective February&nbsp;27, 2012 and Shawn McCarrey, effective February&nbsp;25, 2013.
Ms.&nbsp;Zaderej and Mr.&nbsp;Engels employment agreements renew for one year periods on each anniversary of the effective date and provide for severance benefits upon termination of the executive officer&#146;s employment: (1)&nbsp;by AxoGen for
any reason other than &#147;substantial cause&#148; (as defined below), permanent disability, or death, (2)&nbsp;by the executive officer due to AxoGen&#146;s breach of the employment agreement and AxoGen&#146;s failure to cure such breach within
ten days following notice by the executive officer of such breach; or (3)&nbsp;by the executive officer within six months of a &#147;change of control&#148; (as defined below) of AxoGen. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon a termination of Ms.&nbsp;Zaderej&#146;s employment for any of the reasons set forth above, Ms.&nbsp;Zaderej is entitled to base
salary in an amount equal to the base salary that she would have been paid for the remainder of the then current employment period had the executive officer&#146;s employment not been terminated or the one-year non-competition period, whichever is
longer. Upon a termination of Mr.&nbsp;Engels&#146; employment for any of the reasons set forth above, Mr.&nbsp;Engels is entitled to base salary in an amount equal to the base salary that he would have been paid for the remainder of the then
current employment period had the executive officer&#146;s employment not been terminated. Both Ms.&nbsp;Zaderej and Mr.&nbsp;Engels are entitled to continued medical and dental benefits (in the form of a reimbursement for the COBRA premiums) and
continued bonus payments to which the executive officer would have been entitled for the remainder of the then current employment period had the executive officer&#146;s employment not been terminated. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under their respective employment agreement, Messrs. Freitag and McCarrey and Ms.&nbsp;Schiaparelli employment are at will. In the event
Messrs. Freitag or McCarrey or Ms.&nbsp;Schiaparelli is terminated without substantial cause either prior to a change of control or 180 days following a change in control the person is entitled to a severance payment consisting of (A)&nbsp;twelve
months of base salary; and (B)&nbsp;an amount equal to any bonuses paid during the twelve month period prior to termination of employment. Messrs. Freitag and McCarrey and Ms.&nbsp;Schiaparelli are also entitled to severance of twelve months of base
salary if the person leaves AxoGen for &#147;good reason&#148; (as defined below) within 180 days following a change of control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, Ms.&nbsp;Zaderej is entitled to full vesting of her outstanding stock options that were granted prior to the Merger upon a change of control, regardless of whether her employment terminates
on or following the change of control. With respect to Ms.&nbsp;Zaderej&#146;s, Ms.&nbsp;Schiaparelli&#146;s and Messrs. Freitag&#146;s, Engel&#146;s and McCarrey&#146;s post-Merger stock options, if a change of control occurs, such options shall
automatically accelerate and become fully exercisable in the event that within twelve months following the change of control they are terminated without cause or leave for good reason. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the executive officer&#146;s employment agreements, &#147;change of control&#148; means the occurrence of any of the
following events: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any person who holds less than 20% of the combined voting power of the securities of AC or AxoGen, Inc., becomes the beneficial owner, directly or
indirectly, of securities of AC or AxoGen, Inc., representing 50% or more of the combined voting power of the securities of AC or AxoGen, Inc. then outstanding; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">during any period of 24 consecutive months, individuals who at the beginning of such period constitute all members of the AxoGen, Inc.&#146;s Board of
Directors cease, for any reason, to constitute at least a majority of the board of directors, unless the election of each director who was not a director at the beginning of the period was either nominated for election by, or was approved by a vote
of, at least two-thirds of the directors then still in office who were directors at the beginning of the period; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC or AxoGen, Inc. consolidates or merges with another company and AC or AxoGen, Inc. is not the continuing or surviving corporation, provided,
however, that any consolidation or merger whereby AxoGen, Inc. continues as the majority holder of AC securities or a merger or consolidation of AC and AxoGen, Inc. will not constitute a change in control; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">shares of AC&#146;s or AxoGen, Inc.&#146;s common shares are converted into cash, securities, or other property (other than by a merger set forth in
(iii)&nbsp;above) in which the holders of the AC&#146;s or AxoGen, Inc.&#146;s common shares immediately prior to the merger have the same proportionate ownership of common shares of the surviving corporation as immediately after the merger;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC or AxoGen, Inc. sells, leases, exchanges, or otherwise transfers all or substantially all of its assets (in one transaction or in a series of
related transactions); or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the holders of AxoGen&#146;s stock approve a plan or proposal for the liquidation or dissolution of AC or AxoGen, Inc. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of Ms.&nbsp;Zaderej&#146;s, Ms.&nbsp;Schiaparelli&#146;s and Messrs. Freitag&#146;s and McCarrey&#146;s employment
agreements, &#147;substantial cause&#148; means: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">commission of any act of fraud, theft, or embezzlement; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">material breach of the employment agreement, provided that AC shall have first delivered to the executive officer written notice of the alleged breach,
specifying the exact nature of the breach in detail, and provided, further, that the executive officer shall have failed to cure or substantially mitigate such breach within ten days after receiving such written notice; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">commission or conviction of any felony, or of any misdemeanor involving moral turpitude, or entry of a plea of guilty or nolo contendere to any felony
or misdemeanor; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">material failure to adhere to AC&#146;s corporate codes, policies or procedures which have been adopted in good faith for a valid business purpose as
in effect from time to time; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure to meet reasonable performance standards as determined by AC, which for Mr.&nbsp;McCarrey includes the failure of gross revenue in a calendar
quarter exceed 80% of budgeted gross revenue. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of Mr.&nbsp;Engels&#146; employment agreement,
&#147;substantial cause&#148; means the commission by Mr.&nbsp;Engels of any act of fraud, theft or embezzlement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For
purposes of Messrs. Freitag&#146;s and McCarrey&#146;s and Ms.&nbsp;Schiaparelli&#146;s employment agreements, &#147;good reason&#148; means the occurrence of any one or more of the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the assignment of any duties inconsistent in any respect with the person&#146;s position (including status, offices, titles, and reporting
requirements), authorities, duties, or other responsibilities as in effect immediately prior to a change of control or any other action by AxoGen which results in a diminishment in such position, authority, duties, or responsibilities, other than an
insubstantial and inadvertent action which is remedied by AxoGen; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a reduction by AC in the person&#146;s base salary; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the failure by AC to (A)&nbsp;continue in effect any material compensation or benefit plan, program, policy or practice in which the person was
participating at the time of the change of control of AxoGen or (B)&nbsp;provide the person with compensation and benefits at least equal (in terms of benefit levels and/or reward opportunities) to those provided for under each employee benefit
plan, program, policy and practice as in effect immediately prior to the change in control (or as in effect following the Change in Control of the Company), if greater. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">81 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pension Benefits </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen adopted the AxoGen SIMPLE IRA plan in 2007. The AxoGen named executive officers participate in the SIMPLE IRA plan. Eligibility is
immediate upon employment, and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The SIMPLE IRA plan requires AxoGen to make
matching contributions of between 1% and 3% of the employee&#146;s annual salary as long as the employee participates in the SIMPLE IRA plan. Additionally, the matching contribution has to be at least 3% for three of the first five years of the
SIMPLE IRA. Both employee contributions and AxoGen contributions are fully vested at all times. In 2012 and 2011, AxoGen&#146;s matching contribution was 3% of the AxoGen named executive officers&#146; annual base salary. AxoGen contributed
approximately $23,000 and $12,000 in matching funds for the AxoGen named executive officers during 2012 and 2011, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director
Compensation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each non-employee director receives a quarterly cash retainer payment of $3,000 for services to AxoGen
starting in the first quarter after election, which cash payment is paid in advance each quarter. Non-employee directors are also paid $1,500 per in-person Board of Directors meeting if they attend in person and $750 for such in-person meeting if
they participate by telephone. No additional compensation is provided for telephonic Board meetings or actions taken pursuant to written minutes of action of the Board. Non-employee directors are paid $1,000 per committee meeting attended in-person
if they attend in person and $500 for such in-person committee meeting if they participate by telephone. The total board and committee member fees cannot exceed $2,500 per day. In addition, all non-employee directors receive an annual calendar year
non-qualified stock option grant equal to 0.1% of the fully diluted stock of AxoGen, rounded down to a 250 share increment, at an exercise price equal to the fair market value of our common shares on the date of grant. Such stock options are for a
term of seven years and are fully vested upon grant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">82 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Director Compensation Table </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the compensation earned by all persons serving as members of our Board of Directors during 2012. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash ($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock<BR>Awards($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards($)(3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert J. Rudelius</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory G. Freitag</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jamie M. Grooms(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Gold, M.D.(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Harper(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joe Mandato(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John McLaughlin (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Service as a member of our Board of Directors began on September&nbsp;30, 2011 when their election at the Company&#146;s 2010 Annual Meeting of Shareholders took effect
as a result of the closing of the Merger. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Service as a member of our Board of Directors began on October&nbsp;4, 2012 when Mr.&nbsp;McLaughlin was appointed to the Board pursuant to the PDL Royalty Contract.
Mr.&nbsp;McLaughlin&#146;s director fees were paid to PDL. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts in this column are calculated based on the aggregate grant date fair value computed in accordance with Accounting Standards Codification (ASC) Topic 718 as
of December&nbsp;31, 2012. </FONT></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_12"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">One of our directors, Joe Mandato, is a Managing Partner of DeNovo Ventures II, L.P. which is a greater than 5%
shareholder of the Company&#146;s common shares. Another director of ours, John McLaughlin, is an executive officer of PDL, with which the Company has entered into the Royalty Contract. See &#147;Business<B>&#151;</B> PDL BioPharma, Inc. Revenue
Interests Purchase Agreement&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">83 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_13"></A>PRINCIPAL SHAREHOLDERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth, as of August&nbsp;5, 2013, certain information with respect to the beneficial ownership of our common
shares (the only voting class outstanding), (i)&nbsp;by each director, (ii)&nbsp;by each of the named executive officers and (iii)&nbsp;by all officers and directors as a group. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:89pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares<BR>Beneficially<BR>Owned<BR>Before<BR>Offering&nbsp;(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage<BR>of<BR>Outstanding<BR>Shares<BR>Beneficially<BR>Owned<BR>Before<BR>Offering (1)</B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares<BR>Beneficially<BR>Owned<BR>After<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage&nbsp;of<BR>Outstanding<BR>Shares<BR>Beneficially<BR>Owned After<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DeNovo Ventures II, LP(2)</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2180 Sand Hill Rd.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suite 200</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Menlo Park, CA 94025</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,426,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,426,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMV Partners I, L.P.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2750 Premier Parkway</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suite 200</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Duluth, GA 30097</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,017,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,017,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Utility Service Holding Company, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">972,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">972,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CHP II, L.P.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">230 Nassau St.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Princeton, NJ 08542</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: John Park</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">886,556</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">886,556</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">278,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">278,208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jamie M. Grooms(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">473,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">473,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John P. Engels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Gold, M.D.(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">277,697</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">277,697</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Harper</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">184,371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">184,371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joe Mandato(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Rudelius</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Greg Freitag</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">183,818</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">183,818</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All directors and executive officers as a group (11 persons) (2)(3)(4)(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,723,695</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,723,695</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In general, a person is deemed to be the beneficial owner of (i)&nbsp;any of
our common shares over which such person has sole or shared voting power or investment power, plus (ii)&nbsp;any shares which such person has the right to acquire beneficial ownership of within 60 days, whether through the exercise of options,
warrants or otherwise. The percentage of ownership set forth above is based on 11,139,939 common shares outstanding as of August&nbsp;5, 2013. Our common shares issuable upon the exercise of stock options exercisable currently or within 60 days of
August&nbsp;5, 2013 are deemed outstanding and to be beneficially owned by the person holding such option for purposes of computing such person&#146;s percentage ownership, but are not deemed outstanding for the purpose of computing the percentage
ownership of any other person. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">84 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Mandato is a Managing Partner of this venture capital fund. Mr.&nbsp;Mandato disclaims beneficial ownership of the shares owned by the fund.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">These shares include 218,534 shares of record held by Mr.&nbsp;Grooms, and 132,883 shares held by the Jamie Grooms Trust, of which Mr.&nbsp;Grooms is the trustee.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">These shares include 107,690 shares held by Dr.&nbsp;Gold&#146;s wife and 125,523 shares held by MJSK, Ltd., an investment trust held by Dr.&nbsp;Gold&#146;s family.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes 5,665 shares held by Mark Friedman and 5,750 held by Jill Schiaparelli. Also includes a number of shares underlying options equal to 22,728, 21,311 and 23,653,
for Jill Schiaparelli, Mark Friedman and Dave Hansen, respectively. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">85 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_14"></A>DESCRIPTION OF COMMON SHARES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following
description does not purport to be complete and is subject in all respects to applicable Minnesota law and to the provisions of the AxoGen Amended and Restated Articles of Incorporation and bylaws, as amended to the date of this prospectus. AxoGen
shareholders are urged to read the Amended and Restated Articles of Incorporation and bylaws for a more complete description of these provisions and other information that may be important to AxoGen shareholders. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Capital Stock </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s authorized capital stock consists of 50,000,000 shares, par value $0.01 per share. The authorized capital stock is divisible
into the classes and series, has the designation, voting rights, and other rights and preferences and is subject to the restrictions that the AxoGen Board of Directors may from time to time establish. Unless otherwise designated by the AxoGen Board
of Directors, all shares are common shares. The holders of AxoGen common shares: (1)&nbsp;have equal ratable rights to dividends from funds legally available therefor, when, as and if declared by the AxoGen Board of Directors; (2)&nbsp;are entitled
to share ratably in all assets available for distribution to holders of AxoGen common shares upon liquidation, dissolution or winding up of its affairs; (3)&nbsp;do not have preemptive, subscription or conversion rights and there are no redemption
or sinking fund provisions applicable thereto; and (4)&nbsp;are entitled to one vote per share on all matters which shareholders may vote on at all meetings of shareholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All shares of AxoGen common shares now outstanding are fully paid and nonassessable. The holders of shares of AxoGen common shares do not have cumulative voting rights, which means that the holders of
more than 50% of the outstanding shares voting for the election of directors can elect all of AxoGen&#146;s directors to be elected, if they so choose. In such event, the holders of the remaining shares will not be able to elect any directors.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After consummation of this offering, AxoGen expects to have 15,325,985 common shares outstanding, or 15,953,891 common shares
if the underwriters&#146; overallotment option is exercised in full. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wells Fargo Bank, N.A. is the transfer agent for AxoGen
common shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Minnesota Anti-Takeover Laws </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen is governed by the provisions of Sections 302A.671, 302A.673 and 302A.675 of the Minnesota Business Corporation Act. These provisions may discourage a negotiated acquisition or unsolicited takeover
of AxoGen and deprive AxoGen security holders of an opportunity to sell their shares at a premium over the market price. In general, Section&nbsp;302A.671 provides that a corporation&#146;s shares acquired in a control share acquisition have no
voting rights unless voting rights are approved in a prescribed manner. A &#147;control share acquisition&#148; is a direct or indirect acquisition of beneficial ownership of shares that would, when added to all other shares beneficially owned by
the acquiring person, entitle the acquiring person to have voting power of 20% or more in the election of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
general, Section&nbsp;302A.673 prohibits a public Minnesota corporation from engaging in a business combination with an interested shareholder for a period of four years after the date of the transaction in which the person became an interested
shareholder, unless the business combination is approved in a prescribed manner. The term &#147;business combination&#148; includes mergers, asset sales and other transactions resulting in a financial benefit to the interested shareholder. An
&#147;interested shareholder&#148; is a person who is the beneficial owner, directly or indirectly, of 10% or more of a corporation&#146;s voting stock, or who is an affiliate or associate of the corporation, and who, at any time within four years
before the date in question, was the beneficial owner, directly or indirectly, of 10% or more of the corporation&#146;s voting stock. Section&nbsp;302A.673 does not apply if a committee of the AxoGen Board of Directors consisting of all of its
disinterested directors (excluding current and former officers) approves the proposed transaction or the interested shareholder&#146;s acquisition of shares before the interested shareholder becomes an interested shareholder. If a tender offer is
made for AxoGen common stock, Section&nbsp;302A.675 of the Minnesota </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Business Corporation Act precludes the offeror from acquiring additional shares of stock (including in acquisitions pursuant to mergers, consolidations or statutory share exchanges) within two
years following the completion of the tender offer, unless shareholders selling their shares in the later acquisition are given the opportunity to sell their shares on terms that are substantially the same as those contained in the earlier tender
offer. Section&nbsp;302A.675 does not apply if a committee of the AxoGen Board of Directors consisting of all of its disinterested directors (excluding its current and former officers) approves the proposed acquisition before any shares are acquired
pursuant to the earlier tender offer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Trading </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our common shares currently trade on the OTCQB Marketplace under the symbol &#147;AXGN&#148; In connection with this offering, we have been approved to list our common shares on the NASDAQ Capital Market
under the symbol &#147;AXGN.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The transfer agent and registrar for our common shares is Wells Fargo Shareowner Services. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">87 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_15"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the underwriters for the offering named below have entered into an underwriting agreement with respect to the shares of common
shares being offered. Subject to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase from us the number of common shares set forth opposite its name below. JMP Securities is the representative of
the underwriters. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:46pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Underwriters</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">JMP Securities LLC.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ladenburg Thalmann&nbsp;&amp; Co., Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,186,046</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters are offering the common shares subject to each underwriter&#146;s acceptance of the
shares of common stock from us and subject to prior sale. The underwriting agreement provides that the obligation of each underwriter to pay for and accept delivery of the shares of common stock offered by this prospectus is subject to the approval
of certain legal matters by its counsel and to certain other conditions. Each underwriter is obligated to take and pay for all of the shares of common stock if any such shares are taken. However, the underwriters are not required to take or pay for
the shares of common stock covered by the underwriters&#146; <FONT STYLE="white-space:nowrap">over-allotment</FONT> option described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The public offering price will be determined through negotiations between us and the representative. In addition to prevailing market conditions, the factors considered in determining the public offering
price are: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the reported price of our common shares on the OTCQB Marketplace; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the closing valuation multiples of publicly traded companies that the representative believes to be comparable to us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our financial information; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the history of, and the prospects for, our company and the industry in which we compete; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenues;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the present state of our development; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Over-Allotment Option </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have granted the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to an aggregate of 627,906 additional shares of common stock to cover over-allotments,
if any, at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. The underwriters may exercise this option solely for the purpose of covering over-allotments, if any, made in
connection with the offering of the shares of common stock offered by this prospectus. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commission and Expenses
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters have advised us that they propose to offer the shares of common stock to the public at the public
offering price set forth on the cover page of this prospectus and to certain dealers at that price less a concession not in excess of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock. After this
offering, the public offering price, concession and reallowance to dealers may be changed by the underwriters. No such change shall change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. The shares of
common stock are offered by the underwriters subject to various conditions as stated herein, including receipt and acceptance by it and its right to reject any order in whole or in part. The underwriters have informed us that they do not intend to
confirm sales to any accounts over which they exercise discretionary authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the underwriting
discounts and commissions payable to the underwriter by us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriter&#146;s over-allotment option to purchase additional shares.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">88 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per<BR>Common<BR>Share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total Without<BR>Exercise
of<BR><FONT STYLE="white-space:nowrap">Over-Allotment</FONT><BR>Option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total With<BR>Exercise
of<BR><FONT STYLE="white-space:nowrap">Over-Allotment</FONT><BR>Option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discounts and commissions payable by us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that expenses payable by us in connection with this offering (including the reimbursement of
the underwriters&#146; expenses described in this paragraph), other than the underwriting discounts and commissions referred to above, will be approximately $560,000. We have agreed to reimburse the underwriters for reasonable fees and other
disbursements of counsel to the underwriters and other reasonable out-of-pocket expenses actually incurred by the underwriters in an amount not to exceed $150,000 in the aggregate. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Indemnification </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, and liabilities arising from breaches of representations and warranties contained
in the underwriting agreement, or to contribute to payments that the underwriters may be required to make in respect of those liabilities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Lock-up Agreements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We, our officers and directors and holders of 3,330,852
shares of our common stock have agreed, subject to limited exceptions, for a period of 90 days after the date of the underwriting agreement, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise
dispose of, directly or indirectly any shares of common stock or any securities convertible into or exchangeable for our common stock either owned as of the date of the underwriting agreement or thereafter acquired without the prior written consent
of JMP Securities LLC. This 90-day period may be extended if (1)&nbsp;during the last 17 days of the 90-day period, we issue an earnings release or material news or a material event regarding us occurs or (2)&nbsp;prior to the expiration of the
90-day period, we announce that we will release earnings results during the 16-day period beginning on the last day of the 90-day period, then the period of such extension will be 18 days, beginning on the issuance of the earnings release or the
occurrence of the material news or material event. JMP Securities LLC may, in its sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject
to lock-up agreements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Electronic Distribution </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus in electronic format may be made available on websites or through other online services maintained by the underwriters, or
by their affiliates. Other than this prospectus in electronic format, the information on any underwriter&#146;s website and any information contained in any other website maintained by any underwriter is not part of this prospectus or the
registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or the underwriters in their capacity as underwriters, and should not be relied upon by investors. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Price Stabilization, Short Positions and Penalty Bids </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with the offering the underwriters may engage in stabilizing transactions, over-allotment transactions and syndicate covering transactions in accordance with Regulation M under the Exchange
Act: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">89 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Over-allotment involves sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase, which creates
a syndicate short position. The short position may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they
may purchase in the over-allotment option. In a naked short position, the number of shares involved is greater than the number of shares in the over-allotment option. The underwriters may close out any covered short position by either exercising
their over-allotment option and/or purchasing shares in the open market. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Syndicate covering transactions involve purchases of shares of the common stock in the open market after the distribution has been completed in order
to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at
which they may purchase shares through the over-allotment option. If the underwriters sell more shares than could be covered by the over-allotment option, a naked short position, the position can only be closed out by buying shares in the open
market. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the
offering. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These stabilizing transactions, syndicate covering transactions and penalty bids may have the
effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in
the open market. Neither we nor the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor the
underwriters make any representations that the underwriters will engage in these stabilizing transactions or that any transaction, once commenced, will not be discontinued without notice. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Listing and Transfer Agent </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have been approved to list our common shares on the NASDAQ Capital Market under the symbol &#147;AXGN.&#148; The transfer agent of our common shares is Wells Fargo Bank, N.A. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriter and/or their affiliates have provided, and may in the future provide, various investment banking and other financial
services for us for which services they have received and, may in the future receive, customary fees. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_16">
</A>LEGAL MATTERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain legal matters in connection with the securities offered hereby will be passed upon for us by
Morgan, Lewis&nbsp;&amp; Bockius LLP, Philadelphia, Pennsylvania and Kaplan, Strangis and Kaplan, P.A., Minneapolis, Minnesota. Certain legal matters in connection with this offering will be passed upon for the underwriters by Orrick, Herrington
&amp; Sutcliffe LLP, San Francisco, California. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">90 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_17"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements of the Company as of December&nbsp;31, 2012 and 2011, and for the years then ended included in this prospectus
and registration statement, have been included in reliance of the reports on Lurie Besikof Lapidus&nbsp;&amp; Company, LLP, an independent registered public accounting firm, given on the authority of said firm as experts in accounting and auditing.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">91 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_18"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have filed with the SEC a registration statement under the Securities Act of 1933 that registers the distribution of the common shares
offered under this prospectus. The registration statement contains additional relevant information about us and the common shares. The rules and regulations of the SEC allow us to omit from this prospectus certain information included in the
registration statement. Statements contained in this prospectus as to the contents of any documents that we have filed as an exhibit to the registration statement are qualified in their entirety by reference to the exhibits for a complete statement
of their terms and conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we file annual, quarterly and current reports, proxy statements and other
information with the SEC. You may read and copy this information and the registration statement at the SEC public reference room located at 100 F Street, N.E., Washington D.C. 20549. You may obtain information on the operation of the Public
Reference Room by calling the SEC at 1-800-SEC-0330. Any information we file with the SEC is also available on the SEC&#146;s website at http://www.sec.gov. We also maintain a website at <U>http://www.axogeninc.com/secfilings.html</U> through which
you can access our SEC filings. We have included our website address in this prospectus solely as an inactive textual reference. The information contained on, or that can be accessed through, our website is not part of this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">92 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc532389_19"></A>AXOGEN, INC. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="index"></A><A NAME="toc532389_22"></A>INDEX TO FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Audited Consolidated Financial Statements </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_1">Report of Independent Registered Public Accounting Firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_2">Consolidated Balance Sheets as of December&nbsp;31, 2012 and 2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_3">Consolidated Statements of Operations for the Years Ended December&nbsp;31, 2012 and
2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_4">Consolidated Statements of Shareholders&#146; Equity (Deficit) for the Years Ended December&nbsp;
31, 2012 and 2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_5">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;31, 2012 and
2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_6">Notes to Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Unaudited Condensed Consolidated Financial Statements</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_7">Condensed Consolidated Balance Sheets as of March&nbsp;31, 2013 and 2012</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_8">Condensed Consolidated Statements of Operations for the Three Months Ended March&nbsp;31, 2013 and
2012</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_9">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March&nbsp;31, 2013 and
2012</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin532389_10">Notes to Condensed Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U><A NAME="fin532389_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the Shareholders and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Board
of Directors of </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have audited the accompanying consolidated balance sheets of AxoGen, Inc. as of December&nbsp;31, 2012 and 2011, and the related consolidated statements of operations, shareholders&#146; equity
(deficit), and cash flows for the years then ended. These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audit.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an
audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of
expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures
in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our opinion, the consolidated financial statements referred to above present fairly, in
all material respects, the financial position of AxoGen, Inc. as of December&nbsp;31, 2012 and 2011, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the
United States of America. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ LURIE BESIKOF LAPIDUS &amp; COMPANY, LLP </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Minneapolis, Minnesota </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;12, 2013 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_2"></A>CONSOLIDATED BALANCE SHEETS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2012 and 2011 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current assets:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,907,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,190,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,050,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">797,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,151,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,760,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">133,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total current assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,295,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,882,475</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Property and equipment, net</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">247,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Goodwill</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">169,987</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intangible assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">573,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">899,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Deferred financing costs</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,252,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">295,276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,230,563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,495,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liabilities and Shareholders&#146; Equity (Deficit)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current liabilities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,479,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,585,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current portion of long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151; &nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">434,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total current liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,479,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,019,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-term debt</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,403,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note Payable &#151; Revenue Interest Purchase Agreement</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,060,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,423,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Shareholders&#146; equity (deficit):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $.01 par value; 50,000,000 shares authorized; 11,122,573 and 11,062,188 shares issued and
outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110,622</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,908,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,391,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,848,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(48,430,935</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total shareholders&#146; equity (deficit)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,829,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,071,471</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,230,563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,495,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:237px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_3"></A>CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Years ended December&nbsp;31, 2012 and 2011 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenues</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,691,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,849,470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cost of goods sold</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,961,877</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,426,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gross profit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,729,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,422,926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Costs and expenses:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales and marketing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,883,953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,378,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,427,211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">697,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,220,599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,315,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total costs and expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,531,763</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,391,653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Loss from operations</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,801,936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,968,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other income (expense):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,391,342</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,094,657</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense &#151; deferred financing costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(986,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,223,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value of warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,305</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,972</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,985</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total other income (expense)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,354,214</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,250,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Loss before income taxes</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,156,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,219,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Income tax benefit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">738,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net Loss</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,219,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred Stock dividends (assumes all paid)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,028,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss available to common shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,247,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted Average Common Shares outstanding &#151; basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,089,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,697,390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss Per Common share &#151; basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:235px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_4"></A>CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#146; EQUITY (DEFICIT) </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Years ended December&nbsp;31, 2012 and 2011 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Series A Convertible</I></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Preferred
Stock</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Common Stock</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Additional<BR>Paid-in</I></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Capital
</I></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Accumulated</I></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Deficit</I></FONT>
</TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Total<BR>Stockholders&#146;</I></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Deficit
</I></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Shares</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Amount</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Shares</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>Amount</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance,</B> December&nbsp;31, 2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,544,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,205,624</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,056</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,934,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(38,183,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(27,111,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,044</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,044</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">987</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director Stock Compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conversion of preferred stock, debt, and accrued interest into Common Stock and shares exchange in Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,544,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,001,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,447,936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,372,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred Stock dividend payable forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,076,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,076,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant Liability forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,607,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,607,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merger Closing &#151; LecTec shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,305,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,050</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,804,866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,847,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">423,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">995,763</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">173,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">173,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series B preferred stock dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(292,330</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(292,330</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series C preferred stock dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(515,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(515,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D preferred stock dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(220,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(220,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,219,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,219,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance,</B> December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,062,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110,622</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,391,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(48,430,935</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,071,471</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">495,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">495,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,069</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,652</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock Grant for Services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancellation of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merger Closing &#151; Fractional shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance,</B> December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,122,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,908,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,848,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,829,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:50px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_5"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Years ended December&nbsp;31, 2012 and 2011 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from operating activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,219,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash used for operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">273,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">127,080</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67,147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss on impairment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">299,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss on abandonment of license</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of deferred financing costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">352,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,223,126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">161,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">495,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,044</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors Stock Compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock grant for service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancellation of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value of warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(62,305</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest added to note payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">780,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(252,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(368,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,390,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">142,249</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(53,757</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(105,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash used for operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,661,858</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,079,290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(48,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,610</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquisition of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(78,825</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(68,856</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash acquired with Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,201,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash (used for) provided by investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(127,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,112,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of note payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,961,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repayments of long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161,292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,732,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debt issuance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,309,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(434,772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,652</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash provided by financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,505,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,358,851</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,716,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,391,733</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents,</B> beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,190,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,799,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents,</B> end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,907,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,190,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supplemental disclosures of cash flow activity:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">649,108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,029,753</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supplemental disclosure of non-cash investing and financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments of long term debt with proceeds from note payable (this amount represents a payment made by PDL directly to MidCap
Financial SBIC, LP)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,838,706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conversion of preferred stock, convertible debt and accrued interest into common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,497,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accretion of dividends of Series B preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">292,330</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accretion of dividends of Series C preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">515,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accretion of dividends of Series D preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">220,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock dividend payable forfeited with the Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,076,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrant Liability forfeited with the Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,607,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debt discount related to warrants issued with debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">173,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net assets acquired on Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,847,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Note and accrued interest retired with the Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,555,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors stock compensation included in prepaid expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_6"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2012 and 2011 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Basis of Presentation </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying consolidated financial statements include the accounts of AxoGen, Inc. (the &#147;Company&#148; or &#147;AxoGen&#148;)
and its wholly owned subsidiary AxoGen Corporation (&#147;AC&#148;) as of December&nbsp;31, 2012 and December&nbsp;31, 2011 and the years then ended. The Company&#146;s consolidated financial statements have been prepared in accordance with
accounting principles generally accepted in the United States of America. All significant intercompany accounts and transactions have been eliminated in consolidation. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Organization and Business </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Business Summary </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, LecTec Corporation (&#147;LecTec&#148;) completed its business combination with AC in accordance with the terms of an
Agreement and Plan of Merger, dated as of May&nbsp;31, 2011, by and among LecTec, Nerve Merger Sub Corp., a subsidiary of LecTec (&#147;Merger Sub&#148;), and AC, which the parties amended on September&nbsp;30, 2011 and August&nbsp;9, 2011 (as
amended, the &#147;Merger Agreement&#148;). Pursuant to the Merger Agreement, Merger Sub merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the &#147;Merger&#148;).
Immediately following the Merger, LecTec changed its name to AxoGen, Inc. In October 2011, the Company moved its corporate headquarter facilities (principal executive office) from Texarkana, Texas to 13859 Progress Blvd., Suite 100, Alachua, Florida
32615. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Merger, </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all outstanding AC convertible securities were converted into shares of AC common stock and exchanged for shares of AxoGen, Inc. common stock;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all outstanding AC warrants expired unexercised; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all outstanding shares of AC common stock, including those issued upon conversion of AC convertible securities, were exchanged for shares of AxoGen,
Inc. common stock at a ratio of one share of AC common stock for 0.03727336 share of AxoGen, Inc. common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all outstanding options to purchase shares of AC common stock were exchanged for options to purchase shares of AxoGen, Inc. common stock at a ratio of
one option to purchase shares of AC common stock for an option to purchase 0.03727336 share of AxoGen, Inc. common stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A
total of 6,221,077 shares of the Company&#146;s common stock were issued in share exchange, and an additional 558,267 shares of the Company&#146;s common stock were reserved for issuance upon exercise of AC stock options which were converted into
the Company&#146;s stock options. Upon completion of the Merger, all AC securities were cancelled. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Immediately following the completion of
the Merger, former AC shareholders owned approximately 56.8% of the outstanding common stock of the Company, LecTec shareholders owned approximately 39.4% of the outstanding common stock of the Company, and certain investors owned the remaining 3.8%
of the outstanding common stock of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For accounting purposes, AC was identified as the acquiring entity and LecTec as the acquired
entity. The merger was accounted for using the purchase method of accounting for financial reporting purposes. The purchase method requires the identification of the acquiring entity, based on the criteria of Accounting Standards Codification
805-10-55-12, Accounting for Business Combinations. Under purchase accounting, the assets and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
liabilities of an acquired company (LecTec) as of the effective date of the acquisition were recorded at their respective estimated fair values and added to those of the acquiring company.
Accordingly, the consolidated financial statements and related footnote disclosures presented for periods prior to the Merger are those of AC alone. The consolidated Statement of Operations for the year ended December&nbsp;31, 2011 includes the
operations and cash flows of AC through September&nbsp;30, 2011 and the combined operations and cash flows of AC and LecTec subsequent to the Merger. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The common stock of AC has been retrospectively adjusted to reflect the exchange ratio of one share of AC common stock for 0.03727336 share of the Company&#146;s common shares as established in the Merger
Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is a regenerative medicine company with a portfolio of proprietary products and technologies for
peripheral nerve reconstruction and regeneration. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical
reconstruction and regeneration of peripheral nerves, the Company has developed and licensed technologies which are used in its products. Its product portfolio includes Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, which the Company believes is the first and only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve
is severed), AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector that protects nerves during the body&#146;s healing process after surgery. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary of Significant Accounting Policies </B></FONT></TD></TR></TABLE>

 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Revenue Recognition </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds.
Revenues for manufactured products and products sold under a distribution agreement are recognized when the product is delivered to the customer, at which time title passes to the customer. Once product is delivered, the Company has no further
performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for
shipping are recognized as revenues when products are shipped to the customer or end user. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Cash and Cash Equivalents and Concentration </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to
be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is
not exposed to any significant credit risk on cash and cash equivalents. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Accounts Receivable and Concentration of Credit Risk </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on
a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#146;s financial condition, credit history and current economic conditions. Accounts
receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received. As of December&nbsp;31, 2012 and December&nbsp;31, 2011, there were no amounts deemed uncollectible and there
was no allowance for doubtful accounts recorded. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concentrations of credit risk with respect to accounts receivable are limited because a
large number of geographically diverse customers make up the Company&#146;s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Inventories </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Inventories are comprised of implantable tissue, nerve grafts,
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finished goods</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,143,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,374,817</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Work in process</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Raw materials</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">862,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">240,423</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,151,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,760,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventories are net of reserve of $537,798 and $433,706 at December&nbsp;31, 2012 and 2011, respectively </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Property and Equipment </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furniture and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2-5&nbsp;years</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5&nbsp;years&nbsp;(or&nbsp;lease&nbsp;term&nbsp;if&nbsp;less)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Processing equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5-7&nbsp;years</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Major additions and improvements are capitalized, while replacements, maintenance and repairs, which do not improve or extend the life
of the respective assets, are expensed as incurred. When assets are retired or otherwise disposed of, related costs and accumulated depreciation and amortization are removed and any gain or loss is reported as other income or expense. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Intangible Assets </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Intangible assets consist primarily of license agreements for exclusive rights to use various patented and <FONT STYLE="white-space:nowrap">patent-pending</FONT> technologies described in Note 6 and other
costs related to the license agreements, including patent prosecution and protection costs. Such costs are capitalized and amortized on a straight-line basis over the underlying terms of the license agreements or estimated useful life of patents,
ranging from 5 to 20 years. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Impairment of Long-lived Assets, Including License Agreements
</U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted cash flows expected to be generated by the asset. If such assets are considered to
be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. For the year ended December&nbsp;31, 2012, the Company recorded an impairment loss of $129,667;
there was no impairment for the year ended December&nbsp;31, 2011. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Goodwill </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Goodwill represents the excess of the purchase price over the fair value of net assets acquired. Goodwill is not amortized, but is tested for impairment annually. The Company utilizes the income approach
in estimating fair value. The Company&#146;s 2012 annual goodwill impairment analysis indicated a significant decrease in the carrying value of goodwill, due to declines in the associated revenues, resulting in a $169,887 impairment loss being
recorded for the year ended December&nbsp;31, 2012; there was no impairment for the year ended December&nbsp;31, 2011. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Deferred Financing Costs </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company capitalizes all third-party costs incurred, including equity-based payments, associated with the issuance of long-term debt. The costs are amortized to interest expense over the term of the
debt using the effective interest method. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Advertising </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Advertising costs are expensed as incurred. Advertising costs were approximately $56,000 and $17,000 for 2012 and 2011, respectively, and are included in sales and marketing expense on the accompanying
consolidated statements of operations. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Research and Development Costs </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and Development costs are expensed as incurred. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Income Taxes </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition
of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not
that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available
net operating loss carryforward may be limited under Internal Revenue Code Section&nbsp;382 as a result of changes in ownership. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company
identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing
authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax
benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company&#146;s remaining open tax years subject to examination by the Internal Revenue Service
include the years ended December&nbsp;31,&nbsp;2009 through 2012; there currently are no examinations in process. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Preferred Stock </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company accounted for its preferred stock under the provisions of Accounting Standards Codification on <I>Distinguishing Liabilities from Equity</I>,
which sets forth the standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. This standard requires an issuer to classify a financial instrument that is within the scope
of the standard as a liability or temporary equity if such financial instrument embodies an unconditional obligation to redeem the instrument at a specified date and/or upon an event certain to occur. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to conversion in connection with the Merger, all or any number of the Series B, Series C, and Series D preferred stock was originally redeemable by
a majority of preferred shareholder approval at any time after January&nbsp;7, 2015 at a redemption price determined in accordance with the Company&#146;s Certificate of Incorporation, plus accrued and unpaid dividends. The Company has determined
that its Series B, Series C, and Series D preferred stock required temporary equity classification as its obligation to redeem these instruments were outside the control of the Company. Permanent equity classification was not currently applicable as
the preferred stock was not currently redeemable but may become so in the future. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-10
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Fair Value of Financial Instruments </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these
instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company&#146;s long-term debt approximates its carrying value based upon current rates available to the Company.
</FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Stock-Based Compensation </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan (see Note 10) is
measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee&#146;s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant
using a Black-Scholes-Merton <FONT STYLE="white-space:nowrap">option-pricing</FONT> model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of
comparable peer companies which are publicly traded, for the periods prior to the merger, and based on the Company&#146;s common stock for periods subsequent to the merger. The Company determines the expected life based on historical experience with
similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining
term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following
weighted-average assumptions for options granted during the year ended December&nbsp;31: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:86pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Years ended December&nbsp;31,</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected term (in years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">117.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk free rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite
service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of
change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the years ended December&nbsp;31, 2012 and 2011
as they were deemed insignificant. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U><B>Earnings (Loss) Per Common Share</B> </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Earnings (loss) per common share (EPS) is calculated for basic EPS by dividing net income (loss) available to common stockholders by the
weighted average number of common shares outstanding during the period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The basic loss attributable to common stockholders was computed as
follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Years Ended December&nbsp;31,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,219,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less preferred dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,028,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss attributable to common stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,417,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,247,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">There were no dilutive instruments as of December&nbsp;31, 2012 and 2011. The basic and diluted weighted average shares outstanding
were 11,089,425 and 3,697,390 for the years ended December&nbsp;31, 2012 and 2011. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-11
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Use of Estimates </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Recent Accounting Pronouncements </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s management has reviewed and considered all recent accounting pronouncements and believe there are none that could potentially have a
material impact on the Company&#146;s consolidated financial condition, results of operations, or disclosures. </FONT></P>
 <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Merger </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, LecTec completed its business combination with AC pursuant to the terms of the Merger Agreement (see Note
2). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition. The
total acquisition price of $11,847,916 has been allocated as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> 7,201,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notes and accrued interest receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,555,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">169,987</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(379,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total purchase price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,847,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the unaudited pro forma results of the Company as if the Merger had taken place on the first day of the
period presented. These combined results are not necessarily indicative of the results that may have been achieved had the companies always been combined. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Year
Ended</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,914,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net Loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,610,775</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted net loss per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average shares &#151; basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,957,705</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-12
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Property and Equipment </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment consist of the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furniture and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">572,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">535,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,564</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,564</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Processing equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">995,815</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">988,716</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: accumulated depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,502,304</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,318,639</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">247,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intangible Assets </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s intangible assets consist of the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">772,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">899,231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">291,907</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: accumulated amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(261,928</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(291,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intangible assets, net</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">573,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">899,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">License agreements are being amortized over periods ranging from 17-20 years. Patent costs are being amortized over three years.
Pending patent costs are not amortizable. Amortization expense for 2012 and 2011 was approximately $127,000 and $67,000, respectively. As of December&nbsp;31, 2012, future amortization of license and patent agreements is expected to be $58,400 for
2013 $55,300 for 2014, $46,000 for 2015, 2016 and 2017. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2012 the Company determined that the carrying value of certain patents were not
recoverable and exceeded their estimated fair value. As a result, the Company recorded an impairment loss of $129,667 to reduce these patents to their estimated fair value. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>License Agreements </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has entered into license agreements (the
&#147;License Agreements&#148;) with the University of Florida Research Foundation (&#147;UFRF&#148;) and University of Texas at Austin (&#147;UTA&#148;) and Emory University (&#147;Emory&#148;). Under the terms of the License Agreements, the
Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The
effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an
agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products.&nbsp;One of the agreements also
contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees.&nbsp;Also, when AxoGen pays royalties to more than one licensor
for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%;</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under one of the agreements, if AxoGen does not achieve certain regulatory milestones, which AxoGen has not achieved, AxoGen would owe an annual
license maintenance fee starting on August&nbsp;31, 2012 of $120,000, escalating to $240,000 on August&nbsp;31, 2013 and August&nbsp;31, 2014. In 2012, AxoGen decided to abandon the license and as a result recorded a $147,826 loss on abandonment of
license. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from
the third party to the licensor.&nbsp;Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sublicensee fees for its own
use of the technologies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License
Agreements; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently, under one of the License Agreements, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research
or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee.&nbsp;Other milestone fees are due if AxoGen develops certain pharmaceutical or
medical device products under the License Agreements. No such products are currently under development. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalty fees were
approximately $167,000 and $115,000 during 2012 and 2011 and are included in sales and marketing expense on the accompanying consolidated statements of operations. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-Term Debt / Note Payable </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term debt / note payable consists of the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loan and Security Agreement with financial institutions for aggregate of $5,000,000 with 9.9% interest payable monthly through
September 2012; principal and interest payable monthly for the 30 months thereafter maturing on April&nbsp;1, 2015, collateralized by all the assets of the Company and subject to certain financial covenant restrictions including minimum revenue
requirements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> &#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue Interest Purchase Agreement with PDL for aggregate of $20,800,000 with amounts payable monthly at 9.95% of Net Revenues
through September 2014; and the greater of (i)&nbsp;9.95% of product revenue or (ii)&nbsp;specific quarterly amounts varying from approximately $1.3 million to $2.5 million per quarter through September 2020. The minimum annual payment amounts are
as follows: 2014 - $1,250,805, 2015 - $6,781,440, 2016 - $9,232,642, 2017 and 2018 - $9,000,000, 2019 - $9,063,000 and 2020 - $6,939,000.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less unamortized debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(434,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-term portion</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,403,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Note Payable </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, AxoGen entered into a Revenue Interests Purchase Agreement (the &#147;Royalty Contract&#148;) with PDL, pursuant to which the Company sold to PDL the right to receive specified
royalties of 9.95% on the Company&#146;s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of AxoGen&#146;s products Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Connector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector. The Royalty Contract has a term of eight years. Under the Royalty
Contract, PDL is to receive royalty payments based on a royalty rate of 9.95% of the Company&#146;s Net Revenues, subject to certain agreed upon minimum payment requirements of approximately $1.3 to $2.5 million per quarter which begin in the fourth
quarter of 2014 through the third quarter of 2020 as provided in the Royalty Contract. The total consideration PDL paid to the Company was $20,800,000 (the &#147;Funded Amount&#148;), including $19,050,000 PDL paid to the Company on October&nbsp;5,
2012, and $1,750,000 PDL paid to the Company on August&nbsp;14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between the Company and PDL, dated August&nbsp;14, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-14
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
2012 (the &#147;Interim Royalty Contract&#148;). Upon the closing (the &#147;Closing&#148;) of PDL&#146;s purchase of the specified royalties described above, which was concurrent with the
execution of the Royalty Contract, the Interim Royalty Contract was terminated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company records interest using its best estimate of the
effective interest rate, currently the Company is accruing interest using the specified internal rate of return of the put option of 20%. From time to time, the Company will reevaluate the expected cash flows and may adjust the effective interest
rate. Determining the effective interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams. Payments made to PDL consist of interest and principal. Based on
current calculations of repayments, using actual payments to date, an estimate of future revenue streams and an estimated effective rate of 20% (calculated using the put rate in the agreement), principal payments are scheduled to begin in April
2015. All payments made prior to this date are interest only payments. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Put Option </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, on October&nbsp;5, 2016, or in the event of the occurrence of a material adverse event, our transfer of
revenue interest or substantially all of our interest in the products or AxoGen&#146;s bankruptcy or material breach of the Royalty Contract, PDL may require AxoGen to repurchase the Assigned Interests at the &#147;Put Price.&#148; The Put Price is
equal to the sum of (i)&nbsp;an amount that, when paid to PDL, would generate a specified internal rate of return to PDL of 20% on the Funded Amount, taking into consideration payments made to PDL by the Company, and (ii)&nbsp;any &#147;Delinquent
Assigned Interest Payment&#148; (as defined in the Royalty Contract) the Company owed to PDL. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Change of Control; Call
Option </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in the event of a &#147;Change of Control&#148; (as defined in the Royalty Contract), the Company must
repurchase the assigned Interests from PDL for a repurchase price equal to the &#147;Change of Control Price&#148; on or prior to the third business day after the occurrence of the Change of Control. The Change of Control Price is equal to the sum
of (i)&nbsp;an amount that, when paid to PDL, would generate a specified internal rate of return to PDL of thirty-two and one half percent (32.5%) on the Funded Amount, taking into consideration payments made to PDL by the Company, and (ii)&nbsp;any
&#147;Delinquent Assigned Interest Payment&#148; (as defined in the Royalty Contract) the Company owed to PDL. In addition, at any time after October&nbsp;5, 2016, the Company, at its option, can call the Royalty Contract for a price equal to the
Change of Control Price. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Board Designee </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, during the term of the Royalty Contract, PDL is entitled to designate, and AxoGen shall appoint an individual designated by PDL, who shall serve on the Board of Directors of
the Company (the &#147;Board&#148;) until the Company&#146;s 2013 Annual Meeting of Shareholders (the &#147;2013 Annual Meeting&#148;). For the 2013 Annual Meeting and each annual meeting thereafter during the term of the Royalty Contract, the Board
shall nominate and recommend the PDL designee as a director nominee to serve on the Board until the next annual meeting and shall include such nomination in AxoGen&#146;s proxy statement for the 2013 Annual Meeting and each annual meeting
thereafter, provided that the election of the PDL designee is subject to shareholders&#146; approval. Should at any time there become a vacancy on the Board as a result of (i)&nbsp;the resignation, death or removal of the PDL designee or
(ii)&nbsp;such PDL designee failing to obtain the requisite approval of the Company&#146;s shareholders at any annual or special meeting of the Company&#146;s shareholders and where no other individual is elected to such vacancy, PDL shall have the
right to designate an individual to fill such vacancy, and AxoGen shall take such actions necessary to appoint, such individual to the Board. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Preemptive Rights </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, PDL has preemptive rights
with respect to certain new issuances of AxoGen&#146;s equity securities and securities convertible, exchangeable or exercisable into such equity securities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Restriction on Dividends </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, during the period
from the October&nbsp;5, 2012 to December&nbsp;4, 2016 (or the payment of the Put Price in the event PDL exercises its put option on or prior to December&nbsp;4, 2016), AxoGen </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-15
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shall not, nor shall it permit any subsidiary to, declare, pay or make any dividend or distribution on any shares of the common stock or preferred stock of such entity (other than dividends or
distributions payable in its stock, or split-ups or reclassifications of its stock) or apply any of its funds, property or assets to the purchase, redemption or other retirement of any common or preferred stock, or of any options to purchase or
acquire any such shares of common or preferred stock of any such entity (collectively, &#147;Restricted Payments&#148;), except that: (i)&nbsp;each subsidiary may make direct or indirect Restricted Payments to the Company; and (ii)&nbsp;the Company
and each subsidiary may purchase, redeem or otherwise acquire Equity Interests issued by it solely with the proceeds received from the substantially concurrent issue of new shares of its common stock or other common Equity Interests. For purposes of
the Royalty Contract, &#147;Equity Interests&#148; of any person means any and all shares, rights to purchase, options, warrants, general, limited or limited liability partnership interests, member interests, participation or other equivalents of or
interest in (regardless of how designated) equity of such entity, whether voting or nonvoting, including common stock, preferred stock, convertible securities or any other &#147;equity security&#148; (as such term is defined in Rule 3a11-1under the
Securities Exchange Act of 1934, as amended). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Guarantee and Collateral Agreement </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Royalty Contract, on October&nbsp;5, 2012, AxoGen and AC, entered into a Guarantee and Collateral Agreement (the
&#147;Guarantee and Collateral Agreement&#148;) with PDL, pursuant to which (i)&nbsp;AC unconditionally and irrevocably guarantees to PDL the prompt and complete payment and performance by AxoGen when due of the &#147;Secured Obligations,&#148;
which include the Company&#146;s obligations under the Royalty Contract, and any other obligations that AxoGen may owe to PDL under the Royalty Contract and other transaction documents; and (ii)&nbsp;each of the Company and AC grants to PDL a
security interest in certain collateral as specified in the Guarantee and Collateral Agreement for the prompt and complete payment and performance when due of the Secured Obligations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>Long-Term Debt </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, the Company entered into the Loan and
Security Agreement with MidCap Financial SBIC, LP (&#147;MidCap&#148;), as administrative agent, and the Lenders listed on Schedule 1 thereto (the &#147;MidCap Loan&#148;). The credit facility under the MidCap loan had a principal amount of $5.0
million and a term of 42 months, and is subject to prepayment penalties. Under the MidCap Loan, AxoGen was required to make interest only payments for the first 12 months, and payments of both interest and straight line amortization of principal for
the remaining 30 months. The interest rate was 9.9%&nbsp;per annum, and interest was computed on the basis of a 360-day year and the actual number of days elapsed during which such interest accrues. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The agreement contained customary affirmative and negative covenants, including, without limitation, (i)&nbsp;covenants requiring AxoGen to comply with
applicable laws, provide to MidCap copies of AxoGen&#146;s financial statements, maintain appropriate levels of insurance, protect, defend and maintain the validity and enforceability of AxoGen&#146;s material intellectual property,
(ii)&nbsp;covenants restricting AxoGen&#146;s ability to dispose of all or any part of its assets (subject to certain exceptions), engage in other lines of business, change its senior management, enter into merger or consolidation transactions,
incur or assume additional indebtedness, or incur liens on its assets, and (iii)&nbsp;covenants requiring the Company to meet certain minimum Net Invoiced Revenue as defined in the agreement, or maintain a cash balance of 80% of the loan principal
amount. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The MidCap Loan was secured by all of AxoGen&#146;s assets. The lenders also received a ten-year warrant to purchase 89,686 shares of
AxoGen&#146;s common stock at $2.23 per share. The fair value of the warrant was $173,736 and was recorded as debt discount and was being amortized through interest expense using the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-16
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
effective interest method over the term of the debt. Amortization of debt discount was $12,207 for 2011. The Company also recorded $317,990 in deferred financing costs which were being amortized
over the term of the loan. Amortization of the deferred financing cost was $22,714 for 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;21, 2008, the Company entered into
a Loan and Security Agreement with two different lenders, as subsequently amended (the &#147;2008 Loan and Security Agreement&#148;), which provided for a loan with an aggregate principal amount of $7.5 million. The loan&#146;s maturity date was
October&nbsp;1, 2011. The loan bore interest at a rate of 18%&nbsp;per month, as amended, and was secured by all of the Company&#146;s assets. Upon the execution of the 2008 Loan and Security Agreement, the Company recorded $155,556 in deferred
financing costs which were being amortized through interest expense on the accompanying consolidated statements of operations over the life of the term note. Amortization of the deferred financing costs was $12,963 for 2011. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In conjunction with the 2008 Loan and Security Agreement, the Company also issued warrants to purchase a combined 280,803 shares of the Company&#146;s
Series C Preferred Stock, immediately exercisable at $0.7345 per share, expiring on May&nbsp;1, 2018. The fair value of the warrants was recorded as debt discount and was being amortized through interest expense using the effective interest method
over the term of the debt. Amortization of this debt discount was $11,436 during 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2010, the Company executed six amendments to
the 2008 Loan and Security Agreement, resulting in the issuance of a total of 28,561,272 additional warrants for the purchase of the Company&#146;s Series D preferred stock, immediately exercisable at $0.1198 per share, expiring on varying dates
during the year 2020. The total fair value of the warrants of $2,160,879 was recorded as deferred financing costs during 2010 and was being amortized through interest expense &#151; deferred financing costs on the accompanying consolidated statement
of operations. The Company recognized $990,792 in amortization of these costs for 2011. See additional discussion related to the accounting for the warrants at Note 9. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;11, 2011, the Company entered into a waiver and seventh amendment (the &#147;Amendment&#148;) to the 2008 Loan and Security Agreement. The Amendment waived the event of default resulting
from the failure to pay the balance due under the 2008 Loan and Security Agreement by March&nbsp;31, 2011, increased the annual interest rate to 18% beginning April&nbsp;1, 2011, and extended the maturity to the earlier of an acquisition event
(including the Merger discussed in Note 4), or October&nbsp;1, 2011. In connection with the Amendment, an event of default would occur if the Company fails to receive proceeds from equity and/or convertible subordinated debt financings of at least
$2.5 million by May&nbsp;31, 2011 and an additional $2.5 million by August&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, the Company paid the
entire outstanding loan balance under the 2008 Loan and Security Agreement. The Company also paid a loan pay off fee of $109,436 which is included in the amortization of deferred financing costs for 2011. The warrants issued to the holders of the
2008 Loan and Security Agreement (see Note 9) expired upon the effective date of the Merger. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>2010 Convertible Debt and Warrants
</U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2010 Convertible Debt is convertible automatically into shares of conversion stock, defined in the agreement as a future
&#147;qualified next equity financing&#148;, or its Series C preferred stock. The debt is also convertible at the option of the Company in the event of a future equity financing which is not considered a &#147;qualified next equity financing&#148;.
The conversion price is 65% of the price per share paid at the next equity financing, as defined in the agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon issuance of the 2010
Convertible Debt, the Company recorded a total of $122,900 in deferred financing costs which were being amortized through interest expense on the accompanying consolidated statements of operations over the debt term. Amortization of the deferred
financing costs was $87,221 for 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Merger on September&nbsp;30, 2011, the 2010 convertible debt of $1,338,455 and
$2,359,091 and accrued interest of $263,371 were converted into 2,581,963 shares of AC common stock using a conversion price of $0.0572 (65% of price per share paid at the next equity financing or $0.088) and 0.03727336 exchange ratio. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-17
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>2011 Convertible Debt </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;3, 2011, the Company issued an 8% convertible note payable for $500,000 to LecTec related to the Merger. On May&nbsp;31, 2011, the Company issued additional convertible notes payable under the
same terms of which $2,000,000 was issued to LecTec and $500,000 was issued to certain AC shareholders. The notes were collateralized by all assets of the Company and subordinated to the Company&#146;s 2008 Loan and Security Agreement. Principal and
interest accrued under the note was due upon the earlier of June&nbsp;30, 2013 or a change in control other than in connection with the Merger. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;29, 2011, the Company issued an additional subordinated secured convertible promissory note in the principal amount of $2,000,000 to
LecTec and $500,000 to certain AC shareholders on the same terms as the $3,000,000 notes issued by the Company in May 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The $4,500,000
notes to LecTec were retired on September&nbsp;30, 2011 after the closing of the Merger. The $1,000,000 notes to certain AC shareholders were converted into 423,709 shares of AxoGen, Inc.&#146;s common stock using the $0.088 conversion price and
0.03727336 exchange ratio. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stockholders&#146; Equity (Deficit) and Temporary Equity </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>AxoGen, Inc. Classes of Stock </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc.&#146;s authorized capital stock consists of 50,000,000 shares, par value $0.01 per share. The authorized capital stock is divisible into the classes and series, has the designation, voting
rights, and other rights and preferences and is subject to the restrictions that the AxoGen Board of Directors may from time to time establish. Unless otherwise designated by the AxoGen Board of Directors, all shares are common stock. AxoGen has not
designated any shares other than common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Merger, 32,709,676 shares of AC common stock were converted into
1,219,199 shares of AxoGen, Inc.&#146;s common stock using the 0.03727336 exchange ratio. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, AxoGen sold to certain
investors in a private placement 423,709 shares of common stock at $2.36 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;10, 2011, each non-employee director of
AxoGen was granted 5,455 shares of AxoGen common stock, valued at $2.75 per share, in lieu of a cash retainer payment for the director&#146;s services through December&nbsp;31, 2012. The Company recorded $15,000 of directors fee included in general
and administrative expenses and $60,000 in prepaid expenses related to issuance of 27,275 shares of common stock to five directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>AC
Classes of Stock </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AC had authorized 133,000,000 shares of common stock with a $.00001 par value. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC had authorized
103,408,891 shares of preferred stock with a $.00001 par value which the Board of Directors is empowered to designate and issue in different series. At December&nbsp;31, 2010, the Board of Directors had designated and issued 2,544,750 shares of
Series A Preferred Stock; 17,065,217 shares of Series B Preferred Stock; 16,798,924 shares of Series C Preferred Stock and 67,000,000 shares of Series D Preferred Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with the Merger, on September&nbsp;30, 2011 each share of Series A, B, C and D convertible preferred stock, for a total of 53,555,857 shares, were converted into shares of AC common stock
and exchanged for 1,996,206 shares of AxoGen, Inc. common stock using the 0.03727336 exchange ratio. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-18
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Series A Convertible Preferred Stock </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2004, AC issued 2,544,750 shares of Series A Convertible Preferred Stock (&#147;Series A&#148;) at $0.4421 per share for an aggregate price of
$1,125,000. No dividends accrued or were payable on the Series A, except upon the declaration of dividends on AC&#146;s common stock, payable at a rate per share of Series A equal to the amount the holder would be entitled to receive had all of the
Series A been converted to AC common stock. Upon liquidation, Series A holders have preference to any distribution of any of the assets of AC to the holders of AC Common Stock after Series B, Series C, and Series D preferences have been paid. Series
A has no redemption option. Each share of Series A is convertible into AC common stock at any time at the option of the holder by dividing the Preferred Original Issue Price by the Conversion Price at the time of conversion, which as of
December&nbsp;31, 2010 is equal to the purchase price of $0.4421. The conversion price is subject to adjustment, as defined. The only election right for Series A is to vote along with AC common shareholders to elect two directors to the Board. Each
share of Series A has voting rights equal to the number of AC common shares as if converted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Series B Convertible
Preferred Stock </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2006, AC issued 16,847,826 shares of Series B Convertible Preferred Stock (&#147;Series B&#148;) at $0.46 per share
for an aggregate price of $7,750,000. The holders of the Series B are entitled to receive a cash dividend in preference over shares of AC common stock and Series A shareholders of AC at a rate of 8% of the issued price, per annum. Upon liquidation,
the Series B holders have preference to any distributions of any of AC&#146;s assets equal to the Preferred Original Issue Price plus any unpaid dividends after Series C and Series D preferences have been paid. At any time on or after
January&nbsp;7, 2015, the Series B shareholders have the right to redeem shares equal to the redemption price upon written request of at least 55% of the holders of Series B. Each share of Series B is convertible into AC common stock at any time at
the option of the holder by dividing the Preferred Original Issue Price by the Conversion Price at the time of conversion, which as of December&nbsp;31, 2010 is equal to the purchase price of $0.46. The conversion price is subject to adjustment, as
defined. The holders of a majority of the Series B, C and D Preferred Stock have the right to elect three directors to the Board. Also, Series B, C and D will vote together with Series A and AC common shareholders to elect two directors to the
Board. Each share of Series B, C and D has voting rights equal to the number of AC common shares as if converted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC is accreting dividends
on the Series B, based on the stated dividend rate of 8%&nbsp;per annum. The Series B dividends accreted for the year ended December&nbsp;31, 2011 was $292,329. A total of $3,152,603 in Series B dividends had been accreted as of September&nbsp;30,
2011 and were forfeited in accordance with the Merger. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;11, 2010, 7,065,217 shares of Series B, representing $3,250,000, were
converted into 263,344 shares of AC&#146;s common stock at the election of the shareholder. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Series C Convertible
Preferred Stock </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2007, AC issued 16,518,121 shares of Series C Convertible Preferred Stock (&#147;Series C&#148;) at $0.7345 per
share for an aggregate purchase price of $12,132,559. The holders of the Series C are entitled to receive a cash dividend in preference over shares of AC common stock, Series A and Series B shareholders of AC at a rate of 8% of the issued price, per
annum. Upon liquidation, the Series C holders have preference to any distributions of any of AC&#146;s assets equal to the Preferred Original Issue Price plus any unpaid dividends after Series D preferences have been paid. At any time on or after
January&nbsp;7, 2015, the Series C shareholders have the right to redeem shares equal to the redemption price upon written request of at least 60% of the holders of Series C. Each share of Series C is convertible into AC common stock at any time at
the option of the holder by dividing the Preferred Original Issue Price by the Conversion Price at the time of conversion, which as of December&nbsp;31, 2010 is equal to the purchase price of $0.7345. The conversion price is subject to adjustment,
as defined. The holders of a majority of the Series B, C and D have the right to elect three directors to the Board. Also, Series B, C and D will vote together with Series A and AC common shareholders to elect two directors to the Board. Each share
of Series B, C and D has voting rights equal to the number of AC common shares as if converted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-19
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC is accreting dividends on the Series C, based on the stated dividend rate of 8%&nbsp;per annum. The
dividends accreted for the year ended December&nbsp;31, 2011 was $515,577. A total of $3,403,651 in Series C dividends had been accreted as of September&nbsp;30, 2011 and were forfeited in accordance with the Merger. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;11, 2010, 5,445,882 shares of Series C, representing $4,000,000, were converted into 202,986 shares of AC&#146;s common stock at the
election of the shareholder. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Series D Convertible Preferred Stock and Warrants </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;7, 2010, AC issued 39,156,876 shares of Series D Preferred Stock (&#147;Series D&#148;) at $0.1198 per share for an aggregate price of
$4,661,326, net of issuance costs of $29,667. Of the total shares issued, 16,694,489&nbsp;shares were issued for $2,000,000 in cash. The remaining 22,462,387 shares were issued in conjunction with the conversion of $2,617,000 of principal and
$73,994 of accrued and unpaid interest under the 2009 Convertible Debt (see Note 7). The holders of the Series D are entitled to receive a cash dividend in preference over all other shareholders of AC at a rate of 8% of the issued price, per annum.
Upon liquidation, the Series D holders have preference to any distributions of any of AC&#146;s assets equal to the Preferred Original Issue Price plus any unpaid dividends. At any time on or after January&nbsp;7, 2015, the Series D shareholders
have the right to redeem shares equal to the redemption price upon written request of at least 66 2/3% of the holders of Series D. Each share of Series D is convertible into AC common stock at any time at the option of the holder by dividing the
Preferred Original Issue Price by the Conversion Price at the time of conversion, which as of December&nbsp;31, 2010 is equal to the purchase price of $0.1198. The conversion price is subject to adjustment, as defined. The holders of a majority of
the Series B, C and D have the right to elect three directors to the Board. Also, Series B, C and D will vote together with Series A and AC common shareholders to elect two directors to the Board. Each share of Series B, C and D has voting rights
equal to the number of AC common shares as if converted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC is accreting dividends on the Series D, based on the stated dividend rate of
8%&nbsp;per annum. Dividends accreted during the year ended December&nbsp;31, 2011 were $220,444. A total of $518,426 in Series D dividends had been accreted as of September&nbsp;30, 2011 and were forfeited in accordance with the Merger. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;11, 2010, 9,000,617 shares of Series D, representing $1,078,274, were converted into 335,483 of AC&#146;s common stock at the election
of the shareholder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In conjunction with the issuance of the Series D, AC also issued warrants for the purchase of 8,347,236 shares of
AC&#146;s Series D Preferred Stock, immediately exercisable at $0.1198 per share, expiring on January&nbsp;7, 2015. The investors paid additional consideration totaling $10,000 for the purchase of the warrants. The warrants are considered offering
costs related to the Series D issuance and their fair value of $517,529 was recorded net against proceeds on the issuance of the stock during 2010. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-20
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Preferred Stock Warrants and Warrant Liability </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Preferred Stock Warrants </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At September&nbsp;30, 2011, the outstanding warrants to purchase the Company&#146;s Series C and Series D preferred stock which were issued in connection with certain financing arrangements and amendments
to existing financing arrangements were expired unexercised in connection with the Merger. Information relating to these warrants at December&nbsp;31, 2010 is summarized as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:33pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Warrants</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Remaining<BR>Number<BR>Outstanding</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise&nbsp;Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series C Warrants-2008 Loan and Security Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">280,803</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.7345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D Warrants-2009 Convertible Debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,368,948</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D Warrants-Series D Preferred Stock Issuance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,347,236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">*Series D Warrants-1</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Amendment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,243,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">*Series D Warrants-2</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Amendment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,694,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">*Series D Warrants-3</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Amendment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,462,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">*Series D Warrants-5</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Amendment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,260,440</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">*Series D Warrants-6</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Amendment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,900,685</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,558,259</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Warrants issued to lenders in conjunction with amendments to 2008 Loan and Security Agreement (see&nbsp;Note&nbsp;7). </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Warrant Liability </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The warrants issued in conjunction with the 2008 Loan and Security Agreement (see Note 7) are issuable for Series&nbsp;C preferred stock. The warrants issued in connection with the 2009 Convertible Debt
(see Note 7) and the Series&nbsp;D Preferred Stock (see Note 8) are issuable for Series D preferred stock. Both the Series C and Series&nbsp;D preferred stock are considered contingently redeemable based on the shareholders&#146; right to redeem the
shares on or after January&nbsp;7, 2015. In accordance with Accounting Standards Codification on <I>Distinguishing Liabilities from Equity</I>, since the warrants are indexed to contingently redeemable securities of the Company, they are classified
as liabilities upon issuance. As liability classified derivative financial instruments, the warrants are initially and subsequently required to be measured at their fair values as defined in Accounting Standards Codification on <I>Fair Value
Measurement.</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The change in fair value of the warrants between each reporting period is recorded in the statements of operations and was
estimated by the Company using a binomial lattice valuation model. The following assumptions were incorporated into the valuations for 2011 and 2010: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">$0.1198&nbsp;&#150;&nbsp;$0.7345</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Market value of stock at end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">$0.01</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividend rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33.47%&nbsp;&#150;&nbsp;62.86%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.03%&nbsp;&#150;&nbsp;3.18%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected life in years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.40&nbsp;&#150;&nbsp;9.90</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares underlying warrants outstanding classified as liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,558,259</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recorded income of $62,305 for 2011, as a result of the change in the fair value of warrant liability between reporting
periods which was recorded in other income (expense) on the consolidated statements of operations. The total balance of the warrant liability as of September&nbsp;30, 2011 of $2,607,510 was forfeited in accordance with the Merger. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-21
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stock Options </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AC has a 2002 Stock Option Plan (&#147;the AC Plan&#148;), which allows for issuance of incentive stock options and <FONT
STYLE="white-space:nowrap">non-qualified</FONT> stock options to employees, directors and consultants at an exercise price equal to or greater than fair market value. Under the provisions of the AC Plan, AC authorized for issuance 18,144,658 shares
for purchase pursuant to options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. has a AxoGen 2010 Stock Incentive Plan (the &#147;AxoGen Plan&#148;), which allows for
issuance of incentive stock options and non-qualified stock options to employees, directors and consultants at an exercise price equal to or greater than fair market value. On September&nbsp;27, 2011, LecTec amended and restated the AxoGen Plan to,
among other things, increase the number of shares of common stock authorized for issuance under the plan by 2,300,000 shares. The total number of shares authorized for issuance under the AxoGen Plan is 2,750,000 shares. As a result of the Merger,
options granted under the AC Plan were assumed by the Company so that each stock option pursuant to the AC Plan so assumed continued to have, and be subject to, the same terms and conditions of such stock option immediately prior to the Merger,
except that (i)&nbsp;each AC Plan stock option is exercisable for that number of shares of Company common stock equal to the product of the number of shares of AC common stock that were issuable upon exercise of such stock option immediately prior
to the Merger multiplied by the Closing Ratio (&#147;as defined in the Merger Agreement&#148;) and (ii)&nbsp;the per share exercise price for the shares of Company common stock issuable upon the exercise of such assumed stock option will be equal to
the quotient determined by dividing the exercise price per share of AC common stock at which such stock option was exercisable immediately prior to the Merger by the Closing Ratio. The options to employees typically vest 12.5% every six months over
a four-year period and those to directors and certain executive officers have vested 25%&nbsp;per quarter over one year or had no vesting period. Options issued to consultants vest over the service period ranging from three to ten years. Options
have terms ranging from seven to ten years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation expense was $495,077 and $250,044 for 2012 and 2011, respectively.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a summary of stock option activity: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Weighted<BR>Average<BR>Exercise&nbsp;Price</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term(Years)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at December&nbsp;31, 2010:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">447,659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,141,952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LecTec stock option from Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">464,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(98,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at December&nbsp;31, 2011:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,945,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">267,576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(354,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(58,341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,799,991</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable at December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">941,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The average fair value of options granted at market during 2012 and 2011 was $2.99 and $0.42 per option, respectively. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The intrinsic value of options exercised during the years ended December&nbsp;31, 2012 and 2011 was approximately $173,000 and $190,000, respectively.
The intrinsic value of options outstanding at December&nbsp;31, 2012 and 2011 was approximately $288,000 and $1,126,000, respectively. The intrinsic value of options exercisable at December&nbsp;31, 2012 and 2011 was approximately $0 and $391,000,
respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-22
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Merger, all outstanding options to purchase shares of AC Common Stock were exchanged
for options to purchase shares of AxoGen, Inc. common stock at a ratio of one to 0.03727336. The Company recorded $19,769 and $38,521 incremental cost in 2012 and 2011, respectively, related to this modification. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total future compensation expense related to nonvested awards is expected to be approximately $1,405,000 at December&nbsp;31, 2012 which is expected to
be recognized over a weighted average period of 3.04 years. The following table represents non-vested share-based payment activity with employees for the year ended December&nbsp;31, 2012 and 2011: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Number of<BR>Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Weighted<BR>Average&nbsp;Grant<BR>Date&nbsp;Fair&nbsp;Value</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nonvested options &#151; December&nbsp;31, 2010:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">325,575</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,141,952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(195,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nonvested options &#151; December&nbsp;31, 2011:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,263,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">267,576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(317,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(354,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nonvested options &#151; December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">858,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Income Taxes </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and their
respective income tax basis, as measured by enacted state and federal rates as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Deferred tax assets:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net operating loss carryforwards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,182,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,065,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Charitable contributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory Reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">365,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">163,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">361,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,602,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,592,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Deferred tax liabilities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(154,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(160,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(51,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(51,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total deferred tax liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(206,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(211,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,396,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,381,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18,396,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15,381,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2012, the Company had net operating loss carry forwards of approximately $48.3 million to offset future taxable
income which expire in various years through 2031. A valuation allowance is recorded to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that a portion or none of the deferred tax assets
will be realized. After consideration of all the evidence, including reversal of deferred tax liabilities, future taxable income and other factors, management has determined that a full valuation allowance is necessary as of December&nbsp;31, 2012
and 2011. The valuation allowance increased by $3,015,100 and $3,572,000 during 2012 and 2011, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-23
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net income tax benefit of approximately $738,000 for 2012 was the result of the Company&#146;s ability
to utilize net operating losses and franchise tax adjustments which resulted in tax refunds. The Company had no income tax expense or income tax benefit for 2011 due to incurrence of net operating losses. The Company does not believe there are any
additional tax refund opportunities currently available. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employee Benefit Plan </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company adopted the AxoGen Simple IRA plan in 2007. All full-time employees who have attained the age of 18 are eligible to
participate in the Plan. Eligibility is immediate upon employment and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The
simple IRA plan requires the Company to make matching contributions of between 1% and 3% of the employee&#146;s annual salary as long as the employee participates in the Plan. Additionally, the matching has to be at least 3% for three of the first
five years of the Plan. Both employee contributions and Company contributions vest immediately. In 2012 and 2011, the Company match was 3% of the participating employee&#146;s annual salary. The Company contributed $102,189 and $66,687 in matching
funds during 2012 and 2011, respectively. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commitments and Contingencies Operating Leases </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operating Leases </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Company leases its lab space under one-year lease agreements, currently expiring in September 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Its corporate office space lease
agreement expires in April 2014. Estimated future minimum rental payments on the leases are as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Year ending December&nbsp;31</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,964</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">TOTAL</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">179,979</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total rent expense for the Company&#146;s leased office and lab space for the years ended December&nbsp;31, 2012 and 2011 was
approximately $176,000 and $171,000, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Service Agreements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In 2008, the Company entered into a biostorage and management services agreement with a vendor. The agreement specifies monthly administration fees, storage fees based on volume, and retrieval fees per
specimen based on lead times. The agreement can be terminated with 90 days written notice. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2009, the Company also entered into a two-year
tissue processing agreement with another vendor. Tissue processing fees are based on a per donor batch rate. The agreement requires minimum annual purchases of $160,000 and either party may terminate this agreement with six month written notice. In
2011 and 2012, the parties agreed to an extension for an additional twelve months and amended the agreement to provide for automatic twelve month renewals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">In August 2008, the Company entered into an agreement to distribute the
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> product worldwide in the field of peripheral nerve repair, and the parties subsequently amended the
agreement in March, 2012. The agreement has an initial seven-year term from the date of the original agreement and following such initial term, the agreement automatically renews for an additional seven (7)&nbsp;year period provided that the parties
agree to meet at least ninety (90)&nbsp;days before the end of such initial term to review whether the purchase price of the products obtained from Cook Biotech need to be adjusted and reasonably agree to such adjustment in writing, where such
agreement shall not be unreasonably withheld. The Cook Biotech agreement also requires certain minimum purchases, although through mutual agreement the parties have not established such minimums and to date have not enforce such provision, and
establishes a formula for the transfer cost of the AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-24
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2011, the Company also entered into a Master Services Agreement for Clinical Research and
Related Services. The Company was required to pay $151,318 upon execution of this agreement and $20,416 per month for 42 months starting in January 2012 through August 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Certain executive officers of the Company are parties to employment contracts. All such contracts have severance payments in the event of a Company change of control, provided certain conditions are met.
One&nbsp;contract has a severance provision in the event of termination without cause.</FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-25
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_7"></A>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></FONT></P>
 <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">March&nbsp;31,<BR>2013</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current assets:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,200,447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,907,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,179,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,050,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,420,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,151,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">142,033</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">187,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total current assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,941,871</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,295,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Property and equipment, net</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intangible assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">590,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">573,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Deferred financing costs</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,208,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,252,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,851,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,230,563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liabilities and Shareholders&#146; Equity (Deficit)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current liabilities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,418,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,479,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total current liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,418,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,479,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note Payable &#151; Revenue Interest Purchase Agreement</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,438,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,857,342</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,060,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commitments and contingencies</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Shareholders&#146; equity (deficit):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $.01 par value; 50,000,000 shares authorized; 11,127,869 and 11,122,573 shares issued and
outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,279</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,169,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,908,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(61,286,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,848,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total shareholders&#146; equity (deficit)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,005,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,829,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,851,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,230,563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>See notes to condensed consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-26
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_8"></A>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(UNAUDITED) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Three Months Ended</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">March&nbsp;31,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">March&nbsp;31,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenues</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,142,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,653,430</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cost of goods sold</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">560,243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">439,158</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gross profit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,582,689</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,214,272</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Costs and expenses:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales and marketing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,893,541</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,628,608</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406,943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">296,131</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,605,759</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,230,608</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total costs and expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,906,243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,155,347</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Loss from operations</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,323,554</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,941,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other income (expense):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,067,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(125,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense &#151; deferred financing costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(44,216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34,951</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total other income (expense)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,113,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(168,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net loss</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,437,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,109,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss available to common shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,437,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,109,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted Average Common Shares outstanding &#151; basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,124,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,062,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss Per Common share &#151; basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>See notes to condensed consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-27
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_9"></A>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(UNAUDITED) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Three Months Ended March&nbsp;31,</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from operating activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,437,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,109,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash used for operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,691</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,687</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of deferred financing costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">157,860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest added to note</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">858,151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(129,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(96,329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(269,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(365,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(106,033</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(60,814</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(78,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash used for operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,651,186</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,478,289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26,007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(29,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquisition of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(41,236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash used for investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,422</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(70,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of fractional shares from Merger</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash provided by financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net decrease in cash and cash equivalents</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,706,954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,548,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents,</B> beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,907,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,190,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents,</B> end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,200,447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,641,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supplemental disclosures of cash flow activity:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash paid for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">172,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>See notes to condensed consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-28
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC.</B> </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin532389_10"></A>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(UNAUDITED) </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. Basis of Presentation </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the &#147;Company&#148; or
&#147;AxoGen&#148;) and its wholly owned subsidiary AxoGen Corporation (&#147;AC&#148;) as of March&nbsp;31, 2013 and December&nbsp;31, 2012 and for the three month periods ended March&nbsp;31, 2013 and 2012. The Company&#146;s condensed
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements of the Company for the year
ended December&nbsp;31, 2012, which are included in the Annual Report on Form 10-K for the year ended December&nbsp;31, 2012. The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all
adjustments necessary for a fair presentation of results for the periods presented. Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated
in consolidation </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Organization and Business </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Business Summary </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. Peripheral nerves provide the pathways for both motor
and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, the Company has developed and licensed, patented and patent
pending technologies. The Company&#146;s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen&#146;s products offer a full suite of surgical nerve reconstruction
solutions including Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, which the Company believes is the only commercially available processed
nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site,
AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector, a porcine submucosa ExtraCellular Matrix (&#147;ECM&#148;) coaptation aid for
tensionless repair of severed nerves, and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector, a porcine submucosa ECM product used to
wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. Summary of Significant Accounting Policies </B></FONT></P>

 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Revenue Recognition </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds.
Revenues for manufactured products and products sold under a distribution agreement are recognized when the products delivered to the customer, at which time title passes to the customer. Once a product is delivered, the Company has no further
performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for storage
and shipping of products are recognized as revenues when products are shipped to the customer or end user. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Cash and Cash Equivalents and Concentration </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to
be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is
exposed to any significant credit risk on cash and cash equivalents. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-29
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Accounts Receivable and Concentration of Credit Risk </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on
a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#146;s financial condition, credit history and current economic conditions. Accounts
receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received. As of March&nbsp;31, 2013 and December&nbsp;31, 2012, there were no amounts deemed uncollectible and there was
no allowance for doubtful accounts recorded. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concentrations of credit risk with respect to accounts receivable are limited because a large
number of geographically diverse customers make up the Company&#146;s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Inventories </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Inventories are comprised of implantable tissue, nerve grafts,
Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">March&nbsp;31,<BR>2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,<BR>2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finished goods</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,246,213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,143,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Work in process</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">149,561</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Raw materials</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,024,479</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">862,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,420,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,151,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventories were net of reserve of approximately $459,000 and $538,000 at March&nbsp;31, 2013 and December&nbsp;31, 2012, respectively.
</FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Income Taxes </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition
of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not
that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available
net operating loss carryforward may be limited under Internal Revenue Code Section&nbsp;382 as a result of changes in ownership. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company
identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing
authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax
benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company&#146;s remaining open tax years subject to examination by the Internal Revenue Service
include the years ended December&nbsp;31,&nbsp;2009 through 2012; currently there are no examinations in process. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Share-Based Compensation </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen&#146;s 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the
employee&#146;s requisite service period. The Company estimates the fair value of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-30
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option pricing model that uses the assumptions noted in the table below. The Company estimates the
volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded for the periods prior to October&nbsp;1, 2011, and based on the Company&#146;s common stock for periods subsequent to
that date. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on
the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock during the periods reflected
herein and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the three months ended March&nbsp;31:</FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:100pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>Three months ended March&nbsp;31,<B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>2013<B></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>2012<B></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected term (in years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84.90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">118.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk free rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite
service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of
change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the three months ended March&nbsp;31, 2013 and
2012 as they were deemed insignificant. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Use of Estimates </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from
those estimates. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Recent Accounting Pronouncements </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s management has reviewed and considered all recent accounting pronouncements and believe there are none that could potentially have a
material impact on the Company&#146;s consolidated financial condition, results of operations, or disclosures. </FONT></P>

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. Intangible Assets </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s intangible assets consist of the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">March&nbsp;31,</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>(unaudited)<B></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">802,994</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">772,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: accumulated amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(276,615</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(261,928</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intangible assets, net</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">590,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">573,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-31
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">License agreements are being amortized over periods ranging from 17-20 years. Patent costs are being
amortized over three years. Pending patent costs are not amortizable. Amortization expense for the three months ended March&nbsp;31, 2013 and 2012 was approximately $15,000 and $29,000, respectively. As of March&nbsp;31, 2013, future amortization of
license agreements is expected to be approximately $44,000 for the remainder of fiscal 2013, $55,000 for 2014, $46,000 each year for 2015 through 2018. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>License Agreements </U></B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has entered into multiple license agreements (the
&#147;License Agreements&#148;) with the University of Florida Research Foundation (&#147;UFRF&#148;) and University of Texas at Austin (&#147;UTA&#148;). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses
for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements
extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach
after written notice. The License Agreements contain the key terms listed below: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products.&nbsp;One of the agreements also
contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees.&nbsp;Also, when AxoGen pays royalties to more than one licensor
for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from
the third party to the licensor.&nbsp;Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sublicensee fees for its own
use of the technologies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License
Agreements; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently, under one of the License Agreements, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research
or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee.&nbsp;Other milestone fees are due if AxoGen develops certain pharmaceutical or
medical device products under the License Agreements. No such products are currently under development. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalty fees were
$47,031 and $37,265 during the three months ended March&nbsp;31, 2013 and 2012, respectively, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-32
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. Notes Payable </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notes Payable consists of the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">March&nbsp;31,</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">2013</FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue Interest Purchase Agreement with PDL for aggregate of $20,800,000 with amounts payable monthly at 9.95% of Net Revenues
through September 2014; and the greater of (i)&nbsp;9.95% of product revenue or (ii)&nbsp;specific quarterly amounts varying from approximately $1.3 million to $2.5 million per quarter through September 2020. The minimum annual payment amounts are
as follows: 2014 - $1,250,805, 2015 - $6,781,440, 2016 - $9,232,642, 2017 and 2018 - $9,000,000, 2019 - $9,063,000 and 2020 - $6,939,000.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,438,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-term Notes Payable</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,438,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,580,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Notes Payable </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;5, 2012, AxoGen entered into a Revenue Interests Purchase Agreement (the &#147;Royalty Contract&#148;) with PDL, pursuant to which the Company sold to PDL the right to receive specified
royalties of 9.95% on the Company&#146;s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of AxoGen&#146;s products Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Connector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector. The Royalty Contract has a term of eight years. Under the Royalty
Contract, PDL is to receive royalty payments based on a royalty rate of 9.95% of the Company&#146;s Net Revenues, subject to certain agreed upon minimum payment requirements of approximately $1.3 to $2.5 million per quarter which begin in the fourth
quarter of 2014 through the third quarter of 2020 as provided in the Royalty Contract. The total consideration PDL paid to the Company was $20,800,000 (the &#147;Funded Amount&#148;), including $19,050,000 PDL paid to the Company on October&nbsp;5,
2012, and $1,750,000 PDL paid to the Company on August&nbsp;14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between the Company and PDL, dated August&nbsp;14, 2012 (the &#147;Interim Royalty Contract&#148;). Upon the closing (the
&#147;Closing&#148;) of PDL&#146;s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim Royalty Contract was terminated. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company records interest using its best estimate of the effective interest rate, currently the Company is accruing interest using the specified
internal rate of return of the put option of 20%. From time to time, the Company will reevaluate the expected cash flows and may adjust the effective interest rate. Determining the effective interest rate requires judgment and is based on
significant assumptions related to estimates of the amounts and timing of future revenue streams. Payments made to PDL consist of interest and principal. Based on current calculations of repayments, using actual payments to date, an estimate of
future revenue streams and an estimated effective rate of 20% (calculated using the put rate in the agreement), principal payments are scheduled to begin in April 2015. All payments made prior to this date are interest only payments. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Put Option </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the
Royalty Contract, on October&nbsp;5, 2016, or in the event of the occurrence of a material adverse event, our transfer of revenue interest or substantially all of our interest in the products or AxoGen&#146;s bankruptcy or material breach of the
Royalty Contract, PDL may require AxoGen to repurchase the Assigned Interests at the &#147;Put Price.&#148; The Put Price is equal to the sum of (i)&nbsp;an amount that, when paid to PDL, would generate a specified internal rate of return to PDL of
20% on the Funded Amount, taking into consideration payments made to PDL by the Company, and (ii)&nbsp;any &#147;Delinquent Assigned Interest Payment&#148; (as defined in the Royalty Contract) the Company owed to PDL. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Change of Control; Call Option </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, in the event of a &#147;Change of Control&#148; (as defined in the Royalty Contract), the Company must repurchase the assigned Interests from PDL for a repurchase price equal to the
&#147;Change of Control Price&#148; on or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-33
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
prior to the third business day after the occurrence of the Change of Control. The Change of Control Price is equal to the sum of (i)&nbsp;an amount that, when paid to PDL, would generate a
specified internal rate of return to PDL of thirty-two and one half percent (32.5%) on the Funded Amount, taking into consideration payments made to PDL by the Company, and (ii)&nbsp;any &#147;Delinquent Assigned Interest Payment&#148; (as defined
in the Royalty Contract) the Company owed to PDL. In addition, at any time after October&nbsp;5, 2016, the Company, at its option, can call the Royalty Contract for a price equal to the Change of Control Price. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Board Designee </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under
the Royalty Contract, during the term of the Royalty Contract PDL is entitled to designate, and AxoGen shall appoint an individual designated by PDL, who shall serve on the Board of Directors of the Company (the &#147;Board&#148;) until the
Company&#146;s 2013 Annual Meeting of Shareholders (the &#147;2013 Annual Meeting&#148;). For the 2013 Annual Meeting and each annual meeting thereafter during the term of the Royalty Contract, the Board shall nominate and recommend the PDL designee
as a director nominee to serve on the Board until the next annual meeting and shall include such nomination in AxoGen&#146;s proxy statement for the 2013 Annual Meeting and each annual meeting thereafter, provided that the election of the PDL
designee is subject to shareholders&#146; approval. Should at any time there become a vacancy on the Board as a result of (i)&nbsp;the resignation, death or removal of the PDL designee or (ii)&nbsp;such PDL designee failing to obtain the requisite
approval of the Company&#146;s shareholders at any annual or special meeting of the Company&#146;s shareholders and where no other individual is elected to such vacancy, PDL shall have the right to designate an individual to fill such vacancy, and
AxoGen shall take such actions necessary to appoint, such individual to the Board. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Preemptive Rights </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, PDL has preemptive rights with respect to certain new issuances of AxoGen&#146;s equity securities and securities convertible,
exchangeable or exercisable into such equity securities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restriction on Dividends </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Royalty Contract, during the period from October&nbsp;5, 2012 to December&nbsp;4, 2016 (or the payment of the Put Price in the event PDL
exercises its put option on or prior to December&nbsp;4, 2016), AxoGen shall not, nor shall it permit any subsidiary to, declare, pay or make any dividend or distribution on any shares of the common stock or preferred stock of such entity (other
than dividends or distributions payable in its stock, or split-ups or reclassifications of its stock) or apply any of its funds, property or assets to the purchase, redemption or other retirement of any common or preferred stock, or of any options
to purchase or acquire any such shares of common or preferred stock of any such entity (collectively, &#147;Restricted Payments&#148;), except that: (i)&nbsp;each subsidiary may make direct or indirect Restricted Payments to the Company; and
(ii)&nbsp;the Company and each subsidiary may purchase, redeem or otherwise acquire Equity Interests issued by it solely with the proceeds received from the substantially concurrent issue of new shares of its common stock or other common Equity
Interests. For purposes of the Royalty Contract, &#147;Equity Interests&#148; of any person means any and all shares, rights to purchase, options, warrants, general, limited or limited liability partnership interests, member interests, participation
or other equivalents of or interest in (regardless of how designated) equity of such entity, whether voting or nonvoting, including common stock, preferred stock, convertible securities or any other &#147;equity security&#148; (as such term is
defined in Rule 3a11-1under the Securities Exchange Act of 1934, as amended). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Guarantee and Collateral Agreement
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Royalty Contract, on October&nbsp;5, 2012, AxoGen and AC, entered into a Guarantee and Collateral Agreement (the
&#147;Guarantee and Collateral Agreement&#148;) with PDL, pursuant to which (i)&nbsp;AC unconditionally and irrevocably guarantees to PDL the prompt and complete payment and performance by AxoGen when due of the &#147;Secured Obligations,&#148;
which include the Company&#146;s obligations under the Royalty Contract, and any other obligations that AxoGen may owe to PDL under the Royalty Contract and other </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-34
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
transaction documents; and (ii)&nbsp;each of the Company and AC grants to PDL a security interest in certain collateral as specified in the Guarantee and Collateral Agreement for the prompt and
complete payment and performance when due of the Secured Obligations. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. Stock Options </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company granted 153,000 shares of stock options pursuant to its 2010 Stock Incentive Plan for the three months ended March&nbsp;31,
2013. Stock-based compensation expense was $259,912 and $157,860 for the three months ended March&nbsp;31, 2013 and 2012, respectively. Total future stock compensation expense related to nonvested awards is expected to be approximately $1,437,000 at
March&nbsp;31, 2013. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-35
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>4,186,046 Shares </B></FONT></P>
<P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g532389g90w05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>AXOGEN, INC. </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Common Shares </B></FONT></P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Prospectus
</B></FONT></P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>, 2013 </B></FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>JMP&nbsp;Securities </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>Ladenburg&nbsp;Thalmann&nbsp;&amp;&nbsp;Co. </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART II </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Expenses of Issuance and Distribution. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the various expenses to be incurred in connection with the registration of the securities being registered hereby, all of which will be borne by the registrant. All amounts
shown are estimates except the SEC registration fee. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEC registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FINRA fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,605</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer agent and miscellaneous expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">133,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">560,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Indemnification of Directors and Officers. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Minnesota Statutes, Section&nbsp;302A.521, subd. 2, requires the Company to indemnify a person made or threatened to be made a party to a proceeding by reason of the former or present official capacity of
the person with respect to the Company, against judgments, penalties, fines, settlements, and reasonable expenses, including attorneys&#146; fees and disbursements, incurred by the person in connection with the proceeding if certain statutory
standards are met, unless the Company amends its Amended the Restated Articles of Incorporation, or the &#147;Articles of Incorporation,&#148; or its Amended and Restated Bylaws, or the &#147;Bylaws,&#148; to prohibit or condition such
indemnification rights. In addition, Minnesota Statutes, Section&nbsp;302A.521, subd. 3 requires payment by the Company, upon written request, of reasonable expenses in advance of final disposition of the proceeding in certain circumstances unless
the Company amends the Articles of Incorporation or the Bylaws to prohibit or condition such expense advancement rights. Under Section&nbsp;302A.521, subd. 4, the Company may amend the Articles of Incorporation or the Bylaws to prohibit or condition
such indemnification or expense advancement rights. A decision as to required indemnification is made (i)&nbsp;by a disinterested majority of the Company&#146;s Board of Directors present at a meeting at which a disinterested quorum is present,
(ii)&nbsp;by a designated committee of the Board of Directors consisting of two or more disinterested directors, (iii)&nbsp;by special legal counsel selected by the board or a committee by vote pursuant to clause (i)&nbsp;or (ii)&nbsp;above,
(iv)&nbsp;by an affirmative vote of the shareholders, in which the shares held by parties to the proceeding is not counted in determining the presence of a quorum and are not considered to be present and entitled to vote, or (v)&nbsp;by a court in
Minnesota. For purposes of clauses (i)&nbsp;and (ii)&nbsp;above, a director is disinterested if he or she is not a party to the proceeding for which indemnification or expense advancement is at issue. Section&nbsp;302A.521 contains detailed terms
regarding such right of indemnification and reference is made thereto for a complete statement of such indemnification rights. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Article 7 of the Articles of Incorporation provides that, to the fullest extent permitted by the Minnesota Business Corporation Act as
the same exists or may hereafter be amended, a director of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Company shall not be personally liable to the Company or its shareholders for monetary damages for breach of fiduciary duty as a director; provided, however, that Article 7 shall not eliminate or
limit the liability of a director to the extent provided by applicable law (i)&nbsp;for any breach of the director&#146;s duty of loyalty to the corporation or its shareholders, (ii)&nbsp;for acts or omissions not in good faith or that involve
intentional misconduct or a knowing violation of law, (iii)&nbsp;under section 302A.559 or 80A.76 of the Minnesota Statutes, (iv)&nbsp;for any transaction from which the director derived an improper personal benefit, or (v)&nbsp;for any act or
omission occurring prior to the effective date of Article 7 or any predecessor of this provision. Neither the amendment, modification or repeal of Article 7 nor the adoption of any provision in these articles of incorporation inconsistent with
Article 7 shall adversely affect any right or protection of a director or officer of the Company with respect to any act or omission that occurred prior to the time of such amendment, modification, repeal or adoption. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Bylaws provide that the directors and officers of the Company shall have the right to indemnification provided by Minnesota Statutes,
Section&nbsp;302A.521, as now enacted or hereafter amended. Under Section&nbsp;302A.521, subd. 2, indemnification will be available only where an officer, director or employee can establish that he or she: (i)&nbsp;has not been indemnified by
another organization with respect to the same acts or omissions; (ii)&nbsp;acted in good faith; (iii)&nbsp;received no improper personal benefits; (iv)&nbsp;in the case of a criminal proceeding, had no reasonable cause to believe the conduct was
unlawful; and (v)&nbsp;reasonably believed the conduct was in the best interests of the Company or, in certain circumstances, reasonably believed that the conduct was not opposed to the best interests of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company maintains, on behalf of its directors and officers, insurance protection against certain liabilities arising out of the
discharge of their duties, as well as insurance covering the Company for indemnification payments made to its directors and officers for certain liabilities. The premiums for such insurance are paid by the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to possible indemnification of directors, officers and controlling persons of the Company for liabilities arising under the
Securities Act pursuant to such provisions, the Company is aware that the Commission has publicly taken the position that such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Sales of Unregistered Securities. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following list sets forth information regarding all securities sold by us in the three years preceding the filing of this registration statement which were not registered under the Securities Act:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2011, the Company sold 423,709 shares of the Company&#146;s common shares at $2.36 per share to certain investors who were
accredited investor (as defined in Rule 501(a) of Regulation D promulgated under the Securities Act). The proceeds of this sale of approximately $1,000,000 was used for general working capital purposes. This offering was completed in conjunction
with the Merger. Purchasers of Company securities were certain shareholders of AC prior to the Merger and included AC&#146;s Chief Executive Officer and certain members of its Board of Directors. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;29, 2012, the Company issued 7,500 shares of its common shares to an individual who is an accredited investor (as defined in Rule 501(a)
of Regulation D promulgated under the Securities Act) as compensation for investor relations services this individual rendered to the Company. Such party had no relationship to the Company except as a service provider. The aggregate value of the
shares issued, determined based on market value of the Company&#146;s common shares was $21,375 and was reported as an operating expense in the Company&#146;s consolidated statements of operations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above-described transactions were exempt from the registration requirements of the Securities Act pursuant to Section&nbsp;4(2)
thereof or Regulation D promulgated thereunder, as a transaction not involving a public offering. With respect to the transaction listed above, no general solicitation was made by either the Registrant or any person acting on its behalf; the
securities sold are subject to transfer restrictions; and the certificate representing the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
securities contain an appropriate legend stating that such securities have not been registered under the Securities Act and may not be offered or sold other than pursuant to an effective
registration statement under the Securities Act or an applicable exemption from the registration requirements thereof. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;16.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibits and Financial Statement Schedules. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Underwriting Agreement (Incorporated by reference to the Company&#146;s Amendment No.&nbsp;4 to Registration Statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-188597)</FONT> filed with the Securities and Exchange Commission on August&nbsp;5, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement and Plan of Merger, dated as of May 31, 2011, among LecTec Corporation, Nerve Merger Sub Corp. and AxoGen Corporation (Incorporated by reference to Exhibit 2.1 to LecTec
Corporation&#146;s Current Report on Form&nbsp;8-K filed on June&nbsp;2, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No.&nbsp;1 to Agreement and Plan of Merger, dated as of June 30, 2011, among LecTec Corporation, Nerve Merger Sub Corp. and AxoGen Corporation (Incorporated by reference
to Appendix A2 to the Proxy Statement/Prospectus included as part of LecTec Corporation&#146;s Amendment No.&nbsp;2 to Registration Statement on Form S-4 filed on August&nbsp;29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 2 to Agreement and Plan of Merger, dated as of August&nbsp;9, 2011, among LecTec Corporation, Nerve Merger Sub Corp. and AxoGen Corporation (Incorporated by reference
to Appendix A3 to the Proxy Statement/Prospectus included as part of LecTec Corporation&#146;s Amendment No. 2 to Registration Statement on Form&nbsp;S-4 filed on August&nbsp;29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Articles of Incorporation of AxoGen, Inc. (Incorporated by reference to Appendix&nbsp;B to the Proxy Statement/Prospectus included as part of LecTec
Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August&nbsp;29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. Amended and Restated Bylaws. (Incorporated by reference to Appendix C to the Proxy Statement/Prospectus included as part of LecTec Corporation&#146;s Amendment No. 2 to
Registration Statement on Form&nbsp;S-4 filed on August&nbsp;29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of Kaplan, Strangis and Kaplan, P.A. regarding the validity of the common shares being registered</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent License Agreement, dated as of August&nbsp;3, 2005, by and between AxoGen Corporation and the Board of Regents of the University of Texas System (Incorporated by reference to
the Company&#146;s Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Standard Exclusive License Agreement with Sublicensing Terms, dated as of February&nbsp;21, 2006, by and between AxoGen Corporation and the University of
Florida Research Foundation, Inc. (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sid Martin Biotechnology Development Institute Incubator License Agreement, dated as of September&nbsp;26, 2006, by and between AxoGen, Inc. and the University of Florida Research
Foundation, Inc. (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Nerve Tissue Processing Agreement, dated as of February&nbsp;27, 2008, by and between AxoGen Corporation and LifeNet Health (Incorporated by reference to the
Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment to Amended and Restated Nerve Tissue Processing Agreement, dated as of August&nbsp;9, 2011, by and between AxoGen Corporation and LifeNet Health (Incorporated by
reference to the Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Amendment dated March 12, 2012 to Amended and Restated Nerve Tissue Processing Agreement, dated as of February 27, 2008, by and between AxoGen Corporation and LifeNet Health
(Incorporated by reference to the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distribution Agreement, dated as of August 27, 2008, by and between AxoGen, Inc. and Cook Biotech Incorporated (Incorporated by reference to the Company&#146;s Current Report on
Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.5.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment dated March 14, 2012 to Distribution Agreement, dated as of August 27, 2008, by and between AxoGen, Inc. and Cook Biotech Incorporated (Incorporated by reference to the
Company&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December 31, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*10.6.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue Interests Purchase Agreement, dated as of October 5, 2012, by and among AxoGen, Inc. and PDL BioPharma, Inc. (Incorporated by reference to the Company&#146;s Amendment
No.&nbsp;1 to the Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*10.6.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Guarantee and Collateral Agreement, dated as of October 5, 2012, by and among AxoGen, Inc. and AxoGen Corporation and PDL BioPharma, Inc. (Incorporated by reference to the
Company&#146;s Amendment No.&nbsp;1 to the Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.6.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interim Revenue Interests Purchase Agreement dated August&nbsp;14, 2012, by and between AxoGen, Inc. and PDL BioPharma, Inc. (Incorporated by reference to the Company&#146;s
Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.6.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment dated July 26, 2013 to Revenue Interests Purchase Agreement, dated as of October 5, 2012, by and among AxoGen, Inc. and PDL BioPharma, Inc. (Incorporated by reference to
the Company&#146;s Amendment No.&nbsp;3 to Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (Registration No.&nbsp;333-188597) filed with the Securities and Exchange Commission on July&nbsp;30, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">LecTec Corporation 2010 Stock Incentive Plan, Amended and Restated on September 27, 2011 (Incorporated by reference to Appendix E to the Proxy Statement/Prospectus included as part
of LecTec Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.8.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of October 15, 2007, by</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">and between AxoGen Corporation and Karen Zaderej (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.8.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Executive Employment Agreement, effective as of September&nbsp;29, 2011, by and between AxoGen Corporation and Karen Zaderej (Incorporated by reference to the
Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.9.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of May 6, 2003, by and between AxoGen Corporation and John P. Engels (Incorporated by reference to the Company&#146;s Current Report on
Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.9.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Executive Employment Agreement, effective as of September 29, 2011, by and between AxoGen Corporation and John P. Engels (Incorporated by reference to the
Company&#146;s Current Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease dated as of February 6, 2007, by and between AxoGen Corporation and WIGSHAW, LLC, its successors and assigns (Incorporated by reference to the Company&#146;s Quarterly Report
on Form 10-Q filed on November 14, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.15</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Employee Incentive Stock Option Agreement (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on September 26, 2007)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of October 1, 2011, by and between AxoGen, Inc. and Gregory G. Freitag (Incorporated by reference to the Company&#146;s Annual Report on
Form 10-K for the year ended December 31, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.17</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of February 27, by and between AxoGen, Inc. and Jill Schiaparelli (Incorporated by reference to the Company&#146;s Annual Report on Form
10-K for the year ended December 31, 2011)</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment dated February&nbsp;27, 2013 to lease dated as of February&nbsp;6, 2007, by and between AxoGen Corporation and WIGSHAW, LLC, its successors and assigns
(Incorporated by reference to the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.19.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loan and Security Agreement, dated as of September&nbsp;30, 2011, by and among AxoGen, Inc. and AxoGen Corporation, as borrower, Midcap Financial SBIC, LP, as administrative agent,
and the Lenders listed on Schedule 1 thereto (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.19.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to Loan and Security Agreement dated August&nbsp;14, 2012, by and between AxoGen, Inc. and Midcap Financial SBIC, LP. (Incorporated by reference to the
Company&#146;s Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.19.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subordination and Intercreditor Agreement dated August&nbsp;14, 2012, by and between AxoGen, Inc., PDL BioPharma, Inc. and Midcap Financial SBIC, LP. (Incorporated by reference to
the Company&#146;s Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.20</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of February&nbsp;25, 2013, by and between AxoGen, Inc. and Shawn McCarrey (Incorporated by reference to the Company&#146;s Quarterly
Report on Form 10-Q for the quarter ended March&nbsp;31, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiary of the Registrant (Incorporated by reference to the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Lurie Besikof Lapidus &amp; Company, LLP</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#23.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Kaplan, Strangis and Kaplan, P.A. (included in Exhibit 5.1 above)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#24.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#101.INS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Instance Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#101.SCH</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#101.CAL</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#101.DEF</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#101.LAB</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Extension Labels Linkbase</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#101.PRE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Presentation Linkbase Document</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment has been requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment has been granted for portions of this Exhibit pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 as amended. The confidential
portions have been deleted and filed separately with the United States Securities and Exchange Commission. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed herewith. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">++</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Included on signature page. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+++</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furnished herewith. In accordance with Rule&nbsp;406T of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-T,</FONT> the Interactive Data Files in Exhibit&nbsp;101 to
this Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> are deemed not filed or part of a registration statement or prospectus for purposes of Sections&nbsp;11 or 12 of the Securities Act of 1933, as amended, are deemed
not filed for purposes of Section&nbsp;18 of the Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">#</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial Statement Schedules </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the
financial statements and related notes thereto. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;17.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Undertakings. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery
to each purchaser. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to
directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final
adjudication of such issue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned registrant hereby undertakes that: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1)&nbsp;or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the
time it was declared effective. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Amendment No.&nbsp;6 to Registration Statement to
be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Alachua, State of Florida, on the 7th&nbsp;day of August, 2013. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AXOGEN, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;/s/ Karen Zaderej</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement
has been signed by the following persons in the capacities and on the dates indicated. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Karen Zaderej</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;7, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Karen Zaderej</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(Principal Executive Officer)</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Gregory G. Freitag</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;7, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory G. Freitag</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(Principal Financial and Accounting Officer)</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman of the Board</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;7, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jamie M. Grooms</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;7, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Robert J. Rudelius</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;7, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Mark Gold, M.D.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;7, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>John Harper</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;7, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Joe Mandato</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;7, 2013</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>John McLaughlin</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">*By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;/s/ Gregory G. Freitag</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gregory G. Freitag</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Attorney-in-fact</B></FONT></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Underwriting Agreement (Incorporated by reference to the Company&#146;s Amendment No.&nbsp;4 to Registration Statement on Form S-1 (Registration No. 333-188597) filed with
the Securities and Exchange Commission on August 5, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement and Plan of Merger, dated as of May 31, 2011, among LecTec Corporation, Nerve Merger Sub Corp. and AxoGen Corporation (Incorporated by reference to Exhibit 2.1 to LecTec
Corporation&#146;s Current Report on Form 8-K filed on June 2, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1 to Agreement and Plan of Merger, dated as of June 30, 2011, among LecTec Corporation, Nerve Merger Sub Corp. and AxoGen Corporation (Incorporated by reference to
Appendix A2 to the Proxy Statement/Prospectus included as part of LecTec Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 2 to Agreement and Plan of Merger, dated as of August 9, 2011, among LecTec Corporation, Nerve Merger Sub Corp. and AxoGen Corporation (Incorporated by reference to
Appendix A3 to the Proxy Statement/Prospectus included as part of LecTec Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Articles of Incorporation of AxoGen, Inc. (Incorporated by reference to Appendix B to the Proxy Statement/Prospectus included as part of LecTec
Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. Amended and Restated Bylaws. (Incorporated by reference to Appendix C to the Proxy Statement/Prospectus included as part of LecTec Corporation&#146;s Amendment No. 2 to
Registration Statement on Form S-4 filed on August 29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of Kaplan, Strangis and Kaplan, P.A. regarding the validity of the common shares being registered</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent License Agreement, dated as of August 3, 2005, by and between AxoGen Corporation and the Board of Regents of the University of Texas System (Incorporated by reference to the
Company&#146;s Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Standard Exclusive License Agreement with Sublicensing Terms, dated as of February 21, 2006, by and between AxoGen Corporation and the University of Florida
Research Foundation, Inc. (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sid Martin Biotechnology Development Institute Incubator License Agreement, dated as of September 26, 2006, by and between AxoGen, Inc. and the University of Florida Research
Foundation, Inc. (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Nerve Tissue Processing Agreement, dated as of February&nbsp;27, 2008, by and between AxoGen Corporation and LifeNet Health (Incorporated by reference to the
Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment to Amended and Restated Nerve Tissue Processing Agreement, dated as of August&nbsp;9, 2011, by and between AxoGen Corporation and LifeNet Health (Incorporated by
reference to the Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Third Amendment dated March 12, 2012 to Amended and Restated Nerve Tissue Processing Agreement, dated as of February 27, 2008, by and between AxoGen Corporation and LifeNet
Health (Incorporated by reference to the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2012)<B></B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;**10.5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distribution Agreement, dated as of August&nbsp;27, 2008, by and between AxoGen, Inc. and Cook Biotech Incorporated (Incorporated by reference to the Company&#146;s Current Report
on Form&nbsp;8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.5.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment dated March 14, 2012 to Distribution Agreement, dated as of August&nbsp;27, 2008, by and between AxoGen, Inc. and Cook Biotech Incorporated (Incorporated by reference to
the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*10.6.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue Interests Purchase Agreement, dated as of October 5, 2012, by and among AxoGen, Inc. and PDL BioPharma, Inc. (Incorporated by reference to the Company&#146;s Amendment
No.&nbsp;1 to the Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*10.6.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Guarantee and Collateral Agreement, dated as of October 5, 2012, by and among AxoGen, Inc. and AxoGen Corporation and PDL BioPharma, Inc. (Incorporated by reference to the
Company&#146;s Amendment No.&nbsp;1 to the Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.6.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interim Revenue Interests Purchase Agreement dated August 14, 2012, by and between AxoGen, Inc. and PDL BioPharma, Inc. (Incorporated by reference to the Company&#146;s Quarterly
Report on Form 10-Q for the quarter ended September&nbsp;30, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.6.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment dated July 26, 2013 to Revenue Interests Purchase Agreement, dated as of October&nbsp;5, 2012, by and among AxoGen, Inc. and PDL BioPharma, Inc. (Incorporated by reference
to the Company&#146;s Amendment No.&nbsp;3 to Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (Registration No.&nbsp;333-188597) filed with the Securities and Exchange Commission on July&nbsp;30,
2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">LecTec Corporation 2010 Stock Incentive Plan, Amended and Restated on September 27, 2011 (Incorporated by reference to Appendix E to the Proxy Statement/Prospectus included as part
of LecTec Corporation&#146;s Amendment No. 2 to Registration Statement on Form S-4 filed on August&nbsp;29, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.8.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of October&nbsp;15, 2007, by and between AxoGen Corporation and Karen Zaderej (Incorporated by reference to the Company&#146;s Current
Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.8.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Executive Employment Agreement, effective as of September 29, 2011, by and between AxoGen Corporation and Karen Zaderej (Incorporated by reference to the Company&#146;s
Current Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.9.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of May 6, 2003, by and between AxoGen Corporation and John P. Engels (Incorporated by reference to the Company&#146;s Current Report on
Form 8-K filed on October 6, 2011)</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.9.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Executive Employment Agreement, effective as of September&nbsp;29, 2011, by and between AxoGen Corporation and John P. Engels (Incorporated by reference to the
Company&#146;s Current Report on Form 8-K filed on October&nbsp;6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease dated as of February&nbsp;6, 2007, by and between AxoGen Corporation and WIGSHAW, LLC, its successors and assigns (Incorporated by reference to the Company&#146;s Quarterly
Report on Form 10-Q filed on November&nbsp;14, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.15</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Employee Incentive Stock Option Agreement (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on September&nbsp;26, 2007)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of October 1, 2011, by and between AxoGen, Inc. and Gregory G. Freitag (Incorporated by reference to the Company&#146;s Annual Report on
Form 10-K for the year ended December 31, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.17</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of February 27, by and between AxoGen, Inc. and Jill Schiaparelli (Incorporated by reference to the Company&#146;s Annual Report on Form
10-K for the year ended December 31, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment dated February 27, 2013 to lease dated as of February 6, 2007, by and between AxoGen Corporation and WIGSHAW, LLC, its successors and assigns (Incorporated by
reference to the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.19.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loan and Security Agreement, dated as of September 30, 2011, by and among AxoGen, Inc. and AxoGen Corporation, as borrower, Midcap Financial SBIC, LP, as administrative agent, and
the Lenders listed on Schedule 1 thereto (Incorporated by reference to the Company&#146;s Current Report on Form 8-K filed on October 6, 2011)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.19.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to Loan and Security Agreement dated August 14, 2012, by and between AxoGen, Inc. and Midcap Financial SBIC, LP. (Incorporated by reference to the Company&#146;s
Quarterly Report on Form 10-Q for the quarter ended September 30, 2012)</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.19.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subordination and Intercreditor Agreement dated August&nbsp;14, 2012, by and between AxoGen, Inc., PDL BioPharma, Inc. and Midcap Financial SBIC, LP. (Incorporated by reference to
the Company&#146;s Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.20</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Employment Agreement, effective as of February&nbsp;25, 2013, by and between AxoGen, Inc. and Shawn McCarrey (Incorporated by reference to the Company&#146;s Quarterly
Report on Form 10-Q for the quarter ended March&nbsp;31, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiary of the Registrant (Incorporated by reference to the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2012)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Lurie Besikof Lapidus &amp; Company, LLP</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#23.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Kaplan, Strangis and Kaplan, P.A. (included in Exhibit 5.1 above)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#24.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#101.INS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Instance Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#101.SCH</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#101.CAL</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#101.DEF</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#101.LAB</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Extension Labels Linkbase</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#101.PRE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Presentation Linkbase Document</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment has been requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment has been granted for portions of this Exhibit pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 as amended. The confidential
portions have been deleted and filed separately with the United States Securities and Exchange Commission. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed herewith. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">++</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furnished herewith. In accordance with Rule&nbsp;406T of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-T,</FONT> the Interactive Data Files in Exhibit&nbsp;101 to
this Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> are deemed not filed or part of a registration statement or prospectus for purposes of Sections&nbsp;11 or 12 of the Securities Act of 1933, as amended, are deemed
not filed for purposes of Section&nbsp;18 of the Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>#</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed.<B></B> </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Financial Statement Schedules<B></B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">All
schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the financial statements and related notes thereto. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d532389dex231.htm
<DESCRIPTION>CONSENT OF LURIE BESIKOF LAPIDUS & COMPANY LLP
<TEXT>
<HTML><HEAD>
<TITLE>&lt;![CDATA[Consent of Lurie Besikof Lapidus &amp; Company LLP]]&gt;</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 23.1 </B></FONT></P>
<P STYLE="font-size:48px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g532389g60e21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:48px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We consent to the use in this Amendment No. 6 to Registration Statement on Form S-1/A of our report dated March 12, 2013, relating to the consolidated
financial statements of AxoGen, Inc. and Subsidiary as of and for the years ended December 31, 2012 and 2011 appearing in the Prospectus, which is a part of this Registration Statement. </FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We also consent to the reference to us under the heading &#147;Experts&#148; in such Prospectus. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g532389g23b45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Lurie Besikof Lapidus&nbsp;&amp; Company, LLP </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Minneapolis, Minnesota </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 7, 2013 </FONT></P>
<P STYLE="font-size:48px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g532389g42z24.jpg" ALT="LOGO">
 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g532389g00k21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g00k21.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X00C:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z044P,C(Y1C9$.4-&,3%%,CE&-35"-T0P0S0V
M0S`R-4$B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z044P,C(Y1C5$.4-&
M,3%%,CE&-35"-T0P0S0V0S`R-4$B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HP,S,P-C=C9BUC9#<P+30Y-F4M83,S,"UA
M,3$P93-B9C=B9#<B('-T4F5F.F1O8W5M96YT240](G5U:60Z93EC-V)C-60M
M,&$P,"TT8S5B+3DX-C(M8V4W9&0P835C.64X(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YR<C$U-#$T,#PO<F1F.FQI/B`\+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B`\<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9"`M($%X;T=E;B`M
M($9O<FT@4RTQ05]T<F%C:V5D+F1O8W@\+W)D9CIL:3X@/"]R9&8Z06QT/B`\
M+V1C.G1I=&QE/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z
M>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M`$A0:&]T;W-H;W`@,RXP
M`#A"24T$!```````#QP!6@`#&R5''`(```(``@`X0DE-!"4``````!#\X1^)
MR+?)>"\T8C0'6'?K_^X`#D%D;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#
M`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`-`"V`P$1``(1`0,1
M`?_$`+````$$`@,!`0`````````````'"`D*`00"`P8%"P$!``$$`P$`````
M``````````@!!@<)`@,%!!````4#`P(#!@,&!`<!`````0(#!`41!@<`$@@A
M$S$4"4%182(5%C(C%W&!0B08"I'1,T/PH>%2-%0F&1$``0($!`,&`P4)``,!
M`````0(#`!$$!2$2!@<Q01-182(R%`AQ@161H4(C%K'!X5)B<C-#%]'Q@J+_
MV@`,`P$``A$#$0`_`+_&D(-(1UJ"&T?F``#\0U"A0`!$1$1&@``>/PUQ\*B.
M!D?O^7.*$I"2I7D`Q^$,2SESSQ5BJ;+8%G,Y7-67'*AFC#'^.MLHJB\&I>S,
MRB`+M8[:(5.!054*%:@%-92TCM+J#45(J\7)35KTX,5U%22$!/\`2F0*B>0'
M'E$?=PO<5H[1E=^G+.'+YK,CP45'XR>'^1P32B7.9PQG*&G3^=LU7DL9SG'E
M)BGB!`K@!BXZL)S&W?E%LW4Z]F;EE!>I1;PZ8T,4I2G3$>I`'60J+2NFJ5*4
MZ)L%QU-6(5C5O@LT@('E0T<JE#GF/$$#E&&KMN#KB\@5>OM5VS1MK4K-Z&ER
M5%?TS^!U8S!!X\,1"PX<QGQ)R>\[-J\E<B9;NPI!554=9FG6DX<2AO66;PS0
M\3^7N^>A$C[0U;NJ+YN58&5BZV:EMUM)(!32(R@?RYR%<.$RK&+UT5I39;5[
MZ56+4UQNMU2)E/U%U"R>9Z8*?L`A\UEV%-6,LFS9WQ<]R6W0"EB[Q<I3<BP$
M`HF:/N`2-Y%1`/XDG0KB/\(EUAZKKD7`^HJ&&6Z@GS-S`/>1P$^.`B1]FLE1
M8VA3T]2^]0##+4*ZJT]R5^:0X#-,]L*WKX(N2#2$&D(-(0:0@TA!I"#2$&D(
M-(0:0@TA!I"#2$&D(-(0:0CXT[.Q%NQ+^;FY)G$P\6U7?24G(."-63-FV()U
MUW#A02E3(0H=>M:]/'IKMIF'JVI;HJ1"W:MU02A"`5*43R`[><?)7W"AM5&[
M<;DZAFA905+6L@)2E(F22>7_`*BOGRT]1BX\M/)JP,)3SK'V*&!UF-R9'$ID
M;DN](PF1496ZBF`.631V4H]HI#%7<%'<<Q"5K,W;/8N@T\RS?]6TZ:W4+@S,
MTQF&V%8%*G!^)0_$#@"><:S]YO=1<-:./Z>V^J#1:.02EZL`/5J$B:5H0)>!
M!GX5`A1`[YQ&B;+,K;D=(6_BXKFQ8>22\O,S+95,U]W6!A-WEI^YR%*\:-G0
MF&K)F=)N4.AA4&IAD2C15-<7D5VK5)K:IL30R$AND:'()8&"E##Q*G,B8E$1
MW->U=II3;='$T5*Z9./HPJWDGS]1Y0*BE6'A24SX'A"1J`!U#JG#O.#F$RJJ
MGYJRAS#43F64$55#&$:C4?'5Z,MI9:2T@)2V!@$@)`'+`8=T6`^XJI?-6\EQ
MRK)\3BUJ)P[CA*4H^I`7!-6A,Q=U6O(.82XH)XC)Q,LP5,@Y:O6:A543;TS%
M,9(PEH8@U(<HB!@ZZZ+E;;=>Z!VUW=M+UN6TL+2I(5)2A))3\.,>E9KW=K!<
MV+]9WET]WIGD+;4VHI2N1FI+@'(IPBZ!@V_U<H8>QMD!PD"+J[;.@9E\0H?(
M1^Y9)@_`@=*$%V0^T/=K4CJ>UIL6I*ZRI.9%+4+0#S("B!]HC?EH._KU1HJU
MZC<3E<K*-EQ0[%*0"?\`]0K>O%B[HQ4/?JDQPYP@`P#X"`ZK/ESBDP<`1&=(
MK!I"#2$&D(-(0:0C%0\??I",Z0@TA!I"#2$&D(-(1KN'*#9!=PNH1%!!%19=
M98P)HHHID,HHJJH80*FDF0HB8P]"@%1U09U8(22HR``XDG@/C'6ZMMIM3CI"
M6D@E1.```F23R`$5FO4,YMN\X7(_Q/CB551Q';$@*,D_:*&3-?DXT5$BCDRI
M#!NMUBL42MT_!4Y>X;IM#4^-@]HF=.6Y.JM0LY[_`%"`M@'#HI(P4F8\W(]T
MXU.>Z7W!NZYO+^B=+.A&DZ565;@)RU2TX&1!Q;2J0EV@$\XC'`SM^HS8MDUW
M!S'!NP8M4E%E5%E?D*FV;MR'44=.5#4':43&&@`/34EWGJ>G"KC7O)2V`,RU
M2XRQ))D`,.V(=L"NKW10-EQQQ20<B$'QD83"4X'C+`3P[845UC5U;J8+9"G&
M-E*F`!);@D/+WH<FT=A5K>9&`(<API_YBR*GMV"&K3;U@BZU:F]-TJZP<.O/
M+3"7(K/'Y"7?%U.:)5::,56JJE%"I6*61XZA23P/3!3E']QGW"4:EK0MBW%=
M$);3J3NJ)0G9AC#-YX["->D:.))TDR9NG42@H199`CE<FX$E-Y2C4/#2[W'5
MMKMCMY52T+C-.RMQ:$.',I(3/#"7AD3/[HXV*V:2NU\IK&Y5UM*JJJ&VD/+:
M24%3BLJ4D)4I1S$C`\.,XU+YQ[<5C9$N3%LBDFM=%OW.XM%5)K51%W)`\!DT
M,W`?G,G(&.F8@"&X`.`#UU]5IU51773+>JJ:2:!VAZHF9Y59,Q"CPP,Y1TZA
MTA>=/ZPJ-"UZ`;FS7AGPXYOS9)*?[DD&7+ARBY)A2QQQQB/&]BF`.[:UEV]#
MN:"/5ZUCD"OC^`?B=B<?#6JW4UR%YU'77<8IJ:E:Q\"HD?MC>YH6QG3>CK78
MC@:6A9;(_J2E,_L,*@?\(^-:#3:%1K\->+.6,783(3'&(GN3_J<1F!<JR.,+
M6L-ID):WVK8MRRYK@^FH1TRX`530R!$6CL%5&B`E%4PB&TX[:5#4B=N/;_6:
MYTXC4-?6&A2XLA">EF)3_-,D8?MB&F[WNXHMM=8KTG:[<BY&G0GK.]<-R<,R
M4!("IR`,SVX0[GB'R.6Y/8G+DI>V4;4<A<DU;SB%0D#29$311T!3<>;,@W$1
M<).`,)=H4UC/<W0SFW.J_P!-N/BJ;].ET.R"<%&0!$S(]T9LV4W3_P"O:(3J
MY%(*1SU+C*F@K/(HEB%83&(^^'3@<!]@^[X5_;6FK"[N<9?F!S$HSO#X^ZE.
MOCKCG25909JBHQ$X-X=?$*>\*?\`759B>7G",`<H_`?<-`$?V=>M=5.''AVP
M&/"<>;O"\K4L"UYZ]+WN&(M2T[9C',O/W%//D(V'B8UHF*B[MZ]<'(BDD0H4
M\:F-\I0$1`-(16=Y%_W*V.[1NB5MSCAA%YE*&C'*S)"_[UGE;2@YM9$1(9U"
M031D[F5XPXE'MJ+&1,J3YM@:K+"<(\)@_P#N94I6\(6(Y`<=V-JV?)23=G*W
MECRZG<RK;31RH1(95[`3#)%5^U8B<#K@DL50J=1`!I35(1:HMNXX.[;>A+KM
MJ3:3-NW)%L)R#EV"@+,Y**E&R3Q@];*]-R3ELN4X5H/7KI"/MU`1$/<-!_PK
M^[II"#<'7X#3]H_#2$8W%]__`!2O^'Q\-(1D#`/@/^?M]GC[-(1G2$1*^J7R
M:>XKQU'8>M!\=M>&4VCL)IX@<0<0]CICY:1H<H[D'$XL/ER#T'8"E-2)]M^W
M:-4ZF5J"YHZEHMW^,*Q2M\8E*N1RC&(:>[S=Y[0VEV]'V=THOEU!#A2?$A@S
M3,#CXS-,^[OBOOC#&-Z9@O6'QY8$0:8N*9,*:20&!!E',D`W/)24>F#M1D5'
MI5.JJ>FT/"IA#4Z-5ZIL^C+$J]7=X,VY`_+P\2U$@!IM/&:R<HYB<XU?Z/T3
MJ'7.HV-,:8IU+NBPHC.)-M`S4MQU1F$A(!7-1D2`(>0_MB'Q-8N3GV"3*W-)
M8L;1\'ESD.:/*Z3-=$^\+&?9N(T%2*I0<1'G$YG<SU<K$(`E.0#:P@U<[EK"
M_P!N9UPLM4EQ65V^V)5ER,HQ#M6K`N*(G)*^V)&O62WZ&TK=E;=A=75V9M"+
MG=B@'JON3"FJ$$$(2VH26L$<)IA@C<KR:?`DU*[F960<`!$VY7,D_>N%3>)"
M)E<.W2QQ$>M#&-J0?4H;50YF^C3VUH89@EMN2<#Q.7X3B*P:N%WNLP'ZFYOK
MPDE;JE+5B.U:OC@)SB5+CAQ))A""_JSY5-0M:S+"0)<-E8\D*)W+<]SE'?;H
MR;`P@9G5WM,@U&JIS4.<`(749MQMU#K:O_YCMFXNIN=<L(<J4H"$LH_V(21@
MI!3,%<Y<HFKM'L>G;2@3O5O&TB@M]O;+K-*HYUO/$?DDHP*59I201/G'9P)P
MY+\IN3%W<C+[8"I:=L7>^O1V5<@F;RM\2KM1_"0R=2"1=&$3,594`J!1(F'M
MUT[UZFH]N-O*3;FPK!N-53(0J1Q2VF0<43R)7F`[1'9[;-!5F[NZ];NEJ!HF
MST]2I\`@Y55"EE32`>!"42*^,C%DTM=I:^.T*^/C3KX]=09D!@.$;3SQALW+
M+/\`%\=,+W+?[H2*3HI?1K-C!4`%92Z9%-1..3*2M3H,Z"NL(A0$TQKXZO;;
MO1]3KK55/8F@?3EQ*GE#'*T%"9P_FX#'[8Q)O5N51;6Z!J]2O*`N!26J9'-3
MZP0CY)\QPX"*S[G#L_.<;;VY278J[<24YE>*M^*>.#'`)49$TDZNV9.``/<*
MK*J)(IC7:`$&FI\,:OIZ'<2AVQLB0U;::@>4X@I$TJ3@`>SA/&-3U3MY6W?:
MZY[S7[/ZRIN[+314?,F2^LJ9P(ZA`!X&)3_2LN*XU^->;8&T#L_NZW;JD).V
MDY%)1PQ/*RMLH.(U-XB11(YT'+M@)3`!@$*_#4<_<Q;Z5G<2WO5H5Z!ZF:"R
MD"8`\Q[,)_;$Q?9A=*S_`)1>Z&U957.CJ7'&@J925J9!2"!C(J^V$ZP=ZH67
MIO,]JV/FB-L*WK1?33^!NB2CV+Z-=P;U!)TF1RLNZ?*I)-&S]OM5W!^$??KW
MM8>W:QV[1CE^TD[7U-P]*V^A+@24+2N4P,N(E/G.+>V_]WVL:[<2FTKKFFMM
M+:EU3M.^MH+"FRVDG,K,<.$OB<(4R-Y^YOSGGR3L#CE!6@TQC"`=Q,7Y>T:\
M7;Q-M11E33EYRKE)XW191RR21A9-S4.J8`"M!$0M2JV9TQI+1(ONN*NI_4#Z
M`:>F:`S.+6!E0.9D3)6$7A;_`')ZVW#W-7I?:^DIDZ.HU$U594)(2TPB>=Q2
MB<LS(Y1.9F(\EDSU/,I7E?">,^*]C-;I>BLI&,[D?Q3J5EKK>-$Q!W(PEMME
M4T6$2H9(YTS.%#CVZ"-.FO?L'M^L5HLJ=3;F5QHJ-:9AH8*02,P03S,B)G#&
M+<UI[MM67K4GZ-V<MOJZY*RA+ZDYU/Y<%+:;\H3.<LY$P.R/!V'ZH'(7'F2T
M[)Y&6C"K,6DPUA[J:HPJMKW1:XN%$B&<@B5=5JZ(@FL54Q#E`3I]2FU[%Z]N
M^D+[I?\`4&WU:MUTMJ<2%N`I6$@D@`#B)1;>FO=WN1IC6"-+[KT;207TM.`,
M])UK,1)2RE13(SX2^<,+_N)^;,U+W+9?#*QI99M9S>W8/)V656B@E)<CV<VO
M[%MYV8@[QC&#%/Z@JD/1519+<%"!6&Z6E-3;='YB<P(["DRC913OM53*:AD@
MLJ2%)/:%`$?MAW_H7>G)B.V^.5J\JLL6+;U[Y3S`F[F;//=42SFF-DV`D[58
MPY(B,DD5F+:9FQ;*.EG7;[O:.F0H@`#7K/'#A'="6^J7Z*>6.2_)F'R1Q.L_
M$EA6C.6,BWR*O)3:5HQJ][-)%PFE)M[<AXIV)G+B&.0%U$DB%5,4!-4U1%"'
MC9`YEVOZ-_!CCKA_-"[#*W(J(Q\2U[<L2SI11-I.'A7#DII]]*2"!745:$8B
MX11%=5'N+G(*:11,`B5"(K9WU;?67D<8+<KXC`5FVQQH1=%<$G5,<NI"WC11
MGOE4W1Y:0FTKC<PQES@B,BFB5L)ZB!PURD,N:>/9")4N.7K#L<^<!.2G)A6R
M&%I9=XT6H\6N^SQ=+/K4DI]]%K+6A*PKE0R3Y6$FGA.VJB<>Z@=,Q-XU`=<8
M1%5Q^_N">:^0KHF;;<\>K2R[<SVT),UBV%B:V+J4F9&\:MO+2,PJ@\E7*=JP
MR`J*.NTEW%?E*!R5W:Y9>TR,(3"UO[@WGO9N:&D5F*Q\<N8!I=S2%O'%YK(D
M;3N6$05D4F<C'-9)=\>4:S+!,XBF5RF8#G`-P"!M5RS3FG"+J7W`V^U?NKL.
M_)_;_P!P^5[?\_Y;Z=]2\OVO_;[7R[:_CZ:X0BIMS$OB6SWRSR(ZC3+OTV\\
M>S;:2$3G3;05M$\J*H$+NV-A6[RRE/$QQ#Q'6RO:NUV[0.U5)<:S\IWI!Y\&
M0(?=)&17.:DR*?OC2AOKJ"X;E[YW$6XJJ$M.BC91B9-)E)Q/]"%DS/&</2R?
M8J'!/A>WCXNK;.7(QTE"W#<Z1`3DX*V`9D>R<%'N*"LT31CQ(@8";1%58U?P
M@(8CTU=G-Z]VUUM4>IH^RCJM4Y\JEI,FY@X'Q3)^`E$@=66-GVQ[!)H[<HC<
M'4#X0Z^KQ.A!D74H5*8DGAB1QG#I?3'N#"[WBT>R)"4M,TZ:X;C6R!;MQN8@
MJ\@9\Z+Y)=TRD#_SL<JP(0$S4.4I@'J`ZQI[@J/4;>Y:KRVU4HITH2:=36>3
M8(\2$Y.`GRC,'M,N&A'MH&['4N48N2WWE5C-0MHJ?<69YU)60")$2[#"L9&S
MUP8XG,'DI#1>-ONX"'48VUC>(@9"Y73HGX"'>,TU4(=/>;JHLJF`!6@&'H-M
MV#1N[FY#B*$+N)MG%3KREH90G\1.;`B7$2)PB]=4;B>WS9IIRK0W:$7M1D&*
M9+;CRU"9`44!63^XGN$XBMO:<Y">H9ENW(%ZR5MB#<J@[M''X&<GB[-M<U".
M\@WF;\LRI^P;^6%<I5'JPE30(5,!-J1-FI]!;%:<>J&B*ZX?[*M)\[HQ##$_
M.E2I9U)P2,#C$-K[=MT/<SK2EMKP-NMSBB:>ARDFGI5S2NKJ9C+BC%L*`4"1
ME'.+!N#L-6A@K&MN8VLQH5",@6P%</3)D(\FI94H&DIN1,7JH\DG(F4-41V`
M(%#H`!J&FIM3W?6-^JM17E9-54N%03^%M'!+:>P``3[YQLMV_P!#6+;K25'I
M#3S?3H*-L(S'S.+&"G%GFI9F3.>$ARA6A4`H4"G0`"@]`#V=1'W4U;JEY<L@
M2DF6'&+T'"0QE^R*O_J2\B?UJS:M94)(J'L#%3EQ`LE&BA5&TG<1Q*G<4ZF`
M'[*XM"D%JA40Z$&GCK8+[?=`KTQH[ZZ\T#?KDE1F0066Q_C"L"1GP5SC45[K
M]TCK;<'].43I.E;6YT<!F"W<`ZL&>4E`GE'$RCT>=>8>#;WXF07&[&UF7C!*
MVV-HC'2$HUBD(]12#6(XE7;KRCU=8%Y-0RJE1`3"8_6FO.T3M+KRU;HKUYJ!
MYEQ+ZWPH)6LKS.`R\R1,`2XG`<!./7W'WTVVO^RK&T^EZ*L;?IDL26ZE"&ST
MC-2IA4RM9GRX]T+OZ-UQ%1F,YVRHJ4I5(VU+D`3F*5,@-%Y!@NIN-0HAVW)-
MQN@``>S5F^ZZB4X[::XG%8<;ES)D"!]T9#]A]V0'-0VX**6)LO2.`2!X53/#
MO^&,1P<QE,>N>2>77>,)-.5M5_<CEZ5RW0V,0GG!:W"VCSE$0<,4I@JFQ4M"
M'$P[:@%=2!V;3J5K;FW_`%]LH.7*"J<^D/(%)/(]AX1%+W"#39W@NKVDE]2W
MN/9BM*AD6X3^:I!'X$8@GFJ)!)R0QWACTP&,GB@YOKV='D;;EWW"X!/ZZZE'
M:SD+GCE'".U1NVBV\<9!!+P(D>M!$U=8"M=/>-9^XLT^J\SE!;7"M#>(;#:0
M<A2.\\3$HKG4Z6V_]H;%1H@RJ;^I+#KY_P`CBEE6?Q>:0"</XQGT>L<-9.\\
MI90<H$.M;43%VC#*G`IC-G<T87TH=$:#VS&9MTR=.H`(^_7=[IKZ\AJWZ=2L
M])16ZH?,A/QPD,>R.CV):38?N=WUBI"%>F0VPW/%746C,I6/*7.&-<MYDN5.
M8F3AA:+$F<D,+.C12`#BHJS796\)R[-V_>Z(:H_`=9DVNIOH&SU(_4DAQNVN
MN*F990J:A/O*>/?$<]\[BWJW?F["EDEQRY,,M"4\RT*2DC#CB(@C]1*?E[JY
ML\CQF%CF>Q.1'5BIG7.8?+,;19L;49)DWB)B((-V`"!?``#IK7#7.AZK?<3P
M6\M4^Y2B0/AC&ZFUT?T^W4]$OSM4[:?L2F<_G.+FG,SB[R4RAZ>&#..G#25C
M;5N"/C,0IRTZ-YO+`58VA;-LHN%R1<Q&%%R963DBI`HF00WD$1$1#Q^&/1BF
MPI*<L(_DBUXT/^0V4YJ\D\NQ6)9)>U,OWI-PR\\M<36`D2Q4F252+(MVCA50
MHG*4H"8@AUI759>&<(]OZBM\W1R7Y[Y'MB#+*7,K;]VP/'+%\2HY.Y=O(ZQ0
M;61%-DUG"WS.I^<26756.<!,HL)S#4!'51()F1/&$3+Y-9^NMDSC/*\3I7A_
MC2WL42U@1.-C!;;FU6,NUMJ';1[1NBS<*WNLS2=KI1Y-YQ1#<8QA``$>G$XP
MB/VZ.//(C@-Z=G*2W,_V4[QI=/)_*^$<>VG#.)J$DUIBU+02N.Z[ND0"$D'I
M2I(`1NW/O$M>X/B%!US"DSQ&$(DI_MFL-L$8CDMR)E6*)702-OXNM^2<()B9
MO'L&9KGN4S)V<HF13.JX:%5VB%0"ANFN*CF,X1!T0CWF#ZHP]I,7ALR<OE#E
M!,@*)FMYO?AS&.!25*"2%NQ%1$:U(41'0"8,(_2#[*/:%OVR>7[78[.T.UVM
MH)]K92@$V]*>%-4A%<C$>&V^-,J9YOW(+8&R=C<B\:V!(.WA2G;QMLW=<QIN
M5GE3J%[1&$@@DS3,L:A02.-1H(ZFGKS6*-5Z:LMNM#@`K[54U61)\SS*0VA"
MI?B$E%*3]D:NMOM`C1NK]1:FU(TO+1:GI*$K*22AIY?46X)_ZE`I25\L9&)4
M>;/%'^K;'<'%05P-+=NNU)5Q.6E+/4CK0KQ-\U(W>,'OEA45!J];E**:R93"
M0Q0&@@.H_P"T>Y*ML=0.U[M*X]1OIZ;R"<JTD&>83[^1B8&_^S2-Z=,TU!0U
M;=-=Z-U3K"U24AS.B4@4S\('/''C$-[OTKL\6Z*DC>]_8@L6WT*@[N&4NM^"
M9$"B`G%)!*/0<+J"'4J8"`F&@=-2FJ?<SHBN3DM]LK*NK)$DJ0V9*EPS$3R_
M.(-H]F.Y%M4M^]76ST5O"9N/%QPJEVA*9>*7+A"AXFX>VR^F4(/!L6OE2\F;
MQ(TWG/(4.>+Q+81=P$.ZMFRU@.O=T\4!$S;SQCDW_-VZ=0LW4>\%VJJ+U&IG
MDVZPX]*W4JI/ND^4NN<$-JX+`,Y8#C%WZ*V"L(N/T_0S;MZU`@A3EUKD9:"G
M(.)IV')J==3^`F8)E$WN!L`VA@NVUXV'.ZF[FGE@D+VOJ:$KBY+PF=@`9[(.
MJ?DLT`^1LT3H@V2`"E*&HN:HU5<]5U25ULD6]@*2PPG!ME*N(0.U7XE'%1Q,
M3YV[V\M&W]I-/1DU%VJ3GJJI>+U0X<"I1.*4``!#8DE(X"%[(4"%`H>`:MH`
M`2'`1D`!*1)(DF&8<Y<NW;B?!L[^G<'<$Y?]Y'/:UM!`0[Z67B3/DQ+)SBX,
MD5!;A'L#&[0FH`JB7QIK(FUM@M.H-7,MWZH:I[(T<[JEF7`X)^9'QC"._P#J
M^^Z/V[K'=,4S]1J.J`:8#22HI*L"X>."!B0<(B]].SA#%9*^^K^Y"V"_=P:9
MTK?MFWKL;2L2[>2HJ$>R]PJHF%HZ5(4#@D0YA$#G,8=2+WRW@7;%T-AT#7%"
MVFD]5UJ64I2)(3S`('.4XB![9O;Q1:I3<M0;KVSJTRRE#3#^>:G!-3E1.8,U
M$D'E#K>7W!;`5I\=\DW%BC#K1K?L1%M'=OK083$C*@L22:`NFS9>:<]XRK<Y
MP$-AAIU]FL;[;;OZUJ=<V]C4=W>597'Y.AS+ERE)$YRPEV\HS#O?[==MK;M;
M>*[1MB;1J1NF!8Z165!84F65)40<)S$HA;QHPY.8^0O&#Q_C[)42ZR=!M['E
MW:%I3J#X\6ZDD%SM6CT[5,L=YY6B2BPB42)";J`:ECJ>IVUU0NDJK[76]]NV
MN*=0!4-I49`F92>,@`1S)B!NC*7>C22*RVZ=H+G3&[L-T[A33.>%)FA7C`\,
MR9%7(0]O-/IT2&*>),+=T?&O[FS4PN*,F+W0A4G4D9."ED#,#V[#LD2&.X)!
M+JIJJJ`GN54`P^`!K#VE]_6-0[I.MONII=&.-EEI*_"D%HB3G9XY2PPC/FL?
M:E4Z1V6I[A2-+J]P&GDN5!:2IW,RO--A*/--!,UJXD\3",8QQ?F;*G&C(F!B
MV#>+2>L6[(_,]@L9F!DHE.<;*-E(>\+<CW#YLB@>7,F=)RV2$2]RA@#KJY-1
M:NT9IK<^BUS35;#]NK&E4M3TU3+6/Y:Y<^<^46-H[2.X&L]E+EH!RW5S-=:*
MABXT+3S:D%\&:'Z9LKYI22I/9&EQPY*YVXJ6UD?&ULX>EI&<O5\1XV<2]OW*
MA)V[+)QXQ@JIL6[`22`)I!O(0PE`%`#J8*Z^W7^W>B]RKI1ZD>O;":"E2"4I
M6U-:9YA,%0(&/BYQ\VU&ZFO-E;%=-(TUAJ'+G7/20OI/3;RI+8D0D@D),B9\
M<8<]P'X+9#FLDQ6>\[0CVWXJ'DEKFMN"GDRI3MSW,Y6,\1FI*.&IF46S<+"L
M!5?F65$`V@4*ZQ[O+O)86]/*T#HA?62IH-.OIP;"$RFELC$DRX]D9:]M7MVU
M+<-4C<S<ID,(%4JI88<FIUY9GXU@^1"29RP),1+^M=Z8N;[3Y%W_`,GL08^N
M#(N(<P2"=R7,2S6#B:GK&O5T0$KA3E8*/2.^"#EETP<-W2)#IDWF(<0$`K#Q
M)`!':!]W"-E4O&7/QD2^4)=AKU*_6(NW',#QEP_:EU7*\9P;>Q8.YFV&9%3(
MD;$(-@BVB;BYY-LA%-'+)F4"%?N2%63`H&$X"&[7&*QZ_A-Z:G([#7JE<;+<
MS+:<O)A;A&6?;XO2/C9>5LN-EPBI:;2MN0O)1J6+D;I0G%$?,"140\P8:;OQ
M:K,RERA"2\\>(7)G@ISVF>0-H8ON*^<?!FLN=<87E'6Y*73:[I5S<!;H/:]T
MEBD'#B,?L))15NJ10"B=,2*)F&HZ3,I<H0X#.O*WU,/5[DL>XCP]Q[O/#%IP
M,XC-2,I;3J]K9B%9LR)X\9V\+^DTH,&T%"H.53I,D0,8YA`1[A]FJ0CY_JO\
M5,X88Q=PTXI6E%9JY#N[)M:^,HY4R,SB+TOTDIDR\7\?#]E&353DS1T;&L(U
M9)DS$Y#$;"4PEW'$=(1,#P2L2\>(OHHW1-)V/=A,JW#CO+N15+*2@),M[!=M
MX^>@;<CS096QI<9%LW29*=KM;BE`1I2ND(A<]"WB1F!QSYM;(64<29&LR!Q9
M9%WWB$M>]GSMNLG5T2C4EO1"35Q+,VQ'#X#2SE78`B8"EW:J#*$6I6O*7)ZN
M5).SSXV:*PS:XF\(@W02F#7`BU/<K>$7=O!*"C=(R+90JW=.1-LH#I(2',!%
M=4A"^7U^A7DLM_?/VI]+^U8_]8?J7:\C]![#OZ3]QU^3S7E>YY>OY^VFW^'5
MP6G]0^HH?I'7]7U#Z7+/S3\73Y2GYY8=L6!?_P!#]"[?7/3^C],GU\_Y)?E]
M26.:7D_%PE$<]G?9/ER?HE_^A'Z9]\WTW[2^H_:/E=_S?0?NO_Z#Z=M_TNU_
MMTV=*:RW6>JZ*/K/Z4^K2,^IDZV:>/4Y9I\9\XC58/H/IE?HS_H'Z8ZIR]#J
M>GE/_3G\73X^7E'NXK^E_P"X0^^?U+\SW`\[^J_W1]R][<3?]9^Y_P"?\COI
MO^G_`)-*[NFK<KOU9Z8^B]+T^?I<F27_`,X?#G%WT/\`RWU3?ZB^I>OZF/K>
MMU/Z<W4Y<>'*)*+-^S/MYE]D?0?MOM%\E]O^4^FTV%W[/*?+W?#=O_,KX]=8
MOK?4^H/K\_J9XYYS^^))6CZ/Z!OZ)T?IV&3IRR]W#G\<8]:790-NVG6E*?OI
MKH,^<>G\8Y:I".K\FO797K7PK[:_&E==*NCF7.6;#-^Z?[HX?ER$\LL93EV^
M*4^_C&2]K<.W9NH'A2M.M/\`GKMPF9\</X?PCD,LAEEEQE*7SCD;;3YJ4]M:
M4_?7IJARS$^/*"LN4YY9><^$'RT]E.O[/CK@>EE&:66453_3V\HXAVJA396H
M4I3Q]FN/Y'4/EZF'Q[OWRA\../\`'^,<5.QM#N[-M0IOI2M0I2OMKKDGIS&7
MCC+[,?NBJ9YAD\_+M^4:IOI7F0W^0\Y[-WE_->'LK^=X:[DYNGX,W2^<H^17
MHL_CZ74GSRSGS^<;?Y-0_!7]U?`/W^%-5\4NZ/I,IF?FE]W_`(CG\G7\/AU\
M/#X_#7&*QH,OI.Y?Z=].W[OYGR7EMVZO^_V.NZO_`':0C?#9MZ4V_#PTA'2Y
M\KV%?.>7\K3\[S/;[&VH?ZO=_+INIX^W2$<&7D.P'T_RGE:CM\EV>Q7^*G8_
M+K[](1MZ0CC\N[^'=^[=_GX:0CEI"-)/Z=YYQVO)?4NTCYOM]CSO9Z]CS.W\
+_M5KLW=/=I"/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g532389g23b45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g23b45.jpg
M_]C_X0EG17AI9@``34T`*@````@`"`$2``,````!``$```$:``4````!````
M;@$;``4````!````=@$H``,````!``(```$Q``(````>````?@$R``(````4
M````G`$[``(````&````L(=I``0````!````N````.0`+<;````G$``MQL``
M`"<0061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHP-3HQ-"`P
M.3HP-#HQ,0!E<FEC:``````#H`$``P````$``0``H`(`!`````$```$8H`,`
M!`````$````@``````````8!`P`#`````0`&```!&@`%`````0```3(!&P`%
M`````0```3H!*``#`````0`"```"`0`$`````0```4("`@`$`````0``"!T`
M````````2`````$```!(`````?_8_^T`#$%D;V)E7T--``'_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``2`*`#`2(``A$!`Q$!_]T`!``*_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TK/SG8-8O=0^W':'&^QCF#TFM&[UK!<^K]#I[_3_2?\%_HZ/2CU;,
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MQP.$6M#&`-VUV;K-^/5<W^?MIJ]-O4'[[L=F9^K8_P#1LI:]EM=98'F-Y+6F
M"1(:ZSW$?0]C'>YZY=O2_K;39ZN&,7&.V][,876?9V76&MC/T-=%7J55T4_H
MO9_2\C*SK?\`!T)9G2/KA=TNWI[,FCTK<9M+GOL?;=%;7MN9ZCZ<?U<CJCG;
M;\WU,?['5_1L/UJ_M5J4]'@9V/GX-.?CD_9\A@MJ<\%I+'>YC]K_`'-WL]Z*
M+6.I%U9]6MS=["R';@1N;LCZ6[\U<?U%GUF<&=(?9353G[,2K#;!<<9C6OS;
M_MK*V>A<_']3'LV8EG\Y7]DHH^S_`&W(U[+NOXU=.)1CTBUX)8*6DX]31%=.
M)ZCC3MJJ;^DR,IU;+/3_`*#T^VS^BI3#)^L'VZVK"Z'87Y+MMF2162:&D^RG
M+;:&LP[;';_5KR=F1]GHR?1I^U_9JUOKC79G5NGT_;3NOQ<7(<[-NJ<P'+O+
M[L#TZV7/-C=MS<*FK$_FZ:OT5&1FW48]2MX^1]>FU/==B4NMW.]A>S;)'Z/T
M!6ZO]3K:[_M1=]MOOI]+]6HR?M&(E/25VLM8U[9AS0X!P+7`.^CNK?M>S^VU
M37)]+H^MF$^^VS"INR\VQEV9DES*P]XWT^E7Z=MSJ\.C'JPJ,?>RR_[/]JSK
M:OMOZAD6JZOKC9TRYV0ZAF>ZI]=%=;H:+;K)%US_`/!T8%7Z.GTO6R+:?4O_
M`*39Z#$IZ$D`$DP!J25C=/Z^[J?5/0Q&#[&VKU?4<';WUN)9CY3#_-U8][Z[
M?LOJ?ILVOU,JOT<>JO[7+J.+GV]+Q,6ZM^6-[&]1KJ<S=;4UKMS=V1]DJ?7D
M7-I^UU^SU,9^12LP8?UEP;[3TNK6ZP.OORS7>_(MM8QWVC)?39C^AB]/V_96
MTX[/YNCTL;&M^T5W8B4]6DN3N^LOUC?8[`Q>F_Y3I9ZV36S9<RMKBYF)0Y[L
MG$K];+]*R_>ZUGHT_HJOM=OIJU7UGZT/K:\](+7.N_2UN<T&J@CV!KO6<W,R
M65_I[MGV>GU+&8%7J65Y.52E/1)+FJ?K3F?;7TY>,,:K%>Y_47':[[/6\.;T
MW%<:[[/M.?F_HLC]4;=Z?K58GHVV6LR4NO9O4<BG-QQC^E@4Z76O8X6N:W:X
M?L^Q[Z:_M]]KMG3?3]:JFYGKWWUW^EB)*=5O6\`V9K9<*^G[1?=$L+W%[?0J
MV;K+;ZW,VOK;7_.6U55^I:GLZYTRL4[K23D5MN8&L>XBIWT<B]K&.=C8_P"]
M?D^E4Q<_3@>L'XS>EMJQNEXPOP.C5W%@OLL=;Z%G4`[T\=EGJ8GZ+UOM7OLN
MRKOTJT.E_59M'Z;J-_VG(ML;DY#*QLI=>V/0<YONMLIPFM93A8[[/LM5=--O
MV;[7^L)*?__0],ZA_1O\#_.5?TG^;_G*_P#P;_N-_P!V?25E?*J22GZJ27RJ
MDDI^JDE\JI)*?I9W_BG9_1OZ"[G^E_SM?\U_W2_T_P#P_P!G6HOE5))3]38_
M\TWZ'?\`F_H\_FHB^54DE/U4DOE5))3]5)+Y5224_4.-_2,O^9_G6_S7T_YJ
MK^E_\/\`N?\`=;[.K*^54DE/T=@_S>5_R9_RH[^8X^FS^D_^;O\`?_X7TEN+
MY5224_4X_G3]'Z(_K<NY_D*:^54DE/\`_]G_[1%>4&AO=&]S:&]P(#,N,``X
M0DE-!`0``````%$<`5H``QLE1QP"```"```<`E``!65R:6-H'`(%`#-#3TY3
M14Y4($]&($E.1$5014Y$14Y4($-%4E1)1DE%1"!054),24,@04-#3U5.5$%.
M5%,`.$))300E```````0,>V2H?QN[I3/$,CQ%3Y39#A"24T$.@``````Y0``
M`!`````!```````+<')I;G1/=71P=70````%`````%!S=%-B;V]L`0````!)
M;G1E96YU;0````!);G1E`````$-L<FT````/<')I;G13:7AT965N0FET8F]O
M;``````+<')I;G1E<DYA;65415A4`````0``````#W!R:6YT4')O;V93971U
M<$]B:F,````,`%``<@!O`&\`9@`@`%,`90!T`'4`<```````"G!R;V]F4V5T
M=7`````!`````$)L=&YE;G5M````#&)U:6QT:6Y0<F]O9@````EP<F]O9D--
M64L`.$))300[``````(M````$`````$``````!)P<FEN=$]U='!U=$]P=&EO
M;G,````7`````$-P=&YB;V]L``````!#;&)R8F]O;```````4F=S36)O;VP`
M`````$-R;D-B;V]L``````!#;G1#8F]O;```````3&)L<V)O;VP``````$YG
M='9B;V]L``````!%;6Q$8F]O;```````26YT<F)O;VP``````$)C:V=/8FIC
M`````0```````%)'0D,````#`````%)D("!D;W5B0&_@````````````1W)N
M(&1O=6)`;^````````````!";"`@9&]U8D!OX````````````$)R9%15;G1&
M(U)L=````````````````$)L9"!5;G1&(U)L=````````````````%)S;'15
M;G1&(U!X;$!RP```````````"G9E8W1O<D1A=&%B;V]L`0````!09U!S96YU
M;0````!09U!S`````%!G4$,`````3&5F=%5N=$8C4FQT````````````````
M5&]P(%5N=$8C4FQT````````````````4V-L(%5N=$8C4')C0%D`````````
M```08W)O<%=H96Y0<FEN=&EN9V)O;VP`````#F-R;W!296-T0F]T=&]M;&]N
M9P`````````,8W)O<%)E8W1,969T;&]N9P`````````-8W)O<%)E8W12:6=H
M=&QO;F<`````````"V-R;W!296-T5&]P;&]N9P``````.$))30/M```````0
M`2P````!``(!+`````$``CA"24T$)@``````#@`````````````_@```.$))
M300-```````$````>#A"24T$&0``````!````!XX0DE-`_,```````D`````
M``````$`.$))32<0```````*``$``````````CA"24T#]0``````2``O9F8`
M`0!L9F8`!@```````0`O9F8``0"AF9H`!@```````0`R`````0!:````!@``
M`````0`U`````0`M````!@```````3A"24T#^```````<```____________
M_________________P/H`````/____________________________\#Z```
M``#_____________________________`^@`````____________________
M_________P/H```X0DE-!`@``````!`````!```"0````D``````.$))300>
M```````$`````#A"24T$&@`````#.0````8``````````````"````$8````
M`@`P`#$````!``````````````````````````$``````````````1@````@
M``````````````````````$`````````````````````````$`````$`````
M``!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$````
M`%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<````@
M`````%)G:'1L;VYG```!&`````9S;&EC97-6;$QS`````4]B:F,````!````
M```%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N
M9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E
M;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&
M8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````
M````3&5F=&QO;F<``````````$)T;VUL;VYG````(`````!29VAT;&]N9P``
M`1@````#=7)L5$585`````$```````!N=6QL5$585`````$```````!-<V=E
M5$585`````$```````9A;'1486=415A4`````0``````#F-E;&Q497AT27-(
M5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N
M=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N
M96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R
M5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/
M=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M
M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-!"@`
M``````P````"/_`````````X0DE-!!0```````0````".$))300,``````@Y
M`````0```*`````2```!X```(<````@=`!@``?_8_^T`#$%D;V)E7T--``'_
M[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5
M$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.
M#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`S_P``1"``2`*`#`2(``A$!`Q$!_]T`!``*_\0!/P``
M`04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!
M``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!
M,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?2
M5>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'
MEZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12A
ML4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+R
MLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'
M_]H`#`,!``(1`Q$`/P#TK/SG8-8O=0^W':'&^QCF#TFM&[UK!<^K]#I[_3_2
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ME^A9^?U#)R,BQP.$6M#&`-VUV;K-^/5<W^?MIJ]-O4'[[L=F9^K8_P#1LI:]
MEM=98'F-Y+6F"1(:ZSW$?0]C'>YZY=O2_K;39ZN&,7&.V][,876?9V76&MC/
MT-=%7J55T4_HO9_2\C*SK?\`!T)9G2/KA=TNWI[,FCTK<9M+GOL?;=%;7MN9
MZCZ<?U<CJCG;;\WU,?['5_1L/UJ_M5J4]'@9V/GX-.?CD_9\A@MJ<\%I+'>Y
MC]K_`'-WL]Z*+6.I%U9]6MS=["R';@1N;LCZ6[\U<?U%GUF<&=(?9353G[,2
MK#;!<<9C6OS;_MK*V>A<_']3'LV8EG\Y7]DHH^S_`&W(U[+NOXU=.)1CTBUX
M)8*6DX]31%=.)ZCC3MJJ;^DR,IU;+/3_`*#T^VS^BI3#)^L'VZVK"Z'87Y+M
MMF2162:&D^RG+;:&LP[;';_5KR=F1]GHR?1I^U_9JUOKC79G5NGT_;3NOQ<7
M(<[-NJ<P'+O+[L#TZV7/-C=MS<*FK$_FZ:OT5&1FW48]2MX^1]>FU/==B4NM
MW.]A>S;)'Z/T!6ZO]3K:[_M1=]MOOI]+]6HR?M&(E/25VLM8U[9AS0X!P+7`
M.^CNK?M>S^VU37)]+H^MF$^^VS"INR\VQEV9DES*P]XWT^E7Z=MSJ\.C'JPJ
M,?>RR_[/]JSK:OMOZAD6JZOKC9TRYV0ZAF>ZI]=%=;H:+;K)%US_`/!T8%7Z
M.GTO6R+:?4O_`*39Z#$IZ$D`$DP!J25C=/Z^[J?5/0Q&#[&VKU?4<';WUN)9
MCY3#_-U8][Z[?LOJ?ILVOU,JOT<>JO[7+J.+GV]+Q,6ZM^6-[&]1KJ<S=;4U
MKMS=V1]DJ?7D7-I^UU^SU,9^12LP8?UEP;[3TNK6ZP.OORS7>_(MM8QWVC)?
M39C^AB]/V_96TX[/YNCTL;&M^T5W8B4]6DN3N^LOUC?8[`Q>F_Y3I9ZV36S9
M<RMKBYF)0Y[LG$K];+]*R_>ZUGHT_HJOM=OIJU7UGZT/K:\](+7.N_2UN<T&
MJ@CV!KO6<W,R65_I[MGV>GU+&8%7J65Y.52E/1)+FJ?K3F?;7TY>,,:K%>Y_
M47':[[/6\.;TW%<:[[/M.?F_HLC]4;=Z?K58GHVV6LR4NO9O4<BG-QQC^E@4
MZ76O8X6N:W:X?L^Q[Z:_M]]KMG3?3]:JFYGKWWUW^EB)*=5O6\`V9K9<*^G[
M1?=$L+W%[?0JV;K+;ZW,VOK;7_.6U55^I:GLZYTRL4[K23D5MN8&L>XBIWT<
MB]K&.=C8_P"]?D^E4Q<_3@>L'XS>EMJQNEXPOP.C5W%@OLL=;Z%G4`[T\=EG
MJ8GZ+UOM7OLNRKOTJT.E_59M'Z;J-_VG(ML;DY#*QLI=>V/0<YONMLIPFM93
MA8[[/LM5=--OV;[7^L)*?__0],ZA_1O\#_.5?TG^;_G*_P#P;_N-_P!V?25E
M?*J22GZJ27RJDDI^JDE\JI)*?I9W_BG9_1OZ"[G^E_SM?\U_W2_T_P#P_P!G
M6HOE5))3]38_\TWZ'?\`F_H\_FHB^54DE/U4DOE5))3]5)+Y5224_4.-_2,O
M^9_G6_S7T_YJK^E_\/\`N?\`=;[.K*^54DE/T=@_S>5_R9_RH[^8X^FS^D_^
M;O\`?_X7TEN+Y5224_4X_G3]'Z(_K<NY_D*:^54DE/\`_]D`.$))300A````
M``!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````
M$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P`V`````0`X
M0DE-!`8```````<`"`````$!`/_A$(!H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX@/')D9CI21$8@
M>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS
M>6YT87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SIP
M9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B('AM;&YS.F1C/2)H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z>&UP34T]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T179T
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%
M=F5N=",B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C`O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIP:&]T;W-H;W`](FAT='`Z
M+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B('AM<#I#<F5A=&5$871E
M/2(R,#$S+3`U+3$T5#`Y.C`R.C4W(B!X;7`Z0W)E871O<E1O;VP](DUI8W)O
M<V]F=,*N($]F9FEC92!7;W)D(#(P,#<B('AM<#I-;V1I9GE$871E/2(R,#$S
M+3`U+3$T5#`Y.C`T.C$Q*S`U.C,P(B!X;7`Z365T861A=&%$871E/2(R,#$S
M+3`U+3$T5#`Y.C`T.C$Q*S`U.C,P(B!P9&8Z4')O9'5C97(](DUI8W)O<V]F
M=,*N($]F9FEC92!7;W)D(#(P,#<B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@
M>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#I&0S<X0T4V-S0S0D-%,C$Q038T
M0T)!.#(X1$,V1C`S-B(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#I&0C<X
M0T4V-S0S0D-%,C$Q038T0T)!.#(X1$,V1C`S-B(@>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/2)X;7`N9&ED.D9"-SA#138W-#-"0T4R,3%!-C1#0D$X,CA$
M0S9&,#,V(B!P:&]T;W-H;W`Z0V]L;W)-;V1E/2(S(B!P:&]T;W-H;W`Z24-#
M4')O9FEL93TB<U)'0B!)14,V,3DV-BTR+C$B/B`\9&,Z8W)E871O<CX@/')D
M9CI397$^(#QR9&8Z;&D^97)I8V@\+W)D9CIL:3X@/"]R9&8Z4V5Q/B`\+V1C
M.F-R96%T;W(^(#QD8SIT:71L93X@/')D9CI!;'0^(#QR9&8Z;&D@>&UL.FQA
M;F<](G@M9&5F875L="(^0T].4T5.5"!/1B!)3D1%4$5.1$5.5"!#15)4249)
M140@4%5"3$E#($%#0T]53E1!3E13/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D
M8SIT:71L93X@/'AM<$U-.DAI<W1O<GD^(#QR9&8Z4V5Q/B`\<F1F.FQI('-T
M179T.F%C=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z
M1D(W.$-%-C<T,T)#13(Q,4$V-$-"03@R.$1#-D8P,S8B('-T179T.G=H96X]
M(C(P,3,M,#4M,314,#DZ,#0Z,3$K,#4Z,S`B('-T179T.G-O9G1W87)E06=E
M;G0](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!S=$5V=#IC:&%N
M9V5D/2(O(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)D97)I=F5D(B!S=$5V
M=#IP87)A;65T97)S/2)C;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+VIP96<B+SX@/')D9CIL:2!S=$5V
M=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.D9#
M-SA#138W-#-"0T4R,3%!-C1#0D$X,CA$0S9&,#,V(B!S=$5V=#IW:&5N/2(R
M,#$S+3`U+3$T5#`Y.C`T.C$Q*S`U.C,P(B!S=$5V=#IS;V9T=V%R94%G96YT
M/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@<W1%=G0Z8VAA;F=E
M9#TB+R(O/B`\+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R>3X@/'AM<$U-.D1E
M<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240](GAM<"YI:60Z1D(W.$-%-C<T
M,T)#13(Q,4$V-$-"03@R.$1#-D8P,S8B('-T4F5F.F1O8W5M96YT240](GAM
M<"YD:60Z1D(W.$-%-C<T,T)#13(Q,4$V-$-"03@R.$1#-D8P,S8B('-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#TB>&UP+F1I9#I&0C<X0T4V-S0S0D-%,C$Q
M038T0T)!.#(X1$,V1C`S-B(O/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z
M4D1&/B`\+W@Z>&UP;65T83X@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`\/WAP
M86-K970@96YD/2)W(C\^_^(,6$E#0U]04D]&24Q%``$!```,2$QI;F\"$```
M;6YT<E)'0B!865H@!\X``@`)``8`,0``86-S<$U31E0`````245#('-21T(`
M``````````````$``/;6``$`````TRU(4"`@````````````````````````
M```````````````````````````````````````18W!R=````5`````S9&5S
M8P```80```!L=W1P=````?`````48FMP=````@0````4<EA96@```A@````4
M9UA96@```BP````48EA96@```D`````49&UN9````E0```!P9&UD9````L0`
M``"(=G5E9````TP```"&=FEE=P```]0````D;'5M:0```_@````4;65A<P``
M!`P````D=&5C:```!#`````,<E120P``!#P```@,9U120P``!#P```@,8E12
M0P``!#P```@,=&5X=`````!#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U0
M86-K87)D($-O;7!A;GD``&1E<V,`````````$G-21T(@245#-C$Y-C8M,BXQ
M```````````````2<U)'0B!)14,V,3DV-BTR+C$`````````````````````
M`````````````````````````````````````````````%A96B````````#S
M40`!`````1;,6%E:(`````````````````````!865H@````````;Z(``#CU
M```#D%A96B````````!BF0``MX4``!C:6%E:(````````"2@```/A```ML]D
M97-C`````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@``````````````!9)
M14,@:'1T<#HO+W=W=RYI96,N8V@`````````````````````````````````
M````````````````````````````9&5S8P`````````N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="```````````````N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M`````````````````````````````&1E<V,`````````+%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$``````````````"Q2
M969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````
M``````````````````````````````!V:65W```````3I/X`%%\N`!#/%``#
M[<P`!!,+``-<G@````%865H@``````!,"58`4````%<?YVUE87,`````````
M`0````````````````````````*/`````G-I9R``````0U)4(&-U<G8`````
M```$``````4`"@`/`!0`&0`>`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`
M8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0
M`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!
M60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#
M`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"
MX`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@
M`^P#^00&!!,$(`0M!#L$2`15!&,$<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%
M'`4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[
M!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L(
M'P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE
M"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+
M^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN
M#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0
MN1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C
M$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6
M;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1
M&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4=
M'AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$
M(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LD
MVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&
M*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78M
MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C
M,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`W
MG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC
M/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"
MM4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB1
M2-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/
M`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U
M5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<
MAES672==>%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.7
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MRHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)
MEC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?
MBY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DW
MJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBS
MKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*
MOH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S)
M.LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)
MU,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@
M-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[
M[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GX
MJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X`#D%D;V)E`&1``````?_;
M`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``
M$0@`(`$8`P$1``(1`0,1`?_=``0`(__$`:(````&`@,!``````````````<(
M!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+$``"`0,$
M`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,74G&!&&*1
M)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1E
MH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::G
MJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($
M!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B%C,)L23!
MT4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#
MT^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8
M:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"
M$0,1`#\`W]G=(T>21UCCC5G=W8*B(H+,[LQ"JJJ+DG@#W[KW7:LKJK*P96`9
M64@JRD7#*1<$$'@^_=>ZJ'W]\TNW-U=Y8.?IC<6T,5T9MWY%;9^-NS]KS;1J
MMT]@_-CM.DW#3X/Y(IU[E)JFB@V'TQ\6<)-DI,EN:EIJY:O<FVLI#//34%`%
MR?NO=6\^_=>Z][]U[KWOW7NO>_=>ZK@^2?\`,`FZ7W1GJ/KWI^L[?V!TINOK
M;"?+#LU-XT6S]O\`3R=G[CVQM_![0V7%5X?+-V[W51T6\*'.5^VJ63'PXW"S
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MW[ZV&CJ*.KI\A'3S4$]-/#70U:QO22T<L3I4QU23`Q/3O"S!PWI*DWX]^Z]U
M1%V[\=NQ]F;RV3\.?@'\X?EGUIE-^8VAW1EL$F:ZK[HZD^(?QGCR4&-R6XL;
MN/M?K/>O9>"GW)AJ&KVUU=MV/<KDY?56PA,1@J[P^Z]U8]\5?@=\<OA[@]OT
M'5>W,_FMR[<V50]>4/9_:>[L]V?VB-F4%2U:FVZ7=^[*NNJ=OX"LR#?=5>/Q
M$>.H*VM`JIX)*F\I]U[HX0J*<U#T@GA-5'#'424PE0U"4\SRQ13O"&\BPRR0
M.JL1I9D8`W!]^Z]T'F"W5OS*=F[_`-K9/K*IV]UWM7#[.FVIVA6[IPE6.QMQ
M9V'*U>Z<1B-FT`GS.$Q>QZ>"ACDR&0DA_B%76R1T\)2E>:3W7NA)]^Z]T17^
M9)\V]E?R^/AYVO\`);=U51'*8"CQ^U>L=O5,-57U.].WM\5T6V^N]L4.#QI.
M<SZ/G*U:W(4^/CFK8\-15E0B$0-;W7NJW?AF,7\OLOU_T-CJ'?\`L+HCXE[E
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M3*XS%[EH*>EJZ[;V1KZ">EHLY1TE:DE%55>)J95J(XYE:)WC`<%2??NO=4==
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M=VI52XRM\8BR%`T53%>*5"?=>Z'?W[KW7O?NO=>]^Z]T47Y:_)'-](X?9&PN
MIMK8WLOY0]]YK);*^//5^4KJF@P5=F<90Q5VZ^SNRLAC8Y\KM[H[IW$5<64W
M5DX(GG$<M+C:,293*8Z"?W7NJB.C<34]J_-7=_Q-Z\W3+WI@>M:[;_9/\UGY
MA[IPE%4;A[R^0&!S6-W#U5\;MD5,-358KK3JWKG.;>:%-G8ES0X7#)4XY0]7
M_%:_(^Z]UL8^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK$^6_\TGXV
M=!];5+;`[AZ?WQWSNOL[*_'WJ_JZJW+7Y7(P]VXV?)4N?I^Q-E;(HLYV?B]K
M]9TN*J<KGHZ;%FOJ*."&EH5DK<EC4J/=>Z2/QT[<W1\2?AOW-\B?F'V/VUN[
M+9KL_.=EX[:W:U?A'[HHU[%@V;MGJ3I^CZYQU?'MGJ;=G:^Y6I*C;W7U-.E/
MMAMS4N,JYWJH*ZL?W7NH?Q^_F$9?"=#?)'Y-?,[>W4F"ZBZQW;@J'#;LZAQ6
M<R^R:;<F5QF.H,]T%UGN=<MGLE\G=T;.WWD*+;-/N+`X^BAW7NZKJ\?C*`&E
M2,>Z]UUO?Y&_-?9F?Z*[;[#_`-#O36S^X^_NL.F^OOA!5[>R787?_8&UNQ\_
M0XS/[BW+VOAMRT.!VQVOUULH9#>==@\+B,IM["87#5L-?EZRWWM-[KW7_]'8
M;R72OR*[MW+D\9VE\=-P]G?(^;=V?R=3VG\F]R05'P$^/FVCG<C3[3@Z2Z4V
M/O):CNX+LVCI66BKL73Y7+9!V;/YK&I(:>+W7NB[86CZ'_ES_(?JK`?&?I?Y
M?1?)+=_R0K>J?DUM##=,YPX3YS[`WCUWOS>5!WC1U])%B/CF^'ZRW/0156U*
MG&9C`2[#PM+F\.V/I\4*F'W[KW4]>]?YD':6RNX)<KT/\K<5F=Q?,/;-?\E]
MH;#=,+EOC+\;=A[PP.TMO_&SX3[BK\]LG%?([LKLW`[/I=P;]WUAJJ#:N.QV
M\,L*6LJ)Z2A@C]U[J7OWL3^9CTCW=\Q.Z,9\6^VNR._/D-\/>HZWK'";)H=M
M[U^-WQ(IMA;P[SH:?:<78=?DJ&M[9[+ZFV_N^#=^Z=L8?%U>0['W)DOX;M^*
M#'TD=8WNO=(/<.Y-S9;LK^6OCM]57\P/'_!3X=XVK[`@[W[#Z;[UW)W)\^?F
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MONN#8.=V!ENT\=M;8E"L7>?7O4^[]D9W,YFLW+D:#'UV\67^`X9VAFR&3B]U
M[JQ[,?.;YD[-[^['[OW!\"/GUD.CJ;XU8+;OQ"^,'6>P]I;HK>T]V93=4F6W
MOVC\BZBARC4/QVW_`(Y\;@\)@MNY7)5E?0[9FR>1>EFKJB7&4/NO=5L_%/??
MR`^('SD_F%?);Y6;`W3W'\^,]M/<TF9^.7QD_P!+.]*'M_:=3L'KCM?JJLIM
MU[WVCMWI?H[XL_&W:N'EV+M[.5V0K<_N+<L^X9ZCRS1X[&5/NO==UO\`,4_F
ML=+_`!1^2/RIK.Z?C_W9M#O?M3IW`_'7=]+U3V?EJKKS?/;.(VU%VWUC\2>G
M]O[?IQW_`-2_$K"Y+)UE/N_<>5H_[V9/:626>D>5Y(W]U[JWOX%5<W5VP?CW
M\0_A'T#\@<'\;^J:BHSO<WRR^76Q<]UU5]H4^<ES>\=XYO:.`W]/MCMCLKN?
MN_LO-3Y'*Y>;`8S;N$AGJG1B10T'OW7NE'WO_,&[=HL#2[ZZ&VCUYC.OMP[A
MRNQNB).U,/O3>?;?S6[%B6IIL1M_XR=)[%SFT<K3[!K<E2%VWKG\K3XQ<.SY
MMZ6+!0_Q2;W7NBU[(^0G<GQMP7R,R?R*HNIL3_,Y[<[HZ?ZHS/8F;W5+3_$/
M:6R>P-A;W['Z<KMA[GW4=H9_$?''XU=0[)WUE,S@Z^2ES>Y-\X'.M'4>3<-#
M4K[KW19NH?YNNU/C1\,OE[VKN/L;N;OKY)[A[A[Z/QC^./9NY:G?_P`EM[P]
M>;3V=MO!]C;PZEQ.UMOCXY=9=G;NJ%W=1;?IL=38##;3SF)IL3]_6UD$=;[K
MW35U-_/#['&RMX5%%WUT5\K=U;@QOPMVE1]E[<ZJSO6WQ@^+O;?=5,8^^-T=
M[[VQ.Y,Y4[5^/G3F&R&$EJ:G<&3HMP9'?N6;;-'%#IE..]U[J'\TOYKG8WS/
MW54?#_XD=F=%=$_'#O'L3+_%;MCY,=O1;WQO;>W.N9MD9S<?R`[RP&/R<VT.
MO/CGMS#[+Q-?M_8*=B54&?[,W#5FIP%!'BJ!\K)[KW0Z[-_G`?';I;K>#H?X
MMX_I'973_7/;W3OQ`^,&7WGO6KIL/M3JO9F.QF-[D^3WR:PAAVZ_1/2>.CBJ
M<-ULN:R%/GNU=PTD4N/A-'E*>I7W7NN6P_YZM)WA\X<[M;K';/:B?''J7JS<
MM$G1F/\`CIV3E/F#\H>[=TY_#T^P*[9VQL[MS#P[!ZSQ&UL3D<K3UU?D,=1_
M85\%9G*J@CG@IZ;W7NA_^9O;?R3^.O\`+O.6WG@-W97Y(?)3Y'X+$87XL]*=
MC5M7W-78/NCM*7<69^+70G:^`QRR0[YVQU%39"3-;LHHH:3"T-'G,GC)84I:
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ME?)+?NTL%B*/<NS^J=E]D97_`$C=@=:]==MUJ[0SO<U)2T?7/\6R%##`WED5
M)?=>Z/[\E_YF.#ZOWYMCXU]6+TWFOE54=6[A[L[ZQ79'<6%V]TY\(.D-HX.D
M;>'=GR7WQBXJB9=O8/>>>Q.(Q^%I!0Y+<#5IJ4FHJ**6K3W7NB?_`!R_GK8;
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MU-N;>?\`"R])M?>V^>O4QV<R.WS)+4[?FR7\/J6^ZIY@/=>Z+O\`(K^8Y#U:
M^^9NK^L(^PMK=9[N;J_=79&ZMU5FR]K[H[WDFBAQ/QMZ"V]AMI[V["^0O>>;
MR*R8MJ#`XL8K&Y4_;U.0\]-D(*3W7NB>=+=Y["ZR[*[W^:_S-Z/EVI_,*R)F
MZDSGQ_Z_Q76'8.X_BY\:]F;7Q7;6&QP[QP\NW=HUW667VCNNDW5OKLW<V:Q&
M"DSTR[=CEC7!8Z@]^Z]U/^/?4'QZ_FS_`"+ROS\[:^-V-PG6O2M6W4O3_2G>
M/6S;<[9W9V/C,'A\MDN]/E3UWD*BLV]EIL%M/<]-!U+BLG'E#C-MYFHW`)5F
MS-!!B_=>Z+=L+`_(_P#FV?)?;'REZ,B^/&Q?Y</PA[+W7U[\`Z#L;;FYM];,
M[1[QZWR51USN;YX;2ZOV-D=D;3WAA^J!29C;G5E-7Y>/'XVLCJ<I`L%4OOW7
MNKO>COAOM7K'L"K[W[+WUO/Y'?)K*8-]MS]X=J-BQ5;1VQ5K2R939'2VP=OT
M>-V)TKL3*Y&F^YK*3"T:9#*RE#E*[(&"G:+W7NO_TM_CW[KW10-Z]=[Z[!^:
M?2NZLI@\A2=-?'KJ;L+>V"SR9NGCQVY>_>V:D=:8ZCDP",U742]==14&XRU1
M(J1`[NC5&9E<+[KW1O\`W[KW7O?NO=>]^Z]U[W[KW0)YKXT_'3<F](^Q]P]"
M=,9[L&&MAR<6]\SUALK)[L3*4TU/44V47<%;A)\J,G2STL;Q5'E\T;("K#W[
MKW0V>_=>Z][]U[KWOW7NO>_=>ZI4[,ZO[P^5/\T6GP.X.IMT[5^,/Q#VKU1E
M<1W#N?')BMH;XS6ZZJD[5WALGIN*JI9SOC/;KW1L_:&+W7D0@H=N[<VY78R.
M05FX)0GNO=75$!@58`@@@@BX(/!!!X((]^Z]T6GI[X=?&CH3=&3WMU5U-@]N
M;OR=#)ATW+5U^X-TYK`[<EJI:U]G[*R&\,OGZC8&Q?NI=8P6#;'X=2D=J8"*
M,)[KW0?;5^*V-WKV?\B.RODML?K+L>'L+M+K2NZJV9GL1C>P=N[,V)T#@JNB
MZGW0]'NO;PI\7V?4;NW7N3-2STJR?P],C3P0S%XI9']U[H/MQ_!&I[#_`)@$
M7RZ[&W=M3+=:[+V!UK1]8]2XK8M!0;AE[8V7DMZ5B[[[)WX9#4[IP>U3N"GK
M-OXKPD09F"GKI90^+H$'NO='JP?7VP=L8C(;?VULC:&WL#EZ^MRN5PF#VUA<
M3B,GE,C,*C(9+(8V@HJ>BK:^OJ!KFFD1I)7]3$GGW[KW43=75W6>^\;E<-O?
MKO8N\L1G,MB<]F\5NK:.W]PXW,9S`)0QX+-96AR^/K*7(9;"QXRF6DJ9E>:F
M6GB$;*(UM[KW3@^Q-D2U>XJ^39NU9*[>%5A*[=M:^WL0]7NBMVU%2P;<K-Q5
M#49FS=5M^&A@2BDJ3*](L*"(J$6WNO=*G2+EK#40%+6%R%+%03]2%+&W]+GW
M[KW4.HQV/JZJ@K:J@HJFMQ4L\^+JZBE@FJL;/4TTM%4S4%1(C2T<M11SO"[1
ME2\3LINI(]^Z]U-]^Z]T%2=%=(Q]C5/<,?3O5J=M5G@-7V@O7^U%[#J6IJ%,
M9`\^\QB?[QRO%C8DIE8U)(IT6.^A54>Z]U/J^G^J:VE[+I)NM]D+%W-0U&-[
M<:EVQAZ&I[,HJK"U&W)H-]5M%24]9NF^`JI*(-6R3,E,YC4A#;W[KW0?[R^)
M?QCW]L>3K?=G0?5&5V.>J\?T?2[:39.!QU!B>G<17X;+8CK#;W\+HZ&;;6Q\
M5E=N8VJI<;CWIJ6FJ<=22QHKTT#1^Z]U3C\%_P"1Q\?:7#[M[V_F`_%/XP;Y
M^3';'9VY^P&ZQQ6TL-O?ISH'93YZH.P>IMMOF,<M-V358W;]'0SYS+YB"K^^
MR*K#'JIZ.&67W7NK`1_*2_EIK6YK(K\+.AUJ]Q]KY7NK/2)L^%4R^_L[24M%
MFY,A3K.*>JV=F8J*%ZO:[H=L5%1$D\F/:91(/=>Z&[>'P@^'O8-3N2KWY\9^
ME-Z2[OR?6V6W(NZNO-M[@I\K5].X&JVQU;'-1Y6@JJ2/'[#V]D*JCQE'&B4E
M-!6U2K'_`)54>3W7NJ4_EO\`RE,;\XOYB&WMJY/XS;"Z.^"O5=!U=VOWSV9@
M(*#$[F^;'8=+2R8_%]!8O;^%K_M-N]5[:VUMC$TVZ<E'1XS)UT2K1Q5$BB%Z
M?W7NK3.JOC#N+8GR<R^3Z_V-UQ\8?B1UE1C);'ZKZ+H\)M0?)+N;>VS:#;NZ
M>T^XMO;4Q6&P6W]F]3[5HX<)MK`QI-/E<Q+59BO=10X=![KW0A]1?!;X\=-=
MB5/:V"P&X=T[[ILOOK(;$S/9.[L]OZ/IO&]CY>NSN\-L=*XO<%74XCK+!YS*
M9:L>J?&P19&MCJY(:JJG@T1)[KW098;^75TINSO/N/Y'_(W9&PNX^U>PNRJ7
M*;7K:K&YV/;NW.HMDX/:.#ZGZYW'M*NS=5M;?DNU*_:K[B,V4H:F&GW'D9JJ
MCC@:.)E]U[H;?C_T]O+KO>/RPW#OZJP>8/>/R&J^RMM5F(K\C4D[`3J+JGK?
M;>#S6-KZ.FBQ.8P=/L.6FF2GDJ8*A`DXD4RF&+W7NA[V7LG9O7&U,!L3KS:>
MVMB;(VKC:?#;8V?L[!XS;.U]NXBD732XO!X##4M%BL3CZ=>$A@BCC7\#W[KW
(2G]^Z]U__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g532389g33w70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g33w70.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0,K:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(B!X;7`Z0W)E
M871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!X;7!-
M33I);G-T86YC94E$/2)X;7`N:6ED.C!!0C%&1$$R1#E$,#$Q13(X.3%"030V
M,4)!,3)&.3`Y(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C!!0C%&1$$S
M1#E$,#$Q13(X.3%"030V,4)!,3)&.3`Y(CX@/'AM<$U-.D1E<FEV961&<F]M
M('-T4F5F.FEN<W1A;F-E240](GAM<"YI:60Z,$%",49$03!$.40P,3%%,C@Y
M,4)!-#8Q0D$Q,D8Y,#DB('-T4F5F.F1O8W5M96YT240](GAM<"YD:60Z,$%"
M,49$03%$.40P,3%%,C@Y,4)!-#8Q0D$Q,D8Y,#DB+SX@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0]
M(G(B/S[_[@`.061O8F4`9,`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0(!`0("`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`,J`G(#`1$``A$!`Q$!_\0`_0`!
M``$#!0$!``````````````@&!PD"`P0%"@$+`0$``04!`0$!````````````
M`P$"!`4&!P@)"A````8!`P("!08)"`4'"``7`0(#!`4&!P`1"!(3(0DQ05%A
M%/"1H=$B%7&!L>$R4B,6"D)B<I+2,U07P?&B)!B"LD-3-"498W.3U3:6EUB#
MU#555M;"9)3%)F8W5Z-TE6?7&CA(.1$``0,"!`(%"00%!P<*!0`+`0`"`Q$$
M(3$2!4%187$3!@?P@9&AL2(R%`C!T4)2X6*B(S/Q<H*2LE,5TD,D-)06&,)C
M<X.3H]-55A>S5&34)41T">*D1?*T-28V_]H`#`,!``(1`Q$`/P#WV`J;8/1Z
M`]6I"`K:!?>Z;W?-JE`JT"=TWN^;2@2@3NF]WS:4"4"=TWN^;2@2@3NF]WS:
M4"4"XXMV8B(BR:B(CN(B@EN(CZ1'['I'4G:R_F=Z2HNPA_*WT!?/AF7^!:?^
M@2_L:=K+^=WI*?+P_E;Z`GPS+_`M/_0)?V-.UE_.[TE/EX?RM]`6ZF":("""
M*2)3#N8$TRD`P^C<0*``([:M<YS\7DGK5S8V,P:``MSNF]WS:MH%?0)W3>[Y
MM*!*!.Z;W?-I0)0)W3>[YM*!*!.Z;W?-I0)0+C+M&;T2F>(E5,F`@01%0-@-
ML(_H&`/$0U+'-+%41&@*@EMXIB#(VI"V/N>'_P`*3^NO_;U?\W=?F/H'W*+Y
M*V_(/7]Z?<\/_A2?UU_[>GS=U^8^@?<GR5M^0>O[T^YX?_"D_KK_`-O3YNZ_
M,?0/N3Y*V_(/7]Z?<\/_`(4G]=?^WI\W=?F/H'W)\E;?D'K^]/N>'_PI/ZZ_
M]O3YNZ_,?0/N3Y*V_(/7]Z?<\/\`X4G]=?\`MZ?-W7YCZ!]R?)6WY!Z_O3[G
MA_\`"D_KK_V]/F[K\Q]`^Y/DK;\@]?WI]SP_^%)_77_MZ?-W7YCZ!]R?)6WY
M!Z_O3[GA_P#"D_KK_P!O3YNZ_,?0/N3Y*V_(/7]Z?<\/_A2?UU_[>GS=U^8^
M@?<GR5M^0>O[T^YX?_"D_KK_`-O3YNZ_,?0/N3Y*V_(/7]Z?<\/_`(4G]=?^
MWI\W=?F/H'W)\E;?D'K^]/N>'_PI/ZZ_]O3YNZ_,?0/N3Y*V_(/7]Z?<\/\`
MX4G]=?\`MZ?-W7YCZ!]R?)6WY!Z_O3[GA_\`"D_KK_V]/F[K\Q]`^Y/DK;\@
M]?WI]SP_^%)_77_MZ?-W7YCZ!]R?)6WY!Z_O3[GA_P#"D_KK_P!O3YNZ_,?0
M/N3Y*V_(/7]Z?<\/_A2?UU_[>GS=U^8^@?<GR5M^0>O[T^YX?_"D_KK_`-O3
MYNZ_,?0/N3Y*V_(/7]Z?<\/_`(4G]=?^WI\W=?F/H'W)\E;?D'K^]/N>'_PI
M/ZZ_]O3YNZ_,?0/N3Y*V_(/7]Z?<\/\`X4G]=?\`MZ?-W7YCZ!]R?)6WY!Z_
MO3[GA_\`"D_KK_V]/F[K\Q]`^Y/DK;\@]?WI]SP_^%)_77_MZ?-W7YCZ!]R?
M)6WY!Z_O3[GA_P#"D_KK_P!O3YNZ_,?0/N3Y*V_(/7]Z?<\/_A2?UU_[>GS=
MU^8^@?<GR5M^0>O[T^YX?_"D_KK_`-O3YNZ_,?0/N3Y*V_(/7]Z?<\/_`(4G
M]=?^WI\W=?F/H'W)\E;?D'K^]/N>'_PI/ZZ_]O3YNZ_,?0/N3Y*V_(/7]Z?<
M\/\`X4G]=?\`MZ?-W7YCZ!]R?)6WY!Z_O3[GA_\`"D_KK_V]/F[K\Q]`^Y/D
MK;\@]?WI]SP_^%)_77_MZ?-W7YCZ!]R?)6WY!Z_O3[GA_P#"D_KK_P!O3YNZ
M_,?0/N3Y*V_(/7]Z?<\/_A2?UU_[>GS=U^8^@?<GR5M^0>O[T^YX?_"D_KK_
M`-O3YNZ_,?0/N3Y*V_(/7]Z?<\/_`(4G]=?^WI\W=?F/H'W)\E;?D'K^]/N>
M'_PI/ZZ_]O3YNZ_,?0/N3Y*V_(/7]Z?<\/\`X4G]=?\`MZ?-W7YCZ!]R?)6W
MY!Z_O3[GA_\`"D_KK_V]/F[K\Q]`^Y/DK;\@]?WI]SP_^%)_77_MZ?-W7YCZ
M!]R?)6WY!Z_O3[GA_P#"D_KK_P!O3YNZ_,?0/N3Y*V_(/7]Z?<\/_A2?UU_[
M>GS=U^8^@?<GR5M^0>O[T^YX?_"D_KK_`-O3YNZ_,?0/N3Y*V_(/7]Z?<\/_
M`(4G]=?^WI\W=?F/H'W)\E;?D'K^]/N>'_PI/ZZ_]O3YNZ_,?0/N3Y*V_(/7
M]Z?<\/\`X4G]=?\`MZ?-W7YCZ!]R?)6WY!Z_O3[GA_\`"D_KK_V]/F[K\Q]`
M^Y/DK;\@]?WI]SP_^%)_77_MZ?-W7YCZ!]R?)6WY!Z_O0(B(`0$&I-P'</M+
M^D/$/Y?MT^;N3FXTZA]RJ+*VK\`]?WKL.Z;W?-K'H%ET"=TWN^;2@2@3NF]W
MS:4"4"=TWN^;2@2@3NF]WS:4"4"=TWN^;2@2@3NF]WS:4"4"=TWN^;2@2@7P
M3]13%.4IR&`2F*8`$I@'P$!`=P$!#U:J,#48%4+010Y+C_#,O\"T_P#0)?V-
M7]K+^=WI*C^7A_*WT!/AF7^!:?\`H$O[&G:R_G=Z2GR\/Y6^@)\,R_P+3_T"
M7]C3M9?SN])3Y>'\K?0$^&9?X%I_Z!+^QIVLOYW>DI\O#^5OH"?#,O\``M/_
M`$"7]C3M9?SN])3Y>'\K?0%]`P;!]KU!Z]4(-575TIU!^L'SZ4*:NE.H/U@^
M?2A35TIU!^L'SZ4*:NE.H/U@^?2A35TIU!^L'SZ4*:NE:M_?JE%75TIO[]*)
MJZ4W]^E$U=*^"8`](_3JM%35TKYU!^L'SZ4*:NE.H/U@^?2A35TIU!^L'SZ4
M*:NE.H/U@^?2A35TIU!^L'SZ4*:NE:@,`^O?5"%<'!?=]**NH)OI1-03?2B:
M@F^E$U!-]*)J";Z434$WTHFH)OI1-03?2B:@F^E$U!-]*)J";Z434$WTHFH)
MOI1-03?2B:@F^E$U!-]*)J";Z434$WTHFH)OI1-03?2B:@F^E$U!-]*)J";Z
M434$WTHFH)OI1-03?2B:@F^E$U!-]*)J";Z434$WTHFH)OI1-03?2B:@F^E$
MU!-]*)J";Z434$WTHFH)OI1-03?2B:@F^E$U!-]*)J";Z434$WTHFH)OI1-0
M3?2B:@F^E$U!-]*)J";Z434$WTHFH+1U!^L'SZK0JS5TIU!^L'SZ4*:NE.H/
MU@^?2A35TIU!^L'SZ4*:NE.H/U@^?2A35TIU!^L'SZ4*:NE.H/U@^?2A35TI
MU!^L'SZ4*:NE?0,`^@=*)JZ5]W]^J45=72F_OTHFKI3?WZ435TIO[]*)JZ4W
M]^E$U=*X'<'V?3^;63I6-J*=P?9]/YM-*:BG<'V?3^;32FHIW!]GT_FTTIJ*
M=P?9]/YM-*:BG<'V?3^;32FHK[W`]@_+\>J:5744[@>P?E^/32FHIW`]@_+\
M>FE-17SN>P/E].FE-13N#[/I_-JNE4U%.X/L^G\VFE-13N#[/I_-II344[@^
MSZ?S::4U%.X/L^G\VFE-16X10=AV\/'W#_HU8YHJK@XA:^X;V_0&J:0JZT[A
MO;]`::0FM.X;V_0&FD)K3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)K3N&]OT
M!II":T[AO;]`::0FM.X;V_0&FD)K5.VJY56BPCJRW:T5^GUUB43/)VSR\=!1
M+<``1V4?R2[9N!Q`H[%`PF,/@`".L[;MIW'>+MMAM%O/=7S_`(8XF.D>>IK`
M3Y\@M9O._P"S=W=O?NW>"\MK':XQ[TUQ*R&-O6^1S6UY"M3P6-S*'G!<-<>+
MN64'8K=E>0;=1#!CVLF&'%8O@)2V&T.:[&N$@'_I&PN"#ZA'7O/=[Z7O%3?&
M-FO(+7;8'8_Z3+[]/^CA$K@>AVDKY3[X?7)X$=UY'VVWW5[O5TPTI90?NZ\N
MUN'0,</UH]8Y$JQ<+YTK&VN1)1N(6;;@R`^WQ$)(-9-QT[[;BVAJW+H`?;U=
M_;WZ["[^E"7;(Z[QWGVFUEIE(TM'I?*P_LKSW;_KVM][E([N]R=^OK<'XHGA
M[OZL5O(*]&KSJ2-&\T;"<LX:,<N4'-O'!P\4(BG*9=QU+L:=WE!*5,JMKC4'
M3>/2$X["J\0;(E])CE#7!;Q]._>VV8Z;NS>[3OK&"I997+'3T&=(7$%Q_58Y
M[CP!7J_=WZO.X-[(R#OKMN_]UI)'!HDW*RD9;%QP`[=@=H%?Q2LC8,RX!9%X
MB;BK!%Q\Y`2T;.0DLT1?Q4S#O6DG%2;%P4#H/(^19*+M'C58@[E43.8I@]`Z
M\,NK.XLKA]G>Q20W<3BU['M<Q['#-KFN`<TCB"`5]0V.XV6YV<6X[;-%<;?.
MP/CEB>V2.1CL0YCV$M<TC$%I(*['N&]OT!J#2%DZT[AO;]`::0FM.X;V_0&F
MD)K3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)K3N&]OT!II":T[AO;]`::0FM
M.X;V_0&FD)K3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)K3N&]OT!II":T[AO
M;]`::0FM.X;V_0&FD)K3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)K3N&]OT!
MII":T[AO;]`::0FM.X;V_0&FD)K3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)
MK3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)K3N&]OT!II":T[AO;]`::0FM.X
M;V_0&FD)K3N&]OT!II":T[AO;]`::0FM.X;V_0&FD)K3N&]OT!II":U\[AO;
M]`::0FLK9[@^SZ?S:DTJS44[@^SZ?S::4U%.X/L^G\VFE-13N#[/I_-II344
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M>VN+NX9:6D;Y;J1P:QC&ESW..`:UK02XG@`"5CWE[9[?:27^X3106,+"^221
MS61QL:*N<][B&M:!B2X@!8..6'G,U2IK2-)XKQ#.^SZ9E&3C*=C:N0I3%SN9
M$PU.`ZFTC;5R*#^S<N!;,A,`"0CD@[C]>^&WTK;EN3&;OXBRNLK(T<+2(CMW
M#/\`?28MA'-C=4E,"8R%^>/C3]>>R[))+W>\'8&;EN8)8Z_F:[Y5CLC\O#@^
MX(X2/T15`+6S,-5$S&W`SFYSQFV.4^3E_LE)ISXQ7;"3R(1P[LSF/<"54"43
M%J)XV/K<<LF;]FHX)&HB`@<B:P>GTK?O&7PC\&[1_=WP^LH+O=&8.9;4$0<,
M/](NSJ=*X',-,KN!+%XKW4^G#Z@_J/W"/OAXO;G=[?L4GO,?>ASIW,=0TM-O
M!C9!&X9%X@9B',;(%F5P=Y9G$G!R#-TSQBADBT-BIG/<,JII7!\=P0`'OLH1
MPV2J<3L?<2=AB"A0V`5#;;Z^5^]_C_XF=[WOCEW`V&WNK^XLR8&T/!T@)F?T
MZI*'\H7W?X>?27X)>'<<<L&T,W7=V`5N=P`N7EP_$V)S1;QXX@LA#AQ<:54[
M63=M%MDF,:V;1C)N4$T&4>W18-$"%#8")-6I$4$B@`>@"AKQV5\EQ(9KASI)
M7&I<XESCUDU)]*^C;>*"TA;;VK&16[10-8T,:!R#6@`>8+<<D2>MUFCU--ZT
M<)F2<-7B9'39=(X;'36;KE4153,`["4Q1`=6QET+Q+"2R1IJ"TT(/,$4(/4K
MI6QSQNAG`?"X4<UP#FD',$&H(Z"%;"H8FJ>-Y5Z[QLQ;TN!FW*KNQ46'2^%I
M+J27'J4L4)7TMF%4L*BGBY/'D0;2!1$7"1U@(L3H=S[R[EOULR+?GNN[R%H$
M5P\UN`T9122'WIHP/A$A<Z/\#@VK#R.Q]R]D[J7LDW=2-MAMMP\NFM(AIM'2
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MA"J'`YK[U^_\FJ:5=5J=?O\`R::4JU.OW_DTTI5J=?O_`"::4JU.OW_DTTI5
MJ=?O_)II2K587D3R8Q+Q=HBM\RO8`8(+=Y"N5J/!)W:[E*)$ZONNM1)E4S.3
ME$2]]RH9-HT*8#+*$`0`>S[C>'_>7Q#WD;-W;@UO%#+*ZHA@8?QROH:<=+15
M[S@UIQIYKXI>+7<CP?[MN[R=\[GLXS400,HZXNI!_FX(Z@N.(U/=ICC!!D>V
MHKYD<R\FN5?F79088HH<%)-*B]?"YKF(*N\43@(]@U4*`VK)5@4!JVDSQY#%
M.L]?=I@T,/2W1(<P=S]!.ZOA_P"''@#W>?WDWF:-VYM926]F:#(YQ'\&UC%2
MS5DV./5(_-[B![OY$]_/%SQF^K7OA'W+[LV\T>Q22ZH-NMW$0L8T_P"L7TQT
MM>68%TLNF*,T$3&.=[U\:?8>$OETBF\<DCN8?+6-`17<0:K8,18MF"`('80\
MZ^;/62THP7#I4>HMWTCU%$"@P$1+KD-TL?%OQTK$PR=UO#.3(2`_.W;/S/C:
M6N#'#$1N='%0XF;`KT38MT^GOZ5P)IA%WY\:XLW0EO\`AMA*/P1S/:]ID8X4
M,K&335%`+8DA6!RYYKW,K*+IT6)OK3$L&L<_9A<91B$4Y32,.Q"N+3)A*6AP
MN4OI.1T@41\0(7T:[3NS]-OA7W=C:;FR=N=X`*R7;R\5XTA9HA`Z"QQZ2O,>
M^_UI^.W?"=XL-QCV7;7$TBL(Q&X#A6X?VEP7`9ELC03B&C)1+6Y-\DG#P9!;
MD%FQ1Z)^Y\0.4KL!^O??J`"S92!X^K;;7IC/#[N$R+L6;)M`BI2GRD'_`(:\
M1D\7_%F6X^:D[S]X#<5KJ_Q"[K7_`+53,XZ^:YR>P[.QR.0K0_SCCT5T4YBO
M79=)S:$&74!5G%:NAD?O=M)))^)$WIW;100Z3$+OUE\I[]?3;X>]Z;.1^QV[
M-HWRA+)(`1"7<!+!706'B8PQXS!-*'WSPK^M+Q<[B[E%'WINY.\/=?4!+#=.
M#KAK.+H+H@RB0#(2F2,TH6@G4/4UB?*])S;CNJY2QU+A,U"WQQ9",<F("+ML
MJ0YV[^)E6O4<S&9AWR2C=T@(B*:R8["8HE,/YT]Y>[6[]TM\N>[N^Q=EN=K)
MI>,P1FU[#^)CVD.8[BTC(U`_9/N7WS[N>(/=>S[X]UIQ<;'?1:XW9.:0:/CD
M;4Z98G@LD;4T<#0D4)N'U^_\FM'I74U:G7[_`,FFE*M3K]_Y--*5:G7[_P`F
MFE*M3K]_Y--*5:G7[_R::4JU.OW_`)--*5:G7[_R::4JU.OW_DTTI5J=?O\`
MR::4JU.OW_DTTI5J=?O_`"::4JU.OW_DTTI5J=?O_)II2K4Z_?\`DTTI5J=?
MO_)II2K4Z_?^332E6IU^_P#)II2K4Z_?^332E6IU^_\`)II2K4Z_?^332E6I
MU^_\FFE*M3K]_P"332E6IU^_\FFE*M3K]_Y--*5:G7[_`,FFE*M3K]_Y--*5
M:G7[_P`FFE*M3K]_Y--*5:G7[_R::4JU.OW_`)--*5:G7[_R::4JU.OW_DTT
MI5J=?O\`R::4JU.OW_DTTI5J=?O_`"::52K5HWU=16ZRF^E$UE-]*)K*;Z43
M64WTHFLIOI1-93?2B:RF^E$UE.K2B:RG4.E$UE.H=*)K*=0Z4364ZATHFLIU
M#I1-97`[YOD(ZET!0=IT)WS?(1TT!.TZ$[YOD(Z:`G:="=\WR$=-`3M.A.^;
MY".F@)VG0G?-\A'30$[3H6KX@?9^3ZM4T*O:!/B!]GY/JTT)V@3X@?9^3ZM-
M"=H%\%<P_P"OZMM-"IVG0OG?-\A'5=`3M.A.^;Y".F@)VG0G?-\A'30$[3H3
MOF^0CIH"=IT)WS?(1TT!.TZ%N$6\!ZO;[1_/JTMIDKFNJMSO%^0C]6J:2KJA
M.\7Y"/U::2E0G>+\A'ZM-)2H3O%^0C]6FDI4)WB_(1^K324J%";F?SEQOP_J
M)32`-[;E>P,E5:1C9L[[2[@H]:2=BM2Z74M"5-NN4?MB`+O3E%)N`B!U$O6_
M"CP@W[Q0W.D&JV[MP/`N+HBH'$Q0@X23$</AC!#GGX6N^?/'SZA^ZG@9L>J[
MTWO?*YC)M+%KJ.=F!-<$8Q6X/'XY2"R,8/>SRV3EBS%S0RK/Y`RE>&:"+!J6
M3N=^LIUV&/\`%%+*Z%-NU91[4%Q9L2JG[$7$,2*R$L],":95ESJ*:_1.TL>Z
MWA1W;AV3N[9N<][M$%M%1US>3TJ2YQIJ=0:I9I"(X8Q5Q8P`+\<[[<^_?U`=
M\[GO-WQW%C((F"2ZO)R66>W6NJC6L8VNEH)T6]M$'37$ITL;)*]SCWEWY)L:
MM1Y'!G&-I+8\Q5(`1*]7AWVF67<[/$2F3/(WF78*'/6Z@;K/\#66"WPC9$X@
MY4=*F.;6'M'<*;<=W9WP\0717W>1F-O;MJZRV]IQTV['`=K-EVEW(W6YP_=M
MC:`%L>\GBW;;+W?E\.?"".;:^YDE!=W;J-W+=W#`ONY&$]A;8GLK&%YC8PGM
M7S/<YRB`````````'H``V`/P`&O4<\UX.FB)HB:(O0!Y'^8WX/<R8%D79U8L
M(^.RK56JJAC%9/$GC6LV])L4PB":;])W&K&*4`#K1,;TF'?XH^KONM#V.U=\
M[=@%QK=9S$?B:6F6$GI:6RMJ>#@."_3G_P#9X]^[ETV^^&UW(76HC9N%NTD^
MXX.;;W(;4X!X=`Z@PJPG,E>@_O%^0C]6OB/25^GM0G>+\A'ZM-)2H3O%^0C]
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M%^0C]6FDI4)WB_(1^K324J$[Q?D(_5II*5"^=XORW^K324J%L=\WR$=7Z`H^
MTZ$[YOD(Z:`G:="=\WR$=-`3M.A.^;Y".F@)VG0G?-\A'30$[3H3OF^0CIH"
M=IT)WS?(1TT!.TZ$[YOD(Z:`G:="^@N8/]?U[ZIH3M.A??B!]GY/JTT*O:!/
MB!]GY/JTT)V@3X@?9^3ZM-"=H$^('V?D^K30G:!/B!]GY/JTT)V@77]?\[_:
MUD:5CZD[G\[_`&M-*:D[G\[_`&M-*:D[G\[_`&M-*:D[G\[_`&M-*:D[G\[_
M`&M-*:EJZQ]OT!JFD*NH)UC[?H#32$U!.L?;]`::0FH+2)Q]8_3MJNE4U)W/
MYW^UII34G<_G?[6FE-2=S^=_M::4U)W/YW^UII34G<_G?[6FE-2U%4_'^/5"
MU5!6KN>[Z?S:II5:A.Y[OI_-II2H3N>[Z?S::4J$[GN^G\VFE*A0FYP<SZMQ
M"QP60*FQG\K6Y!VUQM3%U1,DLNB':<VJPII&*LC5H-4X=8`)3O7'2W3$-U#I
M>M>$7A1N/B?OW8$OA[MVQ:;J<#$`XB&(G`S2#+,1MJ]P^%KOG[ZAO'O9O`WN
MG\Y2.Y[Y7K7-L;4G`D8.N)@#46\1(J,#*^D;2/?<SR0V:U7/--^GKSD2UN9>
MQV%XK-6RWSASK%:M^HI#*]A("@FT9I="#)@V*4O@F@B0`V`/TSV_;=J[I[+#
ML^QVS8K&!HCA@CPJ>53F7&KI)'$GXGO)Q7X@[MO6_P#B%WFN>\7>F]?-N5R\
MRW-S*2=+<B:#)K11D43`!\$4;0*!;=KO!I2(CZ57$%X/'T([,_90QCD^-GYP
MR(MEKC;UD-DY2R.4#"FB4>IO&-3?#-@`HJJ+7;;LXM[I^[7Y;-O<S=+G_ACC
MK400`XLB!Q<?BE>.TDQTM;9OG>4WMC%W>VAKK;NM;OULBJ-<TU-)NKDC"2=P
MJ&#%D$9[*+`O=);W6\7*)HB:(FB)HBRK^3>NNES&$B0F[3C$.0DG0!OL9$BM
M?73`_JV!RD00]^OF_P"J=C'>%E7?$W=+8CKI(/82OM/Z"WO;XZN#/A=L=X'=
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MS^=_M::4U)W/YW^UII34G<_G?[6FE-2`?V#].^FE-2U=8^WZ`U32%74$ZQ]O
MT!II":@G6/M^@--(34$ZQ]OT!II":@G6/M^@--(34%UW<]WT_FUDZ5CU"=SW
M?3^;32E0G<]WT_FTTI4)W/=]/YM-*5"=SW?3^;32E0G<]WT_FTTI4+[UA[_E
M^/5-*K4IUA[_`)?CTTI4IUA[_E^/32E2@G]WSC_KU72J5YKYW/=]/YM-*5"=
MSW?3^;32E0G<]WT_FTTI4)W/=]/YM-*5"=SW?3^;32E0MPBNP#Z/3ZQU:YBJ
M'46ON_T?G_/JW1UJ[4G=_H_/^?31UIJ3N_T?G_/IHZTU*U6;<T4S`.+[9EB^
MNNQ`55@*Q6:)R%D)Z8<"*,+6X@B@@"LI-OQ*BF'B"91,J;8B9Q#I.Z7=/=>^
MG>&V[M[,VM[<OIJ/PQL&+Y7TR9&VKCS-&C%P7&>(/?W8?#3N?>]]>\C].V64
M5=((#YI'8101USDE?1K>#15[O=:XCQBYZSA>>1>4K-EC(#SO35@<`1G'(J*&
MC*U`M1.2&K$*F<?V$7$-3=!?`#*J"=8^ZBAQ']6.YG=#:.XO=VW[M[(VEI`W
MWG$#7+(?CED(S>\XG@!1H]UH"_`CQ,\1N\/BKWSN^^O>5];ZY=1D8),<$+:B
M*"('*.-N`XN=J>ZKW.)M'WU>P+8#"5$5`6.0O@"BA2B5,ZGZXI%,(%W\"]0[
M>(CKIM#=>O\`'2G4.-.OCSPY+ANU?V78@TC+JD<SD">=!6G*IIF5LZO4::(K
MBX_Q%E'*R[A#'%`M5R!EXR#R#B'3B)BR[;BI+SAR)PT0D`>(G<N$B@'KUHM[
M[S]W>[;&OWZ]MK77\+9'@/?T,CQ>\]#&DKK.Z_</OGWUE='W4VR]OQ'\;XHG
M.BC&=99:"*(?K2/:.E7''B]D-%;X)_:L%14P)NV$%)\A<--Y8%O0#=1).Y+-
M$%^KPZ5%B"`^`[:T(\0]C<WMH;;>)+7/M&;;?%E.=>P#B.D-*ZS_`-F^]$;_
M`)>ZO>[D&X5IV,F][4)*_E(%V6M/0YPZ5;S)>(,FX=E&,1DRES-2<RS,)&$<
M/DT'$/8(T>G:2KE@CEWL%88\>L/VS)RNF&X;B&X:WFP=Z.[_`'IMWW.P7<5S
M'$_3(&DA\;ORRQN#9(G?JO:T]"Y7O?W#[X=PKN*R[W;?/92SQ]I$YX#HIF8>
M_!,PNAG9B/?B>]N.:MMK?KD5F9\E"JJ/\]Y5N@I[MJGB@(@%1#[)'UOM$3V2
M=7J.=E7W`_@`=?*GU9[DV'N9MNTU_>7.Y:Z?JPQ/K^U(U???_P"SYV1USXD[
MUWA(K'9;+V5>3[FXBT^<LAD]!7I8[O\`1^?\^O@71UK];-2=W^C\_P"?31UI
MJ3N_T?G_`#Z:.M-2Z&TVZNTBM3MQMTPPK]7K,8YF9^<D5#)L8N+9DZW+QR9,
MJB@D3#8`*0ICG,(%*43"`#F[=M=]N]_#M>V1/GW&XD#(XVCWGO=DT5H/.2`!
MB2`M;O&];7W?VJXWS>YX[;:+2%TLTKR0V.-HJYSJ`G#D`230`$D!1/-YBO"<
M@[#R(I9O`!W)'VXY?'WEK@AOKT@>!GBR?_Y'=_UH?_%7BY^J/Z?AGWHL/ZES
M_P"`KTXAY%86SVE/K8>R##7Q*K*1R-@/%-Y=L$8I+$=GC2K!+1T<8_Q96"PE
M%,#@';'?;PWY3O-W&[U]S'0M[T64MFZX#C'K+#K#-.JFASJ4U-SIG@N_[D>*
M'<'Q(9<R=Q=S@W)EF6"8QME;V9DU%E>TC975H=334>Z:T5Y>[_1^?\^N5T=:
M[O4G=_H_/^?31UIJ3N_T?G_/IHZTU)W?Z/S_`)]-'6FI.[_1^?\`/IHZTU)W
M?Z/S_GTT=::D[O\`1^?\^FCK34G=_H_/^?31UIJ3N_T?G_/IHZTU)W?Z/S_G
MTT=::E1N0LEX^Q)3YC(65;U3L:T*OH]^<N=[L<55:S%I[")0=S,T[9LB+*](
M@FD!Q55'P(4P^&K'ED8JXT5S0YYTL!+NA86,D?Q)7E,8\FEX-GFR]Y/5:K&1
M7E<58=NUAKO60PE,9K.S;:L,9)$!#P4:BLF8/$IA#8=8;[V%I]W$>?[`1ZUG
M,VV[<*EH'60JHQ/_`!$?E,98EV<$3D>_QC(OU4T&Q\S8TO-`AA65,!"$<VA6
M+DZO'%$P^*CIXBD7UF`-59>0N^(T/ES`'K5'[?=LQ#:CH(]F:S-5^S5^VP41
M::G/0=IJ]@8(2L!9:W+,)VOSD8Y+U-Y&'F8MPZCI)BN7]%5%0Y!]NLUH:\5:
M:A8!)::$4(7;]W^C\_Y]5T=::D[O]'Y_SZ:.M-2=W^C\_P"?31UIJ3N_T?G_
M`#Z:.M-2=W^C\_Y]-'6FI.[_`$?G_/IHZTU)W?Z/S_GTT=::D[O]'Y_SZ:.M
M-2=W^C\_Y]-'6FI.[_1^?\^FCK34G=_H_/\`GTT=::D[O]'Y_P`^FCK34G=_
MH_/^?31UIJ3N_P!'Y_SZ:.M-2=W^C\_Y]-'6FI.[_1^?\^JZ%34MCN>[Z?S:
MOTJVH3N>[Z?S::4J$[GN^G\VFE*A.Y[OI_-II2H3N>[Z?S::4J$[GN^G\VFE
M*A.Y[OI_-II2H3N>[Z?S::4J$!3W?,.FE*K[UA[_`)?CU32JU*=8>_Y?CTTI
M4IUA[_E^/32E2G6'O^7X]-*5*=8>_P"7X]-*5*ZCO>[Z/SZR])6*<U\[WN^C
M\^FDHG>]WT?GTTE$[WN^C\^FDHG>]WT?GTTE$[WN^C\^FDHM7Q']+Y]-'4E2
MGQ']+Y]-'4E2GQ']+Y]-'4E2O@K[^H?Q^/\`ITTI5?.][OH_/II*)WO=]'Y]
M-)1.][OH_/II*)WO=]'Y]-)1.][OH_/II*+>26\!]`>CT_Z]6N;S5S74R6[W
MO>7Y]6Z`JZRG>]Y?GTT!-96HJIC&`I=A,80*4`](B([``>/I$="UH%3DJASB
M:#,KRT>:-RU/G;+8XLITGW\4X?D7L<DJT5ZF5LOY`.RL-D$Q#"FZ91`@>.CS
M>(=!%U2CLOK]$OIX\-!W.[L_[Q[I'3O'ND;7$$>]#;?%'%S#GX2R=)8T_`OQ
ML^LGQN=XC=]O]RMBFU=S=BE<RK3[ES>#W9I^3F1XPPGD)'M-)5BVU]$KXS31
M%7F-L8W_`"_;6%&QI596WVB1`ZB,;%H@8K9HEL+F2E'JQDF$/$,B?:7=NE46
MZ)?$QPUIM^[P[+W7VQ^\;_<QVNW1YO><R<F,:*N>]V36,#G..073=T>YO>CO
MYO<7=WNC937V\2U(9&,&M'Q22/-&11MS?)(YK&C%S@I.NX7C;QL,=K8S0_*O
M-C,1(YKT1)OV?'&A2:>W4UF;!&J,;!F.58K!LJ@P480O4`D,NX`!`?/8[OOY
MW]`DL1+W<[I/RD>QKMSN&'BR-X='8L<,G2"2?(AC"O9)]O\`"7PC)AW4P=\_
M$./XH8I'MV.SD%/=EFC+)MSD8?B;"Z&UK5IEF`(-C\G<A,N9<00B[=;%D:DP
M^S#8[JS1I3L:P"!1_9-X:B5M&.KK8$B[!W3H*.#[;G4.;<==?W?[D=V>[+S<
M[9;`[F_^)<S.=/=2'B7W$I=*:\@X-'!H"\X[X^*G?GOQ&VSWN]<S8XOX5C;M
M;:V$`!P$5G`(X&TRU:"\YN<XU*LJ!2@&P%*`>P`#;YO1KK*E>>4"R[\<:Z;,
MGEF<L*Q;P/)L\'V5'(>*7[XPKJU.6:U]*;GXV"76ZC,6$DU:*D7;IB5,POSF
M$.H0'7S'W[OAW6\?^[>X;72.;=X#;7C6X"9AD,<;I`/B<PN!:XXCLP`:!?=?
MA1M9[_?2)WTVG?@9H.[UT+[;WO\`>-M(V'M9F0DUT,D:UP>QM`3,YQ%358B=
M?3B^%%Z=?)XQ2M2..=@R5(M^S(YCN*KR/%0@D4&I4LCB!B5`ZMC"F[FEI)0H
M^@Q.@0U^?7U1=Y&;OWZ@V"!U8-KM0UU#AVT])'CK$8B!Y&H7["?0EW*D[N>%
M-SWKNF:;O?KXO944/RUJ'0QG'@Z9UP1P(#2LM/>]Y?GU\TZ`OMK64[WO+\^F
M@)K*=[WE^?30$UE84O.0Y#C7:%4N.5??`27R"LA<[X5NH'<;TR#>F+7HEP!3
M=1"V"R-C.#%'TIQP;^!]?67TL]Q_GMYN>_5ZRMK9`P6]1@9Y&_O7C_HXB&]<
MO,+\^_KS\4SM/=FR\*]LDI?;HX75X`<6VL3Z01NQJ.VG:7]4`K@Y><[7W2OR
ME6<_R1)KL6_D17Q.``]JE`G$TQ'TFBYN>CE3@'N"8('X]?'_`-6]H'[9L=[3
MX+FYCK_/CC</[!7Z._\`[/"_,>]=Z=M)PDL[.4#_`*.69A/_`'P7H/[WO+\^
MOB30%^H.LIWO>7Y]-`364[WO+\^F@)K*=[WE^?30$UE.][R_/IH":RG>]Y?G
MTT!-93O>\OSZ:`FLIWO>7Y]-`364[WO+\^F@)K*A]SIYPX:\OWCK;.1.:7BJ
M\;$F)"4JDQ2[=.TY0R!(H+J0%%JR;CJ3*[?BW.L[=G**$:P16<J[E3`IL>YF
MCMV:G9^7E^@&F1;12W4HBCSXGD.:_,BYZ^8IR:\Q?*;K(N?[>N-=8/G2F.<-
MU]V\;8MQ7$JJ#\,PK4"HIVG\T#?I*\FWI59-^H`F.H1/H13YN69\SJO/EY>5
M,%UUO;16S-,8QXGB?+DH(*N6Z(@59=%$P@)@!54B8B4/2(`<P"(!J%9*W2F*
M<H&*8IRF`!*8H@8I@'T"`AN`@(:JJ+T:_P`.SYE=^XO\K*)Q*NUK?R/&/DK9
MDJ4RK4P]47BL79BG]T:3<JD5P<Q(%E:YP$HB9:H]#9U\8BZ,3O-^HV=8SNCE
M$9^`G+[LL_:M9NELV6`S-'[U@KUCC7JS7Z*@JB41`=@$!$!`?`0$/`0$/:`Z
MZ/0%RFLKYWO>7Y]-`364[WO+\^F@)K*=[WE^?30$UE.][R_/IH":RG>]Y?GT
MT!-93O>\OSZ:`FLIWO>7Y]-`364[WO+\^F@)K*=[WE^?30$UE.][R_/IH":R
MG>]Y?GTT!-93O>\OSZ:`FLIWO>7Y]-`364[WO+\^F@)K*=[^C\OQZKH":RN)
MWO=]'Y]7Z2K$[WN^C\^FDHG>]WT?GTTE$[WN^C\^FDHG>]WT?GTTE$[WN^C\
M^FDHG>]WT?GTTE$[WN^C\^FDHOH+[>H?Q>'^G32B^_$?TOGTT=25*?$?TOGT
MT=25*?$?TOGTT=25*?$?TOGTT=25*?$?TOGTT=25*ZGOF_6^@/JU/I49>VN:
M^=\WZWT!]6FE-;>:=\WZWT!]6FE-;>:=\WZWT!]6FE-;>:=\WZWT!]6FE-;>
M:=\WZWT!]6FE4UMYK7\0/\WZ?KU32KM;>:?$#_-^GZ]-*:V\T^('^;]/UZ:4
MUMYK2*YO:`?@#Z]]5TJFMO-?.^;];Z`^K32FMO-.^;];Z`^K32FMO-.^;];Z
M`^K32FMO-.^;];Z`^K32FMO-.^;];Z`^K32FMO-;J:W@/4(C\VJ%JJ'`Y+7W
MB^_5M"JU/).\7WZ4*5/)0)\Q7DX/'7`,DC77PM<EY1%[2Z.9(X%=Q+=5J'[T
MVQ(`'J(:"BG()MS_`,E\Z0'^2.O9_`SP_'?KOI&Z^9JV#;M,]Q7)Y!_<PG_I
M'BKA_=L>.(7S1]57B\[PH\,9F[9)V?>W>-=I9T/O1@M_TBY'$=C&X-8>$LD9
MX%>2_P#&(^T1$1$1]8B([B(B/I$?3K]+%^'N)Q.::(I4\7N)]XY,STFJR>LZ
M3BZFI&D,E99L101K-1BFZ)GCM--591NC)SHL4S*$;%4(5-,.XN=)+8P^<>(?
MB3M'A_9QME8Z[[Q71TVMG%C+,\G2"0`2R/40"^A)/NL#G8+VSP8\#^\?C!N4
MTL$C-N[F;>W7?[E/[MO;1M&MP!):))=`+A&'`-;[TCF,]Y7+SER*IM8J$IQ^
MXA1<C2\'`X+%WO)BX'1R-R`EFY#&5=VJ>*DW>,:>?8QVD,CV4C(F`RJ92F!$
M-!W/[C;KN.Z1]]O$Z2.[[WZ==O:C&UVUAR;#'4M=,,`^=VIP=@UQ(U'L?$GQ
M5V'9=AF\+_`N&7;_``ZU=G>;@:B^WF1H-77$U&N9;'$QVK=+=)J]@U=FV!8`
M```````>``'@`![`#7LR^8DT1<R/CW\O(,(F*9.I.5E'C6.C(UB@HZ?2$@]6
M(V9LF;9(IE7#ITX4*1,A0$QC&``U%//#:P/N;E[8[:-A<]SB`UK6BKG.)P``
M!))R"R+.SNMPNXK"QC?->SR-CCC8"Y[WO(:UC6BI<YSB```22:!>@/*]*0X.
M>6!+XQEE6R>4,T/FT19R(J$.)K/=#M'MFCT%""/Q+:I4>"%@90NY#+`)@'90
M-?%'=O=G^+_U"1=X+8./=[:F%\1(_P`U!5L3B.!FN).T`.(;AFTK]1.^_=Z/
MZ<?H[G[HWIC'?#?Y&Q7`!!K<71:^X8"*ZFV]I#V)<,"_$8/"P38WH,_E2_TW
M&U71,O/W>QQ=;C``HG*BK).2(JO5@+XE:QS83N%C>@J21A]6OL7?MZLN[FR7
M6_;B=-E:0/E?TA@J&CI<:-:.)("_-?N?W7W/OMWIV_NELS=6Y[C=QP1X5`,C
M@"]WZK!5[CP:TG@O;+0ZA`8VI%0Q[64>S7Z16X>KQ!.D"F.SAF23,KE4`]+A
MZ=,RRH^DRBAA]>OR5WG=+S?MWNM[W`UO;N=\K_YSW%U!T-KI'0`OZ&^[7=_;
M^Z?=VQ[K[0W3MFW6D5O$.;8F!@<?UGD%[CQ<XE57WB^_6MH5NJGDG>+[]*%*
MGDN!+3D37XF5GYQZE&PD%&/YF9D7`@5!A%1;15](/%3"(`!&S1`YQ_!J>VM+
MF]N8[*S89+N:1L;&C-SWD-:T=)<0%BWU_9[78S;GN,C8=NMH7RRR.-`R.-I>
M]YZ&M!/F7BYY*9KE.0F;<@Y;D^\FA99E7]WX]4QC#$5*,*$?5X@A1$0(9I#M
MTNX`;`9<RAO28=?J[W![IV_<CNE8]V;>A?;Q#M'#\<S_`'I7^=Y-.30!P7\_
M/B]XA7GBEXB[IWVN]0BN[@B!A/\`"MH_<MXQC0:8FMU4P+RYV9*IG+6,)W#U
MR&BV<HISS:LTJ?DVPIBF9@XN%2AK7]V*%$1$5XQ.8!NH/ANHF;PUG]V>\-GW
MIVK_`!C;\;)UQ/&PUKJ$$SX=8Z'EFH=!"TW?KN9N?<'O!_NWO`IN3+.TFD;2
MFAUU:Q7/9GIC$H8[]9I627R:YOX#DI>H8QMB3V&YH0+^NK#VFJO2[!ZQ*DH<
M?P:\&^JBT[;N#9W8SAW6/T/AF;[0%];?0)N!@\6MRVZONW.P2GK,5Q;.]E5G
MIS'R3PGQ_P#W?_S@NZ-*+:@D?N!1U#6&21D1B!:!(ID6A(F2215;`_1$2*B0
MQBG`2@(`(A\9]UNX7>WOKV_^Z]F;LVVGM`)(F%NO5I-)'L)!TNQ%1A0T7Z8=
M_?%CP_\`##Y4]^]P;M[;WM.Q+HIY`_LM.L5ABD`+=;<'$$@U%<59$?,CX3``
MB.=8G8`$1VJU\$?#W!5A$===_P"PWBT</\'D_P"VMO\`QEYW_P`6/T]_^I(/
M]FO?_ME,2O66$M<!"6FNOTI6OV2)CIV#E&X*`A(Q,LT2?1[U$JI$U2IN6JY3
M@4Y2G+OL8`$!#7EM]8W>VWLVW7S#'>V\KHY&&E6O8XM<TTJ,"","1RP7O.U[
MI8[UMEOO.U2-GVN[@9-#(VNE\4C0]CQ4`@.:0:$`C(@'!1RR'S<XKXIMTQ0[
M]F&#@K=7SH)34*$79956-<.&R3M-JZ<PT)(,2/"H+$%1$%142$W2<"FW#7=;
M'X2>(W>3;(MYV7:YIMLG!,<FN)@<`2"0))&NTU!HZE#F"0O*.]/U"^#7<K?9
M^[7>??;:VWRU($L79W$AC+FAP:YT4,C`ZA%6ZM3:T<`<%66'>36$<_KSK?#]
MU"ZFK*+)>=6:5^SQS..+(J*IL4EG\U#1K([IT*"@D1(<RHD(8W3TAOK5]Z>X
M'>[N4R%_>BT^4%P7",.DA<YVD`N(;'(YU!45<0!4@5JM_P!P_%OP]\3I+F+N
M)N'^(&T:QTQ;!<1L9K)#`7S0QL+G:748UQ=1I-*"JIS,W,?C=@%XI$Y-R=$Q
MUD2(4ZE1A&[VT6M$#AU)_&0T$@\5BNX7Q+\89OU!XAN'CK/[J>%O?SOK$+GN
M_M\LE@<II"V*$TSTR2%H?3CHU46I\0/'CPG\,9S9=\-XMX=V%*VT0?<7(KEK
MBA:\Q5X=J8ZC')17-YO7$,'0(`7+1T!-TB]"ALP0`-]NOM&LH.Q+MX_W>_NU
MZ,/IB\3C'K__`!H?^7YAU?3V5/6O%S]<_@8)NR'^-&.OQ_*,T]=/F-5/Z->A
M3`PCRGP-R)0<FQ+D".L,DP0^*DJR\0=P=LCFP"!3.G-=ET6K]1F0X@!G"`+-
MRB(`)]Q#7E_>[PZ[Y=QGM'>:RD@@>:-E:6R0N/(2L):'<FNTN/)>[^'?C+X;
M>*L3W=Q]TAN[N-NJ2W<'0W+&Y%SH)0UY8#@7L#V`T&K$*0!#@H<B9`$3',4A
M0'8`ZC"`!N(B``&X^D=<4105*]-J>2_,\\]WS"7O.KFE9H*HSJCSCQQMD)S%
M>'F+9<YHF?F(]Z#/(^4NT`]IP\N-BCQ;LUA`1+#,&H%$.M3JY._N#/.<?<::
M#ET^7GXKLMLM?EK8%P_>OQ/V#S>U06X$\+LC<_>4./.-6.%PAU+,LYFKS=EV
M9GL=CG&L!V7%PNT@W`R97)X]JL1NQ;"<GQDFZ;-^HH*"8L$$#[B41LS^SR]:
MR;JY9:PF9^-,AS/`>7!?IE\5_+IX7<.<:1F,L-X&Q^9!NQ;M[%>+M4ZY=,D7
M^132*1W.72VST8]?/G3Y4!/\*B*$<U`W;;H)I@!==1#8PQ,TTQ\N(I7S^:@P
M7'3WES</UR./4#0#J"\='\31P-Q!QCS5A'D'@FDP6-ZGR-876$OU*J<:VA:D
MRRE0U(60/98&"8)HQL%^^%<L1#/&S9-)N9VP.N4@'64$=)N=JV"0/;32ZN'E
MY8<ZKH-FNI)XW12DES*4/0?NIZUYJ*=9I"E7&G72(74:RU-MU8ML6Y2.9-5O
M(UF=CYMBLF<H@8ATG+$I@$!\!#6M:=+@X9@U6X<`YI:<B"/2OV0F$NG,QT;,
ME#I"9C8^8`H>@H2C)!^!0]P`XVUVS&C2`W*B\^-0:*/W)+F!QCX?U)"[<F<U
MT7#T$^[H0R=HE!-8;*JA_>MZG4(M&0M=H73'P,#%FN!!$.L2ZCEGA@%97`>7
METJ6&">X=IA87'RS/!8=97^)\\K2/FSQ322Y&SD>FJ9(;+%8/52AU``W3WT6
MTS:HFP'0-Z0$613[?R=_#6O_`,6MQ7.OGI[*^I;`;-?$5HP?TEDVXB>9-PHY
MU)/4.,^=*]=;/%LADIG',NTDZ7DZ(CR;`K(.J+:6D9-/(QN8P`H[9$=M$Q$`
M,J&X;YD%W!<?`X:N7\M#ZEAW%I<VW\9A#>>8](4X2J`<Q2AZ3"`!N(`'CZQ$
M1```/6(^`:RJ%8M2L/[[S\_*4C)&2BGW+F*1?1,B^BGR08PS*LFF]C7:S)XF
MDX0Q\JW<IIN4#`"B9C)G`.HHB40'6$=PL@:=H*]1^Y;`;7?D5$>'6/O4NN/7
MF#<..5&-\E9AP?G.N6;%F'7B3#*%^G8ZQ8]J]*<+17WX'WU+9#AZNU103BA*
MLHJ4QDDP.0IC`8Y2C)'=6TH+F/!`SS'MZU!+:W,#Q'(PA[LA@:^BJQCY<_B8
M/*\QC8W=;KMFS)F\S!P=LYL6),8@O3E%$C"0YXR?O4_2/OIOU%^RLU0504#Q
M(<Q=AUB.W6V:ZF)'1Y`>@E9D>SWKQ4AK>LX^H%3@X->;%PF\PM:4@N/N1I)#
M(T%'J3$QB+),">D9)1AD3$(YG(J(7=OXRU0K-10I7#B*>/0:]117!(#%$<BW
MO8+DZ6&CN1S\O2.E8US8W-IC*WW#Q!J/+K61SO%]^LRA6'4\D[Q??I0I4\D[
MQ??I0I4\D[Q??I0I4\D[Q??I0I4\D[Q??I0I4\D%8OO^;2B5*X_?-^M]`?5J
M_2K=;>:=\WZWT!]6FE-;>:=\WZWT!]6FE-;>:=\WZWT!]6FE-;>:=\WZWT!]
M6FE-;>:=\WZWT!]6FE-;>:=\WZWT!]6FE-;>:=\WZWT!]6FE-;>:^@N;]8!_
M"`?Z-M-*:V\UJ^('^;]/UZII5=;>:?$#_-^GZ]-*:V\T^('^;]/UZ:4UMYI\
M0/\`-^GZ]-*:V\T^('^;]/UZ:4UMYKJ>\'M'Y_SZRM'4L(O%4[P>T?G_`#Z:
M.I-83O![1^?\^FCJ36$[P>T?G_/IHZDUA.\'M'Y_SZ:.I-83O![1^?\`/IHZ
MDUA:NX'ZP_3IH5=03N!^L/TZ:$U!.X'ZP_3IH34%\%4`]8_/]>FCJ5-07SO!
M[1^?\^FCJ36$[P>T?G_/IHZDUA.\'M'Y_P`^FCJ36$[P>T?G_/IHZDUA.\'M
M'Y_SZ:.I-86X17T[;^KU_P"O5KF*YKSP*W.Z/R'\VK=`5W:.YKZ50QC`4H")
MC"!0`!\1$1V``\/2(Z%H`J<E4/<30'%>4+S(<ZGS;R;M3>.>_$T[%@*8VJQ4
MU!.U65AG*@VJ62`/L&-*64RY0.'Z;=NCZ@#7Z2>`_<X=TO#^VDG9IW3<:74U
M1B`\#L6'^9%IPX.<[FOQ,^K;Q)?XA>+]Y!:R:]AV6MC;T-6DQ./S$HX5DG+P
M",XV1\E`C7LZ^8E+CA[Q*M_+'(Q*_''<PE"KZC1YD*Z$0!0L1'+J#V(B)!4H
MH/+3.`F8C1$=RI@!EU`[:8@;S+Q0\2]L\-MB-[.&S;U.'-MH*TUN&;WTQ;#'
M4%[LS@QOO.P]U\!?`W??&[O6-MMB^V[L6I:Z]NZ5[-A.$45<'7$M"(VY"AD=
M[K367',3-<?//ZIY?W$*)3CL95Z?CJ;,(UY83J9)R"O(I-3QCJ33'NRL3&2_
M[20=JF-]X2!#JG'L-TM_,O"[NE-9PW/C7XGRF3O!/"Z=AE&%K;!I.L,.#'O9
MA&P4[.,AH]][E[MX\^(5MN-U9?3!X$PB'NC;7,=K*(#4WUZYX:8W2#&2..7&
M:5Q/;3!SW'LXXU'+G7B%CQXNF+\%Q/2NRI^)8*=EYLJ0I_O;>KA)2SJY643"
M'4=`7$:@P:E$1[+)@B3T@81[OP=[SS=^-IW'OA<U$UUN<D;(ZU[&W@8P01==
M'.D>?Q22..5%Y+]2G<6V\+-_V7PWL*.MK#9(9I90*?,WEU)(ZZN*YEI<QD,8
M_#%"QIQ!)@YKU]?-RJVC4.Z9,LT=3,?UB9M]HEE`38PL&S4>NU`W`#KK=``B
MS9(;[JN%C)H)%^T<Y0\=:S>-YVKN_M\FZ[W<16NW1BKI)'!K1T#BYQX-:"XG
M``E;WNWW8[P]\-WBV#NO9SWV\3&C(H6ESCE4G@UHK5SW$,:,7$#%>D/@MY>$
M/QX68Y0RF:,M.:E$!&'9M3D>5O&A7*0IK!%N#E!.7M9TCBFK(;`BV*)B-M]S
M+G^#O&'QPNN_+']W>[G:6W=,'WW'W9;JAPUC-D(.(C^)QH9.#!^M7TW_`$K;
M?X5/C[Y=\C#>^(1;^Z:VCH+`.%#V;LI+D@T=/\,8JV&N,CL5/F5\GFW(#-I:
MS4Y$K[&F(BR%:@'3=43LK!95UTPMMG0$!!-=JLY:)LFB@`(&;->X4=EAU]'>
M`7A[)W)[I?XAN4>C?]STRR`CWHX@#V,1X@@.+WC@Y^D_"OBKZO/&*+Q.\0AL
MVR3=KW2V(/@A<T^Y/<.(^9N!P<TN:V*)V-8XP\&CRI2>4!QZ.]F[1R6L;$?@
MH,CZC8U^(3V*O-/$"%M]A;=9?$L7&+%CTE"^`J.EP#[28Z\Z^I_ON(K2W[@V
M#_WLQ;<75#E&T_N8C_/>#(1R8S@Y>S_0CX6.FOKSQ<W:/]Q;A]I8:AG*\?Z3
M.VH_S<9$+7`T)ED&;%GU[H_(?S:^+]`7Z;=H[FG='Y#^;30$[1W-.Z/R'\VF
M@)VCN:Q2^;)R!''F$H_#L&]%&TYH<*(RX(J;+LL=0:Z*TR8_3]HA;%*]AB7?
M8%$".2^H=?2'TU]R1OG>U_>F\97;MI:"RHP=<R`AG7V3-4AY.,97Q5];GBB[
MNIX=Q=Q-NE+=Y[P.(DH<66,)!EKR[>31$*_$P3!89N"6$0SQR9Q]5W[3XJJ5
MQX-^NP&+NB:N5-5![\`ON`EZ)N8,U8[#Z2N!]@Z^J_&/O=_N;W`O=PA=IW*=
MOR\'/M9@6ZA_T;-<G]$+\_\`Z:O#L>)7B_M>T7+->RVC_G+OEV%L0_0>B:7L
MX?\`K.A75\U-H+?F?>W`E`HRE5QU(^`;`835-@S,(````!U,Q#P]&VN;^G*3
M7X4V<?\`=W-RW_OG._Y2[7ZU8#%X_;C,?\_9V3__`.&C;_R5J\JR9^Z>9=,;
MB;I">J&0X00WVZQ-67,JF7W_`+2)`?Q:I]1MI\UX5W3^,-U;2?\`>AGL>KOH
MJW'Y'Q[L(:T^:L;V+_\`AWR`>F,++]YIN+1R/Q5FK&S;]^:Q%/1E]:&*'4K]
MR*",!:D@$`W[18V2(Z.'H_W,!]6OF#Z=>\7^`^(\5C*ZEIN<+[=W+M/XD)Z]
M3"P?SU]W?6;W,/>WP6N-T@:7[AL=S'>-IGV1_<W`Z@R02G_H@>"\M6OT47XP
M+/?B/GE&X7\N2FR"+UG(9?A9"U8<H,&N<BQR/H=<LG&V>2:"(G-!U6LS[0X]
M6Q5W!44-]CF$OQAWF\&I^]?CM=0.8]G=B5D-]<R##W7C0Z)CO[R:6-XYM:7/
MX"OZ<=Q_J7M.X'TH6%XR6.7OU;R7&UV<)QH^(]HR=[<^RMK>>(FN#WAD>3B1
MA6IE0R!G?)T55*^F]MF0\C6-7=P]6.JN_E91PJ^EIR9?'`XI-6Y3*NWC@_@F
MD0YQ]&VOK'==TV3N=W?DW*]++;8["`8-``:Q@#61L;Q)P8QHS)`7YZ]W]A[T
M>)O?*'9=L$E[WIW:[-7.))?)(XODFE>:T:WWI)7GX6ASCDLW/)#)T)Y</'>G
M<9<%2")<Q7B-<3MNOB*:9)5@D[#X&:O/08#F0FIQXW.Q@R'W^[V+4R@?M"$,
M;Y([A]WKOQW[\W7B!WQ8?]UK.01PVY)+'%OO1V]>,<;2)+@C^)(\#X20/T4\
M6>^6W?2;X5V'A#X;RL_W[W&)TUS=@`2,#O<EO*8D2S/:8;0&O8PQEP.MK2<"
MB"$U9IM)NW3E+#8[%*)HHI$!U+34Y-2KH$TR%#]N^DI.1>+``?IJJJ&]8CK[
M,>^TV^T+WF."P@CJ3@R..-@Q/!K6-:.@`!?F7''N.];DV*,37>[W<P``U22S
M2R.P`S>^1[STN<X\25?;+/$WD/@RL15RRKC&7J5:F'R,6VDUWT+(IMI-P@JY
M;1\LE#R4@O#O'**!Q3(Y*EUB0Q0^T`AKCN[7B5W'[X;A)M7=S<(KF_B87E@;
M(TE@(!<PO8T/:"14L)I4'(U7I/?CP/\`%7PWV>'?^^FSSV6T3R"-LA?%(&R.
M!<UD@BD>Z)S@TD"0-K0C,$*T="OELQA<J[D"C3#F!ME5DD)6&DVJAB&370-N
M=NX*40*YCWR(F1<H'W370.8AP$IA#73;ULVV]X=JGV3>(FS;;<QECVGD>(Y.
M::.:X8M<`1B%P_=?O/OG<SO!:]Z.[D[[;>K*9LD4C32A&;7"HU,<*M>P^Z]A
M+7`@D+T+>8USN##_`)3&3N5M/=%@[AD[$T#3<:E26V6A\E9E[=+$69M^L7-,
M,[DWJ8@/4`QH&]6OR7[\[-+W0WG<-@F=JFL[E\0=Q<`[W'_TFEKO.OZ$_#'O
M-!XA]V-G[V6PT6^Y645PYE:Z'%M98_Z$@='YE^8@0@)D(0!,($*!0$YA,<=@
MVW,8VYC&'UB/B(Z\O7M2]UO\*KQG8T[C?G'EI+1Q/WHS9D(<4U"062`%VN-\
M4D0<S96:AB]16\_D"86*OTCL<8=+?]`-=)LEN.S=.?B)H.H?IKZ`N3[P7),[
M+9IP:VIZS]P]J]6/='Y#^;6]T!<]VCN:Q*>;+Y7O_BD4[`U%<YJ#"L3A^_6R
MZ2LHA1OWZEI]&R5IE7THR*;*V2MLHQ1L9L94ZJQUBF`2@!/`1UK[W;OG"WWM
M('17GT]*V.W[D;%SW%NLN`&=./45`K%O\++P!J7PR^3\F\C\S.TA3.NV4M%7
MQK`N#D$#&*+"HUM>;(@<0\2A)]6P_I>O6,S8X`/?+B[U>JA]:RI.\-V[^&V-
MHZB3ZS3U+(IYJ_F2TGRPN,;6WM(Z-M&9;J16A\>,:2#E06<K-Q$8W3>6NSE1
M4(^_<3'\>H@N_,0Q5'CA5NS(<IW`J)Y-_<LLH</XAR'EY>D+%VZTEW"?34B(
M8N/V#I/#TK\U'.&=<U<I<L3N7\Y7JSY7RM=9`A'4U+G6?.S&=.`3C:U5H5H0
M6L'!-%%2H1\3'(I-T0Z2)IB81$W(R223/UR$EY\J!=Q%%%!&(X@&QCRJ?O*R
M.V3R(/,_J6`9/D5/\?VC&KPE6<7>;H87FM.,SQ%39,32C^6?XT;N%)%->.C"
M&<.(\JQY5%(ANIJ!RF(&4[;KMD?:N;1M/+H\U:UPI58+=WV]TW8-?[Q-*T]V
MO7]N2Q;8QR=?\-Y`IF7<2VV6H^1Z!-L;12KA`NCM9&'EV*A5D%DU$S`5RQ=$
MW2=-E.I!VV4.BJ4Z9S%'#:YS'![#1P6P>QDC#'(*L(H0OT]Z%STC<N^4[(<_
M2(M(-ZYXDY&R38(UH?I:0.3:;4;)"6:&9[F$2-FV1855-J41Z@1.D`^(Z[%D
M^O;_`)G(Z*^C,>HCUK@WV[X]Q^2J3^\`\Q(IZBORSTC+'23.X.*C@Y"J.%##
MN91<X=:RAA'Q$QU1$1'VCKC%WZF9BN=Y=9[P@APAX]4')V1:"UR%.9VOF/</
M5.RVF1NUMDHZ`K4)8LCH5YHZ[\%3(JO)-X=!WTLT72ZZX`9P<@IY$?;2L["%
MI=0DF@J<:9]&`6+)\M#+\U.YK74#07$"@%3ATFN*C-?L>W[%5NF:!E"DVS'-
MZKJZ;:?IMXK\I5[-#K*HIN$"2,+,-FC]L#ALJ51(QB="J9@.03%$!U$]CXW%
MD@+7C@<"IV2,E:'QN#F'(@U"O;PHR-<,2<Q>+.1:#)/8JVUO/^)QC7+!91%=
MPVF+M"P,U$*]L0%=A/P<FY9.43;D6;N#D,`@.VI+=Q;<,<W/4/;1173&R6TC
M'_#H/J%?4OUQW9@2=.4B!L1-PLF0.K?8I%#%*'H]0!KN6-U,#CF0%YSVCN:X
M_='Y#^;5V@)VCN:=T?D/YM-`3M'<T[H_(?S::`G:.YIW1^0_FTT!.T=S3NC\
MA_-IH"=H[FG='Y#JNA.T/-<?O![1^?\`/J_1U*/6$[P>T?G_`#Z:.I-83O![
M1^?\^FCJ36$[P>T?G_/IHZDUA.\'M'Y_SZ:.I-83O![1^?\`/IHZDUA.\'M'
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MUP^C30>2:PG>#]</HTT'DFL+<(J`[_:`?1Z/S:H6D*H=7);G6'M^C\VK?>5U
M2K)<D<JDPM@?*N32JD3?U>H22D%UCT]RS2@$AJTF7?TF^_)%`VWIZ2CKKNX7
M=UW>SOEMO=\@F&XNF"3_`*)G[R7_`+MKAYUYYXL]]!X?>&N]=\`X-N+.PD,-
M>-Q)2*W'_;/8>H%>,Y159=11=PJ==PNH=9PNJ83JK+JG%1990YA$QU%5#"8P
MCXB(Z_51K6L:&,`#`*`#(`8`#H`7\_\`)))+(Z64ETKB222222:DDG$DG,E5
MYB[&ELS!?ZKC:DL!?V.W2[>)8@8#`U:%4`ZSR3D%2@/8C8E@BJY<'_D(I&$-
MQV`=-WBW_;>Z^RW._;N_18VL1>[FZF#6-'%SW$,:.+B%TW<KN?O??[O19=T>
M[T1EW6^G;&S\K0:E\CS^%D;`Z1YX,:30Y+T"<E+-4_+PX>0^(,1N0;7^^E?5
MR+L!2D0FY"4<,T!R#D]Z)?VA'J#59-JP#<0:'<-R$^R@.OBCN#8;IXX^*,O>
M?O,W5LMEIE?'G&U@<?EK1O#22"^3\X;(3B]?J)XN;QL?TK>`T'<7N.[1WFW(
M/@CFP$SY','SNX/QKJ:TMCAQ/9%\36X1%0:\HK%[*VY\M.2)1`KE'$U0%S$=
MXHJ`G:KDX7A63WJ-ONNTAD)`Q1_2!0Y3>D->O_4WWBFVSN9;;#;$M?N5U1],
M*PP`/<WJ+S$#T`A?.'T+=SK???$R][W7C0]NR6.J.HK2YNB8F/ZVQ"<CB"05
MF5Y/\/,1\K6,'^_9IN!LU9(NW@;G5E6:,TVCG2G?<P[Y"0:/&$K$G<_M2IJ$
M!1%43&34)UG`WRMX>^*7>?PWFF_P?L9MON"#)!,'&,N`H'M+7-<Q],"0:.%`
MYIH*??GC'X#=R/&NUMQWE^8MMVM`1#=6Y8)6L<:NB>'M<R2,N]X-(#FN)+'-
MU.#H>USR>,!1K])U9,DY3M3)-0#FBT?W<K:+@@#OVG#QI&R#WH$/`12,D;V"
M&O4;_P"J/OK/`8["PVZVE(^,]K*1TAI<UOI!"\'VKZ"_#&TNFS[KNN\WD#37
MLQV$`=T.<UDCJ<]):>1"R.XFPGB;!L&-<Q-18.G,5RIE?+Q[<Z\W,G3V`BDW
M/O3.9F85W\0!=8Y2C^B4H>&O">\O>[O-WOO/GN\MY-=3"ND.($;*\(XVTC8/
MYK03Q)7UCW(\/.Y/ASMW^%=R-MMK"V<`'EC2Z66F1FF>72RGEK>0/P@+&%YC
MW/!G38F=X]8;FR.+O+(+Q.2K?%.`,G3(IP04GU3B'J!A`;7)HG%-ZJF;_NY`
MQDP$'!Q[/T)X$>#DVZW,/??O5"6[1&0^U@>,9WC%LSVG_,L.+`1^]<`[X![_
M`,=_5E]2MOW=L+GPN[A7(?WCG8Z._N8W86L;A1]M&\?_`*0\5;*X']RPE@/:
MN/9X3<583N&7,BT'%U8;[6.^.&QT2*)',G`UU0GQ+BS3`%V%LP:0Z2KWI'8Q
MFY2&#^^3`?K7O'WMVONSL5[WBW!W^@632#0XR2C`1,YN+R(ZY!Q(_"ZGYW]R
MO#G?^_7>W;.YNTM__+;FYIH02(8"-1N)?RL$0=+3,QAI'QMK[",8X]K&(L?5
M#&=-;_"UNEPC6%C@,4`7=F1`5'LJ]$H;*2,P_55=.#?REE3>K;7Y=]X-]W'O
M-O=UO^Z.U7]W*9'<A7!K&\FL:`QH_*T+]X^Y_=7:.XW=>Q[H[`S1M.WV[8F8
M"KJ8OD?3-\KRZ1YXN<5776'M^C\VM/[RZ2I3K#V_1^;3WDJ5H4<(HIJ+N%TF
M[=!)1=PX7,":#=NB0RJ[A90VQ4T4$B"8YA\"E`1'56MD>X,8"YY(``Q))P``
MXDG`=*M=(R-ADE<&1-!+G'`-:!4N)X``$D\`%Y`.8N=UN17(&\9!0744K"+L
M*O0T#B/2VIE>46:12I">@AYA459!4/3W79@]6OU`\+>YS>XW<FSV1X`W`M[:
MX/.>2A>/Z`I&.A@7X0^/WB6_Q6\4-Q[SQ.)V9C_E[,'\-K`2V,@<#*=4SA^:
M0K,MY1V%@IN'++F66:]J;RS+?=L$HJ0052HU2<+M4U$NH-RI35D,Y..W@<C1
M(WB&VOE;ZFN]AW7O3;]U;5U;3;(M4E,C<3`$@],<6@=!>X+[^^AGP]_W?[@7
M??Z]9IW'?)]$)(-1:6SG-!%<A+/VA-/B$49Q%%`;S;VG8Y8H.0#8)+$]&<[[
M;=0H.K#'B/H\=@9@&O:/IFEU^&KF'_-[E<#TB)W_`"E\Q?7-#V7C:R2G\79+
M1W71TT?_`"%83@%+_<O,C`3H3]!75R7ACCOL`EGH"9AP(/M`QWH!KL_&JV^:
M\+-ZC`J6VH?_`-G(Q_\`R5YG]+][\AX^=V9R:!U\Z+_MH98J>EZ]8MFKT5<J
MW8J?.)D7A;7!2]:ED3EZBGCIR/<1CS<!#81*@Y$0]A@`=?FOM]]=;5?P;I:$
MB[MIF2L/ZT;@]OK"_;K=]JL]_P!HNMBW(!VWWMM+;R@\8YF.C=ZG'SKQ1WFG
MRF/;K;J'-IF3EZ999NKR!3%$@F<PDBXCSJ@4?'H<=@%"CZRF`=?K/L^Z6^^;
M3:[S:&MM=V\<K>J1H=3S5H>D+^>;O/L-YW5[QW_=K<`1?6%Y-;OPI[T3W,)'
M0:5',$%4L)AV`!$PE*(B4NXB`";I`W27Q^T?I#?;Q'8-;&G%:2I(#<:5RZ_O
MP7ID\MKB$E@:B#EK(C`C3*^0XE-4J#Y$"N,?4-P";U"),"@=36:FTB$=20^!
MDDRI-QV$BO5\`>/7B>_OEO/^[6Q/+N[=C)2K3A<W`JTOPSCC)+(N!.I_%M/V
M"^DKP(9X9]VO]]N],09WVW6`&CQ[UE9NH\1&N+990!)/D6M#(C0MDK@6Y09?
M>9VSWDS)BZZBK"9L;ME6DCG,<C.HPAAB*PU1`?!,GW2T35,`;`*JIS>D1'7V
M9X>=UXNYW<S;]@8`)XH&NE-/BFD]^4GG[[B!^J`."_,SQG[^3^)7B;N_>Z1Q
M=:SW3F6XJ2&VT7[NW:`<OW36D@?B+CQ4XO*/Q"RNF=;)E"8:D<L,/UU%Q"@L
MGUI$NEL5<QL2[+U`)17BX=H_63'TD6%,X;"`#KR#ZF>\\VT]S[?N]:N+9]TG
M(DH<>PA`<\=3WNC:>;=0XKZ-^ACN+;]X/$>\[Y7S`^VV*U!BJ*@75R71QNY5
MCB;,X<6OT.&("RF>9N=D/"_*(.P*8PRN/_@>H`W+(?OO"=HZ8B'@<$.Z'AX]
M(CKYU^GT3?\`NOMW9Y=G<ZOYOR\E?71?9_UA.@_X?=Z[<5/;66CH?\W#0C^C
MJ\U5Y5=?HZOQ376>=+F%_'>61Y;6!2NU"?OK?\V94EFG6(=^$QO,2]4J_<+O
M]I$LC?W9B;^'4CX>C7Y;?4N]C?%3<XHB-+I(7$?K"VBK[5^\GT4-GD\`]CGN
M/B;#<M;_`#3>W%/4%Y:#F`A3',.Q2%$QA]@%`1$?Q`&OGM?7"_4Q\HC%9,+>
M69PLI!VX-9!SA&OWV;3[?0<TWE1R^R5(*+!L`BMU6HI1$?'8@>S7>;=$Z*RC
M:?R@^G'VE><;I-VNX3/X:R/1A]BP!>:[Y]W,?B1SNS%QRX[%PFKCG%C&@PZR
MEXQP[M,^>Y2M*AK/;.[+H6F(*+5N\G2()H]G]EV1^T.XZTVX;I<07;HHBW0`
M.?*O`]*WNU[-:W-DR>XU]HZN1&52!PZ%CR)_%`>9H7?JC>+RGAZ#8;FR[>_[
M&0RZP_\`&KS]7]K_`"EG?[O6'.3TC[ED0\K3ST_,#YQ<Z<%\:;U7^/*-#NSF
MVR5]>U/&=CBK*VJU/I4]97BT1(N+]),X]XX?QS9`%#ME2%[PAT[B&V99;I>7
M%RV)V@,-2<^`)_,L#<MGLK.R?<,+]8I2I%*D@<EA`\\/F`^Y?^8;F*182QW^
M,<&23S`.)FJ:PJ1Q(:@R+EE;[`T3`>UW[A?@D'9U0\5&Q6Q1$03+MK-SG,]X
MX_A::#S9^OU`+;[/:_*V+`?XCQJ/GR'F%%7/D!8BQ/D3S#Z9?\W6K']6Q]QT
MJLUF=(<C6BM5>&FLA,'#&OXUCVZEGD(]G).XJQ3/WR")!.8HQ93B&P;ZKM;(
MWW0=*0&-%<>?#[^L*S>Y966)9"'&20Z<`3AF<O1YU^@=8^6_%*-@[&^E.2O'
MMRU804Z]DFA<TXS=N'35K%NW#QJ5HG9U%G:SE`AB`D4ICJ&-T@`B.VNO==6X
M;4O;I\O+H7$-MKHN`$;ZU_*?N7Y)3Q=NZ>OG3-+X=F[?O73-OT]'89N72R[5
M#H\.CLMU"EV]6VVN`.>&2].&`H<UZQJ1EEWC/^%&M[51XHF\R?FRYX6@BF4,
M4QHZX9[;2DVU;[^(HF@X&4$Q0\-CG]^MVV0LV4@\30>=QKZJKF7Q]IWE')K`
MX^9N'KHO)AK2+IE^DC_#Y<98'CMY;.)KBG%-V>0>3A7><K]-=@I)20BYEZ\C
M\:0CEST]\\7`T=FV601$>V1P_<*`'4J81[+9[<16@?3WW8GSY>JGK7`[Y<NG
MW!S*_NX_='FS]:\S'\3_`&N!L'F5Q,)%MFQ9>D<:<40EK?I%*#A_*RTM=;5&
MIO3E`#*JQU<FV:9!,(F*D8I?0``&DWLM-YI:*$-QZZDU\^:Z'NZUPV\N<<#(
M:>@#VK&EY5F+#YF\R#A70!0%PT<\@*1:98G2)REA,<NE<C3!U``!V3!A5#@(
M^CQUA6+#)>1M&/O5]&/V+8;E+V-A,_CH(].'VK]5!1?N*'4,/VE#F.;P]9S"
M8?5[1UWP!&`R7FU2M'6'M^C\VGO)4IUA[?H_-I[R5*=8>WZ/S:>\E2G6'M^C
M\VGO)4IUA[?H_-I[R5*=8>WZ/S:4<E2N/W@_7#Z-7Z#R5FL)W@_7#Z--!Y)K
M"=X/UP^C30>2:PG>#]</HTT'DFL)W@_7#Z--!Y)K"=X/UP^C30>2:PG>#]</
MHTT'DFL)W@_7#Z--!Y)K"^@L'ZQ1^;_1IH/)-87WNA[2_+\>J:#TIJ;S3NA[
M2_+\>F@]*:F\T[H>TOR_'IH/2FIO-.Z'M+\OQZ:#TIJ;S3NA[2_+\>F@]*:F
M\UU(J^(^`>D?7K-#,%!K'0OG=]P?/IH5-8Z$[ON#Y]-":QT)W?<'SZ:$UCH3
MN^X/GTT)K'0G=]P?/IH36.A:NX7W_1JF@J[6$[A??]&F@IK"=POO^C304UA?
M!5#V?..JZ%36.A?.[[@^?30J:QT)W?<'SZ:$UCH3N^X/GTT)K'0G=]P?/IH3
M6.A.[[@^?30FL="W4U1\=A`/F'\NK7,'%7!P/%;G=-^M^3ZM6:!R5:CFL47F
M\7I:%P%2*.@OT'OV1D7#U,!V%6)IL4XDCD,`>)D_O>29F]FY`U](_3'LS+KO
MI=[N]N%E8D-/)\[PT?L->/.OB3Z[.\;]N\,-O[O0NH_<]U!>.<5K&YY'_:R1
M'S+SM,6+V4?,HR-:K/I&2=MH^/9-B"HY>/GJY&S1HW3+]I1=RX5*0A0])C`&
MON2::*WA?<3N#((VESG'`-:T5<2>0`)*_*.UM;B^NH[*S8Z2[FD:QC&BKGO>
M0UK6CB7.(`',KT/>6+QWC:/"6?,#Y)N\E7KF1Q]4I,H$5369PSLJ&0+'&J[?
M::3-J:#%LU2_IQ\3UAX.3[_#WU!=^+C>+NW[L1%S;9C6W,S,11SVUMHG#\S(
M7=J\'*2:G^;"_5KZ//"BR[M[;>=^KD,DO9'R65M)@0YL3@+V>,_EEN6FWB<,
MX;;5_G7+&WYFF4W>1N5-K@RN3*P>*F,?CZ(0`_4B1XU1+*69R0@#T@LXGY!5
M(X^D2MR`/Z(:]Y^G_NY%L7AS;79:!=[D]UR\TQTDZ(AU"-H(Z7'FOD7ZP^^D
M_>KQIO=L:\G;=EC991"M6ZVCM+AU.9F>]I/$,:."DEY.EZB8N]YCQZ[<HMY>
MW5NMV."34,4JDA^Z#R50F&C?J_O%D&<^1QT!X]I)0VVQ1'7!_5)L]S<[-M>]
MQ-+K6UGEBD/Y>V#"QQY`NC+:\RT<5ZW]`O>.PM.\F_\`=:X>UM_?6D$\(.!?
M\JZ42M',ALX?3/2UQR!6?;NF_6_)]6OB[0.2_3RHYKJ)^RP=3A9"R6F=BJW7
MHE`SF3G)Q^UC(I@@0!$5'+UV=)!/<`^R7?J./@4!'8-95EM]WN5VRPVZ&2>^
ME-&1QM+WN/0UM2?8.*P=TW7:]DV^7=]YN8+3:H&ZI)IGMCC8!Q<]Q`'0*U)P
M`)6#3F!YHSJ>;2N-N,SM]%Q3@JS"<RXLBJPF)%N<#).&M#9+%3=0K1<@B49)
M<I'ABC^P31\%1^OO##Z=XK.2/?N_[627+:.CL@0YC3F#<.%0\C/LFDL!^-S_
M`(1^;WCS]9DFXQ3]TO!]\D-FX%DVYD%DKVG!S;-AHZ)IR[=X$I%>S;'@\XLZ
MI4F\973Y;OK4R]9-(/&%,@WQE?B<HW%J8JCIJF'4#I:HUU98BTX]*.QS&(Q3
M/\0X$R/T5N6Y/N+X=V=E=3<-#73R-I2T@.1/`32@%MO'P`,SAH91WQCL6Q1V
M>UGOYWI87;097,M(7UU;C=-Q<T?B-K`2'7<PP)+;=CNUEU1^@_R].+\IB&I2
M69,FMQ/FK+K8CYZ1Z@FF\I]0>*)OV,#V0(4K"3ES%3<ODDRD*W3(@U`"]DP#
M\2>-_B%;]Y]RC[J]WS3NGMCM+=));/.T%KI*_B8S%L9).HE\E3K"_4SZ6?!N
M[[B['-W^[Y-KXA[ZT/?K`#[6U<0]D-*#1)+[LDK0`&-$4-!H<#D?[IOUOR?5
MKPC0.2^L:CFG=-^M^3ZM-`Y)4<T[IOUOR?5IH')*CFL>/F6Y]/A_CU(56&?B
MWN>8U'5*BNRIT.F58!`BMUER"02J)A]V+D8$.`@(*/\`</$HZ]P\`NY8[T=]
MV;C=,U;5M0$[ZC!TM:0,_K@R$<HZ<5\K?5YXFCN%X5R[-82:>\&_EUI%0T<R
MWH#=RC$'^&YL((R,U1\*\P&P;=/B4NVWV=@$`]'V=_`!`/1K]"NGBOQJZ\EF
MHI'FW5['U,J=$KG'%=K`TZNQ%:B4`R4B`@RB&2+--53:F;"NY%(551_E*',/
MKU\G;O\`3/?;WNMSO%_OK77MU.^5Y^5/Q/<7$#]_D*T'(`!?H;W=^N7:.[&P
M67=O:NZ;V;;86L4$0_Q`?!$P,!/^B?$ZFIQXN)/%0'YA<FD>5F283(:5*/1C
MQ--8U)6,/.EL`NQ82TQ)$?@[+%Q/:`Q97M]OMFVZ-^KQV#V?PN\/W^'&PS;&
MZ[%X);MTP<(^SIJ8QFG3K?7X*UJ,Z4P7S#X]^,,7C7WNMN],>W';3!M[+8QF
M;M]6B660/U=G%3"33ITG*M<:"W7&R9&O<A\&30'[81^6\?J'.([`5)2SQK=8
M1'V=I8=_=K>]_;47W<?>+0BNO;+D><1.(]87*^$.X':O%;NW?@T$>^61)Z#<
M1@^HE>R8YC@J=,#!N"AB_P`D`\#"'I'8`#PU^6(:W2#3@OW\<!K+0<:TS7DN
MYY7''E]Y4Y2LV-'!GT&Z?1K*4E4^V,=,VJ'BVL18I6&,G_>Q3IZR^PJ/]^H4
MZI?L'*(_I7X-;7O>S>'.W;?O[=%VUCG,8:ZF0O>7Q,?7)X:[$?A!#3B"OPY^
MIO?NZG>7QJWG=^Z#C)MSY(V22"G9RW$4;8IY(J9QN>S!WXW:GCW7!61PA;(.
MB9DQ;<K-%,)NNUJ^UB7G(R30*Y9+Q366;&>J+-S[IJF9H"9=,#`)>XD7<!#<
M-=;WOVV\WGNMN.U;?(^*^N+.5D;F&C@\L.D`YC4?=-,:$T7G7AMOFV]VO$#9
M=_WF&*XVFTW.WEFCD&IAC;(TO)&1+6U<T'#4!7!>K?EED%3'W&G-UV8/0%RU
MQY--8=XF<!!1_:4DZ[%.D3E\3"*\T14H@/CMOK\W_#79&[WW^VC:9F?NW7T9
M>WDV$F5X/FC(*_;;QN[S?[K^$7>+O#;2#MF;5*V)X/X[D"")P/\`.F#@5X]2
MATE*4/04``/Q!MK]0SB:K\$UZ-?*(J1H3CW=+@HF!%KSDQZDBH)0`RD;4H>/
MC4-A$-Q(61?NP]F^^OA3ZF]S%YWWM-L::LL]O:2.3YGN<?V6L7ZS_0IL/^'>
M%=_OL@`DW'=WAIYQVT3&-_[R25;?F\78T/@"D4I)<`7O62FSEPD`@!E(NGQ#
MU^L(E#Q$@2<FT]VX:N^F/:!==];O=G#W+.P(!Y/G>UH_88]6?79WA_P_PNV_
MN_$X=KN6[M<X5SCM8GN=_P!Y+$O.<80*4QA]!0$1_``;Z^Z1B:+\FU%7S^VC
M^HW;R_\`%+PIT?W&X-5V><-3;@5&:R7DBY6*9W(.VRO<:)$./I^P`>K7Y$>-
M>Z,WGQ*W7<(S6)]W*&GFV-W9-/\`5C"_HF^FO8']V?!;8-GE;IN8]M@=(.3Y
MF"=XZPZ4A>?EV3N-7*>^W<053W]G60Q=_P`6^O*3DO=U^O\`X@BVE<Q-B*NM
M`!*.@,78VA&Q$RE`",HFF03!$I"^``!4&X;!KTZ",-A:T#(+R29X=*YQ.)<?
M:O&3S`_AZO,9Y,<J^17()K;N,I6F9,R7F]0C&3R;;T)1K79J<<?NNP?I$QLX
M;H/6%<3:HJID54(0Y!*4Q@`!'E;K8KZ:=\S3&&N<2,3EP_#R786G>';;:UCM
MR)*L8`<!G3'\7->87,.,IK"F6<EX=LLG7IJR8KO-FQ[8I6IR"\K6'L]4I5S"
M3"D#)NF4<XD(TDBS4(FJ=!$3]&_2&N?EC=#*Z)U"YI(-,JA=-#*V>)LS00U[
M017.AQQ6<G^'C:#1LQ<V^5JB0`3BMP3R[;(IV<"]#:T61,JL5TJ&#8BRD=4'
MQ0]?28?;K:;0VDDLY_S<=?/75[&E:7?R'PPVO][.T>;R(7GQ,\>2)U)*164<
MR,DJK(R+E4PG5<OWZAG;URJ<PB8RJ[I8YS"/B(B.M14G$YK?4`P&04F<)<(.
M6W**M2UNX_\`&K*F;*G79T:W,S]&JIIZ)B;$$>UDS0[IR*J9$I$L:^16$@;B
M":I1'TZGBM;B<5A8YPZ/+I"QI[VTM7!EQ*QCR*T)I@KRAY1'F6`("'`7D0`@
M("`ACK80$/$!#_>/`0'4O^&WW]R_T!0_XMMO]_'Z5R__``EO,Z_^1'DG_P"X
M2O\`]-Z?X=?_`-T]/\5VS^_C]*R3>8M6\A<6O)<\L#B#D^LS./<FVW+6>LX9
M$H%A;@PL,#]S3EE1A&DXP`YQ;NNWDI!3I$1V$`]8:S;UC[?;8()`6O<22..!
M<?\`E!:[;GQW6\7-W$0Z,-:T$98@9?U5YT4F+N360BX\AE9"470C&"1`$QU7
MT@J1FS2(4/$QU'*Q2@'K$=::A.`S*Z`D`5.07Z\N#L?(8CPMAK$D>F5%MC/%
M6.<>H(D*4I2FJ-0AH!0`#;P$[AB8P^\=>FP0]E"V,_A:!Z%Y-/*)9GRD_$XG
MTFJ_,[\X+*@9D\SCFA<470/(]AF65Q]#K%/UI_=.*HV+QNV(D8/#M=VL*&#;
MPW,.N`W-YDOY7'@ZGHP^Q>D;1%V.V0LXEE?ZV/VJ>?\`#*XQ&Z^9,M>UF_=9
M84P%DVW`L8@&(VF;8K!8WB#;B`@54S6T/1+Z_L#[-9FP1=I?ZOR,)])`]E5@
M]Y91'MVBN+Y`/14_8%^@_P!TWZWY/JUW&@<EP%1S3NF_6_)]6F@<DJ.:=TWZ
MWY/JTT#DE1S3NF_6_)]6F@<DJ.:=TWZWY/JTT#DE1S3NF_6_)]6F@<DJ.:^=
MTWZWY/JU70.25'-<?N^X/GU)H5FL="=WW!\^FA-8Z$[ON#Y]-":QT)W?<'SZ
M:$UCH3N^X/GTT)K'0G=]P?/IH36.A.[[@^?30FL="=WW!\^FA-8Z%]!4/9\P
MZ:%76.A?>X7W_1JF@JNL)W"^_P"C304UA.X7W_1IH*:PG<+[_HTT%-83N%]_
MT::"FL+J!<^(_H^D?;]>L@`T6!J:OGQ/]'Z?KU6A34U/B?Z/T_7I0IJ:GQ/]
M'Z?KTH4U-3XG^C]/UZ4*:FI\3_1^GZ]*%-35K^(]WTZI@JU'-/B/=].F"5'-
M/B/=].F"5'-:1<?T?QC^?2G)4+@OGQ/]'Z?KU6A34U/B?Z/T_7I0IJ:GQ/\`
M1^GZ]*%-34^)_H_3]>E"FIJ?$_T?I^O2A34U;R;@!`=Q*'CZMQ^O5I:KVO(^
M%;G?+^L'S#JFD*[M'="P6^<?)JJV#`,2!Q^'1@;_`"G0&_2*[J3KC/J_""3/
M;\>OL'Z6H&MLMZN?QF:V9Y@R5WM<OS9^OR[E?N?=>R)_=-MKV2G2Z2!OL8H!
M\=:B\9UO*V<P;F46QO$Q5/QV`EW!WF?*KL:K3U6_4`D4<5.-</9@OI$CALW-
MKVCOSN<4M_MO<_51M_*^>YZ+&S;VTX/(3/$<)YM<\+YC\(^[]Q!M.]^).@N?
MM,$=K8_K;IN+OE[9S:X%UM&9KH9Z9(XBO4MB^F1>+L<T+',44I&%'JD%6R;%
M$!66C&**3]T<0#[2SZ0!58YO28Z@B/B.OSM[P[M/WAWV\WVY-9KNYDE/0'N)
M:.IK:-'0`OV@[G=W[?N;W4VSNI9@"VVZRA@'28V`/<>E[]3R>)<2O*%RRC9&
M)Y.Y\92I5"O?\UKD\'N`(&4:R<NO)QRP;^E->.>)'(/H$A@$-?I%X:W$%SX?
M;++;$&+_``V!N'-C`QPZPYI!Z0OQ#\<[.\L/&/O/;WX(N/\`&KI^/%LDKI&'
MJ<QS2.@A6;J]IL=)L,1;*A-R5;LT"\(_AIR'=*,Y&.=I@8H+-W"8@8.I,YB'
M*.Y%"&$I@$HB`]5N.W6.[6,NV[G#'/M\S=+XW@.:YO(@].(.8(!%"%Y]LN];
MOW<W:#?=AN9K3>+60/BFB<6/8X<6N',$@C(@D$$$A3V8^:7RZ9Q)(U6P4:1<
MII`D$[(4**/,'$"](+*_"J-(I5?UB86OB/I#7C,WT[>&<MR9VPWD<9->S;</
MT=0J"\#^FOIZV^M/QTM[$6;[G;II@VG;/LXNUZSITQD])C42,L9]S%G!ZF_R
MMD*P6XK90564<]<D:0$:<=PZHVO1R;.$8G`!VZTT`4$/28=>F=V^Y?=;NC$8
M>[EC#;%PHYS072._G2.+I'=1=3H7A7?CQ0[_`/B/<BY[Z[K=7P8:LC<X-AC.
M/\.",-B8:&E6L!/$E7PQUQLBJG1V^?>3YI.F8I$W72J`BI]V9)SA+$("[6%K
MC1<H.:]55MRF>S*Q`[;41,@41,137(;YW]N-RW=W<OP][.Z[R?Y^Y/OVM@S(
MOE<,)9AB(X&G%^#R*$+TGNGX066Q=VV^*'C+VVW]R:UM+('L[[=Y`*MB@:?>
MAMS@9;IX]V,UC!+FN&0/AEQWGL_7B*Y59QKT="46OI,V6`\3M&!F=781$*J<
M8!Q&PJQ1*A2JVH(J,^X`JS$D)WBXG#J,MXIXJ=^;+N7M$GASW1G?-O$Y<[<;
MQSM4KGR#]X'2#.>48/IA#%IB8&X!GU+X`>%>Z>*'>.#QK\1;2&V[M6H:S9=M
M:S1;LBA)[%T<1^&U@-71:JNN9]4\A=[SI<U`N0,(F,?<QA$1$=Q$1$=Q$1]8
MB.OE`,`%!DOT),KR:G-?.^7]8/F'32%3M'="=\OZP?,.FD)VCNA?2K`8P%`P
M;F$`#?<`W$=O$1\`#0@`550]Y-!2I7E8Y[YY#//(>S/XIZ+JE4/KH-*Z#B+9
MPQAG*P3$VB7<2#]_3QEUBG#Q,V*B'\D-?HSX,]S?]S>X]O#<,T[M>?Z1/S#G
M@:(S_P!''I:1P=JYK\4OJ>\3?_<SQ4NY[.37W>VRMG:4/NN9$X]K*.![:8O>
M'<8^S'`*RF,^.^;LR1<G-XNQK8[K$PT@G%2<A#IL_AVDDHV(\*R,=V[:BHO\
M*H500(!NDIBB.VX;]9W@[\]T>ZMQ':=XK^"TN96:V->75<T'3JP!PJ",:5(-
M,EYWW.\)O$;Q!L9MS[F;1=;A86\HBD?$&Z6R%H=H]YS:NTD$@5H"*TJ%<?\`
MX&>77_Z@[U_Z*)_]::T'_O#X8_\`G5GZ7_Y"Z[_AK\=?_3.X^B/_`"U:')N%
MLK89<P[/*=%G:.ZL#=V[A49M)NF:2;,%DD'BS;X=PX*8C=9<A3;B`[F#74=W
M^]G=OO7'++W<O(;R.!S6R&,DZ2X$M!J!F`:=2X+OEX==]_#V6W@[Z;;<;=-=
M-<Z(2@#M&L(#RVA/PD@'K5&U:2&&M%9F"CTFB;'!28&#PZ182K1V`[^K;LZV
MNY6XN]NN+4Y2P2,_K,(^U:#8KP[=O=GN`P,%W#)_4D:[[%Z%/,JY?ABZG*8;
MQ]*]O(^2(HR]ADF*W2YIE#E"'*H)%4Q`[:=MB1C(M]MCHLNXMX&.B;7Q'X">
M&'^\6Z#O3O4==BL)*1L<,)[AF6!SCA-'.X.DTMQ`>%^J/U=^/)[E;`>X/=B;
M3WLW:`F:1AHZULY`0:$8MFN15K*8LBUOJ"Z,KSY0--L]EB[7,0,(]DHBBPB-
MAMC]LENU@H9Q*,85L[>JB(%("\E())D(&YS;F,`=)#B7[9O=UV^PN+:UO9F1
MW-Y,8H6DXR/#'2%K1T-:23D,!6I%?RRVSN]O6\V5]N.UVTLUCMMN)[E[1[L,
M3I&0M<\],DC6@8DXFE&N(ID0`P"4?0("`_@$-AUL,L5IEG8R1EIQEKRF$IP[
MHSF;A/W"Q];#";K7%Y3;O!Q8+.1`=^I_$),7(B/I%;?7QYL/=J/NU]2ILPT-
MM)OF;F'EIGMY'T'\UYD;_17Z6=[^_$_?CZ'!N;GE]_;BRL;DUJ[5:WD,=7=+
MXA#(?YZP4:^PU^::]4WEXLV<7PYPT1J8G^_,K3*NA+X]3U]=+"9?J$/Y903*
M4?7]G7YS>-\TEQXI;J9?P/A8/YK8(J??YU^V'TK6T5CX!]WV6]*21W,COYS[
MN>M>D4`\RQ8>;3D]M:\XU+'$>Y(NVQ=4.J5*F?J(E9KFLC+.VYR@.P+-H-I'
M]6_B45!#VZ^B_IJ[OOV[NA<[],TA^XW7N5XQ0`L!ZC(Z2G.E5\5?7+WRBWKQ
M%L.Z5L\.BV:QK)0Y7%V1*YI',0M@Z14A01X[8K=YJS;C;&K=(ZC:Q69C]^*$
M*8Q6E8C3_>EE>*B4!Z"(0K-;81V`3B4/2(:]B[\]XXNZ?=*_W^0@206[NSZ9
M7>Y$T=<CF^:IX+YH\)NY4_B'XC;1W1B:70W5XSMC0T;;Q_O+AQY:8FOI7"M!
MQ5C?XJO'KB+Y)\4\H-6G:@;9@BRX_153()6Z,ECJ^.98L>`[`4IDX>^-Q*7]
M0OL#7Y#=Z&/^:CF?4ES34\R#4GSER_HK[H2,^4EMV`-:Q[=+1P;IH`.@::+R
MM.$S+(+)%-TF5243*;]4QR"4IO\`DB.^N777#-?JG>73RLQUS$X@82RKCNPL
M)J09X[IM2R7`-G*2\Y1,D5BN1T):JY9HY(QG48X&38J.&AU"E3>,EDETA,0^
M^O3=LN(KNT8]AJZE#T'B/+ACD0O)-S@GL;U\,HH-1+3P+2<"/+-<#S#N>^*O
M+VX]6G+=_FF`7Y_$RT9A+&XKD"S9'R*=BJ6#:Q\6(_%!6X9^HDZF)`Q0:LV:
M9@,853HIJ-RO8;"V,CR-9P:WF>5/;R5=LLKC<KD0QC]V#[SN#1QQY\AQ*_+5
MEY>5L,O+V&=>*24[8):3GIR16$15D)F:?+R<J^5$1$14>2#I10WO-KS0DN)<
M[XB:GSKU@-#0&MP:!0=0R7IO\J;'$K7_`"3/.3S/%H'3F+]39['D2Z(F(JJ0
M&.<:FE+$1$VWBGMD9P!MO0*8^S70[9"\;1=3MX@CS!I_RBN5W><'?;*W/PM(
M)ZW.P_LKS`!ML&WHV#;\'JUSJZM?H:?PV52BZOY7]8G6BS=5_D3..:;3-&2V
M,HBZC)F-I#)FX$/$%D(NJ(GZ1\0*J'MUWW=R.FW`_F<3ZZ>P!>;]YYGG=2S@
MUC1ZJ^TJ8/FH^8Q#^6UQQC<OI5F!R)D.X7V#HV.<:3DZ\KR%G4.!Y.XRRK^.
M:/Y!O'52MMS+**$1.3XIPV2,(=T-9>ZWXVZW$@&J1QH!6G7SX5X+#VBPDW2Z
M,-=,36DN<!6G(9\3ZJK!GC/^*7ON0KA3\?Q_`!G8KA>K-`TZLPU2ST_*ZEK%
M99-K#P\>U1DL6N1`SJ1>$*(B80(41,/@`CK21=Y7O>(Q!5[B`*.S)P'X5OYN
MZPBC=*;FD;0226<!C^90C_B@LIN;=SCQ#C!8Z*9L.\;JTI+1[5T+QI'VK)UE
MG;1+MTG`I(?$@G%1\<4JO;(*J8%-TEWV#![QRZ[UK,M+,>LG[@%G=U(R+!\Q
M_'*:=30`/758??+KQ67-G/3A]B]5O\2RLW(7&BTNB).LAH&LV!M<)\5"["`I
M!"U]?JW\.G?6JV^/MKZ*,X@R"O4,3Z@MUN<WR^W3S#,1NIUD4'K*_5!M=QCZ
MA`6J\RJJ:,;4H&Q7*24/]E-)A7(M[//3F$?`"D;L3".O37AD<1+O@`]2\E8Z
M1[PP4U$@>G!?D*6^UO[[;[=?)10ZTG>;79;I(JJ&$RBCZUS;Z?=F.8PB83"X
MD#;[Z\I>\R/,AS<2?2:KV5C!&QL8R:`/0*+V"_PHF-"MX/FCFYPAL9]+XFQ!
M$NC$]*46RLEYL**9]O1W):,$X!ZP+OZM=9W7A![68YU`'F!K[0N+[WW!:Z"!
MM,G./J`]A7K[[Y?U@^8===I"XSM'="=\OZP?,.FD)VCNA.^7]8/F'32$[1W0
MG?+^L'S#II"=H[H3OE_6#YATTA.T=T)WR_K!\PZ:0G:.Z$%<NP_:#T>P=-(3
MM'="XOQ/]'Z?KU?0J+4U/B?Z/T_7I0IJ:GQ/]'Z?KTH4U-3XG^C]/UZ4*:FI
M\3_1^GZ]*%-34^)_H_3]>E"FIJ?$_P!'Z?KTH4U-3XG^C]/UZ4*:FKZ#C^C^
M(?SZI3F@(6KXCW?3I@JU'-/B/=].F"5'-/B/=].F"5'-/B/=].F"5'-/B/=]
M.F"5'-=*98=Q\/6/L]OX-90C%%`7"J^=X?EM]6G9A-03O#\MOJT[,)J"=X?E
MM]6G9A-03O#\MOJT[,)J"=X?EM]6G9A-03O#\O\`5IV834$[P_+_`%:=F$U!
M.\/R_P!6G9A-03O#\MOJT[,)J"=X?EM]6G9A-03O#\MOJT[,)J"=X?EM]6G9
MA-03O#\MOJT[,)J"=X?EM]6G9A-06ZFOZ=_#T>S\VK71JH-<EN=\/;^3Z]6=
MFJU/-85_."@'"S;!%Q(03-6ZMXJKE0`^R1=R6!F6)#"'H%5-LX$/;T#KZQ^E
MZ]8R3>=K)_>.%O,!T#M&.]!+?2OSQ^O?:)GV_=K?V@]@QUY;./)SNQE8/.&R
M4ZBJ.K=-98[XF<&VK\B;=#*_+:EY$MZI@`I7*"SM\WKJ3HP_I(HPC-L8`-X!
MN8?7K:7^Z2[YXE]\)827/VWNS/;0#D0UIE(Z3(YX]"T6S]WH.Z7@=X;PW`#&
M;WWYM+ZZ.0>TN>V`.Z!`UAY9E9W55Q[JO4/VNX?J]'IZAW]?MU\<MC]T4RHO
MTM>7:S4XU*QC<X^"*W(.52REB]_$Q&3D8]M&S\/,K"QAKLRCT^U&N0DDTUBQ
M=B8-0!`%%2BW<H$3*<R8I@8WT'X0>,;>Y%L>[O>%DLO=XO+XWL&I\#G&KQIP
MUQ./O4!U-<7$!P=0?'/U(?3+)XJ7C>^?<V6"#ODV)L<T4IT17;&"C'=H`1'.
MQON`N&B1@:'.86U=B86X!\OD79V?^2LRJ8AQ)\2A/4]5B?8=@.F\"P@B9,?2
M`[^C7TLWQI\,'1"7_%H@",C'.'=1;V5:KX8D^EOQ[CG,'^[L[B#34V>U+#TA
M_;Z:>=7CHGE:<D;,X0-;G%)QO&G,'Q"TK/)V*53(/I[$36`?H*J[>@JCM$-_
M6&N5WGZBNX>WL<-L;=W\XR#(^R8>M\ND@=3'=2]![L_11XN;Q*QV_/V[:+0_
M$9)A/*!^K';]HTGH=(P=*E&IB#B3P:`'DHU-R&Y",(X9J-@["I'-X2J$1*0Q
M;188LHNX*A5YHL)3%=RAWK]4P@5H05#!MYV.\_B9XP'LK=W^!]R'R:'21!QD
MFK_FHW^[)<2D5&B(,C`J930+VL^'_@;]-P[>\9_O5XIQ0]K'#.6-BMJ4_P!(
MGC&N&S@:ZA$EP9IG&@@;J-1U^#N.V2.961T>2W*EZ[?8^2.0]"I*K=U$1]I8
M(+"JS1BH1<X.H+&:*@`8!4V>S0AUG'I,<XS=[^_.P^%>PGN!X<,:S>R/](N`
M0]T+B*.+Y!A)=$88?NX,@*@`8GAOX3=[OJ![VM\7_&J1\G=5I!LK,M=$RY8T
MU8(X2=4.W@XC526Z^)QHYSCFB1,@W11;-DD6S9LBDV;-FR2:#9LV;IE1;MVZ
M"0$20;H(D`A"%`"D*`````:^47-?(\R2$ND<22222234DDXDDXDG$E?H/&QD
M4;8H@&0L:&M:T!K6M:*-:UH``:``````!08+<[X>W\GUZM[-7U/-.^'M_)]>
MG9I4\T[X>W\GUZ=FE3S4.^=.>!P9Q\M$A%O?A;G>"J4.E]LX%<H/IEJJ68FD
M=MS%&"@@65*?;8K@Z(?R@UZEX/=S!WP[[V\%RS5M5F1<3UR+8R-##_TDFD$<
M6A_)>!?4IXE'PT\*[V\LY-'>#<0;*TH?>#Y6GM91G3L8=;@>$ACYKRR`40`"
MD*8P^!2$*`F.8?04I0#<3&,/@`>D1U^BY/$X!?BD`20UHJXY+UD\0L1EP7Q[
MQ]1W+<K>PN([]ZKCX%!0UJLY4Y&006,&PF-$MS(,0W]!6H:_-7Q/[S'OCWWO
MMW8=5DV3L8.78Q5:TC^>=4G6]?N9X$=P1X;>%FU=W)6Z-T=#\S=<_F;@![VG
MF8FZ(>J-26[X>W\GUZX#LUZ]4\UA%\X5'KD./[X-O&/R*R$?Z#JIN"A_^T'7
MUS]+CM,&]P_KVKO5,/L7YQ_7U"?FNZUS_P`U?L]#K5WVK"W[/<(#\WCKZO7Y
MXJM965O.7[ZI(2"TG<K_`'J::-2;%[\E,R[TR$=&L&J)`*0A2E*D@@F4"II)
M$*4``I?#4VUML_=?91!`([79;.%QY-8QM7.<3Z7.)J223B2NDO;WO+W_`.]!
MNKITVX=Z-RN&M'&265Y#(V-`P'X6,:*-:T!HH`O2C@SA]6L7<9;5A.0(S>VS
M*E5EFV2IY("J`[LDS#KLV#%FN.QC0]167(FT]`'4(HOL!E1V^".^'BA?]XO$
M&V[VPE[-MVVY8;6,_ABC>'.<X?GF`)?R!:S)J_7[PV\`=I[E^#U[X=7(9)O>
M]64K;^88ZKB6)S&,:[^ZM2X"*E`7!TM`7E>861CGL/(R$/)(F;R,2^>1<@@<
M!`Z#Z/<JLW:)@'80,FX1,4?P:_0B">*Z@9=0'5!*QKVGFUP#FGS@A?C->V=Q
MMUY+M]VTLNX)71O:<VO8XM<#U$$+)-P34/EK%?)_B:LZ23>9#I!;W02.3@5%
M.XUA9HFHF`F$"D!VX2C#*"'H30.8?1KP3QC:.[7>/N]XE-:3%8W?R]S3/L)0
MXC^J#*!TN`7U_P#3,YW?KN3WR\#I'M%QNFW?.V0=@WYJW+017]=PMR>36./!
M8V9&.D(>1?Q$NR<QLM%/74;)QSQ(Z#MA(,ECMGC-TB<"G27;.$S$,40W`0U[
MW!/!=0,NK9[9+:1@<QS35KFN%6N!&8(((*^0+VRN]NO)=OOXWPWT$CHY&.!#
MF/82US7`XAS7`@@Y$*9N#^?6=<`XX'&%.3ILG`M7DB]@'5GA7<G(UM255,Z>
MHQQF\HQ:.69WRAW!$G22Q4U3GVW*;IUY5WO\%^YW?7?O]X=T-U'>.:UL@BD:
MQLH8*-+JL<X.T@-)86DM`XBJ^@_#?ZH/$KPO[H_[F["W;YML9(]\#KB)TDD!
MD.IXCTR,:YI>2\-D:\!SG<#11"LUEG[I8YNV6B4=SEDLLH[F)J5>&[CN1DY!
M8RKA<X$*4H"=0^Q"$*!"%`"E`"@`!Z?M]A9;380[;MT;8;"WC:R-C<`UC10#
MT9DXDU)-5X-O.\;KWCW>XWS>II+G=[R9TLLCL7/D>:N.',G````4````6?SR
MV^*<EA^MO\QY#BU(W(-\BTV%=A'R7;D*G25SI/#J/D3@"C.;M"R22BB1ME&[
M1),A@`ZBA"_%?CUXCP=Z;]G=;8Y!)LEE(72R-/NS3BK:-(P='""0'#!SW.(J
M&M)_4CZ1O`^\[@[/)W][U0NA[U;G"&00O%'VUH2'$O!%62W!#7.:?>9&UH-'
M/>T4'YW/!F;YT\+I:*QU%??&<,'3ALN8GBT0)\=:3,XQ>-O&/V)C"&[^W5A0
M3,DQ'9:48M4_#JW#Y=WS;'7MD>R%9V'4WIYCSCUT7W7W?W)NW7X,QI;2#2[H
MY.\QSZ"5^;ZLBNV67:NF[AH[:+KM';-V@JU>,W;54Z#IF\:KD37:NVKA,R:J
M2A2G34*)3``@(:\UQ!H<UZMGB,E7>.\L94Q!+N;!B7)N0L6SKQN#1[,8ZNED
MI4B^:%$1*V?.ZW)1JSUN01$2D5$Y2B(B``.KXY987:H7.:[H)'L4<L,,XTS,
M:]HX.`/M7!NV0,AY3L);)D>\7G)EL=%0CDIN[V:PW:QKD45*1K&M7TZ]E)(Y
M%7!P!)ND;8RA@`I1,.CY))7:I'.<_I))]:K''%"S3$UK&<@`!ZE?+DWQ!S-Q
M$3PDSSE!C4;;F[$Z68X^CO"*)6.H5E_:)VN0L=<&Z@`$=97[>#^.69;=UDDY
M326Z5P4(2>ZLY[/LQ<#2^1FJG$"I&/3AEPXXK&L[ZWONT-L=4<;]->!-`33H
MQI7CU+W2>2QQWK[KR:\;XNN#7MPW)FI9QG[>';`55(3,<S9JJW=@0W]XJE46
M;-1+?]4NN[V2S:[9FL=E*'5_I$_91>==X+MPWY\T9QA<P#K:`?;5>![D/@'(
M7%K-N2>/N5(MQ%7?%ME?5R0!9(Z:$S'(J"I`6N)4.4"O(&V0AT'[)<FY%$%P
M\>H#`'`7-O):3NMIA21AIU\CU$8A>DVES%>VS+J$UC>*]7,'I!P*FYP.\WCE
M_P"7E5K)CW#+ZA6O&5FFUK0MC[*=<?V&$A+2Z:MF;^?J[R&G*[-PCF5;LT0>
M(E<G:.3(D.9(%-SCF6&[7>W@LATF,\'5(KS%"%@;CLEEN;Q+/J;*!34TT)'(
MU!!Z%'#F1S?Y%\[<G)Y8Y'75"P2D3&JPU3KD+'IUZAT&OG7^+<1-0K:*RR,:
MB[<%!5VY65</7BA2F774Z"`3'N[VXO9>UN#4\!D!U?><5EV.WVNW0]C:MH":
MDG$D])]@R'`+T@?P[GE:V-M9X;S!^0%7<PL=&,G1>+--GV1VTG+R,LV6CW^;
MW\<[(1=I$,HQPJUK8J%*=TLNJ_(`)I-5%.F[N;.]SOG[@$-I[@(SK^(]%,O3
MR7)]Z-Y9H.V6KJD_Q".%/P#IXNY9<U@\\X[*09?\SGF+9T7(.X^#RF?&D0J4
M_6F$;BJ!AL?@1(0$0!/X^`<&V#PW,.M%O,G:[I,[D[3_`%0![0NBV&'L=H@8
M<RS4?Z1+OM4L_P"'#QE^_?F9U>V+M^\PPOA_*V1%%#%ZB-Y22BV6.80XCZ"*
M?$7=0Q/>F.WHUF=VH3+N8<!@QCC[&_:L+O5-V6T%@SDD:W_E'V+V,^;+E<</
M^6SS,N:#KX606PG8*/#J@<"'^^,GN&..&14AWW[N]H,8`#Q^R.NRWAQM]LFD
M&>@C^MA]JX398NWW:",XCM`3U-][[%^8$0I2%*0H;%(4"E#V%*```?B`->7+
MU]?H7_PX.,QHGEG4VP*H`A(9IS#E7(:BIB@4SB/:S++',(H8V^YDOA:08Q!]
MA_#7HG=NW+-K$A'QO<[UT^Q>7]ZI^TW=S`<(V-;ZM1]J^9+YDYEL.1Z1(,\G
MW/'U;S!9K'%81I&-)6CPDBQKD!R<8\78B4FXJZX5R;'Y>R-9;`9S:'\3+SU1
M@6D&D2-:J"_ZG2D<EY*^<!I>`YY:T-TBGO!H)#FG434&E0`#3.I58K&!D+@6
MM<]C07EU3B8^T(!:YNEH'N@@.-<3A@LLO'#*-FRCBY.6O;:%;9"J%WR;B/(A
MZPDY0JTG>,/WZP8[G[%5FSY=R]95VU+P!9-JU65559)N_ACJ*&1$YMW:E\L5
M9`.T:YS33*K202.@TKT9+27<;89J1D]DYK7-KG1S0X`](K2O&E5?;OA[?R?7
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MK3O>\WR_'II":T[WO-\OQZ:0FM??B/>/S!JF@*O:)\1[Q^8--`3M$^(]X_,&
MF@)VB^"OOZS?+\>JZ0J:T[WO-\OQZ:0FM.][S?+\>FD)K3O>\WR_'II":T[W
MO-\OQZ:0FM.][S?+\>FD)K6ZFJ`[^GU>G_7JUS>2N:_!;G<#Y?Z]4TE7:U%G
MF7A-?/V`K93HA`J]NB3-[A22#T@9>Q0)%S!%D.80`AIV+<.691$0#NK$$?`-
M>B^%?>QO<KOI;;K<NIMDE89^B*2GO_\`5O#7GH:>:\6^H'PYD\4O#"^[OV30
M[?8"VZM!A4SPAW[L$Y&:-TD0X:G-)P"C;DO%4MFWR\<4,:.T=&NM`I./[G6H
MUNF=*5&=H\4K#62$;H[`LE-II_&D32V!07B!4]NH==YL'>.V[I>.&Y3;NYO^
M$WMW<P2N.+.SN'A\4A.1C)[,DY:'%V2\B[W]R+[Q$^E/8[;NXQQ[Q;5MUC=6
M\;:B3M[.(PW$+0,1*!VP#?B,K`W,JM^,7/O%F5ZK%0V3;/#X[RQ%M48ZPLK0
MZ2@X6QOVA"MU9J"EGYD8])5^<G6NQ742<-UQ,4I3I@4VM1X@^"_>/NWN,EWW
M?MY;[NW(XNB=$#))$TXB.1C:N(;DV1H+7-H20:A='X-_5!W+[[[+!MW?&]M]
MI[\P,;'.RY<(8IWM&DS0RO(C!D(U/A>YKV/+@T.;1RF@KDK'*+87JV0J&DS`
MO7\4I<ZT1OT;;]7>-*`GT[>O?7E+=@WU\G9-LKPR\A!+7T:*KZ$?WO[IQP_,
M2;KM;8*5U&[MPVG.O:44>,@<Z^,>/]VHY%:WF>.<46E:QHU6N<J]="/2FU2<
MQXA")*J'^R'<=E'<?0.NXV7P>\0-Z_>?(NL[,"IENB(&-'$D._>$#/!A7E7>
MCZE/![NQ^Y_Q:/<MR)HVWV]INY'NX,#F4A!)P]Z48\%&K(W(WD'=FL<B>*D^
M,%.M8F1J=>8QY;ORQRJD?P!K0Z,F5%.H(.2#TJ2;Q-J@R`>OXE3;I'O=B[B]
MR=HDD<V2/O#NEMC-*YW8;/9GG<7!KVQ'")A>Z3+LVYCR/O7XL^*7>*&*-\,W
M<[8+["V@8SYOO+N0_+9V8T_+!PJ'7$K8F0X.$[_A-48/X5-7#EI;,TP3>.B$
MY%*P1&&#S)[8XD)TIA51N&>;PM^VR;=@.<3%9%Z89@8QBI);"<@Z[O=XKRL8
M[;>ZDSGW)88WWVCL0V/(P[=;C"T@PIK-9Y``7.J`5NO#GZ>H996;YX@VS8K$
M2":+:3+\RY\U21=;S=G&_NZDD1"EK"2X,8`Y[%DD`Y2@4I2E(4A2D(0A2D(0
MA"@0B:9"[%(F0@`!2@```!L'AKP<M)-3B3Y57UL'```4#0*`#``#``#@`,`.
M`7WN!\O]>FDIK3N!\O\`7II*:T[@?+_7II*:T[@?+_7II*:U%#D7Q%H')R7K
M4I?[5?HY"IQSQA#PU8D85E%)J2+DKF0DEDI"$DUU)%X"**1C]P"@D@0`*'B(
M^D=Q?$S>O#ZVN+?9;:R>^YD:Y[Y6R.>0T4:T%LC`&MJX@4K5Q).5/#_%KP'[
MK>,M[9W?>F^W2**QB<R**WDA9&"]VI\A#X9'&1]&M)U`:6-`&9-EJGY8O'2I
MV>O6A*6R5,KUR;C)UO%S4Y`KQ#]Q%.TGK=K)MVU::KN&*BZ!>Z0JI!.7<N^P
MCKK-R^H'OSN6WS[<Z.PB9/"^,OCCD#VA[2TEA,K@'`'`D&AQHO.]B^C7PGV+
M>;3>H[C=[B6TN8YFQS30&)[HW![6R-;;M<YA(&IH<VHPK0E9&3+=1C&-XF,(
MF$?#Q$1W$?3[=>%!E!09+ZU,A<23F5\[@?+_`%ZKI*IK4:>1?%O'')U"HM\@
M2-LCBTQ:96BCU:0C6"BPSA(Y-X1Z,A%2H*D($8F*?0"8@(FWWW\.^[B^(>^^
M'S[E^RLMGF[#`_MFN=3L]6G3I>RGQFM:\,EX_P"+7@KW2\98K&+O3->Q-V]T
MIC-L^-A/;",/#^TBEJ!V;=---,:UJHMF\J3CH/Z-LRZ7V_\`?U8-O\]3\->B
M#ZC^_0SMML/_`%<O_C+Q0_0_X2G*_P!^'_76W_VJO%@W@9@W`E\;9&K*]OL5
MDCH]TSACW"1B)!G"N7I`0<R\<W80L89.5%F)T2*',<$DU3](`80,'+=[_&3O
MAWSV9VQ7XM8+"1X<_L&O:Z0-Q#'%TCZLU4<0`*D"N&!]!\-?IC\-O"_O,SO9
MLSKZ[W>*)S(C=/BD;"YXHZ6,,AC(ETDL#B2&ASJ`.H1-@%0`0$-P$/$!]X?C
MUY+H7T7KHL=V0O+4P/D6]6V^R%BR/#R%QGI"QR,9!R5<0B&LA*+"Z?`P1=UQ
MVY206='.ITG5.(&./CML`>Y;'X^=\MBV>VV6""PE@M86Q-?(R4O+6"C=1$H!
M(%!@!@%\G]Z_H^\,>]O>6^[T7EWNUO=[A=/GDCAD@;$U\AU/T!UNYP!<2ZA<
MXU)QI14=@KC1Q'Q#RF&FX\SU8I'D7C"I(WZP8@D;'7%IU#'UN:J0;>9FX5"L
ML7+BNR829"@H@OU)J&3$W3N7?6=Z?'3?N^6TW'=7<[?;1'*UCG:&R"1FEX<U
M[:RN`((&8(H2.*W?A_\`2?W,\,^\MGW\[OWV]&YMGR-;VLD#H9`^-\;XY`V!
MKB"UQ-`YIJ`0<%<#-'&?BARKR9D&O(64D%GO&[6H+Y1&A.T"6"&;W6+<2='<
MWR`?LU8E^K8(=@HJU<$$CI1%+8ZNQ2@&!W&\8^]7<N,[19OBN]KBH>PFJ>SU
M5/[M[2'L!Q.GWF9D-!)6W\5_IG\/?%.X'>#<XI]N[P38&[M2QIGT>[^^C>'1
MRN;@"\:)"*`O(`I'</*(JWQ0&-G:Q"RZ_%(*'%@[Z/8"XV040/[^WM[M>J'Z
MF]Q[.@V>#M:9_,/TUZNRKZU\_CZ#MC[>I[RW7RU<ODX]5/YWS%/V5+3!W`KC
M[@^39V5K$R5]N,>H5=A9+VJTD"13D@@8CN&@&C9K"L7:1@`4UE$W"Z0AN10H
M^.O-.]_C+WV[WV[K"26.RVIXHZ*W#FZQR?(XF1P/%H+6GBTKW3PV^F'PL\-K
MR/=[>"7<]_B-67%Z6O$;LPZ*%K6Q,<#BU[FR/;FUP.*FN*NXB(B(B(B(B/B(
MB/B(B(CN(B.O)M%,!DOHHO)-3FO@*["`@(@(#N`AX"`AZ!`=_`0U72536L"O
MFH^6+Y7F26[SD?R/OZ7#*Y6JQ,Z_*9OJ+YA$0=XN4JT>NX]&YTI_$RM>L=FD
M&L6N<7B";!^Y*B85G"@@`ZYK>=GVIX-W<N[%[C34"`"3S!P)P/2>:ZC9-[WJ
M(BSLV?,1M%0PXD`9T-00,<L1T+#%@OR/^`/(Z_J47"WF[5'*DXBS<S)J13L9
M5Y"_NH-D("]?1S":OR'W@DQ3,`KJMFBY$0^T<I2ZT-KW?VZ\E,5O>!SZ5H&B
MI']8^?!=!==Y=ULHNUN;!S&UI4N.FO31N%>&*]#O"OR6N#7"6=B[_5ZA-9?S
M##F(O%94S0[CK))5QZ4-OCZ55&$?&TZIR!1_0>)M%Y%+^0Y+KJ+#N]86#A*T
M%\X_$[&G4*4'72O2N4W'O)N6XM,3W".W/X68`]9K4]5:="J/GEY2/&'S$LB4
MO)V=+'F*$LE%I"U!B"XWM5>@8]S"K3\E8Q7DD)JI6-9Q(D?RBH%4(HF7M[`)
M!'<PW[CL5INDK9K@O#VMTC20,*UX@\U9MG>"\VJ)T-L(RQSM1U`G&E.!')3]
MPUBVI8)Q'C+"E$(^)2\346M8^JWWHNBZE#PE6BV\4Q<2CIN@S0<R;I-OW7"A
M$DBJ+',8"%`=@V4%LRV@9;Q_PV-#1U`4QZ5J[BY?<SON)*=H]Q<>52:X*)'.
M7RS^)GF#1,8&=J?(L;[7&!XVI9AH$@A6\E5^..H=<(=6359R$99:X1RH94L?
M*-7:"2AC&1[)CF,.%N&S6>Y`?,-(D&3A@X='2.@U"SMMWJ^VMQ^6<.S)Q:[%
MIZ:<#T@A807O\*QB<\FHI&\T\GMH051%)H^P]37LLFCU;@F>2;V^/9*J@7PZ
MP:$`1\>GU:Y__<R*N$[Z?S1[:CV+I!WXFTXV[-7\\T]%/M4\^*O\/KP%XVV*
M*O%LC;ER8N\(Y0?1+G-3F'4HL9(MCE5;OF^,JZPCZ])N&ZQ0.F$L>42(8`$"
M=0`.MC9]U]OM7"22LL@_-EZ``/35:R][V;G=L,;"V&,YZ*ZC_2)KZ*+.>BN"
M!T#)$3*#;L@BD4A2(ID;@0J*)$B=)$T$B$`I2%`"E*``&P!KH=&%."YK75>?
M2Y_PW?!7(%TN%\L62.4KJR7NV6.YSRR5_HA4UYRUS3V>E3H)FQBJH1$\A(*=
MLHF,8I=@$1$-]<W)W3V^61TCWS:W.).(S)K^5=3'WPW**-L3&0:&M`&#L@*#
M\2D'PEX"<"O+$LK[)F*LQV64?\E):K\=:U,Y(OU2M\5/7#]X):5C*#2'E/K$
M0W_>F8FH-PFX1454V/'"F;MG3,`SV&U[=M+NVAD<3*X,!<0:FIP%`,:@^A8N
MX;MN>\L[&:-H$(,A#6D$"@]XU)P`/K4WN9?$K''.+`\WQVRQ/7JO42PV*JV.
M7=8\EHJ%L+M>GR83,7'F?3$+/L_NQ6233473^'ZSBB38Q=AWV-]M\>X6YMIB
MX1D@G2:'`UX@K6[?N,NVW(NH`PR@$#4*C$4.1"P\?_VQ_E]?_K"Y3_\`Q!H/
M_P#2_6D_W0VW\\WI'^2M_P#[Y[I^6#^J[_*6<;CC@RC<7,%XMX]XS/,J4;$=
M6;U2M.K`[:OK`\:(NW<@M(33YDSC6CN5?/WRJRRB3=$ACG\"!KH+6T99V[+:
M*O9L%!7-<W=WDEY<ONIJ=K(ZIIEYNA1=NG!IV[L5_<8TR56JI3,F*O'<G5;U
MBY[D5WCB0E\GP^:YYWAJ8CLD4-I!,9/,4&A:DHZ:93;1A/"HJWZ6BJC$<&;:
M=;RZ-S0TFH#FEVDDU)80YM*G&A#@"33#!9L>Z@,:)F%TC.+7:=0#=`U@M=7W
M3IJ"TD9XXJ8^*<;5O#M`@,=U966>QL($H[=S5A>ED[-:;'8IF0LUNN5IDRHM
MB2-GN%IF'DD_6(DDF9RY.":::8$3+L(+=L$8B94@<3F2<23TDU)Z5@3W+[B4
MROH":8#(`"@`Z```.A7#[@?+_7J;25#K3N!\O]>FDIK3N!\O]>FDIK3N!\O]
M>FDIK3N!\O\`7IH*%ZXW>]YOE^/5^D*/6G>]YOE^/32$UIWO>;Y?CTTA-:=[
MWF^7X]-(36G>]YOE^/32$UIWO>;Y?CTTA-:=[WF^7X]-(36G>]YOE^/32$UH
M"^WK'Y?CTTA-:^_$>\?F#5-`5>T3XCWC\P::`G:)\1[Q^8--`3M$^(]X_,&F
M@)VB?$>\?F#30$[1=,9P/4/VO6/K#VZRQ&*+#,V.2^?$#^M](:=F%3MNA/B!
M_6^D-.S"=MT)\0/ZWTAIV83MNA/B!_6^D-.S"=MT)\0/ZWTAIV83MNA;GQ`_
M(-4[(*[M6I\0/R#3L@G:M3X@?D&G9!.U:M)G`[^G;Y@U41A4,HX+3\0/ZWTA
MIV85.VZ$^('];Z0T[,)VW0GQ`_K?2&G9A.VZ$^('];Z0T[,)VW0GQ`_K?2&G
M9A.VZ%NIK^`[[CZ/6&K71\E(R35T+=[X>P?GU;V95VKI3OA[!^?3LRJZNE<=
MHDS8$438M46::KIT^43:ID0(=X]7.Z>.A(F!2]]VZ4,HH8`W.H83#N81$;Y#
M+,0Z9Q>X-#17'W6BC1CP```'``#(*&"&"V:66S6QL<]SR&@`%[W%SW4'XG.)
M<X\7$DXDE1KRGP_XX9BD74W<<;L4;$]4,L]L=7>O*M+OES_I.)$T2JDQDG)O
M291P@JH8?28==]W=\3^_G=:!MIM=^\V+!1L4K6S,:.3=8+F#H:X#H7D'?7P!
M\)._]V_<M_VB)N[2$E\]N]UM*]QS=)V1#)''BZ1CG'B596/\LSB@S<@X<0M[
ME4P-U`S?W=9-L(;[])AC(Z.=&+_]%`??KJYO'[Q)ECT,ELHW?F;;BO[;G#U+
MSZU^COP1MY>TE@W.=E?@?>$-ZOW<<;J?TE?VL\>*#C@@,\.56E8IZD@2<W.,
MKC>T9&.00V.2*FK5\>C%*B`B`+K_`!X`/B"`#L.N+W#OOO6^GM>]-S=[EC40
M/E,-K7]>.'27C]5O9]+UZ=M'A-W8[I-$'<"RV[9"6T==QP-N;^G*.:YUB,_K
MO[8<1&#BKB4C&-'Q^\DYB#BUW=KG=OWBO=C?N;'>[$(>(%E[3*'6D3M"C^@T
M0%!DD'@FB0``-:/=]_W?>HH[6\D:W;8?X5O$T16\7\R%E&UYO=JD=^)Y*ZON
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MX&>HD,";E3(5&CP7BQ$!,E.1K,2>)M<?=6LQW:XO+4$W=NV)P'YFD/UL_I`8
M?K`+L;.YA&S6UA=FEG<OF:7?D>"SLW_T7&A_5)0G.BNTB?\`-VYT8'^`O<9+
M8&\NNW8A^\FSMW'.9S(F.YFGU8MFBXX0D5!J]CL90E8](2N168K-0Z5!\*C<
M&QF_W.VHYO90%O\`2:0*@5R)Q&?#-5.V/E;MVU756.$MP'TY-<":$\P,#EB"
MK^<7.07(=ERAPGCQSE+ESR=QAENO7YAG"9Y"\*+%QVA\)9#KM5_>FI6[&]N2
MQC0HMG0+?*,7D*>`E%I%RW,HU53<"H)@-DV%Q??.QPO=-+"\.U%\3F!A`J"#
MH8`#2FDZJ88\\2^MK(V,LP9;P3QEI8(YQ(7M)H0X:W$N`H[4*`XU"MQB7(7F
M%W+RU<C\V@Y0RESR\>@S60,8XDB,7XYC:HRJN",PV*0M<=)N2P*\I9;WE['-
M5D8Q^J!6[9D11L5BFDLD9=2.!^[2;._<NVU2Z-36Z6@48\U&6)<T4KTX`4J9
MKB/9X][9M9@#;?6&N<7.)K(P4(QH&L<01SQJ:8*ZN<O,2N,=+Y]Y`X3D6UAX
M[\6?+XJ&=92IF:,',-DGD+RB,QL."(">G2-%9]E$X^QV@G)2#9BY;F5++D[O
M4()[7W.[2@R75M4VD-N'$4&+WU+*\:!HKA3!X*@M=IC<V&TNL+R>[+`:XMCB
MPD(&57.P%1^%4=QLY(\EF/(/C77W65N6O)BI9K4G:[R289IX.6;`6/<*3ZM&
MD+36<BX>O!,84U"$HJ-MCON):'F'TJHY:/$'!5P6*8=66-SN'SD3'NFEBDJ'
MZHG-#30D.:3&V@P`H2[//"IDO;6Q-G.\,MX)(J&/1.'N>-0!:]NMU74.JH`H
M0117O\W&8L$/3.#LO4:6&1[3%^8_QI?U['YIR)K);I+MH_(2C&M#8IY-:$@P
MEE@!+XIV0S='JZC@(!K-WT/9';.C;K?\W'1M0*GWL*G`5YE8O=_0^2Z;(_1&
M;*6KJ$Z1[M308FG(*Q>0KME_+?F`>67!<A.(S;ANPKN7<OW/&^1&.1<>9GF,
MGWZ)P[86AL'#*XS91A:'`3,%(N)9XK(BND_^[2())@?<X85P^>7=+3YV'Y<-
M<]P<'!^HACO=]WX:BI).>FG!94++:#:+U]G<?,DQL#FEKF!K2\>_1WQ$&@%*
M4K51ZG>?_)_),%G'D/B7)7*%I=J'ES)];P#Q)Q]PBM63N-F0J/A^\OJ9^[&3
M\R1N-)F9E\@923@'JR\K&6!@WK+M=%`$?V*H#B/W+<93)=6YE]V1P9&(G.8X
M,)!#G",U<ZF8>-->C',;M=A`Z*SN&P=F^-IDE=.&R-<]H=5K"\`-;7(M)<,:
MXK(.>Z\GN6W)S/E#Q+R#L'$RC<7*9@1-C7X7'%"NTWD7,^;<;FRRZ2RV?(4/
M).$<<4J)=,H@\3%#&/G2XNE3.DSE3`NWK?WU[+#!+V#(6LP`!+G/&KWJ@X`$
M#2*&M?>R6HT6.WV,4UQ$+B6=TF)<YH:QCM'N:2/><:FIJ!A@H3L?,!Y"6O`?
METT6VY3R32\A\F*-R"RAR"SIQYP`;-&4V]<PID!]3F%8Q+C:`IMLAH`]GFI-
MHDZG7,.\2BXMEU"47#D%!U@W2\EM;:(N<V>4/+WL87.HP@4:`UU*U&.DT`YF
MJVCMJLX[N\E8QCH8'1MC9))H;5[:U>XN!-`#1H<*D\@JHE^87,V(XE9S)`6_
M(B5[Q[S&XJ8CX^\D<_<<)##]BRUB7.N0*##/5<AXKLE6JT9*2U1D)B2@Y=[%
M,V!7[<B2R/PRR@*:O-]N;;)X]X2-FC:R1["W4'N8*%I:VM*N!(#:@5%"HVV&
MVNW"+4&=D^VE?)''('ACHVN/NN!)`-`X`DTR-0KVSV>N0/!S.?)*FY8SW:^7
M-#J?E[9`YI5\,A4['E%L5<R%BR].:C+T^%>8W@:\R3QW;B.4%$VKE-PYC`3'
MI7/]HQ\LSW>W7$T=Q*9HVVAF%0`0YIH0-('NGIRYK%9;6FZ6L,EO$VWE=>-A
M.ESG`M>VH)U$^\.8P/)66XY<KN4SC)?$6P.<H\K.0@Y[N-2@.3V++UP8MF),
M#8DKF1JV[DV]_P`%9.)C*O.8.N8OLZK)FH:9FI9*?BE3.A.4^Q@Q+2\W$S0N
MU32B0@/:8G-8W4"=37:!0--!BYVH8K)O+*P$-PP,MX>R:3&YLX>]Y:::7MU&
MI<*GW6C2<%=W!F8>54[C+F]RHR3RWI-8I.%LC<V</8;I&0Z/7H;#M.)C3(DC
M%4W*V<+?`1*MYL`TE=J2/91T<F4J\:GLL5V]<]89-O+?/BN;R6=K8HGRM:'`
M!HTN-'/(%32E*"F',FHQ[J"Q9/:V$-NYTLK(7O<UQ+SJ:"YK`3I&K,D\>0"H
M'C'R4S1-<K^/^%8KE#RRS!0^2.%,ZNK-D3D#Q6KV#HBLY-H-1K-@KF0>+SF9
MQ?07TQ#-74VN=2)E&$M&IM!9F544.<Q1Q[2ZO'7D=MVLKXIHW^\^/2*M`(<R
ML;<,<B'`89\9KVSM6V$MT8;>.6&6.C8Y2\EKB06RT>ZAPS!!K56CX;V'*>$.
M&G!9&)RM*VYMF+S6WV,)=C;J5C5PW@*3)YJY"Q%QBJTHTJB#A@]N\_7_`+[<
MR75]Y,7KM9%BNW:=*(661GM-MMGAY<U]Z6D%K<!KD!`PXD5KF"32@4^XBWNM
MRNM3`TQ6`>*.=B[1&03C^$'33(@`D$XJ^DOE/F#F7"7+_G1CKE-.8@B^/F0.
M2D9@KCBRHF.9K#MFI'%"6FH*=2SL\GJ\]O\`/V'+4G4)(QW$=+1@0B"[?X<A
MA(;?)=)N%Q;W&Y13:&PND#&4;I(B)!UU!<2XM.3A0'#)8K8MNMKJWVN:`2.F
M9&7R:G!X=*`1V=#I`8'#`@ZL:JNHW)7*#F-RP3QGC7DK;.+&%IK@/Q;Y-.F=
M$HF.;5D:-OF:9N[))Q4%8<@5V<:Q<-V&J?WKWF[E9PG'H)-A:]UPH>X2WU_=
M]E#*883;,D]T-)JXNH*N!IEC@>BF*B=%8[;8=M/"V>Y%W+%[SG!I:P-Q(:14
M\L1F:UP4N?+JS;D7/?#_`!?D/+LJQL63$Y7*%!N5GC(IK!-+9+8IRM=,:A:_
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M#VCII*:^E.Z'M'324U]*=T/:.FDIKZ5NIK"`#MX^CTZH13-7!X.>*W>^;V!J
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M><['K)]D_'"DDS85VE+,QGGH?Y5.8Q@UEJP!+'8EY9KW%G`,'Q$A0`B9`)K!
MBV*PB%RP!QBNC[S:X-S^&@%,22.1R6PE[Q7\QM7G2)K048[B[+XZFAP%#E49
MJX6'.(EEH>3J?EC,'*G.G*"Q8KJ<[2L.,,F-J)5J]0(JSM64989Y_$8XK]=0
MR#D27A(Y%BI/3/?7(W[G:3346.<9;7;##.VXN)I)I&-+6:M(#0<R0T#4XY5-
M>/,J&YW6.:!UO;6\4#)'!S].HEQ&(%7$Z6@FNEOG."O3QSP74^-6#J/@*JOY
MBST^BL+!&,WMO^[W$M+,K+99ZS22$P$:S81RR9G%B70`I$2`+<"@;<VXCE6=
MI'96K;2,ET;014YFI)QX<5BWM\^^NWWL@#97D'W:T%``*5KR4?<$>7=QUP-Q
MPS'Q8CV=FOF*L[RES<9#1O4H@ZG'U?M<$QJ<73&,K%M(X["O8]J$4TC:_P!)
M>^Q1:IGZS*!U:Q+79K.ULY+$:GP2DZM1QH10`$<&@`-Y469=[[>WE]%N#M++
MB$-TZ1A4'474-:ESB2[G5;N(>%TY1+_C.\Y3Y6Y]Y)-L#PLO!8%J&2R46`K]
M`),P9:HO8[(>@5VOO\L7QK4@&-;2T\HL9NBHHH5+XA05=6VNT]A,R:::27L@
M0P.T@-KQ.D`O=0G%U<R<S5+G>&30R0V]M#`9B#(6ZB74-:#43H;7$AN?.F"O
MEGC`-5Y!CA8;7,V&&_R-SYCWD-6?W>/'$^]K9C@DR2(A9W[Q9/>NNO@FU/B2
MH=ER/07H4+X[YMU9QW?9=H2.RE;(*<2VM`:\,<>*Q+._?9=KV;0>VA=&:UP:
MZE2.G#!:<R8#KV:+WQOR++6*R5RP\8\NNLPTK[@+$G9S<M(TV=HLK7[,E*,'
MJBD#(P5A7`PM3MW2:Q2'*H&VPVW5E%=R0RO)#H9-0I2AJTM(-1D03E0I:W[K
M2&>!C6N9/%H=6N`#@X$4.8(XU"BM8?+EB9-YD:H5CDOGS''&',F19;*>5>*U
M+4I+*F6*T6B8;V*^1M=R,O7E<I8_HV1IYN+J:AHJ0227.LN5%1`BYRZU[]CC
M<][62R,LY'ZG1C30DFI`=36UKB34`\32E2M@S?W-#)'P0OOXF!C)7:M0`%&D
MMKH<YHP:XC@*UHH]<MH(:+R?R5:X"J>81B9+*6&L>5B:N7".FP>6:5RC0JS2
M=AX_&MFBW-'M$AQ]RC0H]R$2RLX.8TSJ&?E.1VF+<!+A[E&Z&^>^)ETQLD;0
M3$-0DI7W2-+M#VY!U6X?B%,,[;91-81QO=92=G*XAL[BQT5:'4#J`D8XXEM#
M1PRQ5=\>_+[L,7P[X,UF7O5VXU\I>+-,L2]2R-CA6KVV;H`Y6=RLG?\`%%GB
M[:QGJAD:J/(N2:L9)NZ(<IW\<1R@L4Y>L\UILI_PVU8]QAOH`2'-H2TNQ+2"
M"'#('I`(."AO=\C=N=W(QC9]ON'"K75:':*!KP6T<TUJ13@:$*_B/`FEO\2S
M^.;UES+V2+;>^06+N3&3LSVJ0KYKS>LC8DMU2M53CRQ#.&1IE/H;)"ELHM"'
MB6+9%K'@?MF[YS+#EC9H?ES#(^1\CI6R.>:5+FN:X"@&D-]T"@&`RQQ6'_C<
M@N1/%%&R-D+XF,%=+6O:036NISO>)U$DD]&"O+>N,>-LE9NFLVW8).><6;C3
M<N*MEH+L60TF=QG?+>G;[&=ZD5J6:"9=+%,T`Y'14BMCB($[@`<,J6P@FN3<
MRU.J$Q%O`M)J>FO#/)8L.Y3P6@M(J-#9VS!WX@]K=(Z*<<L^A6)Q)P0=XZM.
M&75SY5\A,W8RXTN0><=\,W]2D1E9HCUE!NZM6)"XV2H5Z%MV9)"B5AZHQA3S
M[E5-J406.FJN4J@8=OLPA?'VDTLD$/\`#8=(`P(&HM`<\@$TU'ISQ67<;T)H
MY1%;PQ3SC]X]NHEV-2&AQ(9J.+M(QRP"K)?@WB.0XT\@.+$U,726QYR+O^9,
MDVV3-(1K&TP5DS+>39%?J59^RC4FC9&I6DB*T7\0@N;I0*5P*P";>8[3;&SF
MLG%QBF>]Q-14%[M6&'`Y5\ZC_P`9N!?0[@UK1/`QC6C@0QNG$5XC.GFHJ'JG
M!:U1^;<#\C,C<R>0>8\NX"4L</7I.V0>)H6H2^-[;!MX2S8]=T.KTV.AXQ:R
M&8MG,A84#C/.%6Y"%732*5,L$>S.$\5U+<2ON(J@&C`"TBA&D-I4T!+OBJ,Z
M*63>HG6LUE#:PQ6TU"0"\D.!J':BZIIB`WX<<JK72/+UHU*JM$HA<O99L%)Q
M/S`0YB8IKTR2D%)1+(2:N=F=8V:R4?6&DE,T"0LM\D'JBCY1:5*<Q")N2)EZ
M1OCV:*.-L7:2.BCN.V:#IP-2=-:5+:N)QQZ527?999'S=E&)9+;L7D:O>%&C
M50F@=1H&%!T*F+WY;<);7V9*M7^26<\:\;>1MUE\@YWXP4]O0#4NYV&V+M'.
M1FU<O,O67V1<;5K*B[,#V".B7A$W1EEQ2,AWCZCEV-DCY&LFD99S.+I(QIHX
MGXJ.(U-#OQ`'B:4JI(=_=$V*1\$4E]`P-CE=JU-`^&K0=+BS\)(PPK6BES4,
M!TNC\@K1R(KSB393]GPGBS`P4](L>E2X*EXBL-GL%64A&J30DF@_$]H5;*@H
MX.@#9!("$*8#&-GQV,$5TZZ94.=&UFG@`TN(IT^\5KI+^26S;92`%C97R:OQ
M%SP`:\.%>LE:N-^"*OQCQ+%X>I<O/SU?B;/D2U(25G/'J3"C[)5_LF1)ANJ:
M+9Q[,6C&7LZR+;9(#@V3(!Q,?J,-UE:1V-N+:,DL#G&IS]YQ<<NDX*E]?/O[
MDW4K0'EK109>ZT-&?0,>E7T[YO8&LI8FH<D[YO8&B:AR3OF]@:)J').^;V!H
MFH<D[YO8&B:AR3OF]@:)J')?!7-[`T34%QNZ'M'5VDJS7TIW0]HZ:2FOI3NA
M[1TTE-?2G=#VCII*:^E.Z'M'324U]*=T/:.FDIKZ4[H>T=-)37TIW0]HZ:2F
MOI7T%0]HAII*:^E?>[_/'Z=4TE-72G=_GC].FDIJZ4[O\\?ITTE-72G=_GC]
M.FDIJZ4[O\\?ITTE-72NE,L'4/B;TCZ_?^'6<&8<%C%XJOG>#VF^?\^FCJ36
M$[P>TWS_`)]-'4FL)W@]IOG_`#Z:.I-83O![3?/^?31U)K"=X/:;Y_SZ:.I-
M86KO_P`\?I^K3L^A4UA._P#SQ^GZM.SZ$UA._P#SQ^GZM.SZ$UA?!7]XC\_Y
MM-%.2:POG>#VF^?\^FCJ5=83O![3?/\`GTT=2:PG>#VF^?\`/IHZDUA.\'M-
M\_Y]-'4FL)W@]IOG_/IHZDUA;R2_@/@(^CTC_KU8YE54.KDMSO\`N_VOS:M[
M-7:CS6H%P'TAM^`=]4,?)-17WO%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%
M-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13
MO%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]
M^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@
MIJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*
MU`XZ=^DQR[AL.PB&X>P=A\0TT%-16GO%]^F@IJ*=XOOTT%-13O%]^F@IJ*=X
MOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOTT%-13O%]^F@IJ*=XOOT
MT%-13O%]^F@IJ*=XOOTT%-16D5_8'TZKV::CS7SO^[_:_-IV::CS3O\`N_VO
MS:=FFH\T[_N_VOS:=FFH\T%?P'P_VOS:=FFKI7%[P>TWS_GU+HZE9K"=X/:;
MY_SZ:.I-83O![3?/^?31U)K"I^T7"O4N$=V.SR9(J'9G;(J.#(NG:RSM\X39
ML(^/CV"#J1E).1>+$2;M6R2JZRA@*0@CJV0LB;KD(#1Y=9/0%<S5([1&*N/E
MGD!TE4_0,L47)[1X[IDT:1&.^%%^S<LGT7(M47PNBQ[T6<@@W4<1D@=BN1!V
MAW6JJK=9,JG=15(2R*2*<$QD&GF]O#IR]"OECD@($@I7S^1Z,U<#O![3?/\`
MGU+HZE%K"=X/:;Y_SZ:.I-83O![3?/\`GTT=2:POH+^\0^7X]-%>2IK"^]_^
M>/T_5IV?0FL)W_YX_3]6G9]":PG?_GC]/U:=GT)K"=_^>/T_5IV?0FL)W_YX
M_3]6G9]":PNF,L7J-^$?;[=9(8:+`,PJK8YKR_5,"8<RMG"[J@G4,0X[M^1[
M"'7VSN8ZHP;V9-'(&W*/QDLLU(T0`!W,NN0H>(AJ&ZE99VTEW+_#C87'S"OK
MR4]HQ]Y=1VD(_>RO:T=;C2OFS6-3A-RVY+3F&>1M7S(VK'*#EG@..Q]F!O2L
M1S-%JAL@8USWCR-R55<>5E]"(/*HG<,:V-G::607!2'E']?;_$JIJ/.\&@VK
M<;V6TG%P!/?PT=1M&ZFO%0T84JTA[`<G:0:T=5;W=;.QCNH)+?5;[=,7,U/#
MCI=&XM+C7'2X:'X9!QH,**YS+S+J?<L>265\08?O.2*#8<E8=P%Q^FGTHQQZ
MMG_D3E946\WCB*C+5&$=4>N86>]QG;+'(=U!M)QTHS:M7*L>?N3C>XY(3<6T
M3WPE[(XR3I[21V;17X0S)SCQ#@`2TJ$[/)%,+>ZD9',(WR2#XNSB9DXD'WB_
M-C1F"TD@.5'7'FYE^\3-1XQU2JQG&SE9:N4T;QMR))R[^$SE5<35=3`-BY/K
MY:QK(?=]8@\FN;IBJO?"UM"7CF";2:66^\&2I&8I+VR[E=2EMC$T0[BZ?LW5
M(>U@[,RZFF@U:F"C:@4=6K<*&2+;[:)CK^1QGVYMN96TK&7GM!%H=B2W2\U<
M035M-)QPXQ>5F-.+4OR-F[[YA5LY/QO'W%-GM.2^/MWQ]B&-S!6+'`7"K55K
M+U2ZT.A8<B3Q;RR6%"`<,)!%Y'HOI1JO\<W324`]/G8;!\[I;QT[88R71N:S
M6"'`5!:&85(;0@BI!J*8A:7&X-@;#9-@,T@#)&N>6$%I-"'.>:T!=44-`10U
M75,/-M@TJCFJ0G,-P<[>L0QF`;&TJ6#>1^.<W52[07(3,T3@V"BFV58R%KE=
MK&1*?<I9,)>'D&Y6WPZB"[=\JV6%=.P;\SLY2Z)IFC$9HR1KPX2/$8&L``.#
MCBT]!!(-5(=B>9(FLD<(I3(*R1NC+3&PR$Z"22US1@1C6H(J**:>`N1UMRAD
MG/&%<IX@_P`E\M8#4QE*3L%'9(B<K5F>I68H2?FJ)8H>WQ5?JH$DBGJDDRE(
M]1E_NCIJ`I+N45"*:V5C>/NY9;>:+LIXM)(KJ!:\'20:--?=(((PI@2#5:N\
MMXK>"&Z@D,MM-K`.DL(<P@.!!)PQ!!KB#D"K)9?\P)WC"T9WD8G`\Y>./_$R
MU4BF<H<VMLCUR`E:+.6^$I]IF#T'%3Z(=RF3XK%M3O\`$2-D6&3AU$TG*B;%
M-ZJW4*.+=;J;>673"Y]I`X-E?6FDD!QHVAU!K7`NJ6YT;J(67;;8+B.%KI@R
M\N6N=%'I)U`%P&I]:-+W-<&X.RQH"L<W('E?S]C9KS!+[2D[+!5[$/*+$/#'
M$\;!9BPHC1::PR9/<;X<]\:4ZQ84G+/.9?G6.6#OV,](S#B%A#32:"L4Y"+4
M%?37=]O`?=S1:FQ1SLA:`YH`U&(:J%A.LA]022!J^$Z37<V=GL[FV<,I:7RV
M[YWDL?J.@2G34/`#!HH6@5=IKJ&K"1ED\T>"XU/9?$=ZKJU]D>-Q\;TGDM9,
MA<GL/K9_2O%XCZY8IN/QMCV%HM3'DDZQA!79@>9DXYG5&[\"*)1S=TX06+K,
M&^MM&"&4=HZ(,$KG2-$FIP:3H90%^D.%?AY"I!6%'LC[X"XA.AL^MT0;$_L]
M+20"YQ<>RUEIT@E],W$`A7YN'F'3=4C.7%X0XMWRQ8>X:WS*F.LD9*B\D40C
MJQV+'%:JT\T"C8^50/:G\7*.+<T2E'KP&32`:];P5'J:2Y$LM^\O8R>;Y>0V
MUNY[7.J*U:T.P:*\P"30#.I6'%M3)'6T)N&-N;IC',:6NP#B1[SLJC2:`5+C
MAA4*17%CD'.\BJ5,764K6(XF(;RK1E6[#A#DI2N3U"MC1=@#QZHC<*=7JL:!
MF8-<Y$';!ZR*<14(HD=1,1$,_;KM]_&Z0MC#0Z@+)!(UV%<'`-RXX=16#N,#
M+&41-=(7$5(DB=$YO]%Q-0>!!ZU&C(7F55C%W+2I\9K36,8/VEUS/2\&Q<K2
M.1]7N688*RY"9$/5;#D#`+"F(N:35W4NH1HY3<6(\NU152=BR,B?8,&;>60;
MBVPD;&0Z41C3("\%V1='IP%</BKQI19\.T27&VNOXS("R)TA#HBUA#<PV35[
MQIC\-#E5=SYE67.0>.,>X`JO')K)HVK/G*C%N"YRSUN\4FA7.`K]G9V2=7C*
M5/Y"H^0ZM"3]S_=@\>$RZB7J<*B*BH(***)BF[P3WUM;Q-L:B268,)%*BH)P
MJ'"II3(GEBK-B997$TTE[3LX;=\@!!<TD4%7!KFDAM:TJ*\UW<7S=BJCA:Y6
MV;IEQG7N%^7^/."=E&:MD`^LEJN\WD'$.)'>3G\W$UJ'A%D0F<H$?NT&[!N5
MR+17L@@"R94[QN89:NE<UQ,=PV`U(J27,9JR`S=4B@RX*X;>Z2Y;&QS6B6V=
M<"@-`T->_32I.3*"IPKC51WP_P`E\Z6#DCA*D3N1962K%F\P'S9L/V&)5:1!
M&\ICCCW5WSW#=56.E')N2,*(\1*HU.0Y5U!#]NHJ'AK5VE]>2;LVV?(3";BX
M;2@R9VFD95PTCT+87-K:,L9)F,`D;:6KP:G!TA&LY_BX^JBE'RTYQ(<9<B8B
MQ.PIU#F[AF&O7>T0,YF?/E3XRXG*VHDA6HQU4&63;C7;1'365+"YM"2D;`IM
MDS*,F[ARJNFFF`&V>Y[H-OECATM,DC7$%[Q&WW:"@=1U7FN#0,@2L#;=O-_#
M)<:GB.-S00R,RO\`>!-2T$48*8NKF0*)<.=T=1:=S:LUCQ1.M9/@[AK&>7+W
M6F]R@9$]J5R+AM_E]6H0,]','42@YK:<<I&'D2B[:/5=G"(`D(%&CMU:R*ZD
M?&0ZUC:\BH-:LU4!Z,E='MKI9+5C)`6W4CF--#AI?HJ1GC6M,QDHPYXYT9^H
M^3+'6L'4\^3'S3G;PJX_RU2O-EH%-@HNG\@>/,1D]W5:-/DJ#B606M\F_*1Q
M,2ZD@XAWO=40#X,R;<FLO]VNH+DQ6@U/^8C9I<!2CHVNP(%<S0U)-3A@*#/L
M]MM9H&R73M#3:S2`M!)K'(6U<*TP`R%`12N.*[?-OFVUO!EPO51L^*JJ,C@:
M'QN[Y*03CDMCB(OU6L5^KL+;Y.FX&H$A!$F>2$KCZJ6!J^D5VYJ\V>BJ#5@+
MEV!TB9-SO[+61T<D;:Q!O:#M&AP+@"6QM(K(6@@GX:Y"IP5EKL,EU&R1DCM,
MQ=V1[-Q:0TD`R.K2,.(('Q$9F@4_>1_(*,X\XN1R#^Z\QD6:LEUQOB_&-"K[
M^/A9/(63<OVJ+IN/*RE-SG1%UMA(RTL19[(.BF3CV"*RPIJ&("1]O>W+;.#M
MM.MSG-:UHP+G/(:T5.`Q.).0JM196[KR?L=08UK7.<XXAK6`N<:#$T`P`S-`
ML9_*GG+R96QK*XDQYB9]AGE'#\O>*?'#*D76LT8^F30%&Y*+I6"DW?"V5[9C
M.4JS\^3XABZ@T9&5JZ:]7?)NG"S)<$$3*<_N&[WAC-K!'V=_V\;'`.!HUY%'
M,<64][X?>;4&ITFE3O+#;;+MA<32=I8&WED:2QPJZ/!S7L#@?=-'4#O>%`"*
MJ=&?>19N&7%JO90R!&6"^R\*IB+'<LO<+W5X=)&WWR5A:>:UYCS`A6HJE5:F
MP$R_,XL-I3AD&":1!629%!5-$-S=W7^&V#9Y@7O&AIJ0,7$"KWT#6M!-7.I3
MC1:FTMO\2OS!"0QIUN%&DX-!-&,J7%Q`]UM:\*\5TN+.9,A=;CQGH-JQS48F
M:Y-&Y`+U:S8HSY3L^XN3@L#5NHV-6QPU]J<##-K*RN(6H6J2!F[!W&N&2H+I
MG*=,1AMMS[:2&)\;09S)0M>'MHRF(-!4&O(9<5?/8"**>6-[BV#LZA\9C=60
MD4+232E*YD&N"M=&>8O-7:1Q!5L1<9+;DN^YIFN:4)6ZT.5J-2(R&-PLS`PQ
M%:IBTVNT1Z3-E!W%Z_*\:F:MWCQIU)H?#.1.95.+_&'/[-MO`Y\LIF`%0*=B
M\,))/`UK@"1RXC(=M+8A))<3M9#$(23I+B>V87@`#B,C6@.=0OCOS#[42=CY
MR*XT/I3`*W+:D\)WN8'&:*U&SO\`G9/Y(BL16Y]!8M)4G[V?QG0LD/74.>5&
M69NY-Q'+*H,R-1(N-#O#^U&F"MK\PV'7J_&7!AH-.+6NJ/B!-":4Q5!M3-!:
MZ>EW\NZ;1H--`:7BKJX.<VAI0@5%37!=31.=-UG$*[CG&6-[%R#SM?\`.'-^
M&@H"]7JB8=KE3Q9Q2SJ_QI:+-:+Q!4B39M*U%R<O#PE=:HPDE.29G29GZYCI
M.78H]TD=2&",S73Y9@`2UH#8I-!)(!P!+0/=)-<3@2KI=MC:3-.\0VC(H"2U
MKGDNECU`!I<,2`7.]X-%,!B`NJY3^:&GQ"7JZN7,58XADU:#1[SD+'ZO*V@*
M\A*N%FF!AK%'4W#</3IM/(3*F+?M"2:TU!L9PA%"LC"HF)=6WV]_X>1\Q'&/
M<:YS>U;V@J:'2P`ZJ<]30>"NL-E.XAPMI)"=;FM=V3NS-!45>2-->6EQ;Q4D
MN,^3[S=\Z>8-5;59'<Y7<0<GJ+1L9QSA)HBA5:A+<6<$WY]#L#-VR#A9L[MM
MLD'XBX,LJ"CHQ0,!`*4N=8RR2W5VQYJR.=K6CD#%&ZGI)/G6%>LBBM;.2,4?
M)`YSCS(ED;7T-`PY*S5@\Q"QU^S91DU^-4PKQ^P=RTB.(N5LV!EZJ$FHJU6.
M?QU4XB\US$85X\U/4J-LN4HA&8%:38NFB*QEFI'Q4E0)B.W=[9'N,!^3BN!$
MY^H5!):`X-IB`7#5B",P"LEFTM>R-HG'SDMN9F,T&A`#B6E]:!Q#3IP(.1HJ
M6K/FNXXM?(&M8IB*E67F/K=R4E>*$+=V.=:)(Y=+DN*LDW1CV^6XSM(\UQB<
M+O+]7G$4E-J2GQY2&1?*QR;)8JNHQO\``;GL@QI@,QB!#VE^H$BO99AA<"`X
MFN1(`Q4C]CG9:.G<YPF;`)2TL<&:2`Z@E^$OTFNFE,QJJ%PVOF"9`R;AC%^;
M8S!V0,*XGR%R/P?B.LY!_P`QL0VVPW*4LW*Z/P)/U\U!=5^<=P^/YY%!TJO+
MK_`3'PA52,TVCCX=V>C=VFGMX[@1.C@?,Q@=5I))E$9%*&C3S-'4K0#`JIVN
M*"YDM72LEN&0O>6Z7@`"(R`ZJBKAAAB*YU%0J_K/F&V"4MT#*S7&B7@>.\CS
M1LG!M[F@^7ZI*333*\9EJ:PQ6;&.)6E?2F!QG:;[%(QJKU641D8]P_3-\&X;
M$%R:0;P\R8VY^6^8=#KU#XP\L'NTI1S@!BX$5R(Q43]J:V,M;.#>"V$^C00-
M!8'D:JTU!IK2E"!F#@K*<.>=F<7M1XWL>0.,9*9J'(#D?R2X^U3DBODNH.9E
MW>*9DKD+,4EG.X@AJXV>0V/T:)BA>#0E3R7QX.XXAUV`(K$<'@V[=+HQPB[C
MK'+-)&)-0J7!TA:"V@HVC"T&M:C$4-5D;CMMLV28V<@$D,,<ACTFFES8PZCR
M<7:GZJ4I0X'"B[O#7F\8VS)?J/"0]&@"T',3#+#O#MD@<\4*ZY-=FQ93K3?6
MZ^9,'0,:,_A2'R15Z:^7A'*\C*J(*BW;R*+-PX(F%]MO\-S*QK6-[*37H(>T
MN]T%WOL&+`X`D8G@"`316W.P3VT+W/>[MHBS6#&YK?><&^X\X/+2X:J`<2TD
M!5:AYC-X<<9*%RGF./-`P[CS+$1B>?QD\Y%\P\88Q:62)R959*S*JN5X6G7N
M18RL<#9H2.BD&3V6F&[[XDS9C\,X1)>-XE-DR^?"R.*0,+>TE:T$.:79@.Z*
M``DUR!!"C.TQB^?8-F?)-&7AW9PN=0M-.);AG4U`%*5-05T.&.=TKRBS!Y?M
MGQXI+4G&>:ZYY@T3E''2DG#V2.D;UQK=X_J,:LUM;2.;C8(&%LII)U$2#8C$
M'S-Z0Z[<AOV2=EON9OKBS?#[L4HG#VX$5C+6Y\0#6A%*@XA7W.VBPMKQDU'3
MQ&W+78CW9=1RX$BE0:T(P/%2ESCR=R'C_-^-^.N'\"#FW)^3\190S#%&E<MU
M_$=/@8/%EJQ_5)1M8IR7K5JD#*R[W(34C06+%VKWP`JB143*.$-A=WDL%TRT
MMX>UF?&Y_P`0:`&EH-30G'4*4!]&(P+6TBFM7WMS-V4#)&L/N%Y)>'$4`(RT
MFM2/3@8C6'S><?FIF!)B@X_K3FYYLP$[Y'/J;F[D)CSCU%4>FQ]JDZ"K4PNU
MCC+(RNV2IF^5Z5CXMA'LRLED8U1X[>,D#I=>M=WAA,<9A8WM9(NT(D>V,`94
M#C74XNJ``*>Z22%L6;!-VLK9GN[**;LZLC=(7&FJND$:6AI!))KC0`E7@QQY
M@DQGF[TJG\>N-5RR*UM_'+CWR=?6:TY,HF+(RET+/U@OE>:PUC8SJ,K+.[G5
MG-`=B+2-2>H/Q*H'?;%(F=QDQ;LZYE9':0.>'0QRU)#=+9"X4(Q-1I.50>8P
MKC3;6VTB=)>3M86S214#7.+G1AIJ*4&DZAB:4Y'&FW'>9=C)Q0\.WN4H]IA$
M+IBSE!F'-,(O)L7<UQJIW#Y%["YM"Z-D&1362:C<JHMZG'-6P,QD'[D%RF*D
MF8HAO,/91RN80'1RO>.,8AP?7F0^C0,*DU1VSSB:6)KVDMDB8PTPD,V+-/(%
ME7DXT`HN-Q+\QZ!Y.Y7;8D>4.JU"<L^'WF<:,YHF?J#GQ$M2BYJN0TU4LL$H
MT;')8IRO$EM\<Y-$BM+,'*1W!6\@JHT5*+;]W9?7'RQ8UKW1ZVZ7MDP!`(?I
M^!XJ#3$'&CC0JNX;2^QM_F`]SF-DT.U1NCQ()!9J^-AH17`Y5&*O%=N5-SB>
M3CWC!CGC]-Y/G8+$>-<WW&]*Y1I./:=4*'?LB7B@NU9`EC;.YJ4FH4*(Y>MV
M;!NY&0*)DCG9]`*JSS7TK+[Y&&$O<(VO+J@`-<YS<>.&DD<\JCCCQ6<;K'YZ
M:81L,CF!NDN<YS6M=A3``Z@"213I44L.>;MC7,F0J/!0E(@!Q]F)KEE;#EG@
M<[4.YY->&Q94+5>VSO,>"X.-&PX4A<DUBF/EX1RO(RJB"IFS>119N')$PP;?
M?X;B5C6L;V4NK00]KG>Z"[WV#%@<`2#4\`0":+/N=AGMH7.<YW;1EFL&-S6^
M\0WW'G!Y:2-0H.):2`KBX2\PNT9-6P&_OG&UUARH<L,`W#.O'"SRN<*3:260
MU"H$'DRP4G)B+*`AF&*'KZESI9*/D57DDS%BV<&>@R72,W"2VWETW9&:#LXY
MX2^,ZP:T:':78`-P-0:NP!K0X*&ZVID`F$,_:26\P9(`PBFIQ:'-Q.OWA0B@
M-2*5&*C>Y\W*%O.*N8+1C'URIY`P%QB'D5&73C7G/'O)>LKUE6X$I#QI$6Z<
MQI!4Q#(%>G#H]35U$S$,[:.2K(N%>DQ0PW]XHWPSMHULT<.L.B>V44QKB6@:
MA3+2X&HQ6:-A?%<6Y)<Z&6?LRV1CHC6E<0'%VDCB"T@BE%/BC<J+KDCD1F#"
M-.X^3SZH8#R76L;92S=)Y.I,-`Q[JU8:IN78QY6Z*LW7N=I?HHW5JR>-$R-T
M&Y1*X([5$QFR6WBO99KV2TCA)CB>&N?44Q8UXH,R?>`IAS!.(&IELXX+..ZD
MF':3,+FL#23@]S#5V0^$D''E09J@^3O.T^`\WT/C]7:!0K)?+SCIWDR,?9DY
M&4GC%3;$Q0MAJ>C0L9VF\5VQ,LAY:<2!!<*PR8,DV3)5!99P`."`$.X;J+&X
M;:M8QTCF:O>>(P<=.EE0[4^OX12@H2<5+8[:;NU?=O>\1-?I.B,RN&%=3@TC
M2SIQJ:@#!4_>_,+D:58,I3Q>/D[+<<N/>7*+@CD+G$,FU=A-T/)=O#'Z,_\`
MNMB88AV_R%2,3RF4(9G8Y5.7CU@44<G8-'J;4YC62[OV;GO$)-E%(UCY-0JU
MQTUHVGO!NINHU'&@-%?%M0E9&SM@+V:-TD;-)HYHU4J^ONN>&N+10\*D573<
M=^7UJ/D^0Q#DH9F[S65?,2\P'`>/;`9Y&,6>.:)QK@%;Y7H%RR;QJ:LS&I0T
M>I'M1ZR."'4!1514`VU#M^Z.DNS:25<7W,K6G#W6M#G`4ZFT\ZOO;%@MQ<0T
M:V.S@D</S.D(:36N!J:E6^L/F#9_MF>^.=+X_<?H>Y5&\96\P+#E\KUKRS5Z
M3+6"Q\.IUG4D9:$LTE4I8M:C!526FNCLJF>HN2L3&`Z0K&AFWB[?>PP6<37-
M,DS'`FE>S=IJ#3"M">CC@I6;7:1VDTMY,6R-CMWM(:2`)AJH0#B>'12O%5Y6
M><ER=RCW&./,>6'/.=KMRVYC8GH=-N=XHN):O6:+Q>EX<+U/3N0(:E2*4?0J
MF6QQD;#`I$2]ADW4DB5TJ<"JN$\ANZO#S!%&Z6Y=/*UH-&M#8S1QU-:31M0!
M[I<=0J<R(G[;&&B>9XBM6V\+W$`O)=*#I`:7"KC0DXAH`-!P7,@?,1M639/"
MM%P?QAG+KE[+E2Y*RDW1+MF*G8SBL0W+BAE6J8;RW2+K<ON&WH30(7>S]B.D
M(9F\!ZF5%7X=-%915M<-X?*8X[:`NG>V0EI<&Z#$YK'@D!U?>-`0#7.@!J*/
MVID#99;J<-MXW1@.:PN+Q*PO8YHJ*>Z,02*8BM1C0#GS8H6:BN-1L?XDK+>S
M\C<,R^8HN%Y"<D<?<;*\T<5V_O,73V(*9?K/7[-`Y.S"RN<4Z#[N:%9-@C2H
M/%%TR.2$+`>\,;FQ&*(:Y(RZCWB,5!#2QIH[6\'@`,,:T*F&Q/:Z;MI':(9`
MPF.-TAQ;J#W-!!8RG$UQJ*8*8O,/,\MA'B_<LMI.+/5):#=8B27&KA3Y:R0S
MFZY8QY3G\8V&UQ-BI[X$PLRC1TL=LL4S855&IB+=E4FVW*=UK8NN,6N!9E0D
M:GM%,:CC0X998T6LVV$75^VWP<TA^=0#I8XUP(/"HQZ\*JP-S\P^R56YY75#
MC/+O,%X.YB5CAQD_,)<OU9O,L[?=[#C*J5^V4[$YZ\XG++6(RPY:B$I8CJ2C
MEVZ"AE&HOA(J1/7#>G&L@@/RC)VQN?J%07Z`"&TQ`+Q7$$<*K,CVEKXXQVX^
M;EMC,UF@THT.)!?6@)##2@/315:ERVRODI;-SS$N`'3K!>-)[/V(G'(I]EZI
MP]@2R1A2"M<5;+;6L+/*\YD9S'5:R9`*09'QYA&1=.T#N$XT[0@J&G%_<3F7
MY>'_`$9A>WM"X`ZF!P)#*8M#AIKJK7'32E8ODH(>R%Q-_I3Q&_LPPD:7D$`O
MK0.+3JIIH!AJJK?\6N<4E8<#5U/(41/7#(F,?+#XT\W<DWA:3BV@Y'?Y/Q[D
M"3FH=O'MHM%&'G7$MBAZX5<[&:B:2(!$"`D8#1V.Y%UJ!,"Z9EC%,YWYB]KJ
MCH-6FIRQR4U_MP9=GL2&POOI8&MI\.ES:&M<11XZ<,U:/DWYB>6IWC/R*L/%
M+#T@O8,9\%*]R0R)E68RK6*<.`)S.6#9G*^+(6H0DG4+(.7K_4JVV+-R#<Q(
MB.*W!NF591=P"!,2[WF:6QF?M\=7LM>T<XN#>S+FES0`0=9`%3D*4Q)-%DV.
MTP,OH67\GN271C:P-)[0,>&N)((T-)]T9G/"@JKC27.^<QI.988.*G>LUS\+
MECR^L%UBB)36.:4R"Z<M\/PLXWD*Y9'<(P53CG5@>B\EAGW;GM+G,#-1NW*"
M.I/\9=#,^(M?+)KB8![@%7AN1H.+J^\2L<;:R=D;@]D3#'</+J.=[L+R,17D
M*#2!TU*J4GF$V5JQME#G..3QKRJ@>4-4XF0>"(;+M?FJ?;;_`'G$;7/M<MC3
M-SFJPS*)QRRPX=U+S#MQ`_'L%(]9JDS<JG1Z\C_&'M:Z-\#OGFSB(1AP(+BP
M2`Z](.G14GW:BA%":5C_`,+87-E9./\`#S`9C(6D$-:_LR-%35VNC0-5#6M1
MBI'<8>14[GYAF9K;<8!B2\8(SC8<"WBKHWMADB)7LU<IU$N3B:K]LCH"L)OX
M)\QOC<J`*LD5P[1NX4AA$A<W;[M]ZR0O9V<D4I816N(:UU0:#"CAF`>86%?V
M[+-T1CD[2*6(2--"TT+G-H14X^Z>-%!/(O.K(%;\Q"&I[#(E#8\2Z!E#$G#/
M+U'=_NH-VEN1W(>AV*_UK)4:_<J!;VU9Q?.O*15'S=OLP5=6AP=8.XUW+J9]
MVECWMMN'CY%KVQ.%!4R/%0[5P#28VTKCJ)I[IIMH-MBDV8S%CS?OC?,QV.D1
MQN#2TC*K@)'@YT:.:E`/.>'"0=4L<8SX9@;<WV?"7_*O]XH\9-63?Q*61F^8
MB2P1G:_R\-Q].>\"7X<5@:HG8]??#N:V'^)MKV>AWS'S78Z:CEJUY?#V?OY9
M89K`.W.T]KVC?EC:=OKH:4KIT4K\7:?N\\\:45GJ5YFU6G^5S+BS.U7&!Y6S
M/LU152G<1\D:MFZ5C9?"E<F;E(Q.7*G`TN":XVD+)5X!RH@DWEYQ6/?IBR>$
M24^UJ*'>F2;@+!S6:G%X!9('D%@).MM!IJ`>+J'`JZ79I&;<=P8Z30T1DA\9
MC!$A#06$N.H`D9AM1B*KCXE\S)2WQV"+YEWCU+8+POR4X]Y2Y"XIR$XRO5\D
M3!8#"V.H_+%]C+W2*Y7XU6J"XQ^[6D(==)^_4>%:F2=-V*YRI!'#OH<V*6ZA
M=%;31%[':@[!H#C4`"GNFH()RQ`."NN=F$;IH;:8374$S8WMT%HJ]Q8TM<3C
M[V!P%*X$C%=O+^85=,>X"<<E\W\77>*<6VV$Q;(8*,ZS[CB7LM\GLV6:"KV,
MZ1DM@[BJ]"80FY-E9&TO)/5Y&;AH>-2==]T9PW!!65V[2Q6?SUU!V=NX-[/]
MXVKB]P#6NJ`&'$$FKF@5J:BAL;M<4][\A:3B2X:7B3]VX!HC!+W--29`*$`4
M:YQI04-5O8IY$-^>M.S+1(>*H]0R=@:U03.8_<_+,-G/#%MB\IXQMT7&2%1R
M]4ZY$%="YJ]CEVBX*PJ3ZOSS%(ZK9RW$O>NMKG_%XY86!C9X7"NEXD80]I`H
M]H'`N'PU:X8@C.VYM_\`!Y8I7E[K>9IIJ88W@L<*AS"3Q`/Q4<TY@Y7FXG\;
M'''MC*-5G::44#-Q$U:#5F$[98&;&4D&,U/O[C=T:[4D;-).I:.13CB$CR?=
MT<GVE%W*AS'+E;=MS[-I#LJ4`K4XFIJ:"IKEA@.)6+N&Z-O""![V9-*#"H`:
MVIH*9XXG@%%J?Y99LQ_YC.7:5:;/'O.(<$QXSX:^XU*[!-7>+,T<C,=V^V8U
MR4\MJ#%*=?5NZ7VF?N@\:OG"K-H^G8U1(J8=S?6/W"ZAWJ2"1P^0'9LI0#2Z
M0$M<74K0N&BA-*N;2F*V++.UGV2*:-O_`.1)E?6I]]D3@'M`RJUKM8(Q(:[H
M5J:#YK,E5^.G#Y.Y1M`R;R,RKP\JG)W*+S(^;L;<7JH,-)/'L`W1K\C.P$E'
M3^1;U88A^G&0<?&M6""3)19X[9IF2[D,._.99VXE#'WK[82NUO;$T@X8$@U<
MXU`:`!@:D"E<F;8Q)>W/9:V64=T8FZ8W2FHQQ`(HUH(JXDG&@!Q4K<=\_)?.
MM[K%-X]<:[AD9E8>/7''DL_M=HR51L5QE2H?(M_>F,9#S\;/(2LTYNM94H;G
MN,H]%X@\$%/]X;`FD+C81;J^ZF;%9P.>UT,<M2X-HV35@1B:C2<J@\QA773;
M8RSA=+>SL86SRQ4#7/)=%IJ010:3J&)I3D>'$8^9CBM7'^(<AR5)M4/'W'"?
M)7/6:(E608N9OC=2^)Y%*_EUE<FB31,;)9&V703J$>T;_!_&R`G7`Q4DC%U;
M_C4'8QS.8X!T4DCQA6-L6#Z\R'^X`*5->5%<=GN!/)"'-);+%&P\)738LT\A
MH]\G&@ZUKXF>8K!\F\K#B)_1:I3[#,XA5SC37%`S]0\_L?W093T#`353R>O1
MHV-1Q?EB#5M4<NK$BI*,'**J_P`+(+&:K!JNW;LR_N/EBQC7F/6-,C9,*@$.
MTCW7BHPQ!QH30IN.UOL+?YD/>Z,2]F[5&Z/WJ$@LU'WV&AQP(PJT5"R/=[^<
M/];\^MUH6D[8=*=[^</];\^FA.V'2G>_G#_6_/IH3MATIWOYP_UOSZ:$[8=*
MZ(RX=1O'UCZ_?^'62&FBQW/Q.6:LAR$P;4.2N-_\IL@2$PA1']UQU;+="1/W
M:+>]Q&.[I#7HF.[0G*,9!%S1K=*P#9"9;ID(LZ8@=`%"%4/OC7MBR^@^7FKV
M1>TD"GO!K@[2:@^ZX@!PXC!9-E?R6$_S,(;VP8X-)K[I<TMU"E/>`)TG@<59
M:S\%<0C;;-><*O9'B=8[M@RWX!MCWC55<;XY2FJM;+5!VMO:3,VM/48MLD4M
MQ&O6\%-$3%Q'H3+H0`RA6YDL-VR6XD=+:$V[WPF,F,-%02#7(^\VATNX:B<\
M5ELWNY[-L5T!<L9,V0=J7.H0"*9_"ZH+FY'2.E4@'ERX2@ZC;J!B^TY%PY1I
M.ZX>R_C6JT1_7U(G`6?<+)M$(7-F*$+)!38-K'=4(UM^]<=)_>$-8%@<.%FQ
M7+YXLM%_N_:MC=%`Z2.(N8]H;2D;V4H]@((J:#4'5#L2<7.)D_Q^[?(V:X;'
M+,&/8XN!K)&_.-]",&U.@BCFX`&@`'8DX!428J-P;W/*^8+=G*Z9IJW(IURB
M8.:?2\P5G,6/ZHVH6/;%C^-JU5;X\JE>I>/VQH-&!&(=Q3Z+>/$GZ;H7:IAN
M_P`"B=$YLLDK[IT@D[6H#P]HTM+0!I`#1ITEI!!<#7453_'96RM,4<3+1D1C
M[+WG,+''4X.).HESO>U:@00"VE`N!-\!83*KN\2?)_/^7N2,K<<$V?CFQ<R\
M-BG%#2CXYM=QJ609%Y4V&):-7#IWQ"[4.'DFLNZ7<?"N&!.TW*03%&AV)D[I
M'WTLDSY(C'6C&4:2TU&AH]ZK6D.-:4%`JMWQUN&-V^&*!K)A+@7OU.`<T5UN
M/NZ7.!:*5!S522_#JRY`QQ9\99UY:9RS?"3TUAN9BW,[5<'TIS6W&%<IUG+,
M,]22Q[C6OH6"Q6N;J;1K-R,AWC+L@,#9)JJ85!O=M4DT#H+NXEE:2PBH8VFA
MX>/A:*DD`.)X9`*QFZQ03MN+.VAB>`\&CGNKVC"P_$\T`!):!D<R5(6N8?KE
M9SMFSD"RE)M>V9VK6'ZO:(AT=B-?BF.%FMW:5M>!329IR*;J33OCH7HN%UR&
M%)+M%3`#]69'9LCNY;P5[29K`1P&C52G''4:UZ*+"DNW26D5D6M[*%SR#Q)?
MIK7AAI%*>=1HROP*J&5+EE:14S'EFFXGY$V&B6SDOQ_K"5$4H>;+#CZ/K<*Q
M>O;'-U.3R%1&UMKU-B(VS-H*3:)3C&/3(;LG.LHI@W.R17$TCS)(VWF+3+&-
M.EY:`,R"YM0T!VDC4!PJ:Y]MO3[>*-O91/N(&N$4AU:HPXDX`.#74+G%I<#I
M)XX*K+=PMQI<(#/]<D;1=VS/D5R<Q?RKMZK%:`37A;UBE]A-_`U^M`K#*HHU
M)^K@F+*Z3<E<.Q*[==M8@BEVY';/"^.:,N?IFG9*<JAS.SH!AD>S%:U.)QR4
M<>\31/A>UK*P6[X6UKBUXD!)QS_>&E*#`8+19N)<M_F_DG+&).2F9>/Z6<+#
M6[AFNAT6"Q'9*Y=KA68*(J:=QK\ADJ@6ZP8UL]@I]?81DLYB7`)O4&:2H)).
MBBN-7[4X7#Y[6:2!LI!>UH80X@!M1J:XM):`#0X@`X'%49NK/EH[:Y@AF,((
M8YQ>"T$DZ2&N`<`XD@$8$G&F"KB#X[,*=6>1<+CS*&1<?S_(S,USSM(WVOA3
MW=FQY=KJQIL>]2I+6Q5F:K3J!:-J2@F5K+L9'OHN7":IC`<HDDCVWL89HHI'
MM?-(7EWNES7$-&%6EM/=&8.943]Q,LD#YXXWL@B;&&G51S6EQ]ZA!K[V;2,A
M1=1QIXN0''&6S!<0O$QD;)&=['5+'DJY2%.QMC:.D7%&KIZM5F\1C[$E6J%*
MAS-(I947;SX9>2DW"HJ.7!P(B1.W;MJ;MYD>'.DFF<"YQ#16@H*!H`&?6>=`
M`+K_`'1]\V*+0UD$+2&M#G.IJ-35SR7''(5H!D,U9DWEZUG]]#RC7/F98_&!
M.7D9S>88,CXO%"-4+G=O;RWF6<S5S4H*^4+/49>RF571C'4O_P!V][H05%--
M`B6+_@$?S':B63LA<"<,HR@?JU''3J()X5Y8T`IE?X])V6DPPFX^6,!D)?7L
M].D4;JT`@85`QXC$UOGR>@\43;3"\[EBUS=83P_GRE9XIS6`12=/K!<,:1ED
M1;14HR/'2*PU5)E9UE9)<HM`;=*0F<H]8`?,W"&![8GW+BT1S-D%,R6@X'`X
M8XG"F&(6)M\UPTRLMFM=VL+HW5R#7D8C+'##.N.!4:B\*<<9KD;S;*CR4S5&
M89R-R?HO*^T8,@HK&[&N)<A<=VC'5S>.)6:LV.W658ZO6.6Q[%O'M?._0;@J
MO\8V4[2J.M>=H@NG.DCGE%L^=LIC`;3M&EIQ);K`):"6UXU&!"V'^+SVH9'+
M!#\U';NA$A+R>S<'-P`=H)`<0'4/(Y%7WJ/##&]-R52\H1UFN[F;HO('EGR-
MC&#U>"-%NK?S#C%XK(4,_(A"HNS5NMH.!-#%35(Y(<`^)57#PU/%LMM#=B\:
MYYD$DCZ&E*RZJC*M!J-,>55BR[M/+;NMW!@8^&&,X&NF$U:<\S^+AR`50<F.
M.DYR0B0K*>>;MC"ER=8GJ?>*+%8XP7D^H7B)L("DO)NHC-&.;R%?N48R46;L
M91@=/L)+&ZT%3%3,6_<=L_Q!H89GQQTHX`,(<*UQU-=0]6%,""K-OOVV+M8B
M9)*'!S7%TC"TCA5CFU!S(/I"C=?/+$Q[9:UD7'='SWGC#F)LR\>,7<;,OX]I
MI\:V`;Y3L+4%[C'',RI=,A46U6ZNV)K2'H,)8\>X13F444^X5(W68V'+W>A>
MQ\,4TL=O+"V-[1H.IK&Z6G4YI(.G`T^*@KBL^'O!/'(R>:&&6YBG?*QSM8TN
M>[4X:6N#2-6(K\*N=D#@E1+JOE&<B<EY)H=[R%F[CAR(@KQ`H4R5=XTRIQ=Q
M]7<;8[E*Y`V.N24!.PLC7J__`-[1\NB[2='>+`F9$O;`DL^Q6\TCYFR/9.Z1
MCPX:3I=&&M!`+:$$-%0:UJ<ECP[S/$(V.9&^%D4L9:2X:V2N+G`D$$$$X$4I
M09KZXX;VJ/O%FR+CWEWG3%=HRM&4$G(1S5*?@>09YEN./JRPIC#*;6-MN,[`
MQQ)D2:J<6VCI!Q6R-V*S9JWZ6I%D2+:O.TR"5TT-S+')(&]I01^^YHTZJ%A#
M'$4!TX8#"HJ@W5AA;!/;0R1QEW9U=(-#7'465#@7M!)(#JFI.-#12"Y`X3K'
M(O&;K'-EE[/51;V:E7VG7FE.V+.Y8\R1C:SQMRQ_?*PYEV$O#J3%:L<2BMV'
MS1TR>(BJW<)'25.&LR\L8[V#L7ES?>:YKFGWFN:06N%014$<00<BL*RO);&X
M$\8:[W7-<UU=+FN!:YII0T(.8((S!JH\1O!.HN".YW(N7,GY3RO8.2F!.3UX
MRY.,:#7)FUVCC3\.AB2AH52HU>*IE4QA7XQ`[<6$<T3=J&=.7!G0KK&.&O9L
M4%1+-)))<]LR0O.D$EA&EM`*!HIP%<2:U*S7;S,/<@CCCMA!)$U@+B`)?C=4
MDN+R<:DTP`I0*4>7:;9,DTIU6*EE:WX8G%9*-D&]WID)1+.^!!BJH9Y7YBL9
M)K=MJ%CJU@;JF1?LW#0#J)["FJD<H'ULKJV=<1=FR1T3ZUU-#2>JC@00>/J(
M6OMIFP2]I)&R5E"-+BX#K!:0X$<"#YBH35ORX:G0V-`FL9YVRACG-%%S-F3.
M!LTUBF82;JSUEY!5>%IF7((^(#8[##-<J$_7JQ%@S9QD.W/'O8\CSN+.%7)E
M]3%W>A@:PV\TC+EDCGZZ,))>`'`M+=-"`.%:BM22:[:3?99G/;/#$^U?$R/0
M728",ES#KU:R02:DNQ!I@*4N3@W@WC?`\[A&R0=]R?;IK!;7E@C!R5V?5AX^
MM;GF'DR&RKDJ5N2\-7(1-U*1=CA"%C3LTV20(JJ=Y-0W2)<FTV>"T=$]CWN=
M%VM"XC'MG![BZ@&((PI3IJL>[W>XO&2L>R-K9NQJ&UP[%I8T-J3@0<:UZ%#:
MY\+L^6/D=&0-):7S'7%=ASAHW,Z<:2V=L1V'%$M8:O<8[*MMD*9BF*Q*EGF,
MLN2\@L!4-"2EI+689XZ=221E3&1;%U<NT7<E^&Q!S+$739C5["PD.#SI:&=H
M"YWX2_0#5W(+:1;K:,L2^4L?N)M'0"D;P\`M+&ZGE_9D-:?B#-;@`T\2I3&X
M#UFOFJ=BQ%F[+&'<KTC)G)W(5>RM!QF-[9(GB>7.15LGY?QA8Z==JC,4NRT)
M6TD9+Q8+-22,>O%MEBNCG[W=V/\`@D;"V2WFDCN&OE<'#2<)G:GM(<T@MK2E
M<1I!KG77_P"-2OU,N8HI;=\<32PEX%86Z&/#FD.#J5KC0U(IE2B\E^6U$9-;
M9KB9#E/R&AX'DWCK&U%Y*-8Z+P@ZG\R2F+*RUJ->NDE<)/%KJ9J+F4A&2)):
M(@_@(9X=/J20;=Q8%(+CN]'<F37/,&S,:V3X*O+0`'5+,#04(;09TI4UEM]^
MDMS$YMO`7P/<Z*IDHP/.HM#0^CJ'(NJX<2<%-#&>'*SBR\<@+[!R<X_E>1F3
M(#*=O:2IV!X^%G*]BNB8C:,*V5HT:N$XI:`Q\T<*`Z.X6%XLJ)3@F)$R[6"S
MCMY9IF$ETT@>:TP(8UF&&5&@X\5JI[N6XAAA>&AL$98*5J07N?4]-7$8<**!
MU%X'7FQ9&Y%2F:,O75A@_(//.:Y307'2KH8R6I.1FE?)BN>QC.7FY$JSG*<8
MR+>:&D^DJVG+(-G:D6U[@$1.JFMIX-EF?-,;J1PM771E$8TZ74T%I<=.JFIH
M);7&@R%:[F;>8F00-M8V&[99B(RDOU-)UAX:VN@G2Z@=IJ*GC2DC<;<3I?$&
M15YK%G)+,M1PU(9<LV:GO&MM`XCEJ2:X7FQO[G=X**OLQ07V68+&UMNDLZE7
M4$UEB@FY=*D;.$&YQ1#-CVIT,I-O<2LMG/<_LP&$:G&IHXM+@TN)=IKGD:8+
M`GW,7,`;<00NNA&&=K5X=I:-+26AP87!H`#B,AB"<5MP_"G&,+QUQ!QF0M%Z
M/2L,9IH><:].++P`VB2LV/L]N>0L5%32A(8D6>#=VUT9FX*@V1<#'``$4*M^
MUU<W:+=MG'8ASNRBE:\'"I+9.T`.%*5PRK3I57[M<OOI;\M9VLL3HR,:`.C[
M,D8UK3'//H4>N/G!.^Q<V_FL\Y<NCRB5[G=G[EYC_C7#H8S/C)Q9)W.%SR%A
M>\6:YQ%6+DV8)$HSC><&NNI<6C:=(0ZH"1`C<NOM-DEU.=>2O[$74DK8P6TJ
M9'.8ZH;JPJ'4U?%2OP@+-O=XB<P-LXV=LZSCA=*2[501M:]H:3I%:%NH-J6Y
M9U4A:GPJQE4*1QQH;*S7=[$\9>1ETY,4YQ(JU]5W8;C>9#-4C+5^V`E#(M7%
M414SI*$23:IMG70U;`=8P@J*F>S9[=D,,`<_3#,Z0&HJ7.UU!PR_>&E,<`L*
M3=KF2:>8M8'3P-B=G@UH8`1C\7[L9U&)PRIU&(.&CW"C%KCZH<F\W*<<8&'O
M->H_'24A<0.:]4*]=HR>CD:H&22X^)EFPTVB&L*JU>CWLJ8S(R#9-==T@@5(
M:6VTFU'8QSR_)`.#8R&4`=44U:=9#:^Z"<,*D@*ZYW7YH]M)!#\\2TNE!?5Q
M;3'3JT!SJ>\0,:F@!-5IEN#]<1QIPXH^/LN9'QC:^#41&0.$,JL(/&]QL1HE
M'%@8=G4K75;W4IRAR[RR4T`$723!LO'O2@LU,F43I'H_9H^PMHH9'QR6H`8^
MC2::=!J'-+34=`H<D;N\OS%U+-'')'=DE["7M%=>L4+2'"CN%348%;^&>#>.
M\+V+#5KCLA92NEAPO9>75NC)>[O:HZD+?/<S[6PN647]R5@JS!-G"\7,L`&,
M%BBQ(0JAP6(K]GII:[+!:OB>U[W.B=*14MQ,SM3JT:,CE2B76\7%TR6-S(VL
ME;"TANKW1`-+--2<QG6O0K_2.'ZU)\B*!R46DILERQUB+(^&8B$2.P"LO:YD
MVX8[NLU)R*9VAI0TTQDL:LTFIDG":`(+K`=,YA(8F<ZSC=>,O23VK(W,`PI1
MSFN).%:U:*8\UA-NY6V3[$!O9/E:\G&M6-<T#E0AQKAR42:UY>E?Q?"X9+@+
MD#F+"E]PWBF>P83(T5"8HO3K(V)YW(,QE!*KY$IE_I$W2Y![5[K.NGD+),FK
M%Y'F<+$$RR2RB8ZR/8(K<1FSFEBF8PLU>Z[4TG50M<TMP.((`(J<ZE;*3?)+
MA\OSD,4L,L@DTDO;I>&AM6N:X.%6@!P)(.&5%>B(QQCS`.39?.UTRE>K-?K]
MAC#_`!ZE7]Q;QTQ-W%OA.6R/;6-I0@*%4F4E(7:==9&D7$S\"R)&H((I"DV:
MIE,)LQMK!9SF[ED<Z5\3(S6A+M!<:T:VNHZCJH*=`6*ZXN+VW%I%&QL+)7R#
M22`WM`UM*N)&D:1IJ:])5!X]X=<8I2S\L\KPZDM?X/FS"RM,R;5I62$*E68"
M592L7E:I4>)(QBYVC+Y'M<BZF;.W<&!Z,_LJ((F3*0(8=IL'27%PWWVW0(<"
M<`""'AHH"W422[CJ4T^Z[@V.VMG48^T(<TC,D$%A<<0[2`&MIAIPQ5R,!8"O
MV$EF+&?Y5YKSA2ZU3F]%HU(R17L.QC>OPS`\8G%2EAM-#Q]5[?D2WQ,3%)L$
M9*4>?:;*+'515<*BN$]G82VI`?<2RQ-;I:UP8*#"A):T%Q`%*D\ZBIJH+V^B
MNZEEO##*YVISFN>:DUJ`'.+6M)-:`9TQH**OHW#E8C.0MQY()2$RO;[MA:A8
M,E8%R,>I5D:MCV[7R]1<BV0!H63&9D)+(3Q!UW'!VYFR20$3*?K,:5ME&V\=
M>U/:.B:PC"E&N<X'*M27&N-*44#KN5UDVQ(;V;)72`XUJYK6D<J`-%,*UJHY
MXTX<3^#Z\[HF-N2F9'F"JY5<E0N+^-5AB,1*U"M-[G`65E"TMWDY.A(9;G,?
MTV2L`GA&#N7ZV!44"+.'""!4]84&TNM&&*">0VK6N#(CHTBH-&ZM.LM%?=!.
M&%20%G3[JV[>)IX(A>.<TOE!?4Z2*NT:M`<X#WB&XXT`)4>./WEH*J\<\/8Z
MY=9=R3E28IG"R1XKQ>.DSXUKU0P2QRIBZO8^S3^X5AQY4H>2O%G6BH<L1&3\
MVXD5&T4D)"E4,X765PK+N_\`Z''%N,CY'MM>RTU:!&',#7Z2UH).%`230=))
M.=>[_2]EFVR..-CKKM2[WRZ30\N9J#B0T5.HM:!4]05QY+RVZ_=(')43E_DG
MG#*TADKB>'#1:7?0&%J0UIV'T+I&79@:E5?'^.("!C[.C(Q29%W+I-XDZ`QC
M"D39,I+W=VX)0\W$\KWOA[*M&-HWA0-8,1EC7AD``H&[_+$Z-UM!#&V.X[:E
M9'5?0CWBYQ)&.0I13+QGAJM8KO.?[_!R<Z_E>1>2*YD^WM)8[`T?#3=9Q51<
M1LF-;*T:-7"<6O`4!HX5!RHX5%XLJ)3@F)$R[>"RCMY9IFDETSPXUI0$,:S#
M#*C0<>-5J[B[EN(887AH;!&6"E:D%[GX]-7$84P5G.5G$UQROBI2EV'/%_I6
M)K=2WM#R'B:*Q_@N\UFTQ4DI(DDIV#D\IXWN-DQS?G<5)G8_?,0Z34112041
M23<HD7UB;CM(W$:'S/9`YNES0&$.&/%S20:$BH/(@5%5E;=N?^'.$K(8WW+7
MZFO+Y&D$4H"&.:'-J*Z2.=30T5N[%Y>&/9N>L\='9<R]6<`Y'O6,\GY>XQQI
MZ3(8^R=?<4L*/'P,M)W.=J\EE6`B;,3&=?5L\;'3"+>?<1@'4%(7#H%HI-B@
M?(:22-M'O:Y\51I<YND`DD%P!TMU`'WJ=)K,S?+AC&ET<3KQC'L9*=6IK7ZB
M0&@AA(U.T$M]T'C04[F?X)5A9S'V:@9ERCBW)]?Y79SY<U3)D)%XZL[^OW+D
M;"2-9RM2C56Y527J,Y0I>NRBC=ND\:J/FJI$E@<&.00-0[#`UW:V\DD=P)G2
M!PTFFL.#FT<T@MHX@5Q&!JK6;S+0QSQ1R6YMXX2TEPJ(R"QU6D.#@14T-#E1
M4U%>7G!U"#Q8;'/(S.%0RAB/-'([-4!FJ0C,37:WS<IRO?OW^:ZY;J[8:#^X
M,M#3RSTAFBJ,8T=,%6R1TS#L8AK6[!''H?#/*VY9(]X?[CB>T)+P06Z2"3RP
MH%([?))7R=O!"ZWDBC865>T`1`!A!#M0(ICB0:E5"^X'U=@[96W&.9\J8FS!
M!\@.0O(.JY=@X['=FE823Y1*LCYBQV^J%QJ<M2K1C:<"+9'0:O6AGK5TP;."
M.@42'KO=L<0=VT,LD=SVKWAXTFG:?&W21I+3AF*@AIK@HV[S*1V=Q%%):F&.
M,L)<`1%\#M32'!PJ:D&A!(IBJRPIPPQ?@JY87OE7LE]FK+AN@Y[III*UR,/(
MN\DSO)?)]-S%E[)F07+.'CCN+O/WZG%=)A'@QCFZ3Q5$C8$R(`G/:[1;VDD<
MK'/+XV2-Q(]XRN:][G8#WBX5PH!4BE*4BNMUN;N*6&0,#)7QNH*C2(F.8QC<
M3[H:ZF-2:`US5F+%Y<,'+8`J_%J'Y&Y;@<"1=#N&.K;C^1H/'O(36[PUYN%P
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M=4CD/F*GX6RO=<I9+M_'".B<6/J(>^9FC9A'(;V&N4Q1W^3X.J3]CG%[`I!(
M2H-`FS&4(<K8ZC4U6;3V<C^SGD;:R.<YT?N$:G@ZCJ+=0!)U:0::NC!5?NAD
MBC$L,3KJ-C&MEJ\.TL(TU:'!A(`TZJ5T].*M;(^7%5D(*LUO'?(?.F)8IKP[
MI'!S(YZBSQ3*2F6L(XWBI^+I2TM(W*@6(*7>8I.V2H*2D$DT%PC(*I=LG2DH
MGCOV"(M:R*:6-HMVPNII.MC00VM6FCA4XCGE4`C);OLNMTDT,,CC<NG;4O`8
M]Q!=32X:FF@P=6E.M<.\>6G3K-5;C0:?R%SGB.AY:XSXXXN9UK5(9XHD/\W*
M=B3'3[%=$M+N6NE!LK^DW=O29`\?).806B,HR(FB=-/ME4U;)W=@,;H89I8X
MI(1'(&Z#K`!:#5S26FAH=-`13#`)#OTT<C9I8899HYW2QEQ>-#GN#W"C7`.;
MJ%0'5H<5=.6X-8NF+;.7!>UWQ*0GLU\/LZNFR#BO`R1L_"VIQ]/QQ$MRG@SK
M!`V:.C2*393',X.L8?A56Y=BA,=AM3<?,:Y-?:1OIA2L>F@RR.D5]2QV[S<-
MB$-&:1%-'QRG)+CGF*^[PYU5M^1_#]5VWRIEC#S+)5GSM>.2>'>2E9<5+)F,
M<86/&%]QGB&/P*$YCR=R71+?0)2,>8U9N&\I!V1D\;2Y)-TF"R&R/19?[57M
M+FV[1UVZ=D@HYK2US6".K2YI:?=!!:X$'4<L*36.Z`&.VN3&VT9`^(ZF/>'M
M<\R4<&N:X'50AS2"*#`XJON`F#<J8'H.7I/-LJ[E\F9XY&7O/MB93-N@[_-P
M;>QUZCT^%@K/=*I4J'4K#9/N>B(N7QH:(8Q#11U\(S*=%N54\VS6,UG!(;D_
MOY9G2$5#B*AK0"6AK2:-QTM#16@P"AWF]MKR:)MI06\,#8Q1I:#0N<2&ESB!
M5U!J<7&E3B53,OY:7%ZQ8BRACBR5AI/7S+%OR+D:>Y-251QXMR1B<C9`R$[R
M4UNE7R.-1%Y"25`GCM$8!),OPS1A&MVYTU"=SKC?W?V^2!\4@K/(YSC+0=H'
M.<7:@:8%I/NX4H!G12-[P7[+F.=CZ0QM:T1`N[(M:W3I+=6(<*ZN)))5YT^*
M.,PY<-.:#E_9WN56V*D<:.(=9ZR2HDA+(HJQ`Y;=0#=@DJ3*AZ2Y7KGQZ:Y$
MB0:YFY4@\#!EC:[;_$1N=7?,=GII^&OYZ?GT^[7\N%%BG<Y_\-.UC3\OVFJM
M#JIGHK7X-5'4_-C51]Q1Y==6Q5,X,['(#,]HQYQCELOOL!XCEXO$L74J3'YG
MIMTI%C83DS6\?Q5UR#)Q45>77P$K*R*CT`(0%^\8RRBF+;=WX[:6)XEE='`7
M]FTAE&A[2T@D-U.H'&A)SQ-223EW._R7+)JPPMFN`SM'@O)<6.:X$`N+6@EH
MJ`*<J8*X,#P5PU$4GB?CN0E+;:*CQ'P_DO!]5BIU>&%+(-&ROB)#"MM0R&9A
M%LS*NUJ@B8R9HT6!2N53")1)L4)AL=MV-M`\N=%;1E@!I[P<T-.J@Y#A10/W
MNZ=+<SM#&RW,K9"17W7,?K&FIY\ZX*CFG`<CS$9\&7SE5R)R'CJKQ>-V6"4)
M-+$<!:\`R^&[1"6S$U\K=TK6.8^9O>0Z(]K3%JWD++]XMW4:B=!TU6%PNJ>,
M;%6W^5EN)WPM#>SP8#&6$%K@X,JYP(&+JUIB#4UD.^4N?FX;:!D[B[M*:R)`
M\$/:6EU&M=4DAM*$U!%`I38=Q_?\=L;`3(W(&_<@)J=?L'+>7NE3Q;16-:9Q
M[11J$96JSBJH5.);DDE%1</EW0NW#AP!1*9),I4@V-K;3P!W;S/F<3FYK&TZ
M`&-`QS-:U*U]S<P3EO801PM`R:7NK7B2\DX9"E**\7?#V_3^?65I*Q=?4HI7
M7B%BG(<ART=VUY99)MS%HN,*)D2-(\8-$:PWQ%69ZNTNQ4%XW8ED8FTQKJ<+
M*I.UU7`MY1BV61`@$$IM=+M,$QN3)J(NF-:X<M`(!;A4$5K7&A`HMC%NUQ`V
MV$0:#:O>YIQQUD%P=P(-*4PJ"05:"O\`E^PV-('!*&!^0^8L+7K!O'^%XP_Y
MD1D)BF]OLI8>KTJI88.*R74,A4F>IKZQ5^R.G4A&RK!JQ<LEWSD@@J@L9+6*
MS8A`R+Y2:6*:*$1:J-=J8,0'-<TMJ#B"`*$G,%93]]=.^;YR"&6&68RZ27MT
M/(H2US7!U"*`@D@@#(BJD;CG`4)CS*ULS.I>;U=[[>,+X4PK:9:Y+UU529C<
M'R&0I6'N#L("!@D2V^TR&2GZLJ**:+`132!LV;E`P&SX+`07#KK4]\SXF,)=
M3'LRXAV`'O'4:\,J`+!GW!T]LVUT,9"R5[P&UP,@:"W$G`!HIQSJ2K7U_@AQ
M^A[?R_M#YA8+.RYJQ#^M91IT[*IFJU;JMDCIDF0:UC=NP;,W]6C<E6FQ/K',
MB"ZJJTZX^((8G00I<9FR6;);F1P+A="CFDX`$'4&<1J)+G?K&JR'[W>/CMHQ
MI:;0@L<!B2"-)=7`E@`:W]7!5Q@;!&0<,+MVMEY5YHSI4X*H-:12ZADBNX=B
M4(&*8*QQ8Z7G['C_`![5K3D&YL(R,(Q))R;H0.W45.H@=PJ98)+.QFM322XE
MFC#=+6N#!084)+6@N<`*5)YX5-5%>7UO="K+:*&0NU.<TO-2:U`#G$-;4UH!
MGQI@I-]_WCK8:>A8%6\D[_O'33T)5O)._P"\=-/0E6\D[_O'33T)5O)=.9<O
M4;[7K'\NLH-P6$Z4U.>:A[SMR]>,.<;YNQ8UGFM0NELR/@W#<1D![',99IC$
MF<LRT?$\EDT\9*)JQ+YS1XNVK/FB;PAV8ODT.^0Z760VKWF>:UL#);D-E=)'
M&'4KH[21K"^AP.D.J*X5I7!;79(HKO<!'<`OA;')(6XC7V<;GAE1C[Q;0TQI
M6F*L`+;$'&KDIC^A!FKS"W.3)AM=&\83+MNS/D[CER"G(?$5OR!(UV?M-WC)
M7%L;;8:%KSB7[=74@5V+QB+?M]D3-QP=%K87\<(FOC<$.IK=(^*4B-SB"YP+
M*@`N]S30BF6"SNUO-QVZ2?L;$6S2VNAL;)8@9&L!#6D/+22&^_JJ#7/%45#<
MZN1LGQ:P5R'ML;Q;Q1)\GH7%4MA/'[2)Y/<AKU/K6RE3%SM<(WQSB:J1]KM5
ME1BV[5\T:Q9S,XF.!V:2?'%),ZD+-WOW;=!?2MMXW7(88VTEE<=32YPTL`<3
M2E`W!HKJ.%5,_:K!NYS[?$;J5MLYXD=6&)HTN#6G6]VEHK4$G%QII&-%'>S\
MB.2?.)/R^:M`1]8Q.TR?R)YBXUSE1'=ZY)X8):+IQ1A+>R8D=2N/EZ9FNJT9
MX6'4F"0#U9M)(396[22!9N@H)M;+?[AN[K.&)H87S3-D9JDCU.BU@8@MD`]W
M5I<00Z@-:%;".SV_9OGI9"^4Q00/C<&Q24;.6G`.U1N=CIU`$::EM"0IR>6/
MDOE-EW`#6Z<BI_&%M1?6_,L'4YRGC=%+^\7I>?LJ4MXTN:<TR:5P8.&C*ZW9
MPIF!1=G8-TS/!%<3F'>=WI=RNK+MKXQO!<\-(KJ]V1[3JKA0``-IC08XK2=X
MX]MM+XPV`E:0R,N#M.D:HF.JVAK4DDNKA4FF%%+KD+FVN<<<#YCS[:^A:`P[
MC>V9`>,S&*495>O1+AW$P*/4(`9U8IH&S!$OI,LY*`>(ZVE]<QV%E+>R_!%&
MYQZ:#`><T'G6LL()-POH;&(_O)I&M'14XGS"I\RQ/>7-R;S'<,><F,'0.>J#
MS#Y+8WI>,N0V/++<KJ^=4^><YOI+:0N^%9:U0Y!D("OXKSI6YZOQZI$U$XJ+
MDHHRA#(E$H\QL&X7D]O<6C96W.X1M;(TN=4'6/>82TFC6R-<&\6M<VH&(73]
MX+*UAN+:]DA?:;=(]\3@UOO#LW>[(&G,OC+7'\S@ZBNG5?,MN.7,-N,Y8?Q'
M52U#(&;<)\2^/L=D.W.&\Y,\E+_-MJ_E9WE4U/--LZUB+#<TY69('9`K+696
M+7<->TS=L%E,B'?I[JU^;MH6]E),R&+4[.5SJ.UTR8S+"I<6FAH6DX\NQ16E
MW\E=S.[:.&2>4M;@(6BK-&JE7R#'&@9J`-2'`=+?^4_("W7:N<,K;.U_"V7I
M3F'C'C]E+./']S*$B7.(<A<<KWR9KTQB`V16LS+8[R7D6/HJE3$KX9->'='5
M=LEE%%&QDJ3;A>RRMVJ8MANC=,C?)'6FAT3I@6:JZ7N#=&-=)J6DX*Z&QLHH
M7;O"'36@M'RLCD`KK9*V$A^F@>QI=KPH'"@(P*X=VSAB[AA(<GY''5UYKV?)
MF&.+F;,QM<)<I;)G*WX%RLSQ))5)*2R#C_(^6FTQ(O5XJ9G&<>HZK4T1@Z;2
MIS&;&,FDHFFNK?:77!@?=NN(;:1_9S&1T;]!;5S7O!K0D"K'4H[+*B"WNMW;
M;-N&VC;::YCC[2$1ME89`ZC7L90"H!-'MJ"W/-2FS+S'5Q5D?(5&E%,:TN`J
M/"!KRG0R7DEY;?W8C+9*98-BZ+J]ECJDUD+`_K*KM5`2)13=>:>/%B-FQ#J*
M$*.?>;H;2X?"[LVL;:=MJ<3347%H:0`21U8G(8T6ML]M^:MXYF=J^1]YV.A@
M;4M#-9<"Z@!ZSI`Q*B##^9YFMG1^0Y+!ANJ3N3L+WGA="U+XVFYZXXU7)-:Y
MB972Q;&NGU,SG`K9/I;FJ2#1Z8DEVY&.?D[2A$MTUV^M:W?[L0SZXFFXB?`&
MU;)$'"=^@>[(-;:&N.(/I"VKM@M#-;Z)GMMIF7!=1T4I8;=FL^]&=#M0IA@1
MB*Y%7DRYG[F4[D\P<?*O7^,D'E'%G%RV9XS)=S3^:'U-CZY>G>4*QB2G8C*T
M85ZWCD%1ACJ5D)2=D"ECX]RW;%;LU16'LY%W=[N3)8Q,@%S'`9)'`NH&N+PP
M,R-:,<7.X8:02<,2TMMI#8K^5UR;:6Y$4;:1ZB6AA>Y^;=-7M`:,2":D4Q[G
M'>+)[D5P7X>2$E/R<],3_%3CZ2]+S-LDH:UVQI(0^#\JOYAED,8NTOXB[N+=
MCEF==\NT=?&(NG'6=-<$5B306<E_LUHXN)>ZVCU5<0341O)U4-':FC$@UJ>-
M"H[B]98;U=M#=+6W4NFC06MH9&4TU%6Z7'`$4H,Q4*4_'_$TA@_%3^MO9-B[
MDD(AL@U+$)E(SAX6GTMA4JBP.\2CH4DW8$(6"15DY0K%@1\_.<Z;9%(J9`S[
M2R=:6W9N(U4X<`UH:W@*F@Q-!4\`L"[OVWESVC00VO'B7.+G<305.`J:#B2L
M(7&CE%R,AL$<!<991S/D"U7[/.=^`^<:/DZQV)ZYM64\"9WL:U?SMB*RS1SE
M<6%MB_*0`U<-U1.)JU88<IP,"8CKB[+<;V.SLXKF5[GRRV\@>3[SHY".T8>>
MAU:X_"Y@YKM-PL;%][>W%O$QL,$-S&Y@'NLDC%8W@<-;,0?S->IOX@\Q/+V8
MLQT4M4PJ2<X_W_D3<,"(IP>+>2R^4*;6ZI;+?C[_`(@K5E)S0$^-CBE'N=//
M]X0C21%U%1KQ)0S]9TBX:DW$&]W5S<M,,!?9NF='@R76`TN;VA?I[*A<W%H/
MN@CWB00M1<[-:VMJ_MIM-ZR!LF+XM#BYK7=FUFKM=6EV#B*$@^Z`05O43GCR
M6E>,=#YH7O$."8+`,[;:>RN,75KID>>R?4L9R>:W^(;EEEXF_@(RI,HZIMQ;
M3*D<#A^JBP0=&57$>DJ58-UOWV#-UFBA%D7-#J.<7M:9"QS\0![N#J8T%:GD
MFVK;F[B_:899G7P:[22UH8YXCUM8*$N)=BVN&-*!<C)OF+7R&ECU_'^/JJN7
M(?*O,''7`UYEJ[F3)4%)U/C31$Y3/N8;11<*5^Q7ZTL&>3&DC6Z]'PB;9%T5
MF=Z\>H-R&,-)][E#^SAC%7SOCC<6O<"V-O[QY;&"XT>"QH;RJ7`);[+`]NN=
M[AV=LR61H+&$.E=2)@=(0UI+"'N+JTK0`E30XDYKOV=,0HW3*6,I+&EVB[O>
MZ1+P@UZ_U2(M[:F3JT?#Y&H4)E.O5C(+"D9&AA0?QJ4LQ3>-C*J(',J*/=/N
M-LGFO+7M;B,QRA[FD4<`[2:!S0\!VEPQ&H5&6*U&YP6]E==C;R-DB+&N!JUQ
M;J%2UQ87-+FFH-#0YX54->)&*;;S!P)BOE??^2_*.NYCS:H]R3%-<4YKL%*Q
MGB*,-=9=M!8?K^&623G%\[!5*(B4XJ;/8(J5DY1Z1VJNX(<Q`2U6V6C]TLH]
MRGN)VW,OO>Y(6L8*FC`SX"&@4=J!)-23RVNZ7D.U7TFV0V]LZVA]PZXPY[SI
M%7E_Q@N)JW20`*4'/OJASES)8Y_&65Y#'6*&?$G,W,68X;T].-FKH?D'!S:6
M2KKAJLY:L*+I`<>NZO9,G45RW5@&R:<C&1+I!V9XX4(LW*;N]T7,NC%'_ADE
MP86T)[2H<Y@<?PT+VTTTJ&D'4<0K9=JLXVR6HDD.YQ6HG=4-[(C0V0L'XM08
MX'4<"X$4&!5.X$YU<B<BON'=WR)C;!D'AGF-EC+N$JS'4>PY$D,JTJSXZB\S
MSM?N-@=V!JWIS^OVEGA9ZW<Q39(74>HZ16*]<`)T4Z66ZWT[K66>.)MI=2/C
M&DN+@6B0@FN%#V9!%*BH(<<A?>[586XNX8))G7=I$R1VH-#'->8P6BGO5':`
MAQP-"*#-=3A+S!L\V:(XAY9S/C?"5>PCR^K>;7<"PQG.9#F,HX]D\,XRO^6P
MEK$M9V[.JST1;JOC620^[F::;F,=G;[O'93'Z++/>+V06UQ=Q1-L[EKZ:22Y
MI8QSZFN!!#"*4!!IB[%77FSV4;[JVM))77EJZ.NL-#'"1[64%,06N>,3@17`
M*B<;>:AE5_42YQR5@4ZV`Y[C3EKDLW<8[QIR4@[#A^*Q]C\F4:;3<G9)RSCR
MN8=R"\RK5Q,R:2M9<(,VLX0$DTWK11-T,4&_W+H_FYX/]"-N^6K6R@L#6ZPU
MSGM#'%S<`6T&K`5!JII^[]JV7Y."<?.BX9%[SXB'ESM#G,8QQD;H=B0\$EN)
MH<%5'(W,WF25'"^%+L<W$R@SF3.3?#"NQZ%*E<R21XN%S%DF.B+'B:].9F*<
MM['#+HRL>TDYV)!@JZ8G??"LVZQ6RAY+Z??H[6*8_+QODN(0`TO.#W@%KJUJ
M,15PI4$^Z#116$'=^6[FA_TE[([><G4&"IC82'MID<"0UU:&E2155AE/F?RF
MHI>2\G"8XX[6"&X&8SHEXY4).+%D^-?Y(G['CYSF*V5?CDLJT%&LL*EBQ-%R
MUD+2D]^]9=?X/LMDDSN=27&Y;C!VY;'"YMG&UTV+@7$LUN$?*C,07`U<:4`%
M5';[;MDWR[7R3M?>R.;#@TAH#NS!EYES\"&4HW&I."O=A_DGF[.&?\V4^GT;
M$,5@?!>2J%4)RZ62SWD,L6Z'R%Q[QUFF.4K5,C8%:K1<M$N\AH(N5I"2*@LV
M**::!5B&5/FVMW=WE]-%$R(6<,C6EQ)UD.B9(*-`H"-7$^98=U:65G90RROD
M-Y-&YP:&MT-+97QFKB:D'2:4%:\:*DN</,#(/'F5@:YA]7&5KO9\;7;*,IBF
M;Q3R4S!D2<KM663092;%EQ\AY-EC6COWJ#EBO9+&;X5)Z!2H(+@DN!8MWW":
MQ>V.U[-TW9N>6%DKW$-Z(@=#3B-;L*\#0J79]NM[]CI+K6V'M&L#P^*-H)X?
MO2-;LCH9C3,BH5G93G[R*R#'V*>X^XPP4R@JAY>^"^?<V&9[-D)S,/F66H7*
M5C<XA@TJ&S;Q_P`<G'XV.BA/.%2(M55>L[)T50"(XC]WOIFF2QBBT-LH[@ZR
M:T>'G0--.#/BX?E/#*;M%A`YK+V28O??26P[-K:586#6=6-*O^'C^8<;;\K.
M9F?LT\:.8SKC/%4''=0Q'P+K&9,D7B]3^06^5FUDY$<=YW,E;K>%'&/E(QE7
M)_'-&%N\-/R*BR;B7720101(DJX+C7^Z7E[873MO:R.**TUN<XNUU?&YX#--
M*:6@'4:U<0*"A*R-NVVQM-PM6[@7R2RWIC8UH;HI%*(R9-5:ASJC2,FBI)K1
M94;1F&N84XV2N<[\Z5/6,6X))D^U.'"QE'3]G5\?H6%Z@*JAA.O)32[;L)[B
M)U7"Y0W$QM=-+-':6!O)C^[CAUGS-KZ3[5S<<+KS<!90`=I+-H;AQ+J>@9]2
MQ,^6ARKR_D:'Y"X70S]1.4/(Q?$N.>7&,G-NMTC)TRLV;,\(X8Y&XU3$O!$^
M^(.F85S#$)1K4&Q53QT7/-C@4Y2]`\SL%_<W#)[;M6SWW9MF9J-0"\$.C);4
MAK'B@IB&N%1P73=X+"UMG07;H'V]AVKH7T;1Q$9JV4`X%TC#4US+2KM5?S.;
MIDS#%VSICG"U:0K##(^$^*%"K]TO.T_,<U,F7VMX\R!6+;(U$9V*@\&8:L5M
M;-CS+=-:1LPMG#A@F1J9LHMD1;[-<6K[N&%HC$C(6@NQ,[G!I#B*T8PN%2`2
MZAIAI)QI=BAM[MEG<2N[0QR3.+6X"W8TN:X!U"9'AI.DT#*@'&H'7Y4Y7\CW
M-F+PYN,Q3<09OE^5'%S"-JS_`("&84KC7"O)&A90R4PMF.(W*+:<D*+EJ6-A
MV3J#<DB:5292#YM(-3'.HDDG2?<+XN_PR;3#=FXBC=(S(,E:]P<W5JTO/9EF
M.JA(<.`5;:PV\1?XK$'2V8MII!')2O:1.8PAQ934P=HUYIIJ`6GBMRWY5Q9P
MXN&=CT>_\Y)[)^+>+W)/+\;B/DK:\YWOCKG`F#ZC!6R8M-2R/E=K-IN96M/I
M2/:K.JK+M&YTY54BC90Q$^U=++;;7+-V+[MUQ';2O#)3(Z.3LVAQ+7/KB"0*
ML<!CD52&&XW6*'MF68MY;B*,OB$;98^T<0`YC*8$`FCVG(8J2&1.9[B@7&)K
MLVECBDUR2X`W3F-)9&R#*65M5*A8ZY:\<51A7K$6#;O)1>D&<7[N.3LT5I=4
MR1$FQ#JJ%*;.N-R["0,?H:PV3IRYQ-`06``T_#[W#'DL&WVUL\1D9K?(+YL`
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M>6AA<6M`R<7&CM1H``,`2<-=%;;1\N-PD?<&U=,V)@HP/+PT.>YV):&`%M&X
MDU()%*FUF%L67'DSY=7".5FIJ:N$M:^*6!T,B/I2<A7U^FBGD<098>V2)L&2
M8VRU:7L\M-X\3:219Y!PV?-GG>4[IVQ6[B*TLY=PV.T>XESW6T>HD@N/P/J"
MZH));0ZL"#7A0Y%Y>P[?OMXQH:QK+F330'2/C90AM"``ZHTX@BF%:B>_&+%D
MUB#'D=5K(XC%I0QX!N=I$"N=DRC*K3*KC^"!XX66<%?V21A*BW=RSA$P-3/U
MU$VX?#I)".YL+-]K`(WTU89<@T-'6:`$\*Y8+2[A>QW4YDCKIQSS)+BX]0!=
M1HSH,<2L#&!N57)"L\9N,50R9FO(=GN7(O/G#+-6),HV"R/E[5:,87CEY5,0
M<F<`R4\<Y7,I&421=,5TFBACB>KVY)`0,DT/MQ=EN%\VR@BFE>Z2::![7DG4
M6NF:R2.O$-J#_->!^$KM+VPV]]_<RV\4;8H(9XWL`P#VP.?%(!PU`$5_.PGB
MI\T[S$<O9&SFPC:-A5.S8)<\KI[B^\90N+>2\EEB.AJMD&5Q1:.0CO)[7'Y^
M-C2E5N\0ZZ[V`-(F>MH%,SA5^1X4[(NYCWFZGO`R"#5:&X,6#)=7NN+#(7Z3
M&&APJ6XD-Q+M7NK2R[+:069=--IO!;";%\0826A[8PS5VI<6D`.I0NPTTQ6J
MN\[^33WC;+<Q[#AS!;'`M2OUCAK;#0%TR/-Y9;XQQ_R4EL,9)RJDS6@&%2C$
M*M1H5[8?NP73]8P,%!,H4BI4T;H]TW`V!W1\4(LF/(<`YQ?H;*8WORH-+074
MJ<L^`2;5MPW`;2R68WKF`M):T,UNB$C&9EQU.(;6@S'+'L,N>8I<JO,V2$QY
M0:O,,;-RTE.)>!;W(0^6;_"6"2Q5B20R1R,RE9:;AVOV6]VFKT:?BGE<A8^`
M0(K)2#)PJZ=M6R2BQ+;C?)&O<R",$.N.RC)#W5+6%TCBU@+B&D.8`W$N!J0,
M52VV6&1C7SO<TMMA-(VK&D![PR)@=(0UI<"'N+C@"*`D@*7G$#.&1,[8UD[%
ME;&[K'-QK&3+=CUR!:IDJE5;(<175XY:"RG0*YEZOUG(T73+E%2J8IMI1J*[
M1\W=-^\N5(JIMMM=Q/>VQDN8S'*UY;\+FAP%*/:'@.#7`Y'(@BII5:K=+>VL
MK@1VT@DB=&UV;7%I-:L<6$M+FD9@X@@T&2Q.\9LEYSON8:]*8[O_`#/NE_C_
M`#!.5%2Y!,[T&1I;AC#\1Z+EW,U;2B8R6O4.7&C"Y0$3$P#*NHTU^>83E4S)
M.DP0*Y*7F]ODO9[QKH'W+Y!>3-EU:S"(FO>*`N&BH`:&AAU:L\*TZ7<(K*"U
M<VX9:,A-E"Z+3I$YF<R,U(:=>DDN+NT&G3B,:*1./^=O*R^X$XOY;'$7'*"G
M^;EHQ[CGCS7/WZRC,LZO9K'$7ZYVR[YG=%KD8!*A#X^QV_>L(6$77DW#\46B
MKXH*&62S8=UW*:RM[KLH`^[<UL3=3C0D.<XOP&`:TD-!J30$\1@S[5MD-[<V
MO:SEEFUSY3I8*@%K0V/$XESP"YPH!4TX*@[QR\YKV;,?'?#U%)@&DY6IW-/,
MO&C/4<^?9,>89RHO#\/I7D+C:<BCLV#F\0M&DZG--I%U'G5/*QUE8H(?$.&7
M>.>&;<-VEN(+:$0LNFW3XI![Q8XB`RM(S(&D@D5)#P!4M4T.W[1':3W4W;/M
M7VD<L9`;K96<1.!_"7!P(!R+"30%5N_\Q+.3W,=MK=!PE'7R@XKY'5[C)>J]
M6<7<H+-DJXSC26J%9R_E"@Y#KF/G^!JK4,:3UI7=(0T[(*R3^&B5UW+F/56;
MI&F.\W;KIT<,.N&.<1.`9*7DU:'N:X-,8#"[)Q)+6DDMJ`HALUDVU9)--HFE
MMS,TE\+6-%'%C'-+A(7/#:%S10.<``ZA*J*=Y.<PLK8"Y,9_PM"\>*=AFI5W
ME[7L9/+1+Y/<9P1=\?$,E4EKEUVM$,'./T?O;(E!<*L:\+;NM6)FZZ[Y13N-
M1ODO-TN;.XO;00LM&MF#"2[M/W>MNO\`+BYI]VF`H=1."C99[3;7UO8W9G?=
MO=`7@!O9_O=#M&/O8-<*NKB:@-IBMK%_)/FI+T_AGAXS#C//<B^26#'N<4<A
MV%QET^-H'$6/\>X=7F)J\P<<G%V>Q9DNUZRJS0.UB5V<*R1.NZ`QP3(@I9;7
MF[F"UMBV%]_/$9`XUTB-H94D`BKW%XH`0`,3C@:W-GL[9;NZK<-L+>81Z0&:
MB]SI*!I-0&-:PXD%QP'&J8\YY\A,[6C!^.L/8>PM#7K(6&>0]XR6OE._WS]T
ML>7KC/R.A>.-Z@:PXIE5>S-]K<[9EW:T4J=&-7^',@LNH7H404O@W6^O)8H+
M:*(3/BE<[6YU&NBE$3@*-JX%U:984)/!)]IL+*.:XNY93"R6)K-#&ZG-FB,K
M2=1HTAM*YXU`YK*\*BA/L+$%-4H`"I!ZPZ%``.X4`.4IMBGWVW`!V].NE[-<
MSVC>A?._\MQ^K3LU7M&IW_EN/U:=FG:-3O\`RW'ZM.S3M&IW_EN/U:=FG:-3
MO_+<?JT[-.T:M(K#[/RZNT!6]HOG='V?+Y]-`5.T3NC[/E\^F@)VB=T?9\OG
MTT!.T3O#\O\`7IH"=HN-WR_K:DTJ'M3TIWR_K::4[4]*=\OZVFE.U/2G?+^M
MII3M3TIWR_K::4[4]*=\OZVFE.U/2G?+^MII3M3TIWR_K::4[4]*^@L4?Y7S
MZII3M3TK5W`_6#Z--*KVO2G<#]8/HTTIVO2G<#]8/HTTIVO2G<#]8/HTTIVO
M2G<#]8/HTTIVO2N@,Y-U&\`_2'\NLL,%`L(RXG#BJ.R#2*7E>CVO&F2:O$76
M@WF$>5RVU2=;BYBIR&?D`KAFZ(0Z2R9@,4JB2R1TUVZY"*I'(J0ARQ3VL%U"
MZWN&A\#Q1S3D0?+S'$8J2"]FM9FW-LYS)V.JUP.((\NHC`X*-52X2XAJ]JIU
MND[CR)R>]QJA8D,6Q69^0^2\G5S&G[U5&6H,V[JD/8)8Y%I9Q2IUY&$?2IY-
MZBU<'!-4IAZM:Z+8K.*9LSG3R.C!#!)*]X95I::`G/22`75(!.*V,O>"[EB?
M$UEO$V0C68XF,+]+@X:B!EJ`-&Z149+NIGA[A>3QE@/%<0?)&/XKB\VBV6!K
M;C3)EGI>3<>L8RF.,=K,8^^1[@\H_9S]'=JQLHD\!<CY`_48`5*10M\FR6,E
MM!:#6R.V`$9:\M>T!NFFKB"W`UK7K5C-]O&7,]TX1R/N23*U[&N8\EVNI;D"
M'8MI2AZ,%R\;\0\#XG6Q6YI=?LJ#O#&0\UY5H3^<OEMM4FUOG(9K+-,LSLY+
M624DY6U+V1.<=&+]X+.!;JJ]P@]8;ZK;[+M]JZ-\+7:XGO<TESG'5)762236
MNHY\U2YWV^NQ*V8M+9HXV.`:UHTQ4T```!M*#*E5:BR<&*VTIEFQSB')&5<=
M4+)N::=D7(U+6RA=9*IP5/:Y95S-E:I80A$W:9\8/<Q6HYV\FHW<@@5B_=D3
M!,HD3'&DV&(1.@M))8X))FO>W6X@-U]H]L8_!VCL\:4)IR65'WAD,S;B[BBD
MGCA<QCM#0XNT=FQTA_'V;<149@*666L7T3.%7;4K)$2YF*JWNE$OBD(UDWL4
MRD9S&UNB;U4VTP5@JD:5K[:SP31PXCU1%L\!`J:Q3$W*.RNK*"\C[&X%8M;7
M4K2I8X.;6F8J`2,CQ6MM=PELI.VMS270YM:5H'M+74KD=)(!S%<%168>.6*\
MYSSBTWIO;FUE>XDR#@I_8*5>+'19B0Q3E&6KDW=*D\D:X\9NE&\A(U=L=!<I
MB.F7<<?#J)_$*B,5UM=K>/[28.$AB=&2UQ:2QY!<VHYEHQS&-*5*FM-WN+)@
MBA+3&)6R@.:'`/8"&N`/(.-1D<*@T"H2;X1\9IF.R)#(4)[58/)S#$24]!4*
MTV&CP\/8L")1[;#V2J&PKCYBE0<L4-C#1[5K8HOX>06:1K1%P99-`@:QW;#M
MKA(T1EK9`RH:XMH8Z:'-I\+VT`#FT-&M!J`%.SO!N#'1O,FI\1?0N:'$B6O:
M,<374QU22UU14DBE5H;\)N/)L97G%UC@[GD%GDR]Q.4[[D#(.2+E8,TV+*5:
M1BFM.R0&7492-N5?N-#903)O`.HA>/+#MVQ4FQ$R&5*H;L.W"V=;/:YX>\.<
MYSG&0N%-+M=0YI;I&G21I`H%1W>"_P#F67,1:PQL+&M:QHC##74SLZ%I:ZI+
M@X'43BNNC.#F#>_<WM_D\SYXD[WB.YX%F93D!FN]9/=L\.Y#5CG%UH==2?OV
M,=`,+(ZAF:SIV@W"446:(G%UN0-&;#8@O=,99G21.C)DD<_W'4U-&(`K05-*
MX#%5=WAO:,;`V&!K)6R@11M9^\972XT!)(J:`FF)P5/-_+QXWJ1EW8VI7-63
M7^0L2P6#[#:\IYVR/=[BCCFI7)AD&D1E:GI"734I\G1[E%-9"+?QB;5TBZ;$
M54.LJ)U#Q#NWMFES9.VD<^,,+GR/<[2':A0UP+78@C&N)J<5(>\VXZF.B$,;
M8Y3(&LB8UNMS=+B0![P<TD.!J*&@H%WS#@K@)$M[<6%7+F1K!D^8P/8,A77*
M.9+S>[I:ICC3>%LB8<=O)R8D#?=Z-:M"PJ*-6*31D[1#M*(B`G$TD?=_;HVO
M:1(\O,9<7/<XGL7:H^.`:>``!&%%&[O%?G1H$4;(Q*&-9&UK6B9NF3`#&HXF
MI!QJJOS7Q.Q)GJY%OUP>91K=I=T"4Q-:Y#%&6+KBD<CXKEG[R66QUD<*;)1R
MEHJ[26DG3EH43HNFAW;@J2Y4EUDSRWNS6=],)YNT;+H+"6/<S4PU.EVDXC$T
MXBIQH2%%9[W=V,/80B)T6L/:'L:_0\`#6S4#1U``>!H*BH"O?0*?7<84*D8S
MIC)6.IV.J?6:)4HYPZ7?KL*S4(5E7X%DN_=&.Y>K-8J/2(990144,43&$1$=
M9T%M%;0,MH12*-@:T9T#108]06%/>27,[[F;&:1Y<XY5<XDDTX8E5AUE<(.6
MZP[).45FRI0$2B9%PD=%4H&#Q*(IG$-P\0U5\8.'"BM9+QY%185X4\:5ZQQ/
MJ2U(=J1?"*Q5FT\;'!K+-_?5%E:E')1<41W-`Y!_9(U9JV0%VU?&51=JMD5%
M`$Z11#5'8]O,5M"8SHLW`Q8FK2!05/$<P<Z!;<;YN`ENI0\:KUI;-@*.#C4T
M&0/(C$5(XKEU+B'BBAY+6R11;-FZG-'&1)7+;O#]:SAD"(X_.\F3[MS)3]O<
M8>;2A*X9:?F7:LB^CBB6%=22AG2C(RYA.-&;):17!N(C,RKRXL;(X1ZCB3H!
MIB221\.KWJ5Q23>KJ>V^7F;"\]F&=H8VF70,`WM"*X#`'X@,*T5?U3C]B.F8
M#'C'#5H5<*GIUNH*]2EY1],'=U6]+SSFS1CN6>JJ2*_QRME>"503]Q'N%Z!#
MH+M/%MMK%9?X>QI^4TN;I))P=6HKGQ*@EW.[FOO\1>__`$S6UVH4'O-I0T&'
M`*WLEPRP$\PWAG!\3$V^D5CCLO'2&#+3CW(-HIV5<83;",DX=>Q5O)<4^)8S
MS5BC)M\C-'>'=(S1'JX/4E^OP@?LEBZTBL@U[8H/X9:XA[30BH<,:D$AU:AU
M34%9#=[OVW<UZYS'RW%1('-:YCP2#0L(I0$#32A;04(5\,7T*.Q-4VM1AK-D
M*V)H24I,N;/E*_V+)5ZEY68=B]?/):VV=VZD5B]X0*W;)=EFS1*5)NBDF4"Z
MS+:T9:Q")AD<`2:O<7.)/,G'J&`'`!85S=NNI3*\1M-`*,:UC0!@*-`IUG$G
M,DJ-3K@=@DTW8'L'/9[HE.MUQ>Y!MV%<;\A<H4+!5CN4M+%GYZ:=XWK<XQ:1
M2=GG0%Y*L(MQ'Q<FY454<ME!65Z]>=ALM;G,,[(GOU.C;(]L9<34G2#A4XD`
M@$UJ,2MB-_OM#6O$#Y6,#6R/B8Z0-`H!K(-:#!I()`I0X!=_"\+<#5_+K/,,
M<UOWQ<1E&?SG7<8.\F6QW@2J9QM24BG8LQ5C#*SX:A$7V55F7SD5R)BT;OWS
MAXW;HNECK#5NP[>VX^9#9#[Y>&%[C&'FM7AE::C4GD"20`22K'[Y?/M#:.+*
M&,1E^AHE,;:489*:BT4`YD``D@454U;BSA&F5S`54K]=DFL)QDR!9<H8<;+6
M:8=*U^YVZ/R)%SLC(N5W!UK`V<LLJS92-W8J(I"Y()0`44]IX]ILXHX(F-=H
MMWE[,3@YP<#7G\;L#SZ%%+N]Y-)/*]PUW,89)@,6M+"`.7P-Q'+I6BJ\5L&T
MRN\<ZG`UAZE`<4G-I=84CWUAE)-."4NE0M=$LB<X+U94;8VD*O=I)OVG_=(4
M5P.`=1"[(MILXHX(V-.BV)[.I)IJ:6FOYJAQ&*2[O>S27$KWC7=!O:&@%=+F
MN%/RT<T'!49COA%@[&2#JOP,EF27Q8>IW&AQ''Z[9NR#<^/=3I-]8.8FS5.L
M8HG)9Q!M:^M$/5F;)JZ,\1B&BIDH\K4FP!!!L-C;U:SMC;EI;V9D>8PTX$!E
M:4I@`:@#`4"FN-]O;DA\G8BYU-<96QL;*YS34.+P*UKB2*:CBZJZ-OP%P:3'
M,QBN2MW(VT5%V.-QJ)+AR/R=9IC#QL.V1M;L6N,+3,G+JNZ!(TBP,D%FKXGQ
M+]9-ND@Z7<-TRI!:-@LA;NMBZX=$=.FLKR6:#J88R3[I::$'$F@!)"O/>"]^
M8%RUMNV4:]6F)@$G:#2_M`![P<*U&`%20`<5KN?`7`.0W@/;G+9NG%)JGT^A
M9;14SE>V++DI5:"\=O:G&\EV$6^8M,N'BS2"Z!EW!&Z[J/6,Q<&59;-P3=W[
M"<@R]L?=:U_ON_>AM:=K3XZ5(K@2"6FK<$A[P7\`I$(11[G,_=MK$YWQ&$D5
M96@-!4`C4*.Q4E:3C"CX\L^6+A4HQ6-G<V7*&ON0UC/W#EI)66`HE7QK$N8V
M/5,+2#9M:=38]L#9J5-$3(BIT]9S".QALH8))98@0^9X<[/$AH8*<O=:!@M=
M->SW$<44KJLA86MRP!<YYJ>)U.)J5:C,?$[$V<+JAD&TR>5:Q:%<=R.(;.]Q
M1ERZXK3R+BB2E'<VICO(I*=)1ZMEK32:D'+IJ`';NFRCI<I%P2643-B7FS6=
M],+B;M!*&%M6/<S4TU]UU,QB:9$5(K0E95GO%W90F"+LG1=H'@/8U^EX%-3=
M0-#0`',&@PJ%O57B9@FE1<[#5VM2;./LG&BA<0Y=%6SS+H5\#XSBKC"4ZL)*
M+.#&;2D?'7V3(I)DV>N!6*8YQ%,FUT>T64+7,C:X-=;M@.)_AL#@T=8#CCF5
M23>+V9S7R/!<VX=.,!_$>6EQRR):,,AYU:V^>7?QGR%'.8.22RU7*S-X/I_'
M2^53'N;,@T&N98Q-CRO/*K0('*\=6Y9F-U>TZ"D5VS-\L=-RH@J9%R9PWV1#
M%F[N;;,W01*V,Q"-P:]S0]C00T/`/O$`FASQH:C!94'>/<H':VF)T@F=*USX
MV.+'N(<XL)'NAQ`)&6%10XJ263<.8\S#C$,.7^+>2V.CK40[ROMYA_&%E6N.
MK!`6:N1$P[8JHNI&#4E:PS^/:*&[,@W(=%<#)J'*.QN+""ZM_E9P3![N%2*Z
M2"`>8J!4<1@5KK;<+BTN?FX'`7'O8T!IK!!(KD:$T/`XA=+E[C_C;-UAC;?<
MPMD?;HC'>5L3L+51;K/4.Q(8_P`U-H)MD.O%EJXZ:.@2DC5IDNU6`0<1KM`%
MVITE1$VK+O;;:]>))@\2!CV`M<6G2^FH5'4"#F"*BA5]IN5Q91F*$M,1D8\M
M<T.&J.NDT(X5->!!H:A6RD."_%M[#7FM-<<FK=6R)CW%.-[-5:99K!4*\+#!
M2K17#-RA(Z`?L0K>6,9ECFB45:F)D)I-!DV3475*@D!<8[#MI:]C8RV-[&M(
M:YP'N?`10X/9AI<*$`-'X13(;OVYAS)#+JECD>\.<&N-9/XC22#5CZG4PU;4
MG#$K6PX2<>BXZR?C:V1%SRLUS38J]<,I7K+62+=<\NVZV4I"-;8^LILHGD8^
MU5R9QHE#M?W;6AEHT811+NM0(JHJ=0S8MO;;R6[VOD$I!<Y[G%Y+::3KJ"W1
M0:=---,,4=OM^;B.XB<R(PM+6-8UK6-:ZNH:*%I#ZG7JKJR.%%Q8#A#A1A-2
MMANT]F[.\Q*8QR!A=-UR%SC>\L)0F*\JM(UAD>F5^.EG[6,CFMT90S1)^\,B
MK*+D;)[NMR[B9L5FUY?,9IG&-S/WDCGT8^FIH&`]X`5.9IFJR;[>.8(X1#`P
M2-D_=1L95[*ECB0*G34T%:8G!4G%^7-QD;1=CBK*&8\H)V?!;_C4^>Y;SMDB
M_P`G'82=SM<LK"DUEW*3)`JI*S-U*.<QCZ/(WD6ZS4JBBZROV]0L[M[:UKF/
M$L@="8O?D<ZC"0Z@QPH0""*&N))*F=WDW(N:Z,PQELPE]R-C09*$%QH/>J'$
M$&H-<@%W*'`?CZLVR0%M>YERA-9>K^):OD>Y98S;?+[=+-"X-R&OE'&+,TY+
M2/3#I5ZXN#+"2/1:(N4A$BQ#B=0Y[V]WMO:U[7B5YD:P.+GN<2(W%[,>%''@
M`#Q5A[P7]8^S[&-D3GN8UD;6M!D9H?@!C5O,FG!7)S3Q?Q?G:[0>1K5)Y.JE
MWAZG/X\>V3$65;AB:4N&,[1)(34YC2\NZ;(1Z]CI3J:;%=I(&,DY9N#*&;+H
M]Y4#Y%YM-K>RMGE[1LS6EM6/<PEI-2UVG-M<1Q!R(J5CV>[75C"ZWB[-T+G!
MU)&->&O`H'MU#!U,.1&8-`KI8LQY4,+XSQ]B#'C%:(H.+J=7J%2XIU(.I5S&
MU>K1J$1",7$F_45>R"S9@V(0RRQC**"'481$=95M:16EO':P`B&-@:T9T`%!
MCQ6+<WDUY<R7<[JSRO+G'`5+C4X#+%5\1V<ABG*<H&*(&`?LCX@.X>&IM"@U
M]*B$_P"#G&23QWQMQ:_HKQS4N(V1*WE/`)3VF=";I5RJLH]F8QVI/E=EDYR-
M7?OC&>,G9U6SPJ:0*D'LIB75G8]O=!;VY8>SM9`^/$U:YIJ,<R,<0<"MJW?M
MR;<7%RV0=K=1EDN`HYKA0X4H#A@1B,>97:Q'$7%=:RI(96J%FS=2#S>2C9DL
MF+:7G"_UK!%HRHNZ0?R5WGL21THG7G,A8)-L1W*M$A1BI9X`KO&BZISF-5NR
MVC+HW41F87/UEK9'-879EQ:#3$XD"@)Q()5KMYNI+46LK87AL?9A[HV&0,R#
M0\BM`,&GXFC`$!7'HN#L78ZQ$^P36JZ`XLDT,CM).L34@ZG4Y%GEJPVFT7YD
M]=R*BKIPSFY:YR(]L3;(HK@F38I"@&3#M]M!:FSC;_HQUU!J:ZR2[/F7'V+'
MGW&ZN+H7LCO])&BA%!30&AN7(-"M4?A3QX2P/BOCI"U^T5&AX,EX^S8;G:7?
M[55\IXUN4<M-K$O%7RA%R"5K0ML@:RR1)!TNLN231D'"+M-9)4Q-8IV.P-C'
MM[6N;!$:L+7$/:<?>#\ZFIJ?Q`D$$%97^.;A\]+N#W-?/,")`YK2Q[33W2PC
M3I%!0"E*`BA"O?BK'D;B*L?NQ$6O)-T[LU(V&0M&7,AV+)]WE9:3^&!RL^LU
MF<N'";))-HF1NQ:D;,&A"[(H)]1NK,M;-EI%V3'2.%2:O<7N)/2>'("@'`+"
MNKQ]W)VKVQLP``8UK&@#H`SYDU)XE,78QI6&ZS+5#'[!U%P$W>\D9*D6CR4>
M2RBMORU<YJ_WI^FY?**K(MY.TV%VNDW*()-DS@FF`$*4-5MK*&TC,4`(87O>
M<2?>>XN=Z23AP2YO9KN02SD%X8Q@I0>ZQH:T8<@!CQS*M*]XB8+=<?\`''&E
MO$6>#QOAQ6I/\1R%;O%C@LCXSL-$=.7E0M],R.P>)V:*M<&H]7(5V*J@+MW"
MJ"Y%4%5$S8KMGLG6,>WZ7"WBIHHXAS2W(M<,014X\02#4%90WF]%])N)<UUQ
M+JU@M:6/#OB:YA%"TX8<"`10BJH]UP1P&O0:_2&CW+\)-5K+\QG^/S3!YCN+
M'D(OFJR0$C4K/DB7RZ=TYG9B=L=.E5H9VDX(=A]T]MJDW2211*G"=@L/EVVX
M[4%LAD#P]PDUD%I<7YDEITD'#3A2@"F&_P!\)W3GLBQT0B,98WLNS!#@P,I0
M`.&H4QU8DDDKNC\-<3(Y$DLE0-NS[2)*S6*K7/(E6H&?LC4['>6;Q4&,+&QM
MWR;3(:60C[%:I1C7&2<TZ2,T"P%;E"2(ZW-U7_X):?,?,L,['%P<X-D<UKW`
M`:G-!Q)`&JE-5/>JK/\`&[LVXMGM@>UK7-:71L<YC7$DM8XBH:*G2,=-?=HM
MR)X:83@[K<+9$N\J,*]?9C(EEM>$&V7[PAQUE;5EN)EH;)=E4PRC)IUA.2N;
M>>>KNT2[1P2#I1\DV3>#WP,V2SCF?*SM0QY<71ZW=F2\$..BM*FI)X5)<!7%
M4?O=Z^%D3^R+V!@;)H;VH#""P=I2M&T`'&@#2:8*D6?`;"L=2,=TJ/O?)1@Y
MPX]D38:R,SY$7Q#+V)*U+5:*I4EC:B9$(O\`>[+%KVKP;-JK!NRO&QS-DG`B
M+I)-<D0[O60@9`'7'[HG0[M':V`@`M:[/00![IKB`<\5,>\%XZ:29S+<B4#M
M&=DW0\@EP>YF6NI)U"AQ(R-%=&@<5,$8M>4)]0*DZK:^-,*W/`%0,ULL\X,S
MQSD*V1%[NI9!P_?NGLW;K'<X1&3=3KM5:45>G65,L)UCB.3!M%E:N8Z!A:61
M.C&)^%Q#G9G%Q<`2XXUJ<R5BS[O?7(>V=X<))FRNP'QM:6MI04#0TT#1A2@I
M@KO8]IT)C&B4_'%77FEJY1:[%U:"6LU@E+78E8N';$:,SSEGG'#N:GY0R)`[
MSMTJHNL?<QS"(ZRX+9EO"R"/5V;&@"I+C0<R<2>DK%N+I]S.^XDIVCW%QT@-
M%3G0#`#H&`58_$&_6#Z-2Z%#KZ4^(-^L'T::$U]*?$&_6#Z--":^E/B#?K!]
M&FA-?2GQ!OU@^C30FOI6T+GQ']IZ_:.KM"IK3XG_`,I](Z:.A4UA/B?_`"GT
MCIHZ$UA/B?\`RGTCIHZ$UA?!<^`_M/5[1TT)K"X7Q)_8&I=`4/:CDGQ)_8&F
M@)VHY)\2?V!IH"=J.2XZTHW;F`B[A!(PAN!3G`#;>W;Q$`U>VWD>*L:2%8^[
MBC-'D`]:VOOMC_C6W]?\VKOE)OR.5GSUO^8>E<HCXJG]VHDIX;_8.0X[>W8H
MB.VHS$1F"/,5*)V.^&A\ZU_$G]@:IH"KVHY)\2?V!IH"=J.2^@Y,`^(:IH51
M*.*U?%>[\NJ:%=VPZ4^*]WY=-"=L.E/BO=^730G;#I3XKW?ETT)VPZ4^*]WY
M=-"=L.E=$=<>LWVOY1O5[QUEM8=(ZEKC(:K3WQ_6^C5=!3M"G?'];Z--!3M"
MG?'];Z--!3M"G?'];Z--!3M"G?'];Z--!3M"M?Q`^TOSZII5W:E/B!]I?GTT
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MOZ-U2!_IU41..0/H*IV[1FX>D+:4E6:8;G<I![@.!Q_$4@&'5[;:5V`:?0K'
M74;<2X>E<4;!'`(AW%!V]8)'V'\&X`.I/DIN0]*B-_"#2I]"T&L3``$2BN<?
M44$MA'\9A*&JBQF)QH!UJAW"+@7>A<<;,WV'I;KB;U`)DR@(^\0$P@'XM7C;
MW\7"GG5IW)E,`ZOF7%4LZPALDU3(;VG4,H'X@*">I!M[*^\XD=2B=N4A^%H'
MG7'_`'DD!V`I&X#ZQ!,X[_B%00U?\A!Q+O3^A6?XA<'*GH_2M7[P2H^()([>
MWX<^WS]6J?)6W,^E/G;O.GJ7"<7,S,!,\?1#0`WW%VX;-@#;<1W[S@FVP`/S
M:E9M0E_A,E=U`GV!8TN]-MQ6XFAC'ZSFM]I"Z<N9L?L5%$IZ]TB/V*8P**66
M(2$HDWZB'3^-4-N(%';8-]PVUDGNOO$K0ZTM+M__`%3SZ]*UKN_G=>U<6[AN
MFW18<;B(9=&M=0\Y+X&8[@OE6I'$H["#1VY?COOMX?`LW`#X^SU>/HUDQ=Q>
M]TOP;?<TZ6AO]IP6MG\7/#:VPDWNR)_5<Y_]AKE1[WF/Q]9B(%NKE_L&_P#W
M=6;&XW\!'8#*QS<@CX;>GTCK91>&??&08VK6?SI8A['%:&X\>?"^#+<'R']2
MWG=ZS&T*F77.?!:&_84NCX0WV!O5Q2`WV=PV%[)-=MQ\/'U^[QUG1^$_>Q_Q
MBU9URU_LM*U$WU&^'$7\,[A*?U;>G]M[>K]"H]WY@>.4TU!942\NU2J"5,BZ
M\`R(HGN/[4RA9!X*0B'CT])O3Z=9T?@]W@<*R7%FP]<CO9&%J9OJ:[EL-(++
M<Y!STPLX=,IXX>M=0X\PJK%`?A,8V94>D-OB;!$-PZ]_$![35T/3T^OT[^K6
M<SP9OS_$OX`.B-Y]I"U,OU1;,/X&SWCC3\4\3<?,UWEP72.?,-)L8&6)SB.X
M=`O+@4OV?Y745O`&V-OZ-A$-94?@P:_O=Q]$/WR+7S?5(VA^7V1U>&JZX=-(
M%3[CS!K(/7\+C"`3W$.T+FRR:XE#PW[@)1K<#B(;^CIUF,\&[+#M-PF/.D3!
MZ*N*U<GU0[L2>QV>V`X:KB0^FD;:^:BZM7S`;\8P"CCZFI%V\04D9U81-N/B
M!BJH@`;>K8=9#?!W:`/>O;HG^;&/L*Q7_4]WE)_=[78`=,DQ^T+@&Y]Y/$QA
M)3:&4HB(E*(6`XE+Z@$_WL7J$`]>P;ZF'@_L-,;J\K_U?^0L8_4WWPK5NW[:
M&\OWY]?:JG''-S*3A=5<]?HP&5.8XA\#-"!0$?`H",WN(%+X!^#6<SPL[OL8
M&":[H!^9G^0M;)]1G?21Y>;3;<3^2;_QEM?\:V4/_L?HW_X!,_\`KO5__M=L
M']]=_P!9G^0K/^(GOG_\KMO]2;_QEK3YM941.51.!HY#D'<IBL)D!`?_`.->
M(#].K7>%O=]PTNFNB/YS/\A5;]17?1IU-M=M#A^I-_XR^?\`&SE3_P"L=*__
M``.<_P#7FG_M;W?_`+VZ]+/\A5_XB^^O_P`MMO\`4F_\9;Z?-W)A2@"E:IBI
MMQW.!)Y+</4'2$N</#\.K'>%>Q$^[/=`?]6?^0I&?4;WP#:/L]N+N=)AZNU*
M[R/YZ9$8]!3TJG.D]]U2&=3R?5_YDWQJO9W]>X'#W:Q)_"+9IC475RT_S8SZ
M<!59]M]3'>F`4?MU@\<?>F'H]XT]:J1OY@]H#;XK&-<4#K#?X:Q2R`]OPZ@#
MNL7/V_3L/H]VL%_@W8'^'?SC#C$PX^9P6SB^J+>1_&V>U<*_AGD;AYV.Q\J+
MOFWF$D\/CL5*`/VM_@K>0WA_(V!Q`%\=_3X_@UB/\&C_`)K<!_2A^Z1;.'ZH
MQ_\`I&RN_H70\WQ0^E5&U\P2FGV![CFVM_:+:6A'8?HAZ`5^"$=S>'X/'W:P
M9/!S=!_"OK9W6R0>S4MK!]4&PN_UG:KYG\V6%_MT*K6/._#;G;XV-O48/K[L
M)'/"AZ?'J932IA_J^O6NF\).\S/X3[23J>YO]I@6[MOJ3[AR_P"L1;E">F%C
MO[$I]B[W_C;P-_\`7>S_`*'5_P"R4C^E_P!7_>?I_P"S[]8G_M9WO_NK?/\`
MOF^GRQZ%L_\`B&\-?[^]R_\`EG^C//U=*DB=P'6?^D;U^\=<.V,Z1U+UTR8G
M%:?B0]GTZKV95.TZ4^)#V?3IV93M.E/B0]GTZ=F4[3I3XD/9].G9E.TZ4^)#
MV?3IV93M.E;GQ`>TWTZM[,J[M"GQ`>TWTZ=F4[0I\0'M-].G9E.T*TF<![Q_
M".JB,JAD6GXD/9].J]F53M.E/B0]GTZ=F4[3I3XD/9].G9E.TZ4^)#Y#IV93
MM.D+;2=G.4142%$W6H4""J101(4XE(H(D^R7NE`#=/B)0'8?'?5SHJ'W344Y
M4\WF5K)G.%7#2:GC7"N!PYYTX+EHN/`WJ\0_E;:B<PC-2MD6]\1[_P#;_-JW
M1T*[M%J*X]/K_'O]6VJ%BJ)%J^(^6P?7JF@*O:)\1\M@^O30$[1/B/EL'UZ:
M`G:)\1\M@^O30$[1/B/EL'UZ:`G:)\1\M@^O30$[1/B/EL'UZ:`G:)\1\M@^
MO30$[1/B/EL'UZ:`G:)\1\M@^O30$[1/B/EL'UZ:`G:)\1\M@^O30$[1/B/E
ML'UZ:`G:)\1\M@^O30$[1/B/EL'UZ:`G:)\1\M@^O30$[1/B/EL'UZ:`G:)\
M1\M@^O30$[1/B/EL'UZ:`G:)\1\M@^O30$[1/B/EL'UZ:`G:)\1\M@^O30$[
M1!<@'I\/P[?VM-"=I3-;9WR2>W6<I=_1N(>/XM]]7"%SL@50S-&9HMD\LV)_
MTG5[B%$WT[[:N%M(>%%8;A@XU7%&<3W'9$XAZA$2AO\`BW';4OR9XD*/YP<C
MZD^_2?\`4'_K%T^3/Y@GS@_*?4GWZ3_J#_UBZ?)G\P3YP?E/J3[])_U!_P"L
M73Y,_F"?.#\I]2U%F@-^BV5-_1$!_(&J&TIFX*HNB<FN*IB8F6;<ZCB3?LX]
M+^2#]ZW:$(0/0`?$JI%V#UC[=9]M;2.:&0,<]WZK2ZOH!6MN[VWA)DNY8XF_
MKO:T`?TB%:R8S;BN",<DA>:P50GZ22$PS>*A[NVR.Y/O[MM;J#NYWANO]7L;
MIPYZ"T>EU`N5O>_G<?;B1>;OM['#@)F//H87'U*V\GRXP_'B8J,A)2I@W\(R
M->*%'\"KANV2\?Z6MQ!W`[VSXFV;&/UY&#U`N/J7,7GC7X:6>`OWSN_YJ"9W
MK<UC?6J+><W*$CN#*GVU_P"P3K1+$@_C.X7.`?\`)UN+?PNWV3_6)K6+SO>?
M4T#UKEKSZB>Y\.%E:;A<.Z6Q1#UR./[*HV0YS*[&"(QJD`^/2>6LISA[A%)C
M%)[_`(.O6YA\*&__`*3?'^A%]KGGV+EKOZDW_P#Z!M`_ZVX)]3(Q[50S_FMD
MYQU!'U^E1@#OTB9G*R)R^SQ<2B1#"'O+^+6UA\+MB9_&FNI/Z3&^QI]JYJZ^
MHCOE+7Y6UVZ$?S)7G]J0#U*B'_*[.+[JZ+0PC2FWV+&5V%1Z`'U%.X:.U?#V
MB81UM8?#WNI#2MN]Y'YI'GV$!<Y=>-_B1=?#>Q0C_FX(AZW-<?6J*D,ZYDD]
MP=Y*MG2;?<C21&.)L([[`2.3:``:VD/=/NS;XQV-O7I;J_M$KGKKQ*\0+S^/
MO%]3DV3LQZ(PU46^N-OD^H)&V6=^!O`Q7=@EW!1`0V$!*J\,40V]VMI%MNVP
M?P+>!G5&P>P+GKG?]^O/];OKV6OYIY7>URIU0QEAW6,981\1%8QE3"(^D1%0
M3"(COK-%&X-P'1@M2XF0UD)<>DU]JT`0A?T2%#\!0#\@:K4G,JT-:,@%JU17
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB]!1U]CF`=@'J'<!
MW`?3[-M?';6"@ZE^HSGN#B#2M5H^(#VAJN@*W6[F$^(#VAIH":W<PGQ`>T--
M`36[F$^(#VAIH":W<PGQ`>T--`36[F%J^)]_TCJF@*[6[H3XGW_2.F@)K=T)
M\3[_`*1TT!-;NA?!<>\/G'5=`5"]W0OGQ`>T--`5-;N83X@/:&F@)K=S"?$!
M[0TT!-;N83X@/:&F@)K=S"?$![0TT!-;N86\DX#[7H]7^G5CHZJ1DI`QHM[X
M@/=\^K>S5W;%:BN/3_H'5#&KA-U+5W_>/S_GU3LU7M>KTIW_`'C\_P"?3LT[
M7J]*=_WC\_Y].S3M>KTIW_>/S_GT[-.UZO2G?]X_/^?3LT[7J]*=_P!X_/\`
MGT[-.UZO2G?]X_/^?3LT[7J]*=_WC\_Y].S3M>KTIW_>/S_GT[-.UZO2G?\`
M>/S_`)].S3M>KTIW_>/S_GT[-.UZO2G?]X_/^?3LT[7J]*=_WC\_Y].S3M>K
MTIW_`'C\_P"?3LT[7J]*=_WC\_Y].S3M>KTIW_>/S_GT[-.UZO2GQ'O_`-K\
M^G9IVO5Z5H%T0/2;YA$?R;Z=D4[7J077V!,4=_#P\1]/O]>G98T*=MU+A"[<
M#_T@A[@`OU:E[)G)1]H_FOGQ3@?^E-]`?D#3LV<D[1_-:176'TJJ?UA#\@ZK
MH9R"IK<>)6V(F,/B(F$?:(B.KL!DK<2M"QR-DQ5<J)MDBAN95RH1ND4/:918
MQ"`'X]58#(=,8+G<@*GT!6R/9"W7,0Q@XN(:/2:!6_F<M8OK_5]\9!J+,Y!$
M#(EFV;QQN'J^&8*.G`C_`,G6YMN[N_WG^K6=RX<]!:/2Z@]:Y?<._7<O:O\`
M7]UL(W#AVS'N_JL+G>I6NE^6F$HO<&\[+SB@;[%AJ_('(80W]"\B6-0V';T]
M0ZWUMX=]Z9_CBCB'Z\C?8W45Q5_XY^'5E417,]R\<(H'D?UI.S'K5L9?G#5T
M>HL%0K!("'Z*LK*1L4F/O%)JG*J[;^\-;ZV\*K]V-W>0L')C'//I.@+CK[ZD
M-EC)&V;9=2],LD<8]#1(5;.6YN7QR)@A:A4X@GCTG>*2LRN'L$?]YC4!$/Z&
MVM[;^%FT,%;JYN)#T:&#V./K7'7WU&=YY:C;K"Q@;^N9)3_:C'J5MI7E5G"4
M$W1:FL00WH)"P40TZ0]RSAL\<?[>^MW;^'_=6WSMW2']>1Y]0+1ZER%[XV>(
M]X3IOF0-/"*&)M/.YKW>M6UELK9.G>K[WR!;WI3_`*28ST@W1V'T@"#19N@`
M#[`+K>6W=_8;3_5K.V:>?9M)])!*Y"^[[]\MSK\]NM_(#P[9[1_5:6CU*A7"
MZ[LXJ.UUW:@^E1TLJY4'\)USJ&'Y];9C61C3&`UO(`#V+FI9)+AVNX<Z1_-Q
M+CZ225M``!X```'L`-OR:NJ3FK``,E]T55N%06/^BBJ;^BF<?R`.K@QYR!/F
M5ADC;\3@/.%MK!\,43N1*V('B)W!BH%``V\1,J)"@'B'SZM=[@J_W1TX>U71
MGM3IB]]W)N/LJJ3DK]08;?[XOM&B1*.Q@D[C6V!BCUBEL8KN31,`]P.GT?I!
MMZ=:R?>MEM32YO;.,_KSQ-Z/Q/''!;JU[M]Y+[_4=NW"8?\`-VT[^%?PQGAC
MU8JWLGR8XXPW5]Z9^PPQZ>GJ!7)=/,8O6<2%W*E+J&\3E$/1X:TD_?\`[AVO
M^L;UM+.N[@ZN#RNDM?"GQ1OJ?)]V]]DKRL;G@*\8QP5`2'.?AY%@87/(O&BG
M2'4(1\D^EQVZ^WX?=,<]ZAZO4'CT_:]'CK2S^,/A=;_Q-]V\_P`U[G]'X&N\
ML<ETEK]/GC?=_P`+NONH_GQLCX5_SCV?RX9X*B)#S)N$T<)BJ9RCG0E%0O\`
MW;4;\_`12#<>DR-6Z#`?^0.^QO;K43^/7A)!\6\,=G\$-R[+JA]'-=!;?2QX
M^7(!;W>E8#3X[FS9GT&XKAQY*C'OFL\)VA3&1O\`;),2I@<"1^.+24QS".W:
M*,HUC"@J`>(]0@3;^5OX:U,WU(>$L0)9>W,AI^&UF]'OAF/7ATK>V_T=^/<Q
M`?MME$":5?>V^'3^[=)AU5/0J1?>;YQ!:]SX;_-B3Z"E$GPM&CT`6$VVY""^
MM#42B3?QZ@`!V\!'6LF^I_POCKV?^)24Y6[17^M,/6MU;_1/XV34[7_!HJG'
M5=O-.DZ+=V?053#KSE^+R)C%;4S-+TH)]13EK]0;`8^P_LME;J)B^(!]K;;Q
MUKY/JJ\/&&D=INSQ3^[@&/+&=;:'Z&/%R1M9;[88S7+MKEV'/"U]2IU?SJ,`
MD*46N)<P+F$1ZRKJTMH4I=O`2F3G7HG$1]0@7\.L!_U8]RP/W>V;HX])@;[)
M'?8MI']!WB02>UWK8VCA073O;$VGI*Z5UYV.(R*[,\&Y'<(])1[CJT5EFKU^
M/47LI,WQ.D/#8W<W'V!Z\63ZM>[`=2+9[]S>9FB:?0&N]JSH?H)[ZN96?O!M
M;9*Y-MYW"G67,->BGG73./.WHA53`UX^6Q5`.GH.XR%#H+#]D.KJ23JJY"[&
MWVV..X>S6(_ZM]G#B(]DN2SIN6`^@0GVK/C^@7O"6`S=Y;(2<0VSD(])N`?4
MNO=>=S60(7X+CK.'4ZOM@[R6Q3(!-O`2"C2U#";J]NP;:AD^KC;P/W6Q3%U?
MQ731[("LF'Z!-V+C\QWHMPVF&FQ>37SW07"_\;N+_P#EQ>__`!01_P#M%U#_
M`,7-M_Y"_P#VL?\`VZG_`.`.\_\`5,?^P'_[M/\`QNXO_P"7%[_\4$?_`+1=
M/^+FV_\`(7_[6/\`[=/^`.\_]4Q_[`?_`+M:D_.[A^LG=XXR`)=1>X*>3VYE
M`)N'6)`-1RE$X%]&X@&^KA]7-K4:MA?IXTNQ7_\`MU1WT!WVDZ.],6NF%;`T
MKT_Z6NU_\;BF?_+Q9O\`XCQ?_P!I^LC_`(N-J_\`([C_`&IG_@+#_P"`3??_
M`%/:?[%)_P#<KM$O.TQB)$Q7P+?"*"4O=*E=*^J0AQ`.L$SGA$C*%`?0(@41
M]VLAOU;=WZ#7LMX'<:3QD>;]V*^I8C_H'[V!Q[/O'MQ;7"MK,">50)33TE5"
MAYU6!C'$'.(<NH)](B!T'5-='ZMPV**:DLS*!1#?QZ]P]@^K.9]67<TG]YM>
MYAO08#ZM;?:M9)]!OB*&UBWO9'.KD6W31Z1&[T4\ZJ)EYS/&)QVP>4?-,>)R
MF%01@Z<\*D8-^DNZ-S(93JV#Q`H;;ZSHOJK\/GT[6SW9E<_W<#J>B<56LN/H
M6\68Z]AN&PRT.'[VY;7TVII3K57Q_F\\/G8%^*6RK%")`,(.Z(S7Z#"8`%,1
MCK*\W,4!W$0#;;T#OX:VD'U/>%TH_>'<HC3\5NT^;W97+27/T4>-T->R;L\P
MK^&[<//[\#>KFJZC_-)X2/S=)LIS$:/V_P#ZIX[O"0;$`!WZV<*^3`#[[%#?
M?<!W`-;B'ZBO".8T.XRQG]>VN!_9C<%SUS](GC[;"HV>"48?P[VT.?0Z5APX
MX45PXOS`N&,N)0;<@Z8V$P[`$JTM$/L/40OVCR=?:ID#<X>(B`;`(^@!'6\M
M_&SPIN?X>]VC2?SMF9_;C`]:YF[^FSQULJF7NU?N`_NW6\OJCF<>'+ES"N?#
M<H>-5AZ0A>0&&WYC[=*9<BU9LMN.P@`H/9)LN4VPAX"4!UT-KXA]P;ZGRF][
M4\GA\U"#Z'/!]2Y*^\)/%7;*_/\`=K?8P./R5PX>EK'#T%75B;;4I\I30-MJ
MLZ!P`2C"V2$ENH!Z1`2A'OG`B'V@^</;KI+;<]LO?]2N;:;_`*.6-_\`9<5Q
MU[LV];:2-QLKRW(_O8)8_P"VQJJ7X=?;J[*O3Z>KMGZ=OP[;:S]#Z5H:=2U7
M:QUIJ;7K"VO1JU7KYHJJ0-$Y-97HQ4&@S)+5#(])`B;4521$B0?]&UE@43EV
MP`'H`53D#]77';MW%[O;L3)V1M[D_CBHW'F68L/H!Z5ZCW:\8>^_=MK;?Y@7
MVWMP[*YK)0<FRU$K>CWB!R4P*9S"QQ/@BVM323H\@?8IUUBGFH$Q]]MROV*0
M/FQ!_P#*M@*'K-KSC<_#;>[.K]O='=P\A[DG]5QTGS.\R]Y[O^/?='=`V+>X
MYMMNCF2#-!7^>P:VC^='0<U)R%G(BRLRR%<F(J?8&`!!W#R+9^B`"&X`H+=0
MYD3;?R3@4P>S7"W5K/8R=C?1R0R\GM+3YJC'S+V/;MPL-WMQ=;1<075L?Q1/
M:\>?233J-"NS-W2!N8A@#V@.^WX=M]M0#030'%9C@]HJ1@M!53&'8H"(CZ@$
M=7%@`J<E8'ZC1N)6X/>#TD-\^_Y-6^X>(5Y;(."`H<0W`IQ#V@&X?.&A8T&A
MI5`YQ%0"0M(KB'IW#\.P:KV8.2M,E,U\^(]X_1IV:=H.?K7P5_?].WY-5$:H
M9`OG?'Y".G9JG:!.^/R$=.S3M`G?'Y".G9IV@3OC\A'3LT[0+Z90Q!Z3`)3`
M`"("([[&`#!\Y1`=`P$5&2J7T-#FMQ)<?';W>L??JUT:O9+A@MWOF^0_FU9H
M5_:E:@<#\O'ZM4+%42E:OB!^0!IH*KVG0GQ`_(`TT%.TZ$^('Y`&F@IVG0GQ
M`_(`TT%.TZ$^('Y`&F@IVG0GQ`_(`TT%.TZ$^('Y`&F@IVG0GQ`_(`TT%.TZ
M$^('Y`&F@IVG0GQ`_(`TT%.TZ%\^('Y`&F@IVG0M0+''T%$?Q:IIIQ50YQR"
MU=Q3]4?]GZ]4H.:K5_Y5]*<X^D-OF_/JAIP5S:GXA0+5U#[?R:HKZ!.H?;HE
M`%\T55JZ3=(FZ1Z0])MAZ0_";T!JE16G%5H:5X!49-Y$H-:ZPG[M5H@Q`'K1
M=SD>5P&WI`6B:ZCH3>'HZ-];.UV;>+ZGR=K<2`\1&ZGII3UKGMR[U]U]HK_B
MFXV4#AP=-'J_JAQ=YJ*T$URPPG$`<$+!)3ZI?`$X&"?K$./\US(%C6NWOZ]=
M):^'G>FYIKACA:>,DC1ZFZCZEP6X^./AU8`B*ZFNGCA#"\@_TGB-OK5I)KG%
M");DKF/Y5X/CLO.3#..3']4?AH]O)*#O[.X&NCM?"FZ=C>WD;>B-A=ZW%OL7
M"[C]2.W,J-IVJ>0\YI6QC^JQLA_:"M-,\T,IOQ.$/%U&OI&\"=N/=RSD@>T5
MI%X*!C?_`$$`]VNBMO##N_$!\S)<S._G!@]#6U_:7#;A]0O?6Y)%A#86K.%&
M.E</.]]#_45IYCD%FB<!0KS(<\W24WZD(@[6$1`!_DE");M%"E_Y6NAMNYW=
MBTH8K*$N'%]7G]LGV+B+_P`4_$+<JBXW6Z8P\(BV$?\`=-:?6K52<[)RAQ/-
M3<C)',.XFE91V],(B.^^[QPKZ]=!!:00"EK$Q@_48&_V0%Q%YN=Y>NU;A<S3
M./\`>2N?_;<5T$A+0L*W!W+RT/"M!*)P<RTFPBFQB%$0,<J[Y=ND8I1`0$0$
M0`0U;<WEI:-UWDT43!QD>U@]+B%6SV^^OWB+;K>>>0Y"*)\A/4&-<K03W)OC
ME6!.$_G?$L<<@;F2-?*\[6#W`A'OG:PC[@*(ZY.^\1O#_;?]>WO:HR.'S,3C
MZ&N<?4N\VSP?\5]XH=L[M;Y*TY'Y.=H]+V-'K5EYOS%N&D'W`/F=E,'3$0$E
M<J]QFA,("(?850@2-C[B'I[FVWKUR%[X_>$=E4'=V2N'"*&XD]8BIZUZ#MWT
MI>/VXTT]WY(&GC/<6L5.L.FU>I6=G/-JXL1HG+$1^5[.8HB!3,:?'Q2"GB(?
M94G;`P6`!VW\4@_!OKD[WZI/#.V-+5FZ7)_5@8P'SR2M/J7>;=]#_C1=@&^E
MV2S!_/=/D(\T,#Q^TK/6'SE:&W`0JF!;K+GV'I/8;G7J^GOL.PF3CXVQ'VWV
M_E!X;_CY6]^K?86#_P#';+>R'_G)XH_4ULOM7<[=]`O>F2AW?O)MT(Y0VT\Q
M]+WPCU*SDSYS>1U"F"`P'08TP[@F:;NUBFQ`?4)B,(VOE-M[`$-<O=?5OO+J
MBRV2T8>':3RR?V6QKMK+Z!>[K"#N7>2_E''LK:&+T%[YE9N;\WCEJ],?[I@,
M,0"1M^CX2K3,BLGOU;?M9FSO4S"&X>E/;</>._+W7U3^(\Q/RT&UP-.5(9'$
M>=\SAZEVUC]#?@];@?.7.]W+QGJN8F`^:*W8?6K1S_F=<X)D#@EE"(KI#B/V
M*]1Z.T,4!ZAV(NY@7[D``#!_TF_@'OWYN\^HOQ:NZZ-QC@'_`#5O;M]9C<?6
MNRV[Z0?`6PH9-HEN7#^^N[IWI#9F-]2M-,<ZN8\P4Y9#D;D=,IP$#%B9<D&'
MV@,`@7[E;QO0'VQVVVV\/1L&W.77C-XIW@(FWR_`/Y'B/_X8:NOLOIS\#;`@
MV_=C:B1_>1F7_P"*Y]<N/VE6@F.06>9TQS36;\M2HJ"8QP?9$MKA,PF,<P_L
MU9<R8!U*&\`#8-QUS5UWX[Z7I)N]WW.2OYKJ8CT%].*[.R\,_#G;@&V&P;-"
M!EHLK9IX#,1UX!6WD;-8I<3#+6*=E1-^D,A+/WHF\"A]H72ZF_@0`_$'LUHI
M]PO[K_69YI/YSW.]I*Z>UVG:K+_4K:WAI^2-C/[(',^E=)U%WWV$PCN(B8?'
M_3K#6P7S<OZOTZ(FY?U?IT1?-P_5#Z?]`Z(FX>LH?./UCHB^_8]@A^`=_G]>
MB+<`$Q]6_P#RA`?FT1:^A(0]!@_`(_Z=]$6H&Y#>A00]G@`^/X=PWT1?19G_
M`))B&]V^P_3X:(M@R*I?20?PAL(>ST@(Z(M(D,'LW]FX?ZM$7WM&]I?ZP:(O
MO9/[OGT1;0AL(@/I`=A_%HB:(FB)HB:(FB)HB:(MQ)55`Y545%$5"#N51(YD
MSE$/0)3D$#`.JM<YIU-)#AQ"M>QDC2QX#FG@14*X<%F++E8$@UO*61:^*>W1
M]RW:RQ8%V'J#8&4F@```^.M[9]Z>\VW$&PW&^@I_=SRL_LO"YG<.Y'<O=P1N
MNT;9<@Y]K:P2?VV%7ZKW/[F5603+'<A+^Y(EMTIS[QC:B"!=OLG+9F,OU@.W
MCOKL['QJ\5-O`$&^7KFCA(YLP_[UKUYSN?TW>!F[$NNN[.VM<>,+7VY_[A\:
MNG_XJG-C_P#67"?]D^&__1U0?[S_`!O_`+/?]L]_Z'\W71?\1WBU_P"80_#3
M_5;;^M_"^+U="Y#_`(/?`3_RJX^/5_KMYE^3^-\/1GTKUD:_2I?C4FB+L8J7
MEH%X20@Y21AGZ9@,1Y%/7+!R42^(?MFJB1S![A$0U#<6UO=Q&&[C9+"?PO:'
M#T$%95C?WVV7`N]MFEM[H'!\;W,=Z6D%2-J7+?+E;!)"5>1ES8I[`9.P-`3D
M#$#^268C1:N1-MZ#*E6_'KB=Q\.N[E]5UNV2UE/&,^[_`%'5'H+5ZUL7CKW[
MVC3'?20[A;#A.VCZ?]+'I=7I<'J2E4YH8^D3)DM5<G:JZ.`%5=LNU8(L#>L1
M%`&DDF01_P#O<XA[1UQ&X^&.\P@G;YXKB,9-=6-_KJW]H+UW8_J$[K73@-[M
M+FQF(Q<RD\?[.F0#^@2I&UG*V-;D!"UR[UV165#P9&D4F,EX^'2,=(_"/@-X
M^@"#KB;[N]OFV5-[:3L:/Q:2YO\`6;5OK7K>S]]^Z'>``;1N-I+([\':!DG5
MV<FE]?Z*N!T=!2[$Z2"'V/`>G;U=(CZ0UIZU.)J5U0;I:`!1O!?!*4W@8`$/
M>`#^70$C)4(#A0@$+8,U1-_)$O\`1,(?1XAJ03/'2H76\3N%.I=/("#51,I!
M'8Y!,/4(CX@80\-@UE0ETC233`K7W8;`YK6\17UK@?%#[?RZFT%8O;)\4/M_
M+IH*=LGQ0^W\NF@IVR?%#[?RZ:"G;+61=10P$3`3G,.Q2AON/K_)JA&D5=@%
M<U[GNTL%7%=BDW>;B!TMO1L(G+M\X".H#+%G7U++9#<5H6T\X7)!JMOXF3`/
M;U&'Z.@-6]M'TJ46\U<2`M\C78/M*&$?YO@'T[B.HW35R&"F;;T^-U2M?PQ?
MUU/G#ZM6]J>05W8-YE/AB_KJ?.'U:=J>03L&\RM/PP?]8?Z!^K5>U/(*GRX_
M,5\%J/J5-O[P^H=5$O,*AMSP=ZEI^&4_ZP/F-]>J]JWDK?EW\QZ%I%LMZCD'
M\9@_T:KVK.15I@EYM]:U@V/_`"E-OZ("/TB(:H96\`KQ;N_$1YEN`W('I,<?
M^5M^35AE=T*00,&=2M783]@C[Q,;Z]4[1RKV,?)!03'T`(>\##_I$=!(Y##&
M<A1:RD*3]$`#W^D?G'<=6EQ.:O:QK<@M>J*Y:@*8V_24P[>G8!';\.WHU2H&
M:J&DY!4A/WZC58IAL=PK4*)0$12?S+%-SL'B.S,JQW9A]P$$1ULK/9]VW`TL
MK:>7I:QQ'II3UK0[IWH[M[("=VO[.W(X/E8'?U:EWH"L=8.7>&X;K)'OIRT+
MEW`I(2&61;'$/8]F#QJ73[R@;75V?AQWFN:&9D5NS]=X)_JLU'V+S;=/'CP_
MV^K;62YO91_<Q$-/].4QBG2`592>YQNQZRUC'S5`OB!'-BFE7!O<86<6W:D#
M\'?'\.NHM/"F/`WUXXGE&P#UN)_LKSO<_J2G-1LVU,:W@ZXF+C_4C:T?ME6;
ME.5^;;,H9M%SC&*%01*5K5(%H9V&_@!"+N"2K_J]Y3`.NF@\/>ZUB.TGB?)3
MC-(:>@:&^I>?WWC?XC;NXPVES%!7\-M"W5YG.[1_H-5\9XRY<Y<Z%6=!S[=T
ME_[M0:[=%(TY3CN`D.X;-HHJ8[^D!`NVJ2[]X<=VZMEO-GM'#,=I`'>HE]5B
M1]V_&GOJ0YECWDW!CLB8KHL/54-CIZE=JM>6AS1LG0H7#9JVFKL85K=:ZA`F
M*!MOM*MCS+F0*(>L!1ZO=KG+[QV\+K&H.Y]N1PAAFD]!T!OK76[5]+?CCNE'
M#8S:M/&XN+>'TCM'/_9JI"5OR;^1DF"9[-?L15(I@`3I)2-EL[I/</$.B/@&
M30Q@]R^WOUQ=]]3G<B`D6%GN5R>9;%$#_6D<?V5Z1M?T3>)MT`=UW'9K,',!
M\\[A_4B:T^9RD!7/)3B"%2-<N0THX/\`9%9"I8_9LT_YQ4WDY87QQ#;T"*`?
M@UQU]]4UR21MFRQ@<#-<./I$<;?[2]%VSZ%[,`'?.\LSG<1;V;6CS.EF>?.6
M>97ZKGD_\5XDJ8S\UENX+%VZQ>6N+@6RH_\`[O`5]HL0H^P%Q'WZX^^^I;Q!
MN*BSBVVV:>4+Y"//)(1^RO0]L^B_PDLZ'<9]YO7C/5<1Q-/]&&%I']97XKGE
MS<+:T!.S@V%FU$]OV]LG;795#B`[[J)2,X=F81]?[(`]VN0O?&[Q2OB=6[2Q
M-/"&.&(>8MCU>M>@[9],W@;M8&C8()W#C<2W$Y\X?*6_LJ_57XZX#J1TB5/!
M^)H1;J(1)1CC^K_$]8B!2;.W$:LYZMQ](GUR&X=]N^&Y`G<=VW&5O$.N):>@
M.`]2]"VKPU\.]E(_PC8=GMW\"RS@U?UBPN]:_*P\_OEVQYC>9]R"G:VX9.,4
M80DT^-^)F\>F@E"_N[B9T^C+--QS=N1-H"=IR.YF7Y52%#N(*H^(@4NWG5[<
M2W<YDN'ND=S<XN];J\?4O5-MMH;&V;':L9$"*T8UK!Z&@#)88@[2?@0I"^XA
M2A^0`#6(&@9"BSB]SL7$GSIW0]11^7SZNHK:KYUB/L#Y>CQWTP1-]]_'?Q]H
M^SQ`-_#3I"HM@P>/NV#\7I^C555;9P#8-O7[?'U?7HJ+K%Q\!]GU^CY]45<*
MKI%Q\1]_^GQ\=41=>([COHJKYHB:(FB)HB:(FB)HB:(OO4(>L=$6Z10?1_J'
M1%RRJ#L'C\OP^G146RHJ.W@/R'ZM$7%$1'TCHJKZ!Q`-O#1%][AO=]/UZ(M(
MCN(C[1WT1?-$31$T1-$31$T1-$31$T1-$31%^PMD_P`G+"=B%R]Q3D"Z8T>G
M*)D(F;(WOE9(KZB@9TI%61NB8?:\<"7U`/HU]?[!]3?>JR#8N\-G:W\0S>RM
MO+3S!\1/]!J^`N]?T3]Q-R+I^Z.XWVUSG*.4-NX`?Z1CF:/^L?3@%C^R-Y2_
M*VFF<+U-"DY7C4@$Z:E4L24--*D`!'88&VDAQ[OA^BDY7W'T;Z]DV3ZC/#S=
M`&;B;K;ISPFC+V#_`*R'7ATEK5\Y]YOH\\7MD+I-G;8[Q:MR-O,(I3_U-P(\
M>AKW="@M?,)9DQ<L='(V*\@4L2".[B?JDPSCS``B`F3E0:GBUB[AZ2+&`=>M
M[1WJ[L=X&A^R;C975>$<S"[SLKK'G:O`.\/<3OMW3>8^\VT;C8D<9K>1K/-)
MI,9\SBK6D434\2'(<`](D,!O1X#Z!'UZZ`M<W,$+DPYKOA(*U:HKE\$H#L(@
M`B`[AN`#L/M#V#I4JA`.:KJNY.R+4N@*W=[-$I$'<K5&5<K,?5X"P=F<,A*.
MWB';VUJKW8MEW&OSUK!(X\2P!W]84=ZUTNT]\>]FQ4&T;C>0,'X1(XL_J.U,
M_95\X'F+EV*Z"2H5JSHEV`?O*)%@[,`>UU#+L2=0AZQ2-KD[OPT[N7%3;]O`
M[]5^H>AX=[5Z3MGC]W\LJ-O?D[V,?WD6AQ_I1%@KUM*O'"<XXHX$+9<?2+8W
M@!UX":;/4_5N8K:2;,5`_!W1_#KF;KPIN!C8WC'#E(PM/I:7>Q>@;=]2-DX!
MN\;5*P\702M>/ZLC6']HJZ,?RIP7.BD,A*S$*L)>GIF8*1(1+<=Q*=Q%&D4-
M@$?3OMK0S>'_`'MM*B&.*5OZDC<?,_25V=KXV>&NYEINIKBWDR_>PR`#^E%V
MC?/57(BLEX:FQ(6+OE/<'4VZ$E)Y%DL(CZ`[,@LT5`WNVWUI+C9.\]K4W%I<
MM`X]F7#TM!"ZVQ[X>'VY$"RW/;WN/`SAA]#W-/J58$:MGQA/$J1#UN(!T';O
MOBQ'[(=0]39=4HAU>CW:UW:OB%+GM62=+:>T!;\0PW)U6)@DB.1:_5_9)7:(
MPR!4DP<M`!8"[*"!UMA,'AU`(B7TA[M8[[MY<3&[W.&2S8]OB;&.W9^\ICB5
MU*D*Y$YQ(5`A!,82%[R@])1$>D-Q((^`:R6W<8`!+B>I8+]NG+B6:0VN`J<E
MSXV.5:*G46!,1$G202',80$1^UX&*&VX!J&XG;*T-97/DLJSM)()"^6F5!0U
MZUW6L1;%?0`1$``!$1]```B(_@`/$=4RS1?3D.F;I4(=,P``B50IB&`!#<!$
MI@`0W#0$.%6D$*I:6FC@0>E<147?=3[)4!1\.Z*AC@I^EX]L"AMX%]OKU(WL
MM)UDZ^%,E!)V^MO9AO9\:Y^;S+DZL4R:(FB)HB^@41]`"/X`$?R:H@!.2'**
M9>M0.V0/293[!0_Y1]@T!!-&XE5<"P5?@.G#VJFI.YTZ%*)I>VUB,`OZ7QT_
M%-S!_P`A1V53?\6LZ#;-SNC2VMIW_P`V-Y^Q::\[P[!MXK?WUE"!^>>)OJ+J
MJW4IR*PG$`;XC(<,Z.7<!2B4Y"84$0]1?NYFX3'^MMK=V_<OO3<GW+*5HYOT
ML'[3@N4O?%CPZL0>TW6W>X<(@^4_]VQP]:MC,\T<11H&"/;6N;.&X%%*,:Q:
M!A]`?MI5^@J`#_YK?6]M?##O)/\`QG6\0Z7%Y]#&D>M<;N'U#=Q+2HM67UR[
MHC;&WTR/!_95,-.560[HX*SQ;@6SV==4>E$46UALBAA-^B/PM9A!(`?_`$;;
MWZSI/#_9=K9VG>#=[>W8,ZF.(>F5_P#R5HH_'+O-OL@@[G]V[JZD=EA-.3_1
M@BI^VK@1N/?,MR08/W?PG)4EDX`13<RT+7ZD1(@^@3.;W+&?`.WK!+?W:TT^
M^>!>QC_3-UCNY6YACY)J^:W9I]:W,&W?5=WH(_PS8I-OMW9.?%#;T_I7<A?^
MS55FQ\LOG-D'8<D9<J-9:J["JV?WNPV$Y2F'<Y/NFJQ)(D1*`_H]\"^K?;6J
MF\>?";9L-DVVYG>,BVWCC_;E?K\^E;*/Z7_J$[S_`/\`U6^6MM"<VONYIL_^
M;MXQ'ARU45V*KY*<242K7SD%(N53;"LA2Z(T9@8=OM`$E89M^H8=_086P?@U
MSFX?5/<D:=HV9C6\#/<%W[,<;1^TNKVCZ%K,'7WA[QRO><Q;6C6_MS2O/GT*
M2=5\H_B1`E3-.DR9>7!=A.>;NOW2V4$!W_['58R$$I1]G=-^'7"[A]1_B/>$
MBT-A:,_YN#61_2E?)[%ZAM/T;^#FW@'<!NM_(.,MUV;3_1MV1?VE)"K\&N(-
M/!/[GX]XZ763$!*ZL4<ZMSL3!ML8RUI>R^X^'L`-<1N'BUXE;F3\SO5Z&GA&
MX0CT1-8O3=I\`O!C90/DN[>V.>/Q3,=<.],[I%(F!IU.JJ)&]7J%4K*"0`":
M5>K4)"$(`>@"EC&+7;;7$WFY[GN+B_<+FXG><S)*]_\`:<5Z7M^R;)M#!'M-
ME9VL8R$,$40']1C54QU55/TU5#_TSF-^41U@!K1D`%M2]SOB)*V]7*U-$31$
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M7+Z0_#MHBZ1<@[C\OEX:M55UYBB`^[VZ*JTZ(FB)HB:(FB)HB:(FB)HBU$_2
M#1%R2@/XORZJJ%;"GJU156WHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+]Y
M;75+DDT1?3")TCH'V404`0404`%$5`'T@HD<#)G`?8(#J@P<'C!XR(S'GS52
M=3#&[&,Y@X@]8.!5A+SQ9XVY*%<]VP9C*;=.-Q5D2U6/AY8QQ'<5/O>!3BY,
M%=_'J[NXZ[#:?$'OSL5!M6[7\4;<F]JY[.K1)K;3S+SS?_"3PO[T:G;[L&U3
MRNS>(&1R=?:0B.2O3JJHD7+RE^(ME$ZL"PR%CUP?J$HUFYK2+$@CZ/\`N^W,
MK"'24?454FO2-L^HSQ(L:-O'V5ZS_G8`UW]:%T?K!7C>]_1WX-[H2_;X]RVV
M0_W%R7M']"X;-ZG!1?M?DJ,#&44H?(-X@4=Q2:76B(.A#]4IY&O3C/</:(-?
MQ:[[;OJFF``WC9FD\3!<$?LR1N_MKRC=_H7MR2[N_P!Y'M'!MU:!WI?#*W_X
M:CI9O)XY.Q)CC6[1B.Y(EWZ.U89JN.SAZMV\W`%;$,/L^($/?KMK#ZF.X-P`
M+ZWW*U=TQLE'I9)7]E>:;I]%?BM9N/\`AEWLU\P94FEA<?-+#I']=6&L/EM<
MU*Z)^O"KV>3)N/?JEHI\^F<`#?<B3>=3>#OZ@%(!'V;ZZ^R\<O"V]`INK(2>
M$T4T9])C+?6O/=R^F#QSVPFNQ27#1QMY[:;U"4._95EY[BIR;K`&-.\?LP,$
MR!N94M"L+]`H>'B*\8R>H[>/ZVNIM/$+N'?FEIO.V/<>'S$;3Z'N:5P^X>$?
MBIM0)W#NYO4;1Q^4F>/2QKAZU:>1I=TAS&)+TRX1)B#L<LG5IZ/$H[].Q@=Q
MZ(E'J\/'UZZ*#=-KN16VNK:0'\LL;O8XKC[G8]\LC2]L;V$C^\@E9_:8%2ZQ
MDTA$C@2)#X;D7V3'Q#<-RJ;#XAK/:'.Q94CHQ]BU+W,:=,E`>G#VK6W?_#&`
MS-\+8X#N!VCLR!P$/89!0A@'5'Q:Q21FH=(K[0KHKCL3J@D+'?JN+3ZB%6<?
MDS(,6!?NR_V]H4H;%*A9I;H``#;8"&>&)L`>[6LFV+9[C^/9VSCTQ,_R5T%K
MWO[TV0`M-TOXP.5Q+3T:Z*LV7(?-K$`!')%@5*&^P/?N^1]._P#*?,7!Q_2]
MOL]@:U<O<SNK+BZQA!_5U-_LN"Z*W\5O$:V%(]WNG#]?1)_;8Y5*WY6YR;[=
M5J8NM@'_`+76X)0?';QW39(CX;>'X=83_#[NH_*W>WJED^UQ6WA\;_$F(4-[
M$_\`G6\)]C`N^0YCYF2#94]0=?:`=U:V*8@`>DH?#2"`;&]?AO[-8;_#3NP[
MX1<MZI:^UI6SC\?_`!!8/?-@_KMZ?V7A=JES4RJ0W4>&I"H;>!0C)9(0'<-C
M`<DV)O`/RZQW>%_=YPH);H?TF'_D+-9]0_?=IJ^WVUP_Z.4>L3+=-S;R;N)C
MP%&$?68S6:$?9XB,WOJT>%>Q9":[]+/\A7GZB^^.9M=M_JR_^,OA.<&1$U"&
M5K]!5(4P&.D9&:2!0H#XD$Y)P#D`WM`0$-#X5;*00V:\!YU8?^0@^H[O:UP+
M[7;"`<1245_[ZJJA#S`KB@5(C;%>&%U$S&,=21)?Y(RX"``!3I!?FJ)2E'Q#
M8@>G6`_P=VUY)?N.Z!IX-^7;3S_+D^M;!OU.]YF@-BVK8RX9EPNWU\WS8'J7
M)4YN9QG#"6$Q'BY(1$H(EA<<W>4,GTF(4P?M[=(%<"<P[#W"FVZM@V\-1CPK
M[J6@K=;EN!''7<P,]D+:>8C)7N^H;Q(OS2PVG:@>'965S(1ESN'UY8@YTY+D
MH99YN7'=.NXBL!@74.9,:W@6=/T]:9P!-%R[C'^R9`(8Q=SB(&#TCZ-6/[O>
M%>V8WNY0X#'M=PC])`<W'@<%+'W_`/J#WHZ=MVFY.HX=AM$AS!P#G1OPP)&.
M8S51L<5^9I:-BL\;9?9D5'8#N*W6JHF7?[(B*LJG%F2`.G?<1#;T^O6#-WB\
M"+#&6_VUQ'*66;U,U56R@V#ZLMWPAV[>XVGB8+>W'ID$9&7-5K'<$?,GMH%/
M++OJ^FJ(=063,4/'F(!@ZA$[2OR4FJ3IW\0`FX#X;:U4_B]X&[::6X;,X?W5
MD]W[4C6CUK<V_@/]5&]BM[+-;M/]]N<;*?T89'GU*O8CR@^3%B,"M[S3CV'`
MP@*A/O:\W5T`#^D&QX^+:&,`?^6V'6GN?J5[B60T[1M=[+R]R"`?VGN_96\M
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MOZ]<C7OKTZJJ^2`%:)`W:$(T;E`"E;M$R-D"E#P`I44"IIE*`>H`VUR;R9':
MY"7/YG$^DXKOHP(6=G"`R,<&C2/0*!?=455\U5431$T1-$31$T1-$31$T1-$
M31%XS_XQODNI6^//%GB#"R)D7^8LCS^;;RT;K="AZ9B..+7JFV=D*;<6DG=;
MFJX(`^!E8@!\1+X8-R!(='`>GG]RV6WMHXO/*GI\BO!U0LW9NQ.Y*ZQME:^T
MXZ(@H5.#LLLT;")?']HR(X%F<ON$@ZQ*/:<"ML".&"R28D\\'FYCM)G'7"4I
MV:*Z@0J"T9D.MMG+ARW+X'34DV'PRICF`1#J4(?Q'QWT$KVXT]&"KCSPZ<5+
M%GYI?ET<@E^WRNX-,JI)/NVD]M>+B1ZG8$?!5R#=`(AZ&QAWVV4$??J9MU4:
M9*$=(KZ\U9V;*U`H>@_8JM8<(?*`Y7MG#CCSS!:XDMS]?=E3,H*HQADS+#^S
M;E"6+&+&V.(%W(HKJ[3:2FFFG\T_85:6R-Q#AYQ]H5@<K>0;RGK8R#[$<Q2\
MV0;1NJ\2>TN=:N7"S4A1.44VBITU%#F)ML4@F$1'P].H'VD9QB>.HX'[E<#(
M/C::<QB/5]RQ.Y-XM9]Q(Z6:W_%MPKIVZATSGD(-^W3`Q!$#?M%$2D$/#<!`
M1#;6.^UF9F,%5LC3D<58!=LX0,9)=%5$Y1V,50AB"`@/HV,`:@+7#-7CH77*
M%$0'</'?Q_#MMJU5ZUUJJ6_J]6BJN`=`?9\OR#HBV!1'V!\PAHBT"C[OI^O1
M%\[/X?G#153L_A^<-41.S^'YPU5$%+W#^(0'5$6GM#[_`)M%1?.V.JT54[8^
MWZ-45%O$3]WUCHBY0)^'U:JBXZJ8Z(N(("'@.J*J^:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB+]Y;75+DDT1-$31$T1-$31$T1:RG.3Q(<Y!]I3"7\@AJA`.
M85P<YN1(6HZRJ@=*BAU"_JJ&$Y?F,(AJ@:UN+0`>C!5+WN%'$D=.*Z!]6:Q*
M?_52KUF3\0'_`+RKT,_\2E$A1_WMDMXE((@'L`=M9D5_?P?P+B>/^;(]OL<%
MKKC:MJN_];M+67^?#&_H_$T\%13[!^$Y,#%D<-XG>@=,$C`YQQ3E>I,#"8""
M)H;?I`P[[>W6UA[U]ZK<U@W/<6$&N%S,,?ZZT5QW"[B70(N=DV>2HI[UE;'#
ME_#5+N>+7&=XIW7/'S#"JG2!.L<;U0@])=]@V3C"%\-_9OK/9X@=^XVZ8]YW
M0-__`%F;[7K52>$WA9,[7+W;V-SJ4K\E;_8Q=#_P9\2M]_\`AOP][?\`V+C?
M[&LS_P!T/$?_`,\W/_MW+7?^R'@Y_P"F-D_V9BZH_!CATH<ZAN-^+NI0YCFZ
M(=TF7J,(F'I33?D33+N/@4H`4`\```UD#Q:\36@`;YN%!^N#ZRVJPW>`/@HY
MQ<>[&TU)K_"</4'T'4,%I+P7X<E,4P<;\7[E,!@WB'A@W*.X;E-("4P;AX@(
M"`^O0^+7B:13_'-P_KM_R50>`'@F#4=V-IJ/^;=_EKMQX9<21_\`];\/>/\`
M^9D:'Y"^&L?_`-T/$?\`\\W/_MW+-_\`9#P<_P#3&R?[,Q=VVXK<8V9TU&W'
MK#"1T0Z4S?Y<U902AT"3_I8T_4/0.VX[C^/6(_Q"[^2`A^];H0<_])E^QRV$
M7A)X50D.B[M[&'-R_P!"@/1Q854C+`^#(WH^[\*XC9]HXJIBWQM32"10W@8Y
M1"&W*80]>L&7O?WMGKVVZ[DZHH:W,^7]=;.#P][@6M/EMBV9E#44LK;`\_X:
MJYC1J+%@4(RC4F-`I1(7[OJ-=9=)#'[AB!\-&I"!3'^T(>@1\?3K6R[MN]P:
MSW=T_P#G32.]KBMQ;[!L%H*6EA81`#\%O"WI_"P<<55"(%;ALW(1N'CX-R$0
M#Q'<?!(I`\1#6`XE^+R7'I-?:MLP"/\`A@-'0`/8MXRZY@V,LJ8/890XA](Z
ML#&#(#T*\R2'-Q/G*VM7*Q?-51-$31$T1-$31$T1-$31$T1-$31$T1-$31$T
M1-$31%X&?XC3R_/,$YD<]+)F;&V$KA<L(8XQ50<58V?PJ*;\CEE!H/[+=)5!
MDFJ*R8/;Q9WZ>_2`J$:D'Q\-83XKA[M49!'*HKU4KYO,MQ:F..$:P03C6A7E
M@N?"+E!C]PHVM^&\@0"B8F!096JRS0A1+OU_;,VZ1`/PZA++AGQM(\RS6N8[
MX2%9R0PMD6)1,=S498J8"/4/P+@@E$/2(@9(-O$/0.K-5!0A5H3D<%1;JGRC
M0Z82$6]:=XHB4BB!BB8"^!O5X>G5P;$X^^:!6.=(![HJ5TKJO`'VFQS$.F(C
ML(&*8NWK]`"40U5]K&16)P*C;<.KIE:0KMXLY,<E<#R!)'$V:<C4A9(.GM0M
MIDR,%4]P$4EXU==9@ND(`&Y3)B&L?3*PX%9(+3B%DIQIYZW+RN,"US,-=Q?R
M"K)]DGC.^U1FC*N$!V!0OWDP3*B)S$#;<R!O?H)I!AEU*N8QH1TJOIGFAY77
M(PZG^<7%BRX$L$ET%=V'&SAO)PB2P@/6X!DU314(3K\=@:".VKS,UP]X`GI%
M/8J:6\*CU^U4\\\OGAEG)E][\8.9%$<2*I3')2;^H%;G`,;]!`H.1:JF5$1`
M/[G;?5O90O&%0>C']*>\#@01Z/+TJ*N5_*HY<8U9O)MO05;E6FY15+-T]VUG
MVQT!#J*J!&2IW.PE\?[O4;K1_P"`@H'G-P(Z_P!"Q_6/'MQJKD[.Q5N8B')!
M$#(OV#EJH&PB`_863(;4#HGL-"#55#FG(JCCMC%$0,02B'I`0$!`1_TZCIS5
MRT"A[O\`1HF*^?#^[Y?-HB^_#>[157WX;W:JJ+2+;W:HBVQ;^'HT1;9D=O5\
MOQZ*JT"B(^@/'U!^'V?AT1;G9,01*8IBB'I`P"!@W]H"`#IUHMT"^'H\/:/U
M[>C1%H4(!O1[OR:*BXHM]Q\0\`]VBKDN.LF)?``_-^#\.B+B^C5%5-$31$T1
M-$31$T1-$31$T1-$31$T1?O+:ZI<DFB)HB:(FB)HBP%><3YY%;\L6VXQQ!CS
M&]7SOG&WQZURN]1G;?(U>(QQCM8B[6MOI9]!QTL^&T7&415.Q9'3(!8YJJX4
M$`5;]>NNKSLG!C,^L?<?O^W:6.WFZ:9'DM8,!AF?2%D:\N3EI,\Z.%^$^5=A
MI$1C>8RRQMSMY2H*:?6&*A!K-]M%,2(UF9)E'/7H/$:\5P83HDZ#JB0-P*`C
ME6TAEA$AS-?;U#V+#NH1;W#H0:@4]8JIMZG6.ONJ(OFJHFB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBZR<GHFJ
M04Y:Y]P1I`U:$E[-..U3`1-K#5^.<R\JX4,.P%(BP9J&$?4`:L>X-:233]."
MN:"XT&:_.4JG\5SR\K]BGGX+UR>K$K8IU_#P<Q!M^F-@I"9>O8J.!5-))?=E
M'N");B.X].X^.M=\W$2#(UI'H/I"Z)L18T-8XB@4\J3_`!7E+MS)HRS9QRH-
M@3!/I>G120$RICAL8Q$W31RF!3!ZM3LN+<'W>T:>AU?450M?^J?,KR5_SW_*
M0R"7JR5Q3@HAP]4*FY,V@X5TF5,Y@`ZFZ;9N82[#X@`;ZJ7QO_SI%>8'V*HJ
MT8L'I5P/^,+^'&SEUQUEQO`T]R;]D1^I65V($!0-Q,DZ9"<"AN/K`/'46IPX
ML<.D*H#:UHX+KR>6Q_#X<B&:[K'V=H6H/)L3"8_[TD9&:"8?`O8E2HII&`1]
M8ZJ7#C$T_P`TT0L!R=Z0K$WS^%KXF9&$Y^.G,BGR(G*8R+1[)PLGMW/[H3+Q
MTBH?Q$?9XZ%D5*N;(T>E4H[@6GU*%.2/X1SE76P^\*-=:7DACVG)4BQ$FG'/
M3K=(BV.1-X?MG3W_`$OM:C#+<FHD%:<00JG7D0?,L8V5_P"'E\S#'2;L7''J
MT3Z33N'.O7DF\J7ME`1!0#,UU.L!*'X?'0P.<VHTGJ(JJ:Z.ICZ"L<%^X(\K
ML3J"%ZP1DVM+)J"4BCRK3+8P&*/@<B@-=BA[P'5GR\C1BQWF3M&GB*^A;-)S
MCS%P5NWI&2LJU5JW$#*PCJ1D7D2()?R%8:8^+9"0-O$.V&HW=H.?G5X=PX="
ME#%^:OE^18DA<^8;Q'FR-%J#0SJ<JJ$!8.SX`*J<@Q050,L(>OLAX^.J"5[<
MZT\O,KL"<:%;C3+'EEY=`Z=^Q;DK`LZZ(/=DJRL6SUQ-T??]I\.GUN4T"F'T
M`B7PU7M(7?$*%*"F9]JWC\!^/^4TC/..O*W'-G75*=1"MVAV%6G"^CMHF;R!
MRB*PF';]$H;Z&")V+3BJ"HRH?+I4?,B^73RBQTBXD'6/'\U"(`8_WU7C(3<>
MHD'Z*A%HU5R(%,`>&X!J-UJ^GNXJNJF>"A_+4ZS0*ZK:8@92.70$062=,'*1
MDQ`=OM@=,!+M[]0F-[<P56H.2IXR>WAZ]_6`^'X=6'I5<%I$H;>KY_3MX>CT
M:8>=*+8,4/9ZO:&WTZ=2I7FN*9/?_6'XP]FJ*JSB^6!P1B,JU"?SAD>H%G(9
MO(),:@A(AU,1^'-TNI(6PF`JXBO]@FX"'AK96-J)CJ=\(6)=7'8MZ5E;F?+!
MXZ93M+6P2F/3$E&[=)%4C!9:-C7)D]C%.Z9-A316.0`VW$/$/3K*DL^TFK0!
MJPFW89'0$EY4$>9ODPR$?'2V0..IB"M$QZ[R9QVN!Q4>F;%ZS'KJXFV*L9,H
M_LC!L8?1K%N;4->=.`]2GAN32CL?:O.Y)PDG#2#V*E6#J.D8YRJS?,7J*C=P
MT=(&$BJ"Z2A2F35(8!#8=:X@A;`$$8+A]H`#;_0'TAJBJN$HAU"([?+V:K1*
MKKE40#Y?+;5.I57#'P$0]^J*J^:(FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+DD
MT1-$31$T10QY_P#-K&7E\\6\A\E<F&1D/W=;%A<>TD'9&LCDO*$TBX)3Z-&&
M,/61-\Z0,XD'!0,#&*;.7(@();#C7,XACK^+AY>750%9-K;NN9A&WS]`7B+R
MSPQRC;?*?YC^<!S-[]@Y/\PLB88E<5IS34Z*U%Q#8LQU(B]IBXUSN:""_1S-
MO'P;8`+]WT]DV(3[+Y0-:<QN[)TS\R,/2,O,?13I70,GC%VRS@_ALK7I-#GY
M9UZ%Z?\`R-<B4/%GDN\0[?DFX5ZCUEE!98.M,6220C6R@ESCDO\`8,DU3?%2
M;PXAL1NU367.;P*01\-=5W7V/>>\<L>U[#:SWFX/)HR)I<1CFXC!C>;GEK0,
M20N'[[=Y^[G<Z";?.]=]:[=M+`"99Y`QIP'NL!]Z1YX,C:Y[C@&DKLC^8KR%
MY+YM=8BX.8[K2]71!!)SD_)$!*NE(I@54Z<C=9EH$DVAZS7O$/@FKM%R_<B0
M`!,55`0)]5#P,[D=P>Z3>\WB]?7#=Q-2+2UD8`]U*M@8=)?+)^=[',C;6NH-
M;K/P;_Q2^)WBUX@O[D_3SM=H_96Z0[<+Z&1QC94A]U(W6(H(?[IDC))7T`TF
M1XB;E^Q_69VIU6-B+3=YG(UH`GQ%BN4VW91ZDQ+K@472D9!Q:#:)KD&B8.AF
MQ;I@5%$H=9E5145/\P[WN%GN>XR7.W6D5AMU:101ES@Q@RUR/)?+(<WR.-7.
M)H&M`:/N/NSM&X[)LT5EO&X3[KO%-4]U*UC#+(?B,<,8;'!",HH6-HUH&HO>
M7/=6>M4M\FB)HB:(FB)HB:(FB)HB:(FB*Q^?.0^,N-M1C;;DI_*F-8Y]M4:1
M4:M$J6&\Y`M[QJZ?H5JG5])9L#YXE&L'#QVY<KM(V,8-U73URV;IG5"&69L0
MQQ<<AY>7FK26*%\SM+>&?0J2P+RRQMG^8G*A%0M\QUD>O0;6V/L;92AX2*L<
MC27TDI"MKY4)FHV6[4#(%-+.HFCW3Z"FI`L;(`5J^*V742(>D<XD.DBCN'3Y
M=%5=+`^+$D%N51SY8T(\X"D[J=0)HB:(FB)HB:(FB)HBX#>3:.WKY@V%996-
M%--\L5!0K-!RJ0BI&0.C@5)P\*@<IU")"?M%,`*"4P@4:<:*M,*KGZJJ)HB:
M(FB)HB:(FB)HBQ<^=AFPO'[RH>=F0R2/W7(N\#V#&D$\*?MK)SV9GD=B:.%L
M(>(N$QN1U"@'C]@1]6H9M&FDATQG,\A3[Z*>W!,PTBK@:TZL5^0.2`@CID!O
M.HEZ2E`I5!)OL4`#T"8OLUC#;[&05CN6><46T-U<@T="ZG0?T+Z-84Z0%K+M
M%0'<0_:@7YMCFT.T.(K%-$X'IH@OP![\<C?-5;1Z_/I>*:Q%0]J;@/R#MJ)V
MTWS<@'#H(*O;?6Y-"2#TA;7P]I:>)0>[>G]FH)R^`>D.DWIUCNL;UF)C=[5(
MVZMW8![?2JEC,DY`@42-FLE*M4R'Z_L'<)F$?1XB`AOMMJ(B=GNN:X>93!S7
M?"0?.KHU3EMG.B_'?NQ?;1!C(IHI.C,)1XU4,"!NM(R2B:I3HG*8?240$0T$
M\S12I`*NH%*O'OG`<_\`'"[5>J<ILNPI&0`+=H%K?/&A!*("&[9V=9(P>'H$
M!U47,W/#TJFD'$K))AS^*7\SO&Y/AIW*5?R8S`I2]J\U*'=K_9V\3/F2#1T(
M"'IW-IVS3BYK3ZE=C3`E9$\;_P`7UDZ1;)QV>N)V&<CM3=*:[N*7=12YTQ'9
M4?@Y!"5:"8Q1';P`-]2"X8![H<T]#E;2IQH1U*3;?SYO)@S[6^GD=Y?K>$.[
M5,U=+U^N5687ZE0W46268%A)(""`CN(CK(9>'/M33DYH<HS"W+0*\P:+B+S7
M\*=R,8)F>DL&#WQA('2[C;=!*M"F]!`[99QF"9!'QV]&J&5KC4]DX>=JKV?(
MOKZ53+GR-_(?Y"INW>`/,8K->=OB]V/C9RV517X3N$W(4[>97@9!3I]@_:U6
MD;LXS3]5P*4<,G"O2**/%V_A%I^:[LKQPYG8,R,W[97$4FK,),'CGK\4@!Q%
M/I1LGU;^!@-MJPQVQS+V];?M"H>V'!IZC]X5GY#R"?.ZX\H*(8M<R-ICD""9
M-&FY28S$8X!J'6GM"S;D$A*8"^!13#<?#5X:T#W)&D=)(]H":G$XM<#YC[%&
MZ\X9\U[$K@%^2_!&2RO#)`9)\I)XL=@\70+]DYBS559N4^L2AN!^G5X$N!`#
MAT4/WJSM&'!V?2*?<HEV>O\`"FZNS,\R<=\[\6K&J<Z;J5A(J0G:^U<>@YU(
MR0:-WZ:9#^D`)N`:M<R,BDC"#SH0KVG5BT^PJU$KY=5$OC-W+<;>4F*\A@"A
M0:5"U/PH]T."OZ"(Q\N8A5%0$>GT@&XZQW6T9^!WI5]7"F`/ETJ*64^#_*?$
M`*K7/#-R3C4@ZOON&C%K#"'3$.H%"2<*#UKT"7QW$P>&H3;2-X5'0FH#!V!Z
M58S'N-;/D7(=5QQ"QCQ2PVF>CX)HQ%NL1P15VX(DHH=$Q0.4&Z8F,;<`V`/'
M40:=6FAJKB0!@O?MA?!T/@/"..L.1+%H52!BHLTLX0Z3'!VF@F95,QR#]HZK
M@PG.`[^(ZWT%+>'0/B*T5T_M9:9T4QZ94(]%N=T4@&.<I3B<2[;B(!U`'L`!
M'4IN,*\5C,BPJ>)7(EZK&JJJ`0FPJ@;J.4OV@W+X@(>@0#6MGG+AI=Q*SX(B
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MM7CUQ./TEZI7&[!@@JZ>RRC%HPGK+]T,FJ!UE5G2$>5-(@F,)0`1#Z&VGZ8]
MV@M!N??[=]OV6PI5PU-D<T<G2/=%"T_S72+X]W_ZX>[]UN#MD\)N[N[]Y=TK
M1I#'PL?C0%D4<<UR\=#F0GJ7F)MENYG?Q&G+IC)U/'4,[XJ</5&BJ57CI)*$
MQN[EK$_.N5Y.O;E,E3L-LR8$("2B11,HUK+(2@DEWSBKXEM>W>&5[XD/MMRO
MKIOAO:/=65['NGO!'AIC;!'^Z;.^I:2`60BI<97!?36_;QXV[7X-,O-EVNQ?
MXT;E&T""-\;+7;NUJ[5*^ZEI.^UCHUP!(EN2`&=BTJ=7G68U\R"&\M[*$[R,
MR70RX=AK3A>-<XUJ+BJM$BB:_P`!'5=FPB*?38V,0CX-X5`4T@>E3231`"%-
MT@77H'B9O7@`[N=/M7A[MEU'WC=)%V=Q(V6C6-D:91JFF<X%[<,(\:XD9KR7
MP1[L_5I#XD6F]^+V]V,W<QD-P);2)\&MTCH7MA.FWMF-(9(0XUEH`,`<C;7A
M'Q\X[8=\GK#/F!<PLDYGL6&*TR?H_P"5&)(>,<3T8C/9ZL&/F,?&/K'/IH&;
MOI]T#IR1F6/$B2AS%.90/M4[G_4-NG</P]M.Z_=O;;2.]A;)VEU)5[I'/E>X
M.[)HC!+0\-!DD?EE3!7>(OT@;#XK>+VX=^.^F];A-MMP^(PV$-(V1,C@B88S
M.\RD->Z-SR(HHS5WQ5J3Z@_+MR7QHS7Q.QSF3B3CN7QKA7(2EB6@(FSU]I`7
M&37JEDEZ;(S%I!":L;J4>.9*#7[+ER_<JG0Z1^P`]`>3[]WLW[OG?G>N\-W-
M=WK@0'2'!K:_#&P49&ROX6-`XG%>_P#=3N#W4\-MJ'=KN?86VW[8P@EL0-7N
MH!KED<3)-)3#7(YSN`(&"D_E/*%`PEC:\Y?RK:8NDXWQM692WW2U3*P(1\-!
M1#<R[E<_I4<.5S`5%LW2`Z[IRHFBD4ZBA"CHY'MC;J=DNH8QTCPQ@JXE8QL<
M>=[P3R!QDOW,>2DLR8KXW4&[0.,QR1E?$TC`(7O(UA%8&]&Q9!P4I9[#?K!'
M%2ZGY6C7L,@$>ZJ44U@2Q&WT987D4'G^[[/85F/VZX;*(1I=(16@.0YGR^Q1
MQE/XC/B<=JO+4+BKYB^4:PW`RI[A5N*LDRK1FI-Q.\2?3MF8J_#`F'5U'33\
M/2`:I\^RE=+J]`J/L4G^%S5HY\0ZW8_:I9\"?.2X1>8M;)G&V#;->*SEN#@W
MEF<XJRW4`IUKD:_%KMVLS+5QPQE+!7+$C!KNDP>HMWPO&Q3@H=$$P,<)(;R*
M9Q:,#T^7VE0W-A<6K0Z0`L/$8A7,R5YGW$/%7,BH<"[/:[D[Y)7-E79%E7*U
M0IF?K4&RLL7)V%LZN-S;&)!U-K%56(6F))5X<B4?%=+E4P$,&J/NV,E$5*GS
M^RBI'9320&X%-'21]ZAGG_\`B.?*CP%:9.ECFRRYIL,*[682W^0='<WJMLWC
M=045FZ=WDY&L4Z7%-0H@)X]Z\1$0\#CJQ^X0M=3,<?++UJ:/:KR1NK2&]>'Z
M?4K^<'?.?X$>8'>%,58,R%:H7+?W3(3L?C'*]+=T6S6*)B$`=3#NJ.2O)FM6
M12(:;KN&S5^=XFW*9;LBD0YRWPWD4SM(SX>7\JBN+"XMFZY`-',&H62F]WZB
MXMI\_D+)MSJV/*%561I&RW2ZST;6:Q!,2CM\3*34NY:L&I3F^R0IC]:AQ`I`
M,80`<E[VQBKC18K&.>[2P$N/)8/LB_Q+GE(8_GW5?:9HR)DE1DJ*3B8QGARW
M2]<^R82F5:2]B"J$D6H;;@JW(JF</$AC!MK!=N,0/NXCS_<?:M@S:;MPJ0!U
MD*?'!KS+^('F,1]V>\5+W9+<YQNG7U+S$67'UMI4E72VE232K_=5FXXD-(FD
MU(5T!"LWCDY01,)BE+L(Y$%S'.#3,=?MH%C7-I-:D"44!RQ"I7E;YN?EU<++
M"YI.?N3=.B,BLS=#W&5*93>3<@QJPAN5M-UVB1TV>MO#`.X(R2C-80'<"[>.
MK9;R&,D$^]Y=9]5%=#8W4XU1M.CGD/6K5\:O/3\L/E9D:$Q'C/D,K!Y'M$FW
MA*I6<K42WXP-:9MX(%8P<%-62-2KCB<D%!`C9FJ\1<NE#%(B0YS%*-D5]%(=
M)P=7RX#[2KYMNNH6EY;5@&)%#[%9;SO*/.6&B,.N'0DH;(^!<N<;:7)RY(8*
MM4,Z9+S+QGNE8"TOK,^BZQ`-,B4'%]@B&[N2=-&;EV@2*,L523235CO&ESAR
M(-//3CZ_5Q4FWN#23Q#@?,`[TYY>?@K;^7YAQ]CWF5.8YC25"9N&(>0'*[+.
M5[OAJLT6BX%;X-RUA/$.,<$0]'H.,Y"5J>+Y'+TO6&,O)U=5R>55G*7)RRY?
MAUF:RL-NU_:-:!2AK[,/5QQJ#S"FO)(W0EU2:@`5XT)-?-CCD`0!B"O1)K<+
M3)HB:(FB)HB:(FB)HB^[CX!Z@]`>H-QW'8/5N([_`(=41?-51-$31$T1-$31
M$T1-$7E4_B_LNFH_EBT#&#5<2/,Z<HZ%$.VY3](N*[CJL6^^2(G)Z3HI3S2)
M$?4!Q+[M:W<'#0&_B^P__P!*V.W-)E+N`'Z/M7YG.M0MPOOHT1;I5UR?H++$
M_HJG+^0P:N#G#(D>=4(!S`7*)*22?@F^=%_^C''_`)PCJ5MU<MP;(\#K*L=%
M$[XFM/F"W0FY7PW>JGV_7`A_^<0=]7&\N3\3R>M4$,(R:!U+=^_GX@`*?#*A
M_P"4;ICO\W3J[YR<BCM)'4$[%@Q%0>LI][E.``M&L%-O6"9DQ'^J8?'5/F0?
MBC8?4J]F>#G!:@D(LP""T04!'QZD7!RB`^O8#!MJHFMB/>BQZ"J:)0:M?Z0%
MK!S!^'2A(MQ]J:Q#A^'81#359$?"\'K"I_I`XM/F*YB$FS1V*E)R:)0\0*9,
M#E`?Q&'5M+4_B>/,KZS#@T^==^TM:K8Q>B835*7;P=LSB`_TAVT[.#(2>D('
MR4Q;ZU6#2^ID[?4M$G,7?]JBLJT/XC[MA`0U=V#/PRL]BH)W9NC=579J.?96
ML+HKPUUN%=<("`I+5NYRD<=(0$-A(9J]0,&P^C;5!#*''2]AI^LK^W93%KAY
ME/;%7FI<N,=_#A2^<'(BI@V`"HMUKU)33`@;AN4R$HY?)&)ZMA+XZJXWG-KA
MU@^U`^'I'I"R18F_B*O,GI@H)#RSI>1FA#`7X/*E!KL@99+[/V%GK)M'.]]O
M#<%-]1ZIVXNB!ZJ?9175CR#O+SJ9$;_$7Y0OS`\3G?B;PGSL@XZR21UF:L*]
MD6Y@'<J(.TIA-)90!'<?'U:N^>EC%"R0-ZS3T&JM[&-SJ^Z37D/L7>LN<GDV
M9L9,%\R^4#'5Y^H'5(3V&[?7CJMSF((&4:IM)*IOU!Z@\`$0.'MU"[<&U]^H
M/2T>T44@@%,/:KX8W_\`#7L`)J\09SD/4ZW-D,6S8QRI-RTHTJ+]$QB+LF"$
MI(RZ8LE$#`(=M=4GL-Z@W^SE]S(#&R-\8SK^E:[<'PP0GM9)&..5/T9JC'?&
M+C*^R*:PTB4J],O;-95Q$VE>':-Y!-P4!,J<CT$A%(ZR91#?;<1';707$5C<
M4;)#22N;>'25H8'S,),-P"RE:/\`L*G+B##MTR#$+2T<099.+3Z9!^X730!4
MR0")3!W!+U*.2!U%`/3OKF9HBV9S&FH::5YK8QU>S70@D5*OFE7W];!2&?LS
MMG)$B"=,?24AB[E'[.X"4P>O6/(XC#BLF*$&E<`NI6;%ZC?8\=S``D'J^SX>
MW6M>_M)`T<#BLL,:,`%W</&DWWV`2[AN`AZ"B.X[CZA`=;*-P#0.2P7LU.IP
M5`<A,55W,F+KMC&?;(K1=NK<E!.!52(H"0/VJB*3@I3E,'<05$#%'T@(;ZOG
M+9`,*%(ZM;IKG7]"\(69/)YY9XM<W5PC!PT["5Q\^/$G9R8&D)R%1.=1N[:M
MQ2`O?^'`.M,1WZM]M87RSC4MQ"S6W#<`_!_EDL2LJS=1[MTP?-U6KUDNLU=M
MEB"FLW<(',FLBJF;82J)G*("'MUCD$&G%90-<52YO2/X1_+JTYJY?-41-$31
M$T1-$31$T1-$31$T1-$7[RVNJ7)+44HF$"E`3&,(`4H`(B(B.P``!XB(CJA(
M`J<E4`DT&)*Q7\B_,)F4[\OQSX9TP<WYV66<QLG/,VX2M)I#M`W9?]OMJI,I
M]_#''9TY<+H0S!0-EE5C`=(OT9W%\$;5VRCOUXJW7^$=S@`YD;CHGN`<6UP+
MHVO_``,:UT\@^%K`0X_&_BG]3M^WO([PL\!;#_>'Q&+G1R3-;VEK:.;@^E"&
M3/B/\21[VVL)^-TA#F"AL;>6!,Y'L:66N=N5K#F:_/.AP>CP\Z\0J\00P]PL
M2^L*!6CE=F@/V?@H5*,8IB`@114OB.WW_P"H6UV*Q/=KP=VV#:ME9@+A\;3*
M_P#7;$:@./\`>3F60\6M*Y[NI](-]WJW4=]?J-WJZW_O+)0FTBE<VWC&?9OF
M&EQ:W^ZM6P1--0U[VK%MYY7*I>O*8]\ECRZJ7!1><N3#VMU[,D9C5@R@SUZC
MVLQ%:_B^1E(U,KIM)7YB4TK9GCI0RC"I(&%<W0^,)?EOO+WCWKO)>FXWJ[N+
MR\<<7S/<\CJU&C1R#0UH&0I1?<O<GN?W9[F[:+;NU86FV[5&,([>)L0-.+M(
M#I'?K/+G%V9K59\_+OX-XZ\O'BKCWC;01:RDC#H&L64;TBV!NZR5E>;0;FMU
MP<@(`L1@99`C*+;G$?@XEHV1])3":"V@$,8'XCY>7Z%F75RZZF,CLN`Y!8^?
MXE0YB>47FP"CL"N4./B9P\/M$'*L(?I\?1]H@#^+4&X?PO-]K5D[3_KC>H^P
MK$'DUU\%_"%XK3*.WWC-TID;<?TN[S)LCLP![Q%I\VL1_P#J#1T'^T%G,QWI
MQ\OA7H`\C"(+!>4=P8;F`J!76(Y:P+'4,"292SV0[Q/*.%5%1(1-+M/>LQS"
M!0+XB.WCK.LG`6PU9#[@?M6NW$$WK^D_H6&CE#D7(_\`$%<SC<%^--GF*OY:
MG%VU1T_RIS[7S=+++MPBGJZ;2,JSXQ19S"0NFCAG46H]Q%54CFPN"';MV)=8
M<CGWLVA@/9CR_E^V@6="UFVP=O+C<O\`A'+R_1A4KTNGQCQ#XRX<Q74Y^N8*
MQ-A/`4>W8XG#)JE*B*OC\6;%5B>6@IJ^*)MV]I?(.%S/),BOWB[6<KJ**&.L
MH)L_1!$T-=3`C'I\V7G6JUSRO+AJ+W9TXJ!&;_/\\N#$2$S#8\S9*<JLEQ,7
M+OH_%'%JOV')DH^"$CW$@[.]MC%BWQ_7(!BV:'4>2*\B9%FV3.L)3E)L,$EU
M;8Z6M=)CP!\^%?60LJ+;[LD%]61\R:?IKYBL"7D0$99EY>>8OYW&<8*%Q7B?
M'<9EV;0CX$@-ZQ#6+(C4]_R(TAEC)-229J-BZ)1;*K=*9WTC/$5,4%#B76%;
M4+W3NR'MS\],*XBHJMCN!+(8[)F+W$?<.JIKU45EO*QX+WOSIN7_`"H\P;DW
M,W&I<<+7D2U1=JKU8EY"N3F9G=D!@Z;\?V5F8J)2,-B^D8^;Q$?9562J;AXV
M%&.2.0%W*B5;>$W,A>:AGEAY8GTJZ\N&V,++>(`R@#S=-.=:TY>A>V&@<0.*
M6-*6SQCCSC)@*K45%DG$I52-Q)1!BW302`AV9,'L&Z7F5%RCLJJ]4766$1%0
MYA$1UM/EX&-Q'N@<R/4/N6A=<3O=J+B75\LUXL?+6P;A>\_Q!'*+.>!6T%C7
MACP>M.>\ONIB-4"/H5:AXZ`G<9M&D6N'^ZQU3D[2\G9AJW(((I0L:H5,H)$*
M`:>(#Y@N/P"M:89X8<.9X9<%O[N1PV]K'U[62@^W[AY^*O\`T6$RI_$P\T+U
M:[Y9+OC7RHN*=J0C:G0X)ZO!R.5+"KW%H0KHX`=N.1;K#I?>DM(J$64JD$X;
M,60)NG0N33-#[V:I/[L>7D.G.I)43C'M4```-TX>CR]>?`!>L?#G#[BEQ]I;
M+'F%^.6&,?5!BU*S",B,>UMRZD"%(!#KS\Y+,)&?LT@XVW6<R#IRX6,(B<XC
MK9MMHFC2!ZR/91:5]Q-([4]Q)7FH\[;GYC;@C:'/!G@0QPWQ3S_RC<TR?Y8\
MAJ;`0V.6.**5-$5@JF[EG]/BTU&%[EJ\_<OG4HBV4D8BO?M&Q1>/D%4===/;
M&_LHO=)S/ECZ>OE3;;?;ON&_,7%7QMKI&=3]W1^E7*X`9@_AQN!-&B&%0Y=<
M9LF9O?-DW>2>1V58:=L.2KM:W1?B)J082%DITB%(KZ[]0XMF#!1/]GTF<K.G
M`G7.@?:1-JZI=UBOMKYLO:;;J/<KAQ&DB/@!6E/+S^Q8S?/^Y$\#N;]^X)PW
M`"\8ES!R;G<MR=0EK;A2/*QGB1LU(4F+QM7[(\;0\,[DY(UZ>?%Q(G!95F1N
MY,0Q"G'JAN9(YI&F&M:^>OI/0LO;XY[>-_S`(C`KCZ_+I"]VDI78V>KSJJ7.
M-A[?%R<0G"VB+L,8QG8.R)BV20DTI:)E&[J/DV3]=,QSI+I'3/OXAK=AK7L#
M78M]'\F&"YL$M=5N!7343'6/,65\E3Q?0*/C6JD=KORUG'U2K]*KX/W($!R^
M^YJU'1D<+UP5,H'5%,5#@4`$1``U5L;&?"**KGO>:O))Z56.KU8FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB+P6_QJ.3%5;+Y?V%T'.R#&NYVRQ*-`-Z
M5YF5H=+@ESE]?2G7Y$I1'T;FV](ZT^X.!>&\1]P/VE;?;FD-<_@:?:O##K7+
M9)HB:(OF^WB/@&B*LL=X\O>7+?#T#%]1G[_=9]?X>(K%4C7$Q+/#E#J54!NU
M*?L-6R>YUEU1(BBF`F4.4H".J@$F@Q*'`5.`4VLB^57SPQ3AZ6SC>,$2D;2Z
M\5T[LC1C/5N?MM<@F13&=VJ9J\!*2<@VK+,2#WW1>OX<H"=4I$@$X2&"5K=1
M&"C;-$XZ6G%8\P$!`!`0$!#<!#Q`0'T"`^L!U$I%]T1-$31$T1-$7S1$V#1%
MK`YP]!SE_HG,7\@AJM2,BBWB/'B0@9-X[3$/0)'*Y!#;T;"4X"&JZG<RJ4"[
M)"RV-K_V6P33;U_L)1ZE_P`U8-4..:K4KU%>1S$ST_A/)-LL#Y_*$"ZJQT8Y
MD%EG"R:+9BCWR(N%A,82"N;VZVFU/,4KG5HTCUK7[FT20M:14ZEFRB,>.72J
MTJC$J+%34W6="@;L-RF.&W<7$O2!S!ML&^_NU?-<2:R\$J&"WCTAA#?0LJ/%
M^,D9*%;0"Q6*+2-5^,31,L=DB_$A#*B5Z*(E5<J=6P%$?`H>&HXI'.:2[GY=
M:R'L:"-.05:Y"7.K*OS/HXK$`3.HFL*1Q15%(G0'8<B`&6Z0V*'I``U#<2T:
M0>"DBC.HO)/5Y>HJP3-L9\Y,1(2$,83G`##TE``\=MQV].M9`3KJ,U-F.A5:
M1%PP:H%5%(HK$,L5,H!UE+U"!14\`$>K;</=K-;(:5-!BK"QN=%U2PB[$PG\
M=A]/AXAMX>&WNU(V3M!56EC1DHE\CHU)&I2CHJ15%R,W!T]P#<Q@(;8`W#^4
M.IQ,6-.G-0F#603S7YS_`"0*Z-F_*2CR.^ZW"MSFE3,@)T`D4[HXE,4-MME0
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M`R=(13M)"-3C@*,#6CT[P>\&NZ/@OW89L/=R-LFY2-:;N\<T":ZE&9<<V0M-
M>RA!TL&)U2%[W6!\T3S":)Y;7%*V9SL!8V<R-,&7I>!\=O7`)GOF4I!BLM&E
M=HD,#@*C4FY!E)Q<NP)LD.R4P+.$`-YM=W`ACP^(^77Y%>RV5JZZF#!@P8D]
M"P_?P[_`J\BUO/FP<MCR-KY+\KW-BF\6R-K0ZIJ#QU;WBCFS9/5;KEZHV<RZ
MN4$8PA`(#&JMT4T0*B^,0,2Q@)/;OSX>7EPZ5F[I<MPLX:=DW/K'#S>VJ]2N
MMLM,L"_\2R82^4;F4`_E96X]E'\'^:$2;P]^Y=:[</X?F^UJV>T_ZX.H^PK"
M[GMZ2/\`X1SC:EX_]Z9'HC0/$/`P<F<H29@V]8=+`=M8DAI9,Z0?[06?$/\`
M\P_H_P`E5TORAS1R*X=>7OY(WEXR9/\`.?)'$?$+SF7FB.67"O\`'O#E@J47
M/VJKRDW&B!XV7DXJ?*I8!1.#H&SIO$("+Z24!N#WEC;>(Y@5]`'\@_12G91Q
M327]R/<#SI',U-*>7J&,^>=&;\<_P\GET8<XX\+:C&RN<<N3\I3\;S]GBV4@
M]G+FVC8M7)O(+(,<3M-K+9`<2,<RB(Q4WP"*[MHVV%BR,B>>4_)1!C/XAX^7
MKYX<,!C01NW.Z=+,?W;1C]@'+RXXJK>-WD%8TOC:!SSYKF0<F<[^55H8LK!;
M(/).0;,7#6-Y.003>*4NM5:#D(H9I&O*+"V54.HWB5%$Q!M'HH@4#7166MH=
M.23Y9<!Z_-DK9MR<PF.S`9$.0Q/6<_+,YJQ_G^WK!W`/@;%<1N(F&L7X?R;S
M9GT\5MZ[AVAUJH6%YB""<QKJ_D57K\>UF9,UQE'L56DOB%51<A*."@)A(;4=
MZ(XF".,4<<,/N''S<5)MHDN)S-,XEC,<37'S^GS=*ACYG<-)>7?Y4W"?R:\,
M(%D^2W+J0K\MFN.@A`96?D)RTQ$C;8]?X;J540OF:I..KC,PCTJ0M>73'[`#
MJ"4=G"V%OQNS\O/@0<B05D6I^8NY+V3^$S+H_D&)Z5ZN^#G%2K<(^)N#N,%4
M*V53Q;2F+"SS#9(J8VG(DL8\WD6VKF*4IE5+!<9!VLF)MS$;=I/?I(4`VUM$
M(H@!G3RX#UY56EN9C<3NE/$J,?G*\U2<$O+\S7EB'E$X[*%SCO\`)G"@=P".
MBY)R*S?1R,\V+U%,(46LHR,X8P;@4T>0H_IAJ.]F[**@^(^7EU%2V$'S%RUA
M'N#$]7Z<EY?97#=F\NG^&?M%K^$>0F:/,FR;BY/($DKWD)R*PY=@E)2G55VN
M;9RF66Q947"[@AA`14M#DIMQ$0UK#&^*UUG)Q]OMPKZUN!(RYW0-_#$#3K'Z
M3Z@O2AY#.*:;BCRGN(9*>,>X4R73)7,ERE6`IJ?>MZR#8I1Y.?&+)[BH\K[5
MFUAS%,/4B6-*F.W1L&QL`!!49U^ROVK5;DYSKMVJM!@.H8+,"@!!52[@"*7<
M)W.D!WZ-P$X%V])A*`[!K,=72=/Q4P6!UY+Q$^06M6N:WFW>8WRTS2SA[;D!
MG$VR>I$#9F;.71BH[(>5W%2.[9Q4DDY;BG3*%58Z"0'H$&S=[TAMUAK26H;)
M<G5EUGIY=070[AJM[*.*/X:8^C[23YU[+E\0XA<F,9SB3%3@Q]NLR^-J4L8_
M2``7J%2#,)M@`-M_1MK;?+Q<CZ3]ZT(ED&1*^Q^(<11$DSF(G$F+(F8C7*3R
M.EHS'%,CI6.>(#N@\82+.$0>LG:(^)%4CE.0?0(:"WB!J!CUG[U4S2D4+C0J
MX.IU$FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(OS._XP.^J67S1
M:!2RKB=GC#B3B^+!#K$2H2-NN&1KF]$">@AU&<HT$?6(;>P-:*]?JFZJCUD?
M8MY8-TP=;OL"\J>L-9J:(I0<1^(V7>9N6XK%6*8HX%$[=Y<[L_:N#57'M;.J
M)%Y^QNT@*0#&`AB,V93@X?N`!-(/TSDOC89'4&7/DK'O#&U.?+FO9-Q]\FS@
M_A.LQL'.XIALW7($$5)_(.7&9IYS)//TE%(FJ*.3U6NQ_4`@B@FW65*3^\75
M-N;66V*(>Z!4K"?+,[,Z0?+R^Q9,X'&=)I+<"4NCTRII$;)L2A5JE7ZZ)612
M%3(W`\-',C]@B9``""(E#8!VW#62P,;FL:3M"*@DT\ZE="UMD=K8JN[8+R]:
M6HX(RP&8(/56*"$;)NTV+UFHX08.*K*JR9TWA1%4AFRP`;J$P`.7J9BW,45S
M&N&.2\/7G)>4M"<<W-BY1\8F(H8&?R:#B]XU*10'&*G\W)?"(S%<)NL7]P'L
M@Z23,S,H92'56(4@G;&#LZBX@:SWXS[G+DMA%+K]QWQ<^:\[NL13IHB:(FB)
MHB:(FB)HB:(NV@("8M4Y$5FO,'$K.S\BTB8B.:)F6<O9!\L5!L@DF0!,83*'
M#?V``B/@&J@$F@S0D#$Y+]!7R[>(C+`''S%F(Y9RA#OW+1O,7N64(!BH2LF!
M7DPJIL'4L9N)Q(4/2(E`-;*&,-:!6E5K;AW:/H/A"R@W56#GDH6D41@:.Q]5
M@Z&ZATBDDK+(^'Q,S*J%`#CWSAN0@CL4OLU;,\./9QX,'K*EB:?B_$</+I4A
M\,IR4='/X6L1\7\6[%))Y,/5"=]LF!0.*3,FW<3$`WW-Z`VU&UQ`TLI53%HK
M5V:Z#)-=E4XA*1^*4DD%Y"19F<F<J*E!1N;K.FVZA`G;+TFWV]8;#K&N8G%E
M1CY>M7,-<QU=*L6U4*4H"4@$43,;=81-N8O3L)-A\-@`=8`=04&=5=057,FK
M.YDW#=54J91;-$&101(!"&3;DZ""(%#Q,(>D?7J]\[G45P;Q75(R(I$4.J80
M*/B!1]?M_`.IH9'-!KDK2!6BAKR:O#5"NOVYE2B'95`@`;TCTFV``W\=A'5'
MW('O$^Z%>V,DCFO!1SC68.N0]W68=&QUTS..C80%P8!$XB(>`CXZ1.UQARN(
MH:*$I_TS_P!(WY1U<KEIT1-$31$T1-$31$T1-$31$T1-$7[RVNJ7)+$)SYE)
M;`7*KB9S%D861GL6TM*6QM?#1R`NEJZ$XK.E*_(E^BFY?1%F<JM>H2E7<1_9
MZ@,H3?Z=\&+>V[Z>'/>7PM@FCA[Q799=6^HT$O9B/W:\0U\3`^E2ULFJA`*^
M(/J4O+SPU\8^Y7CI=V\MSW/V\26-YH&HP=KVPUTX%\5Q(Z.M`Y\.@D$BN52E
M7:GY(JT3=Z!9(FWU&=;D<Q4_!NR/&+DAB@8R1Q+^T:/D!'I6;+%3<('`2*$*
M8!#7SENVT;IL.XR[1O5O+:[G"ZCXY!I<.D<'-.;7-):X8M)"^R-@[P;'WKV>
M'O!W:NX+[9+ANJ.:)P<QPY'BUXR=&\->PU:YH((6)?G/Y+V&?,.Y*8WSYR,S
MKF^6J.+6D!$UKCK"$I<=B<L!'R;:9M40NZ/"+VH%,E2#8H3;TCHKQ5J5-ND=
M)-!("Z":S,TNMQ]SRZ/M73VU^ZVA,4;1K-?>X^0X+,.S9,8UFSC8QBSC(R-9
MM8Z,C(YLDSCHV.8-TVC".CV:!2(-&+%HB1)%(@`1-,@%*```:S6M#1I&06`2
M2:G$KD:N5%##G]PGI7F$\9;-Q>R%=[?CRJVFTT:TOK/1FL&\L2"]%L"%A9,F
MR-B:/8OX=^Y;E36,=,QBD\2[#K&N(.W9IX_I!Y'DLFUN#;2B4`$BOLHH89>\
ME[&.3/+,Q-Y8L5GC)%5QSB6[0URCLH.JQ5+'>9S[HLEYM01<K$IJ5ZNHI+RE
MX4#NHE`2)-4PZ3&,8VH7V9=`V('%OER^Q3LOW,NW76D$N&7FHKW^6/Y7."_*
M_P`462C8SE)+(>0,@39IG)N:K5#QL1;KB@R57"KUI-A'+O&L#4ZHS7,#=BBN
MH59XLNZ5,914`));6K8!7-_EY>14=W>RW;JNP8,@K>^;5Y2E#\U&AXOC93*D
M]A;)N%I6RR&/;W&0*%LAE6%P0AT[#7K165)2"=NF3EU7F+ELZ9OFSIFN@.W<
M(H8FJ75K\P!0T(\ONX_INLKUUFXFFICLQU*PN,O+O\XB$2JE-R/YV$O)XL@E
M85A,$I/&NFM\N3E3C5VY'L*TRE:%'TQ%3,C$HF;EEUC/GB!S]X>ZH7Q@;;W)
M'9N=1G4W[RI7W5D27M@]_P#G&@\W1R5T<U>3VUY&^9?A+G[E;/\`,6RE<>D*
M0VQCQG<X^^,B(Q''S!_)U]64R(_N3Y],/G.3WXV2075BP4>JI)MSCTD!35[[
M1IE$LC\/1ZR?1GA@D5X]MJZVAC]YV9'W`<L/253%V\K>KROFNQGFC\DN6%6G
MH_'Y$`Q+@6R5J'IL-CQ.M55S7\?":Z3F07(2IJI+RC^?4$(QM\7-.@6_9@0"
MCG67=_=-TN0;"WN+DDX-BADD]&@'IZEJ=R[U;)L5@Z'=KNSLHZ>\^>XBBZZ]
MHYO5U+(O9N<O#VHBJ6:Y&XO%9(1!1O"3BEJ7`Q?27MU=K,[F_'KTBP\(/%#<
MZ&UV+<-)R,D8A'IF+%X]NOU#^!NS5%[WIV@O;F(93<GT6[95Y]O-5@>(?F;9
M=XTNK=SO1HW'C`TI]ZV+#<=Q]RA8I'(DK-V&-<7J3-<BNH=C#KR](AT82/,:
M.="Q!9RL/7WA(&ZE^FKQANR)?\,8UH&3KBV!ZOXOMZ5S$'UI?3OM^J(;U*^1
MV&IME?%H_P#X=3YYH9A\K?G_`,7K?Q/R1FU:ETV=2K[FG3L)1+G'2N,K12SD
M5H]DK3=Y5%(Q4E?!/X8[-4"H.H]59L82`H!RV7GTY^+K8=#MH+B!AHGMCZA+
MQZE?MWUA?3ZZX$L?>`,=7_.6E\T4Z2;<^U82.+/#CGSQ0:R&-.#_`)ZG$>#P
M^_EWLA%T_(S:=C&;5W(K"JZE(_'62:/?(:K2LB<04=!&/TDUUQ$ZG4<>H>,O
M/!WQ6VBKKC9-Q$;>+83*/3%V@]:](L/J*\!.\+FBV[R;,Z=V37W+8''S3]B?
M4O2QY<V`^5&)J]D"Y<MN<ZO.+*M[EH@T++5(K*(Q!C*G0S85482EU"#3:0XS
M<W,N57$C*G:)++((M4"`4B9^YR#MNOMO>Z+=(Y89C@6R,=&>61I]_4O08MTV
MK>(FS[%)!/:`5UPR,F!KQU,+A3SK"]F_^'SY-8CY>VSF/Y57,&N\<[+;K!9+
M0ICZ^,I^.;5AU<Y$TO;ZG$6*"A;E"VS&TQ+',NG#3D*<C4.A/N*]E$Y=<^QE
M;+KA(`)KCEY>9;J/<XG0""[87`"E1Z.C&F&:OVVX@_Q(.3&R,!E#S1.,V&:\
ML";:4G,)8>CY2^G9F$".EHYZ.(Z@BVDNP)A34(];@500'P`-7&&^>-+W`M/0
M/MIZE%V^UL-8XG%W233VE>AFDU=*D4VJ4Q";LEE3JE=AZ\%EN4R[L5NL9XE@
M@S6G[3//U%7DQ89I9(SEXX.;=1=4P@`%V*&Q8W2T-))*U;CJ<74`J>&2J;5Z
MM31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$7'>.TF#-V^7*X,@R;+NEBM6K
ME\Z,DW3,JH5LR9)+O'BXD(/0DD0ZJAMBE*)A`-7Q1NFE;"S3K>X`5(:*DT%7
M.(:T<R2`,R0%%/,RV@?<2!QCC87'2USW4:*G2QH+G&@P:T%SC@`2:+?(8#D(
M<N_2<A3EZBF(;I.4#%ZB'`IR&V'Q`P`(#X"`#JP@@D',%2-(<T.&1%>6?0<1
MU'$<5]T55^3[_$WW(UN\Z?EFAWNZC2XW!]%0#JZ@1^Y<(4%TY0+^KTOI141#
M]8PZY^Z(,Y+<L/6*_:N@LP1;-KGC[5@1UC+)7P1`H"(^@`$1_`'B.B+WK^4%
M@Z!PIP?PZ>.AD&EERA#(95O$F=,IGTK.VPHO(HRZG00XH0]7^#:-TQW*D!#B
M7[1SB,['EC:#-0R,#C7'!93VYNDYCJ=1U!-L!S#N(`4-MMQ`/'??4@D`%?Q*
M(LQZ%5,,\C"O6R<LD!X\5B&=B4JO>%$I#AVD^V<@_M3B`>D``1`1'8!U5LN(
MU9552T::`+MQMDJV0DVR#A12*>HI,4DE`:K+(-V9CECT#N%$3JJ=AJ/:,8!`
M3I^&_@&KS(X5+<6GU*T,&`XJT-[H]7R=2+10;S!,;+4+C!2-=LT#(($<L92)
MEFQVCULJ5<I]C"FINF?]--0"G*('*`A82Y[#7@KVC25^>1SWX?V'A1R)M&)G
MRCR4IKWKL^++0Z2Z%+#1'[M=)B5X8H=L9R`<(G8/REV`5T.Z4`(J36'A7!97
M2H7Z*B:(FB)HB:(FB)HB^:(O4)Y(?ERN'"\5S`RY%D!JH@J.)8%\@/60#B9)
M6TNDE2[%.L0-FOAN4HB;UZR8F"FMV2QIY2T:&?$5ZL(JOKO%R"&Z:)1*`$$.
MGJW';^J`:N<XO-:^Z%;'%I%3\15Y&T>E%I-F+=L@M(NP,B50ZH=HG<.4I%A\
M0!/H*`^(^G4$LPCP;FL@"F2O"[AK+BZMISK8J<A'RJA(]U+(B":`.7"/6HV;
MHG,#@2I$,.Z@``;AJ)SGQM[3-G%4P."M03[WM70Q0DE2Q+`5A9)NE3E12%PI
MW%^DN_2*BRAAW-OHT27>+31@5I+8\_TJ@Y@B;$RK?JV%,YDS%+X[G`>G<1#T
M[CZ-02L9'4<E(*E4F50QE!ZMP*3P#V^/T;ZA8"X]"J7`#J5`7NX-H5FL`JE(
M)2>D#@`F$`$1)L'Z(^`?/I-*UHIDT*2-FI8+.=O)^,H]:G9%R]*"J*"Y6R`J
MANLX,0W:2(7?Q'JV]&M)\U)>70MH:Z1G^E;$1"&+M'#%>06\V=_<K+-6>3.*
MCZ9?KO5A$=^D%3B)">X"%\-=2UH8P,&0"UM234YJUZG]X?\`IF_*.J*HR6C1
M531$T1-$31$T1-$31$T1-$31%^\MKJER2Z.S5BN76O3%2M\%%V>KV!DK&SD!
M-LTG\7*,5MNMN[:K`)#@!B@8A@V.FH4IR&*<H&#+V_<+_:;Z+<]KFDM]P@>'
M1R1N+7L<.((]!&1!((()"U^[[1M6_P"V3[+OEM#=[1<QEDL,K0^.1AS#FGT@
MBA:0'-(<`1BHGO+:R+AZQR5XX*\B+'AIT_5,Z=XTN#Q[,4A\H`@)6OWB5O*$
M=LR@'2F25C)%0A?#XC7T?9^/6Q]Z+&/:/&'8X-UC8*-NH&M9.T?FTU9I=Q)A
MEB!_(OC/<?I1[T=Q=TE[P_3IWHNMAFE.IUA<N?+://!NL-DU-%*-;<6\[A7^
M*B7(/S2,0=37*7$RI9RC690*>SXID@0?O$R>!G`MJR^G"]PQ0WV&%;?T0T=W
M(^G?O/23N[WEN=HG?_FKQM6M/*LK8\/^O?UJK/$WZPNX]8>^'<JR[PVD8_UC
M;GT>\#,TMWS8\:?*1]2W@\V"-K@%2RKQ&Y(8_=$^RY_[F1?MDCAX'$AYQA45
M3D`0]F^K#]-L]\2[NYWFV&]CX>^6D_\`9NF"O_XT+7:F@=\NY'>K;)1\7[L.
M`/'^.RU)'F7=M/.)XA*!M),\QP:NWVD7]"CE3$'?82B+*U.-Q#\&L27Z7/$Y
MI_</VN9O-MP\?VH0MA;_`%T^!\@I=,WVWDY/M(R1_4N7+MQ\WSA1V^O]XLD"
M?;?L_P"73ON;[[=.XRG:W_Y6VL3_`(8O%C53L+"G/YH4_L5]2V'_`!O>`6G5
M\SNU>7R3J_\`Q*>M4Y(><AQ/2W)!P&:;.O\`R$8^F0;05!]0`+^W)G#<?#]#
M6P@^EGQ)?C=S[3;LYNGD=3^K"?:M/>?7=X+0G186V_W<O!K+6%M?Z]R#ZEU1
M/-1GK2`$Q1PFY#WA54>ENLY:N&;4XC^B)S0-9LQ0*/\`YS;WZR3].=GMQKWD
M[V['9M&8!#C_`-Y+%[%A_P#&/N6[M'^Y?A_WGW%[OA):YK3UF&WN!^UYUV!.
M2_F=7SI+0N#E6H+=?^[D<G69<AD"F_1460E;#2E/L@.XA\,(^[4![@?3[LU3
MO/>^XO7MS;:1#'H!9%./VUE#Q9^KGO'I'=OP\L]LC=^._G/N])$L]H?-V9ZE
MST\=>;;?]QL>><"849K;=;:F5QI/2C8AOTBIJA6)C]H4!V`0D=_YWKU"[??I
MHV7_`%#9MYW:4<9Y71L/6.V9A_U7F62WNO\`6OWE_P#\KWC[N;!;N_#:P-FD
M;U'Y:7_X_G717+@Y>6=/M60>4?F(9[D:52:U.W&[.JVH^JE=A:Q6XMU-6&5<
M(%F)[J91L4R56."4>902$'I(([%U$[QS[K[,TGNEW,V2UTC!\X$S\..$;#_W
MBE;]+G?GO$X?[_\`B1WFOR[`QVI=;1FO`!\\K*</X0Z@NDPSPG\LC)C^BA4[
M3.Y]FLD8?BN0=)=S61[4^_?##LU,-(&-R"T&"8UEJ:(>S;])MV5CD=D5/L=$
MNQMM5=?4UXFW8[';[BQL82,&P6T8`%*T!E[7(<0MY8?11X(6#OF-WL]TW.Z#
MO>?=WLM7$?F%OV%?6IWUS@[Q)JW06%XUXM[K<0*"LK5BV9T0Y0#]-6RJ3"HG
MV\1W'?7&WWB[XF;C4W6_;CI=P9-V0]$08%Z3MGT^^!^T:?DNZNRZFY&6`7#O
M3<&4J[L=AK$T:F"<5B'&3%(J9A`C+'-11("11V,.R4*`=!3!L(^@!US,_>KO
M-.[5<;IN#W5_%=3''SR+M[;N+W'M&Z+39-GB8!DVRMF^R)1AY1Y5X`\6H.MS
M/*5O@VA1MV?RT=6&\WB9E:9:?/`QP2]F?,J_4J58[`:#JT08'4M)&;%81C8Q
M5'*R13%$3.^7>BP(=#NNY1GAINIQEU2>7%5E\..XVZ@QW&P;+.WCJL;4YX<8
MN/K7?K\*N$F5("*LK#`F(YRO6N)C9V`LU(8&AH^<A9QFA(1$Q#2U-?QC=XQD
MV+I-9!9(QB*)G*8NX#KJ]O\`&7Q0V^CK7?K\M&-)'B8>B9K\%P&[?3GX&;N'
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M2'`![2&L8"[#&-@KAVK31:#>-H^J7P3LG[ULV[P]^^Z-H-<UI=PN9N+86XN,
M3P7RR%K022)Y7`8BW<`0J-K/G"1]P;`LGA8N/8Y1;X(;Q>K%>+)263X"$.H@
MX#'&*YF4<+MR*%.9`3-3&((?;)ON&_W#Z7IMKDT.W8WTX&KY>WBMXIW-YCYJ
M\C8`:$!WOBO`Y+D]H^N>UWV#M6[`-KM"[0;N\GNY[1CZ`EI^1VZ61Q:"'%O[
MLT(]YM:J7,!YAO$YM7([[YS]%7.QHLA6FEZ?C3))`<O![CAT:.K36MRCZ-C6
MH&[:)5UU5013`RJICB8P^97O@?XE27\GRFRR6E@7TC$]U:X-P`U2F5C7O.;B
MUK1J)#6@4"]LVWZH_!2+:XOG^\T%_NK8ZRFVL+\:G8EQ9`V"1\<;<FA[W.#0
M"][G5*ZJL>8[AO*4^>HX&IN3,R6HI@($>U:U''4<0YA$I1<RF2[77%TT^H/M
M=IHNH4/Y`CX:R=P\".]/=VR_Q/OE=[?M6V_F)FN7>9EK#**];VCI6)M'U5=P
M^^&Y_P"!^&]ANV_;SP8UMK9,_I27]S`X#GIC>X?E4H*>USK-SC&PY*6J&.X)
MBFY.VQ72G"]RE)!RY;*-T%[UD>6CXALJ2.!7NIL(2.02%P4IE7JY"]L?/=TD
M[G6EF^QV`75]>/(K>3@0,:`02+>U8YY&JE#)/*YVDD-B83J'K^Q0^(VX;C'N
MG>QUCM>W1AQ;MUHXW4CW.:6@WE](R)I#*ZFPVL#&ZP"^XD:-!O)KE5WB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(ONJ(FB)JJ+\?;SWI_]Y/.&\PJ1$PG^'Y#S
M\``FZMP"J0T%5RD^T)AZ4PA^D/5L'AL'AKFI/CQY#V!=)!3L6TRI]I6)?4:E
M6\V:F?NFC`@&$[YVU8E`A>HXF>.$VP`0H;B8^ZO@'K'1%^FWBFNLJOCVBP$.
MBD5C!U*MQ#1N!0*FFSBH=FP;I"1/I$HD20`-O=JZ-P<T%6/!!Q5R%P9E;N02
M,[!5)P55%14J!"`U[(BH"X%%10SHSC8";&$G0`[^(AM20M;&:X8X*S$XA<=G
M\2_(@#9NLX<.5%4T&3=NX7>N.P03JJ)(HI'[A$P*/4`")@](AMXZBK(148_:
MK]+1G@5H^.433.W52,D8!$YNZ4Q!'H'[0?:`HAT]([^S5S)R&Z'5"H6XU')5
MU66S.2K[Q1%J[?/G.R8+BN@QC(9L"Z1$W;I95%8ZXNSB("(F;D1(3?<_4/3F
MP/#FEP%0?8HWMYFA6!OSEN*SOD/Q]<+P$(C)92QF]<WF@OD$4Q?3#%`AF]MI
M:#D-C",S#B5=)'<2J/6:.P?:W#!D]R6H^`K)C]YM.*\1?CZ!`2B`B`E,`E,4
MP#L8IBB`"4Q1#80'Q`=7JB:(FB)HB:(FB)HBGOY=G#J?YA\@:W5QCW'^7-:?
M,YS(LSVC?!I135<BR<,"O@47DP8G;`@#OT;CJYHJ:G)4)P7Z)=`H416*Y`P$
M5&-HR$@XQG&Q46V2(B@U9,T"(H$*F0`(4I4R!X:R-56XGW5"UC=6LYE71;-T
M6_<*F9-,2DW)N)0'K]73ON.P:QI)=)PJI0"5?;!&.XVTR`6>T+I%@(UX<J[3
MXHB;QZN@4%4TDR'$#J@<0#[)?3J&&,RG4[X57!O6KR\@;9&IPK"NF@(MNSDE
M3/H=NL?9RW:-"&1.1\5,Q11,IL4P%W]&LR1S2PMH*4JK*$E0#4GQ:MQ:-]B%
MZC"<Y0$H&*(]7;*'AL4!]NL".X+8]#<!52%E<5;>5G.MV<P`)U`]OZ(;!ZP#
MTB.L9\G:/)X*X-H.A4I,W`(ULJ90")@4AA[GKWV'U#Z_'?53*YK?>."J(P<5
MCCY#YM8PL?)/7#T$&[9)8YA.H!0$"E,83>(^K7.[CN`#>SCQ><!TE;6VM\GG
M^1>/WF5R,?YIOSQHR=G-7(9TNDV*!C=#MP4X@=<WCL8I1#8-;K9;`V<':2_Q
MWXGHZ%B7D_:OTM^!JA&N(;#[Q'W>O6Z6(J74_3/_`$S?E'5BN6C1$T1-$31$
MT1-$31$T1-$31$T1?O+:ZI<DFB)HB^ZHJK=%=<2]`K*B3T"05#"00]@E$1*(
M:MT,K6@JKNTD(TEQT\JX+I7<%`O]_CX"!?\`5N!OCH2+>=0#XB!OB6BN^X^W
M67'>WL/\&>9G\V1[?80L";;MMN?]9MK:3^?%&[^TTKI#X[QVH<JBF/*`=0GZ
M*AZ35S'*.^^Y3FBA,'CK+&^;X!I%]>AI_P#J)O\`+6O/=;NL3J.U[87#_P"D
MM_\`PUW3&!@(L`"+K\!&`7]'[MA(IAT_@^$:([>G6)->WMQC<3S2?SY'N_M.
M*V%OMNV6=/D[:VAI_=Q1L_LM"[L7"XEZ165$H>@HJ'Z0_`7?8-8FA@-:"O4L
M\R2$4+C3K*VM7*Q?-5110YZF5+P5YJF0`QEB\2N1ID2D*)SBJ&(+@*8$(`")
MS";;8``1$=0W'\!_\T^Q3VO^LQ_SV^T+RVVR/S?Q8EN0&%L=_?%(H6->$'&^
MSXMR&A)VFLLZSQ$Y6<U,+7K-<.M:Z8DK;JE7L//IB]14A)Q0?>,+5NATW[9V
MY#DTP]VM,"!APXT/JKYL>"WITRZ7.(=5YJ,Z$-J,\JDMZW5&-<9+88Q;E'E-
M;*IAB,Y:9.F*:QX@>83<L!3^`\S\@([&SJRPO)B*QY@-NED:^JP]_P`ZTK"S
MZW/VE?L+Q=TWGF+-FJ5T[;MR",S!(_!KC723F>8&?0..76L>1T,-7E@^-H-0
M*_#4X<*X5&!SR*B[DSD-R6S!C;#^?\@9PF.-]4Y+43E#E?&TED/(_(6E,*=R
M%PFGQZX_8MAL>UG":$A,9%RLQ7H=ELM:Q\Z;J15J7FY)51FY<#N%LDDCP'5I
MJKQRR'Z:<>2DBB@:]T0:'%FD9`U!J36N0Q`+N%!B%EJY\91=\=^8^%<WY1M>
M-Z#'W'RW.0F#L99*S/2+39<*Q_)J1R/B*^VJA62KUV0K\Z,UE['<2[:Q,.D]
M82$FHS,S1[BI10-),2V74^A!&'JIQ'+GC3"JQ;5HDA,;*@B0$T..FCAR//'"
MF.."QT5K*DI)88S%R`MSK*F'JO3N%'E4X_I''W#.9\@\:N-F"7'*E5_1<ES<
MT"*5PE,88ZI\5`-&<Y*$37EX&`*_^&7;OUP>I4U.+2XDAH:W`8`5]E//@.>*
MG+&A[8Q1SB^0DD!SCIQ'63ZST8*E\08[-R(<TAS;+9D^]258XQ^>CCC'4A1<
MV<B"Q+FEXQR_CQAANN567G+:SOUKI00V0'",6,ZHX>SL42,^.%T#)GVK/>+0
M<2ZCAQ_,T<#C@?8I/=8YS<`W4PY#/0X\L,1CY\B2O1MY8#_&;WR^.'KC#]N/
M<Z:C@C'K?[]-<9J\KH6]M`LBY`@5I^P2,I+(N*K>OO".&..J"<-\*#!%)!%L
MFB396M'6[1F*=?WK47>MEV\G!^JO+JY>7$YJR]TXJS^+.59[_@C+4U@&)SZT
M6(V:,(-A9\3.\U1:BTJ]I]^H3Y9FQ=1&3((KAY$JH*(K-95HZ10'J<-R!]+;
M3XC67>/PX&R]\=LAWJYV5P)+I'17@L'@,;/;7#0YP?:R:63!P<U\+XWOP8\K
MXMW[P;W'N=XS'O-X=;U<=VK+O*R@:R)D^W.W6,F1]M>6;BUCH[^$226SFEKH
M[B.9D>,D0$K(;)F?<?%^&R]Q_1LK=(`(MD7C$];VR-=I!N4SN3Q99#U_(T.)
MRAU'28FG"AN(%$0\-><7?=_N7O9[3NQO9MWG$6N[-,+@>3;R(26K^@R?+GFO
M9+#O=XE]V1V/?CNRV[B&!OM@>+ECA^:3;IS#?1<RV$W8Y%43<Y/@1F]3X'*,
M7B%6?4^Q\+E"I.,5Y"9KB.W0BZM433;>V>$/Z!06$>K]$1\-;;:K?QG[HM[;
MN])N8LAC6TF%Y;.'2(7SP%O\YO6%H-]O/IM\0G?+][H=D.YN%"V_MG;=>M)X
M!UQ':W375_(_/(E5Q`X&NF*$B*X'S#:#UU)(JK;$N;).0R=C]9#H`Z;.NW!V
M?_,ZB$53V*DHF^E6B6X&,R5`-AU%YWRVGO(XM[Y;7;B^)H;RP8VTN0>+I8&_
MZ)<4X@QPO.0E;FNAV[PWW_N8T2>'&^WAVL`%NV[K(^_LBVF#8+IW^GV=1@US
M9KF)N9MWY&3K)1VJR9JR#5%C(*-6ZCYDV>#(-F;TZ1#.FK=^9JQ,^0;KB8A%
MA11%4H`82$WZ0\]E;$V5S8'%\(<0UQ;I+FUP);5VDD8ENIU#A4YKUVW=.^W8
M^Z8V.Y+&E[&NUM:X@:FM?I9K`-0':&ZACI;6@Y.K%*FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HBUIANH0/:<H?.(:HB_&:\W&14E?-+\P]\H4"G4YCY_2Z0$
MQ@`K3(DVS)XFW'Q(@'X-<[/_`!W_`,XKI(/X#/YH6/'4*E78P[TL;,PTD<>D
MD=,14@H;Q^RFQ?MW1S>&X_9*D(ZH14$*HS7Z.V#,M,;10JG)-'S5TB\@(AXB
MZ25(H1VT=,&ZS99)8H_;`R9P$HAZ0UJK>Y--)P(61)&*T.2O`:P_>"BJ9%-D
MBF(0PEVV$3%,/2/HZC!MX`&WCK([4NSRZ5"&`99JHXN:>11DWC%^NT7;-UF[
M==,_0X:I+'$ZP-5A$5&QE3&,!A3$IA`PAOL8=Y1*6XM.-**TM)-%4U0CJY,*
MOQN,^:(%=B\5CA=)/'#05!3$Q3+J,`6?$<J&$13*"1RG-^F)0W,%8@V0GM#B
M0:*TX?",`MH9IS68Q_%,II!5F_:),GPL]CLI=FFH59NH5-RD1=OLH0#=)B)+
M)FW*;80VUD,>8X]-:8>D*S3J<:8@J/EW(2V.H2NH`=W(/I<`9-4$U5SF.1DZ
M.?<$MA22*B0RAE!^R0J8B(@`".KK=GS%VR`8DE2._=1&3DO%AYG7#N(P[F^U
MWC#<W`6['EQEU9>;KL!)M',YC>W3#E=:4B'D,0Y79ZY)/NM=BY1*=-$5#(*=
M'0F)\V\LC;N]QP<WD"*@\C]ZAAF,S:N:6NZ1FL9+:G6QZ8B;.M3CM113M$3;
M1KE<YE/M?8`B29C=>Q!\-O4.L/0_D5,NY=8KR@P1(Y?8XO;)LJB#A)R\J<ZU
M;JMS`4P+I+KL4T5$!*<H]93"78P#OL.ACD&;3Z$!!R75I4BYKF,1"I618Q1$
M![4)(G#P()Q$#`WZ3`4@;B("(`'IU30_D47#4J]F2#=6O321?'[2D:[(3P'8
M=SF2`H>/M'TZ:7<BJT*ZXT>^)N!V;DHAON!D3@(;!N/J]6J4.24*N'B[$UFR
MS;(^HP;RMP2[U1,%IBYV.(J<$P0.<"F<.9&;=LD3B0!W!,@F.;;P#56M+C14
M."]V7EH84XX<9<0U^G5[*.'I&9401?VJ;:Y%I"S^R65=,AG3M04YPZHH(&^P
MB7T`0/#1Q_"/A&:L()Q67,MNJIVX?=]DKDAN'V#1T]$/>KT;=(M7BH#^+4,D
MII17`8XJO*Y7(2R5R1EU9<Z\X#INQA:U')*.W\@NK]HRNZ8&*5#IV#</'?43
M6A[2YQ_><N:NKC2F"O%5*X>@5\]GN+M:O=#@A8^!,H*LFX6`W0=V=B`]:1$P
M+XB8-NGQU<UG9T?*2T#@JDC)HQ5A<L9&5N<\K))D72;)MTFB":H[`()EZ5%2
ME`.E,%S_`&M@U!/<=I\.#4:P#-6&?29O2(](@.VP"/2/OV].L)KB7`<%(17$
M*CI.62:"=54Q0$"B)CF'VAX>CT[ZR"0$`J%$/-&5V<<U<-R.-MBG,80.`>``
M(B(^._JV_!K6WUXQC2.2RX(7.-0,."\RWF%\J73PKFB5^0-\7)]9'BB"H]39
MCN)3[B4=P,KZ`UK=CLG7MR;^<'L6GW>M95[,((Q"RFLC'J6$943&4.8VX[F$
M=Q\1'?Q$1'U^.NX"TN6"ZITIMO[-OEX:*O2NA-XF,/\`.'\NK5<M.B)HB:(F
MB)HB:(FB)HB:(FB)HB_>6UU2Y)-$31$T1-$31$T1;B:2JHB"2:B@E#<03(8X
M@'M$"@.P:M+FM^(@*JT:N5%\T1-$7PQ2F*)3E*<I@$IB'*4Y#%$-A*<A@$IB
MF#P$!#80U1%I,DD8#`=%$X'1.V.!T4C@=LH`E4;'`Q!`[90IA`R8[D$!\0T(
M!S55I1;MFY$$VS9LV3:H$:M4VS=%NFU:I@`)M6Q$4R%;M4P*'2F0"D#8-@\-
M``,DS7Q1JT6*@19FS6(U<)/&I%FC=4C5X@)A0>-2*)&*V=HB<PD5(!5"B8=A
M#<=4+0<TJ5]7;MW12$=MFSM--=%VFF[;HNB)NVQ^XV=ID7(H5-TV4^TFH``=
M,WB40'0M!S2I&2TJ-&:R*[=9DR6;NDC(.FRK1LJW=(&`P&0=('2,DX0$#"'0
M<#%V$?#QTTBE."5.:W")))F`Z:**9R]72=-%),Y>KIZ^DY"%,7KZ"]6P^/2&
M_H#5:#+@BT-VK5FB5NR:M63<ACF(V9-D&C<AE3F55,1!NFDD4RJIQ,80#<QA
M$1W$1'0``4&29YKK+#78.V0[J`LD8VF(=Z9JJX8N@4`GQ#!VA(1[Q!9$Z3EF
M_CI!JDX;.$3IKMUTRJ)G*<H"&78WUYMMTV]L)'173`0'#DYI:YI!J'-<TEKF
MN!:YI+7`@T6OW3:]NWJQ?MF[0LGL9"TN8ZM-3'!['`@AS7L>UKV/:6O8]H<U
MP<`5W(>KQ$1``\3")C#MZS&,(F,8?6(CN(ZQ5GKZKLX`A7`%<%3$#)E7*58$
MS%\2F3!4#`0Q1#P$-A#1ON$EGNDYTPKUT57_`+T`2^\!E7&G57)/3XCXB.J(
MOFJJB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBWF_]^A_YY/\`YY=6N^$]
M2JOQ9_,T4.KYD'/Q0XB8QN9?)/<1$1$=LN6LH;B(B([`&N=F_C/_`)Q]JZ2'
M^"S^:/8H0ZB4B^"&X"`^@0$/GT1>Q?RW<F?O%QDPRFF]-\5%41A%'.!B`8QH
M11>&,W4V$0*9%9D(!X;](!OXCKG9267;V\=1]!Q6:![C2,J>L+*Y4)(`[8S"
MK\S!V8PN5&Q_]Z;J]DY6[A(I@.F)DES)B<H@/43</2.MC$&D#758[B:X*ZY5
M3$[JF[LS'X=LX9F=@BFY61403$[A<C=9=(2`Z[A2&(/2H0I3;!U;!21N@\=-
M*HTUZU7]!N$=4YYC*2L<249$*JF[2Z$CN2(.$C('<-0<I+)BX13.(D`Q0W'T
M&+Z=9EL]K"'''FHWM)R7-),TFXY"43;H'JE03B947KE-HWL;YH#."?KH2`LY
M>09QH3,E)))(HE,LF@FJ8IB@)OLFS&Z9'>X,**+X1CS6)'F_R>Y!\9<DX\G^
M,-T;0#V#;2\A,*.H^/L+"TQTH@2'2:S$=)QS]F9H:/07*9N=,Z/[<WAZ]<MO
M6ZR6%_%'"2&EA)+<>@`UZ`5O-MM6W$#W/`KJ%`<.G[5&=SYZ.93L%3YTX#\-
M<YQD>P7;2LC(8@0K4B5B4J"KAR65HSZ&!DOU-2J"X,U,*(AU%Z>G8=C8[]%<
M:8W/I(<AB/4:CT*&XL)82YP;[@XYI6?-9\D'(X)_\0_E,/\`&LLY17;/[/A&
M]HSZ1TUB*%%1O$W0(,R9-ESF`P.3F!4W6`=7V@W[9G$5P/6W[11:Z@K0X*2F
M))WR$,A]AK@[S(^:7$%S)+IO(NKY+L&0?N2NR!QZ2L_CX.0DH$D>!2E(3O+'
M33$G6!B@(EU=VV&(KU.(]10-`RP62O&O&[DG/-FJW$/SL^,/(-)<$U8Z%RK7
M^/.1I1R]45!(6[E&:I<Q:>VLQ*9(1%QWCB4>KV:H2QQ_SK?6K]1'Y2>I5C=\
M!^>'CZ+*Y+QM\L3D>T*NH4R3?CS#PLA)$$B#Q!Z8M2GX-N8BQT0)U%2*)3AN
M(;=&U`UCL!+ATU^U-9`R]"B):<E\^:*J9AG+R(.%M^1;H$[*]4IEUAB-FX&.
MLJW40=_O400%<1-U`($WVWZM@VO$+ZU:]I/,$?<J:\*.!HHYS_*?BFQ7>MLV
M?P[]/C'A#++R*]6EY6';F,X*54Q69C1311R[.98P@&Q=O$`Z=M]5=;3@5`/J
M5.T:<\U;1YS'\E%P9RXNGDI7ZG_#HD9KFKEI^,335;J("V$ZSR-9HI](I&*(
MF.H8Q=]A/U'`8C%+R=_5_2KP]N`%%O/.3'\,[-B4\MPOY.8S=N4#**%KC%B@
MHP.0X$.5L#>6<IF,)@$1ZRE)N7[(;ZL.&8']4JX"O$*K6&??X95N=DA#2_-6
ME&4604<2S<ULC20J#1J<R8J"P>LRK$.IL14J7<.8P`IOMOO:-&%0P5ZQZU6@
MKS*OM'Y2_AVK&*7W-YBG)2H-E5TR&:3V1\IF()5BIF*D9%>24?LV:`EV4`W2
M`FW]/I&QVG/W#CY<DH*8CUJ[L*MY+#K<T%YS>3V9E')2H(RN8\I%133'H`$B
MD=S;E,H$!/<#"!@^T/4'CX6]G`3BQI\ZKIZ/8KOQ]%\L&40$T#YTE@,H&Z;<
M'V9&4@18YS`"8N`F(-RHV2#81ZMC;E\1``#<:MBMJ:NR(X9\E1S2#3#+G^E5
M_$<1N+MN((0WG#5J60,9--J9QD+#$B*Q5F?6W!RF_JZ)A<&'J5,!3AML`"'I
MWJ;>V=DQV/G^U4&I=38O*'PM>4>TGYD5%LQWQ5>HPVO#2)E-U#E*DD$:Q2$N
MZ0>([B/6`AZ-8DVR[7.*31R4KS(^U2MN9V$%A]BA1?/X4OC[?7LI90YAI/9U
MXHNN)D+-3G#51MUE(D;NFGD2($((&`VR73U;@&VVVLZ"TL[:+L8P]L;<L/:H
M)'R2NUOQ<5!G//\`"T4S&<"K*07)EY)NT6_=602?X_E$&QP+X@<$9U)RH4QB
MB8`*7P)[P$-7ED%<W#K!5A!7F_Y.<!YWC])/&2]Q0G$6IUB@L#1NEW"D,($$
M`;NUP^V7V#J%PC_"254:N.:QPN4A0<+H&'<R*RJ0B'H$4SF((A^$0U$JK9T1
M-$31$T1-$31$T1-$31$T1-$7[RVNJ7)+AR,E&0L;(S4U(-8F%AH]],3,L^4*
MBRBXB+:K/Y.2>+'$I4FC!BW454,(@!2$$=6O<&-+CP50"309K'GQ(\S'!O*'
M`E^Y!62/E>-58QO>ZM5;1'9OE8F(=1U;RI!4*X8"R,^?("FRCJOG*E90@G\.
M*W2*:KT6RINXD<=8T5TUS27X4]GIZ1Z5D2V[F/#6XU'#'$9\.8*E-E#DUQ[P
MHI=F^5\Q46B/,;U2I7J^QTW+#]ZU.GWZUOJ+1;#,1+%%Y)(,+E<XQS%Q>R1E
M'SUNHFB4XD-M*Z9@!.8`!PIQ\ZB;$]Q``.)IZ,_0J(C.<W#:6Q$?/C3DYAE+
M#"%W;8R?9(E;I'P-;ALD/%$4FE`L2T\,:ZK-R<G<I=N-D$FKLQ5DS`3I43$U
M!<1ENJM,>C[^D>E7&"4.+*$D>7EU+7$\X>'LYA&Q\D8SDEB5;!5.L2U/MF3%
M[.C'0%;N2#R/8!2YI"229S$?<W;R6:)M8A1J$B\%XA\.BJ"R0F"XCT:_N^^G
MKXCFA@D#^SI[WG5.S'F'<&8#%=6S;,\J,/1^+;O8+!5*E:UK$H8)ZSU`IE+E
M`,8!%FI:OO6E)$%2:1.Q(:'2V4>=DABF&TW,0:'<3PJ*^W[546\I=IH>NAI[
M%$#G9:,BWEO1[9A6Z567IECBJC=,76E[<Z\VPY<,?.\=91G+#+U2PO8FR5"W
M9&FKL-1^[&A%8Z2D(=9%.+EX=)Q)2:$;W%SJM\AC3/S9=.*OB`&#JUX\ZU'Z
M?N63/`REDD<7T]2SA9TWSQ2:^Z1O2"S>\_N8M:)@,>*7ALY46>HVXU$&-&1*
MY.=Y\3U?$F%QW1U,QQ;#K=P!/\GZ5"\`R4;DL:>'_.*Q+ESB_=^2*>'\AU%]
M0LXX,Q%,8DGYJO*6MW6^1^:*GAK$.9XB7:)C$O\`'UI?6-VZ(($*N1>!DF!M
MG#<1U"RZU-)/Q`CAP)`Y]//S8+(?;:9`T'W2#Z0"2,NCERYJ>4]S#XI5G/+#
MC!.\AL4QG("4D8Z%C\5N[2T2M"\]-1YYB`K*Q/M1T?;[%#$^,CX9RX2E7S40
M50;J$,4PRBYC)`RJ.C#U_8H>PETE]#0%4VMSTX2-[X]Q:MRRP`3)498EZA*T
M+_,RMGML/:6V0XW$BT!-0:;P[Z%DPRA,M(`J;LB/<E'*:)!,8X:KV\8=IKC6
MG#G3GY=:=A+IU:3II^GV*X.0^3?';$A,F*9.S9C:B?Y,Q5'FLKIV6SL(YQ06
M&3G4BPQJ-C:G.+EJ^R$_B7*$(S*0[V461$C=)0PE`:F>,`FM0.5./\G&BM;%
M(Z@`..2J+#>:\1\AZ-'Y,P9D6JY4H4G(2<.ULU.DBR3$DW"/#1\W`2"(D1?P
MUAA7Q11>1[Q%N\:J;`JD41#>YDK'MU`X<<L%1['1NTN%"H:&YNYIR3,Y*=<1
M^%5JY+8KQ-?KCBR=RM(9YQ9@]CD+(6-95>O9*K^"*Y=6DL\R`QI-J9N81>7E
MG-9AW<RS<(-'*Z2)W&L5US(7$1C`=!/L-/33K4[8&`#M74<16G0<O(5ZE?>0
MYH<:*C/8ZH&7,P8^P9FO)<-C&0A^/^6;Q4:]F1G+Y;)((U"I.:HUFI$)*P.9
MJ$D8T1C5GK,SV/6*FN<G0<\XG94"N)IQ''S^7"JB[&2A(!+03CU*A(7S).#%
MJJ>8+A2^2^-+I'X*QC9<R9&80,JNG.1V-JHBJ,K;HN*FFD2XL%=!Z0C,D@Q!
MPP^,712,L4RI-[1<L()`-0*\/3GEY9JXV\H(!'Q8<<^66:@UQ7\\CCOFRUX1
MHV7)W!F*+-R3H$OD_%2%$SPIE:.KT8G+8N@:QB;+[^3QYCM2M\A;+,9+.B$+
M$(S,0F,,[`)(Y@(48V78+@'4]X<".CG3T8]:E?:.:'%M:-.-13GEGAAG@LXI
MBF(8Q#`)3$,)3%'T@8H["`^\!#68""*C)8BAS)\YN/5$J=^NV;<D8ZPY7*7R
M%R!QTCGDKD2NW!Q;;A0A247:1D32_O6;:VQTP[SIW6C-E9F&;MSJ/4TR?:#&
M%RT`EU/,1]_\O#)3_+O)`:#B.1^Y7J:9VQ#+81<\CJ_D&KV3"*./YS)Z&2(6
M41=U5]2J]&2$I)SC65+^R^#;(1:Y5#&`HI*)F*<"F*8`F$C3'V@Q%.C[Z>M1
M=FX/T$4=6BQKP/G1\4+CC3A-FRKVFG-\3<J+X^H>39ZV7J/BY+C).)\9KQR(
MCZO=VL:RE(^<O[I>JM8$8ELX(91U(%,V.NH":*N,+L%K74P/2,Z$Y5-.&9&:
MR3:/#G-)]X#IY@<O/A53<D></#Z*P=6N2K_DABE'!%SF#5JH9))8RN8>TVI)
MY)Q[JGUY@T07L$O<V#Z$>I.H=!F>3:&9..\@F"*@EF^8CT:_5A7VT]?`\E#V
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ML;`\>.V4*Y?T]"8A'[(LL9JW1,LS4`Y4S!MI'.US07^Z2`<2,:^7)4DA<QQ`
MJ0'$5IR4E*ID6@WK'\#EBG7.MV+&%HJK:]5[(,=+-35"7I+R.&7:VYG.K'18
M&K:\2'Q17ACE0^&_:]71]K4HD:6:ZT;11EK@[01[U5&BJ>8AP3O%*R7DBJ<L
M\'S-!P['PLQDRW)7)JT@JI"V>17AZI..'DBFS+)P=PF6QV<,]8`[:R[PO89J
M+JB!!B%Q&6EW`=7W^VBE-O*'!I!J>ORP51L^<7#E]A]ER!2Y-X90PH_N@8U2
MR5)72.AJRWR.85BACV67F#,'4#>>IN8/NE\DV?\`Z/[+[9.JHN(RW56F/1]Z
MH8)0[1I-1T*D:GYC_`F]3F.ZS4.7.#I^QY7L!ZE0H!E<$"S,Q;BRCJ$1J3Z-
M<H(.ZK:9":8K-&4=,$CWK]RF*;9-8_AJ@N8R0!F>K[_955-O*T$D&@ZUVEJ\
MP;@Q1<@2.*KIRVP)5,APM@G*E8*M8,A0L4[K%KKD8,U+UBV/'BJ435;"E$E,
MNBSD7#5P]3*;X8BPE,`#<Q`TKYZC[^*?+S4KI/H7=0O.#A]8<*VCD;#\D<3N
ML'4FQ*T^WY)4LJ3""K5Q3<QK1.G3*$BBSF&5O?N)ID5G%F:_'O\`XUN+9)4%
MTA/47$99K^[[Z>OB.:H8)0_10ZCUK9'G9PN3Q-6\[O.4^#(G#5NL4_3Z]DJ>
MR#!UVJ/[E5(J<F[/359"=7CONNX5Z)K,@N\BGA6[]N5HH!T0-L47S$6D.KAY
ML,^GH\J%.PEU%NDU'1U?>%Q'7/GA*QN6,<?N^4^%T[?F6&H-BQI"(V]J]<6F
M`RL=`F+9=%=D1PQBF>2SN4RUX9!5F::,<I6@+"(!JAN&5#1B3U<<N/LJG82:
M2ZAH.OS^CBNA7Y]<;Z;BV#RKG#)%$PS"VC)^8\65E%U=(_(Z4_.88OUIH]A"
M-DL;M)Y%=\@G6#/))CVP<0!U#LWW;<MU0`;AK&U=BZIRIS/3T*H@>YU&@TH,
MZ\@>72NJN/.2GL<I<?:?C)M5<NX\Y"\7N5')JIY;J=X;/JZ[A^.+3$3N+C8$
M\7'RD=/QE\)E(P&?%=)FCQ8=/:6,H8$[7W`;0MQ!Z>EH^WRJKX[9SP=7ND='
M0X_\FBK/C%S!QIR&P7B[*DE/4VAW2V<5L*<L,DXN6MS:1D<18]S32G%OB)N?
M?O&L0NI3D5(>5:HS"K9N@N,4N)BIF(8@7MG86@N-#I!Q(XJ-\3FO+0"0'$9<
ME):HVVL7ZJ5B]TF>C;33+I7X>UU&SPK@'<-8ZS86"$K!3T0[`"E=Q<O&.DG#
M=4`Z5$5"F#P$-2M(<`X9$*(@M)!S"J9$=EDA]BA!^8P#JI%1147XO7FF,"QG
MF8^8*Q()C%0YE\C>DQP*4P@KE2S+>(%`"^E37.3X3/\`YQ]JZ2#^"P_JCV*!
M^HE*FB+-SY2&:G;)>U8E>/0VBGA+=`HJK"!PB942LI]HV*.^Y&LH5!?I`/`S
MDP^O6BW9ACECN&_"<'>;+U56;;'4PQ\1B%ZI*)-1SV-:K]U)1!1(A^YL!PV$
MI2B!MM^D^_I]^LJ-[7Q@L.04+V$''-7!-,LD6#Q))4QCF-\.B7J'<$>D2[`(
M@(`3Q]`^C?5K7![RPJE*"HXJB++8CM6$>A"?%(+?"]B2.NN*Y5W1%#G%XU$P
M&.V1.B8I3)B)@`Q=R[;[!.YH!`CK3RQ5O25RXM\YC:-,RRCMB"CQ5I&N&J4E
M*ISSILHJY>"]49!TQ[R)9"@F53K``$XE\.H.K6:T]C`9#[<5'0E]."QTYE2&
M\VAZ9V3XD6[%%@4IB=1A$ICJCTE#JZ2"940`/?KCW$7=[)VH#B``MPPF*$!F
M`.*QN9)QJPBG[Y@[(=.#L#)_#2B94P,HFQE6BS-Z9-,^Q#JIMUS&(`^`F``U
M!<6C;*9LD=<'`CS8K+@G==1N8["K2#YU@@ROCV[8$R-9L76-T<LC6G2!4UD3
M"M%340_:HR$)-LDEP.DHREHMRFL7<NY#&,0WVBB`=M%,)&"6(^ZX57//:6N+
M79@JB$;`EX`\C6X[!M\1'J*QSDI?$?2F8R1@W'T"`!MK($O![6N'50^D449:
M:U:2#ZO05-/CEQ.Y9\AF"U@XY4C)TNTC5`$DJD!H:(.Z;F$Y48FQ/7C",7=D
M,/@`+E$!]>^I`8G#W2]A\SA]A]JMK*TXZ7#S@_:%)E3/_G(\$G!?O.[<M</,
MVA@*5S*R-Z1KO[%<5R_"S:JSJOF3[XB<.RY,4VX^D!'>ZDF37,?AD3CZ'4]2
MN[7\P</9Z153<PK_`!5WFJXF:HL+3?JQEN/3*0G<R/3HJ3>J"3K`>_*LD6$@
MX*<I@Z@!8IC=`?:`1,(QN]W^)'3IQ"O#P3@:K);C#^,6DI+X1OR&X28>N@=H
MZ3V3J+UU#/UQ6Z2K*%0L+.R-T04)U`8H>G</'TZ![*>ZY[?.KJ\U/[&_\0SY
M&V=46L=F3C3-XC?OQ(V<J/:'6+1#LQ7Z15$\A`O6;@S<#!]H09#]CU>K5_;S
M-'NR5'(JNEIY*3#:1_AP>2KE)M`9JPC79V5.4P)2IE:0X[KM4J@%=/9B$A&0
M"H<2_I._L]0;"`B`ZD%S<<0US:*FAOD5<AMY$'EF9<:$=8;L>-[.@Y-\2D[J
M%GJ=G,*`@<RB22B1;2?M*'.`&`%""`>D=]MK'3L=A)'3J5PJ#4$J.V2?X6OC
MA."Y5BX8J@'*395A,RD>YWZ![HIHN)23BDE5E!\3A'G*4I?!,1],9=;O'%I]
M*N!QQ(*@3D[^$LQ^NV<KT^U9*KSY)13MHNV$-.Q8)`'4!_B(^NTIR]$RFVPB
M<HE*.VQC`(:!D)=34*)0$98]:Q[Y#_A8LQPB;LU7R6U<&3,4J2,Y"2T,*2BR
MH)E!R+1K;4U!3)U"(`HF)BE$?#T:O^79P*MTE04M_P##K^8M!F<GI-2K>0T&
MS;XQ0M;ML8U>$;&5%NU$S.:<PRYEWIRCV4RD%50`$W2`!J%T3FN^$T/&H]?%
M7`'23JQ\ZB3=_*M\S7$R1W,]QNSO&M$NZ<SJ$CI]^S(FVZ046^,AC+L"I%ZB
M_;[O3L(>.JAA.%316$/`J0HN6"M<M<>N#-)Q+/57=H)%`Z*[N[-5$T#CL!0[
M+HVQ##_)#\8:K21K<''2J5/$8JVS_-^>8TQFZV7,G-E`$W=1=V^QE4$X[`;N
MINGW68WA_*`?1JA?+^8JE0<%:N:R%>ITYAFK=8)43>D7TH[="/O$55#;B/TZ
MB)=6IS551AC"81,81,8PB8PB.XB(CN(B/K$1U:JKYHB:(FB)HB:(FB)HB:(F
MB)HB:(OWEM=4N24->?\`B++W(7B?DWCSA:0;5^?SZ>KX;N]T6F&D.[Q_@V_V
M>+A,^W.!%VBN65MD=B%:70B6)2"9Q(ND=_L%/K'N&O>S0VN)_1[*GH("F@<U
MDFMW#'SC+UJ%T/Y8MMK^8\S5*SY>N7(+BMS,X42G%OD,KDB.PG2+;C69Q,08
M3C7.4.KX8QABZOSC9C0KY98Q1V=FK)L',?%G%<4$DB)8KK9X=09$='^2!D3T
MK(^9&G53WVG#/[23P'1T*U4!Q`\QNM<4,D7.6M[=]SKS1G#CT3D`XPKE2&QU
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M9@J;-=]#-A57;E7(X1DE@=1VEN`=_P`D#`4Q\W+T0QS,HT/<[46D$_TB<_T<
M3U'B\@,"<Q<NYYP9S41X]Y&J\Q`8BS7@&[\;,,\W:?B;,U8B;ADBA7VF9?:9
M=ATH3$]N>VE*EFC[76AF`^&1)'+MW\@=LH@%KXY'4?I-,J4.&60X9<Z<E?'-
M&RK"[IKQ.=:FAY\J\"`LG7#S$S7C]QAPIAV'H"V(&5$I:,6GC'_,^0S&I1CN
MI23FEZXIE-^QBG-X48.I,^[T&Z2/484T0[)$Q',AC:(P"T>0'/+E18<S]<A(
M-1YOL4E&RA4W+=4XCTIKI*''Q$>DJA3&'VB.P:E>TN86C,@A1`T(*\T%F\I[
ME"VXA\#ZMCTU&BL]8KM6+<;<LJN\MC8:M?\`C93^;<7RXA'4382"2.D;QAVV
M59%[!EVW.SLDXT+NHN4HZT6\K0'<W"N>51]HY88\ULC<Q.>X<-)H<,Z$>PT\
MP'!7:3X`9GAN0V8JW=\,Y,SWA'+7/\.:%6R36><R^(,3U)O+Y1I^6(TV5./+
MA#]Z)?(F#+'5TDXDL*UDV-E8QL>DNZ8`*Q4Z,@>R1H<WB,:'V@X=&?2JNN8W
M1G2YP-#@:=52*8DC,U'0I28[\O@T]Q(YW\<LO157K,WRSY.\W\JQ5VJR<4]G
M8R.S/F2?R#@/([F7CVZ3PMQHIDX.21054.M'N(Q%#?9(H!D"W<YKQS.&?,\.
MJGG6.ZX#7,+<0UHY<AA7S>52HE6?R]N8U[XX43,.2B5V=YY/.<].YN<AZ#C'
M,SW%D5>&-!Q78^.5,Q#BO.[6.7_="6Q]BAQ'3M?=NDDHW]X2.D5E6Y71G)(3
M!(8]9'O5RIT4H!G3+##+EB)FW$;9=`)$=*5Z:UKRK6N/3YEDLX#X:D\-4S*\
MW/X:ON%;AE[-TCE2V0V5.2#?D]D.WS!:51J8A>[C=HE5Y6H&9E8NGMV9HF-?
M2**;=@DX4<F7<*)IY-O'^Z+7`BM1Q&%`,C58]S('R!S34`?;7D*^A8_K-Q:Y
M@8JP?E;AI1L$VK,V+'&7L[Y<XN<@<&<X'W$.ZT$V<[GD+)D=4N0+*-G*1>WJ
M&*;[DZ1*"T"[LD;8HULR6<1R3M$4Q@<)V`QM!TU)%`>)/$$<^GA@%,Q\#G"5
MYHZ@!!IP'2#RZ.M7YX_\.N2..LK90RO=9S'EAS',^5_POXO4S.5C7+?WRG)[
M",1GI;)EQEQG(W][75.D;]=8"77<+D34G.T8RJ0JH[!<R"8&M?W@`QQYN)Z_
M+)1R2QN:`!^[UDTPRH*=2A'AW@;SCL&3J+E#--2R<WNT#P+YF<=<I7O/'.-/
MD<\R-G7.M6Q0SA)W%U`B0+0,+X@E[-3Y%PBG%-(98&ZR";Z+:%:(">!L$KA2
MAZ<".+2<\.'"E>2RS<P@U!P\W)PZ^/&M.:EY3..'*#!%Z\J[(M=Q/$Y<_P"'
M;@')\'^0-9A,ITZGRE!G;>SXJNG&3X1];CM(B_4VLR&#Y1N\:1ZWWJN59NHU
M07`QBEE;"^,L(%>>%:?#]W\JQ3)&_M&O-`75'[77S_D68PP`!C`4W64#"!3[
M"7J`!\#=(^(=0>.PZV(RQS6$L!E[X,YUA(Z]6:/PODFZ9)7\Q[F5R>Q!DKC'
MRUH''G.6'Z%GN)A(6!FX9[DR(D,87)A>X1!W'62NSG6#5$B"H-W)@Z2ZAUO(
M`:MJ<.%<J\//F<.M;6.YC&GWB`&Y99TXXGAR]"RL\9JCR$C^*..*1RIMM>M/
M(Q7&LI!95M]<1C!B'EFF?OM%J[6/7H*K0<I,1T,_:)2KR.C(YE(R:+ARV;(I
M+$(&?&R3L=+\\#[#3AY<LEKY',,I<RNFJQH\9^)_*QCCKR?\>Y;PU7<?./+0
MR"^K-^FARK1[Y$Y)IU?X799P-7LN8W0@1/)L6<W>[5&G0BY1!E-L43J+*)$*
MB!C8T4+C36,C3(Y!I%>FM>A94DL8+W1DU<*YY'4#YJ=95JKMY=W*:`ND!FZJ
M04S;7F/_`#`O,;S@CB3$'(U'C[D>S88YI.*X%3O5"RH;X6LP>1*@>N&^-@)9
MU'(OHZ8?I&>)K=)5HG6\HQI499$\3PPKT<.E2QW48:&DD'2,<.0Z_/ARP65C
MAC@[_)WC*CC93'%DP1)6BS9HN<[3YG-BG(.X5ZR9?N]IM4[:9;*G9:L)BUV&
M5GU)MTV9&581S]T=N@NN1/O'SH8R(<J.\XXD\<OTK"G>'2EP-1ARY=%%CEXV
M</>7,,EY;N#<F89QUB^A>6-%Y);J<@*SE:MVG_B8<2&`,@<>ZFRQ[0XB-;W.
MBQ624;V6UW4+.5B9O*1Y&R`2)C@\)BPQ2-D&%-.9H16@(SXY]'++%94LT3F.
M(<XEW#,#&N`X94S//H5<8"X)9RQKCOR7*U-Q%.92O!K!6><>Y\+&6*-51C[!
MDKC*KC2,1JZ[9(A+2RD[^"9W:J&Q>DH.5-]M]6MMI`YCJ?E]6?D4=<M(D!)Q
M)IY_/Z5#?,'#++6.^-'D]<6X.TQ./^6=XPM+>6IGM*M.59T)7B+<L2M+9RYG
MH>P1(I-P7PPWQBQD:_*K"#9*5ERH)_M7Q0-:Z(M#6_C<`*=%`./&HPY$<*JY
MLP<^1Q_AM-1UU-/,:FJS=\MN,Y<[<(,_<0L6R$1BY+(_'2V8,QPY^'<IUJFM
M7-.-6*C%O6L:4SPM2;-6S=@\30*97[N,H!"F-L4<^2$F'LV8$`^L&OMJL*.7
M3,)'8XU]:A)E^D<V>1^,,,O)3A?C[#5VX?9ZXO9^J>+I/D?C>TU;D4YPRYL[
M"XXIJ4Y4:VYC<<4^$C)E*9I<C8RMA//LV97<='II'<AB.CE?&0&Z2,<`17IZ
M3TY]`"RFOB9(#J+FD4QQIEZNC$4XE6X7X2\G,N9+D^1UUQQ4,3S>4?-"X1\K
M)W`KG(E8NCK'^&.*6*D\83-PM=KKJ!Z59<R7QRS3D'#"'5>I(M4&*(/'"Z*A
MBV?+RN]^E*DX8BF5.H8=0%,5)\S$UI9B<,\ZY^G/SFN"JW)/`_-]DQ]SN@(&
M%IA)WD)YKG%[F'CU8U@BV8O,1XDM?"F9M<K-/>R4\79VK;!]E,U8JB*ZQ^V!
M!`7(:E;`YK<1[P</^1EZ"H>W!<TDFF@UZSJS]*^6S@7FJ<QWR#K2<#2'4IDW
MSL,.\[8,KJ<B3(/L`T?+W'*W3$E*++H&*E:D:QC.7(C%*@+@X@FB`@"H!J..
MVD%-8R+>?`MK[,Q@KY+ECI"6DZ2UWKU4KZ50/*#R^>2=^RER0S-C]HA)G7\Q
M;C1S+QK0*WFE;#5IRU1\8\)87C-?(2/R7',7A<69+BK.]>2\"YD`(T=.(E`B
MZS=)T#A&]\#P"`T:01P/Y0/.#QIR'F17#1IUN.H@C]HFI//S<?,:DH?`Z[2\
M_P`5;T]X^RN-?W3\R>T\P<\UK/7)*$Y0W^R,#<.,@8'KN3Y>Q`25JI+NK;7L
M`BE"Q+N0!DA&IR(NA<&4*E5D3C&UM*>^3Q'X2!Q-.'1[%;).TN<6FM6`#+\P
M)Y5X\%?_`!GCOD_QGY0<I@J'&RH9WPYR]Y-4+/:69@S/1\?/<3P0XTQ)BRW4
M;)U#LT*^MEH;XO;8R5E*@%=1DD7Z;XC14(Q0AUQKV<C)--*@D>]0U&`%:\,N
MGI5ID9)%4G2X#+@:$G+S]%.%5$AIQ!YX8PQQ@*@5YID*S8MBN0/F%Y!SAB;C
MARQC^+&0[.\S]RCMV6N,USELW,UH>PN<:UNCV>0+9*["3#"5))2+=44I$&9F
MVK98Y"T``D:G5P)XFF&!\^&?%2,FB#W%V9:T<.0!&1'I!\RW^*GEV<DL1T[@
MW"7"&J,<[P%Q6\U#$5^9L\E&NH1=LY;9JI]ZPO&QEHDVK:8O#(]<A%BR,PX2
M27(L0#NB%55,`4;!)I:*8U)X\V\^H]:K\Q&'O=C0TY?E<.?,JS&;^&F18/''
ME`<38VRQ=.S[EGBDS\N+F-$5]=Q+_?G"FD8IH&0N3,_$6.+%-FBOCFRX\)`0
M,FJ()'6R(NDCN=R`:MDB(T`?&6@'APH<3ED!Y^E&2@F1Q^`.+AUUPP'I\W0O
M2@QCXZ)8,(F&8-8F'B6+.*B(I@B1NQBXJ-;),HV-9-TBE309L&2!$DB%`"D(
M0``-@ULF-#&AHX+7DEQJ5S"CL(#[!`?F'5RM7XXOG20IX#S:?,2CCE$@FY8Y
M:DB@)2DW2G)]6;1,!2")>DZ4@40]8@.X^.N<F.J5SN9KZ5TD&$#!R:L8^HE*
MFB*\.`LM2&#\NTK)3+K.W@I5`DXT)N(OZV\4(A.LP(`@!U!8B91(!\`63(/J
MUCW=NVZ@="<SB#R(R*DBD,4@>."]A6/\FD/#QLI"2`/:_.LVDU&2350RS8\:
M^13=MW10*(G^'504`VP;B4!V$-]<B)G0_NG5&)\W\BVSHVR'6VGWJ_\`$7PI
M2,W3AR(IN16!0Q1ZBEZ>@Q1#K$#>.XB(ZR;2Z:)27&J@ECJP$9KM)+(,<]<(
MMT50#82@02%,/<-N'4`B<"&WV`?0&M@Z^87!K,2L?L7::G)=XZNT>$2/PZJ?
M21/H5*<Y1WW'I$B0"`CXG';T;^[5+B^<82QE:#B5)'!1WO44"+!:RQ-RF'BP
MJN&_Q*I!(8PD%4I1Z!`F^Y0$#I^/I';U^O7*07;[6[,SL8R35;1T(EAT#!P4
M9,CR2E@46.HF4"F4,L!2E#8-Q-L0NWB`$*.WXM9\UV;IGO"BI;PB)WNYUITJ
MY%CX'57S',!TERG8F5%S7BN66J*=V)"_?+N2K!FRJ[.%L[-!VR=OHP#F35:J
M]9EFY^Z!`$#"0=ULES6$Q./PFGW+7[C%IG+P,'"JH'AYY`5@K^:%)3EA9*;8
MZ#7W22U9@:L\?+1M^4`>LB\JJZ19KL&;<0^VS.'=4,&P[E]._#F\<%K3T8KU
MBT/']/QO6(NI4VO1%>@85LFTCHR&8-H^/:H)$`A"(MVZ9$R@`%].VX^O5SKB
MC=,>?-6Z*D%RK)8A'C,\>NU2=,EP,FY:.4$W31T4_@<CENNF=!9(Q?#I.42Z
MQJR2"IQ'EQ5WNM/2H29E\LOA!GD'2^1..&.22;P3'7L-)BCXZL_</ONJ>7I"
ML$+D^YM_VY%@$?2`ZD8^YA'N/<&\LQZ,E0M8XU<!7RXK$_F;^&GX]VDKE_@S
M-=_QH_.*AT82\149D6OE,;<2)IR,8>GV)LD`^`F4,],`>H?7<+O&DC&/\Q:?
M5AZE7LQ^%SAZQZ_O6*+,'\.]SWQ\=RZQK'4K.\:@"JJ?^7-L:L;"9-+[0"-3
MO2=4?**B4/T&R[L=_`-]3-ELI,^TC=YG#U4/J5")FBOND>=OWA8G<L<=N2''
MR6-$9?Q5DG&;Y(QM@NE4L%8;JB!A*86LC(LT(MZ43_RD5U2#ZAU=V8<:1/8Z
MO(T]1HG:.`J]KAZ_6*JG:IG3-&/%R/:C>KI5EP,!R/(*P2\:I]@>HG0Y8.TO
MLD/]H``=M_'57">/X@X*HD#A[I!61C#WGJ^9YA4K5.I\OLP+,FPI`$18;*\L
MT8":)2%`AFD^,BV5!7H#TE'8-_`!$1&S77,`J36LM^&OXP+S!*;\$UR/7<19
M49(E;IJJ356&#E%BIIE(L87E:=0X&46,3J`RA#"7J'<1\-`8CF#Z4U`G@LM>
M&/XQ;!MO^%C^0'%AS$*&%$JDK4[,S?,`=`K^FG&S\<X6(FB78P&%SN(^ST:O
M#(S\+B$KZ5E9PK_$%>4UFGX9)U,O,;R+LITSDMM2B4DD^LXHJ`=[`2$BX6*/
M:W$>R(`7;?;<`U<8I?PN!KT_>JZEDTQGR%X/YB;D5Q1GS&LN+PQ1*G#79A'O
M?`@*?"?!R2C5TD@'2`F2`H%$0#<!U863#,8*_6ZM<*JLKIQ@Q;?(A1U(1E4M
M8`@LHU?3=<KME`%ED114=(NG[&3(!@+OT](=)=QV]NJ"6AJX*A.%"O*CYL'#
M/CG#0D\NZPCC$KHA5>P_@ZU%PKE`.T("*R\:6..KTB43F'M[B8_\K;5[I6$9
M8JU>!'D=3*?6;7)-JW%)Q:"3A0B:*"IC)@!3B`>GW?AUCDU5%%@?`1#WZHB^
M:(FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+DE1>1K_7L64>RY#M:5F<5VJ,"R,H
MWIE+M^1K6Y24=MF*+:OT6@PECN5HDW#MVF1-K',7+@W5OT=)3&"US@T5/L)]
MBN:TN-!GZ/:HT57S`.*]J8.'1KM;:3)1N9<7<?[%3\L8?R]B3(-,ROFX$AP]
M7[S0LATBNVFGQ633.$B0LT_;(P;Y94B1'G=-T:A^9BR=4'J/W=(^Q2_+RTU`
M5;S!!''IZ"JING,;!=*>Y.B1=Y-OEAPYD.FXHR)5<,X+S1FRTP.0[Y0T<GUV
ML%@L6T2TO9)T%#=(2+]9L55K$INFZ;U5NNX12/4SQBM#4CD"?8"K1$\T)H`1
MQ('1Q*I>L\V,1Y*E^*YL36BLV&K\D<QY7PRJ%P;9*Q]D6OW##^/<@VZZTQMC
MJ8QR>5B,F5*9H#EK-PMM-5Q8,TEU4U5W)6[1S&ZX%*LI4`FAZ`[A3HY@_;(V
MW>31P(&&(H1B1QKT\%9'`7F.P%IXD8"Y#9MHF3$K1FE#+SM2M<;^._(+/T;"
M1V*<HVNCOY:4:8MI^296JQ9(B(9N#JRJR7Q+A58&H*`F<B:.X)9J?GJI@#T<
M@>:26Y;)I812@S(&?60NIR#YH^(J/GSC_7V#QUD;CGR"X7Y)Y2TC(&&\69AS
M;D.T/ZEDC%==A6U:I>*ZY:)W]T#4>[2,G*J.HA-9@JQ*559`P&0/0759*#%E
M/L:>%>95WRKNSJ<'ZJ8X#B./2%<*,Y^8\F>0L1`1=QQDOQ0EO+L?<\TN0"TH
M\9M$Z\TRU'T\9)S*O';>)84A"DNU)!P5=F200=)B0YBB4R.K?F_WM/\`-_HK
MY<*>E#:N$>K'M*TIYZ>U7OP%S#P+R6FK15\7SEV;V^GU^LW*7I64<0Y9P?=%
MJ#=E9%O3<D054S%3*3.V7'-I<Q#I%E-,$'#$ZZ!T3G(J`$'(9,QYTC/T>VG)
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M%7Y>2M,*]8X>?RSX%<HOF-<334<]U"VY$!^GE@<$'Q`?`F="<DRYE"I&R#_E
MN/&DV/0S<%C-CPAK"'_<GP@P)1?][X4!4T%PPBHK6M,CRKRKZNFE,53L)*TP
MRK6HI3+/+U^M+)YB_%FKQ%%DGDKF>6DL@TZQ9%BZ'4>+G):Y99KV/:C:7%'L
MUYR1B.LXID\D8NJT/<6BL89W/QD>1R[2.1J"_2(Z?,,R%:]1P]54$#S7+`TS
M%*]=:'S+M,D^8/Q,Q)<4Z3><BS[)\U8XZD[E88?%&6[1CO$##+IVA,7.,]9,
MK5(E*'@H;V#]`[!.U2$4MV%DUUB)('(H(W$8.%:#/`X</-YZ=%5402$9#TC'
MJY^96(Y>^9SC+`\T3&&+OO#)&9(CDWQ4X^W]`N*LPV##]!D,^YDQE3;'5[9F
MVK5Y+%-9RU"XWOIIEC"/IY-T18S4J[<XK$;JV.N1AV>(J!7'B1YLJ\:]"N9;
MN-2_#W2>%<`>&>8IDIU9]SUB'C#CV2RSG*Y)T3',59:C4GEE7AK#/E1GK]:X
MND4Z/"*JL3-S;A:;L\TU:$%%JH4AU@,?I(`F"9TK6,#W\1]WWJ%C'/=I;FK#
MPWF&<2YC'&4,GJ9`LU:AL,WFM8RR-5+UB'+]$R_!Y#O*,(YQS3&F#[51HK+M
MBL>46UD8*5AK&0SQ6>*Z+\("@E4`EGS$=,:UKE0U]&?$?952=A+44%01GPX\
M<N!XKJ9#S*^%L#BXV8+CER0Q[46N:&W'2=CLC8NRU1\AT[.C^MNK?%XNO&*;
M!1V>2JC:YNL-0>QR3V*23DD7#86IUA=-P4I\U%IJ3Y>>GV>L)\O+JT@5-*X9
M4ZU4T+S]XE3N*,Q9L;Y4<QN/<`0]/GLPN[3CS)U,L](B\@U6$NE$5?X\MM-A
M<@NW-O@K"T^[VS6,7<N7AS,B)B\250)<;F$9G'J*IV$M0*8GJ]N22_/CBQ!9
MA1P=*7VP(6\<A5O#TA8D\5Y6=8>K>:+BP8R-5PI;\[M:8MARI9?GD)1J1"NR
M$VWD@=.T&JB9'2Z2)Z?,QUH*D5\O+/D,0G82@5(IA6G'#HS5\<Q9BJ6#:BG<
M[G%9)FX]Q.QE:90V)\29,S9=I&9ERNU&39C1,3U:WVQ9OVV*IEG0M"LVQ2@*
MRJ?47JD>\,%37T$^P%6,87F@IYR![5$.6Y]TZV6#A";`RS"Y4WDSS$O/%7)@
MW.K7JB7_`!9,8^P3G#)EIK\I0[:RJ=KH^3*];,6,V+V/GHT!39NSG!$>X@L&
M-)=4%69BM:]3CUYCH*R(K8N=IDJ!A0CI<T9Y9%49A?S,\<R'&O$68>01'T#D
M7,V2>3M(I&)L&8ORUFB[VN-XZYSR5C67L%:QKCJ#R'D%W#P51IS"0L$D=`(U
MBY?%**B7?;H#>VX&D:JEY)R!X$\AY<<PK'0'66L^$`8D@9@',T"O99_,0XAU
MNJX<N+3)LOD.*S]4IG(.*66%L797S=:K#CJL&9(V_(;^D8KI5LN-5I%*?2"+
M.9D)9BQ2C9$_P2W2[`R`7?,QFFFIKRQIZ*^6=%3Y>6IJ*4YX>W-='8?,TX-U
MB+P3.RN:^\CR8Q@SS!@-O!XORY:[%DK&DE+U^&"QU^MU>@S-F;MT7=C9*O6[
MELV<,F8G=.4TFS=95-\S"2`#4GH/('[0J_+3XX8#I',CGT%5G"<Z^.DOE5'#
M3QYF*I723=Y#85`<@<:N0U`K&4I'%$?*3&08C#-TM^,X>JY=G8*#A'C])A`.
MWSN38ME'#!-TB43Z.G:'%H!+N&!Q]7LKSR"M$#RW5AIXXC#U^WJS6);CYY["
M-ZD\"6?+&-)9GB[EED;+U>Q=&8PXS\TI*_XBIV*ZQD:RL)"ZRSO$]@K7(RS7
M1&KQ2;A"AM&;:M&>/3NC.$F"RA<>.Z<7>^#I<<,.OD*G[.E9,EH`WW'#4!CB
M.CT>D^99H>4V?4.-O'R^9I;UIU>)V(:5N#QS0&ZXQ;W(>5LEV:"Q[B&@E=+)
M'4B?WOR+;8QBY7,F8S)NJJL8@]H2ZRII"R/4W-8D;-;PTF@^P9^I1#RAS_D^
M+W)3$O'SDM',)8;-PDMG(&Z3?'O#6=,IV%]EVBY0H](M<-C['U%9Y'MR>*(J
M!G9*24=2#55R@DT2.LZ()Q1/CBY>)-#Q44X`\@:\^/+#UJ<V[71ZV9ZJ8D<S
MQRX<U,"C<K./639.OQ./\GPUN=6OCM"<L:VK"LIMS'3/'JQRB\+"Y(8RIHQ.
M..R>RC91$&0JEDR&*(G;%#QU.+B$D"N)^W%0NAE:*N%!6GV>U60MOF9<,J=!
M8OGW.2+?9D,T8&3Y08QBL;X.SGE"T6O``J1Q'>44:K0<=6&>B:Y#(RJ"\A]X
M(-%V+<_<63*`:H;F+)M2:5P!RH#RY$*_Y:;B`,:8D#&I'M!518E\PCB3G2VF
MIF+,E3-FDG>+9W-=1E3XKRU!4_*^+*HM%-;;<L(7.Q4B)K6:HVJ/)UBA(%K+
MF36;K/$2]!A.&C;B,\Q4?HZCF,B5:8)&Y@9\QAU\O.MBI^85Q;M;3*#EU8<G
M8X<X>PW-\B+O`9PX^9YP7;2X(K9'0SV6JO4LKXZJ=AO5+AU6AD72\,W?*MG)
MTD54R*K(E/43L)(-105R.0ZP$,,@I2AJ:8$''S%5+@7G!QJY+W*5Q_B*Y6:2
MM<?C^$RU'1MPQ1EC%A+MB>PR00L7E'&;O)]+J+7)./SS9BLE92&,\:H.E$R*
M&*"J0GJR9CW:16I%<O+U5"H^)[!5V5:9@X\E++4RB7SI+U`?H)W`*8@*=!14
M*0PE,8A5-NLI#&*`B`#L(@&_H#5$7W5431%^1G_$25L]6\Z+GBR,GVR2N1:;
M:T/#I[B-NQ)CZP"KX``?;7?G_".N<G;IE+3G0>P+HK5VN!KNOVE86]0J=-$3
M1%EJX$\Q3UB/9X-OSQ4\4F=8M(DU5SE%)JKUK+5M54?$H-S"<[7<0*8@BEX=
M)-^9WNP>T_/0"K/QM_Y0^WTK:V$[7#Y>0T?^$_8?L69B&OS16,2^[Y3NH"&Q
M1[XJB01\2D53^T*>P?H_K`&N8,^D:V'W:^CH*SC$6^ZX4/EDJE9VA#ND7>/5
M2&)N`'.IN'H#T;&]`D]&WB'A[]9$5PUKZR.%1S\LE'V9I1O%<I;)D:4ZK<[P
MIVYO!7I*<3G*7PVZ2E`3F-M[M4EW2#X7$!BO9:O!JT5\ZM)-R:-@<2#AJGW#
M*.CF;I%^R9,ZJH=13]7ATG*&^_CXZQ6$7#B&BK7'#HZ_-@I2TQ4)-"!Z52T_
M`'!L8RB)BG*78X%`!(38H[[]._2._AXZW?R>F-I/(+&;.0[#@5>S@QD]6@Y8
MEJLJX(FSN#(I6X*F$A/O:)4^(:%$HGZ1W244#T=0FV\=@U':O-O=:0<'?9^A
M37;&S0=H!BU>@^"GH*?;I(KJ)D.Z1;B1)7MB55P<@@J9`P;#N)B[F*(`(&\0
MUV,+XYF@29'VKG'`MK15>P%1@8S,S@RJ0"!T>LPF.1/P`4BF$PB?8?1OX@&J
M21=D<#5BI6O717-BQ25*78?#^4!_L"`[`.P@(>!MA_!JH+>"4/#-5M'I,E$U
MV[AH5<YP`K90%@3[)CB&YE/$""41V#?P`/7J=CA\-,U8`?B.=51RXE9KJI'^
MR9(XE$NX#^B80$`$NX#^$/#6.]A:[I4[2%O?>OP;EN^9J?#KI`0Q%$?L_;)X
M`?U_:]OMU$!0Z@:4XJ\BN'!4]97;">:.X^>;1\S&O@.9Y&S#)I*1KL%=Q4*O
M&OD5V2Q3;^(&3$-5+P,7D$E6D4P"Q?9[\L[R^\VG=OK/QRJ-;G'8*=VR8I5D
M,5S!E#"(BNHG3',9!.UNH1'=RQ7`?6`ZM_Q%\>#'D=%<$[#6<6@GJ^U88,[^
M0+B?=[)X2Y`6:L@/6=I7,JU:.MK),=A$J!;35%:O+$)X;=:C%R<`\1ZA],;M
M]C9A.QKAT8%3-L7.'NN(/I6&[,GE@\FL2.7?1`U[($8W,?M2>.;0RDU%DBB.
MRAJ_825VP)F$OI(1)80]`".K6=X=C>=,DAB=TXCTJIVZ^`JUNL=&!]"@7-UB
M;K,JXA9A!Y"3#(_;<Q4TU=0TBW-OX%4:ODTQ#<?0._2/J'6XC,,[!);2L?&<
MB#G]BPW:XSIE:YK@MM"3F(X=U"'4#N)J=8])_P"[]!07)UB!#`/CX^/XM7EL
MK,P4:X')74K7(;(E3.<8&PS$.DH'2HV82+M)J<.HA@,9N"_010O1MU$`!Z1$
M/6.@F>%537Q;YNW-?%0)I4SD1DJ!;MTR)MFJ5CE%V38A>C]FBS7=F0%,I2`!
M2FZB@&X[".I!."/>`]"K5QXE7?R'YT_*G*U95@LFWA*[H*-A0,O,1[)S('.*
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MUD^U=O9_+PY.K\9\%5-[;,;9<RS(<C\E\H.?V-@S!F;C?AWEQ?\`,<+:49*(
M;Y3Q=6IC),10\.V"0@CUZ$?1*L;+Q-::-'Z*?;3``M9&MI49X@8<^.//ED!5
M/FHR\DC"F!.)X9Y<N=:DD%<CB=Y9&6,!R7%!_-2V$H2/P-Y@G,SEU/4_&<ID
M*1K4?C[DGAS*F/*=0*"]ND"C/RDS496_-A>J2JB!%6K=54BQU#%1U1MI(`:D
M8@^L.'`4_$%(^]C.0.8]1;T_JE6P8^5YR:K6+>(&*Y5YA3D+CG"N/L_5'(&"
M;QGKD+A'#J62<I9WD\H4?D$D7$]1>2&:W]-I<JY@5JS86;%N@9VJNQ=)JG.K
MI\K*W"M1CD>KF#RXX=*M^;B)K2AH.%:Y]((S&(/!55Q_X%\WN&\=P?L&%DN*
MV6+SQFX"9)X;W6O7[*&6,84]]9KOF/'&4(6\4Z9@L.Y`EI6IUX*$"3F/?MF#
MQRFKT)JE.`*Z"UE8/PG"GI#1R/(I)=0R9ZA[U<@>+CS'-=$IY+EE>8<5P,\S
M5`DKDAY6%HX0R=Z:1,TE,!G&U<AD>0CW(#*H$.@B3$:=B%5`L>$NG)@P$K8.
MD?VX6_)24K4>3:>0\U>*N^>;P;Q]6JOZ/7T*97"3BSD;$62+;D[+F`N.>+[D
M^Q7"8Q2O&)>2W)SDA;[FDVM`VB;056Y!0$"AC;&B\JD5\RA6JDH_*^4,*[H2
ME$59X87M?J?CUFO/+`?:,UCSS,D8&QX"O*GVFOJ47<ZXPYBW_G;YC5&X\47$
M:=0Y$<".'^$[#ES.5CR+68&D'F7?,2MSMCH<!5L;6R&S3-4V"N2KA[7U9>`.
MFX68`HZ(BY.)87PO>]P`S_RG'D?:.&.*OBD9'&QSB:ASL!T@#F*>OJ4DL6>7
M::AN.:%%?7L5L/\`);AIQ8X>524CE79LE0D!@G`>5L&V2TV1)=HWAPDY%K?F
MSZ/!N[<`=9%7N]G[/5>VS(:0ZF(PXTQKR\U522[+G-<VH(SZ<`/1ADHQ3WEM
M\I^3E`Q_AOE?:<!XUI?'_@UR+X<8UN/'N;OERLF4K'R`Q'4,'*9BMM5N5-HD
M9BVJUBDTI!Y^Y[20L!WDL[.4TB1NU1%6UMM)2F`]TCTUZN?,CIPQO==,!U-J
M27`X\*4ZZY='5RN7G?BOSNY?\>*YBC.</Q'Q]:\#9`XZYAQ&XQOEW/\`-4_,
MN3,&3BJL^PR*M&X_QA<<'XTOU544;,20#J>G8&27(Y[[E-F1)Q5UO*YHP`<.
M5.=3P'VC,XG.C)X8W$BI:<ZCHH/Q>66`RH:5\O;(TMBR5!7AAQ!97Z;SY5\I
M/*]#\\>;$3D*/3IV*I#'=<R/6.:33'A,K5;+T,G*+Q:+5A#H1)JHLHS5744-
MT:N$#Z5-2=5<^BF8:#ZJ]-$-PPNPP;II\/37(N(]?F5&9%\NKFY8\1X5AEK-
MC;(G*&C8>R/CV-YM'YD<K\$<A\'R=SR5:;A2($+ICG'\H]Y>8DQ'7Y&%;%97
M<D<\LDI"JNWB:0R*HI6?+2`98D$9\_-CRH30YG$FE1<Q5XTJ#D#EY\.=0*C(
M8`+L\D>5YF%WF//=G<4_CSR[IW*P,06'*$IGS/')G`#FKY%I>'\=8:R1(2V(
M,'QEFQQF>@7YKC=M/,HM=2#>1S]VX8J+JLP;J(U=;2U..!Y8#EE0\!T#S9&7
M40:!2CA7ISQSJ*8D\_OJN_\``?EX['+.#*%(<<5^-^2?,CQCY@Z.3+=<\EQ^
M:(UC&<A<3Y_R#AA;'$/CJ7JDA*-+!072$)85;)\.K%JMFBS%%5,7*;Y:7M-1
MI4N!)ZC4\.?3YE;\Q'H`-:AI%.L4SKRIP\ZR&\W,!6KDUB6KT"ES,#`RT#R;
MXGYO7?65:108J5[`7(_'.9;-&-U(IA)N?OR6@*<X;1Y13*@9ZHF"JJ28F4+D
MOA+V-;AA3U$'[%C1/#'ZCR/K!'VJ!7+/RR<G9]RARDRY7+CCU*8OG('@IR,P
MM4[//Y)K<).3/$K&%JQQ;Z!ENTX[2C;G2(F^Q]P>!&3-=7D'L8Y*W=G04[)F
MRF(;.0'4TC/"G6.CRZ<EF1WC6L#'`GGZ#Y</M79TSR^\B*AA*S+XKX]\?+)1
MO,)Q!RWR!`T+.6=^0K^[4C%>#+YB5`+#E;,%1A9VQ9.!:U-48]LFP81+.%9)
MIBY,L0`&XVKW#&E<<SS%.0]85/FVAWNUTZ>&&-:Y5/M5V>3/`6R9TYCX9SG"
MW6N0>%)-/&(<T,8RK617F<Y*\5;_`">:>(BD(9NU6B#_`+L96GG9+%]X')\7
M!)-VZ?<Z.@)7VQ+ZL(##F.K$4\^.*A9<!L9#@2\9'KP->.7)1LB_+*R'4^0F
M3GZV+N/.>,+93YEO.7C#(.4^17**F7S%SNU9*A<MV>MK\<J?&2^%\IVJDWF.
M5=U":4DX9'[++[Q;BHT,HO&+9XD_4U5PP&8.5#[1EZ9?FF&.A'[S32M*\*9U
M'L*FUYA''K,_)&BXH@\32<+,0]/S.QN^8L'VS,64./U3Y'XV+4+=`ACJS9@P
MU#6&\UIC`V^;C;(5F5@[C)I:(*S?)]E3<)YHGN`#/A'#+@>-#T<#EDH()&1N
M)>.'*O$<,/:#R4,.,/EA99PFI@!>4?X-J['%7FCYPYV2=)QE-9&F:O"XPRGQ
MEON%87'%-E;M76MAFK9`V2VHKN5I+X9LY:IJKD5(H8C4N,+.32:D5/W.'`=(
M64;R,N!H:"GM:>?ZJ[+$'`WE?Q3'C)EC"KO`&5<R83KW.?%5VQUD>]7_`!UC
MNUXRY<\KEN3E7L=/R3!8TO,[7+UCZ4AHIK)M'-=69RS5=VBFX2,@W65N-JX9
M4-=5?/YCR'`\<E'\RQQ(=4#W2.?NCH(]N"B[8\096\KF3PGD>O7>CY+S%D7C
M?R/Q+ERN.,!\O;S1G]KRCR?M_+5]+8(7XYXJRS(Q[N!R-F24@XRIV96MGL\0
MDS7)(M%6CGHB?$Z/23B1R&7'D0<SEYLE*R5DVIE*--,2>0PY?E'.AK7`X3,\
MNKA9F+"S7RY\HY'"'J\A@?RHF7$C(^/W:SHUYA<I6JZX,R,Y3%!NU<P/W97V
M>/7K"0`7XK$?F(F5-5,#J%E@MS34ZA:6Y=-&C[#B.L*.XN&N!8RM=1Q\[O\`
M*"L#Q^\KODQ3N3O$?.F8W.$;9;N-F>LN9)RKR;>YYY$Y2SURB@[[BW,]`KK@
MF/K]5&N.<%H12F0XP[BM1DB]C6Q8_HCUT&Z)$7%@M92<3P(Q/,$#AAGS(]2O
M^;B#:-'$9"F1!YXY9T!5WJ9P+Y0X,P-Y8[#&$AA#(F;.`.0LW3UCJMRO5ZQ_
MC7)-:SK2\T4*5"`R%$XXN5C@YRJ,<F,WR)7->40>F:KMQ,EU)JC<VT<PZO=)
MKET4IR/L5C[IDE6NU!A&''B#E7HYJ:'F`4/(%YXO2TIC6M+73)N&<D8$Y-U;
M'\8?K>9!E^->8Z-F>6QY!F7!(KB:N4#47\=$@H!`5D5VP&Z=QVR;@.T:FBK@
M?M!^P=2QH"T24)HT@CT@A<:NXR=Y5Y?8UYV4N?9#B&Q<";9A*(@IR,L]:R&>
M9R7F/'V7X25E:O.0<>M!,HZ!K:S20:OC-Y-I)"")VVQ3F+$V)TD@F?3'ATT`
M^Q7NDTQ=@*U#O,0"5`7"_E[\Q^+<-Q@6Q%)<:,AVNF>6VAY?F8D<BW3)M/K%
M;D8:_.L@5[,&/EZWC6R3&0H@CB:?LWL"]2KCE8I6ZB3U+]J`0_*2M((()PRY
M@`<1U\N&*R'W44C=+@0*_:3S%.'/C@KV\7/+\RG@M[QI<6*Y4&53PKY13+R]
M[&$&YL)C2V5&MIH<X:XPQ'T"S*?'QFU47*"BXHR(**$#X7;J,%PLWAP)+<*>
MH`?8K);H/;I;J'O$^:KC]H5'Q/ES\AX'$G`FFU#-M0QUDGB'Y9_)'ADXRC7#
MV-^_@<T9>Q!@>@T'*V.6SB%8*OZ_2+-B9Q(*B\-'O@3,V%%$RG6"=YM7:`T4
MJ&TY8T;CZ17'/BJ-N6]H]QK1SZ\\/>P/IIT9A1GH_E'9Z[V=YV2J_''#<YEW
MRPN2W!UY^[?(3DAR.M%XS)FAQ2EXW-.3\FYFHT7.K5UPZKCI9=LW1=2+('0]
M1GQCAV*1V\@+B>+",ZXGS`^FO65>^ZC(:`/A>#E3`=%2*]5!T!93*?Q:NU>Y
M5\=<]/;!6'%:P]Y?=CXD6"*07E33\E>YG(>#;@A8H<BL6FQ5J2;'%[U,ZB[A
M%YWG".S<2BH8E\%N8GEV%,<NFE/8H9;CM(])K6H]0/WJ=.LQ8J:(FB)HB_+6
M_BO*7^ZOG%9(F02[1<C8,X_W8ING8%A0I9J*LL7P#JW<4HY1'Q\2CK07=3.2
M>/V$C[%OK*GRX`X']*\W&L59::(FB+EQ[]U%OV4DR4%%Y'ND'C54/Y"[=0JB
M8B`[@)1$NPAZP';5KV-D86/Q:X4/455KG,<'-P<#59?,(9R/*PC"6BY!1)<S
M<$Y2*64$X)G2V*NET[F[R15`]`?M"E$#%W#PUPM]MKK=Q`)J,ND<Q]H/%=3;
MW$=S&"1AA7H/EQ4J4,BGG$BN&SDR'H$R)%04*F8`VZ0$1,(D';P'UAKFY+=Q
M))S]JV+!"!I/K7:HV)0Y4Q56.943]!C"7M]10\=^OP\2CJ$6SLCF3YE>`P5(
M&"O-%O4@BFZP'+U%[0&,D<P&*H`AONH4`*H&WB;80`-_QZW]LUL4>@TK@?.%
MIIJO>1C]_);<S<R=LR2*J9_B@**J1P*(G,0H%(<3"/6B<W0("(#]K;QUF2WX
M:RC2:UY*QEJ][E92&LKZ$O$=9&1U$'$9*M7J)B&^V!4E`,<H;`'V3%$2^KTZ
MUAG<Z3M"?>!JMEV`+#'^&E%Z.<;W^,LT)`3*0(@=[&,EP4Z`!<J_9264("A`
M[A%3',`CL/I\==5:W8<P.&>!7,S0ECB*85*DF6TF<-$EP4^T7H`1_E$.'IWW
M\3%,/COK9B8R-SP6*&4*NA7[01TW1.90O<*78Y=]A^R`>(E'U;#JWM'5H**I
M%#0Y*M@F!,D)TE!*3<0$"F$=@V#</'QVWU)VX`%:U"I1=6Z?ALIU*&W$NY3!
MZ=Q`?Q!XAHZ6HS]U*45%C.J'%1NHJ<!3$=B[>DN^X&$=:U]SI!U5P4[6%V2Z
M:4GB`0=E``>@-QWW$HA[O1K"FO=;<*!OEDLB."AJ#BK,VJ\MV""@@L43@`AT
MB("(C[@`=_7K1W%\]M2S/DME!:@BKL&J'%[R%(/`<`#CMI$`PG#K$!*`B(>'
MJ`1UIY9YW@Z\,%GMAC:*MH5AIYL\LX3$<"_1:.4Y"WR::C:%CRJ`8Z:PE$`7
M4`HCT)([[F,/@'X1U-L^SR;M=5(I:-.)Y_RJ.]NVVD&/\8Y>70O-E9K+-6^<
MDK'87RTC+2K@[ETY6.8X[G$1*DGU#]A%$H])2^H`UZQ##'!$(8@!&T4`7)/>
MZ1Y>\U<5TJ:JB0@9)0Z8AML)#"7T#N'H$/7J4.<W%I(*L(!S7(%^L(&%4C=?
MJ](JH)]6_@&_<3!-0!_'J3MG'XP'=8"MTCA4+B*JM#E$3-C)>C<4%C"4/P$6
M*<?$?YVJ%T9S;3J/WJM'<ZKIW':]*2R@"/\`)4)TC_6(8X#]&K2&<"?.%<TG
MB%P?$?3XZL5Z:(FB)HB:(FB)HB:(FB)HB:(FB)HB_>6UU2Y)64Y&\@,=<5\(
M9#Y"9:5GT,<XOBH^9M2E6@75HL7P<G/Q%::%AZZQ.1[,O5)2<0*#='=8X"/0
M4YMBFBEE$3=1YJ2.-TK]#<U&=IYE.`&<1R`>Y'J6?,(3_'*,Q9/V_'&7<2O(
M;)UMKN=Y^4I^#)?%]-K4Q;'EU5RY>89S`1$84[>:3FTQ:/6;-3T0MNFN:33+
MSYY9#CY8T"E=:R-<&GCYJ4SSY#'JQR71R/FD<=*I1,G7'*=,Y$8=G\,Y+P5B
MW)F'+YA]T]S37IGDM-LZ_@^;CZ7CN<OC6ZU7($BY43:.(!]*.!79NFPMP=H'
M;ZH+MI&(][EGQ`X#I5?E7U%"""#CU`GC0\,^KF%5\1YB^`%:OG6S7F"S9@];
MCG@6-Y,9-IN>,4RN,\A-,.2[K(\='V2&ITH^<2<LY7F,62C'X/9-P#Q1HF)?
M][1$:MNFEM7"F%<\\^@<E0VS]0#<1JIU9?>J;O/F=<?L>S\G'3])Y"'J=&=X
MFAL\9;C,3B\Q3QDM>:8NJ3-+I6=K">Q(2L+:64;>H9:?1A8^>0K"4D@>46:D
M/U`-T`:4-*T/0?+'JQ-$%LXC`BM"0.8\O*JK3S"^6UBX28*KN7*[BJRY=E)G
MD-QUPPXJ]9A7$Z[:1>8\O5?'\Y+`V9S,(K][)1<PJW@R"L9%Y8G#!JL`(KG.
M2MQ/V<8>VE"1T8>C^14MXA+(6.PH"?0K?V+S%<>8ZL&;)7*K"YTJJ8PPIQ*R
M(AB.3Q)8&O(N/N/*K)N3<4T.B3;)&VRM3FK5>KI4V$7%P[4C,8IR95:0?G;K
MIF;4%Q[NLT.`P'22,_-3+]%QMR':17XB*G#(`Y<,.E5/8/,&J%2@J!^]/&SF
M'7<M97R3:<7XOXV2N)*JAG'($S1Z,7)-OL-8;ER8IBY]0J_31,Y<3)K2FU[R
M1VI.IT44=4^;:6ZJ"M<JC+G7R'2J_*2!VD\NGB:`<_4KMT7EOCN\WB&Q8XK.
M6<?Y(D>.;WE&[H&4*&O3[+5\;L;ZZQK(,K/'*R;TL7<T+0P.7X%,ZZ2S7H<)
MN#IG((U9<QN=E1Q'Z?1T\_2K)+=\;:G$`T^STJP<KYG^``HV(+QCZ@\B\YCF
M+CO%<LX^FX6Q,E;+S1..4R3_`+NRCDR)DK37HVN,I!TDX;,8ML]?SLJZ8NTV
M#)U\*L)!N@`*"I(!](KAACY4KBJBV=4@D``T]=.&7ES"O3FGEA5:'P?R5S<Q
M9'.\U4FN\:I[D?CIE5&SA4V0JVG0%;S572+=<T>^:0SU@HBYD#'[;EE'E<'$
MG=2[8WR3:8.U9CY>5.FBLCBU3")U0:T4">,GF73<11L'T_E!7^3.6.4'(BA*
M9UJ./L4<')VJR4+BX\[1:9*.?W4IN0,FHL<=5NSVHSQG9IZ38G?PJA3*%%T5
M-%?&BNM+/>Q)-<SAB!TT]*RI;6K_`',&@<:8X$X95R4KL=^8]@')F4*7C^$K
MN:HNG95R3=<-X3Y'67&IXCC7F_*^/?WF_>6C8TR*6:=RCU\H-)FRQ+V1B8V)
ML1HAT$4[>"0@'E%XS401[HKQY8Y?IZJJ(VDH&%"33#K-./FZN-%:2O\`F]\>
M;:KC7]U,*\R[''YQDLB57`,Y%<>7"L/G3(^*7LXWO6-,=.5;8BM]_0S"KR<B
M,K,)Q%44C8UVL67'X98I*?.-K2@]/Z,.LX*ILI1CP\O3P&%3T*<?&[D)0>4N
M*(C+V.6UJAX5]8[O29NLY`@1JEZHM^QG<IK'V1*)=Z_\7(H15EI]QKSMDZ*@
MY=-3BD"B"RJ1R'-/%*)6:AZ/+J6/)&8W:2K&0O/C&KCD54.,]WQ1R&PU=<FV
M2^5'$-DRU0ZO!T;+%BQW"SEIF8^IO*_?[3:XH)2H5I_+Q"T_#PJ$LP;&,W.9
M02IFL;<5>&D4:2:&O+R_E5[H"&%X(-`"1Q%>?IZ5=+D'RFH?'.0Q=6IBH93R
MODO-%@FX'%N&<(5-G<LFW0E0B$[#>IYLQEYVK5N#J-'@UD5I25E)-BT0.Z;(
M$,HY<H(J5GG$(H/B.5<!Z?+V500.F=0?",^/J4#>-?F=J6;C;AF\94QOE[)O
M(//67^9=;QU@#!6*6#O++K'W&WD3D3'KN;LE4F;77:K36N.J9&0+*PO9.:;)
MJSSU-NW[[IR1(8&W6F(.<*DD\>D\3Y>H*9UJYTI8S(`>D@'(8\^"OJ[\S;CZ
M\B,!.\;4SD+G&Q\EZ;F&XXKQQB/$#N4R&<N`+-6J9F2L7J$MDW36.,;;CVW6
M=.,DF\\[8MT)!LNV%?O=A->1UVT-#@,_-E3B1T]'+-6-M9'.+>(\^=:95/#I
MPQR6V'F<X`GJ5@NUXCHW(?D+/\@L<V[+M-Q)A+$IK%EVOXUQW/MZ=D2UY&J]
MCL52C*0A3+ZY"NK-',@:0?SQ3LXY!ZH0VU#>,T@M%3QQI3T^;^7!/E)-1#J`
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M(L2\Q/08F!Q<,;$/(NOS<O-VM1TS!$J;9,%X99W=OH!`:T<^@\./4IX[<.M^
MTH2]QH.C$#[<U?U/S0L`1-*SC<<J8_Y'X`>8"P0/)^TT#.&(RU'(MGX^`Z5C
MC92QY!1MFL,?98QG+)%9/XY1ZTG(AZL@C(,FIW"('O%XRAJ*$#G7A7R]=%8;
M.6HIBT\?/3CU]7(YJ7_'K.L+R$JJ]VJ])S7C^O#:7-=8-LUXLMF&;':HUNUB
MWS2YUZJ7%!A8G-'GV<L48]\Y;-E%C)JD,BF=,Q=2:Q)$Z32*MK2O1UA1.C,;
MPPG,"M.GJ6-?R^_,^+R`Q[QA@L^T+*]/RIR&>9=JU.RZ[Q)^Y_'+*62,86/)
M$B]QSCZR_?SN1"T(XUHZ[UL=S&MHJ9&,>_`/7*R1T@A@N:G0_GG7VU\YZLJJ
M>XMM`,C/A\LNC+I!S5:5+S3,39OJN$;WA*"R[7<?Y;Y`\><2PF2,W\<,E5C'
M^2D<T6:VUE]5,0V129K[2;N</(551%S,I#)P$4<Y#G*^(H'17YL'$4`'6?NP
M_0J?*N!+<WXX`CS5SSY*F,J^9F,IF?B]CCCQ0,IRU`R)Y@4+Q-R#R)L6,&(<
M>[BV@:YF!'+%*Q9>75H2L,A:JY?:$G'%F"0Q(==S'/T&CMP9(^UDUV0[2R@H
M3QY`\.5?,KX;,N:7/X@4'61QX8>?JXWQIOF78%O.5L:X[@*+R$<U',N;;;QY
MP_R'5Q>U9\>,IY5H$7?9:YPE)O"]H"PO8N'+C">;HRRT(C%R;F-6!@NZ3(90
M)#>-J13#'CR%<O-SIR*C%I(6UXX8=9`^T?:%258\RJB)8_P?*V.OY(S3DSD9
MD_EKCW$].XX8;GGLE;)'BUDNXU6TQBL)<[N8E86AH2OIINIB5EVL*\>(KN04
M8MED$2U-RV-H%!QZ!F0/9T(+5[W'3EATY@'ACQX`JJ&GF8X&L-#P;:\=47D'
MEBY\@GV6(^DX!QYBU![GF%6P#:%:/GQ7(=4L%GK=:H;'#5V3)#3#E]-%06E'
M#=M'F>JN$2G&[:&!],3TT]?7Y95HVUD<\L'"GKQZ\E)KCSR*QMR;P33.1F-U
M;`RQM>(NR2\:>[0:M6L<8UJ-CL%5L1+%`J+O5HAW%3%7>D52$YS%*EOZ1V":
M.9LD>L>7L44D9CD,9S4:,=^99@N_8NMG(![CWD7C/C17<2R><H+DID_$R<+A
M_)F,H]VQ:M)C'C^`L]HMKR:M!9-NM"0DI#Q4W,(J@+9J<^Y`A;=M-:B@`KGG
MYNK'GR!4KK61M.))I]^.6!\W2%U[;S/\!QS.[&RCC[D7@&?QVO@F0M])S;BM
MG5[=%8XY&Y&+B;&>:U&D+;K/%&Q.6_`I'SKP'GWC6E43A)L6P@`#7YH#![=)
MPX\_(^@UHGRSB*L(<,<NCR'I%*JXF4.?>!L5VK*M"?,\G72_8JR/B#"RM*QO
M1%K7/9#SAFZE2&2J;AS%Y`DV#"QWJ.QU'C/SP.EX^-K\.JF[?/$D>LQ!NV8Z
M02.'MY888_H!5HMGD`F@SKT4PZ\\,L\,Z*V4EYI_&N$HE2MTS4^1C.SVOD);
M^*)\&Q^#+';,_5GD52\=S&59'%UAQK27=E75DY.CQ2;Z.?1CJ2B'C5^T<@[*
MT44<)/FVZ-5,:]/(G.G1CUU5PM7EVFHRKF.8'/I]."W+%YHO'VJRRR$WC_DH
MSJ-6D\2UC.&5%\-+ML;<8K[FIA49&FXWY`2;RPMK!6+O&H7Z$"QMXJ,FV]5/
M*(!++M`,(E&Z`(P]TTQKSQY8^5:*GRS\14:L:#B:>7W55IN2WF8'KE[Q]C;C
MWC_*=B02\P7CAP]RQGV1Q@R><<V$M;LM0%+S9BV$NC^SL9Q[D"M,)12--),X
M=Q$,)Y,[('AG:2B)8WW6J5K&4TZAQH<QPSY_;C@I66I$;GR9AI(XC(\<N1'1
MCDLO1@V,8`]`"(?,.LY8*_.D_C-L>?<_-7B3E(B(D)?^+LI4EE^G8J[W&N4[
M(Z.7J_E'187UL`AZ@,'MUI;_`/C>KV'[5NMN/[DCIKY>A>.C6"L]-$31$T17
M'QK?7-(FB****C$/%4ROR)B(G;&W*4L@@7^4HB7P.7_I">'I`-8EY:MN8M/X
MQE]RRK6Y=;R5'PG/[UDRJUM*Z0:OVBR"@+)$61604%5D_1'P[B1P,<.VKMX@
M/H'WAKA[F!T;S3!U<1Q'WKJ6%KVC$%E,".*O;#6A)XB)5_LD4\`$>G=NJ(@)
MQ'I$>D`$/QAK'.'#$\5=0CCARXJX,9:GK1-1F"@+(.0Z@*(`8`V\.M$PB4``
M0^C5&BN`KJ\O*JC<0XU<`:?H]*V'<D5-(0^(,9PH80.0PF_9)G,'0!3^@QQ+
MMN;PWU!.`QNIOQT\J*>-XR-`"<O+[URHIIU+]Y78Y!#8#@4=@V`!*`G$/$W4
M;;T>&VL")XD-!@0LET>C'`UHLF_'#(+IM#HPKAT8"1Z9!2-U#^R*!`[291$0
M`PB)MA$?U=;JRF(;HKB%H[F.DA('NE9%*O=$W;)N0RY%TQ3(HL<#_:`?1V]P
MV#J*(?-MKH+9[I&TKB%JYV:#49%7AAIPP$[K9<#%./\`)\1#80'Q'?T[#K.C
M.%''WJJ"E>I5HTMCQL8W<ZC$$H"/B(@4?;X#X`(!JTD\2J:0MMU<3*"L7J$H
MB7]'<1V\/`2@.^P?@U%(V45(50&\\%1CFV(]1S"L4#DW`P]7CTF]/XM_?K5R
MEX)+N2SH@'-]U6UM&14V+=R!%`.H!3!MOX;!Z]]_4&M-//@0Q9T</O#7Z%%^
M3O"LBLY=JJ&!LCU"9P?Q2*.P^``(@`CJ."(!AGE/N\U)*_6[LVX^62QN<O.7
M=9Q%4Y5<'A#OEDU$6+-)0GQD@\.`]E-,@&ZBEZO7Z@\=0VUG/O%X((,(!\1Z
M%-)+'9P=I(??I@.E>77).1K)E.V25NL[M1P]?*G%!`3F,@P:]0BDT;@(CL4@
M?I#Z3&\1]6O3[.TAL8&V\`HP>L\URL\[[B0R29GU*@]9*A31%MG'U?/HBXRI
M@Z1#</$/;[/'15"ZDX[CJBN"T:*J:(FB)HB:(FB)HB:(FB)HB:(FB)HB_>6U
MU2Y)1;YK<<77+GBWEOCDRMS:ANLG,*JR1MSR'6L#:&&MY`J5W,HK#MY"+6>@
M[3K`M@`KA/H,L!_$"B48)XNU9I'`U]HZ.:FAE[)^JE<%%KF#Y:+#EQ?>3MUE
M\EQ-=+G/#W#VF4N*E<>-;U%4C(_#C/V3^05.METK\O,LX7)=!MD]>VL;+UU0
MK(7$8W=$^**=PF=&$VSJ%H(R;PY$GGY9<:B1EP&4J,:N.?Y@!RY>O'AC1T)Y
M;UUE,<*U:S-^#V$YW_B?X;Y_`W#?C!/XG@IB)XGYCB\LN("[/IR_3%AMTU<U
M&2K.+54%!G62.%!(F\%54QK60/+1JH,1A0"M"#4T-.?2KGSLU5;J/ND8N)I4
M$85%>7']%\>97`.#Y=9?X\9.=7M:DQF-98U=SM44(-.6;<D./Z60*#FJ/PA8
MG9G;48B+9YIQ1`R?Q70OU1RDHRZ.A^H.KY;;M'AP\^'Z>H?RJR&X,3',Q-1S
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ML(WG&^2<#6_(_&1X^X^7[,EQN)):E2^1&-LEJ?D&.RP5G&]3\LE`O8\C_J=&
MZ$"P"W=H/%Q:,Z9U->-./5UJ83L:X`"C`YQP/`T\_#KZE&Z-\IW),-QQ>X3<
M/N$V48F>S[8LTA@_-F%<ZWKC?A&/DZ)6*;`53BJ^=YS6S/AU[`RD$]G'3Y&3
M.W?/9Y\@U:1C<4]1_*R=GS=7D*CUTZLZ5-*54OS3.UU4(;3GGZJ^O@*UHKC4
MKRX^2N$G''ZQ8:Y74FR9"HG#NV<+<O7'D5C/(.2_WBHUAR@.68"Z8W;L,NQ5
MC93N.)5VYA8N-L<S,(NH(K0KMX=PW.HN^4D!#@:FOV4Y^S''HJ:&ZC>TM<RC
M>%.NO+RIYE:U/R=)JDPG%R0I$SQ#S/?,(<)L2<),A1W,;C3+97Q?<H+#+Z5F
M*7EK'+""N\-:\975G)V>71?1XNGS"9C7:2*QT%6J;@USK>0!I;0D-`Q`-*=9
MISX\:<*J@N6$N#@0"XG`D9]7FITCS+*!>..JMRX5WCB4VE:13G-TXNW#CPG.
MT/'R-.QQ5WMNQ7*8[/-T_%4;,+HUFF0[R3%RQ@49`_PK-,C8KDPE[HY3X]4)
MC&&'`?9^E8S7TE$F)HZN?3S5&8SXDOL><B\(9X/?&4JWQ!P+CN%J]7)7W+1:
MP/V%_P`<7;_,-.4-*KI,(]0E",V^[3(JJ@9T!_B-B"4T#+72_43F#PRKAS4L
MEQK9HI3$'/E518Q#Y;^7:$_XQ8>MF>,=V7AAPOS[)\A<"TN$Q?8X3D%/33)?
M)#O%%!RUD-[>I.B.:EB%WE!Z<KV'@VLC8BQ[`KH&W2Y,XC^4<26'"/&AZQ3G
MU<`,,.-9OG`*2`?O,*^8UY<<?2>BE>X3\NV3Q%4O+CK"V6HV>/P+R[R)RA)/
M$:@]CR9/1SM3\^55M"1R"D\Z-5E:R;-::RBZQGI718XQ2D3%8ID[F6I:0:\>
M701SZ5#)<!^H4S`&?(@_8I1\1^/3GC!0K[2WEK;712Z\FN3?(0DBTB%H0D<U
MY"YLMN76U4.V</9(SEU5$+.#!1X!BD=J(BJ5),I@3">.(M#OUJ^TG@>GH44D
MFL@TR`'H`'V+%[QW\GRXX:S=QGR;.W_C#,DXQY]RQF17*U;XY3\;R^Y.(9/H
M&8J47_B.S[.Y'FE9&Q0Y\J).'!&;-6-D%8TBA2-`*@W1QF6KQ)J/`G'#B#TX
MY\<>H+)DNFNC+&@XM`SP%".'FX>LK(-R9XYY<OV9.-W)7COD/&U$S5QW:9AI
M:3#,M)M%ZQC=\6YYCJ6WO,+)L*5;*9:8>S0DYCJ%E(EZV>"D<S99JX3[3CNI
M37,+Y:%O#RXTY>5<(8)6QU:\5:?:*T]JB-C+RW^0?'N!XY7G"W(;#TOR:P0_
MYIQ=AL64<-W#_)'+..^;/(!7D/<8!U2:ADIK=J'.T:\1L0XB7C29?I*D:.6S
MA,Z3DBB$3K>70-)]X5Z\37B:>73A*+B-SB'M_=FG'D*#)7?XU>7B[X^9-XK9
M/=Y>2O4[@RC\X$,HN%*::NFRSESG3FK'.=\B7J`9MYV19T.K0%PJ#Y!A#'&1
M5!@[;$,Z,H@JHM=\LXM#">#L:<R#SZ/+,VFX!K0<6\?R@CER5FL5^6UR`XN-
ML(77B_R!PZEFW&V*<[X'O+W-N([K9L67S&F7^2UGY-567BX*EY&K%MK%[Q/;
M[(JBD)I!U'SK5=PDN1L(H*I1FT>WWFXN)-<LCASY=-<>!Q$OS@?[KQ[H`IUC
M'ES]F-16M[.*'ETL.*>2,#7"!RFZN$7AWAA>.+<NWFJXG%S=ZN^2N0<!R'N>
M75G3&34B:^PE;8SD03A4T5@:D?$*1R8B/VY8K7LI`^M:#ET`'IX<E%-=&9FB
ME,?5C]_J5Q..]5OEMY3<N^3]UIMAQ_7;,RQ-Q@PA7[=&*PEHL6,>.S_)-BL>
M7)&%<#\9%0F2\KY=F"5]-P5-PX@8=J^,F0CY,H7Q![Y72.^'(>8G[S7S*.0M
M$;6-SS/6:?=]BHS/OEZP?(J[<W)FXY$>1%4YD\/,+\5SQL!!E&R8YDL/6K.%
MNC\E-)-\^4BY]127RTS60C5&R)`-$&*JJ<CC9.V2V[0G',?Y7^5_*KH[@Q-`
M:,CZ1[I_Y*L)E3RX^1_*:L\C7_*CD7AM]EO*?"BX\',7S.%,-W*IX^I-0R%;
MX.^9"RK=*_<,D6FPV>\W>S5&&$8UB^81<.SCQ10.N=PHL$7RTCZN<:.H1PQP
MISZN/#'FI1<Q,+0QON@@Y\1YNOTX4H`LRK$1:?`=8BL+,C,AC;B`JBU(D0QO
M'J$O<%/?QWVWUG.9J8695!"PP:.!Z5AQXS>6_GG%(\/L>9@SWA^]X`X+Y"R1
MF3#L'CG$MTIN3KSE&\,,N0-;=95LMFR/:ZXA6<;P6:YH44(9@W6F7_PRJXMT
MD#(K84=M('4=_#K7'JIP/+[^@Y<ERQS3I;1Y%":\*UZLU=*F>7A*5/B+Y?7%
M]3+,:_><'LX<=,P/[J6H/4&F2$,#6*R3J]?80AIY5Q65K*2?*DDX5<O"M12$
M3$4`P``VA,8;7U<P!SZ/6JB\I*9`,^GI)^U6KI7EM9[J4[QVQRER%Q$IQ1XJ
M<X;!S'Q-5?\`)VWCG6996R=S;:EL3WC()\E!2$F%/GLY21&$LR@1<R+)!`'2
M:2B9S+4=:O=5E?W=33S@]/M\W%5;=,:1)I_>T%<>5.CH]?52).#>._)^*Y*\
M*>-U6@<K&XA<#^86<<W0]CRMQ5<X=6A<>.J)R-KE0@3Y_?9PM5<SZY4LN:$V
M-9_=:IQJCR"$9":4:KMP25B[+4XPL/%U>C`@<<?1^F4RM9^_<*NHWCG0AW+#
MCF3T+(/@7R[)/"UIX8V-?+,;82\3LE>8/?WK1"H/(TUZ2YQWBVW"/BF:RL\[
M"!4QL2S@W<*J%<EDS(B<A6X&`H3FU+B#7GP_6)Y]*QC<U:YM,Z<>@#ET*)M^
MXN9?X,2V",R8,GLEY%R_!Y$\P1A*N\><.K-R;ISO$G-'D:WY1.:C;:#5\XXH
MME1M])M;*+;P-B)*J0S]RR>)R*#9LX3,E9,SLR-1H#JX9U-:8'[J>?"6*02U
M%,1I.?Y109@^C&OFQGMY96#\J\>O+]X[X<RX@G7LPP5+N4K<62J42^/6K5D?
M(=ZR.5A+-(.1?0"\I`C<DDI!JR>N&172*J*+A1("JFGMF/;#0X$FOJ'EZUCW
M#VOF+F_#]R@%$>2Q)VR+Y,5W*%YX^8@J?(3C_8L-35(X1X:OV*<86[(,ID*F
MY-KO)')F'LBY6ON-E;Y2;)2B`RB89BS0=-)>4;O7[A%=)-&%MJXZ@[`4PP'I
M%"?7CUU60Z\`TE@-0<:GU?R88"@%%*;#?EWF1Q[R,QIR#Q_P,BZYR`PL^P;/
MJ<,N+<I@.PS\),MIIO.66YV6P7>VO5U#+R:3V)@V2:3*$D$3.".7!S$%.]EN
MYS2'@"I_*WU4)^_-1ON`'-,9=AS<2/+CRZ%:N5\I24F^)^(<97',-`S'RBQC
MR=D.8]OS5G##"-YQ#R#S=/P%GQ[:V&8L*C9FCEQ0YS$-@0KS4C*53?PQHE@\
M;*&.W[)Z?*N#*UK)6N(Z^!-.)]7+%\R.T)`I&12@S`PXTKPKZ>:O#C?@#9(%
M]Q2LLVKQ7Q9,<=N65^Y,35*XF\?Y3$.,;8RN'&C(''=C6"M9&XS,S)7-D%V)
M(O;-(;F>-6B;$C-%-))0+FP.(;JH*'D!P(K@:<1DK7S-.L-J0YM,37B#QQHK
M7W;RMY(W)G-69*%%<&+K3.1N7JUFZ])<K^)*^;<OXONS*`I=8N:.(;NPO-9B
MY:KVMC1FK^.CIYL8E=FEUW"1W2)P;%M-LYLGN@&.O('@!Q->'#KZ!>+D&.C]
M6L"F!(XD]7'&JY$CY;^?1G66/('D)B..XHU_S%(#S$Z[5I3#]PE<\%LBF>C\
MB;MAI]?TLEL:06H.,AR<DO%S`0BTF5LZ2:N$Q*@99:@MI!-J)]W57UU/&N?D
M<U4W$>C!IUEM,^%*#ARY4Q\U,QIAW$1]HB/SCK/6"O%+_&D8O"2P!P7S4FW$
M3TW,>5\6O792B/0AD6E05KC4%#`'V2&7QLY$NX[=0^W6KW$8@TP'VU^X+:;:
M15S>)'L_E7Y\^M6MJFB)HB:(FB*X5%R1/T9RD#1=5Q$"N"KB+,H(%*(B'<68
MG-N#5P8/3Z4U/Y0#Z0Q;FTBN6^^!KI@?O\NI9-O=2VY]TG17$+(90LA,;7')
M2<2Z(IU`4CA(H])@4V`3).6XFZD'28>DOS"(;#KD;JR?;O+'8`^6!Y+HH+AM
MRT.;GDKW1\TY,1+^4/H*<#"!0V`?#8VYRAX?H[CK7/>1AQI[%DMC:7=2J%!X
MZ*J0SDXGZQV*0P]1"B.P%'IV]`>KWZU\LAD=5N84K6:0KO1)R?#),RF*<Q3)
M@/3X&ZE"E,;T[B8=QW'6KF>835F?D?Y%GL:'MZ*##[:*4%`D0@FI#D/W.Z8H
MG,81`#`0?$H;>(B&X[:RK*Y:*F0TJ<?0M=<1%QJP54TL>W(@10*BY[0+G+T(
MF/X@0!$H;#N/5U&-\VMI#>R,I0^[7#I6"Z!E*<5)RAW?LE736,':$Q1^V/K`
M1`?'?T^CQ]FMU;;@'_&:%:^6UH<,U>!C;&CHQRF,4"'W`!*;<1V\2^'HWULF
MO8_(YK%,<C<2,%Q)B5;'3,9NX*5<``.HP;!T#ON4P[^L=2ZG4S]*C`]ZA&*M
M99)0A-U$U0ZC`!3`F?[!OL_:$OC[=8=Y22A%*^U9=N'"M>*C[8IT`555>O0;
MM$QWW,?8QP#](H^H0VUHI(XF$O=@`,1S6:TO)TA8V.7G-NDXGB7$(PD6ZTB<
M#E;,&ABJ+J*](AN*:9NL=S>/CZ/7JD-E=;L_LX1IMAF<@IWRPV;-4A_>'AQ/
MES7FMRSEFUY?M+NR69ZJJ!E5/N]AUF%LP;F,/24A-Q**QB_I&]/J#PUW=A86
M^WP""`4YGB2N=N;F6ZD[20]0Y*U^LU8Z:(M(F`/P^S1%PS&$PCX_-Z-O].B+
MBJCZ?F^O15"X0^D?PZHKQDOFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+
MDE'GEAR/JW$3CME+DE=:U:KC6,4Q$3+RM6HR<2M;YT)FTP%291]?2G9*'AU9
M%21L*(E*X=()F*`AU@.VH9I1"S4>?Z>CDI8HC*_0*!0]MOFETK#[#/+#DE@/
M*V`,H86:8.F(+$MFMV%['+9C@.2]]G,5X2?TF]5W(2N+H-U-Y*K3Z'G$YR8C
MVM9.U.Z=.CL@!P,`NB&DN&.%.HX#CCYL^@8J8VI+@&D$'/H(%3P\LL\%1,7Y
MQ>)5L>W2Q26$LH2>2\><B^/G&RS85P_=<)Y[G)&T\H"IJ8;L6/K_`(YR$ZQE
M>("P%[R*Z(23*0CWK-P@Y02!,%#V"]&GWA[W53B.9PS5YL7UP(T^G@3P'0NY
MMOF2*XA5Y7W_`#5B?,](CN-G#OC[R0MO&9]`X=DLB5-?*&5<[T!6/89)I^4K
M%5[G;;&GCAJJ:.^(1B(YN5`Z+]=9TY2:W&XT5<[.@ZOQ=)Y>7"UML9``PC,X
MXX_".73Y<;2\S/,CRK2>.O,:$C,.Y:XH<J,#43CMF:D0-J?8;R9)WS#.6^1U
M<Q82T4YU4;%=:,%A<.8B9KTI"22I'$6^<MS%7.FJFZ)')=/TD#!U>7"AZ^6?
MG&"OBM6EP-0Z.F..1PZN8^W%2`LWFCT;%L9R>_XB,"Y6X_WWC:&!Y#_*RQ6K
M#EJF,GPO*>W3^/\`CX>F7&KY!=8VAY6W7VL/HB30FIABUKRK51RZ>&8E%UJ1
MET>S)<*D4QP%:X5SYCAAU#%6/MJO`81I->9I3$@X<`>5?/@J`BO.+Q*ICO)-
MEFL)9-=Y'Q/G3C7@BU89Q#>,)9_FIB8Y9S:4%A:QXZOF,\@OL;W:,FY`'3=T
MR^\&4FQ>L%T%D"AVE5:-O?=Q'O=5.('$X9^W!7.LG!V!&GKZ">71ZPM7)7S;
M(_B%6ZM=>1?%RVXAKK^D%OET@+[R?X8069ZG&(V>9@)B/JF%"YP?6K-$Q`1D
M6E*K)UE5VDZ;/$V[)1T^(LV)5]TYA;6E"*G^4.(]OGR5L=KVH):02#09_=7R
MQ4CN.^:;[D'FEYA>,IJT'F\9X:-PU7Q'"#&QK-&ML\L8%D;M<E$'C>/:S$@%
MBG4DW9@?++F0$.A+M$W)JL,KWSN:3[N/+@:*DT360L=2CSGZ*JU7(;S.XO`E
MTY20#?BYG+*%*X3PF*KKR>RQ4K#A^'JM$Q[E.E!?T['7(.VWN)NN0)>IUHJS
MN1B6$>506[8YDEC*&115H^[TO+0,`<<.5:\>C/[4CM2]H<2!JRZ^'#U?8"J7
MY"^<+@#CYEG(M!D:E,6^E8*L./*OR"RG&9/P?6%,<S&2HVIST>C5L/7?($#F
M3,J%0K-ZB).QJUZ(6+'MG@IM_C7;=RV1K)=Z'Z:8#/\`E!P]?IP%8[1SX]=1
M4Y#R\N>"J>^>9ZRJ$YR^0@>'?*7)%"X.S][@<]YAJ1,0-\?Q[C'^+J9E^63J
M3>?R5%WFZ2AZ9;P6,SCX=8S0S8`<'2^);]5/FZU+1[H%>'('+5TJAM:$-+FZ
MG'#/F1R54YO\SWC[A&1R@W=1UGO,/C+'7&RVC;*G)T9E5K?>>7UPEJKQXPS7
MYZX6FM0S"XW6/B@L#N0E'+""A*ZY1?/7::9]7.NV"NG'#UUIS&1]HQIBJ-M)
M7`%V'IY5X#E["K"_^-#AM"BS[R0Q7*M<RP'(3&O&M3$S3.W'"9H[F[Y@QQ9,
MLXYL9N4,;D97`D909ZE4Z5*9R[DD91*:8FB@CU'BK<BM@O#V>JGO5IE]E:^7
M560V;NTTU&FE<_3[>I91\0WJUY*QI`7>T8JL&)[3,MI-5;&D];*!=))HHS>O
M&L:HRNF.+%9J'/Q%H;MTGD<\:O1*9HZ3%<B"H*)$RF/+H];L#3'A]JQ7LTR%
M@QQ6.J-\XOC(\KE-L;ZL91A$;;PDRSS;<M9&,@=ZG#X="U&LF"[(_0FE(Y#.
M<@ECNU*L(Y-0[5=&L/U.\!2%$V/\X.(/PUR_3PQ]!Q4YM'@YMSIG^CJ](5H>
M6WF39FP_C[F)<L0T&P6"^80HGEKW"-Q'=:MCJ+9XW;<PKO)PMJ++6U7)$>XO
MDT+%D:-<M3ILTH65%LJU.]:F=J(1.N'Z26UU5`]9%/BPR]6.:D9;-JUKR*$$
MU'4#RZ?*BJ"_\[>5&/>8MNK1.)N:KE5(+R[*KR,L_&*(O7&AI8<4V>.Y$YLJ
MMPMT_DQS?1K-CGK!CVFL$HJ'A9>70=*)]!B-%"N'`'7,C7`\V@Y#&M>%:^OA
MR56V\1:X<0XBM3A0#HQIED*UPX!7?LOFA5=ZPCYSCUQPSCRBKL5Q;Q5S+RY*
M8_D,8TY?$F",UUN<N6-@7B<DW.N/+]EFR5&JRTFE587O.`:1X]3@JKAJDO*Z
M[R+![M`3U'SX5X5^ZL3+4FH>0#4@=)%*\.%?MR!5>.?,DP6I1>6^2ZU#7.X4
M;B/Q7Q+R^FY^'1B&Z.3\5YHQ!>LUTM/'R$G(M'*,VM4:(L54DH5DD1P[1`#B
M4%#%N%TUS7.%<&URY5Z<<L,E:ZV>QS6DBKC3JRS]/M5$8DYJYSR1YA&;>-2'
M'>>?\?Z?A'B5DZO98:67%,:M229WJ^7[%+6.\1;[();I9H2PR5+:PL6QB8A9
M_'/8UXX=$!FY:KFI',]\Q`Q9_+S=S%*TQ]"ND@;'"'.-)#P]%.'(USXKO\\\
MM\^XO\P?BKQ?QYQYF,P8PS/@3-^2[K*0-FQ97)Z-E\?9*PC4DIN/?7[(%550
MK>.8*_N'4XR(V7>R_P![,0C`74:/$R)Y9&2`-^&AQI6F7"HKGY8JV*.-T+GO
M-""/8>@\O5P4:.(/F.93>-*'7N1&(LJ3]4RYS_Y;</Z'RM^\</,J.>Z5GD3R
M!A<)4,^.(&?9Y*_=-M1,9I5X+&M#)!][M`*X*L"AGIHVW18XA_P5=PY$^5*>
MVJF=:M=A%371N%>8'VFN=/0KG8=\W_`N:,YXQQ77JA+M*%G?(U\Q'@K,QLI8
M,G!OU]H#"ZR;A.<P?6\@RF<\8U"YM<<S(UV9G89ND_\`AD1<),BOF8K7MNP9
M*'X.?Z:XY<E8ZT>V+7^(9CRZ_N4J^3/+)3CW>./>*JYA#)&>LI<FYO*-=QE4
M<?S>/*PV0DL4T`^19]Y<;/DFTU>%KU>-")&`79#.E4SEV*W5,8A#233]F[0/
MB(^_I'++CP4<4!D!=4!H/W??]ZB=,>;QBAGC'"UAC<36H<SYHMW(2B(<?[WE
M3!6('N/[)Q0O:N,^007W,&1K[#8D0B*A>Q:QL:O'/Y!>P+2#<S1OV@<J-HW7
M1:P&GOFO#D:'"OV\L\:2,M2Z0MJ-(ICUBHX+N:IYJU,S)7,./>,7'G+W(:ZY
M.Q-?,XVW'4':L.4=YA3&V,,F3&%KJ[OEUN5\:X_F+(?+=:E8.#804A))3QXI
MT\1<IL"`Y-0W=0`T>\>CV8C[<CP%4^5(+M9`:/Y>7E4#,T73Y2\VFDX[XT\<
M.6#/"SF1Q-R+P>SSQ&C?^2_%3`=J@(-Y!L+(G1HJN9CRE6G63,EC#/14*Q@1
M79"H0J1GA5%4@/1]V0&D#`]'0#^;#/CZ55EH7.<TD:F]?,CECEP6O&WF%92S
M!SBJ&)<78#LMWXJY,X*<;^656RFG+8OK,]5HO.UNO:(Y%M\-9LAL+4ZJ<?!0
M[2+/`1\8[FTI=DZ6*FHT605&X3O=,`!1C@/74\^0KE7@50V[&PN<7#M&DCT4
MPRZ>KC7!5!QJ\R/'=OQ3@:8RR]MS!3)?`FS<Y4LSVRIU*@UFY4O%LNW89EB@
MJ59M=I:U>]X_B)J)F'T:W=/&/W9)IJ(.E#)+E3I'=-`HZI;08TZ!TXYCTI):
MOU$MI\5*5Z^@<CZ.I6FR7YV&&\:P<?./L(Y!54KO'O%_)K/]7L&5..V-[Y@G
M'>7:N_OE5KA*7D3*%=G,S9>;8_C%IJ1K=33>G9-A1;BX,_<MVBEIO<B!AQP_
M3AQYJX63S4$BO#IRQZL5E.OF4VM7PM8,TU.#-DB,CJ`ED2O0S.TTZ@DMD([C
M&LU'J_OEDV:JM(J+)Q$NRN57LR^9M&J!3&5,`ATCE.EI'VC,<_5YQR6*V,F0
M,=@:K%G7O.VP!*8JSK>9.AN4KA@;)/'K%<Y3J3GCC?E2@6"R\II=Y`8:?L.2
MM-R2O@NLU=Q,13Y"P/;!)Q0UPS,PN$C]YKW\9MZ"PDCWAT8<N?VCV5RG63@\
M-!%#Z<,^'EZ5(.Q\_K;4JWQR)-<.<NN\N\I<I9!Q1BC$E1RSQRN#.4?4'%=D
MRZ>]'R]%9,#&G^64S6:L[`K_`.*"1:JHG*HP$P%(I7YIU`*>^>CH)RK7AUE6
M?+#4:.;I'W@9TIQSR5K)WS><61%+QX5/$-K:\@[SDC/N)ICCA?<KX'Q*^QG<
M^+LU#P.<?W[S-D&_1&(`K\'(VB%+#.HU_(+V,LXS.T;]OXH[6AO/<!`][J^R
MOV\1YKFVA+R"1H^_+A[>2J"H>:?5<VU["Y^*?'3+O)#)>6\7WG,<QBJ%M^&L
M?N,0T7&F4)7"-P5R'D.[7QMCAU/+YAK\E`032$?RB4\K'.'B*Z<>G\4-WS1<
M`&#WST>S$>0/`55/E2TDR$!@X^0\J@9FBM<S\S_*U(SAYAA,X<5\FUOC-PSQ
M9AW+4A<8F0PV\N^/86T\=)#,-A@KS5H_+$A/V^RVRQ-/NV+)$ME&4.=)0TDY
M0:A\3JQMTX2NU?!0\.0ZSEETJXVK3$TM/[PFF?Z//T##%3YXI<CK3R6J,K<Y
MO!TAB."(,(YI\ZEFO`^=ZCD*)FFCIVHZKMOP1>+E%-)&O]A-.1:/`0Z#ND3-
ME720F4+D02NE!+AZJ?:5!/$(G``U\O+[5*C60H%YVOXIO$)LH^3IF2P-F?QD
MA@[*&%<PMND@&4;LV]O+CJ=<$'83%(C"Y%6.?;^23Q\-8%^TF*O`>W#[*K.L
M'!LX'$@CU+\K36E6[31$T1-$31$T1593+G,4>:;S$4J)BE,4KY@<Y@:R+;?[
M:*Q0'8J@%$134#[29O$/#<!@N+>.YC,4@PY\BIH)Y+>021^C@5D_QQD"!N,.
MVFF"YW+7<B<@BF0A'T8OTAUI/&WB'<('I,'@</M`(AKBKRT?;7&B84:<B*8]
M2ZJ"Y;<Q:X:%W$'@KR)ND7`@=N'6F/3V3`;K$Y>G[/6.Q=S?@#6GFB;J/9X-
MZ?Y/2LV.I:-=*JX-><+@JFX4.")6YA'J.80$QNK<`+X;;](ZU\]J7L<^M6\5
M/%*6N`*D%5YU)-D<%"%4V$W00R@E`2*#N02;;@(AZ]<[-VD3M53V:F>P5',C
M^57FKMM%`B2769,$RAN4#!X>`?H[[;%W'6SL[UKVC&A`6#-"X$\ZJ0U*R.FB
M@9-5<I@%P4W4(B)NWT%W*(;_`&=A`?QZVD4[)`:$:B5B/A(I49<%=DF16:*?
M=3>G3,;82@10/'?T`/LWWU4W,\/O,=B.2=DQV85.S.75629Q(]3<B8-P#<0,
M3WF*'MWU8[?)8L#6O2JC;VOQ&`4?KMR.:0;1[(R\HUC8]HF*B[IT[3;H(E#Q
M$3'5,4A?].K6;M=W$@AA:YTAR`%5>;."(:WFC1SP"Q'<C?,TB'["1@<;.'$Q
M(F%9NG(IIG1C4AVZ.Z5R?;NDW_4`1';P]NNKLM@OKEP?N)#(L#IK5W5T+5S;
ME:P-+;4:GUSX?I6%RT6F=N4T\L%CD%Y*3?*&4566.82D`1W!)$@F$$DB^H`_
M'N.NTAABMXQ%"`U@6ADD?,\R2&KRJ?U(K$T1:3&`/P^SZ]$6SHBXPB`>G1*+
MBJ"`[[>W174]BXFJ*Y-$31$T1-$31$T1-$31$T1-$31$T1-$7[RVNJ7)*!GF
M?X4R=R,X$<C\)88B33>4L@5VFQU-CR/()@<TC%Y3H=B<O".;,]CZ_P!<3%PS
MAV";M8B2XH=H>H3@4<6ZC?)&`S.O5P*R;:1D<NI_PT5F[MY7O^=C/-MGY'\E
M+/E3D%E!?C^2CYMK&)Z#CN+P<QXJY$F\MX/:T;$3U>]5:Q$0R799*5LP3[A^
MC9"/CM!29M2I)IQLMG=F=1H\@4QK2F(Q/(]?L5[KH!X+`-`)X4K7`Y4X>1S5
M=M>!EOLE1IE?S1R$AKI)T3E/QYY/U]UB_C5C+`%79O>/%@+98JE#5:K+STE(
MH722ZCR4G(2[Y=OU=+-%!,!3$VU?@7G(\R>7/'AE[%5UT""&MI4$>T<*#CR5
MK/,8X)W#,^)?,*N^%G<M:LY<JN(N$^.-8QT8:U$Q3)QA+)>0+M"SD?/V&181
MQI*4#*CT5TGYT6A"QR0`8PJF+I<6[G5+,:_<[[7);7#8Z-?\./M:?^2N\O'E
ME2.;87D4]Y(\F[#EK+N?J5A/$B&3*_B6HXPA,98<P1F-'.5=I=/QS%SLXU>2
MENOIW3NP2[Z254=J+)`W0:(-4T!H+1Q%7GWZCB3ZSCQZ>&2J+L-=^[%&8UP&
M-:<L.`]>:N+R4\N?'/)J\\B;_:,@6^LSV=J)Q0KT&Z@(>L/U<27KAOE?(V9L
M19/KZ%E93$+:GO[YY!$)&(EF*L:\8-!;*`8CE02W_*^Z6@X4'I!)Y88E1MN2
MVAIC5Q/]*@/L76(<"KE::)"U'-7(B$NKVN<E^,_(^!>8MXS8PX_UR.>\:+['
M9!BZJ>LU68GY*8_?V7CP+*24A+.CM2#LQ;MR]1#VMMG@@N.1'$GB#QQX9>Q7
M.N6G)M*M(]((X4''E56PY4>523DAD+EK;(/D8^Q17>;>(:OB7.T07`^,<FWM
MO'TZBR&/(@,498N;HDSC>KRD`]`\I#%9/B*ON\[8N(YTY56TEM7.>YS3@X<R
M/8*>FOI2*Z[-C6$5TFOEQ]!'G4W,0\:8'$&:>1F:HRSRTS*<C&>`&<U!/F+-
MM'UDN`,8K8QB#Q;M!4[E\:QL5OBW(+%)V%0Z"=1?'4L4'9R%]<Z^LU4<LYE8
MUA&7V"@5E\M<`:=EJ'\QF'D<B6:'3\QK&=#QG=5V4-%N3XS84/#[W#S24JQ%
MW*99UW(1KT7JB;L42$7*!`$2COJ-UK5SG5SK3S^;[U<VXTA@I\)KZ%05B\NJ
M<89QR3E_"'(6.Q/%YSL5$NN9J9:^,^'<ZO7=]I=/J6/'MUQ+=K\9O(XOEKO2
M:/&-95N[:6*-*Z;_`!C1LV<**B<^V>9-;3@34XD>P4RYU5S+D!FAS0<"/-Y^
MGE12OPUQNJ^()SE/+%E'5Q8\K<_6+/%Q@)^-9$C(9:SXKQKB>4I+8J1UOO>`
M7A<;)*G4<%*HH9ZJF)>@I1&6.#1&8R:@_<!6GFJH9)=;FN`I0?:3SKQ4(:CY
M0N%Z=Q$M/%5CD_(KZ1D\UT;/5-SG-1]6L.0:!<\'NZ4SXT1J$-96,W5+;3<&
MX_QK`U5O$RJ"S.6A6K@BY$SNSF)$+2C""??X'EZN@<\E,;MQD#J>YQ'/.O'F
M3Z5<)]PESQ,X=LF-Y[E/B*9E[/=X2P2Z+SR_L`+8+FJ=$5^0B5\>6G`[JP.U
M[,WEIAZG,J2R]G+(MG[1)-L*+,RS92GRTACT$BM>9R]OK5?FF]H)`W(4X<^J
MGJ4B.&7%VM\+^/E.P!4+&^L\95IR]VE287@H6H199O(UZG\A3L;3*)64TZUC
MG'L+,V-9K`UV.`S.&BTD6Y#J"0RAIXHNSCT.Q]GECR6/+(9'Z_+!0DL?DV<?
M[+CO+F.W-[OS=EE?FDGR\/)MDHXCVH0*\I-*3_&NO$*J1,N&['6;Y<(ARD<0
M5%"W/E!(8W248/E,ZG\5?,<_MPZ3CBIVW3A3`?#3+C3/V>@<E>WD'Y>-+Y!.
M>;K^2R7;*E(\T:!QCJ#MY"0L&]_RJG.*%@LMPQK;Z^WDCG;68SFV3B#E_'O2
MI(*H,NP!P!8QRU-K[KFU..77CGATJUMR6EIH/=KZ#0>P*LZOQ#GQR?<,X99S
M6ODK+>1.'C;B'>)R#QM$8WK$A&-,D9.R$A?H:I-;+:#PDH0,DF8?=YGSI$Q&
M!%C+BHJ<I0M2:%QR`]5>?7]BH;C`@#-Q/II]W)1G0\K.P42HU^H\>>7U[P:C
M,<.L'<),^RB.)J%D"1R]C;C_`$Z;H5!R#51L4BU1P_FEC4;9+QX2J(3<9\.[
M2%2.56:(K:M=:N(`:0/=`.)&7M\^'0I&W0!)<T'WB1T5S^SIZ5Q\J>4VRL$1
ME_'N">2MOXYX4Y!\/\6<,<QXWCL74?*,G*8XP?CZYXLQA*4:\W-^W>4:90H%
MW<1<UU,I'[R0234;'CW8?$@=9N&$9P+:9D<^O#'C7#IQ1MV*@R-!<#7V>O"O
M#T&BD[6.($_C[E2WY'XYS>\K]?M.$,+8.SEB.9QM!6AIDZ(X^-LB(XNL-8O2
MD]%S6+9EJIDM[]Z$2:R[>0111(4K<X&5&1MNYDFII]W&N?2?/GQ4;[CM(]#A
MCP/F`]@7?9TXP6G)7(#CGR7QCFI?#>2\!PN3L?O2/,<0F3ZQD3$.9)?&LY?Z
M8^B)6>K3FLV%62Q3%J1DZU<K&8B*P*-')#@4+IH#(X.'#/$CERZ@K8I1&US2
M*@^T5YUY_P`BMK!^7I2H''.%,;MLC6A:/PGSZN'/J(D58:*!W-VVX9;S+EQQ
MCJ12*Y%)M6V,AF5RR(^3$SHZ#%(XI@=0X!8^UUM`)IB[T$D\E(VY+).T`QT@
M><`=/0J7XT>7E.<5KE6([&_(&-4XW46U76QTG#$OQJP^YR;#Q-Q>6*81QL\Y
M-@;]])+'M1GK*HO%B6*;V`K5NW9N)5=N0X*4CMWLDJ#[G6?9EY9E)+D21Z2T
M:CQP_E]=.A2NR3Q\A<E9[XM9[?6.4BYCBS+9HEH"O-&31>-MJF:,8*XPDT9A
MXLJ1U'$@V"HNT!0*<55@Z#])?'4LD':2!]<OLK]ZB;*6Q.CY^7V*#LSY5<&R
M"D6O%V;W%-S)CK-/,7*5<O%XPS0\RTB6JG-K+JF9,JXAO&)K._C&D[78FT-8
MQ2'E&,M$R[1>+(IW13<.6ZD3[9Q%6G&IX\R3F,>6'1GSF;=!IQ:"*#U"G&HY
M\./52T_)CB]RGQG.8AR%QQ>9_P`HY^/QWR+QURSE/!U0X+XTI-VILE?G&1Z5
M5KCB[-E@J]:Q.G`VJR/AA++565C<1<<9V2192;E=,YXW6[Q0G47#D1[2:T\Q
MXYJ]EPPEP.D,)X@^J@/+HX4HM..?**MM6QOQ<19\BH['64\9>7GBW@9F.00P
MEC[.#*1K5,9RDE)3F#I_)/P+C%%G6L=JDT'<E\#),YQBDR.YCBKM$3DK\J\A
MI!H=(!S&75GY^JF"I\TT%PTU:YY/#R]&/2I,XJ\O>1P3D3C%>\1<@I>!9X/X
M>8@X/Y0K%DQA7K:VSIAG"4@[F:6_:2I[#$OL37K[VEY$73YJ$NW5;/.V#8%$
M4UPD^7<'L<#\(`]`IPSXY\U&;@%KVD?$XGT_R#)45;_*6P_>.(O#OB-.Y)OB
M<#Q!4@(5A?8=E$Q5GREBQ6$D:EE[#=R;)JJM6=#SO2Y'[LGD6ZASE30143W.
MF&K39C2!^+"O52E/(*HNB)'/X&M.O,'K"KC-?E_S-RY`Y!Y$X,SI"8+M6::A
MC^HYEA+7QKQ-R+KLTMBMA*05`OF/$,B.(MSC3($+598T6L?KEH-^U:M#.(LZ
MK<#G/M"#6(T\Y'LS/7AT*L=UI;I>*TZLO+E3K5_N6_%F`Y<<9+AQJLMMDZNQ
MLR6/7;:W-*_7;"5M8L7W2J9!K#NQ466:I5"Y5.1LE.;$FJ\Y22C92-579B"2
M9RF)D2Q&2(QUQ\CY8*"*3LI1(!DHH0'ER9(@C<C[:7EA$/\`+/)>`X\U6W2C
MWB+A1UA&-IW'X^2DVN/6_'I[)/867H%V8Y*73?)/)@\TW5;)J(R8`)4D\<6T
MFD@G$TXGA7C2OKXT61\TW4UVGX:\N-/-PY=-*J-SSRO,QX/?\'(#BSDV%@).
M@\S^4/)S+N6&N%<:Q&)\3.,S\7LB8[2B\=<66-NK4#`8OE[$]CXI*"AI-=ZV
M=2+F45==U198(OE96D:*5ZR/S>?B/3GF5)\VQ[7=H.&7/%OFX>CAD%?1QY44
M9&Q>++E2^0$BSY1T*_\`(C)5RSYD;"F-LK5?-E@Y83U;L^=(S(.")):"K4=5
MG\U28`]=;PDI&O*XC!MD2.W*9W0.)#:.#`&GWAYACGECRY9#IK&+OWB2T:#3
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MX;'Z0ZP$-A*?;[11`?$!`WAMZM<\NC6O1$T1-$31$T1-$564VZS]%ETIB!="
MDH`E*[9J"8S*0;@8#&;NT0,7J*.W@8-CD'Q`=0SP17$9CE%1ZQU*6&:2!XDC
M-#[>M3"H?*>$.Z21LL4>`/U]8.6RZSR*Z^H!V$O2#AL`C^L4Q0_6US]UL+G-
MK`[5T'/T\5N[?>&UI,W2>8Q'HS4S*EDRLVI#_NJ;CWI1,502-W22PIG$0$?!
M,0.41`/8.N8N]ON;8>\US12G05MX+F";X'`DJ],-9`(42"<3$((`AX='CON(
M;B.PE+[=<O=VS\*98U\N:VT$M6ECZ98*XK.WG3`HE\1`H=8B.W@```;;[[B`
M@(^_6J,!&#:@U_D4[H&$G$UZ>A=_'WQ=J.Y7`E*)A'[8@)=S>T1\?#?4S6RC
M%M0H'VX`+B12GD%1EWY7T?&IT4+;<XI@\<@!V['X@7+PR8#T]TS9L"QTDRC_
M`"C`'NUN;/:-VOP3;QO,?$G`>:OV+7SSV5L0)I&@\!F?0%'&]^8;B]BBH:'D
MYBTO-A`C:)9+((F/MN'4[?%03*3<=MPWUM;7N;NLSJW1;&SI-3Z`L6;>MOB'
M[O5([H!`]:Q;YRY#W3-\J!Y-9>*K34P_=];;NU%&_5O_`-KD3AT`^>&#T=0=
M!`_1#UZ]`VK9[7:HM,7O3'-Q&/4.07-WU_+>OJ?=B&31]O,JP&MLL!?=$31%
MH,;8/?\`+QT1;6B+:.?;T?C'_0&BJ/6N"8^V_P"715ZUQS&W^OY>C5%6BT:*
MJ:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(OWEM=4N24<.67(MAQ7PA-Y;<4^5R)
M.'M>-<9X\QU#2;""?Y`RQF?(=:Q5B^G_`+Q2B:\;68^9NEL:%?2:Z:R<>Q*L
MOVEC)E2/%+)V;:C%W+U?:%)%'VC]-:#$GJ`JL2O.#GAR^@\"\BL&,<45C!',
M*@9$X*5V;E,9<B',Y4G.`N:N?F>'8?).&<N3>#XZ>A;RK8X*8J;TDE54'%;5
M5&;9G?`@W06PI9Y'L+0.7H)IR'3P&2RHH8VR->35E'<.+17@2.G/HP64!U9;
M#Q2X7N;=>'E<:6S$.,7$U8U.1O*>8G*DPGBOCKN8[(O+FZT,+#,04<ZD?AD[
M`\K0OG"*:*)&1E1(0<ACC%`'&GI(&(Z1A]V*@<T23EK:TKP`/L-/0L=%0\Z-
M"=PMRUOA\(5.[W_BG9.)T4,!A[+MM>XOR]$\OLE1V,:"_IN1LPX-Q!9X21@9
MQ1X61(_K1HT_PZ1V[]1%<ZB%HN7!KC0$MIZ\N`]GM4IM1J8VI`=7,8B@KP)]
MJR`<:N3>2LI9DY)\=\XX;K&'LP<<V^&[2];T#*CS,%$MF.\\P]QDJ+,,+1*8
M]QC+1]GBI"@2T?,1ZL6*":R":S9RNBL`EO@F,I(I@../'K`Z?1Q44T/9`$&M
M:\N'42./-1`YR^;-&\(LM353G*S@2_4ZEML7R5YK<#R`N2O*:/@\B2\5$/)U
M#"E=P#;:%6&<$66!XR):[M7AGV2"BC<Z74EUVRW!C<1AATX^BGVA216W:M!!
M-3T"GIK]BO7DWS$6&-\:\\,C*8G=RZ?!_DYC/C:\B27))D;)#C(\=QK?IV]L
M]-6G(59*(#D4F46)DGXK?=)A[Y/B`!&GS8T:]/$#/F`>72J&VI((]6)!X<B1
M]BC6EYA')'#64/-AM6<<55:X\:>'&;JO2\;JT_*,>GE$C^X81P#(XHQ/7J2?
M$L+&SJF9+YE-L]>34S9BC67DRHQ`KUHQ(NI"V[?BXC"F`\S3R^T9TZ5,ZU95
MK`??Q!\Q<*XGHX#+'H5R[GYE>2<!K98QWRAXP1%3Y%U:AX,ON',:8:SBCE*D
MYT+R+S@QXTX_IS7)5IQOC%U0[57<Y2[&+L9WT,YCVL<[)),UGB8&0+(+IV.%
M<!Z\N`YCAZ<:1_*BHH[W:FM1RSR)Y'CP74W;S-LNX3IW-E3.?%2K(96X6M^'
MCJ0HN&>02U]K>64^8=Y4I=7:U2Z7?$6+E:W*UMPF(*I23#X=TXV*+AN@;O@%
MX:'W:D>7$!#:C4T!V#J^:@KP)S"IWE7YI&8^(=7B)/,6!>,5#R"6@Y#RE8>/
MMAYHV.S9O?TRES4LE&#CZO8CXN9%92SBPUR+!123F5(2NL9HYXX7ZQ$3O=5-
MR=`=0`TKQ%>H4R\_GXHVU:YY:"2*TJ`*><ZO+DH<<L.6W,[(V:>1.6N.Y9^!
MPQQL\J?%7./#42TY0/L0LD)O--&SY>&F2<RXCB\*7Z#SW,0[C'"46E2IF7)7
MF[>(!R"ZBLJ<K/&DF<]_:-R#<,\\>OESIASRGCACC:&28N<ZG#]7F1P/#'S#
M'.GQ,R%FS(G&S&N1>0-"K-/R).T&LV5S#X[OBV44+1%OJ/`SK2SD>J8_Q@E%
MV:W.7;A0\$@P.W8+"1))VN0P&+G0R.=%K=B?T]0RYK"F8UDFEF6'EF?+@L9>
M./.2D+UQMY,<I3XCP&M4N/O'ZW9SD,,T[ER6Q<IJ1*5N1;M6>(^2^$I;"E9D
M\(7.2:"Y%TZ;KSK".?LSL]W`F(N,(NZ"KJ9$TKC4<#AAU$E3FT]X-!.+@*TP
MQXC'$*7')3S%:7Q?O>8ZK=<=6.=B\1<+Z?RW"1K,NQ4F[E*W[-DM@JGX;@X*
M09LV+.:G[BT9)I2SF0*U3,_`%42$2,H-TMUV;BRF/Z"?L_D5D5LZ5FH$#'[O
MO4;N7_(3G]2,:<?)>UX)I&'LBS'F#<(:37:GACE6ZNL-F*IY'M=G9WG#M_N$
MYB'&R]*;-U&+5I-G&.F(F0;K]QH*XI"B.//-*0TY`BO$\1T#)30PPZG--217
M.@I0'I/I4YN)?)6Z9Z><BZ'E?%T!B7,O%S-;;#.2J]2LA/,IX^EU9[&-"S#3
M+;1[O*4O'<W(14W2<BL@<-GT*R<LGZ*R0@H3H4-F12EY+7"CA^CH',<%BR1A
M@:YIJUPKRXD<SR4-<W^;%&8)Y;0O'V<KN`KE4)3D'AKCQ)K8WY`7*W<@J--Y
MMF:Q4ZW:LC8KC\`GQ11F43:K6V!]"2606\\$48KQ%%4YR-31NN2'`-TFI`SY
M^;UURQH5*RVU1ZJFNDG+##IK]BN#QL\Q>9Y(<H+_`((C*)@JF1>/,@YDQ_8J
M5:N30QG-2N-\1S$S7FN2;+Q+E,3Q>V-LBR<6BYBGD;:)`4H629OU3&!0Z)*L
MG+WZ<*5(SQZZ4X\#7'SJU]OHCUU.0.6&/`&N)'4KF<[>:+_B"RQE]RDXW/YK
M(CNV(M('.^=[SBJ?F?W99Q+DC/&E,Q=@?D!?\C/7)Y$Q7RZ,6V80Q01,X6-\
M00H232]G0"E3TT^PJR*+M*UK0<A7TU(HKH<:^6%<Y,<,\:\RZK1KDS@,CX9>
M9=:XT;(MY^]I+1,=+KRM'B$VP,F]AL"DM!N&,>)2MOCE#)"*:(J"0E&3A\7:
M`$G#[/O22$QR]F2.M8Z,=><U$SO&#+_+.[47CXI0L>T[&4M%T'"'+ACE'-5>
MR5F*[0&/Z%@KD=0+/B/&3G`-U&RV=JA*2*YY.,CSH/BAWOA0%:'YIP;JH#@,
MCE7`5P''A6O'(*<VGO:036IS&=,21B:BF-?O7<5'S>GLQ!Y'KCK!M)NN>(7*
MG&S#N':[@C.DA?,#9LNW*E_;8NC1C?.USQ%C=_2%\=.*!-.+JFYK3Q6-C6B+
MID1]\8@EH;IS0:@&E,:U&/F'3PPZ506NIS0":$',4(IT5XUPQ]"D%9>7/+6L
MVW$/'A?BAAUWR\S(?,5L@*JTY23)^/,9@O"3''7[SY@G,N#@0,A,W,M;,HQ=
M>CZX6EJ/C2`J.%5R,B=TUSIY&G21[U3SZ/U>D</O5K88W`O#OW8`Y5J:X4K3
MAS5NZ]YEF3,LO^,6/\#\6HB<S;R#9\RX>VTS*^>&^/:C@?)7!S(]-Q1F&K6>
MZ5G&>1'U[@EKI:%$HR1AHL%G;8C=<6J9%EOA+771#`2*5KSPIAR/$\CZ\+A:
M@N<-6`I3+'4*C,@<.?Z=&,O,PR+R*B..%=XW<9J_8\Z9CQ'E[-63Z)E?.1L=
M8^P?3\&9E=<=;LR/DFO8OR#*WZPV;-$>[C:T1I`-&[IBS5?O5&9"E2/1MVZ0
MAK1[V/JQY'V<\D?:B(%SW>YA2@K6M>D<N?I5V/+*R[?+SY77%#.&4Y.Z90R)
M+<;$+]='ZCA:VY`N\]'I6"1>LVSARHDO8[-)_``T:=9R"Y6%,NY0'POMI"("
MXU)!'L'WU5MPQHG+6T`QZLRHG8[\XV2N7%O.'+)?%7':;J.)<=4&^J8RQ+S"
M+?LZ4J9OE[K-/1Q1R/QI+80ITSA3(,&UL*B[LQ2RS'XZ/<L2',)2N#6?-D`$
M@&O(Y8'/#`X98E2_)U);5PIS&>66.6.?WJ5/*WS#V'%V;YJPSC$KZ\'X<</\
M4\LW*C2X-X-3(K?*.0LNT%&@,D5Z](DK;R*4Q09P$@HH[3<"_*F**0)"H>]U
MV&@'3P!SYAQ_Y/K4<5KV@KJIB1ER+1_RO4J=<<U^6CW)=6X^PG"6C0O(R:Q_
M>>0-BHM_Y8QK:E4/C96K/`4FH6.PY'H>';PF[S#DNY2KN.;5F.CGL7%C$.G#
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M`'+ACCZE"=7S,[1R>QOBM]1TS8CNV-?-WX1\7\M+XNNUTG\>Y)H>2WM4NKXE
M7L=WQOAJ^R=%N].N2#.2CIBM1QP<-E2!\2W%)<^/)</>0,B#_D]7/E]YG;;-
M8QSCB-.%<\G=?+FLD_//F,3A5C&B7TU3K,Y_F%EVNXC):\FWM_BC!.*#V"$L
MLZ7(.=\JQ=*R(]H%!2_=K[M0=$AW0.9F09-C&0*L98F9-*8Z4IB<SD/+[N:Q
M88^U<1C@*X8D]0XJ--AYI96F9CC@K765+-=<R\.O,`S-6:YAOD-2,L<7;C8,
M`AB-''L]_G"3"BUDM,?*?O>1U%OH]*+0B0=/6\E'2:A43-H'SG2UP^+'+'BT
M<17&N8ZP#@IV0#4YIQ`IGGB"3D<Q3+F*<U';&'FM9PHG#_R_9SD3C_!2?)'F
M3A^!OE(L]TY$NZ5B&QT&JX;QS=LAYSR_8JSQ\<OL7V2PV2_,63&E5VNV(H/7
MX=+Y-J@J<AMR\L;JIJ/,TX`\NGD?N.MV&1X87:&GECF13/'+,D+*YPUY,,^7
MW':EYX:TR0QZYL$G=ZS/T]])A/MX>T8[NT]0[$>N6DD9"I7*DR\G7SOH*9(S
M:%E(ATW<"@B8YDB9,4AD;4BA\A]GVK&EC[-Y96JD_J51IHBW43$*JF94@*)`
M<O=3,`&*HGN'<3,40$#%.3<!`?`0'5K@7-(&!(51@:K\5?S%\"+<7>>G,#`!
MVOP;+&/(;*$'7T0(*91J#JSOINE+D(/H3=5&59*E]0E.`AX#KFY`&R$#X:X=
M7#U+I8G:XVN.9`4,#&*4!,80*4/2(^`!JQ7K@*2!0'9,G6'ZQA$H#^`-M]*J
M[2N4@N5<G4`;"`[&+[!]P^L!T5"*+?T5$T1-$31$T1;K=PX:*E7:.%VBY1`2
MK-5E&ZI1#Q`041,0X"`^_0@.%#B%4$C$8%7:KV>LM5D$DV-SDG39(2=+26[<
MHATD]!-W13+E*(>`])PUKI]HVVXQDA9J/$"A]2RXMPO(<&2.IR./M4BH/G):
M&<8=M.4Z.E9$H?L7C.06CVYS`&P"X;'1<G#;^8?6AF[G63Y0^*1[&<J`^@X+
M:1]X;EK"V1C7.X&I'JQ5A[MR+RO>%W/Q5F=PT<N<W1$P1S,&Z2([@")G"8@\
M6`"^`B)PW]@:W=ILNW6;0(XVEX_$[$]?):VXW*\N2=;R&'@,%9)999PJ9=PL
MLX7/XG6<*J++'_IJJF,<WXQUM``!08!8.>:V]$31%\WV\1\`T1<<[I`@["H`
MC_-`3;?C`!#15H5N$724`1*<!``W'U"`>T0'80#14H5Q3.D>H?M[_@`1#YP#
M8=%6A6D[A("AL<!W]GB/S>D-$H5Q#K`(>`_B\=45U/0N,(B/IT55\T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31%^\MKJER2LOR%P!0^4&(K/A3(X6)"O65S
M6YAE.4V84KMWIERHUGA[S0+_`$:P)(.QA;E1;I76,I'.#(KHE<-2E6251,HD
M>*5C7L(<:#FI(WN8\.;FHI$\M?&$[`9.)EW,.>,YY,S'D+C/?<A9PO\`+8ZC
M<@2+7B)DJ'RM@S'D)$4+'%1QM4\<5ZVQCA=VQCX-%S(JRS]=9R+E<BJ43;9@
MK4G&G+@01D`.'(9E2&Y>2"```#SXBAS).73R4H>3O'ND\L,-6["F1)"S0<':
M).H61G9*2_8QEMJ%TQY=Z_DF@7*M.9>,G84TM4[Q5F#])"08OH]SV!1<MUD3
MG(,CX@Z,1U(`IZO+RR4;'F-^L9_>HG+^6/C*RL\^K98SGR-S1<N2Z_%AUE7(
M-[G\9,)Q97B!DYSEC$[6H0M&Q94J93896R.CIR3)K&BBX;&.*?9<**.#QLM6
M-:1^8CD,L>`IZE*ZZD<6N-/=K3,YBAS->I2^K."J95,_YNY(QCJ>/?L^U##-
M*NS)V]9JUEI$8++D$M-5KT>G'HOV3YT&2I#X\Z[IR1;H1[9$N@_<DBA;%\-<
MN/G^]1OE=(`'4P)]=/N4-\Y>5KC//$SR35?9UY+X^QERUFZ;<N0V&<93^,HV
MAWO(='KU,J,-=%YVQXIM.1X07U9Q[#-9&(9SB$*_^"*<[4!46!2%]M$Y]'&E
M3@,*X4RPKPX'K"ECN9(VT:,`*<<L<Z&G$YK>S3Y76,<Y6W/,P^SAR6H^.N2>
M0<79DS?@S'%DQW&8RN.7<1I8\9UJ_.GTYC"R9"BRR45BF";R\0UFT(62&/(L
MHV!7<PT=:Q@@%U&DBF7"F6'ERXHVYE&(`+@#CCD34UQIFJMR-Y=F)LHWOE1/
MV;(67R8UYH0<0CR!P!%2U-9XVL60:U2JM0*EF>LV`])<9;H>2:G7Z-"G9'B[
M&A&!(Q;9VHT.J0>JORC*$5-".CA0<JY"AH1Z<4%T_`D`N!)KCQJ>=,S7'V*T
MF2?+6C)G%?(9_8KSFSF=R.RCCW%U*JU\S?EVFX8N=:A\%9";Y7Q'`XUO^'L*
M,JIB65J.3"&M8SXU.8>RMA;HJ27Q#<H))VOMFM:75K@.C++(8\,*>G!5;<.<
M\<!4Y"N>>9KUX_:K3<??+3R/=*WS.>\V;G>G4UR_M?$]ZXC"9MK^9LE5V!X@
MS#>YTU[8LIQ6$\1XY+(6V]@H9:&K]0:1,;#I%3354>N'#@ML-L34R8`\A3[!
M3IP5TUS[S2S$M!Q/2*'B3U8J7O(7@%3\_P"4<G94;9TY!X1DL\8/C>._(&$P
MM-XYC8O,&+Z\M>EZG'2<C>L:WRRTJ7K?^94TB1_6GL0NZ;/13<"H)"'+(ZT8
M1I'PTIP//F.DY45C+J2/*E:D\1G2N1&&'&J[NM\`\"5UED2)/^^D[!Y3X58D
MX#W*%F)U@5F^P/AR!R76Z\9JI%0L:]8W26B<KRA)%\17L',5`R#=`2&Z[_E8
MPW2"?(D_:5:ZXD>0XTJ#7V#[`KO\?,'R&!L,P>&9#-.6,U-*S%EK==O>4AH#
M*_1%0804?6ZU6D'^,J-C^$<$JL3&D!L_78JR:[@QUW+A8XATWQQ:&:*FGF^P
M#/BHY)#(_60`?/\`:2HC*^5IBRZ*Y/D.0^;>0_*63R1QIR%Q!+9,MR.)H.R5
M#!N57T)*W.'CK!AW$N,GUIN,I)U6,<)SUC-,/FQX\@H=ON.>_%\N/A+OPD#+
M+S`>7%3&Y?\`$T`>\'<3CYR5J;>5QB2Q&RZ[S_FKD=RDF\W<:83BA=9W+]JH
M,.Z98KJUP?WNJ.*2TQ#C?&K"FW:O6=\#Y*8;)F<JR")':W<<!UZI\FPU+B=1
MZN1&-`*Y]"J+N1H#6`!H/3S!XD\0K@LN"B4Q&4MCFKE1RBY&N<<YVP3GZBR>
M59?#[!:N6?CR_FI*EQ"+#&N'Z'$OHRP/)LY[(\<H*S$R9!`1>(]H`&ORK3\1
M.`IP^P*PW#L:-:*UKGQSS*D-C'`]+Q-D/D5DRL.[`O8>3N2ZOE7(:,N]9.HM
MC9:CB>C8;BT*LW;1S)Q'1*E4Q\Q562<*NU#/3K*%4*F8J1)FQ-:\O%:G[@/L
M"B<\N:UIR:*>LG[5#F?\KW&$];;.^_SXY)0V*+3RPJW-M[QT@K#C%GB<.1==
MR;5<O/K.YDG&*WN5)BL6>^5%N^=P#RQK1C=954S0C<00[$/RK"_436CJ\*^F
ME?73/`*<7<@9H&6FG'*E,JTRXT5R8?@E#DY$8_Y$9+Y!<@\X2V&K)DNY8'H^
M5'&(U*YB.:RW`SM5L1XFT4[$U0RM<H>-J%F>Q<.PL5@E63!HL4PIK+HHKIW-
MA`<"#[K2:##CGD/;7TJUTSBTMH!4"IQJ0,LS3T!57G/B%$YCS#CG/M;S5FSC
M_ES'V/KIAY2Y87?8[*]M^'L@6"LVRS8_G6F3,>9'C8TA[-4&+UG+Q*,?-,5B
M&!-R)#=):R6[9':N)SR/+G7D.76J1SOC&D9><4SY4YE5E@#C-1^-?&6D<5<:
MV+("5$Q[1)B@5FV2UB;.<G-6,RXFWBE@-:V<2P;#;V+V>57;/BLR]#A--0Q#
MF*8359`UD9C:30_<!]BH^9TDG:.I7R*B<MY5V(+F.6)3D#F?D)R3O65<153!
MPY2R!,8OHV0Z'0Z)D:-S!2GE+FL$XMQ2V4R+6LKP4;8&UFEV\K*IR$:W`AR(
M=Y%:,VH<*.)RH.KAE3#HYTQ4@NG@U:`,:\34G/.OJZ57\[P))D3&<_C[.7+;
MECG&96N.*\B8TRE:Y_#]3OV`LA85F'<]CN^8>2Q=AVCTZ.MK:5>&-+.I>*F"
M3J`?#/$SM3&1-3Y1FDC"IIP'#J`]G748)\W)J#N5<*GCUD^73BN+/<!7=D)C
MNWRG,?E@KR/Q58LARM(Y4)NL$)9*B*QE:#JT!?<2_N*GA`,$NL132%)BGI8A
M:K**M9ED212<E<]1C5-L'8D^]6N0^ZGJ^]4;<%N`:`VE*8]/&M>)XJL\,\#<
M'X)LO'*W4AYD!Q/\::ER,K=;DK/9FT^_R!,\KKA3\A9RR/E>17AT7]GR%<+S
M3R29G;92/:I+O'!"MNSV$T*_*L+`PDT%?70_9[5:;AY).&)'JR"M3$>6'BZC
MM</K87SCR,P3;L00^=*6AD7'%AQNK<+SBSD5F*1SOD7&-U_?3&%LK2D,UR3(
M?'04E'QS&<@S)@+=YU*+&4I\HP&K2:X\CGYO+F,:WFZ>[!X!&&&.%.6*E3@/
MCA2>-_&G'?%C&\Y>$J%B_&IL7U2RRDZU6R,VA_AG[="<5LS"+CFG[VLSR!ET
M7J;-,"."$4[8B`[RMA:R/LVDT^X`?8HGRNDD[1U*U_2H@/\`RJ\2WMEFL_(+
M-_(;DE;LU\??^%]]DC(TAB*JWJG8A2M[#(3-M6Y##>(\:1LQ=FE^AH^7+/V!
MI,O_`(F/1(42(&726B-HUP]XDT%!EAGR`Y_I4PNY&_``*FIS-3GC4E<V1\K[
M&]T@N3;+,_(+DQG2U\ML#8_XZ9;R'?[!BR.L"./,9V6Z6BK)T2&H>)ZA2Z=(
M)R%[??$=N-70<G-WCIBX4654I\FPUU$X\J#@1RZ3P""[D;\(:!YSQ!XGH"ZW
MGQQJSIDG(^*LQ\7:Q8FV78+'&1</6;(E,Y;1W%Z4'&]LE:W86-`N;6:X[<@6
MUZH#JSQ9I([N))"6J`<HB:+=;O%>W;<Q5<'-'O'/,\N@TZ^'#BEO*&-+7GW.
M7D1Z.*UX/\KC#=+P1QXQ1F-Z_P`J2.)/+YM_E]7EFV=J16/L@8WRT;'LKEEY
M]W*-`M35^]G<?H$B7A9!!=JT4,91,SD2J)71VH#/>)U$4/H`^SV]:273WN]V
M@`=4<\R1[5VLEY;2-EQ]%4.^\TN9.1EL>VO#MYX_W*XS^#7=FX^W+!,N[E,?
M6VJHQN#8NO9!M/8>J,)9_=65C6EV&Q%>E4!6&ORK=-":TRP'W<>-:^=4%TX.
MU-`'//'U\.%*47<USRUL31CJ>G+9EG/N5+K;N6V`^:ENON0K-1E[%8,S\<ZU
M5:I1&ZB%8QW6*]%4%>)I[--S#L6+<J2913:*MDP*4H6<8XG.O`<NCH"JZ\E<
M"TTH13B>?,])4J<Y8ELN7Z["Q-2SUF#CS.0-A">0M^'O\N'KV90/%R$2[J]P
MK.6,?Y+H]LJ3U*1[QFCF-[B;M!%9-4ADQ`TTD>NA!H0:\/M!]B@C?HK@""*$
M8_80HXX=\N/CWA1QA1W775^FG6%*EROJ[56Q3$#VK\ZYJW*L9`Y`6F\,*]6*
M_&(3=@M57(NP;P2,+$Q23E5%!F"0)%2C%LR@!)-"3Z2#[1[?-)\S)4D4!-/4
M"/85;RK>5Y5Z3C3!%+J?*?E7"6?B<ZDX?BIFAI)86-DC!V*9FGPM&DL`I%4P
MR>C92Q/)5NLQY7+>XP\Y*K.HYJZ!Z1=LD<MAMF$!A.(RRRP'+JS!5PN7AQ>`
M!JSSQ.=<\#U45X(_`.>(;,?%8/\`B*RU=<*X0J^?+7EN>OEUC`R/R'S'D)>%
MA,80.18:CU>F5!]C3&\+,V*5:LF[%HP:/D(E%)L;X<RFJMA<V1H::,%>KT"@
MKB1Y@:*CI@]KBX`R$CS><U/`>M3:UEK&31$T1?F^?Q<G`7)V,^71_,#@*LU-
M@3D!"XJQ]9;6SDHXSR-S[7:A/P[F)E(`BWWNW:S-"H#-XC(&2^%6<`HCW.Z'
M2.CO8G,DU_A/Z:>H+=V$K'1]E^(5]&'VE>.X3G-^D8P[^G<PCO\`..L%;)<I
MLP<NR'.B0HD3$`.8QR$*`B&_I.8OJT1?$7'PW67H*<1-XF`WA]GP\!`!W#WZ
M*A%5NFD#B'V4R@/M$1-]&Q=5JJ:5H!\OO_('W=/U#I5-(6O[P4_ZLGSCI5-(
M3[P4_P"K)\XZ532%\&05]1$P_$8?_N@U2JKI"T_'K^Q/^J;^UHE`GQZ_L3_J
MF_M:)0)\>O[$_P"J;^UHE`@OU_8F'X"C_I,.E4H$!^L`@(@00]8;;;_C`?#2
MJ:0N<#UO^N(?\DW^@-55M"OOQC?_`*SU?JG^;Q+Z=$H5U*RYUC")A$"[_9)Z
M@#_2/OU17`46SHJIHB:(FB+GM8J3?"!64<_>&$@J`5JS<.!%,!`!.`))G$2`
M(@&_H\=31VUQ+A%&]QIP:3[`L>:\M+<5GEC8*T]YS1CRQ(Q54L<99)DQ2"-Q
M[>)`5T^Z@#&ISSL5D@+UBHD"#!05$^GQZ@W#;6QA[O[]<$"WLKMY<*C3#(ZH
MYBC34+47'>SNM:`FZW+;X@TT.NXA;0\C5XH>@JI6O'_/+XG=983RX[2ZQ3[K
M;&]Q73[@;;D%1*&,0#`!@W#?<-]9\?<KOE*W5%M&YN;7,6LY'JC6JE\2?#NW
M=HGW_96/I6CKZV!ISH91@JR4X?\`*1.,:2W^0&6E&SUTZ:(I(42R+OBF:MF#
MLRZ[!&..[;,UDY$@(K'(5-8Y%"$$3)*`7/;X;^(3FAXV/=M)_P#I)_\`(6K=
MXQ>$S'%CN\VPZ@:'_3K;/_M%S@X5\MS`!@XY9AV,`&#_`/(6=#P,&X>`M`$/
M`=9H\)O$PBHV+=*?_J\G^2M:?'GP7!H>]&R5'_U</^4OO_!5RW_^7',/_N-.
M_P#TII_[3>)O_D.Z?[/)]R?^_/@O_P"J-D_VN+_*3_@JY;__`"XYA_\`<:=_
M^E-/_:;Q-_\`(=T_V>3[D_\`?GP7_P#5&R?[7%_E)_P5<M__`)<<P_\`N-._
M_2FG_M-XF_\`D.Z?[/)]R?\`OSX+_P#JC9/]KB_REU3KB+RF9KG;N..V9RJD
MZ1,!,<6M8H=90.791&+43-]D?4([:QI/#+Q%B>8W['NVH?\`TLQ]880LR'QJ
M\(9XQ+'WGV(L/.]MQZC(#ZE33SCIR!CQ<?&X,S"U!J)@<F7QI<TTT!(.QNXH
M:%!,@%'UB.VL"7N+WV@U=ML^Z-TYUM9Z#K/9T6U@\3_#6YT_+]X=D>7_``@7
MUJ2:\AVM2J4?XOR7%=?WICR\QO;2[ZGQ]2GV?0AX_MC_`!$>GTI?9'[0^'AK
M6S]WM_MJ_,V-Y'05.J&1N'/%HPZ5N;;O;W5O*?*;GM\M30:+B%U3R&EYQZ,U
M23J/?L3"1ZQ>,SEZ>HCILLW,7K#J)N58A!#J+XA[0UK)()H325CFGI!'M6YA
MN;:X&JWD8]IXM<'99Y$KAZB4Z:(FB)HB:(OWEM=4N26-SS?+#/U3RW.45AJT
MY,5J?C83&AXZ<@)-[#3#`[C..+V;@S*3CEVSUJ9=FY42.*9RB9-0Q1W*80'$
MO"1&*&GO?85E6@!EQ%</N5ELX>8CR$I3CF%GRC8PPE)</>"N?6&"\T15IF+Z
MVY&Y'5B&F+Y',=[Q:YBNG'-488[1RRT+#P\JTD7%H-&N?]ZC@7;".,+J0`$'
MW0`#EF17K]&=."G^49J,9/[W$CEG0>6%*\5RJKY@>;97FM>..EV@L)8A90>3
M<MTC&F",GU'D'3^1'(FG8\JLS.4_)>!LUSL9'<8,BN\K?=J<@SK<<9RYBX8Z
MPNW@.FRR1;Q<R=IC@W'E3TFA-,SR&9&2M^6C[+4TU=AZ^@5ZL\>`R*J#R[>=
MN5^6-NLU9S([X_X_O41C2*O=DXO15%Y)8JY0X(FI*=:1;JM9%@L^Q$+%93JE
M?575C7=OK+5G%*S*294$U&[E)0)+>:1[R'G"F1`'Z?/@%9<0LB8',QJ<\_T"
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M<7===)GO;<DFM`*CE@">>5!CTUIFENQCK:@`U$T//$@9T../5YU4#7S9N2&,
M,:YHROR`XSH6*HU+C*PSK3)W%V&.8&(*I`Y4G<A8_P`<UKC'?K7R+Q;%I7F:
ML,EE&.?,;15&@E>Q\9*')"E,FU*M>)YF@EX.6%13T88_RFF%#8;>%S@UCL2>
M8/GSPI3IX8\K:<G.8W*V]\2>7E,RI0GE*D,?K\(;A1>0^)L.<M>.5&FU[US(
MQA4,@8=&.Y.U>IW=6]4EO'IJ.'T8Z783,'-D%1LR4*LV&R26?11^KXAC2G/J
MY>L99*L<,6L.:1D[`D&N&%*=?J*E+DOG!E/%%WYG,L:TN%NMRB/-'X?\-:9$
MY<R=?5<>MDN1^'..*BL^P1CV<RZQI`P+[(AW"D9"M%FKEVFN\.B=R[5'563O
M#6M;740./0SG7FKWV["YSC@T:LATOZORK96\P;E%`RM_XV3N.>/DYS$B^<F*
M>%]`M$`]R5!\:I5','&<O+5AE>UP,J_F,F1R5%Q7%3#1Y!-I1168FFC8C=XU
M1='.A<ZXG8PAWQ5I7##"N667LSQPB%O$YP<TGLZ5X\]/7G3AYL,9C<*.0.8,
MX%Y15/.D#C&'R'QBY13_`!SDI+$`6]"E7)M#XGQ#DQM;F49>'\I/PCA^7)XH
MJ,SN7)$/AP`JRP?M3Y%M(Z5A<XU->CD#PZU#<QMC<`S(MKZR/LZ%$FV>:39<
M>YL>89N.)ZX1U0.;5IPMG:?83\@W98MXDNV>"V^)N33]-\<Y@7M%HY3T1D_1
M.(L4T@F%TMB,A$F,ZZE:2*8UR-.61ZL/7BIVVL;F!VK`MY$TZ?4<.KFK$PW(
MSF-R4Y,>6YDC#45B''%RS[P@Y_Y#;TW+$OE*0Q#'8^;9_P",3?#]VG*A3GL?
M.76^2..GL8L"1GL6DP-.OCHN`33*V<6.FD-'@N!`/++W2,,N/M5[88FAS'D:
M:MYX&C@>=,17CPK@M^/\WG-.5Z=QCA\/8DHU4S'E?C'<.2&6'%KQCRHY%8ZJ
M)Z;F&>X_MJ#3J_Q@I4UD$4;QDNGRZZ-AG3L64-$((`9O(/'`(%N%U+)1K*AP
MSPKRZ.G^7(6NM&1^\XU:<L0.)YGD/Y%?ZE<[N8F9LQX,Q/CSC%C'$[^W<)\0
M<R,^Q7)RUY3J%ZPJA:,Q6C&N1,80M-KU$=2]LM;)E4W2D,,FC`D(J!5'VQ5"
MMPN^8F=(&4(.'WG@>'5EAR5I@B9&7DAPJ<O0*X\Z<\^2HOAMYFO(+E-DSC[.
M?\/F_&GE&C?9&L259PIRNAKAQ]JD76[!;,57C,V:K]0(KC?D>$R<QKY(YV6J
MNVR<--RK-!LXED057U=%-,]X)!+#T4'L\N9S5)H(HVFCAK'2.KRZN&2NWS"R
M1S&K_F$>7IB_CC;<315#R?CGF!+9`J.4CY"&"MLACAAAQ]\;.-:2HF+I6L05
MC,>NFW`49)T[%?=(R0!2Y=*)VAIH.BG,<_7PIYTMVQ.A>7C$=?(\E$3CCREY
M68:?6VQR\=B>^\9<@^=QR(X@N2V.R9)D>0L,&9N65JQO3;+6Y%<Y,>P5.QM9
MG;%F2NG;OA=0Y%%47;$Y2-1B[=\4KCB14X<*5(ZQCY<%*8(Y8Q3"32/[(/5^
MDJZ^"_,_SYG?,^-WU.X__O!QDRCR0R+@-LWK^$>61\IXYIE(M-_QZRY*7C.4
MEC]OQ4E*0^O%`$LI7XY\#F%CY1`PR;IXW=-22B>8OU-!+*G"G+IIT?I.2B=!
M&UI:2!(`#F..-*5KQ_1Q4W>8?(;,^';OQ`Q3@BJXJG[URPS;><0I3.8I&X,J
M?16=0P)DW-"UK5:4<AIN?<(!C[LA'%.V*][O:^*:=7Q*4T\DC7!C,SU<G<^K
MH44$;'ASI#1H'V@?;T]2@"^\U3.J-<QEB@<9XT8<J;1R;YG\=+M:(+'O)'->
M"Z]&<(96*9WS*E:Q-A>%LF?;$WO:-QKZ<=#JNFJ,2J]=*O94R35,'.,+J5P#
M&UU\Z5.9X>77ACD?*QT,E?W=.K,"F)\_W8X5M#^8#S=R`IPXQG0N+>)J9G_D
ME`<TG%RC^1LOG;$%!J9.)%OQY7(O)]4@Y#&YLQ2>.LRPUW2EX:,E(5C+%;O6
MY5G*8-UU%9'33!K6XAYJ,J<0!F./4,U8(8:O<35C:9=()(SX4YE7-A?,$R8Z
MO4%QUE\:41IRE1YXV+C3>ZDQE;&XJ$+QSJ6-_P#B0EN3\0"QD["YBI/C?(Q0
MQZ*QBMU+A)$8F'H*)`I\S)713W]7$@'G3+###K*?+L/O@GL]-<CU>VIZ@K1\
M./,VY"<I<E\?)T./A3<:N4)KZZK;^L85Y7Q-RX_5.*KMDM&++_F/-E\Q_$\;
M<C0&3&U;)'/$ZN[;%A9F79H-G$LD"RP5BGF<\$@F,]&'.N7ETYI-!%&T@.':
M#I&//#R\V2EES/YK3?$.[XZCWU(AK)2,GX5Y,2U4DE7\BSGI/DCB.'H]BQ'A
MIL1(#QZC+,L=/2;=$X%%X1['%!/[)C:DGF?&_2VF7W=&>=/6HX86R-).%"/1
MCT]55%*$\U"XVC&V4K:_AL+X0D<-<<^/;S)C_)R65K[$TWG!ES.63<,6_C*V
MIF*&K[(N0E:M)XH>HQ,="-E)^:D)2-(7I26,;4)N9","*T%>=<0>O&GIP%:*
M86S:XU(+C3E2E14\*BOHY55MH#S6^4K[%/)0KCC@WDLL<=<^\=\:V:ZI<>^6
MU3I]:PQR#I*MV'D3=N*,O!S/*TL'C4D>NQ?1<8HZ^\OB&SY)VW9@Z%&TW4@J
MP5+@3C3E3"E/+UB_Y./!Q.EI&1(XUQKE3+T^G*WPIS@\Y*8(JV3Y+(6",GNI
MFRVN"6N/'$+XSQTZ"OV%>&^!7K64"C?J+>(@410FX*4.LXC'Q#)]PQ1#63%*
MXPE[B"0">'3G3J]JQ9H@R70VM,%BX3\T?EFRX].>2UBP#@%E1,C<EK)PVXW0
M=;M&=\@9$L69&7*F\8%C,@Y1I%(QM.R<?C!E4<?RLLO"5D9VT24@R30;`@1\
M4&L'S$PZC4#S.IR^\'KRR/EX2:`X@`GJTUIG3V455)>8WR[8T.'BY+CY1%,L
M63G9@7B)C_(=SQ[R>X[8$RS3L\TF6M*.5:S3\RU-KFF!D,;S$2ZAYF-$LLT6
M>,MV[SH=$,A1US,P4=6O.E,J<QT^K-&6T+S75A3*H)&>=#T>O)=8T\PSF]6$
M[[9,EXSXENZ+QM\P+$G`K/2E%E<R-K?DF1S3=L)UF#RMAV.L#IW"XVCJC'<A
M:^N[AIQW9EI1=G($3>,B`V,J9/.:$_#6ARXT^\9>E4=;PBH:3J+21GP!].71
MF,"KAF\POD*FO_Q#JXRPI_P/!SL-P5-'DF+]_P`4)79>1QN(G^?'Q([XT&"'
M.Y=_W1^`^\0K/^^_>?Q7^YZN^8E[2HIIK2F%*UIRKGT98]"H+>*FDN/:::Y<
M*:NK+ISPZ5W-=\RBY.YBA8KLF,JO'9WKG(?ES0.5U6BGEB?0F*L$<.ZK)9!M
M>:*BFJ<DQ)'RA2KCC8]81?F*V5=W<A5#F(W-M07;C0#.N=,.CTX<!@0JFTH2
M?PTP'&N%>/#WN.-"HY8H\X'.;ZB!R-RUQL7=\:K%Q)S1RT1<XTPURNJ,]@R)
MQOC5',%"H64\OYKQS7<(Y8>9CIYSQ[*:J:K)BUL*94T47[%5-X)MQ,*O()92
MN5`..=,</NZ4=;15T!U'ZJ9@UX95PQ]7H5V\!7?F'/\`F<X;)RC=X<@T;KY8
M.6\E0&.,"2>35ZA6W<CR-XZF&/N1[W*.H^YW.IM)H6*%A8M8\CM%9R!6;5,Q
M2G6SWOG.LGX3RZ.23MB;;CL_S#'C^+GY98E9I];%8":(FB)HB\MG\7!1<FSO
MEFUV\4BTV&/I-%SK3XW-E,8N#&K=NH]Z34BZW+V*,.11LN\I>2HR'/'NA`JS
M0T@MVSE[AM];N(=I!!P\J_9Z%LMM+>U+2,:8>755?F`KI&0651/^DD<Q!_Y(
MB&_X]:=;M:-_L[=0^G]'QV]'I]FB+3HB:(FB)HB:(FB)HBWV[5R\5*W:-UW2
MYQV(BW2475.(B`;%32*8YAW'U!J^..25VB)I<\\`"3Z`HY9HH&&29S61C,N(
M`])P5VZWQXSW<3)!5L+94GBK;=M:,H-H=-C=1ND!^+3BQ;%`1]8G`-=-8=Q^
M^>Z$#;MIW*8'(LMIB/2&4]:XO=?$SPYV,$[OOVSVQ;F)+RW:[^J9-7J5_(#R
MX.:MB%(6^!['&)*B'[>R2M7K)$P$!$#*)3DXQ=%#P]28B`Z[2R\!_%F^IHV:
M>-IXROBB](DD:?4O.-R^J/P&VRHE[Q6LKQP@CGGKU&*)[?6KY07D^<N)7MFE
M%,5U8AQ+W`E[R9\LD41+U"*=:AYTAS%`1\`/X]/I]&_7V?TN^)MS0W)VZV!_
M/<:B/-$R3VKS_<?K<\%K.HLQO%VX9=G::`?//)$1Z.*O7!>27D=P4AK-G>@Q
M(CT]Q.#K-EL!B^!>H"F?'K1#"41,`>(`.P>C?PZVS^DG?G@'<-YLHO\`HXI9
M?[79+@MP^OCNM&2-J[N[E-R,L\$/]@3GEY#&\D#Y)5`1`@VC/MPD3!T]PD!2
M(:&*;]#J!-:1GIP2[[&`!%,=MP';P$!ZJR^DG9&4_P`1WJZDY]G;QL];Y).G
MAR7#;C]?'>20D;1W<L8AP,UU++SS#(8NCCSYU%WH3R<>*T;TC+6/,5C,`?:!
MQ9JW%HG'I(`_LXVHE5*7J*([=P1`#;;CL`ZZ>T^EGPX@_P!9GW2<],L3!^S#
M7U\5Q6X?7%XP75196NQVHZ()Y",^+[FAX#X>%:*[$1Y6O":),0ZF+YJ:.0Q3
M`:<R#<UBF$IQ.!3I1LK%(&((#TB'3XE#Q\=Q'I;;Z=?"2VH3MTLI']Y<SGU-
M>P=&62XR]^KSQ\O`6MW>"W:1_FK.U'"F!?'(>G//T*Z,1P+X;PH)@TX[X_7%
M,$^DTNG-SQA[1C&**GWW,ORJ"(F^UU`('#8#;@`:Z&U\&?"NTIV6QV3J?G$D
MF7/M'NK]O%<E>_47XY7Y)G[S[DVM?X9BASY=E$RG13+A17&BN,?&V#Z/NGC_
M`(99"0I"D.3&M154`$S]Q/\`:N8I=4QB*>("(B;?UZWMMX>]PK/_`%;9=J81
M_P#2PDX8C$L)S7+WGBSXI[A7YWO)OL@))QOKD#$4.#9`,1PI17$CZ!0(CI^Z
M:#18OH,<Y!C:;6F`D.J'2H<HM8Q(2F4+X&$/$P>`ZWT&R[+:_P"K65G'0_@@
MB;GGDP+F+GO+WDO:_.;EN$U0`==S._`9#WI#EPY*IVZ#=H!2M&S9H4A>@A6K
M9!L4A/3T%*BF0"DW]0>&M@QD<8I&UK0!P`'L"U$DDLQ+IGO>2:G4XNJ>>).*
MYH.G(!L#A<`#P``54``#V``&V`-2B1XR<?2H>RB.):VO4%I%PN/B*RPC[14.
M/_W6J%[SF3Z4$<8R:WT!:.L_B/6;<?2/4/C^'QU2IYJ[2WD%IW'VC\^J*M`F
MX^T?GT2@3<?:/SZ)0)N/M'Y]$H%]ZS!Z#&#\8_7JM2J:6\@M8+K!MLLJ&WHV
M4.&WX-A\-5#WC(GTJACC.;1Z%J%TY$!`7"X@/I`55!`?P@)MAU7M)#FX^DJ@
MBB&(:VO4%P'+-D]`0>L6+T!$IA!XS;.P$Q0V*80<)*`)B@.P#Z0#4$D44O\`
M%8Q_\YH=[05D13SVYK;R21G]5SF^PA4'+X?Q#/@(3N)L83`"!0'[SQ]47HB!
M>OI#J<0YS?9[AMO'PZA]NM/==U^[%Z*7FV[?+_/MH7>UAYE=%9]]N^NW8[?O
M.[0?]'>7+.7Y91R'H5IIGA5Q&GP-]X\=,4@8^W4I%UM.OJ>'1ML>O+19@\$P
M#P]6_M-OS-WX3>&5[_'V+;:G\D0C/IB+.7E4KL['QY\:=N_U7O1O%!PDG,PX
M\)A)S\J"EEI_RM^%$[W#)8PF*ZJH`AW:W?;<W[8B4"@9-O+24RS*)>G?84Q#
M<1\-<G>_3MX2WE2W;Y8''C%<S"G4'O>WU+O-N^KOQZV^@?NT%TP<)[.V=7K,
M;(G?M*PEE\F#CQ)"JI6,D99JYS`;M)/5:M9V:0B.Y?V9H:"=G*7T;"ON(>O7
M&7_TI=QYZG;[_<[=W`.,,K1YM$;OVEZ+M7UV>)MJ`W=MKV6[:,RP7$#CY^UE
M:/ZGF5JO_!%@?_F-EO\`M6__`.C!I_V+]3_VY_[5_._0_FZYO_A&L_\`SV3X
MO_E!\/+^/GTY="[+_C\W'_TO#\'_`,^[XN?^J?#T9]*_60U\HK[Y5J<XX3QS
MR,Q3<,*9;AW5@QS?&\2UL\.QEY*!=/48.Q0]JC2HR\0X:R+(49N";*B*2A1.
M4@D-N4Q@&.2-LK=+N:O8]T;M3<U'+(WEV<8<J9:L67+9$Y(!2^W*C9(RSBB`
MR]D"N<?,V9&QD$$6A7O,.$8F9;T:]6.O%JL2!CN&Y4),L2R"12>`V2Z83:LU
M`C!HX8_?T#@<NI3"ZE#2TFI/'T_>?2>:[%?@3@Z3RXEF"TV7D)?)"+NETR53
M<?7[D=ERV8=QIDC($)::Y8[YC/'$G9%(JFV-*$N\PWBC-SBWKY9%8T6DS/T&
M)46[>U[4GRZZ_9APHJ?,/[+LAEYO+KYKM<#<*\-8#O\`(Y0@+3G#*62_W$#$
M\5=.06>\AYXLU#Q>K,1UG<8[I[V^34FM7(.7FHEB\?',"DE)'9-3.7*Q44@!
M%;MC<79N\_WFJI+.^5H:[X1Y>0X+J.0?`#CMR8N<I?,@DRQ7YVWT!CB3+">(
M\TY'Q##YWQ'&/I=_&XPSA#T2<B6F0ZC'J6*210*N";U)E)NVA7(-7*J)DENV
M1VK+GY5',\\^DI'</C:6C+AT9?</0%?*C8"Q/C7(^0,K46JI5NWY-I6(,=6H
M8YX[2@!IF!V%KB\604'605^Y:ZTK,==9!$/@T4A734("G4"2?3(R)L9);Q_2
M?M5CY7R`!YK3]`^P+B6/C?ANV9*NN6+=26UDMF2L`EXQWA&><O9"KVG!IK)9
MK6O2Y.IN5303AM(2UPD0<..UWUV[@43'%,I0"UT,<CB\YY>7#CE1&RO:W2#A
M6OL^Y1]I?EQ\;ZE1[QBN8D<_9=Q#><5O\'K8?SSR0S%F#&=3Q+(*QJAJ91*O
M;K2Z1K81X0S)-A*@=:>C46B*;5\B0FVK&6K&U!Q:>O[SCTJ1UR]Q:<`YO5]V
M70N1'>7A@H^.K[BNZW#DYFNGY!3QLA+M,Z<G<PY7>0T3B"]162:'%5)W9+$L
M-9:Q=NA&KAXY0)]XRR:!$G[IRF4I2T%LQK2''-P/$8^G$E'7$A<'"@(%,A]V
M`]BN+/\`"_CW9)ZZ6J9ITJO+Y%Y-8@Y?6EV2UV-LC(Y\P)"T2NXSM39!)^5N
MRC(**QO#IKQ2(%8/#-S&73.95037"WB#O=S!'/#+I_5"&XF(Q.!KP&.=?[1]
M*L?RLX,5')M.S%,8LJ5$_P`Z\RYNPEG.:L^3,JYPQHSCLDX8J<)C2FW;'61,
M)2S3(^'\A05"@V[".>013(.#G7(\;N$W:Y#V3P5.MHJ:]->`Y]'EBKH9W-]Q
MQ_=TY`\^C',Y_<JB\OGA_-\.\7Y1A;E:HRVY%SGGR[\A,A.8&<R1:J]#6"V0
M%-J#*M0URS%8;3E2\EBZW0V)GDY///CY636<K]ELB9)NE);QNC:=69-?(U-?
M+S63R"1PT_"!3R%`J[OW!CBWD^Q\G;;>,8MYJP\QL*UKCWR$DQFIMHO<L5U&
M-L43`0K'X1\D6K2;)G9EMY*-!L_44;,SF5$S-N)#K:)Q<2,3U]/3TE4;/*T`
M--`W]'W*XE=XV8?J]YPGD>NU5Q'6GCEA.Q\?,2+MI>6&-JV([2IC4\U75H@S
MDT?*J*&Q-`@F\=$4<H`U,!#AWE>IV$0H#E0CCC6G3T*G:2&O6"<.7'UJ.COR
MT>+J%8P_7Z&7,V%9;!$'?:EC3).#LZ9&QCE>,HV4+BO?[]C^<O4%+@_N5'L-
MR7"1^[I<CU%D\226:?#JD`^K'6D9;04!\_W]`XJ47<H=4FOHZ>CI*D#CSC/B
M7%]_ALI5=A:G.08/`]5XV-[7;K]<;W-O\44RWS%\A6%ADKA,3+^RV8]KGW;M
MW-/U7$F],L(++'*``$@@8':_Q4YGE3GR41E>YNC#237(!6LPUP)P=@*\,;?B
MB>S_`%NK5V5ML]4,#AR&RQ(<9J!+WL9<;*ZI^#7EA5ID0P<N;"]691ITUHB(
M<NC*Q[5JH!#$M9`R*34#GP\C0]5,%<^=[V:'4Z\/N]?%5]GKBGC'D;/XCN%N
MD<GU._8*G[#8<99!P[DNU8LN\"E;XMG#WJMKSE6=('EJ9=X>,;(RL<Z(JBN5
MLD<HIJ)E.%9H62$.-`01Y9CR\RI%*Z.H;D1BNI#AOQU&M?N.G57Q81ORQ+SB
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MUI:,B/M!^Q1PMWE[<8+='NFC6.R!1;:VY`9.Y1P>3L5Y=N]`S%0<TYN3<(Y0
ML=-O=>ET9JOP5^C7"C1_`J%6@GC,03.T.":8D@-K&00,'>?[^D_:IFW4K:"O
MNCJZ/N"N11^).'Z)8\+W5!7)=QOF!*[F>LT&^Y0RS?<F715AR"DZQ,977MMA
MN$U)OK<^GW]-CA;&=B9.*1;@@Q3;H?LPD$+0&@XZ>OF#SZ%&9GG5P#L\!PK]
MZ[UGQAP<PY/27,AI1T$N1<OB!A@I_?@D9(P+8WC;%^\[:."`,Y&!3F3/R)HJ
MRA6X2"S!!)H=46Z94PKV$?:=I3&GEY<U0RO,?9D^Y6JM5AW@7@S`E[87#%4_
MGVL5F!F;?8JA@4G(?*SSC-1IR]C,J6AY3\%N[$K3(IDZ=6)\X:1ATUHB)=.C
MK,&C50"&)9';MCDU@X>?[Z>:BO?.^1FAU.O#RX9YE7ES1QVP[R$5Q$MEZH(V
MU3!.9Z?R!Q?W7\@P+7LJT-M+M:Q/JDCW#<LJT9)3BXJ,7/=9N#=!E4S"F3:2
M2-LE-7`U4;)'1UT\13S*S%A\O7BM9:UR"K1:#-5X>2V=J_RBR=9J5=K95;PT
MY`TX]1=U++="M\/)(3&.[/59>DL)%F:,.@V)(?$+'2.+MP"D1MH@TC`5.'JP
MSZ!Y54K;B:H-20!ZL?O*IJ,\MW`==C,C%@+MRKKUYRY;L;9"R!FN+Y79M;YQ
MLEQQ54)>BTV9=9%5M"S\8Y*I3KEFYA^T,`Z1,F!F(=E'HM^586D`XY<>C"E>
MC+@KOFI=0)I2M<A[:9]*DG@#`F-^,]$_R^Q8SGTXQW;K5D.R3]RM4]?;W>\B
MWJ84L%TR!?;M:7LC/6JW6B75[KITX5V`I2))$31333+-'`R-A9P(H?+SE122
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M&PIL'`,SE43,#A8#2=@P"@RJ#QX4Z>@*/MI*@UQ`(\QK]Y5!CY=G&(V:39L&
M*R4+@V9#<CQP^.8,@CQM#D:<XN#9Y#`@S0T#_,P90PR?Q/P_P?WV/WI\-]X_
M[UJ/Y5G::Z^VOIK^GC6N*D-U*8^SX>;V4\AADKR0/%W!-9Y#93Y50]!8H9TS
M5CVIXLR7<%W3UZC9*13.DD3%*0#M9:#:*NVS=HA(N$D"K2;:-9).3*$:H@63
ML(]9>1B>O[_Y/12,RO+!&3[@5C<:>7#QJQ6UE:Q7W&<YG#[ZD7K&L5QMO/(;
M+=VXU4W'^2HQU"7"FT[#,]9G-9C*XZ@WR[%BT7!TC",EC(1A6:8@4+&VK&DX
M^Z13B/3C0]5*<,L%(ZZD<!EJ'&@^[#KYXYKN^/W`/`7&W(,7E6E2><;?D*`Q
M$]P%6[/FG/N4<R.:SA5U8ZY:FN-ZZSO4_)QD/`PTM4V`M5$4"O1(D(+KKF.)
MM716[8G:AGCS^\JV6=\HTNRPY<!3DIJZR%`FB)HB:(H@>8#QI:<QN$?*;C(X
M027>Y?PM<Z[5Q5*4X-;ZRCS6#';\H'`0*HPO4-'J@/I#I\-8]RSM(2T>77U9
M^9302=E*U_`%?B?SK!_&2\@QE&BS"1:.W#5^R<$%-9F_:JG;OV:R9@`Q%F;Q
M(Z1RCXE,00'7.KIUU&B+Z`"80*4!,8P@!2@`B(B([```'B(B.F>`S5"0!4Y*
M[=/P#G+(!T2TG#^2[05<0[3B%I-B?,QW]`F?(QYF:9?>90`UTVU]R^]^]D#:
M-KO[@'(QP2N;_6#=(\Y7&;WXD>'W=L.._P"][59EN;9;J%COZA?J/F"E'4_+
M!YIVLR9CXE"JMU-O]YN5JJL#T`/K48J2Z\N3;V?#;^[7HFV_3UXL;D17;/EF
M'C/-#'Z6EY?^RO(MY^K7P'V<$-WKYR4?AMK>XFKU/$8C/]=29J?DL9QD03/<
M\K8MJA#``J(Q)+-;7B?\WH")@F)SA[G'3[]>@;;])W>^>AW7<MNMAQ#.UF</
MV(V_M+RC>?KQ\/[:K=BV?=[QPR,G86S3Y^TF>/.RO0I)U7R3\8M2)&NV<KU.
M*AL*R56J\#643;#X@FO+/;4J`"'K%/?7?;=])7=Z,`[MO%Y,[B(88XAZ7NF/
MJ7E>\?7MWLF<1L'=_;[=G`W%Q-.?.(VVX]:D=6/*?X95X$C2-3NMS63$!%2S
MWR5234,'K.VJR5:2$HCZO$-=WM_TV>%5B`9[:[NGCC+</`/FA$07EV[?63XZ
M[D2+:\L+%AX06D9(ZG7!G/G4BJUPOXF5+MC"<><6`JCTBFXF*VE:'("3;I-\
M1:5)E7JW+OOOXCKNK#PI\--LI\IL>W:AD7Q"4^F8O*\QW7QV\9MZJ+_O-N^@
MYB*<V[?1;B(*_D)5:K64RI5JK5BN)%`"E3K]>AH4A0`=P`"QC)J```^/X==I
M:;;MNWM#-OMK>!HX1Q,C_L-"\XO]XWC=GE^ZWEW=//&::67_`.(]RJ(ZRR@;
M'55.'L.H8P?,(CK.+WG,D^=:P1L::M:`>I;6K5>FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+W=:_(Q?T"J+_,W-B/'SC?D
M#)9+LM0)]->GTVASS+$LGGB9=9)R-=("C4&KUG#<18Z@]R+:[C99U"+C8X96
M/0%XZ(JNN1!)0=07#]$9(-#Y<B#G130,[24-I4+#BS\Q_G54<5\R:K=JQ`P^
M>./F>/+FHN-K+GG"%<QU(RU(YT9;J>/)%QE3#F%N0N5JRFYJ:;B24CW$5:F+
MMR@HC\2S;+HCW<%EQ+I+>.'&N;@,Z]//S9US'VT0>#B`:X99`GB,.'Z5=JZ<
MV>8V'+YR#XG6&YX7R5G2,Y1\"\`82Y!JX<E:'1*O%\ZHBSRCF?R3AZ,R3.%L
MKS$(8^F"1"#:?8%GW+V-;.E$S=Y12@NI`TM/&IX\P.?7Q'"E%=\K$\"1M=-!
MAYJ^6!XE7L\N&$R36^3/FT0.7,A1.4[_`!?*GCPA-WN#H*6+XZ>(IP:P`O&J
MA1&]EMS2!>-HQ5%%SV7QT7*Z9ER)H@IVB3VU>U-34T.(-1DSCQ4%S30W2*#'
M`Y_$[APZE9'DIS4YI8]D_,SRY0;O@B)POY;.2<,M4,06/#4W.7+/E5MF"L(Y
M9O\`493+),G1:-*L#P^27;6LN(Z"<K_>1FR;DJR/[,\<T[V2D`X`\SR!RK]E
M.M7PV\;XP2'5<,^`]X@=67G7.R'SGY80D9R/Y;5Z=Q$SXS\7N=41PYE^+<KB
MZ6?98R16&.7L580NM^/FU.^,UJCE26LN333%6@4*XYC%HEFV1<"NJ^^(0H;B
M37J!%104%2,>(%<1GF.7.HN%O$&AI#L<:Y9"M#AAA3GQY8QUIW)SF9QAP[YB
MN:)'*];SN(>:SD#B=AG'TEAFPN7-#R!ES.F%\:U>ZJ33S.__`'KC2CP-Q4^`
MH;<(-!Y)%3*$PU(Z-VXXYWBM":FAS)I4CF>%<\^D*6:W87-;3`5J0`*T'0.-
M,N')7OF>7WF3XTQ5.,[W2X"#MLUS0X/8`P;G+/''I#&#.]T;E%D"/H>3QM>`
M<>Y]N1T)W$$J=0&<BRL,>WEF[UK^P(JBX.:]D\Q`94$$C&M>('.O'CT>>.2W
M@!)]X&A-*4R!/+F!ZU9CDWG;G!,Q]JX\.>1%"B<L<;?-X\MO$;?/%0PI,59A
MDO&_(QCB;(U>@[ABJ'S$V:HI5*R7T[2;9HS)V-KA696BI&JCA1P6KWR`B)YH
MX.&-32GN]()SXGAA1&11%IF:"6%IP-*_BQRP^'TGC12)OG)^\8%ROYB$)<+_
M``L-EFAT'RQ<?5'*-%P+>\J6'*N<\\M\FUF/K]1XNKYG"MK3%NL+3X&`B6,K
M$HLSO>_,2+])H"A:]N&AP!&6!J<<2*UKQ/72O$*T0:BS`Z:FHPPP!Y?RTX*)
M-\Y3<D<U8GR7A?DY69:#O?&?S4/)\C86;M&-J9AS(%EI>8N0&"\A187W&^-L
MQ9VH,+,Q3L[I%%>-L`@]8'0,X9M'!5"&C$KGN:UQK0CC7\3.-3[?,%(Z!D=9
M&U!TN%/Z+^@<A]Y69[S"LZ9=X^X0JEKP8K16N2+SREXHX%BG^2:U+W"H1<;G
M_/\`2L3STM(5R!L=3EY->+B+.JNW(C(-C=XA?M;:S9Y',:W305I[6CF.:P8&
M-D>0ZM`"<.@$J`]UYL\E<2ON3O&'(688FS\BL9<AN-6+<$9/PCP_"^V[-Q>1
M>&[#F[_*9GQR?YM@Z3"9-HU;HLXX>3LA;&D$RKB;:1>)%4,)5</YB306UPYU
M.=>=>OS4R6:+>,O:0#0C+B`.BG5ASKFJ&Q3S4S]EI'B]`\@:)&,<IX]\ZA?A
MQ9W4U7'.,+&XK<7Q-R+E^NW>9Q]BO-^0J%`9#-%65JQ>1P6&TUE4I3.0:D<&
M2*SO,S_E]1H:.(X_E)SKCY=%*"WC[?0*AKF@^EP'$8>7GJK%?-OFG++\:,X7
MF[8*E<+9T\R_-W`)_A"MX5G("U0]0K66^26-:'E8,P/<H32KJ\Q3S"K([^/)
M!HQ+UDY5V!-QLH`SRL=K/PU=ACP)Z:>7#!1]C":QBNO2#7K`^\_I4ZN?.?KG
MANKX@IV(;E;('.F;LEO*IC2HX[XYQ?)K(>16=5IT[<+S&5FFVC*.':%4VU=A
M6:4E(V.P3B,:P:(BB":B[E(23W<NANEIH^HXTY\</+S**UB[1]7`E@'EAQ6(
MV!Y,<\.5=S\LGX7*5<XW9>C.</F/<8LKQ\MA1S8(2Y3_`!ZPSF1I"6+(.(JK
MR(-6$79J[5C@[K;:T3D7'658DDRD5$V:2"N,)7/<T%VFE:FII^*F3NC.IK7.
M@64861QN=34#2@XCX>-*\>0RRQ61WS=9+-4+Q9Q4YPMEA+$MT<<W^!%8E+46
ML2DZ$C'7'E%C.GKQAXZ)NM-=%@'4W,MG,K'F>J(S$.@YB5!3(\%TCE7).EH!
MH:C''*H'/I\JK$M@TR'4*C2[V%0?S),<S\.\M_,WRCC/.^%6>1..?EE<.<P9
M/E;/QUF)B!S;9<6M^;UR0K$#44\S-2X<J%L1@G;=\J1_8)-J99N9LJ`)*=W$
MU/`,D>0`XG'%W34U/,E9($9:UD@()>13`4KIZ,*=0]:[_)/F(\\LJY%RO%<-
M,./Y<^`<-\8<@_Y9,,%Q>7V><<A<A,)P^?%:-<\L3.=L2N\&TA&`GFU?BI6-
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MW''F`Y+)1WC'(F&:]DQP:-R-C(8:35ZHNP-4'\>[C7`HMU#J=4S9Y?X8(.(Q
MK7\0&&.(S]62B=;Q?&0X"APRR!..&%<,.O$K=FN:_,7']TRSQ$FKSA:Y9Z:<
M\N*W$C&O)EWAR0J5&KU.Y1\=W?(IS<KI@Z/R0^:3]QH$=5I>!AFB%B8LIN2>
M1@N1*/?*K0W$C`8W9U../1TUY\1PR5&V\4E)&AVFF7G(X95PPH>.:X-UYR\V
MZ%)3?&F,G>/5VY&T;S*.-O"Y;.-CQ=;(#%%UQKR1X[/,^1EEG\65B_N).KY3
MH;9=-C)LHZ<%B\.V14(#,CX?ASKF5@#*@T.8J<@.-<<^/\ES;6)]9,0VF1P-
M:D>;+EZ:8Y*\TS_+C%G#.[S^.8:B\C>9-1QJ"T''5ZHKT2C9'R`21:-Y"1KN
M.IK(BCAJ1M"+KOF->7M29I)XU(R^\4OB`6)F2&6.&HH7#V4Z2>/3EZ5AQMCD
MF#<0PGK/L^Q8N&?,*_6^JX-AK]D@<M9*@/-*X1XBO%'RCQ-RQP@S%A-AE-M*
M3K-.ZXS)E9XSM3J28#]XUV616>U>19*&2<-I$4!4U@&9Q8,03CQ=T=/Z.7%9
MYMF!SC0AM.C'.O`TR^_@K/XRY/\`-;C7QKY+9*DLLU[/L[D'S:<V\-,,UMU@
MR=DI/&MXOG,":H1K^HM(9_1+=*3`5U!PE6,?D7KS5%\=DQ&8[)A'5W;21O<P
M&IJ>?YB.>'7_`"JG81R-:[20W2,N/N@\L?3T\UEKX.9-Y9V^)S'#<N:1,UX*
M1?*VPP[E:WXQKF`YW,=&LM2CY*24L&)(/*F68NKV*C7CXV'%RWE$VTRV%JND
MV14%4NLJUD>X$.Q:.-:\L.)X^I8MU$R-PTU!/`BGGR4]-9BQ%\T1-$31$T1-
M$31$T1:BE,<0*0IC&'T`4!,(_@`-QU0D#$Y*H!)H!4JGK';*I3FQGEOM-9J;
M0@"8SBSS\1`(@`!N(@>6>-`-X>S?6;8[=N.YR"+;;>>YD/"*-\A_8:5K=SWC
M9]DB,^]7=K9PC\4\T<(],CFJ*=S\PCAO1A63D<YUN==(B8IV-'9S5U<"<H>)
M"K5^-=QNXCX`(N`#?UZ]#VOP8\3MVHZ':9X8S^*=S(!Z)'!W[*\BWSZD/!+8
M*MN=_M;B9OX+5LMT>JL+',_;`Z5%"W><Q@>%.<*)C7*-T<)&ZF[J3_=^E1QE
M""(D.)G#Z=DP)U`'I:@.WJUZ)MOTP=[[H`[O?;?:L.8;VD[J>9L;?VUX_O7U
MN>'MG5NP;7NU\\9.?V-JP^E\KZ?T*KQ5\@/+"XY9[Y)YLSVZD\@TFOY<RG=,
MF,,455]7D8FF?OM..K%(5YK8GL$\>23%O*OUS)'!LU$B1RD`OV-S=MMOTG]T
MX7=IO&YW]R[,B)D4#?6)G4\X7F&\_7AW[N&&+N]LNUV;:4#IGSW+_0TV[:^8
MA553?+5X74P2*)8>1M#H@%W=7>RV6Q=9B_RCQXR3.&'J]8?"](^S7H^U^`7A
M/M1#F[6+B0<;B666O]'6UG["\<WSZJO'??:M?OCK2$_AM8((:=3^S=+_`-Y5
M2DJ.'<0T!,B='Q5CBH@F``12O4FMQ;DNWH'XQM&D=F-[Q4$=>B[9W6[L;*`-
MGVVPM:?W5O$P_P!8-U>M>1;UWX[Z]Y'%W>#>-TO:YB:ZGD;_`%7/T^I7*,JJ
M8H$,HH8A0V*03F$I0#T`4HCL`!KH"YQ%"31<H&,!U`#5SHMO5JO31%]`!$=@
M`1'V`&X_1IFJ$@9K=^'7`O4*"P%#TF%,X%``\1$1$-@``U=H?2M#3J5G:QUI
MJ;7K"Z*1L5<ABB:8L=>ARE\##+3L3&`4>HI=C"^>(;#U'`/'UB`>O6'<7]A:
M"MW<01#]>1C/[3@ME:[7NE\:6-K=3D_W<,DG]AI5L9?D9Q[@!$)K.N'XTP"4
M!(XR/414`3&.4H"FE+*J!N9,P>CTAKG;KO[W&LL+O>=JC/3=0>P//)=;9>%G
MB=N6-AW=WR4<Q8W-.'$Q@<0K9R?.WAU$]7Q7(C':PE$@"$8ZEID?M@82[#$1
M+XI@#I^UL/V?7MN&N?N/&7PKM?XF^V)_F%\F?\QCOT<5UEI].GCG>_P>Z^Z-
MK7^(V.++_I9&>;GPJK;R7F=\*8[<"Y7D940`@[0]`O+K?K,)1`#N()FGU)[;
MF`3!X>C?7/W'U$>$<&6YR2']2VN#[8VC#CBNKM/I&\?;KXMFBA&/\6\M&Y=#
M9G''AAGR5`R?FW<1&/5\&KE69$`6$OP-!2;E.*?]V`&E)]@8`<_R1$O@'Z73
MZ-:6X^I[PNA_A'<I<_AMP,LOCE;GP]=%TEI]%'C=<?QV[-!E\=X74KG_``X7
M_#QQQX55!O\`SE..Z'7]VXVS))B!""05F5.BR'.(_;(83VAX=/ME\=^DP&'P
M\/3K2S_5=W$946]ANTF'%L#!T_YYQ%.HU71VWT)>*$E/F]UV*'$UHZZD('`X
M6[0:\JBBHZ0\Z7&B?=^ZL#7]X("3LC(W"M1P*`/3W!5*VCI3M"7<>G83]6P;
M[;^&JG^K;N^VORVS7KN6J>)M>=:,?3UUZ%O;;Z".]KJ?.]X]M8,:Z+:=].5-
M3XZ]-:4Z523WSK60&5",XY.S$[?[$TCDY$AN]T?],1K2SAV@/^J;J$/8.M5-
M]7,()^7V%Q%,-5V!CTTM\NK%;RW^@.<@?-]ZF!U<=%@3AT%UT,:<Q2JI=UYU
M=L,!/@>/%61$!-W?C<A33H#!X=/;!O7&0D$!WWWZM_=K72?5SN1`[+8K8'CJ
MN9'>BD3:>M;>+Z!-E%?F.]%XX<--E$WTZIWU\U%//RX,^\S_`#-N0</AK!_'
M7'T97$5VKG(>1968N3V`Q_7NLOQLC(/TA9M5WYDQ$6S7I*=4VP>.LW;_`*H.
M\=\)+R3:=O@VF+XWNDF<:_D9BT.>>`I@,2>:Y^ACN99,;#)WAW:6_>3I:V"V
M;7I((=I:.)+EZCLI^7CA2ERE;Q;0,AY,RSG6;%JU&N0O[I,H0[HZR"$E(E($
M.[=QL%"]_O.57+C]F@01ZA$!`.6W_P"KWO/LT>MFU;>ZYG=2""L[I#R,A$@`
M!Z`*5QPQ6^V'Z!^XV[']]O>\-M816::EL&5Y1@PDFF6).HY*%?F71'!SRO\`
M%+>%R3EBZYCYB6.%*O7\+42=K,-!0#QTV6<-YZY&4K,Q-QU52/T$3!55%T_'
M8Q"HIF$Q>9/U@>)]XYNW;;MFQG>`1V[@RY=!;M-,'N-P"^2AJV-I#G9G2VA=
MV%C_`/L^O"-@=N6Z[SWB;L>4?OVC99G#-L;1:D8\7FK6<23@O+@;S0<\F4$$
MJ;BP`.ITHI?=%H65'K/TI)!T6<!55,(@4-B[F-Z`UU8^J'O\&^]:;34#$]G,
M!TG^/@/.M.[Z%?"1\A$-_P!X0TGW1VUJ3T"HM!4]0S7HX\N3B3R>Y$8WF^1_
M-61QMQ4XX0L4M+K3LJS>5N<;Q3=(KA::F7MIL+J-ATCHB`(,SI"X4$Y3'$FY
M2&X#=?K5[^MG,&S6FR.@B=26>6.X,0)R9&&W`=+(>#65+LF@YKJ[;_\`9X^$
MC(FMW#<.\CMQE'[NWBFM==/S2$VA#1SJ/=&)/!88?,*\VCCGCO,"F/O+QA)[
M*U`J:ZL?9LO9O>]<;?))NH*3A6@5RK,:J]BJ\!R#V73Q999<H]0)D#8-;S:?
MJS\5+@_,;CM^S1VI`T1]E.V4\WR?Z4X1ZOPQ#4YH^-VJK1IMU^@KP7LX3:VV
M[=X)-TK[SFSVCH8_U`?E`97#\3P6LX#5FH`./.BSV@)0_P`J,.?:`?\`HKN;
MT;?_`)UDV].N@_XL>^G_`);M7HN/_&7-_P#`=X<<-YWWTVO_`-N5V27G99:*
M"0+X0Q>J(`GWA2EKBCW!#;NBF!I-8$>OQZ=^OIW]>WCEM^K7O,*:]HVXY5H^
M<5YT]\T]=.E8#_H([EDGL]_W<#&E8[8TY5_=BM..5>A5"V\[JVE.87G'>J+)
M]/V"M+_.-%"GW#Q,HM`OBG+T[AL!2COX[^K6>SZN=S!_>[%;%OZMS(T^DQN]
M@6KE^@/92T=AWGO&NKCJLXG"G0!,RG74]2JR/\[M@(IA+<<'!`[0]XT9E`A_
MV_AL"1'='+LB([_I&$P:V4'U<PFGS.PN&&.B[X]`=;Y>=::Y^@.Y%?DN]+3[
MV':6%,.DMNL^H45=QOG88B5`OWO@_([$W0D)_NVRUB5`%!']N!`=-H83$3#Q
M((["?T"!?3K<6_U:=V'#_2MHOV&@^"6)_7F&9<.?0N>NOH)[ZL)^2[P;7(*G
MXX)X\.'PNEQ/'EPJK@Q/G)\6GVP254S-!B/7N*U<JLB0.DQ0)N9C<^O<Y1$?
MT?#;;V:W=M]5'AU-_K%MNL/7%"[^S/\`8N:O/H:\7K?_`%6\V*XRRGN&'I^.
MUIAEGC571B?-5X429B$7R#:(,QS=/_?6.[0!""*@$`5%(=K,D*40'JWWV`OI
M\?#71VWU'^$MP0'WUQ"3_>6TWK+`_KZNG!<C>_1[X]6@)CVRSN`!_FKVWKE7
M`2NB/1U]&*N]!<\N'%A*06/(?'[85.GI).K2]:.'4"8@!_WAB8PA!#N@`[F\
M!`?U3;=/9^,OA9?`&'?+)I/"0OBY?WK&4S]O(KB=P^G7QQVPD7'=G<G@<8A'
M...78R2$Y<N7,*]==S5AFW]'[JY>Q=8A5`!3)#Y`J;Y8X"4I@Z4$)8R^_2<!
MVZ=_'766/>SNIN8!V[=-NGKEHN87'T!]?4N#W3N%WZV2O^,;)N]J!F9+.X8!
MYS'3UJYJ)1<)@LW#XA$0W!9N(+I"'M!1+K((?CUT+07MU1^\WF,1Z0N3>1$[
M1+[K^1P/H.*^"`@.P@(#[!#8=42H.2^:*J:(FB+W<)G3611<(J)KMG"95F[A
M!0BS=PB<-R+-UTC&272.`[@8HB40]`Z_(QP+7%C@0]IH0<"#R(.(/05_0(US
M9&-EC(=$X5:X&H(.1!&!!X$8*W&7\.XPS]CFR8CS+2XG(&.;<DP3GJO,F>HM
MW"T3)LIR%DF4A%NX^9A)R!G(UN^CY!BY;/F#UNFNW635(4P6/8V1NEV2D8]S
M':FYA6+J'`7AU1(&XUNLX(K3>,R+9\2W;(2LK-W>TSM\N>";&A;L16VYVJUV
MF;M-FLE%LK5)VU>O'BRZBB1"KF53(4@1"VC;SKARX&O+H"O,\AI4Y5]8HJVR
M9Q,XW9C0S`WR;B&KV[_/U'&R67'3T\RTD[>MAQ5PXQ/*?>\5*Q\I7;!CAVY.
MXAI*)682#%SLLFL"I2G`;:(UPI7U>7\B-FD;2A."[+!/&7`W&6.MT7@G&\9C
MUM?Y]C;+XX:2MEGI>ZVN/@F%:;VFUV"VS=@GI^QJ0D8@BN^=.5'+H4^XL=14
M3'&^.)L>(Q/\GW*V25\E-7!15C_+$X[3'*+D+RES#`,<P6G,>9,1Y?J%=G'%
MSCJICU]A[$..<<5EE8*8SNQL=97?1=EH(V*+>S4(J>)>.P!`@*(E6&(VP=*9
M'$T-,.H#[ON4OS#A$(F@"@./'$G[U>^P<%^(]JSFAR3L.#*M*9F2LU=O*]F6
MD+4G#2V0*?'I150R18L=-K`AC*T9,J<:W21C+')0SJ;8D01[+H@HI"2[Y:/5
MJ%1T</+V<%9V\NDM)P->O'I6F9X)\1+'9,[VFP8*JTX^Y.Q"D-GZ)EI*UOZ/
ME`BX5WXB9L&-7-A4QVA<W!JC%&4L+.+:SQU(YN<7@G3*8*_+QX\G#+"GHHG;
MRX8XM.'/TYK:H?!'B9C:`5K56Q`W/&+Y)QKE]=>VWC)N1YY?)&&I%*6Q19U[
M7D:ZVNTJJX\D4"JQ34ST6#4=P!`2F,`T;;QM-<2:\?-]P^RBJ;B4BA.%#T9U
MY=:JK(W$3C5EN'S%!9$Q#6[(PS_8J!<,NG4=3\7*6ZXXICJ_$XSMY)Z#F8R=
MK5KH3"J1I8J1AW,>\9G9)*$4!0!.-SH(WDDYG]'W!6MFD:`&G`?I^\KH)O@[
MQ/LU,NE!L>%X.?K>1*SA^I709F>NLG9)Z)X_?$FPDZ<7EY9UKPUM.,7#Q1Q$
MSK>11G$'9_B!=F7V4"AMXW#&M:`5XX*HGD!!!I0D^GHR7#I?`SA_CV%GJ_4L
M$5>/C[7D/%66[8H^EKC8IFV92P?*1TUBC(5JLMELLQ9+';Z;+1+9PB^>NUEG
M"J!!<BMMMJ@MHQCC6N>'0>70.E5-Q(10G"GWC[2MSFOQ1@^:>&8;"EIG_N"M
MM\Y\?<NV(PL)!\-BA<)9;J^3I2D@I$3M;E(<]V:5T\:62;.RKQIG`.$R*&3`
M@UFA[4`5H!]X/V*V*7LG:@*FA]8HNF_\/+AA_E(YP>7!447'SO)R&:W!OWQR
M4.1%LQM&X,&>5E<U_OI_G2?(K2'`(Y*8_>#XY.+_`-Q*H#011U3Y:/3IJ<ZU
MX^73GTJO;RZM=<:4Z*=2JW'_``KXIXKBZW"X\P=3JM&U'-8\D*ZW8J3K@\?G
MD],7QZOE@[N2F7SV0N;VFNE63ERZ47!T"JBJQ3KG,J-1;QAN@XMK7ARIR_2G
M;R:M=?>I3UU]JJUAQFP%%U^EU6/Q966M<QUFB6Y%T>(3"2^$K6<9VR6^WS&2
MX\#R!E?WAD+-?IEZIW#*-N](J[)`7H*6I@C(H>9/#CF/+%4[5]2ZN)%/+T)G
MCC1@WDW"5B!SA0D+HUI%F"XTJ1:V*WTJU4VSC&/81Q,5.\8^L-4NM<<24').
M&+TK.012?,ESH."JI&$NJR1-DSP/,9JC)'Q_#Q5I9'R\>%4EBFO82#C]5X;&
M50R=-9HJ$#4)V]4>1J.5+*241LMXJMRIMK@KQ79JR-9QZA("SDD4GK9XLBL0
MZ2IR#9\M'2F-:YX5X]'25?\`,2UU5X4YCASZ@K^9=PIBK/>,)[#&8J3&7W&-
MF;0[:8JLLO)MDE1KLE'35=D&4M$OXZ?AIRNS<0U>L)%D[;OV3QLFNBL14@&U
M(^-KVZ'9*-KW,=K;@Y47!\4>/-=@KO7([&4>M&9+PW7>/N13SD];[3,7K#=3
M872+K]%MMEL]BF+)/,H]AD6<3^*<.SR*WWFL95P<PE$MO8LH6G$$`>BOWJO:
MO)!Y&OGP^Y6YR?Y>O##,<O6I[(6!X*2F*K0:_BAA(05HR'0W$MBVJ%$M8QO>
M1Q_<*L7)=&@"F.#2+L82K1`%50*0`54Z[#:Q'*HZO+U9="O%Q*.-<>./\BD1
ME'$N,\UXUM.'<L4F!OF+[K"DKUGI,ZV.I#2D2BJV<,T`!JJV=L',8\8H.&3E
MJJBZ9.FZ2[=1-5,ARS/8U[2QV2C:]S'![?B"C[6O+ZX85.@Y=QA%<?JDZI6?
MF5699MCK/*7&\2>4S4<KD*;*W6UW:S6&WS-FJQW0J,)<[\)1JNFDJFX*H@@9
M.(6T8!&)KU?=[:J0W$I(=7%N2[ND<'^*&.J.?'54PM`MZNXRS3,[R?WW-7*X
M6>Q9DQU+P<[0LCVV_7*R3]^N%GI\E68XT<K*2;PC9%DB@0@($!+56V\;<16M
M:UXY@_9U]*H9Y2<3A2E.''AYRJBR%Q*XUY88Y@C\BX=J5K;Y\EZ#8LMJOPE4
M)&VV7%47&0V,K228CY-G+5JU4"/AFA8B3AUX]^Q4;D525*J7KT=;QNJ2,3Y?
M9Q5&S2-`#3@/+[2NMHW#3B]C:H4RC4S#=<BZ[0<Q(<A:T5V_LU@G2YV;M9!B
MEEZP7"R3LO<+KD#X&360/)3;^1740$J9A%-)(I*"VBH&G''R\L^E5,TA)=7$
MBBNWE/%F/LVX^M&*LJUAI<L?7-DA'V6MO74FP1D6[209R[$Z<C"/HN9C7L?+
M1S=TV<M'*#ENX0(HFH4Y0'4KV"1NEV2C8XL<'-S"LG1.#W%#&L#'UVI89A46
MD=EZH9\)*6"P7>\7"0S+C]J1C1<AV"_WFT6.]VF=IT>D1M&!)23MLS:D*BDD
M5,`+J(6T7&I->/L]77TJ0SRGCA2G(>@8<5UTMP'X=SS_`#T_G,#UB82Y/J?%
MYX@).7N+VE9`FADXF<4MBV/U[*>CUJ^+ST`QD%;##1T=.*OV:+D[L5TRJ`-M
M&:YT/H\NNJ">04H<LOY<UNUC@CQ+J-`E\81>'FK^F6#(]`R[/LK?=<EY"F9S
M)&*IB#G\;6N8N-^NEENDB\I$M66"L<BK(&:(`U(0$A3$Q#!;Q@<2:YG/A]P5
M?F)2:UX4Y<^`ZRI<G.90YCG'J.<QCF,/I$QA$3".WAXB.IP`!09!0+3JJ)HB
M^^GP#Q$=455UDW-0M:9GD;+-0]<CTRB<[ZP2K"$9E*`"(F%U)N&J```!^MK(
MM;6ZOY1!8Q2SS'\,;'2.]#`2L2^OK':X3<[I/#;6P%2^:1D3?ZSRT>M1,O?F
M`\/,>BLE+9QK,X^0$0/&45&3O3P3AO\`8!6MLGL84VX;?;<D#?TCKT7:/!OQ
M,WJCK;:9XHC^*X+;=OHE<U_H:5X]W@^HSP5[N:F7>_6MQ.W-EH'W3NJL+7,]
M+PH:7CSF\/1?=1QWB7(5R6+U`D]LLA!TB,.(>!3BBW/:)0R8^G84DC;:]0VG
MZ7^\UQ1V][E96K>+8FR3N])[)GK*\0W_`.M_N7:59W:V;<KY_!T[XK5GH!GD
MI_1:5#J\></R2GA62I-2QACMJ?J!)4(J3N4ND4?087DZ^1BS*![?@`#W:],V
MGZ9^XUF`[=;G<+V09C6V!A\T;2^G_6+Q3?OK4\3]QU,V*SVG;(CD>SDN9!_2
ME>(Z_P#54Z%#V\<V>661`62LV>\A`S7Z@4C*[*DIL9TF])`9U%O"$,3;PV-U
M>&O3-I\*_#K9"'6&SV7:C\4K.W=_6F+_`%47BV_>.OC#WE#F;KWBW+L'9LAD
M%LSJTVXB%.NJC+(O7LPY,]F'SZ8>G$3'>2SQS)NSF'Q$3.GRJZYA$?:;7>01
M16T?96S&11#\+&A@]#0`O++F>>]E,][))-.<W2.<]W]9Q)]:X9E4D_TU$R!X
M!]HY2_@](AJ0-<[($J`O8WXB`N\AZY9+$H5&NURPV!4X@4B<#!RLR<PCZ`*6
M-:.A$1VUB7-]8V3=5[/!"T<9)&,_M$+866V;GN;@S;;:YN7GA%%)*?V&N5`\
M@+A7>*+>JN>2SUQ@PMZ:RSVE-\DP\Y79"V,X)1DC,NZ_%.8T923:QBTDW(LH
MFB)"'6(7?<=M<=N/BAX<[547V][:UPS#9FR._JQ:SZEZ)M'@CXP;[0[7W:WA
M[3Q?;NA;C^M/V;?6H.6'S1^&$#W2MLA6&TJI]0`2KT*SN"*"4=MDW4RT@VA@
M-ZAZ]M<1??4;X3651'?3W+APAMI37J,C8V^M>D[9]'_CSN5#+MEK9L/&XO(&
MD=;8G3.]2L;8/.5P$Q%0E:QAEJQB7?MJOPJE:;J"`[!^E,33DA1#Q\4MP]FN
M-O?JO[DPDBPV[<Y^1=V,0/[<A]2]$VSZ$?$JX`=NN[[+:@YAGS$[A_W43?VE
M8Z?\ZN7.)RU3CS%-R[#VUK-D)\^,!ND=A.UAZY&E$`-X[`L'@'I\?#C[WZN+
MDDC;=BB`X&6Y<[]ED3/[2]"VWZ!+%H!WGO/,X\1!9,9Z'2SR?V?TV5GO.)Y,
MR)CA!5##]83$1Z!)7[%.."%W-M^TE+.+<Q@`0#<4=O#T>/AR-[]57B#.2+*U
MVJW;_P!%+(?2^:G[*[[;?H8\);4`[E?;Y=OX_OH(6GS1P:OVO.K-3WF><TIP
M3@EE1A7DSCN!*W1:6P,F'A]DB[J$?N@#P]9Q'T^/CKD[WZB?%N\)T;DR`'A%
M;V[?68W'UKO-M^D7P#VZA?LTETX<9[NZ?7K#96-]2L[.\T.6=C`Q97D1E82'
M`0,G'6IY!I"`@4-@3@_NXA?T0]`!KE;WQ;\3=P!%SONY:3P;,Z,>B/2%W.W>
M`O@MM1!L^Z^S:AQ?;ME/IEUE6?F,HY/L/5]_Y)R#.=>_6$O=;-)`;<#@/4#R
M36`0$%3!^`P^T=<M==Y>\=__`*[N%]-7\\\K_P"T\\SZ5W-CW/[H[93_``W:
M=LMZ9=E:P,Y?EC'(>@*AEC&<'%1R=1PH81$5'!SKJ&$?`1$ZHG,(CMX^.M,X
MN>=3R2X\2:^U="P-C;IB`:T<&@`>@4"VP33#T$('X"E#\@:MH%?J=S*UZ*U-
M$31$T1-$31%/7R\?+OSYYD&?:[A#"4(J*;ETBYN=V=MU!KE%K*2Z`2<Y..R_
MLVX(MU![!##U+J[$*`B.MWM6SF^:Z\NG]CM<7QR4K7+W&#B\@X!:^_W!EDT-
M:-=T_!C.9YGDT<3R7Z:?&/C1BORZ,+U7@QP8J"-QS%-1A'.1<A"GVGL_-G*D
MG)W&[6!)-0L5`,72O@`G'MI[(I`8YM]6]XN\D6W-BM+2+5<`$6UKA5O_`#LW
MZQS<78-'F"Q-EV27=I'WEX_1:8=M-C0C^ZB!X#A0>^>A0!\R+S6L->4U4;M@
MGC[9(S.OF%Y`C'!,E96.+*0AL.N9)(XHLC$*+E!NXACG$S2$()3)F`JSPPJB
M"1?,[:UW'>KY[X)=5PXEMQ>#*,<;>UK6KQDZ3)F9J^C6^H-CL=OLHYKZ/L]O
M:*V]K^*8\)9LB(^/ZWPMPQ/A`G)[,7)/*SR:GY&X9@S#DF<7=.G;I5W/VBR3
M+Y51RN8.LQU.@IC&-L'2DBF'\DH:[N*+:N[^VD,T6^W1`N<2?2YSCBYSN)-7
M.*YZ27<^\%^UOO2W3L&M:*-:T9-:T8,8T>8#,KU`\9?+3XD>5IAB`Y[>;5>8
MEI/*,6UAQ%QTC3&>WBVR:C4R["+K]7<?`OG$D5PJB<TN;]@V+OL"(=*JGG&Z
M[[?]XY18V0DCVZ3X8F^[/<-_.]QPM[8_WCL79,:]Q`79;;MUMLS'S1F-]]%A
M+<OQ@MC^6,"IEFS`:`7'A05*P0>:]YW7)#S-+#^YJ0&PCQ/JKKM8XX\5!X9"
M(39M!,FRF+T^:D;&M5D51V,<RA001,802(4-Q'?[5L$-B63W(8^[C!#`T4B@
M!S$+3CJ/XYGUED-:EK?='/;COQ?')9[9K9;R?Q97']]<?SR/@C_+$PZ1^(N.
M*PHZZ!<TNLD?2E^`_P"4NA5S5UNJ*Y-$31$T1-$31$T1-$575^_WRI'*I5;M
M;:RH00$IZ_9)B&.40]`@:.>-A`0UL['>MYVPZMMN[FW(_NY7Q_V7!:7<^[?=
MW>FEN\6%E=M/":"*7^VURD95.>G,.F%23AN060G"*73TM[')(7!#8FVQ3)6Q
MK-%$H@&P^T-=UMOC-XH[4`VUWN^<P<)7"<>B82+R_>/IT\$-])=?=VML:\\8
M&&V/IMW1*3U1\X7E;`F1)9&6,;XV)L"OWQ45(5\J```"(.ZG)P:!#C[10,&_
MJUZ%MGU1>)%D0+]FWWD8SUPF-Q\\+XQ^R5Y+O7T0^#FXASMJDW;;I3EV=R)6
M#^C<1RDC^F.M2QI/G:5Y<2)9)P)*QX?9!20H=Q;28".P=9R0UBC(XQ0W]!1?
MC^'7I6T_5M8OHW?MED9S=;SA_P"Q*QOH[3SKQO?_`*!]RC!?W5[QPR<F7=LY
MGIEAD?Z>Q'4K]_\`C%\3O_K'F7_L/Q/_`+)5O_M7_P!;?_;3^^_\K_=>_7:?
M\4OAK_<[K\%?X,6?Y?X^?3DO.?\`@>\9/_F-B_B:?]8G^'^\_P!5R_5^+H6=
M_#'*_D)@!5(F+\G3\1#)J`HI4914MBI;G8?$BE8F@=QS8#^L[4&ZOL.`^.O7
M.]'AWW,[XM)W^PAENB*"9@[.<=4K*./4_4.A>!]Q_%[Q(\.G-'=/=;B&R!J;
M=Y$UL[K@EU,;7FP,=^LLL^'/.8C%P:1F?<6.(]41(FO<L7K_`!K(?49R\ID\
MZ(]0#UF!K(+CZ>E/T!KYS[S_`$P3LU7'<[<&O;F(;H:7=39XQI/].-O2Y?8?
M<GZWK60,M?$3:'1OP!N;`ZV_SG6TS@X=/9S/Z&\%E+Q+RJX[YQ(B3&>6:G-R
MBQ2F_=I\]&NVU(Q@_NSUFP$C9=4Y1\!%%-4F_H,.OG[O'X>]]>Z9)WW;KF*W
M!_BM;VD)Z>UCU,'](@]"^M.YWB[X:]_0UO=;>+.>[</X#G=C<#H,$P9(3_-:
MX=*D(<ATS=)RF(8/24Y1*8/Q"`#KC`0148A>D%I::.!!6C55:FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M12F,(%*`F,/@`%
M`1$1]P!XCJA(`J<E4`DT&:M_>\K8OQ>U.\R1D:D45`A1.(6FS1$.Y,`!O^Q8
M.G1)!P80]`)I'$?4&MSM'=W?]_D[+8[&[NWG^ZB>\>=P&D><A<YW@[W]T^ZD
M1F[S[G8;?&!_GYXXW>9CG!Y\S25!O('FL\1*7W4(&?MV4'Z?64J-'JKM&..<
MNX`'WY:U*ZR%,PA^FD"P;#N&^O6=F^GCQ)W2C[R&VV^$\9Y07?\`9P]H[S'2
MO`^\?U>>#6QZH]ON+W=K@<+6!P8?^MN#"VG2W5S4'K_YT=R>=YOBO"5;@$Q`
MQ496_P!AD+*]+X[$5^YX!*OL"&`/'I,Y6+OZQUZQLWTN;7%1_>'=9YG<66\;
M8F]6N0R.\^EJ\%[Q_7'ODVJ/NCL-K;-X27DSYW=![.$0L'47N"A'?_,8YBY`
M!=-YF.2J,>L!BFCL=QD52FY4S;[I@_C6PSPE`H[;F>&'W[Z]5V;P2\,MFH8M
MK9<S#\5RY\YK_-<>S]#%X1WB^ICQK[QAS9][EL[9WX+-D=J*<M;&]KZ9"HBR
M,S;\BR@N)>6M>0)I=01[DB_F[A*J*F,(_9^(5DG8F$P^@/7KTB"UVW9+?1;1
MV]G:@9-:R%@'F#0O&KF]WGO+=]I>37FXWSCF]\MS(3YR]RO+4.)'*"]%3-5<
M`94D&ZFW0[<U&1@F&P^@WQUA3B68$\?3U[:YC<O$?N#M)(W'>=N8\<!,V1W]
M6/6?4NWV;P<\5M_`.T=W=WDC.3G6[XF?UYA&WUJ355\J7F/8^V>2J]*I*!^D
M3'ME]B!<)%,&XB=E62V1SU%]9=@'7![A]0_AE8U$%Q=73Q_<V[Z'^E+V07J>
MT?2'XV;G1UU:6%A&>-Q=QU'6V`3.\RDC5O)8OKCMGN^>*9#D$`%5M5*E.V)<
MH^'44CN7?5I`1#Q\>V(:X?</JEV=E1M6T74IX&::.,>AC93ZUZ?M/T,]XI:.
MW[O#8PCBVWMY9B/Z4CX!^RI'5?R:<`QH)'MN3<L6Q0NPJI1YJO4V:@^L"D1B
M9MZ0@C_]\"/OUP^X?4]WQGJ-NL-NMAP+NUF</2]C?V5Z;M/T1>'=K0[SNN\7
MCN(9V%NT^81RNI_3KTJ1-8\LSA;6>V8V)%;.JGT[K7*XVV;[@E]:C1.681QN
MH?2'8Z?=MKBK_P`>/%*_J!N0MVGA!##'3J)8YW[2]+VKZ6/`W:J$[,Z[>.-S
M<W$M>MHD8S]E2*J_&_CS2NV-4P9B:#41_NUVM"K:SL@^'B#U['NG@F\/2*@C
MKB;_`+\=]-UJ-QW;<90<P;B4#^JUP;ZEZ5M/AAX;;%3_``?8-GMW-R+;2$N_
MK.8YWK5Y6:*,>D5"-;H1R!0`"-X]!)B@4/0`%1:$23`/P!KF)7/G=JG+GOYN
M)<?2:E=O"R.V9V=LUL48X,`:/0T`+\K#^*!Y9*\FO-?RM4(R4._H_%.NU[CC
M6B$<=UE^\5>*O9,I/DDP,8I71LB6-ZP5/^D8D8F`^!0USMR\/E-,AT4\J9>9
M=%:,+(!JQ)QSKY<_.O/#K'62FB)HB:(FB)HB;?+Z]$7WV;^OW>CZ]555\U14
M31$U5$U1$T1-$4RN"'!7/7F'<AJGQVP#75).?G'";FQV1VDL6LT&K)*!]ZVN
MTR!"&28QS!OU&*4P@==0`(0!,.VMGMNVNOWN?(X1640U22$5#1D``/B>XX,;
MF3T+#O;QEFP5&J=YHQ@(!<?/D!FXG`!?IP<0^*F,O+OQ!6^!O!&#C[CFB=8H
MR&=<Z2++I!_))HD2E[A;YYMWC15=CUW!TF#),PGW`$TB"83GT[Q=Y8]O;'86
M4=;MK3\O;DX1CC/<&E-1^)Q.#<AR4&S[*_=7.O[Y^FQJ!+*!B_E!"/R](^/X
MCA18>O-/\ZNC\-:C;.&GE]7EID#/=B([CN2?+UF=%VI'3"J(MWU>QQ*M556Z
MDJR,HHD5=N8[2**'2@*C@3K%\_VO;+K>WON)I'&TE/[ZXQ#[G_FH#FRW;D7_
M`!2?AP]X^D3/M=E8QUS$T7+!^XM?PQ`_YR<<7G`M8?Z5!@O(E@SC_GKF!EEC
M0L25&UY1R-<YH!>.&S=_,.E9"3<=3B3G)(W=,7K65ZUEUU`(0!ZU3D)N<.LW
M'==J[MV<<;P&B@;##&/??3`-C8/;D%J++;=S[Q7,EY*^D.JLMQ*2(V8$XNXF
M@.EC<3@``L^!\O<'/X?NHR<21&C\UO-4DF"8.:^Q=,)_"'%J=1.1=J6WSK(5
M26"\0+G831[)8R)%D_$Q#%!8_GVG=.^%PV\N0&6;#[C3[T,1KB0W`7,XIGC;
MQ&F,I!8.LFEVON[:?+0F1D;VU=3W;FY!&%3B;:V-<`1VKQDVAJO+;RPY?\B>
M;V8)[.G)G)<[DO($XH<I'4FN*<3`1@*'.U@*M"H],=`04>0W0BW;D(0I0\=Q
MW'7:V.WVVWQN9;@F1YU/>XZI)'4IJ>\XN-,`,`T8-```7#;ANESN):V32RVC
M%(XF#3'&..EO$G-SW$O<<7$J-.LU:Y-$75R/I2_`?\I="KFKK=45R:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB][FOV=7\YJ:(@!L<B@>"B1@.DH41*HD<H[E.F<-
MC)G*/H$!`0TX$<#GT]:I3$._$#4'B#S!X'J4J\5\W>5&&R-VM-S'9W,,VZ03
MK5Q52O%>!,!W[*;&S$D%V20^C9LL@(!Z!#7GO>'PI\/N\Y=)NFV6[;IV<L(,
M$G7JBTAQ_G!R]=[I>/'BWW)#8=DWN[=8LR@N2+J&G(,G#RT?S',61/&OG0V=
MH#=IF'"\-.D*!2KSN.)QQ7WQ_0!EC5ZQ!+QZAMMQZ2/4"[^@`UXIOOTNV$E9
M.[.Z2PGA'<QB1O5VD>AP\['+Z5[K_7%NT(;#WTV."X;QELI70NZ^QF[1AZA*
MP=2GQCWS/^'E\!NB^OTKCB17`H&8Y&K<C$MD53`&Z9IZ)";K_2!AVZS.4R^&
MX[:\>WKP#\3-GU.BLX[Z!OXK:5KR1_T;^SD\P:5]#=V_JN\%>\`:RXW&;;+E
MWX;V!\;0>7:Q]K#YR\!36J&0:!D)H1]0KS3KLT4*!BK52S0T_P#9$`$!.G&/
M7*R0["'@<I1#?7EFY[+O&RR&'>+2ZM9!PFB?'_;:`?,O==E[R=W>\<(G[O;A
M97T)%:V\\4WI#'.(\X"K`Q#$'I.4Q#!Z2F`2B'XA`!UK`0148A;H@M-"*%:=
M55$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:Q3.5,RQBF*B4!$RI@Z4
MB@`;B)E#;$*`!ZQ'5*@NTCXN7'T*XM<&EY%&#CP].2LA>>2G'K&G=+>\V8RK
MBZ(&[C!S;HEY*@)?20(>*</Y4RG\T$=]]=7M/<7OIOM#M&U7\[#^(0O:S^N\
M-9^TN"W_`,4?#?NL#_O!ONU6LC<V.N(W2?\`9QE\E>C2H;7OS:>)=4[R-:<W
M[)KU+J*0M7JBD1%JF*.P;2UO<07[(WJ,1!3P]6O3MH^G+Q&W&CK]MG81'^]F
M#WC^A")/07!>(]X?K$\'MG#F;4_<=UG&0@MS'&?^LN718=(8Y0DOGG0Y!E%5
M(_%&&*G73*]1&KVYS<I<YCJ$=B')#0B=<8`I_,$ZX;^W7JVS_2YLUNT3=XMT
MN9P,2V"-D#/Z\AE=3IHU>$]X?KC[QW;S;=S]CL[4G!KKF62YDZ*11"%E>BKU
M8&3S#YG_`"6(HA$)YV<PK\!(+#'=+?XYK)D5=OL&E8R.@^Z@)3!XKOU-P](C
MKL8.[/@'W%(?<G:&W3/Q7,[;F6H_4<Z2A_FQA>=77?7ZK?%$&.R'>!]C)^"S
MMGV4%#P[1C(JCI=*<.*XU:\J_F=>'?WI9*]6*BN[,"CF3R#D"/>3!A./VE'*
M,$-JE%50](@H(&'5]_\`4'X7[3'\O8SW%RUN`;;V[FL\QD[)@'5@H]J^DGQP
MW^;YO<[:TLWO-7/O+QCI,>)$7S$A/7BI15#R5K"J"2F0<_0C`!$HK,Z12I"6
M4`/#J(22L,K#)`;WBU$/=ZM<!N?U2V3:MV;9Y7\G3SM8/ZL;'G]M>L;+]#&Y
M/H[O)WB@CYMM;9\A_KS21#S]F5*6I>4#Q9@^T>S3&5;XN383ED+0PKC!4P>G
M=I68=D[*0?9\4(^_7G^Y?4KX@W=181;=9M/Y8G2N'GE>X?L+UG9_HO\`"6PH
M[=9]WW"09ZYV0L/]&"-KO^\4I*CP9XAT@4E(3C]CYPY1VZ'ME8.[D\ZB^@YE
M;8]F2]6_CX%#7G^Y>+7B3NM1=[S>MC/X8G"%OHA:SVKUG9O`+P9V&CK#NYMK
MI6Y.G8ZY=Z;ATOL4DX.MUNKH%;5BN5ZM-R`!2H5V#BH-(H`````2+:-"[``:
MX6[OKZ_<7W\\\[SQDD?(?VR5ZAM^U[7M,8BVJUMK6,<(8HXAZ(VM7>'.=0=S
MG,<?:<PF'YQ$=8H`&`%%L"YSC5Q)*T:JK4T1-$31$T16NSCEVO<?L*9@SQ;5
M4TJSA;%]\RK.&5.5,AX^A5>3LRK;K,(`!WHQH(D#?<QU``/$=13.#8B3E3JP
MX^I21M+Y`T9DK\0[(-\L>4[_`'K*%P=GD+;DFY6B_P!H?*"83O+%<IQ]8IIR
M<QA$PF6D9%0VX^/CKG"222<RND`#0&C("BI'5%5-$31$T1-$31$T1-$31$T1
M5WC/%V2,SW6(QSB2C6C(]\GE#)Q%3IT.[G)MX"8=2RQ6C--0R+1L3[2JZ@D1
M2('4<Q0\=2Q0RSNT1"II4\@.9)P`Z258^1D8U/(`KZ^0YE>AC"'\*QYFF7ZB
MQMLW,\;L.C(M2/&]8R!E!](VAND)0,L$NSHU;M+")4;;@"@'<F`AAV$0$-M4
ME$,+@QS]3S^1I<!UNP'HKUJ,3AP)TD-'%Q`]`Q/L7)OW\*#YJ]19/']<'C/D
M\K3P,RJ6:TX625-L80*DC?ZY46!S'V`"@#K[0CL&_CM*+=K@"'M%1Q#A[`59
M\Y%4BA-.5/O"@)7?)&\S5]R&QGQPM/$[)M,MN4["\K]=L<LQ9/<<E",;J/)J
M;>9#@7LO4TH.`CTQ=.U?BA.5`OV2B82@.9M^V.NIJ3N$=HUI<]^!#6@8&F9J
M:``"I)`&:LGOH88B]OOOJ`&C,DY#D.)).``).`7Z`W!7A'COR],4(\)>&+2&
MN6=K1%M)GE+RBEVB+9FE]@A9:6<R!.A>,I,$HJHE$1A5"JN#`*@^/68,?O'W
MG9M@9M.U,'S;&ES(W$`1#C/<N&':4QQPC;1K:E4V?8G;LYVZ;FXBQU!M0*F0
MYB*$''1P+J5>?>-!0+"EYOOG(U'"52MO`#RZKU]\)S"+QERFY:Q,A\19K_9G
M.[6=J5*L+14Q&S`A2*(/W+4Q42)'%LU$$^\HOQ.S;-)N[W7MX7NL9'`O<X$/
MNR.@XLM1^!HQDQ)]T^]Z#<WL6SL`T-&Z,%(HQ0LM!A1SAD^<\C\&;O>H&X7/
M+A\J3+'/1S:\BV"S0V".+V+VA)W*W(')"IH:I1D:50%73:.DGQF[=Y(*-2J*
M%V/]K8`W*!NX79[[WHCV][MNVH127T;1VCG&D-LTX-[0M!+I"<(X&`O=T!6;
M3W?-WHW+>S.8YW'LHF"MQ=.S);7X(A^.9V'Y03E?+F/YP.!N).++EP5\F:$<
MTFGS;,U7SESB?H'99;S/VD092\?C#K,=Y0:1**E.(N`.#YRD8!^P83**:#;N
M[\UW*Z_WA\DCY0`_M/XDK?RN:,((,?\`5V8N%.V<?X8SMWWZ*S#;6R$7;0DE
MD<=#;VQ/%IQ^8N,!69WNM=\&HT(\OKITZ?.G+Y\Y</7KU=5T\>.UE'+MVZ7.
M*B[ERX6,=5==90PF,<PB8PCN(Z[1K6L:&,`#`*``4``R``P`'`+A9999Y'33
M.<^9Y)<YQ)))S))Q)*V-54::(FB+JY'TI?@/^4NA5S5UNJ*Y-$31$T1-$31$
MT1-$31$T1-$31$T1?L%Y*\FO#LV+AWBK)MVQ\Y/N9")LK9C?(`AAW$"`XZH&
MP(I;^&YG#@P![=?8FQ?4[WFM=,?>&PM+V,9OB+K>3T?O(R>IK5^??>CZ(^Y5
M^73=T=UO]ME.4<[6W<(Z*_NI@.M[SUJ!N0/*3Y6U(5UJH6A928)"(IFK-E+!
MS"Q`WV'[FMZ$,F"FP?HINE?'T".O7MF^H[P\W(!NX_.;?,?[V+M&#^G"7^DL
M"^?.\?T=>+VS%S]H&W;M;C+L)^RD(_Z*Y$8KT"1WG4)[WQVSWC`ZA<@8:R35
MDTNKK>OZE+K16Q1$!.69CV[R(43\/TBKB&VO5-H[Z]S]_`.S;I8W#C^%LS`_
M^HXM>/.U>$]X/#7Q#[J.([Q[)NEHT9N?;R&/_M6!T9'2'T5F`4()S)@<O<*(
M@9/J#K*(>D#$WZBB'O#74:74K0T7$!S2=((U#AQ]"U:HKDT1;S-RYCG1'T:Z
M<QSU,0,F]CW"S%XF8!W`R;IJ=%<@@/CN!@U;*QD\9BG:U\1S:X!S3YC4>I7P
M22VTHGM7.BG&3F$L<.IS2"/2I+4GF?RNQX5!&KY\R.DS;`!4HV;FQML84A0`
M`3^!MB,V@"8`&VP`&WJUPFZ^%WAWO1+MPV>Q,KLW1Q]B[KU0EA7J&Q>.'B]W
M;#6;3WBW,0MR9++\PRG+1<"444K:CYO'*V![2=C98NOJ!.D#C+5)Q`OE2AZ>
MIY5I:*;E.;V_##X^K7GFY?3;X=WE38NW"S>?R3"1H_HRL>?VEZ]LWUF>+VW4
M;N;-IW&,9]I;F)Y_I6\D;?V%):L>=87I3)=^/(]7@"KBFY`^SZ?$R;&?KVX;
M!ZA<C^'7"W_TL9G:MZPX">W]KHY/^2O4MJ^NC`-W[NUCQ=;7GL9-#ZM?G5_J
M]YP_&&3[9;!5<P5-0VW6*M=@+`V3$?3^UA[(+@Y0]O8`1]FN.O?IF[_05-E<
M;9<CHDDC)\SXJ?M+T3;?K5\*KJ@W*SWJS=QK##,T>>.>O[*O1"^9OPIF@()L
MMNH,YP']G8J+=XXQ-@WV.HA!/FX;^CP.(;ZY:Z\!O%.UK3;6S`<8KB!WMD:?
M4NXL?JJ\"[X`G>7VY/":UNF4ZR(G-]:NE%\W.(,R`"QY'8J`1`P]+^P_<Y]B
MG!,=R3#9@8-S&#;P^T'B&X>.N?N/"GQ*M?XVQ[C_`$8]?3^`N776GCQX+WO^
MK]Y]HK^O-V?&G^<:S].8P5PV'(;`$H`#'9SP\]ZEBMP[.2J<(BN;IZ4@`TP4
M1.;K#;;VZTLW<OOE;_Q]IW-N%<;6;+G\"Z2W\2?#J[_U;?\`97^]3"^ML^7\
M3I56M<DXV?'.FRR/CUXHF7K.FTO%6<G(3<"]9R(RQS%+U#MN/AOK6R;'OD0#
MI;&]:T\3!*/:Q;B'O1W7N'%L&Z;:]P%2&W4#B!YI"N=^^U(_^S:F?^]E>_\`
M66HO\*W7_P"4NO\`L9/\E9'^/;#_`//V/^T0_P"6G[[4C_[-J9_[V5[_`-9:
M?X5NO_REU_V,G^2G^/;#_P#/V/\`M$/^6N&ZR-CEAT?'9%Q^R[O5VOB[M5VW
M<Z-NOM]Z5)U]/4&^V^V^I8]DWN:O8V5Z^F>F"4TZZ,4$W>?NQ;T^8W/;8ZY:
MKJ!M:<JR"JI:1S_@:([OWIF[$+#L'*DL#C)--(9)0^W20Y`F3'*8V_LUL(.Y
MO>^YI\OM.Y/J*BEK-B/ZBU-SXB^'MG7YK?MECTFAK>VV!Y']ZJ!E.9_$F&Z_
MO#D;B,IDQ6*<C2V,Y50#(!NH4I(D'QCF#^2!0'K'P+OK<6_A=XCW5.QV3<C6
MF<+F9Y?'I_1QHN>N_''P<L:_,]Y]F!%:AMPV0X9X1Z_-SX55M)CS)>%,-U@;
M-K*6,01#HK]3O$N)A*)`'MJ(5PB!P'KW`0/L(`/LUO;;P-\5+JG_`.*?&#_>
M30,](,M?4N5O?J@\"[&M=^CF(_N;>ZDY9$0T.?/@>2M!.^;OQ*B^H(A#+%I.
M7T?=U':QB1Q^SX`K8)^+.'I'^1ZO>&NEL_IM\1[C_67;=;C]:<O/HCC=[5Q>
MX?69X.VF%FW>+MWZEJU@],TT9]7!6.L7G4T9`%"U'`-QDC``]M:SW6"A$A'Q
MV%1O$1=@4`/1Z%/S]99?2SNSR#N6\VS!Q$4$DA]+WQ^Q<%N?US["P$;-W=O9
M3P,]U%$/.(XYCZU8*9\Y#/\`9')H_'V(,9Q#I41(W1%.WWR6ZC#L3I:MG\.D
MLH`^H&X@(^KU:[&U^F/N;8L[;>MROY(QF:PV[/26O('])>=WWUM>(NYR_+=W
M-FVJ&4G`4N;N3H]UKXP3_0\RU,LO^;]G$I1JT!D2L1CSQ3>0N.ZQB^-(F?T&
M).6UBQ?=L`'](KDQMO'<=4E[M?35W3PW":RN)V_A?<RW3O\`LX7.;7K:%6#O
MG]9_?X5VBWW.UM'Y.BLX+!@!_P"=N&,?3I#R5V:/EP<^<Q*%<YJSDSB6ZX@9
M="VY1M]_=D*;P,`0L$#F"Z@*(_9!R4OJW`-0/\</![NR"SNKM+I'C(PVD-N#
M_3DI)Y]!66SZ8_J'[ZN$O?K?V0QNS%Q?W%V[_LHJQ>;6`KXTCR6,:1XIK9!S
M5<K`I]D5V-,K4%46BAO#K#XZ55M+TQ1'?80(0=M<GNOU2[[-5NS;5:PMX.GE
MDF=_58(F^LKO=A^AGNO;4?WCWV^N7<6VT$5NT_TY#.[ST!4N:9Y9_#&F@B<V
M*%+DZ2`-W5^M%AL0*'#;[9XY-]'0HB(^KX7I]VO-]T\=_%#<Z@;B+6,\+>*.
M.G](M<_]M>R[']+7@?LFEQV@WTP_%=SS35Z2P/9%_P!W12TJ&*<6X^2(A1,:
MT&G)I@4"#6JA`0ZX=(;%W=,F"3LX@'K,<1UYSN7>+O!O+B_=[Z\NB?[V:1X]
M#G$>I>Q;+W0[I=W&!G=_:]NLFC^XMH8S_6:P./6357!.JJIMW%#GV\`ZSF-L
M'L#<1VUI0UHR`"Z-SW.^(DK;U<K4T1-$7SJ+U='47KZ>OHZB]?1OT]?1OU='
M4.V^VV^E#2O!*BNFHU<N*^Z(FB)HB:(FB)HB:(O/3_%#<A38(\H3,U>8/P8V
M+D==\;\?HCI/TKK1<Y-*7B[II%`0,=->ET-ZV5]0$=;#X#K`OW4BIS]7D*K.
ML&:IZ\A7R\]%^5+K2K=IHB:(FB)HB:(OI2B80`/$1]'B`?2.P:KG@$7S5$31
M$T197O+C\KRS\X5WUOM5K>XUQ#%2`Q24NPB@?V6YRB:9SNFE8(^[42TC8XY2
MD<OW!CE*H;H334.4P!!=WEM8,:Z>KI7_``L!H2!^)Q-=+>`P))K2@%5>R*24
M%[:")N;CSY`<3SX#U+VY\&N%>%.*=;9T?`E%KD(=2.[<Y=%(YD^R-<OB#@L^
M<6:[+%2FI-`CE,I2MDQ3:MR@`$1Z0`-664UYN+M4GNVP'NM;4-Z*\7&HS)JL
M"ZDC@`IC-7$G,=7+J"SJ8^BU4&1`J"SMPZC(@575?<`U*]632*4K@0[9$_O-
M$Z1A[A2F4-N/B&WHW`MRTTOF4C)P<#@.DCGU_H6I,CC4VIJ\#$4Q/Z.."JN\
M3<6O6HDC15]*15@E&*::+2-4/.N),>J)-$,(-NH4[EP[>G3.5-02@4>HPGZ2
M";6QL[<6\QDP$K&F@J#6N(J<JTX^=03RF=@B!JQY%3E2F8IB:?R8U464&LK%
MV&S8\QI+MH^T/(A]+9ZSA-6`J]`X^8W8'!Z]IL-,R#@&A9$[=N*S]W]DCYPD
M<ZB@-FZ)`U'>CO6+)ORMKV7^+AE1A1D#1G-,<:$9,9G4@Z2\T&]V#N_\Y2>X
M[0[9JH!F^=YR9&!FW\SOZ(.G%WDP\SOSC$;W'SGE_>6.:40P[+2*D7FOD(W!
MTGD3DM9`.JUFD(V31.F]CL=.EB["L42K2"(=!"IMC&(KP]GM<++23>N\CW,L
M321PEPDF<,0^:M:1U_A6^63I/>]T>F6[+QUXRPV2-DN[M!:-%##:L_*PY&48
MZY,=)P94^\HNX6\K[CWQ*PJ3G+YL^4PJF&&<C\%BSC5B@XS>7<^7)LU^\4ZL
M\<K(MV=0C!`2&7.XZ2F2$W4H7[(&L=WR=WF9\KW=UQPOJ"\%G;.`H':,7-@8
MVH#II`78TBC<[$(^[T.S2ON-S='/<Q'4YSM781U)HYU0'W,CB#IB8-)S>ZE5
MBQ\Q+S?,]\[&D1B"MQ<9QLX98^.1GB;BCBIRXC*5$1C$3)QDI>WB`H.<@7`4
M1ZU7CT#)D5.<4B%W$1VNT[#;;<QCGAK[AM2*`Z&$XN+`227FOO3/+I7\7`4:
M-)NW>.XO7O9:E[(Y!1[W$=K*,@'D8,CI33!'2-HH#J(JL2?H\`\`#U:WRYI?
M=$31$T1-$75R/I2_`?\`*70JYJZW5%<FB)HB:(FB)HB:(FB)HB:(FB)HB:(O
MWEM=4N231%N%44(4Q2J'*4P;&*!A`I@'T@8H#L8!]^K2UI-2!57!S@*`FA5J
MKE@["N1"*%O>(\:VTRH""B\W2Z^[>FW'<1^\?@"2!3"/K!4!]^NBVOO;WIV0
M@[1N5];`<(YY`W^KJT^I<CO?<'N+WE!'>#9MKO"<S+:PN=_7T!_H<HL6SRQ^
M%UK%0Z>+'M174W'O4>XV>$(0P[^)&+J0E(LH`(^``@!?=KT';O'KQ1VX!IW!
MERP<)X8I/V@UC_VEY)O'TJ^!V[U<W:9+*0\;6YGB]#'/DC_8HHY6;R9<&/Q4
M/4\L95JYAZA30E&]5M;8@C^B`C]W0#LQ0'VJ[^_7;6/U0=[(:#<=NVZX'$L,
ML)_M2-]2\SW3Z(.X-Q5VS[QN]H>`D;;W#1^Q"[]I6&L'DJ6]+K-5.0=5?``"
M*:-EHDU$G,/2.Q3N(F;FR%W-X;@F.P#Z/#QZ^S^J;;74&X[+<,Z8KAC_`%/C
MC]J\]W'Z%]Z94[1WCM)!P$]I+&?.8Y91ZE9N:\GKE,P$_P!SV+#MC(7?H[%K
MG8=50-S[?LY:K(ID$0*7P%3P$VV_@(ZZ>U^I?P^F`^9@W.`],,;P/.R4GU<%
MQ-]]%GBU;$_)7.R731E2XEC)SX20`#AQX]!5K93RN.:L8(]O&D#,%`?TH7(E
M*<=6R?<$2D>2\>J(;_8_1`1/X!X>.N@M_'_PLN,[^:(_KVTXXT_"QPZ<\ER5
MW])WCI:_#M5O,/\`FKRU/"OXI&'HRS]*M[(^7YS0C.L5N/-W<@0A#B,8XK,M
MN"@@``0L;/NCJ'*(_:*4!$H>([!K=0^,OA=/0-WJT:3^<2L_M1BG17-<Y<_3
MGXXVE3)W;OW``']V8),^6B5U3S`RXJDW?#'ELR4.DXXX9?`Y"`H;LT]^[(!1
M+U[@JS!PD<>GT@!A$/1MOK8Q^*'AQ*T.9OFV4)IC,T>HT*TTO@AXQP.+).[&
M]:@*X6SW#TMJ/053P<6^3`[;<>\T>/\`_+6V_P#JO6;_`+_]Q/\`SG:_]JA_
MRUKO_:;Q2_\`3>^?[%<?^&NF-Q]SV4QB&P=F`#%,)3%'&=T\#%$2F`=H00W`
M0UDCOGW/(J-VVRG_`.M0?Y:P#X<^(8):=@WNH_\`H;K_`,):"\=L[KJ$3+@C
M+JBBABID+_E?<A$QCB!2D#J@]OM&'\&KCWV[HL!)W?;0T8_ZU#_XBH/#7Q!D
M<&#N]O1<30?Z!<\?^J7:_P#"ER/_`/ESS#_\,+3_`.J=8_\`[A]R/_.]L_VJ
M+_+69_[0>)O_`*9WK_89_P#PU4+7A/RN>*D1;\:,L"H<HG+WJ2[:I])2]0[K
M.R((E'I]`"8!'T!XZPI/%3P\B:7/W[;J`\)P?4*E;&+P*\7IGAD?=;>-1'&U
M<T>EP`])551_EZ\QI+M=GCA<VX*B<"FD@K,4!!)U;]X)*;:F1`W3]D3@`&W#
M;?<-:Z;QG\,H*ZM\M7$?E[5_HTQFOFR6WMOIO\:[JG9]V+YH-?C["/+GKE;3
MHKGP5<1GE=<SI/H$V'HJ**<I3[S5YH+,2`8_0)3II3KI4IR!]H0Z=^GT;CX:
MU5QX_>%]O6FYR2$'\$%P[AS,8'1UK?VOTG>-]W0G988JC_.75HVF-,0)7&HS
M(IDKF0_E`\L7HD^\!Q!72B(`87MW</CIE[G08>W"5R1`VR?VP`#>(>'@;PUH
M;GZE?#J('L?\3G/ZL`;P_P"<D;U9>I=39?1?XP3D?,?X+;#]:Z+J8TRBA?PQ
MS]:NS!^2YEUQVQL.;,80Y1V[B<1!6V?4(&P;@0SE&OI'$!\/2`>OW:YR[^J/
MNVRHLMJOY3P+Y(8QZC(5V-C]#??.2AW+?=I@'$1Q7$Q'5J$(/J5Y8#R5*FF*
M9K7R$L[W;854:S0H>**;Q#<".)>=FC%W#?Q%(?3Z/#QYB\^J;<75&W;+;LZ9
M;A[_`%,C9[5VVW?0OM#"#N_>2ZDYB"TCC]#I)9?[)5\ZYY0G%"([9IV0RS<5
M"=(G^\+BQA&Z@AL(@*%<@8Y8I3;>@%MP#U^O7)7WU*>(ES46C-NMA^K"YY'G
MED</V5W^U_1CX0V5#N$N\7KAGKN61-/FAA8?VE(:K>7[PUJ`IJ1^`ZA*+I"4
MQ75M7G+@L)B^@QB6.5D&@B/K_9`'NUQ>X>,OB?N51-O%S&P\(1'"/^[8T^M>
MD;1].7@CLU#;=WK*60?BN#+<GT32/;^RI.U>D4FCH`UI5,J-.;@`%!*K5J%K
MX"4OH`PQ+)H8^W\X1UP6X;MNN[/[3=;JYNG\Y97R?VW%>J[3L&P[!'V6Q6-G
M91\H((H?_AM;7SJJ3'.<>HYC',/I$QA,(_C$1'6O``P&`6W)+C4FI6G551-$
M31$T1-$31$T1-$6GH3Z^[VT^[T=ON]!>[VNKK[7<VZ^WUAOT[[;^/ITJ:::G
M36M.%>=.:II;JUT&NE*TQIG2N=*\%JT54T1-$31$T1=3/R8PL#.3)4?B#1$/
M*2I4``YN^,<Q7>`CLF`J#W!1V^SX^/AJA-!55`J0.9754:TIW:I0=J2:"P"7
M;+**,_B$WB:#AF]=1SLK9\D4B3]B9TS.9NX*4I5T!(H`!U;!1KM0JJN;I<6K
MPR_QI6<5#R?!/C.Q=AV6T;EC/EF9`<=S+2+N%QQ25U$@\/V:<5/`0P^(=PP!
MZ=:G<'5>&\1Z^7M*VNW-(:Y_#+R]2\*FM<MDFB)HB:(FB)HB:(FJHFJ(IB\(
M>'EUYG9GC<>5\CJ.J46*$KD2WIME%F]>@>X(%:HF#8BDY.'(*#-+??J$R@AT
M$'44\[+:/M7@NX!HS<[@!]IX#S*YC#([2"!Q)Y#G]W,K]`#CCQGK6'J15,>U
M2(8P5=K\8SAHN,9"*)TA:M5C*K*@80(HHN<IN\<QQ$XG$WVC#KG;:UN;V[-Q
M<@.G>?,,,N0`&`'+I4EU>,CB$<.$3<O5YZG.O-91<?U>+@F#)(R#8ZI")';M
MDVS@%$@,7MF.!ER=9C&4$!2`=B;%$0VZMQ]#L;66V8UHTAO)<?=3-E<7BM>?
ME]BN*K9SQ2@/S/309X],5OO%L"RTOWP$$4VZ0('46,JX4$$BI)[*&$W24HG$
M`UOHX8@W5/[S'8::8=?2M89)2\"WKK:<Z^GJ5N+KEJ1K\/.%DK95\7)X[KDK
M9<OYDM3DC:J\<,8S:_<DS/)$QO@U\M6IF0$`:(&46:F'X5$IC&<&5X/O?WGM
M]E>;+:Z2;M*6@"FIL-<`XM;4EQ_S;*$N.-#0+M>['=Z;=&-N;T._P\$T`-'3
MNS(#C33&W\;B:`5)(JO)?RYYW9S\SNP'X">737[;3^'J5B.G8K(Z5<Q][Y+3
MQ'F[V\9*F'"C=5A6)9ZG\4WACJI(@02&=@)BD2)Y[=76V]SH#O7>B5\NXRN#
MV6Y(<XR4PDEI6KZXM%2R+)NIU7+U?;MKGW<=G8%L%@QNA]R!1K6?W-J,R.#I
M,'/Z&X&??%SR[<(^6ZWAI&V-JEF7E2F5HK*K+%:V*D8B>.DTG+(L>F"`MYJW
M%`2"55;K:(=1OL?8^UXUWK[V[YWMO3%.>SL0<(FFHRK[Y!HYPY5(''%=KMMO
M86-@+;:V.BM,?>(TR2$8$DG$`^8]0*O9-U4>0$39*-F"H,LDXXLIWQ[)%9`C
MVED;2BS]9\]7<MFQTTS1+Z/4<"+5Y']I1B782`7I\,/:FW6TR-N;&5T=RW(M
M.5/:#^(<1S5E\VUN8^RF:QS3A3AR\_W]*\</FC^57<>#4ZED_'XR%SXOW264
M;U^?5.+V=Q?+O%U!:4/("A2E.<3`42QTKT%1?$)T'$J_@?Z"[I][(M^B^5N@
M(]W8WWF\'@9O9]K<QPJ,O(M^V%VV/-Q;U=8DY\6GD>CD?,>G#]KLUS::(FB)
MHB:(NKD?2E^`_P"4NA5S5UNJ*Y-$31$T1-$31$T1-$31$T1-$31$T1?O+:ZI
M<DFB)HB:(FB)HB:(FB)HB:(ONJ*M2M76?]<W]8?KTH%74>96OOK_`/7*_P#I
M#_7JFEO(*O:/_,?2G?7_`.N5_P#2'^O32WD$UOYGTK1UG_7-_6'Z]5H%34>9
M6G14J5\U5431$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1%M.&Z#MNNU=(IN&SI%5LY;K%`Z2[==,R2R*I#;E.DJD<2F`?`0';5%5?&S9
MLS;MV;-N@T9M$$FS1HU13;MFK9`A4D&[=ND4B2""*90*0A0`I2@``&VF29XK
M\M+^*OR]_F=YP>3JJBZ%RQP/B#"N(FQ`/U)-7BE5')TXB0H")2*EE\CJE4]8
MF(&_HUH+MQ=.<:C[#B/:M[8M`MP0*5-?L^Q><+6,LM-$31$T1-$31$T1-$5W
M<%X+R5R-R57\4XJK[F>M$\X3*<Q$U/NZ"C`5(1[/SSPI13CX>.(?J44,("8=
MB$`QS%*-LCV11F60TC;F?+,G@,RKF,<]P8P5<?+S#F5^@=Y>G`:D\6\5U.DU
MV$*Y<-DD):Z6D[;MRMVM"R9%74P_$@"L[:E5(9)HV()@01*5,"A]L1T+G/OK
MKMGM(A:*-;R'#K).=..&04LKQ'$8(SB<SS/'J`X?I6:^G8\8M6A%G2:K9H17
M;9!P@+APZ42*519PHE\6X.44]_T=R%'[`%$2B7756$3H@-+:M!KGGUTK5<[>
M/#L`17J.'1CDKGMX485NJ8_<9%:(*O3E=N$A=/F11(H41.H8W9:$!40.JH"*
M@E,84R=)1-KI8;AOPN`I6@Z#T^70M'-&2=5?>IRX='W=`45N06=L;X2JMFR?
MD.^1&,*Y36#:=M.0)Y!NY3QLWEVJJT8]BH9!1J]N^;+LDF=O3:\@0SE(%?O!
MR1(@$42T/>OO2[:6LVG;FB??YA2.-OO:0<GN'`<6@T%15Q#`2NB[K=VG[L]U
M]<U9M,9]XDZ=9&;0XY-&`D=CGI:'.("\RMVDN5/G+65OBR@0D]QS\O+&DXXM
M:</:'Z[)]:E!<"=7-/)*T@8!LUTED]UVT<'>!B"@)-$?2N/@.Z][MM[FO<_M
M&[CWRD)+G5U1PDYT.3GC)S^'PMH,#[]9;`+JW;+?-=;;/0!L8&F6<#$-#?\`
M-P\0S`N^*4UH!DHXZP6$^+[(<.\;XI"=:)-W$):LJ.&!6CFR2`MUR)KP:3HR
M"Z$&JL'40@KICN8INH1W$?*K@[OOMV_==SD,EP\G$Y`<@.`Y+IIW,BMVPM:(
MH&#W(Q2C1TTX\,/8K^N[#*/$7,*YAV3F6=BP6<3!BHGD'$8@!7#8DJ_<=I85
MVQ$A225,<5#``EW$PCOL8;%L8#CGY>52M4Z6IU8Z!Z/-]RY+5=FQBEW*#-LD
MJZ8[HH&%9HZ:!\.9%90J?6'V%DE.HQ1`?L=8>&VPYHA`!=QY\E&YQ+AJJ:%6
MRR$[I.1*A(XYRY%Q=SQU<:A+1%KB)%%,S1PS?@B4Z*K%0IV;<QE&ZGBB.Z:J
M)'")TSAU:B9+>6URV^M7%EY$X%I;Q(X>?\0R(5S[>*9CHI&@QNP(.((X_H]"
M\#'/KB+-<+>25QQ&L=W)4EP8MHQ79W`]XMBH$PHHI%BH](FFW=2T&J4[!\)`
MV^(0$X!TJ$$?HONUOD/>':8]PCH)?AD;^60?$.KB.@KQ[>]L=M5^ZWQ[$XL/
M-I^T9%0OUOEJ$T1-$7P1`/3HBZI^;J,G[@-^4-"KFKK]45R:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB_>6UU2Y)-$31$T1-$31$T1-$6H"F-OTE,;;Q'8!'8/?MJ
MB)T&VZND>D/2;81+\X>&JHM.B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(MU%,554D@]*BA$P_"<P%#\NK7$-
M:7'(!5&."_&8\VW*0YH\S[GQD4%Q<M9?E3F&*C%A-U@>%IEL?4B$Z#>M(L37
M$2DV\.@`V\-<Y+3M'`9`T]&"Z.$$0MKGI'KQ6/'4:E31$T1-$31$T1-$7>5>
MLSUTLD#4*O&.9FR6>7804'%,TSJN'TI)N4VK1!,B93&V%10!,;;8A`$P^`#H
M2UH+G$!H%23D`,R>I5:USB&M%7'(=*]_GE:>7!4N).,(Z+=),YG*EI%"2R/<
M6:[=PM)/CMRF2B(4Q$?B$*W%"/;:HG,45%`,J?<RFQ>6DN'[I<:F`_*M-&"N
M>'QD#"IX5R%!G59T@%K%V51K</?-,OU:G@.C,XK/]C>JHKD*B:)9MF)$"II*
MO"BV=HJ)D-N*PF,0P`F783$.`@.X>'B.MU8Q`"KA[O5CA[.I:>Y>6G]V23GA
MY>SDI%'9-X=@8H*M%5B`D5J9-)$7"RBG4<$DG.X`4J92[#T&*D`>HV^NDLB'
MX^\(\NGT^6"T5SJ!H*$Y]"QS\Z?,%QIQ3KT>TM<HXF,CV-)VA3:-%,5;#,6F
M?B4F4J2)C8]DC\&O]TLI%HL9-TH1J"SEO\2H5OW`-K=[WZSV6"5UHV*2]CP&
MIU(X:@'M;AYP:P5J&@%[S0-::E=!W<[J[AW@N&=J7LL"<2![\@!(T1#-SC0@
MN^%@J2:T6&3_`(?\N<TIF#Y5>8#,!COC[0Y)X]P;QEC9)N:4?.)I^[7&3$KQ
M)!&]Y-L+HP%FK>_(=!J(]IFF1!--,OR_O_?R:<S6/=^1\MW.2+B\=A++4XLB
M`QCAK@`,2*:CDT?0VW;+9[6V.-T3#-&`61#&&'2``Z0Y/D`-0,AB1B2\WBN5
M\LMBC8NG8]@QQ)A&OJ/4ZICBL+O'[5D4RZBCQS,SQ#-G=FG'IB=Q9=P"IP$P
M`F($`I!U&T;!&]WS-Z"YV>)IGU_H65<;@R,'4[M+IP%74I6F`H,0`.0\^*O/
MA&A&AF+=91L1=1@Z06.@V%,554DB`LD85EMEDW(D4*8`(D;<.H`'70W$3->B
M('0T84HM+)<NDJYQP/7@?N4_(,&[^-N#MQ78J;2L:<>Z[9(]DW?IRC,169@@
M^:-V)(ELZ,NLDX(Q^&!9)0W\LA1`TD!YTM.JG`8$98X4Z:4J#BL2A<6@%PT5
MXFAKG@:UZ*U49\]@PBD@^Z8H&#..74^[&"[D7J3M1RY%19,\E(%9KHMTT6_;
M74#],2=?203AJ`EH>`T:65XXK,@!)&HU=3@*<.7V+&IDO(\5&18,F\/(,K/W
M"-I=:5.11I'L&B))<YOA&R"S>32=@GV2E2,04E"G,8?1OD6]F^60S2.'84KQ
MK6M/,:XK8TQSJTGRQ.76L9'.'%K;G1@V0CBKLHC.6`H.<R!CXR;90S"XP1(\
MSNVT!%ZJJX705?,V"2[%(Q@!!VW*4VX*^'4=U;W_`'=W'2=3MKNW-:2<-+ZT
M:\CIJ03RZES_`'GVMFZV),7^MPU<.JF(\_,<:+RC`.X`.PAN&^PAL(>X0]0A
MZ]>UKQU?=41?!$`#Y>/NU5%L"(B.XZHBZ][Z4_P&_*&A5S5P=45R:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB_>6UU2Y)-$6P[=M8]HZ?OEBMV3%LX>O'!Q`"(-&B
M)W#E8PCX`5)%,QA_!JA(`J<E4`DT&:QE2'-')IWSY2)B:@E%F>.AC"/(J16=
M$8"LH+(KM8DND51S\-T]P0*4!-OL`:UQO)*X`4\NE;<;?%3WB[5QR60.G6.1
MNN-Z_:(X6+>;L53;R+;N(J*1J$ZNQ$!(HW!8JIF*<H02F)W.KMAMU;^.LYKB
M^,.&9"UDC!'*6&ND.]2ASC;E3?Y?)D#3+Y&UF.82$TO7)(6$<]9O6$N85V30
MHJN)-RF4A)<A$E`$@[E,/B&L6.Z>9`QX%*T6?+91-A,D9)(%?,KS<C,[.L1-
M(.+K:48]MLTJ=Z="325<M8^";"=([E=N@X:JBN_>?LT-S@&R:AMAV#4MQ.8J
M!M-16/:VPG)+ZA@]JIJ"S_;H/%:>1<DQD2K)VQ\6/QC3H!@[8R5@,4!(,@[%
M9X_6+'N%SE$HD)U=H"B4#&63#5HG>(];P*G(!7.M6.F[*$FC?B)X*,DE?Y>W
MVNT(9]R)9*K$UQ/MA3**H"*KF;46(4*^P9H&48@:/(!P=N':BAB*E`@J=0CM
MC&1SG'MG$`<`LP1!C&FV:'./$\N?W45&4^2"1OA&N/<AR>(H[HZFDE>[F\74
M<JE/LF5R:,C6\8*KD1`.RJ042EWW4-Z!L:ZKZ1DM'2?(*21NF*LK`]WZH\BI
M[XJR]8UK*;%66FK%C>BM?C*Y88LZ)Z_?(PI#G*[C5V_^YG>'02,H44=DU@(<
M.A-4AB#G13.)[.7X^!YK630,T=M!4Q\1Q"DBLL@V16<N5T6S9LBJX<N7*J:#
M=LW03,JNX<+JF(DB@@D03'.80*4H"(B`!K(.`J<EBK%MFKS,*]6Y)[`88K+.
MZ'9*G;KW:R.';*L++)F$AC044R%"3EVH'#[+A59JFH'B0IRB!APY+L#!@6?%
M8EPK*:='%1H-YB_*1N)9)S#4@D88>LH+X_ED(XR>^_260-+D4$HA_*[HCJ'Y
MF7/#U_>IODH,JFO6L@3[DOD-CPP4Y%RM;K$)=7[5DXKT.F23>P#EK*6MI`Q$
MDY:N7:+\I9)@=1R"(.!`I1(('$!VUE=L[L.T--7Z5B"!AN>Q!);^A;'"7D=D
MOD4SR/(WUC56;.J.ZU'Q(UJ+?1QE7<JA+.G_`,89Y*2(*E20:(]`%`FPF'??
M<-EO*Z6NJF"74#(2T,KC7-5WS&SM9N/N+(RWT]M!N[#*W.*KK9&P-'+Z/^#7
MCI:1D%`;M7K!8RY$X\H%'N=)>H=P'PU=/(8F:FTK566T39I-+JTI5:.'&:KW
MGO%TM>;ZTK[1ZE=).OQ:=<CW<>T/'QL9$+J*+)NY"145<"]?J%Z@.4H%*`;;
M^.D$CI6:G4K55N8F0R:&5I2N*B9R;Y\Y`QGF*R8]QC'4N0A:@DRBY=_/1<C)
MNU[,5#XF;20593$>BDSC3+IMA*)#""R*@B;T`$$MRYKRUH%`LB"T9)&'OK4^
MQ2EX8\A+-R(Q]9YZY-H)G8ZU;S0BR->:.6+$\6ZB&$C&KF;.WK]8%S*G<$,;
MN=)@(&P!L.IH)3*WWJ:JK'N86PO`;721Q5L.:?+J]\>;13:G0XFIOG%@K+RP
MRKVRLI%^JSZ996-8(LV[*4C40(J5HJ8XJ=8B(!ML&^K)YW1NTM`Q"DM;=DS2
MYY.!40%>?_+J+8-K%*TJM)5UP"*J$F_QC96$([2<=(H"C,C*(-SIN"F#MG(J
M/7N&PCJ#YF48D8>=9(L[<G2":]8JI\\2N8,?R0^^:U-5]O4\A5]@G++L(]TL
M\@YZ&,X29K24.=T'QK19BZ72*X;*F5$H*D.10P"8"9,$_:^Z?B6'<6Q@HX&K
M"HAYI\P/-57RW?,?4&`HJD96+?*U:'67K\S.S<H:,="Q$ZB:<TDBLZ6<IG`"
M(H!OX``".H9+F0/+`!@>E9,5G$Z,/>34BJH,WF)\HJNY;GM](IY&ZQ@Z&DY1
M;-5S.@#Q,1LZ-+-E!.(>L"GV]FK/F96YCVJ[Y.!WPN->@@J<F'.<M/RY3+0[
M3@/W=R358UF]7I3^5`\3+)2$K'P2$S%S_P`,17[B824HB:1[B`.63?=3I4+L
M;60RY#F_K+%EM'1N&-6'BKR8/S',Y,<3<;8(1O%/XV/93#95JS>19CL7CI9F
M*$C#OY&5=,53'3(LT6%?I>MCB<I"@GU*21R%QH5%+&&`$'BI":F4*:(FB)HB
M:(FB)HB:(FB)HB:(FB)HBXK^50@H^1GG1BD:P4;(3;DYAV*5M#LUY%<QA\-B
ME2;"(^[4<E-!#LCAZ<%<VNH4SJOPQ+[:7-ZO=XN[U057ERN=JMCI4P[F5<6.
M>D)A901]8J*/1'\>N;)J:KI@*`#D%2FJ*J:(FB)HB:(FB+6FFJLJD@@DJNNN
MJFB@@@F=9==98Y4T444DP,HJLJH8"E*4!,8P@`!OHB]=OD^>5D_Q0E$\C,VQ
M@H96EV1'-3K3IF5P3&L"\*0P*R)U-D&]PF4#;+FW$&*'[$!`YE1UPV\;Z+R0
MV%DX_*"NMX_$0?@'ZGYCD[AAGO;6T^59VTP!N'#W6G\((S/ZW(<.M>L_%E*,
MD=!W%NE#MU"@84S$39()E%4H*%533$4RM@'?8Q#]6P#T`8WCK/VMHIV@^`9C
M(>KA7I\Q*U-VXBK'_'Z3Z\_1UJ:$!32Q?P`*[NI11`HB9BBF+(.M0ZB:>R[U
M/H=%3$3G.8J1C%+L.VP&UTK'LCIII]U3E^G-:5^IY)-0WUG#/++HYKNY,K-J
M4!>)+?"(I*"=HBL!>YW2`1198ZRZAND"I%,;[90'P)X`(ZSX)&",AKO>)J#P
MISZUBR1O+A4>[2G3U#^18(^1O'.CRO)2P9]&"C;1:7\-'5>'A)-56081/W`W
M0-\6JFW(EVHNPGZ$Y!NFZZ7`(](%)UGW^>/$R*YWG?9K/;VO9:2.8]Y!-'/:
MP,U$5+:@#W3PQPQ7N'<7=)=LV2*&=S:QZJ8#5I>XN+:TU`5QZZ<`%L.L?V>P
MM&]AR#($EIHC%O$0M8*FFQ;Q<2BL1N6*BFJ9/@H:(9("8[9L@'2)0\1ZMQ'G
M]G[K_(.:V%A:"<7NJ23F*UZ5M[[O`V8D-P&=![>GK*N)B;&=87L,/"V$\JSJ
M\X(1@/6XIE.S63$>A%!T"*C$Z*A^@R@*`79,HB/3MU%W5Q%(SW7ANH'AQK]U
M5K!/VAU`_>I`AQYME48`XDH-TW?1A5I1HY1=%EE9B&92A?C4T7<8[7^'<BP,
M"C<`*<KH`,4.@Q2[X#M;06N`P&%./HR/$+)U`.JTG'[NGIS5-2>3E:HLZ^),
MB[A7K3M1P&:*1#IH@18PJH**JO'IUW+-V!@*I]D`*J('\0':&-[M>D8@CR\Z
MR6AKV4;@\9\?N4,>2N3VD9`+*K,FZ$Q&*@L94SE<'$NWE$P1>5]!DW^P/:^*
MZC+F.!5!Z0(.PCJ>UMG3RB-PPY_;YCZ5E0D8EA-/+'R\ZPHY)R%,/+`BF^=)
MMF((.G)7+[]JY%,RQ&GP3XT>Z!(Z98Y($W&Y0W)N0/M`.NF991=DXQ?Q>C'A
M6HZ>(5S[O0\!U.RIQ]GZ5UV(LBJU;,4)/G192,*S=O*PY8LD0!*20G")-I-P
MI#.%4R$5=M%"I%,;TI;%-X[#K3;J1+8"&-VF8D/J<ZM.&/"A]"S+=ADE<'`:
M*:<,L:'[NM>:3E7B9U@SD?FC%;ADO'MZI?YY*%07252,>LR;LTQ6'"95@`YD
M5X%^W,0WCN'KU[CLU^S=-IM[^,U$L32?YU*.]#@0O#]WM#8[G-:Y-;(:?S3B
MWU$*P&MFM<MDX[C^#Y#HBT".WB.B+K79MS$_`/Y0T5P7$U17)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB+]Y;75+DDT119Y<7S]U<9&KK1;MRU\=##E`IME$X-H";
MJ<6\!`0(N44FV_K!<?9K%NGZ8](S*S;&/7-J/PMQ\_!0QL>-SP'&ZE7)PW[<
MA9+ZYDEC&+LJ2$?0[IC!D$1#<$UABSK@'K!<!UANC+8`\\2M@R;7=NC&0;3S
MUQ4XN)DU][84@FYC=2L!+3T&<-_$J:;X9)L`_@;R1=O<&LVU=6$=!6MO6Z;@
M](!40>65)6I>4T;=%D,U8W(J5@:KHEZ2M;+&*HDE2D,'@54ZY478>L16,/JU
MBW+-$FH9''SK/LI.TA[-V;</,5M42NSW*',DA9K0F=.O-3LG]E%$RGPS6+:$
M*A%UA@J(!TJR0HB`[;&!/O*^`[;F--Q+J=\/E@DKVV<`8SXSE]I59Y8R66M<
MC49]:#"3K&)636KQ$>FD4&$3,/*X\=Q[END.S=%=*5,`I@/_`$33[/B0NKI7
M@3U(JQHIZE'!#JM-`-'R8]8KY>E1TRUFZ"X>XKI.05ZE"9#Y`YQ-,6.LEMJ2
MKNO4VMHN"'<V%VR3.DL[?/W3Y,4R$41.J=0P=PA$3%4]V\"O!L>*6XW%QN<T
MEOL%EH[5T=.TD?)4LBC+@6M]UI<]Y:Z@T@-JZH^3/JR^I@^`.QV=ILEM%>=[
M]S,@MV2ZNPBCATB2>8,+72>^YK(X@]FHA[G.HS2ZUW'CGJ?DI?H7"')>DT7M
M9`>A`4G)%+A!K<W4K6_`R<(@\1,[>HNXR1>B1N!B&2Z%3D!4JJ9C"3V#Q<^F
M;8]@[K7'>;N9-=%]E&9)H)W-DUQ-^-\;PUKFO8*O+3J:YH(&DTK\U_3C]=?>
MKOGX@6?<7Q,MK!L>Z3"&VNK5CH>SG?A%'-&7O8^.5](VO8&/C>YI.MM=-^&U
M"EJW%WN<9VARUN>`[<T47@%"&%HM&C,H,V\["+`N!F0A(H@+A$4Q(HF8GV@$
M=A^(PW2"X'WF'RHOU/,C7N:QS?W<HS\V15Q_,1SD]CL14"D5UT=BMF5B6PV`
MZ!Q36"F,FL<Z-$@8H@)4)B6D4R*^/VT6QR#N4Y@UE7,ON`#BL&SA':N+OP&G
MG7$\OCC)4"46.SA=()A8K/9WCW]R&LNU1?,*Y!1SQ:-)+-F+DBC92;EWS94Q
M%SE,9!N4@)])CG$:6T0T]HY+R=VLQ--&C-2[DN6W&!LJ_A);,5)ZV3AU&2$8
M[3DG""2[-91H[9K-S1"K8X(K)F(8-C%\/#<-3F>+(E8PMK@XAI46^=^0Z58^
M)5<=8YEHJ4J%JR'7H:%<P2!FD2HRK"4ZZ=-&+86[0$6S!W$E3Z"IE(42;%\-
M0W#VF$%N5?+V+(M&/;<$/!U!I]:[/RPX7X'!]QG#$Z36');],I]O%1""@(5F
M3Q_5(X=*_CWU6T`T%W&JI?&LH')JH3S4)KMU?#5<*;Q>6.V3RA=_22,BHR-1
M,(>SJES^.J7F0\O+-76`]YQZ`KF\8K9'X+X%MLE214]F+&\W!JW/L'WC+R5E
M?15;8``[=PT@_0:I?T1$?0&JQ$1V^ORXJR<&6\[,<P/5BL>O'?$LME:A\K<M
M3Q#R3R)QI:D(Y^X*)S/KU.=5MFGJ8F`=UVL7%G`1#Q+\<76-&PO#G]!\O8LR
M:01OCC&6H>C+RZE('RL+."5GR]3CJ?8DZ[6K4U3$?TE8>2>1+LY?'T]F<1W]
MP:FLS[Q:H;]ONM?TD*S/F33`RO)!U%D/U!7<?5*)*&_@FN]3DIQ0ON$0EB".
MH[DDRTY!2V(I#7FXJ?\`E?D[Q[J'&]]1F5\JU^E7.*F]$B*=77I)\74@:KH0
M2!Y#X<BS*-CXUQLLHJL8@E[7[,#*=(:F?)&V/3@74Z%AQP3.FU4(&JM3AQ47
M?*^QC83W:SY@>M7#2HQ=:=4^,D%TS)HSLS)/XQW)@Q.<`!RVAF49^W4+N0JR
MQ";]0&`([5CJE_"BR+Z0:1&/BK51YXR==]YMU&9/NI\9E"YW90Q=Q_9LBV2P
MHJ=7I`"J$3\=1QC7-UDJ:?W+4C]4#V+T"7*FUO)-<DZ9=(IK/U^=;*,'C.02
M*X[8."BF1XS44`RC.09G,"B"Z8E424*!BB`AK8O8TM((P6H8]S'!S3B%YRN.
M"*M5Y6X_KR8)2C4N2W^/Y5NNDDY:3<!).)2IS+5\V4*=NZ9R$:L<RJ9BB0P>
MD/#6LCPE`Z:?8MS/[UN3^K7[5Z-:Y4*O4$73>L0;"&3?*(JO3-2JG7>':H_#
M-/B7;E5=VNFS;!VT"&.)$$_LIE*7PUM0T-R6E<YSOB*J+5RM31$T1-$31$T1
M-$31$T1-$31$T1-$4=N8-J-1>(G*ZZD4[)ZCQFSY9$E=]NVM#8HMK]$^^X;"
M55`OCJ&X!,+J<,?0:J6'^*T<S3TX+\1-#^Y1_P#-)_\`,#7.+I#FMW1$T1-$
M31$T1-$7HT\EGRYT+\[A^6^88A4T*SEU4<%UF1:G!O,2T8?MO<B23942@ZBF
M+@1;113%%-5R!W`;]M+?B.]F\21TVBT-))&UD<,PTY,'(NXG@WK6]VFT`!OI
M14-^$<"?S'^;PYGJ7M4H&.6\0T;1CQ!<OQ!&YF#A-B+M-7N'[CB,?F1$I54-
MNH`(`E.(AX;=6X:3;[%X#6XAN0H,*\G'B#RSY9JES/K<9#2O&IH>L?>L@E&H
MJD&QB44&*\4T71,Y154:JIG%PX*`J@1DX<"RCU%B#L8H=0`D)0Z=QUV-BPM;
MV1JUH-3A3S`5H.E:&Z=J)=\3\AC@1SK2I5^3UY9G$KN6_::.$>@YR/P`RZBQ
MB@!7!W94"$%!3P-N7J#8.D=M3.N"':F4,/"F9\_6H1`2*N)#^(.7F"I!6H./
MAGK^3*QD%6G=.VCC+"?K<N"G03.DMXMO@TEPV$Q^D.YT]0].L:^OY^R_=Z@7
M#,?:LRTM(R[WZ%HS!\O2H5.<:#+((%>O&D:=RX>-TI!$T<=5D[>'4=K+S2+Q
MP3J476(5$I@$I$BAN4=AW'DKQLDK^UHX=8Y5PYXKIK8MC;H!QKPR\@M*>$(%
M9D8;(E-&=,I1P[2(:7@0*>,,W.BD0(Y%\FYCU5C"4Q2G.9)=/Q(!O#6FGDD#
M,1@,*5'D#T\5M(6M)P./4:>GET+FUA$*S#,(-`B3JEMIM.?C49FM-)%\J_1<
M&!,H*I'2>PKET!#`1-45.CJ$0$`'PU;KC'1)D:FF!Q^PE9[8P[WFG'FN%<[=
M:[%.J33V6=-W,6Z>C"LR`FU38E^)Z6R:S5,$FBRS95$@B4Y=Q4*!@\-]:RY+
MG$O9\0.'ET+,B]WW*"B@/D]:4%M+2;GI,F[^\)-NT4`7H,E2N^E0SHAP%42O
MG1#K`01V$W6&^X`&L"*5X=J-=1^T^D56>"VE!P`'JX]06,;+UQC[-%$9L8LR
M=@5E#D5?O!%@A'IM_CB@^0;=9"JR()$`H'*0W:,7J$HB.X;J`&#WGO\`W=.%
M#4\J^55G1,<`0WR*AVPQW#6X+:B>-[]QF&#YM563I)R]1D9$Z"IUE&23!J/P
M;AHGTK%.X%$A1W`0,)A$&X;K+;-C8QVFW%"XC#2T'&M3D<1AB5D0VK'ZGR#W
MB#GS.1\RM?3Z&JPFG#F=8]"R782>E035.G]\HI_92Z@,F83I*(IB<!V$!V*'
MH'7([SO;9(!!:NHS4:4STDUZZFI`6^L+(L=VDN+R!7D32BQU>>*RA%>1^(K:
MU;_`6>V8`K'[XL3`0'`N:Y,S,'!2+KI'[;AY"()IB8?$Q4`W$=M>U>%<D[N[
M1CEQB9</##6N!#21YB3YRO&^_L,4>[-?'\3H\>FCCC]GF6%D1V#?7I2X=;&B
M+9.;Y@_+HJ]"ZY<=S!^`=45P6QHJIHB:(FB)HB:(FB)HB:(FB)HB:(FB+]Y;
M75+DE]`!$0`/$1'8`]HCZ-418D.1]L?9/S$_AX)%U+MJ^8*=7V,<DJ[7?.FA
MU#RZS-NW*=1=5U*"J`=(")DT2^H-:N=QDEHW&F"WEHP0VX<["N)KZEMWVWY_
MF*(6MW:K24;2(D(<2F4H9X1M'%BNVTB@&1!FE\.0G65(-S!U]6P^G1YG+-+P
M=`Z$B9:MEU1.!D->-5(7A!.IA`Y$@G"Z:2<=)1-A`RRA4TD&SQBZ9O5U#&$"
MII)?=9#',/@`>(ZGLW>ZX'@L7<6^\QPX@CR]*LODNT3_`"9R\PJM.$RD"P,_
MCZNFKUE:_"-4S.):T/BE`1)]XBW#H$0W*B"1/TA'>&1SKB72WX1Y561"QMG`
M7R?$<_N7,XBWI6I9)<TV3.=LPNJ9HLR"P](-;1%"NI&]11\"*KE[[4WK$YR!
MZM5M7Z)-!R/M5+Z+7%V@S;["JDS`I6ZWD?/-4NWQ+)GDV$K5FJ,TFS4>(,+#
M%(BO'*.BH[N$V:[TKAJHHF4_0`CU!L.X72Z6R/:[)P!'F5D&M\4;X\V$@CH*
MB/RGP/;N6F$<17/$+0MER3@R!?4.Z8\;.&Z<])5A9=%U$SL`V<*I$D%&YVXB
M9$I@.L58Y4^I1+H-]3?3-XK[!W(N;WN_WGE%MMM\Z.1DY!+(YF-+"V0@$M9(
MW31]-+7-HZ@-1\`_75]/?>_Q6L-L[W=Q(#>[YM398I+5I`DFMY7"0/A#B`^2
M%^O5$#K>QX+`YS=)C9PWX29?0R[5,L9GITYB3%&))YA>;!-7EDK7GDL\K#I.
M3BH&"BGX(R;Y=]*-T@45!($2I`8"F,J9-,WOOC1XX=R;'N5>[-W?O[?<-\W"
MV?`UL#Q(R-DK2Q\LCVU8W2PG2RI>YY;[NFI'R!]+WTI>*.Y^*&U]Z>^>TWNT
M=UMHO8[I[KJ-T$L\MN\210PQ2!LCM4K6ZY-(C9&'DOU:6NG1<U+=,(6?+C!/
MX>$S3;;73D(LQ1%VZ;`[C))D0R.X=8G<MB$(8H#T+MC`/@8-?FLZN+VY.P\W
M#V+]QFEE1"_XV`&OM5OO,BK$E7;!@1)P4YF3'$9*P1;8>U]ZUZ13"32*;T=S
MMOD#;>GIVU+<M+=/*E%C6;@[6>;J^E9#^"UZ@KCQMQ]'PSMN>6H4:>HV6-2.
M3XR+D6#UVHT<N&P"*A$)5BLFX15$.A03&`!ZBF`,FV<TQ@<5A7;'-G<3D<0L
M3_-3CO4./5DIC.MV6S6)]>&=GLDR:QA%%%IV95JBW%H$8R:#TN7#EP)Q4ZA^
MP&VWCOAS1MC=09K86LSIFG4``*#!5]R1BW5>X4<-8D$S)MWIIZ?>@!1`HOIF
M-5F6HJ#Z.LS>85$`'U;^S59`1$T*V$AUU(5/[R[SQQ^+E9(P4(HX1MEX3ERD
M$!.C)GFSK%25*'B0YHQ1L<H#Z2&`?1K*M:=GTK#O:]N:\@H&>9M>&$_F2JT^
M-<%>*X^IQT)A-`_=^&G;-(?>9XXP$WV>(Q;9H8Y/TBBJ!1\0VUC73@Y]!D%E
MV+"(RX\3[%R.8EI<8ZP1QRXQI+=B1BJ/7KKD)L4W0*#H6BH0\4[*`@)3!+.W
M[DY3>M%(WLTE=IC;&//Y>626S=<SY^%:!6VQI;^:&-\=+T"A8PM2-'G4Y9^X
M*KAQW*K2R5I9%1>NU)9>+.NY3=1QB$2.!MBHE*!?``U1O;-;I`.D]:N>VU>_
M6]PU#I6QY>]A_=GD_4XY0PHHVF!ME153,(EW74B3RS-(X#L(G![!D*`#X]0^
MW2W.F4*MX-4!/(@^7I75\DVYLG<UKI6R+*`2<RE6:`FLATF5000+`598Z`'`
MR8J-A34,7J`2]0>(;:I)5\Y!S)`58?W=J'<FD^TJK.8O#R)XWQM3LU4M<U9:
MY8Y=]7GB-@:QZ,E%RK=D:19JI.8Q-NV=,W[1!8-A2(=)1+TF`WV4L/94/`^7
M0K;:Y,Y+7`!P'!9(.,&8WELX</;A+@R1E<=UB_UU^=@T:1K94:?"N7L8\^"8
MHMV;5=S&.6XJ]M,A3K`8^VYAUEPO)@)XA84\0;<Z1DXCUK'3Y:D,:3Y&%E%"
M]7[NXYM4B<PAOTKR!XF$(;?U"8)(^L:U%9.H+-OC2&G-P69C.N8ZY@K'$[>;
M"\;I/$63IO5(A14A'UCLRB!RQ4;'MQ$%5R%="51PH4!(@W(<YA``#?.ED$;:
M\5K(HG2O#6^?J6%[R^\<RV0N0[*\O45%XG'"4C<)N1,0W84LDLB]90+,#B'2
M+IU(/%G8%WW!-J8?9K`MV:Y:G(+9WCPR'0,W8>9>@#6T6G31$T1-$31$T1-$
M31$T1-$31$T1-$31%CW\VN9/7O*W\Q"82,<JC7AOGY(AB!N8#2&/IB+`0#J)
M_C?:&P:QKIVF$](/]DJ>V%9V?SA[5^,HF'20A?U2%#Y@`-<^NB6O1$T1-$31
M$T194_*^\N&S<WLE)62UL)6-X\4250->)AHFJB]ND@@7XHM"JR_2`&77(4HR
M3HNX,VQP*'[95,`T^\;M'MD/NT=>/'N-_P"4[]4?M'`<5F6EHZY=4FD0S/V#
MI/JS7Z`&"<+P<3&Q,)$0+:O1D3',HV#B`8E8Q49&,2ILXZ+BTDBG0:L6J+<"
M@!2@8.WX@41UQVW[:;B1UW=ESI7DN).;B3S6RN[H,`BCIV8%!3,`<PLKF,<;
M1M?:QKV12`Z#\ZG=<"E\.DDX[IQ`A"K`!E"D15$I!$I"B4?'PUT3F-T4A.@C
M'@M.YP+Z2>]7)2.;L(B/BDDP^(<HD.KVG"Z14P*@(`54BBH@1<Y!*4!$2'V*
M)?9XZ@9),0.VH#RK0?I*JYD8KHJ3U>6"IN2/,2RB"R*"7W.FJC'.%%'#ULTZ
M3@LW$Q"(D,Z44.FI]D_B7Q`!W#5]Q)'V>D.:UO3]E%=`PEQ>02:</O5LB2-C
MB)F=KS%"$F'16*A81F[1,N5XW;'(?[AF&:"_2J19H<54URBCW!W#N&$O2'/S
M3AI)#M9SXBGWK=PP`@$@M&7\AQ\N"[-]'5[)964;+-6=4C&*:).Q",$X@Z,V
MJU.5XS/)&(J+L.D0*"/5T"'H$1W#6MN-SFF-2VF&6/IJLQMDV!A+/>?UUP_0
MJ`M:55Q^$Q4XN8GI*2D&Z2\D8$6;UJBV5)\.#!TL_1.)RG:=*B0DZE""0OV1
M`VX\Y/.7RFE>G$TKU&N"VUJUSXVO>T-'"N)(YX9&M<%:R>E:PA6%8]%S*J.1
M*U(<KQFF1TV140>J+,V"K?MD*CV"%%,G2)@$#`!R[=.L1SG.&E_`4R]BSVZ0
M>;?+RJHG7JXP7[=)X9?M@<H*N7"9R'=-U7!SL#D1$HJM5P24$3'.)OT`$#>&
ML.1NJM0>ORR4K7&M&Y!0SO<L=Z]EF4%('8J@91`K=*3:$7<,P4^*4666>*]:
MC4#"<I>E/J#I,82CL(ZU\LIMW!U#V)P-036OW+-A;K%10N'EY>909OT0NNHF
M]0<H3@K)+IJF=F:&<@NLN42)'00^#513[272"A$Q3,8NVX>&\PG-*2@L#:$4
M'(8\Z9\5LX<O=S*C,RA9)E-N7C)H[CY955P1F8%UDS-"*CVDUA2(NHJF8"''
MK,8Q>HI=A]NM1N=]#+"(II"8&MQ`IC3/'A7ETK?VT5#K:/?/$_=Y!2;Q7B"-
M(8)B678/4ECB0C-82J*G>I(B=PX<(J[@DY(<ACB._24!#Q\-<0RZ%Y-VHP;J
MP%*8#(4\N:GN[AT,79,J'<37/RY+R*>9]F=MFWF9E*6BEA6KE'58XPK:A'8.
MVRT=3"*-7+MH)!%%%![++N%`(3[.X[CXB.OL3N1MK]K[LVT$HI.]O:.%*4+\
M0#U-H%X%WJNQ=[U+IQ9'1@Z=.9_K$K'T<?0'XQ_T:ZM<XMDP[!OHBXBAMM%=
M[2N$H.XA^/5%4+;T54T1-$31$T1-$31$T1-$31$T1-$31%^\MKJER2IJYKV)
MM4["K46'WE:/NIVE`,_B&S4IY1P3X=JL=P[50;ID9G5[P]1@W!/8/$0U8_4&
M'2*NI@KV:2\:\&5Q4+^-G'Z[T^_N+CD*')'!$Q;H(/JDXV15=S4H86SAX;X!
MTY%,S1@=8>H_3N=8!#<0';$MX'MDU2#(+87=U')%V<1K4XX4P"EOE:M.KGC:
M[5=BD#B0F*^\;QJ)U")%5DDNAW'D%54Q4DNMXW('480*7?<1`-94K2^,MXD+
M!@>(Y6O.0*QT0.".2-:C+3%P]6(S;W&(0@YHR=BKP+*1J3U)\=NBH65#M?$B
MF*2@AN)D3G+X`8=:\07#00!GTA;9US9O<USG&K348%2KXP82D\81DS/VYDBT
MN4VK\`DV(X;/!B8!H<JA$BN6BBS<5Y1V'=4Z##LFDF`^.X:RK:$Q@N?\9]BP
M;RX;,X-C/[L>L_H5ALL<<LH#E><M6-H)-S%/)=K:(EZE+Q$>9A,*F2?NTBMW
MCULN7X:8(=0H@7I$I@V'TZ@EMY>U+HQA6O!9,%W#V`CF/O4H<#E_(I)9BQ-+
MY9J-7L;=BR@LJUIFVD&K%^+%Y'N'"J:2\M5I!0?BHYPS4>D$R!S=:.XB4_V%
M#B&1+$96AV4H\J+$@G;!(6'&`^0*@E<Y^OP+Q@,#2+;AC,#-R5M.?=L^K"U1
M+[92K.6+)SW9!NU>C]OH36(T2+X@94NPZPG$-.`+9?0/+RQ6RC:]X]YPD@X8
M5*Y-]=MY&EB[N>=W63+JJJR2@*;!OI.4A(I154@N9"5D7;5!DZ<-6H&*1-!,
MAS*F*`',4!T>:M]Y^H\N'EZ$CJ)/W<>B/B3F5)+!6*+59G-'M^0XPT#4\=Q:
M+;'%*<)G37<R)S?%.K9,-5BE5(J[D#"Z`52E455[8`4J*1>O)@B<ZCGX-;D/
MM6)<3L8',B-9''WC]@5ZN16`:QR*H)Z?/.E(B5CW8R]3L[=`KES`379,@911
ML8Z?QT7((&[3MOUD%0G28IBJ$(8)Y8A*VG%8<,SH7ZAB.(6(%7A3S'Q+8%9'
M':+EVN3J00L^-+TVAUWC4#=12N&CZ1@90B9A^T**J9R%-ZQ].L+L)V&K?45L
MOFK:04?Z"%R'O#/FMF*4;2&1Q5^+1:BP0G,EY`922T>R,H=84&S:.=ST@1N"
MR@G%--(H"<1'T^.AAG>:O]95!<VL0HS+D!_(LH>9N,C'+''JM8="3:Q<_1X:
MKA49\R2RD<VL%:@DX90':1"?%##S3<RR2HE+W4RJ%4`HF)TCEOAUQ!G$+`BG
M,<QEX$FHZ"L5M?XX\\\0/9:'Q]$7B$;RJI22+NA7.%""EA2**2+P5`F&P%4*
MD;8JJB*+@A?`>G;8,,13LP;4>=;`S6DHJ^AIS&*D?QHX`VQK=X_)_(ATS.K&
MRA)]G2RRA;))S4^1<':$I<I@BB[,Z#9V`+F;)K.%'2Q0[IRDZBGFCMG:M<F:
MAGO&Z.SA]/W*C;-Q-Y$9MY-N,@Y/I)82A6*_-7<PY6M%9?J1M!AER)QT4FR8
M2[IXHLXA(])N)2)CLLN8P[!N.K3!*^2KA[M?4%5MS#'!HC-7@<CFLTR9P3.G
MT%!-)(4P(BG]E--)/8")$('@5,A"@4`]``&LZF%%K5A$J7#[D/0>3,-?X2B)
MN*57LRC8&<FC9ZLD9:FJ6E951P1BK,)OB;UYT?\`8F3!7^3T[^&L$6\@EK3W
M:^I;-US"^`L)]\MY'.GWJH*/Q,SZIRXCLK6^D),:6.99J]OI8;)6G9DXL)B5
MEXE;X!K*KR!Q5/\`#%Z`2$Y>KQ`-AV"&7MM=,*U5'7,/R_9M/O::<5-CF[AZ
MWYKPNC6Z'%I3-KB;K`6!A'J/6,=WVJ3>3C93H>23AJS3,FUDNYL8X"8""`;C
ML&LBXC=(RC<ZK%M96Q2ZGX-HH\X-P/GNC<4.16*9JF%8W"XB]-1XX+'75TY,
M+!!1\++E^/:RBS)B9NFR$P]]1/KZ@`-]1,CE;$YE,_N4TLT+[AD@/NC/`J&E
M*XQ\YL92KR1Q_3[A3Y219_=CV2KUJJ30[J/!=-S\(NY+/&*9M\0B0^WZQ0'4
M`BG:<!CYEDOGM9!1Y!'4?N5TX?@3R@RY8&\YG&\(PB6Q2N).R6A?(%J(U$P&
M4;1<:R=N(UJ)@]!3O$4@-L(E';;5XMY7FLA^U6&[@C;2(5]066G#N'*/@RE-
M*/1&*J#!-4SV4E'QR+S-BEU4R)N)B9=)II%6<J$3*1,A"E102*":92E#QS8X
MVQMH%KI97S.UOS]BNGJ11IHB:(FB)HB:(FB)HB:(FB)HB:(FB)HBQ?>=DJ*7
ME&>8F<I^@1XMY!2WZNG<%RL$3$WW#^\*H)=O7OMK#O/X/I_LN659_P`=O6/:
M%^.?K1+?K[HB:(FB)HBF-P9X>V_FMG:&Q7`JNHFKL$D[!DFWH-CKEJ]01<IH
M+'0V3.D,U,+G!LQ(?P[AC*&`2)'UK=VW.+:;)UU(-3ZT:W\SCD.@<2>0YT67
M9VINYA'72VE2>0'+IX#IZ%^C/P\XG8VQ+CBK8<Q]#-JM3ZA'H(1,.W65;&=O
M%>X*S]S("05W<W,OE#.WZ_VP65ZS&W\`UPEKVE_*^[OW%\Y%<:AHY-;R`KEE
M0<5MYW]B&Q6P`CR&1PPJ3SZ\Z\EENQ_C]"O,`(>.<R2Z:3<SEV)2KG*8@&!'
MLIF1(U;(]&ZFR@@``(@8-_'6_B<=(8VM1Z3]PZ."U$N+BYQ'V#GUE7I-(O&B
M"G4\3*":!5VZ22;=P9$P)F30*1R4X-VZ2Q@$IRCX"8=BF'8=I6N!=@,*\Z5I
MFH'`@=/EY>U<Y&4?3#)NV<&<2%99N_BG<N105%VXJIB50O0W,18S1BHH!E@!
M3I(E]D.H1`-03@25((IC@,QT^8<EE0@T#'5KS(]2YM>E(BN@I&QBC]K-`M^P
M+9W9TH?I65()%VD<Z56=L0<MS"+;8`[@^!A'Q#6L?<10D-C#>TJ*5Y'C3GR6
MP9%(\5>28^('W\N:Z"[S`IJJHPCN,=F6<B)3?!.BMECD!-P].NX9+(;KI)F%
M4@=8)G'J(4.K6LN+IKO=+P6UX##^5;"WMW#$M(=3F/8>"M]+L+`Q,R;S\O%S
M4"NZ64B&BR::*3<AVZBI%FI"-C.F9UC)J=O8J@&]([^G6CN']J^C9':*8`\/
MY<5M;<-:*E@[2N/7T]2XI`KR7Q+!R$%"=:I"0\@Z:`8J;8J":!06(5%$'"RQ
M%!WZS`D7PZ0\!UKW1T]YIP'#@LT'GB>CCZU%?($6FU5</6L[]ZO$C]DJQNPD
M=)(5%14<IMTB*B1<@GV('5MTB/V_3K&<QI_>$T>!G7]'2KG&ATC%1<EJVI/Q
MKH[CO6$YFHLW2Z@MDI2N`@!A(\.Q*3M2;!$IQ*L03%$>L!$H>G6#>-,<GON+
M:`4)RZCTJ:%P>W4UM<<@?6HKV.O*Q2*S=.62.BJ==ND[B2BV7107$Y7*"[8C
M(Z_:<IAN5,H@!=P#P'6!*(G3UEQ9IU#+2XC$4QP\_)9<4C@VC0=5:$<156)L
M%0ATVS6/8-=D&@+I$45;]E^X2'_M"8JF^V9)8RPF#<IA$1#80\0UJYK_`%3F
M<OH7UP!J,L,,@?/Z5N8`]K-(X<:=*J#'./JTU<,7J[1&05774*Y!P1(4DFR;
ME%-4YBG,94R8[%^PGMT``^'COKD]SG=+.685-/TGSGTE;2.1W9ZB2!Y46&OS
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MA;`W(`@FE,1C.1!(!]((F<I*'1W_`)@AJTM:X4<`0KFO>PU82#T+IH/&^/:R
MX!Y7Z/58=X4>HCQE",$W:9O:DY,B==(?Z)@U1L<;<6@`JYTTK\'N<1UJV/*[
M*$MAGCGES)D`[29V6M5<35IVX:MWZ2-BEI./A(=91D[(JV>`D]DBG[:A3$/T
M["`AX:[[PP[MVO>[O_M7=V^:7[?<7/[YH):3$QCI'C4T@MJUA%0017`KR+QW
M[[WWASX/[_WTVJ1L6[V5E_H[W-:\-GEECAB<6/!8ZCY`=+@6FF((P4'7_,7,
M;;!+NCS:L;4.8E7S)B;#]@;*1$0Y9S#/(LVDZA+_``<*Z;'B5XNQU=-1,PD1
M!%!P'64J8*)`'LT'A-W2D[ZLWJS$EWX3W.T7M]$0^0.C=:QELEM)(TZP^*8@
MBKM3F^Z2XM<5\RW7U"^(D/A<_NQN;X=N^H6R[P[9M,[3%"YLS;^77!?0PN:8
MG1W-NUS#2,-8_P!\-8'Q@7,M'F7X6KM@FD&E=G[#0*S</W(GLC,K3CMFJ$DF
M_1BW4M`XV?V5#(=FK+-VK^T?MV1$C$`QTP,4`WYW;?IU[W[A80OEN((-]N;3
MYB.T=#=.&@M+VLDNVPFUAF<T81ND)J0'$%=EO?UH^&^S[Q<P06EU=]UK+</D
MY[]EUM['=H'MC=+!MS[@7]S;-<ZKIXX0W2'%H(`K<EWS0AU+%F.%JV&,MW6(
MP4YMS>^WJ$:U]*F(&I]9<V-VA'2;Z525=RLC\,+9NS%(BO68%%!(0Q1-ST7A
M#=MV_:;S<]WVNSN]Z;`;:VD,IN#V\PB:7,:PAK&UUNDJ10%K:D&G:3_4=MS]
MX[P[;LG=W?\`<MO[KNNQ?7L+8!9M^4MW3O;'*^0%TK]!C9#I#JD/<6M+:[LC
MSEP]&-8.5<,[,I`N\&1W("USC5O'N6F/JA/&:M:I"V),CWO.KC;9EXFQ8,6O
M<%14P*&,5'=0+(/!CO9<2S6S'VPO6;T_;(8R7!UU/%J=-)$=-!!!&TR22/I0
M#2`7T:9+OZF_#ZSM[6_FCO3M<G=B/?+F9K6%MA:SZ6VT-P-?O7=U,]D,,$9)
M+G![B(ZO'586YTT/,62X'%QJ=,TZ;N5?E++2'3BY8YNK::8PS3[P?,9M"A62
M==4NP$CBF7*R?@"@E(8HB!@`#97?#P5WONEW=G[R?-PW=G:3LBN&BWN[<QND
M=H:Z,W,48N(M=&F2+"I!`(K37^&OU0=UO$;OE;=RAMUQM^X[A:R7%FXWFWWC
M961,[1[)VV-Q,ZSG[,.>(9QJHUP)!H'=UR"RWDXF6<3\:<(2$%6+_E"'L=SL
M61;'$$L33'^/JQWDG;^)KBRB329L<H[;JI-RN!%%,4PZ@_:=Q+#[B=UN[A[K
M[IXB=\HY[G8MMEBMXK6)YB==74U"&OE`+HXF-+2XM]XU-#[NEVS\6>_O?5O?
MO8O!KPTFM;'O7O=O/=W%_<1"X;86-N'!TD5NXADT\CV/:P/JP:0"!K[2/JT9
MS-O&%.]7OD1F^MY9X_PM7;OV<^YI;.JYA97-S(-H]A78NO55B2NV"/F7:X((
M]QR1;O*D$.@B:HFRGV7<WQ(-ELO<+9KC:^_4UR6NB%PZ:P=;AI<Z5\LSC+$Z
M-H+G486Z6GXBYM-?%N?B9X)-W/O/XN]YK/?_``HMK%LC;A]HRUW9EXZ1L<=O
M%;VT8MYXY7NT-+Y0[6]I]QK'EW+B^9"#*V-:CEG"&3L)/+!C^ZY)HSFXO:G*
M(6R`H$&O8[&R6)7Y1TI6K`VAVYE?A'?B0VQ%#$,8G5%<^$CYMK=NO=?>=MWF
M*"^M[2Y$#9V&"6YD$43@96`31&0@:V9YM!`-,FR^HF*VWYFP=_>[6]=VKB[V
MJ\W"R==OM9!=06,#KBX8X02.-M.V%I=V4M2T^Z\M)9JX-,YN1%JF\&MI3".7
M*-4N0IU6F.K]:?W/^Z'TFE''E.PO$Q-@D)MO&J,R`=-ZHDF54AP4(F9(!4";
M=_!NZVRSWF2VWG:KW=-A`==6T/;]HUA=HJ'OB;&7AV!C#B006EP=1JQ^[OU*
MV&^[GW:@O>[6_P"V;#WL)987US\IV3Y`SM*&**=\PB+:%LSFMU!P>UCHP7CI
M(3GS79N)QM<BX-S''8NR=D1IC"%R=(!32P1+/)3CV`B^S%MK"YGI*+=NV*@F
M=$032)T'(45%""369>^!U_9W6X[2=ZVF3O+MM@Z\DLV]OVG8LC;*^KS$(V/:
MUPHPN)-03I:05J]K^JO:-UL-F[Q,[L=XH>Y&][LS;8=RD^4[#YF29\,>F-L[
MII(G.8XF0,:T:7,:9'M+53UE\R[#,!89=NUK4_/4.N7$*/.Y#86G'C54DJ60
M2BW4E`XWD+*AD6S5AD\5V/((,B)F(43D`P`&^?MWT[=[KZPBDEN((-[N+3YB
M.U=#=.&C27ADMVV$VL,SFC")TA()`)!6HWGZT/#G:MYN+>"SNKKNQ:;A\G-?
MLNK!KNUUMC=)!MS[@7]S;,<[&=D+6EH<6@X5NI(<O2O+):8_%^!<RYKI]"M8
MTF[Y%Q\R@5H9A9&ZJ"4K'5F$D9)M8+LI`G<E!X9HB0B7IZA+L8>9@\*C#M]M
M/WDWO:-GW:^M?F+>UNG2"1T1!+'S2-88K<24/9A[B7<JU`[J[^H$7&\7UKW)
M[K=XN\G=[:K\V=[?V#(71,N&EHECMH7O$]X82X=J8VM#,ZZ2'&V,5SH?1ENY
M#J9#QC8HG'>,+[7<78^/!MHN2NULR3)HI)EH#B*3L[@S^T659<'C`K=!!JP8
MI*%>JD<`"8]'<^"T%SM6PMV'<K>7?]RL9;RZ[0O9;P6C"3\T'F$:880.SD+G
M.?)(6F%ICJX<38_4]>67>#O<_O=LEW;]S]DW2#;;`PMBDO+K<)!3Y%T0NG&2
MYN'?O8`QD<<,+'MN'B;2PU7(\Y8>EGR-&9CPODK$5MH&,QRZUJLW(U"=6N-,
M"=9UH3P4S!2BL0WF4YE\FB=JX.3H'J#KZB"76L@\%[K>&[?<]TMXV_==KOMQ
M^1,T;)XQ!<=DZ;]Y'(P/,9C:7![0:X84(*WUU]3FW]W9-WV_Q#[N;SL&_P"U
M;-_BK;::2UG-W9]NVV!AFAD,39NV>UIB>13W@7:FEJDEA_)K_+-74MKK&E\Q
MBP7>(D@8_(K1A&ST_$+QC"01L2,4R=O%(Z,<*O#(HE7,59043'$A2B`:\\[U
M]W(.Z^Y#:XMQL=QG:P]HZU<Y\43P]S3$7N:T/>`T.<6C2-0%205[)X>]];KO
M[L9[P3;-NFRVKY`((]P8R.>:(QL>)Q$QSS'&XO+6AYU.T%U`"`KJZYE=TFB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB+%WYVJ15O**\Q(AB`H`<7KXKTF`!`#(&C
MEB'V'UIG3`P#ZA#?6'>_P?3_`&7+*L_X[>L>T+\=/6B6_31$T1-$5QL28CR+
MG7(=8Q3BBK2=ROEOD$XZ$@XILLX5.8PAWWSPR1#@SBX]$15<N#[)HI%$1'T`
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M),D>W3M#55!^82?8(5,7`L5CK`7I\0$``>KIW#4]MNFPNE#!?0:W8_$03RQ(
MHH9MLW1@)=;2AK>%,NL#%==-0=M9E%S(5J7%JD`)F>(MT'+8Z72<X.B+,%'*
M;@.UXD$OB(%$3=(CK>.PC;,T:HJ9UU>RN"U3(R7%E0UU<J$>1Z%Q(RSUZ`JY
ME8V:>GE&#ULV78/HXI$'"2O[=*+25;"4@).5^X=10H]0["!S%#IWTUU(7GLZ
MBN?ET+;01@8D>[U^6/E1:VY8*:?G7FJ:Y0N/?^\DY5,701B*JS3XEN8)=N*C
MY2/%0!$6@$4!J;?P$H;AHI712'2T-[0?BQSZ#F>H9+:1LD'O:CV9PIQI[,N/
M%5(O.JHLH61>PGQ\@#%^NY9FG(QK#'!-9-!XDW66_8NG!44R+H>(G#N#Z`ZM
M8#W!U&@BF-:<>?WK*9&27"I::BF&(Y=0X*U4@D#E1G(3B)FKZ054<,CHN>Z5
M,BQURDC)<A%D4BJ!TIB4I2J$34+MX`81U![FK0T^Z#ZUG-)H"10\E2TY+(0Y
M$8R?13,BBZ!BS>I>!VC:2CGZA46QCKK=I-M(I`D<AB%`@*#L&X>$XC8YU&CW
M2:'S@_:**UTFD5.>?EYE%#(U@AW[WH9)*MPV,=\NW,!WKSK5<`9(01.W3%L!
M3](^`[G`/$"CX6/A8\T;0.IGA4XGU=*QWS.:=7X>7W*-;J<<Q[I5U%+NV)G3
M,C*02;J"F<5-Q*]2,J<-P1743W,7Q+T_9W$!#6'=,CD&@AKFG,'G2ASIRK]J
MN@D<WWFZ@:9]'D5:.<>+$1<.$TBN%G`D4."*?4)#$,5,%133V*D0"[]2N_7X
M>L-<;>!K9FQMPC:TEO*I-,<<!^BBZ*U<7,))%2:'T5PZ?TY*RMR.?L-UGF_Q
M15#J-A*!-P*)-E1`!Z3&.*8AU;AOX![-<K<&.*L@TN(]9QI2G0MY;%\CM)J&
M4]7,K'7SNYO(\(\/%LL49G*9FR0J\B<:UYR4B23!N@F45[7+LMU3GB(=,Q!Z
M1`"O%S%)X`)A#?\`A_W/G[U;PZXNR6[;#1TA'2?=C!YG''@*GDL7O+O4.SV-
M0`Z9WNL;7-U,2>@9GS-XU7B\MUML=]M-@NMOEG4[:;3+/)N>F'I^MS(23]4R
MSA=0?04O4/20@;%(0`*```!KZU@@AM8&6UNT,@C:&M:,@!@`O#[BXENIW7$[
MBZ9YJ3T^67(*FS#L4??X?+\6I5"M@1V#?1%Q%#>GYQT55P5#;CM\^J*Y;>BJ
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+DDT1-$31$T1-$31$T1-$31%
M:'.6&H#/F/E\;6B6F8B!>6&KS\@I!?`@\?!59EO.-HI<9!L[0"/>O&B8+;$[
MG27[(@/CKJNY?>Z^[C[ZWO#ML4,M\R":)HDU:6]M&8R\:2TZFM<=.-*G$+S_
M`,3O#K:O%3NF_N;OD]Q!M4MU;SR&'1J?\M*V9L9UM<-#GM;JH*X"A"H3*O%#
M%V7,S8ISI.EDXRZXIDXY^U"'^`)'6QM"21)>`BK6BZ:+K.FD&_`YFYT3I+%3
M5,03"4"`7=]V/$_O+W5[H[IW+LC')L^Z1O:[M-6N`R,+)7PEK@`Z1M-0<"TE
MH=2M:\MW[\!^X_?_`,1=B\3]T$T/>389XY&=EH$=TV&4301W(<USG-A?J[,L
M<UP:]S22`W3:VJ<#*=4)=-O%93R.GC)M<G-X9XL094ED@E(NY)256AG.06U=
M#(+NI'=J#U1X/$BJ)[E.<PB8P]-N?C?NVZVIDN=LV\]XW6@MW7A=<.)8U@8)
M!:F7Y5L^D82]F2#B`*`#AMC^E?NWL&X"*RWO=QW+9N+KUFVMCLV`2.D,IA=?
MMM_GGVI<:&`2M#FU#G.)<XR#Q7@RK8JKN1:VP?RMB;92OM[R!;7,^#'XAW)9
M!(FC+QR96#5J@$6V9I`B@4Q3'!/](PZX/O-WTW/O/N&W[A.R*WDVRQMK6`1:
MJ-9:U,;SJ).LN.IQ!`KD`O6NXWA?L/<3:-XV:TDGNX-\W6]O[MT^C4^2_`;,
MP:&M'9A@TL!!(%:DJPU0X!85J6#,D8(^\KE.Q&4%8E2?N,N_CS71HE5Q9GI+
M&)>H1Y&#:-IBS(#LVYD#I"*B@'`0/L';[KXY]\-T[Z;?WV[.T@NMM#Q%`QKO
MEW&;5\PY[2[47W`=21P<'8-H01CY;L'TI>&VQ>&.\^%YFW&ZL-\=$;B[E?&;
MQHMM!LV1O$>AL=HYFJ*,L<RKGAP(<`+B8=XS-\6V8+E.91NN3;"T@S5R&^^H
MFFU&!AXPX@"KD*]1X.':R]A<(AVU)%\=PX$@F`.D3".M!WL\1G]Y=N_PBRVV
MSVZP?-VLG9OGGED>,AVMQ)(8X@<1%&&MK2M:476^'G@I!W&WL=Y-RWK<=YW>
M.U-O#VL5I:011DXN^7LX8FRW#A[KKB9TDA;6E"25OYOXT1.8;;0\EPU_NV(\
MKXV0DH^KY`HIHQ=Y]RRXG-(04S#S+9Q'2\8J=900(?HV[RA3=9#B74?<WQ$N
MNZ>UWW=V\L;/=>[&X.8Z:UN=8;VC*:9(Y(R'L>*#$5^%I%"*J?Q+\&;#Q!W[
M:^^>W;KN6P=^]F;(RVOK+LW.[*6NN&:*4%DL9+G$-);\;P[4UVE6^>\&,=V>
MJ9(C,DWO)N2KYE)&`2L&7+%,L6UNB`J<BVF*PWID;',4:U5XN(E&B:WPJ38Y
M5]NE0PE`H%WT/C3O^W;GM]SW>LMNV[9-L,IBL8HW&!_;L,<QN'O<99GO8XMU
MEX+<VBM:\E=?3!W0WO8]YL^^.Z;UO'>G?&0-N-UGE8VZB%K(V6W;9QQL$%M%
M%(T/[)K'!_PN=ITAN^IPRC[$2V2>5,UY3RS=[!C2R8E@[M8TZM&+X_J%N;G9
MV,U1@(:(1A26&:9J&2=2#HKA=5,PAX;B(V-\79]O-K;]V=GVS:]F@W&*]DMX
MC,\74\!#HNWED>9#%&X:F1,+6M(&=`IG?3I:;P+^\[]=Y-\W[O)=[-<;7#=W
M`MHS8VETTLN/E8(HQ$)YF$LDGDUO>TG(DDU_.\8J;-_Y#IA/V:+:<>:K8:Q2
M&4>,4"#D\_0T<?ISTMWF"AC2\+&H`Y:]@4D@="(G*8OV=:.R\1]WL_\`&W&"
MWDEWZZBFN'.UU'97)NC$RCA[DCSH?JU.T8`@XKJ=S\$^[NY?[K,;=WL%OW1L
M+BULV1]EI=V]BVQ$\M6$F6&-HDBT:6]KBX%N"ZUKQ-H33'7'?&"<[9C5GCC=
M:Y?*\0XQ0KVV:K*LJY8DMH`P!`[55],++J%:E0,)Q#80`-9$GBCO<N_[_P!Y
M#!;#<>\%G+;2_'2".8,:[L/>KJ#8VM&LN%,PL2/P&[JQ]TNZ7<MMS>?X-W0W
M2WO[<?NZW,]NZ5[/FO<H6%\SWN$88:G`A6WJG`ZH4^730B<K9(1QHTN3F\,,
M7H,:0R1;R3N34EU8=QD%M70R`\J8O5!$8_XQ(JA-RG.;<QAZ'<_&[==UM2^Z
MVS;SWB=:"W=>%UPXEC6!@D%J9?E6SZ1_%[,D'$`4`'&;)]+'=W8=P;'9;YN[
M>YL>XNO6;:V.S8!(Z0RF)U^VW^>?:ZSC!VK0YN#W.)<X]_$\-F-<LMA7JN=<
MVU#&5HR"[RA,8>JDY&04&K:Y%ZC(2:;6W,6"=TCJY).T"BNP;ND@4(`$,H(`
M`ZP+KQ;FW#;H&;GLNS7?>.VL&V<=_-&^200-:6L+H'.-N^5C2=,KF&AQ#5M[
M#Z=K;:-ZNY=C[T=Y=O[F7V[.W*;:K6:."$W3WM?(&W;&"[CMY'-&N"-[=3<"
M\T!'637!2BS*.2T_\R\HQZM^S+'Y_@G+-[``MC/*L>X=K%L54,:&[CX'*#HK
M91)^=<`;H)`02*%%0V39^->]6C]N=_AVVO98[0[;)`YLM+NR<&CLIOWE&T+=
M8=&&^\YVH%ITC!W'Z7>ZVX1;TS_&=[BDW7O(S?H7-?!7;MS8Y[A<6I,57AS7
M",MF+J1L9H+7@R';GN"]5O4/>PREEC)N2KWD6/J==L&29LE6CY=E2JC96%L;
M4BL0,7#(UZ`@9:9C4U7PD2477,`CUE$1WNLO&G<]EN[(]V=KV[;MDV^2>6*T
MC[9S'7$\+H#<32/D,LLK(WD1U<&M&%#04LW7Z7]A[T[;NC>_6^[SO/>C>(;6
MWGW"86T<K+.UN([IMG;0QQ""""6:-KY@&N<\U.H5=6<8%*0I2)E`B:9"IIIE
M_1333*!$R%W_`))"%``]P:\8))-7&KB:D\R<ROIP!K0&M%&```<@,`/,$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$6._S=8@\[Y5_F)Q:8"91?AUGA<@`4IA
MZHVBRDIX`<0+N`,M]]]P](>.L:Z%83T`_P!DJ>V-)V']8>U?C.$'J(0WZQ2C
M\X`.N?71+7HB:(N^JM7G[Q::U2JG&+S5IN$_#U:M0[84RN)6?GY!O%1$<B=8
MZ:)%'C]TFF!CF*0O5N(@`".F&9H!TY#I1>Z/A%Q'HGE585?2-=8PL[S?L=4+
M_F]F&7*29A:$[<D2D!Q?BP1**2<=`JD3^)=IH?$2CU,5%%BHE1;I^#]\N_UQ
M=S?);+6.T8XCM0*N>[B65^'B&$8\2:X#T?NSW5BD<V?<AK+J'LZT`;^MU\?0
M!Q7QWRMRC;#1D]:<DV"S2,G-_&2</(.SJ+,V"<0HDBN)%5TVBJ2ZZYE2D*4$
M0!,O4;J#I'SN5KYY"9W/DDQ]XN)]ZHP)-2:9=>2]*9M]I$-$$;(XJ"E!PKR&
M5:9J*,>V=7>WQK6W)($7FWTLLQDGX-$(]\^,U?F;G%1`4@1*[<$2#?I`Q5>H
MH`8I@WWAC=;V<L5N-!,8#B<2/AKTG,U(%!4#FJ.<SM&O)<6-=[H%<A7T#D#B
M<25<O&<<A7YN6CSV*6V814NN,*Y>LG<0]>L?B&<DDU223=NVDT#9<JJ)Q`X"
M("'2)!`Q8[EL3+!K=#-;R#4#'2:`8#A7!5K))-KQTY>?/&OK65?C1G?/N-K#
M6&V+<U7-A6W<,Q33H=CEWEDKC:03`A))-&#F#R#(47KE$!*9L9("%4`2F(!N
MD%MO&X;=[EG-)$X.)P)TFIRTY4'5CS6GO]LLKUCG7<+'FN#@`'4X'4*&O6LX
M$%G:FY`9%;9=AUJO(LTBM0M%26!.#<K/CD.HXE:VX%1%,H/R@8RB8',(ATCL
M&X:ZRS[T13?N]XCK+3"6/#^LWEST^A<7<[$^$:]O?5GY']')WV'TJ\DU)S30
M[,T>E^\U2>HLTFT^Q43507;N&QD5'\<ZC%A^'51[7V6Y2)@7?<?$VLE[VDB:
M'0;8Y%IK4<Z\#Z_.H8F`C1(7"<9AV%#TCB.E<-W$&G6<>:/;.UHN+E4#2#HT
M:+(BBZ29$5CBW<*&*>1!-%,_[+N)J&_O"$#PU8]O9M[0#/`5\LU)4$]F3[W7
MPY\Z<%5:M93:"074:Y;.1C'Y&[E9;K:E<N=CE9&,KU)HO@-]@AR]1=E?#;H#
M>QM0ZHP=CRRZNCFKQ,R0480X"G7U^?ET=*BSE5)K7&9927,]F@1^'<-BH.0<
M,CLET5#R#,ZAF!43K).P2.+CJ%0_VP$!\!UE0R!L@<['F.%.-.>*CN*]F2!0
M\#QKP\R@S:Y1,QR.%Q144<L#JH`V4(FF&ZX_M$RE.`H@MVA`PFZ1Z1V'PU9,
MV*.3WG"A&'3YOO6*USW1U#>*M._D$U440(FF=4#$(=)!4ZZBFP`94_8$#`FN
M"I]P`Y@``$?'8-M:'<KUC(@PZ?C`-,2>9IGZZ+96=N[M-8U?"3R%>&*Z8RP`
MU>`#?;8#'!5V5))F10IC)BHY$"""A0$QC%*7P'U;>&N'W>Z[67LV`AF(Z74X
MTY+H["#2S6?BP\WZ5#G/.5*CC^`L>2<E23&N8_I4.[DY*7,@9L1-NAU)M0:H
MIF[SR1EUNA)LD0>I18Y2^/CMIX;"ZWC<(MMV]IDN'NTM'`N/'H`%23P&*W+9
MHK2V?<SNTM:*DG(-&?7T#B<`O#/R]Y-6GEGG*TY:L)G;6+7.$)1*ZY6*J%5H
MT8HH2"AP[8%1%X=(PKNU"@'==*G'T`&WUWW7[O6W=G9HMK@H7@:I'?GD/Q.Z
MN#1P:`O$=\W>3>;]UTZHA'NL;^5HR\YS/2>0"C'KH5IULG'<=O4'Y=$6PH.W
MA^/157`4-Z?GT5>E<4?'QU17)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(OWE
MM=4N231$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$49^:M6&\<,N7M,(EWE+5Q;Y!
MP"20!U"HO*8EMS5`@`'B(F64+M[]0W!I"[I%/3@I8?XK3R-?1BOQ(D/[E'_S
M2?\`S`USBZ0YK=T1-$657R5,?,<@^8]@H))JD\:4-ED7*9$5^D4RRU"H,_+5
MQR)3?IF8V06BY0]/4F`^K7+]];I]GW7O)8CID,6D'*FMP:?42MKLD+9]TAC?
MBW6"1SIBO3)F8)YC"7&$DYB:FH"=DYI9Z\02=_'Q%NC^S(+BZ4<+*"L62*L8
MY.KH!(0!0H`4?#YDMZ.GB<30-<'$G)K0:&@)S)P'+->_6_9TUAC1,&4`!^(.
MK3$#`"F//)1E9Q\NRKR\R_628,9<D0P@GQ6C-8[P#13=I(.DW)0*Y1=Q[[M_
M$@F!TA6`X"4`$1UT#2TO:R,%K6O>[34'#42''GJ\ZH7T+@3J?I:"<<,*::>O
M@NL;*3;-PT`7+1E'%ES-)]5X]9J-V<JP2,2-G(Q-8@MD#+J',)R`7X=8BA^K
MQ,)0R@TR=HUO!G[LG-P)]\'[.15#1N@D5<3[W(888J]N*JO$R$L=5>&616`4
M9IW,1I".U%)9959J<Z30%R-5D5"*&'I:&24Z/T$S["73<G:6B*"E=.G'`Z0`
M:5SK7GZE8T.:"\GC6G"N.(Y>55D=PXTA*JR=BT*X5=H)&^&60:-S.RR"#A5,
M#&8](+H,72*HF,W(!0$?M%';P+S<KC+*"X8D>8='33@L:7M'#WLO/CY^:O[=
M,NM1IA95]+-$X\\>BFNT,KTM!5:KB=!I)(J`<%HXSA$J:@*JHB7P`3>`&UD@
MW,UP+>,'42,,Z\^GI6"(FM!=3+U*D,`^8+::#9/W8E6SJUX[?$:HRM+=2R"`
M$61,HH:3HT\"J)V+I0@E[2"AU2B8`+]@?M:[B#:KFUM?F(CJ!))9C2G(BGNG
M/(+1W363/HZC7@8/IE7HXCT+/7B2YU+--01GL47$[R#^&02=1LJ[43M%86(0
MCDL)/,5O]\.LR.)R_$D,<RR8A]LQ2EUDMM_F">SUB9H]YCOB'2/S-Y%M1U+1
MNF%J1V[037!S15KN&=<*\C2BI&_JC'09WSBQRI6*'2[*P,=V\>#*M7!E56P.
M'`@7X,X%4`@=)1Z1(.VL0G3F`7#K^U9P;2I%`.A07LMOD':LH9K,2P-RH-]A
M54(`+$(*33H;HE,=N#D2JF[@=("/2(]0[^%M7C0<2X@@`$<!4DU(KZ>D*!SZ
MEY#O<&)K7CRIDH[R,A]HR8D4<%3ZTQ.<ZA>A$SG]L0A3](=13'\2[%#<?L^`
MZBNI6QLUD-TM-`14`-K0X'U@^8JV&/M'Z`7$N&1%36E?+UJCRF*_=%*B`)(&
M6/NIWR@N;H$_:3`IA,F5$?1L4>KVCKD=RN0]_ND".I-3QQH!EET>M;ZTA+6T
M<"2.60PQ)Z?LX+K;5)LP[$5$N5CL%D1-,.ETDQ)VVQ!,N5%P8Q2_"LRE,`FZ
MB]9Q`-PURUP[LRXNQEH`!R\N2W<32X`-I2OG*\7/F^<[VF><B.N/V))M=_AG
M&$TNUG+*W=#V,GV^-4*C\6":1Q34K=973.DS*(F!5?J5'T$'7T/X:=R?\"M?
M\9W$?_EKAGN@C&)CL?,]^%>3:-YKSOO=O_S3SM5H?]&8[WR,G.'X<.#3GP+L
M<@%A6UZJN&7P?#QT1;&B+B*&]/O_`":*JZ\X[CM^/\>J*Y:-%5-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31%^\MKJER2:(FB)HB:(FB)HB:(FB+4!1,(`4!$3
M"!0``W$1'P``]HCJB*TU=SGB6VV)&JUVZL9.8>+O6L4)8V?:PMA=QJ3I=^TJ
MMJ?Q+6JVUVU;,5U13C'KLYD6ZJA0,FDH8M@D:3055Y8X"I5U]2*Q-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%]T1?-$31$T1-$31$T1-$7
M6S4*A98.<K3DI3MK)!S-><$-^B="<C'44L4V_AL9-V(:CD`+#JP:,?1BKFDA
MPIFOPO[57G51M5HJ3XADGE6LD_6W:1]^M-Q`RSR*63/OX]9%&@@/OUS=*&BZ
M?/%=#JB)HBRB>3/E2(Q/YBV!'U@>MXZ$OBEPQ&[>NC)D;HO<E5.5KU<!8ZH@
MF0B]J68I;F$``3AOX;ZY3OQ:R7?=6\9"*RMCU@?S'!Q_9!6XV&5L.[0N<:-+
MJ>D$>TKT>WY[-S4;>7KG=!]1,F"S53!4&LJLHL^>%=-WL0L999V](U!0B.QS
M)"5`NP;#L7YDAC:^2W>ZAA>QWJ%1Z3F5]",<(]43!^\+!TCAB#P%.`YJAY1C
M&S;N*LR-4<3D-'I/&!8V&=MV<=)F5BUU6AI6':HHFBADBJD$W;*4Q'27[390
M`-K96TLNI[)C20M`Q.6.-#QT^L8C!4?&&M#6NIC7+'U\_(K?QYCQY:1EC0M1
M<-B;G63;F<',HFB+MP=,4&3Q8Q7A&[5`.HQT%!`?$?LZV;[TQB,N(#6D`<M(
M`KEP))ZUCO;&RNLU<ZM<\SSZ5/W&]039,HY!@S$LY,E2A21CF$`H2CLA`041
M,B=N#-)TN"7<0(`#N?J+MOMOK;JY?.7.#JG544X5RZUCN&@X?"!G7+RXJZI6
M\_`KJ1*S]NT9&:EBG+M=+N2)"MB%22,NY6=.%4Y5@8>PHET%$"@`>`B&\#6M
MT:@"'`U/GSH.G-8[WMZSP'#U*,][G)-1\K$M7CF!?+N'**(R?5',II$3D*1-
M5\D`-D7+M(Y@3^,0!$P_I')MN/5[;;1/`F#>TA:`7:<7-ZAF1STXK#F?1E'4
MJ3@*^7M5K*/'2,3:TXR9KG>>+H.462,A*-F3%?J,KU@Z,Z<I-$^M,0[)2J`4
M_5]D!'80]1BB9=6;'Q/&AK@:BHJ<*8X&@XKC+F4,<]]34@\*D#CAS/!9!>-^
M7LCXJ63L-7IBJ;0'*+>RLEI-259+(M3F30C#"Y<)/&"(HK"5,43J"!MC`)BB
M&HMPV>SOY`\2-9.T>XX5J#F0:8$$]`\Q6H9?R6A+':G1D^\"!0]->:R:VZ^A
M:ZQ`V>,=+IM'C503-70*IO8YR!6R+F-D415$R<HR*!BB82]*R`$4`P[CKBKF
M.:#4R1K>W9@:&H/(CG7/](HMN)62QM=&2(WGCPZ^K+KZ%$&QV%98%VZ1&BZ(
ME.8AVZ``)SD6,"ISF,?OKJBF7JZ1`PI@`]/MUK9W#1I&+W4<*=&%1CY<%+"T
MZB:T:VHQZ<:%6>?W(%'.X*$:B<A.LH?%G;@*13&!5$R9@ZQ42_D>`;@`&W'6
MBO\`<0YCHB!0@88D4SKY8<UL[6SH0\$Z@3CA7E0KKF;UPN_2*CVP24`3D_W0
M.\(E3'J`RJICK'%+J^V80`>D-@]>N=?<@1$5]P<*"M>O/RHMO''[U/Q'C7"G
M4L&7G-<]5,*8Y1X]XLFDVN5\MQ<HA='K-<H2%$Q@Z_W=5/\`9`'PDS=5!,1L
M(]*B#0BB@`'4F.NV\-.ZC-^W`[W?LKMEJ\%E1A),#4#I;'@7#(N('-:CO1O+
MMJM/EX'`7TP('-C,B[K/PM\YX!>0H``H``!L`!L`>X-?2B\C7W5$6@X[!^'P
MT1;!AV`=$"X*H_+Y>_17!<(1W$1U17+YHB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB+]Y;75+DEA;\WG._)2,4P'Q+X4YAC<)<F<QL,X9[<W]^I`@C"8DXQ8
MW?SS>KNPL(_`()9OSC9*G4BG'[?PKEZ<H"5%3;7WDCJB-F?I](Z,/2LZTC::
MR2?"!3EGT]5?/17B-YG-.8\4N'/.>6H:ZG$KD)5:G+Y[R]$3:KE?B4]ND&T;
M1-@O5*:PC]U.8RALJE=5:RRC=ZBM6'/8<K-W#47"C>[YND;7TJ#G[:8\:4K]
MU2+!:DR.B!HX95X^75ZZ`\5EY@&:;M&<?J]C/B:DVS;RU>9GON!L<YHRN\QM
M%P?%##HU@P\B^0$M%8VM]EQQ+7A&[P)HVE1L/-RJ)YUJF[<H'2>@VJ+ES@`U
MM"33[.1YC@1PYT&V:VI<[!H%>=2*X5('.F.-,L16PF5N>N=\T'P-Q+QHW'A_
MRJS!S?R'PTY!6UFZKF9`P%&X2P$]Y09"MF#9RP5Z.K5XELKXC<P1Z9)S<"C]
MWEG%%7<9\4Q,D$;IY)0&-%"33U5X]%,QQRPHKVP1QDR/.I@;7#KIPPSKD>&?
M%=_B;)6&./W(7-%`IWFE<C.4F2,*8:S;:LJ\+.1UHIN0I=U-8RK["QK6JMY"
M0PQ2+'1GU:5Z&KQNP?24,NG*D_W0ADB#J-CVPN(8:Y5P`KB.L\?T*]S'SL!<
MT"N1%<,"3T<%+:G<X6]M6\M1(,:K,1\Q3%]DR4U']ZB./\IB5[C;$\AAAE0&
M!0"Z&=I2GW3WP&+`AB?$]`@/9#*^:&IHT_$`<\JD]"QC;FCS7X21EG0C[U%S
MCQYL:&5.7&*.*5UAN+C^7S:_RQ`5::XJ\IYODHOCRW8EJDK>9.L9@,[P;C*E
M('EJW`OTTW==G)D&<LU%HNB!#@X+8+HUX$4)H#R%>0IZSP4CK4AI(K4$9BF9
MIAB:K@X]\UC,5OXY1'*Z=X-O:OAS(+J,QO@E)'D?2IS)&;>1ETSPQP#BS'4-
M2F]*;-*9CR\69XHY4M,U)(.XUFR<*K0XD!(RH7A(/N]6>>`IR.?,=2JZT#2!
MJZ^@8FN=>'+SJK\+9%Y97_S%\\8/Y,151Q3!F\N3&%CA,?84S?:\PXY1F[KR
M`S93I?)4<XMF,<2.H3(1(EBE%KF^[%@60CD#D<BF8$D[=4CYPQU1@.?ZQY#D
M*X(61-M];,2''$C^;TE5!BO@W>JGR+=Y=E#P,86:DZ4YNT@S=5]Y!.X_%S;$
M!:6AB.)BH:'NU<>SKK#C,DL2S.I%I&1CYRTB2D'O+OKFPNUX^SHY\:\58Z9I
MCTC/'UU^]=QYOU_S+CSA>#K`67;#@C)MWY,\/<.QF5ZHVC'D]4(?,W)#'F-;
M,_8M)EC(QKDPP5C7`R:J)@.7</#??5UV7:0P9'_*:/M5+6G:U(J`TGT`J*.*
M_,)R+*\F..3;--M<T6O8MX&^85*<YL:1*#=W"1/)/A3E/!-/O5P38)-ADU&I
M(1_)SE=(DJ1-U`6)HH!3@J0P8[9W@ZW&M`>7-@]&)\V.*R'6[=!8SXB1G4<'
M88\:`>?!5=QG\YRH9[S-@+'3^$XWI0G*AA;%<3QV&.7E;SMG+&TO`8VG,M0D
M!R=Q/"T*!BL?+6JG5QVBH[@9VQLH2?(G&.U#&5(XU.RX<YS1[IU<CEYN'I/+
M!0OMM+7'WO=SJ*#E@>/JPQ7;8^\U+.-BXP8NYPY#X.(XHXCW]M@67E[^_P"2
M]9MM^JM*S%D"OT"P92=XSKN.A32QSC\UG;3!G#R7:2+J&2<+.6<<HF"(T;=N
M+=9;[N'/CTTH>>&-.&"N=:M#^S#JOQX<O/4<LO/BKI\EO-,HO'"R<EHF4H\5
M)UWC_=N-6`X^^V3*4'CBD7+E9R39/K4WQ+-VRPPKBNX[IN),8N(>RVNSNG+L
MS1G*B@A'K.42IK5-X*T:.6>'EF,Z9]%%1EHYS=1//(5^WH.5<1TU55\$_,-@
MN85_SAAYV7!+W(.$(#&UW>6SB_GU/DC@NX4C*3BV1D.K#WU:CXYGH&[UJ>I;
MUI,P<E$I*HIJM':"RR#H.W)%/K>6&E>@UY]`Y'EYZJ.6'LVAPK0US%#AT>=6
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MMW&&#?\`)'%7/;"7`>VX@I.<B.,=SMQS^TQK/X\R#2,PVO&]>=GJSVI97BW3
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MR=0LK6R>B[7C"7E+1QCC;52W#V3CV47+R*<*L5%A(`^C5EU4%&NHY9I1IKAB
M.'5Q+>&`RX^97110NU8D@`\L".IU#7//@K\27,7EM8,A9`PYA7B'BC(F5N.F
M.<<7#E%&3G*24I],@KYE.!EKE4<%8)MW^0TJ^R?>G='BTY-:4FXNJ0;4)%BB
M=03K*F0D^8D<XM:!4"O'S_A^P<Z\K.PC#!(YQTDT&`].?D<*<Z!BO,\ON;+K
MA^F\,N)CG/W^<_##'7-&,L%_SG5L"0E%J=YR/9,=O*5D$9&J7F33M<-)5M5%
M(D0VE2.9`BJ2PM&R0.U;?G"YP:QM3^BO`'[?M5WRFEI=(Z@!/J-*YCCAP4K.
M>F87&">-$EDE%>[LEV^7.+]2,ICJTPU0M*?^9O);$>-W""-@GJC>8PL(H2V&
M3EFXQIEI&*%PU079K+)O$,F8@1U.51[0H(6ETE!R/L/4H^UKS#[ADWF+E'C-
MC#'7'51KA;.B.%\@U7)?+%EC+EM)Q;>(KD]8\V8RXRNL83:=JQ''1=B%>(65
ML;9Q86[%PH@*`]!#8\=T7$#G3#CD,3ATYU`*G?:]FTDDX5X88$BE21CT`&BE
MORMY$I<8,;53(BM3/=26CD!QMP26)3F0@3,U.0^;J5AI*SB\-&2W?)5#W$)$
MS3M$%Z#?L]U'K[I<F23LZ85J?M`^U8T<?:$BM*`GT`G[%&;D[YCL-QFF^:T5
M+XI?69MP\PSQ3RJO+HW!"#C+6KRJR)D3&\:E:'CBNR*&-*%C%]12RECL:HR9
M&D(JY=?"_P"Z="T)N:`D`84X\R1]E>JIX*5EOKTX_$3PY`>VN'3UJU=O\T=_
MA_CJVS?F&`XA/O\`,/-E'P3QYMV#><-<R)QER5:;G!SECDI>^Y\L.,:87#E;
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MMS@6-1`O04D+,WZ:L,%T%V#]D:'ET!)[2"`ZYR6G:.IE4TZETD))B:3GI"@E
MJ-2)HB[&&F9:N3$188%^O%3L!*1TY"2C80*YC9B(>(R$8_;B8IB@LS?-TU"[
M@(=10W`=6R1LEC=%*`Z-P((.1!P(/6%<Q[HWA[#1P-1UA>S&HY1)S0Q;B+E3
M'BYBJKEBPUZE9^9QS9`%JOFVLQ!JU;"/7;7MDC4)YPX1F(U7IZ%&#\"F+UI'
M#7S%N.S2;!O4^R2BK&-?);N.3HG.U`=)%',=QJ*C->];)N[-PVF.YA(^9:*/
M;U9^L@CHHKM9'X\N:5:*C-4FP*PM:FH]JQ^*?6-TY%.=8M53RK919F)W2WQ"
M10.HF1+I4.)C%`H%$H:2"\-RZ:UG8"\.+QI'X3@13AIR'%;N.6D0?B9!0$4]
M!QPSS4P<+PL_`K5F26CB+NV2)4WLN+0H(2";07+<.EP@1145`2<J)B<4^A<!
M\?M>F.XDC?*^..H9RXBHRQX9>=8D@UM-3AY<.G/H4N0:)C((R\N/W&+`J4K#
MC#@51RV5.<RSQOW6RZ:B?Q*>_0H":8#U"&P'UC1N<P4<3U>Q8CFT;I9B36M5
M%/)UH8N).TEA7L>0ST7=@.Q048$<P!UND7G>)(N0?+IF`>LQDS'(<0V`I#`.
MNAV^%QT32"H+M(P-,3@,*^M65T-Q!P&>.-/4HCQ+UI857B=EE%%6@/!.Q6:=
M+@Y2=0AVW3A0R[APFL!PZDNC<#%V*8!$=>CP[7V+F3Q:1(6^\*$#HITX9Y4Q
MHM%<WI<'-:RN.9I578K32*>*DJLS!-IN&=E<DB3JO&R"Z`LA*HCVG+L&\HQ$
MP[=!DA662ZR[CL&VNIM"&6XECJU[2"<_LP/GP.:Y*],QD-'@.(/"N'L5^,=Q
M593EI9`&Y(V";IMQ.XM\RZ^"35$@BT;JO"HJG67.=/H;_$%,?[`B<`#<=;*.
M9S0"\-[1Q(!8*FG0*8=.?.H6EN(I)0"'$@`$@T`_3ZLU(R@6"R*OWM=E'$0W
MK4J`_=3F/E6;MNS75^T@]*"/@D*JFZ:Q15\$CCX"(!KG.]=G:OM/FX`1N$;@
M32M'-`%0:BM>(Y$467LUQ()C;RD_+O%,0,'<#GYE2=NL3RM/7<=(,R,W+5^Y
M2<BNV3(";@H;'*BX0,!0VW'J$?3U`.XZ\EN[\P@S-;5IJW(=)SY\UVUM8F8Z
M*^^*'`^NGEU*USV7?'8IE0.F#05/VSE$X"D*Y=A$$U#'ZU5";"'0(;>&W5X:
MXZXNY`T-)QTXT)I[?,%OH;>,O/+@",?T>91=Y4\LZ%PWP'8,OV8Y9&?<$5BJ
M#5_C2!(W2V2:3@L2R11.Z^))#-U"*N'ZQ0V0:^H#"7?/[O[!==YMV9M-G5K"
M-4K^#&<7']8Y-'%QZU;N-[#M=JZ]N_X;,`T8%SN#1]IX`$\%X2<FY(N&8+_;
M,G7^65FK?=)IY.33]03`3ONU3'39LTA$P-8V/1$J+9$OV4D2%*'HU];;=M]I
MM-C%MMBP,M(6!K1T#B>9)Q<>))*\3OKVXW&Z?>7)K,\U/(#@!R`&`')4-K-6
M(FB+8,.YA]WA\OQZ(MH_H#\.B+KU1]/X/I'5%>N+HJIHB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB+]Y;75+DEC[OOEL\;<Y<I\D\G^3]"QSR@<63%F*L/XK
MQEFO%%,O%)P15,>R5NLEE=4Q&S(SJ;RQY0M]N.]E'XMVBJ:#-NU+UID$PXWR
MX=*7OH0<J@'GS'E0*<3N;$(XR6XDFAS5HJUY3F-X/'D;QK?Y,E)C@]'<G<O<
MC5N'Q*+!Q%`GH+(DD2X4[C;9)EI,*+27'7%>4GTE9&]?(Q00EUUV;-X'P3`$
MG$0M'?"7>Y7+A3/*E.?/AGDI?FL=>D=K0"O'[\NKBNYC?+ENM$KV!%L2<M;C
M`96XF2N7JOQNR9DK'$3EM.(XQ9?+7TGW%G,D`^MU<D\Q52HMZC#)PUB++P=A
M;A!QXJJK"FY%V%HX`>]B#T]'GX#"OGSK3YEIJ"P4(QZ^?+B<:<>JFW(^5U6[
M#B%[$6'D#D\G*EYRC5YN-N9]1@:A5[[6^4'[LL<?L;%5<<.&L]1&N*F&*8IM
M3C4U_P#>+-]6TS).W*SI0SO5?E#V6BOO5KT94Y<N=<,*'-/FCVNL`:*4IT5K
MPIQQPICE3)=E3.`66+-G.'SYS'Y=N.3%AIV!\V<=*%5*/Q_I7'.F0U"Y"$J"
M&4).=2AK5D.PV.VRS:CQY&RQ'S)BR$IQ3:CUB&J-M#K+GFN'3G4'&M:Y#B%<
M;NC:1M#?NH>5/S'@J)Q?Y8-WKLCQ489?Y?V'+V-N&>+,JX-PQ0H7"E1Q0_=8
MRR5@UQQ_0=W^^0]KL4[/9/KE#%NF688I1<:X.W[GW4DNH9<+19NJ-1P%.?#+
MR%.I5^<H':&@%Q/KS\C5=O@+RW,AXDL_!Q>Z<M5LCXU\O1*RPG'W%L!QZHN*
MVDA5YK"=IP5&+Y1LT/:IY_9;_#5.R`924C6\-&/5TU5%(H%W'?1-LR"*D?"1
M7&N((X\J]'4C[S4T@"E37SU!Z.73UJOV/ET56.X%X^X0,<KVR.<XBL-9R%BO
M.D?7H,ELIF6L?9N<9]QM?DJB_<2->E4ZU<S)(.HQPL9O)QI5D3G2%?K3D%K2
M+37WZU'1E]PX*,W),W:$>[2A',8U]JK+`_$O*-"Y)7KE;G/DBEG;*5[P'2^/
MJL57<*U_"V/JI5J/D:W9'CW-5A(ZX7B?46D9.X.?BPE)216,J(G3621[;5*K
M('-EUN-:=?3SKSYE4DG#F:&-H":^SE0<.2G1K+6,HQ<N>,L5RUQ1!8JF;;(4
MIG!YPX^YM3F8R);33EP^P!F"I9=CJ^=FZ?1Z2;2S/*F1BLX!03MDEQ5*10Q0
M(:&6+M*4S!^T'[%+%)V;B>@CT@A1OM?E?87N//3*/-Z7L<^HRSAQ7R)QAR]@
M$&2):%<"90:4RM7')J<TC(H24+;;!CK'L+`OR(MC%>(1C9<52J)[&Q_DQJS]
MW33SU!]&'/+!3"[>(]/X]5:^8_?7K55\?.)O)/"*V-J3-\UQR;Q_Q'6'-*JM
M%D^-&.J]EVVU%C4G=-HL+EW.[&SOPM!J/'G:K?&PM;K;^8<L$C/ECE.X*M)'
M#(QP)=5N(S/FZ/0!3I5LDT;VFC0'&F.'W5])*N'B?AGCK'W!*H<`[6_=9/Q5
M`\<E>-%CE)F-;1#ZYTUY5'M0DW[N,;.7[:*D'D>^.H0J:RH(+%*8I]R@.JM@
M`A[)W1Z@!]BL=,3,9AGJJHZ4[RN*E4^&E2XQ&SMDR7RS3,X1O*F+Y?OXFN/<
ML/>4L!;!L=?S!8JS-!-U2RIMH=%O6WD,]%9H_K:0LS*)B8JJ<8M:,S_>\_+V
MTRP4IN:RZJ#LZ4IT>73FI<X"QER%HCZX2N?.1U9SDXGFT`QK4%1./=9P!3:4
ME#FDSR<FBQ97/(]KLE@M1GR(.U7TR+)L1FF5HU0$ZQE)HHWQDZC48<_MK[5%
M+(Q]-+:''E]@'L5E>0W"RZWS/4!RQXS<D)GBMR/9XS3PG>)U;&-9S;BK,^)&
M%A>6VLUC*.*K),U55U-4.RR;QS!3D7,QLBR3?.6Z@KMU>V6R6W+Y!(PZ3Y<O
MO&9Q(P5\4^AAC>-3/+K]AQ`.>*HR4X+9WE4\0Y2DN<=IL/,?"MPRG.5+/]FP
M-C@^.5:!FBO5.MY`P#(<>*K+5)@.'725&B9%B"=D+8F<XS!X:46[BJ)[/EGD
M`N=[P/W=1X#CP&/.X7#!4!HT$9>51Q.0\V5-ZD>7+&P$MB:_7+-MGR)F:J<V
MY/G?ES)3RF0->0S'E-_@*X\<8ZI,*C%22C#&F.:=C>PQ[*&:(.)1R@A"I@X7
M<KN7#D:BU.G23QJ?01UY4SY><T=<:B:-`&F@](/5GY<NWMGEY5>UW#*5O6R=
M/LU\H\_.,//=XR2K<<LC#V3C)3\/U")QNV6/*D.[A+:AB%!=Q(F*1=H=\H4B
M"@)E$U3;'M-8.3@?[/\`DHVX+8NSIAII_:_REIS3Y=%&S9<>4E[E<FW2J6KD
M/(</[A3[%58J!";P)E7A0\GIO$F2*DK-EEXBV.5;),$</XV48_`N6B:K,X'3
M<&.2UUK5SG@^\<O37VHVZ<&M90:1F.>%/95<&T\(<VYOQAD;&_*#E^6\_?ZF
M+;#B>:PCQQH6`CX2ROAF_P`9E&@YKBT'MIRQ(W2\,KK7XU9=G(/DZ^JT:G;$
M8I@X5.-?EY"TM<ZN5,\QUUXTQ'+).W8'!S&"N->H]5!S&7Z-C(?"SDEF[&CV
MO9OYKQ]HR75\Q<?L[8#NU+XOT^@4C$61N.]O6N4++36-5,BVJ6R@AD%\M\/8
M6[NR,$`:)D+&D8'`RAZ&V<6T<:G"F>'/B>7/T(+AC75:V@-:CG7S`8<,/2MF
M;X2\CVMYNF7,2\V&6(,MY[QM0*+RHL$?QDJ]MJ>0[-C.*F:U3LS8AIEAR6*V
M$<G0]-FS0Y?BI*UPKEJR8J.6*RS7K5&U>"7-=1Q'3GZ3GTU&0H<U<+AE`US:
MM&67W#[ZU-<5<OCUP,Q?QBR;1+OBZ=GV]9QOPIQKPFJ]'F$F\BK^ZF-<D6/)
M#:_3-K[R+J5MUBDK*L60)\(DB=83+E,'7VRW1VHCD#P<`/L(5C[E\C"QW$D^
MG'VJ['*SCM%\J<+OL,S-H?TY@^R'A#()IZ,C&\N[3<X3S70,TQ\85BZ=L43(
M3[^@I,%E.X!D$7)E2E.8@$-/*S6S2.8]1!44;^S?JZ#ZP0HJYF\ONZ<AL^4S
M).9.0M4MV,L9\A*5R'QG54>+N-X7D!1)''=G:7.I8M@.5<?8BV!EBQ"P,B)O
MBI5Y*=DX<ZL<O(BBLJ8V*VT<'`D@AI'/AZL\Q3^DLDW0T%C6TJ#Z_7ZZ="E%
MRZXY->5V$)C$JEVE,:3R=UQ9E.@Y$AH:.L;FCY1PIDNKY:QQ9%ZO++-8NT0[
M&WU%J#^,66;E?,3JI`LB<Q529$L7:,H,'<_.#]@6-$_LWZJ5&->HBBC75^$.
M?8*V<GLSON:SA[R/Y+T'CW1%\AQW&O';''F.8SC]9,C33*"K^'IBTV1"RTB\
M1F2W\;*,Y>9<RQ45554)0BAFX-(!;/:UP!%32F?`D]?'GYU.;AA+3IP;7##B
M!YN'*G,%6=K_`)1L/&P^1K:MG%C4.2MRY!8BY.U/+6",`4'#V+<697PC1;%C
M6J/:]QQ--7&MV2.N5'NDY&W49>8<O[,UE!+\4S%JR,A;\F0#1WO5J,3Z>)!\
MY^Z\WFIPJT%M*8^S@*9<.'76\MRX2YYRY0!99CYALIC,5(S-B?/G'/(V-.,]
M(QE2\#9&Q&E8&K-R7&+B[7.6RA#9`B;5(1ME:S-F#OQSDR3`\><`5&YUL]S2
MUSJBN&?VU(])XY9JQMPUC@YC0,,?*@'JX<5<SC7Q1ON'<V\@N1.6^0*N=\I\
MBZ?@RG646&)Z_B*ET^,P2.3@@(^CUR'LEKDB0[\F37!CEE)&2?D51$QGBI%"
M)(2PPNB<XN-:_I^_F5'+*)&M:!0-_1]W)38UD*!-$31$T1-$31$T1-$7Y4'\
M45B4<7><GR!ETT!;L,STK#.96`=/218\UCV)J$VX3]0@K9J0]ZA#PZ]_7OKG
MKD!LQ`%!]V'V+?V9U6XJ:D$_?]J\]VL=92:(FB+)WY8?/Y_PORNXK.0'4K,<
M6<PNF,+FZHM2*O7$#L`MH?+5,:`?_<KO2%CE5$Z11,^8%4;F*<12$G%=]NZK
M>\FW]I:@-WJ`$PNK2O$QN/Y7TICDZARJ#T?=S>W;1=ALN-D\^\,Z'+53HX\Q
MTT7K[D\!7MD-,F*%D"#OV#[$,=:*=:'LA&(+V%M+LW$PSFT`%;N2"::3H"+%
M%,JP$,4!`-E"C\[B>*&Y?%=1OCO`QS3AITN:0',(S#AQQK7H7M<=U%-#JI[Y
M(P%2"#\)!Y$9<%*JE0Z\6P=LWA6+1\8C=,D4V5<K@7[:RBLBV06#L)-B$0*0
M3)&V$B@E$I>HHZPG'4X2$FF=?O4+C^753S>A6_M5_.16,:`)Y9%P$DR<E!$K
M9>/&,!<#H&4*VV*JFN@98!2.H)TS%$VPZV5M;-DC+JXBAKPQ/)1/#@37`^FO
M2H?V"9KKZW1@*2;HK!V#AD,@3X%W,5-NNL8P@KW#-UE$0<.RF4#M"J!2"3KV
M$V_<[;;O^6<!\8((&37D#CAR'5BM==%[<V@^FOH!\N2V0@ZY5+;+L6=Q)/IF
M5(S5?I1BC<S\Y6@./B`>LD9"'<-05,)`Z"^(E`1VV$-=7:32W5FQ_9.9CJSK
MA6@P-'#HZ%SMR'M?I=0&E*>WRS5PXZ%2=*&:N'`RC9-ZV?,B/UTVT07P%-RH
MV=[M1(EL4I5$S%4Z=MB[!K<VDP<T/8"QVFAY]%1["M%=^[6H!.66.'W*2%15
M7353(PBZRQ(BFU,LW9)@^B3J-S'+UKR!!26D7[90/LE62$@E'P'66P/;^^>7
M]H*XDT.G^;P!YK33:'#035I/KIZ%<-=,7#ALVDX]NXCCN#/$F0-V4:T4^(,)
M7)Q3;%:F[9C"54>D3B(E*`E`?`=#N6Y=BXL8XY5J>'6.7H!698VA>T..!K3#
MK\AT+:R<Z;IGBIY9B>P*NV!V"RJBY@1([B$P*#@R"AD3.EE6QD]E#`)@`-A$
M1\=>);E*ZWN'1-JX-J6XX`$UK3B?L7HEBSM8M1.AYI7GZ>"B?<<HP\'#2$W8
MY9.O4^N(/9&P2[LB#2.A8=FV,Y?.Y-P!!01001((%``.8YMBB.YMAY8NGN[N
M.WMVO?<2/`:P8EQ)P:*<SPX"M5T<=NV*$O>6AK6DDG``#,^88E>*GS!N7S[F
M+GZ5N,:=ZSQ73T3T_#M==E[7W94F:NZTNLWV`4Y2V/RF?+]>ZA"J$2$=DP#7
MUIW([L-[K[*VVDH=RF.N=PQJ\Y-!_+&/=%,"03Q7BG>7>?\`&+^L1/R47NQ@
M\>;STN./0*#@H-:[!<ZFB)HBX^B+:4'P_``C\OFT51]JZU7U_BU17+8T54T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31%^\MKJER2Q;97YBYQQEYAEQX^4S!
MN7^2M*0X.XLS9!8QPW&X@B92%ODSGC,=-M=JL>0\LWC&D/'LY.J5..9QT4>5
M<'>O$3_"M0-\0L7#EF>R<-'PZ:\.FN9'7GP65%"V2'5D[73CT4R!XFGG"O;@
MKS`,!\A+AB"H4LMUACYUX\VKD7C>=O$"SJ\/*0^-,AH8OS3C:0!Q++R</EW!
MUL>MD[/$JM^PU0<`JBY<%36%.X749YY>0QI4Y><]=+76TC03@:'ACY\.&!./
M!7KXS9^J/*W#%*SSCB(M470,DK6%S05KC'L8F4M-4B+5,UB#OK!BQDI0J52O
M[:'"7@U%E$W+B'>-EU443*=LLC)FO89,FCR]F*C?&YC^S/Q*P."^=C3D5/L7
M^,^,_(F2X^S=DRC4JURN5)AP<22TSB*1M4%9W$A5FF676:ZE7I&S4Q]&13^5
MK#4KUX"/6F@DNDJ:QEP'/#:8&M,N%>FO#DI'0%K22144J,<*Y8TIZUWM%YVX
M>R#CS@ADN$A+^A`>8;/1M>PDWD8J#1E*^]E,/9"S:W4R.@WL+IM#MB5/&S]$
MXQZLF8'RB)`**9CJD?-1Z==#3_\`=+N?((+=YD,51J!IZP/:58*L>;9A.RX^
MNN9CX&Y<5_!%##(4/)9OGL30"%!L>2Z'EU3!S##.-DFM]=W#)>1\D9&[4=7`
MAXIS"NWBX-5I!NZ2<(HV_-MQH#AU<Z=>?*OIP5WRK\!45/7Q%>K)5I%>9+1H
M&U9/IW)/`V=^(,MB3C+/<N[0XS,IAVT0Z^$Z_;4*4^?P\A@[*V5%7EP).K@B
M,(=%)YWMDB=Q0Z8'I\VT'2X>]2O#*E>!/#]"&UDI5M"*TXCC3B!QP7'@/,WQ
M4PEY^+Y"XDS-Q&;Q^",E\EZS,YN-B>:CKMAS#C6%D<I2+0F%LGY4?U2^4:*L
ML<[>U6<1CYLR#PO82643732N^8+3^\:0*5]G2?/QZ,Z6F!Q%6$.Q`PKF<LP/
MN7>T'S":]/6J$I^6>-_)'C%*Y"Q3?\T80_SOB<8%2S33,85YK;KM%0?^763;
MXI1\G052?H2BU6M)8:4!@<ZI2F%L[*A:+H`@/!`.67.G/GU=6=+OE7D580X`
MXYX4%3F!PY?<NBP+YF%`SE9>.D>^P!R.PG2N7>+Y_*7&C*>8X7&D=5LI,*EC
M]AE.T0'W)2LF76]4R;9X]>*R[`TU%LFDRQ9.%6:J@%3[IMVTD88.RR^_VTXX
ME4=:O:":@Z30Y_;AZ*G)7!XO\VQY7&IEHI'&'D56L!Y4J4O>,0<F+<&&5<79
M`KD<HG]VNG,+4<MV?*./G5Q:*"YAFU@@6"[A(ABN"M5]D1NCN-;@*9CH^^M.
M.0P5)(#&TN)&!H<\^5:4]:G(4`,8I1,!`,8`$YM^DH".PF-T@([%]([`(ZR2
MH%@<P9YBF875TYG<A.1L%R(IO'_#7(O)'%/#N":_BGC;,P%ZR+!94I&&,94"
MFV*K9$L?(*[\GKY=Y145FKP\;1$F\D`$<E(R.XUKVW#@YSG&H!R!'.F52?LQ
M\ZSGV[=+0RE2*UQZSC0#`>?V*6MD\SO&^+Z+R/L7(3!>?^/E]XOXIKN=KUA2
MZL<8VF]VK#5KLB]/ALA8KG,8Y)NF.+W&I6IDXC)!JE,HR,9((@BX0**[4R\O
MS;6FCP:]%.1/`GAT^C"L3;5[P"P@M/'$<0.(YGRQ4N<"9L?YVAK)//,%9\P.
MPAK(2%@6_(6FP=#GKY"+QS21:7JMUF*MEIG(NM.0="B+><1B)MNX2.FX8(F`
M-YHYNT!(!J.K[_;3IHH9(^S(!(-?+RI58[,$^9[9GL7SENG)O`64L8X@XI<E
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MO62D'G8T[VMSK:,FP1DFYRH")E")4;<@UPR%>&7I_3T*CK=P`((-7`<<SEF.
M/H5O\A^8+;&_%'//("3XY\EN+=4I7'YOGC'>9\@5#C[F2O6:JRSJ'")=P-,Q
M]R)D6KRYA&S"#P]<GY"",+14Q_B>M%1,MC[FH(-0?,>!/!U1ZE(RV.H&K2*T
MXC&M*8C'/I5R,R>895L5W7,]9J_'GD=GNL\7XV%DN4^3\,P>.W]0P8,S46>0
MU(5Q&W+(U/NN4KC7L<23:PS$-3XN;>QL6[0ZRF=+)M1O?<AKB`,&YY??U9`Y
MJ-ENYX!J!JRSQ]`Z\Z9+H<D>9A0ZQ;,AU3$W'[D5RB+BWC]BGE/<K;@V/Q2%
M&:X(S!#7BQU6V15AR7E/'YYZ;<5_'[YVW@VC=65DD^GX1)7I5%.ANV?A&%*\
M.=.?1[,"KA:R8:R&DFE,>0/`'@?O5&R?F#52`Y)R]OF\E,FG"1MY4M(YV,Y4
M:P162<+V[-4O$Q=H9_#QJER?R$]CX6+-I!)F/WGZI")H"Y/N,1NG"6O^;Y?T
M2?T]7H5[;8NB.'[P.IZP%4J/FBXJJG^8/_$7AG.O%<U*X\Y(Y41"64T<3VU?
M(&%L0_<O^9;VNHX1REE'[ER%2_WHBA?U6;-&RR9))(Y"J$(X,A/\P6UUM(P)
MX9#SGS\>A1?+DTT$.JX#"N9RS`50RGF$HT'$-\S5GGB7R?P'4*O'8L>THUO_
M`,A;<?,\EFNZ1./,:4W'LKB[-UTK3"\S-OL48V=,K`^AFL:E()N%W8-R+JI/
MF0*U&(IQ'$TX$_R]%2*_+$D4<*&O!W#/,#+RQHI/X/RU><JL;6.0N-N:.-%@
MJDPQC!KF8'F*9LEH9R,<$@WL%*M.'LC9*JD]#MQZFSH#.F[IJ[+T'1$IB*&O
MBE[2HIB.JGJ)4<D?9T-00149_:`K!6/GS48KDW>^*=4P!R=RM?<6/L*CE*W8
MYH-5=XEQM5<X0ZD[!7RYY"L]\J\9&0-<C4%5I-FD1Q.]ANLNT8.D$CJA8;I@
MD[.ASIPYT\N/0I!;/,?:5%*5X\J\/Y.E41COS.<4Y$N>&6B6(LVU;"7)*^DQ
MCQVY06='%Q,698N4BRGI"FI(5&&R7+YPHM;RBSK+P]4E[%5HQE,[(^*/Q37N
MT-T`-;@>S/'T^VG(=:J+5Q.EI!DY>KJPKC0E4]0O-4QU>X[&>0#\;^4%,XZ9
M1S4IQWB.3EU@<4Q^,(K+KC*<YA:N1DU`Q>5YC*2%)MN3H4L,RM!($\(60>MD
MEE4P.<Z=!=`G`>[6G#.O7]E,L4=;.;F1JTUICEZ*?R%5Q;/,0K6,\_4[!^8<
M`9EQ+$Y*S9'8`QMEFUVKCJ^@;A?;))/H>BR!,7U;-L]GZ"Q_D.58]B)G7U51
M:@=PW%X5HFJ!PN-R`[(EA-`<,>&%":^A6]@2PN!%0VM,<O13UJA7'F2T/&4)
M/R-VB<VYHDI_S#\[\'<=U;$6#HE>ZH7K'->M=PC:6QJ\1D"67N,`QBZ0\:)6
ME92/6>*+D<R#&,:).%T8FW36@DDG'E3/5TG##J"D^5>[2105'/JZ!C[PYK(1
MBJ\R>2\>5:]S6-,B8<E;(Q<.WV,,LLZVPR+3ED)%ZP^[;4TI]FN582?+$9@Y
M3%E*/43METS=SJ$2ES(WB1NH`@>;["5C/;H=IJ#3RXJX&KU8FB)HB:(FB)HB
M:(FB)HB_/\_C1<*&C<R<'^1K1C^PN6,<EX4GI$A-@"0QW:8Z[UU!P<`^T=>/
MR.^[>X[]*`[>`#MIMP:1('&F/LP^VJW&W.JQS.1KY>I>)+6O6Q31$T1?-$6?
MCRA/-S;<5G2O''E;)35GXHV=85(&:"+&UV'!]H=.D2&F(=NX<E=N:&]255-)
M1Z7<.D8.XW)N90IO,._7<)N]ZMVVAK6[OAK;DV9HY\!(!@UQH'#W7'(CL^[G
M>5UE2QOG'Y4?`[BP_E/'0?/I.6%5ZU,D+5QI#U"\4>>BK3CB[P3.0IEWI\HL
MO`SD6[3;*M)>NS31)9-3N-_'MF/WTQ`"&(`D$`\.9`63.MG-<R=I((+:4(P<
M"#D1Q&?F7I\4XFCUM(/',&H.1Z0>!&!45LE'K4E',IS_`/*)C8XEX#E!U+')
M(0Z0)@<7!5BI+N7JY7S<Q3*N.D@*'`>KU&UTNUPSL)A8&NB?A2M#C[*<%"Z=
MPKB-/0/(*-=^J[B<DFDE'M`CC&:MMW$;))."3Y$W0E4"-,[(B,?+QR2H?LQ5
M.54IP$F_2(%[/891"]]N[%H-3J&(PXTJ2TTI6F'%:F_D(8#4ZN`IE_)FKRW)
M.X?#TROV9`JJM=@=X*8!.,0/)QS\43+)EDDFY&J+F,.CV7(%`#"L7TAN(#MM
ML^5URW4!<8WO]YM3AG3#D?PX#U+27+G:0PT#QQZ>/G]*EEAB@12QV#N4,U>)
M/$JM(S;=Q(H)QZ:K]U\/$)S;.1'O+)/UQ.4-D"G*)]Q`Q=AU-\W5Y#6@-:32
MN!\Q%5I[AC\W$U(Z\./D%<"^P#^LW9Y+MH*)8Q4JW(,>$1%HJ19VH))-C/DE
M$1&*10,D0!6(0RY@<`;]#;PAFNI6^Z'.R)<7$\L`W/S\`HXHHI&>\!5IH!QK
MQKQ6FMQ,G/+1SZ.3;NRR2B;!P_3%F],U4`XD*"34JB`MS+$-U`/05/H`3[&W
MZ1Y/<;X2N`CQ-=-./"A)Y<>I;:W@$.K74#,</-]G7Q7!S57UJ[3U$$A!-0MM
M9D210ZCNU3N&3ENKN5-0`*=<42G)MT[I!U`&VVO,N]DC;>1KY2`0T@^8_I)!
MXA=AL%926@5'EY=:\=OFM\\U<B.7'%O%%A^(H==ESNLL6.)7_P!VNEH:&`6U
M20<ICUN("JK`(.PZA3<OR;>)4?M>N^$_<F2R@'>O>F$;C.VL#'#&*,C!Y!R>
M\9<6M-<W8<OWZ[Q,=([8]O=[C329PR<1^`$<`<7=-&\#7!YKVY>9)HB:(FB+
MCCX>&B+;4]`?CT55UJH>GY]45WWKCZ*J:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB_>6UU2Y)8X,OX(Y?P/-"?Y<\77'&*?_>SBAC_`(V2E+Y!V#+-6/$2
MU&R[D[)S*]1TGC:FV].5BTOW_316BU2M5G@MS`5VU#8Y\*>&1\FIF6FG#IZ^
M!_2LN&6-D6A^>NOLZ1R_0H`\Q/+VL-9X;\".)6*KWD%YR75Y0S]4-R*Q[4EH
MP(BN<JV>8I[S#KM9"$+,L,=XLL>,,@6<T6V<NC*HS2=?;H+G>D36"":!P:UM
M"7]`\_\`E'KICDI8KBLCWG!FG*O4![!YJK/]2ZC5<=U2H4"DP[>N4>@UNNTN
MH5^-*5!M`U*IQ3."KT.Q('V4D8R'CT44_8!`UL&LT1Z!2H'F_D^Q8+G:G%QX
ME8>\0^7/ER`YI5+D[/U7B!Q_""M66Y_+MMX;O<X5*S\QXK(54M-5B*WF[#5B
M:Q.(*Z9I(S[2RRLL=U:I9S/Q"!FBS5-98XXC+>02:S3,\O-7CTYD](69)<1F
M'LVU)PSX<Z&OFP`\ZX7'_@!S`QX7RWL79!R#QF=8'\M3*,G.TR9I;?*KG,&;
M:8UP?FG"E(>6:/G(N-I6-K+$0F36IY..:N)UM(.4%ETG[0A2-5K/EIJ:#\-#
MR_*6CI]JO^9A#C(`=9()_K`GGRPP'355C9>$KC&'E86GCC?,CR#6QXLOMVY*
M5K)N*L8V_+[ZNWBN<Q+#S"Q3)1F'8=HC=<GI5V97C6DO!1Z97LH@D[39G`YD
M5`F=$1;Z3\52<B>->%>7V854`E#KC6/A(IG3\-#B5"VJX-S!YJ.8N64CG.RQ
M1</Y#\N%7B(RROCGB[GOC]28;*%QSPKE)JA3ZMRMD$[_`)D<5!*LLY:>5^"C
MH%N#MO$%466,Y6#$9"^9V-<L:X<"!]F7GQJLQ\S+=NEE/BR!KA4'//.N>/FH
MI"USRL[!>*/E[$F6>./E@<>(#*?'#*&#)[-_"?#EBAL\3MAO\7'Q3*Z0J5BI
M5'A<75)HNT-(2-:^\;-]X+%1;?'$02,=6<6\AJ'!HJT\!]E.'2X9<E`ZY8"'
M-+R0X&A)Y=-:X]`X^:^9>*/,G.^0\3W?EY<^-$8EQMQ7GFL8M:\?$\H/U<I9
M?SKB)]A"3R]DH,A0T.GCBM0=%E9$6M4B33Y_CY515244(U034&WF>X.><13E
MP->'Z<\U07$,;2V-IH?N\_''AU"JJ:@<&+Y2ZSY2D/\`O]3U9+RYL<3=-NKU
M-C.*M+[+2'#N4XVL9*GMSMVRI&#:T/B2:B;\S10\>0Q`$%A`NI!"_4P_E:`?
M,#7CTJ,S-(D'YC4>D'[%9KB+Y=^6,+\L8KD?.5+B+QNCF='R=7\HTCA!)YMB
MJ1RLN.07,$O$WG)>(KVQK^-L8%H;V,=2C).,2GIA:2D#D/*`W(<J\<5O*V0.
M/NCC2G/+#].>?.2:X8^/0!4US/\`*?LZN69D/`0'WZV"P5BBF?+QOCW`V<*)
M#90I\'EB;\R.V^8W@*X.X&;G:95;LUS=!YDQO3LF0!5H:5F81RG$KPU@^[ER
M*)MWQEV:IU4B`.O%HX`N_%P\QK]RS/F![K2/<TT/HIZE;#.GE[<G^8%?Y67/
MD#<^/N/LSYDXK5[B)ARHX>>9*MN*L<49IEV/S1=;C>+O<JO6+C;K7>K5&,TD
M6S."9M(9A'))E,Z5776"U]K*\ES_`(O-CA3H'LRXJ1EU''1C`='LQ!Z?:<UF
MP6."JJB@;@!SF/X^G[0B/C[];!HH`.06O6%K(?ENYFR72>?_`!@GK7A#_AEY
MB9OMW*FD9!=-;=/9AQWFF<G<17R"I=YP_)UXN+LBXGB,BXN[S\_[PM',K!NA
M8F:)*"=QK!%K(`Y@/NFG+AT4/3Q%<LL5G_-,JUY!UM!]>&=?LPSQP"I17RT<
MG7#"7+;%;CCAY5O%6=SWQ%RSQW@L@\1L97=A;I6XY+9,F'[PVVP2..Z,[J&)
M4"M!77K+1&P/%70-SB_,#4`6""72X$#%ARTY\L`/1B.E4=<1ES2"X@/!Q)R\
MY/IP4WLG\6LA6?D)C+/%.LN,TW.,^"G([BVPKF1J[-VBMS5_S%8<%V"KS]GK
M\>I'DG<9,#XD<-YN/!VV>NVSTJ:/I.8LA@=J)SJ#Z3IIQZ/TA0LD:&:<1[X/
MFQK[5C/B_)\RV\Q7S2HT*VXL\1H;DYQ>#`L5@+B]9<Z63C8ODE6[,[6OR$LE
M9OD'68V@3C&):'A8^)J\!X,7BXO'KHQ6Y4<?Y26AX898<B.%!Q_25EF\CJ,*
MXY\1B#Q+B<N?Z9AY(XF<QJM=.9C+BK?>.##%_/*6_?.^2V;6>2C9"X]9-G\.
M5+`V0KECB"ID;(5G,D//4RCQLG'0TQ(5K[NG$U04=N6:P)IROMY:N:S^&:'V
M<ZY4'$?8(&314:9`=;13K&/HQ/(_?6&'>`*F#[!R(9TZXQSC'>1^!W%'A9B]
MA+)OU+17DN,N.\Y8]0LUS70:$CG+><9Y/CU2@S,HJ!FCCJ(7=,#59;/:TMZ&
M^IQ-/7T*C[AKBUU*$$D^<`>W%1GFO*"DLAXGCL-Y&RI7&]>'RAL)>7))S%=@
MGTP\:91P[>V%^C\KM8&?;LHJ?Q^,U$-3FB7BJ+A\B11NL5,B@G",VCW$5RTC
MU-IY<.E2-O`S5I&)>3YJ@_H59X6X*YCQ\>_R2/$WR;<.6Q_@J_XXA[=A;`UX
MD39-N=M1BF0IY(A7-/QTM3<"V-@S<IV&ILW]C=O2N$2%?=ML(+WLAD`.IK<6
M\FY^:GM(Z5:^>,TH7T#AQ.7G)]@ZN5ML.^61F/%E3Y2H5W&/`NA5?/&/,68_
M9<%&CW/N6^"$\\J-XE;#D7(UT@KM#UYU2+=D&IRI(*/;U>L$CX<(]J\=$E%B
M`0E@MI`UPYTH,*=/`#U>9RO?=1N<TT.%<<:]'$GU^A2\\NKAM=>'\)G%K8E<
M?4JKY7O];ME`XUX6N>5+_@[CS&0-/:5N;98]LV848RSJN\D32)I>5:LXJ%A6
M:I$4VK3J!9=6>WA?$3J.'+T=7L&?IAN)FS$%HQIGY$^TJ[^.>,TC5>2G.+,M
MCG8J7IW+B$X\0$=68W[Q;3M?C\18CLV,[629=K($9`I8#V#NLCM3JBFF414Z
M3[`-&VY$CG'(U]9J/1YE:^;5&Q@S:L>?#KRM+7Q7M?'RF(<>/*TM%'P!9H)&
M&Y9J8/G(WF1:*)42+MZ<[?5]E2FE0KF=T69&B,I<4[:^0>+)+O"1R:SCMI8Y
MMY6L(TM(`(R%<L.%?77H65\S&YX<2\$D',TSJ>-/-0#IXJT'"+BWS#S=P[X[
MX)R]'88Q7Q7J/*JZYTM*+A#*X<H;Q$8@YU9%SK0<8RM$L=8@Z+18RUWRNQ;Q
M[84I>05=5P0(U8)J.2N$[HHIG"F3-9.-.!!&&!IAS]&8I+)`QY<,9"T9=5#C
MB*TZ*9=(-10OE+YM8W&B$?-N$SU*@^8)6>:%@Y9OJ;?9GFSGNN1/(5]FHE$O
MMD?5M-A39^#@7Z=>(X;STY%R#"-;()-(I$YNT;:R"0/.0=7AS\WFSPX#`(;M
MAC+!4592G(TIT^?`>?&LK*SY>]\@K]CJWJY!IJ[6E>;-R,\Q!XT1:SQ7+V@9
MKQ-E['</CUJ8[$$BW2&?Y(;N':IQ"/,@V4!-4QQ(`U;:O&!Y^P.%?6.GH5C[
MEKH]%,=-/6W_`"5E:UL5@IHB:(FB)HB:(FB)HB:(FB+S)?Q9V`C9;\J-[DUB
MS.YF>,F=,:Y/%9%/K71JMN4D,2VDH]("8&GQ-UC7"OCL`-0,/H#6NW!E6:P,
MLSY\O65G[>_3-I)S!^_[%^7YK3K=)HB:(FB)HBRB^7[YJ>;.#1SX]?1S;-G%
M^Q2Y9"[X"MTBZ;,T55=BN+!C*R$!=YCJWI?WA%VQ#M7"G@X14`=PY+O%W0V_
M?C\R/W.Z`4$C1G3(2-PU#@#@YH.!I@>@VCO!<[92%U7VE<N+?YI/"N):<#T'
M%>I#%-\P]S?K#"^<*L@UK(:+=!%[<L%7`8JH<A<;$474(X9VRO+N#-+?%LN@
MP)3\49=)=,W4?H$>@/,GV$NPS&VWL.9))72\5,9(_(ZF.%#0T(XM&:]!@W6"
M_@[6V-6MS_\`WFYMZLCP)7:6'$JT#'N:O<(>5J\\UD5R0[Q:4BW<*],FB0?N
MT))=Z1<T<9-3MI+D$1;J`4!*)=AUL[*]UW#;BT<V2,LHYH!#QCBZ@%*C.GX@
M:U"Q9W/+""<C4'KQHJZKCY[(R+"K7&0M<K+1I#5Y+X.?B(F781"QP250467B
MY).19.RK]*G;.F*A1*)@'8HAN+>WBTNN+%K&P$!U'!S@7#E0C33@"#0K43O>
MW&0BIY>OSK(''878L:_,5YNO)1A$+%`,[`+]B*=EG$DV\0XB#E<&*1KM&,E2
MB=4RIBE,H8!\3`(:UUT6O<YQTD@X#($DDX'`9X^98SM3J&E:>SR]BXQ9QE'1
MSEH@Q7GE0WC32UH9NA@6C=VFLV7=LVR1A21(]45%7[2P(E.D)B]8"<!T6X[I
MIC<V,>\`"3UC#SGK\Q69;6>J0/>?=J:`<P?7Z%4`6&,"MPK:F,41.Y;MBE62
MZI`6_>>_=H.>^E]EN]5=D(*('/UF`P"`D*'4/.W-R]UDPPT$KN7O.&-/,2<J
MX\<%M([<BY<):Z1YAE7CPH5@-\[GS$TN.M*;\8L5SRXY[M*!Y.X3B2G4_I$/
M+,U6;F:5=IG42+899$ZK9D0AA[*8"L`_9+U9'<ON>>]V]'=-S:YW=ZRDH`X@
M_,3MH2T\V,=B\Y$@,YJ;=]Y;W?VW1;%HW6X;[@`_AL-1KZ#3!@/&KN&/BT$3
M&$QCF,<YC&.<YS"<YSF$3'.<YA$QSG,(B(CXB([CKZ87D9))J<24T5$T1-$3
M1%LG#8?</R'1%M'#P_!HBX"H?+\.BN"X>J*Y-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1?O+:ZI<DHG9ZYM<?..%MCZ#D.6R'-WQY3762G])P[A3+V>;74
ML8,9!>)<Y.OL'AVEW-]1J"$HT7;HR,F5L1XLV7(U*N9!8$X7S-8[3B3U'+S`
M_=TJ5D3WC4*4K3$@8^=0YS+YE4@\Y7\6^,G%N2IEA@<]83B.2<AFZ:P=R4SI
MCVSXPL^1:;1J+`X\D<%L8VN0?[SI3SQ](7.P2O[MU8$&J3]'O.BD"`W&N0!F
M5*Y5Y#S9YUI3'$$*86^F-SI,P:4J!TX_=2M>I9$L\<@L5<<*Q%6W*,O.,VEG
MM\90*/6ZC3;=DO(>0;U-MY%]$4K'^.\?0EBN-TLSJ,AWCLS=@R5!!DS7<K&2
M;HJ*%R'R"-H+LSRY^76?6L=C'2&C>'EFK+.^?G&UCC>IY)=/<O)#?+U8L8TK
M%)^.F>2<B[5D&H,UI*V5:"XYJ8])F)^XK,0@9\_>%B/NMLP$KD[H$3D.:PW+
M`,:ZN5#T]%>!X>I2?+R=&GG44X<:TXA5!C3F]QCR[)8E@Z1D5RXL.;9/,-=H
M5:L%)O=-LG[[<?T&CK,N-KC`VVMPTGCK*%!9N_B'==GDH^65:I++MT5D$5%"
MU;/&XAM?>/#CY=?V%4=!(T%Q'NCCP\QX^;H7`MG/'C#3$;89Q>K%8YJG9RE^
M-9Z=CG&>3,D9"M>=ZW5(V\6C'&,Z-2*I-V;)<O3ZQ*$=3+F$;O(Z&!)<CUR@
MHW7*G:ZYAIAC_)7R\_(TK\O+2I%&TK4X>7\G,*DYOS-.%4!C*F9AN&:755J%
MZRM:,#1*%MQUE2'O<7G&EUZ?M%DPW<,8O*;_`)CTS)C")K;D4H:1BV[QZL=L
MDT(NH\:%6H)X6MH,,<J4QQ^XYT*K\O,32E<,ZX4PX^<+@V+S,>)%;A:_.JS>
M9YU&9QTCE^8B:;Q;Y*7"VXNQ0YDIJ);Y%SG28#%CVW8/K+I[6Y'L&M#*,=.4
M8]RLB@HB@HH6IN6`T%3YC]WW=>!5/EY..G^L,_3Y><*HLL<_^-.+E*_$M[3;
M<H6>Y8B;YTK,/@3$66>0YVN()MHX4J67+D.%J?<PIF,;2Z0,2.DY$[4DD"*X
MM05!!8R8W#?P8\<CEY@?NZ4;`]V)H!6F)`QY8D*N.#^;[+RBX=\5>15MB8.#
MMV>\#8NRK88.L%?)5R+G;Y5XZ<?1T$25?24BG$MG3T2(`X<KJ@F`=9S#N.KX
MY=47:.P%*^H%6R1Z9C&W&CJ!6@H/F><,,G6>AUNF9!O#]CDW(,CB"DY'D<$Y
MRKF%)G,49-3E=4Q$7-=DQ[$XS;9(?3=<>-646I)%4>N4RH(B==1-(]OS+*\=
M-:5H<_1]M>A7.MY&@DTP%:5%:<Z9JJ7WF$\4X[*)<5.;K<`=?YIM\$KY-1P[
MEUQQU99S=R1(-MAJ0Y(H4I3";+)"MC5)$_=YYL.W-'+&G.5^/PVJ&Y8'4QIE
MD<Z]7VUX4JJ=A)IU895I45ISIFK=7KS0.)<6YSS0Z+E=C-YBP5$<A&EQBY3%
M^>Y#'.-KSQZI=GMUNC,TWVD8RL,51X5HVK#A<G[8\A-,TC##(/E3H$4?,1N!
M##B`<:&F74?7YJJX6\@TEPP)'$5Q/7_)QHJFN'F-<9L:2,32[C8+]:<JFP=C
M;D!8:+@G`'(+-\A'XOR,RF3Q^1D&=`QK.R#2B`]K$CNL_(V>-D4DP<($6633
M-07+*4S=T`\R.71R^Q#;2=`%>)`X`\^1"M'=O-`Q?3>3.*:$Q5>Y/P)FG@VZ
MY8XQMN"<5Y:SODV_27^;$#5F)*M4\4PEID7%&3Q_*J2CQ5:+14:+D*55PF80
M;FC^;)DTM%6>>N0/"O$\!]ZO^5/9:B:/K3'`9D9GJ4BY[GKQ?B,<X3R?"W6S
MY0A.2%?<VS!-<P?BS)^:<FY/J\;'LY.?L5>Q7CBI6"_(0E1;2+<DT[?,&B$0
MZ73:NSI.E$T33&YCH"W$D>5:5\L\U%V$E2'"E.>'K*I"S^9QP=IU%PYD:?S>
M"%:Y`)Y)2Q`A'XZRK/6^YS^'W;*.R90FN.X"D2>06&4:=+O@8O*N[C$)XCU%
MPB#43MEP3?,Q4&=3PICY>OHK@JBWE)(IEGY_+/);LKYD/%N`DHE"Q.,[UJK2
MAL;(KY;LO%/DK7<&5A]EYA6G^/HN]9DFL7,:%1Y&8_?&,:N"2CQL6*D796<@
M9JZ*HD0;AC7`8T/0?NIQ''UH()"*BGI%?16O`JN\&9_M.4>1_.G#$Y"P,;!<
M5\G80HU.DHQ.0),SS#)W'6B9BFG-I.Z?NF2KZ/L%J7:MA:(M4P9ID`Y3J=2A
MC)B^8L%-%*@^9I^U'Q!L37XZCGZ2/L5-9Q\PKBSQXOETQAD6S9%>9!QQC^N9
M:R#5<:8'S?F"0I&*+0-E^!R9:%L84"U1T-2&)*A('?O5ERE9%0_:%`3D`U73
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M-,B0#Z,_4I@:R%"FB+48QCCU',8QAV`3&$3"(```'B.X^`!MJ@`&`R55IU54
M31$T1-$31$T1-$31$T1-$31$T11?YM\?FO*WAUR@XVND4UE,TX+R11(CN``@
MWM,G6GRM,?%W`VRL=;FS%P0?2!DP$-07#`^(BE3Y"OF!JI87F.4/Y%?B:NF3
MV-=.HV2;+,Y*.<N(^19N""DX:/V2QVKQLNF;84UF[E(Q#!ZC`.N=72+9T1-$
M31$T1-$5:XYR/>\0WFM9*QE:IJDWNGRK2:KEGK[Y>/E(U^R7(X1.1=`Y!50.
M=,`51/U)*D$2G*)1$-8]W:6U];/M+QC9+9XHYKA4$?8>1&(.(Q4]M<SVDPGM
MG%DK>(]A&1!X@X%>G3B3_$BMEXACB[S(>.,#GFI.CJMGN;<6LXFK9:C2.D3M
M`EI.J.4DZG:7S1%7<RJ*D<Z6`@=1CF]/"7?<E]L[MMFE-!2D<A((I^645=U-
M>U_\X!=+#WBCFPNVEDOYF"K3UL-*=):>IJSO\8<S^61RFDH!UQ_Y8X5:V0EC
M92+.AW1L]Q!DQPT17;BDQEJY<5464FM')H`!"M'CI$#G,)`,`ZT-P[<=J8X[
MCVT3!4:I&ZF8_KLU,`/,N&>-%L&$7;O]'+96D?@=4]>DT?\`LK.:;#!)%.PS
MB+IE8W\T+8KP(RSQ"Z`))LF#5->.*V<*(MTG!690,KMW?`!)X@(CJ9;JWN@3
M#+&\G`T>WU8X=>?)7LC=$:2-<VF56D>G!1BO].R"#M63DZ_6ZY"HO4Q4:OIJ
M#8TFNQD>V3:L73S[W<D-*/"%3ZNI4IDA`!-T;AMK07TUSK,LAAC8'`TU,#10
M4&9J[T&O*JV-NR-PT,$CGD<`XN-<\LE@HYU><UQ)X?P5XJF&[96<[\HAB'C6
M$C\=)J2N)J997`I,P?6FWMEV\;)OV0=:YT&Q%3G!,$Q[74&VPVKN;NN_.;)&
MSY7;Y'#M)B"TEOXNP8X:G.=D)'-:P5J-5*)=;K9;8#\T[M)V#W8J@DD9=H14
M,:#FVNKH&:\*^3<E7?,5_MF4,D3[NSWB[3+N=L4V\Z04=OW9Q.8J*)`!%HS;
MDV3003`J:*12E*``&O>=MVZRVBQBVW;HQ%90L#6-'`#F<R2<7$XDDDXE>=7U
M[<[C=OO;MVJ>0U/`#D`.``P`X!4-K-6(FB)HB:(FB+28-P]_JT1;`AZOQ:(N
M$J'R_!HKA]JX)@V$=450M.BJFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB_>6
MUU2Y)8R;U4.4G';F;G7DW@GCRVY5U/D[A;`5(DJU'YEQ_A^WXFR5QS<92:0'
MWNYR:LQAYG#E^B,F%7=.(E9W,0\DR7,6,>%<D,77RQ2,>XM&H.!X5I4DGJSZ
M>HK-CDC<QH>=+FG#D<ONZ.L*U'!;@1F7BIE[C#+6V2JUBKF+/+KRC@:_V*LR
MADXM#.64N5]7Y`RE7IT'(%;3KC'L"P-(LHU\J@B7X-FW(<B2AP3+2"W>R4.>
M,*?8`JW%PV6*C:@AWJ][[QYU)[S!L.O\SXIH43&<>+ER$D:CEN#O,8GB;DBG
MQ5SOB&5BZ[:(UAEW"&55YNI-2W2)-+FC7$:O-Q*#Z)E'0**K%*+9:>Y:YS1I
M!+J]/V4]H^PPV[FM>2\T;3T]&1]A^U8NI?@;S>LD%Q6S-G)AEGDI9L"VSEW3
ME,$#S4D\0\H(WC)R#E<;R.*$9/E5B2?Q'1\IYMQ,MC!-*;:OY9M#3<3,"@,B
MZ=QJ3AQBB&9K6FG/F#B>0(Y#C3,DY5RS/`7.%:`@<B,!AF#SY<,!CA?:3X29
M-3X>OK#QYXW_`/#CR[Q9R_C^;V!:%EOE)-\C;#>\J5EI7J;82YISE8+/:21;
MGD'AL)FIS+!K.R,?&LG#=07AU`.)+G0N=$7!M'@GB<>>=3EA@3F:*-LS6S"K
MJL+:9##CT#`XXCA14#D+RQLF5'%OE^6&#KMEY"7[C8ER*EN4>/:!R3N?%7(>
M:,B\S"0=XSEEK'&:*?;:$DK;:]F2,641AIR7CXF:KKM1L=PDH@V`1@E:&N`J
M[CG7'J(/2*Y5-3DJMN&.<YKL&&E..66!!X4R'`8*Y>*^%%XC[5PYO]3XRRG'
M)GCSS"\F\GLTUC)?*R1Y092FZY.<*\D\?(+*%OR%9;7=Q>WN8L$S#1QH&*FI
MA*.C&23CXDQA6*G<(WN`#FT&HUK7\I&-:]'$CDK72@%Q:ZIT``C#\0.%*=)R
M!5/<DN$N36W,CDCR!8\?<S<K\>\H*GAE1K$X0Y]W[AQ:L67K$N/W.,)2M7VK
MMLO8HHV0<;72%29R+2:15DIN)=*/VQV*J"R1AH^*1DAT#W3RJ/4"/OK7!5CF
M8Z,"0T<WF`?603]@PQ528MX]<FN&U\R&XX_\0:U><<<B.*7$W%4318+DW6X=
MAQ+O?&_%]OQ:;&=HN^4V:=OR7A=.'M"#N.L,*QE9HSYN^%:*W=)J#:8I&NJ!
M5I:.%:8C#GAE7//!4[2*1M)'8AQ->=>/$=8P'(J?_EXX=O''CA+PQP+DUK'L
M<C89X]X;QI>V43)-IF+:6RGU6)AIQO'2[,QFDFR2?M3@FNF(D5(`&#P'60UI
M9:$.ST?\FBA<X/NBX9%_VK"1P>IW)?E#P-XE<;X[`!:/@VL<P'.;;=RFG\N8
M^>Q<E0^._F"WS.[>!QQBZ$=O,HIY,N-LI2$"`2;%A$QC)9P\%ZX$J;=3$B:]
MXTM`TZR:TID0<_-R].2S)G1L>7%QUZ*4K7,$9>?*OMJ*HQMY;5[QD\-@O(O#
MS)W):J-.3D]DVMYZ:>97E3'''J1H-CY&R.?*Y;LC\7W66$%XC)V+'DLDHM7X
M6GR<'/S<0D[*]1^,5.C*(WM=I<TEFK];B:USIZB.95AFC<W4':7Z>0Y4Y=>9
MKCEAC.**XDYJ9<*/-3P:>,A"W[EMEWS);EB)BG8HP(V;AN3$386>)7-@E"*`
MR@7,@K(H@Z3=&*>/+_>](%TBMW-C>'-&K30>O+CQ\ZMDN`Z6,U)`()X<N'F4
M:<?6ODCQ[\P?-%5Q+Q@?\CKK"^5YY:-0LD3#YIQ?BV(IUOJ5GY;148M8I3(,
M@R++4V0F$G1'3V&))/V:+?J28N16(!8=+P[2!4Z3PJ<2_CPPZ^I3/=%(P/+J
M#5[&LX<<1T=85\N!O`G+7$C-?&B6L\K6[-4<4^7#,<>;Q:Z_(BBR5SG;.5$=
MGBQ0U5KKX$9XU!BV;Q\A%NU44P!HW03.4BINV%[;:0.Q'X3ZVT]OJ4<MTU[!
MIJ"'>H$G[O.H1U+RQ>0>+*9PAO-FQ/<LWR^%\`<@^.^9,%8-YC6GBYD.#1R1
MR5>9TH>2L<Y-IN2,84S(31)HB6/GJ[,SC)`4W#5TV,HY8BD-&P2L]X`XGIZ.
M1'+B0%>^YB?5A-``,:`U./,'GP%<U,WC[PON]$S/P-RA7>/J7':F8@=>8K:<
MM4"?Y'2?(V]0MOY2%QP-3M$[DVS2LW,7>ZY"D:P^D9T&+Z1:1#IP9(':Y![R
MEX@<Y[7::#CGP=4UK7VX]*C=<`,>T.)Y8`9BG"G0,N"ASSCX!<P>2<CS/K4[
M@ZQ9]NF3<O0-KXL\A+/S1>4;!6%<!QLKC27B<7Q'&<ML;,VF4*FO7I@'2CFL
MKL+$[=`^<3A!,5LG&^&>NDUI49`T.`\L!Y^4D4\#6C@:$=-:Y^1\W/,5Q_PI
M?,><J_,4RU9F<>WIG)#+V`;CBUTUE&CU](P>/>,&.\5V9:5CD#F<PB[>WUIT
MDDDX`IUD2E5*`D,`ZRH8GLDJ[+2!ZF_<5B2R-=$UHSQ]I^]4&OQURBIRF\PS
M*I6,7^Y7(_AMQSPMC-P,VQ!W)WS&L1RG9VAE+Q@J?$0T>V6RS#@BZ<%*BN"R
MHD$02/M:Z!Q<^H%32G]8GV*K96AC!7(NKYP`L8\/Y<V><12'&K(<[@_*/(HC
M#RY>&W$_*6.>//.FX\3,@XCS#Q:KMC:*3,;*P&6\08[S%C&XK7=RBJHYECR$
M,_C0<LD%T7ZW3'V4K-):"?='$\*G@6TSXGJZ)^VB=J!('ODC`',]3CD.'V8S
M=XD\.KCA'D9Q]R3#87K^`L2T#R[\A<?W.-(K-$AFF2QWE"\\I:QFD]3+?[%V
M[5?D5H5H\=/9LX&;'?',B0YB]L1K%`>U#G-`92M,3P`X]//%63SAT6D.)<'=
M7YN76J5NW`K+TYYB3&Z1;BM!P+ON5,7<Z<T5-6631L3OFUQ_HTOC"B0[&M`<
M/BZ3>EV]-N\JY[9B!/T=,#B!W/[0ZV<9J"O9Y\J994PPPIQ]U59<@0U-#*,,
M<:C/&N/,'K43C^6Y?JA8,YXEO/#W)_+>@Y8Y.Y4S)5<HP_F6Y4P7@Y[1,V9G
M>YE=PV>..XY7B$XVU8MF9M9!1*N5.?86@L:U='41<KK=NACD#BUS26EU<W4Q
M->!`]#3TTX7":,M#@[2\-ID.`IAA[2.CIOV[XQ\J83F\&0N.6*,O\6JS8N6A
M<H9^O4;S*K%ZX:<B\-.Y$?\`,BRRG#^75E;35.0F8JPU014^Z(2!3CI\WW@O
M-.B)&^)M$,@D!:V@#NL>GU5T^<\1GB,)#C5Y;3D?Y.C4>I9:\4V',-A_S,_S
M@QK6\;?<>7+I7<5A7+PC>/W^PS&?=O[BY,GQ19,OW0LUJ!=U\7!'[IX_L%W4
M-W/#81EQKJ%*.-.KT#RXK!>&BFDUJ,>ODKKZD5B:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(M:9S)*$4(.QTSE.4?88@@8H_B$-4(#@6G(JH-,1FOQ_O/9XN#Q&
M\UCE]C9A&FCJA;LB+9PQZ0I.AH>F9N;IY#;-V`!L`-(.<F7\8`!X$,Q,7U;!
MSD[2V5P//^7UX+HK=^N!KNBGH6(W42F31$T1-$31$T1-$7P/`Y%"B)5$S`=-
M0HB51,Y1`2G3.40.0Q1#<!`0$!TX4X*H)!J,"KHQ^<<VQ*)&T5F;+48V3(5)
M-O'Y(N3-!-,A1*1,B3>93(4A"CL``&P!K6NV;9WNUOM+4O/$PQU].FJSQNVZ
M@`"YN*#_`)Q_WK@3.7,LV-D,98<J9*GHT=]X^:OMKE&/COU;M'TLNW'JW\?L
M^.I8MLVV!_:0V\#)!Q;&P'T@*Q^Y;C(-+[B9P/-[C]JMX!0*&Q0`H>P```\?
M3X![=9RPEJ]6W^O5$31$T1-$7T`$?0`CL`C^(/2/X`U5%\U1$T1;)_TA_%^0
M-$7#5#T_+P'1577*!X_+U:HKEHT54T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$7[RVNJ7))HB:(FB)HB:(FB)HB:(FB+Z`B`@("("'B`AX"`^T!]0ZHBXS1DR
MCVZ;..9,X]FD*@I,X]HW9-$A65.NL*35JFD@F*RZIE#B4H=9S&,.XB(B``%!
MDJDUS7(U5431%QRLV9':S\C-F1^Y0;M7+\C5N1^Y:M#K*-&KEZ5,'*[9HHY4
M,DF<XD3,H<2@`F-O2@K7BJ]"Y&JJB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+PG_P`9KQ.,HWXC\XH&,`>P,_QAR?((
MMQ$P%.,CD?$CEXJF7[)-_P!YVO6IX;]D@#Z`UJ-PC(<).'E^DGK6VVZ04=%Q
MS'V_8O!_K6K9IHB:(FB)HB:(FB)HB:(FB)HB:(GNT1-$31$_T>CW>O\`+HB:
M(FB+9/\`I#^+\FB+CJA](?DT50NN5#T_/JBN"V-%5-$31$T1-$31$T1-$31$
MT1-$31$T1-$31%^\MKJER2:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+&S
MYOG#\O.KRXN4W'AC'DD+M*8]=WS%!1)NX3RSBU0MZH[=H<`$Z*T^_ACQ!S!O
MNA(J%$!`1UB7<?:0FGQ#R]M/,LBUE[*8./P\?+J7XU#U95N':,0Z+CJ,15-0
MHE50.F(D52.0P`8BJ:@"40$`$!`=_'6A71@8]"ZCK/OOU&W]._4.^_MWWWU1
M7+E?&K=L";_:_P"L])MO9MZ-_?I54TA;)7"Y1Z@5.(_SC"8!_$.X:)0+N6ZW
M>3`_H,`])@]@A[/<(:JK2*%;^BHMLZJ:?Z9RE]PB`#\WIT1:/B$/^M)\^BK0
MK;,\0+_*$P^PH"/TCL'TZ)0K:&02V\"*;^_I`/GZATJJZ5M'D#C^@F4OO,/5
M]`=(:532N.+QP/\`TFWX"E#_`$:HJT"T&<KG_25/^(>GY^G;?1*!:>\K_P!:
MI_7-]>BK0)WE?^M4_KF^O1*!;R";YTH"+4CIRJ;?I20*LLH;8HF'8B8&,.Q0
M$?1Z`U>QDDCM,8+G<@*GU*.22*%NN5S6L'$D`>DJOHK%.79D2C"XVR-+"80`
MOW;3;+(`81$@``?#1JP#N90H?A,'MUN;?NQWEN_]4V^^E_F02N]C#S"YR[[Z
M=S;#_7MVVR&G]Y=0,Y_F>.1]"NQ"<1>6E@*12+X\Y<73/^B=U0YZ-3,'=%$=
MSR+-F4NR@;#N(;!XCX>.NBM/"SQ(O0'6^Q[F6GB;>1HSI^-K>/WY+D+_`,</
M!S;"6WG>;9&N'!MW"\Y5R8YW#[LU<N.\O3FG*]';X_VMKU$ZMY.1J\20`!3M
MCO\`><\T.4VX[](AU=(;@`AXZWL/@5XM3TT;)<MK^=T+.C\<@_DQ7,7/U/>`
MMK77WDLW4_NV7$G"O^;A=Z<JX9JX;'RK.:+_`&[U`K$7^T,3>1R+3PZ0*4#=
MP09R;PW;,(](;`([^K;QUO8/IN\69OCLK>/'\=S!Z?=>[!<Q<_6+X#6X/9[E
M=S&E?<LKGT>]&W'BJG9^4!RZ>]/Q!L3Q0&3,<1?7U1;H,`[`B<(N#D1$Y@\0
M$-R;>D0'6TA^EWQ/DIVAVV/#\5Q6G1[D;_NZ5I+CZW/!2&O9#>9L:>Y9@5Z1
MVDK,.NAZ%5K#R7N1J_9&1R)AF.ZTQ,N5.6N#XZ"G2(@D';IR2:P=7AU`;;U^
M.MM!]*/?M].WOMJCJ,:/G=0\L(!7TK17'UW>%\>H6VU[[+0X5CMF5'/&Y)'5
M15(W\E#,9T]W69\6(*]1@Z$6%Q<D$FQ>DW=-#MQ`PCON'3X>T=9S/I+[TEM9
M-VVX.Z&SGUZ![%JY?KU[CM=2'8=X<RF9?;-/H[5WIJN[+Y)&0!*43Y^HA3B4
MO64M1LIRE-L'4!3"Y()B@/H$0#?V!K,'TC[W3'>K*O\`T,OWK7GZ^N[53I[M
M[B1P_P!)@'V'VE=R'DA3VP;\D('?8-]L92@AOZ]A_?$-PWUE?\(M[_Y]#_LC
M_P#QU@_\?NW?^EKC_;X__MD_\$*>_P#F0@O_`(92?_VY:?\`"+>_^?0_[(__
M`,=/^/W;O_2UQ_M\?_VR?^"%/?\`S(07_P`,I/\`^W+3_A%O?_/H?]D?_P".
MG_'[MW_I:X_V^/\`^V3_`,$*>_\`F0@O_AE)_P#VY:?\(M[_`.?0_P"R/_\`
M'3_C]V[_`-+7'^WQ_P#VRZQ;R1[P"IP;\@Z6H@!OV2B]*L2"QB>HRB"<DY33
M/[@4.'OUCN^D?>-1T;W:%G`F"4'S@.('I/6LMGU]]WRP&3NU?B2F(%U"17H)
M8TD=.D=2Z%SY)^7R$.+3-6+G!P-LF5>-N#4IR=6W4<Y(ISVS='CL`&\?#?UZ
MPY/I+[T`'LMVVYQX59./^05L8OKV[DN<!-L.[M;3$A]LZAZ!VC:X](YT5*2?
MDP<D6Y51B\@89E1**?9(I-6Z..L!NGN"(KTY1-+M[CZ3#U;>'IUK;CZ4>_C`
M3;WNU24I2LDS:\\X"!3K6XM?KM\+)2!=[;OL(-:D16SP.65R":]6"H21\H3F
M$RZ_AF6-)@"BH!1CL@,TNX!`W*8@2S&+,`*CX%Z@*._Z0%UII_IA\48J]FS;
MY:5^&Y:*_P!=K,^%:=-%T5K];'@A<4[63=H*T^.S<:5Y]F^3+C2O156WF_+#
MYLPNXEPZ:9(7KW/`7*C2>X$*0VY426--T;J$^P`"8F$0'8/#6AN_IZ\6[3+:
MNU'_`#<]N_U=J#ZEU-A]6G@'?X'?!`[#":VNV9UXF`MX5.-!4*U,[PCY<5M-
M165X\95!)$#"HI'U5_-I@!`4$Q@/"DD"F*`)B.X;@/AMZ0WYN\\(_$VP!=<[
M'N6D9EL+I,O^CU<EV.W>/W@MNK@RS[S[/K=2@?<,B.-/[W1SX_8592;Q?DNL
M@H-CQY>:^"0B"HS=2GXH$Q`=A`XOH]`"[#X>.N2N^[O>#;ZF_L;R`#/M(9&?
MVFA=[M_>WNINQ`VO<]ON2<NRN(9*]6AY5#]!_P!4WIZ?T1_2]GH].M10KH-0
MYA?O*:ZE<FFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB^E,HFL@LFH8@HJ
M=SI`J9BJ"`?8`_64Q@!,^Q@Z1#<0V'</#5"`X%IR*J#3$9K\AG^(.X3%X-^:
M'GREP$7]V8MS"_3Y$X@322.FQ0J&6'TE*R\$Q`2@DFWJ%_;S,2FF41[:#-+T
M`8`USMPPQRD'R_1RZ%T=I+VL`/$8'RZEA.U`LE-$31%R$')T-P``,!O$0'?T
M^X0T5"*K49XX,.X'`H>PI2[!\X"(Z)0+C@!U#@``8YSF````$QC&$=@``#<1
M$1U4`DT&)0D-%3@`KCUC#67KJ)0I^+<B6@#"``>`IEBEDMQVVZE6,<ND4/'T
MB(!K>[?W5[S[L:;7MU]<5_NX)7CTM:0N6W;OSW*V$'_&]WVRT(X374$9]#W@
M^I2)K?EW\S[21-5C@2W1Z"NP@M9EX.I@4#;["=*R2T6Y`/#]3?7=6'@;XK;B
M`Z'9;IC#QE,</JE>P^I>9;K]3?@3M!++CO'92R#A`);CUP1R-]:O_7O)\Y;2
MY$E9=;%M2*<`$Z4Q=E'[I'?U&2K,/.HB8/8"FNUL?I=\3+H!UT=NM0>#Y]1'
MFB9(/6O-MS^MSP7LG.;9-W>](R,5J&-/GGDA/[*OS`>21<UB)'M.?ZC&J#XK
M(5ZF3DZ!?<FYDI.N`8?>*8:[.R^DC=7`'<=[M8SQ$4$DGH+WQ>Q>=;E]?6Q,
M<YNS]V[V5O`S744/I:R.?^TKZ07DIX7;$3&RYFR;,*EV%4(6'JU>1.(#N(%!
MZE9%2%$OA^D(AZ==A9_29W3C`^?W7<)7<>S9#$/VA*5Y[N'UZ=^Y7'_"MBVF
M!G#M9+B8C^J8!ZE>Z"\I/AM$IIED8/(5G4*`=2LU?7;7N#X[B*==8092@(CZ
M`'U![]^NL_IG\*[9H$\-]<.'&2Y<*^:)L:X'</K/\<KUY-M<;9:,.0BLVNIY
MYGRJ]$!Y?'#&N$*1G@&I/Q*`!W+"^LUD4-L)A`3??4Z\3$1ZO'[/CL&NKLO!
M'PIL!2+9;5_3*Z64_P#>2.'J7![E]2OCKNCBZ?O)>Q@\(600#_NHFGUJ[]?X
MV\=ZKL-<P1B"(.7;95MCNJG7W`-M_B',8NX$=A_6UU%EW"[C;::V&S;7$>8M
MH:^DL)]:XG<O%/Q-WC#=.\6]S#DZ]N`/ZK9`/4KJ1\#`1``$1`0,2!?`H14+
M&1O2&Q@\/@FJ&VP','X!'VCKHX+*RM<+6&&(?J1L;_9`7'W.X[C>XWMS<35_
MO)9'_P!IQY#T+O/B'&VW?6V]G=/M\W5K,[1_YCZ5@=E%GI;7J"VA,8WB8QC#
M[1$1_+JVI.:O``R"TZHJIHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(OH"(#N`
MB`^T!V'Z-*D9*A`.:W#++'*)#JJ'((;"0YS'(8/88AA$HA[A#5Q>XBA)(5HC
M8TZF@!W,"A]*Z?[C@O\`ZPP7]]\1_P#4:,_[3_B/^R_]H_G_`*?OUB_)V?\`
M<PYU^!F?/+/IS6=_B&X__,7&5/XLF7+XLNC+H7O-U^2B_?I-$31$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31%]`!,.Q0$1]@`(C\P:IDJ@$Y+Q0_QD?"BU9$Q=
MQ;YFT6MJ2[[%,Q-X$R8DQ5<KV!:N9"D$+'BYTRKZ;14[]C%6QK--5U45`6(K
M+MRBD<@B=+`GLKB]E:VQCDFF/X6-+SP&`:"?Y5F1;A:;9$^3<IHK>W`KJD>V
M-HSK4N("\,U-X5<L+\FFO6<`Y+7;*FZ4WDK7G%99&_G`]LPQ#42!^MU[>_74
M[5X3>)6]-#]OV7<#&?Q/B,3?ZTN@>>JX3??'KP;[N.,>[=Y-J;*!BV.9L[_Z
ML':.KT4JI35/RA>75@%`\XVQU14%.DRPV&ZMW[IN4WI`6E4:6(QU2_J]0![]
M>B[9],/B=>EIO&V-FPY]K.'$?T86RX]%5Y!O/UK^"NVZF[>[=-PD&78VKF-/
M]*X=#ATT\RD]4O)(D#"12^\@(YN78.MG3:0\D#[_`,H`D9V9B"E]@?[J;7H6
MV?21.3JWK>XVC\L%NYW[4CV?V%Y-O7U]6P!;W<[MRN/!UU=-9^Q#%)_\0*3-
M4\G3BU"@F:R6#*UU6#I%0'-@AJ^R.(;=0%;0T"#Q-,WL^*,8/UM>@;;]+7AU
M:`&_GW*[?QK+'&T^:./4/ZYZUY/O'UP^+U^2-JMMFL(^&F&69X_I2S:2?^K`
MZ%)6K>7MPRJ()"PP+5I11+806MCZQ6TYQ#QZE49^8>LE-Q]("ET^[;7?;=X(
M^%6V4['9;:1PXS.EF](D>YI_JT7E>[_4MXZ[T3\SWCO(6'A;LAM@.HPQ,</Z
MU>E2.K&*L6TH`"G8SQ[51*``!Z]2JW$+``!L'[=C&(KCL'\[7>;?W<[N[2*;
M7M]C;?\`101,/I:P'UKR[=N^'>_?C7?-VW.\Z)KJ>0>A[R/4K@`JJ!`3!0Y4
MP\`(4PE(`>P"`(%`/Q:W>IU-()T\N"YK0PG40-7/CZ5HU:KE\T54T1-$31%]
M`!'T`(^KP#?5:%4J!FMP$%S?HHJC^!,X_D#50QYR!]"M,D8S<!YPOHMUP]**
MH>OQ3.'A^,-5[-_(J@EC.3F^D+84.FD`&5422*([`955-,HCMOL`G,4!';4;
MBUF+B`.D@*1H<\T8"X]`)]BZUQ.P310$G<]!-%1*!P2=3,8V5$AA$"G!-=TF
M<2&$!V';8=M8[[RRB=IEFA:[D9&`^@D++BV_<9VZX+:X>RM*MBD<*\JAI%5N
MLI6*DE3(1DK%R:Y=NI&-D6;]8NX`(;I-%UCAN`@(>'H'6%-W@[OV[M%QN%A&
M\<'7$+3Z"\%9\/=GO-<,$EOMFXR1G(MM9W`TZ1&0JE0@)]SO\-`S;C8-Q[$1
M(+;!OMO^S;&\-]8LG>WNG"`9=UVQH.5;NW%?3(LJ+N9WSG);!L^[/<,Z6=R:
M>B)=PEC[("Z7>1H=V61VW[R52L"B.WM[I(XQ-OQZM'>_NB[%N[;6>J[M_P#Q
M%*>XG?D9[)O'^Q77_A+JC5NQD.9,]>GB'(/2<AH:2*<A@'82G*+8#%$!]0ZR
MV]X-@<T/;?V18<B)XJ'SZUBN[I]ZVO,;MKW(2`X@VL]1UCLZA?/W=L0@8P5^
M=$"AU&$(>1$"E#TB80;"``&H3WI[KM>(W;GMPD)I0W4`->KM*J;_`'*[Z=F9
M?\&W;L@*D_)W-*=?9474NR'8`(R!#,`#Q$7Q19@4/>+D$@#\>IO]X>[W_F%A
M_M,/^6L?_=;O3E_A>YU__5+C_P`-=4,U"%,4AIR$*<XE*0AI>-*<YCB`$*0A
MG(&.8PCX``;CK+;N.VOH&7-LXG*DL9K7*E'8UX<UA/VC=XZF2SNVAM:U@E%*
M9UJS"G&N2YZ:J*PB"*Z"PE#<P)+I*B4!\`$P)G,)0$?;K+:YKL&D$]!"P7L?
M'B]KF@\P1[0N2#=<WZ**IMPW`2IG$!#VAL`[AJ01O.0)4)EC&;FCSA?#(K%_
M224+_23,'H]/I#U:M+7#,%5$C'9.!\ZV]A#T^&J*Y?-%5-$31$T1-$31$T1>
MRS!O+7C_`,B6Z08QR%%O)XR15'%)G1_=V[LQ$H&,0U>DCIKR!4]]A58F=(?S
M]?F'WL\..^7<IY_QZRD;9UPGC_>0._ZQM0WJD#'="_;CN#XQ>'/B5&!W5W*)
M^X$5=:R_N;IO1V+Z%]/S1&1GZRD>("41`0$!#P$!#80'V"`^(:X=>G$$8'-?
M-55$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1;A$U%/!-,Y]O3T%,;;Y@'5I<UN9`5P:YWP@E6
M[N66<5X[1%Q?<ET&FI@(AM9+;!12PF*&YBD:NGQ':A@#U%((ZW>V=W.\.]NT
M;/87ET[_`)J&1X](;0><KFM[[X]T>[3.T[P[IMUBW_G[B*,^9KGAQ\P41;KY
MF_#2F@X31R<]NSQ`1*#2@U6=G"+'`=NE&4>-8F$,&_\`+!ST>P1UZ1M?@-XG
M[II+K!MI&>-Q+''3K8TO?YM-5XWOOU4^".R:FLW62_F;^&TMY9:GD)'-CB\^
MNBB9<?.DH+054L?8-M\\(%$$7UQL\/66YC>/28S"&:V5UT>CP%4H_@UZ-MGT
MM[Q(`[>=VMH1Q;#$^4_UGF(>HKQW>_KD[O0DL[M[!>W!X.N9XX&G^A&V=U/Z
M0*B9<_."Y.3Z:[>I5W%V/4E2G(1RR@Y*T2J!3@(%.DZL<FM'=Y/?<#"S$-_Y
M/JUZ+MGTT=PK0AVXS[A>.'`R-B:?-&P._;7C^]_6EXJ;@"S9[7:-N8<BV)]P
M\?TII"RO3V?F45;ASHY>7GNEF\_7YLV6)VU&-9?-::RZ!*)3%!&J,X<0ZP$=
MQ$PB.^O0]L\)?#;:`/E-GLW/'XI6F=WIE+_8O(M[\?O&;?RX7_>+<61.S9`Y
MMLST6[8_:HTRUDLD^Z%[/6.P3KP3&.+N;FY27<]9_$YN_(NG*H&,/I'?QUWE
MK:6=@W18PQ0,'"-C6#T-`7E=]N&X;H\R[I<7%U*36LTCY37K>YQ73F.<X]1S
M&.;VF,)A^<1$=9)).)S6$&AHHT`!:BHJG_024/\`T2&-^0!U4-<<@2J%[&_$
M0/.NN?R<7%%,>6E(N*(4!$QY2291Q"@`=0B8SU=```"^(^[6//<6]J*W4D<0
M_7>UO]HA9=M:7EZ=-E#-,X\(XWO_`+(*M+/\C^/56.=*Q9TQ'$JI"(*(N<@U
M<RY!*8Q1*9!O)+K`8#%$!#IW`0US%[W^[C;:XMO]YVN)XS!N8:CS!Y/J7:;;
MX5^)V\-#MK[N[W.PY%ME<4/G=&!ZU9J=\POAC7C"1UGFLR!RAOT5Z+M-AW_0
M\"JQ4$X;F'8_J/ZA]@ZY2]\<O">P-)=ZMWG_`)IDTOK9&1ZUW>V_3%X\[H-4
M/=N[B;SFDMX>?"29KN'+ES5HISS8^'D2`_=\SD6S&#U0N/WK<@_W?H4L#^$]
M1Q]7\D?=OR]Y]3/A7;#]Q+?W!_YNV(_^*Z/V<.JO;[?]%WCE>G_28-KM!_SM
MXUQX\(62\N?$=-+33'G,X*;%.$%B?+,RH`#VQ?KU&"1..Q!#J.26F5B!XF`?
MV8^@/;X<Q=?5CW,C!^3VS<Y7?K&&,?VY#ZEVEC]!_B+*1_B.];+`WCH%S,1G
MSCB!X<>/1C:N6\ZQ$.L('CHJ8?M=I2;R20H?](!142CJD(C_`"!$`/\`K!OZ
M!US=S]7,8J++82>1DN_:&P=7'GBNRLOH$D-#N7>D`<1%8GHR+[GKQIRPS5KY
M?SGLRN!/]QX;Q9%D'JZ/O&1MTRH7<I`+U&2D8A,XE,!A\"%W`0#U;CSMU]6?
M>I]?D]JVZ,<-3IY#ZGL!]"ZZR^@SN)&!_B&^[Q,>.AEM$#Z62$<.)]=!;F7\
MWOE<_P"L(V.Q)7RF`X%^#IDA(*I]1@$ABJ3-B?$,=,H;!N02B`[B&^VV@N?J
ME\2IJ]A'M<`_5@<XC_M)7##JIT+JK+Z(/!FVI\W+O=R13XKIC`>BD4##0YYU
MY%6ZDO-%YIR'7VLEPD4!^[L$5CVEHBF"@AL"9W4.\.44=OL"(B(>O?6BN/J-
M\6IZZ=PABK7X+:W%*\JQN.'!=1:?2!X!VU->TW$Q%/XE[=&M.>F5HQX^JBH&
M2\P;F=*G,9?D!<6W4<%.B);5R&3*8"=&Q"Q<&UZ4Q#Q$N_2)O';?6DN/'+Q9
MN35^]W3<:^X(HQR_!&W#HRKCFNEM/IE\!K,4C[LV+\*5D=/*<ZX]I*['ISIA
MDJ&?<PN5DD42/.1.8#E,F=(Q4KO,M`,F<1$Q1^#<(#N._I_2#U"&M-/XJ^)5
MP*2[[NE*4PN)&Y_S2%T-MX&^#5H:P=U]C!J#C:1.Q'\X'[E1$EGG.<R)QELT
M99D>XB#=0'>1;>L51`!$024(:8Z#I@)A\!`=::?OKWRNJ_,[ON<E10ZKJ8U'
M(^_DNAM/#CP[L*"RV#98J.U#396PH>8/95!5*.;]?7ANMW>KHZ/T=OJ<VN?7
M-V_$>CJ5D##T;F'P]'CK72;YO<IK+>7;C2F,TAPY8N6YB[M=VX!2';K!@K7W
M;>$8\\&9KH5Y65<E*1S+2KDA!ZBD<2;Y<A3;;=12JKG*4VP[;AX[:P7W5U**
M22R.'2YQ^U;&.RLH270P0L<>(C8/8%+CBOQ$O')"T,#)Q[D*VFY1*N]<$44.
M\(4X"*21E!Z@0\?$V^VN8WS?[?;8R'.U7%.=:?I6VL;*6=VF$:8Z\*`>@>U>
MW[@=PNQ]B2I1T>WAV!))!NEW5D6Z9#;]!-R`8``3"4P>(CKR2XN&;E.;B8-)
M.0(!\YJNOA9);1B%CG#I!/H69_%N,VKF0(F9M_N*0%$XB`](=/B81`QM]M@U
MG;981R25+&Z!T!075U*T4UN+CTE5AFW(!*K$&J527,1RHB**QVZ@E!JCML8P
M](_I>[7KG=/8+2YN!+=M:VRCH3AGT??T+@N\V^7MG:.99ESKU^`Q/NUS=YN"
MBA2Z!.75U\*S26,0ZG4[?*@<P`(FZC]2FXB<1'78]ZN^5G8P_);;I+Z4%`*`
M4HN0[J]SKJXD^>W,NH7:CJ)J3GB3B:JO\DP$/BFJNP%4@.P;F%5<3;'.8"CO
MXCZ`WUXY([YB4W-[0N.-"O662/CC^6L]38QA4$BB\IWF&\D6S4TNT1D`$X"L
M7;N[C_*#T;ZN;-%(\-8UOF`4S8YF-J7.])7EDRUD!Q9I9XKW3&ZU5!*;?[0#
MN.P@(>)1#?\`%KI[&V#:/(`(6LN97$%E20<#TJR3>7E6HF,UDY!L8X`4XMWK
ME$3E`=P*84U"B8`'U#KH&7-S&28Y'M)Y.(]A6EDLK.8`30Q/`RJUIIU5"J%K
MD3(#';X*\W%GLF"(?"V::;[)!MLD'9>DV3#I#[/H\-9L>^;W#_"O+IN%,)9!
MARP=DM9-W8[MW'^L;?8R8U]Z")V//%AQZ57,5R1Y#09BFB,Z9?C^DR)BE;9'
MMZ:>[<!!$!2^]Q3$J11V`!#8`\-;BV[^]^+,UM=XW1E*974U,,L-=,%S]YX6
M>&>X`B][O;)+6OQ65L3[V>/9UQXE7%B^=',&'Z/@N1643`F)1*5_9'$L0>E0
M50`Y)4'I5`$P^(&`0,7P'</#6]MO&'Q0M:=CONXX?FE+^-?QZJ^0R7,7?T]^
M"5]7M^[&T"OY(&Q\*8&/33S9'$8XJYT/YGW-F(`A39A^]R$```LW3*+(F,``
M?]-8];(X4$1/N(B<1'I#V:Z&U^H7Q;MJ`[IVH']Y!;N]?9`^ODN2O?I*\`[V
MI&Q]BX_W5U=LY9#MRT9<!Q*NY!^<3RQC0*65C\3V4@?I&D:8\CUS!N8?TX">
MB4BCX@']WZ"^T1$>GM/JE\2H*"YCVRX'ZT#FG_NY&#U+BMP^A_P:NJFSEWFT
M=^I=->/1-#(?7Q5Z*]YVM_0$I;7@:D2Q=PZU*]:K#7E`#J'J$I)%M9DQ'IVV
M#P\0UU=C]6V],PW+9K24<XII8C^V)0N$W/Z!N[<E3LW>/<(3RFMX9AZ6.@*O
MO6O.MQ`[`A;?A?(L$H(@!U*_.UNS($#UFZ)`M66V#V!N.NRL/JS[KRT&Y[3?
MPGG%)%*/VNQ*\\W7Z"^^T!)V7?MKN&\!-#/`3YV?,!2(JWFM<,;&5(']SMM,
M<*F`HHVJB30D3$0])W=9_>1J4@#ZQ,&NXV[ZD/"F_`[:[N;1YX36\F']*+M1
MZUYCN_T=>.NUDFVL+*^C'&WNXJG^C/V#J^8J351Y8\8KV=!*JY\Q7(N7/3V6
M+BW1D)(G,?\`1)]W6!2*?`H(_P`D4]]_5KT#;/$KP^WDM;MN];;)([)IF;&[
M^K*6.KT47E&]>#7BSW>#G[QW<WB*)N;VVSY6#IUPB1E.G517I_>6L_\`V35K
M^Y^(_P#:"'_[/_B/^V_]G_G_`*/OUUGS^W__`#%OE7^(S+G\673DN#_PK=?_
M`)2Z^+3_``9?B_+\.?1FN]166;.$';999J[:JE7:NVRJC=TU7((&(LV<HF(L
MW6(8-RG(8#`/H'62YK7L,<@#HW"A!`((Y$'`CH*PV/?%(V:)SF3,-6N:2US2
M,BUPH01P((*R#X/\S;D_ATK.*F+"US!4FO;2""R0+A]+-VQ/`$8RZ-3IV)N)
M2_H_%'?)AL'V-O#7C/>SP'[@]YBZXMH7;9N3L>TMJ-83S=`?W9_H",]*^CNX
M7U4>*_<H,M+VY9O6SLH.RO=3I`T<&7+:3-Z-9E`_*LNV&_-?XSY&!K'WU2<P
MI850*10ML1&8J)UMB@;X>W0B"@-TC&$>D7S1F`!Z3:^;N\_T[=^]D+IMG$.Z
MV0R[$Z)J=,,A%3_T;W]2^R^Y/U?^%G>8,MN\)N-BW(Y_,#M+>OZMQ$#0<C+'
M'TE9(*[8Z[;XE"?J4_"6F#=%`[>9KDLPFXM8I@W#H?1J[EMU;>DHF`P>L->'
M7MC>[;<FSW*&6WNVYLE8Z-X_HN`/J7T[MNY[9O5FW<=FN8+NP>,)(9&2QGJ>
MPN;ZUW.L99J:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB^@`B.P`(B/H`/$=45<\`NALEJJU,9FD+C9ZY4F!"B8SRSS
ML7`-NDH;F$%95VT(;8/8(ZS+';]PW27L=LMY[F8_ABC?(?0P%:[=-WVG9(#<
M[U=VUG;@?%/+'"WTR.:#YE#N]^8]PWH0+)KY?9V]\B<R9H_'D-+V]4QR>`E"
M0:-4(+;?T&%WTCZAUZ;M'@?XG;Q1S=M=;1'\5R]D(_JDF3S:*KQ7O!]3G@EW
M>U,DWIE[.TTT6<<EP:_SVM$7G[2BAC>O.CHK/XA#&>$K58%2F$K>2O%BBZRQ
M.`>A4T9!HV)^(&]1163'VB&O4-H^ES=Y:/W[=;>%O%L$;Y7=6J0QM\^DKP_O
M!]<>P0:H^ZNPW=R\'!]U-'`P])9$)G^;4%#>\>;ERLLPN$JLECK&S-8.E+[B
MJYI^5;EVVW+*6QY+(&5']8&I-O4`:]-VGZ;_``\L-+MP-[?2C/M)>S8?Z$+6
M&G1K*\3W_P"LGQ>W4N9M(VS:X#EV4';2#_K+AT@KT]F.I0XO7*KDEDGNA=\Y
MY+F&RI#)J,$[2_A8D4C;]28Q,`>*C!((#L("D.X>G7IVT>'O<;8Z?X5M-A$\
M&NKLFO?7^?)K=ZUXEW@\7/$_O17_`!_?]TGB(H6"=\4=.79PF-E/Z*L.@DM*
M.O\`=DEY1^J?IV;IK2+U50P^C9(J[A4YA'WB(ZZ][FV\?[PB.$#B0UH'GH`O
M/HVONYJ1!TUPX\`7N)\U22KT57C7R'NYR$J>#<KS?7L)54*+86S78WH,9](,
M6;(A1]HJ`&N6W#OSW+VH5W'=MNBIP-Q&3_5:YSO4NYVCPO\`$G?G!NS[!O$]
M>(M9FM_K/:UOK4AZQY9G-*S"41Q(E6$C;#WKC;ZI";`/K%L25?/]P]G9WUQ=
M_P"._A;8##<C<.Y0PS2>O0UO[2])VKZ6?'+=:$[,+1G.YN;>+]D2/?\`LJ05
M:\FSD-)$*>T9$Q+4MQ#J0;NK+:7)0'T[_!0L<S$0#U`L.X^O7&7WU.]RX#2P
MLMRN>DB*(?M/<?V5Z/M?T2^)-T-6[;EL]GT!T\[OV8F-_:5_JYY*D"0B9KCR
M%F7*NP=U&IT)@Q1`?'<$W4Y.R*@A[Q1#\&N.OOJFNR2-LV6)K>!FN'./HCC;
M[5Z)MGT+[>UH.]]Y)W/XBWM&-'F=+*\_L^98]/.KPOQR\K?R_P"WYPJUBOEG
MS]<+;5L38)2N$Y"&A%+O87"TO-S[VL1<`S3E&-3HD')O!144,B9T#<BGV3[#
MPV[_`%.^(;FGY*+;;8'*D+GD>>21W3CIIADO2]C^BGPBC<&[C-O-X0*DNN&1
M`^:&%II_3KCFO!U/>8SS1L!U!6SC-1*:F_["M053KR28".^R9XZ"2<EV]0]S
M?;UZ\]O?'KQ:O7$NWB6)IX11PQ`=19&#ZUZKMWTM>`FV-`9W>MYG#C/-<3$]
M8?,6_LJQ<_R,Y!6HQS6+.&6I?N"(G3=9`M`("(B(C_NR,FDW`-Q'P`NVN-O>
M_O?G<B3?;QN<M<P;F:GH#P/4O1-M\+/#/9V@;7W>V6"F1;96]?ZQC+O6K2/G
M[^45.O)OWTDNH;J.M(O'+Y4YM@#J,HZ55.8=@](CKEYIY[E_:7#WR//%SBX^
MDDKMK>VMK-@CM(XXHQD&-:P#S-`"X0)D+XE(0!]H%`/R!J*@4Y<XYDK7HJ)H
MB:(FB)HB:(FB)HB:(FB)HBEYQ4XMV;/UOC2#'NBU=)VD+QP5,P?%E*<O4FD;
M;P3]H^@?P:Y_?=\@VN`C4.W(]'Z5G65E+=R`-!+%[5^&O%6HX^@Z_6H"'1*X
M[+9-9=-!,N_24-@+L'H+Z]_3X^.O'WNEW6Z^8E)))PKP^Q=@!'90]@R@''IY
M#FLZ=`P&E$LFQ&A`3<+$(!]@+L`B!1'T>`;;[^GU:VT>UN)IQ6&ZZ`Z5=>V3
MT?B*M&:IJ$7EW)#$3*&PG%4Q?TAVW,4@&\1UWW=GN^^]G$0P@;BYQR`'$_8N
M8WS>(MOMW3/QF=@UHS)/`#VJ-E$H5IR;-NY&0!8K%TL91T[4`?M`<X'[:)C!
M]DNWAX>@-=%WHW^SM&-VO9_ACP)'$\^E:CNWL]]*7[GO'QR&H:>`X`<E,I52
MFXGJBB*(-4%6Z`B<P=`'$Q2_:,81V'??7E\]]'`#+,[5.3Q*[IEK),X1QC3!
M3AY9+SA^9'SV@:M'S3!"51,[$CA-!NDJ!E!$>HH`4I1'UCKGO\7GO;CL;>I/
MJ'6M]#M+88NTD&E@]/F'VKQ0\CLY67*-BDG)SN#-U%EC`4#&$`*)A_2\1\==
M]LUB(F"29U7E:/<)L=$0HS'R*@K)&4[JG<WZ]QWZM]_I_#KM(@*"F2YF0DE=
M3K(4*:(FB)HB:(FB)HB:(FB)HB^]1O:/HZ?2/Z/L_!I4JE`O>V`@8`$!`0$-
MP$!W`0]H"'@(:_9W+-?SF@@XC)-%5-$5:43)&0L7RI9S&]XM5$E@'<SVJSDA
M#'6\0$2NDF:Z;9ZF(AXE6(H4?6&M7N^Q[-O]O\IOEI;W=M^66-KZ=1<"6];2
M"MYW?[S]Y.Z=W\_W8O[S;[S\UO*^*O\`.#2&N'0X$+(]BGS<^25*!NRR)&5#
M,,4D)"J.)9E^Z5K[12@4>F=KB)(UPL.V_4XCE3&'TFUXAWA^F_N-NNJ797W.
MV7!R#'=M#7_HY3J`_FR#J7TWW1^LKQ0V+3!WEBLM[LQF9&_+W%/^EA&@GC5\
M+B>)61O&?FZ<9+@5NVOD?=\22:A2@JI+Q/[UUPBHCL8$YJK@XD"I`/B!EH]+
MP].O$=^^F[OYMI=)L[[3<H`<`Q_8RT_F2T;7H;(5],]UOK*\*]Z#8N\,=_LU
MV0*F2/YB&O1+!5].ET+>E9`*!FO#V5D".,;91H=V*<";-Z_9HMW(D$Y0,4BT
M09PG+(*"`_HG0*8!\-M>-[SW5[S=WGZ-]V^\M".,D3PWS/H6'S.*^B^[O?ON
M5WNC$O=?=MOOP>$,\;GBO`QU$@/06A70.0Z8])R&(/L.42C\P@`ZT`(.(-0N
ML+7--'`@K1JJM31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%K(
MFHH.R9#G'V$*)A^8`'5I(&9`5P:YQHT$E6[NV6L58U;F<Y"R51*4D3JW"RVJ
M%BG(B7](J;%P\*^6.'L(F8=;O:N[G>'?7]GLMC>73C_=1/>/ZP;I'G*YK?>^
M7='NO&9>\FZ;?8L']_<11N\S7.UGJ#2H3Y!\U'B#2>\C#6FS9-?I&,0&]"JS
MT[!0Q?6$[93U^+,D(^`'2,J`^H!#7JFS?3YXE;K1]U;V]A">-Q*W4/\`JXNT
M?7H("\)[Q_5QX,;%J98W=UNMP#33:0.+#_UL_8QTZ6ER@GD?SH[>Y[S?%&&:
MY7$.HY49G(<\\L;[HV$"'^Y8(L#'(J;^.QG2Y0]'CZ=>N;']+FVLH_O%ND\[
M^++:-L3?Z\G:.(_H-7S_`-Y_KDWJ75'W0V.UMHZX2WDKIGTX?NHNR8#UR/'!
M0UL'-WG7G!Q\!$9"R(JD\,=).$P[6%H)`X*C_<%4IT6:86``\`[CDY@#U[^.
MO3[/PI\).Z<?;7-E9!S<==[*)#AQI,_0/,T!>([CX\>/_?V7Y>SW+<BQY($6
MVP&(&O"MM'VA\[RJ;B>$W-C+#S[R=88RA)N%Q$YIO([HL*814'J,<SZ]RS-X
M83";<>D##K.N?%3PK[NQ]A'NEA&P?YNV&O\`9MV.:M99^!/CKWPG^9EV/=99
M'8]K>N[+/CJNY&N]"D74O*!Y2SA$E;+,8KH:9Q#K1D+,_L+](GAN)FU:AWS,
M3!^K\5Z?6&N)W+ZE?#^T);81;A>.'%L38VGSRO:[]E>E[/\`1AXM7X#]TFVC
M;VG@^=\SP/YL$;V^;6I-57R5(L@HJ7KD'(.`#I%PTIE$;,^K]<B,C/S;X2AO
MZ#"U'^CK@]P^J:<@MVC96-/`SW!=Z6QQM]&OSKU3:/H7M6EKM_[R2.'XFVUH
MUM>@/FE?Z='F4E*IY2'$B`Z#SJ>2[TN7;J^_;I]U-#C[VE6C80^PCZA5'7"[
MA]1_B/>5%H;"T;_S<&L^F5TGL7J&T?1OX.;?1VX#=-P>/[VZ[-O]6W9%_:4D
MJKP>XB4TJ?W+Q\QRLJD8IBN[#%KVUX)B^(&.XM#N7,8=_5L`>[7#;AXL>).Y
MD_-;S?!IX1O$+?1$&+U#:/`3P9V0#Y'NWMCGC\4T9N'>F=TBD5!U2J5=%-"L
MU6L5M%(I2))5^O0\*1,I0V*4@1K)MT@`:XF[W'<;]Q??W$\[CF9)'OK_`%G%
M>E6&S[/M3!'M5G:6K&C`0PQQ`?U&M51'554_34.?^F<QORB.L(-:,@`MF7N=
M\1)6WJY6IHB:(OS?OXP/E\?*?-C$W$*ORHK53BKC5*Q6]DW<"*!LP9J1C["\
M([1(/;.Y@L;Q\$FF)MS)'?."^'4.M'>R:Y:<!Y?I\ZW=@S3#KXN/L\O4O(AK
M"6<FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*3'&?C=:^0=S81$8S<E@TW299!Z
MFD8>Z`'*)FZ`[=(B8!^T/J#6GWC=H=K@+G$=J<@LFUMI+J30S+BO8]P]X2ML
M9P$9&1L40CCX='N+@D0QB"!0#8PE#Q,;???T>S7BFYW5WNTYDDJ&57<6<,.W
MQZ1BXC-9Y^.^%CPSZ-5=I$<F0Z1$Y2>!1V#;<0\3``>T-;C:[301GIXK`NY=
M2GG:K'!T.-$R1N_(*I@FBV)L93NB78"$('KWVWUV%K9B:4-CP'$\!YUIY9BQ
MFIV7`<2K.PN)9G(<P6VW4RC:*$06;LE1$JADP'J+N0VPID,`_A'6ZO=Y,%H=
MMV@Z8/\`.29:C]W(+60;:Q]R+_<AJN!\#.#1]YXE=EE?-5!PS#&9-7+!G\.@
M8H['23`@)D'<1'<OB&WIUYGNV\V]F"&NJ_B5V>WV%Q=D%P]T\*+S3<WO-"4;
MJ3D!3I4KI02.$?BTU0.D10>HOV.D?$Q!$/=OKAC->;M+@2V$GSG[@NYM]MAL
M6!TH!DX#"GGYE>9Z]O\`)^?K*]EY!23<M5EUCG=K]P4SD,IN8J74(=)`#PW]
M>NMLWV&T1A@+3,:89FJUUVZ>[Q:':17'(4Y>960O.*D*NP6!9N`K=!NH3%^U
MOMX^.WMUU^TW,ERX/-0U<?N+615:,7<U`2YQZ:+Q8Q``-C&]&N^MZAH7+RFI
M*M[K+4*:(FB)HB:(FB)HB:(FB)HB:(OVM<K^7/Q)RRHY?/,:)46=='.JI/8Q
M>GIRYUCEV[J\.W2<UAR/5]H>IB`B/K\1U]`]W?&WQ'[N!L45^;NS:*".Z;VP
MIR#R1*/^T\R^6.]_TS^#G?!SIYMK&W[@XU,MB[Y8DGB8P'0.YXQ>=8X,F^3!
M;6?Q#O#F8X2P(E*)V\%D:(<5V2..X[(EL$`$K%JCT[;&4:-P$?3MKW#8?JAV
MV73'WGVR6%W&2V>)&]?9R:'CJ#W+YB[U?0]O,&J;N3O<%RP#"*]C,+^KMH>T
MC/68V#J6/[(_`_EKB[XA:Q84M,K&-C&`TW2"-KU$F(7T+`>L+2#]%(P>M9ND
M(>L`U[)LGB[X<=X-+;+=;>.=W^;GK;OZOWH:TGJ<5\Z]YOI]\8NZ>I^Y;%=S
M6K3_`!;4-NXZ<_W!>\#^<QO2HG/FKN+=J,)1H[BWZ)S)K,))JO'O45"#L8BK
M1XFBX3.4?2!B@(:]%BDCN(Q-;N;)"14.:0YIZBTD'TKQZ>*:TF-O=L?%<--"
MQ[2QP/(M<`0>L+CZO5B:(M21CH+INFYU&[I$P'1=-SG0<HG*.Y3HN$A(LD<H
MAN`E$!#5'`/88W@.C.8.(/6#@483'()8R6RM-0X&C@>@C$>8J2U`YD\IL8`F
ME3\Z9`;LDS$$L5-RXVZ)V3V`I/NZV)33=-,0#803`FX:X7>/#'P^WXEVY[19
M.E/XXV=B_']:$L->NJ]1[N^-OBUW5`9LO>#<6P`C]W+)\Q'APT7`E`'0**9]
M(\XCD?!=I*[4_&&0FY>D#K_=LI394X!L!C?$P;YQ&"<_I_[%MOZMO#7EVZ_3
M-W'NZNVJYO[)_+4R9GHD:'?MKW'8?K5\3MOHS?;+:MRC&9T26TA_I1/+*_\`
M5*6]/\Z#%3X4$K[AB_UDYM@</*Q-P%M9I&V\3D;/PK#XR>_J^T;;VZ\XW/Z7
M>\,-7;/NEG..#9620N/G;VK?L7L>R_7%W1N-+.\.Q[C:N.;H)8;AHZFO[!]/
M25)ZJ>9[PPM(`5?)DG3UAVW1NM+LL44!'U?&1[&8CO#U_M@UP6X^`?BAM^++
M".Y;S@GB?^RYS'?LKU;:/JM\#]V%'[I+92<KFVGC_:8R1G[2D76>3W&^Y$3/
M6,\XEE15_01+>H!BZ'W&92CQB\(8-_0)`'7$W_<'OQM9(O\`9]RCIQ^7D</Z
MS&N;ZUZ9M7BMX8[VT.VKO#L\U>'S<+7?U9'-</.%>>/DXR71(XB)2,EVZ@`*
M:\5(LI)$X#L("15DNNF8!`0]`^L-<O-!<6SM%S')&\<'M<T^AP!7;VUU:7C!
M)9RQ31G(QO:\'J+205V1D%R?I(JE_I)G#\H:@#V'(CTK*,<@S:?0MK80](;:
MJK5\U5431$T1-$31%]U156HJ:AO`I#F'V%*8?R!H2!F54-<<@2BB9T0ZEBBB
M7T]2W[(NWIWZE.D-4:X.-&XGHQ]B/:Z,5D&D=.'M5!3N4L7U8#C9LF8\KW;`
M14+-7:LQIR```8>I)W*)*!L!@'T>O6XM.[^_[A3Y"PO9J_D@E</2&$+GMP[V
M]T]I!.Z;IMMM3/M;J!A'F=("K#V3G;P]JIE4Y3D)CYRNCOUH5]W(VI7<NX"4
MO[M1TJF<VX>@##KK['PB\3-P`=;[+>M8>,@;$/\`O7,/J7GNY_4#X*[02V[[
MR;:YXS$+GW!_[AD@]:CQ9_-OXC08+%A5LF759/J!,L)1S1C9<P`.W2ZM$G""
M0AA]8I_BUVMA].'B1=T-T+"U:?SSZR/-$V3VKS;=?K'\&]O!%B[=;YXR[*UT
M-/\`2G?%ATT\RC3:?.ICUE!9XVX^R+]X<PD1/<+HB4YA$=D^F(J\.^<*',/\
MD'(>X==UM_TLS-':[YO+&1C/L8#Y_?E>T#KTKR[=OKGMY'=AW7[N2R3$T!N;
MH5/+]W!&\D]&M4F7F5YH>:.X7$^!5JG'.";(O8?%$JH")%/`JI;'DIV>*,?8
M?`P)@'KVUL3X8^`/=:A[Q;P+B9N;7W;!7H[*U&OS56F'C=]5_?FH[G]WG6=L
MX8.CV^0T!X]M>N,=>FG31<=;BAYJ^;BI#D[,CVHQCG<56,[E@8Q-N13<#`K6
M\7M7+4QND=N@WH#P\-2-\1/IY[J$C8=L;<SMR='::B>J6Z(/G"C?X/\`U=]_
M&M_WKWM]E:.S9+N'9@`\X;%I;YBJGJGDKJ.%_CLF<@S+N5!`ZY*73#N'*AS#
MNKW)JU2YE3B/J,+41$?$0]6M?N/U2M8SLMAV:C!EV\]!T>Y$RGFUK:[/]#+I
M']OWI[QZI3F+:V)<>=9;B2IZ^S4J:AY2W$:N?#J3K/(=_<HB!E!L=T6C6+DP
M#O\`M(^J,H'9,?U>Z/X=>?;E]1OB1?:FVCK*SC.79P!SAU.E=)CTT7KFR_1W
MX-;9I=N#-SW&5N?;7)8UW6RW;%AT:E*BF\0N+E`$JE4P'C!BX)T[/7]9:6)_
MN7;8WQUE^^'0&W`!W`P>.O/=S\2N_P#O(T[CO%^]GY6RF-O]6+0/4O6]D\&/
M";NX0[:.[NU1R#\3X&S/_KS]H[UJ0C!JTB6Y&<2S9Q31,O0FTBVC>.:IE`-@
M*1NR301(7;U`7;7%S227+^TN7.DD/%Y+CZ7$E>D6\,-G&(;-C(81DV-H8T=3
M6@#U+D"(CXB(B/M$=]69*4DG-?-55$T1-$31$T1-$31$T1=;-SL-5H2:M-D>
MI1M<J\-*V2PR*YP30CX&`CW$M,/ECF$`*FTC6:JAA$?`"ZLD=I879'[>'K5S
M1J<!FOQ,^8W(F=Y<<K>1/)JQJN#R.<,P7G(2*+D?VD=!S<XZ4J\(4/Y"$#6$
MV;)(O\E-N4/5MKFW'4XNX+I6-T,#.04;=6JY-$31$T1-$31$T1-$31$T1-$3
M1$T12YXH\2+]R<M[./A8UTG64'*82DJ!!*10A3`*J#<Y@V$>D!ZC!Z-:C==V
MAVV$DD=KPZ%D6]N^XD#6"J]FG#3@WC_#,#&1\5$D&00;(_$K%0`HBKL43@!Q
M`#;F,7<3^OZ->27][<;A,99M197!==;6\5K'1A]_B?L&*S88KHC@ZC6/BHL@
MJ"F0@'$F_P!GP\1';?[(!JEO!+*X,:W$J]\K65<_(!3'%_$XUCD(IB@I*VN1
M*":+!J3NK@N8`#8"E\2%`1\1'P#740PQPM$8^+C7@M4XNE<7NR7<0E*;1G5>
MLC.DA>@7XA*.7.`M(XOZ92CW!V.L7U^H!UFW%W';6U''1;<>#G_<%`V-\LNF
M,:YO4U8^>8_F7T##\=)0E?D$WLJD@H5-JQ.51;J`.@.L$Q$$D^H0\1V#;7G&
M\]ZI+AWRFW`:0:88`=9YKL=H[MN(^8NZUI6O$]0\@%Y7.0W-'+V>IE^4CY\D
MT<K*)-(YD98W5U"8J?=Z#=2IA`=_4&N;;;-+_F+YVI^9J<!SI5=2PQQ1F"U!
M;PK3,Y#+'I5&82X86G)DHG8LABX*P4,"Z3!4YRF/N/\`TQA'8W5^J.M9?]Y&
M,/R>TTUY%W!9K;/36XW'!F&E@..5!6GK^]3@LG&RN4BOG:Q44@D5)`2EV1(4
M1`"[!L8`\=_;Z=9^S6\UQ*)IB7./-<_N5_[ACC`8WD/M6&CE!5DXXK_I3`@`
M*H;?J@&XZ]FV6+LV@="X*]?4E83L@I`1\Z`!V^TI_IUW=N<`M%(,5:'66H4T
M1-$31$T1-$31$T1-$31$T1?O+:ZI<DFB+44QB"!BF$I@]`E$0$/P"&PZH0#@
M<E4$@U&!5'V['U!R`T.QOE&I]T:*!L=&TUJ&G0_Y*DDS<*IB'M*8!UL]MWG>
M-FD$VT7=S:R#C%*^/^RX`^<+2[SW;[N]XX3!W@L+*^A.8G@CE];VDCS%0^NW
MEI<-+J9RM_E0-.>.0$1=T"R3M:*DH(?WB,8+Q]!)CO\`R0:='NUZ7M7CKXG[
M4&M_Q'YJ)O"XBCEKT%VELGGUUZ5XMOOTM^"&^ES_`/!_DIW?BM)Y8*'F(]3X
MAU=G3H44;?Y+V*WW4I1,TW^M'^T)6MG@J_;6H;_H!WX\:L[*`#Z1'K$=>B;;
M]47>"+W=WVNSG'.*22$^AW:CV+R'>?H=[I3^]W?WS<;4_EGBAN&]&+/EW>U1
MHL_DRYR8*+#4<K8KL[<NXH%ED;14WBGL*HF$=8&:9A_\^(:[JP^I_NE,`-RV
M[<+=_'08IFCSZHR?ZJ\MW;Z(>_\`;N)V;=]HNXN':">W<>L:)FC^M11\L'E>
M<TH$511QG#V5),1`%:O?*D^[H!_*2;R$E%.Q`0]0I@;W:[.S\?O"V\IJOY8'
M'A+;S-IUEK7CUKSC<OI0\<MNJ6;5!=-'&"[MWUZ@]\;O4"K(3?#?E?7>X,OQ
MVRTB1+JZU6=1?S".Q1,`F*K"A(IG+]D?$HB`^KTAOU=IXG>'=[06V][<2?S3
M-8?0_2N"O_!/Q?VROSO=K>&@9EMN^0>F+6#EP5GI7'&1H)0Z4WCR^PZB8B4Y
M)2F65@)1*8Y1`WQ48D`;&2,'_)'V#KIK??-DNQJM+VSE!_)/$[V//,+B[ONQ
MWFV]Q9?[;N,#AGVEM.SG^:,<CZ"J/734:B)722K4P;;E=)*-C!U!U%W*L4A@
MZB^(>T/'6S86R"L9#AT$'V+2R-=$:3`L/ZP+?;1<0RC-3]-1LI_2,D;\HCJ0
M-D;D'#TJ$OA=F6GT+GL9)W'&`T7)O(XY1`P&C9!PQ,`@(;&`6BR0@("`>/N#
M44L$<XI<1M>/UFAWM!61!=36QK:2OB(_(]S/[)"N;!YWS?6@`M>S/E2'*7]%
M./R';$$@_N_0B$L*6W[$O\GT%`/1K07?=#NI?8WNU[?*>;K:$GCQT5XE=38>
M('?S:\-MWS=X!R9>7`'#AVE.`X<%<J.YK<NHH-F7([+!0Z3$V=6=:1#8Y^X;
M_P"J23S[77Z_2`>`#MX:T4WA7X;7&,NQ[=YH@W^R0NIMO'3QEM,(.\V\`4_%
M.7]/XP[TY^95XT\QSFJRZML\3;GK*4O^_P!<H[SIZ-]A3[U9$2F-O]H?2/KU
MJ9/!#PLE_P#Y/$VGY99V^FDJZ"'ZF_'2"O\`_L,[J_GAM79<JP>GFNZ3\SOF
MJBD1,<P,E`('3W7%#H)U3^(CNHI^[Q0,;Q]@>`:Q'>`GA:YQ(VQXKP%Q<4_^
M(L]GU6>.<;`T[TPTXFTM"3UGL5]'S0^:(>G+\4'X:'0`_P#Q#I_[!>%W_ELG
M^T7'_B*O_%AXXC/>H?\`9+3_`,%?2>:%S2.8"IY>BU#"/@4E!H)S"/IV`I8`
M1'PU0^`7A<!CML@'_P"L7'_B*K?JO\<G&C=YB)Z+2T_\%;B?F"\]YPITX[)]
MO<BX$HD-!XWK"B@=P_4F#91E35CE*<2B!=A'<-P\=4/@UX/VA#I]OMFZ?[RY
ME`PSJ'3!5;]1WU#[@TLM=VO7ZO[JR@)Q.&DMMB<>%,PNU:YP\S^^"8T18.4$
MF1?LF_[@I<W%MOLI]Q(4C1=7CT$BG3+U#TB`*>(COOK'D[I^`>T"ES#L$9%?
MXD['G.AKKE<3RQRX+*B[^_5;W@)-G<][)0ZG\&UEC;E44+(&`5&.!QXU7?-\
M5^:W?/V3A#E$9)4WVCSU\DJJVW[AE=S#*6:'`I053W#8-@'8`\!`!PW]X?IX
MVCWF'8`X?W=NV4Y4_#$_@MC'W1^KSO![LC>]A8?[V[?;MSK^.>/B/*H7:,_+
M2Y\W18IK0JRCB*C^U<7;,XRAB`(@`BHWC7MD<'\##X`4?0/X\>7QU\'MK;2P
M#WD9""RT>@N;$%EP?2Y]0^^/!W4QQ-.9NMS[3TACIB?0KHUOR6<M/5BJ6_,6
M,(%,?%7[CA;-:7HCZ^D7;>MH"/O%0=:"^^J3NY$W3MNV7\SN':/BB;^R93ZE
MUFV?0UWQG?JWK>]JMV\>RBGG=^T(1ZU(^I^2]B5CTGNV9\B6,P=.[:MPE<J;
M40#;J+W7H6AUL/M`2B&N'W'ZHN\<N&U;790#G*^68^AO9#VKT[9_H=[GV]';
M]OFY73ORP10V[?2[MW>Q2PI7EL<,Z2+=4F(T[<[0*'^]WZPSUH[IP#^]5C57
MK2#,81\=OA>D/4&O.MU\<_$_=:M.Y&VC/X;>..*G0'!ID_;JO7]C^E[P0V(M
M>-F%[,W\5W-+/4\RPN;%_P!W3H4M*GC3&]";IM:/CVCT]!(=TR5JJ04,8H[;
M=7>8,45S&]YC".O.=QWW?-X>9-VO;NY>?[V:1_J<XCU+V+9^ZW=CN]&(=@VV
MPLHQD(+>*+UL8#YZJN#J**#NH<YQ]IS&,/TB.M2&@9`!;]SG.^(D]:T:N5J:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(L+_`/$(<D5.,7E%\N;/&OC,;3E&JQ?'
MBH'16[#D\GFR51J<^9JH`E,59GCX\TY`2CU`".X>C6%>R:(J`D./\A]M?,LN
MR9KG%<ACZ,5^1<``4`*`;````![``-@#YM:-;Y?=$31$T1-$31$T1-$31$T1
M-$31$T133XC<-;_R;M<<BPBGR=5*[3!T[*D<II`A#`*B+4^P;)[>!C_-[=:/
M=]Z@VV,BH,WL65:VDER_2P8+VD\,N$$;A:KQ$;'P8QG;121.!4=C'$NPG$^V
MXB!A#Q'U^O7F-R^YW.<S3$Z-6"Z:!L5FS1&/?(H5E^HN,01%(Q4DP`A2$'[/
M;ZA-L`^`[=7X_5K-ALVM`U8J)\IK5V?EZE.VDTU6KP17L='`>9>)=B-*8OV0
M44`0,NH;^0D7?YM;6"+L&ZVC]Z[X0.*Q97"4Z'&D8&*X<F_H>!XF5N]_FV*T
M^HBL\>R;Y1,@(%`HJ&0:%4-L@@F&X>&PCZ]8MY?6NRQFXOW-=<4J!R/WK(@A
MN-SD$%HTB&M*\UYKN=WFL6C(DZ^HF&5G#>O'.HT<3Z/<(D<1.9/:.,7P5ZMO
M$_B`>H->9;CNEYO<CI9G.9;<&Y$_<.2]"VS9K7;&-U@/E(QQP'6>)ZLN2Q8I
MTJYY+$YR*NY:1DUMG[][W5U=U.DAQ%4Y^I0VYS;``;!MK03WUMMS=,F#P*@`
MY^72M\V)]Q[\=.RR)(`H,L.K')3]X]\*X.%*V?S#$KV0/VA.=9(!\0*`[E$Q
M1Z1*(^@-<]+<W^[/TDEL/Y1AGS^Y4DNK>R;2W`[3B_/+ER\RRCTC!40V9$;F
M8E:III@4`*CT@/JW*/M';T:WFV[*RHU!<Y>;A(\DDU-<U'+/U7:0;*0;@`=)
M$E=A-["[@&_AX"`>SPUW^V6[82&8+G[F0O&I>8CF9(()+R2)!+]DRX;;^\=O
M=L.VO0]L-*!<]=8K`OD%R"K]SZ/$QP\/QAX[>_796V06FDYJTNLY0)HB:(FB
M)HB:(FB)HB:(FB)HB_>6UU2Y)-$31$T1-$31$T1-$6H#&+XE$0_`(A^35*`Y
MJH)&2W!77,'2994Q?U3*'$/F$1#5NA@R`KU*XR2$4+B1UKJ'L-"R0=,E"0LD
M'4!]I&(CGP=92B0I]G;9;[12"(`/I`!V]&LF*ZNH,8)98_YKW-]A"PI[&PNA
M2Z@@E%:^_&Q^/])I5&NL08B?"`O,48Q="4IB`+C']15$"'\3E`3PXB`&'T^W
M6TC[R]Y(L(MQOVCHN)A_RUI9>YG<V?&;9]J>:4QL[<Y_]6J6><:>.4@D5%[@
M/#;A(IP4*0V-JB4`.!3%`VZ420VX%,(>G;QUL(N_??>%VJ+>-T#J?_-3?Y:U
M,WA=X9W+`R?N[L;F`UI\E;Y^:,+I'7$7BN]1,W<\=,-'1,8IA*G08!L;<@]1
M=EFC1!<``?4!@`?7OK*C\2/$&)VN/>]T#NFXD/J)(]2P)O!OPDN(^RE[L[&6
M'E:0M.'2UH/K75_\%?$3_P"6[$7_`+IM?[>LC_W2\2/_`#S<O^V*P_\`V,\&
MO_3&S?[.W[USF7#WBC'"H+/CEAU,5@*"G=H\.\W`@B)>D'J+D$]A,/Z.PCZ]
M0R^)?B'/3M=[W,TRI.]O]DBOG63;^"WA#:DF'NSL@U9UM8W9?S@ZGFHNZ9\7
M^-4>J*[+C]AENJ8@IB<N-ZH81(82F$NRD6<NPB4/5OX:Q9>_W?J9NF7>=T+:
MU_UF;_+6=#X4^%UL_7!W<V-KZ4K\E;Y>>,JHV>#\)QX$*QPWBAH5-3NI@WQS
M3T^A7<#=PO3#>!]P`=]84O>SO5,29MTW%Q(H:W,V7+XUM(>X?<6V`%OLFSL`
M-12RMA0\_P"'FJK84JE10E&+I=.C#$.94AHZJP#$Q%#EZ3*$,UCDA(H8O@(A
ML(AX:UTVZ;K<?ZQ=74E13WI9'8<L7%;:WV+8K0@VEC91$&HT6\+*'G[K!CTJ
MI4MFX`5N4K<I0`I2MR%0*4I?T0*5("%`"[^`!Z-8+O?-7^\>G'VK:,`B%(@&
MCH%/8MTRRQ_TU53?TE#&_*(ZM#6C(`*\R/=F2?.MO558OFJHFB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+Q"_QH>>S1V,.$G%Q@\,![;=LCY\
MM+)-42_[E28>/Q]2CN4RB'6FN_N,V*?4`AUMQ$/$NM3N#ZD,!ZQU?R^I;7;F
M?%(1T#R\R\!.M8MHFB)HB:(FB)HB:(FB)HB:(FB)[@\1'P``\1$1]``'K$=$
M63O@MY<]]Y.6:+E[0S<5O'Y%DW!E7Z*K=671(('V*4P%.1JIZ/4)_<&N8WKO
M%!8M,-NX.N2.'!9]I82W)U'"+F5[8.(7#?'N'HB"CZY"MD3,4VY2O"(!VE>D
M"DZ1(4I0]OS^O7`!TM]-VUQ7.M:K?M:VW;V4/+%9C("EL2($!JS:$.<B8#TH
ME`/L!^G]H1Z!$-];-@8UM!0A8Y+G.Y!7GH%,C7DIWG:*1&C0@G,80V2$Y?#<
MP!ZQV'6;8Q,EDHXC3Q/)0SO<QM>*Z'DURLQ;QIHS^R6:59,2,&JI6R9UD_B5
MU0*/;1:H`;K,8YM@`"@(ZP=^[S6>U1=E;4=<G`4S\WE@LK:=DN]SEU/!$0Q/
M`>?D%XY^5G.#*G-VS3J,'+NH&D0C[LLJX@N<BTPEW`$%7YB*%,9-0A@`"``A
MX_:UY9=333S?.[F:O=4@<&_>>GAP7I=G:06D'R]H`7`BIIB>KHZ,SFJ:Q1@*
M2MQV/WXU48D251Z$S$Z#*#N`@)A`A1#?<?LE$?#7)W^^AK^PLZ.DRU</Y5NO
ME61L[:ZJ!F&#/^19;,,8#A8(C9%-BD8P%2`3]KI$1(`;AX_:*._S^W6-9;?)
M>3=I.2YW2M3?;B2W2WW6<`/M61RD8UKR2#?J0(BY+MMN40+Z`#[)=@W``]6N
M[L-JMF,%0`Y<O<W<IKQ5QK3#H0D4<R0)[%3ZBG``#T>'@`"'IW]>MSV+81@`
M%@-E=*[B5ATY>VM-&-?@54"J@14#``].^V^PAX[^K63;.J01@D@P(7DPY;6H
M7<C)@*G5N=;<VX^/VC?CUW.TDFE5H[JE<%APMSCO/%Q`?#J./T_3KM[<>Z.:
MTLF=%0.LY8Z:(FB)HB:(FB)HB:(FB)HB:(OWEM=4N231%3ULM,-2:Y+6JPN#
MMH>&;@Y>*))"NN8#JIH(H-D`$IEW+A=4I$R`("8PZM>X,:7.R"O8QTCPQGQ%
M6)C>6N'962CXML[LQ',F^9QS8[BO'1;E</G";5`5UOBS=I$%50ZC;#TAXZ@%
MU$33%9)L;AH+CIH!S5];A:(VCUV6M,TE(*14(D5Q(_=C07[M)N*Z:!W!6Q5$
MA41;F5`R@@/V"`)O0`ZF>\,;J.06-&QTCPQOQ%6SH'(7&N2[`6L5EW,A+G8N
MY!%*5B#1Z*Z+($S.2(K&<*@=<B:G7T;`(D*8?5J-D\<CM+<U-+:S0MUOIIKP
M-56&1,FU'%L.UF[>\<MVSY\6.9-V+47S]VY%(ZRG8:%.F8R+9$G4J<1`I-RA
MZ3``WR2-B%7*.*&29VF/.BZC'69*;E).9<58LX5A`)IGE)29B@B8Q`RI3J@@
M#Q9R=,RZ;=,RIP\`32#J,(`(;TCF9)4MK0*Z6WDAH'TJ>`-5:Z9Y+#+S3FLX
M7HLQE259F%-W*M>ZRK+8W5T]178)&4<(=0>"IS-D3^DACAXZB=<5-(@7'GP4
MS;32W7<.#&\N*XY[[RQCR_&O\'5F09E#K481,UO*%3#Q$I"ISKY0Z@%]0(G$
M1]6J&6X`U%K=/7^E.RLC@)'5Z1^A5QC?/U7ODJ>J2D=*42^("9-2I69,6[AR
MJF43*)Q;I1)M\4J4H";LJ)HKB7Q*0P;CJ2.=KSI-6OY%62VKXQK:0Z/F/M5]
MM3K%7634W"UJ*>SMBEXR!A(Y(5G\O,OFT;&LT@_E.'CM1)!/J'P*`FW,/@`"
M/AJTN#14X!5`+C1HJ5#6S>89QCKKQ1DTL=EMITCB0[FJ55ZYCA$H["*+^75A
MD7)/89/K*/J$=0&ZB!YA93;.=PK0#K*YU%Y\\=;[/Q-88REOA9F=D6<3$-YZ
MH/BHO9&0<)M&30CF&6F2)*.7"I2%%0"$`1\1`-QU5MS&YVD55'VDS&ZC0@=*
MN!FKE9B+`-@B:QD-U9$Y>9AQG6:4#`'F4BQX/G,<4[E8CMN"*IW+13I+L.Y2
M[[ZNDF;&:.S5D5O),"YE*`\U>*A7:#R33*W?:U\?^[]KC22T0,HS&/?F9**J
MHIG<LC**BW,H*(F`!,.Y1`?7J]C@]NH9*-["QQ8[X@K1YKY28FP!+0,)D1U8
MDI"QQCF8CDH*!/,D!BT>?`J'=*$=-P;G.X`0(78>H"B/JU9),V,T.:DB@DF!
M+*4'2KJ8YO\`7\ITFOY`JGWB-=LS9=Y$FEF)HU^HW;O74>91=D918R('7:'$
MFYAZB;#Z]7L>'MU#)1O8Z-Q8[X@H]Y*YO8#Q3=IO']ID[2M8JZHV0ERP594E
MH]L[<M$'OP?QQ'J!3NFR+@@+%`O[-3<HCN`ZB?<,8[2IF6LTC0]H&D\RKQX=
MS/1<[5-Q<\?N)->&:S3R`<A,1IHI^C(L4&;I4AV9EEQ!$Z#Y,Q#]7V@$?9J2
M.02-U-44D3XG:7YT74YHY"XOP"T@G>29.49?O*K()0K:'A'DTZ>&BB-#OC&(
MVZ4FR:(/4OM*G(!A-L&^PZI)*V(#5Q5T4+YB0S@HW#YE'&T%.@"9)$F^PK!3
M6X$`/;T#.@KL']'?47S<7353?)3_`*OI4A\1\EL+9P6688]N*3Z<;-S.W%:E
MF3N"L1&B>P*ND8V133%^V1$0[BC8ZQ4]_M"4-2QS,DR.*AD@EBQ>,.:V\T\E
M<38!6@VN1Y28:OK(U?/8=C"P+R:<.6L<LBW=+*&0%-NU(5=P4I>XH43COMOL
M.J23,CP.:10235T#`*/G_B4<;>YT=O)/1OMWOW.;=`![>C[^[NW_`"=]1_-Q
M=-5-\E/^KZ5?'%_+/`.7I)O!T^^-D[$['I9URR,7E:F7RFPCV8Y*422:2:^P
M?W;=950?474C)XWX`XJ*2WFC%7#W>8Q5WIN^T^MR*<3-SK5A(*))KG;G2=K`
MU;K&$J3B06;-UF\<@?I$>I<Z8`0!..Q`$VI"YH-"H@QSA4#!5?\`C`?8("`@
M(>H0$-P$!U547S551-$31$T1-$31$T1-$31$T1-$31$T1?EX_P`65FH<G^;9
M8*"W>BXC..^"<08N3;%4ZD&DS/QLAEJ?V*'@5P9;(:*:GKW1`/5K07CBZ<UX
M?RCU46]L6AMN"/Q&OV+S.ZQ5F)HB:(FB)HB:(FB)HB:(FB+6FFHLHFBBF=59
M4Y4TDDBF.HJH<0*1-,A0$QSF,.P`'B(Z$@"IP`19QO+Y\L:PWV4@,G9=A'",
M2"J+Z!J[I`1!QT&(=)U)%'[)O#Q`@[E+Z]QUY_WB[TAA-C88N.!</L6\V_:C
M*.WN#1@Q`/%>O[`/&MC6V3864<T9QR0HMRM&J`())D3('6B4I0`"%-MZ?3OK
M@HF"275/J+SC4XKH7ES&%D-`WD!0+*-0ZXSC&#5LVC6Z!@`I"`=,H]L@_H%$
MP>`CX>G6\B]S`4T^7K6ND-30*\T0R.1Q\.DF<%5=BF32#N&'<?``$N^V^WH]
MFI6FKNS;Q*HT`?%ATJ%7/+S&L3\+*TI3F<DSG,JO&X*)5EHX3[K55PF(HJ2J
MH"8&3<!V$>K[0AZ`\=:O>MY=9C_"MM!??$5>>#1T_=F5M]HV<WI-]=D,LP<*
MD5/5]IR"\B&9^0F=N<.1DSRCV2D5%W"Q6\4S54&$C2'4`$0(7Q3*1(#>*A@Z
MC#Z-</<F+;VNO=P?KN",SGU-'W+L[9G:@6UDW1#QQP/2X\AZ"5.[C)PD5H;9
M.8L3OXVPR?;%9(H&^$;CL'@0GIZB[^(CXCKD=QW*[W=W91`QVPR'XCU\NI9S
M)+>PKV?OS$8N_"*<JY]?H"R?4_!B;9)'NI@()B0X&(7I'\&P>'S:DLMATD22
M9K67.Y&04QJI4U.C/(Y9HN@'V$NCJ(</$0*.^X[B.Y=B^&VNHMK'L:&/)::6
M?M#5ROZP7;HB!E1`@DZ=S;?JCXAL&_VA#U@.MW$YHQ=F%KWAYP;D50V5[:U2
MASD2=!N1N8-NL.H!'^48!'W:K/.PBC#BJ11:27.&"\]O-2[*)LWYTW'5X+`(
M]7K\2AMZ]AUE6A)("LE-*DKRR<D+.9S)/]S]6YU=]QW](_AUZ%M#30+278H"
ML;TZZ!9RIL.^YA^D1UW,#:-6AE.."I_60H4T1-$31$T1-$31$T1-$31$T1?O
M+:ZI<DFB*`7-;((%)7L:,5M]P):;&5,=QZ2]U"!8JE#QW$06<B4?8D.L"[?E
M&.M;3;XLY3U#[5$;)%(?8RF*VP7[I))S3JO:W`'$0,WE)%-5TNV)X`)?@G*`
M)[>HQ!UBR-[,@<:`K-AD$S2>&HCS+,LP6C[E4V+AXD1W%VNM-%7B!MC$<,IV
M*3.Y2'U?;2=&#W#K;"CV8Y$+0FL;Z#XFGV+$,FC*8&S>W36,H*E)MB.Z@]10
MDJZY.`=[U=1)*OO-Q]7480]6M7C#-U'U?R+>5;<V_P#.;Z_Y56V5;+-\C,S-
M:]3^IY$MW)Z_42F!0K1..1/W):SO`V`44'0IF<*'$`,#=-,GZ0``W2.=<2T;
MEP^TJ.%C;2W+Y/BS/V!7^OM9%BIC?B=CIVI'-9MM]_Y#GDRE*\=193G5>NGO
M2(;FD!9*KG3$>D2E;H_W>X#.]NG3;,XXE8T3ZZ[V7$C!HZ?T?>J<<V(\I'VJ
MNXXM47@WCIBA)5.[9/<+%:.IAPW_`&3QXI*];=RZ</5`_9@15,ZH&()C#W$4
M-9FV;;N.][A%L^RPR37LSPR-D;=3WN/!H'I)P``+G$!:S?-[V7NOM$_>/O/<
MPVVVV\1DEEF<&11,'%Q.`Q(``JYSB&M!<0#'FCY6X-Y#N+2DQG)?*J<_)O"1
M\;*V=M)5B`G9)90$446<U+1`-VJCU8P%1!X9N"AC`4!$P@`^M;S]/'BGL6T.
MWJ^V\OM8V:Y&PS1S2L:!4ET;"7$-&+M&N@J3@*KYW[L?69X`=[>\;.[&U;RV
M/<)I!'$^XMIK>"5Y-&M;-*UK6EQP;VW9!Q(`Q("O#=*)QWH%L<PMOO&:V5HA
ME&BY79F;=PJ0H`1Q'OHZ3"-.95`HAU)*$-]DQ1#P,40#Q5S8&NH2ZO/R"^H6
M/NWMJUD>G*GM!%5.*@Y.IERICJTQ%@>/82MI.6L]-3S,L:^2&&C4G[^2DFY2
M))%[C$>^8Y"E(?[72`;;:S8Y&O9J!P"ULL,D<FAX`<<@%@>S#ES)O-+,L34:
ML1V:OOYT\3C2D_$&;1C-F45!&SV`"[HFDU6")W;QTJ!OA$`%-,`*38^O?(^=
M]!EP"VD<<=K%J=G3$_8LB./_`"S\,0L2V#(<Q:KW8C)$-(*QLHI5J\BX$H"H
ME&,F"0RBC=,VX%4<.1.<`W$A-^D,EMHVGO9K#??2D^X`&^E71HW!+!V-\DU;
M)E2+;6[ZIN';YE!2TRE-PJT@LQ<,V;\QGC$LDBXBSN!62V7,452E$0\-7MMF
M-<'*-]W*]A8ZE"L8OF03WWER4E&1#]1*O1*A$@&^X$67:/)]8H`'H'>8+O[]
M8ET:RX\`LZR%(*\R5FZPO`A5\/8JKH$[8P^.J:S4((;"5<(!@HYW#]87"AQ'
MWZV$8`C`'):N4ZI'.YDK"[YE\]\?R%910*=2=7QO7&HD`=P37E'DS.+`/L,9
M)XD(^[;6!=.K)U!;.Q%(:\W+*72K)%X!X?TRTS12@VHN&Z]+':G$""^F7\0V
M>,(L@#MNM)SLHF@`>G=3?U:S&D10!W0L![3-<EHXN*P55NA6++=2Y#YJG'#E
MTO2&$;:)-]N82R5KN5S8E=I',._4DWAU'RXE_D`"7H#;6N`+PYYS"VKGB-S(
MF\</,`LAWE86CN168Z0HIN+61JUO:)"/B!'S9_!R)BE]@'CVN_O$-95H1BWR
M\L%AW[<6OZPK>^:7."XR)BBME/N6)H\S,JI[_HJST_\`"$,(>H3(P/A[M6W9
M.L#H5]@/<<[I\O:K\\<^%.`[YQ^QQ8[S37;JV6^LFFI2PM++8(UZB$B^?*L7
M#5!&0"*;"SB^SMU-S)CT[G`VX[WQPQF+4X>]11374S9BUA]T'DL8N'&+Z"Y3
M4&)Q])KRRL3F=G#P$NUV`\K!,[,I'N7JG8$$S-)"M)+'<;?LC(G/_)UBLPF`
M;^;R]2SI2'6Y+^+?73[U)?S/9TK[.]8A"'W2K6-HX1+O^@K.3DW('\/4(MD4
M?Q;:ENB#(.I06(I$3S=]BESAC@OQ\L^%L;S5QITJYMEEI$#.SDNVMEC8.!D)
ME@G("HV;(/PCVH)I.2`4@(B3[/B`^.\T=O&Z,%P]XCI^]8\MU,V5P:?=!Y!8
MX.77&T.-=]A6L!,2$K3[6R7FJE(OC$2FXMU%.T4I"*>NF96Z:KR,67050=)$
M2,=-4H])3E,(XLT79.IPX+-MY^W8:_$,UDIXUL9CD7B>H9'GK`F-GC'4A5)^
M0?M7+IX:9KJM;9#8T$T':#&5>35<@8P%47Z:B*3L%5R[F.!2Y<596AQS6#/2
M&0L:/=S\O/59"FC5%BT:,6X&!NQ:MF3<#G%0X-VB";=$#J#L*AP23#<P^(CX
MZRA@L,FIJM_551-$31$T1-$31$T1-$31$T1-$31%NHIBLJDD'I54(F'X3F`H
M?2.K7.#6EQR`JJ@$F@S7XS'FVY<'.GF=\\\G%6%RTF^4668B(7$W7W("D65U
M0Z]T&W'=(L)64`)MX=`!MKG):=JX#(&GHP720BD+1QTCUXK'CJ-2)HB:(FB)
MHB"(CXCXC[]5SQ.:)JB)HB:(N9'1S^7?M(N+9N9&2?KIM63%FB=PZ=.%3`5-
M%!%,#'.<YA]6K7O;&TO>0&`5)*`$F@S7H@\NWRPGZ#F,R;F.#*K8NI![!5]V
MD#QI")&`#D5>MR@(*/Q`0W$?`F_A[_+N\G>SYEQL=N=^X_$X8$_H74[9M/9@
M7-V/?X-./IZ5ZR\(X%%M&LE%TSD1:H%32%#L(H;)D`4BI-_LBFF4@;>`;CMK
MFH+?6!+(,:^=;&64XQM/NCT#DLC-,JC1A!)H`T5*=42%,44P^P8OI,'A]H#A
MZPULW".-NEK?0L(DDYJXZ:+5BV*@FB8[@OV42$*)3B?<`*'V=S&$!VUCOD:!
MV;,7$^M2M;4U=FHZ<RN7M*X'8%F\I6Q=`^3K2V=PV**0LH99[.6(Z!@1<+M2
M"9=*,8"<%5UA`"@4.G?J,`:R'R';+7M#AN$H]P<AQ<>0'/G@KK:W-]/H%?EF
MGWC]@Z3Y9+QHPV*<Z\OKI.Y.R4Y?NBV.:>6">LDJFL"C@[U<51;,R']"3=,P
M$2*'V"$``#T`&O/-PWRUVH/=$>UO#F:XEW$GK7>164L[&,D'96P`TCA3D.?7
MQYK,IQGXLURB13,(^"%AW.DQI!R@(KOQ)MNIWE/$PB(^&WH#7%LCW#>)Q=79
M=I-:5R'4LZZNH+9AM[4!L8SIF>ORP61"N5$K-5$B30JAR@`!TDZ^K;T!MZ=_
M7OKI[2QCB(#1YUS\LY<TU/K4CX"!:H%2[R`$.)2F$=O1[ND?9MZ-;Z*$9TP6
MN>\XBN*N0O\`=C!FBNB!.LH"41W#[7N$?'I$!UFO$;(ZMI@L9I>7%KLE86\V
MYM'J=M)R!05,(FZ#;>)A$1`-O=K1W=RQKL%L(8G.%.*AKE>_""3M+XLQ"&1$
M=Q$?'?JV$`$=P\`'6N^;J^E<%D=C[N/Q+`KRWNACMY-,'8*)[KB7<P^H!V'Q
M-MMOKHMKE)<`2L:>$G&F"\U&?;<BK+.VZ2P**&4.`B4V^XB(^_7LFP6KG1AY
M&"X_<Y6QG0WXE$A10RAQ.8=Q$1'Y]=>``*!:$FIJM&JJB:(FB)HB:(FB)HB:
M(FB)HB:(OWEM=4N27$D9%E$1[^6DERMHZ+9.I%^X.(`5%FR0.Y<J"(^'V4DQ
MV]H^&J$@"IR"J`7$-&9*PSC>X:V9D#(60$I!:`=V<LY(1S!!)V[&,CS=</"H
MH+N&R0HD2:MT%-S@`)@<?$1VUJ-8=+VC\J_R+?\`9.9;]E'352GWE5CR0RG4
M,M6.N3]5;338\?".(F4"99-F9U!+(*/&1FX-GKP%"$*Z5`VXEZ?#;?U73R-E
M<'-KDH[2%\#"U],34460'C7-#/83HBHF[BT<Q=5];QW-W(60<LD2CZ]_A");
M>X=9]N:PCH6LNVZ;AW2:^E0(Y1W&`O>4U2U9H5U^[L9^[S^8:=2WWZ]C573E
MTJB1,#`=G#D,=$JH;]94S&WZ"E'6%<N#Y?=X8+9V;'1P5?Q-:<OY5<OA'*UU
M"S7"(<M$"VF0B6SN&DSFW64B&2P_?$2W*;[*9A551<'$OVE")COX$#5]F6AQ
M!^)0[B'Z&N'P5QZ^!5Q).3:0W)W+;B6DF$2Z<X<.WK#R3>MV"(NEH>(*@BV<
M.U4DP<*K)J=)0'J,)3;>O4CB!<.K^7#U*(`NLV``D=ICZUCHY=MY]WY>U+/4
MRNCPL5FY=;*Z;(3").ZSDTZXYF2I_:&/(^<,@*)_L`L=`?2!=OIWZ29MHC\0
M9V7I8-Q?MT@MM6>OM&&4,_7,0/3H#^%5\(?_`+1:V[QS^#5M)M`E.S1;S`Z]
M#*T[(Q2M@=)3_-B<@8X=JZ+C18/P(9003(0ZAU#%3(FF4QU%#G$"D33(4!,=
M0YA`"@'B(CL&OT<+@T:B0`,:\!TE?B+&Q\DC8X@72.(``Q))R`"]4M98V3]^
MN%$3<4A<Y*88?KQ,D)/DRN793)5U3O)S)%BG$SQ+MN05[FX][J'TZ_&SOU)M
M4_?C=)=BT_X.[<+DPZ?A[(ROTEM/PG-M/PTHOZ;/"F'O#:^%&QV_>W7_`+RL
MV:R;<ZZZ^W%O&)`\G'6#@^N.L&N*MY9)1S$<=N<+^!-VHUQ95HJ/,W^RFFUE
MYX8F4^'[>Q2IC%/RE\/`"F#U:Y8&D<I&6I>@N`,T`=\6E1N\LMI%KY_GG#SM
M?>3#&4\M!D/MU]]>8@&DBH@`^/=3C%CE';Q!,YO5OJVUIVF/)77Q/8BF6K["
MLA/,^M<D+5$4!CQX6L;)PSD[`_MSZMVUA4U_A?@6"$0T=+NY6,.\0,J=PH!2
M]92&(`CL.VLF<2FG956%;.@:29J=&%5C+XOY>SK=N16)ZG-9=R/+1+JXIGFX
MQ[;YAXP?1T*U?2C]H[0.[.BY:+)QXD.4=R'*/K`=8D4DKI`*DX\UG3QQ-A<X
M-;6G)6]Y2N%+GRXR>T,;_MN36%21ZA\"(LAAZPF'CZ"@#??5LM72FN=:?8K[
M?W;9I'Y:_:O261N1H1-FD&R31--HD4/0";8A4$P`/<1,-;48BH6E7F]YB/SW
MKECDYFP'XLZEMA:.Q*D/<[B\;&PU;%!/IWW,$B10NP?RM:J8ZYCZ%NK8:+=M
M>55,7S*LGIP\3CSCS".`(G'Q\7:+>DB?[)&T6U&'I\2L!?4)D'#PQ1_40-[-
M37+Q01MR6/8QU+ICU#[59C%O(_`U#XJ7+![Z$O;BXW^$MQ[),M(6%/$*66::
M':0?0Y5GDGBD9#-VC,@&%$#@)5#`3<=AM9)&V(L-=1!5\D,S[@2@C2".>2X'
MEM6@83D5]Q*J`1*ZT6QQ`DW^RH^BA96-F4-]MS`G%K@7^EJEJZDM.85;YM8:
M\B/N73>8K.!+<G)]F!^I*M5"FP>P;CT'-&*3C@H`&X@/<FO$/3OJER?WIKP5
MUDVD`/,E=+DUES7QCC&$B\A2^0H#$SJ/C*]&-6-AC%*\C'+,0^ZX%^:M.SN6
M:#AB3I(@[,4JH%$@]1MPU:X2L;C@T]7V*L9M7O)8`9,\OO4P/+-IF'Y&-LMW
M9LY-YF&L+$B)-2:.T4CX*$G$G'P3ZG-FZ9>T261:JMW2Z_6Y(9,R91*DI]O(
MM&L-7#XPL:^=*"&&G9'RQ4,.=<J>R\J,F-T3BH,<M6JFV`!WZ5(^MQ+<R1?P
M/G*@;?K".L><ATIIDLJT&F!OG/K7H=K<22!KE<@DR]*<)7X.'(4`VV+%Q;1B
M`;>K;L:VC1I:`M,XZG$\RL-_FBW*/DK[C.B-%DUGU2K<Q.3)2&`QF:]K>,2Q
MK1;;?H6/'PO?Z1\>VL0?Y0:P;MU7!O);*P:0QS^9]BFWP"J3RJ<8J<J_2.@X
MMTK8[HFFH42G"/EWY6D2H)1V$`<QL8DL7VD4`=3VS2(NM8MXX.G-.%`IG:R5
MBIHB:(FB)HB:(FB)HB:(FB)HB:(FB+H[19&U-JUIN+TY4V=/K%BM;LY_T2-J
MW#/9I<QM_#I!)B.^HY2&L.KX<O3@KF`EP`S7X8UGL3ZX6>RVZ3.961M=BG+,
M_4./4=1[/RCN6='..X[G,L\,(C[=<V34U73Y8+I-41-$31$T1-$31$T1-$54
M4NE6O(EFBJ=28-_8K)-.2-8Z+CD3++JJ'$`$Z@E`2H-T@'<ZAQ`I`\1'4%U=
M6]E`ZYNGM9`P5))HKXXI)I!%$TND<:`#->JCR[O+`9X6^'N>28AE9<G/VJ"O
M?51*Z8U0JP$.1C&(J;@=SU&`JJVW4(^C8`VUXWWA[TW6]S&SL=4=BTY\7]/5
MT+M-NVB&P8+BZH^Y(R_+^GV+T?88P\[['=&#*+D1,43!N3MMRF(!W!DP$I3F
MV*)0Z>H0VUK[#:B`'D>^#CSIU*6YO=1TM^#U>7%9!*ACOX1LS.*/;1#8!.B/
M2!Q)XE[A3[JE`"^`"/@.MVRVT.U.'NK"[4N;I;_*KR*@VCF9.T38VX)$V#K#
MK`-B@)=]RB(CJ&9P#?=&%54`>>B[1-W5L>U.>RC?#*H1L"V.L@AL"SIVX/\`
M]F9QR!P(9=X_<"5-,GM'??;QUE6K+/;K23>=S]V&,8#F>`'.N5%`_P"8NIF6
M5KC(XX]`Z5YI^0]+M'*OD0]S1G`H20,_^[L;8P9K&<QE.K:2O4R;.S!^Q%ZX
M_O72@!NHJ80WZ0``\;WOO7>WUS)(P%KY#0`9AO!HY#GS*]&V_;;2QMF1-]XM
M%23EJXGIY"N04OL.XB18)LD)=BP+%*J$128MT"HD8%\`2(9'I`#%`-@]&^L'
M:-KDF>)KVA:3DJ7]Z#5L5=7-2MD:$ZB`9E;&*:)1.'93*F0@-BB.P@'A]H@@
M;P_#KM)+`P!K10PA:%MP)2:?&KIU^`23;%,GVR=`=74)0ZO'QW-X>/IUGP0-
MTAYSX+%FEH=`R7</#(LB'!<2@8H`<BI0`I0+[!'P'P`=7R$1U)I1482\4&85
MA+W?21B:[8BQ>T;<Q=QZ?1Z0W$?'?;?QVUH+V\$8+:^ZMA!`7FO%1`R/D0#D
M3!N<IE3"4YMC^(`8=MP]'CM]&N9OKROO<%M[2U).D'K*@ME7(R^SHBRWB5`W
MVQ-NF`!OZ!-[!#6K;=O,H#.:W,>WM<VN-*>7\J\Z7.3D;%1`OH6->@ZDUQ,0
MQ$U`,?J-U%$FP#N5,OI'TZ]E[D[#<[@\3R@B`<3Y9E<;WAW*&R88HR#,1EQZ
MOO6#F:E'DR]6?/5#**JJ&,.XB(%`P[@`;Z]VAA9;QB*,4:%YG)(Z5^MV973Z
ME5B:(FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+DE$#F-D(E<HC.DLW)4Y2\.!!X
M4IP*HE6XM1-9X)@W`0)(OA20#]8A5`]NL2[DTLT#,^Q9]A%KE[0_"WVJVO%[
M`]0M]*D;C?8!*;3EY4S.N(.7#YNFA'Q0'1>OD_@G345!>R!S)@)A,`%;^'I'
M4=M"Q[-;Q6N2FO+F2.3LXC2@Q\ZX7*S#E%H51K-AI5=;0(FL:L5+G;N7ZY7"
M+R-6<,>Y\<[=%)VEV)P#IZ=^OQW\-4NHF,:',%,56RN)99"R0DX5"L]3<[NJ
M/A.Q4"%640LDY979F<BF82A$5Z3C&9)9RW6`0Z9%PX;F21V\4P4,IZ2EWB9,
M61%@^(E3R6O:7`E=\`'I(R\ROQP_Q`V<,)')ED9%7;2360KE7:+DW*I'.4E&
M%@EP*;T@Z3.=FB;]7O"'I`=36L0([1WF6-?3D$0LS&)Z^`46G)I7`N95@;F,
M+NB6@PH%,82?>D$<W4FF;T=24M`.@*/JW4]VL8U@EPS!]7\BS!2ZM\<G#U_R
MK(5F:#Q?8*JQS!)XV=9.;%AHU;O0TR\C'Z%6<)JOF\B=%LY22>H1YW8][8HJ
MHE,(C]DAML^9L;F]J6ZL/4M7;NF8\P->&&O$<586C99Q>UAK/$4GCC=)NMV1
ML6.ML*D\6M\!)MCI*$!O+1CU*6CQ!9NJ8H]1`$Y!V'<`#:MCN$^WW++W;C+#
M=Q/#F/C<6O8YN(<UP-6N'`@@JS==HM=XLI=KWIMO<[=/&Z.2*9C7QR1N%',>
MQX+7M(S:X$*W-/QEABK6M*V8>X(23+(*#KXN#D;2-C?P%?D.OK0DF,7,JKP\
M>JT5^TD8GPXHB`"0Y!`!#T?>/&KQ1W_:7;'N>ZW<FW/;I>T".,O;D6R21L8]
M[2,'`NH[\55XGW:^F#P%[H=X6]ZMD[O[?#O,<FN-Y=-.V)X-0^&*>62*-[3B
MQS8ZL-"PM("NE(/9G$SFP6BURJ-SY/Y/;_<D%7H422'[ELI,"($,8C?J31<D
M(4A4$B;%'ME(3J3[RH^7XQ5)QG=@!R7O`I<4:P:;1F))XG[5?RHX"C6V`9G#
MMF4W<7F#F4[>_0$JYT)N?;E`'#<X^#@T`=%N"9M]E#M^H/`VLED($/9NS.?6
ML26X+KCM6Y`X=0^]8'IFNYKX>Y9823INZK%IK3]<\!8P:'<U:U1JA5&RJC)R
MH4K*7AIED<2.&IC`LF!Q(<J:A0$,`A\+^16S#HKF.@Q:>'$*:1O-+L#FM/6#
M_$$&6?=QCQC][1MQ?-8M%RZ:*MBOTXQU#/71`1.H"@)?%&WVVZ_7J?YMQ;2F
M/ET+%^0&JH<:=7Z597RXJ\K,\DHF7!%9PSJU/M\HJ]*B<[9)XX8)0;8%7!2B
MBFNJ:6.)2B;J-L(@'@.H[8$RU'`*6]-(*<20NMYUXKL^,L_V6[@T=H5C(,RE
M<ZM8TDSBR2F52MUY6*.Z`HHH2\9,(G5*D<0,=`Z9R@(;[)V.9(3P.*K:R-DA
M#/Q#`A7Y<^:7;/W**R0QE#M\@C'`U4MB\^JM722`)=HTXE6QCDW)EA4_;`V.
M\%$%/`3&)]D9/FCHTT]Y1?(-UUU>YRX^E6WX;X*G+==E.2664WD;C#'[B5R*
M]L,^F9$]TL<;\3-&=LP<E(+V,C7I3/73D`[)UDR(D$QC&`D<+"YW:.^$8J^Y
ME#6=A'B\X4Y!6>JC>6YB\L$%I,51;W^Y+SLVF10QC0N/X0`<*L@.4W4B#*M,
M$F9!`0_;J%$/$VK16:7H)]2D<1;6^&8'K\L5F@4X0<5W`*(I8?AFYURJ))*D
MF;6)FYU2F(FJ7JGA`3(F,!@W`0W#QUGF"(#):SYJ?\WL6#3`4T?%_)S&RSY8
M&ZE:RJVK,MU'*4Q47,LXJ,H50-P\.T\/U!K7QU;*!QK3[%M9AVD#J<6U^U5'
MR#7#(/,3(,<FL1<9G,[2G(`4Y3"*3*6BZB5,H`/B!2LQ#;57U=,1QK3[%;#[
MEL#R;7[5FTYH5XLWQ?S)'HI%4^ZJTWFVI.D![85>8C)7K)^J*3-B?Q]0;ZSI
M\83AC3]*UEL:3M/3[5C2\KN?3;9KNU;[Y-K+CI1=)(%"CW'%?L$4N`@4!\3$
M:R2P_@WUBVI`>:\EFWXK$#R<H@Y5N+21Y&7Z[ND0E62>8YJ;49$<$1&080UM
M.8C(K@2+%1^*9L`3`XD,!0-OL.VVHGN':EW#4LF-I$`;QT_8IXW/S3[#(,7+
M6A8JB*],.P4(A*V6QJ60K)57J`BK6%8Q<.D\73,.Y2JJBF)@^T0P>&IW71TZ
M6BF"Q&V`!J]U1T"BL_@OB;E[DO>SY'R^G88>E2\K]^VJTV5):/L-V$QRG4C*
MTP<IHN2H.TR`B+OM)LVC<-D>HQ2)A9'`^1U7X-4LMQ'`S1'0NIA3(+/8Q8LH
MMBRC(UH@PC8UFUCXYBV(";9DP9($;,VC=,/`B+9ND4A0]0!K9`4%!DM022:G
M-<G551-$31$T1-$31$T1-$31$T1-$31$T10N\R&\&QKY>7.J^D5[*M7XB<AI
M!NJ!ND4W:F++,Q9&*;TE.#MX38?;J"X+1"[5R/I`K]BF@%9FC]8+\5Q(!*DF
M`^D$R`/X0*`#KG5T:W-$31$T1-$31$T1-$57T&A6W)]O@J)185Y8+18WR,?%
MQC%$ZJBBJQP**JHD*8$6R!1ZE%#;%(4!$=07-S#9P.N+AP;$T5)\N*OCC?*\
M1QBKR:!>T'RUO*ZC./\`5DY*X)D<7B=225M5I28%4=D,*(+)URNBN05?@DSC
ML=0G27P$QA'T:\>WN[N.\EP'W&N/:V$Z6?FY$CB?4%V5@R/:8CV6E]\X8N_*
M.(!^WCU+T$8VXV5UD1,C<)#O%3!P#DZP*)G(8=P+V5"&0*?</$-M_3MK)LMJ
MMHVUB;B!C^C#-07%Y+([WSF<O6IA5'&X0":1VZ9RI%Z@(HL7L+=8#U*=H2AT
M&Z@_``ZSRQL3?<%#7RQ4#-;SC3+@KE'*=JB*9";+J?H)*B('/UA]G<X;$V'6
MNDD>XD.SSH5.``*#(K=K,%+2SL#R"+=-DT3,Z=.5CAV6K8H"8RBAS?9*8B9!
M$1#<H>T-5LK:>[D.L`1M%2>`'$E63RLA:*5+C@!S*QX<D<VR&<;BGCK%2+QW
M4:BH=DTD4$C@SE)-$!2>S**1@Z77:W$B)Q`2D+N(>)M>;][.\,N_7XVG9FEU
MA!@#0T<X9NZ>CTKK-GVUNW6IO+UP%S)B<J@'AT+K*E@UM%199%^HLZLZQTUE
MDU^CMF2)^D0RQ0$X."B'CK%L>[\<,0EEJZZY'+^527&Y.>_0R@B5[8.GN$`[
MY6(`DN<I4R]/44AM@`>D?$2COK?163A[S6T:M?)<,`I6I4DJC$1[J)5C;&DC
MT%2$X*B7<X;?H_;\1V#;T^G73V+(Y8##<@4`S6GF>]K]<//^54DZ&%C.^S`>
MTW*)@35`>LQ@\=AW](!X>G6M?V;"6M(TCV+(9K=[QS*CS?+:W9B9BFJ4G7UB
MFH<1$HE#_3M[1UI+ZY'P-RX?>MI;1'-V:@)DFV+FFDTQ6!PF!5/L)GZB!T@&
MW@`@`CKCKZ<]IG5;VVAU-(R41KW:E%7KA5=X5JS0(/<.8W;[9@$0-U&W*!2D
M]'OUH;EQ<[2*U71V-NT-I0')8->=?.&!H:#RGU"0++6!T59#K;+@H"8;"0RB
MJA1^P1,1\->B]P^XMYO-P+Z\;HLVTS&?5S)XK0]Z.\UKMEO\I;'5<D&E#Y4I
M^A>=RTV69MLN[G)QXJ\?/%3J*'4.8Q4^H1$")@81Z2AOKZ;L[.WL8&VULT-B
M:/(E>+7%S+=2F:8U>52:A/3]/UZR5"N(("'UZHKE\T1-$31$T1-$31$T1-$3
M1$T1-$7[RVNJ7)+HI2K5B<7(ZFZW`3+E)($$G,K#1TBNF@!C'!%-9XV64(D!
MSF$"@(%W$1V\=6EK2:D`GJ5[7O:*-)`Z"NT9,F4:U081S-K'L6I.VV9,6Z+1
MHW3ZA-VT&S<B:*).HPCL4H!N(CJH`&`R5I))J<2MB3B8J::_!3,9'2[+ND7^
M#E&+:0:]Y+J!-;X=VDLCW4P./2;;<-QV].A`.!`(50YS35I(/0J?_P`O,?\`
M_P!@M-_]UX/_`.D=6Z&?E;Z`KNUE_,[TE52U:M6+9!DQ;-V3-JD5!JT:()-F
MK9$@;$1;MT"$112('H*4``-7``"@R5A))J<UTLC4*E,.SOY>K5N5?*$334>R
M4%%OG9R)%`B1#N73558Y$B!L4!-L4/`/#5"UI-2`3U*X/>T4:X@=97<,F3*.
M:(L(]FT8L&R8HMV+-LBV9H(B)A%%%JB0B":0B<=R@4"CN/AXZJ``*#)6DDFI
MQ*CE9^,U=<S2UIQS9K!B>R+F.HNK5UE"P[A0XB<QC1:3AF=J50X[F(BJ5$1'
M?M[ZQW6S2=3"6NZ%ELNW!NB5H>SIS]*Z4^%\_2)/@)CDI+?=0AT*#&0ZS>24
M2'P,`N$W3-0#B7UBL;\>K!!+^>@Z`KOF+88MB%>DX*Y6,L$4;&+A25CDGL_:
MW0'!U;;"J5[+G%8-EP9AT@A'E7WV.8@"L</`ZA@\-2QPLBQ&+N94,US)-[IP
M9R&2I_''*3#V5,LY&PE5)I^.0\8NY!I.1<HP38-Y7[GD314RYJ[L';C[Z;1#
MX"D<?824(4Y3]`DZC%]$[P>&O>SNSW7V_OCN<+/\!W)C71O8XN+.T9KC$S=(
M[,O;4MQ<#0BM:`^-]SO'#P\[]=_=X\-=BN9?][=DDD9-%(QK&R]C)V4SK9P>
MXRMB?025:QP#@X-+:D=W2<M8OS@AE.*8-"RL'BB^2>.KFM<H:+)65+)$$`9$
M8U22</&3Z/;=8%%=4B(]1@#I\0'6J[Q=R]Z[M,VT[HV,R[K9,NH&1DOD[)_P
M:VZ06N.)TC5A7%;WN9XF]U^_,F]C8I)6P=W]TDV^ZEF#(HOF(?XG9R=H0Z-N
M`+W]F:D>[0@KD-,,<>U4R3S'%^'%VZAA,G,-:M3W#`YRG`H]#U)JHQ$P*"`"
M`&W`P[>G7,OLI(IC!+"]MR,V%A#Q_1(U>I=U%N5O<6PO(+F.2R.4C96NC/#!
MX<6YX9YX9JYL8G7HQ((F$+7XU%%4Z`14,$4Q3371(4RB`1\?VBE713.`F)T=
M9"F`1``$-5^7F8P/,;Q'2M2UU*'(U(I0TP.1I@J"[MI)#$V:)TP<6EH>TNU#
M$MI6NH`@D4J`02,5HFFE;F8R2B[&WKTM#$3*:9CITD6_BT4A_NSRK61!5HW+
MX_9,L4ON'5!!+(6M$;W%YHT!I.H\FX>]U"JJZZMX@][Y8V"(5>2]H[,<WDD:
M!TNHK8P6"^/2:J4_6\48D7,943MY:)J]9D6_>3-N86[A%!TS!5,P^/1XE'V:
MMEM'VTIBN(G1S#-KVEKA7H<`1T*^WOXKV`7%G.R>V=4!\<C9&&F8#F$M-...
M'%4=FOD9C#&%FKN(;72[_D2?O=5DIQA1\?X\#(0NJO%.CL7OWC!I.D?]Q(=N
M<>WV5$@32$3;```/?=UO#;>^]NS7._VMQMMILUI.R&26\N!;L[1[0YK0YS2T
MU!`Q(-2``5Y%X@>-O=?PY[R6/=*_LM\W+O+N%I)<Q0;99F\E[&-SF.>YC9&/
M`!:XU#7`!I)(X]1@#+7'K(EGNT-CG'JN+\A4)*+9VVO6_%D?BZY,F%D_:QA>
MUV2K.&<D=J4>UW0.803,*?28AAB[V>'&_P#<VSL]TO765UM-\).QGLYFW$3C
M%3M!J8!0MKB::<"*U:0)_#SQL[H^)NX[CL>ULW2P[P;28OF;3<K9UE<1B<$Q
M.[-[G5UTP%0_%ITZ7-)D\XFH5DS^\WDW#,HTJYVWWF[EXYK'@Z2.9-1M\>NY
M3:_$I*%$ID^OK*8!`0`0UQT=G>33?+0PS/N:5T-8]SZ'$'2`74(Q!I0A>F3;
MEMMM;?.W-S;1V6HM[1\L;8]0-"W6YP;J!!!;6H(((JK(9!<<:,='J]BOT#BV
M+<7^XQ5?JTPK2X:6>6.X3ZZKF.%J\C(9^Y56=N4C*&?',""9_M**E$0$=KLG
M=/?N\<MU#LUH^:6RMWSSCW6=E%'36YVLMQ%1[@J\\&E<]WI\0^Z/<JWL+GO-
MN,=M;;I>Q6EH??D$\\]>R8SLFO\`==0UD-(F_B>*A5XZI&((V;:R3ZI8NC[*
M]D`E&$@\A:@TG7TJ9S\2638NUVZ<@\?G>#W`72,90ROV@,)O'6FBL[B=CI8(
M9'QL^)S6.<&_SB`0WST737&Y6=I(RWN[F"*67X&OE8QS^`T-<X%]>&D&O!5E
M-K0C>/<IV9Q#-HA\56.=DL3B/;1CTCE,R2[!R6543:.BN$CB4Z1NKK*(@("`
MZ06\]V_LK6.2:2E=+&N>:<Z-!-.G)+N\L]OC[>_FAMX=5-4LC8VZN6IY:*]%
M:JT$G)<?,/6O'S!>+Q[1[ADN4<UK'ZD)4XYE)S;PS5-PZ;-Y*!B1%A'*-5""
M=PX51:'`0#K$?#6XVKNMOF]6=]N.UVKI;/;8>UN7>ZWLF$EN(<07.J#[C`Y^
M'PT7.=X._P!W5[L;EM6S;_?L@W'>[@P63"'O[>0-#C0L:YK&4<#VLA9'B!KJ
M:+GS.)./CF43;6#'6&_ON44%=%K*5VFMI>257,)A51:K((O7JBZ@B/44IA.8
M=_$=:>.PGGA=<Q02/MV?$]L;G,;SU.`+1TU(713;M9VMPRRN+N&*\DIHC?,Q
MDCZY:&.<'.KPT@U7?P^.<1TM8SB#HN-:JZ;`F8SEE7:O$/&P*J`D@<S@&J+E
M#NK&`A!Z@ZCB`!N/AJR.V>^AAC<ZM::6DUH*FE!C08GD,3@I9KV&*OS,S&::
M5UO:VE305U$4J<!7,X#%7%,)C"(G$PF]`B81$WAX;#OX^&K>K)2+3JJHFB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB+$KY\-B-5_)W\P>2*?H%U@1S7=_'Q"W7&I
M54Y/`IA^VG,&#T;>/I#TZP[VO8U'/["%EV=/F&CRYK\?C6B6^7W1$T1-$31$
MT1-$5V,*81R/R#O\3C7%T`M.V25-UG'Q2CHA@0?]YEIEYTB1E'-2^)C#N8P_
M9(!C"`:P[_<+7;+9UW>.TQ-])/(#B5+!!+<2B&$5D/ECR"]G_EQ<"L3\1JK\
M65H%KR[/MFQ;/D*4B$B.T`4%,RD-545A4-#Q+=4HEW`Y'"X#N?V!Y5>[]/OE
MP2066P^!OVGAJ]BZJ#;V6#*DATU,3PZAQI[5GGQW6C)LFY$$'2R@*[]P032(
M+8YCB<4BD.<>D!$HAN`#TCZQU/;L;&P`M-1SS43R7NU`T]BF36(88]`BPK*I
MJ`"9DB',7I6W#805(8#=(G`/;Z/1J<S]F,Z'EP`4?9ZC5W\JN']Y$<I$:F$P
MN5%@!(HK#V>LNW47]0@[>C?V:QWW#7BA)UDX8X*4-(.&#?6JDA*\,L^,U?(+
M'`2E41,"RG<`0,)!2$I#G(`;C^B/SZEM+,7D_9/!I2N>/4H;B;L8M32,UP<S
M,/B:FXQW&V$*[$2R`(VJ5C034F7:":A1-7V10,!VJ#DH=#E41W$OV`](CJ[O
M"R-M@=GAE[*W>/WKF_&[]0<@<G'S!-L+OF!?3,UR@^X#D/UO-P"L'7:K68!@
ME#5:!9,%&R`D4E%BIG>J(@`@<.[L"J1C>D0+N'CKE[2TM+>+Y6RB:P`?%AJ]
M/!;:>>>1QDG>3CEP6V2#Z'!>E!0X`03&\!^R?VJ&'U[_`(AU3L&ZJC@JF7W<
M3FJUBF#@$>\`@4IQ`W4&W2'0&_0*8_H^_61%')354!JB>1Q!H%VKDRC=DX7*
M!"@8BI5P$?#[)!,42>SJ#5[@\-+A2M#51-J2%%ZQV0SIG(?#'!55-LL<2@80
M.F5$QMP`?1X"'X=M<S-.7!U,2`MW'$&T6/3)&0I!02*+F4(+=8P)G!0!*(@<
M2F*80\`V#TZY6\NWG&N*WEK`T\QTJ)=PO36.,\G9%Z1K'MD5E5W"JA0(4P`(
MCOU;;AMZM]MO3K2!LEQ,&BKG$B@6[AB:R,UP`!)*\Z7/'S%%';J4Q]BF1$[D
M%5$)"70.84FY3=93@!R&Z#K#MX`'HU[+W*\.^W<-RWAG[G,-.9/5R7%]X^]O
M8M-CMCO?&;AD.BO\JP73$K)3C]Q*R[UQ(2#HXJ.'3I0RJIS&$1])A'I+N/H#
MPU[I###;Q"&!H9$W(`4"\SEEDF>9)7%SSQ*ZH0W\-2*-;!R?F'15]BXIT_`?
MP#HJ^M</5%<FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+DDT1-$31$T1-$31$T1-
M$31%]!7L_MNV9440%8$B!N=44@%0$B`(@`G4$O2'O'5-.OW*TKA7E7"OF50_
ML_WE"[3C09FF-!TG(+#G0^(N7FN"VF:HB!=4'F74\WY,SC6F4B+--Y/Q\_,(
MIOL9V11%THT<Q=MA(X3MR*+=!%5Q3,)"+JB'UIO?BIW4E[Z.[GW<[;[PCNMF
MM-NE<S46Q.B82V[BJ`X/@D?1Q#:D-U`$L:OSQ[K_`$_]_H/#%GB3MMJ_:OJ)
ML>\NX;U;L?H#IV3R-$FW7!#BUT=U%&71ASP`Z0L):V:0JQ#CC-R2;8_PL[O&
M.,@R%4FLEYERCFO'%-KE9OT_'WVT3A$:E+6+',_.L(>ZPY86/0%!-9=0C8#J
MB8`.<`/VT?B+X>R;[O$6S;A8,W.';K"SV^[N)9K:)UM#'6=D5W%&Z2WD[1[M
M1:T%]&TJ`2WRV?P7\9(>Z7=RY[R[1NTNR7&\[MN>\;?9VUO?SLOKB4-M99MO
MN)F17D9BCC+&O>1&#+J(<X-?5YN(^8WN(;C4X''N1:]7\[Y_P\,Y29!M0:FG
M4\?51S)OK)D12B4F0<0F/OBSF:$49IKN%S&0*?HV*7?5#Q3[I0]ZK3=+Z_L)
M[[9-BONSN&FYG[:ZF#&Q6HN;AHDNM(UD/+6M&HBM25T'_L%XAW7A_N.P;=M.
M[VNT]Z>]6U=M:2-L;46UA:F1\^X&RLWNAL*N,371-?(\F,&E`VLJ^1?&ISBA
MA@#('$?$(S5GP?E^7M!J7&2;I=_9X>ZP/W?9WLO+S\DX?/U7;F$9%=**+B<2
M*F$`#QV\Q[@>(<?>>??=C\5-U[';=YVID/S#V-#89+>35"UC(F!K0T22%@#:
M5:`5[MXO>#,W<2T[I]ZO`+N^+G>^[._RW'RC)7NDN(;R$,N7RRS/?(\O=!"V
M1Q>3I>X@#%1DROQ$S56X+"SZ3B;EE1M:[-:LH\L$Z#!P%\G)C+,^5%S73O*'
M9)6)B[O3*8V5,P9M#J_#(G!RL!2BX(`^C=U_%7N?N-[O$%O+:;8^UMH;/93<
MR2VT<=E%42Z;F)CWV]Q<$"21X;K<.S94]F2/%._O@!XD[-M7=R[O+?<=[AOK
MVYW/O.+&""_GEW2:CX-5C<211WEK:`]C%&7")I^8DHWMFM,NN"V#;1BY_E^X
MRU<N./H'(;^!""H5GC:-4T=X5%P16V(8XH+F0AJ$\?IK@@HV%P=18"]1@``+
MKROQJ[Z;;WE@VK:;6XM+^]L(Y>TN87W$Y_>$4A-W<M;)<M:1J#]`#:T&-5[_
M`/2_X8[YW(N>\/>'<+/<-JVS=YH.QLKF.SM0>Q:0;D;?8NDAL7.!##'K+G4+
MC@&KK+QQVR1F#FU;,@O++EC#U#I6%:S3Z)D7'4Q#0LC8YE_(A)V.(8NW[&:.
M$<D,FY!T7X=(QE$2;'Z?`<G9>_W=[NIX.6NPQ6^U[MO=YO$T]S:W4<DC8HVM
MT1/<UKH_?.AFCWB`''"N6!WI\'N^'B']2=]WMGO]_P"[O=C;N[EO:65_M\L,
M,EQ,^0231,=)'-^[!EF$@T-)<QOO4P-O<O<%&CJY85KL(WREDV,OV;FE_P"2
MV7[G;0D+4K7J-7U6-7BY&<8%A%XQHL65=H-"L4053.(&ZP$B0DWO=3QKEBVG
M>+^\=MFW7%CLSK;:+&W@TPB6YE#IGLC=V@>X:&.>9':2,*&KJ\GW_P#I;M+C
M?^[FS;<W?-[M-T[R,O\`O#NUY==I=.@LH=%M%)/&(3&TMEF9%V3`]IH=8+8]
M/36W`S#&_(2="V<2+KGOCA%T.$A./%'QXW9VNG8^EW:WWE>23U6L-D9E9SEA
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MA[DQ]ZNZS]S[NL[T;E?76WQ/@NCM5A<_+?*[<]\L@:^`/;)/<!KG1UU:CVI(
M-&V3BYFVPV/,T+DC#^4;WD&X7>6;U>W0U!Q3/T8M'(Y(VJBU5S'<K"C)8KC(
M2+(`(LVC/=NF0A.@!`Q";?;_`!*[G6&W[1>=W]VVVRV*TLV&:"2YO8KGY@@F
M836$$19>OD>?>D?)[Q+C6E''G-Z\$/$O=]Z[Q[=WNV#?-S[U;CN4K;:ZBL-K
MGL?D@0VV^7W>[G$FV1Q1BC(HH3V;`QA:VCF-OO-X6O-7S!(EY`<=LH<RJ7'X
M?QS1<'NXI]$V6#KDE#UQHRN)+:TD)F$81%@F)M(YEIM1$Q^DO=3*;K#M\39]
M[]DW+NI&>XN_[;W1WB3=KNYW%KVOBDE9)*YT'8%L<CGQ1QD!MN'`5.EQ%#J]
M2W'PY[T;%XARCQ6[H[WXA]W(N[^WV.ROB?'<0V\D5NQEW\VU\T+(II9FDNO'
M,+J#M&-=K&CN)WB\[_SBX;N0XIF;XWJ5&N,?;JXG:6>58>@VFR2$DK5XVY62
MS2"#N7JM'?O2RPI-R*MT5%EDVA5#!L;$LO$F+_=/O;'_`+SZN\-U>P.@E,+K
M*2YAA:P3/MX86EK)KAK3!5Q#G!K'2EH.&?N7@=,?$'PZG_W%[/NAMVV7;+JW
M^:;ND5C<W+Y3;Q7=Q</#I;:RD>VZTL#HV.?*V!KR*&R(<?,B6?$M]QI?N(&0
M+OR^O%KF7#WDS:I&%4I$:J]LB:\7<8C)"MA,[C(B"@TP*E&,FNRHAL)1ZNV7
MLCW[V#;N]%CWBV/O786?A396L8;M$+9/F'AL1#X'V@BTO?)(:NFD?[O/#4?-
MV^%'>_>NX>Z=R^]?A_NVY_4!N=_*Z3O%<OA-DPON08[J+<#/JCCA@``MXHJ/
MIB#7LQ*W$W$=U:>165<@\BJI)W%C1X#!E'Q)/V21D$8VX/\`'E28M9[()8]C
M*)&E1-8X<KAN,@0P%4<G.*8G,(AYAWH\5(MM[@;9L7<"ZCM)KV?<;B^BB8PO
M@;=3N=%:ZW,.C]U(6N[(BH8`'!H`/NW<'P"N=Z\7]\[V^+ME-N-MMEILMGM4
M\\DC674EC:,CN+[0R4=K6>$21]L"`97$M+B2,G1C"8QC&$1,81,81](B([B(
M^\1U\X@`"@R7VJ27$N.96G551-$31$T1-$31$T1-$31$T1-$31$T1-$6#7^)
M-DU(KR4N;"B0"(OHK#D2?8QB[)2&?<7IJ&^SZ0`I?0/@._CK$O3_`*.X>686
M79?ZRWS^PK\EG6A6^31$T1-$31$T173PWAC(N>[W%8[QE7W4]/R:A!74(DJ$
M7!1PJ%3<3=@?D3.E%Q#/JW.JIMU#L4@&.(%'#O\`<+7;+5UY>.#86CSD\@.)
M/)306\MS*(807//E4]"]K'E^>7]4N../4(.!BFU@O#EFA)7V^?#`FZGI`ADR
MG39&?&,LWB&AC]MLT2*`F`.X("(B.O%=SO[WO)?.N)-0M&?PV<`,JGF3_(NU
MMK:';(!&VAG=\3O8!R'M6;/'^*4'35`KMBQC71R'2ZS)+JK(.FQU12,[1,JB
M("ZZB"/1TE3\`VWUGVD<+?W<H#7$=.&?M\W4L69SG5<S%JF53(QO&PS,%F96
MRZ22/<,B8!$"IG'I(&P@)RF,41W,&P!K,,XC=0944.@.'G5PQD%%S@N1J*Z9
M`*)ED"$4^QN($\#`<@%/ZC>)0'P';6*^8DA[15O/RP4FC"AP78QD<TD5S.&I
MSM@$>V;<@'(L3T@)P'8X"<Q?'I$1)X#T[:B9$R22K*M/EY&F7)'O+6XXCR\L
M575HM*>.:\D=FY1&TS;4R$?W#&[\<S$#$7>'3V'K,4OV4C"&W6&_B`:W=U>#
M9+)O9D'<)FT'-K>)/L'3U+"A@-_<$OK\LPY#(G]/'H4;Q-(.E1^-%5Z!S'44
MW+U/!!0>L[LP@<QENHYA'T[^O7(!LLKB7U<X^G]*W/[MH&G##R]"Y[6-*@NF
M85^CO"44C["JD<NYND_<#PW.(;"4=MM9+8PT@DTKZ%87UR&2KY!,"I@F<ANL
MI#;=0'`.D/$3%$=P%,WI`!]6LP"@IQ4.)*VG#QJFDAV%`3$I#F.EU%*7J*;T
M@41``V`?'U>.H72-#06GS*\--<,E:BQ7U%%^,.X?(-&[I-9,IS@`F[P$,`!L
M`_9*8/7Z]:J:_':]A(0UI'K67%:G0)!B:^I0`R!>',#&2ZR+\.Z9R_;MR)%`
M2J)=8E^UTB`E`-]P]'IUQ5[>&)CR'<2%T%O"9'M:!BL?F0[(5I75[),N4XN)
MC#*N7[I9?H0V\3"?[8AU&'?T;ZYTNFG(8T5<3@!QKP'2NAM88HW$G*E2>725
MY?.>GF%2EXD);&&)I4S>N(K*MI:;;'\5Q`.A5NT5*.QS&V'J/Z`WV#7N_</N
M`VUC9NV\-K.<6L/J)'V+@>]/>HSEVW;>:0#!SN)YXA8;U%%%3G55.=550PG4
M44,)SG.8=S'.8PB)C&'TB.O9``!08!>>$UQ.:T:(MHQ1#\'MT1:!#?TZ(MI0
MGV#B'ZIOR#HJBE5T^J*]-$31$T1-$31$T1-$31$T1-$7[RVNJ7))HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HBP%_Q/!SD\E'ECT"8.NP<?4S])A+NF;/F/>H
M#;?I%$0#[(^`ZPK[^">K[0LRQ_UAOG]A7Y0>M&MZFB)HB:(FB*1W%WBSECEQ
MDQIC3%44599-,C^SV:0!1.NTV"!4I%Y>9=%#[2@@(@W:D$7#M0.D@;`8Q=;N
MNZVNT6QN;DXG!K1\3SR`]IR"R;6UENY1%$.L\`.97MUX(^7'2>+U'BZU68Y:
M;=23EL^NUU<I$3E;9*H`4AG9A.!B1L>0Z92M&0&.5$#;AUF$YC>1W\][OUX+
MV^%+<5#&`U#17AP+CQ)&/5@NNM^QVZ`P6V,AIJ<134?L'0/:LSM-Q.G"*HJM
MV;A@T5Z`>%</`=."G*`CWDUT6Y4RD,10VQ1+L41$-9MM;QQLJT.TC.I]=:+&
MEE+W$DC5R4C8:+;QR22;(Q>T"FQU3@<Y550V(4RA3D.8.KP\/#<?1X!JAD`.
M%,^E6T)SR`]2K)JS.NY2(1/[*G482F(FGTD`?M$ZCF(4#%$VW2(;[:D[-LKQ
M3[O,J!VG!RJ&&AG#5955J`IAWM@,3I17./B!B]P"F15!/?T&`0'?4,44C'DQ
MX&OG].2O<]M/?R\ZNG'0#*";?O1*MW"S<BBA6\8V``>R3DB(KD;$:E,"?6!B
MB`B```%W]`>&M]9[:RW:+ZX#G8^ZP?$YU*THM;-<NEK;Q$##%W`"N=5&2PNY
M"Q3KB8D4"F<'77_9+&<)%;MRF,FDR;)^)4#,RB7H(8``1WW].^N3NS-=W3KF
M4?O-1K6N'ZHY4Y+=0]G#"(F'W*</:>=5WD1!B0&SEN91,#]2:ICB!E$U#``E
M4314`/`IMA^R/2(^L=M2QP%H;(W^3I4;GZC0Y*HVL65F<Z2X)[*$!9)=)N42
M'5(8!.8Z6W:4%0?M`/240$1*(!JX,TG2:4.6"NSZ_+!<:7ET&2:B;MP4@)D.
M8AS#ML!1]!>C;P.`[;>(;:MEF9&*..("N8UQ=I&)49+[D5$C5(8]P85U3E,@
MD(B5/<AMC"4VP_I](@("/CMKF;N^:QE(JUKU+:6]KC[X%%"W).17CYP#G^X=
MG`4RJ=W8A!`>DXBF7?;8`\!`=<?>;@Z:2I-*E;F&WT"@%2%#W-&5(2FUI_8)
MJ5;LXIBS4<23M=P4$=@(910=U!+L;[.^P#Z=:\LENI&VT`<Z5YH`,:E;2VC;
M'6:<AD3,R<@.?#T+R.\Z_,9N6<9*5QSCN7=P^-&3I9LLY:K*)+3O;,)#"0Q3
M`(-#;#]KTF]7AKZ`[D^']OM43-QW5HDW$@$-.(9^E>>=XN]$EZ]UGMYT60)J
M1@7]?1T+%%[Q\1'Q$1\1$1\1$1'Q$1'7J:XM-$31%\T1:!(`^CP_)^;1%M*$
M-T'\/Y!O7_-'1`NBU12)HB:(FB)HB:(FB)HB:(FB)HB_>6UU2Y)=<YF(=E(1
MD0]F(AE+S?QGW)$O)-BUE9K[N1*YD?N>-7<)O93[N;F!1Q\.13LIB!C])1WU
M:7`$-.950"02,@NQU<J)HBZ2R6>LTR#?V>Y66NT^LQ1"*2ECMDY%5JOQI%#=
M"9I":FG;&,9E4/X%%14O4/@&K'/:P5<5<UKG&C<UQZG<J=?81O9:'<*G>JV[
M,<C6Q4NRPEL@7*B6W<30F*^^D8Y51/<.HI5!$-_'1CVO&IN7G'M1S7,.EV!5
M1ZO5J:(FB*WLGEC',6AD0XVZ&E'V)E89GD2OUUXA8;55)>S1D=,5.NRU:BE'
M,NSLMQCIEDK$,5$B.)`KU`R)3%5*88W2,;45&H<.*O#'&F&!5H<*<M,9YRLL
MO4*\A*Q%@BCR296DD[KLDB[7AU5DI6-^,K<U,MV4VQ*V65["H@@\0;.5&+AX
M1F\%O:V5KC3R\O:KGQN8*G)2+E)Z!@S1I)R>@X,\S(HP\,2:F(Z)-,2[G?X:
M(B2R#EL,G*N=A[;9#N+'V^R4=2.<UOQ<2K`TNRX+D%DXP\DXAB24<>9:,V\D
M[AB/FAY=K&O%EV[21<QA5A?-X]VX;*II+G3*DHHF<I3"8I@!45T\52AI7@N;
MJY431$T1-$5*2M]H4#,LZW/7ND05CD2MS1U>F[?78B>D"NU#I-#,8:1DFTD[
M*Z53,1(4TC`H<H@7<0$-1ND8UVDUKU%7ACB*C)5:8IB&$IBB4Q1$#%,`@8HA
MX"`@/B`@.KP0149*U:=55%M)+MW`*"W<-W`(K*-EQ;KI+@@Y1$`6;+"D<_9<
MHB(`=,VQR"/B`:H#556[JJHMI=PW:I'<.W#=HW3Z>XX=+I-FZ?6<J9.XNN=-
M)/K4.!0W$-S"`!XB&J$T%2JK>$-O`?`0\!`?5JJHOFB)HBX:DE&HOV<2M(QZ
M,K(MWKN/BEGS5*3D&D:+<))VPCU%2O'C6.,\1!PHF0Q$!63ZQ+UEWMJ`:<2J
MT-*\%S-7*B:(FB)HB^@&_@'B(^``'KT14W5[C4;NRD9*EVFO6V.A[)8Z=+/Z
MU,,)MG&6ZG2SF`MU7D',<NX19V&KSK-9E(,U!*X9NDCI*E*<H@%H<UV1!HJD
M$9A=\DNW7%8J#ANN9LL+9R5!=)8S9R4A%#-G)4CG%NY*FH4PIGZ3@4P#ML(;
MUK546[JJ)HB:(FB)HB:(FB+!1_$MQZDCY*/,T$T2K&8IX1DQZ@*/:(SS_C(3
MKEZA#8R95/2'CX^&L2]'^CN/1]H678_ZRWS^PK\F;6A6^31$T1-$4X."O`?-
M_/7)X4O%\2#"FUY5D[R?E&8.DRJ&/H)=8I3+2$BZ.DV6FWB8&!DR`W6L<.HW
M2D4YRZW<]SAVR`RR>])3!M0*]))P:T<2<NM9%M;/N9-#,!S\LSR'%>WOC9A;
MAUP*QO%XTQNA+WB1CFRKJR+5-@R6=VJQ"V_WNR6:\2+9I][NTNDY4_AT5&S5
M/8J!"D#Q\5W?O1M\ETZYNY'W-U3!D8]Q@/!KG4%!S`-3BN[L-DO.R$<;6PPG
M-S_B=TD#'J!IA@%(9'G@PJ==5-3<#PGW.#EN`+6.XS3]^JIN=/[0QC-FF19<
M@;@1/JW,.XB(B&L*'O@X-$-G8MT$@`.>YQ)Y>Z`/,%F/[N1AY-Q=$.`J2&@`
M#GB2LBO'G([O(-,>9%R+BV&Q;5VS11<9-*U23S[8@`MFA&,@P3^->.`VZ4DC
M;EZMA$==WVD%G9?-;JR.&335P:XD-KDVI^)W``"N?!<MH=<7/86#GR,)HTEH
M!=3,T&31S/M5P*W>\:W232;T^VLRR:JXI)UN>:JP<FZ.4%#=N+6="+1\J9-,
MXE3(KUF#<.G6DMMRVC=7_P#X^8=I6FB1I8ZN.#2?=)SP!KT+-FLKVS;6YC]R
MGQ-.H#I(S`Z2**[*,*LD(I"BJ@LF<15;J]2+DH^(E`=Q,`@<GZ!@'U;>/AK,
M="6>[B'@Y'-8S7M/O?AYJ[<*QC6T2XE)9ZDRBHQ`[]VY63`@$21V`2B4`W.X
M4+L4H!XJ'V#81UT%E!"VU-S<N#8F#42>0^WES/!:NX?))-V,8JYQH!7RP]BC
MU9LB2=OG5'<4JXCF$<J/W.P3Z0.T:*$%,XKF*8047=D$3J[_`,K[(>`!KG;O
M=[B\N>WMR8V,-&`<!]YS=TK;064=M%V<H!+LSS/W#@MR.9.Y$"N5NE954W0H
MBY`B:FQBFW!,$Q(03`382]0?:ZO3XZL>Z2<]HXZG'G@<<\J*]K6,%&Y*I&K)
M!JV,FT3ZB=20&:J"(F!(-P4*V.(CVU$S;?9^UMMX>`ZM:UK64;Z/N^Y7$$FO
MK703<^UCE?L*`=8BH)N!4Z``2=/0``8=ME`3'QV^R?81]FL2XN&L((.-?+%2
M,8YPRQ"BY>,CM3K+QR#TJ:S=RXW4$"F*0%#="B8E.8`.F`[@&X@!=]<]>7S7
M#0#B*XK:6]N6C53WCP4&;[=4TUUXQ)P)E$W"IQ.139,J'2<Q>STCL4Q3*".W
MMUQM_=Z?<;BZOJ6]MH"?>.5/+U*$>;\Q5;$]0?W.]6=O&5^.:+++KOG($74.
M`&$J;8AC;J*J?H^'KUKK2UN[^[9;6C723O/N@"M?T<^"VM8+>%T\Y:R%F;B<
MJ_:<@O(MS>\P6]<FYQ_6ZV\>UW%;1PJBSC4E#HN9U),PE(Z?](@8J"H!U`3T
MFW\?#PU]']S>X=IW?C%Y>@2[J1F<0SH'2.:\O[P=YIMT<;>UK'8#AQ=3B>OD
ML;VO1%RB^Z(FB)HB:(FB+0I_=J?T#?\`-'1%3FJ*1-$31$T1-$31$T1-$31$
MT1-$7[R^NJ7)+QP^9/R1;6;G7G[EU5J9R5N-L\HZS\?*9Q=>XJP)F[(6&INQ
M4VT%RCYE,9?,JT:H3&,Z6O,8@MB5.=!,OVXL_N855>RD8J@Z:5W:2.E`)`/#
M5Y^&&%`<0MM"P-B$1+??K6M/-QQQQR-5E(\P7S`LO<5KYB"VX7ROBR^8=YV8
ME@H+$#7(3-JWA^']KDI2I,8#G#=)JK5]Q+V;B$O#9.CB6Q.<<$3868D0@S>)
M-Y1T1":2XDJ-+L"/,.?4/72F..$$4#'-.L'4TGS]'7G3J-<L;HSCSECE/D'R
M"XTU;FS>,)$X0<5^.=O5R=&8KP)+6+D7F;,D#E6;DLM9EB[=C^<K$9AB"'%Q
M&BE>JB%?*L[=OP&13!!L";M9'$ASJ$#H`K4CE]QSQ&0=G&UH<&:@XGG@``>?
M3T@#GQB#A&[57S*^8O$:R<Q\85"Y5R9\H/#_`#&XY\9KM'-9O#MGY&Y-O]BA
M^0M^A:5<#/:Y=+;0JXPKK&#-*(OE:_"3XNR@0RQG`6:@^5IEQ!:":Y"M>>5,
M/3A0E7Z'11.$=:ZR*\:"GZ:TY="Z]7DC7>/='Y\EX^<"X/RR^4N)LB^64AFV
M&@'6!K?5[U4.2/(Z&I4),!$8B"5Q,E+EQS+V-D[>`U))$!\D<ZG<;H&2OAEH
MQ[F4!!;D.FG,UXXI)$2]C7DN:0XXDURKR'0I^<J^8$W@#E'RHJ=VR=-XWP#B
M?RO67(Y&1JM#KEVNE0RG-Y_R=C%K=JI#S$6Z6M]C-%Q$:VBX2044AG3XB?>2
M`JBQQ&Z?4>][NGHSTD\N:L9;!S3@=0?3S5:.CFH35/E1SRPK>^3^-<N..1$7
M&-O*OY(\R\/O>6SGAK9LSUG*N$I.%@F<JQ0XFUJ-HL-59`MT:K.ZY8TI=5M(
M,2@BN9`SA$;1.[WNS)H!QIS`X8<>E7NMV4:2`"7TPJ,,<ZXY@\E=Q*_<Z8#$
M7!5G:^::]@R1YE=_P#0UK_$<>L-TVO\`%:#=<;LF<B<E.<,P2D98B6B_Y,CJ
M2A`QKBYK3[-C(K'?-V12@5D6X2S=E5QP<<ZY4U5X89=(\V"H8X3*6M:?=&69
M-:`<<:5X4KS5>\(\0SK7DCYP>*;UF+(N4IU#D!P_<M\OW&-Q[$Y)3D8SA]A>
MV4N6?M*%3*=0G<O2Y6/9&1.6&;IOB-"?%)J"=43W1L#IG"M<Z'S-Y4]BLE=2
M%A`IT>=WG4PN.W#*MX#M\G;F$K$D!XZEIDE8I\-88&LR%YL"4BPL&49YM:;K
M>GZETEH.578=ABX912#=4YA06<&*N3)9!I=4FHS\Z@DFUBE*8*!OG/X%KG)^
MZ^5I@6T24E!,,D<U<FQ$=:(58Z$Y2;<SX6<C)FA9`@5B'3,G/8_O$9'33$>H
M`^*8)[^&^L>[`+Q7*GL#RIK1Q;K(ID,\OB;GT*`E&\P/(=5SCYF'+&PT^*DN
M4W$SR>\)4O/.-%BJ%@H7E+@?D/RNK5Q!^@W78+EQ[.S2#2VLS%6;]^J2K90J
MR93]TN,)"UP</B#?L>?1]BRNP#F:#@PNKYB6#CQY]*F+6<K^9[C".R5?+?$<
MHYS$:'#+DSD6YY$Y11?E[QD5C_/5!Q?^_6';7QYB^*=WLLVYI-HD&DFV>UVQ
MM;`T;MDV*X2!Q!R"\KI9&XL<33.I;S`R!/3GCTJ(0PN-'@#'"FO'`G&HZLE4
MZ.5.<>!N)?&?GUF#ENKG&C2Z_$3)?*?$S#`.)<<4:F<><PU1K5\LV*D2,!&R
M60U7>-YK)L)<9!V^F%!4;UEZ"2;9FY.S3N$L[8Q*3[I/W@X4KTY\%:8X'2.A
M:WWJ8=>?/S9<?31>6N>'*Z8J3Z_X8>V68H/+GS(R\+^(J^,JS@^2N56P7A7'
MV14,HYBQG*9IFZ=BVT9!Y"98PY96]67MTDZA6D89DY9M72O0T=4[>5PU$D,+
MJ<,..>`PH<^!%:\:M@BKIP+PVO'HI4`$\1EC4$*>W`B8YI*2&>JMRIJ>:F-`
M@9S'TGQSN_)13C`GGRR0EAKTJ7)=7OC?B;9);&DG'4BVQ*)X:6.QB'[UE*"@
MNDJ=H*QLFW<XEV-8^&1/[)H%CSM8T-TT#SG2M.CXA7^18GN9V,(W+GFO<QJ6
MOY:U6\Q:;G?+?XEP59:7.7X_UBNX4F)W(?*"/;6B4N>9YR,M-.93;DZ0JR%.
M:R$RW+&]8)`<K<1PY6ETI#0">H'\3^9]@)P65`YK(`YSBT:CE7DWD,?/08YJ
M1G'?'_/R(S1C+R]E>=+B@1O%ORV^#UORC>H/#V/\P7;).8)[(^=J!;U8>[Y?
M82+AE4I6*QFS8/'#]@]DWC5H@LU/&N#NCKWETL=&-)]UM3U^]7GG3ETX%1_Z
M.ZLCA\4A`Z![O2.=<#T9+J8?E/RO4PC0_,9<Y]F'-5NW/J+XX.^#9Z!BXF*X
M[#%AYL/>%[2H1=G1J2>;O^(VO()$MKJ85L:C)9^DNQ&*(RZ>AVLF8=[VJG"M
M*TK2GGSIT*[LV:BW1[H;6N-*TU4K7+ASXU5F\3W/.O"[BSYPO,B`SOD;+`X0
MYL>8":"P1;:5@YKC&:R&ZR#3H>$R?;)NNX]J&0TS0#J73?/6*5EC815BU4ZD
MVY1,N6&.4L:YS<">%1TD<*X4IF,^"GDB:Y[8W4+0*5QX4'.E37D<A6M:*ZZ_
M(OS*^*E3Y`YSR-COD]D_"6->%/(;,UBDN7S7@C"I1G(C%M?B+1C%'$3?A;>Y
M&R'Q3D%J:83FXB5;R0Q+5DU7;2HF.MW,@2/;5S"2`TDUTG$=#3ZSD>.8..8H
MR6M<`"7`"FH8'^<.HX9\EU/F28(Y,POE=9[N.0_,`RIF-&[X[X[6">B76(^-
MT%46UQ?<@L(R[R:Q&^J^,8V7@<:K-))1%.)D7$ZX[1&BWWD!RN/BHY:F($N!
M->8P...7(4QJ<<^=T)9V]`S3Z<13(X]-<,^6.$P;PRY0N.5^&>`K+FQFF!2E
MN/\`G3E9?N2:.-.-*.><@A6<L8VQ=2L/U!A_DJ&&:Y5:@M>EI>:=H51>7>MP
M8MQ<(D564/5LKCI;JHRG,4R!&.FG&F1RPXJAC;0OT5>74I1U<R"::J\.>9-:
MX*)]+Y6<W.0<GP)PM4^1==Q!;\E9+\T?!^=<Y5["%"NZ>46O!>YI8\J.6,=T
MJUG7JE.L]P&+-(;%%[!-'[MT4S!V@FV12H9YBYL8.?\`E$9^:OJHKA;PM:Z1
MPPS`Y>Z#CZ:<%GJI,-/5RFU2OVJXO\B6>#KL/$V*_P`K#P=>E+O-Q[!!K)VR
M2@:RT85N%?S[M(SI9K'H(LD%%!(BF1,"E#9MU!HU8NHM<ZE3IP;58^N3E\R7
M!<\.*%*Q=$XYDK7:.&OF-VBJ&O5:KZI_\Q*,GQB#'T:ID)6-4NU+H\I.6+IG
MVL4_:-I-`B1W9%C-&PI8MR]S7-#:5IRZ6^?T>U9$#8W,<9*AM1['?;3-62\O
M#.6;YK,8X>Y8Y1YHU[DH]P"ID*X\;^56!^.--QM(SL%9:;!9$R=Q3R_QVK98
M2U8UIEFL*<2,2[GY5X5A,,'3A--8#*'LMI2^0M)KAS&>'(?:2I+F$1LU!H%7
M=.6-*U-?4`IAVK,&0XWS)>.?'EC,D3Q1D+AKRARW9JU]UQ:B\ID#&F9.,]4J
M4PC,J,SSC4L17<C2R1VJ#@C9;XH%%DSG32,21\Q9*6D@-H<_Z/WE0LCUQ$M!
M+]0&'4?N6-)QR.Y^92P/1[Y25L_6VAQG-OS%,6\B+/PVH7':R\K*UC#"?(+)
MF,^-<=CBB9I8?N)-4^/3KJ3.TO&$;(VE9-NU,D50SATJ./)/)F3^[J>0XN''
M#(#@3RXK*9!$7:0/WFEIIB1B`2<//QISI@J;DN;'(+,TYQ(P/QCR)R\S;6[K
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MVV18<M,CMGM@EXRKQ\/78Z2F%DC+.$8]JU:)JG,"*29`*0)+6OO8X\_Z3E%<
MTJV@H-(_LA02QK.YKXJ5CSVN9,#GC).0F''3ECRWOK/CO/4O#*.,;U;HCB=@
M2S5.=N-B@<:1N563>I?><>W.A%SC!LXBX5,ZZ:CA5TLMCLD<QCG--!4X8'\(
M/*M*"E:K(>UKW1QD#$`5Q_,1SI[5-[%=JY)8#Y;\4\&Y3Y16/EO5.8''C.F1
MYUW;\?XDISS%F2<%L<1V-2W8K6Q+3Z=V<'WUCDY>+)$S8S3I@[08*(R2AE7!
M5)&2O;*!74#G0C.H'(>O'+%1/C:Z-S@W06G#/$$$\2>7#/DJJ\P3EY:>$%RX
MT9JG9@@\:)P.1^-\R5(\9%J*RV3$<$V',?'!U'3IV1YR-E9RTXAEJHU:-W";
M>0>V9L11-14B`EEN99(R-)HWRZ.0])"LMXF2AS377P]GHJ<>@*'_`!)YA<U;
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M'#+&7:WC_F9D?#$%9XW)`8.@:_@?("T?'V63&..U8,WQ&;TB*ZXN$4W6K1</
M(<UIPYGK:.'#$Y*0VT?NO(S&0K3)Q&>/`+)G@6TYRQ=SNS)P]R7GFX\F:83B
MUC/E%5;OD:I8OK-^QI8[%ER_XFLV/)!?$5*Q_6I.D6U.KHS->3=QOWBQ%J^1
M^)<H@022P3.,H;6K2!RY$\`..'IKPICS1-$>L#2X.(ICCEP)-#SQ62'6P6&L
M/?\`$`0`V3R:N?S`J8*&9X?AK"4!*!ND*OD^@V%10`,8H`*:,:8V_I#;P`?1
MK#O21`0./W$_8LNR_P!8:>7\GVK\A/6B6^31$T13R\NO@U8^>V?T,8M9\E+Q
M[48<E]S'>C-U'3NNX^92\?&O&U;9%3,E*76Q.WY&<4U4,FF9<XJG-VT3ZP-S
MW&#:[-]Y<'W6C+B3P`'%36\$ES.V",5<[T"G/D%[;0I-(Q+B6+P9AZB%PIA6
MF$;EC:C"1;95V_!@<6,C;\BR"/PC^Y6UR*`KR4H[55,JY4$I``"@`?/'>7>M
MPWG5\R9(X-5=.8`!H2X"GP\3E7`957INRV%M8/;V08^6E*GB3D&G'/@,Z9JP
MTE+OC2[Z$CW9I9!=)RB,@CUD-*`V,1F@*:ZP)N"H'1,40(80#I``UQL>N340
M_4T/`KSPIGG3H73N:QK6$LTR4)H<FXURR\ZN=QNF>-R&=J7AW-N1)%C99^N3
MN0,?T2)KTN_5R$>D$.\L4.A+-FKEA&N(1OUG[;DZ(KC]I,3]LQ1[SNQ96L(N
M-XN@]_R89I:UNH:GU`=_1`PKQ(/!<UODT[VQ6,(##<%P<7&AHT@TZ=7&G`'F
MLDUKNV0\Z3Q:G5H9>I4>!*#&!BCQ[E*"8&,`IE*HJF9M][3"R?2)S$,80,.P
M@7T#J]RGW+O%>F`A[6`G2VAT@GF>+CA4Y\*#)+6.TVJW[3W2XYGB:<AP:.`R
MZ2I(5#CH6DQY7$I)/',@Y,V<O):9:D[1CH-@00*@W*L+:/20((E13()1#<3'
M$3B(CU%KW+DM8@;B4C$'$8`@4RK04QIZ2:U6FGWYDSOW3!Q&!QYYTQZ?5@I/
MX\G':"",19)-&>:)%4^$D#B@:0@DDP'9-^H<V[N-$H@)=S',D;T#MKJ;!KXF
M-AOI!,P9.PU,Z''BWK)HM/=%LKC);-,;N(QH>KD53V4[X6S.$J]7%#C7HTZ@
M@("*/WM(@;?[PZ`3%06R.XD2W`0#<3[>C6!O6Y?-O%I:U^48>K4[\W4.'I63
MM]GV#3--3MG>H<OO]"ZVLPB:[4H+G`''0<`42Z%DT55")'!LZZ2]8_$>``;Q
MZ3CN&P[ZP8(VN90FA]G0>M3RNJ2:>[Y8^95>V;+,DB%V*F8I#%.03]*B`@!5
M4'*?6(F4(.PD$@ATE-MMZ]3M:YO73R/4HR0<%3\E8$TDC#U=H[94%%')DP!)
M8C@Q@(HCN<#*`F4Q0.'B)#>O;T033MIAF,^7ES4D;"<!Q]*C-D*YMW$:]6;.
M2',603*4$@`J@"!3&-T]77N":91`=@$``-]@'7-7MTQT+BTXZEMK>W+'@.Y*
M#%HN[527E/BW`B*R2H)JMU@$B*SP"E2ZU``5`*<"?AZ_'7*R70)<79X\5NFQ
M'2`P>06//DKR(Q[QWI4WD+(E@%&*C`4:P[`%R!*3D@("=-DP0$"JN3G.'3OL
M(]/B.M?8;9N&^;C'MUBPOG?Z`.+G'@T<ULWW%K86;KR[=HB&?,G@UHXD\O2O
M'IS!YK9*Y:6Y5Y-N7$)1(]<X5NFMUS?"MT"G,*3J1Z!`KIZ<H[CON4GJW'QU
M],]TNYMAW7MZBDNY/'OR$?LMY-'K7E&^]X+G>9=/P63?A8/:[F3S4,==DN?3
M1$T1-$31$T1-$6A3^[4_H&_YHZ(J<U12)HB:(FB)HB:(FB)HB:(FB)HB_>9(
M<R9RG(.QB&*<H[`.QBB`@.P@(#L(>O74D`BAR*Y)6CQU@C$&)J':,88\H4-7
M*%=[)DFX7.M$4D95G:[1F&:E;#DZ;L+B<?2DA+O;I+S;I5X*ZQR]*O:3`B1"
M)EB$,8!%*U/VU]JE,LA(=4U&7HI[%:VD<'.)..X.?K55P334H"T8%JW%J=B9
MY6?NC1[QQI;&:C:WA0I+K-6$S+'C!K87G<CVXI)NU5NZY[RI$SDM^7CI0XX`
M=5.2J9Y3QIC7SX?<J2R)Y<W#'+,3CR#OF%_OACC'&3'"-8.RR3EZN2LAA:/%
M$6>'L@3]9O\`#S^6L7I'1`PP5J<S,>8QU!%(165ZQMXR,:Y4S\O1ET()Y6FH
M.9KEQ\N.:K_//#/B[R8J%(HF;,*U2U0.+5D%L5GBSS5`LN)UFD<VAD?\K;KC
MF5J5TQRF6(9(M#)0[]FBHV132.0Q$R%+<Z"-X`(P'+R]F*HR:1A):<3GY?>J
M&HOEU<)L<8LR_ABL<?*JI0.03)G'YS;6J:NM_M.6VT6DNC!C?<C7VSV7(U@<
MUH')SQ*RLKWHE8W=9F04`#A06\8:6TP/G]?WU53/*7!U<1YO5DM5-\N_AA1F
MF2VD7@R)G3YHQ@KA?,$KD>W9'RY8\HXN5>O7Y:=?+1E2Y7&PV2.:N)!7X91P
MY,Y:)B5-!1-,A"EI\M%B34U\OMXU5?F)L,:4/##V+10/+LX;8U<6U_5\,BZG
M+]A^U<?KK:;ID?+F3+I:L*74T>-@QE,7/(]^M=H=55<L6@1J@#LHQQ"B5H9`
M%%.M\O'CGB*8^5>"H9Y2`*Y&O+%7;R7QAP/E[#L#@+(>.V,WBFI)T<*;7FTQ
M9J[)T=[C))HACV<H]TK,W#7JG6FFI,4RL):-DFTDB4#!WQ!10#W&&,M#:8#^
M7RIYE:)9&N+P?>*VL"\6\!\86UV;8+QVUHALESL5:<B2'[P6^U3MZM,+!-JT
MQL]LL5WL-EGIRQFAFB:3AZNY.Y=F+W%SJ*B)QK'"R,EPS/E]G'%'RODH''`*
M_P!L.PCL.P;;CMX!OZ-Q]6^VI%&K=73$6.<DV;%%NNM18V2T8/NSW(V)99TO
M)).:5=Y*I3]$?6&,28/6K9V[<5&T2#$2.TW"`)N3&`@*`0Y8WQL<=3^'Z1]I
M5[7N:"!D13[50\9Q:X[0^5LVYO88?IB>4N25.KV/L]VEPQ</_P#-FF5:*6@H
M2OW2!D'3JKRC-O".#,UC?`E5>-=DG)U2%*`6]A%J+J8GR^U7=K)H#*^ZW)6;
MQUY;7"W%:\NXI.&7;9K)XZN&($8:>RKFN\56IXLR''EB+EC['=3N^1K%6,7U
M>PQ216JC:O-(P"-DR))"FF0I0M^6BP::Y<_LZ.B@Z%?\S+G7&O+S>?SJ3CG$
MF-'N(U<"/:;#O<-N,:_Y.N,>/2.'<`YQA^ZP4D:8X*X<*/5XHU5*#(1.L*XI
M^(J=?V]2]DSL^S_"HM;M?:5]^M5;B:XB\9[%QWKG$V:PS4'_`!UIT#4:Y3\7
M&))H15184%1JO1WE5F&LDA:J[9:D\9).8^99OT9AL[)WR.@6,8XVF",L#*8#
MT^7Z.05W;2!_:5]XKF8%XNX0XSM[>EAVK34.]R!(Q,K>;%;<C9.RQ<[8]@&3
MB-@!G+MEJXWBV.VL&P>+(LVWQA6S8BI^A,!.81JR)C"7-K4\\?TJCY'R4#N'
MF]BKN-Q%CB(RM<,ZQE28M,LWVD4O&EQO*:\D:2G:-CV4LLW2JVZ;*O5(A%I`
M2EODUDCHMTESF=F!10Y2D`E1&P/U_B_E^\JFMQ9H_"#7R]"Y#'&%`C<H63-+
M&L,6V4[?1:EC.RW0BS\9.7H=$G+39:C6G"!W9HQ-E!3MVE7*1TT"+F.].!U#
ME`A25T-UZ_Q?R_>534=.C\-:^7H4?VO`GB&RSC_Q&-<*Q"652WMYE9%W^\U\
M/16N79&/4BI#,3'#BEJ/AQAE]\Q64*K:$8$DX<ZAU1<]XYE!C^7CU:C7.O1Z
M/MSZ5)V\FC17"E.FG7GYLEW33A9QB993RCF-OBU`MPS=&V*,S#%JVV^N<79,
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M7)"!SP.5`S8Q@[3%M46C^*"?&+<MD$DSMQ*DF!;C!&:9X=)\O+DJ">0$D4QZ
M![**\=3XQ\?J%_D6%(Q-4JDEQFK5PI^!6M?;NXQCC*MY!BXV'N\;!,&SPC)Q
M^]+")0!ZN]3=.5EBF7%3OJ*J'"WB!!`Q"H9I#6I/O9J^FIU$K4WK!6(\HV:'
MMV0*##6ZRP>/LHXHB9&5&04,VQUFQK7F.5J@+-N]08.HN\-*I').^ZDHL4K4
MH)'3W/U121,DQ?P'W'[`I&2/C^`T\C]Y5K<!\)^,O&.>D;5AK'4A"VJ1JS6A
MA:+=DC*N6K)#4!C()RK7'U3G,O7B]2=+HB<H@DY-#Q*K)@JN@DHHD<R*0DHR
M%D9U-K6E,_+[NA5?*^04=2E:Y4]BJ#/7%#`/)IQ1I#,]&=6&;QHZGG%$M-=O
M&0\97.M(6QFTCK?"L+KBVV4NUFJ]P8,&Z4M$JO%(R1*W2^(04%),2U?$R0@N
MK4=/EY9JC)'QU#<CYU:F0\N#A8[H./L8QF%AHU-Q/8LCVK&C+%&3,PX?EJ3,
M9?FAL.4/N&U8OR#4K6VBKS,[+OXXST\><Q"`5`@)D`M@MHQ3/#S>RGJ\ZN[>
M6I-:DTS`.66:[^W<!>(%TQ[B/%\AA.'@JI@-*20PDOCNS7S%-TQ6E.IBG9DZ
M7DW&=JJ>28@EP$PJ3@!+&";<#WG_`,0M^TU7Y>.@'+S>S[*()Y`2ZN)\X]!P
M7`F?+UX>3N-<9XG=8@58U+#=BM-LQB^KN2LNU3(=0L=\5?+9!EF.8JS?HG+K
MIQD5227_`'A!U.+IS?7_`+X5;H)TT^7CH!C4<>/'CY_OJJ]O)4FN?H]&7!7S
MPC@;#W&VA)8MP30(3&6/$+#:+6WJ5>/)'BT+#=9IS8K3)H_>K^1=$5F9MXJX
M4*"G;*<X]!2AX:DCB;&*-\O*JC?(Z0ZGFI5`_P#!SQN#-ESY"DQMVLGY)BW<
M3DM9"XW]O0<EHOZ:&.WC_(V&D;43#EZL#BAD+#GDY2!=2(QZ::0K;)DZ;3!&
M233/T>CR]"N[:0,#*X#T^G-=7Q^X/<5^+=@E+5@S%"-1LDG5F=!1FY2YY$R!
M(5K'4=(!+,,94!?)-NMYL;8R9RA".$Z]`?=L0"J*1A;CV4>@R%D9JVM:4\ON
MRZ$?-)(*..%:^7WG%7<R]A/$V?:O%TK,U#@LBU2%N])R1%P5A3=*,65YQQ/M
M;12;$F5FZ:*F=P,ZS36(0YC(+`!DEDU$3G3-<^-DE-7#^7[%:Q[F&K33!:66
M$<2QV6\@YX8T*":YARM1JOC3(N042.RSMMHE+7F7-7KDF/Q0L@:1"T^ZZ5$D
M4G"A3D*JH<J*`)VM@B:[4`/*OWJIE>YH82:`^7L5`67AYQLM7'VF\6)O%,8.
M",=,*,SQQ28V;MT`[Q[_`):J-UL>2U#NT%8([(-1LE-4;$-'RS"50DT/M`"X
M@<X&=C&6!G`>G"GW#)5$L@>9`?>.?G42L]>5?@&X\;LL8%P54*[BE?.N6>+V
M1,R6:<L&2+5*Y,:<>\RX^OKX;A:I>S3UVEKA/TJIO(E*7,\!\9R[3677$4P4
M)$^V;I.FNHD>BH)]G&I4K+EX>"\^Z`</,0/:IE8+XMX%XTC=U<+T9S7I/)$M
M'2]\MEEN=]R=D*Y+P31:.K3:SY'RE:;I>I>)JT:X4;Q;!61,QC4E5`;))]U0
M3RQ1"/'$N(%5#)*Z3/(9#DK^ZF4:@'YK=.4O_EC>8)44$A6<2O#_`#TNU3*&
MYC.X3'\S86HE`-]S%<1)1#WAK'N6ZH3T`GU$?:I[=VF=I_6'M7XQ"9NI,AOU
MB%-\Y0'7/+HEKT1?!$``1$=@`-Q$?4`>D=$7M<\H;"##CUPWH;I%".B,J\B7
M[?-M^L#A5J=V-,2;*%Q+4S.4D%3M(R)C2_>!D%-S_>,LKN``4-O$^_N^ON]R
M&UVK@UENZKB3@2/N.'.J[KN[MHCM77TS23(*-'+^48]2D5>)V8G)%RL[D%EW
M@=H5^ZH<_;;*/5F_21$`,F1$JR@@)>D`W$1]^O(IIIKG]Z]Q<22,?4!T9^=>
MA6T4%N-``;A4=?$])R7=8MP]:<B6)F[;NG457F+QTE+2PMQ6%<%69#*,(U$5
M$T'$DT4`%5>I0C=LF(&5,&Y2FW6T;:^Y8XOJVU=AJICJ&/NC"IH<<:-&)*Q=
MSW"*V<-/O3C\/`C+WCC094XFE`,U7EWH6(@ME#D,75)B[R/C`UF-5<RRZAY:
MPP\[.Q_P,HC%."FCDWT4\%%,7*(=EJL5/H2*4!%8VWEW-MD#:[+K9&"PR$O)
M[4--0"0`"!S:!@2!AB=9':.NOW^ZEKGD'0P#X*C/,D=1)-:$\EVT)GGS"4)-
MFC*\D:C5V:"1TB-*CC-JO'.3)*$!0SF,M`R2;!43?:`A7"Y$_$I3&](["'O'
MO!E>^UN'L&)$5(Z"N(`!::TR'$K'=LNU/C#)(@ZAIK)=4BE*UU#/CPZ%-6G\
MW.05:C/@,BDKV3F`.5&\L68KC6NOG30QB@B>.&`55:H`8I1.4>V;<!W$-PV#
M.C[Y[F&AMVV*:!V#@YM#Z1DL9_=:Q>:VSGQR<*&H/F/KQ\ZFIB_+^*,K-6[6
MMO'F-[\N)P2K5IE47$/,G\0%"(F1,<I5OM;%15'[8!Z"ZV-M<[=N0_T%SK>\
M/X)#5CN@.X'H.?0M3<V-Y9'_`$AHD@'XFC$=)'VJ\H4-XFX5+*+(HN3J&%,B
MAD_B2G,&PJ=)"]E5L/1N4Z8B8OIV,`ZNELI8G:9:`GT]?*G5ZU`RX:15@PZ,
MOY?+!5&S9.(M$#@NB4P%*V54450.F[7,80*142I]H@"`@8##T>/CMU`(:`.C
M%213+@:GRZO2A<UQID<^/E[?0J&N-O3;]1#!VC-5#'4*<1$[=OW#D636Z#E$
MZ:#D1`Y1'Q(;?;UZP;N[`J,B/4*XCS'-3P0EV)QJHOV/)[)TE(@9R44$I%5)
M($UR`J4ZA`(8R>YB&!ND`@80$-S&-X:Y^:_UAV/NU\O,MM%;:"",Z*+\W>"-
MPG`F$UG2C=-ZN@@LN=%N#L4!30ZE6I0.D"@+CX?B\-<V^\`+Q)C@>HGS9+9-
M@)TEAP)'!8H>6'+_`!SQFHDA?KPN!5G(.&-0K;!0B<S9Y=$1.5%`BQC.3MR&
M#[:Q@Z4R>O4>Q[+?]X[YMC8-':'%SC72QOYG'V#BLZ\N;;9[0W5V3V=<!Q<>
M3>GGR7CJY/\`*G*'*N^.KA?Y-5.-077"LU)JNJ,+7&)SCT)-T1-TK/#$V[JY
M@ZSCZ-@\-?3/=KNOMW=FS["T&JY<!VDI'O//V-'!HP\Z\IWC>KO>9M<YTP-/
MN,'PM'VGF3BHTZZ1:=-$31$T1-$31$T1-$6A3^[4_H&_YHZ(J<U12)HB:(FB
M)HB:(FB)HB:(FB)HB_>7UU2Y)8'>4/FDY8X_YJR$:G2N(LZ8:Q3R$Q)A?(U!
MQSQAY93,[C]AD.[8ZQ]8V^1>:;"8=<7:5E^F2M]!\>NK1BR0)D0CW*S=ZX*8
M,!UP\$T(H'`9'HXY>G%9K+=CFBN#BTG,=/X:5.68J%6^>><G-6I_^)QD3%57
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M<3&6<*G,)CG'<3&$1'6=$?W+3^J/8L2;^,^GYC[5`#C]Y@?,:VXQX%<ILT5'
MC"VX]\U\QT7`KO'V+H[*R&7L9SN6Y.XUK%V2/WVMELD:E98M];JNW:3-=)"H
M*1K60^(0E78MSE4P/FY6M#CB,>7``_:.'G*S/E(W.,;2=0ICYSPIT<_T;$-Y
MC?,1GQNSYS9N^(.,J7'7#EVY/8FJ5%K-MRFKG7+&1<9<F;-QHPT]=OY!@?'>
M,JC9;HP8MIXBAIQZ1`ZT@W%`HIL"7FXF%7'X*D<,P33D>'2,CS"M%O"2&5/:
M$`\L"`>D&E>CB.174<QN3?.;#^&^9_'G+\[Q\CLX3'EG<HN6.`LX\=XG+]%A
MZFO@]E#UC,E'DX2R7VQ6YO=ZBGD"+?TVVL)9BDZ=F%1U&MQ:]M>AFG<QP&>B
MM<N%<,<\1]P.9D4.MKA6@D`(SS.'+D>?7R[[(G./E)Q<PYP]HN69G!5HSMRL
M0<+T?(U*P+RNRA2\<XDQIAFGW2\7')&(\;3F2,SY9R8\E["R9($C'D##J*2/
MQ3UTV(V.5Q1L\S&AIJ7$\JX5QR.0->FE*%5[&*1[B,&@#C3&G2./G%:X46_C
MWS(N2N2:ACS%L#BNCL.3>7.7URXPXRRGD+$O(S#'':WX\H6!U^2-JY-,,.Y9
M:U/.QX^(H[)S`?NI]Y@5Q;FQR)S/P`"L$@GF<T`#WRZ@PITY'APS\_%6&"(/
M))_=AM30UXTS'IRRX+K<TV7S/HCFSY?V-VV6.(L1:K=CKGPYFF\53^1(80R0
MQHK+`[RKVJ[XT1RQ'S+.Q1$-8A3CV(RTJ2(D#/ET7BZ3PB*%DSKD/:*D$URI
MS%./5Q.''-71"W+'FF``SZCT>CS*<WF1Y*?X:\OGE+E)>*)8I6B8:<3CJ(B[
M7?,>HRL@C(P3=XC'V['UDK61*NU4<.#F27C95J^33`"BL.Y^K(N'%D53B:GF
M.!Y%06[=<H`P\P/$<U&;./+_`)L(90\Q.O8!@N*L;1?+]H.-<CKN,OP^6[#<
MLPGL_'E?.\[C]`M-N%6@*(55O'+M6EB-]YBV.HF4\2OT'6/`^YE#WAN3:\N8
M'1S'/J4T5O$YC'/)J[]/0:Y='6N5)<HLBV#ECP?MX05,#$'(C@9R-Y#XNB6\
M[EF,R#2YVOXSX^WZQ062X^.O+;#.2HF7"_LD(MRO7/O6#!FY,U<I"]6$[MI"
MYKR/=.7]8#@?;[%5L#-+V`G4W/+\I/+#$<U76.^=E^N6'O)^R0^I5,:2?F/3
MN/HK)<>T-._`4!&X<1,J<BWBM`%>45<BJULE!;L$OO([T/@%U>H#+="A;W7#
MVQ->,R*_LD_8K&6[73.BJ:-=3]H-^U1?@/,PY=1'#_)_/_*V(N-3/CS3'V9,
M>T;'M$GLS36<\C91KW*:5XQXADI0R<%+5BE4BQ69LB69CV+:RSH)=3IEU**I
MQI+>VG#3)_F\1PSK3H/HJ.O$*_L(-8B!/:?9IKU>SB,,UUM?\V7+^-8OD;/Y
MNQ_'YHIV(^*UMY#P60,3<6.8O$JLLLD56W52DM.-UM-RU@7368D;U+7I@O!V
M.,>$4^#8R)GD2B**0G-N9!4O&`;Q%,>7&I^XFG.CK:.K0QPJ74S!PYX4Y>L8
M\KF47_B\8^:]Q:9\K+-@"3E97R].94Q%P7'JL9-JT#6I`N;>'@3E?L*^0[U<
MOWY5KZ[HB$=.((0QW28N#*,$.LA=(W2.F!?^7[6])X4Y=2H\1"W/9_G'L=T#
M[>M2LY<<@N0&.\Y<../7'F*PQ^\W*F7Y!QLO=,V,KU,0./HO"^+6.0TYV+KE
M#G*[(6J0<*.#HC&K/6*3H.D/C&O2)S23S2,E;&SC3UDCC]XZU9#"Q\;I'DT"
MA%=O-1RWC''08XOE1QHVY;,N<V1>#DW:ZGCO/N3<%-C8WPU&\CY+/L7AS%;2
M[9]GHV0PU8XH$ZBT>J*MK`[43<S",<V5>!'\U(65`QK^G+JIQ\_%2?+,+\#[
MFFO+C3,TXUX>;@NKC?-!Y5+8W;M(?"./[WEASSTXZ\1J/?KEC+D]Q-P7F^E<
M@ZG(V)OD*OU;-E8D,N8^G<?2T<YB9Q$J5H8`X9"HU,N#I--&QUU,,Q05/"F&
M'7SZ2KVVD;O>U<,J@FN/&M.'1FJIRSRTY&\;+UR3G\RU7"EHSO@3RB<N<LEE
M\56?/#3!T])T/.6124VGH8ZNER^"02=0\"T&5F_@TK$HN=9NB^*P!%N09I&.
MHZO:`&N/($C`'3E3@J-@C>WW#^[U`9"N)`S(KQ*JZW\GN5M4D(C$_)V.X]/*
MYS"X6\J,DXDD^/T=DV(G<27K$&(8&Y6"@7:1R!9)E#),-.4N^_%1]@8LJVJA
M(1JB"K#H724*?/(0&/XT_M`</T998U2.")Q)CK[N=?YI/13U]!5L>!/(CE;B
MK%_D_4#."7'^P80Y>\::9C^ECCV.R<3+V+Y_&?#A'.%9LU\NEKL;JL9+;W:F
MT.02EVS*!@SQ,HNB#=P_2*=4]\4LS=#"*U;T<JC'S'@.FJMFCB=VCVDZFN^V
MGV\SYE2.`?-YS5G:[<=;Q6<;1EDP?R/S35\?LL.UGBGS:;9<QAB/(-E>5>H9
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M\;;3DM@U;2,GCSCY-Y`8LI#O&92$C3<6N;,T:/\`L+(.3-'CN,*1;H434$AC
M=)BFV,&6YYCA+QG7_E46$QFN72>*QQ8'YJ\MW=N\OF:Y(0/&A+%/F&XCL]PK
ML)A6+RHVN^#+76>."?)AH6PVN\6B3ALG5ZR4V.DFKA)M"P;B)D`;D36?I=Q8
MV.RYEJT.R/.@Y\17D>`\ZR)((@QQ83J::>P='/F>*CYQR\W3-N?+UQEN4)C2
M,L>$N4&5ZO3&V(:IQ4YM1V5\-8KR,]?Q]$SC:>4UGIR/&&^,X@H1[^TL(]FP
MBV3!\J,=+OQ9@=U9\U-IU`$C$Y8988\O*IXR&TB'NEP#AQJ#UX9^OB,,Z5]5
M^=7F,73BUF?FE7\(\2WN(<.2')L&6,8J;S1/9VRI`<8^1%PH%IEH9%)2,I%.
MDY7%^.YM1C&'<3*[F<2;+]:;=<6"5YFN*&3_`#8KRX&G7T<59V,&H1ZCK-/6
M`>KV85Z%<K/GFIQN-0Y'9+Q=4(/+G'?C=Q*P-E^5MK%Q8`G+WGOF!;H=KQBQ
M-7W,(UER-*VZQU+,K#9%T(J5E4FE@C!9H*'/V5J&[>22T#33U^W/`=8-$9:@
MT#S1Q=ZAZJ]9&1"L[3?,TY8-2Y_BU\'(<J)VB\3LD<A<=/,*\2N;O&&(+E''
M,M78MQQVL[#DQ5I*1OCZT,;3]ZP4E7%22\@TA))`T.FX%KUU;<3D'`X-XBF/
M1G4FOW#F=;P@CW@`74S!PY\*##UCII+_`,O7EO8N5;;)SV5Y$\0\]L:>G3DC
ML^.N/\V89R1C2QSJ4PYEZMF?#^=;7:;C`-5$&B(PL@L6,7?&2=D59D,D`ZFM
MYG2DU.`IT<^%3ZZ=2CN(6Q:=-<:]/KH/57K5NN>_-C,.`<EEQ_@6ZX>FK?!X
M1>Y<F<(+\4>6W*K,$L5&4L;>*D[*[XVST37,"XIL2<$+-G.V!)VX7?).U$&Z
MR+4Y1MEF<UY:T\.1./F]I%.&=4BA8YFI]?BIF![<_,5T%.YQ\I>4>0>+./\`
MB_6^/.,$.1_EP47GC,6O/4;DC)*^/I"ZW.K5AK08:LX\M6/6]V:==F*D9RXD
MH@R`)F<@*^X--0_-2%PIE2O[(=T>HA3"UC:*R$UU4Y?B(Y'E7++I778O\P?D
M5R7I7"6CX4I>$\>\DN3-+Y,7_*EBR2WO5[PMB&J\/LJQ^"LHR50J5<L5&NF0
M9#(&59R/2KK)S-1@1\4NNX>K+J($27N;<2O`:T>]7'S4KRXD<?N-CK>.,N<X
MG0*4\]2.?+E]XNAY23J].<%\E`R9)P,M?&GF1>8''VE[4TIQM4%)=CR%L3=V
M6HL+*_E9V,K)52#\$U=.7"S9`2IF4.)>H;[75J?K^*O_`"G*VZT^[IRTC^RU
M92-9JQ$T1-$5O,OTU+(V(<MX\63!9*_8LR-2%$3!N54MLIDW`=H0]8*?>&VW
MOU%,TOC+1T>T*^-VAX=R7X:JK1PP678.TS(NV"ZS%TD8!`R3EFJ=LX3,`@`@
M)%DA#\6N;73+1HBVE_[E;_S2G_,'1!FO>_C\%&V.\+10"BV:53`^*68_=Q#N
M`$(_&].,L8`[A>ON#U&Z`V`!';T[FU\K=X;@3[W=S5HULSJ<<C3'KX^A>T;'
M`8=K@92I<P5K@,0<L%<^!KB-NO$3]\2J<!&3+HD=.S[AB7X:/9%,HX*Y3*&V
MRRB:@=)3@)0.8HB.W5K5V,++JY;#/(V*%[P7.(R`Q)X5)&72MC<2?+6SGQ-,
MDS&U8T'$G`4RRKB>A2GM$LQD&:%'H+)6N41@S"+,Y045"0FG`&`ZQG*@@FLW
M8KKD%4P"`"Z4-UK;@)2EZ*[W"&=HL[%G9[<QH`IB7#C7D"<3Q<<3R6CM+1['
M&[O#VEX\ZC7)N>7,@4`_+PYJEXNFMXQ4RI6HI*%.FH^Z$@,4ZW0`%,40*)$U
M@`0\0#I,(^K?6"&#6`?@X$9X8TZ5F.<S0=%=7"OE@J^4@(J7:H`9LD1XV2Z#
M`($%%1<P]L`6W#<JI4QZ3@(AX])M3R&'W7`4DI0_93J6-'VK:\6UP/ES7#>P
M7P[,$'3/K=M54@3=@.XMDS%[J(."`&ZA?$`W'[([B`>W5`_W33201[P^T<BL
MJ-Q#P032N'EZE1:\&LV6(Z(D4%!7!PW%!50BB"B9RG(JCT^!3I*%\``0\-A`
M=PU"UNH:"ZC\*<#U_I"GJPN)IP-3@1U+*'QSS<O:FT)CR_R1%+6W:E-4;.Z,
M`GE$D0,L:N3@',1163*4`.W4$0,8`,`B)A$3=OM6Z"\8-OO'?Z8S^&\YN`_`
M[F?RD9\>GD-QV\6Y==6P_P!&/Q-Y5_$.0YCA@J^OUU;Q)'QOARF.;N_$-FW[
M-HF=10&ZR2F_;*9P"@%,`F#I`P&]`#XX=_<-:#ACC4#`<CYU';0%],<LCF5#
M#(V96[[XD"/&R*4J@D@BV<+"5;J:(&(=R44$S'5,X<`(F`=]@'8!VWVY:\W%
MS\`:`TPKC0#-;BWL]`QX?;P45)B1F8P73R0$'*RB!7Z`=X`*LS^PH5)@83@!
ME""OL5'T@(#L`#Z-++*]C2YQX5&/#A3U8+8QM#R&CJ\_EQ4!^;7-S'G%+&3V
MQ75PD^N%C25)2*"FN8+'9'A>V*:ZB8'.>-B69R`+IPIX;?9#<P@&LW8.[^Y=
MY[[Y6T:1'4&20CW8VGB>9(R;F3T54=Y?6>T0?,SN!.(:T9O(X"O3F<@.97B_
MY#<B\F\FLA/\AY,F%'CI4RJ,'"-SG+"5>)%03(1,,T$>A)%,NW6H(=Q8P=1A
MU],[!W?V[NY8BRV]N)IK>?B>[FX^P9#(+R[<]UN]VN.WNG8#X6_A:.0'M.95
MBM;M:U-$31$T1-$31$T1-$31%H4_NU/Z!O\`FCHBIS5%(FB)HB:(FB)HB:(F
MB)HB:(FB+]Y<!$!`0\!#Q#\.NJ7)+&)?O*PQ7?S94K;C/W*&KX.R_G5KR9M/
M'"G7#',3BLN;_P#,:M98G;4VDGF+)/)Z\!:\@U=*5?5UU8%X('SA99%LD84@
M2Q#:,+JUXUX5].?KIG@LIMU(UH%!4-IQRZJT]7)7^M'"C$%MIG.JBRDA=TX7
MS"W=B>9U49S$4D_BE;-@FH<>)$,=+JP*Z4"0E$I+-5('J<F)9(RJHB9,Q42W
MBWC#2P5H13U`>P*QT[W2"0TU`U]9/VJW.3O+OHE^N%IM]2SMR/P,.4L-4[`^
M>8/"EJH<-&9TH>/(.:K5%=6UU;L<7.:JEWKM>L3V/+.U=U!R+B.6!LJH8B2`
MI1NM&$D@G'/+G7ESZNO*E[;N04K0T.&>&%.'1SK[5+_"V+ZS@K$N)<*TY646
MIN&L<4/%E47FW#=Y-+5C'E8BZE!*S#IFSCVCJ54BXA(SA1)N@F=83"5,A1`H
M9(:&L#!D!18[G%SB\YDU6*GR]_+/M>(,(<+T>4V7,S7BU<7FSBZT[C1.6G%4
MI@'$69U7-SCV%PA'6/J!"VZ_NZG7K6Y"`3GK).,89=ZHL@3XA-$Z&%%:ZFCM
M,!CRQJ,>%>C&N7#"F9+=G63%QXX\#UTZ<AF?/-^&X0X&C^+V3.'\O&V*WX4R
MY.9UL%SCK%.`G8%WW(+*5NS%<#Q-@@&<(YA%X*[W)=Q!.6Y2NXSX9J?NJ+)=
MTV2Z!AC+.!)/IK]Y_EQ6/VS^T$GXA3U4'V*WM1\O+'"*F6)+.F7L\\MK1EWC
M[8.*,M;\_P!BI`S-9XZ6U-P%MQO3VV*:!C*"CG-S>*I.YR?<,W4_+NV30[AV
M)6R:86"U:*DDXBG+V4K7R.5+G7#S0-``!KASK7C7IZ,3ABNG+Y=<6ZQSBFHS
M_*[E98LB<>;4E9.-O(Q>9PU"YNP?'DHC?&CRC0[ZLX:AJ)?Z+9:8@+2=8VZ"
MGAFS'[SE05DFZB-/E&%H!.1Y#[O;7,Y\+A=/#BX`8C'$_?[*9`#"M:CL/`V-
MNV/:]7LA<G^5-ZRW1<SI9_Q?R>FK=CEEF;$N2$:HO1!3QQ%P&+HC#T)CU_2Y
M%_&2%77J[N'E&TH\%VFLLL"I'RK=-*XUKD.753GPICB"J?,NU:J"FFE,<O37
MUKI[-Y?H6=GB&PN^8'+=//\`A2UY6LU.Y/J3>&)7*'W=FV#B*YDG'SJIS6&)
M#"2&-)2*KD;\%$M*LV"*<QZ+ENJ5?NG5&V!()<=0ZO92GJX!5%R0"T-:&GAC
M[:U]?$\U)?D+Q_IG)OC[DGC=DR3M`T?*U*"C6Z8@'\;&V]:.,K'KN)%E(.(E
M]$M9=TXCBJ'.+$Z/4<W2D4!`"S/B;(W0XFG\H^U0QR.C?K;2JI1WQ+Q@]F^8
ML^L]MP/N<-5K=/S&4DI'%;QT55L./<'1JE%3&&,>&>GIS\ZJIW9I`AGX`H!2
MI@*0QFVC)<<:N^\'ET*X3O:&@4HW+U_>HETGC5E1SS"XR+.\0_N'Q;X&<7,Y
M<:J#=;ED^EW>U<C6N5(+`=&J[]G3::DG)4Z)@J;AYPK,K3A8YRX?/$TFK44N
MI4L#8I'.$9!#&Y>D'/(Y?H4YF:V,N::ROSZ,"/MZ>M5'B/RP,;XDG^,3Q/D+
MRFOE'X6V]Y9N+&';S<\>+8SQ/&N,>WG%["H*-:WBZNVK($57*7?G3&+?6*5D
MIE@U0012=@F+@'$@LV9$FE".'$4^WC7K5OS;P=0#=1()SQH0>?,8THKV0O!C
M`4;Q(LO":6CK/;<&6U7)SF9:SUA.UMP/,IY7L^:I.3B;566M?>04U5L@V@[V
M!?,R(NXQ1FT4!0ZJ(J'E,##'V?#$^<U^_P`CBHNV?VHE_$*>H45'LN"#6PTW
M*&->0_*GE=RSQIE/#UBP9*8_S=:\81U;BZ79A9?'S;4F'L3XND9K*3<D<D5K
M:95P^E&@@<Z(D455.>,6C0".BF0^P#[\<PI#=/)!I0AU<SGYR5R<-<%HS%V;
MZAR*NO);D[R.RM0\-7;`=2E\Y67&CB'A\:7JP8^LDJT3KF-\6X[C7-H&1QI&
MBO-K`I)20]9GJBX@AV;H[=K':ZDFE.'V`<A^E6/G+V=F``VM<*]/,GF517,[
MBQF#D%R5X%WW&>1KMAROX%F>4DK?LL8UD<:%O50-DG"["GTEO%US*E2OM:ML
M98Y]N=J_;&AGG:0_:"9#8JH1SQ/?.US1@`/MY@Y5K[%)#,V.%S#F>O'+D1Y<
MUW!O+;PF3$%<QTPO><8C)%4SK.<I8?E9&W>(2Y+AR6M;.2A[?F&0M"U57H\H
M]MM5EUZ_(0"]?/5E:T*<66-(U11*G=\I'HT\:Y_HR^SHI0*GS<O::^BE/+'A
M6M:]*JAOP@C9N-HZ>9N1_)7D+8\?\E<7<I:];,HV/'+1>/O6((^0CZC5H:JX
M]QE2:+6L<JDDUEI!A'QK=Z^=J"LH\ZAU3Y1A^(GS4&=.0Z.2?-/I0`#"G$X8
M\STJAN=?"XF=,:\Q[SC9"5E^1F:/+LS)PHI%=D+!#P]&DF-K&WVVL)NE)%JU
M&+FGEXL((*R"\@FS29"`&3*)15U6:W:[5(*ZZ'^R0J0SF,AAIV>H$^D'[%R\
M2^7_``D"JQN.:\XY\Y#9%;<<IOCG4'N6YS&9V6#*!D:O0,?E.'QA&XRQIC^"
M<66TN(!BB\LDPA,2[EK&-D/B.QW2K49:M(J_/S<#7@.-.OI577+@?W=`*]..
M%.)//]"NW`\-<35V(X.0K"0NAVGE^,FS#!IG,M%*K2J#7`$[QO3_`,Q#%@DT
MYXXT"PKK&^#+&@,D!%=NT`H&F[!E0<?=%/41]JB[9_O9>\<?2#]BMIBG@''8
M-GZNRQ)RIY:43C_2\@K9'JW$R&NF.!PO"/'$^YM"]%8S[W%CO."6&3SKQ54M
M1"V?=:2!_@TP(Q`K8(?DVY5PKR%?32N733HI@I3=/(H0":4X^RM/5Z\54;O@
M+@Q]Q1OW#MP^R#_EC?\`(61,KK3S>QL&>0ZOD;(.?I7DVC:ZC8&L&E'1\A1<
MP22<A!E<,72*23)!%T1V3N]V5T#3&8ZFA-?77[5&)GB02BFH`>H4]BMA(^61
MCJZ)<BWV:>07)O.]TY2\6'O#[*5[R%9L8Q\DTQ$\F+--E)CZMT+%-/HM%FVS
MRVNS`=M&*-5E#=YP@LN8ZAHA9QXDDU/*@X$<!TG@."E^<D`H`*5KQ/$'B:YC
MVJ>-KH$'<<96;$\LK()UBUX[F\8R:[)=%&7)79^JNJ>]6:.E6Z[9*4+%.S&3
M4,B=,JVQA3$OV1R'1M<S0:Z:_;58[7N:_6,U8Z*X?8IB"\)R-GMP4+P)@WE>
MPH5S*12Q9:/?8&>\=5_\PR?<A23ZHT%^=7_=`CB_>.RHE%+=`8Q;Q@@XX#[_
M`+RKS,\APP]XU/I!^Q6LQ#P%C\#3E.CL3\J^6U/X^X]NRMYI/$QA=<<J89KQ
MU)5W-IT!O8G.+5\Y.,,LY-ZH9M4U;:>,;H`1H39DF1L6/Y-F5<.H>VE<NGS<
M%+\V_,@$TXUQXXBM,^CUXJ1O'K`%#XTXK;X=H1YJ5IZ%QRS=C%N+IC,/W4GF
MC*%SRW<F3Q1G&Q;->(_>6]OD6R(H;D8`FDH94Y3*'R!&T1]G^''UFO\`(L=S
MR]VLYX>H449</>6#Q)PMQ0RYPN@:U;+%@[-U@MM@OC2W6UT\N"I["2$95J-@
MKE#-H.6KS##\!4X2,IAFPE=0#.#8]M8ZJ(JGA%K&&%E3CZO++JIRJI77$CI!
M(?B"J6M<,KO&0]QA[;S[YWY("P8X=XTJDI.Y"Q'5YO%[1>4A95O>ZM(8VPI3
M/WARW'JP""*5@LA)M46BKE$Z1BNW/<HVU#:@',4R'V`?;[:W.N7.()`P=7,Y
M^<GU4588!XE16$\B9&S5:,QY@Y$9SRE4*)CBS9;S.ICAI.(8UQG(VF9I5$@Z
M]B3'N,:1&1,;.W64?N'(QJTD^=NQ,LY,F1)(E\<#8W:O1EAGR`YGAQ.:LEG=
M**'+SGES)/`<52.8^"]9RMEZZYDKV>>1.!IS+N+:OAG/$/A"S42$B<T4.BK6
M]6C-YY];\=W2S4NQ59"^R[5"8JS^$D5&3TR2BIA(DHG:^U8]Q=E7JZ^/3RIU
MJL=P^-NG,`UX\J>SG55+@?A/A_CM:\*W&A/[NYE,#</:APBI*-BF(M^Q<8=I
M-F@+7#R$\BR@HU5[>3R5;;E7>(J-VAT1.4K4IA`Q:BUC!K4Y4_9T\N2.N9'B
MAI\5?63[2K3)>6KBRMTO`L!B++^><'WGC;/9WDL7YJH$SCI_D=&O\E[W+9$S
M/CNT,;WC:WXYMM$M%CD6ZR+5Y!'7CUXI@X;K$<('55H;5F&DFH/1QZQ3U<`@
MN'U)(!#@,,>&'`U4BN+_`!EI/$['<_C>B6;(MS96G*^4LT6*T96LK2W7B;O>
M8;2YN5UD)6?9PT$F^(ZG7BBB74W[A"FV,<VP;210MB&&)/Z3]JLEE=*:F@I_
M)]BD7J91)HB:(M]J<J;ENH;]$BZ1S>\I5"B8/Q@&K'@N86C,@JH-#5?B=<]L
M7*X3YQ\Q,1JMA:%QUR<SC56:&PE`L7&Y'L18<Y0$"_85B3(G+ZMC>'AKG91I
MD<W@"5TL3M4;7<VCV*)NHU>MM4HF34*'I,0Y0_")1`-$7Z%6+7M,O?'+B9DN
MK`Y3:9`PGBN630<LB]T(Z-I\)6IULLJA^Q/(1D]`&2.([%.!AV]>WS%WKM8[
M/>98CA*Z1Q.!I2M01Z*^=>N[!/)-8-)-8FL`'7CAZ"<N2O\`P5,&5KZ`ID,F
M0KP#*I&3*`J"W%9)(5#"7K3_`.B/U>/B'LUH!$7QAP)I6HY+9ND[.0TIJI3R
M]BO#%5(21ZPCNHX:MP=E$$MC@79`RPD#8W44A"B/3L(F`=_?K<6L'O:7'`UQ
MX+7RRN)J,\!P54K55V=,ITCIE./0X<%5*50RQ#`*1E/4!TER@`ATCU%,)1]`
M#J8P%GNR5`'E6JM$@<?>XKXC"(M'G>[P(QI@^(65`ICB1<H]"J8]1B@([B&W
M5XB'AO\`9U9)&T4K@1Y55S7%U<EMN(M-RRG9$\G\&X*=1!E%.B*%6E6HI]2K
ME`Q"BD*"0EV$H_:$1\/?%$R-MN99'@/K0`X./Z.2O=)^_;&UM12I.8"I90\2
M4S9)H@=MNV*)U'9NH%5T_%00*)0*)#CXAOL?I#;65$896BGO$<#FK'F4'$X'
MDN&[:.&[AI)QQW+)VV>HNF3YLL4!3>-S$5;.DME"J$424VVWW``#6;#9O!$L
M3LL@YI!'4['S*-T\9!C<*-ICCGYE<W-&4Y24A8RWF6)\3:DT&E@;%[;9-A-P
MJ:2,@L)#]PBS6041!=("EW+U=([^`ZQ-\G>7_,/(U28$#"C@,2.@Y^U06,#6
MGL&CW65IQP.741DH'R=G!V=V8#JN7(*%<-'3@3&*5N8`*XV1$A035(J(%3Z0
M^R'B/L'BRXNFQ-30^8+?"(@#AP/25`;GYYC-6XJ5J'15%M<\O2=>394NC`\!
M,K(B`KF+9K41-,JD?`-WJH=)``JKXY!(F(%`QPZSNQW4O^]=QIKV=A'0/D(K
M0?E9P+SRR;F>`.KW7=+78X=3AKN)"2U@.?"KN(;T\<AT>/G,V:LE\@+_`#.3
M,KV9Y:+7-*F,==P8Q&4:T`PBWB85@!A0C(IF4>E-%,```\1$3"(C](;3M%AL
MEDVPVYFB!N9S<X\7./%QY^84"\LOKZYW&X-Q=.U/.0R#1R:.`'\JM9K9+#31
M$T1-$31$T1-$31$T1-$6A3^[4_H&_P":.B*G-44B:(FB)HB:(FB)HB:(FB)H
MB:(OWEM=4N26,V*\QI_+9#Y)1Y.+63H[C]P]RMF+&_)+E;-Y`Q9%8YI$?AS&
M$;E":M59H[B<_P`ULCF-&RB+=TPC(G=@HLD/Q#@QE$T<%MTYQJ![@SZ,*C*M
M.NGL*S'6P:!4^^ZE!S-:'A3UJT&#/-_H>:LF8ZQE+4"HT0G(2B9*M.")>C\J
ML`Y[OR3VA8YE\I*UG-N*\<O7[_"5TE,?PSN18D,YLD2F\9*1[QTBZ%-)6UEV
M7OTTSRH,?7AER5TEF6,UU&'EPQSPQI[2NSQ!YB.2+S4>&F/,+\>LA\G<N\A^
M`M-YDI6;(N6,087;-*PYEJ74GRN6IZ)J1()G;IJ6MR!^FJUI=FH\4%--DU:@
M99)\TX"C14Z:XCH!X4Y\`?0JNM`#5Q`!=04ZR./2.)]:B]R%YL\B>7#GRUZM
MQ;Q_G&D4KEDGRQGLLU['7(/'&`\W,;OQ8!6CVG#'^:TE7[@TAH.CWXCY^]DX
MCM!8TV+9%)1-$RR:D$\SY-+3@TC*E<<N'3A3,4Y%3001QZG.-7#IIAGQZ,>6
M-,PIC+^92K60E[M_P[WR<X6XSSTQXF7;F&_RE2E9Q+)$1D6+P%8\@?Y,&C4[
M19\/5S-[PM?F;.21;/SNDW+]"(58)]\<@7#F.TT_=AU*X\Z9Y>;/KS6-\M5M
M:CM"*T]?7ET4Z>"JUCYB<G)92Y)UUKQ9R:WP1P[RODG'/);E9,Y!Q7"8SH41
MC/$%?S%-V^OT][.%RED11K"V%%%]&Q<48S#K2/\`$K&4,BE5MTYQJUON#/JH
M"*FN'73V(ZV:RC7N_>'(=-2.5.&&*X+#S#[O5,)7#E5R/XAW7CWQ8B,&N,]5
M7)+[,F+KY>I.$>K5T*'0[[B2*-"/<;9-R:TM+,\8T)*S,6S7$[>3D&*I-A,N
MG$%[P!'3#A7HS]E?,J.MAJ#&.K(32GV]773HJMKBCYF-9Y%Y\+QOM%)QQ1<C
M3^*;'F:@#B?E;A;E?7YBJTJ=J\#=ZW=Y;$2B`XWR35UKK%KF8+)OXF1;*KG8
M2CH6BQ0K!==H_2^GK'MZQ]Z3VIB;K!J*_P`GEGT!</E7REY9XHY[\4,$8)P:
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M+T9_-&0F]!>M9)9`?N*&*J^;,229WIED6\LMV6.T@4ISQ/JP^SIX*.&T,K-=
M<#EY?=4]"R)Q.:Z99^/\?R2IZKJP8[G\)H9YJZ@HC&/YNER-`#(L,4Z#DJAH
MV0D8-5,IB*`;L*G$#;]([Y)E'9=K3`T]9I^GJ6,(SVG9G,'V9J#&`O,<MN6K
M1PZ+D3B9;L$XNYZ4=Y9^-^1IO,./+Y+/9V/PTIGD:QDNA5%F"M`;V#&T=(OH
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M6MM9'-_6KZN?K&7-4#Q2\S*L\B\^)\;[12<<47(UAQ39,RT`<3\K<*\KH"7J
MU)G*O!7>M7B4Q$HB.-LDUA6ZQ:XL%DW\3(ME5S,)1T+18H4ANNT=I?2O4>KC
MUC+TJL]J8FZQB*_R?;R/0%=KE#S)LN`\QX0P#CCC+DKDSEC/V/LX7VEUZ@W+
M&]$CHEM@UWC%M.#=;1D^;K]?KD`_+DU`?O'OKJHJH%1(T<*."`62:9T;@UHJ
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MDLOY`8\;+C9^&_'?.`\>\Y\J&V2*9%O:O>(FRP%(R)9ZI@UVS5M5ZQ1A^[65
M",LDR238O$U6KY5C'OD&9U#T==D/I0:`:<>GCEPZ\\"KFVNI@-??(J!Z/OZN
MD+J\S^9E<\7R?-.4J_#FZY*Q%Y?EN2AN2>54<SXWJ!RUEMAW'><+/.XHH4JR
M?V._6"H4;(`.744[/"-ER-.EM(+.%OATCKI]:M'NYY'*@///'C15;:@T!<`X
M](SJ1[1PJJMO'F'S1^3-MXQ<>N/\?GFW8VIF(KY>TIWD;BS`UMEX'-$0O9JN
M.$\>9`9O)?+9XZL-_B)%TJX@HM!X8&";M5T18B1UV[7IC&6>!/&AZ*==/;0V
MT.C7(:?R5'D*GHR5H,5<ZN4[?+WF?!D_CRC8./G#K-.56L)D",RYC.*E*90,
M:<2,;9OB*8-*9UQ.S7*2R)(2IY$DDNX5/$?O$5HN)RQARC:VYE#G:L8QQH>0
MI]GI5QMXC&PM/[QP'$<S7#/^17.H7F.V^R5OCG?[[PRRYA7''*_+G''$^#;#
M?,EX@E)^RJ\@Z-=[P6U3-&HT[9YFFQ-.94Y(!;2BC9])H2:"I4VQTUT"7"[=
MIUD>Z<NG#'&OERSI8;8!QC!]\`U](IPZ?M5>98\Q#'N(;%RSJLQCN\V*Q<89
MWBA1H6OU9U!NI[.V4>9+=)KAS'5":2;F*CX24>VIZUC7+N3=ILFY%3NU#D11
M.`WNNJ.<VF(R\QISYGRS5K;5SF-?44.?1@3[`5&'E)S6\P3%R/%1NPX5,L=6
M_(_.;$N%;!6DN2.'<A57*^.[KC#*EI6JE;OCNGQCVI33N?J::$@Z<1#!:,48
MD^&<.V[SK+!+<3M:#\))Y'*F>/+J]BFAMX'/+2=5!S`QKZ//4CGP5U;%S[)A
MFX<KIO.E3RC7Y'!'&;AIDB8X^P$OC&_QC#)/)&_YDQQ4,;8IMD)"5J4MF0LA
M7NNQD.\=RTJ:OE,=DJT39$*^46F%P6M+G5+J#A2A)/GX4QZ.=5%V`<0&TH7'
M&O`4\V1KATK5;/,HG\*5/E$/*'BY8\,9<XU\5IOF4SQ?7LNTS+D-E_"=?>R4
M#.GI>2H.$@&,7=JG<(].*FHN0C$TVBT@S7;.'K5<%2VMO#I.H>]2HP/*O']'
M#/-7?*5<-)JRM#Z:?;PKD5=K$',F_6WD36..V;.,%CX\SV5L*7//F#9=]EFA
MY3+<Z7C>PT.OWZ`O$?26J3?&V0J]_F="/`8HO9Z.=-72@)R`K('3&2.=SI-#
MQ0<,".('3S&6'2HY(`QFMK@<17SC]!SH>A7@R[R:JF$\S<?,57F'?1\#R!C\
M['C\HJ2#-"KTV=P5CE/+4C7K&S63!VHM9\>QL[(-%TU"D2+`N"G*/640OEG[
M-X;G4?R8^FO0%9'$9&.<"*CR^X#I*B5QY\TG'/)RN\7'-'Q9D.O6?E!:^353
M<TVU.8Z.LV$H[C92G]RGKI?6GPW6NPLD5+U)6,;H%25$EQCU#&Z0-U0LNP\M
M:<"3CAU@<>=.>?HF=:.8'.S`&'J)]5?05';RZO,$SO*<>/+%;\GL%W=6O\O*
MG2\55CE98<OT>V6?(&<U\6V[)+.7OF*H9!:?KM/R7$X_E_NR8/+.)#XA-$KZ
M-8]X#%BBN'L8-7P4SIE[M<#EPJ/712S6S7R.[,C77*OZU.L9C/K!*[S'W+B[
MY#S/Y<KF.R9D=''^1.3/FV8[RJTO"]-CS6>(XR,<RP-586%O0:]6Z^[J5`G*
M2"T"91L,@1@W;J/EW+X7#A4^9W;-H32O1^9P]=*>U#`!`Z@&K#*O)I^TKL</
M>=1AS+V3<$PK&FTN/P]R>R6SQ1A&_P`7RCP==LQN;%96TNXQQ.Y3XK5E^XR)
MBVE9+-#"FQ<'?R4E%J/699AA'&64!"YM[5^(&CS^W+RX*QUDYL9=7WAY'R.'
M25FDUL5@IHB:(FB)HB:(OR>/XF/$!\2><KRG63;_``\7EMMB_-<1LF!"+%O&
M.:\A/+$V`.L#V^$DNHWI%0#:YVX:&S$-R'V8>T+H;1Q=;M)S\C]JP+:@60FB
M+VR>0GF.L<@N%!<$2[P"Y#XCWR3049F6ZWKW#669-Y/UR?9)``KBA7+J+Z/6
M$H"FEW6P'$.X77C'B%L[3N+;UU0V0`AW`$"A!\]#_27>]V+ZEL8&_&TY5\X]
M(KZ%G^I='"*(*3D!,14JB2@'1!,/ABB8B;HB1@`B:Y2])B@.P=`_BUQ45O1E
M'8&GJ_DR6^DEUN-,<?+UYJME8I*..L/3WG`H&ZA'MHB9FH00!TW*`"!SE'<0
M``$0*)@V$`V&]L>@Z<CY8JA?J'1Y8*ENIHP*1,ZB::/?(*+A538J9G/6)2"0
M#`!3%4\`']$W4.WCMK.;'\R--!VO$<_O\R@)+?>S!]*[MM#1BL8[D#-D7KLJ
MBJ*S$RP)-$E3G(0KU1D<.ZLIT[&3VV3,(;[>G:?Y(MC$KAJ;R)J&^7!1=N=1
M:TX\^)\N*M99TVG?:%(;8C9,$W#DY%`5,H!@(BFZ()^@H$*7T;["(^GV5=M[
M7N#8=+FD5H17'SY*2&X<&N[0T(X\^:ZDSTZO<2!NDHB).Z'25!UL4VQ1(4H@
M5=$">`@7<?1J7_#@UGOQ`$?JD'TBH(4;KAI?0.SZ1[/:J*?).5WA3II(;$$2
M@BW.=,1`?`0!$!`>L?67U[:SH+1C1E(T<J:A_(H9)L<*$]=#_*K29ND9:,AJ
MG#.3F9@L^G7IF(D,#@I&YHHQ12*KT&(FN8=S](_;'I#?PUQG>J2EVV*ONZ<J
M`4RY=?E1;G96B1KI,SSKAC584_,"\Q"#XILG]$IJ<;9<^3<,!(N"==3J'QXP
MDFJA&EMM)6ZQ.J90Z@781ISB*RI2JKE[/V3YO<CN;<=XYS>W@+-H8ZA.1D(_
M"W_E.R'25#O^^0[1;B"$A]^\5`S#1^8_8./4O*%=+O;\CVB7NM]LDO;;9/.3
M.Y>?G'BKZ0>K#X%`RJHB"2")?LI)$`J21``I"@`;:^C;.SM=OMVVEE&V*V8,
M&M%`/O)XDXGBO*KBYGNYC/<O<^9V9/E@.0&`5+ZR5"FB)HB:(FB)HB:(FB)H
MB:(FB+0I_=J?T#?\T=$5.:HI$T1-$31$T1-$31$T1-$31$T1?O+:ZI<DH2TO
MA-48W'/.S$N0K&O>:%SKS3GW)5SCH^./67]9J>?L9T[&,]2&<@,A+_'2,5&5
MA5=&4`B`"JY+_NQ>UN?%CM]#',)J'"F7\N:R'SETC9`*%OWU5F^/7"KD3B)S
M4*K<<P<2[3C*@8_LN/F5EHO"IEC?DADMD_H\E2*K*Y,R8EE29JD++P:+Q)[*
MJUN"8A/.D!+TLD%E$1C9;R-<,:4XXX_M?8/L4C[ECP10X]6%.7NU]?I54<3>
M`IN+]SXJVTV4T[K_`,,_EWUG@89@2GJ0(W(]=O6/KI_F@1R:Q2P02;L*+\-]
MT"1T8@NNOXLW;Z3U;:4-=7X:9?JAO/HJJ2W7:`#32CJY])/VKHL#>76IA&Q<
M,[`&74[$;B/:>?5F^')2E(L;V/."^S5W3:$5-9GX5P<:#+_#&.)7OWMV^L"M
M>KH"ORM2"3@.C]8GGTT5#<U#A3X@./(45OYWRULERL?=N/#3D-3V7`?)')UY
MRDMF'E</23K/:,A.9I8\CKC@RO9H+D9"G,L-V[-S,\DJY7JB]A:13QQ&).1*
M9-TG:;9Y.FON5KZZ\^DY#C2O*HN&BCJ?O0VG1E2N7+IZ5*&E<+ZM%5'GICV^
MV)6[T;GCF;,F2+C$,HTU<>5>IYHPMC_"]@H[:0-(2OWD^:Q5+6=)28)MPZWA
M2_#AV>I26.W#(C%4T/W`=.=%9)<&242THX>VI/VJ/:O`SD;E3CE;N''*;E1C
MO)/'=U@IKA>H2N-N/CS'^=7LS57]1>XJS'DFW67*5^HDC<\='I;1=2,AX".A
MIU^8ZSE--'I:A$+>0L[-QP&76>.9Z<QQK2F"O^88).U8TZJ]%.K+[?/7%7KX
MT<=^1>+[X%DS#?N'T]`QM)?U5HTXY<.38$N5RGGCV'5)>[]<Y/*V0!9'39QJ
MY3P,(U:1JSEZ94RHE111+?#"YCZG++CCTXN/V*V:9LC=(!&->'HP:%SN3'&G
M+^0\W<>.2W'K*F.,;Y?P)5LW8V&/S'C2RY0QM<\;Y\)CMQ:VCJ,IN0L:6>%M
M=?G,6Q+R->(OU6ZA.^W71$JI5"731/<YKV9C[P>8Y#RRMBD8UKF/!+3YLJ]!
MYJU5X\NY:Z\9/,3X[*9<08+\^<S93R\>WDI*JZ.+U<FUO%<`I!?<(VA-2V%B
M%,:&6!<';#O%>@3H**0F4C^4&@M!-">701SZ5?\`,_O!(1B!3UU7494X"Y,)
MR!S?GGCE?>,$.MR8+2Y;+-2Y5<53<B&E;R11J1$8U891Q%.P62\9S$0ZF:16
MXMO)U^5,_BG#R.3=(J-C+.2*I+=Q>7-R/J]!;EAS/VW1W(:P,</AY4]!J"I]
MR./7TOA*3Q+)V!FO*3&(I'&4E;&%980$>M)2M'7J+ZSLJ9$N$XR$9*NW)WB4
M4U6*W;)B#=-0"%*;4YC+HNS)QP]1JL<24D[0#B<.M1-J_!C]W:QY7U;5R0C(
MI^7#&,XQPL>IJ(IYD2;<2+;Q:4$J'[P*C22.`M(S(E,>4V*B+7<1/WRV=@06
MD'%K0,N0(KZ^E2=MB\T^,_:#]BLOQP\O'+O%N1QCCG&V4N*[WC5B.^-IVG+V
M_APRFN7#7&;*QKV"-PRXS>ADUA2EPAVZP1;2WC6/OTD:DF8Z1WI1=F@%J\'2
M#0<\</VA[/O4KKIKP=33J(H<J=?PD^O[E,#BUQ@B^.^"K#@JPSC+*$%:<K<G
M<A3JKR`^YX^3A.2N;\E9=E*8^B%I*9*Y:PT=D52'66%7I?%0,MVD04[1,EL(
M$98>->'23ZJK'=*7/$@P(`'H%/6H0X6\G['^/^&/)OA]D?,UTRP')!6)KQLQ
M.H6,B[UC[%.(82LU+B/CV%:R#FP1<TCQKK%*C`;*O0,WFGX.UW*!0=JDU`+,
M!A%:NX</+T9X]"G==N=(V0"E.'/GZ?9@I-<:.._(O%]\"R9BOW#V>@8VDOZL
MT:<<^'!L"7.YSSQY#JDO=_N<GE?(`L3I,XU<IX&$:-(U9R],J942(HHEOAA<
MQU3U<<>G%Q^Q633MD;I`.)KP]&#0KKW3CP-NY;<>^4?[VE8%P3ASD?B<:2,*
M9R>SCR`E<+299TL^$FB6)+5?\H1(+<6C@7GQX""B/9V4E?%K>'5R^]I^Q1-D
MTQN93,CU5^]0XO/E\Y5A<R\@LE<;LC<5X"!Y0W1ME*_P7)WB$ER&L>-,LK4^
MN4:S7G#-JC,GXX.K%VR*J,>]7KMA1?L&LPDJX06*DY5;:QG6I#O<^$]>'[0^
MW[%DLNAI`>"2.K'KJ"J[DN(G)K'68\Q9,XH\E<4XTB.3!L7SF<:]EOCQ(Y07
MA,G8TQW7<2*Y9PC^ZN5L:P=?D[CCNHQ35Y`SC.6AFSR.1<M]B&6;J7=A*UY+
M'9^7,<@*XDTKSK9VT;F!KV_#E0^VH/$D\!ZE:[(7EK9,MK7/.!8'D54Z]P9Y
M0Y]E>0>9<4/L024MGAE(7>Y0.1<RXIQKF%#(L;3(7&F8;S!J/'2\C59"9AV\
MJ_;-%C@=NJVM=:N+R*^X34^5>D\./52YMT&M%1^\#:`^0KA0<?MK>*\<"SW/
M%_FEXX_S12CA\RF3N<BG+_N@HY+AP+=Q:QQQK!%1C^\2(W@&`T#[XW*K%]PK
MKX78HI]\\HMZ,<VN8I^R!SZ*J/M_?8^@]TY<,R?-G161YA>6CD'EVHPI%JR%
MQ8-B9E5\85NJW:T<1CV+F-Q^5HK.ODGYSC9R(8Y7A4*A/VB8@SR,>\?1#A2O
MO'9Q*#U,A$M1/MGEW`@UQIEQYX=8%?-@I67+6#`.KUX'KPQZB:4]*N?8>$&8
MAOW.=G1\W8WB^/O/N)N,KDZGV[$UGL.7Z'E"T<7H?C/]^4'(D5DV`JKVFJM:
MA"3+J/DX%9[WD';=%T0KDBR%QMWEQ;7]V>0ZJ<>@??RL$[:-+@3(WC7/$G'#
M/'-5EE_A;9+MQBXJX>H.58:HY8X;VOC1DG$F2;/1GEJHTU?N.%4"EHI7S'\=
M:J],NZ9?:X_DFSINQFFSY@+PBR+@ZB``>K[:L36`U+:^>IKS\V85&W&F4R4P
M=Y=73DK"2/EFY+R(ERSM^9>3<`^SCR/R!P]S-0[]BS"1J=5>/>6>%:B$MBA[
M`TJT9&NSS(=1+8H]N+YK*RB#U^P.Y1.X3,LD=O9\H\DO)]\_>#SYC[E)\V`U
MK`W]V,^D4(Y#@?M5Q,H<3N9&=:34I#*W)GCXGG##')/#O)3C\\H'&RZP>$ZO
M/8HB[9!2M<R-5IW.M@R/?(W)L1>)`CM9K8(H\*<K<61#BFH*U7P2R-JXXCAY
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M$]QN&;Y4<<N2_P"^!6Q<`\?<]8+&FC!F5-:1S;+8,E`LQ9W[T3+#EK?^3`D%
MH+5P+K[Q`>ZEV-E<@PU>'5RK[0?L6*)*1F.F9!]%?O5N/,&X21W//"E9Q(XR
M+*XFDZOEJH9%C[W!Q0R\NC`(1MCHF5J4T1+*0ZC5/*N&+Y8JTJZ!809EDP<"
MDN"7:,GA[8#&E/+V5]*NAE[%Q=2M1_)ZZ'S+J*#P$J&.N=6:>9D!;E6\/E'"
M47C&M831@2(5S&ER>QV/JODS)L%*DDA35=Y'H>$:)%N&9&3<40KYU#+J_$]"
M=C+8MDUEU?,/(9#T=*O=/JB$=*4.=?+F?2J9H'E[GH_'[RRL%CE=.2'RZLDX
MMR"I9@IJC0N7`QMB#*V*ABDHD;(X-2AF!R=\<"QG$GV`9"ET'[O<)0VU8A%7
MU?JZ>?G5S;G3.Z;3F<J](/V+I<6>6VTQ[-\8)&4RDWM4;QWSGYAF89.&/2UH
MQ._QW/66RI(.:>+DMG='@`QVVR:9!1WTNOO4&HF*DT[@`G0VE7AU<C7+]8GG
MTJINR6%@%"1G7H:/L]:ISC%Y?69N+KK#N-:GE?BO-<<<&R[%"GR4OPU8?\7L
MMC"`!RE4L763-[;)J%(!_7X\6K$]O:5=*:?-&93G1([45<C:VV>UU`:`9''_
M`"J?LT]JK)<M>TU!U$=%.OX:^O[EEBUGK"31$T1-$31$T1?GO?QG^$!A>1/#
M#D>T8F!MD?#5YP[-R"9/V9IC$]Q2M4.DY.`>*ZT+E%0J>_\`(;"'JUI;]I$@
M=A0^7M)6XVYP,;F<0:^G^1>+#6`MBFB*87!+F;D;@=R0IN?\>IEEVT=WJ[D6
MBNG`MXC)F,YM1$EKI,JH!%/AQ>H(D78N@*8["2;H."`(I[#KMUVV#=;-UK,!
M7-I/!W`_8>A95G=26DPE833CU+]-C".9<5<C\&X[SOB&:_>#'64:TRL%9>&4
M:C+19U6Y1DZG9&S511.*MM6?`9K(-#"`D63Z@#MJ)&-XS?;?):3NMYFTD96H
MSP^X^Q=Y;7#9V"6,^X5IM#]1$R(%W[^Z@%3*.W>2(!1[+?<"G(NMM]D``1`2
M`(^O6I[,EV(JRF?+S_?P6=J:T$DT)5(/T6KQNU6E&A?ATE4S?LS.4"KG`Q3J
M-W0)E(<Z/64#&VW`1#<`\=9,%N\8Q>=IR/2#ZZJ%\V-"<3QY8+HF\NZCI%8K
MAX*:QA,LV**Q313YNJ/4B*;C]LDD.QQZ0ZR@8-MRB.MU:N,Q,3XP7CI(?Z./
MK6%/I8!(QU&^KSG@J,F)8X.%EE`42!Z[.)R'("GPRYR&Z2HJ"4I%4U"AN&YA
MV`1]7CJYEBQV`HXCD:.\XS\]%5\Y%.`ZJCTKH%)QMN/V0#I4*194C94_V@)N
M8WH,GUCZ?T@`/4.MHQO9``OIT%P.'+GZE@/)<XT%3SH<U2;A\N[>$38E!8SA
MT4B)BDV<*KKF(1$J:0$-VC#Z-Q/X:QKB^B@:=3G&3D*T^\UZED1V[GZ30!E*
MU.)/V!8+?-E\U&,X^VJ3XZX-D8R[Y@IR!X:U6!X0DM5<86&01([L`I*"`!/W
M)!=1-`C3N&9QXH;K@9011UA[7W-N.\=W\]NKG,VEKB0!0.D<<"&\6L``:3QH
M=.=5)=;[%M4!@M6@WSO0QO`GF[&H'"N.&"\C5@L$Y:YR7L]GEY"?L4_(.96;
MFY9TH]DI22>*&6<O'KI83*++*J&](^`!L`````:]DM[>"T@9;6S&LMV-`:T8
M``<`N$FFEN)733.+I7&I)S)74:E4::(FB)HB:(FB)HB:(FB)HB:(FB+0I_=J
M?T#?\T=$5.:HI$T1-$31$T1-$31$T1-$31$T1?O+:ZI<DL==Q\T7B_1[7DNO
MS,7GY>M8/S)_D1GG,L3@*_R.",(7\YZLDV+D?*9&1(-E755;I&]^18!((1:3
M@%Y'X-OLJ.&;M@(I\-?L!Y=//#BLL6DA:3QI6GD>C#GP5P)'G[Q\9<D+1Q.C
MVV:+?FFAW;'U(R)&T'`V4[Q3<:JY.J4%=:C;,D9+KE<?4"AT%U"6)OWI:4D&
MJ2*I5P$HD;K*$D^8&K2`2!3@<B*\O4HQ`[1K)`!K3$8T-,,53M%\R#CQD.[4
M>K0<'GEC5\NS4W5\$9QLV#;K6N/^?[;"0L[8PJ^'\GRK=!C892S0=7D75<5=
MH1[&TH,SGB'#THIB>-MVPNTX4Z_;P'IZJJ1UI*&!^9Y>6?V<5<.O\W..]KQ9
MQAS!7+/-S%2YA7ZK8PP.U9U68-:K%>+,UM+YQ!S56.D24JJU(94>:5LQGI4R
MP)(IS\2)13V&_P":C#0ZN?7AQ/#DH_EY"\Q@>\/Y!Z50%;\QSCI:LB4^E1D=
MFU&F9(R4XPQC'DA*85N<9Q<R5EI&0DX5O1:5F=RW+%RKJ;GX5W&Q$F=LC`3<
MD@+6/?N5CI%4L^<CUZ3\/K]%/MZL5)\G+H#Z8GA^GRIQ5-0'FD\7K)9:Y$QT
M7G]&F6//,OQ@#.<M@*_0V`(3/L9DJ8Q`VQM.Y1DF;>,2?3^1H4T4QD&J3N%,
M]<-D%WB"ZQ4@K\VW7IIACSKG3`4Q^_!4^5DT:^@'ARKSY8]6*LE4O-+<6EGY
MB3&9P]E/&2O#:^\H*S7,P6CC[EN:P*RK''W#-<R0G8\NV*,>L51LCY]).E@@
M(MRS>R\1\"9D*:CU,^HX[LN+FFE17$8C`<!3$>=226@;H(KC3#`'$]9H?8K_
M`%Y\Q_"6.)YSCUS4>0>8,H5G!6*>0=ZKO'CCQD/)#>#Q=E*/LSB+OCARU*$9
M#Q!EZ5)F"-=/S39B)D2;MWBO6!;W78:.!/G'$CD>7G5C;20XG`>8\`>?(^;B
MJON//[C_``$7@QY1D,J\AI?D?C1'-F(Z5QNQ=8LKW:<PD=K`.5LP3$*S",1I
M]`;'M,>U!U++LUW,@Y*R:HKNRJ(DNDNF,:"W'U>685K+:1[BTBE,//T<\CER
M5\N.^>\<\I</4K.N('4\_P`?7_\`>`*\K9JW*U"Q`O5[;/4>=93%7G$6\Q"2
M#"RUIXW.W<ID5**7VBAOMJ6.5LC-?#CY&BA>PL?H.:LECWG=B7*V4D<<8\Q_
MR0M5==Y`N^*6'(**P'=7'&=]D3'#^?AKO74<O$2%B@U@+)5I&(-,.&J,`O+M
M#LT'RJPE*:(7+72]F!@*\R<.@!3&U>V,2'"M,\,^DE4[C'S(N-.6<AT^C5E'
M,K."RE/7&J8-S19<,W*NX%Y#6N@,YV2L]7P?E"0;%B[E-#&5:4<Q)54F2%C;
MQKA6(5?)IB;5HNV%Q%,.OVX8#IQPQ%0JFTD:T..9X>KGCU<\%B4H/G'<AW-7
MKW)2SXKS-8,4YAYGUWC#2<%1W![)D$C0J5*<C;OB,;#7,YHVV0D<VYM"KX]7
M*\@"1K)FVM,@6-(B!F^RN)\V\.UU%"<JGGU$=9&*R_E(R.S%=0&>!X5YCS`^
ME>@N(RLTG,-K9F;47*T,S+2K#<T\>6W',_7,Q)IP#24<C`/,8/2%L;>U2(Q@
M@TCA*#ASWDNC^\+K8MEU1=I3AY</L6N+*2=G7C18S^-7FB.N0W%SB1F^<QW;
M<"VG.^1N)M$L?^:."<M-<57*8Y%R,DP6J_'JV&E&1[0LX6C138V%=9Y$1954
M%GR:J:Y"ZQ8[LN95Q:*4KF3Z!3RHLJ6TTO+6`G/U>FOJXJ6%*YXXAR/E13&M
M$H7(VTUY/(MTQ$;D'#X&NCSC*3)..7LW$7JM+9?22%BT:5BQ5M_$.9I9HG7A
MEVBC--^=8`*,PNFF4Q@5`KE4G#H`^U1&U>(Q(<*TSPSZ253V,_,8P9EAK(V:
MJT+DVCB4F/;]E.J<@I_CM?87`V2Z)C>)=3M@GJ#D)PW.D[;R,,Q5=0@23:+&
MP-R=V.^(3$##:V[:2</='''B:"N&'E2JN=:2-`_,>&'WXTZ%>N+Y4X9F`XEB
MPFIA7_C<BUIGCT!Z]()#8V#?#CO/*BD]UE`*HH&-F2CD"N^D1<@#?^\'4HG8
M:8YBO'IZ.@\E"8G`.)R:?MI]JLM4_,>XYW/(-*IL3&YM;4[*.0'F)L2\BYO"
MMRAN,.6,GM%9=LC2Z!F-ZW)&2[J>?0#YK"R*K=M!V!VV,C&/G9SI`I$+QA?I
M.77]E/MZJJ5UK(V+M#Y>7)2FS!E%EAJA2=^?4?*V2$X]]#1J%+PICV9RCD>9
M>SLFWBF9(:GP?2Z<-6RS@%7CI51!FP:D.NX532(8P3RR=DPNI7RYT*AC89'A
M@S*QO\@_-<IN.>.5TS%C;$.:)C(V+>37&CCKEG`>1<-W>OY8QJ\SW?\`'[!*
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MQ'EQKBN=_P`=N&ELXO\`"-=IG(;(YZQE2OX2R-EC&&![S>,#XQRU8%H5)+'U
M[RE#-5(Z.F(8UA8EG'#1![&UL[LA95TR."A2'77O:(Q4TPZ^'#[>NBHVW.C7
M(=(^SRK3"IX54.>&7FJ5W)>/</->0=<RQ"W;*/(3,G'AIF:-P'<:_P`9%,GP
MO(;+.-\38Q#)JR7W)^]-FK%0CF1'C8CB&<3B@M5'J;U06Y;8[JA#'CB>=<R,
MJ?;T9X*26U(!>S(`<N0)_DY8J]MY\UGBCCN8R4A9&'(+]R<)9I?\?LXYJB..
M^3)O".'\HLY>"@&L)<L@1D4X;ND)B=L\<T;K0S>6!)9\@#HK;O)">XWC*X"K
M?/\`=]N'-6BTD(X!U,O3]QZU<^@\_,`7%3.#6V(96X_2/'C',9FG)D/R9Q99
M<+3#+"$W^]!(?,<1&V$BSF6HKUW2Y1J<2@23:/F9FKIF@X.FF>YMTPUU84\]
M?9R/53&BM?;2-IIQK^C[Q0\:X*G*SYC^`9@UX2MU1Y%X0>4[".0>2,9'<@,!
M7;$LCDW!^*V#23R%>L5L["EW+.I464FQ4D(5?X"PLB2+4[A@DFL!PM;=L.JM
M!3KZN6'#I5SK25NFF-?+T=.2T8V\R'`>4['!U>`IO)*"?Y`PW;\Z8->9`X[Y
M#H<;R,HM$K\-9;8&#?WA9-)2X66(B;''KEB5VL>^?-W9%V1'#<>\`7;:D$4P
M\N&'EA14-K(`#GCCT>OH^Q1_XN^;=1<M\.\/<E,PX8Y`8WM63HK%,1#4R%P%
MDEVPS#EO+(3YJ_CSC`I(D7<Y>6%O6GCM==)P5K'QR)G;QPBW`QRQQWE8M3Z5
M%./MP]E?M4DEF1+H8:@U]`-.>/JQP61S"698S.=.<V^.H&9,8*QUBE*K+TO.
MV,9[%%^BY>(18.5SJ5Z<!5*4A';:214:2D<Y>QCP!,"*YS)J%+E0R]JW52GE
MSH*K%EC,3]!-?+U*[^IE&FB)HB:(FB)HB:(FB)HB:(O+]_%N8!-E;RL6N6&#
M,R\OQCSYCR_+KI)]Q9"GWTDABFRD,)0$Q6HRUHAUE1_1`&X&'T:UVX,JS6!E
MF>K^7U+8;>^DN@G,?I^Q?F(:TZW*:(FB+*;Y8OFKYM\MR]OD(5!3)7'>^R35
M?+N"960%G'RZA"$:!<Z-**).0IN1XQF4"I/")F;/DB%;O4ED@(*>HW7:(-SC
MX-N`,'?8>CV>I9UE?26CZBICY>7L]B]]/'OD5QUYM8T-F3C1D>&RE6&$>T7L
M%.20199&QU(.BM%U*UDFC.%TYR(=LU'()'=-B.(]QV^XU<'3\0X&?99K.0ES
M2+@#,?"[AD2/0*^A=-%N<=P``:,/`\..'Z5V*YTS`JH+APJU*#A)HU^(*J1@
MJ"G4W%`QP57230`H@4H#N8/`QMP'6(S;HY'Z9XW,EX:33#J.!'1A13R7CF-#
MXBTCC7CZ%2QW!$.A-VFLFFJ50'`MBD?)+).2AUK))*JH"L(KE-[`\-]]_`<A
MNUU=_$#F'(OJ'#E2E:4ZU"Z_`'PD.Y-Q!^]4=*MF[HRHH.GBX`<VQD4%FH@?
M82]TP'4[13[&$NVQ@\-]2BSN6'5(^.@YNU5'H^U4%U;N;I8'8\A2BZEG".GR
MPHH(NG)2H*.UDG+L/AF;1JD99Y(/7:XH-6#)!ND*BJZRB:*9"B8Q@`!'4%U*
MYK0TAKCPTM#?(#F5+`QGQ'4,<03J\B>07GD\QWSG8K%IYG"G"6X15BR&=%>*
MNG(.OC\;7Z`;K%)Y`XC>J`=A9+,<I1(XGRE58LP$2LA64'OIYNQ]V)[Z47NY
M`LLABUF3G]?%K/0YW0,\;<MVCMV&"W.JX.!.;6_83T9#CC@/*4Z=.GSIT^?.
MG+Y\^<KO7KUXNJZ>/7CI4Z[IV[=+G47<NG*ZACJ*',8YSF$1$1'7IC6M8T,8
M`&`4`&0`R`7(.<7.+G&KB<2MC551-$31$T1-$31$T1-$31$T1-$31$T1:%/[
MM3^@;_FCHBIS5%(FB)HB:(FB)HB:(FB)HB:(FB+]Y;75+DEYNJ_C#E+R;K7F
M]\/,:8RQI'X8Y%^8SR&QYD7DK;LON&$YB^GV?'_'MIE$(3!;7'CZ1NMN"I(*
M)5M5*?:L3R+LJKT[9-J)7&FB:]X+&Y&E<.BF=*<3]_/:R&.-S97'W@,!YSTU
MY8T]/#++AOC':*?F+S&K';7[!''O+N[XI=T`T#,+NK3&U"J<2,<\?[*M/HKL
M6R$58"3U6=JM`(JY*J@"2QC%,84RYO8.=(YSJ5H/2-)Y95"PS-^[:UM</O=]
MA6-3AAY95LXY6'B]0[IP>XUV9;C/.58A>:2'+O-4FXL,5C>%?PE+RC3.+,Y7
M)%I6<URS`K4'L<ZD"P$6Y7>*-'BR'90'&CMY->APJT#C6F7.GL/G65)=,+"Y
MIHX\LQ^UZZ>928X_>7ID+%O.S(V5K39ZI(\0J).YSRQPUQE$.'Y;;CK-/-0:
MN]Y42,ZU4:I14;"UZ2@YT*@+910R+>]RQ3%(``74K+9XF+L-(RSZ^@9Y@<"1
MR4+[D&$,`]\Y\N73PIZ`5%/B=Y65DXVSN`\76;A-QTR[$X%RQ59^%YG3'+O-
M$<^D*-1+P-II-^-Q6<5N7CFG(6OQR#4GP*;X*P::0%ZD\20.#8D3;>5K](KA
MERZ,=)'EGP4S[F-["3@2*'#''/\`$/+"G%232X%9Q+P0A^-9W]"-D-AYC;;E
M>LY_>-^-:'%Z/F<N>89VJ4I]Q_$#;/\`*E8$@9_#`E]\[MN_V_V^LCL7:.G5
M7C^>O+DL;MF]KKQIHIY]-/:NON_$[EB%>\V'CI5,>XOL6*?,`5Y.9-QGG9_F
M4U=E:-=LX<6:AA^+QI?,2*T&1DUF[._4PIS3D?*K-B1+T%C(BNB9N>-D<L;7
M04]TMSH<Z`9TZ.M2OEBD>V<U#FN&'1J)^WJ4DL%\6LF8WY$9YRG8'=54J^2^
M#_"_CM7D8V8=N91/(''YAR#;7EQ*,E8QLDUKJRF4HW[O=%544<@5?J22Z"]<
MD4+FDUI7#^TX\ND*.>9D@:&UP/\`R6C["L:<'4;9Y5K'@-<+=G?@]3,KP/EQ
M4[A+E2B\HLXVK#E$F0X_V:)OQ,F8/R1$8ZN"]T=5>PW)ZVE*XM%Q[N:8NF2C
M9=%5`Q#8SH3'1SB,6<P/P@<1GB>'*I"R62B;4&@TU@Y$YNKB!D,`#GQH.61#
MR=ZS<JAY;W%QED.)=U^TS,=D_(+^/6AY6NN4XW*6=LGY-KDBE7[`(3T$C,5B
MVLWS=F_V>MD'!"+_`+4I]95J'=@:C$DY\:@>16)=:3.:'W</4**,6.>#_(B"
MYA0N2Z5B.L\.<>.LQ99NG).:POS6RMD/#'*O'=[@;Y&_=#+A;/TV&Q_C7*]W
MLM@B;#+V!/X!:&DV#H[=Q)G==0PB*7M2`,`2<:TKPY#/D*])4[IHNR`=4F@'
M"HI3CB>>>!Y!<C!_#'F`PK/E]\3LLUC#->X]>71EB@Y%CN0].RE*V*\<AH;`
M50O5+P+`Q.&%J'#+8JG)AG;6CNZN'\X_;$4CEV\>+M-[W$+/EYGCLB!1H..6
M8IG3'(9>OA<+B&-QF;4O<:D>>OW^K*F/;$X(\BJIP%PGA^N(8UL^>N/'/0>:
M,%47UVD*_1,BQ,'S>R7R*CL>J9"&K22U4F[#CB\$;E>*Q3EJRF2=I4#(`9;4
MSX7F($?$TGUNKU\.2B$S#*ZOP.:!7E[M%EMH<C=;7C^%?Y.I++%UWGH9X2TT
M:)N3/)#2I.W9WK0K%M=&,/7&%F.1@*2QE4F;=,%3F2#J`G<-E,+WQU<*.\X]
MN(]:Q7AK7D,-6@K#7B#AKS$:<4N#?$C(>/<255#@-R<X6VV,RO`YK5MD;G3$
M_'*Z3[RSVF+IPX^AIK'MG=55*.6;Q$@NY[[]TN@"Y$FY5UL`02N;H-*M-!@<
M<AG3H]?IS3-"UY>"[WP:Y5!QR]/JKQP["B\+.2E;YH068,:8AI_$"K$SWD7)
MN?[7BCFEE>_8/Y88]LD9=D4X"5X035+B\?4K*>2+!+PTO8)X@,U8A^R=KMG<
MFHX+U7B&3MM(J&5)KCZ<1IKYJ])5'31=CCBZ@`&&%*<?B]=.%`J,X^^7OR)K
M^2+!'Q6-Z_P3P!:\&\B,99HP[BWF;E3E!@++5RS#6A@:79L*\?KU4JS6>.\)
MCZ=?OYPZS`L2Z63<!%@Q41.=P2QL$KCIR:.OF#QH.'`#IYJ1US$T:OB>>H4P
M(',X=)//!5OA'BUSBD++Y7-<S=B[!..L;^7C5[OCV[V^EY]FL@VW,1'G#ZS<
M9*_=J!4QQ35F=/@)-R_0?K,I625EFQW!B]/0VZW%T<4NIM<--1QY&G#F3T4P
MSSBDEAT/#:DOQ]8//H\JT%E^)'E:6?CA+<>,6VCA+QRR>QX]Y$J<C%<TG_+O
M-#=[*T['M@4E*-D=GQ6?5R5CXOD%&QK=H51A\>%92ER*NT'I6YB-BVQV\C90
M,:-]&'3I(\L^"DDN8WQDC`N%*4Y^<>GU<5DR\Q+!.7N0^"*Y2\1D:V/[FS7C
M*^93PY(93LN$8WD=AJKNY0]WP3(Y9J3-_,4UG:5GK)\83)&8R0Q01[T2M':Q
M@RKIDCV>YP\LO+ED2L6V>QDM7C#R\NC/@L9,#Y76>(O$?/5C0\,<8^.DIG7.
MO`CD/Q\X_P"/<F3LYCV-D.'4]C6\3U(R1D!/&T$,-8\CS=`4;.)AC$R#1)P^
M!?\`;II&44Q6V\H!<`.'1Q:<J?JY9]966ZZB-&8D8U/F<.9_-U=2FO/4SFDM
MRPP7S<BN-.,7D\^XWY)XNYGP#(<G8QC(8UCK#GJD94J>3JYDY+%;RM9&9GB*
MNZ2E(=)FP=ME7"!4%G'2H8*B.9NF0?$13(X8`99Y"N-/.HM4!:8B3H!J,L<\
M*^?SJ!D_Y7_).UY-KTW;L*8!R!E.G>8ECKE')\_\B\AKM9<M7?`M/Y2,\NPF
M-<=X<DL?RJ>'I6H8B;M:J:$;R[2N]B+'X45CO!.D[&4R@G@X'+IKR/#"@-![
M)/F(A%I&%6D4\U.?.IJ14U60K`>-.9/%3)^3,74+$V%\I\>,L<P\H<DF&=)[
M.<M1;IC>B\@\BADS+E+L^'4L96*0O=[J$Y+2Z%9=,)QO&2C-5D5\=B*"P*7B
M.4.<P@$/SSZ\Z$#,TKT9<8G21.8'U(>T"@ZA0<1R%:#GGA2T]<X$9PB>"O&?
MC<Z?T(^0,/\`F"T3E!:'"=B?J5M7&E:\P*W<H'[6'E!@RN'EH-C><133:&;H
MI&E.I`5@('>&X0NTMZ'5X_F!Y<@K3,PR.=C0LI^S3VK3D'@/G*T<1?,#P9&2
M%!)=.3_/NQ<G,:+NK'((P37',KGC`62VK>SR!8-1>(LX5_&4D!FB2#E,KHR)
M.\(*&.2(6KQ&0:5JWGPK7ATJ5URQTK7XZ0#Z_.JKYL>7I=.8&6>7[T;=7Z;C
MSD7Y<5:XF5JP*K2$A.P66*[G[)67F4M8*PR39*.J`#:QQA'9F\@1VY)\2B0J
M9@(H-TEM(Z@%,&`>@$?;_(J1738P<"27D^8EI^Q1JJGEXY!F:IFZ&/P"XR\<
M,E6GAWR8P;#9KA^:>9<_.I;).:L;'I#=ICZK7*EH!0\5620,#F8?2RH3*#=!
ML@1HX,0ZH1-MI'!P.8'&O,9>[CYO0I3=1@M()I6N`Z_UCY5Q4Y"\4,F'RAY6
M-N6>U8(;AIB#,%!S$))=T>0=3%^XT4C$$.K26YHPJ<^S3M-><'7.NHS$C02*
M`4QC"0)?EG@L(IAU\'%W+#/TJ'YEE'YU=]U%#2D<0.4$5Y?^,N#&9N%O'WD%
M`\8W^.*W39@W,6V8L?9<K]%?W0T+F7%-LJ6+V=XX[9FJ2"L.Z:)NGQ>Z=Y(M
M"/T4R$6<6B*01EA%2TBF!Y4Y8Y#*G7Q5QEB[82M)&H&N6%3U^VO.G!2DXHXE
MYV\?<)5.H2;VI7Q_/\MU9Z2I><>0>1LZ6;CIPGL+5LE(8_K?(&:@X^V9SRY3
M9.-4?18S*8L$TI<[#XMPDQ274FB;,Q@KF7#GEYP3YSCPK0"L4KX7R$BND-H.
MOS4'HZZ8K)]K-6(OFB)HB:(FB)HB:(FB)HB:(HH<[N/3?ECPLY4\;5D"+N<Q
MX)R-3X(#E`W8N"U>=R-'>$`P"'=87./8+$]ADPU!<1]I$6TJ>'L]5:J:!_9R
MM?6@!7XH2[9TR779/D%6KYFNLT>M5TS)+MGC50R#ILLD8`,FJ@NF8ABCX@8!
M#7.KHUMZ(FB)HBN-BO,.6<&6YK?L+Y+O>*+LR*5)"TX]M,Q4YOX<KA!T+)P^
MAG;15Y'J.&R9SMUNX@H)`ZB#MJR2*.9NB5H<P\"*JK7.::M)!6<7%G\2%S>J
MD>PB\LT/`>?2,BHE/8['4YG'][>@FGVSJ2%BQI.UZ,DG:^P&.LYC5CB<-QWW
M$-:V79[5^#:@<`<0.JN/K64R\F9QJI<?_P!R[2'RPGD>%5J8I?`B0"1?(")>
M=#U40,N4@R6)"G^[^H1$@&,90-@WW$1'6`[8*$]F8Z'F#PZB%D#<74`=6OET
M*VTW_$AJ)E$:EPMA%77=$?B;WFZ;DFW9#JZ2C&U2DU@QE=A\3"YZ?#]$=4'=
MXN;I?(UH_4;3UDGV*O\`B1::M:21^8U^P+$GRX\T;E_S'*_@+Y?B4;%;LX`G
MA?$R+FE8[.@GU%1+8&S9VM-7=T5,0`RTR[>[F#J*4GHUG66R6-F[M*&2?#WG
MT-*<A2@ZP*\RH9]PN)QIKICQP'3G4YGV+'@`````````;``>```>@`#U`&MN
ML%?=$31$T1-$31$T1-$31$T1-$31$T1-$31%H4_NU/Z!O^:.B*G-44B:(FB)
MHB:(FB)HB:(FB)HB:(OWEM=4N26@B220J"DBBD*RAEEA2232%98X%`ZZPIE*
M*JQP*`"<VYA``W'P#5$6O5431$T1-$31$T1-$6PX:,WA4R/&;-Z1%8CA$KQH
MW=E1<)^*;A$KA-4$ETQ_1.78P>H=4(!S5:T7),8QS"8QA,8PB8QC"(F,(CN(
MB([B(B.@``H,D6G551-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1;B:ADE$U2>!TSE4*/L,0P&+](:M(#@6G
M(A5!H:C-?CV>>-Q<'B'YJ/,+%C&./'5&>R:\S)CQ,$P(U-1LUH)9(BF\?L`%
M%G"/I]U&``>!#L3%_D[!SLS2R4@TK7R]>"Z*!_:0M=T4]"Q/:B4R:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M"G]VI_0-_P`T=$5.
M:HI$T1-$31$T1-$31$T1-$31$T1?O+:ZI<DFB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(OS5OXQ;_P#Z9X;_`/9C_P#PUQ[_`/4K_P!I_P#])V6__;#_
M`/%O_P!Y[ZT=]_&&67#K/KY]*W6W?P#_`#OL"\G&L)9Z:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M"G]VI_0-_P`T=$5.:HI$T1-$
131$T1-$31$T1-$31$T1?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g532389g42z24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g42z24.jpg
M_]C_X0]]17AI9@``34T`*@````@`"`$2``,````!``$```$:``4````!````
M;@$;``4````!````=@$H``,````!``(```$Q``(````>````?@$R``(````4
M````G`$[``(````&````L(=I``0````!````N````.0`+<;````G$``MQL``
M`"<0061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHP-3HQ-"`P
M.3HP-#HU-P!E<FEC:``````#H`$``P````$``0``H`(`!`````$```#'H`,`
M!`````$```"N``````````8!`P`#`````0`&```!&@`%`````0```3(!&P`%
M`````0```3H!*``#`````0`"```"`0`$`````0```4("`@`$`````0``#C,`
M````````2`````$```!(`````?_8_^T`#$%D;V)E7T--``'_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`",`*`#`2(``A$!`Q$!_]T`!``*_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2DDDDE*22224I4L$DYG49)(%[(!/'Z#'X5U4L'^F=1_X]G_
M`)XQDE-U))))2DDDDE*22224I))))2DDDDE*22224__0]522224I))))2DDD
MDE*5+!_IG4?^/9_YXQE=5+!_IG4?^/9_YXQDE-U))))2DDDDE*22224I))))
M2DDDDE*22224_P#_T?54DDDE*220;,S%JW;[6@LC>`9(W$,;N:WW-]SDE)DD
M+[3CR!ZK)+?4'N&K/])_4_EIVWT/V[+&N]20R'`[MOTMO[VU)214L'^F=1_X
M]G_GC&5U9^+8RK(ZI;8X,8RYKGN/``Q\<N)24Z"2I_M7``87V>F;&66M;8US
M';*?Y][J[&ML9Z?\MJ7[7P/LOVO>[T@XUN'IV;VN'TFV4;/7JV-][_4K]E?Z
M3^;0XAW">$]BW$E3?U?IU8N=9<&-QX]1[@X-U/I_HWENV[]+^B_0^I^E_1?S
MB)=G8M%S:;;-CWB>#M`U@VV`>G3OV_H_5<SU?\&EQ#N%4>Q;"2I5]8Z?8*B+
M'`7$AI=6]@!:-WZ;U&-^S[VG]#Z_I^O_`('U$;$S,?,J];'<7,F#N:YA!@.]
MU=K6/;N8YMC/;[Z_TGT$A('8A1B1N"G22210I))))2DDDDE/_]+U5))))2E0
M'2]U]EMCXW6;V-;$032YV^1[M_V=7TDE.9=TW%8(LN+&VDM`.T398+*V;=/W
M+GM]+Z'_`((C?LW'.0+]P=#]^T@$<AS-O[NRQGTT7+Q?M'I0X--3R\$MW:['
MUCG_`(S<JE?2',MIL-C3Z+R\,#(:=Q]S=N[Z+/IT?Z.[](DITUEBBG(_;%%[
MME-MFVQX.V&G&QPYVX_1VK466,89?[8Q2XL%]@K+V\C=C8[=P0.QZI&XZ-;'
MHPZ\6EU?465V;<BVJR&L:"6[+K*L:SVUTXGTW5_0_P!-_.)-^S-Z,(ZA3]GL
M=L=>ZH.;8YQ<VUN17:]_J6/:=UO\W^D9ZO\`,;Z58JZ/DLJK=]H9]HK%Q!],
MFL&UNUE==;K/4;C4N]_H^M[_`/@TW[+SOV<_$%U/J7$F^TUO/J;]S+G61<VS
M>]CO\':ST]GI?S'Z-1\)_=Z=_P#T)DL?O=?Y?HM-M72L8Y['Y\%]1JN<YOZ0
M!TM^T95D?K3JW#91>[]'35^B5O+Q<3)R\7)ORZXL:XTL<ULNK`-Q^S.L)V;J
MG;<US/Z3C?H[$9W22^J^M][G'(-37O(U]&H,:_']FQFV_;D;_397_2K/8C7X
M=M]E5KK&M?0][F.:R3M>Q]36^]Q^CO\`4?\`Z38CPFJK^7%_>1Q#>_Y4Y&+1
MTZ,2MO46/&18;"-HFU[`VEOI/M=;;1^A8S%LWOL]>A_H?X5:'0J,:K$>['M^
MT"U^Y]H#F@EK64LV-L+W;&TUU_X1_P#P?Z/V(-?2,\/8;<FI[#:ZZ^KTW!KK
M"6[+&3:_^:V>HRF[UZ_M#_4_P./55;Z5@VX-#JK+&OW/W-96TLK8T!K&LIK>
M^YU;?9ZCF^I_.OL0A$@CTTJ4@0?5;=2224K&I))))2DDDDE/_]/T<]6J!(]#
M),$B119&AC]Q+]KT_P#<?*_]A[?_`""O))*:/[7I_P"X^5_[#V_^02_:U/\`
MW'RO_8>S_P`@I9E699=4<<[&MU+]Y'<;MU,;+6[%2_9V>ZI['0?5/Z1IL<9.
MRJOU;+-OO9[+?T'_``B2FW^UZ?\`N/E?^P]O_D$OVO3_`-Q\K_V'M_\`(*#<
M7J`L83<[;+RZ'3#BYSF_3:YOI^EMKV[/T*C5C=2:<<N>2&/.\&PD%A(]UGYS
M[?I;/\"DI+^UZ?\`N/E?^P]O_D%#I5K;K^H6M:YH=D-]KVECA%&./=6_:Y:*
MS&,-AZQ6VL7E]D"ESMC7DXV/^C?8`_8U_P!'?L24Z/J5G;#A[]6:C7O[?WDX
M(<`6F0>"%SC>AYD5"JEF,[T[6/<'-+&>H;2^O'I97OQV6>K^@?C9#/2K_G_5
M_P`/:P.E75VXE[J*\84V7.&/6Z6TUVM#?2JVM96_?:SU7>SV;_T:8)R/Z*\Q
MC^\[,A.L%W0;CDEP97Z/K&OZ3@?L=A^VWLV@;?5=G_H__"JEZ77&V!CW.;]I
ML#3L>7[&D/\`M5S7NKVU[-E7V7=^_P#S"7&1O$JX!TD'<26&S#ZVZMC2YU;G
M/WV;KB\-#BQME%9:/TE->/O95;9^E?D?IOU;]&B8N%U1K]CSMQ_LSJ=CK762
MX-I90^8W?FY/K/;^_P#X?_!+B/[I5PC]X.LUS7B6D.'$@SPI+F\+I'5L7'+:
M&^@26#8U[`=[:_29<]V/512_'J?_`(#T?6O_`,-99_159LPNLV.WN<)ITK=O
M]SI=9ZSZH:/1?=C/935N?^A_\%>A,U\I48"_F#MI+(&-UD`-+R^O:UQ'J187
M$BJVK<UC?97C-]6O]+OLRO\`#?X55[^F]<MPG4VV^K9:STK&BTM;/IUL9;N]
M/^;]7[3Z]7I_I_5_ZVD9G]TJ$!^\'?2223UC_]3U5)43G9H)'[.O(!(!#Z-0
M#]+^D?G)?;\S_P`K;_\`/H_]Z4E-Y)4OMV7_`.5V1_GT?^]*7V[+_P#*[(_S
ML?\`]Z4E-U)4OMV7_P"5V1_G8_\`[TI?;LO_`,KLC_.Q_P#WI24W5DOJLNKZ
MW34'&RQVQ@8[8Z78U#?99+=C_P!U^Y6?MV7_`.5V1_G8_P#[TJ'2WNLR.H/?
M6ZEQR&S6\M+A%&/SZ3K*_=_72.H4#1MH_9>M,=ZK-[K0P4-<][7@-I-M;,KT
MW/\`3];+]3UW?]LV?01K!]81O-3MQ9N96UXK`<!]HV7V%ON]33$]K?3K_P"#
M_P!#L))G!XR^U?Q^`^QPLG(ZY50;&[]K&6.+W-K^ALO=4Y]3?=]IK>W&^@[T
M[/\`0_SGI.\=>L!J(L]-X<&']&UQ8=P><A]<>EE-;L^R_9OT?^G_`."W$DN#
M^M+[5<?]4.7BV=3IOC(J<:"T`-8&PUSG-8/HFRRW=N?98_?7Z+/\&@WXG4SF
M9!K%GHW757@BP``X_P!FVUL;OW-JRH?ZS/\`NM;_`-REM)(\&E64<>MT'(Z3
MB]0Q\@5Y`L=170T5VV6>H=SW%[\>WW;G68T?H\C_``M%E?\`A*G^I3R\#/?9
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M[=:YI.K(:'`-8W?].UM9];^76M)))2EFU66UV=5LI9ZEC+FN:S]Z,?&.T1^<
M[\U:2I8/],ZC_P`>S_SQC)*:AZQG`FW[&[T`[;`:_P!30?:O4V>G]#[!_P##
M#]1_EJ=?5,T6"N_&V0X^I;#_`$VM`]=VI9_W&LJ;_P"&_6I_P2U4DWAE^\NX
MA^ZX'[1ZH'.I)<7NVD`5Q8T;G;K&[F"E]3MOH_U[$1G6\USJQZ`<7/`+`UX)
MDM:_&8YX:W[1B-<ZS(?_`#/Z/_COLVVDAP2_>*>(?NAQ;^MY+;;&LK8RH.:&
M6/:]P:PM]1N7<ZOV>AD._0T,9^D]3_K_`*$Z^J=2<ZI[\45UV.:#60_U&@V,
MQ7;SM]/>UUOK_P#%5_\`7:]=)+AE^\CBC^ZI)))/6J22224I))))3__6]522
M224I))))2DDDDE*5+!_IG4?^/9_YXQE=5+!_IG4?^/9_YXQDE-U))))2DDDD
ME*22224I))))2DDDDE*22224_P#_U_54DDDE*22224I))))2E2P?Z9U'_CV?
M^>,9752P=OVSJ,3/KLW3$3Z&/]"/Y/[R2FZDDDDI22222E))))*4DDDDI222
M22E))))*?__9_^T7=%!H;W1O<VAO<"`S+C``.$))300$``````!1'`%:``,;
M)4<<`@```@``'`)0``5E<FEC:!P"!0`S0T].4T5.5"!/1B!)3D1%4$5.1$5.
M5"!#15)4249)140@4%5"3$E#($%#0T]53E1!3E13`#A"24T$)0``````$#'M
MDJ'\;NZ4SQ#(\14^4V0X0DE-!#H``````.4````0`````0``````"W!R:6YT
M3W5T<'5T````!0````!0<W138F]O;`$`````26YT965N=6T`````26YT90``
M``!#;')M````#W!R:6YT4VEX=&5E;D)I=&)O;VP`````"W!R:6YT97).86UE
M5$585`````$```````]P<FEN=%!R;V]F4V5T=7!/8FIC````#`!0`'(`;P!O
M`&8`(`!3`&4`=`!U`'````````IP<F]O9E-E='5P`````0````!";'1N96YU
M;0````QB=6EL=&EN4')O;V8````)<')O;V9#35E+`#A"24T$.P`````"+0``
M`!`````!```````2<')I;G1/=71P=71/<'1I;VYS````%P````!#<'1N8F]O
M;```````0VQB<F)O;VP``````%)G<TUB;V]L``````!#<FY#8F]O;```````
M0VYT0V)O;VP``````$QB;'-B;V]L``````!.9W1V8F]O;```````16UL1&)O
M;VP``````$EN=')B;V]L``````!"8VMG3V)J8P````$```````!21T)#````
M`P````!29"`@9&]U8D!OX````````````$=R;B!D;W5B0&_@````````````
M0FP@(&1O=6)`;^````````````!"<F1456YT1B-2;'0```````````````!"
M;&0@56YT1B-2;'0```````````````!2<VQT56YT1B-0>&Q`<L``````````
M``IV96-T;W)$871A8F]O;`$`````4&=0<V5N=6T`````4&=0<P````!09U!#
M`````$QE9G15;G1&(U)L=````````````````%1O<"!5;G1&(U)L=```````
M`````````%-C;"!5;G1&(U!R8T!9````````````$&-R;W!7:&5N4')I;G1I
M;F=B;V]L``````YC<F]P4F5C=$)O='1O;6QO;F<`````````#&-R;W!296-T
M3&5F=&QO;F<`````````#6-R;W!296-T4FEG:'1L;VYG``````````MC<F]P
M4F5C=%1O<&QO;F<``````#A"24T#[0``````$`$L`````0`"`2P````!``(X
M0DE-!"8```````X`````````````/X```#A"24T$#0``````!````'@X0DE-
M!!D```````0````>.$))30/S```````)```````````!`#A"24TG$```````
M"@`!``````````(X0DE-`_4``````$@`+V9F``$`;&9F``8```````$`+V9F
M``$`H9F:``8```````$`,@````$`6@````8```````$`-0````$`+0````8`
M``````$X0DE-`_@``````'```/____________________________\#Z```
M``#_____________________________`^@`````____________________
M_________P/H`````/____________________________\#Z```.$))300(
M```````0`````0```D````)``````#A"24T$'@``````!``````X0DE-!!H`
M`````SD````&``````````````"N````QP````(`,``R`````0``````````
M```````````````!``````````````#'````K@`````````````````````!
M`````````````````````````!`````!````````;G5L;`````(````&8F]U
M;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````
M3&5F=&QO;F<``````````$)T;VUL;VYG````K@````!29VAT;&]N9P```,<`
M```&<VQI8V5S5FQ,<P````%/8FIC`````0``````!7-L:6-E````$@````=S
M;&EC94E$;&]N9P`````````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N
M=6T````,15-L:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N
M=6T````*15-L:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````
M````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````````
M``!"=&]M;&]N9P```*X`````4F=H=&QO;F<```#'`````W5R;%1%6%0````!
M````````;G5L;%1%6%0````!````````37-G951%6%0````!```````&86QT
M5&%G5$585`````$```````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q4
M97AT5$585`````$```````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!
M;&EG;@````=D969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R
M=$%L:6=N````!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC
M94)'0V]L;W)4>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*
M;&5F=$]U='-E=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````
M"W)I9VAT3W5T<V5T;&]N9P``````.$))300H```````,`````C_P````````
M.$))3004```````$`````CA"24T$#``````.3P````$```"@````C````>``
M`0:````.,P`8``'_V/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;
M`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01
M#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``
M$0@`C`"@`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,`
M`0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#
M`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"
MT4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6T
ME<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$
M!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,5
M8W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]522
M224I))))2DDDDE*5+!).9U&22!>R`3Q^@Q^%=5+!_IG4?^/9_P">,9)3=222
M24I))))2DDDDE*22224I))))2DDDDE/_T/54DDDE*22224I))))2E2P?Z9U'
M_CV?^>,9752P?Z9U'_CV?^>,9)3=22224I))))2DDDDE*22224I))))2DDDD
ME/\`_]'U5))))2DDD&S,Q:MV^UH+(W@&2-Q#&[FM]S?<Y)29)"^TX\@>JR2W
MU![AJS_2?U/Y:=M]#]NRQKO4D,AP.[;]+;^]M24D5+!_IG4?^/9_YXQE=6?B
MV,JR.J6V.#&,N:Y[CP`,?'+B4E.@DJ?[5P`&%]GIFQEEK6V-<QVRG^?>ZNQK
M;&>G_+:E^U\#[+]KWN](.-;AZ=F]KA])ME&SUZMC?>_U*_97^D_FT.(=PGA/
M8MQ)4W]7Z=6+G67!C<>/4>X.#=3Z?Z-Y;MN_2_HOT/J?I?T7\XB79V+1<VFV
MS8]XG@[0-8-M@'IT[]OZ/U7,]7_!I<0[A5'L6PDJ5?6.GV"HBQP%Q(:75O8`
M6C=^F]1C?L^]I_0^OZ?K_P"!]1&Q,S'S*O6QW%S)@[FN808#O=7:UCV[F.;8
MSV^^O])]!(2!V(48D;@ITDDD4*22224I))))3__2]522224I4!TO=?9;8^-U
MF]C6Q$$TN=OD>[?]G5]))3F7=-Q6"++BQMI+0#M$V6"RMFW3]RY[?2^A_P""
M(W[-QSD"_<'0_?M(!'(<S;^[LL9]-%R\7[1Z4.#34\O!+=VNQ]8Y_P",W*I7
MTAS+:;#8T^B\O#`R&G<?<W;N^BSZ='^CN_2)*=-98HIR/VQ1>[93;9ML>#MA
MIQL<.=N/T=JU%EC&&7^V,4N+!?8*R]O(W8V.W<$#L>J1N.C6QZ,.O%I=7U%E
M=FW(MJLAK&@ENRZRK&L]M=.)]-U?T/\`3?SB3?LS>C".H4_9[';'7NJ#FV.<
M7-M;D5VO?ZECVG=;_-_I&>K_`#&^E6*NCY+*JW?:&?:*Q<0?3)K!M;M9776Z
MSU&XU+O?Z/K>_P#X--^R\[]G/Q!=3ZEQ)OM-;SZF_<RYUD7-LWO8[_!VL]/9
MZ7\Q^C4?"?W>G?\`]"9+'[W7^7Z+3;5TK&.>Q^?!?4:KG.;^D`=+?M&59'ZT
MZMPV47N_1TU?HE;R\7$R<O%R;\NN+&N-+'-;+JP#<?LSK"=FZIVW-<S^DXWZ
M.Q&=TDOJOK?>YQR#4U[R-?1J#&OQ_9L9MOVY&_TV5_TJSV(U^';?95:ZQK7T
M/>YCFLD[7L?4UOO<?H[_`%'_`.DV(\)JJ_EQ?WD<0WO^5.1BT=.C$K;U%CQD
M6&PC:)M>P-I;Z3[76VT?H6,Q;-[[/7H?Z'^%6AT*C&JQ'NQ[?M`M?N?:`YH)
M:UE+-C;"]VQM-=?^$?\`\'^C]B#7TC/#V&W)J>PVNNOJ]-P:ZPENRQDVO_FM
MGJ,IN]>O[0_U/\#CU56^E8-N#0ZJRQK]S]S65M+*V-`:QK*:WON=6WV>HYOJ
M?SK[$(1((]-*E($'U6W4DDE*QJ22224I))))3__3]'/5J@2/0R3!(D461H8_
M<2_:]/\`W'RO_8>W_P`@KR22FC^UZ?\`N/E?^P]O_D$OVM3_`-Q\K_V'L_\`
M(*695F675''.QK=2_>1W&[=3&RUNQ4OV=GNJ>QT'U3^D:;'&3LJK]6RS;[V>
MRW]!_P`(DIM_M>G_`+CY7_L/;_Y!+]KT_P#<?*_]A[?_`""@W%Z@+&$W.VR\
MNATPXN<YOTVN;Z?I;:]NS]"HU8W4FG'+GDACSO!L)!82/=9^<^WZ6S_`I*2_
MM>G_`+CY7_L/;_Y!0Z5:VZ_J%K6N:'9#?:]I8X11CCW5OVN6BLQC#8>L5MK%
MY?9`I<[8UY.-C_HWV`/V-?\`1W[$E.CZE9VPX>_5FHU[^W]Y."'`%ID'@A<X
MWH>9%0JI9C.].UCW!S2QGJ&TOKQZ65[\=EGJ_H'XV0STJ_Y_U?\`#VL#I5U=
MN)>ZBO&%-ESACUNEM-=K0WTJMK65OWVL]5WL]F_]&F"<C^BO,8_O.S(3K!=T
M&XY)<&5^CZQK^DX'['8?MM[-H&WU79_Z/_PJI>EUQM@8]SF_:;`T['E^QI#_
M`+5<U[J]M>S95]EW?O\`\PEQD;Q*N`=)!W$EALP^MNK8TN=6YS]]FZXO#0XL
M;9166C])37C[V56V?I7Y'Z;]6_1HF+A=4:_8\[<?[,ZG8ZUUDN#:64/F-WYN
M3ZSV_O\`^'_P2XC^Z5<(_>#K-<UXEI#AQ(,\*2YO"Z1U;%QRVAOH$E@V->P'
M>VOTF7/=CU44OQZG_P"`]'UK_P##66?T56;,+K-CM[G":=*W;_<Z76>L^J&C
MT7W8SV4U;G_H?_!7H3-?*5&`OY@[:2R!C=9`#2\OKVM<1ZD6%Q(JMJW-8WV5
MXS?5K_2[[,K_``W^%5>_IO7+<)U-MOJV6L]*QHM+6SZ=;&6[O3_F_5^T^O5Z
M?Z?U?^MI&9_=*A`?O!WTDDD]8__4]525$YV:"1^SKR`2`0^C4`_2_I'YR7V_
M,_\`*V__`#Z/_>E)3>25+[=E_P#E=D?Y]'_O2E]NR_\`RNR/\['_`/>E)3=2
M5+[=E_\`E=D?YV/_`.]*7V[+_P#*[(_SL?\`]Z4E-U9+ZK+J^MTU!QLL=L8&
M.V.EV-0WV62W8_\`=?N5G[=E_P#E=D?YV/\`^]*ATM[K,CJ#WUNI<<ALUO+2
MX11C\^DZROW?UTCJ%`T;:/V7K3'>JS>ZT,%#7/>UX#:3;6S*]-S_`$_6R_4]
M=W_;-GT$:P?6$;S4[<6;F5M>*P'`?:-E]A;[O4TQ/:WTZ_\`@_\`0["29P>,
MOM7\?@/L<+)R.N54&QN_:QECB]S:_H;+W5.?4WW?::WMQOH.].S_`$/\YZ3O
M'7K`:B+/3>'!A_1M<6'<'G(?7'I936[/LOV;]'_I_P#@MQ)+@_K2^U7'_5#E
MXMG4Z;XR*G&@M`#6!L-<YS6#Z)LLMW;GV6/WU^BS_!H-^)U,YF0:Q9Z-UU5X
M(L``./\`9MM;&[]S:LJ'^LS_`+K6_P#<I;22/!I5E''K=!R.DXO4,?(%>0+'
M45T-%=MEGJ'<]Q>_'M]VYUF-'Z/(_P`+197_`(2I_J4\O`SWV9T4W/KML:XD
M>F7OVNFIE6Z^MMN'L_GJK?LEK/\`A_TBZ-)`XP15E(F;N@\_;B=6L+SFXYMQ
MW5U"RG%O()#'6_H:&V'&]-WZ2NV^SU_TVST_4_P2+T_&ZI3GNLLKWE]58OOM
M<(W!M3=N*ZMSWO9[+=[+\>G]/_A/TJVTDO;%W9T5QFJH.!@X68*`17DXY&97
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MH_\`'L_\\8R2FH>L9P)M^QN]`.VP&O\`4T'VKU-GI_0^P?\`PP_4?Y:G7U3-
M%@KOQMD./J6P_P!-K0/7=J6?]QK*F_\`AOUJ?\$M5)-X9?O+N(?NN!^T>J!S
MJ27%[MI`%<6-&YVZQNY@I?4[;Z/]>Q$9UO-<ZL>@'%SP"P->"9+6OQF.>&M^
MT8C7.LR'_P`S^C_X[[-MI(<$OWBGB'[H<6_K>2VVQK*V,J#FAECVO<&L+?4;
MEW.K]GH9#OT-#&?I/4_Z_P"A.OJG4G.J>_%%==CF@UD/]1H-C,5V\[?3WM=;
MZ_\`Q5?_`%VO722X9?O(XH_NJ2223UJDDDDE*22224__UO54DDDE*22224I)
M)))2E2P?Z9U'_CV?^>,9752P?Z9U'_CV?^>,9)3=22224I))))2DDDDE*222
M24I))))2DDDDE/\`_]?U5))))2DDDDE*22224I4L'^F=1_X]G_GC&5U4L';]
MLZC$SZ[-TQ$^AC_0C^3^\DINI)))*4DDDDI22222E))))*4DDDDI22222G__
MV0`X0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O
M`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``
M0P!3`#8````!`#A"24T$!@``````!P`(`````0$`_^$0@&AT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7
M-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T82!X;6QN<SIX
M/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS
M+6,P,3$@-C8N,30U-C8Q+"`R,#$R+S`R+S`V+3$T.C4V.C(W("`@("`@("`B
M/B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO
M,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(B!X;6QN<SIX;7`](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(@
M>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R(@
M>&UL;G,Z<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C945V96YT(R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.G!H;W1O
M<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R(@>&UP
M.D-R96%T941A=&4](C(P,3,M,#4M,314,#DZ,#(Z-3<B('AM<#I#<F5A=&]R
M5&]O;#TB36EC<F]S;V9TPJX@3V9F:6-E(%=O<F0@,C`P-R(@>&UP.DUO9&EF
M>41A=&4](C(P,3,M,#4M,314,#DZ,#0Z-3<K,#4Z,S`B('AM<#I-971A9&%T
M841A=&4](C(P,3,M,#4M,314,#DZ,#0Z-3<K,#4Z,S`B('!D9CI0<F]D=6-E
M<CTB36EC<F]S;V9TPJX@3V9F:6-E(%=O<F0@,C`P-R(@9&,Z9F]R;6%T/2)I
M;6%G92]J<&5G(B!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.D9%-SA#138W
M-#-"0T4R,3%!-C1#0D$X,CA$0S9&,#,V(B!X;7!-33I$;V-U;65N=$E$/2)X
M;7`N9&ED.D9$-SA#138W-#-"0T4R,3%!-C1#0D$X,CA$0S9&,#,V(B!X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z1D0W.$-%-C<T,T)#13(Q
M,4$V-$-"03@R.$1#-D8P,S8B('!H;W1O<VAO<#I#;VQO<DUO9&4](C,B('!H
M;W1O<VAO<#I)0T-0<F]F:6QE/2)S4D="($E%0S8Q.38V+3(N,2(^(#QD8SIC
M<F5A=&]R/B`\<F1F.E-E<3X@/')D9CIL:3YE<FEC:#PO<F1F.FQI/B`\+W)D
M9CI397$^(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B`\<F1F.D%L=#X@/')D
M9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY#3TY314Y4($]&($E.1$5014Y$
M14Y4($-%4E1)1DE%1"!054),24,@04-#3U5.5$%.5%,\+W)D9CIL:3X@/"]R
M9&8Z06QT/B`\+V1C.G1I=&QE/B`\>&UP34TZ2&ES=&]R>3X@/')D9CI397$^
M(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)
M1#TB>&UP+FEI9#I&1#<X0T4V-S0S0D-%,C$Q038T0T)!.#(X1$,V1C`S-B(@
M<W1%=G0Z=VAE;CTB,C`Q,RTP-2TQ-%0P.3HP-#HU-RLP-3HS,"(@<W1%=G0Z
M<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB
M('-T179T.F-H86YG960](B\B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](F1E
M<FEV960B('-T179T.G!A<F%M971E<G,](F-O;G9E<G1E9"!F<F]M(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W`@=&\@:6UA9V4O:G!E9R(O/B`\
M<F1F.FQI('-T179T.F%C=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240]
M(GAM<"YI:60Z1D4W.$-%-C<T,T)#13(Q,4$V-$-"03@R.$1#-D8P,S8B('-T
M179T.G=H96X](C(P,3,M,#4M,314,#DZ,#0Z-3<K,#4Z,S`B('-T179T.G-O
M9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!S
M=$5V=#IC:&%N9V5D/2(O(B\^(#PO<F1F.E-E<3X@/"]X;7!-33I(:7-T;W)Y
M/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI
M9#I&1#<X0T4V-S0S0D-%,C$Q038T0T)!.#(X1$,V1C`S-B(@<W12968Z9&]C
M=6UE;G1)1#TB>&UP+F1I9#I&1#<X0T4V-S0S0D-%,C$Q038T0T)!.#(X1$,V
M1C`S-B(@<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/2)X;7`N9&ED.D9$-SA#
M138W-#-"0T4R,3%!-C1#0D$X,CA$0S9&,#,V(B\^(#PO<F1F.D1E<V-R:7!T
M:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A/B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(#P_>'!A8VME="!E;F0](G<B/S[_X@Q824-#7U!23T9)3$4``0$`
M``Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5```
M``!)14,@<U)'0@```````````````0``]M8``0````#3+4A0("``````````
M`````````````````````````````````````````````````````!%C<')T
M```!4````#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R
M6%E:```"&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5```
M`'!D;61D```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#
M^````!1M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#
M```$/```"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY
M."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)
M14,V,3DV-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````
M````````````````````````````````````````````````````````````
M6%E:(````````/-1``$````!%LQ865H@`````````````````````%A96B``
M``````!OH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````
M)*````^$``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```
M````````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````
M``````````````````````````````````````````!D97-C`````````"Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`
M`````````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92`M('-21T(`````````````````````````````9&5S8P`````````L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``
M````````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V
M,3DV-BTR+C$``````````````````````````````````'9I97<``````!.D
M_@`47RX`$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G
M;65A<P`````````!`````````````````````````H\````"<VEG(`````!#
M4E0@8W5R=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%
M`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`
MMP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R
M`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!
MV0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B
M`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#
MH@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$
M!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&
M)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L
M![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)
M>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI
M"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-
MJ0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)
M$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2
MPQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;
M%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8
MU1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ
M'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?
MZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"
M(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH
M#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN
M+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q
M2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W
M-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[
MJCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I
M06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'
M-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*
M39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3
M]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF
M6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A
M]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#
M:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q
M.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ
M>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!
MS8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HID
MBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3
MMI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SW
MG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF
M_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#J
ML6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[
MI[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&
MQL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1
MOM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0
MW9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI
M1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50
M]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@`.061O
M8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"
M`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P/_P``1"`"N`,<#`1$``A$!`Q$!_]T`!``9_\0!H@````8"`P$`
M````````````!P@&!00)`PH"`0`+`0``!@,!`0$````````````&!00#!P((
M`0D`"@L0``(!`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3(@`(,11!,B,5"5%"
M%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:
MLL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*
ME)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V
M]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B$T%1!S)A%'$(0H$C
MD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B
M\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G
M=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*
MVNKZ_]H`#`,!``(1`Q$`/P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=%<^%555UOQ9Z8JJZLK,A5S;6D:>LR%74U];4/_&,FNNHK
M*N6:IG?2`+NQ-@!]![]U[HT?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_]#?X]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%6^$7_9*72G_AJ2?^
M[G*>_=>Z-3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__T=_CW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5;X1?]DI=*?^&I)_[N<I[]U[HU/OW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[K__2W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW15OA%_V2ETI_X:DG_NYRGOW7NC4^_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO_]/?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=%6^$7_9*72G_AJ2?^[G*>_=>Z-3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__U-_C
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5;X1?]DI=*
M?^&I)_[N<I[]U[HU/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__5W^/?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW15OA%_V2ETI_X:DG_NYRGOW7
MNC4^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO_];?X]^Z]U[W[KW7O?NO=1:Z5X**LGCM
MY(:6HECU6(UQQ.ZW!(!&H>_=>ZKGQ'=':W8&'V8D.ZJ>2IR>YNA,G59_;&V\
MKA:/:^<W;NG*8K<77V=QYR,C[DQRX>B3(2!IH5",!/\`L30GW[KW2NHN_P#M
MB5MJQU4>(CR:OB*&BP`VEEHJCNG(2=EYS8FZDP5>]8]/LV7:^%Q,61E1A4>-
MZCS2_P"1*"?=>ZPS][]T8W$9++&/#Y],MMO=^7QD,&TLAC#M"EVMW-2=>29R
MNG?(U$>6IX]K9+^(U"2+`B/3>0?Y-Y2/=>Z-=U!N/<>Z]A8C-[IDP%3DZB?*
MPQY+;5>F0Q.9QM%E:RCQF722&-::"KKJ*!&J8H6EIXZC6(7:+0??NO="9[]U
M[JL3;^[MY[%_EB83=.P*BKH=S8W8.,2'*T3>*HP.(R._X,7NC<@JQB\X<9#M
MK:];65\M:**K-#%3-4"&0QZ"'.;;N\L>7=SNK!BMRJK1AQ52ZJ[UTMIT(68M
MI;2!JH:4Z/N6+:TO-]V^VO0#;LS8/!F",46E5KK<*H74-1.FHK7IJZ\[$[$R
MNR_CED\+VCN2;:N-^666ZNSE31[IC[3P/<NW*FFW5)BZ[`=R9W"T.Z=V]9XF
M1/'3S2QM7U-?1/%/D*J"`&8);?N&X2V?+TL.YR&U7=6A8A_'6X0A])6X90[P
MKP!(U%E(:1E7(GOK&QCN]]CEVZ,7+;:LR@IX+0,"E0T"L424\2`=(5@0BEL*
MOXN]I;>S_;_;.4V_\HJOM/KM8DV_4T._]\[0RF7SG;4G8&<Q$N;ZTV3B&HJ_
M8G75`8_[L4%+%2TU-N#(4ODI896B-;7J^6-TMY]VW66WYF-UM_P$2RQLS3^*
MRZH8UH8HA_8JH4"5UJH)&N1-S#MT\.V;;'/R\+:^^(&.-PJP^&K:99&J))3_
M`&K$DF-31B*Z$+#N?N&OCAW?L[8'R?SFZ-A;EW?L'<J]L;X[]J]B;9V?]UMW
ML:IW5L7M'O"BZN?+?&K=NX=SX?'O1;-I\54M$*&&E_R-,I401AFYW>0+=V=A
MS,\MA++$_CR71B2.J3%XIKD0ZK.1W5--N$--(7L$K*!#;[6A-K=7O+R1WL<4
MB>#';"1WHT022&W,VFZ149M4Y<5U%NXQJ2<KK7L/?];NOXO[SWIV1GJ;9.\_
MBUN_/;IVMNC;N&V;2Q;GVC1=75^=[-WC6%5J/OZ],U.\$6NAQM!1.[B!GD,B
M##;=POWNN6;R\W&064VV2,Z.BQC7&(2TTAXU.HD"JHJU.FIJ`M?V-DEMS#:V
ME@ANXMQ14=&9SH<S!8D'H-(J>YF:@K04)7]^]U]I3=Y]_4VS.XJC!R)M?M_$
M;9Q&7WH\J[2P6W.I]J;JVYV!F>H%VI78;8/6$%9%DJS"=EQ5^1FS5=E*.GK*
M%Z)1'&&;_>=T;>]^6SW<H?"N%16D_LU2!'25K?05BA!UM'>!G,C.BNA3`$%G
MM.W#9]E:ZVL./$@9V6/XV:9T:-9M8:24C2LEJ501JCLCA\E-4?=&87JRGS=3
MWOV5M6IVCVEE,A\>\?F.Y,'NS,]R;&Q%3UC-O+!56]-MX/=NS?DQV'ALYE\M
MA<'M>',5%/6_=^.2JE>E2NI$R;S-^ZUF;?+F)H;IC:AKA9&N(U,/B*9$62.\
ME5F>..$2$-JH7)4.BA]IB_>+0KL]O(LML!<E8&18)&$OAL(W9'M8F54DDE*`
MK2H4!BC&&^-_8G9N6^6'8>T:_?&2WSB%@[DK>R8&W_@=T;1VEDL+V3A:#J#'
M[0V%1J=S]+U%)L[(5F,R6+S7VM7E:V@FJ4BK8X?XG*(.7=PW*7FK<+1[UIXJ
M7!F'BJ\<9691`(XAWVY$99'232SLI8!POB$DWZQV^+ENQNDM%AEK`(OTV1W#
M1,9B\A[)P7"NKQU5%8*2A/ABSCW)74?=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U_]??X]^Z]U[W[KW7O?NO=8Y8HYXI(95#Q31O%(AO9XY%*.IL
M0;,I(]^Z]TV8#`X?:V$Q6W-OT$.+PF$H:?&8K'4YD,%%0TD:PTU-$97DD*11
MJ`-3$_U/OW7ND1W'V+)U1UWG]\P[?K=T5&)%!#2X6AE%.]75Y3)4F*I//5-'
M/]K1QU-8K2R".1@H]*DD#W[KW28D[_VAC)\[C-PT&Z,7F-JX"FW'GJ<;9S$D
M!PL61QF'W'GL3JIDK*[`[4R.34UL[0QLM*K5$:R0JSCW7NA.V=NW$[ZV[0;J
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M:^@$LCUAIXHXGJ2&TYG>2WV4_NU"9[LP.8W_`$X2NJE1(D<H<E0!$8E9:DOI
M`!8ZN>74CN-W'[P8""U$R!T[Y0=-:%'DCT@$GQ!*RM0!=1)"JCJ;M+<>Y.W]
M\]:;TZ3VUL/*8?;%!OS'U^VMU8;>M?0X6JW-D\+MW#=H'&X/&8[:.^\]!C/X
MQC*.EK<M3RT)E/W*R4SZU6U;I<7&[WNVWFRQP2I$)04=9"%+LJ+-15$<K`>(
MBAG!6O=535/N6W00;79W]INTDT;2&,AT:,%@@9FBJQ+QJ3H=BJ$-3MHPH%F9
M^2O8V,VAWO/ENI>FL%F^EZW;NX]]X;+]GYJOVS5;>W;@\OFJ'#'+8OJN:KR?
M<5/6XNAII<?#CZC#U,V0@6ERT\R20H5S<Q[A':;ZTNU6:3691Y5:9BA6168+
MJ6"K7`*J"@4QDLNF5F!4&,6P6$EULPBW.[>*[#+&RPJ'#(RJ6H9J"`@L0Q8.
M`IU1@$$B#CNY.\ZCM3ISKG=74/6-"G9FRJK=V\,=0]G9S-[PZOP>,VW0S;NG
MS^*?K:EP62Q\.^,M0[?HFBR"#)S3/*`D=/*%7Q[QO;;IL^W76TVR_4PF20"9
MFDA54'B%E\$*1XC+$M'[R2<!3TB?:MG7;MTO[;<[@FWE"(3$JI*Q8Z`I\4L#
MX:M(U5[``,EATL\SVYGZ#N/>/5FVNFZG*Y;"=)R;^VON.NW#MS;U%O[*4F=@
MP\.QL8S+7Y#$X?'5.2A^YR5='%%%),PIZ>I",Q63;M/'O%YM=MLY:5++Q4<N
MB"5@P7PEXE5!(J[``$]JM0])(MLA?:K7<9]U"QO=^&ZA68Q@KJ\0\`S$`T5:
MD@=S+7H`Y_E5OVEZQH=]4O1G7V1QVP]^[FV9ODT/:4,&%?/;:W3A-GX?!]$Q
M5NQ*;<.]=Y;SJ,_,,52Y'&;<A:>CDIS4?Y132RD3<T7R[8E\FR6[1P3O')2:
MBZD=8U6VK$'DDD+'0KI$*J5U=RDG2\N63;@]FV\3J\T*21UA[M+(SEKBDA6.
M.,*-95Y31@VGM8`6.G/D#6]B=U]L==Y';6TMG1;8K]R0X&GJ*G?E#V1O.BV=
MN5=G56[*G$;CZSVQM.OVY)/"#'/B,YFGI8:BC$XB^Y2QKM&_ON&\[KM\EM%"
M(F<*"91-((W\,N5>%$*5X&.632"FJFH=%NZ;(MCM.VWT<\LID5-1`C,49=-8
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M(*&A*L""&5E89#*P#*1P8`]++"^N-MNX+VU($T9Q4`@@@AE8'!5E)5AY@D="
MWMKXT;`VYMW:^#;)[RW!6[<[67NRLW;N'/I5;JWCV3]O74<NX-WUM%08['UZ
MST=:(/M::EI*2."G@CBBC2)5]EEMRW86]O;0&2:1X[KZ@N[5>2:A&N0@`'!I
MI"JH`4``#HPGW^]GGN)A'$B26W@!%6B)%4'2@))&16I+,22223TS]6_%[$]3
M56X9L)V]WCG:7=&Z)=WYG&[RW=@=Q4]9FJW<<FX<S)55T^T8<YD(,W&ZXR5*
MJKG$&(ABI*7[>.*/2UM?+,6U-<-#NU[(LLOB,))$<%B^MJGP]1U?`=3&D8"+
MI`'3FX\PR;DL`FVNS1HX]"E$92%"Z5H->D:?C%%%7)9M1)ZA[>^(/6F$.4DR
M6X>R]\5&1RW7=1!7=@;REW9D<3M?JK>?]_\`9'6^/R.0H?OIMAXW=)-1/!62
M55=D.%JZJ<)'HI;\I;;#XADN+F=F>(@RR>(52"3Q8X02*^$'R0Q9G_&S4%+S
M\SW\OAB."WA55E%(TT`O,GAR2D`T\0I@%0%7\*BIJ,M9UE@:K=F[M]15F:Q^
M[=W;"Q?74N<H*Z)*O`X##UFY<E12[:6>EJ*?&9+^)[IGJ9)6259988"ZD1`$
MX?;8&N[N^#NMW-`L6H'*JI<C14$`ZG))S4A:C'14NX3+;6UF51K:*8RZ2,,S
M!`==""11``,4!:ASTG]R]&[0W=75.5SF2WA+EJSJNOZBJ,MC]TY'!Y4[>R.3
MQV9J,O3Y+!-C:S'[M3*8N*>/(4SPR1.#I`!M[3W.R6EV[2SR3&4VI@+!RK:"
M0Q8%:$2:E!#BA!X=/V^[W5JBQPQQ",7(F"E`PU`%0I#5!2A(*FH/GT"4OPCV
M@V1VMN&G[E^0E'N_;>8W%N6LW>F^L!69;>&Z]R46#PE1NO=U!E=F9':];N'%
M;0V[2X+&5--CZ1L7B!)#2B)IYY)"4\EVADM;A=XW`7<;NYD\52TCN%4O(&C*
M%EC18T*HNB.JK34Q)L.;;K1<0-M5B;6150)X;!412S!$(D#A2[&1P6;6]"U:
M``7-F_'W:>S>QLKV8NY.P]U9>>GSU%M?$[YWA6;JV_UK0;LR5'F-V4'7U)D8
M6KL/3;CR6.IVF^XJ:QZ>"GCI*5J>C1:<&UGL%K9[A+N7U-Q+*0P199"ZPB1@
MSB('*AR!6I:@`1=*#3T676]W-U81[?X$$<0*ES&@1I2@*H9",,5!-*!:DEFU
M.=70[>SSHGZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_T=V.K^8W
MQ=H*RMQ]9WEU_3UN.K:S'5U-)F5$M+78^IEHZVEE7QG3+354#HP_#*??NO=1
M_P#9T/BI_P`_WZ\_\_2_]>O?NO=>_P!G0^*G_/\`?KS_`,_2_P#7KW[KW7O]
MG0^*G_/]^O/_`#]+_P!>O?NO=>_V=#XJ?\_WZ\_\_2_]>O?NO=>_V=#XJ?\`
M/]^O/_/TO_7KW[KW7O\`9T/BI_S_`'Z\_P#/TO\`UZ]^Z]U[_9T/BI_S_?KS
M_P`_2_\`7KW[KW7:_,_XJL0H[XZ[N38:LVBCG^K-&%4?XD^_=>Z@?!YTE^)O
M1L\3!X:G9J54$B_IEIJK)Y&HIYD/%XYH)593^01[]U[HU?OW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[K__TM_CW[KW7O?NO=>]^Z]T0ZC^4VYZW)YBBHJK8U5AI<CLLT6\
MZG$9S%XS8^'W#V!N/9V6J=\X*KSZ9,+C8\)`J-4SX5Q55L;3QPP/$S^Z]T@%
M[Z[$J.N\5BWWIC<975ZXW*P;HJ$J?[S[X?.?(?)[2JL;U[-*]-1146U=N44:
M3":DKIC2U47D6%!]PWNO="/E_D1VKC]O[2R\&,V))4;VSO:0Q;Y%VV_M^BH>
MN\]+@<1M6LS6=W/14K;EW@\;3_<>5/`D4@@HZHJQ7W7NG"M^1._J7,]I89H.
MO(<AMC#Y/);;I9:^63!TO\)W'@L/5P;JWE%F!287,0T^6:/[++46%CJ<BJK3
MU,E+KJ%]U[HP_36^JKL78&,W+7F,Y%ZW-XS(F#$U6'I35X;,UV,<TD$^1S5-
M50Z*9?\`*:2NK:&H?4]/,\14^_=>Z%+W[KW5=O5FY]N;,_ER[:W/N_M')]+[
M8Q'6D\^=[-PB8Y\[M?'2;DJJ>HFP(RF-S%*,[DDF^RHF%+/.E54QM`AF$?LF
MYAN;>SV7<;F[W-K.V2.K3+34@J`=.H,-1^%>TG41I%:=&VQ6\]WN]A;VNW+=
MW#/VQ-72YH2-5"ITCXFR!0&II7HK\/:VZL5#T3D:GOFKWQ@*/.[DK]L]44G?
M^5INYM\T>9[RVSA-L;,J]U["QNX-H=_=A=?[9A-#F-OSYCS4QR#Q5DALN3>,
M5W2ZB78Y&WTSP"1RD`NF%Q(&N45(R\0>.ZEB3MDB,E1K(<\)3(;;;;2'>(UV
M80S%$#S&V!@C*V[L\@20J]M%(_<D@2AT@J.,84FP>RNT=Q8KY"T.V/D3O.MW
MTW079F^.S):JFQ>Y(?COW)MCL/<.&QNU-L;;R=$]'UU75>T\=74U+AJ[S+HQ
M4&3:GJ&>:2J46&Y;G<1<P);<PS-??032S5"N+2X25U"(C"D1*!@L;5^!9=+$
MDLQ>V&W02;(]QL<0L_K8HXJ$I]3`\2L7=@:R@.5)=:?&T>H4`4RO<?:F]>M^
ME?CMWI19_<%3#!C=M;?W?@XT2NH-UYGN+8"[5V!DMR1B$3S-0]QY+!+Y$\86
M.NG9N./8DW?=+W;MFY>WQ+B0J%19%XB1KB+1$7Q7%P8LBF&;H@VO;K2_W;?-
MG:!`2SLC<"BP2:Y`OVP"3C7X1T#O7W;W:W6PWOMS>W9F:W3FOC1C]G]![BR^
M_,955E+V/VEVYO[;^:VCV/EH,+#@XZV=.K*_&FG\E;C,?'49&6.IJZ2,O4Q%
M&W[MNFW?6V][N3RS;:L=J[2@D33SRJT<S!=-?T"E*LB`N0S(*L#6]VS;;_Z2
M>TV](XMP9[E1&0#%##&RO$NK53]8-6BNU%!56-%*NV_\X-V9+`[.FS&(Z_P-
M;OY=YQX3<V0K,A2[1P]%T9V5O[;OR'WCNB.?,!*##;/ZYVQC]PTE$N2U2'(&
MG^]F1%G=5;\ZW4D%FTT-O&\_B:7)(C46TTJ7<CU;"QPHLJKKSJTZR!J*6?E&
MVCFNA%+.Z0^'J0`%V-Q%&ULB47+/*[1,VC&FN@$T"8S'SOWYM[K6HW]6#J/,
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M.X>4[+<)T$4<T,#P1A6JK#Q/I/&=Z:265G%*?IJ*D"0L-`3OS"[0WIM/OK=X
MPW<LFR&V;U[T?G]H[2/><NP\OE,AF>P-ZP[F;8W1G]Q]RXGY$[ASV.Q<-"N.
MR%;CX6J/#2JR-,)XT_-VYWEKOMWX.\>`8;>V:./ZGPF8M+('\*V\-UNV8*%T
M.RBNE12NH/\`*^WVESLUKXNU>-XL]PKO]/XB@+'&4\2X\1#;*I);4JL:5;-*
M$5LK\UMYXG,91I\%L(XA<[O:CKL"]5F(MX=-X#K_`+?VCUY4Y_N[QUU528>G
MWKMW.U&4QS""B@I&6`>2NIGEJHC27G.\AFE+00>#KD!6K>);K%<1Q%KG)"B1
M&+IA0O;EU)8%L?*=K)%'IFF\71&0U%T3M)`\H6WP"WALH1LL6SA&`4IBN^8.
M^'W]N;([=DV_58#([JJNJMNY*LR-/4=5;9IMH=B]UX[_`$@YZLR.>V?22YK?
M-)M&#%TX.:H:&:KBC$4K$)'.F?FZ^-_<R6YC-NTI@1B08$$<MP/%8EHQJE$8
M0?J*I8"A.`RA.5[065NDX<3K&)F`!$SEXH#X:@*YTQERY_39@I-1Q(5E=\VM
MW8NA6'-[0VC@LY_HMQO?M6SY#<.;P./Z9R>RJ.CI\L*O"X^?(YC,R=VUBX:.
M.EIV#XUEJ2B*'F16_.EU%&!-:1)/]*+HY=E%N8P`U5!+-]2?#`4?!W4`JP3)
MRE;2/6&ZE>'Z@VPPJL9Q(25HQHJ^`-9).&[:G`*:C^;O:\E%O&2BV;LC,3=6
M_P"FU]YS4M/G5.>H^N-U=6;:PF3PU!AL_NJEVWC(*?LN7(YR?^(YZ*"DP\II
MFE\VJG3#G7=2EV4LX7-K]3XE`W<(7@164*SA%`F+R'7*`L9TUKVJ#RCMH>U#
MW4R"X^GT5T]IE29V#%E0L28@L8TQDLXU4I1C+?$_?^Y>P\;W=D-R;TP&_#@^
M_P#=VV,)G=HR3/M'^`8O:FQ9:*DVU'/4Y&6EQZ5%9-)+#][7K%623JM3(H%A
M)RK?W.X1;U)<WD<Y2_D16C_L]*I%0)4F@J22-348MW$=$',EE;V,FT);VCPZ
M[)'97^/47DJ7P*F@`!TK50.T=&N]BGH-]>]^Z]U__]/?X]^Z]U[W[KW7O?NO
M=130T1$JFCI2L_D\X-/$1-YF5IO*"EI/*R`M>^H@7]^Z]UR-'2-XM5+3MX?)
MX;P1'Q>8WE\5U_;\I_5:VK\^_=>Z\])2R1I%)34\D4<JSQQO#&T<<R/Y4F1&
M4JLJ2'4&`N&Y^OOW7NO?:4NNID^VI]=8B1U;^&/751QHT:)4MIO.B1N5`:X`
M)'T]^Z]UEBBB@CCAACCAAB18XHHD6...-`%2.-$`5$118```#W[KW7/W[KW5
M=75_:$?2O\N/;G:<NR:KLG^Y76=1EX=@T%504=?NZK&XZNEHL#05.4BFQ\5=
MD*RI1(?*I4RE1^;^R?F#<EV?9K_<FM/'$*5\.H!<U`"BH.23C!^SHVV+;CNV
M[V&W"[$'BOI\0@D(*$EB!0T`&:>72_?Y.=;XSLO9_7^$V)BJ;;]=USM/M./?
ME;4XK;V!VW7=@[GVY@,7M:''08JMR)WCE=M;BDR2^%$AE2-*:26-JA64D/,N
MW1[E:6$%BHMVMTG\4E45#*Z*J4"D^(R.7Q@T"DC57HV'+]_)M]U>S7C&<3O#
MX8!9G$:,Q>M0-`=0F<C+`$+TNL?\JOC=4XI,]BMWQ5%/N:NV_'20X_8V]9<Y
MNV;=>SLSO';.0Q.WJ?:IW#NC'9[9NU:^JI*ZFIJBEG@H)D64M$R!='S3RZT0
MGBNZK(RT`BDU2:XVD0J@36X:-&*L`5(4@&HITC?ES?ED\&2U(:,-6LD>E-#J
MC@L7TH5=U!4D$%@:9KTH%^2?0=158W$IV!@ZA,GA\3F\;4)0Y2;`U%+D]JS;
M^P5'%G%QK8%<]D=G43Y:DQAG&2FHH_-'`4`/M1_6/8F>.(7Z$,BL#1M)!3Q5
M&JFG48QK5*ZRHJ%ITQ^X=Z59)/HG!5BI%1J!#^&QTUU:0YT,]-(8T)KTPYKY
M2?'*&BFI=P[H$8R=1N7&9;;N7V!OC^-0+M';F"W1NJ3=.TZO:AS>'Q&$V?N2
M@R=559&E@HX\751U)D\!UA/-S/RZ$9;BZ^(N&1HI-0\-%=]:%-2JL;J[,ZA0
MC!JZ<]/Q<N[Z75H+?X0A5EDCT][,B:'#Z69G5D`4EM8*TKCI&[W[B^/V*WI4
M;LQSG?W86UJ"+K["X"CDRD>W30[@WALC$;^&RJW(T:[`R^X\-3;KQDVX/X=-
M49*+'PQ4]1XX_3[27N[[!%>-=1GQ]PB7PE45T4>2-9?#)'A,ZAT,N@EP@"M0
M=*K/:]ZEM5MG_1L9&\1F--5521H_$`/B*K%'$>H!2Q++4]+WK/M7H[>^2H=L
M;9CV=/NH?[GJ[';0PM9G-O8?,UF$2M_=WC3;7QN!I]PUVUZZ.=(:AJ7(S4,V
MKQ&,GVNV[=-EO)([:V$)N?C(C4LBL5K_`&@0*'*&M#I<J>%.D5_MN[V<;W%P
M91;_``@NP5F4-3X"Y8J'!%150PXUZP[^[AVML;OOI_J7*[!BJAVGB=_YE>QK
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MWJ/9$NN];HQ*U2%!\327`K@5&HTS^?12*[YO8==@=75N0ZWZ:=.S]Q;LVQ7T
M51W92MUIM#'[$7;*5%#NC>51U.D=!N@Y3<U+30X>MQ-'#&ZF5JM8-,K!.3G6
M(6&V/)MMG_C,DB$&Y'@QB+14/(8,/J=0(V10#G7IH>A*G*,IO=P1+Z[_`,7C
M1P1`?%<R:Z%$$V4HA)=78GAIKCH<.P/D]1;=WAO_`&1@>J\SOC(;;VQLFDP5
M>V1PN"P6_M\]@=E-U=2];8S(99)##28#/5-.V:R;QR45&DTD:I//3SQ*=W_,
MR6]Y?V4&UO/)'%&%-559999O!$*EO)6(\1R"JU(`9E8`HLN7GGM;*[FW%(4D
MDD+"C,T<<<7C&4A?-E!\-,,U`20&!Z#;&_,R@I]V]5=;S=6;3V+GMSRYO:^]
M,?NWLC&;<Q&R,YM?L=.KZ[9.T,KCMF9;#;_R]55T<M;C:9Y<)'6T"TP4I45"
M4Z%L7.$:W>U[<=KB@GE+)('F5%C9)O!,<;"-EE8D%D%8PRZ>#,%"^3E5VMMR
MOAN,DT,85XRD19I%>+QA(X+JT:@$*YI(5;5Q52Q&OMKN?-](9S96(Q'2U7F^
MMLCEME[=SN\,3N/;F`7"Y7?F[J39>W=O[)V)X)\WO[/4U54K6U])3K0QT^,&
MN&6IG!IE.MVWF;99[*&+9B^W,\:-(KHNEI9!&B1Q4+2L"=3*--$RI9NWHIVS
M:H=WANY9=V"7ZK(RH59M0C0R,TDF%C4@:5)U5;!"CNZ0^\OF!-MZKWW@<5U-
MFY]U[=[JVKTAM'';UW9MOK_#;SS>Y]H5.]8-UU6X*LYG^Z6RGQ6+K$HIJBEF
MK\E/%"D-)_E4)9%><W-;M?00[4YNH[U+:,2.D2R,\9D#ESJ\./2&TDJ6<@`)
MW#I9:<KB=;.:3<T%M):/<.8T:1HU1Q'H"C3KDJ5U`$*H)JW:>@\S'SSS--M[
MK_L7;O2<&Z.JNP-@[L[%I=PP=L8+%;HQ.WNM=H9O<O:62R6ULEMV/"_P79F3
MQ=/BQ7QYQZ:OJ<G2/"?%+J!?-SU,MO8;A;[*)=KN('E#B=5=4AC9YB4*:=,9
M4)J$FEBZ$8/2Z+DV)IKVQGW8Q[C!,D17P6*,TKJL(#AM6J0$OI,=5",#D=?_
MU-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T1OXV=?
MXKM#X/\`5.R,U6Y3'8[+;<Q-3+6X::GI\E!-@M['<-$U-+54M;3KJK<5&KZH
MFO&6`L2"$.Y6$6YV<ME,[+&Y4U6@(TLKBE01Q4>7#I987LFW7<=W"BM(H84:
MI'<I4UH0>!/GQZ50^&'5J)H@R^](%&\-\[PCT93&,T,F^-];6WXVWH&DPKM%
MM?:E7M*FH<-1@Z:#&O)"&8L'4A_J=M8%%EF`\:63XEQXDJ2Z!V_`AC"QK^%"
M1\^CK^M>XG)BB)\*-.!_T.-X]7Q?&X<L[?B:A^72RVW\:=C[7W1UWNV@RVZ9
MLCUKM;9>TL'#5UV/DI*O';%V/O[8.)FRD<>+BEFK*C$=B5LM0T;Q(]3%"RJB
MJZ.LMN6[*VNMONXY93);11QK4BA$44L2ZNW)*RL32F0*4%04L^_WEQ;WUL\<
M82XDD=J`U!DDCD:F<`-$H%:X)^1`9XSX-=9X0?;X/<^]\+0/@*+'SOBI]N46
MY_[R8[8T?7M-O?';[AVZN\MOYHX*"*:2#'5E+0/D($J/`"94E+8^2=MA[8+F
M=(_#`.G0'UB/PA()0GB(VD`D(RJ7`;3Q!,).;]PF[IK>%WUDBNHII,GBF,QZ
MM#+JJ`64MI)6O`A(GX,4^,W/05&U^R=T8+;NX*+L=.TI,<NV,;E<N^\]C]<=
M>PX;:^*@V=/@<)M^HP&RI):A@%KJ6O=:BGFU22`)#R0L=S&UKN,L=O(LWC4T
M!F\2.&+2B^&452L9)_$K=RG)Z4_UP,ENZW%A&\Z&+P:ZR%T22RZG)<,S!I`!
M^$J-+#`Z$./X7];0U>/IX,]O*FV?MC)UF;Z\V+3UV-3!=?9C,Y7!9/<55@ZF
M3%RYFN@RPP?@2GR%15PT4-=5_;A'DB:`P')VW!XU6>86D3%HH@5TQ,S*7*G3
MJ(;32CE@H9]-"051'FN_*NS0Q&ZD4++(0=4BJ&"AA72"NJM5"EBJZJ@&N3&_
M$C#[6S&*W/LOL#=^)W+M+8^8VIL;(UD6W:E\/6Y';N3P%%69VJH\'C\EO?;.
M(GR1R5/M[+S5F&@RB"IA@BD`MN+E2&UFBN;._F6YB@9(R=!TDHR@L0H,B*3K
M$4A:,/W*H/6I.9I;B*2WN[*)K>697D`U#4`P8A06(C=J:3*@5RG:21TL.W_C
M5M+NU'DW=N/>..R4FPYMBC+;3R%!@ZZC2HW5M;=TNXL1-)C*]\7N%:_:J01S
M1G0E'5U$6D^34JO=N7+3>@3=W$RR>!X6I"%(JZ2:U[3I>J``C\+,*9Z2[7OU
MSM)I;01-'XWB:7!8&B.FELBJT>M#^(*?+I.9SX<]3[CQ'9N`R]1NJ;#=H[>W
M1MW*4-)E:3&+M^#<>[7WK19+9\^-QM+48#,[-SPAEPE0C,U`U+"P#.FHIIN4
M-JN(MR@E:4PW4;HP#!=`>3Q`8Z*"K1M0QG\.D>8KT_#S3N4$NWS1+'XMNZ,"
M03JTIX9#U)#*ZU$@_%4^1Z&>GZUQ]-U10=24^X=WT6-QNQ<=L2CW7BLXV%WS
M2TV*PM/A:+/TF>Q,%&E'N2):5*CS10K":@<Q&,F,G*[;&NU1[2MQ,(U@$0=6
MTR@*H4.&4"CXK4"E?*F.BHW[MN3[FT$1D:8R%"NJ,DL6*E6)JF:4)K3SKGH!
MZKXBTU=B\Q2U?>7=3YG?-=F9.X-R05VP:*J[?PV<PN"VS4[?W1A*3846T\)2
MX_;&VZ3'8^LP-!B<G04OF$-2K5$SL1MRFKQ2J^]WOC3LWU#@Q`W"LJH4=1%H
M4!$5$:)4=5K1JL23E>9F22)EVBT\*$+X"TD(@969PR,9-;$NQ9ED9T8TJO:!
MTRS?`#X\X_.Y/=&P<1FNK-PU6UZ';V&R6Q,HM,NTLCB]\T?8N-W=MO'9NES>
M)I-PT^Y\?%(_D@EHZB$R12P.LTVMAN0N7TGENK&)[6X,016B:GAE91*)$#!E
M#AP#D%2*@J035T<Z;V\,=O>R)<P"0LPD%=8,9B*.5*DJ4)X$,#0AA04=YOAO
MMBLP^+VSE.TNV\MM2KKJK,=I[7KLKM1L)W7GZW?,W8]7GM[4T.T(7P>3K-US
M?OOMIL$)L:D>/<&DBBB1X\H6SPQ6TNYW;VI8M.A9--RQD\8M(/#[27X^#X54
MI&>P`!H<TW"RR7$>W6RW(`6%P'U0*(_""QG7W`)P\7Q*-5QW$DN^=^*F$J>Q
M-D;_`-G=@[RZY@V%3Y"/![(V]C-@9?945?N'<-1G=X;EAQN\]F[FK*#>.[J6
MI?%U.5IJB&LI\4SP4;TWEF:1Z?E>%]PLK^SW":W$`.F-%B:.KN6D>DD;D22`
MZ"X(8)54*U)+4/,<JV-Y975E%.9B-4C&19**H5$JCH"B$:PA!4O0L&H*/?8/
MQIVYOQ.RW&[=U;=K>T-Q;$W+G)Z*AV-N+'Q5?7^&HL)B:`;9W[L[=NU<MAZN
MGH(YJBGR-%6#[I$FB,4D<95[<.6[>_&Y'ZN6-[F2)V($3BL2A5&B6.1&4@`D
M.K=U&%"!1JRW^>R.WCZ:-TMTD1:F1321BS'7&Z.K`D@%67&#4$UBXKXG=5X;
M%5&"QYW%#B9NALC\>8Z4Y2%VH]F9W(9/*[DRE)+)0L8MT[CR&2$M74V,#/30
MZ855-)I%RKM<,301^((C8FTIJ&(V+,[#'QN35CPP***=6DYEW&619GT&47HN
M:TXR*`$!S\"@4`XY.<]?_]7=1K)OFT*ZO_A^-^+#XT5];_"S69OMJ*N;%BJE
M_AWWZP;?F@2O-%H\_C+1B75INMO?NO=8!4_.,?7"?%%C_ANCMY/]A_QZ#_[?
MW[KW7,5GS?\`SM[XJ'_6WCVZO_RBO?W[KW645OS9_.V?BR?];?/;2_\`S.VO
M[]U[KO[[YL?\\O\`%K_T/.V?_M<>_=>Z]]]\V/\`GE_BU_Z'G;/_`-KCW[KW
M7OOOFQ_SR_Q:_P#0\[9_^UQ[]U[KWWWS8_YY?XM?^AYVS_\`:X]^Z]UV*[YK
M7&K:WQ;*W%P-^]L@D?FQ/6Y`/^P]^Z]U&^#OE/Q-Z-,XB6H.S5-2L#.T"U)R
MF2-2M.\BI*].L^H1LP5BEB0#<>_=>Z-;[]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z_];?
MX]^Z]U[W[KW7O?NO=%`WQ\F\KLG>6X]G56T,=4U>WZ^:DFJ%S,Z((]V4&-@Z
M6>5#0,1+V!N^IJ<5*JEOM'I&=3)^@>Z]TE=S_)7?\VV=^U^+VHFU(=MY:BQ5
M#NJMFI9,=19C`=I[<V)NC!Y^/*PM'#'G?NJLTU3!%**.G'[VF?0#[KW2@J?D
M[G:"HQ<>2VOMRCQV.WMG]G[ZW.F?K<AMO'2X7<^`P$=5BI:'%RYE,?5P;BC=
MJ^JHEHJ>MB:BE=)75_?NO=)>7Y(;YP.1R>0JHL-FMN46V=TM18>65%W'7;E3
MY"9'J/#UTE30T-/3C!XN-8ONHXXS)'``2\L["_NO=&VZVW3F=X[3H\UN#;=5
MM7,&LRN/K<7421RQR28K)56.7)4+I(\JX[*QTPJ(8YPE1"LGCE42(WOW7NEW
M[]U[HA'0>_JKJWX)=7=AQXQ,KBMH;8H,UN^(O,D]!L.EW;4'?6X*)88Y#45F
MU]JM5Y)(&TK/]H8]2Z@P+=WOVVRPFW`1:HH2K2>HB##Q7'J434]//33%>C#:
M[)=QO8K$R:9)053YR$'PU/H'>B5\JUZ9*GYM[M26OJJ3J:DJ,;M^LFV'N"E&
MY:U\P_<N_0,G\<-H8(Q8!\=D,'VSMNOPU349%I$7%R[DH$*2!:AHP@_.EV#(
MR;2#'&?"8:SJ^HE[K2->VA6=#&2]>PS1BA[J"E>4K4A%;<B)''B*=`T^!'BZ
M=NZH:%PX"T[Q$YJ.VN>7YTKC:>?=65V?C3UUEM5=LO.T&:K9<CD]M=7Y>DQ/
MRFW)7T3XK1]ET[#)5U]&M.9'R]#C9R/$^E3L\[^&K74MHO[O?,;!B2R0L%O7
M(T\+?N9:5\14;@:#JHY/\0BWCNF^N7$BE10/*I-HH->,^%:M-#,O$5Z3?R`^
M1W9&'ZSV7O/#Y["]>9[)]9]P[OS6"ILWAJ['8>;'83;&Y>OFW/E\IBJI\*\6
MVLO#6UA,`$$=3*VB5$0E/OW,6XQ;;97D,Z6\[6UQ(RAE(6BH\6MF4Z>Q@S8P
M&)H0!THV78;"7<+NUEA>>%;B!%8JP+59TDT*"-7>I5<YH!4$GJ'7_+3LFE[/
MJL,DNS7JXVI^JJ:GBRKU'3/]\\MV918JB[+JMUBCAW&,5BL/4?P>LHE(']X2
MM`KAY!.M).:]Q7<WA!AU"D`&JMOXC3!1,7IKTJI\-E_W[^G6IU=63EJP;;UE
M(ETYF)TTGT+$28@E=-2PUJW^^N^E!0KO:_S0R&=W7M."?$==5&T,MO3!=89>
M3:^^*K<&XI<]E=A56_*SM3:25&'Q%%F^AL?3T4L29>5*>6HI:>IKK1Q4YBD7
M6W.+SW5JK16YM'F6%M$A9]31&4SQU50UL`"/$-"5#/@+0H[GE1(;:Y(EG%TL
M32KKC"KI$@C$+T9BMP20=`J`2J9+5&'=?S0S&#W1O6@I,-UO2X?%]BS=.[6Q
M^ZM[UN$WK-NB,;,D_P!*.X\1!AZ^CI.C(:3>D5;59*.59J;&)3U(,HKXXX-7
M7.,T-S>QK#;B%+@VZ!Y"LFO]/]9U"D"VI(&9P:A`K9U@+NVY4BFM[1VEG,K0
M>.Y2,-'H[_T5;4";BL94(10OJ7&@DMV-^8/:6=KJK&X/8_6E2=I;SV5UMO#+
MU6\<Y!B<]N??G<^4Z3Q.X>O33X.L:MV539:"'(/)4OYYG@K,;'^_"M2S<?-V
MYSNT<-E;'PIHX9&,C!7>6X:V5XJ*:QA@'))J:/&.Y=1<DY7VZ%%DFO+@"6*2
M5%"+J5(X!<,LE6%)"I*@`4%5D.#IZ-]T=V'DNTNM,+O#-8S&XC.2Y/>&W,Y0
MX6OFR>'3.;%WIN'8N9J,365-/2U4F,KLGMN6>G6:-9HHI522[JQ(MV3<)-TV
MV&\FC5)BTB,%.I=44CQ,5)`.DE"145`-#D=!?=[&/;K^6UBD9H=*,I84;3)&
MLBA@"14!@#0T)%1CH6?9KT6]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_
MU]_CW[KW7O?NO=>]^Z]TRU6V]O5U3-6UN!PM965+XB2HJZK%T-14SR8"KEK\
M$\T\L#RROA*Z=YJ0L2::5V>/2Q)]^Z]U`EV-LJ>IS%;/L_:TU9N%8$S]7+M_
M$R5.<2FEBGIDS$[TAER:T\\".@F+A'12+$#W[KW7!-A;&C7!I'LS::)MB22;
M;2)MW#JNWII:@5<LN#5:,#$R252B5FI_&3(-1YY]^Z]U(FV;M"I"K4;5VW.J
M4V;HE$V#Q<H6CW+4&KW'2*'I6`IL_5$RUL8]-5(=4H8\^_=>Z=,5B,5@<?2X
MC!XS'X;%42-'18S%45-CL?21L[RM'2T5'%#34Z-([,0B@%B3]3[]U[IP]^Z]
MT5'X4P0U/Q,Z9IJF&*HIZC9]1!/!/&DL,\,N6RT<L,T4@9)(I$8JRL""#8^]
M,H8%6`*D4(/GUL$J0RDA@<'HSXQ6+5648V@"M44=6RBCIPK56/6G2@J6`CL:
MBA2DB$+_`*HA$@4C2+4\*+AX:TJ#P'$4H?M%!3TH*=6\23_?C<".)X&M1]AJ
M:^M3UA."PC0Q4[8?%-!!'6PP0''TAAAAR89<C%%&8=$<>05V$Z@`2@G5>_O7
M@0D!3"ND`TP//C^WS]?/K?C3`EA*VHT\SY</V>7IY=1)MI[5J'KY)]M;?G?*
MQK%E'FPV.E?)1+0)BUCKV>F8UD:XR):8"34!`HC_`$`#W0VMJQ<M;1DMQ[1G
M&G.,]N,^6.'5Q<W*Z`MPX"\.XXS7&<9SCSSQZ@'K[8385]MMLC:#;=DQTV'D
MP)VUACA9,145AR$^+?%FB^Q;'3U[&=X#'XFF.LJ6Y]T_=]AX)MOHH?I].G3H
M73I)J5TTI0G-*4KGCU?ZV]\43_5R^/JU:M;:M0%`:UK6F*\:8ZS3;'V54UBY
M"HV?M:HKTP$NU5KIMOXF6L7:\Z&.?;:U+TC3#`31L5:C#?;L#8I;WMK*R9_$
M:TB,GAZ*E%KH/%*T^$_P\/EU47EVJZ%NI`FO734U-?\`'2OQ?TN/SZ\=C;):
MHKZL[.VL:K*X&+:V3J3M_$FHR.V($:.#;E?,:3R5F!AC8JE'(6IU!("6]^^A
MLM4C_1Q:FCT,="U*#@AQE1_"<?+KWUEWI1?JI-*OK`U-0/\`Q#.&_I#/SZET
M.U=L8RDI*#&[<P./H<?3XRDH**AP^/I*2BI<)5/78:FI*:"GCAIJ?$5TC34J
M(JK3RL70*QO[NEK;1(D<=O&L:A0`%``"FJ@`#`4Y6G`Y'57N;B1F>2=V=B22
M6))+"C$DG)88/J,'IUI:.DH8134-+34=.):B804L$5/")JJ>6JJI1%"J)Y:F
MJF>21K7>1V8W))]NJB(-**`M3@"G$U/[3D_/IMG9SJ=B6QDYX"@_8,#Y=2?=
MNJ]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_0W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW15OA%_V2ETI_X:DG_NYRGOW7NC4^
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO_]'?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=%6^$7_9*72G_AJ2?^[G*>_=>Z-3[]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z__TM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]T5;X1?]DI=*?^&I)_[N<I[]U[HU/OW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__3
MW^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW15OA%_V2
METI_X:DG_NYRGOW7NC4^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_]3?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%<^%4`IOBSTQ`M71UPCVM
M(HJ\>:XT4_\`N8R9UTYR5!BZ[1S;]RGB:X/%K$^Z]T:/W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
(O=>]^Z]U_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g532389g54c00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g54c00.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!X17AI9@``24DJ``@````&`#$!`@`1
M````5@````$#!0`!````:`````,#`0`!`````$O8`!!1`0`!`````0```!%1
M!``!````Q`X``!)1!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E`$2@
MA@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<
M'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-
M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,O_``!$(`24"*`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0``
M`````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%
M$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U
M-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MX>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#
M!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q
M$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?H
MZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`+']L:I_T$KW_P`"'_QH_MC5/^@E
M>_\`@0_^-4J*^KY(]CX7VD^[+O\`;&J?]!*]_P#`A_\`&C^V-4_Z"5[_`.!#
M_P"-4J*.2/8/:3[LN_VQJG_02O?_``(?_&K,6HZB(_-EU.]"]A]H?G]:RE&6
M`]36M!;1W5X8YM_DQ0/,50X+;1T![5Q8O64:4=+W;?6R[>IV87F:E4>MK)+I
M=]R&;6+F9LO++)CH9)"33X=9N47RQ<W$2G_GG*P'Z&K2^'!-?7D,=VL202*B
M^8I);<A<#CT`-2_\(D_R9U&$>8%9?W3<JS!0?S8<5D\)@TK+1]];FRK8UN^Z
M^5C/GU'5(B&74[TH>A^T/_C4/]L:I_T$KW_P(?\`QHVL+::)\9C8K^56-#T^
MVOY9DN"V0%$2A]FYV;`!.#6N&G[DE4U<7:]M^S,:T).<?9NW,KVOMW*_]L:I
M_P!!*]_\"'_QH_MC5/\`H)7O_@0_^-7=/\.O?P>8;N.`EV0(R%C\I4'D>["G
MR>&)8[.2<WD1>./S&BV'/3=C/3H#71ST4[?H9*EB&N;6WJ9_]L:I_P!!*]_\
M"'_QH_MC5/\`H)7O_@0_^-4JU]+TNWU"V4M)*DOVN*%CQMVMGI[\5<E"*NT9
MTW4J2Y8O7U*O]L:I_P!!*]_\"'_QH_MC5/\`H)7O_@0_^-:(T"*[NU6WG-O$
M\$<H$P+,"[;0IQ[T\^%2(5F;480C*74^4W(4`M^6?TJ/:4>OY&OL<0]OS,O^
MV-4_Z"5[_P"!#_XT?VQJG_02O?\`P(?_`!J&\M6LKV>U=@S0N4)'0XJ?3+2"
M\-TLK2!X[=Y4VXQE?6K:@ES6,DZCER7U]1/[8U3_`*"5[_X$/_C1_;&J?]!*
M]_\``A_\:TKS0H#?6D%G)MBF+J9G8M\R#+9&`1^O6I%\).X+#48=@95W>6W5
MMNT8]]X^E1[2C;7\C7V&(NTM;>?S,G^V-4_Z"5[_`.!#_P"-']L:I_T$KW_P
M(?\`QI-1L#ITT<9F659(Q(KJ".#D=#[@TNE6T=YJ"02I*ZL#\L9`/XD]!ZFK
M]SEYK:&7[WGY+Z^H?VQJG_02O?\`P(?_`!H_MC5/^@E>_P#@0_\`C6CJ&C6<
M%@TUK-)(5\MUD;[KJ[E0,>HQFI7\(R*>-0A8!RC'RV&,$@GWY6H]I1M=_D:^
MQQ%[+7YF3_;&J?\`02O?_`A_\:/[8U3_`*"5[_X$/_C4VJZ.VEI`YN4G6;."
MJE<8`/?V85GPJKSQH^_:S`'8,MC/8>M7%0DN9+0RDZL)<LF[^I:_MC5/^@E>
M_P#@0_\`C1_;&J?]!*]_\"'_`,:V9M#T\0W`A,K7**2(6EQL(7<PR%PQ'X>E
M5;?PT]Q8)<K>Q!FB$OEE&R`0Q`STZ*:S52E:[7X&KHXA.R=_F4/[8U3_`*"5
M[_X$/_C1_;&J?]!*]_\``A_\:NZCX=?3[*2Y^V13"-]C*J%3G<5/7W%8M:0]
MG-7BC*I[6F[3;7S+O]L:I_T$KW_P(?\`QH_MC5/^@E>_^!#_`.-;,&@V,EC'
M=L+H#A73>N2Q*C/3Y<;LX/;'K5:U\-FZ:<"^CC$<\D0W(3NV8R>/J*S]I2UT
M_`V='$:)/?S,_P#MC5/^@E>_^!#_`.-']L:I_P!!*]_\"'_QK3;PK*D$CF^A
M\R-"YCV-V#'&?^`&N?ZBK@Z<_A,JBK4[<S:OYEW^V-4_Z"5[_P"!#_XT?VQJ
MG_02O?\`P(?_`!K1TG2+*]LO.N#.A1QO8,,%2<<#&<?[7KQ0/#HN;^:**=((
ME$1C+DR;_,^[R`/Y5+G23::V\C14J[BI)[^9G?VQJG_02O?_``(?_&C^V-4_
MZ"5[_P"!#_XUJ_\`"*'8CG4H0DB"1#Y3<K\O/_CPXK!N(6M[F6!B"T3LA(Z$
M@XJH.E/X?R(J1KT_CNOF6?[8U3_H)7O_`($/_C1_;&J?]!*]_P#`A_\`&KWA
MW0AK4MQYC.L<49P4ZER#M_#CFGW6A0F^AAMY7A1UF+&;YBOE,P)X]=N:ESI*
M7*T4J5=P4T]'Y_(SO[8U3_H)7O\`X$/_`(T?VQJG_02O?_`A_P#&M?\`X1"3
M_H(P8\SRL^6WW^,#]1S6+J%D;"Y$/FK*&C6174$9##(X-.$J4W:/Y"J4Z]-7
ME=?,?_;&J?\`02O?_`A_\:/[8U3_`*"5[_X$/_C4^@:4-8U5+=RRPCYI"GWL
M9QQ[Y-6;[1(H;:V\C=YS2)%,SO\`<9LX&W`].N30Y4U+EMJ$:=:4.=/3U,_^
MV-4_Z"5[_P"!#_XT?VQJG_02O?\`P(?_`!K4?PHZKN&H0L@W;V\MAM"[LG'?
M[C5GZOI#Z3)$K3I,)`2&52,8.".:(SI2=E^03IXB$>:5[>I'_;&J?]!*]_\`
M`A_\:/[8U3_H)7O_`($/_C45A!'<ZA;P2L5B>15<KU"YYK=N]!LXK.2:,R@M
M"\\+"3<NU0O7Y0>=WMC%$G3BTF@IPK3BY1>WF8_]L:I_T$KW_P`"'_QH_MC5
M/^@E>_\`@0_^-:4?A:66V65;V+>R*_E[&XW`'&?H:KZGH#:=9_:1=QSKOV$*
MA4CEAW]U-"G1;LOR&Z6(2YG>WK_P2K_;&J?]!*]_\"'_`,:/[8U3_H)7O_@0
M_P#C5*NEL=$TZ?3XKF5Y/EB$D[>:1M)SM&-AX..HS3FX05VB:4:M5VC+\3'_
M`+8U3_H)7O\`X$/_`(T?VQJG_02O?_`A_P#&K\?AYI[J]C,Z6PMY?+"OE\_*
M6ZC'93VJQ_PB+@H#J,(+[2O[MN0S;5/XDBI=2BM_R+5'$O57^\R/[8U3_H)7
MO_@0_P#C1_;&J?\`02O?_`A_\:INI1V0]5)!K6T/2H=2^T-,S8CV*JJ^TLS'
M`YP:N2A%<S1E3]K.7(GJ5?[8U3_H)7O_`($/_C1_;&J?]!*]_P#`A_\`&M2X
M\/1![>""5UF:98':3E263?D`=`.G>E7PHSQ^8NHPF,!26\IN`P!7CWS6?M*-
MK_H;>PQ-[+\S*_MC5/\`H)7O_@0_^-']L:I_T$KW_P`"'_QI=4TUM,FCC,R3
M!U+!E!&,,5(Y]U-58(O.N(H@<;W"Y],G%:I0:ND82=6,N5MW]2S_`&QJG_02
MO?\`P(?_`!H_MC5/^@E>_P#@0_\`C6]<^&[*))_*,DDF&$"F;`8KNW'.WMMZ
M''?FL^U\-O=V"7*WD2L\?F"(H<X^;'/3^`UDJE)J]OP-Y4,0GRWO\RC_`&QJ
MG_02O?\`P(?_`!H_MC5/^@E>_P#@0_\`C5Z^\./8V,MS]LBE\HX=%0@CD`\G
MTW"L>$!ID!Z9JN:GR.:6B,W&M&:A)M-^9J)J6H1())M3O<GHOVA_\:KRZM<2
MON>21SZNY)K5L].L;^!FN5N$D#[$99!AR%+D8QZ#KGN*@3P^EUJ$D,%R(8Q%
M#(OF@L<R8PO'H3UKS:-&E6C[3$:MZ^27E8]"K*O3]RB]-O-OSN01:S=%!%]L
MNHAVV3,`/R-13:EJL+X_M.](/0_:'_QK0_X14B%)6U&$(ZEU/E-RHVY/_CU9
MU]`]LLD$I!DAD,9([X.*I1IT*L?9?#)V:[>:O^),_;5*<O:Z22NG^CM^!<T/
M5=1DU_34?4+MD:ZB#*T[$$;AP1FBJF@?\C'IG_7W%_Z&**SS-)3C8[LFDY4Y
M7?4SJ***]H^;"BBC!]#^5`!6A%+(VR>WE:*XCZ,IP15#!]#^5*I=#E=P/TKF
MQ%!U;2B[26WZI^3.BA6]G=25T]_\UYD_VJ\A=V\^96=M[G<?F;!&3^!/YU(E
MYJ,A4"ZG^4``ESP`01^H!_"BWGDDD".N>.N*G>.5N%?:/9:\^OCYTI^SJ12?
M?5K\%<[J.$C4CSPDVNVS_,K7#B.+RMVYV.6-16]W<6C,UM/)"6&UBC8R/2IC
M8L3DN?\`OFC[`?[Y_P"^:JAC,'2ARN=V]6[/5_<16PV*J3YE&UM%JM%]Y%%>
MW4"A8KB5%&2`K8QG!/\`(?E3CJ%ZRLINIB&&U@7/(QC'Y<4_[`?[Y_[YH^P'
M^^?^^:W_`+2P?\WX/_(R^I8OM^*_S*=2)/-&A2.5U4L'PIQ\PZ'ZC-6/L!_O
MG_OFC[`?[Y_[YI_VGA/Y_P`'_D)8#$K:/XK_`#&'4+PSO,;J8ROC<^XY.#D?
MD0*#J-Z4"&[F*`%0N\X`/44_[`?[Y_[YH^P'^^?^^:G^TL'_`#?@_P#(KZEB
M^WXK_,JR2/-*TDKL\C'+,QR2:6.62(L8W9"RE25.,@]15G[`?[Y_[YH^P'^^
M?^^:K^T\)_/^#_R)^H8F]^7\5_F,DU"]EE262ZF>2,%49G)*CI@4HU*^`P+R
M<#(.-YZC&#^&!^0IWV`_WS_WS1]@/]\_]\U/]I8/^;\'_D5]2Q?9_>O\RM+-
M+,5,LC.5&U=QS@>E.M[J>SF\VVF>*3!&Y#@X/45/]@/]\_\`?-'V`_WS_P!\
MT_[3P=K<WX/_`")^H8J]^77U7^9'+?7<T8CEN97C#;PK-QN]:=_:=_S_`*9/
MR23\YY)Y/\S^=.^P'^^?^^:/L!_OG_OFE_:6#_F_!_Y%?4L7V_%?YD$UU<7"
MJLTTD@7[H9LXX`_D!^5,CD>*19(V*.A#*P."".AJU]@/]\_]\T?8#_?/_?-/
M^T\)MS?@_P#(EX#%-W<?Q7^82:KJ$JR+)>SLLHPX+GYOK4:7]Y&@1+J95"A0
M`QP``0!^1/YU)]@/]\_]\T?8#_?/_?-+^T<%_-^#_P`BOJ>+WL_O7^9')?7<
MT;1RW,KHQRRLV03G.?SYJO5S[`?[Y_[YH^P'^^?^^::S/"+:7X/_`")>`Q3W
MC^*_S$&JZ@&1A>SAD78IWG@>E1QWEU"NV*XE09)PK$<G&?SP/RJ7[`?[Y_[Y
MH^P'^^?^^:7]I8/^;\'_`)%?4L7V?WK_`#&G4KX[LW<QW#!^<\CD?U/YFJM7
M/L!_OG_OFC[`?[Y_[YIK,\&MI?@_\B7@<4]X_BO\QD>H7L,2117<R1HVY55R
M`I]11_:%YYSR_:IO,<AF;><DCH?PI_V`_P!\_P#?-'V`_P!\_P#?-+^TL'_-
M^#_R*^I8OM^*_P`QG]HWI55^US;57:HWG@<<?H/R%0.[2.SNQ9V)9F/4D]35
MK[`?[Y_[YH^P'^^?^^::S+!K:7X/_(3P.*>\?Q7^96BFE@?=%(R,01E3C@C!
M%2O?7<LPFDN96D";-Y8YVXP1]*D^P'^^?^^:/L!_OG_OFC^T\'_-^#_R!8'%
M)62_%?YC?[3O\?\`'Y/][?\`?/WO7Z\"H))9)F#2.SD*%!8YP!T%6?L!_OG_
M`+YH^P'^^?\`OFA9E@UM+\'_`)`\#BGNOQ7^95CD>&19(W9'4@JRG!!]:F>^
MNY4B22YE9(CF,%B0I]14GV`_WS_WS1]@/]\_]\T?VG@W]K\'_D"P.*2LH_BO
M\QG]HWQ4K]KFVG.1O/.<Y_\`0F_,U'/=3W)4SS/*5SC>V<5/]@/]\_\`?-'V
M`_WS_P!\T?VE@U]K\'_D#P6+:LU^*_S*J.\4BR1L4=3E64X(-3RZC>S)*DMW
M,ZRD&16<D-CUI_V`_P!\_P#?-'V`_P!\_P#?-#S+!O>7X/\`R!8'%)62_%?Y
MC%U&]486[F`P!@.>@&!^E-EO+J:/RY;B1TSNVLV1G).?S)_,U+]@/]\_]\T?
M8#_?/_?-']I8/^;\'_D'U+%[6_%?YE.K<6J:A#'''%>SHD?W%5R`OTI?L!_O
MG_OFC[`?[Y_[YH>98-[R_!_Y!'`XJ.T;?-?YD2WMTA<K<2@NVYB&/S'!&3[X
M)'XT_P#M.^)4F\GRH`'SG@`Y'Y'FG?8#_?/_`'S1]@/]\_\`?-']I8/^;\'_
M`)!]2Q:Z?BO\RH2222<D\DU)!=7%JS-;S21%EVL4;&1Z5/\`8#_?/_?-'V`_
MWS_WS0\SPCT<OP?^0E@,4G=1_%?YD9O[P^3FZE_<?ZKYC\GTI1J-ZJ%!=S!2
M`"-YQQT_+`I_V`_WS_WS1]@/]\_]\TO[2P?\WX/_`"*^I8OM^*_S*\T\UP09
MI7D*YP6.<9))_4D_C4?0Y'6KGV`_WS_WS1]@/]\_]\U7]IX3^?\`!_Y$O`8E
MZN/XK_,1]5U"02![VX82*%<%S\P]#3$O[N)`D=S*JA=H`8@`<\?J?S-2?8#_
M`'S_`-\T?8#_`'S_`-\U/]HX/^;\'_D5]2Q>]G]Z_P`R.2_NY8W22YE='Y96
M8D'IU_(?E4"DJP8=0<U;^P'^^?\`OFC[`?[Y_P"^:?\`:6#M;F_!_P"0OJ.*
M;NX_BO\`,E,T\D<;V\SJ8VWJH;&UO4>]5_MMZD[R_:)EE<@N^XY8@Y&?H:E2
MTDC.5D(/^[4Q\Q(V+?,0,CY:X(8Z%#W*;4X]-TUY;69VRPLZWOSO%]=FO7<A
MCN=0E54^TS"-05&6.`#C('Y#\J9>SF1MI<NQ.78G))]ZC>YF<8P5'L*AP?0_
ME7HPH5)U%4K65MDOS;."=>$8.G3;=]V_T-#0/^1CTS_K[B_]#%%&@@_\)%IG
M!_X^XNW^V**Y,T^./H>MDG\.?J9U%%%>R?.A7K?P_4'PG#D#_6R?^A5Y)7K?
MP^_Y%.'_`*ZR?^A5P9E_!^?^9ZN3_P"\/T?Z'4;5_NC\J-J_W1^5+17@GU`F
MU?[H_*C:OH/RI:*`$VKZ#\J-J^@_*EHH`3:OH/RHVKZ#\J;--%;PO--(L<4:
MEG=S@*!U)-<3X2^)=EXP\57^D6-C.EO;0>?%=R'`G7<%RJXS@YX/M0!W&U?0
M?E1M7T'Y5"E[:R7)MTN(WF')16!(^OI4]-IK<2:>PFU?0?E1M7T'Y4M%(8FU
M?0?E1M7T'Y4M%`";5]!^5&U?0?E2T9H`3:OH/RHVKZ#\J6B@!-J^@_*C:OH/
MRI:*`$VKZ#\J-J^@_*EHH`3:OH/RHVKZ#\JYG_A+3)XP'AN.Q*7"L7DEED`C
M,6W(*$9RYS]S@@9/2NGH`3:OH/RHVKZ#\J6B@!-J^@_*C:OH/RKF+[Q@+7Q9
M!X<6R/VN=E9)I)0(C&023D<A_E("$<]>E=10`FU?0?E1M7T'Y4M%`";5]!^5
M&U?0?E2T4`)M7T'Y4W='OV93=_=XS6)+9ZZWBV.ZCO4&D"/#0=R<>F.N><YK
M"U%776[QX@#.MV'54B(EVB(?,'_N@]N]:1II]3*52W3J=SA<D8&1VH`4C(`(
M]JXR%[N#F6ZN_+D6U-Q<'[ZJ5<G!QP,X'M5"QO[RVL[2.*YN%N58K#;8XDC\
MMV!(QU+"J]CYB]LNQZ'M7T'Y4;5]!^5<SI]YJ)\,:A.'=Y4#&!G;<WW03R0,
MX.?Y5COJMS'<R_9=0O)X8YU\MG)P1^[R#QENIX.!U-)4FW8;JI),[[:OH/RH
MVKZ#\JX7^T+UX7:"_N6`=_M);.V/$N%`('R@C(R,]*UVU"XAL-&N9I+A(WW>
M>77)/R-MW8'KBDZ30*JF='M7T'Y4@V$D#:2.OM7&:%J%[<7ELKW=S)/YJK+$
M^=HB\H$DC'7=3+F26TUG5%%S=PHSO(-A/,FQ-@Z=#\W'?&*?LM;![56O8[5F
MB3&]D7/3)`I04)P-I/7%8&KVRZA9:9;WEJCW-RRI(S)DQC&Y\>G3'XU6TR(I
MXB"K&RS))<>>=I'[LD>6,^F.GTI*"M<;GK:QU.U?0?E1M7T'Y5Q5Q-J2FXF6
M[O01]I<(#\H*2*$`&.F">.]%S-J2_:)DN[T,!<N%!^4%)%"`#'3!/'>G[+S)
M]JNQVNU?0?E1M7T'Y4M%9&PFU?0?E1M7T'Y4M%`";5]!^5&U?0?E2T4`)M7T
M'Y4;5]!^5+10`FU?0?E1M7T'Y4M%`";5]!^5&U?0?E2T4`)M7T'Y4;5]!^5+
M10`FU?0?E1M7T'Y4M%`";5_NC\J-J_W1^5+10`FU?0?E12T4`?/=%%%?6GP0
M5ZW\/O\`D4X?^NLG_H5>25ZW\/O^13A_ZZR?^A5P9E_!^?\`F>KD_P#O#]'^
MAU-%%%>"?4!1110`R66.&)I975(U&69C@`5BG7Y[T-_8]@UQ&/\`EZG;RH?J
M">6'T%'B2WFF2RD^S/=6<,V^YMX_O.,<''\6#SBL7Q0(?%NE1Z39>(X](MI&
M`O%,969X_P#GFI8C9GG/!K>,+1YDK_H<\YMSY'+E_-^ESF'?6_BKJ5SI27T<
M/A6TDVW5U;1D"\D'_+)"3ED'<]#6'K*2>'/'GBF:.[E8Z=X=B>-4Q$K`,H"$
M*!A?I7M&D6VDZ1I=OI^F&WBM+=`D:1N,`?X^]<7XC\`?VUK'B/4DUN"+^U]-
M2Q6-TR(<,I+9W<_=/&!UJ.:2>B_`OD@UJ[_,FA\4V7AKP=H\T.F+)K6K0));
MZ;:<O-(R@Y)/(49Y8]*CO?%VM6$$4>HZWX3T^[\O=,A>29U?NH12"<=,YY/:
MJ<7@BRL/"=];'Q1#_P`)%=VJVS:J[C,4:X`CC4'Y$P,8'/.:I0Z-/'X2N="M
M+_0+&2:)83<Z;9RR2LO1V9NI8C(_$\T<E23O9L%.E!<J:1!;?%_69_#(G@TJ
MVO-4N]0-GI:0APMXJ_?DVGYE4<=^I]C6MXJ\9>.?"ND6^JW>E:&8Y)8X?L:7
M$C3,[=@<`$_3/XTOAGPU;Z)XC;5!;WMY%:VJV6EP1VC(+:(?>)+$9=CR3[FK
M6K:/J>O>-['5]0T^Z;2M-B8VEHNP-Y[<&1LMC@=/I1[*0_:P)U\<:OKVIS:=
MX3TFWN3:82]OKR8I;Q2XYC4J"78=\<5GZE\1M5\-W_\`8VLPZ1/K$P5H5M;A
MTBB0YR\S./E[8`R3^54/"6F>,O!=@=&MX[673!.T@NIK21I@&.3E4)!/XU8C
MTJ^L?'NK:_HNJ:1*-41/-M=722)XBHP-A`Y'^>U+V<^P>UAM<MZ7\0M2N?%F
MFZ+,NCWT6H"3]]I4TCFV*KG+[E`P?6K'@WP)JWASQ+>ZE>ZRUU%,&`3>QWDM
MD$@\+]!GGVXKJM">Y:P\W49=.>ZW'<UB"(E'8`GD_6M!+NWDF\I)D=^N%.<?
M7'2ILR[HFHHHI#,:7PEH$TKRR:5;M([%F8KR2>2:9_PAWAW_`*!%M_WS5B3Q
M+H44C1R:WIJ.A*LK72`@CJ",TW_A*/#_`/T'=,_\"X_\:`(?^$.\._\`0(MO
M^^:/^$.\._\`0(MO^^:F_P"$H\/_`/0=TS_P+C_QH_X2CP__`-!W3/\`P+C_
M`,:`/!OC7HI\)WNGG2KVYAL+Z66Z-GNS'%,BJ-R=QE3C'M[U['H7A[P]JWA_
M3M0;1[4-<VT<K#81@LH)_6O'?CGXAMO$E]IMKIADFL[&22*:[5<P&9PI55<=
M2`/UKV?P_K.A:7X<TVPEU[3#);VT<3G[9&?F"@'OZT`6_P#A#O#O_0(MO^^:
M/^$.\._]`BV_[YJ;_A*/#_\`T'=,_P#`N/\`QH_X2CP__P!!W3/_``+C_P`:
M`/$_C?HG_",6EM-I$\UK8:E.#/;(WR+-&OR.O<?+GC/;->B^!=%T77O`^CZG
M=Z3:&YN+96E(4\L."?QQ7G?QY\00:[96UGI6Z[M=.E$EU=0C?"DCKA%W#C.-
MWZ"O2/`&IZ-HG@+1=.N]:TM+B&V42*+N/ACR0>>O-`&[_P`(=X=_Z!%M_P!\
MT?\`"'>'?^@1;?\`?-3?\)1X?_Z#NF?^!<?^-'_"4>'_`/H.Z9_X%Q_XT`0_
M\(=X=_Z!%M_WS6O;6T-G;1V]M&L<,8VHB]`*SO\`A*/#_P#T'=,_\"X_\:TH
M+B&Z@2>WFCFA<922-@RL/4$=:`(FU"S6^6Q:YB%TR[A#N&XCUQ5>;6K>&\:W
M\J=PCJDDJ)E(V;H"<Y].W&>:C?P[ITFOIK31,;Q%P#N^7IC./7%5[G2]2$U\
M+&X@BCNW$C/(NYD.T*1C&"#@?K6B4#-N99D\0Z7$L+FZ1HI9#&)%.55@N[G\
M*8+W1WO#<R>3'<+*;=9)``6(`Z'TY'-9"^&M21BZO:$ENC.Q`'E&,_P^^1V[
M4/X2NMS*MTIC?=&PWE?D.WGH<GY>G';FKY8=R.:?8Z*]OK"VQ!>SQ)YHP$D/
MW@>/ZXJM:ZEHEO&L5K<VJ(SE0J$#+=_Z5G>(+*]GU#;:VYE2XBCB=ST3;)NS
M^6:BE\-7YM+:!);?$484\E?F$F\]!D@C'![\\U*C&RNQN4KNR+5IXITCYH;=
M'1%W,`$"@_/M)'/<G-:*ZYI;)(ZWT!6/&X[NF3C^?%8\GAN],6Q98#N1T8DG
MC,PD&..>.*AGT*]L5L+N)4N)+)`OE)GYSO)_+!_.J<:;V8E*HMT=`M[8QQ17
M$!1UO)!M>+'[PXZY]@.OH*C.NZ=^Z*W*/'(S)YBD;5*KN.3VXK-M]+NTTC1U
M>,"6`L)4`!"AU89QWQN'%43X2U"6/;+<6X/F+)G<S9*IMQT&!D#CL#248=6-
MRGT1T1US2P$)OH!O^[\WOC^=68;VVN)I889XWDB.)%4Y*_6N=;PW>S3ZC<R2
M6ZR7L178I)"'*XYQR,+^=6])T*:PO+F668.KJZ(0Q/#.6Z8XZ^])QA;1C4IW
MU1?.M:8L;2&^@"*_ED[OXO3]#2W.KV5G<F"YF6([%8%CP<D@`=\\&L>U\.W4
M=S92RR08M?+0!<_.B!QD\?>RP_+K5R\T>:Y\0VVH+)&(H@F5.<G&_P#^*%+E
MA?<.:=MC0DU*RAM$NY+J);>3&R0MPV?2F2:QIT3R))>PJT0#."W0<?XC\ZS/
M[$NXM+TZ&)[=Y[0ME9,^6VX,/3WJK-X8O)8T@$MN(HIC,C`$%BQ!((Q@`8/Z
M>E-1AU8.4^B-:7Q#I<=M+.MTDJQ`%Q&<D`L%SCZFGOKNG(R;KE!&Z;UDR-IY
MVX^N:R;CPY=R(WER6^[=,PW9P=\RN,\>BD4L?AR[%Y;7#2P?)+YLBC/!,A<@
M<>^*?+#N+FJ=C7_MK3>`MY"Q,9D`5LDKC/\`(&H+7Q)IMS:_://$4?RC,A`Y
M9=V/RK)MO#-_;WT4IFMS$D[2X!(X(8=,<GYNI^E-A\,:A%&&$ML91%Y.TLVW
M;Y80MTZ\9HY:?<.:IV.DBU.RGNWM8KJ)YTSNC#<C'7^8IAU;3QG-Y",*6/S=
M@VTG\^*S=/T&>RO8)3+&R1/*>^2&50/Q^7FJDGA6=]5:Y$\0A-R'"<Y\H_,R
M_B_-+EA?<?-.VQ>'BS3"V"TB\Q@DKP-^<=_:M&74[&&UCNI+J)8)/N2%N&^E
M8=KX<O(&MPTL!1&@9CDYS&7R`,=]PJ2XT"\?0K.QCFA$D(97;)&001P<9'7\
M>E-QA?1B4JEM4:=YK5A96LMQ)<(5CSE5.22%W8'O@@_C3DUC3I`<7<0*Q^:P
M+8(7&<G\ZP6\-:@\9A,ML(RK'=EL[C"(\=.G&:2[\.WTD,A+1'8[7"K&269R
M%^3D#Y?E_E1RP[ASS[&ZNNZ4Q`%_!DY(^?TZ_E52]\5Z59A"96E#QM)F(9``
M..?QK-L-%U"X^WWDR0V\EVDJI&Z[MI9@02".G'_UJ5?#%^T-RKS0AI4F`^=F
MY<H1DD?[)HY::>K%S5&M$=)9WL-]$TD).%<H01@@C_.?QJQ6=I-O-%]LFG3R
MWN+@R!,YP,!?UVY_&M&LI))Z&T6VM0HHHI#"BBB@#Y[HHHKZT^""O6_A]_R*
M</\`UUD_]"KR2O6_A]_R*</_`%UD_P#0JX,R_@_/_,]7)_\`>'Z/]#J:***\
M$^H"BBB@`J*:V@N!B>".4>CH&_G4M%"=@:ON9SZ!I$A^;3;7\(@/Y4T>'=&!
MR--MO^^!6G15^TGW9G[*G_*ON*D>EZ?#CRK&V3']V)1_2K)0;"JX7(P,#I3J
M*EMO<M12V1YG9_#+7;';%;^-+Z.UW?-&@(.-J#&[.?X3CTS6A;^!=<2:^%QX
MOO;BVN+66W2)Q_JRQ.T]><#`]3S7>44AGF;?#GQ&;..V7Q?+%'DB2.-&5-FT
MC:HW<=?T%='H_@RWL?#T^C7L@NX#,\D+MDL@.,#DG!'M74T4TW%W0I)25GL<
M_;^&8H;1(6%O*`,%98`P_`C!J_9:2EDJB!F@`/,<;$H?P.<5HT5<JLY;LSC1
MA'9!11169J1F"$G)BC)/^R*/L\'_`#QC_P"^14E%`$?V>#_GC'_WR*/L\'_/
M&/\`[Y%244`<E<>$)KKQ:NM_:(((X9$*6J1[XYL*07D!Q^\`)"D=!Z]NI^SP
M?\\8_P#OD5)10!']G@_YXQ_]\BC[/!_SQC_[Y%244`<EJWA";5/$D.IQW$%I
M%;&-EB2/<+DJ<_OEX!V\[<<@DG/:NI^SP_\`/&/_`+Y%244`1_9X/^>,?_?(
MH^SP?\\8_P#OD5)10!']G@_YXQ_]\BGA0H`4``=`*6B@#"E\1M'XLCT/[!,R
MNF[[0.@XSTQT[9SUJC>:Y?6NJS_.3;Q7(BVM$!'M\L-C?UW9Z?A75UFRZ%83
MW,D\L;L9&WLAD;86QMW;<XSCO6D90ZHRE&?1]3,M_$-Y))M>U02S"'R(?,X&
M\,V2V/1:@LO%5S]@AGN;97C#&.>57P0X5G.%QR,`#K6VVB6#)M\I@=L:AE<@
MKL!"X.>",FJ(\)VBWD+K(XM8A_Q[<D,=I7).>>"??WJE*GU1/+474ELM?%WI
M%U>^2FZW)!5)058X!&&.!W`I(]?>31;B^6V4RPS>28Q)\K'<!D,1T^;TJZ-(
MLQI\ED4=H9.6W2,6/3').>,#\J@FT&V?3+FQB>2-;B02.Y<LV[().2>^*F\"
M[3L43XH99H8VM%!,ODR_O<D-OV?*,<CODXJF_B34I&\X0Q0VY@$BKOW-_K0F
M>GH3Q6T?#FF_*1'(",$D2L-Q!W`GGD@DG)IS^'].>..,PML2/RP!(W*[@V#S
MSR,U2E370EQJ/J8T_BFXDF$,,21,&)R&#Y7:^`>P.5!XS5[3->DN[JWLI(!Y
M[1AY'#<;=BL&QCN6QCVJ=/#6F(ZN(I"478H,K$!>0`.>@W'\ZFL](BM-0DNU
M8$F%+>-0N-D:]`3W/O0Y4[:($JE]69<OBSRC.CVJ1RI*$C22;;D9/+<<#Y<\
M9'(I+CQ>D"@_9"<JD@!?'[MDR&/''S'%:)\.Z:=Q\IP2?E82L#'R3A3GY1DG
M@5++HFGS2>9);@MY`M\[CP@.0/KGOUI7I]@M4[F.WBYE5F%I&RQ(S3.)OE&'
M"C:<<@DCFFW7BBXDL)C901_:(HW>1O,W(H5@N5X^;.<]JV?[#L-KAHF<NAC9
MGD8D@MNZD]<@'-,F\/Z?<0K%*DK`!@6\UMS`G)#'.2,@=:?-3[`XU.Y#J>N2
M:=>21BU62&&*.65_,P0&<KP,<],]:IP>*WNVBCMK2.269U$8\_@*P8_,<<$;
M>1[UM7.EVEX\KSQ;C*BQO\Q&55MP'YU%#HEC`T;)&^8G#Q[I&.S`(`&3P.3Q
M23A;5:C:G?1Z&1)XOV.(OLJ+)DHYDFVJK@ME2<>BY'U%=%:7*WEG#<H"JRH'
M`/49&:IOH.GN\S^4R22R^<SI(RMNQMR"#QQQ6A'&L421H,(@"J/0"IDXM>ZB
MHJ2?O,=1114%A1110`4444`%%%%`!1110`4444`%%%%`!1110!\]UV'A:YM;
M'0KFYU)D>P^T;&A-MYA9BH_B[?\`UJX^NR\(7EE%IEQ:W5QIZ^=./W5U$7W<
M#!ZXZU]+BOX9\=@7:MOT>YCZ_)HEQ]GN='C:`R;A-`V?DP>#^//2KVA^-KG0
MM,2QBLHI55F;>SD'DYK)\0Q"'Q#?1*L2A),;8DVH.!T':LVFJ4*E-1EJM]29
M5ZE*M*4-'MH=S_PLV]_Z!MO_`-_&_P`*<GQ*OY&PNEP$_P#71O\`"N$JX[?9
MHE1/OMU-<>(HT:=H0A>4MM_FWZ'70QF)G>4ZC45OHONV.V_X6#?@?-86J_\`
M;1O\*&^(6H`973K9OI*W^%>?$ECEB2?>E21HSE3BL_[-FE=23?:VGYW+_M5M
MV=[=[Z_E8[@_$R^!P=,@!_ZZ-_A2?\+-O?\`H&V__?QO\*Y&8+/;B8###K50
M`GH":VP]&A5C=PLUHUYF5?&8JE*RJ73U3LMON.Y_X6;>_P#0-M_^_C?X4?\`
M"S;W_H&V_P#W\;_"N&HKH^I4/Y?S,?[1Q7\_Y?Y'<_\`"S;W_H&V_P#W\;_"
MC_A9M[_T#;?_`+^-_A7#44?4J'\OYA_:.*_G_+_([G_A9M[_`-`VW_[^-_A1
M_P`+-O?^@;;_`/?QO\*X:BE]2H?R_F']HXK^?\O\CN?^%FWO_0-M_P#OXW^%
M'_"S;W_H&V__`'\;_"N&HI_4J'\OYA_:.*_G_+_([G_A9M[_`-`VW_[^-_A1
M_P`+-O?^@;;_`/?QO\*X;!'4&BE]2H?R_F']HXK^?\O\CN?^%FWO_0-M_P#O
MXW^%'_"S;W_H&V__`'\;_"N&HH^I4/Y?S#^T<5_/^7^1W/\`PLV]_P"@;;_]
M_&_PH_X6;>_]`VW_`._C?X5PU%'U*A_+^8?VCBOY_P`O\CN?^%FWO_0-M_\`
MOXW^%'_"S;W_`*!MO_W\;_"N&HI_4J'\OYA_:.*_G_+_`".Y_P"%FWO_`$#;
M?_OXW^%'_"S;W_H&V_\`W\;_``KA\'T/'M24OJ5#^7\P_M'%?S_E_D=S_P`+
M-O?^@;;_`/?QO\*/^%FWO_0-M_\`OXW^%<-13^I4/Y?S#^T<5_/^7^1W/_"S
M;W_H&V__`'\;_"C_`(6;>_\`0-M_^_C?X5PV#Z&BE]2H?R_F']HXK^?\O\CN
M?^%FWO\`T#;?_OXW^%'_``LV]_Z!MO\`]_&_PKAJ*?U*A_+^8?VCBOY_R_R.
MY_X6;>_]`VW_`._C?X4?\+-O?^@;;_\`?QO\*X;'M001U&*7U*A_+^8?VCBO
MY_R_R.Y_X6;>_P#0-M_^_C?X4?\`"S;W_H&V_P#W\;_"N&HI_4J'\OYA_:.*
M_G_+_([M/B5?R-A=+@)_ZZ-_A4__``L&_`^:PM5_[:-_A7$NWV6%57[[=351
MB6.6))/K7GPPRQ/O4THQZ/=O\=CMECJE#W9R<I==DE^!Z"WQ"U`#*Z=;-])6
M_P`*KGXF7P.#ID`/_71O\*X=)&C.5.*LRXGM_.`PR]:?U>-":C52E%Z7VL_-
M7%]>JUHMTY--:VT>GEH==_PLV]_Z!MO_`-_&_P`*/^%FWO\`T#;?_OXW^%<-
M1@XS@XKN^I4/Y?S./^T<5_/^7^1W/_"S;W_H&V__`'\;_"C_`(6;>_\`0-M_
M^_C?X5PU%/ZE0_E_,/[1Q7\_Y?Y'<_\`"S;W_H&V_P#W\;_"C_A9M[_T#;?_
M`+^-_A7#48(Z@TOJ5#^7\P_M'%?S_E_D=S_PLV]_Z!MO_P!_&_PH_P"%FWO_
M`$#;?_OXW^%<-13^I4/Y?S#^T<5_/^7^1W/_``LV]_Z!MO\`]_&_PH_X6;>_
M]`VW_P"_C?X5PU+@GL?RI?4J'\OYA_:.*_G_`"_R.X_X6;>_]`VW_P"_C?X4
M?\+-O?\`H&V__?QO\*X:BCZE0_E_,/[1Q7\_Y?Y'<_\`"S;W_H&V_P#W\;_"
MC_A9M[_T#;?_`+^-_A7#44?4J'\OYA_:.*_G_+_([G_A9M[_`-`VW_[^-_A1
M_P`+-O?^@;;_`/?QO\*X:BCZE0_E_,/[1Q7\_P"7^1W/_"S;W_H&V_\`W\;_
M``H_X6;>_P#0-M_^_C?X5PU%/ZE0_E_,/[1Q7\_Y?Y'<_P#"S;W_`*!MO_W\
M;_"C_A9M[_T#;?\`[^-_A7#X/H?RI*7U*A_+^8?VCBOY_P`O\CN?^%FWO_0-
MM_\`OXW^%'_"S;W_`*!MO_W\;_"N&HI_4J'\OYA_:.*_G_+_`".Y_P"%FWO_
M`$#;?_OXW^%'_"S;W_H&V_\`W\;_``KAL'&<&BE]2H?R_F']HXK^?\O\CN?^
M%FWO_0-M_P#OXW^%'_"S;W_H&V__`'\;_"N&HI_4J'\OYA_:.*_G_+_(]#T[
MXB7=[JEI:-I\"K/,D982$D!F`ST]Z*XW0/\`D8],_P"ON+_T,45Y>/HPI22@
MK'MY5B*E:$G4=[,SNU=YX87[/:21:=KH`)6211IYE(8J,C/MC'X5P==[X8M[
MJST26&>WUB$SRB9)+*,<KM&.3ZUZ>+_A_P##?J>+E_\`%V_/]&C`\4:>+6\6
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M3MW`G:5[_P`ZRIY6F/W2%'08J+:?0_E71AZ3Y).IHY._IV_(Y:M?EJ1=-745
M;U.ATJ70TME6\C@>0NY+2AMP&Y=O3V+?E4DTGAXV,T4<=OY@B_=R`-O+;2>O
MKNP*YK:?0_E1M/H?RK=THMWYG]Y"Q$E'EY%]PE;>CZA;6]FL5VRE%O890A7)
MVC=N/3GM6+M/H?RHVGT/Y5I-1FK-F-.<J<N9(Z87>E2ZD7OG@NBL$,;2N&VN
M^\;V'?A2>?:GFX\.K:HRV]H9F1RRE6X8`;1^)S^M<MM/H?RHVGT/Y5E[&/\`
M,_O-_K,OY5]Q8U'[/_:5S]DQ]F\P^5CIMSQ5C2+N.V:[65U6.6V=.5SENPK/
MVGT/Y4;3Z'\JU:BX\K9@I24^=(Z>_OM-N]3L99YHYXU$GF*&=HPNWY!@\@YZ
M@<=*E2?PT5+/!:!M\8"[7QM.S>?P^?\`*N3VGT/Y4;3Z'\JR]C&R2D_O.CZU
M*[;BG?R\K%[5FLGGA>R6-%,0\Q8\X#Y/K[8I^A2QPZJDDMTMJ@5LR$>W0'!P
M3TSVK.VGT/Y4;3Z'\JTLN7EN8<\O:<]CI-4U*TNM,9!+"6=DQ#$#A'#L78<=
M"".>]67G\,L21!:+MD;:`K_,H+!<_4;:Y+:?0_E1M/H?RK/V,;64OQ-OK4V[
MN*?R-?6WTN2*V;3TA1^?-$0(_A4]_?=^59MJ=MY`3(L>)%.]QD+SU([@5%M/
MH?RHVGT/Y5K%*,>6YA.;E/GM;T.PNM5LY+>\A:^B9"I`>-W$DN$PI/`!R>H/
M053M9=`_LV..>*V\_P`A=SX;=OVMG]0GYUS>T^A_*C:?0_E62HQ2LI'1+%3E
M+F<4_D=#JTNAR:=,+**W2X$G[LQA@2N\CO\`[.#7.GI2[3Z'\J-I]#^5:02@
MK7N859NH[VMZ'8VNJV*:;#&^HQB[4+LDP<(OREE^[\O"D8YSD^M4;&YT/]^U
MS!;MON)67S%;*I\I0<?\"KG-I]#^5&T^A_*LU1@KV>YN\7-VO%:'4O+X<^SS
M1K%;9$9"/AMQ;#]_J$_.N5'2EVGT/Y4;3Z'\JTA%0ZW,:M1U+>ZE;LCIM$U&
MVL]-1)KV(/Y@9(V!PAR>3@?^/`^V*%N=&DU6XENVCN%;R5W2EV`_YZ%3UP.V
M:YG:?0_E1M/H?RJ'2C=N^YJL5-14>5-(ZK[1X<$43"WLS(T0:12K85_DX^GW
M_P`JYJZ\I;Z?R,&`2MY?^[GC]*BVGT/Y4;3Z'\JJ$(QZW^9G5JRJ6]U+T1TF
MBW>GV5^;B^+`/&41]FY5!!S^)X`I][?Z9<7T+2R17$:"=U!!VJ"/W2'Z$=/>
ML"&;">7*I*?3I3_LD;\I(<>F*\J$H87W:UTEHFM5;Y;,]*4YUX_NDG?5I[W_
M`%1T4D_A@)N2"T+%B"-K\+M8@CWSM%9&H_95>9[0*L$@4JJYP"5&0,^^:IB&
M"(YDDW>U0SSF4X`PHZ"M%'ZQ.*IWY4[MORZ(B=7V4&YI*71+]31\.75E9:S%
M<7Q(1"-C;=P5L]2/0#-7]2O=/N;2RB^TATCF0!%+8$?.XNIX!^E<U17HRI*4
M^>YPPQ$HT_9V5CK/M'ALI,?L]H&5&:,!7^9@S@#\MA_&LG76TQY86TU8E7#!
MQ&"!UXZ^U9-%$:/*[W85,2YQY>5+Y%K39DM]4M9I"H6.56)8'`P>^*Z2_P!4
ML)+"X1;M9':)Q)'EF\R0A-I4D9(7#=>E<C13G24Y*3Z"IXB5.#@EN=1#)X=-
MJD<L=N'$:9?#;BVT%O\`Q[(JKJ\FC2Z?_H44$=P)?^608$KEQW]@A_&L&BI5
M&SO=E2Q+<>7E7W!78:;J]I#IELC7D*31Q;(T+R`!N=V_`X]B*X^BJJ4U45F1
M0KRHMN)T4-QHWVN_><1SJ\_[IY]Q;9L;G/\`O;1S5PS^&@T8$%H0P1G)5^"7
M&X?0*3^5<C14.@GU?WFD<4TK<J^X=)M$C[/N[CM^G:MKPY>6EF;K[3*(G=5"
MOD@@`_,`1WQVZ&L.BM9P4X\K,:=1TY\Z.IN;[2KF2Q266.2V$RML*G]U&(\%
M3CIEN<"G)<>'#`7>WM!*!&0NUL$D#?\`D<URE%9>P5K)LW^MRNVXK[C2UEK!
MYXFT]8U38P<1YQD.P!Y]5VFJ,#(MS$THS&'!8>HSS4=%:QC96.>4^:7-8[6\
MU?398KI%O5"RJ=VQW#$?/L"\<]1D'@5FV,NA#38H[F*W\\P_.Y#;@YWY_P#9
M/SKG**R6'25DV=$L9*4N9Q1T>I2:$^G7"VD=NLZG]TR!@Q`*^OL6_*N<HHK2
M$.16O<PJU/:.]DO0Z+1-7CLK!8);H@23$%&R1$H4D-C_`'R/RI\=UI$NK3R7
MOD3J4@3S'#89@0)&&/;)S7-45#H1;;ON:K%245%I-(ZK[1X=6VC86]F9FC+.
MI5OE8;<#\?FKG;\6XU"Y%J0;?S&\K']W/%5Z*J%/D=[MD5:_M%;E2]$:.@?\
MC'IG_7W%_P"ABBC0/^1CTS_K[B_]#%%>5FGQQ]#W,D_AS]3.K>TZZ\3WEM(;
M&]O#!;J`Q$N%0=A_]:L&NT\(><^C7D7V!KR#S"=L,P60$J`>#U&,5Z6(ERPY
MK)^IX^#CSU.6[7H<E>FZ-[-]M,AN=V)3(<MD<<UVGA7P=IFM:%'>W37`E9W4
M^7(`,`X':N2UJXGN]:O+BY@,$TDA+1'JGM^6*]-^'W_(IP_]=9/_`$*L,94G
M"@I1=GIL=67T:=3%2C-76N_J1?\`"N-#_OWG_?T?X4?\*XT/^_>?]_1_A774
M5Y'UNO\`S,][ZCAOY$<G'\/-%C?<KW>?>4?X5-_P@FD?W[K_`+^#_"NFHK"J
MW5?-4U9M3H4Z:M!61S/_``@FD?W[K_OX/\*/^$$TC^_=?]_!_A7345G[*'8O
ME1S/_"":1_?NO^_@_P`*/^$$TC^_=?\`?P?X5TU%'LH=@Y4<S_P@FD?W[K_O
MX/\`"C_A!-(_OW7_`'\'^%=-11[*'8.5',_\()I']^Z_[^#_``H_X032/[]U
M_P!_!_A7344>RAV#E1S/_"":1_?NO^_@_P`*/^$$TC^_=?\`?P?X5TU%'LH=
M@Y4<S_P@FD?W[K_OX/\`"C_A!-(_OW7_`'\'^%=-11[*'8.5',_\()I']^Z_
M[^#_``H_X032/[]U_P!_!_A7344>RAV#E1S/_"":1_?NO^_@_P`*/^$$TC^_
M=?\`?P?X5TU%'LH=@Y4<S_P@FD?W[K_OX/\`"C_A!-(_OW7_`'\'^%=-11[*
M'8.5',_\()I']^Z_[^#_``H_X032/[]U_P!_!_A5Z[\4Z-97TME/=D7,.TR1
MI"[E,C(SM4]147_"8:)_S\S?^`DW_P`31[*'8.5%;_A!-(_OW7_?P?X4?\()
MI']^Z_[^#_"K/_"8:)_S\S?^`DW_`,31_P`)AHG_`#\S?^`DW_Q-'LH=@Y45
MO^$$TC^_=?\`?P?X4?\`"":1_?NO^_@_PJS_`,)AHG_/S-_X"3?_`!-(WC+0
ME4LUU*`!DDVLO'_CM'LH=@Y45_\`A!-(_OW7_?P?X4?\()I']^Z_[^#_``KH
MK>XAN[:*XMY%EAE4.CH<AE/((J2CV4.P<J.9_P"$$TC^_=?]_!_A1_P@FD?W
M[K_OX/\`"NFHH]E#L'*CF?\`A!-(_OW7_?P?X4?\()I']^Z_[^#_``KIJ*/9
M0[!RHYG_`(032/[]U_W\'^%)_P`()I']^Z_[^#_"NGHH]G#L'*CD?^%<:'_?
MO/\`OZ/\*/\`A7&A_P!^\_[^C_"NNHKK^MU_YF<WU'#?R(Y'_A7&A_W[S_OZ
M/\*/^%<:'_?O/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:
M'_?O/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H
M_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*ZZBC
MZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*ZZBCZW7_`)F'
MU'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'
M_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[
MS_OZ/\*/^%<:'_?O/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/
M^%<:'_?O/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O
M/^_H_P`*ZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*
MZZBCZW7_`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*ZZBCZW7_
M`)F'U'#?R(Y'_A7&A_W[S_OZ/\*/^%<:'_?O/^_H_P`*ZZBCZW7_`)F'U'#?
MR(Y:T\`Z/9WD%U$]UYD,BR+ND!&0<C/'M174T5E.K.IK-W-J5&G25J:L?/==
MMX/AN?["O+G3K>T;44N`L<MQV7:,X]_\:XFNL\*:/::EIEZQMHKF\5MJH[XV
M+MR"![GC/:OHL5;V>O\`7Y'R>`O[96WL_P"MF8.L_;/[9NO[09&N]_[TH1M)
MP.F/;%>F_#[_`)%.'_KK)_Z%7F6M06UMK=Y!9L&MDE(C(.>/K]<UZ;\/O^13
MA_ZZR?\`H5<N/_W:/R_([,KTQDK]G^:.IHHHKQ#Z4****`"BBB@`HJ!KVU23
MRVN(@_\`=+C-3]1D4`%%(2%&20![T9&,Y&*`%HHSBC(H`**"0!DG`I`P;H0?
MI0`M%(64'!89],TM`!1110`C,%4LQ``&23VJ#[?9_P#/W!_W\%321I+&T<B*
M\;@JRL,A@>H(KD&.@&_O+.V\&FZ:TD$4KPV4`4,5#<;F!/!':@#J?M]G_P`_
M<'_?P4?;[/\`Y^X/^_@KF/*TK_H09O\`P#MO_BZ/*TK_`*$&;_P#MO\`XN@"
M:VU;2H?&NKEK^UC_`-#M0^Z95R^Z4]SS\I6MG^W='_Z"MC_X$)_C6!Y6E?\`
M0@S?^`5M_P#%T>5I7_0@S?\`@%;?_%T`;_\`;NC_`/05L?\`P(3_`!H_MW1_
M^@K8_P#@0G^-8'E:5_T(,W_@%;?_`!=7=)T_PUK%E]I@T&RCVR-%)%+9QJ\;
MJ<%6&#@T`:7]NZ/_`-!6Q_\``A/\:/[=T?\`Z"MC_P"!"?XU'_PC6@_]`33?
M_`1/\*/^$:T'_H":;_X")_A0!D^#[ZQALM0LXKN`V]KJ$T<&)5P$)#@#GH-Q
M'X5T7V^S_P"?N#_OX*I_\(UH/_0$TW_P%3_"C_A&M!_Z`FF_^`J?X4`:,<T4
MREHI$<`XRK`T^J]I8V>GQ&*RM(+:-CN*PQA`3ZX'>K%`&#+<:^/%L<,=O$=&
M,>6D.,YQ]<YSVKG-1U&_M-2N84GFV6TDD/WSR9_]7GZ=J[_>N_9N&XC.W/.*
MSIM2TA'OC-)"&M`KW)9.5[J3QS^%;0GY&,X>9@W.K:C9Q7")>KB*=X8E,0+;
M8T!R6)QG/7/\ZLZ1K=Y>:A")+B*1)I'0PJH!C`C#!L]>IQ^-;4<VFWD(<>0\
M9?<-Z@9;`YY[\CFF6,6EVKS/:K#&[R-O.,'(X(Y[<?2AR5M@47=:Z'.RZQJ$
M-]JB0W*K';&27:R;MV&48R>@P3TI+77[N*VN$:=`RSQK$'Y)#2N&Z]>`/I74
M,^G^8Z-Y(9D#,Q``*L?7H<D?I3;;3].BCCABBA?RQE2V'8`G.<GGD\T<\;:H
M7)*^C.<BU[5$.G!Y%F::&.9]L2J&#MC;UXP!GCK5K1+^YNK^6::[$I:Q27RU
MP!$2S?+CU]SS6XSV"W$,9$/FH#Y?RCY`.O/\-)%)IZ7+QP^0LK()'VJ!N!)`
M.>^2#2<DUL-1:>YR?_"1ZK':QAIUDDECBE#K$OR[D9B,$@8RHY^M69->U*WL
M9]3EEC,$5SY30",?*"G'/?YB*Z6:.PC1EF2W"JH8JRKPJ]#CT%)#+8W5DLZ>
M4UM-AP67`;T.#3YX_P`H<DOYCEVU_58YY[=GC$B*8]SHJJ'`3G.>Y8]1@<5I
M1ZS.='L+DR*'>[6"9G0`8W$'OCMU'%:=W-IMM'<7%R;<`)^^8@$E?0]S4A^P
MFW\D_9S`,?(=NT>G'2DY)K8:BT]SFM/U^_N+NSW7$3+)Y0,(09</ORP/MM%.
MNKZ\M==OXEOQ&DDJ@-(H*Q`1;N![D8_^O7016FGP7DEQ&D*S;`I(Q\JC.,#L
M.:D9+&X9BR6\I8`L2%;('3/TI\\;Z(2A*VK,#7=5NSX5AEC6:":Y@WO)&C'R
M@%W'D=,GC\:ALKQY=3MY1<RF9[PQ&(N?]3Y61\A]\'..]=2TMNT85I(BCC`!
M(PP_K4-G)97@^V6HB<G*>:JC/!P1G\*2DE'8;@W*]SFKS6-42YNS'=QJD;7.
MU#$#@1*&`S[YYIL^M:IYEP\=W&B+]H94\H'`C16`S[YQ77&W@.<PQG.<Y4<Y
MZ_G2&V@.<PQ\YS\H[]?SH]I'L'LY=QT+F6".0C!90V/J*?0``,`8%%9&H444
M4`%%%%`!1110`4444`%%%%`!1110`4444`?/1Z&O5M'T9!H\5S<:#8.[0KL2
M#&]P1U8M@<UY4>E=6G@W4[G3H+O3KY+I9`IV++MV`KDYYZ@\8KZ+%I-).7*?
M(X"4HRDXPYON_P`F8>MH8M:NT:T2T*OC[.A!$?`X!''_`.NO3/A]_P`BG#_U
MUD_]"KRR]M9[&]EM;H8GB;#_`#;N<>O>O4_A]_R*</\`UUD_]"K''_[NOE^1
MTY5_O<KJVC_-'4T445X9]*(S!5+,<`#)-<5=7$T\YU4.PC^T!$7=V'/2NHU>
M.ZFT]X;109)/E)+8P.]9-SX:4:8JVZ9NP!DE^#ZTQ"ZZ6LKZTU.)B03AEW?>
M_P`BJJ"98!>32L);PLQ*G[D8&2![G@5;BT>\OIP=1"K'%%LC56SSC&?ZTD&D
MWG]E-;W$*L\+$P_O<9!ZC(H`YZXUNTM-1&G3QR*N0LAB5=J$]N1ENHR:W;75
M/[*L;I620K$C-&'<'D'&/IFLV738)KQ+F>P2.Z3`Y61B2.A(QAC^-;$>BF\L
M;B.Y)B\V,I&&P6'.2S>Y-:U72:CR+7J<]%5E*7M6FKZ>AB16L-[IJZQX@U&X
M5)FQ&D9(`].`#[U%J'V0V>DV>FW,TL,MRWSN2"3D#'./6K<>G>([;37TM;>U
MN+<@A)"X^4'TITOAG4(=,TQ[;RVO+1BS(6X.6SUK(Z2QXS=WDTNT1F!EF_A.
M,]!_6LOQ)<2ZIJ%Z892MOI\>.&QN;//^?:M";3]9O[P:E?QP0O;H?L\"R#E^
MV2??G\*2T\'*VCRM>*3J+AF!$G`/;V-`BKK]\;CPUHW[PKYN"Y![*,'^=-TQ
M(/\`A)H3HD]P]G&FZX:1CMQSZ_A4MMX>U9CI45S!&(;20LY\P'@L#T_"KQT2
M^MO$-]=6L*"VG@95VN!\Q7CCZT#,SP_HL.O17MU<RSJWG$(R/C'?^HJ?PREU
M>7DMK->S-'82Y0AOO<D8/MQ2Z98>);#3WL;>VMX0[%C.T@)&>.*Z#0=%31;-
MH]_F32'=*_J?0>U`&K1112`9*[1PNZQM(RJ2$7&6/H,D#/U-<==7&N6^OKJV
MF>&;YA.BPWMO+-;H'5<[9%(D/S+DC!Z@]L"NTHH`YW_A*+O_`*%77?\`OB'_
M`..TG_"4W?\`T*FN_P#?$/\`\=KHZ*`.<_X2F[_Z%37?^^(?_CM'_"4W?_0J
M:[_WQ#_\=ID/B/5[RYO8K/P]YJVEPUNS->HI)&#G&.A!!J?^U?$7_0LK_P"#
M!/\`"@"/_A*;O_H5-=_[XA_^.U@WNH:Q::G+JNA>&=76>?'VJSG2$17!`P&W
M"0E'`XS@@@#(XKH1J_B%LX\-(<''&H)_A2_VKXB_Z%E?_!@G^%`$-GXGU*XC
M03^$=8@F(RR[H"H_X$9!5S^V[_\`Z%K5/^^[?_X[4/\`:OB+_H65_P#!@G^%
M17.OZY96TEU<^&6\B)2\ABO4=@HZD+CDX[=Z`+?]MW__`$+6J?\`?=O_`/':
M/[;O_P#H6M4_[[M__CM:MO<175M%<0.'AE0.CCHRD9!_*I*`*MC=37<+/-8W
M%FP;`2<H21Z_(S#'XU:HHH`PY?#,,OBJ/7C<S"1$V^4#\IXQ^7M63JGAW4+K
M4KR2&-?)NY2LV7'S1A%*_P#CRX_&MJ3Q+81>(TT-A+]J==P(7Y>F<9^E4;WQ
M/)8W]RCI#)#!+Y9A0DS%=FXN!TP/\FMXNI?Y?@825.WS_$HQ>'+UHI!/:1LW
MV>=4W,IP[*@7'IRIY]J(/#=XTC-<VD;DR1G+,IX$Q9O_`!TUK2^)HT@=Q9W"
ME1C,@4`.5W*IY[C'YTD7BFV6")KN&2$F-6D88*JY3?MZYSBGS5.PN6GW,QM%
MU&*VFB6R619(Q"`&0[%\UR2`3C(5ACZ^U6])T:ZM=>-R8?)M@&V+\O"E5"J2
M"2<8Z=*O0:W-/K$%E]@FB1XW9S+@%2-N,<\C#=O7ZTC>)(%D=#:W/#ND9"C]
MXRD!@.>.O4X%)RF]+#48+6^QDS^';EP[+:(7DDN6D*N%9@S`IS]!_C3+70M3
MBOK6[>!"D."8,J`_[QCD@'`90P;CC/2M"Z\5H+4/96<TSE%D.=H509-F"<]<
M@],U-'XEC614GMY5+3F'<H&U3OV`')Y.?3-.]2VPK4[[E/4]&O+J^N2ENKF6
M02)<EE^5!'M,>.O)_#FGZIH]W/H>FVL$2Y@4"6(!3SL*\`D#@G/ZTMGXK#1M
M)>P;%"Y5H^1G86P<]^#BM*ZUN&TFMHI(9B\Z;\`#*C('//)&>@R:5YII6&E!
MINYSEYX9O9+.14MHWG::0LY9<NIC`&3[D5)=Z!=20SM%IT8>:YE?JFY5*87J
M<8SGUQV%:Z>*+)MI:.9%;E68#!4AB&Z]#M(]:C/BRS$+2&WN<;<J,+ER"H*@
M9ZC<*?-4["Y:?<P1HU_>+=QK9%)D&UY&8`R?N479GN,C.>E6[KPW>;KC[);Q
MQ;Y)\%2HRC;-H^AP>*V&\36D<DL<D,Z-&IX('+#&4&#U&X>WO2PZZ?[-O+RX
MM73[/<&'REP6/(`[XSD^M'//L')#N8G_``CEZ\5P7MD8M`XA5M@\MC(&P`#A
M>!G@UT.@V<EAIIMY(%B999#A<88%B0>/8BJX\3VFZ-6AG1BQ20$#]V=Q49Y[
ML,<9I(_$]L\4;O:W,7FHCQ*ZKEPS!1CGWS]*F7/)6:*BH1=TS<HK!/BRR$6_
MR9R2X"KA<LI!(;KCD`\=?:MT'<H(Z$9K)Q:W-%)/86BBBD4%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`'SW77^%+&*[TBX9K%M2=;E5^R^=L$:D<R?7M
M^%<A6WHFCRWMI/>C5H-.AC<1%Y)"NXD9QP17T^(5X;V_KRU/B\(VJNBOOV_7
M0IZU;06>MWEM;/OABE*H2<\>F?;I^%>F?#[_`)%.'_KK)_Z%7E=[;K:WDL"7
M$=PJ-@31'*O[BO5/A]_R*</_`%UD_P#0JY,?_NZ^7Y'=E7^]RTMH_P`T=311
M17AGTP4444`%%%%`!6+JVB2ZC=_:8KHP2)"8XB!G!)^;([@CBMJBJA-P=XD5
M*<:BY9',V_AS4HG*'5Y?L_RJ%4D'8".!Z<#'%/NM`U*42B'6)47S,Q(6/"'D
M@GJ3G]!71T5K]8G>_P"B,OJM.UM?O9BW>A-?Q6$5U=,ZVZMYAP,R,1C/.?>J
MC^&KQ(%BMM2F1`S?*96`5?X,8/\`#^M=+125>:T3'+#4Y.[1S">'-3BF5H]7
M=5\PN_7+9.<D9Y..,=*/^$=U-X8_,U3,R.7\S+G)VD`XS@')'`XKIZ*?UBI_
M2)^J4_/[V86G:)>6]TDMSJ,LD:$L(1(Q&XXZD\D<$X]ZW:**SG-S=V;4Z<::
MM$****@LK7UV;&V,PM;BY(('EVZ!F^N"167_`,)*_P#T`-:_\!U_^*K=KD=.
MU'Q1JQO##+I$)MKJ2W>&2*1F3:>,D-W4J?QH`T?^$E?_`*`&M?\`@.O_`,51
M_P`)*_\`T`-:_P#`=?\`XJF>5XN_Y^M%_P"_$O\`\51Y7B[_`)^M%_[\2_\`
MQ5`&-I&O36%]K$USX>UT&ZO#*@2RW#8$50<@_P"R:PO&/B_41<&31;?7K.X2
MW+7J36VV-;?GYP#G:Y((#?GG%=MY7B[_`)^M%_[\2_\`Q58&O^#O$>OSQ3OJ
MMA:3)L#M;1R`2HK;E5U8D,`W(R/YT`3^'?%VE)H=NFD^']>^R*"!BR9CNS\V
MXDY+9SDGO6I_PF"_]"_X@_\```_XU5TS1_%.D6!MK:\TF0EFD:2:*4M([')9
MCNZDUMZ!JZZUI:7#)Y5RA,5U!WAE7AE/X]/48-`&=_PF"_\`0O\`B#_P`/\`
MC2'Q>C*0?#WB`@\$?8#_`(UTM%`'&>&M7N-,\/6EE-H&M;H0RC_1UX7<=O\`
M%_=Q6M_PDK_]`#6O_`=?_BJW:*`*]C=F]M5G-M<6Y)(\N=0KC'L":L444`1&
MVMS<BY,$9G`VB78-P'IGK55M)@:+4$+/_IV=YXRN5"\?@*HRR>(?^$MC2..+
M^Q?+^9CC.<?GG/X8K'O9Y[?6;FZ59,1WZ)YHF/3RP?+V=,$]_>M8P?<RE-=5
MU-Z7P];32DM++Y389X<C:SA=H;IG./Y56'A&R)_>RR2`H%;<JY)"[0<XR.,<
M#BL*;7]1;3HKHR@2*[%'(7O#N((!(X)[\^M2WE]J$6L3;KUY#9+($&Q0.?+^
M8@=<!S^56H3[F;G!ZV.E@T?R;R&[>\N)ID#@F0@A@V.,8X^Z.E4D\,"03&ZN
MI"3-))$$QB/<V[N.>@R#D=:SO[;U,R7/EW2R1VL,TBL(U/G[6P#QT`SSCKBE
M?7;Z*\C@BO$NT4J1*D:J)<R;2I)(Z#^[[4E&?<IRAV-2/PQ;1VTL(N)SYB!-
MWRY&)"XQQCJ:;)X6MWF$OVJ<.)/,SA3\V_?Z<<^E1ZOJUU::C,D5Q''Y,*O'
M`Z;C<$A\XQSQM']:R;KQ)?0"6*/4(Y3'")Q*(T^;Y<E,].#CC[W-"51ZW!NF
MNAJS>%8_LR6T4FZ)IHY)#*>0$[+@=^G/K6EJ6CPZG+$TTLJJF,HI&&P0?P/'
M48-<OJ&KWMS!J$(O1M*R_+&H!A"A"ISUYR>M,O=:NKE9X%U',)&Y9%5%("2H
MO;GN<D_AQ3Y)NSN+G@KZ&[_PB5C]@FL]\@CD*8*A5*A3D#('/4C)YI[>%K)I
MIW5G02G=A57Y26#'!QG''0GBLBWUF\CDNE6Y7]S<XCB(!-SNE*G!]AZ5?T75
M+ZX$OVBX24M:"X4F,#82SKCCJ/E'O2:FM;C3IMVL6I?#-E+=74Y9PUQDG`7*
ML<<@XS_"."<5,NB1C3Y[22XFD\^;SGD.`Q;(/88Q\HKDKO5KV\LF62];S%AE
M)>,`?P*>".".?J.];FEZQ>7.NM;-(9(`9$Y"#`7&UA@Y.>>V.1BB49I7N$9P
M;M8LGPO9F[%P7D+[V<Y"G.6+8R1Q@D]*F_X1^T/]F[FD/]G@B/)'S#;CYOY_
M6M:BLN>7<UY(]CGU\)6D=JUO'/*BM\IPJ8*XQ@C&#UZGGWK=AB6"".),[44*
M,G)P!BGT4.3>X**CL%%%%24%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M'SV>E>D:9)K,F@6LL<VA)$VU0DJ_PA>"3G[WM7F]=IX/NBFC7-M!>6$%S]I6
M0K>#Y2FT`D>_%?1XR-X)]CY'+Y6J.+ZHYS7B#KU[B6&7]YC?"NU#P.@KTKX?
M?\BG#_UUD_\`0JXKQE?V-_<P-:/#)(C2*SQ)M&W(V@^IZUTG@O7])T[PW%;W
ME_##,)')1SR`6XKFQ2E/#1LM=#KP3A2QLKR5K/7UL=U16+_PEWA__H*VW_?5
M'_"7>'_^@K;?]]5Y7L:G\K^X]WZQ1_G7WHVJ*R%\4:&PR-2@/XTC>*M"3[VI
MP#\:S46WRI:ENK!*[:L;%%8O_"7>'_\`H*VW_?5'_"7>'_\`H*VW_?5:>QJ?
MRO[B/K%'^=?>C:HK('BC1&&1J4'YTC>*]"3[VIVX^IK-1;?*EJ6ZL$KMJQL4
M5B_\)=X?_P"@K;?]]4?\)=X?_P"@K;?]]5I[&I_*_N(^L4?YU]Z-JBL7_A+O
M#_\`T%;;_OJC_A+O#_\`T%;;_OJCV-3^5_<'UBC_`#K[T;5%8O\`PEWA_P#Z
M"MM_WU1_PEWA_P#Z"MM_WU1[&I_*_N#ZQ1_G7WHVJ*Q?^$N\/_\`05MO^^J/
M^$N\/_\`05MO^^J/8U/Y7]P?6*/\Z^]&U16+_P`)=X?_`.@K;?\`?5'_``EW
MA_\`Z"MM_P!]4>QJ?RO[@^L4?YU]Z-&^^W?9C_9YM_M&1C[1NVX[].:Y6;0_
M%@UDZK8WNCVD\BA+E/*E>.X`^Z67(PPZ!ASCCFMG_A+O#_\`T%;;_OJC_A+O
M#_\`T%;;_OJCV-3^5_<'UBC_`#K[T5?*\:_\_6@_^`\W_P`71Y7C7_GZT'_P
M'F_^+JU_PEWA_P#Z"MM_WU1_PEWA_P#Z"MM_WU1[&I_*_N#ZQ1_G7WHJ^5XU
M_P"?K0?_``'F_P#BZ/*\:_\`/UH/_@/-_P#%U:_X2[P__P!!6V_[ZH_X2[P_
M_P!!6V_[ZH]C4_E?W!]8H_SK[T5?*\:_\_6@_P#@/-_\761>>&_%\VH_VE9Z
MIH]A?$!9)8+>0K,HZ"1"V&QV/!'K70_\)=X?_P"@K;?]]4?\)=X?_P"@K;?]
M]4>QJ?RO[@^L4?YU]Z*MM%XUC3%S=:%.W]Y8)8_TW&I\>*_[VB_E+_C3_P#A
M+O#_`/T%;;_OJC_A+O#_`/T%;;_OJCV-3^5_<'UBC_.OO0S'BO\`O:+^4O\`
MC1CQ7_>T7\I?\:?_`,)=X?\`^@K;?]]4?\)=X?\`^@K;?]]4>QJ?RO[@^L4?
MYU]Z-*Q^V_95^WFW^T9.[[/G9CMUYJQ6+_PEWA__`*"MM_WU1_PEWA__`*"M
MM_WU1[&I_*_N#ZQ1_G7WHVJ:8XSG**<G<>._K6/_`,)=X?\`^@K;?]]4?\)=
MX?\`^@K;?]]4>QJ_RO[@^L4?YU]Z-;[/`%V^3'MR3C:,9/6E\J,L6,:9;@G:
M.:R/^$N\/_\`05MO^^J/^$N\/_\`05MO^^J/8U?Y7]P?6*/\Z^]&NL,2`!8T
M4`;0`H&!Z4@MX1LQ#&/+^Y\H^7Z>E9/_``EWA_\`Z"MM_P!]4?\`"7>'_P#H
M*VW_`'U1[&K_`"O[@^L4?YU]Z-@QH9%D**77@,1R/QJ/[+;[0OV>+:"2!L&,
M^M9?_"7>'_\`H*VW_?5'_"7>'_\`H*VW_?5'L:O\K^X/K%'^=?>C1@L+6W,Q
MB@1?.8M)QG<3_3VIXM+89Q;Q#(P?D'-9?_"7>'_^@K;?]]4?\)=X?_Z"MM_W
MU1[*K_*_N8O;T/YE]Z-800AE(BCRN2IVCC/I3EC1/NHJ\8X&.*Q_^$N\/_\`
M05MO^^J/^$N\/_\`05MO^^J/8U?Y7]P_K%'^=?>C6%O`J[1#&%YX"COU_.E2
M&*-BR1(K$`$JH!P.U9'_``EWA_\`Z"MM_P!]4?\`"7>'_P#H*VW_`'U1[&K_
M`"O[@^L4?YE]Z-JBL7_A+O#_`/T%;;_OJC_A+O#_`/T%;;_OJCV-3^5_<'UB
MC_.OO1M45B_\)=X?_P"@K;?]]4?\)=X?_P"@K;?]]4>QJ?RO[@^L4?YU]Z-J
MBL7_`(2[P_\`]!6V_P"^J/\`A+O#_P#T%;;_`+ZH]C4_E?W!]8H_SK[T;5%8
MO_"7>'_^@K;?]]4?\)=X?_Z"MM_WU1[&I_*_N#ZQ1_G7WHVJ*Q?^$N\/_P#0
M5MO^^J/^$N\/_P#05MO^^J/8U/Y7]P?6*/\`.OO1M45B_P#"7>'_`/H*VW_?
M5'_"7>'_`/H*VW_?5'L:G\K^X/K%'^=?>C:HK%_X2[P__P!!6V_[ZH_X2[P_
M_P!!6V_[ZH]C4_E?W!]8H_SK[T;5%8O_``EWA_\`Z"MM_P!]4?\`"7>'_P#H
M*VW_`'U1[&I_*_N#ZQ1_G7WHVJ*Q?^$N\/\`_05MO^^J/^$N\/\`_05MO^^J
M/8U/Y7]P?6*/\Z^]&U161#XHT.XGCABU.!Y9&"(H;DDG`%%1*$H_$K%PJ0G\
M+N>)5VG@ZZAATB\1;Z*TNC,&+M:F8[`._MFN+KJ_"NJV-OI]UI]U/+;O.^5>
M./=ORN`OU!Y'UKZ/%1;IV2/D,#)1K)MVW_K=&'K4OG:U=R?:%N-S_P"N6/8'
MX'.WM5"M'7YOM&OWTWD/;[Y2?*==K+]1V/?\:SJVI_`O0PJ_Q)>K"K:(EO$)
M)!ECT%55QN&>F:U8;6.[OBLQ?RHH'F(0X+;1G`/:N/%MRG"C>R=V_1=#IPD;
M1E42NU9+Y]2@UW*3P0H]J<EXX.)`&7Z5J+X<\Z^O(8[M(T@D5%\Q22VY"X''
ML#4W_")2?)G48!O"LO[MN5+!0?S8<4I4,'R\KBONU^\TB\;?F3?WZ&)<0J%$
ML?W#VJ152VC#N,N>@]*=$ACBDCD_@?;^1JY8V5O?7\J73E46,%`&VY8L``3@
MXZ^E<:J2G/ZM.3Y4W=]6E:R_'4W]DDO;07O.UET3UN_PT,QKN4G@@#V%.2[;
MI(`RGVK2M/#KWGG$W,=N8YI(MCJ6/R8SR/K4K>%)EAD<WL'F(A8Q[6[;N_\`
MP!J[)4,';EY4OEK]YSQEC+\R;?S_`$,:XA"8=/N-^E05:4YT\Y]>*NZ7I5OJ
M-LI,DJ3&ZBA;IMVMGD=\\56%JM4Y*H[\K:N9UZ//4C[-6YE>QD45O#0([N[5
M;:X\B)X(Y0)P68%VVA3CWI__``BKB$2MJ,`1E+J?+;D*`6_+/Z5T>WAU9G]5
MJO9?D<]14]Y;/97LUK(0SQ.4)'0XJ?3+2"\-TLK2!XX'E3;C!*^M:.22YC%0
M;ER=2C16_>:%!]NM8+.7;%,74S.^X;D&6R-H(_7K4B^$I'!8:C!L#*N[RVZM
MMVC\=XK/V\+:LV^J5;M)7L<Y15S4;!M.GCC,J2K)&)%=00"#D=#[@T:5;1WF
MH)!*DKJP/RQ$`D^Y/`'J:OG7+S=#+V<N?DZE.BMW4-&LX+%YK:>20KL=9#C:
MZNY48'J,9J;_`(1&0R,BZC`Q3=N_=L,!20Q_,5'MX6NV:_5:M[)7.<HK2U71
MVTM('-Q',LV<%%(Q@`]_9A5"%5>>-'W[68`[!EL9[#UJXR4ES+8RE3E"7++<
M9172S:%8+#<>2TK7**2(6E`*$+N8$A<,1^'I5:W\-27%@ERM["&:(2^64;(!
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M.Z#_`&U+<;V=8XD."G4N0=H^G'-.NM"A-[##;S-$CK,6,W)7RF8$\#H=N12=
M:"ERE+#5'!32T?\`PQA45T?_``B$N?\`D(08\SRL[&^_Q@?J.:QM0LC87(A,
MJRAHUD5U!`(89'!HC5A-VBQ5,/4IJ\E8JT5J:!I/]L:JENY981\TK)]X#../
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MFK'_``B,@*@ZC`"^TJ/+;D,VU3^)(J77IK=EK"UGJD<Y12NI1V0]5)!K6T/2
MHM2^T-,S;8MBJJN%+,QP.2#_`)]*N4U%<S,J=.4Y<JW,BBM^[T")&MH(9'$S
MW"6[M)RI9E#9`'0#..]/'A*1HA,NHP&(@'=Y;<9Z<5'MZ=KMFOU2M=I+8YVB
MKVIZ:VF31QM,DH=2P9`1T8J1S[@U5@B,UQ%$#@NX7/IDXK1235T8RA*,N5[D
M=%=5<^&[*%)_*:223#"!3,!O*[MQ^[VV].._-4+7PW)=V*7*WD*L\?F"(JV<
M?-CGI_":R5>#5S>6$JI\MKF)16U?>')+&REN?MD4OE'#HJL".0#R?3<*Q:TA
M.,U>)C4ISINTU8**W=(TNPOK$O<"X27S"BLKC:Y"ER`,?W1USU(H3P^MUJ$D
M,%R(8Q'#(OF@L?WF,+Q[GK4.M%-I]#18:HXJ2UN85%=#_P`(JPA65M1@".I=
M3Y;<J-N3_P"/5B7=N]I>36SD%XG*$CH2#BJC4C/2+)J4*E-7DBWH'_(QZ9_U
M]Q?^ABBC0/\`D8],_P"ON+_T,45Y.:?''T/=R3^'/U,X].*ZFRN?!T"V\LL.
MIFYCVLQ7&W>,$XYZ9KEJ*]:=/G5KM>AX5*JZ;NDGZJYH:[?1:EKEY>P!A%,^
MY0XP<8`Y_*L^BMG3?"NKZM9K=V<$;PL2H)E"G(.#P:&X4HJ[LD)1J5IMQ5V]
M=#&J_;7+Y1HY6BN$^ZZG!K6_X0+Q#_SZ1?\`?]:/^$"\1?\`/K%_W_6N3$.A
M62]])K9W1UT*6)I-_NVT]U9F/YFH1.[)-+N=M[,K?>;!&3[X)_.I4N-2<KNN
MYE"@`9?H`01C\0#^%;,7@KQ(KKNMX]G?]\M6&\%:TXPUM&1_UV%>?7QM:FU#
MW7YI7_7<[J.!YUS6DO)Z'+7,P(\M#GG+-ZFK%K>3+\UO</!/C:60X)%;W_""
M:M_SYQ?]_A_C1_P@FK?\^<?_`'^'^-8O$T/9J,8R4EK>RW>]]=;FBPF*YW*5
MK/2VNW2VG0YQ9-0MP5CFE4$D_*W4GJ?QP*E2XU)R3)>3*",-E^HY_P#BC^9K
MHAX,UL#`MH_^_P`*J2^"/$DC'-O&5SP//6MZ.-JU[Q?+'S:_+4SJX+V-I)2E
MY(YZXE4@11_<6HTGFB0I'*Z*6#X4X^8=#]1FNA_X0+Q#_P`^D7_?]:/^$"\0
M_P#/I%_W_6O2HRP]*"@I+[_Q//JT<54GSN#^YF&=1O3.\YNI?-?;N?=R<'(_
M(@4IU&]*!#=S%`"H7=P`>HK;_P"$"\0_\^D7_?\`6C_A`O$/_/I%_P!_UJ_;
M4/YE^!/U?%?RR^YG.2RR32M+*[/(YRS,<DGUI8Y9(2QC=D+*48J<9!ZBNB_X
M0+Q#_P`^D7_?]:/^$"\0_P#/I%_W_6J^L4=N9?>3]4Q-[\C^YF')J-[++'+)
M=S/)&"J,6Y4$8.*4:G?JNT7DP&0V-_<8P?PP/R%;?_"!>(?^?2+_`+_K1_P@
M7B'_`)](O^_ZU/ML/_,OP*^KXK^67XG/2SRSE3+(SE5VKN.<#TIUM=7%G-YU
MM,\4F"-R'!P>HK?_`.$"\0_\^D7_`'_6C_A`O$/_`#Z1?]_UI_6*%K<R^]$_
M5<3>_([^C,*6_NYXA%+<R/&&WA2W&[UIXU2_!8B\GRV03OZY.3^9K:_X0+Q#
M_P`^D7_?]:/^$"\0_P#/I%_W_6E[:A_,OP*^KXK?EE^)@375Q<*JS3/(J?=#
M'..`/Y`?E4<<CQ2))&Q1T(96'4$=#71_\(%XA_Y](O\`O^M'_"!>(?\`GTB_
M[_K3^L4=N9?>2\+B6[N#^YF-)JVHRK*LE[.RR\2`M][ZTQ-0O(T")=2JH4*`
M&X``(`_(G\ZW/^$"\0_\^D7_`'_6C_A`O$/_`#Z1?]_UI>VP_P#,OP*^KXN]
M^67XF%+?W<T;1RW,KHQRRLV03G.?SYJO72_\(%XA_P"?2+_O^M'_``@7B'_G
MTB_[_K36(HK:2^\EX7$O>#^YF,NK:B@0+?3C8NU</T'I445[=0KMBN)4&2<*
MW<XS^>!^5;W_``@7B'_GTB_[_K1_P@7B'_GTB_[_`*TO;4/YE^!7U?%?RR_$
MQ#J=\=V;R8[A@_/U'(_J?S-5:Z7_`(0+Q#_SZ1?]_P!:/^$"\0_\^D7_`'_6
MFJ]!;27WHEX7$O>#^YF'%J-[#$D45W,D:-N55;`4^HH_M&]\YYOM<WF.P9FW
M<DCH?PK<_P"$"\0_\^D7_?\`6C_A`O$/_/I%_P!_UI>VH?S+\"OJ^*_EE]S,
M3^TKXJJ_:YMJKM4;N@XX_0?E5=W:21I'8L[$LS'J2>IKH_\`A`O$/_/I%_W_
M`%H_X0+Q#_SZ1?\`?]::KT%M)?@)X7$O>$ON9SL4TL#EX9&C8@KE3C@C!%2O
M?WDLPFDN96D"%-Y;G:1@CZ<UN_\`"!>(?^?2+_O^M'_"!>(?^?2+_O\`K1[>
MAOS+\`6&Q*5E"7W,Q?[4O_\`G]G^]O\`O_Q>OUX'Y57DEDF8-*[.0H4%CG`'
M05T7_"!>(?\`GTB_[_K1_P`(%XA_Y](O^_ZT*O06TE^`/#8I[QE]S.=CEDAD
M62)V1U(*LIP0:E>_O)4B22ZE9(CNC!;[I]16[_P@7B'_`)](O^_ZT?\`"!>(
M?^?2+_O^M'MZ#^TOO0+"XE*RA+[F8G]I7V&'VN;#@JPW=0221^9/YU'-=7%S
MCSYGDP2PW'/)QD_H/RK?_P"$"\0_\^D7_?\`6C_A`O$/_/I%_P!_UH5>@OM+
M\`>&Q35G&7W,YR.1XI%DC8HZG*LIP0:L2ZE?3)*DMW,Z2D&16;AL>M;?_"!>
M(?\`GTB_[_K1_P`(%XA_Y](O^_ZT.O0>KDOP!8;$I64)?<S$74KY!A;N8#`&
M`W8#`_2F2WMU/%Y4MQ(\>=VUFR,Y)S^9/YFM[_A`O$/_`#Z1?]_UH_X0+Q#_
M`,^D7_?]:/;T/YE^`?5\5MRR^YG-5;BU74((XXXKV=$C^XJN<+6U_P`(%XA_
MY](O^_ZT?\(%XA_Y](O^_P"M#KT'O)?@$<-B8[0DODS!6^ND9V6YE!=M[G=]
MXX(R?P)'XU(=4OR5)O)LJ`!\_0`Y'Y'FMK_A`O$/_/I%_P!_UH_X0+Q#_P`^
MD7_?]:/;4/YE^`?5\4OLR^YG-DEB23DDY)J6WNKBT9FMYY(BZ[6*-C(]*W_^
M$"\0_P#/I%_W_6C_`(0+Q#_SZ1?]_P!:;Q%%Z.2^\2PN)3NH/[F81O[MO(S<
MRGR.8LM]SZ4X:G?"/RQ>3!.!MW\<=*V_^$"\0_\`/I%_W_6C_A`O$/\`SZ1?
M]_UI>VH?S+\"OJ^*_EE]S.>FN)K@@S2O(5R`6.<9))_4D_C48.#D=:Z7_A`O
M$/\`SZ1?]_UH_P"$"\0_\^D7_?\`6G]8H_S+[R7A,0]7!_<S&?5M1D$@>^G8
M2+M<%S\P]*C2_O(D"1W4JJ%V@!N`.>/U/YUN_P#"!>(?^?2+_O\`K1_P@7B'
M_GTB_P"_ZU/ML/\`S+\"OJ^+WY9?B84E_>2QO')<RNCG+*6R#TZ_D/RJO72_
M\(%XA_Y](O\`O^M'_"!>(?\`GTB_[_K36(H+:2^\EX7$O>#^YF!'=7$2HL<S
MH(W\Q`#C:WJ/>G"_O!,\PN91+(07<-RQ!R/R-;O_``@7B'_GTB_[_K1_P@7B
M'_GTB_[_`*T>WH?S+\!_5L5_++[F89U&]**ANYMBJ55=W`!QD?H/RJ"21YI6
MDD<O(YW,S'))]:Z/_A`O$/\`SZ1?]_UH_P"$"\0_\^D7_?\`6A5Z"VDOP!X;
M$O>$ON9EZ!_R,>F?]?<7_H8HKH-)\%:[::S8W,UM&(HKB.1R)E.`&!-%>5F-
M2$Y1Y7<]S**4Z<)*::UZG'4445[A\R%>M_#[_D4X?^NLG_H5>25ZW\/O^13A
M_P"NLG_H5<&9?P?G_F>KD_\`O#]'^AU-%%%>"?4!1132Z!MI8`^F:`'44F]=
MVW<-WIGFDWIDC<N1U&:`'452;5]/5]INH\YQG/'Y]*N*RNH92&4\@@]:`%HI
MDDT47^LE1,_WF`H\Z+:&\Q-IZ'<.:`'T4UG1,;W5<],G%#2(F-[JN?4XH`=1
M37D2-=SNJCU8XI(YHI1F.1''^RP-`#Z*B^U6X;;Y\6[TWC-29''(YZ4`+111
M0`4444`%%<;XH\6W^@:C]A2VMG^U(#;W)<[;49"M)<#'"`GAAP3QQUKHK.\@
M@LX8KC5(+B95`>8LB[SW.!P/I0!H456_M&Q_Y_+?_OZO^-']HV/_`#^6_P#W
M]7_&@"S15;^T;'_G\M_^_J_XT?VC8_\`/Y;_`/?U?\:`+-%9NH:FB6$S6-W8
M&Z5<QB>8!"?0D<CZUS_A3Q9+XMU!YXY(K*UMTVFR9@TLS'_EIG_GGP=I'WN2
M<=*`.RHHHH`****`"BL*75-77Q9'IZ:;NTUDRUUSP<>O3KQBLJ_U&^M=5N9U
MFF$,5V(@3(#'CRP=FSKR>_O6BIMF;J)'945REOK.I-,$D>#SKD6X0[6\N/>K
ML>,YSQCK56Q\2:A%IL,\IAECC<Q2AL[W(1GW`YQC@#I3]E(7MHG:T5@6NNW#
M:%?7L\(,EMG;A&0/\H8<'D#G'X51E\1ZC;7<L$OV20PS*K>4K993LYZ_+]\\
MGVXI*G)C=2*U.MHKDV\1:DJ)A+:1IF<($4Y0+)LY!;YB1T`QSFM*/697@TJ0
M>2PNP^]ES@80MQGIR.])TY(%4BS:HKE]*\0WU[);/*MOY4LRPE$4[@3'OW9S
MT[5&VKZE!JNI0)-`RHTDJ>:APJHB':,'ON_G3]D[V#VJM<ZRBN;U>\GD@L;I
M&GCM_(:XF2&94?&%/?KC)XJ;7-8N[%D-H(2GV9YV\U22=I4`#!&/O4E!NPW4
M2N;U%<G<^(M2@$R!;4R6XF,A*-A]A0#'/'WO?I6YI-Y/=Q7"W`C\V"=H2T8(
M#8QS@].M#@TK@JB;LC0HHHJ"PHHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@#Y[HHHKZT^""O6_A]_R*</\`UUD_]"KR2O6_A]_R*</_`%UD
M_P#0JX,R_@_/_,]7)_\`>'Z/]#J:***\$^H&NZQHSL<*HR3[5P]S*9Y3JI<;
MC<`(F>0HZ&NLU:WN;NP>"V*AG.&+''%9UUX;A;35BMT070`S(2>?6F(AU_%I
M>VFIPE?,/!']X?\`ZC5"2-X+..Z<>;+>;I)"#_`.V?J1FM6#1+B><R:BZ,%B
M\N-5.<<8S4<>A79TLVTKIOB<M"RL>0>JGV-`'+3:K#::NFF-!(PC<(9?,Z,<
M<JO3'/?K6Y;:I+I5A?\`SK(8U+*H'"ONV_EWJ)M+NOM)D.G'ST`$<S1AGR.G
MS=./7K6E%HT']GW%K?2Q13W$716&55>_OSR36U25.2CR*W<YZ,:L')U973>G
MDC%BL+`:3%J^O27-S)<MP%).WK_A4=W]AN&T&TT]'%L9F8"3[Q^89_D:O1Z)
MX@CTYM.ANK26R<85FSD*?3TJ:?PO>Q6FFO9SQ"\LQ@YSM8YSQ6)TAXL`N-9T
M:TQD&7<?ID#^AK#U^8:Q=ZA=B51':;8X5+#YN>2!^=:UUIM^)FU+5;ZTCN]A
MCMD+[54^N?;)-6(/"%M_8!C:.)[]D)$VXX!/3'M1:RN*ZO8S?$=Y'=V&A"0D
MQNH>3`R<<`_UINDK;G7YKS2$>&PMH2TH=OO?*>,9SUJ_9>&]12\TI[EH#%9@
M@@,23R2.WN*G;P_?1ZIJL\!A$5Y"R(-V,$XZ\?6@9F>&_#UCJNC37%VC>8TC
M!9`Q!4`#\.N:L>$H&U"%A<32LEE-F$AN.>H^G`_.EL=%U]-,_L^*[M(;0DY=
M,LQR>>:Z72=+@TBP6VA);G<SGJQ]:&!>HHHI`%9MYI=Q=7)ECUK4+52`/*A$
M.T?]]1D_K6E10!Y3-X8U75_%6MRQW3:KIR[+5XKR98LRJF<G;'AU7?PI&,Y.
M#72:3\/=/L=%MK6Y,3SQ11JTBVT)`*]<;D)P>ASZ<8K2\+L-^MQ='CU2;</]
M[:P_0BMR='DMY4C?8[(0K8S@XX..]`'$P>'[8V<VIQ:=8W<$<TLD,"V\!^TP
MX^4!L`+@Y(YSZUT2>&O#\B*ZZ-IQ5@""+=#Q^5+9W,$?A-9YE,<,-J?-$D&S
M`52&R@Z#@\"K>DQ^3HUC$1&-EO&N(E*J,*/N@\@>@-`&/JVB:'96B^1H^D"Z
MF<0VZSP*J-(>@)"D]`3^%,7P1IH=2R0%0[L5^Q0\ANB_<_A[?KFM;5"Z7&G.
M&N-@N0'$2*P.5(&_/1<]QSG%:-`'GGC#PAIT'AF:"T2/[;=K'96Y:VAQYKN`
M'.U`<XSG'&`>*R-+^$4GVZ![V46@B5S)<6LJ&:5V[JWE`H`>1R<<`8KNO$^%
MN=!E?`C34XPQ/8E'4?J0/QKH*`,5="NU4*/$FKG`QR+<G_T56K;Q-!;I$\\D
M[*,&67;N;W.T`?D!4M%`!1110`5ES1:(NJ8F6U%]+V;&YLC'YXXJK+X?GD\6
MQZT-1E6%(]IMAG!XQZ]._2JM_:WRRZI!!8F>:[D62"9L;$P@`)/8J1D?6M(Q
M71F<I/JC>?3;%XVC:UB*,JJ05'(7[H_#M6?-H6DVMRFHR*(H[9,!.!&H`(Z8
M]"?SKG;O3K]K>3[-8720E0$1B25E"'+;<]SCYO49I'L;G4?[4$5K,[?OA*6Z
M2':FU1SU!S6BA_>,W/\`NG826MC9Z9/%M2VM2IWE?E`!ZFJ5CX?T>.W*)`EP
M!(Q+R`,=W`(Z>P_*N>N-,O)Y;](].G6&6"4*C#(8Y4IR3UP#@8&.E2QZ=J&\
M%+6X0F4FV)X$/[W)+<\`IC^5+ELOB'S7?PG20:#IMO!+"+5'$K%I#(`2Q+%N
M3]34MQ9Z?)%!:3P0E,XBC91@$#M^&:QM!L;NQ9RT$B[[0%@S?>EWO^1QMK$C
MTS5R2L-M<1$IN!.0`WEL&Y)Y))`SWZTN6[?O!S62]TZRTT_2;*XNKJ%8E>,_
MO&X_<X4<>PP`?QJ8Z=IE_P#Z2UK!-YN'WE`=W'!_*L6WTXOH6NP1V$L4<Y8P
MP2#EOW:@=_[PK-N-'OS"8([6<2[SYLBG"O$2NU1SV_3!]:?+=_$'-9?"=C>V
MMC+$);R&%HX`7#2*,(!U-#0V6H;F:.*?`,3$C/!P2O\`*L/Q'ISO!'##:2SV
MRVTL:1Q<[9"!L)Y^O-9_]D:B]UJ$@MY0XAD-LQ;`WG:..>N,XJ8Q35[CE)IV
ML=8VFV3ERUK$3)NWY4?-NQG/UP/RI]H;9HWEM=A21V9F3^)LX)^N17*6NG7J
MO:^?:W+P;F,*1DIY!+J<G))`V@]<]QWJS#I<@\-K8BTD0_;@9$7Y<IYN200>
MFVAQ7<%-]CJ:0D`$GH*X*>QO+42FX@E\GSU1T0']\#,-H!W<_+QP!Z5/]@U.
M.XL&^RW&4V_,"6*H6?Y3SQ@%<]<_A3]DNX>U?8[6.1)HEDC8,C#*L.A%.KEO
M#5L^FE?MMM,MS<,L2,W.%6-3SSP,@_C61>PO>:K/;1QS27?F3>:Z,<%"Z;1U
MXP/Y&DJ:;M<;J-1O8[V66."%Y975(T!9F8X`%10W]K<,%BG1R25`![C&1^HK
MB]0TB\DNKN.+3YO*998PH!8$?+LY)Z<'`QQ3KK1;E9IXK:QE5#<2'*<!D)CQ
M@Y]`U-4X]R75E?8[JBO/[VVEM+V>WEAF"O.HL%!.$_>@L1ST(-=)J;MJ6G6\
ML=O/+;K<?OX`,.ZC<.F>1G!J73M;4I5+WT-RBN;\/Z;=027,]W&XN3%&B.[9
M_@&1U]<9^E8T^FWYTQ4CT^[$P0B1B^X&;8?F"Y]?XL_A35--VN#J-*]CMC>V
MRPRS&>,1PL5D;=PI'4&IZX2?3+Z9KPQ6-PLLCRO([=)4(7:HYY.?Y&M?0+/4
M(-5O9;I656W`D@X=MY*G.>?EP.`*)4TE>X1J-NUCI*BN+F&UC$D\JQJ6"@L<
M9)Z"N#M+8W^HQPK%-(Z,GVQ@QVN1*V3G/I^E30:/=S7BI/I\HA$\3E7&0,,X
M8Y)YX*\\?I3]DENQ>U;V1VL%W;W./)F23*AQM/522,_H:FKAK31KGR[6!K"5
M(E\E9E(P"0\A8]>1@K^=16J2Q:AIUM<I,;Q98-F6R4C`;<#S^/Y4.DM;,%5>
MET=]1116)L%%%%`'SW1117UI\$%>M_#[_D4X?^NLG_H5>25ZW\/O^13A_P"N
MLG_H5<&9?P?G_F>KD_\`O#]'^AU-%%%>"?4!1110`4444`%8^J^'XM5G:=YY
M(Y?*$<;)U09.?KD'!K8HJH3E!WB1.G&HN62NCG(?"4<<[,]]/)"SAC$W0@'(
M!.?I^5)/X22:/:NH7"D2$KSD*G90,]LGFNDHK3ZQ5O>YE]5HVMRF5=:.\UU%
M/%=;&2`P'?&),J>_/0U3'A5#<O(]Y*RLV2H&-RY!VGGD<8&,8KH:*2K32LF5
M+#TY.[1@#PM&`2+R=7S\CJ<%%^;Y1[?-^E0P>$C!Y7_$QE<(Q)5URO..0,\'
MCKSUKI:*?UBIW)^JTNQS"^#E555;^50JX!5<$<$''/0YR?>NBMK>.TMHX(5Q
M&@P!G-2T5,ZLY_$RZ="G3^!6"BBBLS4*R[W3M2N+II+;6YK2(@8B6WC<#\6!
M-:E%`'&7&B>(M'U?^V-/U%]268J+^S:**-I54$*R'``89P<]0!Z4JZKXC$:@
MZ=JQ81.I;R+?ER?E;&_MZ=Z[*B@#AUFU(S,\VBZR8S+'.4A\F+=(HP2Q5\L&
MP,@\<8K8_P"$BU#_`*%?5/\`OJ+_`.+KH**`.7O=5N-1LY+2[\):I)!(,,I:
M(9YR.C^HJLFJ^(5P#IVK-CS,YAM^=WW/X_X?U[UV-%`'`:PVNZQI%Q8RZ?JR
MM)"@CE$$&8YE8,)1\_7('':H[/6OB/-$89-"LTN1PLDD>(F']XD39'J0%^F:
M]#HH`Q%A\4;1NU#1PV.0+&4C/_?VM:V$ZVZ"Z>-YP/G:)"JD^P))'YFI:*`"
MBBB@#,?7].CUQ-':?%ZZ[@FTXZ9QGUQS5:7Q`T6IO;M;Q^2MP+<OYOSY*AMV
MW'09]:T6TRQ;45U!K6(WBKM$VWY@*S[GPW!<S3S&3;++<+-Y@0;E`4*4SUP0
M#^=:+DZF;Y^G]()?%%C'%'-B3RBS*Y9"&`";@0.X(QCZU&_BFV2^6`6TZHJN
MT[NA7R\8P,=R=P_,5`?!T7V(6XNBI#$[UCZC9L&>?3_(JU<^&H[F\NKAKEAY
MX;Y0OW2=F#[X,8_.J_=$_O27_A)+`,%/G!MKNX,1_=A3AMWI3D\16#M&N9E9
MFVL&B(,7.T;_`$R>*KKX90FZ::Z9Y+J)TE8)MRS,#N'IC`&*;+X:-S=1W-U>
MF>48#EH^"`VX!1GY?QS2M3'>H:%WK-E8W0@N)&4[=S-M)5!SC<>V<''TJLWB
M;3TC+,)U8<E#$=P7&=Q']W'>GWNB_;+J:07<D45Q&(YXT49<`,!SV^\:S[CP
MF]T7>7469Y(O);,(V[0,*=N?O#GGWZ415/JPDZG1%F\\3VMO#=F*.666W#87
M80'*XS@]\9%)=^*+:WAE,<%Q)+&1^[,97/S!6P?8D9JO'X9FF^UBZN@%<R"$
M(GW=P4%C_P!\]/UI3X5D=WDDU$O(RLI<P\DEU;GGL5QCTIVIDWJ="Y#XBM'<
MI(LB$2F-B%)"?,5&X]LD5/9:W9WZRM$9%$:>83(A7*Y(W#U&0?RJBOAD*\W^
MF'R[F427">6/GPY8`'/'7'TJU8:(MB<BX9O]&%OG:`1AF;/_`(]^E)J%M"DZ
ME]2G=^++>*U\^WMY9<HSA2I4D``@CCH0>M:5OJ]K<WAM4\Q9,'[Z$`D8W`'U
M&1FLH>$E\ID:];+*Z_+$`HW*!D+G@\9/J3VJW8>'TLM3:^:82.2[#Y,$,V-W
M.3Q[?SH:IVT$G4OJ;.,]:***R-@I`H!)`&3U-+10`4444`(0"02`2.E+110`
M4444`%%%%`"!0,X`&>N*6BB@`I-HW;L#/K2T4`%%%%`!1110!\]T445]:?!!
M7JW@*ZMX?"L223Q(WFR<,X!^\:\II"H/4"L,105>'(W8ZL)B7AJG.E?2Q[[]
MOL_^?N#_`+^"C[?9_P#/W!_W\%>!;5_NC\J-J_W1^5</]EQ_F_`]+^VY?R?C
M_P``]]^WV?\`S]P?]_!1]OL_^?N#_OX*\"VK_='Y4;5_NC\J/[+C_-^`?VW+
M^3\?^`>^_;[/_G[@_P"_@H^WV?\`S]P?]_!7@6U?[H_*C:O]T?E1_9<?YOP#
M^VY?R?C_`,`]]^WV?_/W!_W\%'V^S_Y^X/\`OX*\"VK_`'1^5&U?[H_*C^RX
M_P`WX!_;<OY/Q_X![[]OL_\`G[@_[^"C[?9_\_<'_?P5X%M7^Z/RHVK_`'1^
M5']EQ_F_`/[;E_)^/_`/??M]G_S]P?\`?P4?;[/_`)^X/^_@KP+:O]T?E1M7
M^Z/RH_LN/\WX!_;<OY/Q_P"`>^_;[/\`Y^X/^_@H^WV?_/W!_P!_!7@6U?[H
M_*C:O]T?E1_9<?YOP#^VY?R?C_P#WW[?9_\`/W!_W\%'V^S_`.?N#_OX*\"V
MK_='Y4;5_NC\J/[+C_-^`?VW+^3\?^`>^_;[/_G[@_[^"C[?9_\`/W!_W\%>
M!;5_NC\J-J_W1^5']EQ_F_`/[;E_)^/_``#WW[?9_P#/W!_W\%'V^S_Y^X/^
M_@KP+:O]T?E1M7^Z/RH_LN/\WX!_;<OY/Q_X![[]OL_^?N#_`+^"C[?9_P#/
MW!_W\%>!;5_NC\J-J_W1^5']EQ_F_`/[;E_)^/\`P#WW[?9_\_<'_?P4?;[/
M_G[@_P"_@KP+:O\`='Y4;5_NC\J/[+C_`#?@']MR_D_'_@'OOV^S_P"?N#_O
MX*/M]G_S]P?]_!7@6U?[H_*C:O\`='Y4?V7'^;\`_MN7\GX_\`]]^WV?_/W!
M_P!_!1]OL_\`G[@_[^"O`MJ_W1^5&U?[H_*C^RX_S?@']MR_D_'_`(![[]OL
M_P#G[@_[^"C[?9_\_<'_`'\%>!;5_NC\J-J_W1^5']EQ_F_`/[;E_)^/_`/?
M?M]G_P`_<'_?P4?;[/\`Y^X/^_@KP+:O]T?E1M7^Z/RH_LN/\WX!_;<OY/Q_
MX![[]OL_^?N#_OX*/M]G_P`_<'_?P5X%M7^Z/RHVK_='Y4?V7'^;\`_MN7\G
MX_\``/??M]G_`,_<'_?P4?;[/_G[@_[^"O`MJ_W1^5&U?[H_*C^RX_S?@']M
MR_D_'_@'OOV^S_Y^X/\`OX*/M]G_`,_<'_?P5X%M7^Z/RHVK_='Y4?V7'^;\
M`_MN7\GX_P#`/??M]G_S]P?]_!1]OL_^?N#_`+^"O`MJ_P!T?E1M7^Z/RH_L
MN/\`-^`?VW+^3\?^`>^_;[/_`)^X/^_@H^WV?_/W!_W\%>!;5_NC\J-J_P!T
M?E1_9<?YOP#^VY?R?C_P#WW[?9_\_<'_`'\%'V^S_P"?N#_OX*\"VK_='Y4;
M5_NC\J/[+C_-^`?VW+^3\?\`@'OOV^S_`.?N#_OX*/M]G_S]P?\`?P5X%M7^
MZ/RHVK_='Y4?V7'^;\`_MN7\GX_\`]]^WV?_`#]P?]_!1]OL_P#G[@_[^"O`
MMJ_W1^5&U?[H_*C^RX_S?@']MR_D_'_@'OOV^S_Y^X/^_@H^WV?_`#]P?]_!
M7@6U?[H_*C:O]T?E1_9<?YOP#^VY?R?C_P``]]^WV?\`S]P?]_!1]OL_^?N#
M_OX*\"VK_='Y4;5_NC\J/[+C_-^`?VW+^3\?^`>^_;[/_G[@_P"_@H^WV?\`
MS]P?]_!7@6U?[H_*C:O]T?E1_9<?YOP#^VY?R?C_`,`]]^WV?_/W!_W\%'V^
MS_Y^X/\`OX*\"VK_`'1^5&U?[H_*C^RX_P`WX!_;<OY/Q_X![[]OL_\`G[@_
M[^"C[?9_\_<'_?P5X%M7^Z/RHVK_`'1^5']EQ_F_`/[;E_)^/_`/??M]G_S]
MP?\`?P4?;[/_`)^X/^_@KP+:O]T?E1M7^Z/RH_LN/\WX!_;<OY/Q_P"`>^_;
M[/\`Y^X/^_@H^WV?_/W!_P!_!7@6U?[H_*C:O]T?E1_9<?YOP#^VY?R?C_P#
MWW[?9_\`/W!_W\%'V^S_`.?N#_OX*\"VK_='Y4;5_NC\J/[+C_-^`?VW+^3\
M?^`>_+>VKL%6YA+$X`$@R317B.@*O_"1Z7P/^/N+M_MBBN+%X94&DG>YZ>!Q
MCQ47)JUCL_\`A5__`%&/_);_`.SH_P"%7_\`48_\EO\`[.BBCZ_B/YOP7^0O
M[+PG\GXO_,/^%7_]1C_R6_\`LZ/^%7_]1C_R6_\`LZ**/K^(_F_!?Y!_9>$_
MD_%_YA_PJ_\`ZC'_`)+?_9T?\*O_`.HQ_P"2W_V=%%'U_$?S?@O\@_LO"?R?
MB_\`,/\`A5__`%&/_);_`.SH_P"%7_\`48_\EO\`[.BBCZ_B/YOP7^0?V7A/
MY/Q?^8?\*O\`^HQ_Y+?_`&='_"K_`/J,?^2W_P!G111]?Q'\WX+_`"#^R\)_
M)^+_`,P_X5?_`-1C_P`EO_LZ/^%7_P#48_\`);_[.BBCZ_B/YOP7^0?V7A/Y
M/Q?^8?\`"K_^HQ_Y+?\`V='_``J__J,?^2W_`-G111]?Q'\WX+_(/[+PG\GX
MO_,/^%7_`/48_P#);_[.C_A5_P#U&/\`R6_^SHHH^OXC^;\%_D']EX3^3\7_
M`)A_PJ__`*C'_DM_]G1_PJ__`*C'_DM_]G111]?Q'\WX+_(/[+PG\GXO_,/^
M%7_]1C_R6_\`LZ/^%7_]1C_R6_\`LZ**/K^(_F_!?Y!_9>$_D_%_YA_PJ_\`
MZC'_`)+?_9T?\*O_`.HQ_P"2W_V=%%'U_$?S?@O\@_LO"?R?B_\`,/\`A5__
M`%&/_);_`.SH_P"%7_\`48_\EO\`[.BBCZ_B/YOP7^0?V7A/Y/Q?^8?\*O\`
M^HQ_Y+?_`&='_"K_`/J,?^2W_P!G111]?Q'\WX+_`"#^R\)_)^+_`,P_X5?_
M`-1C_P`EO_LZ/^%7_P#48_\`);_[.BBCZ_B/YOP7^0?V7A/Y/Q?^8?\`"K_^
MHQ_Y+?\`V='_``J__J,?^2W_`-G111]?Q'\WX+_(/[+PG\GXO_,/^%7_`/48
M_P#);_[.C_A5_P#U&/\`R6_^SHHH^OXC^;\%_D']EX3^3\7_`)A_PJ__`*C'
M_DM_]G1_PJ__`*C'_DM_]G111]?Q'\WX+_(/[+PG\GXO_,/^%7_]1C_R6_\`
MLZ/^%7_]1C_R6_\`LZ**/K^(_F_!?Y!_9>$_D_%_YA_PJ_\`ZC'_`)+?_9T?
M\*O_`.HQ_P"2W_V=%%'U_$?S?@O\@_LO"?R?B_\`,/\`A5__`%&/_);_`.SH
M_P"%7_\`48_\EO\`[.BBCZ_B/YOP7^0?V7A/Y/Q?^8?\*O\`^HQ_Y+?_`&='
M_"K_`/J,?^2W_P!G111]?Q'\WX+_`"#^R\)_)^+_`,P_X5?_`-1C_P`EO_LZ
M/^%7_P#48_\`);_[.BBCZ_B/YOP7^0?V7A/Y/Q?^8?\`"K_^HQ_Y+?\`V='_
M``J__J,?^2W_`-G111]?Q'\WX+_(/[+PG\GXO_,/^%7_`/48_P#);_[.C_A5
M_P#U&/\`R6_^SHHH^OXC^;\%_D']EX3^3\7_`)A_PJ__`*C'_DM_]G1_PJ__
M`*C'_DM_]G111]?Q'\WX+_(/[+PG\GXO_,/^%7_]1C_R6_\`LZ/^%7_]1C_R
M6_\`LZ**/K^(_F_!?Y!_9>$_D_%_YA_PJ_\`ZC'_`)+?_9T?\*O_`.HQ_P"2
MW_V=%%'U_$?S?@O\@_LO"?R?B_\`,/\`A5__`%&/_);_`.SH_P"%7_\`48_\
MEO\`[.BBCZ_B/YOP7^0?V7A/Y/Q?^8?\*O\`^HQ_Y+?_`&='_"K_`/J,?^2W
M_P!G111]?Q'\WX+_`"#^R\)_)^+_`,P_X5?_`-1C_P`EO_LZ/^%7_P#48_\`
M);_[.BBCZ_B/YOP7^0?V7A/Y/Q?^8?\`"K_^HQ_Y+?\`V='_``J__J,?^2W_
M`-G111]?Q'\WX+_(/[+PG\GXO_,/^%7_`/48_P#);_[.C_A5_P#U&/\`R6_^
MSHHH^OXC^;\%_D']EX3^3\7_`)A_PJ__`*C'_DM_]G1_PJ__`*C'_DM_]G11
M1]?Q'\WX+_(/[+PG\GXO_,/^%7_]1C_R6_\`LZ/^%7_]1C_R6_\`LZ**/K^(
M_F_!?Y!_9>$_D_%_YEBP^'/V'4;6[_M7?Y$R2[?L^-VT@XSNXZ4445C5K3JN
-\W<Z*&&I4$U35KG_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g532389g60e21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g60e21.jpg
M_]C_X0J017AI9@``34T`*@````@`"`$2``,````!``$```$:``4````!````
M;@$;``4````!````=@$H``,````!``(```$Q``(````>````?@$R``(````4
M````G`$[``(````&````L(=I``0````!````N````.0`+<;````G$``MQL``
M`"<0061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHP-3HQ-"`P
M.3HP,SHS-P!E<FEC:``````#H`$``P````$``0``H`(`!`````$```"-H`,`
M!`````$````R``````````8!`P`#`````0`&```!&@`%`````0```3(!&P`%
M`````0```3H!*``#`````0`"```"`0`$`````0```4("`@`$`````0``"48`
M````````2`````$```!(`````?_8_^T`#$%D;V)E7T--``'_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``R`(T#`2(``A$!`Q$!_]T`!``)_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2DDDDE*22224I))))2DDDDE*22224I))))3C2[_`)SD28]'
MB3''[JV52_9P_:G[0]0SLV>G&GQW*ZF8XD<5]9$CR7S(/#72("DDDD]8_P#_
MT.UZ/U^W]@YG5>IN]1N'=DAWIM`/ITO<UC6L_.?L:K.1]9^FX[,E]C;8Q!CF
MW:R2?M7]'],3[_\`A%BXW2OK`WHW4NB/P6L9E_:WU9?K,(W6N<^FMU+??[]W
MTTS^B=<R:<Y[\5M-F0[IWI5^JUVF*\'(+GCV[FM"9<J^BZ@ZQ^L%%659=DV6
MXV/5@G+LQ;J=KF@6.K]5UFYUGJNV[?LVQ7>E]8Q^I&YC*K<>_&<UMV/D-V6-
MWCU*G%H+V[;&?REE=>Z%U#J.;G.H#6UY'3?LU5CB(]86FYK'-^GLV_GJQ]6>
MFW80RK+,&OIXN<S94VUUUA#&PY]]SG/9]-S_`$MG^#1!-^"-*<EGUBZM^VW8
MXRJKA^TG88Z<*QZOV<#<[+;8UV_;3^=O9L]BW:?K)@7=2/3VMM!]1]+,@LBE
M]M3?4OHKMG^<K8U_YGYBPQT'K+^J6#[)754>J?;V]0-C=XJ&V:&5-'J_IMFW
MWN]/](C8/U>S*.O/O?A4NK&5?DMSW6N)V6!SJ::<5KF[+6/L].VQ[/YI`&7X
MI--F[ZU8F3TO)R<9V1B"IM5E>0^C>'UV6"IEV.QSMEK+/H>Y[+*_YSTU/#Z_
M8.J9F#E3:\YHQ\.JIHW-8*:[[;;=?YFMS_?<[_BUD_L+KS\#J6,S$9B4Y+:7
M,PVW!]7VAMS;,J_#G^C8UM3=_HO_`,(K)Z#U*CKMW6J*9O.<V/T@]^$^IE.0
M-A.UKZ[OTW[_`.B2N6BJ#HL^M>#:ZYE%-[RQES\=WI^W(^SGT\AN(=WZ7TW_
M`-1"Z+U3J.3]5+.IY%A=EFJVUKW5AC00TOK]%C?YW';_`(.QW\ZJ?3.A=7IR
M,6FZEK,?I;,UM60+`[USE.W4[:OI4[&?SOJ+1Z9TW-H^J-?3+6!N8W#=2:]P
M(WECF[=X]OTDA9W[*-,L3K9J^KN#U+.#[[\FNKV4,W.LMM`AE=;?:W<[][]&
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M6>WZ*5R_EY*H.YD?6;`H-S/3NMMIR1ABFM@+[+C6,G91+FM=^A]_NV+1Q,JK
M,QJLJG=Z=S0YH>TM<`>SV/AS'+E[>C]5NQNHG)Z<V[[=FMO^SMO:RQC!2RME
M^+DB&UY=-[&_270]&KZA5TO%KZF\69K*P+W@S+A_*_.=^\B";00&R<B@$@V,
M!&A!<$OM&/SZK/\`."H6_5[IMMK[7M=OL<7.]QY.J8?5SI@:6[7PX@GW'\W=
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M]NW=^=Z?TDB<NNG:E`8^[8?U3'8Y[7-L&P;@=NC@"UA]/][W/:DSJF,_2'M=
MN#=A;KN+_1V_V7_20'=(>ZQ[S=.^0"6^Z"ZNQN]^[W;/3]-B:WI]_P!I8^O4
MUFZUMA@-WV:U5[9W.]-_O2XLO958^[;MR+&9U&.`-EK'N<>\MV;8_P`Y4W=3
MR/LF+;NJJ=>][7O>#L:&^I'YS?W%9NQ,FRVB]EK66TM+7RW<#NV[X]S=OT$&
MGI5K/099<U]6.]SV,V03N#_:X[G?Z1&7N$FKK_T3_P!#0."A=?RXO_06W@Y#
MLG$JO>W8ZQLEO]THZ22D%@"S?BL.YK12BZNMSFN<T.<PRPD`D$Z>W]U2210I
M))))2#[9C?:OLF_]8V[MD'CQGZ*.L;_UJ#_Q/\%LID)&7%?21C]BZ<0.&NH!
M4DDDGK7_TO54E\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27
MRJDDI^JDE\JI)*?I3_UHS_-?S/\`UWC_`*E:R^54E'B_3_OR7Y/T?[H?JI)?
M*J2D6/\`_]G_[1*H4&AO=&]S:&]P(#,N,``X0DE-!`0``````%$<`5H``QLE
M1QP"```"```<`E``!65R:6-H'`(%`#-#3TY314Y4($]&($E.1$5014Y$14Y4
M($-%4E1)1DE%1"!054),24,@04-#3U5.5$%.5%,`.$))300E```````0,>V2
MH?QN[I3/$,CQ%3Y39#A"24T$.@``````Y0```!`````!```````+<')I;G1/
M=71P=70````%`````%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E````
M`$-L<FT````/<')I;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA;654
M15A4`````0``````#W!R:6YT4')O;V93971U<$]B:F,````,`%``<@!O`&\`
M9@`@`%,`90!T`'4`<```````"G!R;V]F4V5T=7`````!`````$)L=&YE;G5M
M````#&)U:6QT:6Y0<F]O9@````EP<F]O9D--64L`.$))300[``````(M````
M$`````$``````!)P<FEN=$]U='!U=$]P=&EO;G,````7`````$-P=&YB;V]L
M``````!#;&)R8F]O;```````4F=S36)O;VP``````$-R;D-B;V]L``````!#
M;G1#8F]O;```````3&)L<V)O;VP``````$YG='9B;V]L``````!%;6Q$8F]O
M;```````26YT<F)O;VP``````$)C:V=/8FIC`````0```````%)'0D,````#
M`````%)D("!D;W5B0&_@````````````1W)N(&1O=6)`;^````````````!"
M;"`@9&]U8D!OX````````````$)R9%15;G1&(U)L=````````````````$)L
M9"!5;G1&(U)L=````````````````%)S;'15;G1&(U!X;$!RP```````````
M"G9E8W1O<D1A=&%B;V]L`0````!09U!S96YU;0````!09U!S`````%!G4$,`
M````3&5F=%5N=$8C4FQT````````````````5&]P(%5N=$8C4FQT````````
M````````4V-L(%5N=$8C4')C0%D````````````08W)O<%=H96Y0<FEN=&EN
M9V)O;VP`````#F-R;W!296-T0F]T=&]M;&]N9P`````````,8W)O<%)E8W1,
M969T;&]N9P`````````-8W)O<%)E8W12:6=H=&QO;F<`````````"V-R;W!2
M96-T5&]P;&]N9P``````.$))30/M```````0`2P````!``(!+`````$``CA"
M24T$)@``````#@`````````````_@```.$))300-```````$````>#A"24T$
M&0``````!````!XX0DE-`_,```````D```````````$`.$))32<0```````*
M``$``````````CA"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8`
M`0"AF9H`!@```````0`R`````0!:````!@```````0`U`````0`M````!@``
M`````3A"24T#^```````<```_____________________________P/H````
M`/____________________________\#Z`````#_____________________
M________`^@`````_____________________________P/H```X0DE-!`@`
M`````!`````!```"0````D``````.$))300>```````$`````#A"24T$&@``
M```#6P````8``````````````#(```"-````$P!!`'@`;P!'`&4`;@`@`"T`
M(`!%`'@`:`!I`&(`:0!T`"``,@`S`````0`````````````````````````!
M``````````````"-````,@`````````````````````!````````````````
M`````````!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG````,@````!29VAT;&]N9P```(T````&<VQI8V5S5FQ,
M<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P``
M```````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E
M3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E
M5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0````0`
M````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P``
M`#(`````4F=H=&QO;F<```"-`````W5R;%1%6%0````!````````;G5L;%1%
M6%0````!````````37-G951%6%0````!```````&86QT5&%G5$585`````$`
M``````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$`
M``````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A
M=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E
M9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E
M`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO
M;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T
M;&]N9P``````.$))300H```````,`````C_P````````.$))3004```````$
M`````CA"24T$#``````)8@````$```"-````,@```:@``%+0```)1@`8``'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`,@"-`P$B``(1
M`0,1`?_=``0`"?_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]522224I))))2DDDDE*2
M2224I))))2DDDDE*22224XTN_P"<Y$F/1XDQQ^ZME4OV</VI^T/4,[-GIQI\
M=RNIF.)'%?61(\E\R#PUTB`I)))/6/\`_]#M>C]?M_8.9U7J;O4;AW9(=Z;0
M#Z=+W-8UK/SG[&JSD?6?IN.S)?8VV,08YMVLDG[5_1_3$^__`(18N-TKZP-Z
M-U+HC\%K&9?VM]67ZS"-UKG/IK=2WW^_=]-,_HG7,FG.>_%;39D.Z=Z5?JM=
MIBO!R"YX]NYK0F7*OHNH.L?K!15E679-EN-CU8)R[,6ZG:YH%CJ_5=9N=9ZK
MMNW[-L5WI?6,?J1N8RJW'OQG-;=CY#=EC=X]2IQ:"]NVQG\I977NA=0ZCFYS
MJ`UM>1TW[-58XB/6%IN:QS?I[-OYZL?5GIMV$,JRS!KZ>+G,V5-M==80QL.?
M?<YSV?3<_P!+9_@T03?@C2G)9]8NK?MMV.,JJX?M)V&.G"L>K]G`W.RVV-=O
MVT_G;V;/8MVGZR8%W4CT]K;0?4?2S(+(I?;4WU+Z*[9_G*V-?^9^8L,=!ZR_
MJE@^R5U5'JGV]O4#8W>*AMFAE31ZOZ;9M][O3_2(V#]7LRCKS[WX5+JQE7Y+
M<]UKB=E@<ZFFG%:YNRUC[/3ML>S^:0!E^*339N^M6)D]+R<G&=D8@J;597D/
MHWA]=E@J9=CL<[9:RSZ'N>RRO^<]-3P^OV#JF9@Y4VO.:,?#JJ:-S6"FN^VV
MW7^9K<_WW._XM9/["Z\_`ZEC,Q&8E.2VES,-MP?5]H;<VS*OPY_HV-;4W?Z+
M_P#"*R>@]2HZ[=UJBF;SG-C](/?A/J93D#83M:^N[]-^_P#HDKEHJ@Z+/K7@
MVNN913>\L9<_'=Z?MR/LY]/(;B'=^E]-_P#40NB]4ZCD_52SJ>18799JMM:]
MU88T$-+Z_18W^=QV_P"#L=_.JGTSH75Z<C%INI:S'Z6S-;5D"P.]<Y3MU.VK
MZ5.QG\[ZBT>F=-S:/JC7TRU@;F-PW4FO<"-Y8YNW>/;])(6=^RC3+$ZV:OJ[
M@]2S@^^_)KJ]E#-SK+;0(976WVMW._>_1L3?\ZL`TT6-IR'V9%MM#<=M<VMM
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M:<D88IK8"^RXUC)V42YK7?H??[MBT<3*JS,:K*IW>G<T.:'M+7`'L]CX<QRY
M>WH_5;L;J)R>G-N^W9K;_L[;VLL8P4LK9?BY(AM>73>QOTET/1J^H5=+Q:^I
MO%F:RL"]X,RX?ROSG?O(@FT$!LG(H!(-C`1H07!+[1C\^JS_`#@J%OU>Z;;:
M^U[7;['%SO<>3JF'U<Z8&ENU\.()]Q_-W1_U:;>6_EC7][_T%=6.OF-^3__1
M]'PLR_(R;ZWM`KJ<6`C2'`G]'S^D_1;;?[:BS/R3?<][&##I>]EC]=S=C19Z
MCOWFO^CM:U1QND.HRVY'K;@TNAFWG=/O>[=_/>[9ZO\`HU)_22^R[=>[T+B]
MQJ`CW6-]-VYWYS6_F-VJ$>Y0T-WW#+Z+.HJNS)W5\9K-SF6`C<7L+?<T-#;'
M.?K]'TWM>D[JV.QI<YE@VEVYNW4!@:Y[W?R-EC7(;NDO>VS?=+[66,<X-@>]
MC*60W=^8VM1R.F766EK'Q7<+!8^`=H>VJO;MW?G>G])(G+KIVI0&/NV']4QV
M.>US;!L&X';HX`M8?3_>]SVI,ZIC/TA[7;@W86Z[B_T=O]E_TD!W2'NL>\W3
MOD`EON@NKL;O?N]VST_38FMZ??\`:6/KU-9NM;88#=]FM5>V=SO3?[TN++V5
M6/NV[<BQF=1C@#9:Q[G'O+=FV/\`.5-W4\C[)BV[JJG7O>U[W@[&AOJ1^<W]
MQ6;L3)LMHO9:UEM+2U\MW`[MN^/<W;]!!IZ5:ST&67-?5CO<]C-D$[@_VN.Y
MW^D1E[A)JZ_]$_\`0T#@H77\N+_T%MX.0[)Q*KWMV.L;);_=*.DDI!8`LWXK
M#N:T4HNKK<YKG-#G,,L)`)!.GM_=4DD4*22224@^V8WVK[)O_6-N[9!X\9^B
MCK&_]:@_\3_!;*9"1EQ7TD8_8NG$#AKJ`5))))ZU_]+U5)?*J22GZJ27RJDD
MI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZ4_]:,_S7\S_
M`-=X_P"I6LOE5)1XOT_[\E^3]'^Z'ZJ27RJDI%C_`/_9.$))300A``````!5
M`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P`V`````0`X0DE-
M!`8```````<`"`````$!`/_A#MAH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53
M>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T
M82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V
M,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX@/')D9CI21$8@>&UL
M;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT
M87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z
M>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SIP9&8]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z>&UP34T](FAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T
M;W-H;W`O,2XP+R(@>&UP.D-R96%T941A=&4](C(P,3,M,#4M,314,#DZ,#(Z
M-3<B('AM<#I#<F5A=&]R5&]O;#TB36EC<F]S;V9TPJX@3V9F:6-E(%=O<F0@
M,C`P-R(@>&UP.DUO9&EF>41A=&4](C(P,3,M,#4M,314,#DZ,#,Z,S<K,#4Z
M,S`B('AM<#I-971A9&%T841A=&4](C(P,3,M,#4M,314,#DZ,#,Z,S<K,#4Z
M,S`B('!D9CI0<F]D=6-E<CTB36EC<F]S;V9TPJX@3V9F:6-E(%=O<F0@,C`P
M-R(@9&,Z9F]R;6%T/2)I;6%G92]J<&5G(B!X;7!-33I$;V-U;65N=$E$/2)X
M;7`N9&ED.D9!-SA#138W-#-"0T4R,3%!-C1#0D$X,CA$0S9&,#,V(B!X;7!-
M33I);G-T86YC94E$/2)X;7`N:6ED.D9!-SA#138W-#-"0T4R,3%!-C1#0D$X
M,CA$0S9&,#,V(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z
M1D$W.$-%-C<T,T)#13(Q,4$V-$-"03@R.$1#-D8P,S8B('!H;W1O<VAO<#I#
M;VQO<DUO9&4](C,B('!H;W1O<VAO<#I)0T-0<F]F:6QE/2)S4D="($E%0S8Q
M.38V+3(N,2(^(#QD8SIC<F5A=&]R/B`\<F1F.E-E<3X@/')D9CIL:3YE<FEC
M:#PO<F1F.FQI/B`\+W)D9CI397$^(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE
M/B`\<F1F.D%L=#X@/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY#3TY3
M14Y4($]&($E.1$5014Y$14Y4($-%4E1)1DE%1"!054),24,@04-#3U5.5$%.
M5%,\+W)D9CIL:3X@/"]R9&8Z06QT/B`\+V1C.G1I=&QE/B`\>&UP34TZ2&ES
M=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)D97)I=F5D
M(B!S=$5V=#IP87)A;65T97)S/2)C;VYV97)T960@9G)O;2!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+VIP96<B+SX@/')D9CIL
M:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N
M:6ED.D9!-SA#138W-#-"0T4R,3%!-C1#0D$X,CA$0S9&,#,V(B!S=$5V=#IW
M:&5N/2(R,#$S+3`U+3$T5#`Y.C`S.C,W*S`U.C,P(B!S=$5V=#IS;V9T=V%R
M94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@<W1%=G0Z
M8VAA;F=E9#TB+R(O/B`\+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R>3X@/'AM
M<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(B\^(#PO
M<F1F.D1E<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A/B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#P_>'!A8VME="!E;F0](G<B/S[_X@Q824-#
M7U!23T9)3$4``0$```Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q
M``!A8W-P35-&5`````!)14,@<U)'0@```````````````0``]M8``0````#3
M+4A0("``````````````````````````````````````````````````````
M`````````!%C<')T```!4````#-D97-C```!A````&QW='!T```!\````!1B
M:W!T```"!````!1R6%E:```"&````!1G6%E:```"+````!1B6%E:```"0```
M`!1D;6YD```"5````'!D;61D```"Q````(AV=65D```#3````(9V:65W```#
MU````"1L=6UI```#^````!1M96%S```$#````"1T96-H```$,`````QR5%)#
M```$/```"`QG5%)#```$/```"`QB5%)#```$/```"`QT97AT`````$-O<'ER
M:6=H="`H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P``
M```````2<U)'0B!)14,V,3DV-BTR+C$``````````````!)S4D="($E%0S8Q
M.38V+3(N,0``````````````````````````````````````````````````
M````````````````6%E:(````````/-1``$````!%LQ865H@````````````
M`````````%A96B````````!OH@``./4```.06%E:(````````&*9``"WA0``
M&-I865H@````````)*````^$``"VSV1E<V,`````````%DE%0R!H='1P.B\O
M=W=W+FEE8RYC:```````````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```
M``````````````````````````````````````````````````````````!D
M97-C`````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92`M('-21T(``````````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````````````````````````
M9&5S8P`````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$`````````````````````````````````
M`'9I97<``````!.D_@`47RX`$,\4``/MS``$$PL``UR>`````5A96B``````
M`$P)5@!0````5Q_G;65A<P`````````!`````````````````````````H\`
M```"<VEG(`````!#4E0@8W5R=@````````0`````!0`*``\`%``9`!X`(P`H
M`"T`,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`
MF@"?`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-
M`1,!&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!
MJ0&Q`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G
M`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#
M6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q
M!'X$C`2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%
MQ075!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]
M!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(
M^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<
M"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-
M#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>
M#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2
M!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.
M%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7
M]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[
M&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>
MZ1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O
M(MTC"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<F
MZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV
M*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O
M_C`U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38
M-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ
M-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B
M/^)`(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%
MFD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:
M2^),*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92
M,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+
M61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@
M!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]
M9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O
M'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X
M=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_
MA'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$
MB&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1
M/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IH
MFM6;0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D
M5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XM
MKJ&O%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FX
MT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8
MP]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.
MML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQ
MVG;:^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F
M#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_
M\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^
MW/]M____[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"``R`(T#`1$``A$!`Q$!_]T`!``2
M_\0!H@````8"`P$`````````````!P@&!00)`PH"`0`+`0``!@,!`0$`````
M```````&!00#!P((`0D`"@L0``(!`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3
M(@`(,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$
M5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI
M:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8
MV=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B
M$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V
M160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=7
M9CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI
M^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5
M;<=56_\`#FT])_$,G]C_`*%DD_AW\2K_`.%^7[!?WOX9]Q_#_/?^WX]?^/N!
MA)+_`,$`T?CR>#^Z:Z=;:*Z1G1737YTKU+I2/_6=#^$GB?O'XM*ZOBX:J:J?
M*M.K)/<\]1%U[W[KW7O?NO=?_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1:U^.T*_)U_DC
M_?&J,S[*&SO[E_P6F^T"BG$'\1_C?WWW)DXOXO!;_:O8"'(RCW!//G[T;4;3
MP/`\,4X4U>)JK7Y:?SZ%_P#6MOZFCE'Z!=/U'B^+K->-=.BE/SU?ET93V/>@
MAU[W[KW7O?NO=?_1V??B#\]=TR?`_P"2OR\^5.4GW3C_`(_]V_+^AR\G7NS,
M?19C_1;T;V=NC";>Q>*VW2UU)2Y?/46VL1'$9'GB>LF&IV!)/LAV_=2^VW=_
M=5TQ22`_#6B&G]$>1(KP&"QH6)K=V*B]MK6V%#(B<2>+"OSZ&C?O\SOXX]<8
MKN[,[@Q?;,M)T#0_%7(;WCP^P_XK6UD7S$GCI^I(-J4%-ES5[AKH9I57+4\2
M+-2.0D2U#D*79=\LH5NF=9*0B(M1:_VWP4SGY^GE7II-MN)#`%*5DUTS_OOX
MJ^GRZ0M7_,$V-M7M/=V].U-U=N=-]8;,^"-?\HMV]#=I]!4NV]S;,PF&[AW#
MLV;?F=W;3;@R>[H]\YJFQ"T-+LH4#`P3050F^XE,"M'=XH[B26XDDB@6T\4Q
MO'0J`Y&HFI.HTH$IZ&M<=7%@[Q(D2(\K3Z`RM4'M!H!2E!QU5^71G?B_\P-A
M?*6;LW!X39/;74W8O3>9VUB.R^I.\=FQ;(['VI#OC;D.[=BYJNQ5#E]PXF;"
M[PV]*T]))!72NCP30SI#-$Z!=8[C#?\`CJL4D<T9`9'&EAJ%5-*D4(X9]0:'
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MI)76R!RO8SH*L@:O$`'RH:$`FG16^WSI;BX+)32&*U[@K&BL1Z$T\ZY%>BT[
MR_FJ=4=I?&+NCM+JO*_(#H&FV9@>G]_;*[;W9\;:;>E'V!U5V9W!A^OMO]F=
M1[:RVYZ3:V_=K;KR,-7C98:W(XW-XBGJ4KYZ",&F$R2;?(9=ON;F%I80NDJQ
MC#%E+A=2J6RI)IG21DTQTICVR6.YABE$<E2P*AZ4(6I#$"H(XX!!X5Z4G3_S
MYSU+\I/DKT+VM-DM^9JH^:]!T!\:NO\`K7:&*J-T[?Z]H/COUQVGO??G8#KD
MZ!Z?K39N3W!52Y/<M:P2&>LI\?"D]2\,+N6^ZDWM[:2U9Q<:$4::Z="L6I@Z
M5U"I[CY\,"LMBOTUO/%VKX.IR2:5U%0!QR:8'Y]*[%?S6.CMW9/L3!;#ZW[^
MW%6X+8_?6\^G<TO6:P[4^48^-F>@VCV_BOCUD9-P15N]LIL[=-7%3RT]33XR
M2LAUU%']Q`C2C:[_`&LC3)%#,Q"R%#IQ+X9HXC->XJ?6E>(J.J':YE$;/)&`
M64-G*:\KKQBH^WY]![\+/D_\A>S_`.53O'Y5=F;MRF;[LJNK>\.S\+G\[U9M
MO8FT\=6X;:V9SVT8.O<!A:B:GWOU)AZBDB7#YFO<5^=HT,M4%=B`UME]>3[!
M)?SR$W/ANP)4*,`D:0/B0>3'+#CTY>6UO'NB6L:`0ZE!`8DY-#4^3>H&!Y="
MYU/\VI=I?R\/BQ\HN^J'>?8_8O<76G1D#[9Z9ZXK,_N_LON/MC"XO^';=V;L
MO",N,Q#YW-54C"6MJZ'$8Z!6DJ:N"%"X56NY$;18WUR&>:2-310*LQ6M`,"I
M\L@$X&2!TS+9ZK^YMH"%C1FRQH`JGB3\OS/47_AU'H2;9_4^X,7UQ\C-P[M[
M=[/[IZ0Q73>W.J3E^WMM=R_'[$9_,=H];[OVO#GUH\=G<##MJK43T]958V30
M)?N5I[S"G[^M#';NL,S22.Z!`M7#Q@EE(KQ%#P)'SIGJW[LGURJ9(PB*K:BW
M:58@*0:<#7[?SZ1&%_F3=.;SWEU-W+A.WM[8+X];G^"/?GRSS?7N7Z4QGA7:
M_3N\=HX?=V[MT=D'<4FX-J;TZ[J*JJQ#[7I**MILG--),*J\$7D;3>;>5X+M
M;EA9&U>4J4'!2*L374"N05`(J>/"MFV^5$EA:(&X$ZH"&\V!H`*4(/'57'IT
M"W7W\V":7L[Y;=L=G;7[:V5\6NH^A?AGOG:/5FZ^HL9@.],+N/Y#[^W?LFIS
MU50T^XZQ=Q[:W')-A9Z:1:YJ>G@BJ2EY$D3VFBY@4RW]Q-%*MG'%"P4J`_ZC
M%0:>8.#7413@`0:O2;7^G:Q1LAN7>0%@U5H@!IPP1GRZ-_V)_,QZ*Z^F[,PZ
M;+[LWQO;KOY,X?XC8WKK8FQL;E=Y=I]W9CJ>@[N7`]74N1W/A\5FL=C>M:N7
M(U5975>-BC%%/&NN41)*93;Q;PB>D,KR),(]*@%F<C50"N,9[M/RXK5)'MTT
MGAG6BHT>NI-`%KIJ<>N,5Z.;U)VCM7NOK/9';&R?XVNU=_[>Q^Y,+#N;;V9V
MEN.DI:^+4U!N#;&X:/'YO`9O'3AX*JDJH8Y8)XV0CBY,8)DN(8YXZZ&%144/
MY@^?226)H9'B>FI33!J/R(X].]1O[8E)45%)5[UVE2U=+-)3U5+4;CP\-135
M$+%)8*B&2L62&:)Q9E8!E/!'M"^];/$[Q2;M;+(I((,J`@CB""U01Y@]*DVO
M<Y$62/;IV1A4$1N00>!!ID=<!V'L!D>5=\[/,<3Q))(-S84I&\XF:!'<5NE'
MF6GD*`\L(VM^DVU^_-E(+#>+72*5/BQXK6GXO.AIZT/IUO\`=6Z`@';;BIK_
M`*&_E2OEY5%?M'KU_]*Z_K3XJ_/W'_#3YN_`G.?%W;."P?>Z_.G>/7_?\_R#
MV!D,54;E[GW?N?='66S\MUQBZ.KW%C8<]%FD@FR1J_'0LNJ:(7-@7#8;N-MW
M3:6L%"2^.5D\1:5<DJ"HR*UXUQZ="*2ZL#=V5\MT2T?A@KH/!0`Q!X8]//K#
MG/A1\WNS=F?*W,9WH3!]?[J[=W!_*5DV+LI^Y]A[HJ3A/B)O[%5O;U;FMR8V
M2BP]!EL+A,>]9%3IKBJ]214LT\NJVCM>YSQ7[26@1Y#::1K5L0GNJ:@#A_FJ
M>M"\LXVM56<LJ">ITD?V@[:#_5\Z=&?^>'P8[]^3?=GRFR&PJ+;>)VIVQ_++
M'Q[V/O3<&>HDH6[QQO?60[*QFV,U@J8S[@HL!6XJ.G\^42!X8A,P75(FDKMV
MVJ[OKJ_:(*(Y+'PU8G\8DU`$<:4\^D]C>P6T-J')+)<ZR!_#II4'A7Y=#5_+
M2^.&[.BX>^-Q;E^*G7WQ*H^Q\_UW%MO9&#[@W)WOV;G<?LO9K465W%VUV3E-
MS;CV]7SR[IS-?%@J3%^$4F(1/N09GTQJ]ELFM!<NUBMOK*]H8NW:"*L^I@<G
MMI2@P1Y],[C<+/X"K<M+I!SI"C)X**`\.-?/AU7O3?`SYCY?Y1[OA7H#KG9>
MR<A_-7A^<>$^8U3VELVH[!PO36#GPDE?U7MK9.!Q-=ON:;LJ@V_)05-)7U]/
MB8Z;+3^>G+!F),-IW%K^0?1HL1O_`!Q-J74$%.P*!J[@*4)IDU'2_P"NM%ME
M_78O]+X?AZ334?Q$G&*UQG'0D]'_`,O?MWKWYVY_L+-?&+J')[;I?E;\COD9
MAOEMN3N#=.4RU/LGM+#;JR?6/7?6W1.!W!BZ#:W8.W-T;N.*S^9R=!+25&"I
MZAH'J*BJC\+UKL]S#NKS-8QE/J))!*7).E@2JK&"*,":,Q%-(-*DX:FOXI+$
M1K<OJ\)$,84<5I4EB,@@5`!X]`2OP5^>69Z$^:W5>!^/&S^B-C]Q8/H'<&W?
MC9@/D!@=]=35'R<V]\AL+O'O3M3XYRY+[5ND>D-];'PT>3;;&5-+4-F=1BI8
M7:0RIFVO=GM-SMDLUBA=8],8=2ID$NIW3^!&7.EC6N!PZ?%[8K/92M<%W0L"
MY4AM!2BJ_P#$P.*CRZ'.3X'?(_8GSJ[%^=?7_6L%9V//\]MEFFE3LS;E/!V'
M\`-^=![4ZU[EH/X!6Y&#&8K<>SNQ@^YZ2EJVBR60FP4,<5P\-U1VF[BW67=H
M(:SFZ'X@-4#(%<`5X@T?-"2*4X$L_76[V4=E))^GX!\CB4,2N?0CM]!7K'\:
M/@U\MMC]A]"['WUUSM7;_6/PDV5_,'P&Q>W*3LO"9V7Y&UGRUWO'E^N/X-L.
MCIXLUUK_`'8VV\G\<;,2`??A8Z0RP7E&K':MPBFM(9856"U6X"OJ!\3Q6JM%
MXK0?%7SX8Z]<WMH\<\B2$RS-$2M*:-`SGSJ>%/+CT=#XU?'#N7K[^4?LSXL;
MQVS08OO3$_#G<O4F1VG!N3#9+&T^_LCL'/X*CPZ;IHZB3!34KY*NBC-6LIIU
M5M1;2"?9I9V5Q#R^FWLO^,BW*4J..D@9!(_F0/7I'<7$,FZM=*U8#,&K0\*@
M\./1)]N==?S0/^&^NK_BE2?&:LZ<S/2-!\7-@[MR?7ORPZU@W[\B.F=JU!Q7
M>FT^M]X8ZDHH>CMRY;"8.D7^(U60$[4&1J8J*HBJ460%<<6^#:(+#]WZ&B$:
MG3*NJ1!API%-!H`:D^9`Z6-)MOU\ET;G6KER*H:(Q^$D?B%?*GV]%BVIU#WC
M\-=Z?RZ]O97H/;.%['RO\P7^83V1U'\<L)W5@:NAJMC;Z^/785=L[:&.[=SD
M5525.6PNUIV,E1E8TGKJBC83-$U0L@116MWMTFT*+(>+]7<.L8<4TM&:#6:C
M%:5;B>-">E3S07B7["<F/Z>)6?2>(<5.G[?3A^70C["_EA_+:AZ(ZVZ>S^V=
MH8S*2?RD_G3\7]U9Z'>V%R&&VCWW\DNUMN=A[&VA/!%(,CG,10T<,]/79>CB
MDHDDIV96(>/4[#L5^+.&W=%#_N^:(FH(#R,&`.:XX5`(XYX5:DW*U,\DRL2/
MJHG`H:E44@G_`#`]9MX_"CYV=P=:?,_)Y_X\X#8&]NVOBW_+RZVZ[V%-W=L'
M<LFX-V?%CM+)[M[#Q-9N;'21X7;U17XDJ:"2H9Z)WFC#5)/E$6I=KW6Y@W-G
MLPDLEO;JJZU-3$Y+"O`5'"N/GQZ\EY8Q2686X+(DLI)TD4#K08\_GY]+W='Q
M`^4^]NN?FE6=G_"_;/8;?)WYM[/[E3J3$?)?;6SNR]A]>XCX[[2V=@.V>AN[
M\>N/Q>S/D!UOVQM:BJ(WK#CX9*!*R.&6:.2/[A0=OOWCW*2?;%=IKI9`GB+J
M`$:@,CG`=6`.10BHR#EL7=JLEF(KPJ(X2NK02"=1)5E\U*GR\Z=7)_#G;OR`
MVE\6^BML?*C<=!NWY"X+KG`8SM?<>.JX<C%E=T4E.8IIZK*4U)0TN7RZ4BPI
M7UD4,<596K+,@T./8CVY+N.QM4OW#7@0!R,Y^WS/J?,YZ*+MH&N9VM5(MRQT
MCY?ZN'0;[H_E]?'#=^Z-R;OS6(W3)FMUYW*;CS$D&Z\A3P29/+U4E96O!3HN
MB"%IY250<*.![C'<?9/D3=-PO]SN[6Y-W<S/*Y$S`%W)9J#R%3P\NA]9>Z?-
MNWV5G86\\`MX(EC2L2DZ5%!4^9H./3?#_+G^,T&/R.,CPV[!2Y2LPU?5J=W9
M$NU1@8,]3X\H^FZ*D>XZK4!^HLM_TCVROL7R`D,\"VMSX<C1LWZS<8Q(%_E*
M]?7'ITZWNSSBTL4QN(-:*ZC])>#E"W_5M:>F?7K_T]U7I3N+?G8G8G;&W\_@
M\11;8V1N7+[6IZZCIZNCJ,3N?&9O)0TVT*FMJZ^IIMU9&MV/3T.?GJ*.*GCH
MDR20,K<-[CSE/FG>=\WSF2RO;.)-OM+AX0R@J4E21@("Q8B9FMQ'<,R!0@E"
M$'!Z&G,7+^V;3M.QW5M<R->7,*R$$@AHV1290`H,2B8O`%<L7,98$<.F7"][
M=BS;W[&S6;P&T:+H;KC=W8NS-U[@AJJY-U;07KW:./W6-YY4SU1I<SB-P25<
ME$*&AHS4TC^*0R2*T@5):<X[X^[;[=W=E;)R;875U!-("WC0_30K-X[U-'20
MDQ^'&FM#I.I@311<<M;2NW;3;VUU.W,UW!!+$A`\.7QY6B\):"J.E`^MVTL-
M0H"!5WKOESUQB\-+ELGMSLN@J*!-RU6>P$^SV.X-L8G:>W]N[MR^=W!119"6
M"BPR;4W519".999#)!(5"^96B"J;W,V*WM6N;BPW!'02F2,P?J1)#'%,\DBA
MB%3P9HY`P8U4T`U@KTQ%R)NT]PL$-W9LK>&$<2]DC2O)$B(2H)?Q8W0B@H16
MNDANLV3^677F'H*^NR.W.RZ>3$5>\8\UC'V=*,IA,7L7%[8SVX-RY:E-:!1;
M?AV]O"@KXY6;RO3RV\8E!C]VN/<G8[6&::>POU:)IQ(G@'7&END4DDKC5VQB
M*>.0$FI5OAU=O58>1MVN)8HHKNS(D6+0WBC2[3-(B1J:9<R1.A`P&'&F>G3,
M?)[K_`Y'<6/RN'W[2#!8F;.4%;+M&K%)O+%4FX=O;5KJW9BF85N8IJ7.;IHH
M5D>&".J$I>F:>-68*+KW!V2SGOH+FUO5\&(R*QA:DZ++%"S09U.!)-&M2JAZ
MUC+J"0Q!R;NMS%:2P7%JWBR!&'BBL3%'D`EQ1"4C<T!)6E'TD@=<\/\`)WKG
M+G[8T>[\7EQFL)MQL#EMO/39=<[F^PJ[K/\`A8AAJJFFEJ,1N*@9Z\QRNE+1
MLLS,02!NU]P=BNNSPKJ.Y\6.+PWBH_B27+6NB@)!*2J3)0D(A#$TZ]/R;NT`
MU^);O!X;R:UDJNA(!<:JD`@-&U$J`6:JTZ4>Y>P<YB.\>K>MZ6GQKX#>FSNR
ML_EZF>*H;*0UVT)MH1XN.@F2H2FCIIESTWG#Q.S%4TE;&Z^_WN\M>;N7=AC2
M,V5W:W4CD@ZPT!AT:36@!\1M502<4(S5'9[5;3\M[UN[L_U5O<6Z*`1I(E$N
MK4*5J-`I0CSK7HM5;\F=_MU/T1O&3+]6[(R79^]M\[=W+N7>='EO[D;=QVUT
MWY-CZADCW%C*FGER+;6IJ8O+5Z//4W%@0``9N?\`>OZM\G;HUSMUI/N%W<12
MRSJ_T\2Q?4%33Q4(+>"J5+TU-T,(^3MK&^<S;>L%[<Q65M#)''$5\:1I/!##
M^S8'3XC-0+6B]&GZ0W_D^T^IMA]A9G!C;F4W7@8,I68A#4M3P2M)+#]Q0M61
M05;8S(I"*FE,J+(:>9-7-_<B\H[U<<Q<M;-O=W:>!<7,(=DS0&I%5U`-H:FI
M*BNEA7/0*YCVN'9=\W/:K>Y\6&"4J&Q4C!H:$C4M=+4--0-.A4]B/HDZ][]U
M[IHK\!@<K7X;*Y3"8C)93;M34UFW\E7XVCK*_!5=9224%758:LJ(9*C&5-50
MS/#(\#(SQ,48E21[J41BK,H++P-.'V>G6PS`$!B`>/SZ=_=NM=>]^Z]T&@[@
MZX/9[=,C<T'^DQ<(-Q-M;['*_<#"F/RBN^_^Q_A.CQF^C[CR?[3[(/ZT;%_6
M$\J_O`?O_P`'Q?!TO7P^.K5IT?EJK\NCC]P;O^YOZP?1G]S^)X?B56FOAITZ
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MNUW>[YXW,,XV2]>ZE-NJA3XUW"('9Y`U)(XU&N*-H^US5F8*!TU!SNMO:[3X
M>RQ'=;5((Q,S%AX=O*94"I2J.Y.F1P^4%`!4GIJR'Q,S.:QFZ_XWV73UNX]Y
M[-[+VEF<Q2[.CQU`B[SZXV;UGMVJH,,F>J/MH]MX?9R3SQM42&MJ:B2SPH$4
M)I_;6[N[?<A=[^KWUW:W4+N(-*_KVL%K$5C\0T$20!F&H^(S-0H`!T_%SS;V
M\UC]-LY6TM[BWE13+J;]*XEN)`SZ!7Q'E*@Z1H51AC4]-'87QHWCN#=-9B\-
MGX(=M]BX[MNDWCN2?"45<-M8K>.Q^H]EK@J?%3YNCJ:ROS$&RJF:"NC)6D?T
MR1,MBR;>^0=TO=QEM[6]`L;Z.]6>4QJWA)/;V4'AA#(I9G$#LL@PAPRD<7]J
MYPV^ULHYKBU)O+1[4Q1AROB-%-=3:RP0@*AF4,A^(9!'DX5GQ%RU?G=U9>L[
M*IZPYZ+)T--6U6T/-N;^&UF]-A[NQE+N'<4FX7?.0[9H]DKBL;3Q04=+24<N
MM8_*9"[\OMG<S7FXW4N_JQF#J&,%9=+3V\R"67Q/U!$MN(8E"HB(:A=6JK4?
M/<$5M96\>SE?"*L0):1ZA#-$Q2/1V&0S>)(Q+LSBA-*4;=R_'_?,?9.`R^UA
M'6U&U*SY$]HXG=>4CQU+MU-X=HUE76]?[-J\*N5ERN<FVGN*;^(23R)3T8B6
MX=99="IK_DK>%WZRNMN`=[9]SNTF<*(O'NV9K:!H]9>0PRGQ"Q"I08(9J!ZS
MYIVUMHNH+TE4G6PMFB749/"M@%GE#Z0J"6,:`H+-4\"HJ1DWCU/V)N/=?4W8
M>'W[MW;V\]A;7SNWL^:S9\^XL)GCNP;6EW#+CZ89_!U&+O4;=/VS%Y"BR^I3
M8@BK=.6]\O\`<>6M[M=Y@@W6RMY(Y-4!ECD\;P3*5'B1E,Q=N30-D8Z#]AOF
MTVEEOFU3[9++M]U,CI241NGA>)H#'0X;$G=PK3!Z#K9OQ:W-@CU?B-Q=B8#<
MVR^IMZ[CW;MW`G8"TE96Q;EH-Y4E9C,WD:K<>3I:X0S;N,L<JTL94P+Z=5F4
MBVKV[W"S/+UM?;Y#<;5MEW+-%']/1F$JSJR2,97#4,U0=`II&*Y!MN'.MG<_
MOJXM-IEAW&^MHXI'\>H'AM$0R*(U(J(J$:C\1\L$YRJJJ%4!54!550`JJ!8`
M`<``>Y6````&.H])KD\>N_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6I'_P!O/9__
M`!"B?^X"^X$'_B0;?]*G_GT=2^?^G-C_`*6/_/W5E?N>^H@Z][]U[KWOW7NO
M_]7?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW5>R?]O&9O^96_\R@3Z?\`,U_^`*_J_P"K%_T3
M[A(?]/S;_DG?\DO_`*C/A_ZM_P"3J5/_``4P_P!S?]S_`/J&X_\`'^K"?<V]
-17U[W[KW7O?NO=?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g532389g90w05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g532389g90w05.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X0LX17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P(#<N,``R,#$R.C$Q.C`Y(#`Y.C$Q
M.C`S``````.@`0`#`````0`!``"@`@`$`````0```-&@`P`$`````0```#L`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```*"@````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"0`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54._(IQJG7WO%=58ESW&`%'*R:<3'?D7NV55B7._@/
MY3OHM7"=4ZQD=2R/5M&VJLS12=6M_P"$>/HV7*?E^7EE/:(W/_<AJ\WS<<$1
MUG+Y8_\`=2=O-^L[W_T=WV.@ZLM>SU+[!^]CXFC:Z_\`ALKV+/9UKIOJ3DXV
M3F"?YS(OW.CRQALQ6_V%E>E<X>L_VMLU%EA@O\V[O?9_93&EXJ%P(=7N],N:
M>'1O#7M=M<W<WZ"T(\OBB*^FAK_G!R9\YGD;-=_4.+3^Y+T/?].;A645Y6#+
M:+1(:"0WP/Z(^UCVN5U8_P!5*WLZ+47<6/L>T?R2YT?YWTEIY.13BT/R+W;*
MJFESW>067DC62403*I&([EV\,[PPF0(7$3/2,=$J2H=/ZU@=1>]F*YQ=6`YP
M<TMT=('TOZJOILHRB:D"#V*^$XS'%$B43U&H4DDD@N4DJ/5>M=,Z10+^H7MI
M:XQ6W5SWG]VJIFZRS^RU9&)_C"^K.3>VCUK*=[@QMEU;FU[CH-UFK:_^N[$E
M/2I)))*4DDDDI__0Z+ZV=2=D9OV)A_08IET:[K2/_137;/ZZ#A=+L&0,?TQ9
MU#TS<ZMT%M#8FKU&/_1VY=VYGILL_18^_P!7WJWT#`&1U-^;E"7>I=96T_O,
M?M<_^S99[?\`BU7KOZSTOK&5>,5]UE[WAPV/+7M+MU;JK*VN_-6F#43AQD7"
M-ZGAXYGYO_0G$,>*8YC,)$9)T*'%[6./R_X7[C6IZ)UO,N)=CV->X_I+L@[1
M\7.=[W_];:K#L&N^ZGH.`_U0VPVYN6!H7`>F[;_P>/6[8SW_`,\]7,C,Z]U!
MS<6UOV06B1B4G].]OC?8[=]DQ_W[;/3_`.)O6UT?I%73:-H#3<^/5>T0-/HU
MUS[O2K_]2)F3F)1%R,>(?)"'R@_ORE_59,/*0G*H"?"?YS+D],C'_-PA^CQ_
MI-VBFNBEE-3=M=30QC?`-&UJY_K^0_J'4L?H=!]I>VS*([`>_;_UNO\`2_U_
M06SU3/KZ=A695FNP0QO&YYTK9_G+ENE=*ZYE,=U/%R&4OR"_=8XG<Z7>]P]E
MGL=8U0<O'YLLB(UZ82EM[I_[UM<Y,GAP0B9<7JR1A\WLQZ?X:7ZM#TNMYN,P
M[!LM8PG6/3LVL_K;6N2J^M74<9V35FM;;=6#74UC2W]*UWID.@N]GYRHXF8>
ME=:MNRW>I93ZK;BT_3>X3Y?3L4<JS/QLO'ZSE,:RS)><AC`(T86C86G]ZGZ'
MY_Y_\XK9Q"60F41(3A'@[RG'I'_NFA'/*&("$I0./)/C`%QACG^E,?WY>AUK
MNO=9Q15A/#+>IY&TENV&U!_MJIVAWZ2]_P#.6>[TJE*CK/6</K%?3^HNKO%C
MF-<:Q$>I]!['>SZ+OI[V*B,G'J^M3LK+L`HWFUMG(+'5?JK]/S=I8IXM=G7.
MOWY=(_5V;HL,@"*_1Q_[;G_IMBC..`B28#A]KW#*O\I+Y80++'+DE,".61F,
MPQ1A=_J8?/DR1_2XG`Z>S_GC]<GVYDOPV![Q7,`8]3O3QZ!^[Z]EC+K_`/2?
MI%>^LV)]3.K.H;A=4P>F&H/JO-=8.]I]C&>G4ZEOZ-ZR?J9UG$^KO4\EO56O
MJ)J^SV[6ESZ[*W>YKZV_I-K_`-]JCBT]+S_K3TUG1\1V-TNR]@H#]Q]7[.?M
M.7;-KK=WT?3>W?[&?SGZ19[KO39OUEZL>I4_5?ZO"NW+H:*LC/R`2W=6T>LY
MM;3_`(/_``KW^I^E_0UUINE?6OK6'UC,Z-UXTWV8M5EHR*1MUKK;E;7?FNK?
M2[]RM]:Y7I#.B6]6SV_6JU]!:ZPN`=8P^N;'OO#W4?I-W^C9_A4<6=(;T7J?
M4NG]/MPJW-^P8V7=DOM]7[0]M=S64V#8U[<1CG6O]1_I?S/O24Z?3/K9]=>I
M=.SLBAN*1B5MMNR'-V"L!K[;&55ES_7O>S_2?HZO^NK=^H?U@ZGUK'R_V@66
M'&>P5W-;L+@]N]S'L'LW5_R?WUS^*6=/_P`6>5>7!K^JW.:PSR+'MQ(G_P`+
MTOL6S]078W3_`*N,R;WAIZA?98P@$RUI&,SZ(/M_0_\`324__]'N\K[%O9]B
M]?[5ZUWI?98G=+?MN_[1^K?9_7V>MZW^'_F_TB<_;]H^U?;8[^GZ,?\`LI^F
M7S<DI^@V_P`/^<_P6H?FEOT_F_YK;]/^7R/TYTO]F>B[[!MB?TO[^[_A]WZ3
M?_75U?*R2BE\QW_POF;&+Y!\O^!\GT?J+,^P;&_;O2]/=[/7VQN@_1]3\_:B
M4^CZ3/0V^C`]/9&W;^;LV^W:OEE)#]$;_P#<I'SGY=O\-^FKOV#ZS_7^R>MN
M]^_T]V[^7N]VY'S/V=M;]N]';)V>OMB8UV>JOEY)..\?F_E^XQ])_P`W_+_.
M/TSD?\W_`$ZOM/V7T]H]#?Z<;/S?2G_!_P!16\;[+Z+?LNST-=GI1L_L[/:O
MEM)*7RCYM_TOE^B8?.?DV_1^?_"_JOTGU7_FG]I;^U_L'VF!M^U>EZD?F_SW
MOV*VS]D>KB;/L_J['?8(V;MD#UOLGYWI[-OJ>BOF%),97Z2ZG_S1^UC]K?8/
MM<#^D^EZD?FSZWOVJUE_L7['5]M^S?8I;Z/K>GZ4P?3]+U/T7T/H;%\QI)*?
MIFW_`)O_`+/I];[)^SI'V??Z?H3#MGH[OT.[Z?T$0?L?[+1L]#[)_P!IMFWT
MX_X+9[-G]5?,222G_]G_[0_F4&AO=&]S:&]P(#,N,``X0DE-!"4``````!``
M````````````````````.$))30/M```````0`2P````!``$!+`````$``3A"
M24T$)@``````#@`````````````_@```.$))300-```````$````'CA"24T$
M&0``````!````!XX0DE-`_,```````D```````````$`.$))300*```````!
M```X0DE-)Q````````H``0`````````!.$))30/U``````!(`"]F9@`!`&QF
M9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!
M`#4````!`"T````&```````!.$))30/X``````!P``#_________________
M____________`^@`````_____________________________P/H`````/__
M__________________________\#Z`````#_________________________
M____`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X`````
M``0`````.$))300:``````-I````!@``````````````.P```-$````:`$4`
M>`!H`&D`8@!I`'0`(``Y`#D`7P`Q`"``7P!%`&$`<@!N`&D`;@!G`',`(`!2
M`&4`;`````$``````````````````````````0``````````````T0```#L`
M`````````````````````0`````````````````````````0`````0``````
M`&YU;&P````"````!F)O=6YD<T]B:F,````!````````4F-T,0````0`````
M5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P```#L`
M````4F=H=&QO;F<```#1````!G-L:6-E<U9L3',````!3V)J8P````$`````
M``5S;&EC90```!(````'<VQI8V5)1&QO;F<`````````!V=R;W5P241L;VYG
M``````````9O<FEG:6YE;G5M````#$53;&EC94]R:6=I;@````UA=71O1V5N
M97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y<&4`````26UG(`````9B
M;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG````````
M``!,969T;&]N9P``````````0G1O;6QO;F<````[`````%)G:'1L;VYG````
MT0````-U<FQ415A4`````0```````&YU;&Q415A4`````0```````$US9V54
M15A4`````0``````!F%L=%1A9U1%6%0````!```````.8V5L;%1E>'1)<TA4
M34QB;V]L`0````AC96QL5&5X=%1%6%0````!```````):&]R>D%L:6=N96YU
M;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L=`````EV97)T06QI9VYE
M;G5M````#T53;&EC959E<G1!;&EG;@````=D969A=6QT````"V)G0V]L;W)4
M>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90````!.;VYE````"71O<$]U
M='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG``````````QB;W1T;VU/
M=71S971L;VYG``````````MR:6=H=$]U='-E=&QO;F<``````#A"24T$%```
M````!`````(X0DE-!`P`````"B8````!````@````"0```&````V````"@H`
M&``!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B
M90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,
M#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.
M#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#/_``!$(`"0`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!!0$!`0$!
M`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'
M"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"
M(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#
MTW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W
M$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P
M,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S
M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$`
M`A$#$0`_`/54._(IQJG7WO%=58ESW&`%'*R:<3'?D7NV55B7._@/Y3OHM7"=
M4ZQD=2R/5M&VJLS12=6M_P"$>/HV7*?E^7EE/:(W/_<AJ\WS<<$1UG+Y8_\`
M=2=O-^L[W_T=WV.@ZLM>SU+[!^]CXFC:Z_\`ALKV+/9UKIOJ3DXV3F"?YS(O
MW.CRQALQ6_V%E>E<X>L_VMLU%EA@O\V[O?9_93&EXJ%P(=7N],N:>'1O#7M=
MM<W<WZ"T(\OBB*^FAK_G!R9\YGD;-=_4.+3^Y+T/?].;A645Y6#+:+1(:"0W
MP/Z(^UCVN5U8_P!5*WLZ+47<6/L>T?R2YT?YWTEIY.13BT/R+W;*JFESW>06
M7DC62403*I&([EV\,[PPF0(7$3/2,=$J2H=/ZU@=1>]F*YQ=6`YP<TMT=('T
MOZJOILHRB:D"#V*^$XS'%$B43U&H4DDD@N4DJ/5>M=,Z10+^H7MI:XQ6W5SW
MG]VJIFZRS^RU9&)_C"^K.3>VCUK*=[@QMEU;FU[CH-UFK:_^N[$E/2I)))*4
MDDDDI__0Z+ZV=2=D9OV)A_08IET:[K2/_137;/ZZ#A=+L&0,?TQ9U#TS<ZMT
M%M#8FKU&/_1VY=VYGILL_18^_P!7WJWT#`&1U-^;E"7>I=96T_O,?M<_^S99
M[?\`BU7KOZSTOK&5>,5]UE[WAPV/+7M+MU;JK*VN_-6F#43AQD7"-ZGAXYGY
MO_0G$,>*8YC,)$9)T*'%[6./R_X7[C6IZ)UO,N)=CV->X_I+L@[1\7.=[W_]
M;:K#L&N^ZGH.`_U0VPVYN6!H7`>F[;_P>/6[8SW_`,\]7,C,Z]U!S<6UOV06
MB1B4G].]OC?8[=]DQ_W[;/3_`.)O6UT?I%73:-H#3<^/5>T0-/HUUS[O2K_]
M2)F3F)1%R,>(?)"'R@_ORE_59,/*0G*H"?"?YS+D],C'_-PA^CQ_I-VBFNBE
ME-3=M=30QC?`-&UJY_K^0_J'4L?H=!]I>VS*([`>_;_UNO\`2_U_06SU3/KZ
M=A695FNP0QO&YYTK9_G+ENE=*ZYE,=U/%R&4OR"_=8XG<Z7>]P]EGL=8U0<O
M'YLLB(UZ82EM[I_[UM<Y,GAP0B9<7JR1A\WLQZ?X:7ZM#TNMYN,P[!LM8PG6
M/3LVL_K;6N2J^M74<9V35FM;;=6#74UC2W]*UWID.@N]GYRHXF8>E=:MNRW>
MI93ZK;BT_3>X3Y?3L4<JS/QLO'ZSE,:RS)><AC`(T86C86G]ZGZ'Y_Y_\XK9
MQ"60F41(3A'@[RG'I'_NFA'/*&("$I0./)/C`%QACG^E,?WY>AUKNO=9Q15A
M/#+>IY&TENV&U!_MJIVAWZ2]_P#.6>[TJE*CK/6</K%?3^HNKO%CF-<:Q$>I
M]!['>SZ+OI[V*B,G'J^M3LK+L`HWFUMG(+'5?JK]/S=I8IXM=G7.OWY=(_5V
M;HL,@"*_1Q_[;G_IMBC..`B28#A]KW#*O\I+Y80++'+DE,".61F,PQ1A=_J8
M?/DR1_2XG`Z>S_GC]<GVYDOPV![Q7,`8]3O3QZ!^[Z]EC+K_`/2?I%>^LV)]
M3.K.H;A=4P>F&H/JO-=8.]I]C&>G4ZEOZ-ZR?J9UG$^KO4\EO56OJ)J^SV[6
MESZ[*W>YKZV_I-K_`-]JCBT]+S_K3TUG1\1V-TNR]@H#]Q]7[.?M.7;-KK=W
MT?3>W?[&?SGZ19[KO39OUEZL>I4_5?ZO"NW+H:*LC/R`2W=6T>LYM;3_`(/_
M``KW^I^E_0UUINE?6OK6'UC,Z-UXTWV8M5EHR*1MUKK;E;7?FNK?2[]RM]:Y
M7I#.B6]6SV_6JU]!:ZPN`=8P^N;'OO#W4?I-W^C9_A4<6=(;T7J?4NG]/MPJ
MW-^P8V7=DOM]7[0]M=S64V#8U[<1CG6O]1_I?S/O24Z?3/K9]=>I=.SLBAN*
M1B5MMNR'-V"L!K[;&55ES_7O>S_2?HZO^NK=^H?U@ZGUK'R_V@66'&>P5W-;
ML+@]N]S'L'LW5_R?WUS^*6=/_P`6>5>7!K^JW.:PSR+'MQ(G_P`+TOL6S]07
M8W3_`*N,R;WAIZA?98P@$RUI&,SZ(/M_0_\`324__]'N\K[%O9]B]?[5ZUWI
M?98G=+?MN_[1^K?9_7V>MZW^'_F_TB<_;]H^U?;8[^GZ,?\`LI^F7S<DI^@V
M_P`/^<_P6H?FEOT_F_YK;]/^7R/TYTO]F>B[[!MB?TO[^[_A]WZ3?_75U?*R
M2BE\QW_POF;&+Y!\O^!\GT?J+,^P;&_;O2]/=[/7VQN@_1]3\_:B4^CZ3/0V
M^C`]/9&W;^;LV^W:OEE)#]$;_P#<I'SGY=O\-^FKOV#ZS_7^R>MN]^_T]V[^
M7N]VY'S/V=M;]N]';)V>OMB8UV>JOEY)..\?F_E^XQ])_P`W_+_./TSD?\W_
M`$ZOM/V7T]H]#?Z<;/S?2G_!_P!16\;[+Z+?LNST-=GI1L_L[/:OEM)*7RCY
MM_TOE^B8?.?DV_1^?_"_JOTGU7_FG]I;^U_L'VF!M^U>EZD?F_SWOV*VS]D>
MKB;/L_J['?8(V;MD#UOLGYWI[-OJ>BOF%),97Z2ZG_S1^UC]K?8/M<#^D^EZ
MD?FSZWOVJUE_L7['5]M^S?8I;Z/K>GZ4P?3]+U/T7T/H;%\QI)*?IFW_`)O_
M`+/I];[)^SI'V??Z?H3#MGH[OT.[Z?T$0?L?[+1L]#[)_P!IMFWTX_X+9[-G
M]5?,222G_]DX0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H
M`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`
M;P!P`"``-P`N`#`````!`#A"24T$!@``````!P`(`````0$`_^$22&AT='`Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2?ON[\G
M(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX*/#]A9&]B92UX87`M
M9FEL=&5R<R!E<V,](D-2(C\^"CQX.GAA<&UE=&$@>&UL;G,Z>#TG861O8F4Z
M;G,Z;65T82\G('@Z>&%P=&L])UA-4"!T;V]L:VET(#(N."XR+3,S+"!F<F%M
M97=O<FL@,2XU)SX*/')D9CI21$8@>&UL;G,Z<F1F/2=H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C)R!X;6QN<SII6#TG:'1T
M<#HO+VYS+F%D;V)E+F-O;2]I6"\Q+C`O)SX*"B`\<F1F.D1E<V-R:7!T:6]N
M(&%B;W5T/2=U=6ED.F8T,SEA-3<Q+3)A,&8M,3%E,BTX9#,P+6%A860U.3-C
M9#-D9B<*("!X;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+VUM+R<^"B`@/'AA<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO
M=&]S:&]P.F8T,SEA-39F+3)A,&8M,3%E,BTX9#,P+6%A860U.3-C9#-D9CPO
M>&%P34TZ1&]C=6UE;G1)1#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*/"]R9&8Z
M4D1&/@H\+W@Z>&%P;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0])W<G/S[_X@Q824-#
M7U!23T9)3$4``0$```Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q
M``!A8W-P35-&5`````!)14,@<U)'0@```````````````0``]M8``0````#3
M+4A0("``````````````````````````````````````````````````````
M`````````!%C<')T```!4````#-D97-C```!A````&QW='!T```!\````!1B
M:W!T```"!````!1R6%E:```"&````!1G6%E:```"+````!1B6%E:```"0```
M`!1D;6YD```"5````'!D;61D```"Q````(AV=65D```#3````(9V:65W```#
MU````"1L=6UI```#^````!1M96%S```$#````"1T96-H```$,`````QR5%)#
M```$/```"`QG5%)#```$/```"`QB5%)#```$/```"`QT97AT`````$-O<'ER
M:6=H="`H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P``
M```````2<U)'0B!)14,V,3DV-BTR+C$``````````````!)S4D="($E%0S8Q
M.38V+3(N,0``````````````````````````````````````````````````
M````````````````6%E:(````````/-1``$````!%LQ865H@````````````
M`````````%A96B````````!OH@``./4```.06%E:(````````&*9``"WA0``
M&-I865H@````````)*````^$``"VSV1E<V,`````````%DE%0R!H='1P.B\O
M=W=W+FEE8RYC:```````````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```
M``````````````````````````````````````````````````````````!D
M97-C`````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92`M('-21T(``````````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````````````````````````
M9&5S8P`````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$`````````````````````````````````
M`'9I97<``````!.D_@`47RX`$,\4``/MS``$$PL``UR>`````5A96B``````
M`$P)5@!0````5Q_G;65A<P`````````!`````````````````````````H\`
M```"<VEG(`````!#4E0@8W5R=@````````0`````!0`*``\`%``9`!X`(P`H
M`"T`,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`
MF@"?`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-
M`1,!&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!
MJ0&Q`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G
M`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#
M6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q
M!'X$C`2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%
MQ075!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]
M!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(
M^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<
M"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-
M#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>
M#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2
M!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.
M%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7
M]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[
M&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>
MZ1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O
M(MTC"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<F
MZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV
M*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O
M_C`U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38
M-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ
M-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B
M/^)`(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%
MFD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:
M2^),*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92
M,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+
M61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@
M!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]
M9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O
M'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X
M=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_
MA'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$
MB&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1
M/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IH
MFM6;0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D
M5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XM
MKJ&O%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FX
MT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8
MP]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.
MML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQ
MVG;:^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F
M#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_
M\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^
MW/]M____[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"``[`-$#`1$``A$!`Q$!_]T`!``;
M_\0!H@````8"`P$`````````````!P@&!00)`PH"`0`+`0``!@,!`0$`````
M```````&!00#!P((`0D`"@L0``(!`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3
M(@`(,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$
M5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI
M:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8
MV=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B
M$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V
M160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=7
M9CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI
M^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#?X]^Z]U[W[KW75Q_4?[?W
MJHK2N>M5'KTC-][]V?UQMVMW5OC<F&VOM['Q225F5S60@H:9`BAA'&9;O4U#
M_P!B*-7D<\*I/LPVW:]QWF\BV_:K%[B[<_"@+$?.@\OF:#Y]$N_\P[/RQML^
M[[]N45IM<2DO*[`::?P@Y8GT`)^758V=_F%[\[=SU?L[X;=.5^^EI&:GR';&
M_6EV_P!?X'0S))75,<XI(XJ6)1K4U=732NI&F%OI[G.U]GMGY<L[?=/<[FF.
MP#KJ2T@4S74J\!0+735JKD8(/6*6Y?>6Y@YPW"YV/V2Y/EOV4Z6W"Y80V4?J
MSEPHU`4-"V00:9Z1,NW)MV5T3_*W^8_BL?45#:J[K?IK?&!V1@J*5B2:1\S1
M5+5LBQ?H+-`E[?J)Y]KX[MK195]N_9*>.V4=L]Y`T\K$<7&H::,<JHX#H/R;
M?'NEZB^[_P!Y2!I'(K96,P@AC-/AUH23\R30^6.C3]>_$'XLYO&1YO8VY]X;
MQ3T_[^S$=_;\RU8\]O1*U?A=U+!#47%[!%'^%O8!WWW%]P(C]+OMO%:GAX36
M<4?Y`-&#3\SU+W+7LM[07@_>G+FY7E\XH2Z;M=R`GU(28J*^E`/0=&>V3L;.
M[%FCQ\&^MS;KVN;+%CM[3KG,[B9+CQ_9;I"4V1K:(`6,5<*F0?591^DQY=WB
M;@3))8)'-QJE`I^>FO\`@IU,VS[/=[(BPINDDNVUH%N*O(/0*XS]FKH7O9?T
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MLW+V_N0]@_)/,5NZ,M'^YL_I/`U,^$P&(IY`LM/+GGBDF?;>(=7!,<?DS=:+
MZY($TO[S;Y9Y+LN7+2/8?;NQCM[>@\7<YUUSAN'Z28\0@@T)HJ5K1JD=<Q>=
M/<;=.=]R/,_N9>/=RU/@[;%*T4"KQ[F%0*BE10EZ4J./00[Y[V['WYBZ7:]5
MEH=L["QJB/$=<;(@?;.Q,9".0!A:.4'+5;'U2U5?)554K\M(?8QV;V[Y:VBX
MDO[BW>_W]VU27=R1)*[?(\%7T50`/MST`-\]T>:-YM4VFWW&2QY;C71':6R"
M&*-/0@$F1O61R6/K2@Z!H1QIPL2`?[2J@?ZP```'L>:FH!A0/)>`ZCL-HJJ-
M(XJ35\L2>-?EZ=#]\;>^]W_'3M+;6^-KY*KI\4F4H:?>&WXZB5,7N7;<]0L>
M2H\A1J3#+/#3.TE/*5UPRJI7@L#'WN3R%M//7+&\VEU;0_O.*'5;RD=WB4KI
M!]:\?+J5_:'W-W[VTYSV#=[#<)EV9Y@EU;@]K)6FLCA0^7GUN3X^OI<E0T60
MHY!+2U]+35E-(/I)!5PI40./^#Q2`_['WRPE1HI987Q(C$'Y$&G7=.WN([FW
MMKF)JQRH&7Y@BH_EU-]TZ?Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z__1W]R;`G^@)_VWOU0,DXZT30$]$*^;_P`R,+\7]E"BP[4F7[6W;252
M;0P,A$L>,B%X9-TYR*_[>+H9C^U&;-53KH7TAV65_:/VKG]R]Z9+K7%R]"P,
MTG"JC(6/^)B:5SA<]8\_>%]\K/VBV`164J2<U7,1\"(4)6M!XD@KVHH)(-#5
M@!UJ^9_?^Z-V;GRV^]UYBLW)O;-UK5]9GLL_W4Z5)Y%3!&UH%FAX2G0*(:95
M'C0$+;HY8;!MNU[59;+M>WQV]E"@2B8+CU;YGSZX\;KS-N>][[N7,>ZM)>;]
M<.2\[L27!_H<$"<!3CTBY96=Y)YY))997,DLLKO++++(Q9WDD<M)++([7+$E
MB?J?9\L$-I;I&@5$7U(%?VT`I\R.B"1KB>X$L[DS28"Y/#T`J<_(=*Y=A;O&
M/ARU7A9\1BJGFFR.?GI-OTM4MKZJ1LS444E6EC^J)7'^/L.S\V<O02-"=S1Y
MEXJ@9R#Z$J"*_GT?KRES(8TFDVEXHF%5,C1QZA_$`[AJ?,@=2AUQNZ;`Y?=&
M.Q]-G=O;>2GEW#E=O93&YN#`0U4JP4]1FHL=4SU>-I)IW$:S2QK"7].J_'MF
MUYRY>NMPM-M:^\&XGDT1F56C5VIJHK,,T'Y_+I^3DOF./:[[>A8:]MM8]<SH
MRR"(5T@/H)H6/#Y<2.'24QN-JLQE,;AZ*%JBNRV1H,71PH"SRU=?5PT=/$JK
MZF:264#CG^GLXW&^MK3:-POIY--M"A9C\A7AZ]%.SVD^Y;QM&WVJUN[B41JO
M]*OGZ=;OFU,.V"VQMS".=;8;!8?&,^HDLV/Q]/2L3_6[1>^0M[()[V_G0]DD
MI8?83U]!FS6SV.T;79OF2.!%;Y$*`:=*,FPN?;%0./1CT%G:7=O5G2>'H\_V
MIO+%[,Q&0R"8J@K,F*F05F0>%ZC[:G@H8*NJE9(8V9V":$`]1%Q<_P"7>5^8
M.;;N:QY<VN2[NXU+,J4!"@@$U8J*5('&N>@=SA[@<G\@6<.X<X[[#86<D@1&
MDU4=B">T*&)%`:FE!Y](;K;Y;?'7M_=$>R^MNT,)NS=$M!692/$4%+EX:AJ#
M'^+[RH#U^.I("L'F6XU:N>![,N8_;[G/E*P&Y\Q\OSVMB6"ZVT$5/EVLU/SZ
M(^4O>3VSYZW3]R\I\VVU[N6@OH36#I'$]RK7\J]&+5@X)'T!M[!WF13J2U97
M4,IJ.N7OW5NO>_=>Z][]U[KWOW7NO>_=>Z`ON_Y-?'_XV8&GW+WQVYLCJS$5
MKR1X^3=F:IZ&MRLD0)E3$8A#-E\N\87U"F@E(_/O8!/`=:)`X]$*C_GC?RRI
M,PN'_P!F+B35*L7\5DZ_['3"C4VD2MD#M32(1]2VFP'U]VT-UK4.K&>HNZNI
MN_-F4/8?3'8.UNRME9"6:GIMQ;2RM/E*`5=/;[BBJ3"WFH:^GU#R03I',EQJ
M47'NA%,'JW'H4/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__2WD^]
M^ZMK="=7;J[-W;*!C\#0L*.B1U%3F<U5#PXC"T2GEZG(UC*G'Z$U.?2I/L0<
MH<MWW.7,&W\NV$9,\S@.:5$:5[F/J`*GH$^X'.^U>WW*>Y\T;LP\&%#H6H!D
M>ATJ">!)Q\N/6GUVOVEO'N??^X.Q]^9*3);BW%6--,2W^2XZCB+1T&'QL7"T
M^-Q=-:*)0.0"QNS$GJ7R?RGM7)?+]GL.VQJ(X?B<+E_4D<:GCQ^77#+W!YVW
MSG_F?<N:]_G>7<YI-,8KVQP5Q%3A5<584%!PZ>>J>D]Z=N/FJW"QT&%V;M.E
M_B&^.Q-SU)Q>R]G8T69JC*9-E;[BMDC_`,Q14XDJJA[*B\W]E_-/N)L7)YBM
MKAI)]YNQIM;>-:RRL<#6O^@BO%GJ!T:<C>VF]\_-N5Y9'P.6MN.J[O)#X<,:
MC)T,?[7'DN2<`=*K<.\M@]:5*X3I?$5&3RM)&AJ^WM^X:+^\U?/+$#Y]F[0K
MC58G9.+:.0-3S31U&592',D5]`(-JY?YBYG#W?.U\R6#/FPC8Z,9I+,I!D_T
MJZ5!]>A'OF_\L\FLMER)MVO<BG^Y]P`9*'`>W@:OAJ37]1BVL<`*=`3E<ME,
M]7SY7.9*OS&2JI"]3D<I5U-?6S,Q)_<J*J265E6]@+V`]R98V6W[3;K;V$)@
MLT^%(T5](^P@L17)8D]1-?7E_O5P\NX7GU%_)EFF([OL8X7Y*HIY^?5A/Q%Z
MTKMF],?(_P"3.]Z44?72].[QZTVQ19`>*/>^X]V?9T""E@D4&KH,=6>%(Y1=
M6J7.F_B8C'CW>YCBYAYQY#Y!V%UN.91N$=VSH`-$:#*/IH*D"IX4&#QZRM]A
MN3+CE'V^]T_=#F5&AY8_=KV<<$O]C++(0-8CQ4JS"A\SD=,_\MCHJO[<^0^W
MMRUE)Y-G]1M3;RW#5SQ%J6HS,'D7:N(O8*\U3DU^Y9?J(J8D\'E?]X?G&#EW
MDE]EBE'[ZW$:%5332GF_V$8`^?1?]TWVW?G/W)M-]DM2=CV>4O,S`D&5LQQC
MAEL&O``<.MJL?0?ZP]\[_MX]=B/RZPU,@BA=R%(4`G6XC0"XNS.>%"CGWZBD
MJ&\R!ZY)Q_/JCL$4LQ`C'Q$F@"?C8GY+4_EUJ]_-[N+</RP^1&0VGL$R9C9G
M6U%N+&[7IJ9K4E2FW<;497?6[974$&%_X9(D4QN&IH([?K-^@'M)RWM?M;R'
M'S'S'$J;IN+QE=0!(5V"K'0URU0U1\^N1'WAN>-W]Y/<M]AY8<S['MD=P(-)
M.DQP)JEF.FARPTBO`'Y=)C^6MFDQ'S!ZVU2:8LWC=X8,@M82&NVW65,2$W^O
MDHU/'Y'LY^\-`EW[6;R@C3PEN83A`"VDUXC@*-Y]$GW2;Q[3WSY<,[A6>VG2
MI+$`O&&I0GCBGV];$G8'RP^/?46Y)=F]E=G8':&YHJ*CR38G*1Y3[@T&0C+T
M=4KP8^>%XIE0V(<V((-B"/>"&Q\C\X<S6GUVP<O7-W9@Z2T:Z@A`&&/K_GZZ
MF\S>[GM]R;N"[9S7S/:V.X/&LBI(2I=7X$"GVC\NE_L3N3K?L_:DF^=@[LQ&
MY=GPR9*&;<-)4/#CH)<.JME$J)*N&!J?[)6!<N%`4WO;V5[OL.\['?IM.Y[=
M+#NS%:0LI#G5\./GY="'8.<N6>:-DEYCV'>(+G8XW99)E;L30M6.>-.!Z#'9
M_P`R/C;V!NK%[)V5VE@MS;HS50]+C,/B8,Q4U=5-$KO-ITXP0K#"D99Y6<1J
MHN6`]G&X<A<X;18?O7==BEM]MX>(]`I/H*\?RZ#&R^\GMQS'O<7+FQ\QI=;T
MPKX<:LQ`]21@?GUR[3^8GQSZ:KYL/OWL_;^/SM.0)\!CI*C/9JG)(!6JQV$I
MZ^>E=;_ID"M_A[4<N^W/.G-*B39M@GEA/!M-%_::#\ZTZ3\X^]GMGR)=/9<Q
M<T0K>+QCBK-*H]61`2HZA=7_`#5^-'<68@V[L7L_$5FX:IBE'@LK3Y#;V4KF
M`OIH:7.4E`:U[?18B[G^GMSF'VSY[Y7MWNMXY<GCMEXOVLHS3)4FG[.DG*/O
MW[3\[W2V&P<W0/?M\,3AXY&H*FBNHX`9ST'G\PWYL[2^"OQMW-W!F(X,KO"N
M<[5ZIVC)(0=U=AY.CJ9,135*1LLXP6)2%JW(RK^BEA90?(Z`@2*LFK%*&AZF
M`L**:X(J/LZT8NI^M?EI_-R^6DF,R6[ZK>78^XHI\_O3?NZI9DVIUEL6DJX(
M:FJI\;1+]MA\!C9*I*?'8NB2,U%0Z(/4TDH>!\/!S7JOQ=6;_.'^07!\7/B[
MO#O[KSOK.=CYOJS$0[DW]MK<NTL9M_'Y3;JU$%/FLAM2IQU=5UE'58A9_/\`
M;5;3B>&-_P!Q'"@^\3Y=>T_/H&_^$]O?&[]@?.:BZ9Q^8JCL+O+96\:?<FV_
M.TF.;<6S<'4;FV]N6&C+>.#*4T-!/2/,H#M3U#*Q("@-DU)/5A@=;I_=?R&Z
M1^..U1O/O+M#9O6&VV<PT^0W;F:;'/7SKIO2XJ@O)DLO5@,"8J6&9P.2`/>N
MM]$?VA_.?_EL;UW33;1Q?R7V]CLC65*T='7;HV[O+:FW:BI=_'%&-R;@V]C\
M+"LK?I>69(S_`*KW<H0">JA@>K#-W=F;"V'U[F^U]W;KPN$ZYVYMZ;=N:WE/
M6I-@:+;4%,*R3-_?4?W$=1CS2$2(\7D$BD:=5Q[J!4TZV<=%6ZS_`)E/P4[C
MW93;&ZR^3'6^[=UU>,S6:BQ-'5Y.D*X?;F+J,WG<K4UV3QE#CJ+'XK%4DD\T
MTTL<:1K];V!WH/GUK4.@<SO\Y_\`EK;?W;)LZL^3>VZJNAJ?M)\OA]O;SS>T
MX9PYC?5NO%;=J\$\,;BQE29XN+AB.?>_#;KVH=61[0W?M??^U\%O79.X,1NK
M:6Y\92YG;VX\!7T^4PV9Q5;&):6OQU?2/)3U--,AX93P;@V((]U(H:=;!KTH
M_>NM]?_3O#_FW=Z2[L[1V]TAB*N7^!=;T:9O<L4,K_;UV[\]3I)2P5$0]$CX
M/"Z=-[E7JW^A'O-[[KO)R6%A?<W7<'^-7<I2-B!B!0:LIXU+"A\L=<N?OL^X
M<^]<U[;[;;9<@0V4`ED`)TM.Q!T,*\`E/G7HD_Q4^+VY_DYOYL)25/\`=[8N
MVH(\SV'O6H0BEP>"21S)3TKM:.7+Y"."585)T1A'DD]*$&9/=#W-V_VYV8,%
M$_,EQJ6WB!Q4BB,WG@D'!S2@Z@#V5]H=Q]W^9)HXYWLN6[$:[NX<"@502X0D
M4R`5SZUZ/;UA2[1^6?R(VM\?>K\<-K?$+HO[C=61VU0F2-.S:O;M=3TPW1NR
M6/3+F*W=&7>)8FJ2Y6A5VX:2RP)S&N[^V7(-SSIS/(UU[G[["`DQ[F@5ZETC
M!^!E`%*4-3UDYRI#MWN[[H;;[<\EPBT]F.60)YDCPETZ85IJ8D9R3A@4IQ&!
MTU=Q_P`J_P"0V:[6WAF-C9/8N=VCN3<N7SF+R&3S<^#K\9196OGJX<96XLT$
MZEL9%((E-.6C9$72%'I!IRA]Y7D^PY<V>SW6QO$O8K95=1I8/(/B<$Y#-YZN
MB3G_`.YM[B;CS?O.X\N3V4NT7-P7B9GT&&$_"A4^2YHB4`\N/0Y].?RJMA]9
M^3L#Y-;_`,1N/%[<@;,U^V\69L'LFEI:)1.\NZ,YDC!7Y&B@8>N*-::-[`$L
MI((.YO\`O-;_`+](VR<@;3/97<_Z8FRTQ5O)0.P`_836N>I'Y`^YMROR>C\S
M^[&_0WUA:CQ&C`$=M$5%2TI>KM3AVLH.,=%!^8?R3K?E)NO:'17Q[P%12]1;
M=S>/VWL[;^&HEQ=/OO=CLU)CZRFQ4*PQT^(Q\&K[.%E'BB+U$@74NF4?:3V_
M7VXL-VYXY\O5/,D]LTXE=@6@115E4G\<GXOF:#J%/?3W3D]V=TV3VS]L+*O)
M\=XEJEO`"!=RM1A.`.WZ>(<:C54<>KT/A]\;L;\9^FL+L<&CK-TY`_QW?>=I
M8E_W+[EK$7S11R,"[T&'@TTM-<_YN,M8%S[Q!]R.>YO<;FB\YA[EL#5;="3V
M1#"\?Q'B?*IQCKH3[+^V-I[4<EVG+ZZ'W*0"2YE4#]28C^8C^%*^0R3T:\FR
MD_T%_P#;#V`J&E!\74O$T!)\AU7)_,B^2S])=*5.U-N9`4O87:BU.W,(]-(1
M68G`Z%&YL\FEM<+0T4HIX'_X[3@C]!]S3[$\A/SSS='<7$%=DL3K<D89U!T*
M:X(+`5'&@ZQ?^])[IMR'R)/L6V7*IS1NJ^#'DC0CD!VP01VDBOS/1)?Y:_QP
M2?J;N+OC<-&'EW1LG>G7^P$FCU.N+&)K(-T9B-G#?\7&M5*1&')6"6W#>Y/^
M\)S[%+S1R_RGM\SFVAGMWF7&E75@%1*<%`-37SIU`/W3O:UCR5SO[C[I%^K<
MV-U:6ZD94"-EF<$Y[V`TGJM[XB9H[;^3O0^4\AA6+LK;F/G:X4^'+U#8:6,D
MVL)%K-)_P]Y$>[4$5_[7\S1JM5,*NOJ"D8/\_/K%7V6O9-I]Y.1Y9(WC_P!V
MBHQ)XAB\=,?):]6R?S?>H%K-K=>]UXRFUUFWLA/LC=52J`DX7,L]9@)9B`+1
MTF826%6/T-4`/K[QF^ZYS>EAO.]<JWDKB*\M_P!,!V4!P2#0`@5(`K]G6:GW
MW^0EW#8M@Y\V^S1[JRFT2U16'A`=M32N#7SIGJI'8_=O;-!U5FOCAL.;(-B>
MS-YT&1JJ/"_<R9S+35%''BFVM0K"P,=!G*F.!ZE5YD\85O0S7R=YGY)Y1CYE
MM_<3?;A`NVVNAU?N&H#M:K5)8#AZ5ZPAY1]Q^=HN3KWVMY/2;5NNY"5=%5JK
M@*R46@">H'$\>C];YV7+_+J^/6-7'U=*_P`H>^DJ,17[JHW5Y^M=GT=/!4Y?
M';6G(#PU8>IBIWJUMY:ERZ^F)![@W9=XN??OG5Q=L[>W>R5=8:468UHOB#@1
MZ`9I]O63&_['%]U;VNM4L:2^ZW,!"/.M#+;1$5(B)R&'PL345K04IT$7P$^'
M^%^5.X=\[D[*KL^FR-J/24U4<56BGRNX]U9@RUC0U&7J(ZJ<1T5(GGG87ED:
M5!J`O<5^]WNM<^VMKM.Q<J"**\F3O&D:57TH*5!X4/ET!ONT>Q=E[S;AO^^\
MX75R=FMFTJ5<B1I">#3-5S^WHI_?VR:#IGOGLK8VS\KD9*'K[>M71;=RTU1I
MRU(*%J>KH9'JZ98/\NQTD@7RQA-3)?@W]RER3NHYVY"V*_YAL;>22\L&=QX2
M@`\.TTK\\GC\NH4]SMI'ME[E\S[1RKNES'9[9>T0Z]3-I&H!V.:$]K4(QT6W
M^>9\FLWW7VK\<.O*NLJ&INL_CML3=6XZ03'[*?L3MC#T.XLOD#3`Z$JH<!3T
M,0)NP$C@$!B/?,_?K2"PWW>[*#^RBNG5?]*&:G\NNV'(^Y3[MRCRY?W@I=R6
M4+-Z$L@)X_/JW'_A-STWC]F?&'NKY"9BFHZ:N[+[(GP%#F)XHTJ(=E]88J)*
MA?N2-<5!+N/*5KR`'2S4X8_I%B23B.A:OGUE[*_X4(?`/L3;6\.L.P>B.\=[
M[(W%#D]L[EPE;MW9-3@=RX@5,E-403Q2;YIY9\;D%A#:6"EHV`(Y(]Z5-0K7
MKQ:G2@^)W\PO^6C)LSY#]Q_'OX<4?30^+?4E7V1F=UU?6/6FU<CD7RU1)M[;
M^R\+N;;]=F,U%F]WY604D8=@C(Y!)_2?%*4SUL'K7`VGN#LK^:[\\=GT_P`B
M.V*?:E%V)N'*5.7S^5RU)C]K=3]:8*BKL]6;:V13YRJ@PV*\.-I/LZ)7]557
M3+-/Y&+7L4`SGJNHUIT=G^<)\$/@Q\5.JNF-X?%'>R9;<N>WE6;,W=@1VCC^
MR/XQB8MNUN63<]5##554N(KJ:OHDBE,0AI)A4A1$I47V"7!!Z\0!GJ=UU\G]
MU4W_``G^[XZ_W-F\ID91\A,%T+L.JKZZ>IJ*?:>Y:G:O8-;MJA>9VD3%XC'X
MK))'$IT113B,`(`/?@H#"G7B:@]$K_E6_!G)_/+Y`;BZXJ=Z;CZ]ZWVUU_D,
M]VGN#:9A&?R&WJ^OHL9CMFXUJI):'5N3*E#.)UDB%+32,8W(4>]LVD`CK0%>
M@^_F5?%CKOX9?+?>GQ_ZPW?N#>>V=LX#9N6:NW0<<^=QF2W-A(<O4X.MJ,52
MT-%5&C@GBD2188VT3!6!*W/E;57KQ%.MSO\`DA;;S&V_Y9_QS&9JZFH.=H]Z
M;FQ=/4R.XQN#S6^]QSXFAIE<GPTOVJB9$`"KYN![;?XNK+PZMB]TZMU__]0Z
MV]J?.]\?)+M*ODDE<Y7?&_=R9ROYMC=LX'(UK3RLQU!63'4D5+3K]&J)(D'Z
M@/?4"SOK/VY]L-IM)4'C6UG';Q_\.DEI(S#UT!JGY`]<,-]M=T]UO=SFV>/4
M&FW"6=IC_H,<;-$J'R[RM!7S/5W':77LGQ*_EU]@8_:-!'B=W9W;^(BW7D<?
M'IJJ:KWG7XO$Y.-JI+3/#@\1D'HHF8@<-(1J=B</>5M]?W(][MGDWQS)9QW-
M$#?"RQJS)0"@XJ&/KP..NAO.6PK[+_=LYAAY>LP+V:U196458>.%60LQJ3AB
M,\*U%.J@?A3\I8?BCV?DMTY/`5NY-K;FP']V]QX[%3T\.4@@AK(JW'Y#&/5%
M:>>6AF1@T3L@E1S9@0/>6/O%[8W_`+C;);6>W7:C<89_%C+$A14$,M!Y&HH.
M`].L$?N\>[\/LSS)=7FX6<]WMES`(G2+3J"H08ZZJ@E<U)[F\SU:[NC^<1TM
MCJ!Y=H==]B[DRK1L8J7+KA-M8Z&;2=`J*W[_`#%24##GQPM?\>\9MH^ZSSU>
M3M%NE[:VULK5:5C6B^H%`.LSM^^_-[9V-NTFU;+N4U\%_LY=$,2L>%9*,0"?
M(#\NJ^.W^[?D5\L\='NKM'*5/7'2-1DDH-L;)VU!6QS=@9HSJ:3;^R\!*ZY7
ML;<<[E1]U4#^&T-];%"`C2_RURW[>^V<CV6PB+=^;*'Q+F4GP;-0*&64FJK$
M/)5[R>L<>=^?/=3WLM?WAS<+K9/;[Q%$4$*N);XL?TX+=*_XRKL0'E8>&HK@
M$=6I?!KX6TW4L-/VUV)MVAQ?8-?0_:;-V@'7(?Z+]OU<2^;[ZM9-&1[`S:F^
M3K0!XU_8B"(I7WCK[O>Z-YS0\W*^V;C+/M`E!FF':LSKBL=*%8!3]-1\0[FJ
M>LO?N_>PZ<AQ_P!<.9MI@MN9YH]%M;IW_1PMD@DX:9^+MG0256@P+.XUM&@(
M((6UM1)']>?R?<+&@)"_#UEF0NJH-0.'_%=-V4RU#A\97Y;*UD./QF-HJK(9
M"NJ66."CHJ."2HJJF>1O2D4$$;,Q_H/?K:"YO)XH;52\SN%50*EB30`>=2<=
M([V_M;"QN-QO9UAM8T9F9N"JH))-<4`%>M2#Y1]S;B^57?VX]TX"@S>7Q;NV
M`Z]V]04M7DZZ#:F&#^*>GQ]%'+,)<HR2U\^E.#+ZN%%NEWMKROMGMIR)M]KN
M-U%;7$H$\TY.E79S_9$G@4J!QS3KBI[V<[[K[T>Y&^;EM%G<7%E&_A6L*(SO
MX$:Z&E18Z,=35:HX<>EIM7O+YT['VCC=A;47M#![1P^-;#X["476#"EIL>ZR
M>6+4VV&ED,HE<R2.Q=F8DDGGV0[CR;[);QN5YO-]N%H^ZR,)"WU+Y<$4H-=!
M]@%.A'M7N/\`>*V38;7ES:K7<;;:$B\%47;M`"%6#59T-2035CW$YK7HIVS,
MM4;=WWM+-WD@J\)O';^4DU*T<T,^.SM)52@H0#'*KQD$$#2?<K\S;>EWRIO4
M$:*]FU@S+I:NHZ*`_D`,=0ORC>7=MSMRY?&/08]UA!+L:HZN2Q(/J6..KP_Y
MG'RXVW#M:M^-FR4QNY=P[HAQDN_JV2"*OIMKT#205^.Q%$`'#;KKITC<$7:D
MCL;>1AIPU]@O;6\GW7^ON]N;;9K!B035=1J>ZN.P?S/RX]"/O6^]NSQ[`GM;
ML+_4;S?P"261`L@@09"*I!#2RL"M.*CAQZIXZ*[#K^B^\M@[]JZ&6&396[J9
M=P8ZLIUBJHL;)*^+W!2RPU2!J:LAH:B6VH*Z2(/H?>5O/^RV_-O(^_;?83B>
M&:$S(Z_B:E5-1Q`P*<.L$?:SF&Z]O_<3E3>+N`Q_XW$CJXS"C4J&!^%Z&IX$
M'HYW\UO=C[B^1V`Q\$PGP^"ZNVS-B)$<M%41[DJ,AF):N(7*E9T:(!A]0@'X
M'N*/NP;8=OY*WR>9*74URT4GE54---!@$$'AGJ>_OJ[\VZ^YVU06\C-8Q[;;
M2Q%33^V?+`C)#*1\O,=66_RR\9A=B_#FEWGD)(Z.'-Y[?&\\[7NVD)1X>JEQ
MD<LDEP`M/C\(/J;`$^\>/?>[N=Z]U;[;H(RTJZ8HQ2M"?\-2P`ZRQ^ZE9[7R
MS[#6N^W;:!/)<SSO4C48I6"GCBBK2@P?/K7OS4V>[X[JRM1C:>6NW#VSV16R
MT%-&&>1JC=.??[5`%N5CI:6I4M^$1"3P/><MA)9\C^W-DMV1%;6.VD$'B&*X
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MQ0P52YW'Y*F&.IZ'"3,=**_D9?5:X/F-*4Z\,]'.^2'\L?\`E&?$+L:@ZK[V
M^:W?.R][9+;5)NM<;1[,Q6XEI<'7U=71T,^2J-L=?96*@EJY:&5HXI;2-&NL
M#202SK;UZO3HM?\`,GVKT+\>OB/\//CU\8NP]W=G=5=I;N[3^6(WIO/&?P/-
M;ACRE+@^MMM3R8E\)MZJAQ<$>)KOLGEI5,B7=2RL";(Q+9ZT0`.K=/\`A,[U
M*<+T-\@.ZZNF`G["[-Q.R,14M'ID.(Z[P?W58L4AY:&7,;LD#6XU0_X>]R>0
MZTOGUK1?S!>R#WI\Z/D_OG#2R9&FW/W9N;`[9-S*U1C=OUL&R=OQ0@7U+-3X
M>,H!QZ^/?H^!Z\WEU]%'XQ=74_2?QUZ/ZDIHA$O7G5FR-JSJJZ`]?BMO4$&3
MFT?53/DA*YOS=N>?;;9)ZL.'0Z>]=;Z__]6_3!?&S<_6&4^?\]/MZKS.XMOY
MGK[=.S:*&D+5.XNM:GL*7LO-#"J%U5;5N.V^:258R2TU.T9%_>6>]^XMAS;M
MOLQ#->,L;P7,=TM>V*X\(P1&G`%JC/IUSCV/VFWKDJ[^\%=PV(EOH+ZVEMDI
M_;6`F^HD?YM74/RZM\VWO7I?Y0]:5T>'R^V=][(WI@UHLYA1D(9ZJ&ER,`-3
MC<QC4F%;B,C3-=2DB1RQ2QZE/`/O'*ZM>:>2-]$D@:TW&UDK#)0CN&*UX,".
M%#0@Y'EUFE8[QR'[I\IRV27MO?;%>6X$\*%?$C<T/AR"M04.!48(QCJL3LK^
M6#\3]FUD^2S/R&SG7&$F9Y:;#9S,[,FJ8HKG334%3E(X,I7E20J*4FE8@#U$
M^\@MG^\A[E7%O#:VW+%O>3*E/$$9/^V:F*_/'6)_,WW/_9FPN;B]N>>YMNLY
M)-1C:1,<<+W`ZO0T/V'I%[5Z*Z&V9N"GP7QVZ7W5\@.Q(Y8FI-[=QP5*[1PL
MTO--E:?9\]%B*.2AATB1*O*0TE%8?MRSO:,I]T]P>==_A9N=.9EL-CXO!:D)
M,X\T5A4@^H!..D.S>V/MURU>1Q>U')L_,',RXCO+]]=M$3^,QL%5_4!D`%!Q
MZL1Z(^(\.S=VKW-W+N#_`$G]Y55.M/29>H@BCVMUY0.A7^`]?87Q04>,IJ=7
M*?<1P0,1<1I&I.J)N:.?IMRL_P"KO+UH;3EM*@@8DFS77<.,R/\`;7%.LC^0
M/9JWV;>HN=N;[IMRYU*XH@2VLPPS%;QTTJ!DZA3CCH\$2*$MI'#&U['Z'CW'
M"KX8TJQ(ZGE0$%$8:?EY?+\NLWOP%,#AU[HAWSXVEWYV5U`>L>BML)EYMZ5R
M4^]<K)N'%X/^'[8HRE1+BH1D:JF>J;/5&F.31PM.C@_J`]R;[2[SR=R]S-'O
MW-TU+6SRJ::@R<58^0T\0?6G6/OWBMD]Q.:>0KKE7V^MM<U\X660-1E@)I(H
M->#"H(\QCHLW\N7X1;]Z.WKNGL_N;!46&W3#CO[M;)Q=/E<=F/MJ#(HLV=S4
MD^.FGAAFJ$BCI8TN'">0D68>Y(]\?>#:>=]NVGEKEN0G:(F,KU!&ICPJ#Z'-
M?7J)?NO_`'?]^]O-[W3FSG2V1-S$`@M1BJ(?CT^E16H''/5PLBZE`_Q_V_!X
M]XRNL?:"*$L,_P`_\G6;;`D&GH<>N".M8+>O\MWY<Y#>^\<GA.O,9/BZ[=VX
MLCB:G^^FUZ=Y,=59NMJ\=.(I<BDD3O32(VD@,IX-C[S^Y?\`O!>V=GR_M%A<
MWT\4\5HD4BI#X@8JH#5J",_S\^N1G,OW4/>'<.9^8MPL-E@DM9]QEGC+2^&1
MJ<E2*<2/+T\N/1SOA-_+QWCM'L*K[>^2V-I9MP8+(_>[.VQ-E:'<B5F<DO/+
MO'<%=3S5<%1/22FU+"SLWFO*X]*>XJ]W???:]UV&+E7D.1EV:4?XS(8Q`R)4
MT156G:>)-/.G4\^P'W7MYV+F)^=_="V1MYM)=5M"9/'21](`D<M7N7\/I0'H
M(?F%_+Q[TWK\@]^;VZ>V?CL[LW>]13;D>6?<N!Q#T>X,A3C^\-(:3)5E-/HE
MR$;3JP721,1]1[$7M5[^<I<O\CV6Q<R7$BWD!*=H9JQZB4J?FA%1T#??7[KW
M/^_>XVZ<Q<@[-;3;3?N)I`T_AZ92BZR$!`!U@T(SY].O:/P&^0O;?2_56?RN
M(Q.*[RZSVW)UOG-MY#<&-J*?>VR<#52R;.R]!GJ2>JHJ?/4%#4FF>*=T22.,
M>I2!J2<H^]O*O*7-G,]K!(S\C7UPTX;31H7D-6`&*"OGQSZ=+N=?NU>XO._(
M/)&XSPA.?]KL9+*\7547%NI_Q5HG/&:)0*.36O#HOF!^-G\Q^GV/6](8S;&_
M<)UM6SU3U^W:G<FVL?MB9:VH\]=&]?\`Q)I3CJR<>66%'\<C$DH;FX\O^=/N
M\3;I_7.YN(I=^)#$*D^L$9!0M@/Z$\.HTV[VT^]A:\O1<@66T7\/+(U+I$T*
MHP<]P95()5B26`XYZLL^#O\`+RIOC[F:;L[M'(XG<W9GV<]-A,7BD:HV_LN&
ML@9*R:&JJ8HI<GGYXW,1G")%#&6$8);7[@KW;]\-QY]1MGVF$6O+JT%.$DH4
M@KK(X@$`D'K*;[NOW8[7VJDCYAYGF6]YKUL\>@#P[5F4AJXR^2`WD<@UZ+G_
M`#?/Y1^0^<4F"[JZ5S>"VWW[L_;[[9J,)N`?8;:[.VS2SU&0Q>-R&:AAE?";
MEPT]1+'1U4JO320S&*4QJJ.L`HQ`TU[>LPFX$>I)_,\3]IZUL\!_*6_FP;*W
M/5X':'1_96U*RM=*"MSVT>T=M8';]?$&*+]YN#"[TH8*JB4$F\EP%_`^GNY*
M'C3JN>CNI_PGB^1M%\;NP-];FSN(WG\JLO6[;?8/56!W?CX-MXR"HS^/?=^2
MWOO_`'']I1Y_<#8+[@Q1PR+3(P!\L[L`K;&A[<#JP'KU<%LG^5&^\?Y1NR_@
M_P!G5%)LCMBDI:KL0YVFEI-P4.TNZJC<69W'2RSSXUYJ?*X9(LD<96-3NQ>D
MDD:,E@GNM3QKUN@].J!-A?RZ?YT/PF['SM?\>]E[PQ.7S-#)@<CO'J#>>R<S
MM?=.$2H,U)]_2YVOIR8DG'FA6MH8JBE<DC2;W=JI7/5*$'HX7QE_D5_*3Y`]
MQ#O/^8YO6HI<77YBDSVZ]KU&[X=Z]J=E34WB^WQ>?S^.FJL+M3;TD$*PS)#4
M2U*4X\,,4-PZL=>7545/2L_FQ_RM?G!\IOE>F[>@>H-K572&QNI^N.K^MXY.
MQ=C;6IZ/%;:H*ZKKZ.AV]E<O2UF,HJ/)Y5X(E,2!HX5*\>]@TX=.=72?!#XY
M=I_$7^7)M+IJ+;-%#\@,'UYV)G:_;U'G,34T4_;FY9]PYC%8X[ABJ/X*\`K:
MFCIVJ?+X%2/46L/>R2>)Z]UK4?&'^1U\^,;\F^C]W]Y]8[7PW7&&[;VIO7LC
M-4_9NQ,_5QXK"YZ/<V3\>*QN8J*W(29&LI!`4C1F_>U'T@^_`D<#UZ@/6T_\
MI<)WYD]Y;=GZ]K-[+M.+'8M11[%K)Z>:;(KDLBVXZ/)I25U!44>3RF.:B7%Y
M2H9L=CVBF$H1I`S:Z]TB_P"[/SJ_YZ^E_P#/[M#_`.MOOW7NO__6WRGM_>.?
M_BQ:OX$+7U?Q^WWLU_-_NO\`@E_TWY\NNWMT<$^+CY?Y/GZ=$LNGZN?_`''K
MX1^*M?\`;_T/7\^J#^U_]'O^ES>/]XO]D(^\_C-5?_1__LS_`/?#];?\?G_H
MN_W`_P`7M_G=/%]7^/O*OE;]Z_U=M_I_ZU>'0?\`1N\+\O&_4IZ?/KGYS5_5
M_P#KGO7U/^M_XFHU\/\`?/C\?]$\#].OKHZ$[I/^[/\`>BE_@G^R8_PFS_=_
MZ//]+G^F31?^S_I!_P!_I;_CI]C^Y["G,WUFF3Q_W_JQ_;_2^'_U2[?LKT/N
M2?W9]4OTO]2_"\)O[+Z_Q>(X_4?J4]:8ZM>Z&^W_`+KUOVG^C3[;^*U7A_T:
M_P`4^UT:VM_>'^-_[EO[Q?\`*QY_7J^ON$-WU>.-7CUS_::?Y:<4ZRKY*\/Z
M&3P_W=2H_P!Q==//X]>?L_/H<3_L/K^?]]]?93T-.N_?NM=>]^ZWUU_MO=3P
M;A_J]>MCAUW[WY^7#K77O>^O=>]U'GPZ]UT?]A_L?>SY\.'7O3KW^V]Z\CPZ
M]Y]>_I]/]]_3WOR/#KPX==^]]>ZZ_/X_XG\>_=:'GUW[]U[KWOW6^O'Z'_B?
MI_L??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[^O\`K_\`$#Z_X^_=>Z][]U[KWOW7
+NL?_`%+]^Z]U_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
